﻿

Science-Based Medicine: Medicine, Public Health, Dentistry and Pediatrics. A Critical Guide for the Health Practitioner and Consumer. 2025 Edition. 
by Executive Editor Steven Novella. Managing Editor David Gorski. Series Editor Mark Crislip.
Contributions by The writers of the Science Based Medicine blog.
Published by SBM
2025

   Table of Contents
Title Page
Introduction
About the book
HORMONES
RISUG: Birth Control for Men | H Hall
“Female Viagra?” Misleading Headlines and Regulatory Dilemmas | H Hall
Hormone Replacement Therapy for Menopausal Symptoms: Setting the Record Straight | H Hall
Estrogen Matters | H Hall
Birth Control | H Hall
Menstrual Synchrony: Do Girls Who Go Together Flow Together? H Hall
The Medical Medium’s Thyroid Pseudoscience | S Gavura
Is thyroid replacement a performance-enhancing drug? | S Gavura
Hypothyroidism: The facts, the controversies, and the pseudoscience | S Gavura
Overtreating the thyroid | S Gavura
Adrenal fatigue: A fake disease (updated) | S Gavura
REAL MEDICINE
Medicine past, present, and future: Star Trek versus Dr. Kildare and The Knick | D Gorski
An Overly Pessimistic View of Medicine | H Hall
Irritated by the Skeptical Inquirer. Again. | M Crislip
Old Doctor Yells At Clouds | M Crislip
What Doctors Feel | H Hall
Doctors and Dying | S Novella
What Not To Say When Someone Is Sick | S Novella
Bouffant caps versus skull caps in the operating room: A no holds barred cage match | D Gorski
Five steps to add ten years to your life expectancy | S Gavura
American Mortality Ticks Up | S Novella
Aging and Longevity: Science for Spring Chickens | Science-Based Medicine
Drug therapy is still sending too many people to the emergency department | S Gavura
How do we avoid harming the elderly with prescription drugs? | S Gavura
‘Start low, go slow’: The smart, safe approach to drug dosage in the elderly | H Miller
Choosing Wisely: Five things Pharmacists and Patients Should Question | S Gavura
Choosing Wisely: Changing medical practice is hard | D Gorski
Expanding the scope of practice of advanced practice nurses will not endanger patients | D Gorski
An experiment in paying through the nose for “unnecessary care” | D Gorski
Why Doctors Order Too Many Tests | H Hall
An Egregious Example of Ordering Unnecessary Tests | H Hall
Serologies | M Crislip
A Skeptical Look at Screening Tests | H Hall
Too Much Information! | H Hall
Ecstasy for PTSD: Not Ready for Prime Time | H Hall
A Blood Test for Fibromyalgia? | H Hall
MyMedLab Offers Expensive, Useless, Nonstandard Lab Tests | H Hall
Dr. Amen’s Love Affair with SPECT Scans | H Hall
False balance in an NBC news story on whole body MRI scans | D. Gorski
Adios Aduhelm | S. Gavura
Tonsillectomy Indications and Complications | S Novella
What Is Type 3 Diabetes? | S. Novella
DIY Diabetes Treatment | S Novella
Generic GLP-1s are here (for some) | S Gavura
Doves, Diplomats, and Diabetes | H Hall
OPTHOLMOLOGY
Eye Drops for Dry Eyes | H Hall
CDC Reports Fourth Death Blamed on Contaminated Eye Drops | C Jones
First Whole Eye Transplant | S Novella
Anti-VEGF treatment of Macular Degeneration: Science-Based Success | D Weinberg
Macular Degeneration, Genes, and Grandma’s Vitamins: To test or not to test? | D Weinberg
Mast Cell Activation Disorder – Yes, It’s Real | S Novella
Pegcetacoplan, a new treatment for macular degeneration | D Weinberg
Pegcetacoplan (Syfovre™) for macular degeneration: an update | D. Weinberg
A Bionic Implant to Restore Vision | D Weinberg
Do We Need “Evolutionary Medicine”? | H Hall
Thumbthing Worth Reading | H Hall
Product B: Here We Go Again | H Hall
Misleading Ad for Apeaz | H Hall
Do custom-compounded pain creams actually work? | S Gavura
Just How Addictive Are Opioids? | H Hall
What are the risks of touching fentanyl? | S Gavura
The (Cold) Drugs Don’t Work | S Gavura
Medicine Must-Haves: A Pharmacist’s Guide to Your College Student’s First Aid Kit | S Gavura
Stocking Your Home First Aid Kit: A Pharmacist’s Guide | S Gavura
Dual Sympathetic Reset for PTSD | S. Novella
Generic Drugs and Global Deception | H Hall
Geopolitics and Drug Shortages | S Gavura
Smart Drugs Are Here | S Novella
Revolutions in Drug Delivery | S Gavura
How the “Don’t take this medication with grapefruit juice” warning originated | S Gavura
The Polypill Comes of Age | H Hall
Fixed Dose Combination Drugs: Consensi Is a Bad Example | H Hall
Sex and Racial Bias in Cardiac Care | S Novella
Swearing to Treat Pain: Helpful Approach or Just Another Distraction | C Jones
Are Muscle Relaxants an Effective Adjunct for Treating Acute Low Back Pain? Yes and No | H Hall
Platelet-Rich Plasma (PRP) Injections: Lots of hype, no convincing evidence | S Gavura
Crizanlizumab for Sickle Cell Crisis | S Novella
New Drugs for Sickle Cell Disease: Small Benefit, Large Price | H Hall
“Mystery” Illness in Colombia | S Novella
Medical Science in 2024 | S. Novella
Melanoma: A Pseudoepidemic of Skin Cancer Prompts New Screening Recommendations | H Hall
Acetaminophen: Still the pain reliever you should trust? | S Gavura
Tylenol May Not Be As Safe and Effective As We Thought | H Hall
Tylenol Ramblings | M Crislip
How to Choose a Doctor | H Hall
When To See a Doctor | H Hall
Re-thinking the Annual Physical | H Hall
Is the Annual Physical Unnecessary? | H Hall
Low Dose Aspirin for Primary Prevention | S Novella
Is Midstream Urine Collection Necessary? | H Hall
Surgery Under Hypnosis | S Novella
Point-of-Care Ultrasound: The Best Thing Since Stethoscopes? | H Hall
Constipation Myths and Facts | S Gavura
Breathing Easy: Treating Allergic Rhinitis | S Gavura
Botulinum Toxin: A tale of medicine, beauty, and danger | D Weinberg
DIY Botox: Why Self-Injecting a Neurotoxin Is a Terrible Idea | S Gavura
Hope, Evidence, and Hard Questions in Duchenne Muscular Dystrophy | S Gavura
First Pig Lung to Human Transplant | S Novella
Breakthrough Heart Xenotransplantion from Pig | S Novella
Pig Heart Xenografts for Infants | S Novella
Ivermectin to Control Malaria — A Cluster-Randomized Trial | T Noonan
Science vs. Hype: The Unproven Promise of NAD+ IV Therapy | S Gavura
STATINS
Statins: The Impact of Negative Media Reports and the Risks of Discontinuing Treatment | H Hall
Statin Side Effects | H Hall
Statins for everyone? Not so fast. | S Gavura
New Study Finds that Statins Prevent Cardiovascular Deaths | S Novella
Can statins make you an asshole? | S Gavura
“New vaccine replaces statins?” Not So Fast! | H Hall
Statin Side Effects Revisited | H Hall
Review Recommends High Dose Statins | S Novella
The Cholesterol Wars Continue | S Novella
Are Cardiac Calcium CT Scans Useful? | S Novella
A closer look at penicillin allergies | S Gavura
G-Spot Discovered? Not So Fast! | H Hall
Progeria | H Hall
Vyleesi: New Drug for Hypoactive Sexual Desire in Women | H Hall
TENS for Pain Relief: Does It Work? | H Hall
Your gout, your fault? | S Gavura
Making Waves or Just Noise? A Look at Shockwave Therapy | S Gavura
An Alternative to Appendectomy: Antibiotics | H Hall
Appendicitis: Surgical vs. Medical Treatment | H Hall
Ian Harris on “Surgery, the Ultimate Placebo” | H Hall
The Apple Heart Study | C Labos
An Owner’s Manual for the Heart | H Hall
The Monoclonal Antibody Revolution | S Novella
Air Dryers vs Paper Towels | S Novella
Everlywell: At-Home Lab Tests That Don’t Make Sense | H Halll
Experts slam CAM lab tests, call for better regulation | J Bellamy
CHRONIC FATIGUE SYNDROME
IOM Recommends Replacing CFS with SEID | H Hall
Treating Chronic Fatigue Syndrome with Cognitive Behavioral Therapy and Graded Exercise Therapy: How the PACE Trial Got It Wrong | H Hall
A New Test for Chronic Fatigue Syndrome? | S Novella
Rituximab for Chronic Fatigue Syndrome: Jumping the Gun | H Hall
Chronic Fatigue Syndrome: Rituximab Revisited | H Hall
Health and Wellness Coaching: cautious optimism and some concerns | J Bellamy
Colonoscopy: More Misinformation from Mercola | H Hall
Hypnotherapy For Pain and Other Conditions | S Novella
NSAIDS AND ASPIRIN
Aspirin Risks and Benefits | S Novella
An aspirin a day to prevent heart attacks, strokes, and cancer? | S Gavura
Anti-inflammatory drugs and heart attacks: How real are the risks? | S Gavura
Anti-inflammatory drugs: A closer look at the risks | S Gavura
The evolving story of the harms of anti-inflammatory drugs | S Gavura
Do anti-inflammatory drugs effectively treat spinal pain? | S Gavura
Another way ibuprofen can kill us? | S Gavura
Salonpas | H Hall
Osteopenia: When Does Decreased Bone Density Become a Disease Requiring Treatment? | H Hall
Evenity for Osteoporosis | H Hall
Innovations in Blood Transfusions Will Save Lives | H Miller
PUBLIC HEALTH
Messaging and Public Health | S Novella
Science-Based Public Service Announcements | S Novella
Dr. Joseph Ladapo’s assault on public health in Florida: Will it be coming to the federal government next year? | D Gorski
Update on the Zika Virus | S Novella
Zika virus, microcephaly, and calls to bring back DDT (Rachel Carson revisionism edition) | D Gorski
Heat A Growing Public Health Problem | S Novella
The Health Costs of Fossil Fuel | S Novella
The Healthcare Costs of Fossil Fuels | S Novella
Air Pollution and Public Health | S Novella
The Health Effects of Air Pollution | S Novella
Do Helmets Prevent Head Injuries? | H Hall
Picking Cherries in Science: The Bio-Initiative Report | K Foster & L Trottier
Health Effect of Wind Turbines | S Novella
Don’t Text and Drive | S Novella
The cost of repealing mandatory motorcycle helmet laws | D Gorski
E-cigarettes: The growing popularity of an unregulated drug delivery device | D Gorski
Vape Nation: Vaping Is Bad, Kids | B MacBeth
Vaping is Bad: Respiratory Illness, Banning Flavors, and Bad Behavior | B MacBeth
Negative Health Effects of Vaping | S Novella
Smoking: The Good News and the Bad News | H Hall
Smoking Cessation | H Hall
Smoking Cessation and the Affordable Care Act | H Hall
Anti-Smoking Laws – The Proof of the Pudding | S Novella
The 4-Day Work Week and Health | S Novella
Delaying School Start Times for Sleep Deprived Teens | C Jones
Sleep Duration and Health | S Novella
Firearms as a Public Health Crisis | S Novella
Docs v. Glocks: government regulation of physician speech | J Bellamy
Gun Violence as a Public Health Issue | S Novella
AMA Decides Gun Violence is a Public Health Issue | S Novella
The adverse health effects of the lunacy that is Daylight Saving Time | D Gorski
Myopia Epidemic | S Novella
Zapping Antipsychiatry ECT Nonsense | B MacBeth
Flame Retardants Have Ignited a Flaming Controversy | H Hall
Are Humans Cooling? Probably Not. | C Jones
Reverse Ageing Hype | S Novella
Is Ageing a Disease That Can Be Cured? | S Novella
Aging: Is It a Preventable Disease? | H Hall
Cold reality versus the wishful thinking of cryonics | D Gorski
If You Think Doctors Don’t Do Prevention, Think Again | H Hall
Health Benefits of the Weekend Warrior | S Novella
Biohacking Backfires: When Self-Tracking Can Harm | S Gavura
In Pursuit of Patient Safety | J Thomas
Human Sex Determination: Psychic Sperm and the Gambler’s Fallacy….. | C Jones
Disparities in Regional Health Care Costs | S Novella
Motivation to Exercise in Mice | H Hall
Move | S Novella
The Data Is In – Exercise Is Good For You | S Novella
No evidence IV vitamin drips can treat infertility | S Gavura
Does “therapeutic ultrasound” actually work? | S Gavura
New Blood Pressure Guidelines: Why Are Previously Normal BPs Now Classified as High Blood Pressure? | H Hall
Signos Sells a Continuous Glucose Monitor, But Not to Diabetics | H Hall
Another ADHD Denier | S Novella
Dry Drowning | H Hall
The Marvelous Dr. Mütter | H Hall
DENTISTRY
Is Dentistry Science Based? | G Ritchey
The Wisdom of Third Molar Removal | G Ritchey
The Six Month Dental Recall – Science or Legend? | G Ritchey
Do You Need Daily Treatment to Repair Damaged Enamel? | H Hall
Mercury amalgam fillings and you | G Ritchey
Antibiotic Prophylaxis For Dental Procedures | G Ritchey
Dental X-rays and Brain Tumors — Oh My! | S Hendry
What’s in that tube? | G Ritchey
Pulp Fiction | G Rictchey
Preventing Tooth Decay in Kids: Fluoride and the Role of Non-Dentist Health Care Providers | C Jones
Antifluoridation Bad Science | S Novella
Fluoride: Still Not Poisoning Your Precious Bodily Fluids! | G Richey
Cochrane Review on Community Water Fluoridation | G Ritchey
Fluoride and IQ | S. Novella
The Fluoride Dragon Cometh! Or does he? | C Pearcey
Some Data on Fluoride | S Novella
May the Floss be with you? | G Ritchey
Dental Management Of Obstructive Sleep Apnea | G Ritchey
The Frenetic Frenum Freeing Frenzy | G Ritchey
Dr. David Villarreal’s “Holistic Dentistry:” Full of Holes? | H Hall
Cranial Osteopathy in Dentistry | G Ritchey
(Dys-)Functional Medicine Comes to Dentistry | G Ritchey
Journal of the American Dental Association Falls for Tooth Fairy Science | J Bellamy
The Sleep Bank | C Jones
Nobel Prize in Physiology or Medicine 2026 | S Novella
Science-Based Satire: Hiring a Doula for Dental Procedures | C Jones
Science-Based Satire: Alternative Medical Adverse Events on the Rise | C Jones
Science-Based Satire: NASA Teams with NCCIH to Study Alternative Medicine in Space | C Jones
Science-Based Satire: Florida Authorities Report First Case of Mosquito-Borne Fentanyl Overdose | C Jones
Science-Based Satire: A Powerful and Ancient Practice is Revolutionizing Medical Venipuncture | C Jones
PEDIATRICS
Pediatrics & “CAM” I: the wrong solution | Science-Based Medicine
Pediatrics & “CAM” II: just wrong | J Bellamy
Alternative Medicine and the Vulnerable Child | C Jones
Quackery for Kids | C Jones
Here be Dragons: Caring for Children in a Dangerous Sea of sCAM | J Snyder
Medical Lore in Modern Pediatric Practice | C Jones
Medical Neglect of Children | H Hall
Baby’s DNA in Mom’s Blood: Noninvasive Prenatal Testing | H Hall
The Science of Mom: A Science-Based Book about Baby Care | H Hall
Should the Incidental Discovery of Nonparentage be Disclosed? | C Jones
Is today’s generation of children “the sickest generation”? | D Gorski
The Business of Baby and the Monkey Business of Margulis | H Hall
The Bendectin Controversy Redux? | H Hall
The ACOG Releases Watered Down New Guidelines on Immersion During Labor and Delivery | C Jones
An Update on Water Immersion During Labor and Delivery | C Jones
Water Birth (Again) | H Hall
Vaginal Birth After C-Section: How Safe Is It? | H Hall
Lotus Birth: No Benefit, Plenty of Risk | C Jones
Hiccups: From Acupuncture to Quantum Touch | C Jones
Do Canadian Babies Really Cry the Most? | C Jones
Separating Fact from Fiction in Maternal-Fetal Medicine: Anti-D Immunoglobulin for the Prevention of Hemolytic Disease of the Fetus and Newborn | C Jones
The American Academy of Pediatrics Weighs in on “Alternative Perinatal Practices”: Part 1 | C Jones
The American Academy of Pediatrics Weighs in on “Alternative Perinatal Practices”: Part 2 | C Jones
The American Academy of Pediatrics has an Integrative Medicine Problem | C Jones
American Academy of Pediatrics Calls for End to Pediatric Codeine Use…Again | C Jones
Adverse Events Linked to Pediatric “Alternative Medicine” in the Netherlands | C Jones
Breastfeeding Improvement Initiatives May Increase Risk of Newborn Falls | C Jones
A Nuanced View on Breast vs Formula | S Novella
Questioning the Evidence for Breastfeeding | H Hall
Breast Milk Testing: Scaremongering, Not Science | H Hall
Using Intranasal Breast Milk to Treat Premature Infants with Intraventricular Hemorrhages | C Jones
Yes, You Can Swaddle Your Baby…But a Sleep Sack is Probably the Safest Option | C Jones
New AAP Policy on Circumcision | H Hall
Does acetaminophen during pregnancy raise the risk of behaviour problems? | S Gavura
Hitting Children in School: Bad? | C. Jones
Update: More Evidence Supports Delaying School Start Times for Sleep Deprived Teens | C Jones
Fever Phobia | C Jones
Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Umbilical Cord Blood Banking | C Jones
Separating Fact from Fiction in the Not-So-Normal Newborn Nursery: Undescended Testes in Babies | C Jones
Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Pacifiers and Nipple Confusion | C Jones
Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Vitamin K Shots….. | C Jones
Separating Fact from Fiction in the Not-So-Normal Newborn Nursery: Newborn Jaundice | C Jones
Separating Fact from Fiction in Pediatric Medicine: Facial Nerve Palsy | C Jones
Separating Fact from Fiction in Pediatric Medicine: Infant Teething | C Jones
Separating Fact from Fiction in Pediatric Medicine: Burping Doesn’t Prevent SIDS, and Other Gas Related Nonsense | C Jones
Separating Fact from Fiction in Pediatric Medicine: Infant Gastroesophageal Reflux | C Jones
More Evidence that Ignoring Safe Sleep Advice Puts Babies at Risk of Unexpected Death | C. Jones
Nightmares, Night Terrors and Potential Implications for Pediatric Mental Health….. | J Snyder
Peanut Allergy Prevention Advice Does a 180 | S Gavura
Cleveland Clinic Drops the Ball in an Attempt to Educate Parents on Safe Sleep | C Jones
Baby Translating Technology: Revolutionary Parenting Tool or Confirmation Bias Bonanza | C Jones
Amber Waves of Woo | J Snyder
Melatonin poisonings in children are increasing | S Gavura
Kangaroo Mother Care, Skin-To-Skin Contact, and the Risk of Sudden Unexpected Postnatal Collapse | C Jones
From the Vault: Infant Teething Myths and Misconceptions | C. Jones
Vitamin K Refusal – The New Anti-Vax | S Novella
Update on Vitamin K Refusal | S Novella
From the Vault: Newborn Vitamin K Shots Save Baby Lives | C Jones
The CDC and WHO Have Reported an Unusual Cluster of Severe Pediatric Hepatitis Cases | C Jones
More Data Supports Delayed Antibiotic Prescribing for Kids with respiratory infections | C Jones
Delabeling Penicillin Allergies: A Public Service Announcement from Science-Based Medicine | C Jones
Clinical Practice Guidelines: Cholesterol Tests for Children? | H Hall
More Evidence Supports Infant RSV Shot Safety and Effectiveness | C Jones
The 2022-2023 Respiratory Virus Season Hits Early and Hard: Part 1 | C Jones
The 2022-2023 Respiratory Virus Season Hits Early and Hard: Part 2 | C Jones
RSV Season is Here, So Where is Our Beyfortus? | C. Jones
A Common Virus Wreaks Uncommon Havoc in a New Jersey Nursing Home for Medically Fragile Children | C Jones
The Overuse of Antibiotics for Viral Infections in Children | Science-Based Medicine
Hospitals Slow to Adopt Pediatric Pneumonia Guidelines | C Jones
Nirsevimab is Great News for Infants, Caregivers, and Exhausted Pediatricians | C Jones
Home birth tragedies lead to changes in Oregon | J Bellamy
Vaginal Seeding. Ew. That’s nuts. Hmmm, interesting. | M Crislip
Vaginal Seeding: To Swab or Not to Swab Your Newborn Baby | C Jones
Cases of Newborn Syphilis are Increasing at an Alarming Rate | C Jones
More Newborns are Being Diagnosed With Syphilis as Adult Cases Continue a Dramatic Rise | C Jones
Pediatric Hepatitis, A Medical Rorschach Test | J Howard
Separating Fact from Fiction in the Newborn Nursery: Hepatitis B Vaccine for Newborns | C Jones
CDC Data Reveals Frustrating Infant Death Statistics | C Jones
U.S. Infant Mortality Increases for First Time in 20 Years | C Jones
A Rational Approach to Managing Acute Pain in Children | C Jones
Audio Therapy for Postoperative Pediatric Pain: Randomized Controlled Nonsense | C Jones
The Buzzy: Revolutionary Acute Pain Management or Simple Distraction… | C Jones
Music for Reducing Pain in Newborns | C. Jones
Efforts to Encourage Breastfeeding Like the Baby-Friendly Hospital Initiative (BFHI) May Have Unintended Consequences | H Hall
A Nice Chat with The Infant Feeding Alliance on Breastfeeding Promotion Pitfalls | C Jones
CDC Warns Against Honey Pacifier Use After 4 Texas Infants Develop Botulism | C Jones
Pertussis Cases are Rising Sharply in 2024 | C Jones
A Perhaps Not-So-Unexpected Spike in Pediatric Brain Abscesses C Jones
A Desperate Choice | H Hall
CDC Issues Warning: Be on the Lookout for a Surge in Pediatric Paralysis Cases This Fall | C Jones
CDC Issues Warning as the Virus Associated with a Rare Polio-Like Illness in Children Returns | C Jones
The Shocking Link Between a Popular Toy Company and Preventable Infant Deaths | C Jones
Infant and Toddler Swimming Programs: Are They Safe and Effective? | C Jones
Summer is Here, and Infant Swimming Programs are Still Unproven | C Jones
Drowning Deaths Continue Post-Pandemic Rise | C Jones
More Marijuana More Problems for Young Children | C Jones
More Marijuana More Problems for Young Children Part 2: Additional Problems for the Aforementioned Children | C Jones
Young Children are Ingesting Dangerous Batteries at an Alarming Rate | C Jones
New Study Reveals Increase in Babies Injured by Nursery Products | C Jones
Think Twice Before Giving Young Children Reflux Medications | C Jones
A Medical Myth: The Centers for Disease Control and Prevention has quietly changed their standards for early childhood development | J Howard
Separating Fact from Fiction in Pediatric Medicine: Nocturnal Enuresis | C.Jones
Inappropriate Antibiotic Use is Rampant in U.S. Pediatric Hospitals | C Jones
Separating Fact from Fiction in Pediatric Medicine: Ear Infections | C Jones
A Popular Class of Antibiotics May Increase Risk of Birth Defects | C Jones
Seizure Medications Safer Than Previously Thought for Breastfed Babies | C Jones
Corporal Punishment in the Home: Parenting Tool or Parenting Fail… | C Jones
Psychic Mediums and Grieving Children | S Novella
Pseudoscience in Child and Adolescent Psychotherapy | H Hall
A British Teenager is Blind, But Not Because of Junk Food or “Fussy Eating” | C Jones
New Research Reveals a Startling Increase in Pediatric Foreign-Body Ingestions | C Jones
Rabies Claims the Life of a 6-Year-Old Florida Child: The Tragic Case of Ryker Roque | C Jones
Have Researchers Developed a Potential Microbial Miracle for Phenylketonuria Patients? | C Jones
Topical Barley Flour for the Management of Newborn Jaundice: A Real Study Done by Actual Pediatricians | C Jones
“Hands On Learning Solutions”: Untested Solutions for Problems That May Not Even Exist | H Hall
The Windi: Revolutionary Relief for Colic or a Pain in the Butt | C Jones
Science-Based Satire: 8th Edition of the Neonatal Resuscitation Program to Address Tongue-Tie | C Jones
Science-Based Satire: American Academy of Pediatrics Releases New Guidelines on Corporal Punishment | C Jones
Science-Based Satire: Pacifier Vaporizer Manufacturer Denies Marketing to Infants | C Jones
Science-Based Satire: More Parents Relying on Fetal Body Language Analysis | C Jones
Science-Based Satire: Area Child Killed by Unwieldy Backpack | C Jones
Science-Based Satire: More Parents Turn to Kinesiology Diapers for Fussy Infants | C Jones
Science-Based Satire: Integrative Baby Monitor Combines the Best of Conventional and Alternative Features | C Jones
Science-Based Medicine Reviews: Medicine, Public Health, Dentistry and Pediatrics
A Critical Guide for the Health Practitioner and Consumer 
2025 Edition

Executive Editor Steven Novella MD
Managing Editor David Gorski MD PhD
Series Editor Mark Crislip MD

   Introduction
Steven Novella
The world of health care is becoming an increasingly complex and challenging place. The internet is changing the way we generate and access information, and health information is one of the most popular uses of the internet. It represents an unprecedented democratization of information and opinion. 
While there are many advantages and benefits to such information access, there are also many challenges to health professionals, regulators, academics, and consumers. There is a proliferation of health related products and services, with many provocative health claims. Regulations are generally not keeping up, and often have been watered down, in the face of this onslaught of claims and products. 
The consumer is left with an overwhelming array of health claims, many of which challenge and even directly oppose the traditional experts and institutions. 
The mission of Science-Based Medicine (SBM) is to be a source of reliable information and analysis to help navigate the wild west of health information on the internet and elsewhere. The authors who contribute to this series of e-books are all physicians and other health care professionals who have a great deal of experience educating the public about complex medical issues. We especially take on controversial issues and try to expose pseudoscience and fraud wherever possible.
The Philosophy of Science-Based Medicine
The philosophy of SBM, at its core, is simple: Safe and effective health care is critical to everyone’s quality of life; so much so that it is generally considered a basic human right. Therefore, health care products and services that work and are safe are better than those that do not work or are unsafe. 
The best method for determining which interventions and health products are safe and effective is, without question, good science. Therefore it is in everyone’s best interest for health care to be systematically evaluated by the best science available.
Too often the nature of science itself is misunderstood or misrepresented to the public. Science is not an arcane and privileged discipline. By its very nature it is meant to be transparent and public. Science is nothing more than a systematic and careful use of evidence and logic to evaluate factual claims. And good science possesses certain virtues that are not unique to science but generic to all intellectual endeavors: fairly accounting for all available evidence, using valid and internally consistent logic, using unambiguous concepts and language, proper use of statistics, being quantitatively precise and accurate, and above all being honest.
And yet there are numerous and powerful influences in society that strongly appose the scientific basis of medicine. Driven by some combination of ideology or the desire for profit they wish to eliminate standards of science in health care, or (often under the guise of “health care freedom”) create a double standard in which unscientific methods and products can thrive unchecked. Others simply lack the training or knowledge to achieve minimal standards of quality for scientific medicine. And even the best traditions of scientific medicine can benefit from more critical analysis.
Recognition of the need for careful scientific analysis in medicine partly stems from a recognition that it is very difficult (almost impossible) to reliably assess treatments anecdotally. Human perception, memory, and cognition are prone to a host of flaws, weaknesses, and biases that will tend to mislead us, especially towards conclusions that we wish to be true. Placebo effects, confirmation bias, and simple statistics can make any intervention seem effective, even when they are worthless or harmful. 
Science-Based Medicine vs Evidence-Based Medicine
Within the practice of medicine there is already a recognition of the need to raise the standards of evidence and the availability of the best evidence to the practitioner and the consumer – formalized in the movement known as evidence-based medicine (EBM). 
EBM is a vital and positive influence on the practice of medicine, but it has its limitations. EBM tends to focus on clinical trial results to the exclusion of scientific plausibility. The focus on trial results (which, in the EBM lexicon, is what is meant by “evidence”) has its utility, but fails to properly deal with medical modalities that are highly implausible, or seem to defy well-established findings in science.
All of science describes the same reality, and therefore it must (if it is functioning properly) all be mutually compatible. Collectively, science builds one cumulative model of the natural world. This means we can make rational judgments about what is likely to be true based upon what is already well established. This does not necessarily equate to rejecting new ideas out-of-hand, but rather to adjusting the threshold of evidence required to establish a new claim based upon the prior scientific plausibility of the new claim. Failure to do so leads to conclusions and recommendations that are not reliable, and therefore medical practices that are probably not safe and effective.
The SBM Series
This is why the authors of this series strongly advocate for science based medicine – the use of the best scientific evidence available, in the light of our cumulative scientific knowledge from all relevant disciplines, in evaluating health claims, practices, and products. 
Some of the articles here will analyze individual studies, and explore the strengths and weaknesses of their methods, separating what the study really tells us from how it may be represented in the media. Other articles will summarize what many studies tell us about a specific medical question. 
We will also explore health information on the internet, separating out which information is reliable from that which is misleading, erroneous, or possibly even fraudulent. Likewise we will critique mainstream media coverage of health topics, giving the reader specific tools for to critically analyze health information for themselves.
Other articles will explore topics related to health regulation and academia. Regulations have struggled to keep up with the rapidly changing health care market place, with critical gaps that leave the health care consumer responsible for their own protection. Academic institutions themselves, long the defenders of high standards of scholarship in all fields, including medicine, have been infiltrated by promoters of pseudoscientific belief systems. The result is that there is no longer any single reliable guarantee of scientific integrity. 
The SBM series of e-books is organized by topic, such as acupuncture, chiropractic, homeopathy, and many others. The books are collections of essays, not intended to be a systematic reference, but rather to explore the various scientific issues related to each topic. The goal is to give the reader critical thinking skills and a deeper understanding of, not just the current findings of science, but the process of science, specifically how it relates to health care and the topic of each book. 
Science-based medicine can serve as your pocket guide through the wilderness of health information.

As of 2025, there are over 5000 essays on the Science Based Medicine website. I do no know about you, but I find it difficult to find any post I wrote, much less one written by another contributor. 

So I have updated the books and include almost all the articles through 2025. The volumes are

CAM Concepts
Chiropractic
COVID 
Critical Thinking
Diet and Nutrition
Ethics and CAM
Herbs, Supplements, and Diet
Homeopathy
Infections and Immunity
Law and CAM
Media and Internet
Medicine, Public Health, Dentistry and Pediatrics
Miscellaneous CAM
Naturopathy
Neurology and Psychiatry
Placebo
Quackademic Medicine
Regulation. FDA and FTC
SBM or EBM
Stem Cells, Genetics, AI and Gender
Supplements, Vitamins and Herbs
Vaccine & Anivax
Vaccines and Autism
Vaccines and Preventable Infections

The articles are roughly organized by publication date and topic. Many articles will be in multiple volumes as an essay of, for example, chiropractic and law will be found in both the chiropractic volume and the law volume.

You may find the organization a bit odd. I do. But 4700 plus articles are difficult to organize and I have more to do in my retirement than work of these volumes.

Still, if you find I have missed a nentry or some glaring error, drop me a note and I will fix it for the next edition.

About the authors
Steven P. Novella, MD – Founder and Executive Editor Science Based Medicine.
Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD.
David H. Gorski, MD, PhD – Managing Editor. Science Based Medicine.
Mark A. Crislip, MD. Editor, Science Based Medicine Guides. 
He did he editing of all the volumes so is to blame for any mistakes.
As to all the other contributors, if you are interested click on the ‘Link’ at top of each essay to go the SBM site, where further information about each author can be found.
A Note On References

The chapters in this book were originally blog entries at ScienceBasedMedicine.org.
Blog and web pages lend themselves to hyperlinks to sources and references that are tedious to translate into footnotes for this ebook.
Under the title of each essay is a hyperlink, cleverly titled ‘Link’, to the original blog entry with all the hyperlinks and references, as well as the comments to the blogs, which often have interesting and thoughtful insights by our readers, as well as some curious comments by the not so thoughtful.
Graphs, tables and links to videos are not in included these essays due to issues of copyright and permission. However, thanks to the ‘Link’, the graphics are a click away.
Thanks for reading the site.
Mark Crislip 






Hormones


RISUG: Birth Control for Men
Harriet Hall on May 15, 2012
Link
According to an enthusiastic article on the Internet, “The Best Birth Control In the World Is For Men.”
It’s called RISUG: Reversible Inhibition of Sperm Under Guidance. It involves a minor surgical procedure in which the vas deferens is exposed and pulled outside the scrotum by the same techniques used for a vasectomy. A copolymer, powdered styrene maleic anhydride (SMA, for which the method was previously named) combined with dimethyl sulfoxide (DMSO) is then injected into the vas deferens. The polymer coats the walls of the vas and kills the sperm as they swim by. The mechanism is not understood, but the developer thinks the polymer’s mosaic of positive and negative charges causes the membranes of the sperm to burst, rendering them immotile.
RISUG is rapidly effective: in a phase II clinical trial in India, viable sperm were absent as soon as 5 days after the procedure. They say there have been no pregnancies in the first months “other than a handful of cases in which the RISUG was not injected properly.” (One wonders how they determined that it was not injected properly: by the fact that pregnancy occurred? Could this be just a rationale to explain away failures? Or to spare patients the embarrassment of discovering the wife had another sperm donor?) The contraceptive effect is said to last for a decade or more; it might require repeat injections every 10 years.
In contrast to vasectomy, RISUG can be reversed by injecting DMSO or bicarbonate and using a combination of vibration, a low electric current, and rectal massage to dislodge the polymer and move it through the vas deferens.
It is not yet approved in India, but it has already been patented in several countries. Efforts are underway to seek FDA approval in the US under the name Vasalgel, but don’t look for it on the market anytime soon: preliminary studies on rabbits are just getting started. 
It sounds crazy, but there is evidence to support it. A search for RISUG on PubMed brings up 18 articles. Some are lab studies, some are not directly relevant, and some are reviews of contraceptive methods; but there are a couple of very encouraging studies in monkeys and a report of a phase II human trial with 12 subjects. 
An article in Wired calls it the revolutionary new birth control method for men and includes a video so you can watch the actual procedure. It says:
It’s the brainchild of a maverick Indian scientist named Sujoy Guha, who has spent more than 30 years refining the idea while battling bureaucrats in his own country and skeptics worldwide. He has prevailed because, in study after study, RISUG has been proven to work 100 percent of the time. Among the hundreds of men who have been successfully injected with the compound so far in clinical trials, there has not been a single failure or serious adverse reaction. The procedure is now in late Phase III clinical trials in India, which means approval in that country could come in as little as two years.
There are some worrisome red flags here: lone genius, battling the establishment, reference to “study after study” when Phase III trial results are still pending, and the claim that it is 100 percent effective. No contraceptive measure is 100 percent effective, not even hysterectomy: abdominal pregnancy can occur even after a total abdominal hysterectomy.
Conclusion
RISUG may be a promising means of birth control for males, but it’s too early to draw any conclusions. The current media hype is unwarranted. Science will have to run its course and complete well-designed clinical trials before the method can be recommended.

“Female Viagra?” Misleading Headlines and Regulatory Dilemmas
Harriet Hall on September 29, 2015
Link

The FDA recently approved flibanserin (brand name Addyi) for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The story of flibanserin illustrates several of the issues we have confronted on this blog:
    • It was hyped in the media.
    • Misleading headlines called it the female Viagra.
    • It was initially rejected by the FDA and was approved only after extensive lobbying efforts.
    • The drug is only minimally effective and has a lot of drawbacks.
    • Two of the three supporting scientific studies claimed effectiveness based a surrogate measure but failed to show any measurable improvement in sexual desire.
    • A campaign to support “women’s sexual health equity” pushed for approval, framing it as a step towards correcting what they perceived as gender bias (they claimed the FDA was biased because it had provided Viagra to help men have sex but hadn’t done anything to help women have sex).
    • And the validity of the diagnosis of HSDD itself has been questioned.
What is HSDD?
According to the official diagnostic manual, DSM-5, the diagnosis of hypoactive sexual desire disorder requires:
lack of, or significantly reduced, sexual interest/arousal, manifesting as at least three of the following symptoms: no or little interest in sexual activity, no or few sexual thoughts, no or few attempts to initiate sexual activity or respond to partner’s initiation, no or little sexual pleasure/excitement in 75%-100% of sexual experiences, no or little sexual interest in internal or external erotic stimuli, and no or few genital/nongenital sensations in 75%-100% of sexual experiences. Symptoms must persist for at least six months, cause clinically significant distress, and not be better explained by another condition. Simply having lower desire than one’s partner is not sufficient for a diagnosis. Self-identification of a lifelong lack of sexual desire as asexuality precludes diagnosis.
Other drugs for sexual dysfunction
HSDD has been treated with testosterone and Bupropion. There is some evidence that they can be effective for some women, but they are not without drawbacks. Testosterone has been recommended to increase desire in men, but it probably only helps those whose testosterone levels are abnormally low. Drugs like Viagra are effective for erectile dysfunction in men, but they don’t increase sexual desire. They are used by men whose libido is working just fine but who are unable to sustain an erection. Viagra (sildenafil) works by increasing blood flow to the penis when there is sexual stimulation. It also increases blood flow to the genital area in women, and studies have shown increased sexual satisfaction in postmenopausal women who complained of sexual arousal disorder, but that’s not the same thing as HSDD. Other treatments for HSDD have included individual and couples counseling, education, and stress reduction.
What is flibanserin?
The new drug is the first to be approved for the treatment of HSDD. It was originally investigated for depression. The mechanism of action is not known, but it is thought to affect sexual response by increasing dopamine and norepinephrine activity and reducing serotonin activity in the central nervous system.
In two clinical trials, 45% and 39% of participants reported a meaningful benefit from the drug compared to 35% and 27% from placebo. The results suggested that ten women would need to be treated to benefit one. It increased the average number of satisfying sexual events, but only by one a month, and only after 4 weeks of daily treatment. In those trials, there was no significant difference in desire. In a subsequent third study using different questionnaires, they were able to demonstrate significant increases in desire and decreases in the distress associated with low desire.
Side effects included drowsiness, hypotension, fainting, dizziness, nausea, fatigue, insomnia, and dry mouth.
Regulatory history
The 291-page FDA Advisory Committee Briefing Document is available online.
In 2010, an FDA committee voted 11 to 0 that the overall benefit-risk balance had not been sufficiently established due in large part to failure to reach statistical significance on the pre-specified endpoint of sexual desire. Approval was denied.
In 2013, additional studies were submitted to the FDA with more data on sexual desire assessments, safety, and interactions with alcohol and other drugs. Approval was again denied. The FDA accepted that efficacy had been established; but safety questions remained, and they didn’t feel that the modest benefits justified approval. A Formal Dispute Resolution was filed, requiring further study to determine whether the drug impaired driving ability.
The FDA held a 2-day public workshop to obtain patient and expert views. They investigated “other indicators of meaningfulness.” A lobbying group was formed with the name “Even the Score: Women’s Sexual Health Equity.” A petition was sent to the FDA and letters written to congress calling for gender equity in drug approval. Lobbyists used slick PR materials. The “patient perspective” became part of the approval process.
On June 4, 2015, the FDA Advisory Committee recommended approval: 18 members voting to recommend approval but insisting on label warnings and other management measures, and 6 members voting against approval. Several members who voted “yes” said they did so with great misgivings because of the drug’s modest benefit and possible side effects.
On August 18, 2015, the FDA approved the drug for marketing. But it did so only with some extraordinary precautions. The label includes a boxed warning that users should not also consume alcohol and that the drug should be avoided by women with liver disease and by those taking drugs that are CYP3A4 inhibitors. Only prescribers and pharmacists certified through an online course will be allowed to prescribe this medication.
The FDA is requiring the company that makes Addyi (Sprout Pharmaceuticals) to conduct three well-designed studies in women to better understand the known serious risks of the interaction between Addyi and alcohol. And to top it all off, the company promised the FDA that they would not advertise the drug on radio or television for the first 18 months after it went on the market. I don’t remember hearing a similar restriction for any other drug; isn’t that an unusual provision?
Backlash
Some women’s groups criticized Even the Score as a distasteful attempt to use women’s rights as a cover to get an undeserving drug approved. One doctor said “To approve this drug will set the worst kind of precedent — that companies that spend enough money can force the F.D.A. to approve useless or dangerous drugs.” She called flibanserin “a mediocre aphrodisiac with scary side effects.” She said that the clinical trials were restricted to healthy women, but that if approved the drug would be used by a wider range of women, resulting in “an epidemic of adverse events.” The FDA was accused of having succumbed to “emotional blackmail,” valuing the comments of lobbyists and patients over the science. The satirical paper The Onion reported that the FDA had approved a new female-libido-enhancing man named Gabriel. Using him every day was shown to activate the regions of the brain associated with pleasure, increase blood flow to the genitals, and boost instance of orgasm by almost 40 percent. He was promoted as a safe, effective option, but it was noted that he became less effective when mixed with alcohol.
Questioning HSDD
The DSM diagnosis of HSDD has come under criticism. It is little more than a convenient label that serves as a starting point to investigate what are probably a number of diverse causes of the included symptoms. There is a lot of normal variation in human sexuality, and asexuality may be a normal variant rather than a mental disorder. Both the social function of the diagnosis and the scientific and clinical criteria have been questioned.
Conclusion: Controversial and questionable
The approval of flibanserin is being applauded in some quarters and censured in others. Subjectively, the drug will help some patients experience more desire and less distress from lack of desire, but objectively it can only be expected to provide 10% of the patients who try it with one additional satisfying sexual event per month (masturbation included). This raises a lot of questions. Should every drug with a similarly low effect size and a similar benefit/risk ratio be approved, particularly for conditions that are not life threatening? Was approval based on public opinion rather than on science? When is it appropriate to approve a drug that requires warning labels and other risk-reduction measures? Is the FDA doing a good job? Should the media have reported the story differently? What do you think?

Hormone Replacement Therapy for Menopausal Symptoms: Setting the Record Straight
Harriet Hall on May 17, 2016
Link

Whether you call them hot flashes or “power surges,” the symptoms of menopause can be very distressing. They were routinely treated with hormone replacement therapy (HRT) until the Women’s Health Initiative study in 2002 persuaded many patients and doctors to abandon that treatment. The results of that study were misunderstood by some and questioned by others, and there continues to be confusion about what the evidence shows and how menopausal symptoms should be treated. We have learned much more about this subject since 2002. HRT is still the most effective treatment and can be used safely under the new treatment guidelines.
The history of hormone replacement therapy
In the second half of the 20th century, there was much enthusiasm about estrogen. Mimicking the estrogen levels of a young woman was seen as a way to remain young and healthy. Doctors recognized that there were risks, but they seemed minor. There were studies showing that HRT protected women from the increased risk of heart disease after menopause. Few if any doctors prescribed it solely to prevent heart disease, but cardiovascular protection and osteoporosis prevention were seen as added benefits that served to tip the balance towards a decision to prescribe it for menopausal symptoms.
Then the Women’s Health Initiative study (WHI) dropped a bomb. It found that HRT didn’t protect women from cardiovascular disease after all. It showed that HRT did more harm than good. The number of prescriptions dropped by as much as 80%. Many women turned to alternative treatments that had not been studied anywhere near as extensively as HRT.
The Women’s Health Initiative study
The WHI found that women who took HRT were more likely to develop coronary heart disease, stroke, deep-vein thrombosis (blood clots), and breast cancer. That was the message that came out in the media, quickly followed by accusations that doctors had been killing women by prescribing HRT. That was flat wrong: there was no difference in all-cause mortality between women who took HRT and women who didn’t. And they found benefits: there was a significant reduction in the risk of colorectal cancer and osteoporotic bone fractures.
The study’s findings were far more nuanced than the media reported. The WHI study was really two separate studies, of estrogen and of combined estrogen/progesterone. Women with an intact uterus shouldn’t take estrogen alone because unopposed estrogen stimulation can cause endometrial cancer. But by age 60, one-third of women have had a hysterectomy, and they can be treated with estrogen alone. The greatest risks were found in women who took combination estrogen/progesterone. When estrogen was used alone, the risks were considerably less.
As the data were analyzed and reanalyzed, it became clear that the patient’s age makes a difference. Taking estrogen close to the time of menopause caused little harm and provided a number of benefits. This graph is from a 2016 Perspective article in The New England Journal of Medicine.

It shows the data for women 50-59 who took combination HRT (panel A) or who took estrogen alone (panel B). Red is bad, blue is good. You will probably be surprised at the amount of blue. For estrogen alone, HRT only increased the risk of deep vein thrombosis while it decreased the risks of coronary heart disease, stroke, breast cancer, colorectal cancer, all cancers, all fractures, death from any cause, and diabetes. For combined therapy there were four areas of increased risk, but treatment decreased the risk of colorectal cancer, all cancers, all fractures, death from any cause, and diabetes.
HRT recommendations
Numerous professional organizations have examined the evidence and come up with new treatment guidelines. The “2012 Hormone Therapy Position Statement of the North American Menopause Society” provides a good overview of the evidence and concludes:
Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years. [ET = estrogen therapy, EPT = estrogen/progesterone therapy.]
It stresses individualization of treatment and consideration of personal risk factors.
Bioidentical hormones
Today, 35% of current hormone users are taking bioidentical hormones from unregulated compounding pharmacies, despite concerns about contamination and dose consistency, and despite the lack of evidence for their safety and effectiveness. “Bioidentical” is something of a misnomer: they are “identical” only to one or two of the long list of sex hormones in a woman’s body, and there’s no way they could mimic the complex dance of all those hormones as their levels fluctuate naturally over hours and days.
For a good overview of bioidentical hormones, see the position statement of The Endocrine Society. Their findings are summarized in this table (click to embiggen):
Non-hormonal treatments for menopause
The North American Menopause Society has a position paper on non-hormonal management for women who are unable or unwilling to take hormones:
    • Recommend: cognitive behavioral therapy, hypnosis, paroxetine, and possibly a few other prescription drugs
    • Recommend with caution: weight loss, mindfulness-based stress reduction, soy isoflavones, and stellate ganglion block
    • Do not recommend: cooling techniques, avoidance of triggers, exercise, yoga, paced respiration, relaxation, over-the-counter supplements and herbal therapies, acupuncture, calibration of neural oscillations, and chiropractic interventions.
Conclusion: Once again, the media got it wrong
Hormone replacement therapy fell into disfavor following the Women’s Health Initiative study, in part because the results were poorly reported by the media and were widely misunderstood. HRT remains the most effective and best-studied treatment for hot flashes, and the benefits outweigh the risks if treatment is individualized, if it is started close to the time of menopause, and if it is used for a limited period. It has significant benefits for a number of other health conditions like osteoporosis, and in the 50-59 year age group it appears to reduce all-cause mortality.

Estrogen Matters
Hormone replacement therapy in menopause is safer and more effective than we have been led to believe. A new book examines the evidence and sets the record straight.
Harriet Hall on September 4, 2018
Link

Estrogen replacement stops hot flashes cold and is a veritable Fountain of Youth. Estrogen replacement is dangerous: it kills women. It prevents heart disease. It causes heart disease. The message keeps changing. What are we to believe?
Avrum Bluming is an oncologist whose practice has been 60% devoted to breast cancer. Carol Tavris is a social psychologist, feminist, and skeptic who writes the column “The Gadfly” for Skeptic magazine and whose many books include the classic Mistakes Were Made (But Not by Me). They were alarmed by the many misunderstandings about menopausal hormone replacement and they collaborated to set the record straight with an extensively referenced new book, Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women’s Well-Being and Lengthen Their Lives – Without Raising the Risk of Breast Cancer.
Background
Back when I was practicing in the 1970s and 80s, it was standard practice to offer menopausal women replacement hormones. But doctors were not prescribing willy-nilly. The evidence at that time showed that it was by far the most effective treatment for hot flashes and other menopausal symptoms. The evidence at that time showed that estrogen reduced the risk of osteoporosis and heart disease. In my experience, it was not being prescribed just to prevent those diseases, but prevention was seen as an extra added benefit for women who needed estrogen to control menopausal symptoms. There was a small risk of blood clots and other adverse effects, but the benefits were thought to outweigh the risks.
Hormone replacement therapy (HRT) came in two flavors. Women with an intact uterus were given a combination of estrogen and progestin, since unopposed estrogen was known to cause cancer of the uterus. Women who had had a hysterectomy could safely take estrogen alone (ERT). Estrogen was contraindicated for women who had had breast cancer.
As of the 1990s, the evidence indicated that estrogen reduced the risk of heart disease by 40-50%, hip fractures by 50%, colon cancer by 50%, and Alzheimer’s by 35%.
A 1997 article estimated HRT would prolong life by 3 years.
The Women’s Health Initiative (WHI)
Then came a bombshell. In 2002, the results of the WHI study were trumpeted in headlines with the message “OOPS! We were wrong. Hormones do more harm than good!” They were essentially saying “Hold your horses!” (an apt expression since the most commonly prescribed estrogen, Premarin, is made from pregnant mares’ urine).
This study had a huge impact because it was a gold standard study: large, randomized, prospective, placebo-controlled, and double-blinded. Subjects were randomized to receive either hormones or placebos and were followed for 15 years. It was published in one of the most prestigious medical journals. The study was stopped early when it detected an increase in breast cancer, coronary heart disease, stroke, and pulmonary embolism in women taking estrogen and progestin. The study was seen as definitive evidence that HRT was dangerous, that the risks outweighed any benefits.
Thousands of women were scared into going off their hormones. Sales of Premarin dropped from $2 billion to $880 million. Some of these women tried other remedies and then went back to Premarin because it was the only thing that worked for them. Doctors learned to prescribe more selectively, and sales started rising again. The new mantra was “the smallest dose for the shortest time”.
What did the WHI really show?
The media misrepresented and misinterpreted the WHI findings, giving the impression that HRT was killing women. Not so. Over 10,000 person-years, women on estrogen plus progestin had 7 more coronary events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers than women who didn’t take hormones; but they also had 6 fewer colorectal cancers and 5 fewer hip fractures. In the estrogen-only group, there was a decreased risk of coronary heart disease and breast cancer. And in both groups there was no increase in overall mortality. These women were getting more of some diseases and less of others, but they weren’t dying any faster.
Over the years since the initial report, there have been a number of follow-up studies of the same cohort of women, introducing nuance and even reversing some of the findings. Bluming and Tavris report those findings in detail and they describe how the original WHI study was flawed.
Menopausal symptoms
Many troublesome symptoms are reported by menopausal women: hot flashes, loss of sexual desire, painful intercourse because of vaginal dryness, difficulty sleeping, palpitations, unexplained and uncharacteristic anxiety attacks, difficulty concentrating, fuzzy thinking, and more. DeLuca’s book The Hormone Myth questions how many women experience these symptoms and to what degree. And whether all of those symptoms are really due to low hormone levels or might be due to other factors in their lives. It’s undeniable that some women do experience severe menopausal symptoms that interfere with their activities and reduce their quality of life, and that estrogens are by far the most effective treatment. The WHI did not address these symptoms at all; in fact, the WHI patients averaged 63 years of age, past the age when menopausal symptoms are most likely. Surely relief of debilitating symptoms should be factored into any discussion of the risk/benefit ratio for an individual patient.
Breast cancer
By 2000, numerous studies had shown that estrogen did not increase the risk of breast cancer, not even in high-risk BRCA1 patients; in fact, there was evidence that it reduced the risk.
The fear of breast cancer rested on two studies:
     1.  1989 study in Sweden showed 440% increase in risk of breast cancer among women who had been on HRT. But it found no increased risk in women taking estrogen alone. And the 440% was based on 10 women who developed breast cancer instead of the expected 2.2. With such small numbers, it could have been a statistical fluke. And it was not even statistically significant!
     2.  1997 Lancet study showed no significant increase in breast cancer among women who had taken HRT in the past, no matter how long they had taken it. But it found an increased risk in women who were still taking HRT and had used it for 5 or more years. The increased risk was small: 0.6 cases per 100 women after 10 or more years.
The Women’s Health Initiative found a 26% increase in risk of invasive breast cancer in women taking combined estrogen and progesterone. But the fine print said that the 26% figure “almost reached nominal statistical significance.” In other words, there was no significant increase. And there was no increased risk in women taking estrogen alone, not even a non-significant increase.
The WHI continued to do follow-up analyses and publish updated findings:
    • In 2006 a follow-up analysis of the same cohort of women found no increased risk with combined estrogen-progesterone treatment. This time, the news didn’t make headlines.
    • In 2008, another follow-up found a nonsignificant increase in all-cause mortality and no increased mortality from breast cancer.
    • In 2010, another follow-up showed an increase in breast cancer deaths (2.6 vs. 1.3 per 10,000) in women on HRT compared to placebo. But this was not statistically significant.
    • In 2018, the WHI investigators announced that the dose of estrogen in vaginal creams is not associated with an increased risk of breast cancer
The Million Women Study followed, reporting an increase in breast cancer with both estrogen alone and combined estrogen/progestin. But only in current users, not past users. Bluming and Tavris ask, “If estrogen is a major risk factor in breast cancer, why would having taken it for years not be a problem but taking it at the time of study be a risk?” Birth control pills contain the same hormones, and most studies have shown no association with breast cancer. And survival rates for women with breast cancer are higher if they were taking oral contraceptives at the time of diagnosis.
They provide a table of risk factors that have been associated with breast cancer. Estrogen reduces risk (0.77 relative risk), the WHI reported an increase in risk with estrogen and progesterone (1.24 or 1.26 relative risk). Other things that increase risk include fish intake (1.14), multivitamin use (1.19), alcohol (1.26), French fries (1.27), night shift work (1.51), increased carbohydrate intake (2.22), left-handedness (2.41), and electric blanket use (4.90).
They go on to discuss research pitfalls like data mining and substratification analyses, which in one case led to the finding that aspirin had an adverse effect on mortality for patients born under the astrological signs of Gemini and Libra but was beneficial for patients born under all other signs. A 2000 study from the National Cancer Institute found no increased risk with estrogen alone, and an increased risk with combined therapy, but only in women who had used hormones in the four years prior to diagnosis and who weighed ninety pounds or less.
Even though some research indicates a 2% increase in breast cancer, other research shows that women on HRT live longer and have a lower death rate from breast cancer.
They stress that correlation is not causation. So how can we approach the mosaic of findings with breast cancer? They show how each of the Bradford Hill criteria for causation supports the finding that smoking causes lung cancer. Then they show that the hypothesis that estrogen causes breast cancer fails to meet any of the Bradford Hill criteria.
They say, “it is time to relegate the “common knowledge” that ERT and HRT cause breast cancer to the dustbin of discredited ideas along with the theories that radical mastectomy is the best treatment for primary breast cancer, that anger causes peptic ulcers, and that stress causes tuberculosis.”
Osteoporosis
They explain that bone density (as measured by DEXA) is not the same as bone resilience (a more clinically meaningful factor that can’t be measured). Osteopenia has no medical meaning; it doesn’t predict risk of hip fracture. The authors chastise Big Pharma for promoting medications that are less effective and cause more side effects than estrogens. Meds like Fosamax should be used for osteoporosis, not osteopenia. The bisphosphonates can even cause hip fractures.
No therapy is more effective than ERT and HRT in preventing osteoporotic fractures of the spine and hips. It reduces risk by 33-50%. But it requires ten years and possibly lifelong treatment. Women age 65-74 had a 63% reduction in hip fractures, but if they stopped taking estrogen the reduction quickly dropped to 18%.
Bluming and Tavris don’t recommend estrogen for osteoporosis prevention in all women: the vast majority will not develop osteoporosis or die from it. But the research is persuasive that high-risk women would benefit from continuing to take estrogens.
Alzheimer’s disease
Alzheimer’s disease is common and devastating, and the available treatments only ameliorate some of the symptoms but do nothing to slow the progression of the disease. There is evidence that we already have a powerful preventive: decades of research have indicated that estrogen helps preserve the cognitive ability of postmenopausal women and reduces the risk of Alzheimer’s.
In 2003, the WHI Memory Study found just the opposite. Estrogen plus progesterone doubled the relative risk (1.8% vs 1%) of dementia in women over 65. Bluming and Tavris say that finding was statistically significant but neither compelling nor clinically relevant. The absolute risk was small, the subjects were not all healthy and were not representative of the typical user, the sample size was small, and the increased risk was found only in women over 75 and in the first year of use, suggesting pre-existing dementia. And there was no increase in the mild cognitive impairment that should precede dementia. The reports tended to neglect the finding that there was not a statistically significant increase in risk with estrogen alone. A 2004 follow-up reported that the increased risk was only in women who were cognitively impaired at the outset, not in women who were cognitively healthy. Bottom line: the finding of a small increase in dementia risk could not be extended to all forms of HRT or even to the women most likely to start HRT.
There is abundant evidence, including evidence from animal and lab studies, that estrogen started early in menopause can prevent or delay the onset of dementia, including Alzheimer’s. And it has even more benefits for the brain: it stimulates the growth of nerve cells, promotes brain plasticity, enhances the action of glial cells, improves cerebral blood flow, and much more. Numerous clinical studies support those benefits, and three large meta-analyses found that HRT was associated with a 34% decreased risk of dementia and a 40% decreased risk of Alzheimer’s.
Heart disease and stroke.
The evidence shows that when HRT is started soon after menopause, it can reduce the incidence of heart disease and strokes.
Pre-existing breast cancer
Conventional wisdom says women who have had breast cancer should not take estrogen. That conventional wisdom was never actually supported by any good evidence. Bluming’s breast cancer patients wanted relief of their menopausal symptoms, so he started looking into it. He found that neither lowering estrogen levels by removing ovaries or raising levels by becoming pregnant had any effect on the recurrence of breast cancer. He did his own study and found that HRT had no effect on the recurrence rate. Numerous other studies subsequently confirmed his findings, with only a single study pointing the other way. In fact, there is evidence that HRT may reduce the recurrence rate and prolong survival.
Progesterone
Estrogen alone appears to be safer than estrogen plus progestin. They discuss the difference between progestins, progesterone, and micronized progesterone, which appears to be the safest form.
Colon cancerThere’s another added benefit. Data from the WHI study showed that women on any form of HRT had a 30% lower risk of colon cancer. Other studies have shown that HRT in pill form (as opposed to the patch) is associated with a lower risk of colon cancer and a lower mortality rate from colon cancer if they do get it. Most, although not all, studies confirm these findings.
Ovarian cancer
Oral contraceptives reduce the rate of ovarian cancer by up to 80% and the reduced risk persists for nearly 20 years after the pills are stopped.
Hormone replacement had been killing women?
When the results of the WHI study were publicized, the prescription rate for HRT fell by 70%. The incidence of breast cancer declined in the next 8 months, but this can’t be attributed to fewer women taking estrogen. It takes longer than 8 months for cancer to develop, and the decline actually started three years prior to the WHI announcement. And in Norway, even though women went off HRT at the same rates, the rate of breast cancer diagnoses did not decline.
Many people seem to be committed to the ideas that a natural phenomenon, menopause, has been medicalized and that hormones cause cancer. When researchers have conducted re-analyses that contradicted their earlier conclusions, they have typically waffled, looking for other explanations, seemingly unable to say anything good about HRT. Cognitive psychologist Daniel Kahneman calls this “theory-induced blindness”, where adherence to a theory makes people unable to see its flaws or accept new evidence.
Taking the lowest dose for the shortest time?
There is no scientific basis for the recommendation to take the lowest dose for the shortest time. The North American Menopause Society advises clinicians to move away from this simplistic advice and instead prescribe the dose and formulation that meet each patient’s needs and concerns based on the woman’s age, time of menopause, and any unique health risks she might have. The book provides a long list of organizations that endorse the continued use of HRT after the age of 65.
Criticisms of the WHI
The WHI was widely trusted because it was a large gold standard trial. But Bluming and Tavris show that in this case the gold standard had feet of clay. They list ten key problems:
     1.  It was rushed into publication before most of the co-investigators had even seen the draft. There is reason to think some of them would have objected. Later one of them published a blistering account of the violations of the scientific process.
     2.  The initial finding that HRT increased the risk of breast cancer was not statistically significant.
     3.  The subjects were not representative of menopausal women: their average age was 63.
     4.  The sample was not representative of healthy women. Nearly half were current or past smokers; more than a third had been treated for high blood pressure; fully 70 percent were seriously overweight or obese.
     5.  The findings were inconsistent and contradictory: in 2002, a nonsignificant increase in risk, in 2006 no increase in risk; and women taking estrogen alone were subsequently found to have a lower risk.
     6.  Some of the findings were the result of data mining.
     7.  They claimed that estrogen didn’t even help alleviate menopausal symptoms, but there was no basis for that claim: they had not studied women who were actually having menopausal symptoms.
     8.  Initial claims that HRT increased the risk of heart disease were later reversed: women who started HRT in the first ten years following menopause actually had a reduced risk of heart disease.
     9.  Reports of an increased risk of stroke were the result of statistical manipulations. When the data were independently analyzed, the supposed increased risk of stroke vanished.
     10.  Many of the WHI investigators have continued to promote alternatives to HRT that they incorrectly maintain are just as effective. Most of their suggestions are no better than placebos.
What’s more, some of the investigators had voiced their stated agenda to prove that hormones were harmful.
Despite revelations about the WHI’s flaws, many people still consider WHI the definitive proof that hormone replacement does more harm than good. Even John Ioannidis, a notorious critic of research that is paid for by industry, and author of an important study showing that most published research is wrong, believes that the data implicating hormones as a risk of breast cancer are strong and scientifically reliable. He and Bluming have agreed to disagree.
Understand, then advise
They suggest a new maxim. Instead of primum non nocere, (first do no harm) primum certior fi, tunc mone (first understand, then advise).
This book is a refreshing change from the usual book that promotes an agenda by concentrating on one side of a divisive issue. As a male, Bluming is not a candidate for HRT; his only agenda is to help his patients. And Tavris is not a candidate either: at her age, she is well past the ten-year window of opportunity. They rigorously present the evidence on both sides and the disagreements among scientists. And they don’t presume to tell patients what they “should” do. They advocate individualizing decisions based on many factors such as the severity of menopausal symptoms and the patient’s risk of osteoporosis, heart disease, colon cancer, etc.
Estrogen is the only really effective treatment for hot flashes and other symptoms of menopause. It has a large effect on the quality of life as well as many other health benefits. The authors say the real question is notwhether it helps, but whom it helps and when. There appears to be a critical window of opportunity: the decade following the onset of menopause.
They quote Sir George Pickering: “If you are a clinician, you must believe that you know what will help your patient; otherwise, you cannot counsel, you cannot prescribe. If you are a scientist, however, you must be uncertain — a scientist who no longer asks questions is a bad scientist.”
Bluming says:
The practice of oncology thus requires a constant dance between what we know and what we must learn; perhaps that’s why we say that surgeons perform surgery but physicians practice medicine.
Conclusion: Estrogen vindicated
Once considered a veritable fountain of youth, estrogen replacement got a bad rap with the Women’s Health Initiative study. This book is an exhaustively researched and meticulously reasoned vindication of hormone replacement therapy. Estrogen matters: it’s the most effective treatment for hot flashes and other symptoms of menopause, and when started early and used continuously, it has important health benefits and can actually prevent some of the adverse events it was thought to cause. Bluming and Tavris tell estrogen’s story in a way that is both accessible to the general public and appropriate for professionals. What’s more, they provide valuable insights into understanding research and how even the best randomized controlled studies can lead to unjustified public fears and injudicious clinical recommendations. Very enlightening!

Birth Control
Harriet Hall on October 18, 2011
Link
From a message posted on Facebook:
 Is the pill safe? The International Agency for Research on Cancer in a 2007 study made by 21 scientists reported that the pill causes cancer, giving it the highest level of carcinogenicity, the same as cigarettes and asbestos. It also causes stroke, and significantly increases the risk of heart attacks. Several scientific journals have stated that the natural way of regulating births through the Billings Ovulation Method has no side-effects, and is 99.5 % effective.
The Billings Ovulation Method (BOM) is a method of natural family planning where women are taught to recognize when they have ovulated by examining their cervical mucus, allowing them to avoid intercourse during fertile periods or conversely, to have intercourse during fertile periods when pregnancy is desired. We used to call people who used the rhythm method “parents,” but BOM is more reliable than older abstinence methods.
I’m a big fan of oral contraceptives. They contributed to women’s liberation by giving us a reliable method of planning, delaying, or avoiding pregnancy.  They also have medical uses that go beyond contraception. Birth control pills (BCPs) have had such an important impact that they are known as simply “The Pill.” We have always known they were not 100% risk free; but we also know they are less risky than pregnancy itself. There are other methods of birth control; but they are generally less effective and less convenient.  For those who want permanent solutions, tubal ligation and vasectomy are available; but even they have occasional failures. What does science tell us about the effectiveness and safety of BCPs as compared to other methods? 
Effectiveness
According to the Wikipedia entry, the Billings Ovulation Method has a failure rate of 0-2.9% with perfect use and 1-5% with typical use.  (They cite the original references for these figures). The corresponding numbers Wikipedia gives for “the pill” are 0.3% and 8%. The American Congress of Obstetricians and Gynecologists’ numbers for the pill are a bit less optimistic: they say “With typical use, about 8 in 100 women (8%) will become pregnant during the first year of using this method. When used perfectly, 1 in 100 women will become pregnant during the first year.”
A handy table on the FamilyDoctor website compares the failure rates of various birth control methods. It lists periodic abstinence methods as having a 20% failure rate, but that includes the less effective rhythm methods as well as the methods based on mucus examination. 
Cancer? It causes some and prevents others
Information on cancer and oral contraceptives can be found here.  There is an increased risk of cervical cancer, but most cases are related to HPV infection, so hopefully the new vaccines will eliminate much of that risk. There is an increased risk of liver cancer in low risk populations but not in high-risk populations. The risk of breast cancer may or may not be slightly increased: studies do not agree.
On the other hand, the pill clearly reduces the risk of uterine and ovarian cancers. And a meta-analysis found that the risk of colorectal cancer is also decreased.
The magnitude of these risks is small. I couldn’t find any information about overall cancer risk: whether the increase in some types of cancer outweighs the decrease in others.
What the IARC really said
According to the Facebook poster, the International Agency for Research on Cancer (IARC) said oral contraceptives were as carcinogenic as cigarettes and asbestos.  That’s not what the IARC said at all. It does classify estrogen/progesterone in the same group 1 category as cigarettes and asbestos, but all that category means is that there is sufficient evidence to prove carcinogenicity in humans. It does not in any way imply that oral contraceptives are as carcinogenic as cigarettes and asbestos: they aren’t.  And the IARC entry clearly states
There is also convincing evidence in humans that these agents confer a protective effect against cancer in the endometrium and ovary.
Other Risks
BCPs increase the risk of deep venous thromboembolism and ischemic stroke. There is disagreement over whether they increase the risk of myocardial infarction. The absolute risk of all these conditions is low. It is greater in smokers and in those with other risk factors, and it is lower for the newer low dose BCPs.
The ACOG has prepared an excellent patient education pamphlet  listing all the risks, benefits, side effects, and contraindications.  It concludes:
 The pill is a good choice for women who may want to get pregnant later. It is a safe and effective way to prevent pregnancy. It is easy to use, convenient, and reversible. The pill may protect against some cancers. Some benefits of pill use last months or years after you stop taking it. For almost all women, the benefits of pill use outweigh the risks.
Benefits
Critics of hormonal contraception fixate on the risks, but there are also a number of health benefits. The ACOG patient information pamphlet explains that BCPs reduce the risk of
    • Cancer of the uterus and ovary
    • Ovarian cysts
    • Pelvic infection
    • Bone loss
    • Benign breast disease
    • Symptoms of polycystic ovary syndrome
    • Anemia (iron poor blood)
    • Ectopic pregnancy
    • Acne
They also
    • Help to keep periods regular, lighter, and shorter and reduce menstrual cramps
    • Reduce symptoms of endometriosis and fibroids
    • May help with migraine headaches and depression.
    • Can be used to schedule periods to avoid an inconvenient time (i.e. a wedding).
Other options
There are many other birth control options: condoms, diaphragms, other hormone delivery methods like cervical rings and injections, IUDs, spermicides, periodic abstinence methods, and therapeutic abortions. Some methods have the additional benefit of protection against sexually transmitted diseases. Some methods require specific actions at the time of intercourse, which some people object to as interfering with spontaneity. The periodic abstinence methods have the disadvantage of requiring periodic abstinence.
I remember reading years ago (the reference is long gone and I don’t know if the information is still valid) that when all factors were considered including the risks from pregnancy itself when contraception fails, the safest method of birth control was to use condoms and do therapeutic abortions when they failed. That resulted in statistically less morbidity and mortality overall than any other method. Of course there are other considerations that make this a less than ideal option. Emotions and religion create a lot of bias in the area of birth control. I suspect some people who reject oral contraceptives as “unsafe” might be quite willing to take other medications that have a similar safety profile but are not connected to ideological concerns. 
Conclusion: The Pill isn’t like a cigarette
BCPs are not risk-free, but the Facebook poster was wrong: their risks can’t be compared to the risks from cigarettes and asbestos. There are other good alternatives that some individuals may prefer for various medical and non-medical reasons. For any method of birth control, the risks must be weighed against the benefits. Pregnancy itself is far riskier than any method of pregnancy prevention.
The safest, most effective method of birth control is orange juice. You may ask “Before or after?” The answer is “Instead of.” Most women and their partners would not consider that a satisfactory option.

   Menstrual Synchrony: Do Girls Who Go Together Flow Together?
Harriet Hall
Link
When women live together, do their menstrual cycles tend to synchronize? It’s been a long time since I first heard that claim. I didn’t believe it, for a number of reasons. I had never observed it myself, I saw no plausible mechanism to explain how it could happen, I thought the statistics to prove it would be problematic and complicated, and I suspected that confirmation bias and selective memory might have persuaded people that a spurious correlation existed. How often do women say “Oh, look! We’re having our periods at the same time”? How often do they say “Oh, look! We’re having our periods at different times”? Now that many years have passed since my first encounter, I thought it would be fun to revisit the claim and see whether science has supported it or rejected it.
A perusal of PubMed and other Internet sources left me confused and amused.
Synchrony Is Difficult to Define
Consider that the normal menstrual cycle can vary from 21 to 35 days and can last 2 to 7 days. Consider that some women are regular and consistent, while others have variable patterns, even “regularly irregular” patterns. Consider that anovulatory cycles and other conditions often lead to menstrual irregularities that fall outside the normal range. Consider that strenuous exercise and other life events can affect menstruation. Put all that together, and you can see that often cycles will overlap simply by chance, and that it is difficult to define synchrony.
If two women have regular 28 day cycles and 7 day periods, the maximum number of days they could not overlap is 14. On average, their periods will be 7 days apart, and half the time they will be closer.
How could a 21 day cycle ever “synchronize” with a 35 day cycle? For example if you compare a woman with a regular 35 day cycle who starts on January 1 to a woman with a 21 day cycle who starts two weeks later on January 15, their next periods will coincide almost perfectly (Feb 4-10 and Feb 5-11) but they will diverge after that. Would it count if the last day of one woman’s period overlapped with the first day of another woman’s? What if half the periods coincide and half don’t? The whole thing is problematic.
What Does the Literature Say?
It all started with Martha McClintock. In a paper published in Nature in 1971 she found that “social interaction” in a college dormitory setting could have a strong effect on the menstrual cycle. A follow-up study in 1998 tended to support the hypothesis that pheromones were involved: smelling armpit secretions of other women could either lengthen or shorten cycles depending on what part of her cycle the donor was in.
I’ll summarize rather than trying to cover everything published on the subject. A Scientific American article did a good job of reviewing the literature as of 2007. Suffice it to say that about half the published papers support the synchronization hypothesis and half don’t; and the half that do have been harshly criticized for their poor design and poor statistical analyses. So we haven’t reached a consensus, but it’s looking more likely that synchronization is a myth.
A study in a nursing journal assumes that synchronization occurs and addresses the subjective meaning of the experience to
assist nurses to understand the holistic aspects of this everyday experience of women and to design effective strategies and techniques to help women gain knowledge about their cycle functions, promote healthy attitudes toward menstruation as a process, and acknowledge and honor this natural, healthy aspect of their menstrual cycle.
I will be kind to those nurses and apply Thumper’s rule. (In Bambi, he said “If you can’t say something nice, don’t say nothing at all.”)
What About Non-Humans?
It was originally thought that other primates and other mammals demonstrated menstrual synchrony due to pheromones, but recent studies have shown that it doesn’t occur in chimpanzees, hamsters, mandrills, or golden tamarins.
Do Human Pheromones Exist?
The existence of human pheromones is controversial. Pheromones are chemical signals released by one individual that affect the behavior of another individual of the same species. They can be useful for alarms, food trails, sex attractants, and other purposes. They have been well documented in insects and even in plants. In one memorable demonstration, a drop of oleic acid was all it took to persuade other ants that a live ant was dead; they dragged it back to the trash heap over and over, ignoring the fact that it kept protesting its trips to the ant graveyard by vigorously kicking, and that it kept “coming back from the dead.”
In humans, pheromones have been postulated and even sold as sexual attractants. But there is little or no peer-reviewed evidence to suggest that any pheromone influences human behavior. No human pheromones have been identified, and the vomeronasal organ that detects pheromones in other mammals is rudimentary and nonfunctional in humans.
Other Explanations
Not knowing if it occurs hasn’t stopped people from speculating about why it occurs or about why it doesn’t. The evolutionary reasoners have chimed in with just-so stories both about why it would and wouldn’t offer a survival benefit. For instance, if everyone ovulated at the same time, it would be harder for a woman to get a man. Or being banished to the menstrual hut at the same time would allow women to bond and collaborate on social enterprises. I was particularly amused by one chain of reasoning:
Synchronization also doesn’t make sense because during their mentrual cycles, women often experience lack of energy. These spells of low energy among women in a tribe would be detrimental to a hunter-gatherer lifestyle. Furthermore, if all of the women get pregnant at the same time, they won’t be able to help each other. Given our anthropological history, evolution should select that women do not cycle together. (errors in the original)
And this comment on the Scientific American article left me rolling on the floor:
Astrology explains this for better than modern science. Normally close friends have similar sun, moon positions in their horoscopes. The moon and mars determine the menstrual cycles. Astrological harmony makes them friends than living together which in turn is the cause of synchronization. Even if they are living far in different continents they will be in sync. In India any normal astrologer can check a woman’s horoscope and can tell the date of her menstruation time ( especially used when they have to attend auspicious ceremonies) and plan the events. (errors in the original)
Conclusion
Do women’s menstrual cycles tend to synchronize when they live together? As so often in medicine, science doesn’t provide a clear answer. Even if the phenomenon occurs, and even if human pheromones cause it, so what? It’s a matter of curiosity, not of clinical importance. When there is a reason to manipulate ovulation or menstrual timing, pharmaceutical hormones work very well. The paucity of evidence for human pheromones suggests that if they do exist, their effects must be too small in magnitude to be very important.

The Medical Medium’s Thyroid Pseudoscience
Anthony William calls himself a “Medical Medium”. He has no medical expertise, but he provides medical advice based on claimed communication with the spirit world. What could possibly go wrong?
Scott Gavura on May 4, 2017
Link

It seems increasingly difficult for consumers to sort out credible medical information from complete bunk. Thyroid conditions have their areas of legitimate medical controversy, but the sheer volume of pseudoscience and dubious advice on offer buries the fact that most thyroid diseases are well understood and highly treatable. Two weeks ago I examined a clinical trial that answers an important question about whether or not treating a laboratory-diagnosed form of low thyroid offers patients any meaningful benefits. Since that post I’ve received several emails and messages from people seeking more information about treating thyroid dysfunction. I was pointed to a thyroid post on Goop which I have to admit, left me a bit shocked. Sure, Goop’s advice is dubious, but I didn’t realize the website lets totally unqualified individuals give medical advice, especially when that advice is based entirely on claimed communication with the spirit world. This was my introduction to Anthony William, the “Medical Medium”, whose apparent claim to fame is channeling ghosts that give medical advice. Since William was also on your list of suggested blog topics for me to write about, I couldn’t resist diving in. Take a deep breath.
Ignorance of science is seemingly no barrier when you have the spirit
The website Psychic Gurus (yep) tells me that a medium is someone who can communicate with spirits (spirit guides, angels, etc.). All mediums are also psychics, but not all psychics are mediums. It’s worth noting at this point that no medium has ever been proven to be legitimate. Probably the strongest critics of mediums are the “mentalists”, who know it’s all a con, and are more up-front about the fact that any apparent “skill” of a medium is based on insights derived from the real world, and not based on supernatural abilities.
Anthony William has an extensive and detailed disclaimer on his Facebook page which gives a more concise summary of his qualifications than his own biography. In short, he advises:
    • His information is not a substitute for medical information or advice
    • You should never disregard medical advice based on his writing
    • He is not a medical doctor or healthcare professional
    • You should speak with a medical doctor or healthcare professional before acting on any of his advice
    • Quack Miranda, etc.
With that in mind, here’s what William says about his own abilities:
Anthony William was born with the unique ability to converse with a high-level spirit who provides him with extraordinarily accurate health information that’s often far ahead of its time. Since age four, when he shocked his family by announcing that his symptom-free grandmother had lung cancer (which medical testing soon confirmed), Anthony has been using his gift to “read” people’s conditions and tell them how to recover their health. His unprecedented accuracy and success rate as the Medical Medium have earned him the trust and love of thousands worldwide, among them movie stars, rock stars, billionaires, professional athletes, best-selling authors, and countless other people from all walks of life who couldn’t find a way to heal until he provided them with insights from Spirit. Anthony has also become an invaluable resource to doctors who need help solving their most difficult cases, and has recently released his NY Times Best Seller “Medical Medium.”
The Spirit’s views on hypothyroidism
Judging by William’s writing, his spirits are channeling straightforward alternative medicine approaches. His advice seems largely similar to the pseudoscience that you see offered by naturopaths, homeopaths, and other alternative-to-medicine practitioners today. Reading his writing, you’ll quickly discover you have adrenal fatigue. Gluten needs to be avoided. You need a detox, and so on. But the thyroid seems to be a focus for William, likely because he has a book about thyroid on the way. There’s just too much to wade through in William’s 7,000+ word opus to respond point by point, so I’ll touch on some of the highlights. (TL; DR: William blames the Epstein Barr virus for causing thyroid issues, and recommends herbs and supplements to cure it.) William’s advice isn’t supported by any credible evidence, yet that doesn’t stop him from making very specific statements about the causes and treatments of thyroid disease:
The Medium	The Science / The Translation
“because without true insight into what causes thyroid illness, medical communities aren’t yet able to offer remedies that heal the underlying problem”	There are safe effective medical treatments for thyroid conditions that can enable people to live normal lives without symptoms.
“Currently, the autoimmune theory proposes that in certain conditions, a person’s immune system becomes confused and starts attacking part of the body. In the case of Hashimoto’s, patients are told that the immune system mysteriously produces antibodies that target and damage the thyroid gland as though it were a foreign presence. This hypothesis will not hold up over time. Why? Because it’s not the real answer.”	Hashimoto’s thyroiditis (chronic autoimmune thyroiditis) is a common cause of hypothyroidism, seen in up to 10% of the population. There is sequential thyroid failure duo to an immune dysfunction. The cause is believed to be a combination of combination of genetic susceptibility combined with environmental factors.
“What medical research has not yet uncovered is that the body never attacks itself; it only goes after pathogens.”	There are numerous autoimmune diseases where the relationship to infection is unclear or unproven.
“It’s also important to keep in mind that while science has advanced in its understanding of many aspects of physical function, the thyroid gland remains largely a mystery.”	Most mysteries of the thyroid can be addressed by consulting medical resources, or asking an endocrinologist.
“In over 95 percent of today’s thyroid disorders, including Hashimoto’s and even thyroid cancer, Epstein-Barr virus (EBV) is the cause.”	There is no evidence this is the case.
“(The other 5 percent of thyroid problems come from radiation exposure due to chest X-rays, dental exams, and/or plane travel.)”	Ditto.
“It [the thyroid] uses this memory of homeostasis to transmit radio-like frequencies (not yet detected or measured by medical science or research) that delegate tasks and responsibilities to multiple body systems and organs.”	How the thyroid, and thyroid hormones work, is well documented. As evidence by thyroid replacement therapies, medical science has developed an effective treatment.
“When EBV enters the scene, this ideal functioning gets thrown off, which in turn throws off the entire endocrine system. To compensate and power the body, the adrenal glands pump out excess adrenaline, which is one of EBV’s favorite foods. The virus feasts on the adrenaline in order to get stronger, multiply, and go after its ultimate target: the nervous system.”	No. Virus don’t eat adrenaline.
“Hypothyroidism can cause body temperature fluctuations, a bit of fatigue, and dry skin—that’s it. What about all the other symptoms typically associated with low thyroid hormone levels? They’re symptoms of the EBV that’s infecting the thyroid, not low levels of thyroid hormones. Aches and pains, muscle weakness, memory issues, mood changes, and more: these are viral symptoms, not a result of hypothyroidism.”	Thyroid replacement alleviates symptoms of hypothyroidism. They are not symptoms of an EBV infection.
“What’s really happening is that back when Epstein-Barr was in Stage Two and hiding out in your liver, it weakened the organ and burdened it to the point of creating a sluggish liver.”	There’s no such thing as a “sluggish liver”.
“It’s worth noting that even if haven’t been diagnosed with a thyroid condition, a viral infection of the thyroid and the effects I just described could still be behind your struggles to lose weight.”	(Here’s where the supplement pitch begins.)
“In some cases, instead of causing an underproduction of thyroid hormones, EBV prompts the thyroid to overproduce them. This is called hyperthyroidism—and the diagnosis that many people with hyperthyroidism receive is Graves’ disease, an illness tagged as autoimmune that leaves far too many patients feeling that their bodies have let them down.	William isn’t even internally consistent, blaming EBV for both promoting and suppressing thyroid function.
“It wasn’t until the publication of my first book, Medical Medium: Secrets Behind Chronic and Mystery Illness and How to Finally Heal, which includes a chapter on hypothyroidism and Hashimoto’s, that the truth finally reached the public about EBV as that underlying cause.”	There is no clear evidence EBV causes Hashimoto’s, despite William’s claim.
“It’s time to reclaim your power and understand that Hashimoto’s is a label and not a judgment or life sentence. The reason for your suffering does not come from within. Your immune system is not going haywire or out to get you. It’s this virus—this invader—that’s causing the damage, making you feel miserable, and holding you back in life. Your body just needs the proper support, which I’ll describe soon, to triumph over the virus.”	Hypothyroidism is almost always a lifetime treatment.
“When the immune system isn’t able to destroy the virus altogether, it goes with its fallback option: attempting to wall off the virus with calcium. That’s what thyroid nodules are: calcium prisons for EBV cells.”	There’s no evidence of this.
“Your body fights for you. Your body is on your side. Your body loves you unconditionally. It just happens to be up against a pernicious adversary—one that can be tamed with the right approach.”	In essence, your disease, your fault.
“With adrenal fatigue, the adrenal glands can produce adrenaline and cortisol erratically, sometimes flooding the bloodstream and sometimes holding back. In this case, your adrenals may be overactive when you’re getting your blood drawn even if the doctor’s office is your favorite place in the world, and so, again, the results can be inaccurate.”	Adrenal fatigue is a fake disease.
“Millions of women unknowingly walk around with hypothyroids that wouldn’t register on today’s tests.”	Hypothyroidism is laboratory-diagnosed. There is legitimate medical debate about treating laboratory-diagnosed thyroid dysfunction when there are no symptoms.
“If your thyroid is in need of help, you’ve come to the right place. Below are foods, herbs, and supplements that can help restore a damaged thyroid, strengthen the other glands of the endocrine system, and lower the viral load specifically within the thyroid—as well as insight into iodine and a warning about a food trend that’s derailing many who suffer with thyroid issues”	There are no specific foods, herbs or supplements required to treat hypothyroidism.
“Among the most healing foods for thyroid conditions are Atlantic dulse, wild blueberries, celery, sprouts, cilantro, garlic, asparagus, radishes, kale, parsley, butter leaf lettuce, spinach, hemp seeds, coconut oil, Brazil nuts, kelp, and cranberries. Variously, they can kill EBV cells, provide micronutrients, repair thyroid tissue, reduce nodule growth, flush toxic heavy metals (which feed EBV) and viral waste, and boost production of thyroid hormones. For maximum benefits, consume at least one cup each of wild blueberries, celery, cilantro, and asparagus daily.”	You cannot heal Hashimoto’s hypothyroidism with food, and specific foods will not “boost” thyroid function or “flush toxic heavy metals”.
“No matter what food belief system you subscribe to, whether paleo, vegetarian, or the like, it’s a good idea to remove eggs, dairy products, pork, canola oil, soy, corn, and gluten from your diet while you’re dealing with a thyroid issue. It’s not that these foods cause inflammation, which is the theory you might have heard. Rather, these foods feed EBV, and then the EBV creates inflammation.”	There is no need to remove any foods from your diet in the belief you are “feeding” EBV.
Same whine, new bottle
William the “Medical Medium” offers alternative medicine, with a supernatural twist. William may genuinely believe he has a gift. But he has no medical knowledge or training. His ignorance of medical science is evident from his dismissal of it. It’s worth remembering that William has enough sense (or caution) to write a disclaimer that emphasizes that anything he says should be reviewed with a medical professional. If you’re seeking credible, science-based advice on thyroid issues, this medical professional’s advice is to ignore anything suggested by the Medical Medium, and to discuss your questions with your family doctor or an endocrinologist.

Is thyroid replacement a performance-enhancing drug?
Scott Gavura on May 9, 2013
Link
Has one physician uncovered the secret to Olympic Gold medals? And is that secret as simple as undiagnosed low thyroid function? That’s the question posed in a recent Wall Street Journal column entitled U.S. Track’s Unconventional Physician. Like the story that Steven Novella described yesterday, this narrative describes the medical practice of Dr. Jeffrey S. Brown, who sees thyroid illness where others see normal thyroid function. He has his critics, but his high-profile athlete patients have won a collective 15 Olympic gold medals. Case closed & Q.E.D.? Not quite. The WSJ actually does a pretty good job questioning the validity of Brown’s claims, which are far removed from the current medical consensus:
In athletic circles, Brown is a medical hero. He’s a paid medical consultant to Nike. The most renowned running coach at Nike, Alberto Salazar, calls Brown the best sports endocrinologist in the world. And athletes in growing numbers are coming to share Brown’s belief that heavy training can suppress the body’s production of the thyroid hormone, leaving them too exhausted to perform at peak. On the wall of the medical office of Jeffrey S. Brown is a photograph of Carl Lewis, the nine-time Olympic gold medalist. Lewis is one of several former or current patients of Brown’s who have climbed the Olympic podium, including Galen Rupp, who won a silver medal in the 10,000 meters at the London Olympics. “The patients I’ve treated have won 15 Olympic gold medals,” said Brown. Among endocrinologists, Brown stands almost alone in believing that endurance athletics can induce early onset of a hormonal imbalance called hypothyroidism, the condition with which he diagnosed Lewis and Rupp. Brown said he knows of no other endocrinologists treating athletes for hypothyroidism, a fatigue-causing condition that typically strikes women middle-aged or older. Several endocrinology leaders had never heard of hypothyroidism striking young athletes.
Now when I read “unconventional” and “stands alone” my skeptical alarm starts ringing. There is no shortage of debate about thyroid disease, ranging from the utter nonsense offered by “alternative health” practitioners to valid scientific discussions about the thresholds where normal function is considered abnormal and subject to treatment. Brown is an endocrinologist, however, and he’s treating elite athletes who are pushing their physical conditioning far beyond that seen by most medical doctors and almost all endocrinologists. So what’s the basis of the concern? The WSJ story goes on to discuss two different issues: What the proper threshold is for thyroid disease, and whether thyroid replacement is performance enhancing. Let’s take each of these in turn. I’ve covered thyroid diseases and its related pseudoscience before, and a summary of the standard approach is necessary before we look at the some of the broader questions that have emerged from the story. All I know about these patients is what the WSJ is describing, so for the sake of brevity I’m going to focus on the types of cases that Dr. Brown appears to be identifying and ignore other causes of thyroid disease, which would require different treatment approaches.
The Diseased ThyroidSimplistically, they thyroid gland acts as a sort of thermostat for the body. If it runs too high, you’re hyperthyroid: heat intolerant, anxious, a high heart rate, and maybe some diarrhea. If it runs low, you’re hypothyroid: cold, tired, constipated, and possibly even depressed. These multi-organ effects are triggered by the presence or absence of two thyroid hormones: thyroxine (T4) and liothyronine (T3). Normal thyroid function is something you never notice. But low thyroid function is common (4-10 % of adults), particularly in women. The overwhelming majority of cases (95%) of low thyroid, or hypothyroidism are primary, and the major cause of primary hypothyroidism (in parts of the world where we get adequate iodine) is autoimmune thyroid disease (Hashimoto thyroiditis). That is, the body attacks its own thyroid. As the thyroid’s function decreases, and T4 levels drop, the pituitary releases thyroid stimulating hormone – it’s effectively trying to “turn up the thermostat” to continue my analogy. A highly elevated TSH signifies thyroid dysfunction. There are other tests that can be done to confirm the diagnosis, including measurements of circulating T4 and antibody measurements, but TSH is the test we rely on as the primary diagnostic test.
Like any laboratory measurement, what’s considered a “normal” TSH is based in part on clinical studies, but also on the testing standard. Most labs identify an upper limit of TSH at 4 to 5 mU/L, but there are proponents of both higher and lower thresholds. Consequently there will be variations in practice between physicians in what they consider a “high” TSH and what’s considered “normal”. There is also some debate about a condition called “subclinical hypothyroidism”, where there are some laboratory signs of a thyroid dysfunction (a “normal” T4 and a slightly elevated TSH), but it’s not sufficient to warrant a diagnosis. A Cochrane Review suggested that treating subclinical hypothyroidism doesn’t seem to result in meaningful differences in symptoms or quality of life, nor does it decrease cardiovascular morbidity. But neither did these studies look at the performance impact in elite athletes.
Not unexpectedly, Dr. Brown is a proponent of a using a low threshold to diagnose thyroid disease, setting a threshold that most endocrinologists consider normal:
According to American College of Endocrinology literature, the range of normal TSH level is broad, from 0.5 to an upper limit of near 5, depending on a patient’s gender, age and other factors. In practice, many endocrinologists consider TSH levels above 4—combined with symptoms such as fatigue—evidence of an underactive thyroid. Brown and a small camp of other endocrinologists argue that thyroid insufficiency can be signaled by a TSH level as low as 2, for which Brown cites some recently published research. By their standards, about 10% of the population is hypothyroid—double the 5% that is cited by mainstream endocrinology. Jeffrey Garber, American College of Endocrinology president, said hypothyroidism increasingly is being diagnosed in people who don’t have it, by endocrinologists whom Garber labeled as “alternative.” “The alternative crowd is saying, ‘Gee, this is why you’re not feeling better, because these [mainstream] doctors are clueless,’ ” Garber said. So if this reporting is accurate, Brown is looking at the same test results and seeing what he believes to be thyroid disease, where his peers see normal thyroid function.
Perhaps not surprisingly, Brown has his defenders, including bloggers who rail against “mainstream” endocrinologists who “stubbornly cling to the outdated ideas that hypothyroidism is easy to diagnose”. Sound like familiar rhetoric? It will if you’re a regular reader of this blog – every “maverick” physician will invariably have their defenders. But they’re usually not Olympic gold medalists:
Medical privacy rules forbid Brown from naming all the athletes he has treated for that condition. But among those who have publicly acknowledged being treated for thyroid problems by Brown or unnamed other physicians are American runners Ryan Hall, Galen Rupp, Amy Yoder Begley, Bob Kennedy and Patrick Smyth. “I knew hypothyroidism was kind of like something that was being diagnosed more among elite runners,” said Smyth, a marathoner who in 2011 started feeling chronically tired. When a physician near his California home found no evidence of thyroid dysfunction, Smyth flew to Houston to see Brown, who conducted some blood tests and diagnosed him with the condition. Smyth, now retired, said the medication never enhanced his performance.
The WSJ suggests that there may be some relationship between the rigorous training and the thyroid function itself, in which case the thyroid supplementation is simply restoring “normal” function. This seems to be what Brown believes, seeing dysfunction where other physicians see normal thyroid activity. Setting aside whether or not these athletes actually do have “low” thyroid, we can ask if thyroid treatment is actually offering a performance benefit when administered to patients with a TSH between what appears to be Brown’s cutoff of 2 and the standard cutoff of 4 or 5. Certainly Brown thinks so, or he wouldn’t be prescribing thyroid replacement. Given the extent to which these athletes push their bodies, even a subtle amount of fatigue, if ameliorated, could potentially improve performance. And overtraining leading to fatigue is likely a risk for athletes training at this intensity. From this perspective, it raises the question of whether thyroid replacement can be considered a form of doping – a recovery-enhancement or fatigue-deferring boost not available to athletes who didn’t go see Dr. Brown. T4 is a hormone, after all, and it will have effects on fatigue and recovery from exercise.
One of the differences that thyroid replacement has from other forms of sports supplementation is that there is a clear peak point – normal thyroid function. Thyroid replacement in the absence of real deficiency could create a hyperthyroid state which would possibly hurt athletic performance as much a hypothyroidism. Overt hyperthyroidism causes anxiety, insomnia, weakness, perspiration, and mood swings – nothing an athlete wants. Even subtle hyperthyroidism could have negative effects for elite athletes. And the long-term consequences are significant. Thyroid replacement is a life-long commitment. And long-term it has side effects including cardiovascular and bone risks – excess thyroid is a definite “bone eater”, with bone resorption stimulated and osteoporosis being the result.
ConclusionThe Wall Street Journal‘s profile of Dr. Brown and his unorthodox management of elite athletes raises interesting questions about the basis of disease, the conditions for drug treatment, and the implications on the ethics of sports. Over time, thyroid replacement could go one of two ways. It could continue to be treated like inhaled anti-asthma medications, where asthmatic athletes who require treatment would otherwise be at a serious disadvantage in athletic competitions. We’d consider this simply a leveling of the playing field for those athletes. Or it could be that thyroid replacement could be scrutinized even more closely, perhaps requiring better documentation to justify use in an athlete, requiring clearly-demonstrated medical need based on a specific set of parameters, recognizing that there’s thyroid replacement, and then there’s unnecessary supplementation. From my personal perspective, I’m skeptical of medical mavericks who haven’t yet produced enough evidence to convince their peers and change the medical consensus. Until I see the evidence, I’m staying skeptical of Dr. Brown’s approach.

Hypothyroidism: The facts, the controversies, and the pseudoscience
Scott Gavura on December 22, 2011
Link

As glands go, we don’t give the butterfly-shaped thyroid that straddles our trachea too much thought — until it stops working properly. The thyroid is a bit like your home’s thermostat: turn it high, and you’re hyperthyroid: heat intolerant, a high heart rate, and maybe some diarrhea. Turn it down, and you’re hypothyroid: cold, tired, constipated, and possibly even depressed. Both conditions are associated with a long list of more serious health consequences. Between the two however, hypothyroidism is far more prevalent. The mainstay drug that treats it, levothyroxine (Synthroid), is one of the most prescribed in the world.
One of my more memorable pharmacy experiences involved levothyroxine. The store had recently changed its prescription labelling standards: It switched from listing the brand name, to only including the generic name (with the manufacturer in parentheses). Few patients noticed. But one elderly patient, taking Synthroid, was furious, and accused me of making a dispensing error. I assured her that levothyroxine was the active ingredient in Synthroid, and she was getting the exact same product as her last visit — but she would have none of it. Her symptoms had worsened, she said, because the medication wasn’t the same. “I want Synthroid — this levothyroxine stuff does not work,” she screamed at me across the counter. No amount of reassurance would satisfy her — I think we eventually resorted to custom, typewritten labels.
I mention this anecdote not to dismiss the symptoms of hypothyroidism as sensitive to placebo effects — hypothyroidism is a real condition with objective monitoring criteria. But this episode was one of my earliest lessons in understanding how perceptions can shape expectations of effectiveness — something that I’ll come back to, when we look at the controversies of this common condition. Any the treatment of hypothyroidism is not without its controversies – most of which occur outside the realm of medicine, and can more accurately be labelled pseudoscience.
Hypothyroidism is the consequence of the thyroid gland failing to produce enough thyroid hormone. The body produces two thyroid hormones: thyroxine (T4) and liothyronine (T3). Primary hypothyroidism is the result of insufficient production of T4 by the thyroid gland. (Secondary hypothyroidism is a consequence of pituitary or hypothylamic disorder.) The overwhelming majority of cases of hypothyroidism are primary, and the major cause of primary hypothyroidism is autoimmune thyroid disease (Hashimoto thyroiditis). Iodine deficiency can cause primary hypothyroidism too, but it’s rare in developed countries. There are other causes of hypothyroidism, including drug therapies. But to keep this post to a reasonable length, I’ll restrict my focus to primary hypothyroidism, which seems to attract the most treatment controversy.
The prevalence of hypothyroidism varies with gender, age, the population surveyed, and the definition of hypothyroidism used. A recently completed large survey suggested an overall prevalence in America at 3.7% — presumably this will be similar in other countries where iodine deficiency is equally rare. Hypothyroidism is much more common in women compared to men., and increased in prevalence with age.
The presentation of hypothyroidism varies based on severity, from no symptoms at all, to severe cases with coma and organ failure. Patients with untreated primary hypothyroidism may describe weight gain, cold intolerance, dry skin/hair, constipation and hair loss. While the assessment and treatment of hypothyroidism is based around patient-relevant symptoms, the diagnosis of hypothyroidism must be based on lab tests, owing to the non-specific nature of the symptoms. Three laboratory measurements evaluate thyroid function and are used to diagnose hypothyroidism:
    • Thyroid Stimulating Hormone (TSH), secreted by the pituitary, is the primary screening measure in most situations. The normal range is usually reported to be 0.3-5.5 mIU/L, and a diagnosis of hypothyroidism is likely when the TSH is elevated above 10. The less functional the thyroid, the higher the TSH. (Values will vary for what is a “normal” TSH depending on the lab.)
    • Free T4 (FT4) is evaluated when the TSH is abnormal. The usual range is 9-19 pmol/L and will be reduced in hypothroidism.
    • Free T3 (FT3) has a usual range of 2.6-5.7 pmol/L. It may be reduced in hypothyroidism, but its value is not useful for diagnosis.
The treatments
The standard therapy for hypothyroidism is synthetic levothyroxine (LT4) alone, which supplies FT4 to the body. The body converts FT4 to FT3 as required. LT4 is effective for the vast majority of patients and is the mainstay of treatment guidelines. Many patients need to take nothing else; once their dose is determined, they take one dose a day, forever. LT4 is lifetime therapy. Benefits of LT4 include very accurate tablet standards, stable absorbtion and steady blood levels, and good tolerability.
Liothyronine (LT3) (Cytomel) is uncommonly used for thyroid dysfunction. The active form of thyroid, administration can cause wide fluctuations in FT3 levels, increasing the risk of cardiovascular harms compared with LT4. If LT4 is like gradually turning up your home’s thermostat, LT3 is akin to big fire in the fireplace – it can work quickly, but it’s difficult to maintain a consistent effect. With a less desirable risk/benefit profile, LT3 is generally used only in patients intolerant to LT4, or in those who are unable to successfully achieve treatment success and symptom resolution on LT4 alone.
Combination therapy (LT4 + LT3) occurs, but isn’t supported by good evidence, despite what you might expect from the testimonials. Trials comparing LT4 to LT4 + LT3 have shown no benefit over LT4 alone — and sometimes LT4 alone comes out on top.
Some physicians, patients and particularly alternative medicine purveyors advocate that dessicated thyroid (ground up pork thyroid) has advantages over LT4. This may be based in part on the naturalistic fallacy: the idea that using a “natural” thyroid source is better than “synthetic” levothyroxine. The evidence doesn’t support such a conclusion. In fact, judging by the evidence with LT4 + LT3, the evidence points the other direction. Dessicated thyroid contains a mix of T4 and T3. The lack of any randomized head-to-head comparisons make any comparison difficult, and renders claims of superiority unproven. While some patients seem to prefer it to T4 alone, the unpredictable stability, and potential for batch-to-batch variation make it less attractive from a patient perspective, and consequently treatment guidelines generally advise against its use. If combination therapy is felt to be necessary, using synthetic LT4 and LT3 together allows more precise and consistent dosing. Yet there exists a vast network of websites dedicated to locating sources of dessicated thyroid and shipping it to countries where it’s not available.
Treatment goals and monitoring
The assessment and treatment of hypothyroidism is based on symptoms, and is guided by laboratory monitoring. Monitoring includes measurements of TSH and more rarely FT4, with the goal of putting both into the “normal” range. And improvement can be rapid, usually starting within a few weeks, with significant improvement as levels normalize.
The controversies
Normal ranges
Laboratory monitoring is a critical component of evaluating thyroid function. Redefine what’s considered “normal” and you redefine what it means to by hypothyroid. While the upper limit of “normal” TSH is generally accepted to be around 5.5 mIU/L (it will depend in part on the lab standard), lowering the upper limit will move millions from “normal’ to “subclinical hypothyroidism”. There’s a debate as to whether the upper limit of a “normal” TSH should be dropped to 2.5 mIU/L. Confounding its critics, the medical “establishment” that is criticized online doesn’t yet seem convinced that revising the definition is necessary – which would create (on paper) millions of new patients. . Perhaps it’s because there’s no clear evidence of adverse consequences for not treating TSH values in the 2.5-5mIU/L range. So narrowing the range may do little for patient outcomes. Still, this is an area of continued controversy.
Subclinical hypothyroidism
Subclinical hypothyroidism is generally defined as a “normal” T4 and a slightly elevated TSH: That is, some laboratory signs of a thyroid dysfunction, but not sufficient enough to warrant a diagnosis. Symptoms are not always present, and can be vague and nonspecific: dry skin, constipation, depression, poor memory, etc. Subclinical hypothyroidism can only be diagnosed based on test results. The clinical significance of the condition is unclear. A recent Cochrane Review suggested that treating subclinical hypothyroidism doesn’t seem to result in meaningful differences in symptoms or quality of life, nor does it decrease cardiovascular morbidity. Given the risk/benefit perspective seems unclear, treatment decisions need to be individualized, and based on the severity of individual symptoms.
Screening
Routinely screening thyroid function in adults is controversial. Screening may be more reasonable in higher-risk patients (advanced age, family history, those with signs/symptoms, etc.). Screening would be expected to increase the likelihood of treatment and over treatment, and consequently exposure to the potential risks (not well understood) of long-term thyroid treatment. Given the uncertainty about the benefits of treatment of subclinical hypothyroidism, screening may not be necessary in those at low risk and free of typical symptoms.
Is measuring FT4 enough?
Guidelines recommend routine monitoring of TSH and FT4, but not FT3, as T3 is felt to vary too significantly to normally guide treatment (though it may be useful when LT4 therapy is initiated). The alternative approach discounts the evidence and guidelines and advocates treatment with LT3 alone, or a combination of LT4 and LT3. At the extreme, some groups advise against laboratory monitoring and suggest relying on symptoms alone. It’s the alternative approach that may have driven the continued interest in dessicated thyroid, which persists on the market despite quality control and dosing challenges.
Switching brands and using generics
Some countries carry multiple brands of levothyroxine, and regulators may allow brand substitution – that is, they are deemed to be interchangeable. But even in settings where switching is permitted, health professionals generally try to keep patients on the same brand, to minimize the remote chance of any variation in effects due to formulation. (So the protestations of my customer, if not based in science, were consistent with usual pharmacy standards.) Looking at the data, however, there’s probably more variation in absorption based on food effects than any potential variation between brands. And the FDA recently tightened the quality standards for all brands, reducing the likelihood of variation between tablets or between brands. Still, taking the daily dose at the same time each day is probably equally important to maintaining stable blood values.
The pseudoscience
Are lab measures enough? Or even necessary?
A popular alternative approach to thyroid treatment is body temperature measurements, which are felt to be a proxy for thyroid function. While it sound plausible and could give you the impression of “taking control” of your hypothyroidism, there’s no persuasive data to link the two. Body temperature does not accurately measure thyroid function and should not be used to guide treatment.
Over-the-counter supplements
There are several over-the-counter thyroid supplements on the market, some of which contain animal-sourced thyroid gland. A recent study tested these supplements: 9 of the 10 had animal hormones present, some with amounts comparable to prescription drugs. Given the questionable quality control and potential for batch-to-batch variation, OTC supplements are a potentially dangerous choice for treatment.
Beyond the glandular products, there are a host of nutritional products targeted at consumers with hypothyroidism. Some of the common ingredients include:
    • Kelp and other products that are sources of iodine; however, iodine deficiency isn’t an issue for most.
    • Dong Quai, tyrosine, pantothenic acid (vitamin B5), ashwagandha, bladderwrack, schisandra, ginseng (Siberian and American), astragalus, rhodiola, selenium, zinc, copper and dozens of other ingredients that haven’t been demonstrated to have any meaningful effects — or to actually address the root cause of the condition.
Regulators like Health Canada don’t make it any easier: they approve multivitamins and iodine-containing supplements with “thyroid” in the name, or with recommended uses like, “Helps in the function of the thyroid gland” which, while not entirely incorrect, are misleading, given iodine or vitamin deficiency isn’t a relevant contributor to most cases of hypothyroidism. I could label the same supplements, “Helps in the function of the index finger” and be equally accurate.
You brought this on yourself
Well, that’s what Christaine Northrup suggests:
It’s no coincidence that so many more women than men have thyroid problems. Thyroid disease is related to expressing your feelings, something that until relatively recently had been societally blocked for women for thousands of years. In order to have your say—and maintain your thyroid energy—you must take a fearless inventory of every relationship in which you feel you don’t have a say. Ask yourself why you don’t. Are you a silent partner in a relationship? Does your partner make all the major decisions? Is it worth it? Did your mother have her say? In what ways are you like her?
Depending on your answers, I would urge you to skillfully and empathetically begin to say what is on your mind regarding the decisions that affect your life. Make sure that when you say what’s on your mind, you do so at the right time and remain detached from the effects. In other words, try not to force your will on others. For example, it’s okay to tell your best friend that you are worried about the character of her new boyfriend, but be aware that she may not necessarily be ready to hear your remarks. It’s not appropriate to “turn up the volume” as she’s rushing out the door to meet this new man.
OK, Dr. Northrup, I’ll try saying what’s on my mind. This advice is unadulterated magical thinking. Stop blaming women for autoimmune disorders.
It’s the adrenals
No, hypothyroidism is not adrenal fatigue – a made-up condition without any demonstrable evidence that it actually exists. Given the “symptoms” of adrenal fatigue overlap with those of hypothyroidism, screening for hypothyroidism is an appropriate element of any workup for unexplained fatigue. The same applies to taking hydrocortisone for hypothyroidism – while there are recommendations online, there’s no good evidence to show this is either safe or effective.
A little boost to help me lose weight
The thyroid is a convenient villain when confronting weight loss. If I can toss in a final anecdote, I had my Labrador Retriever’s thyroid function evaluated when she became sluggish and gained 20lbs over 12 months. It turns out, she actually was quite hypothyroid, and her activity level and weight responded well to levothyroxine, calorie restriction, and more exercise. In the obese, hypothyroidism is rare in the absence of other symptoms. And if there’s no hypothyroidism, manipulating thyroid hormones is inadvisable.
Making sense of it all
While there’s a lot of dissatisfaction with thyroid treatments online, the vast majority of patients find levothyroxine to be a simple and highly effective daily therapy. There are some true controversies in the treatment of hypothyroidism, but they’re buried in vast amounts of pseudoscience and bad treatment advice. So I advise my newly diagnosed patients against complicating treatment unless it’s necessary, and to start treatment with positive expectations: Synthroid is a top dispensed drug for a reason: It works. And despite the controversies, and the outlier opinions, the medical consensus on the treatment of hypothyroidism is quite strong. That means ignoring the noise, focusing on the relevant outcomes, and taking a stepwise, science-based approach to treatment.
Other references
Desiccated thyroid vs. synthetic thyroid supplementation. Pharmacist’s Letter/Prescriber’s Letter 2008;24(10):241013.
Towards Optimal Practice. Clinical Practice Guideline Working Group. Thyroid Dysfunction.
AACE Medical Guidelines for Clinical Practice for Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. 2002
Disclosure: Scott treats his Labrador Retriever with levothyroxine.

Overtreating the thyroid
For decades there’s been debate about whether thyroid medication is necessary for a mild form of thyroid dysfunction. A new trial helps answer that question.
Scott Gavura on April 20, 2017
Link


Levothyroxine was one of the first drugs I dispensed as a pharmacist where a patient became visibly upset with me after receiving (what she thought) was a generic version of the drug. The store I was working in had recently changed their labelling to show the generic name, instead of the brand name, on each vial. The drug being dispensed didn’t change – just the label. One patient, who had been taking Synthroid (a brand of levothyroxine) for years, was livid with me for suddenly giving her “levothyroxine”. I tried to explain that the drug was the same one that she’d been receiving, that levothyroxine was the generic name for Synthroid, and that I hadn’t actually switched anything. She wouldn’t accept my explanation, stating that her symptoms had worsened since “you switched the drug”. It was an early lesson in how perceptions can shape expectations and even symptoms, in this case, a form of nocebo effects.
The thyroid doesn’t get much attention despite thyroid medications being among the most dispensed drugs in the world. When people start thyroid medication it can become a lifetime therapy. Yet there are persistent concerns that thyroid disorders may be overdiagnosed and overtreated, and that millions may be treated with thyroid medication unnecessarily. Now there’s new evidence to answer an important question about when thyroid medication might be necessary.
Hypothyroidism is the consequence of the thyroid gland failing to produce enough thyroid hormone (My old post gives more background, but I’ll repeat some here). The body produces two thyroid hormones: thyroxine (T4) and liothyronine (T3). Primary hypothyroidism is the result of insufficient production of T4 by the thyroid gland (Secondary hypothyroidism is a consequence of pituitary or hypothylamic disorder). The overwhelming majority of cases of hypothyroidism are primary, and the major cause of primary hypothyroidism is autoimmune thyroid disease (Hashimoto thyroiditis). Iodine deficiency can cause primary hypothyroidism too, but it’s rare in developed countries.
Hypothyroidism may have zero symptoms, but in severe forms can cause coma, organ failure, and death. Patients with untreated but mild primary hypothyroidism sometimes describe weight gain, cold intolerance, dry skin/hair, constipation and hair loss. While the assessment and treatment of hypothyroidism is based around patient-relevant symptoms, the diagnosis of hypothyroidism must be based on lab tests, owing to the non-specific nature of the symptoms. Three laboratory measurements evaluate thyroid function and are used to diagnose hypothyroidism:
    • Thyroid stimulating hormone (TSH), secreted by the pituitary, is the primary screening measure in most situations. The normal range is usually reported to be 0.3-5.5 mIU/L, and a diagnosis of hypothyroidism is likely when the TSH is elevated above 10. The less functional the thyroid, the higher the TSH (Values will vary for what is a “normal” TSH depending on the lab).
    • Free T4 (FT4) is evaluated when the TSH is abnormal. The usual range is 9-19 pmol/L and will be reduced in hypothroidism.
    • Free T3 (FT3) has a usual range of 2.6-5.7 pmol/L. It may be reduced in hypothyroidism, but its value is not useful for diagnosis.
Subclinical hypothyroidism is generally defined as a “normal” T4 and a slightly elevated TSH: That is, some laboratory signs of a thyroid dysfunction, but not sufficient enough to warrant a diagnosis of hypothyroidism. Between 8-18% of adults over the age of 65 are reported to have these laboratory findings. There may be no symptoms, or they can be vague and nonspecific: fatigue, dry skin, constipation and depression. However, there’s an association with coronary heart disease, making the overall significance unclear and raising the persistent question of whether or not it should be treated with medication at all. A 2007 Cochrane Review suggested that treating subclinical hypothyroidism doesn’t seem to result in meaningful differences in symptoms or quality of life, nor does it appear to decrease cardiovascular morbidity. The USPSTF is also skeptical. It notes in a 2015 review:
A large magnitude of overdiagnosis and overtreatment is a likely consequence of screening for thyroid dysfunction, particularly because the disorder is defined by silent biochemical parameters rather than a set of reliable and consistent clinical symptoms. The high variability of TSH secretion levels and the frequency of reversion to normal thyroid function without treatment underscore the importance of not relying on a single abnormal laboratory value as a basis for diagnosis or the decision to start therapy. Currently, it is not possible to differentiate persons who will have advancing thyroid dysfunction of clinical importance from those whose TSH levels will remain biochemically stable or even normalize. Treating the latter group (at a minimum) will not lead to benefit, and these persons may experience harms associated with antithyroid medications, ablation therapy, and long-term thyroid hormone therapy.
There’s some data cited by the USPSTF to suggest that the threshold at which physicians initiate thyroid replacement therapy in subclinical hypothyroidism may be dropping, and consequently more people are being treated. Given the high number of prescriptions, it’s possible that millions of people with no symptoms of hypothyroidism are receiving thyroid replacement therapy. So an important question that’s been asked for some time is if treating subclinical hypothyroidism offers any meaningful benefits to patients. Now we have a trial that gives some important information to answer that question.
Does treating subclinical hypothyroidism help?
This new study from Stott and colleagues, entitled “Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism” was well designed to answer an important clinical question: Does treating subclinical hypothyroidism offer patients any meaningful benefits? This trial was funded by the European Union, and sponsored by several non-profit entities in Scotland, Ireland, the Netherlands, and Switzerland. Supplies of levothyroxine (T4) and the matching placebo were donated by Merck KGaA. The study was randomized, double-blind, and placebo controlled, recruiting 737 adults over the age of 65, who had what would be deemed persistent (3 months to 3 years) subclinical hypothyroidism (they defined it as a thyrotropin level of 4.6 to 19.99 mIU/L, and normal free thyroxine). Patients were excluded if they had taken any thryoid medications, medications that can affect thyroid function, and several other medical conditions. Participants were randomized 1:1 to treatment or placebo. The active treatment arm started with a low dose of levothyroxine, with gradual dose adjustment (by computer algorithm) to bring thyroxine to the normal range (0.40 to 4.59 mIU/L). (There was a mock dose adjustment in the placebo group.)
There were two primary outcomes: thyroid-related quality of life scores, and tiredness scores, measured using standardized tests (from 0-100 with a significant difference being 9). Secondary outcomes included general quality-of-life tests and several other measures, including grip strength. While they had initially planned for cardiovascular events to be a primary outcome, that was changed mid-trial owing to difficulties recruiting patients (which meant the trial would have been underpowered.)
The average age of participants was 74.4 and about half were women. After one year, the average thyrotropin level had decreased to 5.48 mIU/L in the placebo group and 3.63 mIU/L in the treatment group, with a median daily dose of 50 μg of levothyroxine. In short, the levothyroxine did exactly what was expected, which was to bring the thyrotropin down to the normal range. Despite this, the investigators found no difference in the mean change of thyroid-related quality of life scores or tiredness scores between the two groups. There were also no meaningful differences in any secondary outcomes either. In short, treating this “subclinical hypothyroidism” had no effect on any relevant patient-reported or objective measure.
What this means
I love clinical trials that answer a specific and relevant therapeutic question, with the potential for widespread benefit. Overtreatment is a significant issue in medicine, and it’s essential that any medication be initiated with an objective and relevant purpose in mind. This trial showed clearly that treating older adults with subclinical hypothyroidism has no meaningful or apparent benefits to patients. Consequently, it will provide good evidence to inform physician and patient discussions and decisions in evaluating whether or not thyroid medication may be necessary at all.

drenal fatigue: A fake disease (updated)
“Adrenal fatigue” is not a real medical condition, but some claim it is real and that medicine is ignoring it. What does the science say?
Scott Gavura on June 29, 2017
Link

While Scott Gavura is taking a summer hiatus from blogging, here’s an update to an an old post, on a popular topic.
One of the realities of being a pharmacist is that we’re easily accessible. There’s no appointment necessary for consultation and advice at the pharmacy counter. Questions range from “Does this look infected?” (Um, yes) to “What should I do about this chest pain?” to more routine questions about conditions that can easily be self-treated. Pharmacists have an important triage role — advising on conditions that can be safely self-managed, and knowing when medical referrals are necessary or appropriate. Among the most common questions I’ve received in my time working in a retail pharmacy are related to stress and fatigue. Energy levels are down, and patients want advice and solutions. Some want a “quick fix,” believing that the right mix of megadoses of vitamins are all that stand between them and unlimited energy. Others may ask if prescription drugs, herbal supplements, or even caffeine tablets could help. Evaluating vague symptoms is a challenge. Many of us have busy lifestyles, and don’t get the sleep and exercise we need. We may also compromise our diets in the interest of time and convenience. With some simple questions I might make a few basic lifestyle recommendations, talk about the evidence supporting supplements and vitamins, and suggest physician follow-up if symptoms persist. Fatigue and stress may be part of life, but they’re also symptoms of serious medical conditions. But they can be hard to treat because they’re non-specific and may not be easily distinguishable from the fatigue of, well, life.
This same vague collection of symptoms is called something entirely different in the alternative health world. It’s branded “adrenal fatigue,” an invented condition that’s widely embraced as real among alternative health providers. There’s no evidence that adrenal fatigue actually exists. The public education arm of the Endocrine Society, representing 14,000 endocrinologists, recently updated their advice on a common medical question, noting:
“Adrenal fatigue” is not a real medical condition. There are no scientific facts to support the theory that long term mental, emotional, or physical stress drains the adrenal glands and causes many common symptoms.
But if you search the internet, there are hundreds (probably thousands) of posts arguing that your doctor (and the entire medical community) is wrong. But the scientific facts are clear when it comes to adrenal fatigue. It’s a fake disease, and there’s no credible scientific evidence to support it.
Invented by a chiropractor and naturopath
The adrenals are a pair of glands that sit on the kidneys and produce several hormones, including the stress hormones epinephrine and norepiniephrine that are associated with the “fight or flight” response. Can you tire these glands out? In the absence of any scientific evidence, chiropractor and naturopath James Wilson coined the term “adrenal fatigue” in his 1998 book of the same name. Take a look at Wilson’s own extensive questionnaire, at adrenalfatigue.org. Do you ever experience the following? You may have adrenal fatigue.
    • Tiredness not usually relieved by sleep?
    • Having trouble getting up in the morning?
    • Get low energy, moody or foggy if you don’t eat regularly?
    • Feel worse if you miss a meal?
    • Need salty or sweet snacks or caffeine to keep going?
    • Eat lots of fruit?
    • Feeling run down and stressed?
    • Muscles sometimes feel weaker than they should?
    • Struggling to keep up with life’s daily demands?
    • Can’t bounce back from stress or illness?
    • Decreased sex drive?
Some lifestyles are apparently more vulnerable to adrenal fatigue, including single parents, shift workers, an “unhappily married person”, and the “person who is all work, no play.” There’s no information provided to substantiate the quiz, qualify the vague terminology, or link to any relevant literature. (Of course there is the usual Quack Miranda warning on every page which makes all of this possible: “These statements have not been evaluated by the Food & Drug Administration … etc.”)
Based on this quiz, it’s safe to assume that adrenal fatigue is the most prevalent fake disease in the world. And sure enough, that’s what its proponents think too:
Dr. John Tinterra, a medical doctor who specialized in low adrenal function, said in 1969 that he estimated that approximately 16% of the public could be classified as severe, but that if all indications of low cortisol were included, the percentage would be more like 66%. This was before the extreme stress of 21st century living, 9/11, and the severe economic recession we are experiencing.
What does the evidence actually say?
So let’s look into the medical literature on adrenal fatigue. There’s not much in Pubmed, though there is a systematic review from Cadegiani and Kater entitled “Adrenal fatigue does not exist: A systematic review“, which notes:
Theories on adrenal impairment as the genesis for fatigue are tempting, as they allow for a treatable condition. Despite the widespread use of the term “adrenal fatigue” by the general media and certain health practitioner groups, in this systematic review, only ten citations were found with this exact expression, and they were all only descriptive and did not perform any test regarding the HPA axis and “adrenal fatigue”. Studies that tried to correlate the HPA axis and fatigue states used the term “burnout” instead of “adrenal fatigue” to denote adrenal depletion. Therefore, a distinction between the “general information” and the actual scientific literature regarding this condition is evident.
And also:
No confirmed methods of clinical screening for AF are available. Indeed, the popular questionnaire developed by Dr. Wilson and published in the first book exclusively dedicated to the description of this supposedly disease has not been cited in any indexed databases.
The conclusion is important, so I’ll quote it in its entirety:
To our knowledge, this is the first systematic review made by endocrinologists to examine a possible correlation between the HPA axis and a purported “adrenal fatigue” and other conditions associated with fatigue, exhaustion or burnout. So far, there is no proof or demonstration of the existence of “AF”. While a significant number of the reported studies showed differences between the healthy and fatigued groups, important methodological issues and confounding factors were apparent. Two concluding remarks emerge from this systematic review: (1) the results of previous studies were contradictory using all the methods for assessing fatigue and the HPA axis, and (2) the most appropriate methods to assess the HPA axis were not used to evaluate fatigue. Therefore, “AF” requires further investigation by those who claim for its existence.
Why is adrenal fatigue a “fake disease”
One of the hallmarks of alternative medicine is the “fake disease”. Fake diseases don’t actually exist – they are invented without any objective evidence showing that they are real. Fake diseases tend to emerge from vague symptoms which can’t be attributed to a specific medical diagnosis. This is not to say what patients are experiencing isn’t real – the issue is the diagnosis, and the practitioner making the call. As has been pointed out by other SBM contributors, it’s understandable to want reasons and answers when you have debilitating symptoms. But symptoms need to be studied in rational and objective ways in order to understand the underlying illness – call it the “root cause” if you prefer. The diagnosis guides the treatment plan, so getting a diagnosis right is essential. While a group of vague symptoms might lead a medical doctor to run tests to rule out serious illness, alternative medicine providers seem to jump to the diagnosis and techniques they prefer, even if they’re completely unvalidated, or made up out of thin air. It’s your Chi. Your energy fields. It’s wifi. It’s gluten. In this case, it’s your adrenals. Rather than offer a guide to proper care, a fake disease is a distraction from the truth.
Adrenal fatigue is a prototype fake disease. Defining a cluster of symptoms in general terms is the first mistake. Symptoms need to be collated in a rational way to understand the parameters of the disorder. With adrenal fatigue, there’s no objective operational description, nor is there a validated symptom score, as the systematic review notes. Using a vague list of symptoms to identify patients is the second mistake. While laboratory tests are advertised for identifying adrenal fatigue, there’s no persuasive data to suggest that any testing used by naturopaths is valid in any way.
Adrenal fatigue shouldn’t be confused with adrenal insufficiency, a legitimate medical condition that can be diagnosed with laboratory tests and has a defined symptomatology. Addison’s disease causes primary adrenal insufficiency and usually has an autoimmune cause, with symptoms appearing when most of the adrenal cortex has been destroyed. Secondary adrenal insufficiency is cause by pituitary disorder that gives insufficient hormonal stimulation to the adrenals. Some liken adrenal fatigue to a milder form of adrenal insufficiency — but there’s no underlying pathology that has been associated with adrenal fatigue.
While adrenal fatigue may not exist, the same can’t be said for the treatments. When you’re treating a fake disease, anything goes. Everything from homeopathy to herbal remedies to hydrotherapy, to traditional Chinese medicine and vitamin supplements are advocated for treatment. The endpoints of treatment are as nonspecific as the criteria for diagnosis. Wilson, conveniently, has his own supplement programs, and there’s no shortage of solutions out there.
Conclusion: Symptoms are real, adrenal fatigue is not
While adrenal fatigue may not exist, this doesn’t mean the symptoms people experience aren’t real. These same symptoms could be caused by true medical conditions such as sleep apnea, adrenal insufficiency, or depression. Accepting a fake disease diagnosis from an unqualified practitioner is arguably worse. Patients don’t receive a science-based evaluation of their symptoms, and they may be sold unnecessary treatments that are probably ineffective and potentially harmful. The Endocrine Society’s guidance is entirely appropriate:
Doctors urge you not to waste precious time accepting an unproven diagnosis such as “adrenal fatigue” if you feel tired, weak, or depressed. If you have these symptoms, you may have adrenal insufficiency, depression, obstructive sleep apnea, or other health problems. Getting a real diagnosis is very important to help you feel better and overcome your health problem.
There’s no question that it would be frustrating to be experiencing fatigue symptoms and then to be told by a health professional that there is nothing medically wrong. But that is arguably better than the distraction of treating a fictitious condition.

   Real Medicine

Medicine past, present, and future: Star Trek versus Dr. Kildare and The Knick
I love the new Cinemax series The Knick, which is set in 1900 and portrays a brilliant maverick surgeon named Dr. John Thackery on the cutting edge of medicine at the time. I also love Star Trek‘s Dr. “Bones” McCoy and have recently come to like the old radio show featuring Dr. Kildare. Looking at how the three shows portray medicine in their respective times led me to speculate on how much medicine in its time really is or isn’t barbaric, as McCoy would put it.
David Gorski on September 15, 2014
Link 

I’ve been a big Star Trek fan ever since I first discovered reruns of the original Star Trek episodes in the 1970s, having been too young (but not by much!) to have caught the show during its original 1966-1969 run. True, my interest waxed and waned through the years—for instance, I loved Star Trek: The Next Generation, while Star Trek: Enterprise and Star Trek: Voyager pretty much left me cold—but even now I still find myself liking the rebooted movie series. In the original series, my favorite characters tended to alternate between Spock, the Vulcan first officer and science officer on the Enterprise, and Dr. Leonard “Bones” McCoy, the ship’s chief medical officer. I sometimes wonder if my love of these two characters had anything to do with my becoming a doctor and researcher myself. It probably did.
One aspect of all the Trek shows that always interested me was its portrayal of medicine in the 23rd and 24th centuries. After all, what doctor wouldn’t like to have a device like the tricorder that he could wave over the patient and come up with an instant diagnosis and course of treatment? Who knew, of course, that nearly 50 years after the first Trek episode first aired, we would have technology that makes the communicators on the original series (TOS, for those Trek non-fans) look primitive and large by comparison and that we’d be well on the way to developing devices that can do some of what tricorders did on the show. Throughout all the shows and movies, the medical technology of a few hundred years in the future is portrayed as vastly superior to what we have now, with 20th century medicine at times denigrated by “Bones” McCoy and other Star Fleet medical personnel as barbaric quackery.
A confluence of events and media led me to want to explore a couple of questions. First, which procedures that we consider state-of-the-art science-based medicine will be considered “barbaric” 50 or 100 years from now? Second, is the contempt expressed for the medicine of the past (e.g., by “Bones” McCoy) justified? These are questions that I’ll explore a bit with the help of the Star Trek universe, a recent new cable television drama series, and a couple of articles that appeared on medical sites as a result of the premier of that series.
Star Trek: 23rd century medicine vs. 20th century medicine
Perhaps the most amusing example of McCoy’s contempt for the “primitive” medicine of the 20th century occurs in the 1986 movie Star Trek IV: The Voyage Home. (I found it particularly amusing because I was a third year medical student when the movie came out.) For the purposes of this post, you don’t need to know the plot, other than that it involves the crew of the Enterprise time traveling to San Francisco in the year 1986 to obtain something from the past that would save the Earth of the year 2286. During their mission one of the crew, Chekov, is seriously injured fleeing from the military, captured, and as a result taken to Mercy Hospital for emergency surgery. When Dr. McCoy learns of this, he begs Captain Kirk not to leave Chekov in the hands of 20th century medicine. So Kirk and McCoy disguise themselves as doctors and infiltrate the 20th century hospital where Chekov is about to undergo emergency surgery in order to rescue him. It is during this part of the movie that this hilarious exchange occurs:
For those of you who can’t play the YouTube video, here’s a transcript that shows you what I mean. First, “Bones” encounters an old woman on a gurney in the hallway and asks her a question:
McCoy: What’s the matter with you?
Patient: Kidney… dialysis.
McCoy: Dialysis?! What is this? The Dark Ages? Here! You swallow that and if you have any more problems, just call me!
Later, as the crew is escaping, McCoy encounters the woman again, who’s telling everybody that McCoy had given her some pills and she grew a new kidney.
In another scene, Kirk and crew are in an elevator with some interns, and McCoy overhears the following conversation, not being able to stop himself from butting in:
1st Intern: So, Weintraub says radical chemotherapy or she’s gonna croak. Just like that…
2nd Intern: And Gottlieb?
1st Intern: Well, what’d you expect? All he talked about was image therapy. I thought they were going to punch each other.
McCoy [Muttering and shaking his head]: Unbelievable…
1st Intern [Turning to McCoy, having heard his muttering]: You…have a different view, Doctor?
McCoy: Sounds more like the goddamned Spanish Inquisition!
Kirk [Turning to the interns and shrugging shoulders]: Bad day…
Later, Kirk and McCoy kick a neurosurgeon about to operate on Chekov to drain what sounds like an epidural hematoma out of his operating room at phaser-point, and McCoy proceeds to save Chekov’s life with his 23rd century technology.
You get the idea: In the fictional Star Trek universe, to a physician of the 23rd century what physicians of the 20th century do appears as barbaric as the practices of 18th century physicians appear to us physicians of the 21st century. What really got me thinking about this question again was the premier of a new historical medical drama on Cinemax entitled The Knick, which tells the story of Dr. John Thackery, fictional chief surgeon at the Knickerbocker Hospital in 1900. As a surgeon, I can’t help but apply the same sort of eye to surgery as practiced 114 years ago as Dr. McCoy did to medicine practiced in 1986. Unlike McCoy, however, I can’t lather up the same level of contempt for the fictional surgeons of the Knick that McCoy can for the hapless doctors of Mercy Hospital.
The Knick: What a difference 114 years makes!
Although I subscribe to HBO, I don’t subscribe to Cinemax. Consequently, I was only able to view the first episode of The Knick using On Demand, and have since only seen the first three episodes because HBO happened to show them all in a block about a week after the third episode aired. I haven’t seen episodes four or five yet, although I’m seriously tempted to subscribe to Cinemax for the remainder of the season just to see the show and then to drop it after the show’s run ends. However, the episodes I’ve seen are enough to pique the interest of any surgeon interested in the history of surgery. Producer Steven Soderbergh likes to brag about the measures his team has taken to assure historical accuracy with respect to the medicine practiced and the surgical procedures portrayed, particularly how extensively his show has used the Burns Archive, a trove of more than a million historic photographs (a few of which are digitized and displayed here, unfortunately without much in the way of text or captions to tell the viewer what they are), to recreate the look of medicine in the early 20th century.
Of course, it being a fictional show, there are things that The Knick takes some creative license with, such that I wondered about them immediately. For instance, body snatching to supply hospitals with medical cadavers and fights between ambulance drivers over who gets to pick up patients were apparently not as prevalent as The Knick portrays, given that New York was one of the first states to pass “anatomical acts” in the mid-19th century to discourage trade in bodies and body snatching. By 1900, such activities would be a risky, at best, crime not likely to be particularly profitable. On the other hand, given the level of endemic corruption in New York in 1900, characters like corrupt Health Inspector Jacob Speight who takes kickbacks to refer patients he finds with reportable infectious diseases for which the city mandates treatment to the Knick and the equally corrupt hospital administrator who works with him are not implausible.
One thing I noticed in the very first operating room scene (and in all the operating room scenes in the episodes I’ve seen thus far), surgeons are depicted operating bare-handed. Instead of scrubbing up and using rubber gloves, as surgeons have done for many decades now, they dipped their hands into antiseptic solution right before the start of surgery. It turns out that the great surgical pioneer upon whom Dr. Thackery is loosely modeled, Dr. William Stewart Halsted had pioneered the use of rubber gloves in 1889 or 1890 because his scrub nurse (with whom he later fell in love and who ultimately became his wife) had begun to develop severe contact dermatitis as a result of the nasty chemicals (mercuric chloride and phenol) used to disinfect the hands of the operating staff at the time. Rather than have her reassigned, Halsted requested the Goodyear Rubber Company, as an experiment, to make “two pair of thin rubber gloves with gauntlets.” At first, only assistants used them, but within a couple of years, the surgeons at Johns Hopkins, where Halsted practiced, were using them. So it seems a bit of creative license that the surgeons at the Knick would still be operating bare handed. On the other hand, it’s not too beyond the pale that some surgeons might still be operating bare handed in 1900, given that it wasn’t until 1899 when Halsted’s protégé Dr. Joseph Bloodgood (what an awesome name for a surgeon!) published a report of 450 hernia operations using gloves, observing that the infection rate fell by nearly 100%. Bloodgood’s report led Halsted to take himself to task, asking “Why was I so blind not to have perceived the necessity for wearing them [rubber gloves] all the time?”
Think of it: A man with one of the most brilliant minds in the entire history of surgery responsible for so many surgical innovations, from emergency blood transfusions, to cancer surgery, to something as mundane as a bedside chart to track a patient’s vital signs and the use of surgical gloves operating room, a man who first laid down surgical principles still taught to all surgeons today, such as a completely sterile surgical field, hemostasis, gentle handling of tissue, careful anatomic dissection, and exact approximation of tissues, and Halsted couldn’t immediately figure out that wearing sterile rubber gloves instead of dipping one’s hand in caustic chemicals to disinfect them was a superior means of preventing surgical infection!
Other examples, although perhaps anachronistic, are found in the fictional world of The Knick. For example, the very first OR scene in the very first episode portrays the attempt by Dr. J.M. Christiansen and Dr. Thackery to perform a Caesarian section on a woman with placenta previa, after having failed at this procedure eleven times before. They fail again, with the mother and baby both dying. As a surgeon, I found this scene particularly disturbing and effective. As I watched the impressively realistic pools of blood form, overwhelming the ability of the pedal-driven suction to clear them, the surgeons frantically working, and the nurse reporting a faster and faster pulse (and ultimately no pulse), all as dozens of doctors and trainees observe the procedure, I couldn’t help but wonder how surgeons could actually save anyone in such an environment.
The same question came up later in the same episode, when a man with a bowel perforation had his injury repaired primarily. The surgeon who did the repair was taken to task by Thackery on rounds for not resecting. Later, the patient develops intra-abdominal sepsis, requiring Thackery to operate on him using an instrument he had constructed himself to resect the nonviable bowel and sew it back together. While I admit that this part made me wonder (bowel anastomoses were pretty standard procedures by 1900; so I’m not sure why this would have been so revolutionary), I still had to marvel how any surgeon could expect any patient with a bowel resection to survive intra-abdominal sepsis after a bowel perforation with no antibiotics as adjunctive care for the drainage and resection.
More examples included a man with an aortic aneurysm, for whom the treatment would be a galvanic procedure (using electricity to induce thrombosis of the aneurysm), an attempt to reconstruct a woman’s nose lost to syphilis using a tissue flap from the arm that necessitated the arm to be attached to the nose for several weeks to provide a blood supply (a technique still in use today for some reconstructive procedures), and the portrayal of Dr. Thackery anesthetizing a patient using a cocaine epidural. A lot of these weren’t exactly 1900 medicine, although they were generally from within a few decades. Dramatic license again. The point, however, is that medicine always operates within the context of the existing scientific and clinical knowledge of the time. Of course, The Knick is a vision of what medicine was like in 1900 imagined by a man of 2014. However, it’s also informative to look at medicine as portrayed in the media contemporaneously, as we will see. To do that, I leap from the world of The Knick to 50 years in its future.
Dr. Kildare, or I’d rather have a bottle in front of me than a frontal lobotomy
Over the last few years I’ve become a bit of a fan of old time radio, having discovered Radio Classics on Sirius XM Radio. In particular, I discovered The Story of Dr. Kildare. This particular radio show stared Lew Ayres as Dr. Kildare and Lionel Barrymore as the irascible Dr. Leonard Gillespie (the latter of whom was actually hilarious, by the way). It’s an episode of this show that demonstrates perhaps the clearest example of a standard of care that turned out to be disastrously wrong.
I sometimes listen to Dr. Kildare not so much for the stories themselves, but because of what a time capsule the show represents when it comes to how medicine is practiced. Most of the radio episodes I listen to tend to be from the early 1950s. One episode remains stuck in my mind, an episode that originally aired February 1, 1950 entitled “Angela and Steven Kester“. The episode begins with Dr. Kildare showing up in his office on a typical morning to cover a long shift on duty. He’s greeted with a phone call from an old friend named Angela Kester. Kester used to be a famous concert pianist, but in this phone call she frantically begs Dr. Kildare to come right away to her apartment because she’s convinced that her husband is planning to kill her. Dr. Kildare protests that he’s on duty and can’t easily leave the hospital, but she’s so upset that he tells her he’ll be right over. On his way out the door Dr. Kildare runs into Mrs. Kester’s husband Steven, who has come to visit him. Kester tells him that he’s very worried about his wife, who, according to him, appears to be exhibiting obsessive behaviors, playing the same piece over and over again, sometimes practicing 16 hours a day. Apparently, five years prior at a concert at Carnegie Hall, she suffered a breakdown and couldn’t perform in front of an audience after that. Kildare informs Kester that his wife had just told him that she thought Kester was trying to kill her. Kester, not surprisingly, is horrified, and the two of them rush over to the Kesters’ apartment, where they encounter Mrs. Kester feverishly playing and yelling that her hands are being controlled by the music.
Later, we learn that Mrs. Kester’s father had been a “second rate” pianist who had wanted his daughter to succeed where he failed. Recognizing Angela’s talent at a young age, he spent lots of money on lessons for her and pushed her harder than any father should push his child, taking pains to make sure that Angela was constantly reminded of just how much he had sacrificed for her. We also learn that she had undergone insulin shock therapy, a treatment in which large doses of insulin were administered to induce a hypoglycemic coma, a treatment that fell out of favor a few years after this particular episode aired because not only did it not work but it was very dangerous given that hypoglycemia can easily kill. We then learn that Angela Kester had undergone many cycles of electroconvulsive therapy, with little or no improvement. Much discussion occurs about how Angela couldn’t tolerate another course of ECT or insulin shock therapy.
Around this point, Angela tries to commit suicide by shooting herself in the chest, but fortunately for her all she did was to give herself a pneumothorax. Dr. Kildare operates and easily saves her life. Angela’s suicide attempt, however, leads Dr. Gillespie and Dr. Kildare each independently to delve into the medical literature looking for answers (one of the better aspects of this particular episode, as disturbing as the solution they both ultimately found was). The solution they come up with? They both decide that a prefrontal lobotomy is Angela’s only chance to be “cured” of her condition.
So, even though Dr. Kildare was a fictional surgeon, in this episode we see him diagnosing Angela with paranoid schizophrenia (which in all fairness was probably an accurate diagnosis), obsessive-compulsive disorder, and neuroses. In any case, not surprisingly, given the framing of the choice in such terms, the decision is made to go ahead with the operation, even though Dr. Kildare is not a neurosurgeon and appears not even to have performed this particular operation before. None of this stops Steven Kester from agreeing to the operation on behalf of his wife, and the operation proceeds. Dr. Kildare whips out the leucotome (a special instrument designed to use in performing prefrontal lobotomies) and does the operation, drilling a hole in Mrs. Kester’s skull and using the leucotome to cut the connections between the prefrontal cortex and the underlying structures. Naturally, Dr. Kildare’s surgical skill is copiously praised when he finishes the operation. After a few days of suspense, during which everyone wondered whether the lobotomy had been successful, Mr. Kester demands to see his wife, who is initially afraid of him, but then, after she recognizes him, declares that her “hands are free,” meaning that she didn’t feel the compulsion to play anymore. She is declared “cured.”
From the perspective of 2014, this episode is disturbing in any number of ways. First, there is the demonization of mental illness that shows through even a seemingly sympathetic script. Words like “lunatic” and “lunacy” were thrown about not by lay people but by Drs. Gillespie and Kildare themselves to describe Mrs. Kester’s mental illness. In some ways, the desperation is understandable. 64 years ago, there was little that could be done in such cases, and it is not entirely surprising that a sense of desperation led to the conclusion that desperate conditions call for desperate measures, such as insulin shock therapy (a dangerous therapy that didn’t work), ECT (which could work and is still occasionally used in the case of severe depression refractory to medication but was hugely overused then), and, of course, prefrontal lobotomy.
Interestingly, this particular episode of Dr. Kildare aired right at the height of the lobotomy craze (and, quite honestly, that’s what it is best described as, as is evident from Mo Costandi‘s description of the rise and fall of the lobotomy). It’s therefore no coincidence that this episode aired in 1950. No doubt the writers were doing what writers of medical series frequently do now: Feature a new medical or surgical treatment as the focus of drama.
Discovering this episode a few months ago simultaneously fascinated and appalled me. Like most TV and radio shows, Dr. Kildare is a time capsule both of the popular perception of how medicine was practiced during its time and of how medicine actually was practiced at the time. We had the young gun surgeon, highly skilled and compassionate, willing to take risks and push the boundaries paired with the old curmudgeon of a doctor who serves as his mentor and, despite his crankiness, is often revealed to have a heart of mushy gold. The show featured portrayals of medicine as practiced then, and, much like medical TV shows today, had medical advisors to guide the writers. In 1950, the prefrontal lobotomy, although admittedly controversial even then, was an accepted standard of care that we now view with horror. But how many others are there?
Is today’s standard of care tomorrow’s horror?
All of this brings us back to the central question of this post, which was mirrored when The Knick first premiered over six weeks ago, by Dr. Sanjay Gupta at MedPage Today, who asked the question Is Today’s Standard Care Tomorrow’s Horror? To supply fodder for the article, six physicians were polled by e-mail with this question. The answers were rather interesting, although some of them were more about politics than actual science-based medicine. For instance, Cherie Binns, RN, answered the question this way:
Talk of limiting care for geriatric patients or the multiply handicapped child (especially at birth) and limiting access to resources for those with chronic health conditions that utilize a majority of services and healthcare dollars available are certainly, if they become standards of care, something that will be mocked, misunderstood, maligned in another generation.
She also laments how the Affordable Care Act allegedly prevents patients from seeing skilled health care providers. Whether that’s true or not, it’s not really an answer to the question, at least not as far as I’m concerned. Even though few people would be unsympathetic to this point of view, her response is really is more a matter of value judgments and resource allocation than it is a matter of the scientific standard of care.
Disappointingly, a lot of the responses were like that. Only one respondent, Dr. Murali Doraiswamy, was bluntly honest:
Ninety-nine percent of treatments today will be viewed as harmful or unethical in the future; for example, most psychiatric treatments given to children or most back surgeries.
Personally, I think Dr. Doraiswamy vastly overestimates what percentage of treatments will be considered harmful or unethical in the future, given the high percentage of treatments currently used that are evidence-based. For instance, there are many surgical conditions that can’t be fixed unless the anatomy is fixed. The operations aren’t going to go away; they’ll simply evolve to become less invasive, as they are doing now with the introduction of laparoscopic and robotic surgery and as the treatment of breast cancer has evolved from radical mastectomy to much less invasive procedures. Conditions like hypertension are still likely to require medication, as lifestyle changes, although they alleviate a lot of hypertension, won’t be enough for many people.
A more common example that came up was the use of “shotgun-style” or “one-size-fits-all” treatments, or, as one doctor put it, a “carpet bomb” approach to medicine. Of course, one doctor, Dr. John P. Higgins, has the opposite problem to go along with demonizing the past, namely a Pollyanna view of the future, in which he proclaims that “targeted and individualized therapy for a patient’s unique physiology will be used, with precision efficacy and near zero side effects.” There is little doubt that we will be able to target our treatments more and more effectively, but “near zero side effects”? Whatever Dr. Higgins is smoking, I’d want some if I could stand to inhale.
Let’s take an example that our good Dr. McCoy aimed his contempt at. It’s a treatment that’s commonly demonized not just by those who are—shall we say?—not completely down with the whole science-based medicine thing but even some physicians, chemotherapy. If you do a quick Google search, it doesn’t take long to find posts decrying chemotherapy for cancer as setting the standard for barbarism in the field and even as “criminal.” Of course, there’s no doubt that chemotherapy is toxic and can be brutal (although it’s getting less so, thanks to better supportive care and more targeted therapies). However, as I’ve pointed out before, death from cancer can be far more toxic and brutal. When an ugly death is the consequence, chemotherapy’s risk-benefit ratio becomes more acceptable. Moreover, contrary to the claims of those who like to label chemotherapy as ineffective, chemotherapy, used appropriately, works. It’s also important to remember that most people who call modern treatments “barbaric” have an agenda that is not necessarily science-based.
Of course, there’s no doubt that chemotherapy has way more toxicity than we’d like, but to proclaim this issue a “crisis” is exaggerating. It’s more like a longstanding problem that will require research to overcome. Crisis or not, efforts are in full swing to find more targeted and less toxic therapies. It’s also true that individualized therapy, now more commonly referred to as “precision medicine”, will come to the fore. However, the process will not be as easy or fast as the hype promises. For every success, we will see failures. Moreover, we still don’t know what, exactly, “individualized” treatment will mean, even as quacks try to define it for themselves. Advancement in science-based medicine always occurs by fits and starts.
A rebuke to Dr. McCoy
As much as I love Dr. McCoy as a character, in that famous Star Trek IV hospital scene, he is dead wrong in his sneering contempt for medicine 300 years before his fictional time, just as I would be wrong to express the same sort of contempt for physicians from 1714 for believing diseases were a result of imbalances in the four humors, surgeons in 1900 who practiced without the benefit of antibiotics, or physicians in 1950 who were believing the case reports about frontal lobotomy. Physicians all practice according to the standard of the time, and that standard is based on the science as understood at the time. It is ridiculous to criticize physicians for not knowing something that hasn’t been discovered yet. In 2014 I hold in the palm of my hand a computer (my iPhone 5s) that is hundreds of times faster, drives nearly 2.5x more pixels, and holds thousands of times more data than the first computer I ever bought for myself, my clunky Mac LCII. Should I heap scorn on the computer engineers of a mere 22 years ago because computers then were so much less powerful than what we have now? Those engineers did the best they could with the technology they had.
I would also point out that science advances incrementally, building on what is known before, although there have been moments of rapid advance. It turns out that 1900 was a time of such advances in the field of surgery and medicine. Indeed, Dr. Thackery gives a remarkable eulogy in the very first episode for his friend who committed suicide, the very same Dr. J.M. Christiansen, who calmly walked into his office after his attempt at a C-section failed and the patient died, placed a sheet over the couch in his office, picked up a gun, laid himself on the couch, and shot himself in the head. This eulogy is particularly remarkable for its view of medical progress:
In particular, Thackery notes:
We now live in a time of endless possibility. More has been learned about the treatment of the human body in the last five years than was learned in the previous 500.
Many have said the similar things during the last few years, given the revolution in genomic medicine in which we currently find ourselves, and it’s true. We do live in a time of endless possibility, with amazing technology and science almost unimaginable by even the generation that preceded us. So, yes, I’d be shocked if some, or even a lot, of what we do right now as the standard of care is overturned even in the remainder of my career. I’ve already seen it just since I first entered medical school in the 1980s. It will continue, and that’s a good thing.
We are all products of the time in which we live, and we all have a tendency to view history through the lens of what is known now. To have a true understanding of the history of science, however, it’s important to try to put yourself in the shoes of physicians and scientists of long ago and take into account what they knew then and what tools they possessed. For example, the Halsted radical mastectomy is often decried as a “brutal” and “barbaric” operation. And so it seems to a surgeon of 2014. But remember: In the 1880s, when Halsted first conceived the operation, there was no chemotherapy, no radiation therapy, no adjuvant therapy of any kind. Breast cancers tended to present at an advanced stage. If a woman with breast cancer was to be saved, surgery alone was what would have to do it, without the highly effective help we surgeons now receive from our colleagues in medical and radiation oncology. In context, based on the understanding of cancer of the times, the operation made sense, and Halsted’s results were better than those of other surgeons. Similarly, today chemotherapy seems “brutal,” but it works. It’s the best that we have.
Going back to the fictional past of the Knick (and the real past), physicians in 1900 were just as clever, just as dedicated, and just as desirous of curing their patients as physicians are now. What they lacked then is the knowledge and technology that we have now that allow us to do what we do now. Medicine stagnated for hundreds of years, until the latter half of the 19th century, when it began to embrace science, and its failures tend to occur when it forgets science. Yet medicine advances nonetheless, thanks to science. It might do so in fits and starts. It might go down blind alleys. It might fall for fads based on less than rigorous science. But eventually, it advances, and we obtain the knowledge and develop the technology necessary to improve. Even in the fictional universe of Star Trek, I’d bet that the physicians of 1986 were no less clever and dedicated than Dr. McCoy. The difference is that Dr. McCoy had tricorders and other products of the science and technology of 2286. Science is what got us from the world of the Knick to where we are now, and science is what will get us to the world of Dr. McCoy.

An Overly Pessimistic View of Medicine
Harriet Hall on October 21, 2014
Link

Sandeep Jauhar wrote Doctored: The Disillusionment of an American Physician to express his frustration with the modern system of medical care in America. I found the book profoundly disturbing. If his experience is representative, I can understand why so many people have been criticizing doctors for only caring about money. His experience was so different from mine that I wondered if I had led a sheltered life as a military physician and was oblivious to what was going on in the civilian world. After further reflection, I think Jauhar is unduly pessimistic. Whatever the opposite of rose-colored glasses is, he’s wearing them.
His personal experience of medicine
Dr. Jauhar is a cardiologist who works in a large teaching hospital, where he had been hired to develop a program for patients with heart failure that would implement the most up-to-date medical knowledge and provide the best possible medical care. After long, grueling years of school, residency, and fellowship, he is elated to have finally finished his training and started a job where he can accomplish something good. But he soon sinks into despair. He is appalled by the realities of life as an attending physician, the many ways in which the “system” interferes with his efforts to provide the best care to patients, the unethical behavior of other doctors, and his inability to support his family.
His family, which soon includes two children, is living in a one-bedroom apartment; and even so, he can’t make the rent payments without large cash infusions from his wealthy father-in-law. To supplement his income, he moonlights by working for doctors in private practice; but he is abusively treated by unethical, money-grubbing employers who are gaming the system to make money by doing unwarranted tests and procedures. He envies his brother, an interventional cardiologist in private practice who is making big bucks doing procedures; but he is unwilling and unsuited to engage in the kind of politics that his brother is constantly obliged to use to keep up the flow of referrals (schmoozing with other doctors and fawning on them). By the end of the book, Jauhar has moved to suburbia and his wife has returned to work, so there is finally a prospect of making ends meet.
I just couldn’t relate to this. I have never encountered a doctor who didn’t make a living wage, although I have heard of a few who unwisely tried to live beyond their means. As an Air Force physician I earned considerably less than my colleagues in private practice, but I always had more income than I needed to maintain a comfortable lifestyle. He doesn’t say what his salary is. According to a 2011 survey, the average salary of a hospital-employed cardiologist was $254,000. I find it hard to wrap my mind around the idea that a large teaching hospital would pay a subspecialist so little that he would be unable to pay the rent on a one-bedroom apartment. He seems to be protesting that doctors in general are making too much money while protesting that he doesn’t make enough. Something just doesn’t add up.
Unwarranted pessimism
In a book review in The Wall Street Journal, Dr. Thomas Stossel says:
Dr. Jauhar also invokes what I term “the great American medical guilt trip”: the fact that we spend far more on health care for allegedly worse health outcomes, including higher mortality, compared to other countries. This self-flagellation is an apples-to-oranges comparison of vastly different geographies, social structures and cultures. After subtracting homicides and automobile fatalities, the mortality discrepancies largely disappear.
He also points out that Dr. Jauhar’s view of the past is too rosy. Jauhar compares today’s doctors to a mythical, highly respected, noncommercial medical “knighthood.” Dr. Stossel says he was there and can attest that no such nobility existed. And he points out that in Jauhar’s specialty, death from heart disease is 60% lower today than in the 1950s. He also points out that despite the statistics Jauhar offers on physician discontent, medical school applications rose by 38% between 2003 and 2013. There is a lot wrong with modern medicine, but there is a lot right, too.
The problems he cites are not hopeless
Rather than just complaining, why didn’t Jauhar offer constructive criticism from his privileged point of view as an insider? A lot of the problems that frustrate him are far from insoluble; they have been identified and efforts are already underway to correct them. Here are some of them:
Patients are transferred without records, so doctors don’t have all the information and have to repeat tests that have already been done. (This is a minor glitch that should be trivially easy to fix in this age of information and Internet communications.)
Patients see a number of specialists who don’t communicate with each other. They don’t have a primary doctor who knows them and cares about them as a person. (That’s the reason I specialized in family medicine; it is feasible for a primary care provider to take responsibility for all the patient’s medical care, coordinate referrals, put the specialists’ recommendations into context with the patient’s over-all needs and personal preferences, and translate medicalese for the patient and family.)
Insurance companies overwhelm doctors with paperwork and long telephone battles to get necessary tests and treatments authorized. (This kind of problem is typical of any bureaucracy and there are several conceivable remedies: a single payer national health insurance, competition between insurance companies with survival of the less obstructionist ones, better utilization of ancillary personnel to take the burden off doctors, etc.)
Medical residents are required to go home after a certain number of hours, and continuity of care is lost. (The previous longer hours had the drawback of sleep-deprived doctors endangering patients. The best balance to achieve both training goals and patient welfare goals is still being worked out and impassioned debates are ongoing in medical journals.)
Procedures are reimbursed, but time spent talking to patients is not. (It could be. Reimbursement scales are constantly being revised, and they could be revised to support the goal of doctors spending more time with patients, which both doctors and patients want.)
Terminal patients in hopeless situations are kept alive when it would be kinder to let them go. (It’s often the patient’s family who insists on “doing everything possible.” It would help to have more discussions with healthy patients and their families about advance directives, and time spent on these discussions could be reimbursable.)
A lot of unnecessary tests and treatments are ordered. (The medical profession is self-critical about this issue, and is constantly trying to improve the situation with initiatives like Choosing Wisely, consensus recommendations, policy statements from professional organizations, etc.)
Unethical doctors are gaming the system to make more money in disregard of patient welfare. (We have medical boards that ought to be dealing with such abuses. In practice, they are not doing a very good job. They tend to mostly target cases of drug abuse or sexual misconduct and tend to give substandard care a mere slap on the wrist — just think of the Texas medical board’s ineffective response to Burzynski’s obvious misconduct — but surely there are things we could do to make boards more effective. Isn’t it the responsibility of every doctor to notice when other doctors are using substandard and unethical practices, to confront them directly, to report them, to speak out, to stop referring patients to them? Peer pressure might accomplish a lot.)
Conclusion
The book is an affecting, well-written human-interest story of one man’s experience, but the picture it paints is darker than it needs to be. He admits he suffers from depression and has been getting counseling; I suspect his depression has clouded his perceptions. Some of what he describes represents a typical human trajectory in any lifetime and any job. We grow up. The ideals of youth run into the obstacles of adult reality. We have to earn a living now as best we can, and we don’t have the option of holding out for some ideal job that may not even exist. Aspirations of the perfect succumb to compromises with the possible. “I would never do that!” is replaced by “I had to do it!” Campaign promises are shipwrecked on the political realities of office. Black and white becomes gray and nuanced. A father’s absolute intolerance of abortion changes to reluctant approval of at least one case when his own teenage daughter is raped. We learn that the world doesn’t work the way we wish it would. We adapt. We learn to live with the things we can’t change while we try to change the things we can.
Whatever its faults — and I don’t deny that it has a great many — the medicine of today is better than the medicine of the past and far better than any alternative. Best of all, we are not sitting on our laurels: medicine is self-critical and constantly working towards even better medicine. We could adopt Jauhar’s pessimism and wring our hands in despair or we could be cautiously optimistic and get to work. He has identified a number of problems. That’s only the first step. Now it’s up to all of us to take the next step and look for solutions.

Irritated by the Skeptical Inquirer. Again.
Mark Crislip on November 15, 2013
Link
I have a confession. I have been interested in issues skeptical since high school when I came across a copy of the Zetetic at Powells. In the pre-digital era I had a complete library of Zetetic-Skeptical Inquirers (SI) that a decade ago was tossed in the recycle bin along with a similar collection of MacWorlds. I have been interested in skepticism a long time and, here is my confession, I no longer find much of the subject matter covered by SI all that interesting. Even big ticket topics like the existence of God are uninteresting. It is not that the topics are not important, they are, and each generation has to relearn why Bigfoot or haunted houses or UFO’s are nonsense. But for me it is a large serving of been-there, done-that.
So while I subscribe to SI, it is more from a sense of obligation to support institutions I think are important than from an expectation that I will be either educated by the content or entertained by the style of the writers. I usually skim the magazine while accomplishing tasks that do not require my full attention probably because SI is the only magazine I still receive in dead tree format, the rest of my life being digital.
So I ran across “Taking our medicine: What hope for skepticism in healthcare?” by Kenneth W. Krause and after skimming it I was irritated. So I read it again and I was more irritated, which is often a good sign. But I could not quite put a finger on what it was. So I read it again and then went for a walk and thought about it.
All the facts were fine. I had no issue with the content of the article. It was the adjectives that irritated me. And the essay was, from my perspective, incomplete. It was like reading a relationship/birth control article by the Pope. Sure, he knows the facts of the situation, but not being an active participant in the process and with an agenda to promote, vital information will be missing or distorted.
Regular readers of the blog know my background. For the last 24 years I have spent most of my waking time taking care of inpatient infectious disease patients in Portland, Oregon. My hospitals are not for profit and several are teaching hospitals. As Chair of Infection Control I have also been involved in many of the quality and safety initiatives in my hospitals. I have gone from the young whippersnapper to one of the old geezers at my hospital and am one of the few who have institutional memory as to what has happened in health care over the last quarter century.
For those of you who want some Science-Based medicine with links and references, this essay will come up short. This is a reflection about what it means to be a physician and how it may impact patient care. It is based on me and my experiences and observations. It is probably not applicable beyond the walls of my hospital and perhaps the walls of skull. Just today I was talking with a colleague who travels widely as part of her job and she was contrasting the culture of East coast and West coast medicine and noted that in Portland we have a distinct shortage of ABHD’s (arrogant butt head doctors) and that the academic docs in ****** (I do not want her to even remotely be at risk for getting in trouble) are a vicious bunch of backstabbers. So your mileage may vary.
The basic thesis of the essay is probably summed up by the following quotes:
[The] so called “medical-science” and American healthcare in particular prospers best in a self-serving culture of secrecy, arrogance and denial.
and
Medical overuse is a money-hungry green monster, say healthcare experts Rosemary Gibson and Janardan Singh. It not only “thrives on the fact that too little scientific evidence exists to justify a great deal of today’s medical practice,” it also “wants to prevent good science from informing policymakers and the public about what really works.”
He characterizes patients as “easy marks” evidently about to be swindled by “common and expensive overuse” of the medical industrial complex. Evidently doctors and hospitals are conspiring to give everyone unneeded expensive care.
There is no shortage of perverse rules and regulations with unintended adverse consequences in medicine. The biggest change I have seen in health care revolves around length of stay. In the old days a patient would be admitted, you would do a history and physical and generate a differential diagnosis, a list of possible processes that could cause the patients symptoms.
The patient has, say, a fever of unknown origin (FUO), a notoriously difficult diagnostic problem. In the old days the definition for FUO was a fever that persisted after 14 days of evaluation in the hospital. 14 days in the hospital. Wow. And I was always amused that Madeline was evidently admitted for a month for a simple appendix removal. But I digress.
Then you would order tests for the more likely causes, wait for the tests to come back, evaluate them, then do the next tier of tests, methodically working though the possibilities, sometimes taking several weeks to reach a diagnosis.
These days with length of stay an important driver of cost and reimbursement when a patient is admitted, all possible diagnostic tests are ordered at once, regardless of how likely the result will be. It drives me nuts to see, but in the era of short hospital stays it is better to get everything all at once and see what the final diagnosis is. It is one change that certainly drives increased testing. This is one example of many where rule changes in payment or care have had unintended adverse consequences for diagnostic testing. No good deed ever goes unpunished.
The article makes doctors and hospitals all sound like greedy dirt balls out to scam our patients and he gives numerous examples of the over use of medical care and its consequences, all driven by the need to make money. And I will reiterate: all his examples are true. But incomplete.
Everyone wants to make money, even ID doctors. Hospitals are expensive. The payroll, infrastructure and utilities are expensive. My hospitals spend millions a year in free care on the un- and underinsured. There are some doctors and institutions that are driven primarily by the need to make money, but making money does not appear to be the primary driver for testing for those I work with.
Medicine has a lot of uncertainty in diagnosis and treatment. I have been at it for 30 years and it does not get easier with time, you just get more comfortable with your limitations. I wonder how much increased medical utilization revolves around the more fundamental concepts of responsibility and accountability.
When I see a patient I am responsible for making the right diagnosis and treatment and often there is a lot of uncertainty with both. If I am wrong people can suffer and die. Even if I am correct, the decisions I make can result in harm or financial ruin. It is often our responsibility and accountability to our patients that can drive medical testing.
After my Dad retired from a career as a cardiologist I noticed he became more alert and active and I commented it must be nice to be rested after a lifetime of night time calls. He said it wasn’t the calls that ruined his sleep, although he received enough of them, but it was the worry that kept him awake. The worry that his patients would do poorly and the worry that he was doing all he could to make them better. I understand that worry. Bedtime is the time to perseverate about patients, to worry and fret about them, often to the detriment of a good night’s sleep.
Early in my career I had a patient admitted Friday afternoon with fevers for two weeks, a new aortic insufficiency murmur and conjunctival hemorrhages. Endocarditis (a heart valve infection), I thought. Get blood cultures and start antibiotics and I didn’t think I needed to call the tech in for a weekend ECHO. Aortic valve endocarditis is a dangerous disease that can decompensate quickly, but the patient had no signs or symptoms of valve failure so there was no need for the ECHO as the patient had no indication for surgery. I left for the weekend.
When I get back from the weekend the blood cultures were still negative and I was puzzled. They should be growing something by now so I ordered the ECHO and there was no endocarditis. Instead there was a dissecting ascending aortic aneurysm, a very rare mimic of endocarditis. I have not seen one like it before or since. I had sat on a dissecting aneurysm for 72 hours.
I do not know what is the worst thing that can happen in your job. In mine it is that through error, omission or commission, I injure or kill someone. You cannot imagine the sense of mortification I felt that I had missed a diagnosis that easily could have killed the patient. He was repaired and did quite well, but to this day I cringe when I think of the case. It is not for medical-legal reasons. I do not give a rat’s ass about being sued. I care about not hurting patients. I care about making them better. The more certain I am with my diagnosis, the more likely I am to not miss an unexpected diagnosis and the more likely I will give the appropriate therapy.
And that is nothing compared to the feeling when you discover that a patient who you thought was doing well has taken a turn for the worse. A couple of years ago I had a malaria patient who was admitted on Thursday and by Friday I thought he was doing well. But when I returned on Monday he was on a ventilator and ECMO, almost dying from severe malaria. I did nothing wrong mind you, it was the natural history of the disease. You can do everything right and still have a bad outcome. But that horrible sinking feeling of dread in the pit of your stomach you get when a patient does poorly is something everyone wants to avoid. It is horrible when a patient does badly because I am responsible and accountable for that patient, even if I do nothing wrong.
And that in turn is nothing compared to the feeling when a patient dies. Jesus. Even though I did everything right, a death is awful. The horrible sinking feeling of dread in the pit of your stomach is magnified many-fold. I am responsible and accountable for my patient and death and complications are a failure of that responsibility. As a recent blog entry noted
“Of course,” the young surgeon said, with complete sincerity. “Everything is my responsibility.”
That responsibility has consequences, the most important of which is
When a person trusts you with his life, the bucks stops with you.
I want to maximize the chance that my diagnosis is correct since the consequences of being wrong can be horrible. It is a difficult calculus as to how much uncertainty about the diagnosis is reasonable. How many tests do you need to maximize diagnostic certainty? A lot of tests get ordered to increase the certainty. You need the right diagnosis to embark on the correct therapy.
There is also the worry that the patient has an unlikely process that if missed could be catastrophic. If you think a patient could have a pulmonary embolism, a blood clot to the lung, you will probably order a CT even if it is low probability because if the patient did have a PE and you miss it they could die. And as a corollary you remember those surprise diagnosis of the past, the ones you didn’t expect that were revealed on CT or MRI. Sometimes testing yields unexpected and important pathology and those cases often have an excessive effect on future testing.
And unfortunately part of diagnostic utilization is due to the ghosts of failures past. If you have ever missed an unusual diagnosis on a prior patient you will remember it far more clearly than your successes. And if a similar clinical situation arises, or even one that is close, you are likely to order the tests even if the diagnosis is unlikely.
It is always a difficult road to walk: you want an accurate diagnosis, you know that everything you do can cause harm, you do not want to miss a catastrophic diagnosis and you do not want to repeat past mistakes. And this in the context of initial uncertainty as to the diagnosis.
And above all I want to help people get better. I doubt most people reading this will believe it, but what drives most of us in medicine is to make our patients better. I want to relieve their suffering, cure their infection, improve their health and get them back to their life. Unfortunately the medical literature so often is not clear cut as I would like as to what to do for patients. It is a constant problem applying the literature to a specific patient who may not match the profile of the patients in a study. You have to do your best with what you have and above all you have to do your best for your patient.
Arrogant is an interesting term used for physicians. It has certainly been used to describe me. The interwebs say it is “having or revealing an exaggerated sense of one’s own importance or abilities.”
Which is a curious adjective. I am expert in my specialty and few in the US have my knowledge base or my experience. There are about 8,000 ID docs and 660,000 physicians in the US out of a population of 314 million people. With the exception of those ID docs who have been at it longer than me, it is safe to say I know more ID than most doctors and everyone else in the US. If you are admitted to the hospital with an ID problem, there is no way you will ever be able to gather the knowledge required to make an independent decision about your diagnosis and therapy.
I find it odd how the expertise of physicians is denigrated. I do not see it with engineers (if drivers were more involved with bridge building we would have better bridges) or pilots (flights would be on time if more passengers were involved with flying the plane), although I suspect there are even more jailhouse lawyers than ersatz physicians.
An even more difficult problem in health care is health literacy, which is “the ability to read, understand and act on health care information” and depending on the demographic, affects half of Americans. We have a physician in our system with an interest in health literacy who has been a champion for improving and simplifying the material provided by the hospital. As an example, we are rewriting all out material so it is at a 6th grade reading level, the US average. As Dr. Breger likes to point out in his lectures, half of patients do not have the wherewithal to understand medical care, and
40-80% of medical information is forgotten upon leaving the provider’s office or facility and nearly half of the information retained is incorrect.
What we really need is a better class of patients and physicians, where all the patients are strong, all the doctors are good looking, and all the health care is above average. But we are stuck for the time being with humans, with all their flaws. While most would like their physician to be an unholy blend of Marcus Welby, a boy scout and God, the reality is vell, Doctors are just zis guy, you know?
It would be nice for patients to aggressively represent their own interests, but most cannot, especially when they are ill. Probably half the patients I see in follow up do not remember having seen me in the hospital because of medications, stress, sleeplessness and other factors. Perhaps my bedside manner sucks as well. For good or ill, given the complexity of medicine and the limitations of many patients, it is my responsibility as your doctor to be your advocate and to strive to make the right diagnosis, start the right therapy and get you better. The best most patients can get is a Readers Digest understanding of their disease.
The characterization of medicine as filled with money grubbing bastards who provide unneeded and dangerous care for profit is true, but narrowly true, one small aspect of health care, and of all human endeavors (except, of course, journalism), but not all of health care.
“Taking our medicine” was at its core the kind of essay I would expect from the Health Ranger or Dr. Mercola, although not reaching the levels of total nonsense of Food Babe in its understanding (my current standard for the ultimate in health illiteracy).
“Taking our medicine” has familiar construction I often find in the SCAM world. I see similar articles every day; it is the first time in my faulty memory to find a Mike Adams-style essay in the skeptical world. These essays have a pattern:
1) Present facts but make sure they are without nuance or context. Mention the deaths from health care but conveniently fail to mention the responses: The Institute for Healthcare Improvement’s 100,000 Lives Campaign, which in 2006 claimed to have prevented an estimated 124,000 deaths in a period of 18 months through patient-safety initiatives in over 3,000 hospitals. Or the 5 million lives campaign. Or any number of quality improvement initiatives that have occupied my time and improved patient care.
The amount of work we have done to decrease complications in my institutions has been prodigious. We have applied, to use Mr. Krause’s quoted phase without his intended irony from the quotes, “medical science” to patient care and in our system we estimate that we have prevented over 2,000 infections and 200 deaths since 2006. Mentioning medical complications without noting the response to those deaths is a sure sign that the author is disciple of Andrew Lang.
As is, I suppose, putting doctor in quotes, as he does in the essay. It is probably the equivalent of calling me Mr. instead of Mark or Doctor or Crislip or hey you. In the blog comments, calling one of us Mr. is probably 100% sensitive and specific that the writer is a wackaloon, especially if addressing Harriet or Jann.
2) Use inflammatory adjectives and phrases that cast your protagonist in the worst light possible: self-serving, secrecy, arrogant, denial, money-hungry, green monster, highly-caffeinated, gleefully sell anything, easy marks, misplaced trust, lucrative, cozy economic relationship, forsake journalistic integrity (no, not the author in SI, a different forsaker), dysfunctional, left in the dark, etc.
3) Make sure there is an aura of conspiracy. Doctors and hospitals are monolithic institutions that are working to prevent you, the consumer, from knowing the truth so that they can bilk you out of your hard earned money, harming you in the process.
4) Make sure the protagonists are represented as totally evil and without redemption. Never mention the good. We probably killed Kenny as well.
5) Have simple, yet all encompassing, solution. Explanations exist; they have existed for all time; there is always a well-known solution to every human problem — neat, plausible, and wrong. ~H.L. Mencken. Twain or Mencken as Americas best writer ever. Discuss.
Kevin Trudeau may be heading to jail, but the spirit of his oeuvre now lives on in SI.
Or maybe not. Perhaps I am a gullible, biased and naive, an apologist for the medical-industrial complex. It is probably my ongoing confirmation bias, but the only two articles I can remember concerning real medicine in SI are this one and the Spector article and they were both suboptimal. At least when SI has an article about a SCAM they have authors who know the topics; I am not so sure it applies to real medicine.
Again, every problem with medicine noted by Mr. Krause is true and I can come up with many more. Medicine in the US is a mess in many ways and I have no good answers short of making me the all-powerful emperor of healthcare.
Medicine is also an incredible profession. At the end of the day I can look in the mirror and know that I have made someone’s life better, I have relieved suffering, cured a serious illness, prevented an early death, decreased morbidity, made the diagnosis missed by another, eased anxiety. In my job I make the world materially a little bit better every day through the practice of good, science-based medicine.
I am also of the opinion that being a doctor is more than being a “human being providing a competitive service.” It is odd as a lifelong skeptic and atheist to consider medicine a higher calling, with obligations and responsibilities for service to my patients that transcends a technical-financial relationship. But I do. It is why I have patients, never clients or customers. That is an old school attitude that I do not always live up to, but I try and it marks me as an anachronistic dinosaur. Damn it Jim, I’m a doctor with all the intangible responsibilities that accompany the job.
I find the job impossibly complicated, filled with uncertainty and I never seem to have enough knowledge. If I am lucky and careful, I get through the day without complications or bankrupting my patients. But I start every day with gleeful anticipation of the challenge, the responsibility and the fun that I know is to come and finish each day satisfied that I did my best for my patients with the tools at my disposal. Despite the many flaws there is no better job or more noble profession.

Old Doctor Yells At Clouds
Mark Crislip on January 21, 2025
Link
I’m at that age, 67 going in 68, where it is reasonable to yell at the clouds. Which, come to think of it, may be a good title for another collection of my SBM essays.
Aging does indeed suck, but it is, usually, better than the alternative. As we, and by we I mean my family and me, age we get the endless joys of accessing health care. I have it pretty good. Straight Medicare with a supplement. No way would I ever go on an advantage plan, given I have already spent enough time arguing with those institutions when I was in practice. I am only two years into retirement, so I still know most of the doctors who care for me and mine. Still, I am much more of a patient, as virtually every organ system save my liver, which I exercise fastidiously, is on that slow fail that proceeds oblivion.
I will admit that, as a patient, I am not always so impressed. There is a long tradition of doctors writing about becoming patients and they have an epiphany about what it means to be a patient. This ain’t going to be that kind of essay. I have had multiple medical issues over the years and I have found the experience to be fine. My care has always been professional and caring. Still the case. But of late? So some observations, taken with a gain of salt substitute, about some trends for the practice of medicine upon me and mine.
Half-Assed
Half-assed was the term my father often used to describe the result of my chores around the house as a kid. In retrospect, I can’t disagree with his assessment. I wish I had asked him before he died if a good job would be full-assed or zero-assed. I guess it depends on whether the goal is full or zero.
But I have been impressed with how often the basics of medicine are perfunctory. Cursory? Desultory? Superficial? No, I’ll stick with half-assed.
What I am referring to is so many health care providers I am in contact with as a patient or an observer (such as when my wife or mother sees a doctor) to a half-assed history and maybe a quarter-assed or three quarter-assed physical.
It is sad.
When I have a medical problem, I organize the history before I see the care provider so they get a classic presentation of the history of the present illness, like I learned as a medical student. Six minutes tops, succinct and perfectly organized. So I know my providers are getting the right information to make a diagnosis. I do recognize there is the problem in that my presentation also includes my bias as to what I think my problem is. I am well aware that, in regards to my own health, I am not the most reliable of historians or clinicians. The doctor who diagnoses himself has a fool for a patient and an idiot for a doctor and all that.
But for some family members, I have witnessed the most superficial of history taking. I know why. The abdominal pain that brought them into the ER? Going to get a CT to see what’s going on. So why bother with a careful history when the technology and blood tests will likely reveal the diagnosis? I am old and old school. I was taught and practiced that a careful history determines the diagnosis and then the tests are ordered to confirm that diagnosis, not to make it.
And when the CT is negative, everyone looks baffled because they have not bothered to make a clinical diagnosis first. Surprise.
I also find that providers rely more on what they read in the chart than what the patient has to say. And that is always a mistake. I learned early that the best approach to a new patient was to go in mostly blind and gather the information needed from the source. I was kind of an asshole, for when I was called for a consult I told them I wanted no more than a 5-word question they wanted answered. I assumed everyone else had it wrong and the approach occasionally paid off.
And the exam?
How many heart /lung exams are I seen that were both brief and though the gown or shirt? Too many to count. One anesthesiologist’s stethoscope was not on my chest for a complete cardiac cycle. It is rare to get a cardiopulmonary exam done that I think would provide any meaningful information to the examiner.
And abdominal exams? Usually a brief push on the belly while the patient is sitting up. I have yet to see anyone do the classic look, listen, percuss and palpate.
Most of the time, I just laugh, as I know the exam isn’t likely relevant. I have no cardiopulmonary issues and do not need a heart or lung exam before surgery. It is not like they are going to find an undiagnosed aortic stenosis that might cause an issue with anesthesia. But it might be with the next patient if they bothered to really listen.
So why are the exams so half-assed? I think two reasons. One is that technology is better than the exam, although more expensive. You will get more information from an ECHO or a CT or an ultrasound or an MRI. Or even a chest X-ray. My pulmonary attending years ago said the lung exam is what you do while waiting for the CXR to develop. And I kind of agree with that.
But finding pathology is fun and, on occasion, you will pick up pathology that the technology will miss. Little things, but important. How many times did I note the patient had blue sclera and talking with the patient revealed they likely had Ehlers-Danlos, unnoted for decades? Or the embolic event in the nail bed that meant endocarditis? And the exam can confirm what you think is the diagnosis from the careful and complete history. Ff you bothered to take one.
The main reason these exams are half-assed? Docs can bill at a higher level if they do them. So even if you have no heart or lung issues, you will get a half-assed heart-lung exam to bump up that billing code. I never did that. I was told many times that I could bill more if I did, but I never thought it was ethical to provide unneeded care for the sole purpose of billing. Everything you do for a patient should only be for the benefit of that patient.
I should add there is a difference between the initial physical and the follow-up physical. An initial evaluation by your HCP should be complete. After that? Likely should depend on what the problem is.
I will say the exam is not always half-assed with all health care providers. The docs I see often do the exam correctly. But they are all old, at least in their 50s. I have found the younger the provider, the more half-assed. And, sadly, MDs are more half-assed than NPs or PAs.
Grumpy old fart grousing about the youngsters today. And get off my grass.
Surgical Dunning-Kruger
Medicine is difficult. Very difficult. Trying to diagnose and treat patients with the most up-to-date information is hard. I always thought the online textbook UpToDate should be called ImAwaysBehind.
There are a lot of reasons why docs are slow to change practice. I often followed the motto of ‘Be neither the first to accept the new nor the last to abandon the old.’ But the medical literature exists to be applied. I admit sometimes it was uncomfortable. The first time I gave high dose gentamicin or oral antibiotics instead of intravenous for an osteoarticular infection, it felt like I was performing an unnatural act. Nice thing about unnatural acts: they rapidly become natural.
When treating infections, you always want to provide optimal therapy. If you have several options with equal efficacy, then you go with the least toxic and least expensive. Unless you have a dysfunctional work environment. I know the following was not meant to be an indictment of the hospital work environment, but this is in the New England Journal of Medicine by way of an ID doctor at one of the premier hospitals in the US, Brigham and Women’s Hospital, Here is the meat, with inside baseball/inside infectious disease commentary. From On the Inpatient ID Consult Service, Oral Antibiotics Have a Rocky Road to Acceptance
I bring you now a blended version of several conversations I had with surgical colleagues when I recommended oral antibiotics for their patients:
Me: I heard from your resident that you wanted a PICC line (an iv used for home antibiotics MC) for Mr. Smith. Did you see our consult note?
Surgeon: Thanks for following him. No, didn’t read it — what did it say?
Me, not at all surprised that the attending surgeon didn’t read our Masterpiece:
This is a blended version, so evidently, it is common for surgeons, later identified as Dr. Orthopod P. Neurosurgeon, to not bother reading the consult note. Jesus. Dr. Orthopod P. Neurosurgeon chooses to be ignorant of the advice of experts? Right there, you have a problem. As the attending physician, surgeon or otherwise, you should know what is going on with your patients, and that includes reading the consultation you requested.
My masterpieces were always read, in part because I made them readable. A consultation was rarely more than a page and a half typed, and ended with a concise summary of what the patient had, what tests and therapy needed to be done and a few abstracts from the relevant literature.
I will note as an aside, and I do not know if it applies here, but ID docs often take a perverse pride in writing extremely long notes instead of getting to the point. As if they are paid by the word and not the deed.
We recommended that he go home on trim sulfa, one double-strength tablet twice daily. (I might have said Bactrim. OK, I did.) The organism is susceptible, and it has excellent oral absorption. That way we can spare him the PICC line and all the risks and hassles of home IV therapy.
Surgeon: This was a very severe infection — I’d prefer we be as aggressive as possible in treating it.
Me: Understood. But there’s literature now showing that oral antibiotics are comparable to and safer than IV. I’m especially comfortable in recommending it when there is a high GI-absorption option like Bactrim, a susceptible bug, and there has been source control, as in this case.
Surgeon: Thanks for sharing that — I’m not up on the ID literature, but this infection threatened to get into the joint (or bloodstream or CNS — it’s a generic conversation). In the OR, we drained frank pus, and had to copiously irrigate the site with 3 liters of sterile saline.
Me: Yes, I understand it was bad. But it sounds like you got it all — that’s probably the most important thing. Another thing, he’s taken Bactrim before, and we know he tolerates it well.
I too am annoyed by the term frank pus. How is that different from pus? It isn’t. And 3 liters? That’s not much. I use more when I wash the dinner dishes or flush a toilet. Not impressed.
Treating infections is first and foremost about the source control. If the infection is drained, then it is mostly cured. Wanting to give IV under these circumstances is a waste. In the Middle Ages, they did not take prisoners, and it was someones job to walk the battlefield and cut the throats of the wounded. For many infections, that is the role of antibiotics. They don’t win the battle; they dispatch the remaining losers. As I like to say, no debridement, no cure. Know debridement, know cure.
I’m not up on the ID literature. Note, the data suggesting that oral is equal to iv for a variety of infections had been building since the turn of the century. One definitive study was Oral versus Intravenous Antibiotics for Bone and Joint Infection in the NEJM in 2019. Five years ago. It is hardly cutting edge therapy. Dr. Orthopod P. Neurosurgeon has been willfully ignorant for half a decade. And allowed to bully others into providing second rate care.
Surgeon: Maybe use orals for a milder infection, but not for an infection this severe. I told him after the surgery he’d be going home on IVs. If we use oral antibiotics and it fails, I’d feel bad we didn’t attack this as hard as possible with IV antibiotics.
Well, perhaps you should not give advice antibiotic advice when you do not the know of what you speak. Leave it to the pros from Dover, and yes, I know they were surgeons. I have long noted there is only one sign in medicine that is 100% sensitive and specific. Anyone who thinks a given antibiotic or its route of delivery is big gun, strong or powerful is an idiot who is a Jon Snow about the treatment of infectious diseases. Bet you a dollar Dr. Orthopod P. Neurosurgeon uses those or similar adjectives. The only question is if an antibiotic gets necessary levels in the body space that’s infected. Bacteria don’t care how the antibiotics get there.
Me: OK, we’ll set up the home antibiotics.
Surgeon: Great, thanks so much. Really appreciate your help.
Oops. The Pros from Dover shanked it into the water. Sigh.
Me: No problem. He’ll go home on 6 weeks of IV colistin.
(That’s an ID joke, ha ha. It really was ceftriaxone.)
Oddly, I am not laughing and I am a (retired) ID doctor. Just isn’t funny.
The rest of the essay is a justification for what looks to be a very dysfunctional work environment preventing the patient from receiving optimal care.
So what is wrong here? The person with the least knowledge is deciding on the care of the patient. This jackass, and Dr. Orthopod P. Neurosurgeon is a jackass, a Dunning-Kruger personified, gets to decide on the best antibiotic therapy. Dr. Orthopod P. Neurosurgeon would not tell an oncologist how to treat a cancer or a nephrologist how to do dialysis. Yet somehow she gets to determine the antibiotics? Next up, RFK Jr. will take over the infection control program at Brigham and Woman’s.
As an aside, this can be a problem for the infectious disease doctor, where other physicians feel they can ignore or change ID orders. That happened to me, but very rarely. I tried to be relentlessly nice as a consultant. Always considered the five A’s of being a doctor. Ability, Accountability, Affability, Availability and Appearance. Well, 4 out of 5 ain’t bad. But if you are nice all the time, when you do get angry, it makes an impression. I would channel my inner asshole and I would ask the offender: Would you change an oncologist’s orders? Would you ignore the nephrologists dialysis orders? Are you board certified in infectious diseases? Do you have 25 years of experience taking care of patients? Do you read the ID literature? (Which the above Dr. Orthopod P. Neurosurgeon commonly and unsurprisingly, does not.) Is it not profoundly disrespectful to ignore my expertise?
After than I had no further issues. Had a reputation that way. So the rules were clear. Consult me, we do it my way, because, unlike you, I actually know what the hell I am doing. I’m responsible. Otherwise do it yourself.
There are cases where the best approach is uncertain and requires a consensus. And there can be many reasons you would opt for iv instead of oral therapy. But that is not what was being presented here. This is meant to be a clear cut case with oral therapy is appropriate but not provided because of Dr. Orthopod P. Neurosurgeon.
The patient went home on equivalent but far more expensive and potentially toxic therapies for no other reason I can see but to appease the uninformed ego of Dr. Orthopod P. Neurosurgeon.
I have seen no end of odd complications of home iv therapy, from line infections to lines breaking off and moving downstream to the pulmonary artery to transfusion requiring blood loss when the dog chewed off the iv cap while the patient was asleep.
And no end of patients who lost jobs, houses and had to declare bankruptcy from the expense of home iv antibiotics. I think it is unethical to send someone home on unneeded expensive and toxic IV when oral therapy is equivalent for the sole reason of appeasing Dr. Orthopod P. Neurosurgeon.
It could be argued, and is, that there are many ways to skin a cat, and that the outcomes are equivalent.
Imagine if you will (we watch the Twilight Zone every New Year’s Day while we de-Christmas the house, so Rod Serling is fresh in my mind) you are driving down the street and the check oil light pops on, conveniently next to your car dealer. You pop the hood and check the oil. Dry. No oil can be catastrophic.
It turns out there is a loose connection and the mechanic finds all you need is a quick bolt tightening and 6 quarts of oil. Instead, the cars salesman tells you need to replace the oil pump, put in a filter you don’t need, gives you 6 quarts of the new synthetic, Rocefoil at 10x the cost, and keeps the car for 4 days to do it, so you need a rental to get to work.
Same outcome either way. And you were not told all you needed was a bolt tightening and some 10W40.
And if you were told? You would be fine with that? Doubt it.
To paint with broad brush strokes, from what I could tell from conversations with colleagues over the years, this sort of practice is more common in academic than community hospitals and more common on the east coast than the west. But I ain’t getting my orthopedic or neurosurgical infection treated in Boston by Dr. Orthopod P. Neurosurgeon anytime soon. Way too dysfunctional a work environment to assure me I will be getting the best, safest, least expensive treatment. And I wonder just how good the cardiopulmonary exam of Dr. Orthopod P. Neurosurgeon was.
Nepotism
So, are you interested in the NBA? Specifically the Portland Trailblazers? Because who doesn’t like to suffer? I am married to a hardcore Minnesota Vikings fan. I know suffering. But if you are interested in the Blazers, allow me to be a Joe to his Hunter, or Donald to anyone but Mary, and point out that my son has a new podcast, Blazers are Cool. If you want the wit, the charm, the trenchant analysis that only a Crislip can offer, check it out. Like and subscribe. And I will let you guess which one is my son.

What Doctors Feel
Harriet Hall on July 30, 2013
Link
Doctors are often accused of being unfeeling technicians who treat their patients like cases of disease rather than people (think Dr. House). We were taught in medical school to remain detached, not get too close to patients, and not show our emotions. That attitude was epitomized in William Osler’s essay Aequanimitas. But doctors have feelings like anyone else, and no one is Spockishly rational. A patient might reasonably say “I don’t give a damn how my doctor feels as long as she gets me better,” but emotions affect everything we do, influencing clinical decisions and patient outcomes. This subject is investigated in a new book, What Doctors Feel: How Emotions Affect the Practice of Medicine, by Danielle Ofri, MD, PhD, an associate professor of medicine and an accomplished writer who has written extensively about her experiences in medicine.
She tells anecdotes from her training to give the reader a feel for what it was like to be in an extremely stressful situation with time pressure, conflicting duties, lack of sleep, life-or-death responsibilities, the highest expectations, and the impossibility of both getting everything done and doing each thing well. It reminded me of times in my own training when I desperately wanted to just somehow survive the day and not kill anyone. Medical residency can be almost as stressful as a war zone, and has its own PTSD victims, complete with flashbacks.
Part of the stress is being suddenly immersed in a new culture with its own tribal customs, slang, in-jokes, and a foreign language: “82WM w/PMH of CAD, CVA, MIx2, s/p 3V-CABG, c/o CP, SOB 2 wks PTA. BIBA s/p LOC. No F/C/N/V/D.”
Empathy for patients tends to diminish during training. And it’s important: in one study the diabetic patients of high-empathy doctors had 40% fewer complications.
Everyone makes mistakes. Ofri candidly confesses some of her own mistakes and near-disasters and the emotional impact they had on her. When doctors make mistakes and a patient is injured or dies, or almost dies, it takes a terrible toll: guilt, shame, fear, defensive practice (ordering unneeded tests and getting rid of rude, demanding, or noncompliant patients), and soul-corroding damage to their core sense of self.
And then the lawsuits! 75% of doctors in low-risk specialties (pediatrics, dermatology, psychiatry) will be sued for malpractice by age 65; in high-risk fields (neurosurgery, cardiac surgery, obstetrics) it’s 99%. Fully 19% of neurosurgeons face a lawsuit each year. Not even a seemingly perfect doctor/patient relationship can prevent lawsuits. She tells about a family doctor who delivered a child with cerebral palsy and remained close to the family as he cared for them over 20 years. He was devastated to be sued for obstetrical malpractice at the 20 year mark even though he understood the financial motivation: the parents were afraid there wouldn’t be enough resources to care for their son after their death. Even if the suit is frivolous and the doctor has not made a mistake, the legal process is emotionally draining and can last for years.
Doctors who have been sued are more prone to burnout, depression, and suicidal thoughts. In a recent Medscape report, 23% of doctors characterized their lawsuit as “Horrible. One of the worst experiences of my life.” 39% of lawsuits lasted between one and two years; 11% dragged on for more than 5 years. On the upside, 57% resulted in no monetary award to the plaintiff. The long-term effects? 29% said “I no longer trust patients; I treat them differently.” And some of them practiced defensive medicine.
Ofri discusses problems with American medicine: the increasing burden of paperwork, the decreasing time for patients. Hospitalists spend only 18% of their time on direct patient care. Patient outcomes are better when doctors are happy in their jobs.
She describes the emotional ups and downs she experienced over many years with a favorite patient, a plucky single mother with progressive heart failure. As an illegal immigrant, she was ineligible for the heart transplant list. Finally she got a green card and a heart. Dr. Ofri describes her own joy at hearing the news; but then she has to describe her sorrow when the patient promptly dies of surgical complications.
The “system” often sets doctors up for failure and helpless frustration. She reports a trivial but telling example: residents were required to be in a conference that lasted until 1 pm, and also expected to arrive promptly at 1 pm in the clinic a quarter of a mile and 2 slow elevators away. A simple change to a 1:15 pm clinic starting time solved that problem.
More serious problems of burnout and lack of sleep are being addressed by limiting hours on duty and facilitating discussions and group support efforts. Much more can be done, such as allowing more time with patients, and Dr. Ofri’s insightful book can help guide us in the right direction. Acknowledging the role of emotion in medical practice will be a critical factor.
Osler wrote his Aequanimitas in 1889. In 1927 Francis Peabody wrote:
One of the essential qualities of the clinician is interest in humanity, for the secret of the care of the patient is in caring for the patient.
Ofri is clearly a Peabody-type doctor but she also embodies some of the best qualities of the Osler-type doctor. An ideal mix, I’d say. It was a privilege getting to know her through this book.

Doctors and Dying
Steven Novella on February 27, 2013
Link
“I intend to live forever. So far, so good.”
– Steven Wright
The humor in many of comedian Steven Wright’s famous one-liners is that they are simultaneously familiar and absurd. At some level we all know that we are going to die, but as long as we are still alive (or a loved-one is alive) we can cling to the irrational hope, the impossible denial, that death remains a distant abstract concept, not an near inevitability.
We all need to come to terms with death in our own private way, but often those terms are not private because they drive our use (for ourselves or others) of increasingly expensive health care. Two essays over the last year by doctors explored this issue, noting that when doctors face their own mortality they often make different health care decisions for themselves than the general public.
In February of 2012, Dr. Ken Murray wrote an essay in The Wall Street Journal – Why Doctors Die Differently. His primary thesis was that doctors choose less end-of-life care for themselves than the average patient. They do so largely because they are intimately familiar with the futility of much of what we do for patients who are likely going to die anyway. As one example, CPR has a success rate of about 8%, with only 3% of people receiving it going on to have a near-normal quality of life. Those numbers are pretty grim. Meanwhile, TV depictions of CPR are successful 75% of the time with 67% returning to normal life. Sometimes the person wakes up during the CPR, is fine, and then goes on to thwart a terrorist attack without missing a beat.
For the general public, receiving CPR means surviving and going on with life. For doctors, receiving CPR means prolonging the inevitable and just adding unnecessary additional pain and suffering in the process.
Even when told the numbers many people will cling to that 3%. Physicians live it, however. They see first-hand the outcomes and it is real to them.
A second essay by Richard Senelick from last year, Why Dying is Different for Doctors, focused on being comfortable with one’s own mortality. His point is that the more familiar an individual is with death the more they have likely come to terms with their own death. This allows people to “die with dignity.” He did cite two studies, but they did not support his premise. One Israeli survey showed no variation by specialty correlating exposure to death and personal anxiety about death. The second study he claimed did show a relationship, actually didn’t. It showed:
The results confirmed an inverse relationship between the use of repression and overt report of death anxiety for the physicians tested. Frequency of exposure to death seemed to have no effect on defensive style. The physicians most frequently exposed to death (internists) did not employ the most repression, as expected.
Anxiety over death did decrease with age, but that is a general trend not unique to physicians. Of the two hypotheses above, familiarity with the futility of certain care, rather than decreased anxiety about death, seems to have the more compelling case.
Unfortunately, there isn’t much more published about the attitudes of physicians toward their own end-of-life care. Physicians are far more likely to have made advanced directives – Murray cites an article indicating that 64% of physicians compared to 20% of the general public have made advanced directives (instructions for what to do and not do if they are gravely ill and unable to communicate their desires).
Issues of death, advanced directives, and futile care are increasingly important as the cost of health care continues to rise and is generally considered to be unsustainable. I was extremely disappointed to see, during the debate about Obamacare, that these critical issues were effectively sidelined by painting them with the politically unpalatable label of “death panels.” This term exploited one barrier to effective end-of-life counseling and advanced directives, lack of trust of the system.
Doctors and certain other health-care workers know first-hand that some interventions are not likely to be worth it in some situations, and can comfortably choose to forgo expensive and painful interventions that are truly futile. Their families who trust them also make similar decisions. But for the general public, without first-hand knowledge, they have to have enough trust in their doctors, the hospital, and the system to believe that when they are being told that a certain intervention is not worth it that this is a fair assessment.
Some comments to Murray’s article reflects this attitude, for example:
In other words, 99%, can you please die quickly? the rich need those machines.
I have personally encountered such pushback – families who fear that the system is willing to sacrifice their loved one in order to save money. In fact, there is a kernel of truth to this. It is ruinous to everyone if, as a society, we spend health care dollars we cannot afford on care that every specialist involved knows to be futile, or to have only the tiniest sliver of a chance of an outcome that is something other than horrible. People don’t think about society when they are making such decisions for loved ones, however. It’s also the physician’s job to advocate for their patient, not society. Discussions focus, therefore, and as they should, on what is best for the patient.
As a society, however, we do need to balance what is optimal for individuals and what is best for society, which is really just about considering all individuals. To a degree we are dealing with a zero-sum game in that health care resources are being rationed and increasingly will need to be rationed. Spending health care dollars on futile care for the dying will take resources away from others who are more likely to benefit.
Right now there is no good mechanism to avoid truly futile care, other than individual physicians counseling families and patients in each situation. To be fair, much of the time, in my experience, people make very reasonable decisions and generally follow the advice of their physicians. It doesn’t take many exceptions, however, to spend billions on futile care. Utterly worthless interventions should be the low-hanging fruit in terms of reducing health care costs, but it seems to be off the table.
It seems that more study is needed into how people (including doctors and other health care workers) make decisions about end of life care. The system does need to do a better job overall in confronting these uncomfortable issues. Doctors need to discuss these issues more consistently with their patients, more of whom should have advanced directives. Even worse than merely futile care is futile care the patient does not want, but we are obligated to give because that was never documented.
These are all difficult, controversial, and even painful topics to discuss, but we can no longer afford to avoid them.

What Not To Say When Someone Is Sick
Steven Novella on March 30, 2016
Link

I understand the impulse, but you are well-advised to resist it. When someone you know has a serious illness, maybe even dying, you want to say something to them that is helpful, positive, and hopeful. The hopeful tone takes away some of the sting and the awkwardness of not knowing what to say to someone who just told you they are dying.
The problem with this approach is that you risk making the other person feel worse just so you can make yourself feel temporarily better, to ease the discomfort of that one encounter. It is really easy to rationalize this behavior to yourself; you are just trying to be helpful.
Sick shaming
There are multiple problems with this approach, however. The first is that it makes the person with an illness feel terrible. As Steven Thrasher said in a recent excellent editorial (which you should read in full): 
Talking at someone with cancer about what they should do, rather than being with them in a morass with no easy answers, is not you helping them. It is you unfairly shaming them for having failed at self-help, which isn’t even a thing.
He further says that telling people what they should do to treat their illness blames them for being sick, further isolates them emotionally, and is condescending.
The desire to offer such advice is ultimately about feeling in control, but that control is an illusion.
Alternative medicine makes it worse
By all accounts, one universal experience of those with a serious illness is that people come out of the woodwork to offer them advice about which alternative medicine they should be using to cure themselves. The experience is even worse for those with any fame, for then they have hordes of fans giving them unsolicited advice.
I have experienced this myself with sick family members, and have heard it from many friends and patients, and documented it in many articles. Sick people are just inundated with terrible advice.
What alternative medicine gurus are selling, more than anything else, is the illusion and false hope of control. If they were truly interested in helping people with practical interventions, then they would follow proper due diligence. They would prove to a reasonable degree that their treatments were safe and effective. In other words, they would follow a valid and transparent process of science, and their treatments would not be alternative.
Further, if their treatments truly worked, they would want them to be available to everyone, and the only way to accomplish that is to prove it with science.
Instead, we have an industry of fake treatments, often lacking even basic plausibility, that are either already proven to be worthless or even harmful, or are simply unstudied. They prey on desperation and false hope. Further, like any good pyramid scheme, their customers become their best sales people.
What you are doing when you advise a sick person to try an unproven alternative treatment is saying that the medical profession is crooked or incompetent, and that you know better than the world experts who have dedicated their lives to studying medicine and looking for treatments. This is the Dunning-Kruger effect but with immediate practical implications.
You are also saying that the sick person is not taking their illness seriously, that they have not explored all options, and that they are better off listening to you than their own doctor.
Remember this – you are not their doctor. You have no business giving them health advice. If they ignore you, you have only managed to make a sick or dying person feel worse. If they listen to you, then you now have responsibility for the outcome.
Sick people are emotionally vulnerable, that is why they are preyed upon by charlatans. Whatever their intentions, what actually happens is that the sick person and their family are simply victimized. They are given false hope, which is likely to be dashed, adding to their emotional burden.
I have seen this myself – patients who spend the last year of their life not dealing with their ultimate mortality, not getting their affairs in order, and not spending time with their loved-ones, but instead living in an unstable state of denial fueled by the false hope of a magical treatment. When those hopes ultimately come crashing down, they are doubly devastated.
They may also be lured away from scientifically proven therapies. This, of course, is the ultimate harm – sacrificing a real chance at a cure or at least maximizing their length and quality of life while pursuing unicorns.
There is also financial harm. The possibility of a cure is emotional blackmail. Most people would spend anything at a chance to save a loved-one. They will mortgage their house, do a fundraiser, go into debt – whatever it takes. They can’t say no, and take the chance of living with the guilt that they could have saved their loved-one if they just spent the money. At in the end, all they have is the added burden of financial ruin.
That is what you are offering to people when you suggest they turn to alternative medicine when they are sick.
Conclusion: Sick people do not need your medical advice
When people have a serious illness, they do not need your medical advice (unless you are their physician). You wouldn’t tell an engineer how to design a bridge, or a lawyer how to argue a case.
What they need is your emotional support. Just be there for them, with all the pain and discomfort that implies. People don’t want platitudes or simplistic advice – that just minimizes their pain and makes them feel as if they are alone.
If you want to offer practical help, then ask them what they need. Maybe they need someone to watch their kids, or drive them to their appointments.
They don’t need you to insult and shame them into wasting time, money, and emotion on false hope.

Bouffant caps versus skull caps in the operating room: A no holds barred cage match
Over the last few years, AORN and the American College of Surgeons have been battling it out over AORN’s 2014 guideline that has increasingly led to the banning of the surgical skull cap in the operating room in favor of the bouffant cap. Lacking from this kerfuffle has been much in the way of evidence to support AORN’s guideline, but unfortunately that didn’t stop the ACS from appealing mainly to tradition and emotion in objecting to it.
David Gorski on August 20, 2018
Link

And now for something completely different.
Any time the skin is violated, there is the possibility of infection. Surgeons, of course, have known this ever since they started taking sharp objects to skin, either to remove limbs or organs or rearrange anatomy for therapeutic intent. We also know that the risk of a surgical site infection (SSI) varies depending on the procedure. Today that knowledge is codified into surgical wound classifications:
     1.  Clean: These surgical wounds are uninfected and without preexisting inflammation, and tracts where bacteria might reside (e.g., respiratory, GI, GU tracts) are not entered. These wounds are closed primarily; i.e., stapled or sewn closed at the end of the procedure. Examples: Removal of skin lesions, mastectomy, thyroid surgery, hernia repair, splenectomy.
     2.  Clean-contaminated: These are wounds in operations in which the respiratory, GI, or GU tract is entered, but in a planned, controlled fashion. There is no unusual contamination with the contents of those tracts, because they are entered in a controlled fashion and contamination is minimized. Examples: Cholecystectomy, small bowel resection, Whipple operation, gastric surgery, lung surgery, colon surgery.
     3.  Contaminated: These wounds occur in cases such as dealing with open, fresh accidental wounds; cases in which there is a major break in sterile technique, gross spillage from the GI tract or acute nonpurulent (no pus) inflammation.
     4.  Dirty: “Dirty cases” are, as you might imagine, quite dirty. They include, for example, old traumatic wounds with devitalized tissue; existing bowel perforation, infection, or even gross abscess. The point is that the gross contamination and organisms are present before the procedure begins. Examples: Incision and drainage of an abscess, repair of perforated bowel, peritonitis, wound debridement, and the like.
The higher the surgical class, in general, the higher the risk of a postoperative wound infection. Or so surgical dogma has traditionally taught (more on that later). Also, in general, preoperative antibiotics are administered before cases that are class 2 (clean-contaminated) or above, and primary closure of the skin is generally not recommended for class 3 (contaminated) and above. As is true of so many things in medicine, the rules are not necessarily hard and fast, but this is the simple version taught to medical students. Also, determining what does and doesn’t work in terms of preventing SSIs has turned out to be not as easy as one would think. There’s a lot of dogma here, and recommendations have changed over the years.
SSIs, not surprisingly, have become a focus of quality improvement, with great effort, particularly by the American College of Surgeons’ National Surgical Quality Improvement Program (ACS NSQIP®). I’d like to focus on just one controversy that’s been brewing over the last few years that (finally, I hope) has probably been resolved and in doing so have what I hope to be a fun change of pace from my usual rants. So today I will be discussing a fairly focused topic and a major study that was just published in the August issue of the Journal of the American College of Surgeons addressing a critical question: Bouffant vs Skull Cap and Impact on Surgical Site Infection: Does Operating Room Headwear Really Matter? In other words, does the choice of headgear to keep that nasty hair of yours away from the surgical field matter? (Spoilers: It doesn’t.) Before we get to the study, let’s take a look at the debate and its history.
Skullcap versus bouffant?
Anyone who’s been in the operating room (or watched medical dramas on television) is probably aware that surgical headgear comes in two forms: the skullcap or the bouffant. The skullcap generally looks like this:

As you can see, it’s tight and lean and actually fairly good-looking. Indeed, here’s a selfie I took a few years ago, before my hospital got rid of the surgical skullcap (and before I grew my current beard):

Not bad, if I do say so myself. I almost look like a real surgeon in this photo.
Then there’s the bouffant cap. You can actually see one in the picture above, but the head of the woman who’s wearing it is partially obscured by the surgeon wearing the skullcap. Here’s another surgeon wearing a bouffant cap:

As you can see, it’s basically a much looser-fitting cap with elastic to keep it on the head. Most older surgeons, particularly male surgeons, also detest it.
Throughout my nearly 30 years as a surgeon (if you count my residency), I’ve used both varieties of caps. I tend to prefer the skullcap because it’s better-fitting for someone with short hair, and the bouffant cap tends to migrate on my head as I move around doing operations. The one downside to the skullcap is that it flattens my hair to the point that, when I come home after a day in the operating room, my wife sometimes makes fun of my “operation head”.
Why, you might ask, should anyone care about this? If you don’t work in an operating room, there’s probably no good reason to care. Among those of us who do, the issue has become, rather oddly, a pretty passionate debate. For example, take a look at this article from two years ago in the Boston Globe:
Surgeons for years have stepped into operating rooms wearing their surgical cap — a snug covering that ties in back and comes in standard-issue blue or hundreds of personalized designs.
But a crackdown appears to be underway on that almost sacred piece of headgear.
Inspectors in January reprimanded operating room staff at Brigham and Women’s Hospital in Boston for having the hair around their ears uncovered during surgery — and for sporting visible facial hair. And a New York surgeon was written up for showing 3 inches of hair at the nape of his neck.
For sure, other operating room staff wear surgical caps, but they have long been the hat of choice for many surgeons. The problem is the hats usually leave small amounts of hair and the ears exposed — a situation that an influential nursing group says could promote infection.
Regulators have taken the nurses’ concerns to heart, forcing some hospitals to switch to shower cap-like “bouffants,’’ which can be pulled down over a wearer’s entire head.
To be honest, I’ve never really used a cloth skull cap in the operating room, and whenever I’ve seen a surgeon sporting one I always wondered when the last time it had been washed was. If such a cap, no matter how spiffy the design, hasn’t been washed after every one or two days of use, personally I couldn’t help but think: Ew. So instead, I wore the disposable paper caps.
Basically, what we’re looking at here is an ongoing spat between the Association of periOperative Registered Nurses (AORN) and surgeons, represented by the American College of Surgeons. AORN guidelines in practice ban the skull cap and require the bouffant cap, while ACS guidelines state that skull caps with minimal hair exposure are acceptable. Why do I say the AORN guidelines ban the skull cap “in practice”? Continue reading and find out.

Cage match: ACS vs. AORN
To be honest, I’ve rarely seen a tiff between two professional organizations over a surgical guideline based on so little evidence and infused with much emotion. Reading each side’s position statements while writing this post, I had a hard time not concluding, “A pox on both your houses”. (I realize that some surgeons will likely view me as a traitor or apostate for saying that. Such is life.) In any case, let’s look at the ACS response to AORN’s guidelines. First, it is remarkable how much broad agreement there was between the two organizations. On the other hand, I was a bit embarrassed at how the ACS stated that its “guidelines for appropriate attire are based on professionalism, common sense, decorum, and the available evidence”. Why is evidence listed last? And who cares about common sense? However, here are the areas of general agreement, except for some quibbling around the edges, which I won’t discuss in detail:
    • Soiled scrubs and/or hats should be changed as soon as feasible and certainly prior to speaking with family members after a surgical procedure.
    • Scrubs and hats worn during dirty or contaminated cases should be changed prior to subsequent cases even if not visibly soiled.
    • Masks should not be worn dangling at any time.
    • Operating room (OR) scrubs should not be worn in the hospital facility outside of the OR area without a clean lab coat or appropriate cover up over them.
    • OR scrubs should not be worn at any time outside of the hospital perimeter.
    • OR scrubs should be changed at least daily.
    • During invasive procedures, the mouth, nose, and hair (skull and face) should be covered to avoid potential wound contamination. Large sideburns and ponytails should be covered or contained. There is no evidence that leaving ears, a limited amount of hair on the nape of the neck or a modest sideburn uncovered contributes to wound infections.
    • Earrings and jewelry worn on the head or neck where they might fall into or contaminate the sterile field should all be removed or appropriately covered during procedures
    • The ACS encourages clean appropriate professional attire (not scrubs) to be worn during all patient encounters outside of the OR.
Now here’s another kicker. The ACS response stated:
The skullcap is symbolic of the surgical profession. The skullcap can be worn when close to the totality of hair is covered by it and only a limited amount of hair on the nape of the neck or a modest sideburn remains uncovered. Like OR scrubs, cloth skull caps should be cleaned and changed daily. Paper skull caps should be disposed of daily and following every dirty or contaminated case. Religious beliefs regarding headwear should be respected without compromising patient safety.
Indeed, among surgeons, much is made in this debate about how the skull cap is presumably the “symbol” of the surgical profession, and maybe it is—or was, at least when back when nearly all surgeons were men with short hair. These days, an increasing percentage of surgeons are women, most of whom presumably have longer hair and can’t use a skull cap because it doesn’t cover their hair adequately. To argue in 2016 that the skull cap is the “symbol” of the surgical profession revealed a blindness to the reality of surgery today. Maybe the skull cap was once the “symbol” of the surgical profession, but I would argue that, even if that was once the case, it shouldn’t be any longer. Stick to the evidence and not some emotional attachment to the days of yore, when men were men and women, by and large, were not surgeons. Also, most of the people in the operating room are not surgeons. There are nurses, scrub techs, anesthesiologists, nurse-anesthetists, and the like. They probably don’t care if the skull cap is a “symbol” of the surgical profession. Yes, we surgeons tend to think we’re the center of the universe.
Indeed, all too often the surgeons’ argument basically boiled down to “I like it and have been doing it this way for 20 years,” even if the surgeon has to stretch quite a bit to make reasons that boil down to, “I don’t like bouffant caps” sound like something else:
None of that is to say that the AORN position, at least with respect to surgical caps, is particularly evidence-based. (Unfortunately, you have to be a member of AORN to see the actual statement on the AORN website. WTF, AORN?) Take a look at its response to the ACS guidelines, particularly the part where it responds to the statement about how the skull cap is symbolic of the surgical profession:
Wearing a particular head covering based on its symbolism is not evidence-based, and should not be a basis for a nationwide practice recommendation. Several types of evidence exist that support recommendations that perioperative personnel cover their head and ears in the OR. This evidence includes the fact that human skin and hair is naturally colonized with many bacteria, and perioperative personnel shed microorganisms into the air around them. We know airborne bacteria in the OR can fall into the operative field, contribute to the overall air contamination of the OR, and place patients at risk of surgical site infections. Completely covering the hair can reduce the number of bacteria introduced into OR air by perioperative personnel.
I’d say that the ACS needs an icepack for that burn, compounded by AORN’s other retort that, “until an evidence-based definition of ‘limited’ or ‘modest’ can be determine[d], there is no way for facilities to enforce such a recommendation” that only “limited” hair can be left uncovered.
However, despite invoking “evidence-based” definitions, notice that AORN didn’t cite any actual…oh, you know…evidence to show that wearing surgical skull caps is associated with an increased SSI rate. It makes a not unreasonable argument in terms of how the skin and hair are colonized with bacteria and how surgical personnel can shed them. However, that’s an argument that pretty much relies on prior probability. Yes, it’s not unreasonable to point out that exposed hair might shed bacteria onto the surgical field. However, surgeons used to do a lot of things to decrease SSI rates based on ideas that seemed to make sense at the time but were later found in controlled studies either to make no difference or to be counterproductive. Extensive shaving of the surgical site, particularly the night before, comes to mind. Nowadays, we don’t shave surgical sites unless there’s a lot of hair, and then we only just use clippers to cut it very short right before surgery, right before the surgical prep with antiseptic solution.
There was at the time of AORN’s recommendations basically no evidence suggesting that choice of surgical headgear influences SSI rates. Even the Boston Globe story noted that two large reviews of published studies in the last five years before 2016 showed little or no evidence that surgeon surgical headgear choice affected SSI rates. It also noted AORN’s argument that there can’t be any randomized controlled trials because such a trial “would potentially expose patients to the risk of infection from health care workers whose skin and hair were uncovered…” I agree that such a study would be impractical, but not for that reason. There is what I would call genuine clinical equipoise in the question; we honestly didn’t know if headgear made a difference in SSI rates and the evidence to that point suggested that it probably did not. AORN was way off-base in claiming that such a trial would be unethical because of lack of clinical equipoise. The real reason it would be impractical is because no one would want to agree to be randomized to one type of cap or another. Logistically, such a study would be a nightmare.
Let’s come back to the problem. In practice, the AORN guidelines for surgical attire have resulted in the banning of the use of surgical skull caps. Why do I say “in practice”? The reason is simple. AORN’s recommendations have been, in essence, adopted by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), the organization that accredits hospitals in the US, and the Agency for Healthcare Research and Quality (AHRQ), the U.S. Department of Health and Human Services agency dedicated to research and evidence-based guidelines to improve the safety and quality of health care. Remember that story above? Who were the inspectors who cited the hospitals for violations of surgical headgear standards? JCAHO. As a result:
After it became aware of the increased scrutiny, Beth Israel Deaconess Medical Center in Boston took away surgeons’ traditional scrub hats. Dr. Daniel Jones now wears a bouffant pulled down over his ears — but he’s not thrilled about it. “Doubt the ear hairs pose any threat,’’ he said in an e-mail. “Some actually wear a scrub hat under the bouffant to dress it up.’’
And that’s what’s happening all over the country. The OR leadership in my own hospital declared that skull caps would no longer be allowed, again, based on no evidence.
Amusingly, AORN is a bit annoyed at this whole controversy. Indeed, last year, it issued a statement denying that its guidelines ban the use of skull caps. It pointed out that the 2014 guidelines stated, “A clean surgical head cover or hood that confines all hair and completely covers the ears, scalp skin, sideburns, and nape of the neck should be worn.” AORN bases this recommendation on the observation that hair can harbor bacteria that can potentially fall into the surgical field. Indeed, AORN took great umbrage at the suggestion that it has “banned skull caps” in its statement, lamenting how its position had been “misrepresented” in media reports. If this PowerPoint presentation on the official AORN template on getting rid of the skull cap and advocating for bouffant caps instead is any indication, AORN was most definitely advocating for getting rid of the skull cap.
The study
At this point, readers who aren’t regulars and don’t appreciate my tendency towards liking to pontificate on the history of an issue before getting to the study under consideration are probably annoyed that I haven’t gotten to the point yet. So here we go, let’s get to it: “Bouffant vs Skull Cap and Impact on Surgical Site Infection: Does Operating Room Headwear Really Matter?”
The authors note in the introduction the factors associated with increased risk of SSI:
Approximately 300,000 surgical site infections (SSIs) occur each year, accounting for approximately one-third of hospital-acquired infections.1, 2, 3 Many factors contribute to this, including surgery type, glucose control, and patient body temperature. Recent attention has been given to the type of headwear as a risk factor for SSIs. Little research is available on the efficacy of various head covers in reducing the incidence of SSIs. Despite the lack of clear evidence, there is an ongoing disagreement over which form of head cover should be recommended in the perioperative setting. The American College of Surgeons guidelines indicate that skull caps with minimal hair exposure are acceptable, and the Association of Perioperative Registered Nurses recommends bouffant caps with coverage of all hair. In addition, they recommend covering the ears, sideburns, scalp, and nape of the neck, on the basis that hair and skin in these sites are known to harbor bacteria that can be dispersed.4, 5, 6, 7 However, no scientific evidence has shown a significant advantage in SSI reduction with either cap. This study aimed to determine the influence of surgical cap choice on SSI rates by comparing the incidence of SSIs based on attending surgeons’ use of skull caps or bouffant caps in the perioperative setting.
So how did the investigators, led by corresponding author Shanu N. Kothari, MD at the Gundersen Health System in La Cross, WI, approach this problem? Basically by reanalyzing data from a large randomized controlled trial that looked at whether clipping hair at the surgical site affected SSI rates. (It didn’t, by the way. The only reason we tend to clip hair these days is for convenience when there’s a lot of it.) Basically, data from this randomized study were re-analyzed to determine the impact of surgeon preference for bouffant vs skull cap, regardless of whether hair was clipped or left intact. In brief, patients were grouped based on the attending surgeons’ headwear, and the primary end point was SSI observed. Additional variables included preoperative comorbidities, operative approach, and procedure type.
Overall, there were 1,543 patients in the analysis, with attending surgeons wearing bouffant caps in 39% of the cases and skull caps in 61% of the cases. The authors found that patients whose surgeons wore a bouffant cap tended to be slightly older, have a lower BMI, and were undergoing primarily hernia/other procedures. Six patients in both the bouffant and skull cap groups had a history of colonization with methicillin-resistant Staphylococcus aureus (MRSA). Use of perioperative antibiotics were the same in both groups. The raw numbers showed that SSIs were observed in 96 (6.2%) of patients, with 8.1% in the bouffant group and 5.0% in the skull cap group. However, after adjusting for the type of operation and surgical approach in a multivariate logistic regression model, no difference in SSI rates for skull cap versus bouffant cap was detected.
This study has a lot of strengths. It was pretty large, with over 1,500 patients, and, because the study being reanalyzed was a study explicitly designed to examine SSI rates between a control and experimental group, the diagnostic criteria for SSI diagnosis were standardized and rigorous. Of course, its key limitation is that it is a post hoc analysis of an existing RCT dataset looking at a factor not incorporated into the previous design. The authors also noted:
The previous study data were biased toward male patients, as inclusion criteria consisted of adequate body hair to warrant hair clipping. Surgeon cap preference was linked with their specialty and procedure types. For example, the vast majority of foregut cases were performed by surgeons who preferred skull caps. In addition, although the head covering of the attending surgeon was known, we did not document the head coverings that other members of the surgical team wore. Also, the study was conducted in the setting of elective general surgical procedures and excluded vascular, anorectal, orthopaedic, obstetric, and gynecologic procedures. Analysis of cap material, including measures of pore size and comparison or particle counts, in addition to quantifying microbial sedimentation rate, were beyond the scope of this study.
Despite those limitations, when taken in the context of the evidence base existing before this study was carried out, these data are yet one more strong piece of evidence that choice of surgical headgear almost certainly doesn’t matter and doesn’t impact SSI rates. As the authors note, this is consistent with what we knew before, and this study isn’t alone. For instance, a large retrospective study by Shallwani et al failed to find a statistically significant change in the SSI rate from 13 months before to 13 months after the new AORN policies.
Tradition versus evidence in the operating room
One aspect of the study above that led me to learn more about this issue is a recent publication by Bartek et al, “Naked Surgeons? The Debate About What to Wear in the Operating Room“, which was cited by the authors. This particular opinion piece with targeted literature review pointed out how steeped in tradition, rather than evidence, so many infection control procedures in the operating room are and how heterogeneous and conflicting the evidence is for many of them. It’s a fascinating read and appears not to be behind a paywall; I recommend it.
Here’s an example that my UK colleagues might appreciate. It’s another AORN guideline that vastly differs from the recommendations in the UK, specifically the recommendation by AORN that all OR personnel keep their arms covered, amusingly under the topic of “The Right To Bare Arms”:
On the topic of covering the arms, AORN recommends: “When in the restricted areas, all nonscrubbed personnel should completely cover their arms with a long-sleeved scrub top or jacket” [1]. Interestingly, AORN’s recommendations and the United Kingdom’s NICE’s requirements are contradictory: As above, AORN recommends wearing a “long-sleeved scrub top or jacket,” whereas NICE’s policy is “bare below the elbows” [1, 22]. The fact that 2 large, guideline-producing bodies would recommend completely opposing practices under the rubric of evidence-based medicine is suspicious. Old studies looking at airborne bacteria show, among other things, that women wearing stockings shed more bacteria than women with bare legs [23]. NICE took the stance that handwashing is what is key and clothing with sleeves does not affect bacterial colony counts, but that it could affect practitioners’ abilities to wash their hands. This conclusion too has been refuted [7].
Perhaps some of my British colleagues who read this blog could chime in in the comments, but I must confess that I was amused by this controversy.
Bartek et al also note that, the further we dive into the question of bacterial shedding from people’s skin, the murkier things get. For example, they note that men shed twice as many bacteria as women, but no one has ever advocated for a restriction on men in the operating room. They also note that the release of bacteria from scrubs and street clothes was studied and found to be roughly equal; yet scrubs remain standard and street clothes are banned in the OR. Based on the previous findings, if decreasing SSIs is your goal there’s no real reason not to allow surgeons to come into the OR in their street clothes and to gown up over them, the very way surgeons were portrayed as doing in one of my favorite medical dramas of all time, The Knick. I also note that the surgeons in the year 1900 portrayed on The Knick also operated without gloves. (The wearing of sterile surgical gloves by surgeons and anyone who can touch the operative field is one of the few things that have been definitively shown to reduce SSI rates, a finding first reported by a protégé of William Stewart Halsted in 1899, a year before the fictional events portrayed in the first season of The Knick.)
Perhaps the most amusing observation was this:
Another set of studies reached an even more drastic conclusion: Naked men shed approximately a third to a half as many bacteria as the same men wearing street clothes or scrub suits [27, 28]. Perhaps “scrubs” actually live up to their name: rather than “catching” squames, which the skin sheds perpetually, they may in fact be “scrubbing” these bacteria-laden squames from our skin. If we are to adhere to the strict prescription of evidence-based medicine, ought we to disrobe prior to entry into the operating room? We argue no, although for reasons that are outside of how it would affect bacterial counts in the operating room.
Who says there’s no room for humor in the peer-reviewed medical literature?
There are other common practices that really don’t have a strong evidence base for them. (Some would even argue that the surgical site classification is lacking in that respect.) For instance, there is no evidence that wearing surgical masks prevents SSIs. Indeed, there’s even a Cochrane review that suggests otherwise, and Bartek et al point out that masks have never been shown to be effective in preventing SSIs. However, if your purpose is to protect the surgeon and others working on the patient from being splattered with blood in the mouth or nose, then requiring surgical masks makes perfect sense, just as requiring protective eyewear does. That’s likely why no one is proposing that we surgeons stop wearing them. Certainly, as someone who’s been sprayed in the face with blood many times over the years (although much less frequently and with much less volume ever since I restricted my practice to breast surgery), I’m grossed out by the thought of operating without a mask.
The bottom line is that, although the reaction of surgeons and the ACS to the AORN recommendation struck me as rooted far more in emotion and tradition than anything else, the ACS did have a point. There was no evidence that choice of headgear has a significant impact on SSI rates, and there is no evidence that it does. In its response to the AORN guidelines ACS would have been better served by ditching the bit about the skull cap being a “symbol” of the surgical profession, which struck me as a callback to our more-than-a-bit sexist past, and sticking to the evidence. Similarly AORN would have done well not to overreach and extrapolate beyond what the evidence justified in its recommendations. Finally, I can’t help but conclude that this entire kerfuffle was an example of how the smallest disagreements all too often result in the most protracted fights.

Five steps to add ten years to your life expectancy
A new study identifies five lifestyle decisions that can add over a decade to your life expectancy.
Scott Gavura on May 3, 2018
Link

The United States is one of the world’s wealthiest countries, and spends significantly more on health care (per capita) than any other country in the world. However, the life expectancy of Americans is relatively poor (79.3 years) compared to residents of other, comparably wealthy, countries. Lifestyle factors have been implicated as major factors that may contribute to the poor health outcomes. A past meta-analysis (a study of studies) that looked at over 500,000 participants in 17 countries suggested that up to 60% of premature deaths could be due to unhealthy lifestyle factors. Now a new study examines the potential impact of these factors on the American population. The paper, published in Circulation, is entitled “Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population” and is from Yanping Li and colleagues at Harvard’s School of Public Health. The paper has concluded that adopting five simple lifestyle factors can extend your life expectancy by over a decade. 
What this study looked at
The authors looked at data from the Nurses’ Health Study (78,865 women over 34 years) and the Health Professionals Follow-up Study (44,354 men over 27 years). These long-standing studies followed thousands of individual who answered periodic questions about medical history, lifestyle, smoking history, exercise frequency, and dietary habits. The five modifiable lifestyle factors studied were:
    • Eating a healthy diet – assessed using the Alternate Healthy Eating Index Score, and including scores in the top 40%.
    • Maintaining a healthy body weight – a low-risk Body Mass Index (BMI) defined as 18.5 to 24.9 kg/m2.
    • Exercising regularly – low risk was estimated at >30 minutes per day of moderate or vigorous exercise (including brisk walking).
    • Not drinking excessive alcohol – defined as 5 to 15 g/d for women (about one standardized drink per day) and 5 to 30 g/d for men (up to two drinks per day).
    • Smoking history – low risk was defined as never having smoked.
Non-modifiable risk factors like high blood pressure or cholesterol levels were not assessed in this study.
The authors scored each subject as either low risk (score 1) or high risk (score 0). Each subject therefore received a score of 0 to 5, with higher scores indicating a healthier lifestyle. I will not go into the statistical analysis (the paper’s free, online, if someone wants to comment).
What this study found
Here are the characteristics of the patients, stratified by score and study:
The authors noted (edited for clarity):
Each individual component of a healthy lifestyle showed a significant association with risk of total mortality, cancer mortality, and CVD mortality (Table 2). A combination of 5 low-risk lifestyle factors was associated with an HR of 0.26 (95% CI, 0.22–0.31) for all-cause mortality, 0.35 (95% CI, 0.27–0.45) for cancer mortality, and 0.18 (95% CI, 0.12–0.26) for CVD mortality compared with participants with zero low-risk factors. The population-attributable risk of nonadherence to 5 low-risk lifestyle factors was 60.7% (95% CI, 53.6–66.7) for all-cause mortality, 51.7% (95% CI, 37.1–62.9%) for cancer mortality, and 71.7% (95% CI, 58.1–81.0) for cardiovascular mortality. We observed a similar association between the low-risk lifestyle factors and mortality before 75 years of age (Table I in the online-only Data Supplement). The low-risk lifestyle factors were associated with lower risk of cause-specific mortality in women and men similarly.
In Figure 1, below, you can see the life expectancy gain realized based on the number of healthy lifestyle factors in place:
As you can see, all five factors lead to an estimated increase in life expectancy of 14 years (at age 50) for women with the healthiest lifestyles. Men gain an estimated 12 years for those with the healthiest lifestyles. They note:
We estimated that the life expectancy at age 50 years was 29.0 years (95% CI, 28.3-29.8) for women and 25.5 years (95% CI, 24.7-26.2) for men who adopted zero low-risk lifestyle factors. In contrast, for those who adopted all 5 low-risk factors, we projected a life expectancy at age 50 years of 43.1 years (95% CI, 41.3-44.9) for women and 37.6 years (95% CI, 35.8-39.4) for men. The projected life expectancy at age 50 years was on average 14.0 years (95% CI, 11.8-16.2) longer among female Americans with 5 low-risk factors compared with those with zero low-risk factors; for men, the difference was 12.2 years (95% CI, 10.1-14.2).
It’s not all-or-nothing. Even adopting one of the five factors is associated with a beneficial effect that can be measured in years of benefit.
Interestingly, there were a few confounders found. Those with the healthiest lifestyles were more likely to use aspirin (ASA) and less likely to use vitamin supplements.
Simple but not easy
A significant contributor to the overall poor life expectancy of Americans is poor lifestyle-related factors. Following all 5 factors could offer an incremental (to someone aged 50) 14 years of life expectancy for women, and 12.2 years for men, compared with those that have no “low risk” lifestyle features.
If a healthy lifestyle was a drug, it would be the most effective drug ever, and a pharmaceutical company would charge hundreds of thousands of dollars per year for it. But this magical “non-drug” doesn’t come with a long list of side effects – or a price that will bankrupt you. Many of these factors are achievable at modest (or no) cost. You don’t need to eat organic, take supplements, or make drastic dietary restrictions to extend the quantity and quality of your life. If you’re already doing all five of these actions – congratulations! Absent any medical issue that might need treatment, you’re doing everything you possibly can to ensure a long, healthy life.

American Mortality Ticks Up
Life expectancy in the US decreased slightly in 2015. While this is a one-year phenomenon, and the long term trend continues to be one of increasing life expectancy, there are some interesting lessons in the data.
Steven Novella on December 14, 2016
Link


Last week the CDC released mortality statistics for 2015 showing that overall life expectancy in the US dropped slightly from 78.9 to 78.8 years. As usual, women enjoy a longer life expectancy than men: men dropped from 76.5 to 76.3 years, while women dropped from 81.3 to 81.2 years.
There is a lot of hand wringing in the press over what this means. This is the first time that life expectancy has decreased in the US since 1993. We have come to expect a continuous if slow increase life expectancy as a consequence of advancing medical technology, and we take interest when this trend is reversed. I have to say, however, that I do not find this single-year, slight down tick to be very worrisome. One year is far too short a time frame to establish any trend. It would be surprising if there weren’t ever any fluctuations in the baseline trend of increasing life expectancy.
Further, the average life expectancy of the entire population, while interesting, is of limited utility. You find the real story when you dive deeper into the statistics. Even then, we need to pay more attention to long term than short term trends.
The deeper data dive
There are a couple of ways to divide up the data to get a clearer picture of what is going on, by demographics, and by disease or cause of death. By cause it is interesting to note that cancer deaths continued to decline in 2015. Every other category of cause of death went up slightly. Heart disease, stroke, and diabetes all went up, leading some to speculate that obesity is a significant cause of the decrease in life expectancy in 2015.
It is clearly the case that we are having an obesity epidemic in the US. While there are those who still doubt it, the data are unambiguous. It is more difficult to establish what the causes of increasing obesity are with the two main contenders being increased calorie consumption, and decreased physical activity. Which social factors are, in turn, leading to these two factors is even more difficult to determine, as are potential solutions.
In any case, it seems likely that increasing obesity is making itself felt in the survival statistics, but this has been a long term trend and would not necessarily explain the 2015 life expectancy down tick. The second biggest increase in terms of age-adjusted death rate was among “unintentional injuries.” This category included accidental overdoses from recreational drugs, such as opioids. There has been a recent spike in such deaths, and this is compatible with a short term change in the overall life expectancy, but it does not explain the whole picture.
Suicides also increased, and this has also been a recent trend. Some argue that this is part of the overall economic downturn. When people are out of work or economically desperate, they are more prone to drug use, to suicide, and overall do not take as good care of themselves, in addition to being subject to all of the health risks associated with poverty.
Alzheimer’s disease continued its trend of increasing the death rate. This is largely attributed to an aging population, as the risk of Alzheimer’s increases dramatically with age. Why, then, did this trend continue even as life expectancy did not increase? The increase in mortality was largely in younger populations, while the 65+ demographic did not increase.
Turning to demographics, I think the most interesting data is in regional differences. Causes of mortality are not evenly distributed, nor are the trends. In the Northeast, death from violence has been steadily decreasing, but it remains high in the Southwest. Heart disease has been decreasing overall since 1980, but not in the Appalachians.
This regional data can be useful is guiding public health measures and in identifying specific problems that need to be addressed.
Deaths rates, short term and long
It is interesting to examine this snapshot of mortality and life expectancy in the US. I do think some of the reporting has been overblown – this is just one year. It is more enlightening to examine the trends, but we definitely want to keep an eye on the numbers to see if 2015 is more of a fluke or an indicator of shifting trends. We obviously won’t know for several more years.
Meanwhile the long term trends are fairly clear. Overall life expectancy has been steadily increasing. We still don’t know how long this trend can be maintained, and if we will start running up against diminishing returns from advancing technology or even biological limits to lifespan. Death from cancer continues to steadily decrease, and this has been a persistent success story for modern medicine (again, despite ill-informed critics or those with ulterior motives).
Vascular disease (stroke, heart disease) and diabetes do appear to be dominantly behavior-driven diseases. For this reason there are dramatic regional differences in prevalence, and these are probably the diseases most modifiable by public health measures.
Diseases of poverty, including unintended injury and suicides, are an even thornier problem as they are tied to complex economic issues.
Also, it seems that degenerative neurological conditions, like Alzheimer’s disease, continue to be a major problem and deserve to be a research priority. There doesn’t appear to be any cause for the increasing Alzheimer’s incidence other than the aging population. The disease cannot be treated or cured (there are only symptomatic treatments, but none that alter the course of the disease), and we don’t know how to effectively prevent it. We simply need to continue to do research to find answers.

Aging and Longevity: Science for Spring Chickens
Harriet Hall on June 16, 2015
Link

We’re all going to die, but we don’t like to think about it. I’ll reach the proverbial threescore years and ten next month, so I’ve been thinking more about it, wishing I knew some reliable way to ensure that I would live many more years and remain fully functional until I suddenly collapsed like the Deacon’s wonderful one-hoss shay. There are myriad “longevity clinics” and “anti-aging” formulas, and every centenarian has an explanation that is the direct opposite of some other centenarian’s explanation. But what does the scientific evidence say? In his new book Spring Chicken: Stay Young Forever (Or Die Trying), Bill Gifford has done us a great service by investigating the latest scientific evidence about aging and presenting his findings in an engaging narrative form. He interviews some of the major players and introduces us to health fanatics who are convinced they can prolong their lives by doing things like monitoring their own blood cholesterol levels on a weekly basis, exercising obsessively, severely restricting their calorie intake, fasting intermittently, deliberately exposing themselves to stress like swimming in icy water, competing in extreme athletics, taking boatloads of hormones and supplements, experimenting on themselves with investigational drugs, and doing other questionable and sometimes bizarre things.
Are there limits to human life expectancy?
There is no documented case of anyone living longer than Jeanne Calment of France, who died at the age of 122. Jay Olshansky thinks biological forces limit how long we can live. Aubrey de Grey thinks some people alive today will live to be a thousand years old. Gifford explains the controversy and the reasoning behind both sides. Will we someday be able to re-engineer human biology to overcome the limits? The jury is still out.
How long do we really want people to live?
In Anthony Trollope’s 1882 novel The Fixed Period, a society votes to euthanize all citizens at age 68 to spare them undignified suffering and cut down on the state’s expenditures on unproductive people. One of the characters agrees that it is a good idea…until he approaches that age himself!
Physician Ezekiel Emanuel recently got a lot of attention with his article in The Atlantic saying he wanted to die at age 75 before disabilities impaired his quality of life.
If people lived longer, it would create problems for society like overpopulation and insufficient food. George W. Bush’s Council on Bioethics argued against aging research; Gifford says it concluded that it “would result in nothing more than vast numbers of unhappy old people hanging around, getting sicker and spending everyone else’s money and making grumpy remarks at holiday dinners.”
Not just long life: healthy aging
Most people would like to live as long as possible if their quality of life could be maintained. Even Jay Olshansky is optimistic that we are on the verge of a breakthrough about aging that will rival the discovery of penicillin, that will enable most people to delay the most debilitating diseases of aging, that will transform health care and even benefit the economy. Unfortunately, while we are waiting for that breakthrough, many of the people who are trying hardest to beat aging are really only making things worse for themselves.
Misguided efforts
What Gifford calls “the Fountain of Youthiness” has become a big business. Bioidentical estrogens, testosterone, human growth hormone (HGH), supplements, diets…the hype is endless. Longevity clinics and anti-aging remedies abound. Physicians like Dr. Oz and Andrew Weil and non-doctors like Suzanne Somers and Ray Kurzweil sell millions of popular books. Customers spend countless hard-earned dollars on unproven dietary supplements and devices. The American Academy of Anti-Aging Medicine has 20,000 members. But Olshansky says there is no such thing as “anti-aging medicine;” he says the secret to aging is that there is no secret.
The hype for HGH is based mainly on the misinterpretation of a single small study in The New England Journal of Medicine. In response to the hype, that journal later took the unusual step of stating in a strongly worded editorial that the study’s results were not sufficient to serve as a basis for treatment recommendations. In fact, HGH may accelerate the aging process. “Knockout” mice that lack growth hormone live longer and are much less likely to develop the diseases of aging.
Research on the causes of aging
Research looking for uniform markers of aging have found that there are none. The aging process is too varied, chaotic, and idiosyncratic; it’s different for every individual. Some 80-year-olds are barely mobile while others walk as fast as the average 40-year-old. Two random 20-year-olds will have much more in common than any two 70-year-olds. The aging trajectory seems to be largely determined by one’s health in middle age; the good news is that most key midlife risk factors are modifiable with lifestyle changes.
Many centenarians have “bad” genes but also have “preventive” genes that protect them from developing the diseases of old age. A gene that inhibits CETP (cholesterol ester transfer protein) is protective, but CETP-inhibitor drugs haven’t panned out. Centenarians have high levels of insulin-like growth factor (IGF-1), but their cells are resistant to it because of another gene variant. Most of us have the opposite of longevity genes: our DNA dearly wants to kill us.
What about evolution?
The diseases of aging are often called the diseases of modern civilization, but mummies from Egypt and Peru had arteriosclerosis, and humans may be hard-wired for heart disease. Can evolution explain the diseases of aging? They may impair the survival of the elderly individual, but there is little evolutionary advantage to surviving past the period of reproduction; the latter part of life becomes a sort of genetic garbage can full of irrelevant traits. In fact, some of the very genes that benefit us in youth may actually end up killing us later in life. For instance, the gene for hemochromatosis appears to have protected younger men from the bubonic plague in the Middle Ages, and it only causes harm later in life. Gifford quips, “Once we hit middle age, evolution pretty much takes its hands off the steering wheel and cracks open a beer.”
There are trade-offs between immediate survival and longevity. In the worm C. elegans, knocking out the IGF-1 gene doubles the lifespan, but when knockout worms were mixed with regular worms, the knockouts soon became extinct, because they reproduced ever-so-slightly later. This is mirrored in Ashkenazi Jews, who have fewer children later in life and live longer than other groups. Gifford says maybe having kids really does shorten your life!
Another hypothesis is that nature doesn’t need a possum that can live for 15 years if it is only likely to survive for 3 years in the wild. It is uneconomical for nature to invest more than is necessary to keep the body in decent shape for as long as it’s likely to live. Why pay for a Ferrari if a Chevrolet is plenty good enough to get you where you need to go?
In general, larger animals tend to live longer. (Dogs are an exception. Chihuahuas live longer than Great Danes, but this is an anomaly of manipulative breeding.) Humans are actually pretty long-lived, both relatively and absolutely. Only a few animals live longer, including the Galapagos tortoises and Ming, the Icelandic clam that researchers killed at the age of 507 (what an unfortunate clamity!). The longevity quotient is a measure of actual vs. size-predicted longevity. Only nineteen species have a higher LQ than humans: eighteen of them are bats, and the nineteenth is the naked mole rat. Long-lived species seem to have hardier cells; their cells resist toxic chemicals better in a dish in the lab.
Cells are programmed for death
Alexis Carrell, who invented cell culture, thought that cells could keep dividing forever; in his lab, they seemed to be immortal. (But his experiments couldn’t be replicated; his assistants had probably been introducing new cells into his cultures.) Hayflick overturned Carrell’s hypothesis when he discovered that cells predictably died after 40-60 divisions; this became known as the Hayflick limit. It was later explained on the basis of telomeres, repeating DNA sequences on the end of chromosomes that shorten every time the cell divides. The shorter the telomere, the shorter your life. I explained telomeres in a previous post. It seemed only logical that telomerase, the enzyme that repairs telomeres, ought to be a magic bullet for aging. So far that hasn’t panned out; mice given an experimental drug to increase telomerase didn’t live longer and they got more cancers. Anyway, some animals with very long telomeres and lots of telomerase actually have very short lives. It’s still not clear whether short telomeres actually cause aging and age-related diseases or whether increasing telomerase might increase the risk of cancer.
Another clue is interleukin-6 (IL-6), a cytokine that fights infections and heals wounds by inducing an inflammatory response. We produce more IL-6 as we age, and older people develop a low-grade inflammation that has been implicated in virtually every age-related disease. It gets more complicated. Old people still have a majority of cells that are still dividing, but they have a small percentage of cells that are senescent and that secrete a brew of inflammatory cytokines. It’s like a catch-22: cells go senescent instead of turning cancerous, but they create inflammation that helps make other cells cancerous. If we could figure out how to remove our senescent cells, we might be rejuvenated.
The worst senescent cells are found in fat tissue. Obesity is responsible for 14% of cancer deaths in men and 20% of cancer deaths in women. New evidence suggests that fat acts as a huge endocrine gland and may be the body’s most important organ for aging.
Stress, antioxidants, and naked mole rats
Gifford says much of what we think we know about stress is wrong. He discusses the health effects of psychological and biological stress, particularly oxidative stress. Antioxidants are another anti-aging candidate that hasn’t panned out. Antioxidant supplements do more harm than good. They diminish the benefits of exercise, prevent activation of the body’s own antioxidants, and interfere with the body’s repair mechanisms. Oxidative stress is beneficial, perhaps even essential to life. Increased levels of oxidative stress actually lengthen lifespan in worms. Bottom line: a little stress is good for us, and antioxidants are irrelevant to aging.
Naked mole rats, weird creatures that live underground and look like “a penis with fangs,” have high levels of oxidative damage, but they seem to undergo some kind of stress response that keeps them alive for decades. They don’t develop cancer, even when slathered with the highly potent carcinogen DBMA. It’s not even clear that they age. Their mortality rate doesn’t increase with age, and the females never go through menopause. The patterns of gene expression are the same in a four-year-old as in a twenty-year-old. They have achieved negligible senescence. But they are so different from humans that they can’t tell us anything about our own aging.
What might work?
Exercise may be the most effective “drug” for warding off many of the ills of aging. Studies show it has a multitude of benefits.
Severe calorie restriction has been shown to prolong life and improve health in a number of animals. Two studies in monkeys have produced contradictory results. A University of Wisconsin study found that calorie-restricted monkeys lived 30% longer; an NIH study found that the calorie-restricted monkey were not living longer, but their control monkeys were living as long as the Wisconsin calorie-restricted monkeys, probably because the University of Wisconsin monkeys were fed a diet comparable to a human junk food diet and the ones at the NIH were fed a healthier diet comparable to a Mediterranean diet. And while the NIH calorie-restricted monkeys didn’t live longer, they were healthier. It seems what you eat is as important as how much you eat.
Starvation has been shown to have surprising effects on health. We evolved in an environment where food was not constantly available, and our bodies are hard-wired to survive substantial periods of starvation. Intermittent fasting prolongs the life of yeast cells and improves the symptoms of asthma in humans. It increases the level of brain-derived neurotrophic factor and may help stave off degenerative conditions like Alzheimer’s and Parkinson’s. There is a cellular complex called TOR; when it is turned off, the cell goes into maintenance mode, recycling damaged proteins and cleaning up cellular junk; and fasting suppresses TOR. In one experiment, when patients fasted before chemotherapy the chemo was more effective and they had fewer side effects. Cancer cells have de-evolved and become specialized but less adaptable. “Cancer cells are dumb…when we fast, our healthy cells get smarter, or at least more adaptable to stress.”
Rapamycin inhibits TOR. In fact, TOR stands for “target of rapamycin”. In animal studies, rapamycin has been shown to extend not only lifespan but maximum lifespan, slow the formation of senescent cells, reverse cardiac aging, decrease inflammation, and strengthen bones. And it’s already available: the FDA approved it in 1999 for preventing rejection in transplant patients. But don’t get too excited yet. Gifford says:
The fact that you’ve read this far means, of course, that you are far too intelligent to take a powerful, possibly dangerous drug just because you read about it in a book written by an English major who has no business giving anyone medical advice.
Rapamycin has side effects. It’s a powerful immune suppressor that may impair response to pathogens. It increases insulin resistance, which would increase the risk of diabetes. An anti-aging drug for use in healthy people would have to be very safe, “safer than aspirin.” Since rapamycin works on basic pathways for normal cellular function, it is likely to have unpredictable unwanted effects.
Diet interacts with IGF-1 and TOR in ways that can be either good or bad. High carbohydrate diets are probably worse than high-fat diets, and high-protein diets may be equally bad.
Preventing Alzheimer’s? He cites a 2011 study showing that if 7 risk factors are addressed (diabetes, midlife obesity, midlife hypertension, smoking, depression, low educational level, and physical inactivity), fully half of all Alzheimer’s cases could be prevented. Another study found that people who had been physically fitter at age twenty-five remained more cognitively intact at age fifty.
Growth differentiation factor (GDF11). Supplying older mouse cells with the blood of young animals had a remarkable rejuvenating effect that was eventually attributed to GDF11. Researchers are looking at possible drug candidates that would activate GDF11 and possibly treat heart failure, muscle wasting and Alzheimer’s. It’s too soon to tell whether this will pan out.
In an appendix of “Things that might work” he lists:
    • Resveratrol: an impressive array of lab results, but disappointing results in clinical trials.
    • Alcohol/red wine: some evidence of benefit from moderate consumption. In one study the subjects who drank between 3 and 5 glasses a day were half as likely to die as the controls.
    • Coffee: lowers the risk of diabetes and reduces overall mortality by 12% in people who drink 4 or 5 cups a day
    • Curcumin: Beneficial, but has bioavailability issues and requires huge doses. Pharmaceutical research found that if you try to make it more absorbable, it becomes toxic.
    • “Life Extension Mix”: More than 20 miracle nutrients; testing showed it significantly decreased lifespan in mice.
    • Metformin: a diabetes drug that has a lot of other beneficial effects. Reduces the risk of heart disease and cancer in humans and extends lifespan in mice.
    • Vitamin D: important for health, but supplements don’t seem to reduce overall mortality.
    • Aspirin and ibuprofen: anti-inflammatory effect, some evidence of benefit for heart disease and longevity. One study found that ibuprofen was associated with a 44% lower risk of Alzheimer’s.
Gifford doesn’t recommend any of these as an anti-aging remedy.
Conclusion
Science is just beginning to understand aging and age-related diseases. The secret of aging is that there is no secret. As Gifford puts it:
Aging science has put together the edges of the puzzle…but we still don’t know whether the picture in the frame depicts a battle or a massacre. The secret to aging? Use it or lose it may be the best we can do for now.
Although he is a non-scientist, he has done an excellent job of explaining the pertinent scientific literature and putting it into perspective. He provides references for the scientist and makes the story interesting for the layman. What is really refreshing and what distinguishes his book from other books on the subject is that he stresses the uncertainty of our present knowledge and doesn’t try to tell readers what they should do to reach a ripe, healthy old age. I highly recommend the book.

Drug therapy is still sending too many people to the emergency department
Prescription drugs continue to send thousands to the emergency room every year. Many of these adverse drug events are predictable and avoidable.
Scott Gavura on December 1, 2016
Link

No drug is free of risks, or the potential for causing harm. Every decision to take a drug needs to consider expected benefits and known risks. One of the ways we can reduce harms is by studying drug use rigorously. Only by understanding the “real world” effects of drugs can we understand the true risks (and benefits) and design strategies to reduce the risk of iatrogenic harm — that is, harms caused by the intervention itself. Adverse events related to drug treatments are common. Some lead to hospitalization. Studies suggest 28% of events are avoidable in the community setting, and 42% are avoidable in long-term care settings. That’s a tremendous amount of possible harm from something prescribed to help. A new study published this week shows that adverse drug events (ADEs) continue to cause significant problems, sending over a million Americans to the emergency room every year.

Understanding adverse events
An “adverse event” is an undesirable outcome related to the provision of healthcare. It may be a natural consequence of the underlying illness, or it could be related to a treatment provided. The use of the term “event” is deliberate, as it does not imply a cause: it is simply associated with an intervention. The term “adverse reaction,” or more specifically “adverse drug reaction,” is used where a causal relationship is strongly suspected. Not all adverse events can be causally linked to health interventions. Consequently, many adverse events associated with drug treatments can only be considered “suspected” adverse drug reactions until more information emerges to suggest the relationship is likely to be true. In many cases, such as with adverse drug events, the relationship is more obvious. Anticoagulants like warfarin (Coumadin) affects the ability of the blood to clot, and are used to reduce that risk. Doses must be customized and adjusted to keep the effect in the desired range: Too little, and the blood may still clot, causing heart attacks and strokes. Too much, and unwanted bleeding can occur. And warfarin’s effectiveness can be changed not only by other drugs, but by your diet. It’s a drug that can cause harm, but is also very effective.
Sometimes the best medicine may be no “medicine” at all. Fellow bloggers like David Gorski and Mark Crislip have written about the Choosing Wisely campaign, which aims to reduce unnecessary, wasteful and potentially harmful medicine. But a decision not to use a medication can have its own harms, like the case with warfarin. Ultimately, treatment decisions are personalized: we must consider individual patient characteristics and preferences in assessing benefits and risks. In a world with perfect prescribing and drug use, harms wouldn’t be eliminated, but they would be minimized.
This new analysis of ADEs is from Nadine Shehab and colleagues from the CDC. Entitled “US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014,” it sought to understand patterns of ADEs that led to emergency department (ED) visits. Data was extracted from the National Electronic Injury Surveillance System – Cooperative Adverse Drug Event Surveillance (NEISS-CADES). 58 hospitals participated in the survey. At each site, data abstractors review the records of every ED visit and look for clinician-diagnosed ADEs. ADEs causing hospital admission were noted. Relevant drug- and patient-related data were extracted and then subsequently coded by CDC investigators. There are a lot of qualifiers that need to be understood before we look at the findings:
    • Abstractors included prescription & over-the-counter drugs, dietary supplements, homeopathic remedies, and vaccines.
    • ADEs included adverse effects, allergic reactions, effects from excess doses, secondary effects (choking or injection reactions), accidental ingestions (e.g. poisonings), and vaccine reactions.
    • This was an analysis of ADEs transcribed by abstractors, so the ADE had to have been identified in the clinical record. Any ADE not identified would therefore not be included.
    • Events EXCLUDED included withdrawal effects, drug failures, occupational exposures, intentional self-harm (e.g., overdoses), and recreational drug use or abuse.
    • Emergency departments in integrated systems like the VA or Kaiser Permanente were not eligible for inclusion.
The key takeaway I had from this list is that the results will be a dramatic underestimate of ADEs. Not only did the ADE have to be severe enough to lead to an ED visit, the ADE had to be identified in the ED. Having said that, the accompanying editorial notes that excluding integrated systems like the VA means that systems that may be more effective at preventing ADEs were omitted.
The results
Based on the abstracted data, ADEs were tabulated and numbers were extrapolated to estimate the total number of potential ADEs in the United States.
42,585 ED visits were examined. An estimated 4 ED visits per 1,000 individuals occurred annually. This results in a national estimate of 1.3 million ED visits per year, suggesting a 10% increase over 2005/06. Perhaps not surprisingly, 34.5% of these adverse events are occurring in those over the age of 65. In this group, there’s an estimated 9.7 ED visits per 1,000 individuals. And remarkably, over 27% of ADEs that are identified in the ED lead to a hospital admission. Table 1 shows the breakdown by age and type of ADE:
Note how the likelihood of an ADE leading to a hospital admission approaches 50% with increasing age. The authors have compared their findings with 2005/06 data and concluded that the number of ADEs in older adults has increased from 26.5% to 34.5%.
It’s also interesting to note that it’s a single drug, rather than a drug-drug interaction, that led to the majority of ADEs presenting in the ED. The risk of ADEs goes up dramatically with more drugs taken simultaneously, so this finding surprises me. The most common finding was actually an excessive (supratherapeutic) dose. Importantly, medication errors were documented in 10% of ED visits for ADEs. These are warning flags that prescribing quality is poor. And this isn’t just the fault of prescribers, pharmacists aren’t catching errors, either.
Let’s now look at the drugs causing ADEs. Not surprisingly, the anticoagulants like warfarin top the list. Antibiotics came in second, followed by diabetes drugs. These top three categories were associated with almost 50% of the ADEs documented. I won’t show the entire table as it covers two pages, but here’s the top drugs:
And while many consumers believe that dietary supplements don’t cause adverse events, herbals and vitamins were associated with more ADEs that some widely used categories of drugs, like gastrointestinal products, and approached the ADE frequency of drugs like the nonsteroidal antinflammatory products:
The drugs implicated in the ADE reports varied by age, and below I’ve excerpted the overall results. Not surprisingly, anticoagulants lead. And in children under the age of 5 (not shown here), it’s also not surprising to antibiotics are associated with the most ADEs. More alarming is the fact that antipsychotics are the second-most commonly associated drug class with ADEs in children and teens aged 6-19.
Finally, I will show the entire table 5 which details the types of harms that are being identified in the ED. Bleeding was observed in almost 80% of ADEs involving an anticoagulant. Moderate to severe allergic reactions were observed in 18% of antibiotic-associated ADEs. Hypoglycemia with moderate to severe neurological effects in almost 50% of ADEs associated with drugs to treat diabetes. Finally, moderate to severe neurological effects in a third of those reporting an ADE associated with an opioid medication:
More needs to be done
One approach that I’ve written about before is called deprescribing or more crudely “drugectomies”, which involves discontinuing drug therapies if the expected clinical benefits are small. The approach involves an examination of every prescribed drug and confirming that it’s still medically appropriate and necessary, while considering patient preferences and overall quality of life. Anything with unclear benefit is jettisoned. And patients can sometimes feel much better as a result with a simplified medication schedule and the possible elimination of any drug-induced adverse effects. An even better approach is not starting drug therapy at all, when the benefits are expected to be minimal. Antibiotics continue to be overused for respiratory infections that are often due to viruses, not bacteria. And this data shows that antibiotics are sending more people to the emergency room than you might suspect.
Reducing the incidence of ADEs is not something that will respond to “quick fixes”. It requires health professions to reassess the prescribing and use of medications. It also requires continued scrutiny of “real world” use of drugs to ensure that the overall toxicity risk can be understood. Crucially, I think more effective collaboration is necessary between physicians and pharmacists who must work together to manage and monitor medication use. Adverse drug events can’t be eliminated, but this study gives more evidence to suggest that far too many people are hospitalized as a result of their drug therapy each year.

How do we avoid harming the elderly with prescription drugs?
Scott Gavura on June 7, 2012
Link
Is the best medicine no medicine at all? Sometimes. My past posts have emphasized that the appropriateness of any drug depends on an evaluation of benefits and risks. There are no completely safe interventions, and no drug is free of any side effects. Our choice is ideally informed by high-quality data like randomized controlled trials, with lots of real-world experience so we understand a drug’s true toxicity. But when it comes down to a single patient, treatment decisions are personalized: we must consider individual patient characteristics to understand the expected benefits and potential harms. And in a world with perfect prescribing and drug use, harms wouldn’t be eliminated, but they would be minimized. Unfortunately, we’re not there yet. There is ample evidence to show that the way in which prescription drugs are currently used causes avoidable harms to patients.
The art and science of medicine is a series of interventions to improve health. In making these treatment decisions, we strive to minimize iatrogenic harm — that is, harms caused by the intervention itself. High up on the list of of avoidable harms are adverse events related to drug treatments. Audits of adverse events are astonishing and shameful. Studies suggest 28% of events are avoidable in the community setting, and 42% are avoidable in long-term care settings. That’s a tremendous amount of possible harm resulting from treatments that were prescribed to help. And the group that is harmed the most? The elderly.
The Hazards of Aging
One of the early lessons of pharmacology is that “Children are not little adults” and “Seniors are not older adults.” That is, we cannot assume our understanding of how a drug works in a healthy adult is automatically applicable to either the young or the old. Systems for eliminating drugs may not have developed (in the young), or may have declined (in the elderly) so the usual dose of a drug may be much lower. Children and the elderly have different physical characteristics, too. There’s a different ratio of fat to muscle compared to adults, affecting how drugs are distributed throughout the body. In the elderly, the net effect is that drugs are usually not excreted as quickly, increasing the risk of accumulation and toxicity.
But that’s not all that happens. As we age, our odds of having medical issues increases significantly — and along with it, the likelihood we’ll be prescribed one or more drugs for each illness. Despite the fact that drug use is exceptionally prevalent in the elderly, our knowledge of the risks and benefits in this group can be limited. Few clinical trials deliberately include the elderly, or those on multiple medications with several medical conditions. The effects and side effects in this group may not be as well known. Add in other medications, and you increase the risk of drug-drug interactions Combine this with the normal effects of aging, like decreased mobility, vision impairment, and hearing problems, and you’ve got patients already disadvantaged if drugs exacerbate these conditions.
While all drugs have the potential to harm, some are demonstrably worse than others, particularly in the elderly. Mark Beers, a geriatrician, published a list of of potentially inappropriate medications (PIMs) in 1991. His list focused on nursing home patients, and over the next decade expanded it to include those that were potentially inappropriate for anyone over the age of 65. They key word, of course, is “potentially”. There are no hard and fast rules about appropriateness of any drug, as a unique set of patient circumstances (e.g., allergies, other medications) can mean that a potentially inappropriate medication is the most appropriate one. But some drugs are rarely appropriate, and that’s what the “Beers List” included.
There were multiple criticisms of the list when it was published. The methodology was essentially expert opinion — not based on systematic evaluations of harms. But, the list has been used extensively, and cited in hundreds of papers, linking the use of PIMs to poor consequences for patients including adverse events, hospitalization and death. The list has also stimulated further research, which has confirmed that some PIMs are directly associated with harms.
The list has been updated several times, and the most recent version was published earlier this year.
The Beers List
The most recent version of the list was derived based on a literature search followed by voting by experts and finally, an expert panel discussion. 53 drugs made the list and were categorized as follows:
    • never appropriate
    • potentially inappropriate, depending on other diseases/conditions
    • use with caution drugs — safety and effectiveness data are still emerging
So what drugs should be avoided? I’ll refer you to the full paper [PDF] or you can jump just to the entire list. Here’s some of the bigger categories of drugs that generally should be avoided in the elderly:
    • Antihistamines and other drugs that block acetylcholine (e.g., Benadryl), which can cause blurred vision, confusion, and constipation.
    • Antiparkinson drugs used to treat the side effects of antipsychotics, which are both ineffective and cause further side effects.
    • Antispasmodics (e.g., dicyclomine), an old class of drugs with little demonstrated efficacy yet considerable side effects.
    • Some drugs to treat blood clots (e.g., ticlopidine) which have been superseded by better tolerated, more effective drugs.
    • Nitrofurantoin, an antibiotic used to treat bladder infections, despite the availability of safer alternatives.
    • Alpha-1 blockers (e.g., terazocin) for hypertension, when better tolerated, more effective drugs exist.
    • Alpha-agonists (e.g., reserpine) a old group of drugs now rarely used to treat high blood pressure, because better, safer alternatives exist.
    • Some drugs used to treat heart arrythymias (e.g., amiodarone) which are often unnecessary
    • The drug digoxin when used at high doses to treat heart failure.
    • Older antidepressants called “tricyclics” which have significant side effects (and are rarely used today, as a result).
    • Antipsychotics, both older drugs (e.g., haloperidol) and the newer ones (e.g., risperidone), a wildly overused group of drugs which increase the risk of stroke.
    • Barbituates like phenobarbital, an old group of drugs dating back a few decades which cause tolerance and dependence.
    • The sedative class called the “benzos” like diazepam (Valium). They all increase the risk of falls, congnitive impariment, and motor vehicle accidents.
    • The “non-benzo” sleeping drugs such as zolpidem (Ambien) which largely have the same side effects as the benzos.
    • Hormones such as testosterone (potential for cardiac problems, and rarely necessary) “dessicated” thyroid (safer alternatives exist) and estrogens like Premarin (few documented benefits in this population).
    • The narcotic meperidine (Demerol) as it has a toxicity that’s unique to narcotics — safer choices exist.
    • Almost all non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen) due to the high risks of stomach ulceration.
    • Muscle relaxants like methocarbamol which have unclear efficacy but a documented side effect profile which may increase the risk of falls.
While the list covers many of the drugs that come to mind when you think about side effects, there are several products on the list which are rarely prescribed to anyone — elderly or not — so why they’re still included is unclear. At the same time, there’s no mention of the entire class of narcotic drugs which are often used inappropriately for pain control while raising the risk of tolerance to its effects. There’s also the drugs used to treat Alzheimer’s disease, the cholinesterase inhibitors, which lack convincing efficacy data yet continue to be used widely to treat dementia. Overall, the list focuses heavily on harms while it seems to give a pass to drugs that lack convincing evidence of efficacy. From my personal perspective, no side effect is justified if the drug doesn’t work. So most over-the-counter treatments for coughs and colds should also be on the list, given they have little evidence of efficacy and don’t affect the underlying illness.
I’m not the only one that would modify the list, or seek to improve upon it. There are several others French version, a Norweigan version, the Zhan criteria, the STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) tool, and one called the Drug Burden Index. Still, the Beers list remains the most well-know and understood. With its 2012 update, the authors have made a significant effort to put the list into practice, creating a number of resources. There’s a summary for patients and caregivers (PDF), and nicely, a summary of how to talk to healthcare providers if you or a family member is taking a drug on the list. There’s even an app for the Beers list.
Another criticism of the Beers list is that long lists can distract from the real drivers of hospitalization: A study looking at preventable hospitalizations found that warfarin (Coumadin) alone causes one-third of hospitalizations, while insulin, antiplatelet drugs, and oral diabetes medications cause another third, with other “high risk” drugs making up a minority of admissions. While this study focused on admissions, and not overall harms, it suggests that focused efforts to more effectively manage diabetes and antithromibic medications may be most effective in reducing drug harms.
Some physicians and geriatricians call for more efforts at deprescribing or “drugectomies” as a means of reducing drug-related harms in the elderly: Ruthlessly discontinuing drug therapies if the expected clinical benefits are small. The approach involves a careful consideration of each drug, confirming that it’s still medically appropriate and necessary, while considering patient preferences and overall quality of life. As data emerges suggesting these approaches look promising, we may see more standardized approaches to deprescribing in the future.
Conclusion
Screening tools like the Beers list can be helpful and empower patients and caregivers to check for potentially inappropriate medications. The elderly are already at risk – drugs which increase the risk of harms should always be questioned. However, all treatments are ultimately individualized, so there are no absolute rules. Importantly, all drugs have the potential to harm: not just the ones on the Beers list. There is good evidence to suggest that prescribing and drug use in the elderly can be significantly improved. Until we more carefully consider the patient-specific benefits and risks of medications, there will continue to be substantial and avoidable drug-related harms.

‘Start low, go slow’: The smart, safe approach to drug dosage in the elderly
Lower starting doses with cautious titration reduce toxicity without sacrificing effectiveness
Henry Miller on March 19, 2026
Link

“Preventive medicine” has lately become a hot topic. The safety and efficacy of vaccines and the impacts of “ultra-processed” foods on health have been prominent. One issue related to the prevention of illness that has been largely ignored, yet is increasingly important as the U.S. population ages, is the inadvertent overdosage with common drugs in the elderly, who often require lower doses. Greater awareness by both clinicians and patients could reduce the morbidity and mortality from overdosage.
I was reminded of the issue recently when a physician colleague of mine treated an elderly man who presented with signs and symptoms of a bleeding gastric ulcer – abdominal pain, black, tarry stools, and anemia.  The cause was too high a dose of one of the most common over-the-counter pain relievers – ibuprofen (brand names: Advil, Motrin).  The patient had been taking the drug at approximately the same dosage intermittently for decades without a problem, but what he didn’t know was that a lower dose would have been more appropriate at his current age (mid 70s).
Aging alters drug metabolism and effects
There is a large body of evidence showing that for many medicines, lower starting or maintenance doses are appropriate for older adults because aging alters drug metabolism (pharmacokinetics) and drug effects (pharmacodynamics). Studies of geriatric pharmacology consistently show reduced renal and hepatic clearance of drugs, higher body fat/less total body water (changing the ratio of distribution of drugs in the body), and increased receptor-level sensitivity for several drug classes. Together, these make standard adult doses more likely to cause toxicity in older adults. And because kidney function commonly declines with age, many drugs cleared by the kidneys require dose reduction keyed to creatinine clearance, a measure of kidney function
The FDA is acutely aware of this phenomenon. In 2024, the Agency published guidance to assist developers of new drugs “planning to conduct studies to assess the influence of renal impairment on the pharmacokinetics of an investigational drug.” It provides recommendations on when and how to conduct such studies.
These are several of the best-studied examples:
Drug classes with direct evidence for lower dosing
Anticoagulants (“blood thinners”)
Over-anticoagulation causes excessive bleeding, the signs of which include:
    • Easy bruising or unusually large or spontaneous bruises
    • Prolonged bleeding from cuts, nosebleeds, or bleeding gums
    • Heavier or prolonged menstrual bleeding
    • Bleeding under the skin causing purple or red spots (petechiae or purpura)
    • Blood in urine or dark/tarry stools indicating gastrointestinal bleeding
    • Vomiting blood or material that looks like coffee grounds
    • Coughing up blood
Warfarin (brand name, Coumadin): Multiple cohort analyses show a stepwise decline in maintenance dose with age, even after accounting for genetics and comorbidities – approximately 20%-25% lower from “young” to “elderly” groups. The authors of a large study concluded that warfarin dose requirements decline significantly with age, with older women requiring the lowest dose. They found that “the practice of starting warfarin therapy at 5 mg per day would result in over-anticoagulating a significant number of older patients and recommended lower initiation and maintenance doses in this age group.”
Apixaban (Eliquis): The FDA-approved label calls for a reduced dose (2.5 mg twice a day) when two or more of these conditions are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL; this was embedded in the landmark ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) program to preserve safety and efficacy in older subgroups.
Sedatives/sleeping pills
Zolpidem (brand name, Ambien): After pharmacokinetics and pharmacodynamics data showed higher next-morning impairment (especially with slower clearance) at usual doses, the FDA mandated lower recommended doses. Clinicians and patients are advised to use the lowest effective dose in older adults.
Benzodiazepines generally: Classic pharmacokinetics and pharmacodynamics studies show markedly prolonged half-lives (e.g., diazepam) and greater pharmacodynamic sensitivity (e.g., triazolam), which increase the risk of falling and cognitive impairment at “usual” doses. One clinical study recommended that, on average, the starting dose of triazolam should be reduced by 50 percent.
Cardiac drug
Digoxin (Lanoxin): Aging and reduced kidney function reduce clearance from the blood and narrow the safety margin of this important but potentially highly toxic drug. Observational studies and controlled trials link lower serum levels to better outcomes, lending support to trying lower doses in older patients.
Antidepressants
Citalopram (Celexa): FDA has warned of dose-dependent electrocardiogram QT prolongation — a warning sign that the heart’s electrical system is unstable and may be susceptible to a dangerous arrhythmia. Therefore, the maximum dose for patients older than 60 is capped at 20 mg/day.
Evidence-informed rules of thumb
    • “Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn that in many older adults, lower starting doses with cautious titration reduce toxicity without sacrificing effectiveness.
    • Use geriatric prescribing tools. A particularly valuable resource is the American Geriatrics Society’s Beers Criteria® for potentially inappropriate medication use in older adults, a comprehensive list of medications that may be dangerous in older people. Such resources flag medicines that need avoidance, dose reduction, or extra monitoring in people older than 65.
Key Takeaways & Recommendations
    • While many drugs are lifesaving or improve the quality of life, they can also be harmful, especially in vulnerable populations. Not every medicine needs to be lowered just because the patient is older — but many do, and there are solid data to prove it.
    • The best evidence for dosing reductions in older adults exists for anticoagulants (warfarin and similar drugs), sedative-hypnotics/benzodiazepines, digoxin, and certain antidepressants.
    • In practice, dosage decisions should be individualized according to kidney function, liver function, body composition, drug interactions, and frailty, generally adopting a “start low, go slow” titration approach. Use the lowest effective dose for the shortest necessary duration, and closely monitor older adults.


Choosing Wisely: Five things Pharmacists and Patients Should Question
Scott Gavura on May 24, 2012
Link
Is the health care spending tide turning? Unnecessary medical investigations and overtreatment seems to have entered the public consciousness to an extent I can’t recall in the past. More and more, the merits of medical investigations such as mammograms and just this week, PSA tests are being being widely questioned. It’s about time. Previous attempts to critically appraise overall benefits and consequences of of medical technologies seem to have died out amidst cries of “rationing!” But this time, the focus has changed – this isn’t strictly a cost issue, but a quality of care issue. It’s being championed by the American Board of Internal Medicine Foundation (ABIM) under the banner Choosing Wisely with the support of several medical organizations. The initiative is designed to promote a candid discussion between patient and physician: “Is this test or procedure necessary?”. Nine organizations are already participating, represent nearly 375,000 physicians. Each group developed its own list based on the following topic: Five Things Physicians and Patients Should Question. Here are the lists published to date:
    • American Academy of Allergy, Asthma & Immunology
    • American Academy of Family Physicians
    • American College of Cardiology
    • American College of Physicians
    • American College of Radiology
    • American Gastroenterological Association
    • American Society of Clinical Oncology
    • American Society of Nephrology
    • American Society of Nuclear Cardiology
ABIM has partnered with Consumer Reports to prepare consumer-focused material as well, so patients can initiate these discussions with their physicians. How did this all come to be? A candid editorial from Howard Brody in the New England Journal of Medicine in 2010:
In my view, organized medicine must reverse its current approach to the political negotiations over health care reform. I would propose that each specialty society commit itself immediately to appointing a blue-ribbon study panel to report, as soon as possible, that specialty’s “Top Five” list. The panels should include members with special expertise in clinical epidemiology, biostatistics, health policy, and evidence-based appraisal. The Top Five list would consist of five diagnostic tests or treatments that are very commonly ordered by members of that specialty, that are among the most expensive services provided, and that have been shown by the currently available evidence not to provide any meaningful benefit to at least some major categories of patients for whom they are commonly ordered. In short, the Top Five list would be a prescription for how, within that specialty, the most money could be saved most quickly without depriving any patient of meaningful medical benefit.
Health care professionals are, in general, self-regulating professions. That is, governments entrust them to set the standards for their profession and regulate members, in the public interest. Consequently, attempts by payors of services (i.e., government and insurers) to guide medical practice are usually met with substantial resistance. No-one wants insurers interfering in the patient-physician relationship. That’s why it’s exciting to see this initiative in place -it’s being driven by the medical profession itself.
As a pharmacist I’m also a member of a self-regulating profession, one in which the public places a considerable degree of trust in. In order to maintain the public’s confidence, it is essential that the pharmacy profession maintain the highest professional and ethical standards, and do its part to reduce unnecessary testing and investigations. With this in mind, I’ve taken up Brody’s challenge and developed my own list of Five things Pharmacists and Patients Should Question. While eliminating them may not provide the most savings to patients, they are pharmacy-based, widely offered, and offer little to no benefit to consumers. Here are my top five candidates:
#1. Food Intolerance Blood Tests
IgG blood tests like Hemocode and YorkTest are clinically useless for diagnosing food intolerances, yet pharmacies imply otherwise. These tests claim to identify sensitivity to hundreds of products – yet not one has been validated. That’s because there no proven correlation between positive results on an IgG blood test and a true food intolerance. Not only are these tests use to shape dietary modification, they’re also used to sell supplements – another unproven use of IgG testing. Yet despite recent cautions against this testing, it continues to be offered. Not surprisingly, the American Academy of Allergy, Asthma and Immunology (AAAAI) included IgG testing in their own Choosing Wisely list [PDF] -it’s the #1 recommendation:
Don’t perform unproven diagnostic tests, such as immunoglobulin G (IgG) testing or an indiscriminate battery of immunoglobulin E (IgE) tests, in the evaluation of allergy.Appropriate diagnosis and treatment of allergies requires specific IgE testing (either skin or blood tests) based on the patient’s clinical history. The use of other tests or methods to diagnose allergies is unproven and can lead to inappropriate diagnosis and treatment. Appropriate diagnosis and treatment is both cost effective and essential for optimal patient care.
If the AAAAI, who are the clinical experts, recommend against testing, then why are pharmacies selling IgG tests?
#2. Body Chemistry Balancing
It may surprise the internal medicine specialists out there, but some pharmacies offer tests that they claim can provide insight into metabolism, nutrition, and the need for supplements:
NutriChem Biomedical Laboratory is the starting point for good health, whether you need to measure the effect of your existing nutritional supplementation or you have specific health conditions that need to be addressed naturally. A unique profile of your biochemical makeup will help you discover what you need to lead a longer, healthier life.Our most popular testing package, the Body Chemistry Balancing (BCB) Test, is a combination of specific panels that allows us to take a look at your body’s biochemistry as well as your current hormone status. Included in the BCB test is a thirty minute consultation to review your results and discuss your health goals.From the results of the BCB, a proactive plan of action can be developed for you. This may include a customized vitamin and mineral formula to balance your body chemistry and recommendations for bio-identical hormones that are tailored to improve your individual symptoms of hormone imbalance.
Who needs it? Pretty much everyone:
In our experience, regardless of whether you’ve been diagnosed with a disease or are experiencing a lot of apparently unrelated symptoms, there are underlying nutritional or hormonal issues that have not yet been identified. This causes your body chemistry to be unbalanced.
An unbalanced body chemistry can:
    • cause mood and anxiety issues
    • lead to fatigue
    • trigger vitamin and mineral deficiencies
    • affect nutrient absorption and gastrointestinal health
    • worsen your ability to deal with stress and fight infection
    • create hormonal problems in both women and men
    • ultimately, can lead to disease
What does altered body chemistry really mean? Usually a trip to the intensive care unit, followed by death. This is Biochemistry 101. But positioned as a way of “individualizing” your care and determining you need supplements, pharmacies are taking a page out of the alternative medicine playbook. There is no published information to to suggest that pharmacy-based tests can determine the need for supplements or for specific amino acid supplements, as this sample test suggests [PDF]. Given these tests have not been validated, the information they provide cannot be considered credible. Tarot cards, anyone?
#3. Breast thermography
Why do we screen healthy people for cancer? The answer seems obvious: Detect abnormalities sooner, which presumably leads to earlier care and better outcomes. But there are several factors to consider. The perfect screening test would be 100% sensitive and specific – but no such test exists. To evaluate the overall benefit a screening test, the implications of both false positives and false negatives must be taken into account. False positives lead to unnecessary investigations and treatments. (Not to mention terrifying the patient.) False negatives mean that actual disease is missed.Enter the controversy on mammograms. There is justified debate on the utility. In particular, overscreening those at low risk of breast cancer appears to be harming more than it benefits.(This has been a discussion point for several years here at SBM, David Gorski’s post is a good launching point.) Likely driven by this vigorous debate on the merits of mammograms, thermography has emerged as an alternative therapy offered by naturopaths, homeopaths, and some health professionals. Tumours need a rich blood flow to grow, so cancer cells secrete chemicals to stimulate the development of new blood vessels. More blood flow means warmer tissue. Thermography, sometimes called digital infrared thermal imaging (DITI) uses infrared measurement to detect skin temperature differences. It’s not just for breast cancer, claim some pharmacies. One pharmacy notes the following:
Non-invasive Painless Conditions Detected with DITIArthritisArteriosclerosisBreast Health EvaluationCarpal Tunnel SyndromeChronic PainChronic Nerve InjuryDeep Vascular DiseaseFibromyalgiaGallbladder DiseaseHeadache Evaluation (cervicogenic, migraine, cluster, sinus)Inflammatory DiseasesNeoplasia (breast, skin, testicular)Neck and Back ProblemsPeripheral Nerve AbnormalitiesReynaud’s DiseaseSinus ConditionsSkin AbnormalitiesStomach ConditionsSoft Tissue Injuries/Sports InjuriesStroke Risk AssessmentTendonitisThyroid ConditionsTMJ DysfunctionWhiplash Conditions
Let’s focus on a single use – breast cancer detection. While positioned as a diagnostic wonder, the evidence is lacking. There are no controlled trials[PDF] that have compared thermography with mammograms. Evaluations show that thermography is worse than mammography in terms of sensitivity, specificity, and predictive value. That is, it gives more false positives, leading to unnecessary worry and investigations, yet it misses actual cancer. For this reason, thermography is not considered a credible or useful screening tool. This is nothing new – it’s been that way since 1977. A new study announced earlier this month reinforces this finding, suggesting that thermal imaging is not even useful in addition to mammography. Despite the lack of any credible evidence, thermography remains a service offered by some pharmacies. The bottom line with thermography is that it hurts and harms more than it helps. There’s no credible reason for pharmacies to offer it.
#4. Heel Ultrasound Bone Density Testing
With an aging population, preventing diseases more common in the elderly has emerged as a looming health care challenge. Fractures in the elderly can be devastating, with the resulting immobility leading to spiral of other illnesses, hospitalization, and premature mortality. Osteoporosis, the thinning and weakening of bones, is a significant contributor to the risk of fragility fractures. One in three women and one in five men will have an osteoporosis-related fracture in their lifetime. The medical objective is to prevent osteoporosis from occurring, as medications to treat it once it is in place only offer modest benefit.Assessing patients for osteoporosis is not recommended until age 50, and is based on a detailed history and evaluation of risk factors. Dual-energy x-ray absorptiometry (DEXA) is the gold standard for measuring bone mineral density. But American Academy of Family Medicine, in their Choosing Wisely advices, notes that DEXA screening for screening is not warranted in women under the age of 65 or men under the age of 70:
DEXA is not cost effective in younger, low-risk patients, but is cost effective in older patients.
Despite the limited and narrowly defined role for bone-mineral density evaluation, ultrasound devices that are purported to evaluate BMD are offered in some pharmacies:
Make an appointment to have your bone density tested to determine your risk for possible fractures and the development of osteoporosis.
    • Painless ultrasound heel test
    • Consultation with a pharmacist regarding bone health and osteoporosis prevention
    • Information on risk reduction
While pharmacies position heel ultrasound as a useful screening tool, expert associations advise against their use:
The scientific community has raised concerns about the technological diversity, standards and instrument precision regarding these devices. Quality assurance is another issue: as yet, no formal training or accreditation process for commercial operators exists. Further, heel ultrasound detects fewer cases of osteoporosis than DXA and experts aren’t sure how to deal with the discrepancy between results from the two tests. Many people who undergo ultrasound testing require additional DXA test later, leading to more expense and inconvenience. At this time, DXA remains the diagnostic “gold standard” for identifying individuals with osteoporosis. Moreover, QUS is not sufficiently sensitive to changes in bone structure to be used to monitor ongoing therapy for the disease.
And advice has been issued to family physicians[PDF] who may be presented with ultrasound test results administered by pharmacies:
Currently there is no requirement that operators of ultrasound equipment have formal training in measuring bone density or participate in any formal quality assurance programs. Indeed, none of the private companies offering this service that we have spoken with have had training or accreditation through the International Society for Clinical Densitometry (ISCD) or have developed an ultrasound program that meets the minimal OSC recommendations. Therefore, there is no guarantee to you that measurements are being performed correctly and accurately. Even in the hands of experts, there is uncertainty over how to address the high disagreement rates between the two tests. Ultrasound of the heel detects far fewer cases of osteoporosis than does DEXA and many people (probably the majority) who have had ultrasound testing will require additional DEXA testing. This duplication in testing is inconvenient for patients and generates additional costs. Finally, there is still no scientific consensus on how to use ultrasound measurements in defining fracture risk or diagnosing osteoporosis. [emphasis added]
Published guidelines on the prevention and treatment of osteoporosis do not recommend ultrasound screening as a useful technology. There is no evidence to show that they have any role to play for either screening or routine management of the disease. There is no demonstrated need for pharmacies to offer bone density ultrasound evaluations.
#5. Saliva Hormone Testing
Hormone replacement therapy (HRT) was routinely used by women for decades. Not only was it effective at reducing menopausal symptoms like hot flashes and sleeplessness, it was believed to reduce the risk of osteoporosis, and possibly even heart disease. There was data to suggest some risks existed, but the balance of risks and benefit was believed to favour the use of HRT. The Women’s Health Initiative (WHI) study was designed to provide conclusive answers about the risks and benefits of HRT. And it did, showing that the risks outweighed the benefits in most circumstances.
The term “bioidentical” refers to hormones that are not produced in the body, are but biochemically similar to hormones the body produces. Bioidentical hormones include estrone, estradiol, estriol, progesterone, dehydroepiandrosterone (DHEA), and cortisol. Some drugs are FDA approved and contain bioidentical hormones. But this isn’t what celebrities like Suzanne Somers are promoting. In the popular media, bioidentical hormone therapy refers to products that are custom manufactured in a pharmacy, and are claimed to be safer and more effective than “conventional” HRT. No persuasive evidence exists to show this is the case. BHT often contains combination of estrogens such as triest (estriol, estrone, and estradiol) and biest (estradiol and estriol). Both are arbitrary combinations of estrogens based on weak evidence.
Some pharmacies offer saliva tests to monitor a patient’s response to BHT, and other conditions:
Why Test Hormones in Saliva?Hormone imbalance can lead to symptoms such as mood swings, lowered sex drive and hot flashes. Saliva hormone testing may reveal hormone imbalances that contribute to chronic health problems like insulin resistance (pre-diabetes), thyroid dysfunction, estrogen dominance and androgen (i.e. testosterone) deficiency. Saliva hormone testing can also be used to monitor hormone replacement therapy (HRT) and is often used in anti-aging and disease prevention pro- grams.Which Hormones Should I Test?Generally speaking, we recommend a basic panel of estradiol, progesterone, testosterone, cortisol and DHEA-S for women and a panel of cortisol, DHEAS, estradiol and testosterone for men, to get the best view of how the hormones interact with one another.Even if you have many symptoms of hormone imbalance, it is important to discuss your symptoms and health concerns with your compounding pharmacist before considering saliva hormone testing. Hormone balance is only one aspect of good health and it is important to have realistic expectations about saliva hormone testing and hormone balance. Our staff can help you determine whether saliva hormone testing is right for you.
Despite the claims made by pharmacies, saliva tests are unreliable and considered to be pseudoscience. As per the North American Menopause Society:
Saliva testing to determine if a woman has the “right amount” of hormones has not been proven accurate or reliable. Even blood testing of hormone levels has the drawback that levels vary throughout the day as well as from day to day. More important, the desired levels in postmenopausal women have not been established. In addition, an individual woman’s physical comfort may not even be related to her absolute hormone levels.
The single best method to monitor hormone replacement is simply to see if menopause symptoms (e.g., hot flushes) are alleviated. BHT advocates argue that compounding and saliva allows patients to “balance” their hormones. But the science shows this is implausible. Estrogen and progesterone levels vary day-to-day and hour-to-hour. There are no published studies to demonstrate that single or multiple saliva tests reflect hormone need, or can be used to adjust doses accurately.
Experts advise against it. The testing hasn’t been validated as useful. So why do pharmacies offer saliva testing?
Conclusion: Pharmacists should take science more seriously
Pharmacy, a self-regulated health profession, has a choice to make. It can move to assume an expanded role in the health care system, as a credible contributor to health outcomes, focused on optimizing medication use and minimizing drug-related harms. But to be taken seriously as health professionals, the profession must offer the highest levels of science-based care. Do pharmacists want to be part of the problem in health care? Or part of the solution? The list above is a proposed starting point for some overdue reflection on pharmacist-provided services. None of the tests listed here have any established scientific credibility. Ending their provision today will signal that pharmacists take their professional obligations to patients, and the public, seriously.

Choosing Wisely: Changing medical practice is hard
One of the hardest things to do in medicine is to change practice in the face of scientific evidence that what you’re doing isn’t working. Quacks never change, but medicine does. The change might be slower and messier than we would like, but change does happen. Choosing Wisely is an initiative designed to bring about change by discouraging the use of interventions with little evidence or minimal benefit.
David Gorski on October 19, 2015
Link


We here at Science-Based Medicine like to point out that arguably the most striking difference between science-based medicine (and the evidence-based medicine from which we distinguish it) and alternative medicine, “complementary and alternative medicine” (CAM), or (as it’s called now) “integrative medicine” is a concerted effort to change for the better. In other words, in SBM, we are continually doing studies to improve practice. These studies take on two general forms: Comparing new treatments with old to determine if the new treatments work better and, as has become an imperative over the last several years supported by more research dollars, comparing existing treatments in order to determine which ones work better. In the case of the former, we are trying to add to our knowledge and thereby add more effective treatments, while in the case of the latter we are trying to weed out treatments that are less effective and/or less safe or that cost more money to produce the same results. Indeed, the rise of an explicit framework, evidence-based medicine, is a result of the desire of medicine as a profession to improve what it is doing. (Yes, I know this blog frequently criticizes EBM, but in the case of treatments that have science behind them EBM and SBM should be—and usually are—synonymous.) This is in marked contrast to CAM, where treatments based on prescientific vitalism never, ever go away, no matter how many clinical trials show them to be no better than placebo and basic science shows them to be ludicrously disconnected from reality.
An example of this imperative to make things better is Choosing Wisely. This is an initiative launched in 2012 in which the American Board of Internal Medicine (ABIM) Foundation challenged specialty societies to produce lists of tests and interventions that doctors in their specialty routinely use but that are not supported by evidence. The explicit goal of Choosing Wisely was to identify and promote care that is (1) supported by evidence; (2) not duplicative of other tests or procedures already received; (3) free from harm; and (4) truly necessary. In response to this challenge, medical specialty societies asked their members to “choose wisely” by identifying tests or procedures commonly used in their field whose necessity should be questioned and discussed. The resulting lists of “Things Providers and Patients Should Question” was designed to spark discussion about the need—or lack thereof—for many frequently ordered tests or treatments.
Let’s make no mistake here. Choosing Wisely was a big deal and remains so, which is why we here at SBM have blogged about various initiatives several times. Specialty societies have produced dozens of lists of interventions (usually in groups of five) that are commonly used but not supported by evidence. The biggest cancer specialty society, the American Society of Clinical Oncology (ASCO), produced a list for which two of the items involved my specialty, breast cancer (more on that later). Some of the lists have been stellar; some have been relatively self-serving. For instance, while I applaud the American College of Medical Toxicology and The American Academy of Clinical Toxicology for rejecting the use of homeopathic medications, “provoked” urine heavy metal tests (where the patient receives a chelating agent before the urine test, thus guaranteeing high levels of metals in the urine), and the like, the choice of Choosing Wisely metrics seemed a bit self-serving to me in that it avoided the likely far more common misuse and overuse of more conventional laboratory tests.
Be that as it may, now that Choosing Wisely has been around over three years, it’s natural to want to ask: Is it working? Has the initiative had an effect on the use and overuse of tests and interventions that don’t benefit patients? This is a difficult question to answer, given the large number of Choosing Wisely lists, and, given how long it takes to do studies, three years is really not enough time for a full assessment. It is, however, sufficient time to get some early indications. Last week, there was a major study published in JAMA Internal Medicine that suggests the answer to that question is, for the most part: Not yet. Indeed, Sanjay Gupta, MD characterized the results as “disappointing.”
Choosing Wisely: Not affecting practice that much thus far
Let’s go to the tape, as I like to put it, and examine the study, by Rosenberg et al., “Early Trends Among Seven Recommendations From the Choosing Wisely Campaign.” Now, it must be pointed out right off the bat that this is a study done by an insurance company. The investigators are all affiliated with Anthem, and led by Alan Rosenberg, MD, the firm’s vice president of clinical pharmacy and medical policy. Anthem, of course, is not a disinterested party in that, were Choosing Wisely recommendations to result in widespread change in medical practice, it would likely save the company millions, if not billions, of dollars. None of this is to denigrate the study; it’s actually a decent attempt to assess the impact of Choosing Wisely. The reason to mention who did the study is mainly because it affected study design. Basically, of all the interventions initially included in 2012 Choosing Wisely lists, these seven interventions were chosen because their usage could be analyzed via commercial insurance claims data using the International Classification of Diseases, Ninth Revision; Current Procedural Terminology codes; and whenever appropriate, National Drug Codes and Logical Observation Identifiers Names and Codes. The seven measures were also chosen to represent a wide variety of Choosing Wisely recommendations:
     1.  imaging tests for headache with uncomplicated conditions
     2.  cardiac imaging for members without a history of cardiac conditions
     3.  preoperative chest x-rays with unremarkable history and physical examination results
     4.  low back pain imaging for members without red-flag conditions
     5.  human papillomavirus (HPV) testing for women younger than 30 years
     6.  antibiotics for acute sinusitis
     7.  prescription nonsteroidal anti-inflammatory drugs (NSAIDs) for members with select chronic conditions (hypertension, heart failure, or chronic kidney disease).
You can read the details yourself for these recommendations, including the rationale for each of them, in a table provided in the paper, which is not behind a paywall.
The next part of the analysis was relatively straightforward conceptually, if not methodologically, and that was to analyze the usage of these measures in the target population listed in the Choosing Wisely guidelines before and after the publication of Choosing Wisely in the second quarter of 2012. The number and percentage of members with claims for low-value services for each recommendation were assessed quarterly for at least ten quarter through the third quarter of 2013, with the starting point for assessing each measure ranging from 2010 through 2011, based on data availability. In the case of one measure (cardiac imaging), the investigators had to use a random sample for their analysis because the numbers were too large.
So what were the results? A picture is worth a thousand words, as they say, and here’s the money figure:
And a table shows exactly which interventions changed and by how much:
As you can see, of the seven low-value services analyzed, there were modest, but statistically significant decreases for two of them (imaging for uncomplicated headache, 10.1%; and cardiac imaging in low risk patients, 10.2%). However, as the authors note, although these declines were statistically significant, the effect sizes were modest to marginal and “may not represent clinically significant changes.” Think of it this way: On an absolute basis, the decline was only 1.5% for imaging for headache and 1.1% for cardiac imaging in low-risk patients.
In contrast, the frequency of the most highly used services either remained stable, as in the case of preoperative chest x-rays and low back pain imaging. The use of antibiotics for sinusitis also remained essentially stable. Of note, this is an intervention received by over 80% of the target population, which is particularly depressing, as it indicates that the vast majority of patients with uncomplicated sinusitis who don’t need antibiotics are getting antibiotics and that Choosing Wisely has done pretty much nothing to change this, at least in the population insured by Anthem. Also depressingly, two of the interventions targeted by Choosing Wisely actually increased significantly during the study period, the use of prescription NSAIDs for members with select chronic conditions and HPV testing for women younger than 30 years, which increased by 12.5% and 25%, respectively, during the study period.
This study is not without limitations, the main one being the same limitations as any study based on administrative claims data. For instance, studies based on claims data often do not adequately capture the clinical circumstances leading to the ordering of a service or test, which means that some “inappropriate” usages might actually, taken in more fuller context, be appropriate for individual patients. It is also very difficult to separate trends due to other factors from temporal changes measured by quarterly sampling. The authors note, for instance:
It is likely that several factors in addition to the Choosing Wisely campaign may have been responsible for changes or lack of changes in frequency of low-value services. The first is secular trends and preexisting patterns. For example, during the study period, guidelines from different organizations regarding Papanicolaou testing in young women converged around the notion that those younger than 21 years should not get Papanicolaou tests. This might explain the relatively rare use of Papanicolaou tests. At the same time, HPV testing became more widely available in the marketplace and its use increased over time.
Indeed, the marketplace and availability of tests are often huge factors in driving the use of tests. Another factor to consider is that this is a rather specific population: Patients with commercial insurance through a large health insurance company. There could conceivably be differences, potentially even large ones, if, for instance, Medicare or Medicaid claims were studied. Even so, the best that can be said about the results of this study is that, taking the most generous interpretation of the data possible, Choosing Wisely has had a marginal effect on the use of only two of seven guidelines and appears to have had no effect at all on the other five. Indeed, the authors note:
Frequency of the most highly used services either remained stable (preoperative chest x-rays and low back pain imaging) or decreased slightly (sinusitis antibiotics) during the study period, which underscores the view that simple publication of recommendations—such as the Choosing Wisely lists—is insufficient to produce major changes to practice.
That’s because change is hard, and more has to be done besides just putting information out there.
Choosing Wisely and quality improvement
I don’t believe I’ve discussed this before, but I have personal experience in evaluating adherence to Choosing Wisely guidelines. The reason is that I am the co-director of a statewide collaborative quality initiative (CQI) for breast cancer care, and we chose to examine adherence to one of the ASCO Choosing Wisely guidelines, specifically: Don’t perform PET, CT and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis. Basically, this guideline recommends against the routine use of advanced imaging (PET, CT, and bone scans) to stage women with clinical stage I or II breast cancer because the yield is so low that the vast majority of “positive” findings will be false positives and result in delays in care and possibly harm due to additional tests, including invasive biopsies.
Working with our director and team to decrease the use of these tests in women with early stage breast cancer has been an eye-opening experience for me. I can’t go into too much detail because of my position and because our results haven’t been published yet, but I can discuss a couple of issues somewhat generally. For example, although our CQI has a large database with many data elements meticulously entered, it has proven far more difficult than I would ever have guessed to accurately capture scans of this sort that might be considered inappropriate under Choosing Wisely. The reason is that advanced scans are not considered inappropriate in women with early stage cancers who have symptoms suggestive of metastases, and frequently in the database the existence of such symptoms doesn’t show up in an automated search, necessitating a chart review to determine whether imaging was appropriate in a given case or not. It took us a long time to develop a process (far longer than I would have expected) to make sure that clinically indicated scans under this Choosing Wisely measure were not being inappropriately flagged as low value. This is just the sort of issue that a study like Anthem’s would miss, because it does take a chart review to identify clinical aspects that would move a patient out of the population targeted by Choosing Wisely measures. Then there was another issue that never would have occurred to me, namely how to exclude scans ordered for other indications. To say that I’ve learned a lot about how difficult putting the “rubber to the road” and implementing measures like Choosing Wisely is an understatement.
Our CQI’s experience is similar to what’s been published in the literature. For example, Hahn et al. examined the use of advanced imaging in two western HMOs and found that about 15% of early stage breast cancer patients received at least one advanced imaging test, with wide intraregional variability in testing rates. In a study of Canadian oncologists Simos et al. found recently that:
The majority of breast cancer doctors are aware of and generally agree that guidelines pertaining to staging imaging for early breast cancer are reflective of evidence. Despite this, adherence is variable and factors such as local practice patterns and disease biology may play a role. Alternative strategies, beyond simply publishing recommendations, are therefore required if there is to be a sustained change in doctor behaviour.
Changing practice is hard, even when the physicians agree that a guideline is evidence-based. This difficulty is supported by another study by Simos et al., who compared rates of use of advanced imaging in early stage breast cancer pre- and post-Choosing Wisely and found that there was no reduction in advanced imaging after publication of Choosing Wisely measures and noted, “Broader knowledge translation strategies beyond publication are needed if recommendations are to be implemented into routine clinical practice.”
Quite true.
Evidence is not enough: Change, even evidence-based change, is hard
As I’ve learned from personal experience and studying the literature, implementing evidence-based change is not easy. There are a number of barriers to changing practice, not the least of which is sheer, old-fashioned inertia. Practitioners don’t like to change because change is uncomfortable. That’s why, whenever I point out how medicine changes in response to evidence, I also point out that this change is often slower and messier than we would like. There are also incentives, particularly financial, for ordering low-value tests and treatments. Hospitals make money when CT scans are ordered, for instance. These issues are acknowledged in an accompanying editorial by David H. Howard and Cary P. Gross, but they also point out an important issue:
High-quality evidence is critical for identifying and discouraging the use of low-value care. In the absence of this evidence, health care system leaders and administrators may have difficulty convincing front-line physicians to change practice patterns. Frequently, however, such evidence is lacking. Many of the interventions cited in the Choosing Wisely campaign were deemed low value precisely because they have not been tested in trials. For example, the American Academy of Neurology recommended against carotid endarterectomy for patients with asymptomatic carotid stenosis because no recent randomized clinical trials have compared carotid endarterectomy with medical management.2 Observational studies are useful in identifying potentially low-value services, but trials that ensure the comparability of the treatment and control groups through random assignment are the best approach to convincingly determine whether a service is low value.
Although it is not feasible to conduct a trial of every service mentioned in the Choosing Wisely recommendations, the lack of high-quality evidence will hamper efforts to reduce low-value care. Clinical training increasingly focuses on the use of evidence to guide patient management. Clinicians are more likely to respond to a recommendation to avoid a low-value treatment if the recommendation is based on sound evidence than if it is justified on the grounds that the treatment has never been proven to be superior to another treatment. The absence of evidence is not the same as evidence of ineffectiveness.
I couldn’t help but notice a parallel in this argument to CAM, in that saying a CAM treatment has no evidence of effectiveness is has less of an effect on physicians than saying that a CAM treatment has evidence of ineffectiveness. Actually, that’s probably not true, given how CAM advocates are now invoking the power of placebo as an explanation of how CAM treatments “work.” But I digress. I’ll stop.
The above point, however, is an issue. As I like to say at times, part of the reason why comparative effectiveness research—and, let’s face it, that’s exactly what we’re talking about here—is so unattractive to many clinical investigators is that it doesn’t test anything new, and we like to test new things. Testing old things is, to some degree, about as exciting as watching paint dry. Until recently, it wasn’t particularly well funded, either, because there is little incentive if there is only a downside, a risk that the trial will produce a negative result that will discourage use of a company’s product. Moreover, as the authors note, patients and physicians tend to be reluctant to participate in trials of interventions already in practice for which they have strong prior belief of efficacy.
Noting the variable history of physicians changing their practice based on negative clinical trial results, ranging from results that had little effect on practice to results that had an immediate effect on practice, such as arthroscopic surgery in patients with osteoarthritis, epidermal growth factor receptor inhibitors in metastatic colorectal cancer, and percutaneous coronary intervention for patients with stable angina, the authors make a proposal:
We propose that research funders and other interested parties, such as the National Institutes of Health, the Patient-Centered Outcomes Research Institute (PCORI), the Agency for Healthcare Research and Quality, large payers, and patient advocacy groups, undertake a major initiative to identify and fund randomized clinical trials of costly and established but untested treatments. Studies that test the equivalence (or noninferiority) of treatments with markedly different costs should be prioritized based on the potential effect of their findings on health care spending. When the costs of various treatments or approaches to practice are unknown, studies should include costs as an end point. Although other randomized clinical trials aim to identify treatments with superior outcomes, value-based research would answer the question, “Can we achieve equivalent outcomes at a lower cost?” In addition, implementation science can shed light on which trials have an effect on clinical practice and identify mechanisms to increase the effect of new evidence. Developing an infrastructure for conducting these types of trials will become even more important if the US Congress passes the 21st Century Cures Act,10 which will lower the barriers to US Food and Drug Administration approval of certain medical devices and drugs. If enacted, it is likely that even more treatments will enter practice with limited evidence of effectiveness. Information from postapproval studies will be even more important than it is today.
I found it satisfying that Howard and Gross basically agree with me about the 21st Century Cures Act’s likelihood of allowing medical devices and drugs with limited evidence of effectiveness being approved by the FDA. That aside, the key to improving science-based standards of care is to provide the rigorous evidence.
Where I disagree with Howard and Gross is in their seeming assumption that high-quality evidence for or against a procedure is almost enough. As I’ve learned in my own experience in writing for this blog, that is only the starting point. Systems need to be constructed to monitor practice and compare it to science-based guidelines, and mechanisms designed to encourage cessation of low-value tests and interventions and the adoption of tests and interventions supported by evidence. Then there’s the part that’s the hardest of all: Testing whether making these changes results in improvement in outcomes, which is just as hard, if hot harder, than setting up the system. In another accompanying editorial, Ralph Gonzalez describes the difficulties and what needs to be done to change. Key among these efforts is a realignment of incentives is:
To actually reduce wasteful medical practices, delivery systems and clinician groups must (1) accept and commit to the Choosing Wisely challenge and (2) develop and implement strategies that make it easier for clinicians to follow Choosing Wisely recommendations.
A better alignment of incentives is critical for getting delivery system leaders to commit to the Choosing Wisely campaign. In a fee-for-service system, most delivery systems continue to get paid for tests and drugs, regardless of their appropriateness or indication. Payers are able to pass on these costs to employers and patients, creating a vicious cycle. Some possibilities for breaking this cycle include intense pressure or demand from consumers (eg, through continued grassroots efforts from consumer groups involved in the campaign), new regulations such as from the Centers for Medicare & Medicaid Services or the Joint Commission that require monitoring and reductions in unnecessary medical practices, and/or required external reporting of benchmarks tied to the Choosing Wisely recommendations.
Therein lies the challenge. You can’t change practice if you don’t know what practice is. That’s a major value of CQIs, measuring what is being done and comparing it to the best clinical guidelines. Generating the high quality evidence necessary to construct guidelines and translating that evidence into change will require a sustained effort against. As much as physicians want to do the right thing for their patients, changing behavior in large numbers of people is among the most difficult human endeavors of all.

Expanding the scope of practice of advanced practice nurses will not endanger patients
David Gorski on January 6, 2014
Link
One of my New Year’s resolutions for 2014 for the blog, besides looking for talented bloggers to add to our pool of awesome bloggers, was to try to look at areas of science-based medicine that we don’t often cover (or haven’t covered before), such as the delivery of health care. Fear not, I’ll certainly do enough posts on the usual topics, but I am going to make a conscious effort to diversify a bit, if only for my own personal growth. Ironically enough, in the couple of months before the end of 2013, just such an issue came up in my state. Uncharacteristically (for SBM at least) the topic I’m going to take a look at has nothing to do with the infiltration of the pseudo-medicine known as “complementary and alternative medicine” (CAM) or “integrative medicine” into academia or CAM practitioners like naturopaths or chiropractors trying to lobby state legislatures for greater scope of practice to ply their pseudo-medicine on an unsuspecting public. It does, however, have to do with expanding the scope of practice of a group of medical professionals, and, unexpectedly and disappointingly, it’s a proposal that’s had considerable resistance from various physicians’ societies in the state. I’m referring to advanced practice nurses (APRNs), often referred to as nurse practitioners (NPs).
Before I go on, it’s necessary for me to point out my conflict of interest. No, I haven’t received funding from the all-powerful American Association of Nurse Practitioners (whose influence, actually, is dwarfed by state medical societies and various physician groups). I do, however, have a very personal relationship with a nurse practitioner, namely my wife. However, I would point out that she hasn’t been an NP that long, and I routinely worked with NPs collaboratively long before the idea of becoming a nurse or even an NP was even a germ of a thought in my wife’s brain. Make of that admission what you will as you read on.
Advanced Practice Nursing
Nurse practitioners are different from physicians in that, first of all, they are nurses. However, they are nurses who have undergone advanced training such that they are qualified to manage common medical problems within their scope of practice. Another way that they are different from physicians is that their scope of practice is generally defined by the state laws that regulate their practice. A physician, once licensed in a state, can practice virtually any kind of medicine legally. It is the professional societies, not state laws, that determine the specialization of physicians. In practice, of course, I as a breast surgeon/surgical oncologist, can’t practice urology or internal medicine, for example. My hospital privileges don’t include them, nor would insurance plans reimburse me for them, nor would malpractice plans insure me to practice these specialties. The law, however, would not stop me. That is how, for example, Stanislaw Burzynski gets away with billing himself as an oncologist, even though he has never completed an oncology fellowship or even an internal medicine residency. (I still can’t figure out how he used to manage to get insurance companies to reimburse him for his services.) I would, however, rapidly run into roadblocks actually practicing.
NPs, on the other hand, go into training with a specific scope of practice. My wife, for instance, is a Pediatric NP. In addition, there are Family NPs, Adult NPs, Geriatric NPs, Women’s Health Care NPs, Neonatal NPs, Acute Care NPs, Occupational Health NPs, Certified Nurse Midwives, and Certified Registered Nurse Anesthetists. As the AANP describes it:
NP students determine their patient populations at the time of entry to an NP program. Population focus from the beginning of educational preparation allows NP education to match the knowledge and skills to the needs of patients and to concentrate the program of academic and clinical education study on the patients for whom the NP will be caring. For example, consider a primary care Pediatric NP. The entire time in didactic and clinical education is dedicated to the issues related to the development and health care needs of the pediatric client. While medical students and residents spend time learning how to manage adult clients and complete surgery rotations, a primary care pediatric nurse practitioner student’s educational time is 100 percent concentrated on the clinical area where the NP clinician will actually be practicing.
Most state laws are specific about NP scope of practice. NPs who practice outside of their scope of practice can rapidly find their licenses in jeopardy. Confusing the issue is patchwork of laws in different states regulating NP scope of practice. These range from regulating APRNs as licensed independent practitioners, as New Hampshire does, to having in essence no scope of practice beyond that of a registered nurse. Let’s compare. In New Hampshire, APRNs have the authority to perform medical evaluation/management; basically, they can diagnose and prescribe treatments within their scope of practice, and there are no requirements for physician collaboration, direction, or supervision. In Michigan:
…there is no statutory or regulatory scope of practice for an NP. According to statute and regulation, NPs have the scope of practice of a registered nurse. Physicians can, by Michigan state law, delegate their authority to perform medical acts.[7] So, because NPs in Michigan cannot perform medical acts without delegation, they cannot be considered licensed independent practitioners under The Joint Commission definition, but they would be licensed independent practitioners under the HRSA definition.
The AANP has a map of the US to show what sorts of practice APRNs have in each state, which range from full practice (like New Hampshire) to restricted practice (like Michigan) to something in between that the AANP calls “reduced practice,” like New Jersey, where I practiced for eight and a half years, in which their ability to prescribe depended on collaboration with an MD, but otherwise the NPs could practice nearly autonomously.
Now, you might ask, what does the HRSA have to do with anything? There’s still more confusion, because the federal government’s definition of an independent practitioner is different from that of many states. The US Health Resources and Services Administration (HRSA) also defines “independent contractor,” and, to confuse things still more, its definition conflicts with that of the Joint Commission:
Under The Joint Commission’s definition, in states where they are not required to be supervised or directed by physicians, NPs are licensed independent practitioners, but they are not in states where such supervision or direction is required by law. To HRSA, however, all NPs are licensed independent practitioners. The HRSA definition identifies as licensed independent practitioners NPs “or others permitted by law and the organization to provide services without direction or supervision.”
As the author of the above article drolly notes, if readers are confused, they are not alone. I don’t wish to dwell on this confusion other than to point out that it was Senate Bill 2 in Michigan that got me interested in this topic. The bill is designed to allow NPs to practice independently here (i.e. for Michigan to become like New Hampshire in that respect). More importantly and relevant to SBM, I also have to point out that the opposition to this law from medical professional societies was largely not science-based, and it was because of that opposition that the bill barely squeaked through the Senate only after being amended in ways that arguably watered it down and appears currently stalled in the House. Indeed, that is what disappointed me most of all. I don’t wish to dwell on the politics and health policy aspects of NP practice overmuch. Obviously more than just science determines law and policy needs, although it is not outside the range of SBM to point out that, with the projected shortage of primary care physicians over the next couple of decades, better utilizing providers like NPs to pick of the slack should be on the table as an option.
In which physicians protect their turf
An example of the sort of rhetoric being used against SB2 can be found on the Michigan State Medical Society website, there is a link to a pre-packaged letter to send to Representatives, as well as to a statement by the President of the MSMS Kenneth Elmassian, DO, that reads:
Every discussion in Lansing about health care and health policy should start and end with what is best for Michigan patients. The Michigan Senate today picked special interests over the health and safety of Michigan families when they voted to approve Senate Bill 2, which reduces educational requirements for those who practice medicine, risking patients’ lives and sending the signal to health care providers that medical education simply doesn’t matter.
Senate Bill 2 is bad medicine. Lawmakers in the state House should do what the Senate wouldn’t—reject this dangerous special interest legislation and instead put patients first.
On the MSMS Government Affairs YouTube channel are multiple short videos of MSMS members repeating the same dubious arguments:
The letter the MSMS is trying to get doctors to send to legislators, an effort that the Wayne County Medical Society is supporting by including a link to the form on its website (even going so far as to refer to SB2 as a “dangerous bill”), is no better, repeating the same point about fewer years of education, asking:
Consider this: if nurses were given this broad expansion of scope, what would happen if something went very wrong in the course of treatment–something that a nurse doesn’t have the education or training to handle? Are you willing to put patients in this precarious situation?
This is a transparently weak argument. To illustrate what I mean, let me ask: What happens when a physician encounters something in the course of diagnosis or treatment that goes very wrong and he doesn’t have the training to handle? He calls in other physicians who can handle it! Seriously, by this reasoning, no gastroenterologist should ever be allowed to do colonoscopies because he can’t repair a colon if he perforates one, and no cardiologist should be allowed to do angioplasties because he has to call in a heart surgeon to fix the problem with an emergency bypass if he messes up a coronary artery during a balloon angioplasty, a known risk of the procedure. The key is not being able to handle everything, as every physician specialist knows. The key is to be able to recognize when you’re in over your head and can’t handle a problem and not to be too proud or stubborn to call for help from someone who can handle it. You know who taught me that? Pretty much every surgeon I ever trained under. To quote Harry Callahan, “A man’s got to know his limitations.” This is true whether that person is a physician or an APRN, and APRN training pounds a knowledge of those limitations home.
I’m not likely to win friends among my peers by saying this, given that multiple Michigan medical societies oppose the bill, but, as a member of the MSMS myself, I do not support the stance of the MSMS, and I was particularly disturbed by the faulty reasoning and fear mongering being used to defeat this bill. Indeed, I’m actually rather embarrassed for Dr. Elmassian, who sounds more like a TV pundit or a politician running for office than a physician with that insulting bit about “special interests.” Seriously, I expect the President of my state medical society to make better arguments than that, even if I happen to disagree with his position. After all, I could equally argue that Dr. Elmassian is protecting physicians’ special interests against competition, which I rather suspect the MSMS is. Next, the whole argument about “reducing educational requirements” is disingenuous, particularly the nonsense about “sending the signal to health care providers that medical education simply doesn’t matter.” By that reasoning, I suppose the 17 states in which NPs can practice without physician supervision and the Institute of Medicine, which recommends that NPs be allowed to practice to the full extent of their training don’t care about medical education. The main reason that NPs don’t have as many educational requirements as physicians is because they specialize from the very beginning, unlike physicians, and they deal with a more limited scope of common problems. The AANP actually has a retort to this argument that I fully agree with:
Head-to-head comparison of educational models is not the appropriate measure of clinical success or patient safety. The appropriate measure is patient outcomes. Forty years of patient outcomes and clinical research demonstrates that nurse practitioners consistently provide high-quality and safe care.
This brings us to the real issue at hand that science can address and is thus inarguably part of science-based medicine and within the purview of this blog: Do NPs provide quality care? The AANP and Michigan Council of Nurse Practitioners argue that they do to the point that they should be considered independent practitioners. The MSMS and other medical societies argue that defining the scope of NPs would endanger patients. What does the evidence say? (Sorry about that link.)
The existing evidence base
Unfortunately for the MSMS, the evidence isn’t with it. In fact, I find it rather telling that none of the physicians’ groups arguing against laws expanding NP scope of practice seem able to cite any science. The reason, of course, is because they likely know that existing outcomes research looking at the effects of NPs on quality of care does not support their position. Let’s do a quick perusal of the literature, shall we? There are lots of studies; so I have to pick and choose, as well as take a look at a systematic review (non-Cochrane) and a Cochrane review.
One study, a chart review from 2008, compared the family practices in Pennsylvania and New Jersey to examine a single disease: Diabetes. Investigators audited 846 charts of patients with diabetes to compare adherence to American Diabetes Association guidelines for diabetes management between practices that employed NPs, physicians assistants (PAs), or neither. Practices with NPs performed better at providing some types of diabetes care, primarily monitoring tests, than physicians only or physicians with PAs, the latter two of which were statistically indistinguishable from each other. Whether there were confounding factors to account for the differences was not clear. These types of studies do exist in relative abundance. This is not new news, either. Copious evidence for the equivalence of care between NPs and physicians for common conditions that NPs are trained to manage exists dating back at least to the 1970s. For example, the Burlington Randomized Trial of the Nurse Practitioner was published in the New England Journal of Medicine in 1974. This study involved a large family practice in Burlington, Ontario:
…when two family physicians in Burlington, a middle-class suburban town of 85,000 just east of Hamilton, approached the Faculty of Medicine of McMaster University for possible help in introducing this innovation into their practice. For at least two years, their practice had been “saturated” — accepting no new patients or families because of inability to manage an increased case load. The physicians believed that their office nurses, with appropriate additional training, could assume a substantial portion of the responsibilities for primary care.
The NP training was as follows:
Before the study began, the nurses attended a special training program conducted by the schools of nursing and medicine at McMaster University. The emphasis of this program is on decision making and clinical judgment, rather than on procedural skills. The graduating nurse practitioners are qualified to become not physicians’ assistants, but co-practitioners, sharing the family physician’s responsibility for continuing care of patients. The nurse practitioner learns to evaluate each patient’s presenting problems, and to choose from three possible courses of action: providing specific treatment; providing reassurance alone, without specific treatment; or referring the patient to the associated family physician, to another clinician or to an appropriate service agency.
Patients were randomized either to NPs or one of the two family physicians at an allocation of 2:1 to doctors versus NPs, because at the time a case load half of that of a family physician was considered manageable for an NP. The resulting conventional group contained 1058 families (2796 members) equally divided between the two doctors, and the nurse-practitioner group comprised 540 families (1529 members), equally divided between the two nurse practitioners. Over the one year period of the trial, the number of deaths between the two groups was not statistically significantly different, nor was there a difference in physical status in terms of physical impairment, activities of daily living, or disability. The investigators noted a 5% decrease in gross practice revenue, but that was because the physicians were not billing for NP services. It was estimated that if the practice could have been reimbursed for their services, the increased volume of a 22% rise in the number of families under care could have produced a 9% increase in income.
Of course, these two studies are not examples of studies comparing physicians with NPs practicing independently. One of the earlier such studies I became aware of was a randomized study published in 2000 that randomly assigned 1,316 patients to nurse practitioners or physicians for primary care follow-up and ongoing care after an emergency department or urgent care visit. (Ironically, the study was published in that mouthpiece of the American Medical Association, JAMA, and is available in full text for everyone, no pay wall.) The outcomes compared included patient satisfaction after initial appointment (based on 15-item questionnaire); health status (Medical Outcomes Study Short-Form 36), satisfaction, and physiologic test results 6 months later; and service utilization (obtained from computer records) for 1 year after initial appointment, compared by type of provider. There was no difference in any of the parameters between physicians and NPs, other than that patients with hypertension were found to have a barely statistically significantly lower diastolic pressure at six months when treated by NPs and that patients rated provider attribute scores slightly higher for physicians. The study had limitations, such as being primarily a Medicaid population and thus not necessarily generalizable to an overall patient population and only following patients for a year, but overall it strongly suggested equivalent short-term outcomes.
There are multiple other studies. For instance, a randomized study from 2004 similar to this one found no differences between the groups in health status, disease-specific physiologic measures, satisfaction or use of specialist, emergency room or inpatient service. However, given that there are enough of these studies out there to result in systematic reviews, let’s check out the systematic reviews. For example, by 2005 there were enough studies for a Cochrane systematic review on the topic. Cochrane concluded:
The findings suggest that appropriately trained nurses can produce as high quality care as primary care doctors and achieve as good health outcomes for patients. However, this conclusion should be viewed with caution given that only one study was powered to assess equivalence of care, many studies had methodological limitations, and patient follow-up was generally 12 months or less.
A more recent systematic review from 2011 by Newhouse et al. examined the published literature between 1990 and 2008. Authors included randomized controlled trials or observational studies of at least two groups of providers (e.g., APRN working alone or in a team compared to other individual providers working alone or in teams without an APRN), conducted in the United States between 1990 and 2008, and reported quantitative data on patient outcomes. The review started at 1990 because practice and interventions have changed since before then, and studies in which health outcome effects could not be isolated to the involvement of NPs in patient care were also excluded. They found 69 studies (20 RCTs and 49 observational studies) that met these criteria, of which 37 were about NPs.
Among the conclusions:
    • This systematic review of published literature between 1990 and 2008 on care provided by APRNs indicates patient outcomes of care provided by nurse practitioners and certified nurse midwives in collaboration with physicians are similar to and in some ways better than care provided by physicians alone for the populations and in the settings included.
    • Use of clinical nurse specialists in acute care settings can reduce length of stay and cost of care for hospitalized patients.
    • The results indicate APRNs provide effective and high-quality patient care, have an important role in improving the quality of patient care in the United States, and could help to address concerns about whether care provided by APRNs can safely augment the physician supply to support reform efforts aimed at expanding access to care.
Although there were limitations in this study, including heterogeneity of studies, limited number of randomized designs, often inadequate descriptions of NP versus physician roles for purposes of the studies examined, and the difficulty in attributing to the NP specific outcomes, at the very least we can say that this review of the literature does not support the contention that expanding the scope of NP practice is likely to result in decreased quality of care. Taken in its totality, the medical literature on the subject does not support the fear mongering about SB2 in which the MSMS has been engaging. It’s shameful. There might be political or economic reasons to oppose the specifics of the bill (although, if there are, I haven’t yet been convinced of any of them), but there are no scientific reasons to oppose it on the basis of patient safety and quality of care. The MSMS and the rest of the Michigan medical societies who make this argument are, quite simply, wrong. The scientific literature does not support them, and I rather suspect that they know it. If they had any outcomes data to support their fear mongering, they would have cited it. They don’t, because there isn’t any. Even the Institute of Medicine says so, and I bet any of my colleagues who oppose SB2 can’t prove me wrong.
I support increasing the scope of practice of APRNs/NPs commensurate with their education and training. Existing science and my own personal experience that began when I first started working with NPs in 1999 lead me to that conclusion. If there were strong arguments against this from a patient safety standpoint, believe me, I would have grave doubts. (After all, I am a physician, and I recognize that my inherent bias would almost certainly be that physicians provide better care, making me more inclined to take such arguments seriously if they were evidence based.) There aren’t, at least none that are scientifically supported by outcomes data, which is why the reaction of my fellow physicians to such measures, which occurs in every state where such bills are introduced, saddens me. It’s pure turf protection, nothing more. My recommendation to my state medical societies would be to spend less time trying to shut out APRNs and more time trying to prevent naturopaths from being licensed in Michigan. That would prevent far more harm to patients than the worst fears the MSMS can conjure up about expanding the scope of practice of APRNs.

An experiment in paying through the nose for “unnecessary care”
David Gorski on December 23, 2013
Link
Rats. Harriet stole what was going to be the title of this post! This is going to be something completely different than what I usually write about. Well, maybe not completely different, but different from the vast majority of my posts. As Dr. Snyder noted on Friday, it’s easy to find new woo-filled claims or dangerous, evidence-lacking trends to write about. Heck, I did it just last week, much to the continued consternation of one of our regular readers and commenters. Examining certain other health-related issues from a science-based perspective is more difficult, but I feel obligated to do it from time to time, not just for a change of pace but to stimulate the synapses and educate myself—and, I hope, you as well—about areas outside of my usual expertise.
We spend a lot of time writing about the scientific basis of medicine, clinical trials, what is and isn’t quackery, and how “complementary and alternative medicine” (CAM) subverts the scientific basis of medicine. However, SBM goes far beyond just that. At least I think of it this way. That’s why I’ve looked at issues that go more to the heart of health policy, which should be based on sound science and evidence. That evidence might take different forms than it does for determining, for example, whether Medicaid results in better health outcomes and by how much health insurance does the same. As is the case with policy issues and economics, conclusions are muddled and messy. The error bars are huge, and the number of potential confounders even huger.
One of the most vexing problems confronting the US health care system is the issue of cost. As has been documented in many places, the US health care system spends more per capita than pretty much anywhere else in the world for outcomes that are, at best, equivalent to those of the health care systems of other industrialized countries. How to fix that problem and “bend the cost curve” downward is the single biggest problem our current health care system faces. The Affordable Care Act (ACA, a.k.a. “Obamacare”) tries to make steps in that direction by emphasizing comparative effectiveness research and finding ways to encourage the use of less expensive treatments that are equally effective and to discourage the use of unnecessary procedures. This is a problem that long predates the ACA.
It’s also a very difficult, seemingly-intractable problem. Part of what contributes to it is a host of practices that are not supported by evidence or science but that continue. A classic example, of course, is the prescribing of antibiotics for viral illnesses. Patients, under the mistaken impression that it will help them, demand it, and physicians, even though they (usually) know better, are all too often willing to acquiesce to their patients’ requests because it’s far easier and takes less time to acquiesce than it does to explain why antibiotics are not necessary. Nor are doctors entirely blameless in this, as we all-too-often hate giving the impression of “doing nothing.”
So what’s the answer? According to this story by Sharon Begley entitled “In healthcare experiment, patients pay more for ‘bad’ medicine” that I saw late last week, it might be behavioral modification:
When Tanner Martin, 17, developed excruciating back pain last year, he was sure he needed an X-ray to find out what was wrong. So was his mother, who worried that the pain might indicate a serious injury that could cause permanent disability.
But Konnie Martin was no ordinary parent. As chief executive officer of San Luis Valley Regional Medical Center in Alamosa, Colorado, she is at the center of an experiment, known as value-based insurance, that could transform American healthcare.
One of the central features of a value-based system is a financial “stick.” If patients insist on medical procedures that science shows to be ineffective or unnecessary, they’ll have to pay for all or most of the cost.
In Tanner’s case, when he and his mother went to the medical center, they were invited to watch a short video first. The best approach to back pain like Tanner’s, it explained, is stretching, strength-building and physical therapy; X-rays and MRIs, according to rigorous studies, are unlikely to make a difference. If they insisted on the X-ray, they would have to pay $300 on top of the basic cost.
They passed on the imaging, knowing they could change their minds if Tanner’s condition worsened. After three weeks of therapy, his back was as good as new.
As you can see from this anecdote that introduces the story and the problem, the basic idea is to make patients pay more if they insist on tests or treatments that, according to science and evidence, won’t help them. The concept seems sound on the surface, but is it? And what is the evidence? The clinical encounter described above came about as a part of a two year experiment by San Luis Valley in what is commonly referred to as “value-based health insurance” or “value-based health care.” It’s nothing new, but with the advent of health insurance and health care reform, health policy wonks have been taking more interest in it.
Not too long ago, Scott Gavura and I wrote about an initiative by the American Board of Internal Medicine Foundation (ABIM) known as Choosing Wisely. It is an initiative in which a challenge, if you will, was issued to professional societies to identify five practices in their specialties that are ineffective and add no value to patient care. As I described, in oncology some of those practices involve imaging for extent of disease in breast cancer (which is very commonly done but has never been shown to improve patient outcomes) and a variety of other practices that are still common in oncology and oncologic surgery. Value-based health care sounds to me like Choosing Wisely on steroids. It could be the logical next step in the progression. Obviously, if a treatment or diagnostic modality has not been validated by science and clinical trials, it doesn’t make sense to pay for it.
The evidence base for value-based health insurance, however, is rather sparse. Begley notes that the San Luis Valley Health experiment only involves 725 covered members and dependents. That’s not an unreasonable number for a pilot experiment, but it’s far from enough to be able to tell whether value-based health care can deliver on its promises. The experiment is going to wrap up at the end of this year, and the data are to be analyzed in 2014. However, at most what will be able to be determined is whether costs are decreased.
One of the experts interviewed by Begley for the piece was Dr. Mark Fendrick, director of the University of Michigan’s Center for Value-Based Insurance Design and a professor of internal medicine. Since the University of Michigan is just up the road from where I work (well, if you consider 45 miles or so “just up the road”), I figured I’d peruse its website and see what it says about value-based insurance:
The basic V-BID premise is to align patients’ out-of-pocket costs, such as copays and premiums, with the value of health services. This approach to designing benefit plans recognizes that different health services have different levels of value. By reducing barriers to high-value treatments (through lower costs to patients) and discouraging low-value treatments (through higher costs to patients), these plans can achieve improved health outcomes at any level of health care expenditure. Studies show that when barriers are reduced, significant increases in patient compliance with recommended treatments and potential cost savings result.
Note that the concept is not just to penalize care that is not scientifically supported but to reward care that is by decreasing barriers to receiving it. For instance, this is one of the studies cited by the University of Michigan. Basically it looked at the effect of an insurance plan reducing copayments for five chronic medication classes, including: angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs); beta-blockers for hypertension and heart disease; diabetes medications (such as oral therapies and insulin); HMG-CoA reductase inhibitors (statins); and inhaled corticosteroids (such as Advair for COPD and other chronic pulmonary conditions). Copayment rates for generic medications were reduced from $5 to zero. Copays for brand-name drugs were lowered 50 percent (from $25 to $12.50 for preferred drugs and from $45 to $22.50 for nonpreferred drugs). All patients in the treatment firm (treatment and control groups were organized by company, not by individual patient) who were already taking any of the intervention medications without a contraindication were eligible for the copay reduction, beginning with their next prescription fill. Copay relief was also available for those who were not taking the medication if they were identified by the clinical alert system as patients who would benefit from the medication.
The study design was temporal, with results examined pre- and post-intervention. For each drug class, people were selected for the sample in a given year if they used the medication within three months of the study year and didn’t have a contraindication for its use or if they were identified as having a clinical indication for the medication but didn’t use it within the previous six months. The overall results were that, compared to another health plan, participants in the plan that decreased its copays for these medications demonstrated reduced nonadherance by as much as 7-14%. Obviously, there are a lot of shortcomings to this study, such as the question of whether the control group is adequate, but it does indicate that there might be merit to this approach. It also suggests that “value-based” health insurance might actually not be the best way to control costs, because lowering the copays actually increases cost, at least in the short term. Whether that short-term increased cost is later compensated for by decreased costs caring for complications of these chronic diseases over the long haul is something that is yet to be determined.
Indeed, according to this recent review, cost savings from value-based insurance designs have been elusive:
While these copay changes to incentivize the use of certain technologies show improvement in some process indicators, they have not yet achieved cost savings.21 For example, the same Blue Cross Blue Shield study found no cost savings.19 Another recent article by Choudhry et al (2011) found no significant difference in costs between a group with no copay for cardiovascular drugs and a group with regular cost sharing.22 The lack of significant cost savings may be due to the short follow-up times in these studies —usually 1 year. More research is needed in the area of cost savings of incentivizing the use of certain services. This will become especially important as the ACA has also required that insurers provide all the USPSTF recommendations free of charge.
In lieu of long-term follow-up, modeling suggests some long-term savings, but these analyses have often focused on raising copays for “low-value” services. For example, the 3 main treatments for prostate cancer vary greatly in their average costs with no evidence that the more expensive treatments result in better outcomes. A radical prostatectomy costs $7,300, brachytherapy costs $19,000, and radiation therapy costs $46,000 on average. Newer forms of radiation treatment can cost close to $100,000 per case, and have not been shown to have any clinical advantages over any of these less expensive options, including watchful waiting. A simple VBID policy would be to modestly increase the cost sharing for these services to encourage more use of the cheapest and equally effective prostatectomy. The authors of the same prostate treatment study estimate $1.7 to $3 billion could be saved directing patients toward the lower-cost treatments.
This suggests another issue. Surgery might be the cheapest treatment for prostate cancer (yes, contrary to what many believe, surgery is often the least expensive option for treating certain diseases), but it is the most invasive and likely to have the most impact on quality of life, with its known complications of retrograde ejaculation and erectile dysfunction. True, radical prostatectomy costs even more if, as is all the rage these days, the da Vinci robot is used. It’s always better with robots, isn’t it? I’m sure Sheldon Cooper would agree—except that it isn’t always. There’s no compelling evidence that robotic prostatectomy results in better outcomes than current laparoscopic prostatectomy. Add to that the problem of overdiagnosis and overtreatment of prostate cancer, which leads to the question of which prostate cancers even need to be treated and even what the very definition of “cancer” should be. The new focus on cost is going to force medicine very quickly to decide how much it values quality of life, because treatments that are effective at eradicating the disease but less so at producing high quality of life are often cheaper.
This is just one example, of course. There are thousands of examples, ranging from common mild conditions to common serious conditions to uncommon conditions. One area, however, where such initiatives might bear fruit and change behavior is by simply hitting doctors and patients over the head with data indicating which treatments do and do not have science and clinical evidence behind them:
The very idea that some diagnostic tests and treatments might not help patients comes as a shock to many Americans.
The Choosing Wisely message is difficult to convey to the many patients who “think that when it comes to medical care newer is better and more is better,” said Dr. Yul Ejnes of Brown University’s Alpert Medical School. “So when patients have more skin in the game (in terms of cost), they’re more likely to ask, do I really need this?”
San Luis Valley Health is self-insured, and the experiment involves only its 725 covered employees and dependents.
The experiment puts medical services in green and red “buckets.” Green is for procedures that should be encouraged because they are cheap and effective, like vaccines. Red is for expensive ones that, research shows, are usually unnecessary, ineffective or even harmful. They include endoscopy for heartburn, surgery for enlarged prostate and the imaging tests that Konnie Martin’s son declined.
Patients (and, unfortunately, a lot of doctors) have a tendency to assume that more care must be better, when in fact often it is not. We here at SBM have discussed how and for what diseases that is often the case many times in the past. On the other hand, policy wonks seem to make a related assumption, namely that “preventative” care will save money, an assumption for which the evidence is at best mixed. The reason is obvious. Preventative medicine costs more and results in more costs treating the diseases and conditions that it uncovers. However, it is not entirely clear that it saves money in the long run through earlier treatment and intervention to prevent the complications of chronic diseases and diagnoses other diseases at an earlier point in their courses. As value-based insurance advocates admit:
It has that potential, although whether the kind of patient targeting VBID proposes saves in long-term costs remains an open question. “Does it make good business sense?” asks Chernew. “It depends on how it is designed. It certainly can. Lowering copayments itself does not necessarily save money, but the programs are designed to make people healthier. We do know that the long-term benefit still requires a comprehensive look.”
Notwithstanding a lack — so far — in established long-term savings, the concept is most certainly gaining favor with large employers, including several members of the National Business Coalition on Health, who are pushing for VBID when they solicit vendors.
That is the crux of the issue, as I’ve mentioned. Will the short term investment yield long term savings? No one knows, and the evidence is mighty sparse. However, it’s another truism in medicine that it’s not possible to wait for perfect data. We have to make the best judgments we can with the science and data that exist now, hopefully making adjustments as new data and science are reported.
Another issue that comes up is the perception of fairness. Communication is the hard part. Consumers love carrots like reduced copays, but they aren’t particularly fond of sticks (like making them pay much of the cost of “unnecessary” tests and treatments out of pocket in addition to their existing health insurance premiums), so to speak, which are perceived as punitive, even if employed in the service of “encouraging” patients and practitioners to use more science- and evidence-based medicine and to stop using medicine that is not supported by science. Advocates of value-based systems claim that they don’t intend to penalize patients for treatments in which the evidence is conflicting, or, as it was stated in Begley’s article, “subject to debate.” However, this question really does bring up an incredibly dicey issue: How much evidence is “enough” to demonstrate that a test or treatment is not of value and therefore should be subject to financial disincentives? Doctors will disagree. If a physician tells a patient that he really needs a treatment, and that treatment is one that is not covered, the patient will feel abused and betrayed, as will the doctor. The example above, in which the patient is offered education, might be the way to handle this problem, but it requires physician buy-in.
More and more, I find myself having to consider issues that I never had to consider much before, such as quality of medical care and cost of services. I never really saw myself ever becoming a health policy wonk or a quality of care analyst, but increasingly such skillsets are becoming necessary to my career. Part of the reason is because, quite through a strange quirk of fate that landed me in the right place at the right time, I find myself co-director of a statewide quality initiative for breast cancer care. I’ve had to learn, and the curve is steep. It’s a fascinating and ridiculously complex area that makes some of my old lab experiments seem very straightforward in comparison. (I am, after all, used to being able to control most variables.) However, it is every bit as much a part of SBM as clinical trials and bench research. We as SBM advocates would do well not to neglect it, because it really is where the “rubber meets the road.”

Why Doctors Order Too Many Tests
Harriet Hall on July 1, 2014
Link

While cleaning out some old files, I was delighted to find an article I had clipped and saved 35 years ago: a “Sounding Boards” article from the January 25, 1979 issue of The New England Journal of Medicine. It was written by Joseph E. Hardison, MD, from the Emory University School of Medicine; it addresses the reasons doctors order unnecessary tests, and its title is “To Be Complete.” Today we have many more tests that can be ordered inappropriately and the article is even more pertinent and deserves to be re-cycled. He says,
When challenged and asked to defend their reasons for ordering or performing unnecessary tests and procedures, the reasons given usually fall under one of the following excuses…
He lists ten excuses:
     1.  To be complete. (This implies a need to go beyond a rational diagnostic process. “Complete” is a nebulous concept; you could always do one more test.)
     2.  The “they say” excuse. (Who are “they” and do they really say that? If they do, do they say it for science-based reasons or is it just an opinion?)
     3.  The “we’ll get in trouble if we don’t” excuse. (This expresses student doctors’ fears of the attending physician, who may not actually chastise them for not ordering an alpha-fetoprotein test on every patient.)
     4.  The “if we don’t order everything at once, it won’t get done” excuse, commonly given in large city hospitals. (Should rational health care suffer because of institutional inefficiency?)
     5.  The “as long as he is in the hospital, we might as well” excuse. (Why should a patient’s care depend on where he’s located or how readily available a test is?)
     6.  The “academic” excuse. The false idea that the evaluation of a patient should be somehow different or more complete in an academic institution. Here Dr. Hardison quotes a dictionary definition of an academic as “very learned but inexperienced in or unable to cope with the world of practical reality.”
     7.  The “malpractice” excuse. I have personally heard this excuse all too many times. One of my friends was challenged on the witness stand about why he ordered an x-ray in a trauma case when he had testified that it was not really indicated by the patient’s findings. He answered, “I ordered it so I could tell you here in court today that I had done so.” It’s a sad state of affairs when doctors make decisions based on fear of malpractice suits rather than on the patient’s welfare.
     8.  The “protocol” excuse: the patient is a candidate for a study that requires these tests for its protocol. (Best find out first if the patient is really going to be enrolled in the study and consult the researchers or wait and let them order the tests they need.)
     9.  The “if it were my mother or father, I’d want it done” excuse. He comments, “The parent who has his child for a doctor had best beware.” (In other words, when doctors are emotionally invested in patients, reason flies out the window.)
     10.  The “how do we know he doesn’t have it?” excuse. (Carrying that excuse to its logical consequences would mean ordering every possible test on every patient, and getting a lot of false positive and irrelevant results. A better question is “do we have any reason to suspect he might have it?”)
     10.  I can think of two more excuses:
     11.  The “knowledge is good” excuse. If anything is abnormal, we want to know. The more we know about our bodies, the better. (That’s not always true; sometimes we are better off not knowing irrelevant or insignificant information.)
     12.  The “fishing expedition.” I don’t have any idea what’s wrong with this patient, but maybe if I order a lot of tests, something will turn up. (Not only is this an admission of incompetence, it’s likely to turn up misleading information, to lead to the wrong diagnosis, and to do more harm than good.)
Too many tests can be hazardous to your health for several reasons:
    • Because of the way normal values are determined (testing a lot of presumably normal people and cutting off the ends of the resulting Bell curve), there is a good chance that one out of every twenty tests will give an “abnormal” result that is not really abnormal. Being 6 feet 7 inches tall falls at one extreme of the Bell curve but it is “normal” for that person and doesn’t mean he has a disease.
    • False positive results become increasingly likely when a disease is rare and/or when the patient’s history and physical don’t already point to that diagnosis.
    • Following up on false positive results can be a wild goose chase, with more unnecessary tests and procedures. There’s no way to tell for sure whether a suspicious shadow on an x-ray represents a deadly disease or a harmless artifact without invasive procedures that carry risks.
    • Imaging procedures and other tests frequently identify “incidentalomas,” abnormal findings that are mere curiosities and that have no impact on the patient’s health other than to sometimes cause unnecessary worry.
    • Some tests involve potentially harmful radiation; and even the simple act of drawing blood can cause pain, bruising, and a tiny risk of infection. Even minor risks are not justified if the likelihood of benefit is too low.
    • Lab errors occur: machine malfunctions, misreading results, mixing up samples, recording and transcription errors, etc.
    • Overdiagnosis leads to unnecessary treatments.
    • Tests cost money, sometimes a lot of money, which is not healthy for your own wallet or for society’s health care budgets.
The need for a test can be informed by scientific studies. Does routinely ordering x-rays on all patients with ankle injuries improve outcomes? No, it doesn’t. Simple sprains are much more common than fractures, and x-rays expose patients to radiation. Science-based guidelines like the Ottawa ankle rules have been developed to help clinicians decide when to order tests.
Another consideration is “what difference will the test make?” What are we going to do differently if the result is x rather than y? If we can’t answer that question, we probably shouldn’t be doing the test. That’s particularly pertinent in genomic testing, where patients may be told they are at high risk of developing a disease that they can’t do anything to prevent.
And then there’s CAM. Many tests offered by CAM practitioners have not been validated, some are known to be bogus, and some are used to diagnose bogus diseases.
And then there are the patients who demand tests because of something they read on the Internet.
Conclusion
Every year there are more tests available for doctors to order. Doctors should not order any of them without good reason. Doctors should be guided by good judgment grounded in science. Patients should not be hesitant to question their doctors if they don’t understand why a test is being done or what difference the results will make.

An Egregious Example of Ordering Unnecessary Tests
Harriet Hall on July 8, 2014
Link
Last week I wrote about doctors who order unnecessary tests, and the excuses they give. Then I ran across an example that positively flabbered my gaster. A friend’s 21-year-old son went to a board-certified family physician for a routine physical. This young man is healthy, has no complaints, has no past history of any significant health problems and no family history of any disease. The patient just asked for a routine physical and did not request any tests; the doctor ordered labwork without saying what tests he was ordering, and the patient assumed that it was a routine part of the physical exam. The patient’s insurance paid only $13.09 and informed him that he was responsible for the remaining $3,682.98 (no, that’s not a typo). I have a copy of the Explanation of Benefits: the list of charges ranged from $7.54 to $392 but did not specify which charges were for which test. It listed some of the tests as experimental and not covered at all by the insurance policy, and one test was rejected because there was no prior authorization.
The tests were done by Health Diagnostic Laboratory, Inc., a company that offers an advanced comprehensive menu of biomarkers. Here’s a list of the tests they did on this young man:
    • Lipids: total cholesterol, LDL-C, HDL-C, Triglycerides, Non-HDL-C
    • Lipoprotein Particles and Apolipoproteins: Apo B, LDL-P, sdLDL-C, %sdLDL-C, Apo A-1, HDL-P, HDL2-C, Apo B: aApo A-1 Ratio, Lp(a) Mass, Lp(a)-P
    • Inflammation/Oxidation: Fibrinogen, hs-CRP, Lp-PLA, myeloperoxidase
    • Myocardial Structure/Stress/Function: Galectin-3, NT-proBNP
    • Platelets: AspirinWorks (urine) Ppg/mg of creatinine
    • Lipoprotein Genetics: CYP2C19*2*3, CYP2C19*17
    • Coagulation Genetics: Factor V Leiden, Prothrombin Mutation, MTHFR (C677T), MTHFR (A1298C)
    • Metabolic: 25-hydroxy-Vitamin D, Uric Acid, TSH, Homocysteine, Vitamin B12
    • Renal: Cystatin C, Estimated Glomerular Filtration Rate, Serum creatinine
    • Electrolytes: sodium, potassium, chloride, CO2, calcium
    • Liver: ALT/GPT, AST/GOT, ALP, Total bilirubin
    • Renal: Creatinine, BUN
    • Thyroid: TSH
    • Others: Albumin, Total protein, Ferritin
    • Omega-3 fatty acids: ALA, DPA, EPA, DHA
    • Omega-6 fatty acids: Omega-6 total, Arachidonic acid, Linoleic Acid
    • Other fatty acids: cis-monosaturated total, saturated total, trans total.
They did not report hemoglobin, hematocrit, blood glucose, or hemoglobin A1C, but they nevertheless commented:
    • Glucose and hemoglobin A1c are in the normal range and are consistent with normoglycemia
    • There may be some evidence of insulin resistance. There is evidence of adipose tissue insulin resistance.
    • There is evidence of hyperinsulinemia, suggesting beta cell strain. There is evidence of beta cell dysfunction. Elevated Proinsulin to C-peptide ratio has been associated with beta cell failure and beta cell dysfunction.
At the end of the lab report there is a long list of comments explaining the associations of various factors with various health consequences. Helpful information, like the fact that the patient’s genotype shows that he would be a normal metabolizer of the drug clopidogrel. Finally, the patient is encouraged to contact the lab to set up an appointment with a Clinical Health Consultant to discuss his exercise needs at no charge.
According to most published guidelines, a routine physical on a 21 year old male should include BP, weight, updating immunizations (and offering HPV vaccine), inquiring about risk factors, and counseling, as appropriate, about lifestyle issues like safe sex, smoking, alcohol, diet, exercise, etc. NO lab tests are recommended except for possibly checking lipids or HIV status, which most guidelines do not advise in the absence of risk factors.
I will not comment further, as I feel incapable of moderating my language.
Addendum: August 7, 2014
The young man in question called the doctor’s office to complain about the charges. They referred him to the billing department. The billing department said there was nothing they could do and he should call the lab that did the tests. He called Health Diagnostic Laboratory and they told him to just forward the check for $13.09 that his insurance company had sent to him. They told him he would not be billed for the rest of the charges. I don’t know how they can do business this way, but at least he doesn’t have to pay.
In response to a fraud alert issued by the Inspector General, Health Diagnostic Laboratory has recently dropped the “reimbursement for shipping and handling” kickback to doctor’s offices.
This is all very reassuring, but my flabber remains gasted at the doctor ordering all those tests on a healthy young man.

Serologies
“You keep using those words: positive serology. I do not think it means what you think it means.”
Mark Crislip on December 15, 2022
Link

There are multiple ways to make the diagnosis of an infectious disease. The best is growing the organism from a sterile body fluid. Although it would appear that there is no sterile body site. Bladder, lung, and perhaps even the brain have a non-pathogenic microbiome. The key word there is non-pathogenic. These organisms don’t grow in cultures. Bacteria, including pathogens, occasionally transiently access the blood and show up in cultures but can be clinically meaningless. A true positive (as opposed to a contaminant) but an unimportant positive. Still, I like a positive culture. It helps sum up my concept of ID: me find bug, me kill bug, me go home.
Next down the list of diagnostic utility is finding DNA/RNA or body parts of the organism in the blood or other body fluids. The former sometimes provides too much information and the latter can be problematic. As examples, cell-free microbial DNA assays can sometimes find DNA of multiple organisms in the blood, none of which were clinically expected or relevant. And the 1-3 beta-D-glucan, which detects a fungal body part, may be elevated when there is no fungal infection. Like all tests, they have to be judged within the context of the clinical presentation.
The most problematic way to make a diagnosis is serologies: measuring antibodies in the blood directed against an infection.
There are two antibodies that can be used to diagnose an infection. IgM, which is the first antibody class the immune system makes against an infection. It kicks in around day 5-10, peaks around 21 days and is present in the blood for around 3 months. Usually. There can be great variability depending on the infection and IgM can be problematic.
IgM tests also suffer disproportionately from false-positive results, which can lead to misdiagnoses, inappropriate therapy, and premature closure of a diagnostic workup.
IgG is the other useful antibody. It kicks in around day 5-10 and lasts a lifetime. IgG is the antibody that can give lifelong protection and the antibody whose levels can be boosted with vaccines or re-exposure to the pathogen. It is the only wing of the immune system that can be boosted. IgA and IgE have no routine diagnostic utility.
If you have a positive serology, then you must have the disease. Right? I wish. There are several serologic scenarios that drive me bonkers. The first is Epstein Barr Virus (EBV).
It is not uncommon for EBV serologies to be ordered in clinical situations that I call Nutrimatic medicine: a clinical presentation that is almost, but not quite, entirely unlike EBV. You can fill in other pathogens for EBV. But it is remarkable how often tests are ordered when there is no clinical indication. Diseases have patterns. If the pattern is not that of, say, EBV, then do not order EBV serologies.
Often EBV serologies are ordered in patients who have a fever and only a fever. None of the clinical features of EBV like a sore throat, enlarged lymph nodes, hepatitis, cytopenias etc. And the test is positive. Then the patient is sent to me to explain the serologies.
Since most people are exposed to EBV when young, the majority of the population will have positive serologies. To complicate the issues, EBV, like all herpesvirus, persists in human cells. Unlike love, herpesviruses last a lifetime. When a process activates the immune system, it can also activate herpesvirus replication, leading to a boost and higher titers of antibodies.
I remember back when I was an intern, EBV, because of high EBV titers in Chronic Fatigue Syndrome (CFS) patients, was thought to cause chronic fatigue syndrome, rather than a marker of CFS, and not a good marker at that.
I would like to say those who order EBV serologies are required to interpret that serology, but so often the person ordering the tests is, well, let’s say lacking in a sophisticated understanding of EBV.
So I have to tell the patient: the serologies is meaningless since (almost) everyone has positive serologies, the test should not have been ordered in the first place, and EBV has nothing to so with your, usually resolved, symptoms. Blah.
Lyme testing is the other problematic serology. Lyme testing has two steps. The first is a screening ELISA, meant to be overly sensitive. Then a confirmatory western blot. There are many other Lyme tests, such as PCRs, antigen tests, and labs that offer their own, in-house, tests. All of these are problematic.
Lyme testing gets to the heart of the matter of prior plausibility in interpreting the results of serologic tests.
There is zero Borrellia in the Willamette Valley. None. Zilch. Nada. At least as of now. But who knows with the future. One of the many consequences of climate change is the range of infection vectors is changing. The ticks that spread Lyme, and other diseases, are spreading north and east, so perhaps Borrellia will migrate to the Great Pacific Northwest some day. And pathogens can spread due to human behaviors, such as Rocky Mountain Spotted fever in Arizona due to pet dogs. Pathogens get around, sometimes by the damndest methods. So you can never be 100% sure there wasn’t some weird method of infection acquisition.
Every test has a false positive and false negative rate. It is one of the annoying characteristics about serologies. The results are not black and white, but shades of probable gray. I sometimes wonder about the sensitivity of some tests. For example, the urine antigen test used to diagnose histoplasmosis was developed from a strain out of Indiana. Strains in the Caribbean, which somewhat antigenically different, can be missed with this test. For some organisms, the farther you are away from the index strain, the more genetically separate they become. It can be quite dramatic with malaria, where the P. ovale in Asia look and acts identical to the P. ovale in Africa, but the two cannot mate. Classic Darwin.
That may be true for Lyme as well, as the farther you get from the index Borrellia of the NE, the more antigenic distance you see. Does this make a difference in testing? Don’t know for strains in the US, but the US testing for Lyme is not as accurate for detecting European Borrellia.
And then there is the potential of cross reacting with other spirochetes, like syphilis and relapsing fever.
Lyme serology, like other serologies, is not as simple as one would like. And it is compounded by the fact that, like EBV serologies, they are ordered when they shouldn’t be.
For example.
The patient lives and works in suburban Portland and has not left the area for a couple of years. He does find a tick after yard work which he notices immediately and removes the tick. It happened to me this summer as well. I found two attached ticks on my abdomen after a day trimming bushes. It gives me the willies. Ticks and leeches. Ew. Second most horrifying scenes in the movies is when Bogart has to remove all those leeches in the African Queen. The worst? Maybe because I was just a kid when I first saw it, but it was the amputation scene in Gone with the Wind. I digress.
As mentioned, there is no Lyme in Oregon. And the tick has to feed for at least 4 hours before passing on Lyme. So no reason whatsoever to test for Lyme. But the patient asks his primary physician for testing and money is wasted when it come back negative. At least the patient did not see an ND (Not a Doctor), who love to send off non-standard Lyme testing that often comes back positive. But that is a story for another day.
But the patient has vague orthopedic complaints. Muscle and joint aches that are new in his 50s. Just wait until you hit the 60s. I do not think I have a single part of my body that doesn’t ache. Maybe my hair. And that’s likely because I do not have much. Six months in, because of the symptoms, the patient requests further testing, so a very-much-not-indicated western blot is ordered. Really. Might as well just burn a stack of dollar bills.
The western blot was negative for the IgG and positive for IgM. He has Lyme!
Nurp.
First, if this were Lyme, which it isn’t, the blot would be consistent with acute Lyme. Six months in the IgG should be positive as well. It isn’t. And the IgM western blot is notable for false positives.
But more importantly, a positive test done in a patient with no risks is going to be a false positive. That’s the SBM part of this entry.
In trying to figure out what a Lyme, or other serology, means, you have to know not only the sensitivity, specificity, false positive and false negative rates of the test, you also have to know the prevalence of the disease. And with Lyme, the added complexity of the operational characteristics of the test also depends on the stage of disease.
So how to put that information to work? Wiser heads than I have discussed this, for example here and here. I am lazy and the statistics, especially Bayes, makes my brain hurt. But you can plug the information into the formula and do the calculations yourself. It is the concept I want to emphasize.
When the incidence of a disease is low, most serologic positives are false positives.
As the incidence of disease falls in a community, the more likely a positive serology is a false positive and the patient does not have the disease. But it is simpler in Oregon: no Lyme in Oregon equals no Lyme in the patient. So I explained to the patient why the result was meaningless and he should never have asked his doctor for the Lyme testing. And the doctor should not have ordered the test. When I get these requests, I tell the patient I am not a drive up the window at McDonald’s. Unless they want an Oreo McFlurry.
This is contrasted with the patient I saw the same week who, after a tick bite in Connecticut (the state, not a nickname for a body part) three months ago, now has a Bell’s palsy. I almost didn’t need Lyme testing to know what the patient had.
Not all serologies are as problematic as Lyme, but it is remarkable how often I see serologies ordered in patients who have almost zero risk for the disease. If I were a patient, I would be pissed if part of my copay was for completely unneeded tests.
A couple of years ago I was admitted for less than 24 hours for small bowel obstruction. My bill was $10,000, I had to write a check for 10%. I looked over my charges, and there was nothing on the list I considered inappropriate. But if I had to pay for even 10 bucks for an unneeded Lyme test, I would be pissed.
Ordering these tests a waste of money and time that often only adds confusion to the case and an unneeded ID consult. I wonder about the ‘unneeded’. Some days I think all ID diagnostics and therapeutics should require ID prior authorization. I have this recurring nightmare where oncology is approached like ID. Multiple fear driven therapies are given in the absence of appropriate diagnostics.
Lyme and EBV are not the only serologies that gives me a headache. Syphilis? That would be a blog entry in itself to go through all the issues with that infection.
The take home: A positive serology for an infectious disease may be meaningless.

A Skeptical Look at Screening Tests
Not all screening tests are worth taking. And in particular, some screening tests are worthless.
Harriet Hall on July 23, 2013
Link
I’m going to follow Mark Crislip’s example and recycle my presentation from The Amazing Meeting last week, not because I’m lazy or short on time (although I am both), but because I think the information is worth sharing with a larger audience.
We’ve all had screening tests and we’re all likely to have more of them, but there is a lot of misinformation and misunderstanding about what screening tests can and can’t do. Screening tests are done on populations of asymptomatic people and must be distinguished from diagnostic tests done on individual patients who have symptoms. Some tests are excellent for diagnostic purposes but are not appropriate for screening purposes.
We’re constantly being admonished to get tested for one thing or another. A typical example was a recent Dear Abby column. She got a letter from a woman who had been screened for kidney disease and learned that she had a mild decrease in kidney function. Abby was shocked to learn that 26 million Americans have chronic kidney disease, and she advised her readers to get their kidneys checked. This was terrible advice. It superficially seems like good advice, because if you have something wrong with your kidneys, you’d want to know about it, right? In fact, if there was anything wrong anywhere in your body, you’d want to know about it. By that logic, it might seem advisable to test everyone for everything. But that would be stupid. It would find lots of false positives, it would create anxiety by picking up harmless variants and anomalies that never would have caused problems, it would be expensive, and it would do more harm than good.
What makes a good screening test?
Just one example of how screening tests can harm: If we screened everyone with urine cultures, we would find asymptomatic urinary tract infections in fully 30% of elderly women. Treating those infections provides no benefit. Giving people unnecessary antibiotics would only cause side effects and contribute to antibiotic resistance in bacteria.
So we need to be selective about what tests we use for screening. Here are some of the criteria for a good screening test:
     1.  Disease has serious consequences
     2.  Screening population has high prevalence of the condition
     3.  Not too many false positive or false negative results
     4.  Test detects disease before critical point
     5.  Test is safe – causes little morbidity
     6.  Test is affordable and available
     7.  Treatment exists and is not too risky or toxic
     8.  Treatment is more effective when started earlier
Sensitivity, specificity, prevalence, and predictive values: a Bayesian analysis
Would this be a good screening test? A press release said “Breaking news! New blood test 87% accurate in detecting Alzheimer’s with an 85% specificity rate. Now we can diagnose it earlier so it can be treated effectively.”
Unfortunately there is no effective treatment for Alzheimer’s, so on that basis alone this wouldn’t be a good screening test. But let’s ignore that for the moment and look at the numbers. What does it mean that a test is 87% accurate and 85% specific?
It means the test is positive in 87% of those who have Alzheimer’s (sensitivity) and negative in 85% of those who don’t have Alzheimer’s (specificity). But those numbers are meaningless unless you know the prevalence of the disease in the population being tested. If you test a population of 10,000 people where the prevalence of Alzheimer’s is 5%, here’s what happens:
	Number	Positive test	Negative test
Have Alzheimer’s	500	87% of 500 = 435	65
Don’t have it	9,500	1,425	85% of 9,500 = 8,075
Total	10,000	1,860	8,140
65 people with Alzheimer’s will have a false negative result and be led to believe they don’t have it when they really do. 1,425 people without Alzheimer’s will have a false positive result and be led to believe they have Alzheimer’s when they really don’t.
If you test positive, what’s the likelihood that you actually have the disease? To get that, you divide the number of true positives (435) by the total number of positives (1,860) and you get 24%. This is the positive predictive value (PPV). If you test negative, what’s the likelihood that you truly don’t have the disease? The number of true negatives (8,075) divided by the total number of negatives (8140) works out to 99%, the negative predictive value (NPV). So this would be a good test for ruling out Alzheimer’s, but it wouldn’t be good for ruling it in. A positive test would only mean there was a 24% chance that you had the disease. The predictive values will be very different for populations with a low prevalence and those with a high prevalence. Screening tests are much less accurate when the disease is rare.
Mammography
When a woman gets a mammogram, she usually gets a postcard in the mail a few days later. It will say one of two things: “Your mammogram was normal” or “Something looked suspicious; please come back for further evaluation.” If she gets the second postcard, just how worried should she be? Women who get that news tend to panic, but only 10% of them actually have breast cancer. (This percentage is average; it will be higher for women with risk factors. The numbers aren’t important; what’s important is to realize that a positive screening test is not a diagnosis. In most cases, further testing is needed.)
We tend to overestimate the benefits of mammography because of lead time bias, length bias, and over-diagnosis bias. David Gorski has explained those concepts in detail. We know mammography over-diagnoses cancers because there are 22% more diagnoses of invasive cancer in women whose cancers were detected by mammography than in unscreened women who were diagnosed with cancer. That means there must have been cases of invasive cancer in the unscreened group that spontaneously resolved or lost their invasiveness.
Evidence-based recommendations for mammography have recently changed from yearly starting at age 40 to every 2 years starting at age 50. But that’s for the general population. Women at high risk may still be advised to have earlier or more frequent tests.
Mammography saves lives, but it is not as good as most people think. If 1,000 women are screened yearly for 10 years starting at age 50:
    • 2-10 will be over-diagnosed and treated unnecessarily
    • 5-15 will be diagnosed earlier without any change in the final outcome
    • 500 will have at least one false alarm
    • 250 will undergo biopsy
    • 1 life will be saved
    • 999 would have lived just as long if they had never had a mammogram
(Important: these numbers are for the population as a whole. The benefits of mammography are greater for women at high risk.)
PSA testing for prostate cancer
Prostate cancer is very common but isn’t always harmful. It is found in 80% of autopsies where the men died of something else. Many more men die with prostate cancer than because of it.
The screening test for prostate cancer is a blood test for prostate-specific antigen (PSA). This is not a yes-or-no test. It must be interpreted in the context of the patient’s age and risk factors and the rate of rise, and any cut-off level is arbitrary and will miss some small percentage of cancers. If the PSA test is positive, the next step is biopsy. Typically, 12 needle biopsies are done, 6 on each side. They find cancer in 25% of patients. But if you go back and do more biopsies, you’ll find cancer in 25% more patients. Theoretically, if you could see every cell in the prostate, you might be able to find a cancer cell or two in almost everyone, most of which would never progress or kill the patient. So you have to decide how many biopsies are reasonable. If you find cancer on a biopsy, the next step is treatment, and treatments for prostate cancer are not benign.
In a large European study, screening resulted in an absolute reduction in deaths from prostate cancer of 7 per 10,000 men screened. We can look at this in terms of number needed to screen (NNS) and number needed to treat (NNT). To prevent one death from prostate cancer, 1,068 men would have to be screened and 48 treated. But here’s the kicker: there was no reduction in all-cause mortality. The overall death rate was the same in the screened group as in the unscreened group.
If a prostate cancer is localized and low grade, it is reasonable to observe the patient and not treat unless he develops signs of progression. A recent study compared surgery to watchful waiting and found no reduction in deaths. Within 30 days of surgery, 1/5 of the patients had complications including deaths. 2 years after surgery, these long term complications were present:
    • 17% were incontinent
    • 81% had erectile dysfunction
    • 12% had bowel dysfunction
Popular advice has been “Get tested; it could save your life” but current expert advice is “Don’t get tested; it does more harm than good.” (Mainly from impotence and incontinence.) Emotional anecdotes abound. One doctor wrote an article titled “The New York Times Killed My Patient.” His patient refused PSA testing because he had read that it was not recommended; he developed invasive prostate cancer and died. Another doctor wrote about the opposite experience: his patient had insisted on testing. He was diagnosed with low-grade localized cancer, the kind that can be observed without treating. But he couldn’t face living with the knowledge that he was harboring an untreated cancer. He was afraid of surgery and opted for radiation treatment. He developed radiation proctitis and had rectal pain and bleeding for years. He became impotent and lost bladder control. He told his doctor he would rather be dead than live wearing adult diapers.
The American Urological Association initially disagreed with the recommendation not to screen, but they have re-considered and issued these new recommendations:
    • Don’t screen men under 40 or over 70
    • Don’t screen men with a life expectancy of less than 10-15 years
    • Don’t screen men age 40-50 who are at average risk
    • Consider screening men age 55-69 who are at average risk
    • Consider screening high risk men of any age
    • Before any screening, doctor should discuss risks and benefits with patient
The United States Preventive Services Task Force
The USPSTF is an independent group of experts who keep up with the current medical literature and issue recommendations based on the best available evidence. Their recommendations are frequently updated and available online. They’re not perfect, but they’re the most trustworthy source we have, and I rely on them. Their recommendations are not meant to be a cookbook. Their website explains:
The USPSTF recognizes that skilled clinicians serve their patients by individualizing recommendations…to the specific circumstances, values, and perspectives of the individual patient.
They recommend some screening tests be done on everyone: screening for high blood pressure and obesity. Other recommendations are different for different age, sex, or risk groups:
    • Pap smear (age 21-65, every 3-5 years)
    • Colorectal cancer (choice of tests, age 50-75)
    • Diabetes (only if blood pressure is elevated)
    • Cholesterol (men over 35; women and younger men only if they are at increased risk)
Sometimes the recommendations are complicated. Screening for osteoporosis is recommended for women aged 65 years or older and for younger women whose fracture risk is equal to or greater than that of a 65-year old white woman who has no additional risk factors. Men should not be screened. You almost need a translator to decide whether some of the recommendations apply to you: that’s what your doctor is for.
The USPSTF recommends against doing these tests as routine screening tests because they do more harm than good:
    • Annual chest x-ray
    • TB tine test
    • Scoliosis check
    • EKG
    • Teaching patients to do breast and testicular self-exams
Sometimes they’re not sure, and they say so. For glaucoma, they say there is insufficient evidence to recommend either for or against screening.
A recent study found that routine physical exams don’t reduce mortality. Routine visits to a doctor can still be worthwhile, but the physical exam itself (the laying on of hands, looking in the ears, and applying a stethoscope to the chest) is largely a waste of time in the absence of symptoms.
Questionable screening tests offered to the public for profit
Several companies offer ultrasound screening. They come to town, set up in a YMCA or church, and offer “tests your doctor won’t order”: EKG, echocardiogram, ultrasounds to check for narrowing of the carotid arteries, ultrasounds of the abdominal aorta to check for aneurysms, screening for peripheral artery disease (PAD), etc. They offer glowing testimonials from people who believe they would have had a stroke or ruptured aneurysm if they had not been tested, that this screening saves lives. They don’t divulge the reason your doctor won’t order these tests: they do more harm than good. The only one the USPSTF recommends is abdominal aortic aneurysm (AAA) screening and they recommend it be done only once and only in men age 65-75 who have ever smoked. The companies will gladly test everyone and will repeat the test every year when they come back to town. Their advertising is deceptive and their testing is more likely to harm than help.
Electrodermal testing is done with a biofeedback machine hooked up to a computer. It diagnoses all kinds of bogus conditions and “imbalances” and tells the operator which homeopathic remedies and supplements to sell to the customer. It’s about as useful as a Magic Eight-Ball.
Some chiropractors use surface electromyography to locate your subluxations. The test is useless, particularly since there’s no such thing as a chiropractic subluxation.
Whole body CT scans were popular for a while; they were offered in free-standing CT facilities on request, without a doctor’s orders. They exposed patients to the same amount of radiation as 923 chest x-rays. They found abnormalities in 37-86% of patients, creating anxiety and leading to unnecessary follow-up tests that were sometimes invasive and potentially life-threatening. Fortunately they seem to have gone out of style.
When pharmacies in the UK started offering glucose and cholesterol tests, the number of visits to doctors increased, but only 10% of people with positive tests needed treatment.
Talking20 does 17 tests on a drop of blood and plans to increase this to hundreds or thousands of tests you don’t need.
Direct to consumer genetic testing is offered by several companies. They don’t test your entire genome, only specific SNPs (single nucleotide polymorphisms), and they report probabilities based on imperfect data. They might tell you that people with the same SNP as you are 30% more likely to develop Parkinson’s disease than people with other SNPs. So what? There’s nothing you can do to prevent it. And remember, genetics is not destiny. Having the gene for a disease doesn’t mean you will necessarily get the disease. Gene expression depends on environmental factors, epigenetic factors, and complex interactions with other genes. Genetic testing that promises to give you personalized diet and supplement advice is quackery. Our access to genetic information currently exceeds our understanding of what that information actually means.
The latest wrinkle is uBiome testing. It analyzes the genome of the bacteria that live on you and in you. I don’t know what you’re supposed to do with that information.
Conclusion: Screening isn’t simple
Screening tests can be very valuable but they can sometimes do more harm than good. They should be chosen judiciously, and the USPSTF offers sound recommendations based on the latest available evidence. More information is not always a good thing; sometimes it’s better not to know.

Too Much Information!
Harriet Hall on April 23, 2013
Link
Some people would like to manage their own health care without having to depend on a doctor. They consult Google, diagnose themselves, and treat themselves. The Do-It-Yourself trend in lab tests continues apace. Without a doctor’s order, patients can get legitimate and/or questionable lab tests directly from various companies such as Any Lab Test Now and Doctor’s Data (which has sued Stephen Barrett for exposing their fraudulent “urine toxic metals” test on Quackwatch). Now a new company, Talking20, has jumped on the self-testing bandwagon with an innovative product that allows people to prick their finger, put a drop of blood on a card, and mail it in from anywhere in the world. Multiple tests are done on a single drop of blood. Results will be available online within a week or even sooner.
What does it cost?
Talking20 has several options:
    • U-Pick Pack. For $99 you can select 5 tests from a list of 17, including Cholesterol (Total, HDL, and LDL), Estradiol (Estrogen), Progesterone, Testosterone, Homocysteine, CRP, HgA1c, Cortisol, and Vitamins A, B6, B9, B12, C, D3, and E. This works out to $20 per test, far less expensive than most other labs.
    • 2 year Gold Card Pack: For $995 you get 24 cards and they will do all the tests currently available on every sample you send in. They anticipate that hundreds of tests will be added over the next 2 years, including numerous proteomic and metabolomic tests.
    • 3 year Gold Card Pack: for $1295 you get 36 cards for all available tests. You can use these once a month or at any time you choose within the next 3 years. That works out to around $2 per test, which will drop much lower as more tests are added to the program.
    • Designer Pack: for $4995 you can request a new test and their team will move that molecule to the front of the development queue and give you 36 cards. If they are unable to provide the requested test, the money will be refunded.
How is it done?
They use mass spectrometry, which they say is the gold standard by which other tests are validated. I asked a company representative why all labs wouldn’t use gold standard spectrometry directly instead of conventional tests. Here’s what she answered:
Mass spectrometry has been used for decades in the analysis of various analytes from small samples. Liquid chromatography combined with multiple reaction monitoring mass spectrometry is an emerging technique for examination of molecules from dried blood spots. As the quantitation of endogenous and exogenous molecules from dried blood spots is still a field of investigation and specific methodologies are currently in development, our testing platform does not meet the requirements of a clinical diagnostic test platform and will be offered for research use only.
So – other labs are not using this technology due to the fact that it would interfere with their ability to meet clinical diagnostic requirements. For the personal tracking and research use that we are hoping to facilitate mass spec is the best option. We trust the accuracy of our data and actually believe it is equal or better to lab results. For regulatory purposes we do not plan on seeking certification for clinical or diagnostic use, as the cost to us would force us to raise our prices above what we want to offer to our consumers.
What are customers led to believe?
There is a disclaimer on their website:
Products sold by Talking20 Inc. have not been evaluated by the FDA and are intended for research use only. They are not intended to diagnose, treat, cure, or prevent any disease. The information provided by www.talking20.com is not a substitute for a face-to-face consultation with your physician, and should not be construed as individual medical advice.
But elsewhere they claim that their results “will be just as accurate as any other testing service”. I think most customers will be led to believe they are getting reliable tests whose results they can use to guide their health care.
Customers are encouraged to track changes in lab test values as they experiment with things that might influence those numbers. An example in their video is a woman with familial high cholesterol who eats hamburgers throughout a day and does a series of tests during that day, finding that her cholesterol rises more than she expected.
They are also told that there is great research potential in having large numbers of consumers tracking lab results and making correlations. There is even a research consent document. I think it is unlikely that any such research could be published or relied on without validation of the accuracy of their tests. Even if their results were validated and they accumulated a huge body of data, fishing in that sea might catch more old boots than edible fish. Good science requires more systematic data collection.
What’s the benefit?
As with any screening test, an occasional unexpected finding will lead to earlier diagnosis of a disease, and there will be testimonials that screening “saved my life”. Following cholesterol levels at frequent intervals may help motivate patients to comply with diet and medication. Patients may reconsider their use of vitamins and other diet supplements if they find no correlation between intake and improved blood levels, or between blood levels and symptoms. Patients who were going to get these tests anyway will save money.
What’s the harm?
People will be doing these tests and drawing their own false conclusions. They have no way of knowing what the results mean for their health. Some of the problems:
    • Definition of normal. Normal test results are determined by testing a large number of presumably normal people and cutting off the ends of the resulting bell curve. Typically, everything within 2 standard deviations of the mean is arbitrarily defined as normal. But that doesn’t mean every individual outside 2 standard deviations is abnormal, nor does it guarantee that everyone within the limits is normal. Imagine measuring the height of thousands of people and defining the extremes as abnormal. A man who is 6 feet 7 inches tall would be defined as abnormal, but that height might be perfectly normal for him, and someone in the “normal” range might have an excess of growth hormone with acromegaly.
    • False positives. Even without considering lab errors, when you do 20 lab tests on a healthy person, you are likely to get one false positive. Doing 100 tests would give you an average of 5 abnormal results that were of no significance to the person’s health, but that would lead to worry and further testing.
    • Uncertain meaning. Let’s say your vitamin E level is below the normal limits on the test. Does that mean something is wrong with you? Does it mean you should take vitamin E supplements? Would raising the level improve your health or reduce your risk of death? We don’t know: the necessary studies have not been done.
    • Margin of error. There is a margin of error in any lab test. If you repeat a cholesterol test 5 times in a row, you will get 5 different readings. I once had a patient who would agonize over a 5 point difference in successive cholesterol readings, and was not able to understand that those results were not significantly different. Blood alcohol tests have been ruled inadmissible in court when the lab failed to report the margin of error; a blood test showing 0.93 with a 0.20 margin of error might mean an actual level of 0.73.
    • Temporal fluctuations. Some blood levels can fluctuate widely over the course of a single day. In the case of female hormones, the levels vary continuously over the menstrual cycle. A quick glance at this graph shows why a one-time measurement of progesterone or estrogen levels is misleading. A level that is normal in one phase of the cycle would be abnormal in another phase. Women who adjust their use of bioidentical hormones as advised by Suzanne Somers are acting outside the realm of science.
Services like Talking20 are likely to attract the hypochondriacs, the worried well, the obsessive-compulsives, and the self-absorbed navel gazers. They are likely to do more harm than good. If you have ever had an abnormal test result and continued to worry even after a follow-up test was normal, you will know what I mean. People will inevitably draw their own conclusions from the data, resulting in unnecessary worry, expense, and useless lifestyle changes. Doctors are likely to be confronted with patients concerned about insignificant findings and false positive results from these tests, and some patients may come to distrust their doctors over these issues and reject conventional medical care.
Conclusion: More tests do not equal better health
Sometimes doctors order a lot of tests in the hope that something will turn up and are left scratching their heads because the “serum porcelain level” is elevated and they have no idea what that means or what to do about it. Ideally, doctors shouldn’t go on “fishing expeditions” in the laboratory. They should only order lab tests when they understand the test and when the results are likely to affect the management of the patient. Consumers indiscriminately doing 17 tests (and eventually hundreds or even thousands of blood tests) on themselves is a very bad idea. When the testing method has not been validated, it’s an even worse idea.
Of course, if this technology is validated and developed to the point that any number of indicated tests can be done on a drop of blood at very low cost, I will be among the first to celebrate.

Ecstasy for PTSD: Not Ready for Prime Time
Harriet Hall on November 27, 2012
Link
Hundreds of desperate combat veterans with Post-Traumatic Stress Disorder (PTSD) are reportedly seeking experimental treatment with an illegal drug from a husband-wife team in South Carolina. The Bonhoefers recently published a study showing that adding MDMA (ecstasy, the party drug) to psychotherapy was effective in eliminating or greatly reducing the symptoms of refractory PTSD. It was widely covered in the media, for instance in this article in the NY Times. It was only a small preliminary study, and the treatment is not yet ready for prime time; but media reports have sparked enthusiasm not justified by the evidence.
The Study
The study is available online. To summarize the highlights:
    • Subjects were 20 patients with chronic PTSD refractory to both psychotherapy and psychopharmacology. 85% were women, mostly victims of sexual assault or childhood abuse, and there was only 1 subject with combat stress.
    • Randomized.
    • Placebo controlled: 12 patients got the active drug, 8 got an inactive placebo
    • Method: preliminary and follow-up psychotherapy, 2 day-long sessions with 2 co-therapists and an overnight hospital stay. Subjects got two doses of MDMA during each session and alternated conversation with periods where they were encouraged to focus on introspection.
    • Assessment instruments were CAPS, a structured interview, and IES-R, a self-report of response to stress. Neurocognitive testing was done and vital signs were monitored.
    • Rescue medication with Zolpidem and benzodiazepines was allowed when needed. This did not appear to influence results.
    • Protocol amendment: After safety and efficacy were established, an amendment to the protocol was approved so that the last 9 subjects received a third dose of MDMA to prolong the effect and gather data about dosage for future trials.
    • Crossover extension: 7 out of 8 subjects from the placebo group were enrolled in a subsequent open-label phase with MDMA; one declined because she had already improved so much on the placebo.
    • Exit poll: 95% correctly guessed which group they were assigned to.
Results
    • Clinical response was defined as >30% reduction from baseline in CAPS total severity score. The clinical response was 83% in the MDMA group compared to 25% in the placebo group.
    • 100% of the 7 subjects from the placebo group who were subsequently given MDMA open-label had a clinical response.
    • All 3 subjects who had been unable to work due to PSTD were able to return to work.
    • There were no significant changes in neurocognitive tests.
    • Side effects occurred, ranging from jaw tightness to insomnia, resolving over hours or days, sometime requiring short-term drug treatment; none were felt to be serious.
Limitations of the study
This was only a small pilot study, not the kind of evidence needed to justify forging ahead with treatment of patients with PTSD. The subjects were almost all women who were rape victims. Its applicability to war trauma is entirely unknown. Further studies with combat veterans are in the works.
The study is characterized as blinded; but the blinding didn’t work, since 95% of subjects were able to tell which group they were in.
Subjects may have been influenced by the reputation of MDMA as a recreational drug that produces euphoria. MDMA is illegal, and this study required a special Investigational New Drug (IND) permit. It was financed by the Multidisciplinary Association for Psychedelic Studies.
Over-reactions
In a 2010 news report, Mithoefer
expressed concern that publicity about the study might lead some people to self-medicate with ecstasy. PTSD patients should not use the drug on their own, Mithoefer said, because there are risks, such as elevated blood pressure and pulse. Also, ecstasy purchased on the street may not be pure MDMA — or even contain no MDMA at all.
In the NY Times article there is a quotation from Brig. Gen. Loree Sutton, a psychiatrist who recently retired from the Army:
When it comes to the health and well-being of those who serve, we should leave our politics at the door and not be afraid to follow the data. There’s now an evidence base for this MDMA therapy and a plausible story about what may be going on in the brain to account for the effects.
That’s inaccurate; there is not an “evidence base.” There is only a pilot study with scanty, preliminary, unconfirmed evidence.
A military spokesman put the cart before the horse:
Completing the studies necessary to make this treatment available will require increasing financial and political support from both within and outside the military,” he said. “We provide men and women in the armed forces with the most advanced tools of war. It’s time we gave them the most advanced tools of healing, too.”
It’s not a matter of doing studies necessary to make the treatment available, but rather a matter of doing the studies necessary to determine whether the treatment really is effective and is a feasible option.
Other Questions
The use of another illegal drug, LSD, has been advocated by some psychiatrists for a multitude of uses. Experiments using illegal drugs are always problematic, because researchers tend to be advocates for legalization and may be biased by their emotional investment.
Prolonged exposure therapy is a widely recognized therapy for PTSD. The rationale for using MDMA is to suppress anxiety and allow patients to talk about their traumatic experiences without feeling excessive fear and hyperarousal. Various possible (and plausible) mechanisms for its usefulness are discussed in the introduction to the study. Another technique that has been used to facilitate patients’ engaging with psychotherapy is Eye Movement Desensitization and Reprocessing (EMDR), where the eye movements themselves don’t actually do anything.
The patients in the placebo group improved, too; so a large part of the benefit could be attributed to the psychotherapy. Should the specific psychotherapy techniques they used be further investigated and improved? Was there something special about the effects of MDMA, or might legal anti-anxiety drugs be just as effective?
After WWII, soldiers suffering from “combat fatigue” were given sodium pentothal (“truth serum”) and were allegedly cured by re-experiencing the trauma. Such treatments apparently didn’t really work that well, since they quickly fell out of favor. Most references are from the 1940’s. One flight surgeon found that distributing liquor at mission debriefings was effective at “settling” his fliers, but I don’t think that was ever formally studied.
Is it essential that patients be guided to re-live their traumatic experience? It sounds plausible, but I don’t know and doubt that anyone does. Is it possible that PTSD could be treated without that, by accentuating the positive and concentrating on avoidance and coping skills? I don’t know. Is it possible that PTSD could be prevented by early debriefings right after the event with the assistance of alcoholic beverages? I don’t know, but it’s an intriguing thought. Maybe some research group could get a grant from Jack Daniel’s.
Conclusion
The addition of MDMA to psychotherapy might prove helpful in refractory cases of PTSD, but the preliminary results of this one small pilot study will need to be confirmed by larger studies in combat veterans before the treatment can recommended to patients. Unfortunately, the history of medicine is full of equally promising treatments that didn’t pan out. Probably the most typical course is this: a strongly positive pilot study is followed by larger studies with weaker positive results, then by studies with equivocal or negative results, then reports of serious side effects or other problems, and eventually by rejection of the treatment. I sincerely hope this one will prove an exception to that course, for the sake of suffering veterans with few remaining options. But I am not optimistic.

A Blood Test for Fibromyalgia?
The FM/a test is advertised as a definitive test to diagnose fibromyalgia. It isn’t definitive. It is expensive. It has not been shown to change patient outcomes.
Harriet Hall on May 11, 2021
Link

I was surprised to learn that there is a blood test to diagnose fibromyalgia, the FM/a test. Is it accurate? Is it useful?
Fibromyalgia is still a disputed diagnosis. Some think it is a discrete disease, others think it is not a disease because there are no objective abnormalities on physical examination and there is no objective diagnostic test. It is hard to distinguish from other medically unexplained conditions such as chronic fatigue syndrome. It shares many features with other conditions like polymyalgia rheumatica, rheumatoid arthritis, lupus, and others; but those conditions may coexist with fibromyalgia.
Fibromyalgia is characterized by (1) widespread pain lasting at least three months involving both sides of the body, above and below the waist, and including the axial skeletal system, and (2) tender points in 11 out of 18 specific paired anatomic sites. It is associated with anxiety, depression, cognitive difficulties, fatigue, headache, paresthesias, and sleep disturbances. Diagnosis used to require the clinician to evaluate tenderness by palpating the 18 anatomic sites, but that was rejected as unreliable. Revised diagnostic criteria require pain in at least four of five regions and rely on a widespread pain index (WPI) score and a symptom severity scale (SS); symptoms must have been consistent for three months and other diagnosable conditions must have been ruled out.
The website for the FM/a test lists 12 symptoms: chronic fatigue, joint aches, chronic painful or tender areas, leg cramps, mental/brain fogginess, restless legs when you sleep, poor sleep, anxiety/nervousness, trouble concentrating, feeling depressed, frequent headaches, and numbness or tingling. It says if you have four or more of these symptoms, it could be fibromyalgia and you should take the FM/a test to find out for sure. It says FM/a is the first definitive test for fibromyalgia. That is misleading. The test is far from “definitive” and their symptom list includes complaints that are common for a lot of people who don’t have fibromyalgia.
What is the FM/a test?
According to an article by Straub and Monsey in the family medicine journal American Family Physician
FM/a is a cytokine assay of in vitro stimulated peripheral blood mononuclear cells. Production of cytokines by stimulated immune cells in patients with fibromyalgia has been shown to be significantly different from that of healthy control patients. Based on the concentrations of four cytokines, a cytokine/chemokine composite score, calculated as 1 / (1 + e−x) * 100, on a scale of 0 to 100 was developed. A score greater than 50 is considered positive for fibromyalgia.
Accuracy
A study comparing fibromyalgia patients to healthy controls reported that the test had a sensitivity of 93% and a specificity of 89%, with a positive likelihood ratio of 8.5 and a negative likelihood ratio of 0.08. A study with a more appropriate comparison group of patients with known rheumatoid arthritis (RA) or systemic lupus erythematosus ( SLE) found a much lower specificity of 70% with a positive likelihood ratio of 3.1 and a negative likelihood ratio of 0.1. It would be more meaningful to study patients with clinically suspected fibromyalgia, but no such study has been done. There has been no research evaluating the accuracy of the test in the general population or demonstrating any change in patient outcomes.
Downsides
This is far from a perfect test. Some problematic concerns:
    • Patients must stop taking any medications that may alter their immune systems for two weeks prior to testing. These include anticancer drugs, disease-modifying antirheumatic drugs, steroids, and turmeric.
    • The false positive rate is higher in patients with SLE (29%) and RA (31%).
    • The cost of the test is $1,080.
Conclusion: Expensive test, not definitive
The claim that this test is definitive is advertising hype not supported by the evidence. There is no indication that it is useful as a stand-alone test for fibromyalgia or that it has any effect on patient outcomes. Having four of the symptoms listed on the website does not justify testing and would be a waste of $1,080. The test is covered by some insurance carriers, but in my opinion it probably shouldn’t be.
There is still no widely accepted test to diagnose fibromyalgia.

MyMedLab Offers Expensive, Useless, Nonstandard Lab Tests
Direct to consumer lab testing is good marketing but not good medicine. For instance, there is no reason to spend $199 to measure glyphosate levels in your blood.
Harriet Hall on February 6, 2018
Link

One of our regular commenters forwarded to me an email that had slipped by her spam filters. It was from MyMedLab, whose slogan is “Lab Tests the Easy Way.” It starts out:
What is glyphosate?
    • Glyphosate was patented as an antibiotic
    • Glyphosate kills bacteria in the soil
    • The same bacteria exists in our gut
    • Do you have glyphosate in you?
It goes on to offer tests you can purchase to test your entire family (and your tap water) for glyphosate – at $199 per test.
Glyphosate, of course, is the weed killer sold by Monsanto under the brand name Roundup, a product that has provoked widespread controversy.
Immediately, red flags went up and alarm bells went off. When I went to the website, I was appalled by the huge variety of non-standard and non-indicated tests customers could order for themselves. And by some of the prices.
Glyphosate testing is worthless
MyMedLab uses Great Plains Lab to do their glyphosate testing. Great Plains is listed on Quackwatch as a questionable lab offering nonstandard tests. MyMedLab also uses other labs on the non-recommended list.
The Great Plains page on glyphosate is a prime example of pseudoscientific scaremongering. It offers this graph showing a correlation between autism and glyphosate use on corn and soy crops.
Similar graphs have shown a correlation between autism and random things like organic food sales or pirates. They are meaningless. Correlation is not causation.
Great Plains says, “Recent studies have discovered glyphosate exposure to be a cause of many chronic health problems.” They say the evidence suggests it causes cancer, disruption of the microbiome in the gut, diabetes, depression, autism, stroke, cardiovascular disease, hypertension, Alzheimer’s, Parkinson’s, multiple sclerosis, kidney failure, even intestinal infections.
A more realistic assessment of the evidence shows that the concerns were raised on the basis of animal and test tube studies, and there is essentially no evidence of harm to humans except in the case of large occupational exposures. A 2017 review article published in the Archives of Toxicology found that glyphosate exposure was well below the levels considered safe. It concluded that risk assessments have not identified concerns for consumers.
What if your test shows you have glyphosate in your blood? What does that mean? It probably only means that modern laboratory analysis is capable of detecting minute levels of pretty much anything you could name; but that doesn’t mean that those levels cause any significant harm to health. Our bodies have always been exposed to toxins from the environment and even from the very foods we eat. Our livers and kidneys have always done a good job of dealing with them, especially when the amounts are small. Remember the basic principle of toxicology: the poison is in the dose.
If there is a smidgen of glyphosate in your blood, what could you do about it? In my opinion, there is no need to do anything about it, and nothing you could do anyway except perhaps become active as an anti-Monsanto protester. Steven Novella has characterized glyphosate as the new bogeyman, and David Gorski has written about it is being irrationally demonized by people who have ideological objections to big corporations and even to science itself.
Bottom line: direct-to-consumer glyphosate testing does nothing but deplete the customer’s wallet and stoke unreasonable fears and paranoia.
Other questionable tests available from MyMedLab
Shomon Thyroid Baseline with Expert Review. You get a panel of thyroid tests including TSH, Free T4 and T3, plus Thyroid Peroxidase Antibody (TPO) and Anti-thyroglobulin antibody, followed by a personal coaching session with Mary Shomon.
Mary Shomon is not an endocrinologist or even a doctor. She is a patient advocate, activist, and author. The web page warns that these tests and expert reviews are not a replacement for the services of a primary care physician.
TPO antibodies are useful to help diagnose the cause after you have been diagnosed with thyroid disease; but they can be present without thyroid disease. The test is not indicated as a screening test.
The panel offered by MyMedLab is not appropriate for screening for thyroid disease; there will be too many false positives on some of the tests that will only muddy the waters. If you have abnormal test results due to thyroid disease, you should see a qualified doctor who can treat you, not waste time with a “patient advocate” who has an agenda. In fact, it would make more sense to see a doctor in the first place to evaluate any symptoms you may have and to determine which tests are indicated.
Science of You: Wellness. A panel of “the same 65 health values used in a yearly checkup or insurance physical,” including CBC, UA, lipid profile, liver function panel, and metabolic panel. No, those 65 tests are not part of a typical yearly checkup, and even the practice of a yearly checkup is questionable. If you do that many tests on a perfectly healthy person, you will be almost certain to find one or more values outside the normal limits, just because of statistics and the way lab normal limits are defined. Indiscriminate screening tests do more harm than good. The web page says certain results will “provide an option to purchase a one-on-one conversation with a growing list of their “experts.”
Precision Nutrition Panel, for $800.
Science of You: Leaky Gut, for $199, nonstandard tests for a fad diagnosis not recognized by mainstream medicine.
Science of You: Autism, for $149. A panel of tests that have nothing to do with autism.
Food Allergy IgG, for $325. Not a reliable test. It shows exposure to a food, not allergies. In fact, a positive IgG test can indicate tolerance to a food, not intolerance.
A Shomon Autoimmune Profilee, to be used in conjunction with Shomon’s book Living Well with Autoimmune Disease. For $148.06. I wonder where the six cents came from.
More. The list of available tests goes on and on and on. Some of them are standard medical tests, others are nonstandard tests whose significance would be difficult or impossible to interpret.
Conclusion: Good marketing, but not good medicine
MyMedLab says they offer an affordable, convenient way to get lab tests, better manage your health, improve prevention, and facilitate early diagnoses. They say you can get lab tests before you see your doctor, to make best use of the appointment time. Actually, I would guess that it’s more likely to make bad use of the appointment time as the doctor tries to figure out whether the results of those nonstandard and non-indicated tests mean anything for the patient’s health and whether any follow-up testing is needed. Doctors will also waste time reassuring patients who are worrying unnecessarily about meaningless results.
I can imagine certain situations where direct-to-consumer testing might be reasonable. It could eliminate the cost and inconvenience of a doctor’s visit just to order routine testing. For instance, a diabetic patient might monitor his own A1C levels and not need to see the doctor as often. But in general, in my opinion, this kind of testing is likely to do more harm than good, sometimes at great expense for unnecessary tests. And insurance will not pay for lab tests that were not ordered by a doctor. There is a reason we have doctors: they have expert knowledge and are better equipped than patients to make decisions about what to test and when to test.
MyMedLab says, “The company was created to allow consumers to make informed health care choices for themselves and their families.” I don’t think they are giving their customers the information they need to make truly informed decisions.

Dr. Amen’s Love Affair with SPECT Scans
Harriet Hall on March 19, 2013
Link
Daniel Amen loves SPECT scans (Single Photon Emission Computed Tomography). And well he should. They have brought him fame and fortune. They have rewarded him with a chain of Amen Clinics, a presence on PBS, lucrative speaking engagements, a $4.8 million mansion overlooking the Pacific Ocean, and a line of products including books, videos and diet supplements (“nutraceuticals”). He grossed $20 million last year. Amen is a psychiatrist who charges patients $3,500 to take pretty colored SPECT pictures of their brains as an aid to the diagnosis and treatment of conditions including brain trauma, attention-deficit hyperactivity disorder (ADHD), addictions, anxiety, depression, dementia, and obesity. He even does SPECT scans as a part of marriage counseling and for general brain health checkups.
SPECT imaging uses an injected radioisotope to measure blood flow in different areas of the brain. Amen is exposing patients to radiation and charging them big bucks because his personal experience has convinced him SPECT is useful. So far, he has failed to convince the rest of the scientific medical community.
Amen has just published an article in the journal Alternative Therapies entitled “It’s Time to Stop Flying Blind: How Not Looking at the Brain leads to Missed Diagnoses, Failed Treatments, and Dangerous Behaviors.” It amounts to poorly-reasoned apologetics with false analogies, testimonials, and pretty pictures that don’t prove what he thinks they prove.
Previous Criticism
I have written about Dr. Amen before, both on Quackwatch and on Science-Based Medicine. Amen’s attorneys complained that my Quackwatch article was unfair; we responded to the attorneys by asking a series of questions, and I commented on their inadequate response. When you google “Daniel Amen,” “Amen Clinic” or even just “SPECT scans” my articles appear early in the list of hits.
It’s not just me. Amen has a lot of other critics. Psychiatrist Daniel Carlat wrote “Brain Scans as Mind Readers? Don’t Believe the Hype” in Wired Magazine, describing his own evaluation by Dr. Amen. Amen told Carlat his scans showed too little activity, a pattern of angst, and a predisposition to depression (that part was a slam dunk, since in taking a medical history Amen had already elicited the information that Carlat had had a short bout with depression). He recommended a multivitamin, gingko, less snowboarding, and more tennis. An expert at UCLA later reviewed the same scans and explained that the findings are meaningless because they haven’t been validated by controlled studies to determine their diagnostic specificity. Carlat likens Amen’s spiel to the cold readings of palm readers.
The Skeptic’s Dictionary has critiqued Amen’s PBS programs, calling them “infomercials.” The PBS Ombudsman received a flurry of complaints about the use of Amen’s videos for fundraising drives, but weaseled out of taking any action by saying decisions were made by local stations and the programs were not officially endorsed by PBS.
Neurologist Robert Burton wrote an article called “Brain scam” in Salon. The title says it all. Among other things, he is appalled that Amen claims to know how to prevent and treat Alzheimer’s.
In an article titled “Brain scans: not quite ready for prime time” Dr. Thomas Insel, the director of the National Institute for Mental Health, characterizes brain imaging as “still primarily a research tool.” He cautions that “entrepreneurial zeal capitalizing on scientific advances needs to be tempered by reality checks.”
In a 2012 article in The Washington Post, Neely Tucker reported:
Officials at major psychiatric and neuroscience associations and research centers say his SPECT claims are no more than myth and poppycock, buffaloing an unsuspecting public… the disconnect between Amen’s public image and professional reputation among the elite in the field has come to defy logic.
He includes a number of scathing quotations from those elite.
Amen’s New “Flying Blind” Article
Anecdotes. He starts with an anecdote about his nephew, who had attacked a little girl for no apparent reason. Amen did a SPECT scan and found a large arachnoid cyst; after surgery, the violent behavior stopped. This is a touching story, but anecdotes are not evidence. Cysts and other brain abnormalities are frequent incidental findings on brain imaging and arachnoid cysts are often asymptomatic even when large. Even if the child’s violent behavior was due to the cyst, a SPECT scan was not necessary to find it. An MRI would have found it, with better anatomical detail and no need for radiation exposure.
He asks,
How could a child psychiatrist know what was going on in Andrew’s brain unless he or she actually looked at how it functioned?… psychiatry remains the only medical specialty that rarely looks at the organ it treats.
He suggests that if the brains of recent mentally ill mass murderers had been looked at, their crimes might have been prevented. That might be a persuasive argument if “looking at the brain” actually corresponded to understanding what the neurons were doing or had any predictive value. It doesn’t.
He presents more anecdotes: after an addict saw the “toxic pattern” on his scan, he stopped abusing alcohol and cocaine. After a depressed patient’s scan showed a pattern “consistent with brain injury,” further questioning led her to remember a fall from her bike a month before her symptoms began.
Defensiveness. Next he switches into defensive mode, trying to answer some of the criticisms that have been leveled against him.
     1.  Scans will not give an accurate psychiatric diagnosis. He admits this is true, but argues that a diagnosis doesn’t tell us if the brain is overactive and needs to be calmed or underactive and needs stimulation. He gives another anecdote of a patient with hallucinations: SPECT scanning showed areas of increased activity, leading him to investigate further and diagnose Lyme disease. He says “In my psychiatric group’s experience, success rates increase when psychiatrists use clinical histories plus scans.” [Emphasis added.] Remember that Mark Crislip has called “in my experience” the three most dangerous words in medicine.
     2.  Not enough research has occurred. He admits that more work is needed, but switches into tu quoque mode, saying that only 11% to 14% of the recommendations of other specialties are supported by A-level scientific evidence.
     3.  Scans are expensive. He says they cost about the same as MRI scans. But the cost of an MRI varies, and only the highest prices correspond to what Amen routinely charges for SPECT. And MRIs are arguably done for reasons that are better grounded in evidence. No other psychiatrist routinely orders MRIs on every patient. And MRI scans don’t use radiation.
     4.  The scans use radiation. He argues that CT scans do too. But CT scans are arguably done for reasons that are better grounded in evidence. They are not done routinely on every patient.
     5.  SPECT is not ready for clinical use and should be left in the hands of researchers. He argues that a useful medical procedure should not be withheld from patients just because researchers haven’t chosen to study it, and that there are no financial incentives for such research, since the imaging tools already exist. (I don’t think I need to point out what is wrong with that reasoning.)
Ignoring the real criticisms. He is really responding to a straw man characterization of what his critics have said. He ignores other criticisms like these:
     1.  Patients should not be subjected to the radiation and expense of a SPECT scan without credible evidence (from controlled, peer-reviewed studies) that it is likely to help them.
     2.  He is relying on experience and anecdote rather than on acceptable scientific evidence.
     3.  He has not validated that scans show what he claims they show.
     4.  He uses unscientific terminology like “your brain is cool at rest.”
     5.  He has not shown that his outcomes are better than those of doctors who do not do SPECT scans.
     6.  He has created his own idiosyncratic classifications of illness based on scan results, classifications that go beyond the DSM and that have not been validated elsewhere. For instance, he divides ADHD into classic, inattentive, over-focused, temporal lobe, limbic and “ring of fire,” and obesity into compulsive, impulsive, impulsive convulsive, sad, and anxious.
     7.  He prescribes inadequately tested natural remedies, irrational mixtures of nutritional diet supplements, hyperbaric oxygen, and other questionable treatments.
A riff on traumatic brain injuries. He goes on to talk about unrecognized damage from traumatic brain injuries, recommending that SPECT scans be routinely used on military personnel and those at risk of sports injuries. But he has only his own anecdotal impressions that SPECT scans can add anything useful to the usual diagnostic process for TBI, which already includes CT and MRI scans.
Conclusion
Amen fails to make his case that “Not Looking at the Brain leads to Missed Diagnoses, Failed Treatments, and Dangerous Behaviors.” He accuses conventional doctors of “flying blind.” But maybe he is the one flying blind, blinded by delusions born of exalting personal experience above rigorous scientific testing and allowing the lure of celebrity and riches to cloud his judgment. Isn’t it curious that while he claims to be at the cutting edge of scientific medicine, this article was published in an alternative medicine journal?

False balance in an NBC news story on whole body MRI scans
Over the weekend, NBC News aired a story on whole body MRI scans. Although it did include the usual cautions about false positives and the harm they cause, the caution was diluted by the story’s focus a rare case of a woman who had a brain tumor detected. Overall, it was false balance that reminded me of vaccine/autism stories 20 years ago.
David Gorski on February 19, 2024
Link
I hadn’t intended on writing about the profit-driven and non-evidence-based product that is “whole body scanning” again so soon, given that I just wrote about this perennial money-making medical venture last summer in the context of companies offering newer products that add artificial intelligence to the scanning analysis without demonstrating that AI actually improves specificity and/or sensitivity. Of course, the AI is always proprietary, which doesn’t allow independent investigators to determine how and if it works, and the companies promise to do clinical trials, while continuing to charge customers up to thousands of dollars per scan. At the time, I noted that various “whole body scanning” products had been hyped for at least 20 years before and that one of my earliest forays into medical skepticism occurred in the early 2000s when I was faculty at a cancer center in New Jersey and noted radio ads for AmeriScan, Dr. Craig Bittner. The overblown claims being made for the scans, which included breast MRI and various whole body CT scans, being able to “catch cancer early” and save lives led me on a bit of a crusade that I wrote about back in 2005. Ultimately, AmeriScan went out of business, as whole body scans of the type it sold went out of favor, but bad ideas in medicine are evergreen. It was thus inevitable that, as the technology progressed by leaps and bounds over the next two decades, other companies would see profit potential selling old wine (whole body scans) in a new bottle (AI-augmented CT and MRI).
And so it was, with companies like Prenuvo seemingly thinking that whole body MRI + AI = profit. I was wondering whether there was room for the “old fashioned” sorts of whole body scanning. I need not have worried. As I was idly flipping channels Saturday night waiting for our dinner companion to be ready so that we could go out and get some food, I came across NBC World News Tonight and a story entitled Medical professionals weigh in on growing trend of people getting full-body scans to screen for cancer:
On second thought, maybe there isn’t room for old-fashioned MRIs without AI, because I learned as I watched the story that—spoiler alert!—Ezra, the company selling these scans and whose CEO is interviewed in the story is selling an AI-augmented whole body MRI scans that is claimed to reduce screening time to 30 minutes.
The NBC story on whole body scans was practically an infomercial
As this story appeared on my TV, let’s just say that I immediately got a vibe similar to what I used to get watching stories about autism 15-20 years ago, when reporters routinely seemed to think that they had to interview parents convinced that vaccines had made their child autistic whenever they did a story about vaccines or autism. In these stories, reporters would focus on the human interest story about the parents and the child and then include a couple of doctors almost as an afterthought as the token skeptics to tell the audience that the science overwhelmingly shows that vaccination is not associated with an increased risk of autism and autism spectrum disorders (ASDs). Overall, it was false balance in that science had no chance against the sympathetic human interest part of the story about a family dealing with autism. The very best impression left by these stories was that there was a real scientific debate going on over the topic—there wasn’t—while the worst impression coming from this stories was that vaccines really did cause autism. Fortunately, over the years, the press learned, particularly after Andrew Wakefield was disgraced due to losing his medical license in the UK, the retraction of his 1998 Lancet case series that had sparked the 21st antivax movement, and Brian Deer’s devastating exposé on his scientific fraud, and false balance became much less common, although sadly it’s not gone.
This story reminded me a lot of that. Here’s what I mean.
The story was bookended with the story of a woman named Andrea Schaffer. Ms. Schaffer, we’re told, had purchased a whole body MRI scan as a “present to herself” last June. When NBC reporter Vicky Nguyen asked Ms. Schaffer why she had purchased the scan, Ms. Schaffer mentioned that she was a 44-year-old woman whose mother had been diagnosed with breast cancer when she was about her age. We then learned that the scan had found a cancerous lesion in her brain, shown here:
Yes, that’s a big brain tumor.
Ms. Nguyễn then asked Ms. Schaffer, “Do you think the scan saved your life?”
Ms. Schaffer, of course, replied, “Yes.”
First off, let me just say that I’m very happy that this tumor was found in time to do something about it with surgery and whatever other treatments were offered to Ms. Schaffer. I never want to see patients die of cancer when that can be prevented.
My good wishes to Ms. Schaffer notwithstanding, though, no matter what the rest of the story would go on to say, who might be interviewed, or what studies might be presented, I knew upon seeing how it started that the story was going to be hopelessly slanted. Here was a woman who, concerned about her health given her family history of breast cancer, had purchased a whole body MRI scan, which then found a “cancerous brain tumor.” We were not told what kind of brain tumor—which is actually rather important information given that different types of brain cancer have different prognoses—only that this woman clearly believes that the scan had saved her life. And why shouldn’t she believe that? From the perspective of the patient, surely finding the tumor must have saved her life! True, the tumor was only found about a year ago; so she isn’t that far out from her treatment. But surely she would have died, right? Maybe. Probably, even.
So what’s the problem?
Ms. Nguyễn, in fairness, did follow up the brief snippet of her interview with Ms. Schaffer with a quote from authorities trying to tell us what the problem is. However, watching such a story constructed in this manner, by the time audience hears from those authorities, it’s too late. Ms. Schaffer’s belief had been conflated with actual cause-and-effect, leading to the message being indelibly imprinted that a whole body MRI scan had saved her life.
From there, went on to note that these scans have proliferated, promoted by celebrities like Kim Kardashian and Maria Menounos, the latter of whom had a stage II pancreatic neuroendocrine tumor discovered (PNET) on a Prenuvo scan. It is important to note here that PNETs are much less aggressive and deadly than the more common run-of-the-mill pancreatic cancer, although in fairness I also need to point out that it was a PNET that ultimately claimed Steve Jobs’ life. You might read stories about Maria Menounos and see this story about Andrea Schaffer and then ask again, “What’s the problem?” Didn’t these scans save these women’s lives?” The question of screening asymptomatic people for disease, be it cancer or whatever, is, unfortunately, a much more complex question than that, and there are, in fact, harms from such screening that have to be balanced against the rare cases like those of Ms. Menounos or Schaffer, something this story did in such a perfunctory fashion that it almost might have been a brief infomercial for Ezra scans. Yes, Ms. Nguyen quoted the American College of Radiology’s statement that these scans are expensive, not covered by insurance, and can result in unnecessary medical tests and procedures, all of which is totally true, but sounds a lot less convincing coming hot on the heels of an interview with someone like that of Andrea Schaffer.
Any consideration of the potential harms of such scans was then undermined even further by what followed next, an interview with the founder and CEO of Ezra, Amit Gal, described on the Ezra website as a “software engineer and entrepreneur with a 15-year track record for building successful technology companies, and bringing them to a worldwide stage.” Mr. Gal, predictably for one of these stories, enthusiastically hyped how his company “has helped our members find numerous types of cancer,” which is all well and good but rather useless information without knowing which cancers, how many, and the denominator of how patients were screened. In other words, how many is “many of our members” and how many members underwent the scans to detect those cancers? It would also be helpful to know how many required additional workup and tests, particularly additional invasive tests, to rule out disease and were ultimately found not to have anything requiring treatment, as well as the complication rates for those additional tests.
The overall impression given was that early detection is always good. Of course, doctors serious about developing screening tests for asymptomatic populations know that this is not always the case—and often not the case—and that there are harms involved with any screening test. None of this stopped Mr. Gal from noting that his test “might find cancer, or any of 500 other diseases” and that “the vast majority of Ezra scans” don’t find anything but do give you “peace of mind.” That made me wonder: What’s the false negative rate of the scans? Every test has false negatives? In other words, how “peaceful” is the “peace of mind” provided by these scans? After all, MRIs are great at detecting some cancers and diseases, not so great at detecting others. Of course, Ezra had an answer for that, as the next shot showed Dr. Dan Sodickson, Chief of Innovation at NYU and Ezra’s chief scientist, saying that the Ezra scans are best if you get one every year. (Of course they are. Ezra needs a steady, predictable income stream, after all.) Sadly, Dr. Sodickson didn’t even present anything resembling a scientific rationale for saying this. Then, when Ms. Nguyen asked him whether it’s realistic to expect someone to pay several thousand dollars a year for these scans for “peace of mind,” his response was telling: “I think it is, if it provides that confidence about health.
After that avalanche of promotion, the story finally brought out the token skeptic, Dr. Matthew Davenport, a professor of radiology at the University of Michigan, who tried valiantly to say the things that needed to be said about a test like Ezra’s. For example, when Ms. Nguyen asked him if he thinks that the result of these scans will be more tests and medical procedures that will cause harm to patients, Dr. Davenport, to his credit, answered that “unquestionably” that will be the result, citing more testing, biopsies, procedures, and operations as potential harms and concluding that you should check with your doctor before shelling out $1,350 for the most basic Ezra scan (or $2,500 for the “advanced” scan). (I also couldn’t help but note that Ezra offers financing options with no-interest monthly payments, so that you can go into debt to get a scan.)
Of course, this being a story with false balance, Dr. Davenport’s valiant attempt to inject some evidence and science into the discussion was immediately undercut by how the story was bookended, with a shot of Ms. Schaffer walking next to a pond, with a voiceover saying that she plans on getting another full body scan this year, after which she said, “You can’t put a price on it. This saved my life.”
See what I mean? NBC News and Ms. Nguyen can defend themselves by saying that they did quote the American College of Radiology and did interview radiologist who has a different view of these scans. Unfortunately, the way the story was bookended by a compelling anecdote of an appealing woman who was fortunate that a whole body scan spotted her brain cancer in time for her to have it surgically removed and, even more pointedly, got the final word, that final word being that you “can’t put a price on” the scan and that the scan “saved my life” gave a message that was anything but balanced. Let’s put it this way. Even if the story had not been bookended with the story of Andrea Schaffer and concluded with her saying that the test had definitely saved her life, placing her story instead somewhere in the middle, this story would still have been false balance, anecdotes against science.
Anecdotes, not much science
Whenever I see a story like this, I immediately become curious about the company, its product, and what, exactly, the product is claimed to be able to do and then compare all that with current scientific recommendations. The Ezra website immediately struck me as being long on anecdotes and hype but but very short on science. Sure, it says, “Our Scientific Advisors participate in authoring and publishing research papers with our Ezra team to maintain the highest scientific rigor within our work.” Yet, there’s no link to the article shown, and when I looked it up I didn’t see how it was evidence for the utility of scanning asymptomatic individuals at average risk of cancer because it was an article about identifying areas suspicious for cancer in the prostate using MRI. In fairness, it’s likely a perfectly fine article on one of the techniques developed by Ezra, but it is not evidence that their products do more good than harm. Also in fairness, I found other such articles by searching PubMed for “Ezra” and “MRI,” but none of them address the elephant in the room, the question of whether scanning asymptomatic people for cancer improves survival or even just the question of whether it does more harm than good.None of that stops Ezra from claiming on its website landing page without evidence, “Our annual scan catches potential cancer earlier, making it easier to beat.” On another page, the company states, “Screening is our best defense against cancer. And we’ve perfected it.” Is it, though? And have they, though?
And have they, though?
Unsurprisingly and typically, in lieu of studies Ezra does have a fair number of anecdotes like that of Ms. Schaffer, although, oddly enough, I could not find her story on their website. That led me to go back and see if it was an Ezra scan that she had actually gotten. I’m glad I noticed that her story wasn’t on the Ezra website, as I did some additional Googling and fairly quickly found Ms. Schaffer’s website, Not Just Broccoli. It turns out that she is a “nutritional oncologist” who offers “terrain testing” that looks at the “The Terrain 10”:
    • Circulation
    • Inflammation
    • Oxidation
    • Microbiome
    • Blood Sugar
    • Toxins & Detoxification
    • Hormones
    • Immunity
    • Stress & Biorhythms
    • Epigenetics
“Toxins and detoxification”? Uh-oh. Ms. Schaffer also notes:
As we take a deep dive to find out why your body is cancering, we individualize your nutrition plan based on your health history, biology, environmental exposures and DNA. In order to have a complete picture of which areas of your terrain need work, we must do extensive testing.
The types of testing we recommend are genetic testing, extensive blood marker panels which include cancer drivers and inflammation markers, as well as home glucose and ketone testing.
Why your body is “cancering”? She turned “cancer” into a verb?
She also offers food sensitivity testing, which is generally a bogus test. She is also treating her cancer with unproven, non-science-based dietary interventions:
In February 2023, I did a preventative full body MRI at a company called Prenuvo, and it found that I had a 2.3 by 2.4cm mass in the right temporal lobe of my brain. About the size of a walnut. I had no idea, I was asymptomatic. I have been on a journey through the medical system since, culminating with surgery at Barrow Neurological in Phoenix, Arizona on April 5th, 2023. After surgery, I was released from the hospital and returned to mostly normal function remarkably fast. I credit that to the talents of my surgeon, Dr. Smith, and all the work I did preparing for surgery. As soon as I found out about the tumor, as my training instructs, I immediately went on a therapeutic ketogenic diet (also known as therapeutic carbohydrate reduction- very different from internet keto), and worked to mitigate any other contributing factors I could identify. Two weeks after surgery, once pathology came in, we found out that it was a malignant grade 3 oligodendroglioma. While this is shocking news, my surgeon luckily was able to remove the full tumor and we are utilizing my diet, while monitoring labs (and using them to know where I need to work on my health), to avoid recurrence. The goal is to avoid chemo and radiation in my case, due to my cancer being of the brain.
And on her Instagram page:




View this post on Instagram










A post shared by Andrea Schaffer (@notjustbroccoli)
Fortunately for Ms. Schaffer, nothing heals like surgical steel—as we surgeons like to say—and a skilled neurosurgeon was able to completely remove her malignant brain tumor. Again, despite my pointing out her “alternative” and “integrative” nutrition practice, I really am happy for her. I also note that, while she was one of the lucky ones for whom a whole-body MRI did more good than harm, her anecdote doesn’t let companies like Prenuvo and Ezra off the hook for making grandiose claims for their scans and recommending them yearly, as Ezra apparently does. It’s the companies whom I blame, not Ms. Schaffer, as well as NBC News, which left out a lot of relevant information in its story and constructed it so that it came across to me as a two and a half minute commercial for Ezra. This struck me as odd, given that it was just in October last year that NBC News medical correspondent Dr. Kavita Patel did a decent story cautioning against the hype for these tests, in which she brought up a good point that “full body MRIs” often use fewer “slices” and less detailed images than targeted MRI imaging a specific organ or area of the body.
It’s true, too. Targeted MRI scans generally take much longer, more detailed scans of limited parts of the anatomy based on the clinical indication, thus producing more detailed images. For example, a targeted pancreas scan takes around 30-45 minutes to do. In comparison, Ezra’s “Whole Body Flash” scan (the least expensive scan at $1,350) takes only 30 minutes to scan the whole body (except lungs, which do not visualize well on MRI because they are filled with air). Its images can’t possibly be as detailed, AI or not. Moreover, Ezra does not use gadolinium contrast, which is used for most MRI scans in order to outline the blood vessels more effectively and provide more detail. In fairness, I understand the desire not to use gadolinium, particularly when there’s a concern about potential cumulative gadolinium toxicity with repeated MRI scans done over many years (although the risk appears to be low), but there’s a price to be paid in terms of less resolution and less ability to pick up abnormalities. I also can’t help but note that the more expensive ($1,950) Full Body Scan takes 60 minutes, and the most expensive ($2,500) Full Body Plus Scan adds a screening CT scan of the lungs.
But what about the actual evidence, rather than corporate hype? First of all, a recent review article on whole body MRI (WB-MRI) states these recommendations succinctly in its conclusion:
The use of WB-MRI for cancer screening is recommended by current guidelines for subjects with cancer predisposition syndromes, including Li–Fraumeni syndrome, hereditary pheochromocytoma–paraganglioma syndromes and constitutional mismatch repair deficiency.
I note that these are all hereditary cancer predisposition syndromes in which affected patients have a very high lifetime risk of developing a number of different cancers. But what about patients at average or low risk of cancer, which is the general population targeted by ads for whole body MRI scans? The review notes:
…all the reports provide the number of subjects in which a malignant tumour was suspected, with cancer detection rates from 0% up to 10%. This wide range is probably a consequence of the small sample sizes of many studies, and the above-mentioned technical heterogeneity. Taken together, findings suspicious for malignant cancers were reported in nearly 2.0% (119 of 5809) of the screened subjects. Unfortunately, the number of studies in which follow-up and verification of findings was performed is lower, comprising 3287 screened asymptomatic subjects, in whom there was a 1.5% overall rate of histologically confirmed malignant cancers. This rate of malignant tumours detected with WB-MRI in asymptomatic subjects of the general population should not be ignored, justifying further studies. However, critics highlight the high rate of indeterminate incidental and false‐positive findings, which can lead to unnecessary additional examinations and treatments, with potential negative psychological impact [74, 75]. Therefore, the clinical utility of WB-MRI for cancer screening in the general population remains a matter of debate.
Last summer, the Dana Farber Cancer Institute blog published an article bluntly stating:
There is no evidence that full-body MRI scans are beneficial for people of average risk. If there were clinical evidence that they were effective, such as a clinical trial showing that many people benefitted from these scans, then they would be incorporated into standardized screening protocols. The United States Preventive Services Task Force (USPSTF) recommendations and the National Comprehensive Cancer Network (NCCN) provide excellent, meticulous analyses of screening technologies, and neither entity currently recommends full-body MRI for average-risk screening.
Regarding some harms:
If a full-body MRI finds a suspicious signal on the pancreas, the next step is to do an endoscopic ultrasound. A doctor will put a little camera down your esophagus and into your stomach to look at the pancreas. If they see something suspicious, they’ll take a little piece, a biopsy, for investigation.
These procedures introduce a risk of complications, even when performed by experts with low complication rates. In the average risk population, the risk of pancreatic cancer is low enough that many of those biopsies would be false alarms. It’s a lot of potential harm, possibly even the risk of death, that isn’t necessary for most of those people.
That is exactly what I’ve been saying all along, going back over 20 years and going back to the days of my blogging about AmeriScan. I can also understand someone like Mr. Gal, who has no background in medical screening, being well-meaning and thinking he’s saving people by offering them these AI-enhanced scans. However, radiologists really should know better. Most do, but not all. They’re the ones who sell products like whole body MRI scans, even though there’s no evidence of benefit for people at average risk, they aren’t covered by health insurance, and they have the potential for causing more harm than good, exceptional cases like Andrea Schaffer notwithstanding. Even the presence of Siddhartha Mukherjee, M.D., D.Phil., author of the excellent book about the history of cancer Emperor of All Maladies, on Ezra’s list of scientific advisors does not change that.

Adios Aduhelm
The controversial and never-proven-effective drug to treat Alzheimer’s disease, aducanumab (Aduhelm) has been discontinued.
Scott Gavura on February 15, 2024
Tweet

Pharmaceuticals are tightly regulated in the USA, and we expect regulators like the FDA to maintain consistent standards for approving a drug. In exchange for the costs and risks of toxicity or side effects, we should anticipate that if a drug has been approved, that is actually effective. It could be reducing the likelihood of death, eliminating an infection, or improving quality of life in some way. But the expected benefits should be understood, and they should be meaningful.

Regulators sometimes approve drugs based on “surrogate” measures. The surrogate doesn’t mean anything in and of itself, but it believed to be proxy for something that is meaningful. Ideally there is a well-established or proven relationship between the surrogate and an outcome we care about. A number of factors go into an assessment. It may be reasonable to approve a drug based on a weak surrogate, if the condition it treats has no other good alternatives, and the preliminary evidence is promising.
When the FDA approved adacanumab for the treatment of Alzheimer’s disease in 2021, it did based on on an unconvincing surrogate, creating a major controversy within and outside the agency. Private insurers largely refused to cover it. America’s biggest insurer, Centers for Medicare & Medicaid Services (CMS), said it would only fund the drug when part of a clinical trial. There was little use of the drug. About two weeks ago, the manufacturer announced that is discontinuing the drug. With this discontinuation, the confirmatory trial that was mandated by the FDA (to see if the drug actually works) is also abandoned. The only positive out of this whole debacle is it ends further funding and research into a drug that lacked any strong signals that it worked.
The Therapeutic Challenge of Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurological disease that is the most common cause of dementia. AD tends to be a disease of the elderly that commonly presents initially as memory impairment (particularly of recent events) and progresses to include greater deficits including inability to problem solve, and impaired judgement. Overtime, AD can include psychiatric and other behavioral symptoms. Progressive disease is inevitable, but the rate of decline can range from a few years to decades. AD is common, and affects an estimated 6 million Americans, with that prevalence expected to increase as the population ages.
How AD develops is not known, but it produces changes in the brain that are destructive, progressive, and irreversible. A common feature of AD is the accumulation of protein called “beta amyloid” in the form of plaques that are thought to interfere with signalling and eventually cause cell death. Another feature is called “tau tangles,” where tau protein fibers twist and collapse, which are also thought to cause cell death.
Despite decades of research there has been little progress in developing medications or therapies that can improve symptoms or slow the progression of the disease. A class of drugs called cholinesterase inhibitors provide modest benefit for some of the symptoms of the disease, but do not affect its progressive nature. Memantine, another drug, works differently from the cholinesterase inhibitors and may provide some benefit in moderate AD. In the past few years, new drugs from Eli Lilly (donanemab) are moving closer to approval and Eisai’s drug Leqembi (lecanemab) was approved in 2023.
Unimpressive Evidence
I will refer the curious reader to my 2021 post on the Aduhelm approval for more details, but will include the highlights here. For over twenty years, researchers have pursued treatments against beta amyloid after trials in mice showed promising results. Biogen has been studying aducanumab, an antibody which targets beta amyloid, for years. Two large Phase 3 clinical trials called ENGAGE and EMERGE were established to evaluate the efficacy of the drug in patients with mild AD. These were 18 month trials that measured the effect of aducanumab in early AD. Patients were randomized 1:1:1 to low-dose aducanumab, high-dose aducanumab, or placebo, and the drug was given as an intravenous infusion every 4 weeks. The primary endpoint measured was the Clinical Dementia Rating Scale Sum of Boxes test (CDR-SB), which can assess the severity of Alzheimer’s dementia. In March 2019 both ENGAGE and EMERGE were discontinued after an independent data safety monitoring board concluded that the trials were unlikely to meet their primary endpoint. That is, in the language of clinical trials, they were discontinued “for futility”. However, in analyses done after the trials were stopped (i.e., a “post-hoc” analysis), the manufacturer claimed that the drug was actually effective, and it intended to pursue regulatory approval. (Post-trial or “post-hoc” analysis like this can be important to generate hypotheses, but are the statistical equivalent of shooting at a wall and painting the bullseye around what you hit.) In short, the manufacturer claimed that after the futility analysis, additional data was made available that provided sufficient evidence of efficacy to merit moving forward with seeking approval.
It’s worth noting that despite the lack of efficacy, the drug had harms. It can cause swelling of the brain called amyloid-related imaging abnormalities (ARIA), common to this category of drugs, which can cause symptoms like headache.
Aducanumab was reviewed in November 2020 at an FDA advisory committee meeting. Among those documents included endorsements from FDA staff members supporting the manufacturer’s contention that the drug is effective. The report also contained comments from other FDA staff members criticizing these efficacy statements, and the manufacturer’s reliance on post-hoc analyses, which were (justifiably) described as biased. Ultimately the panel votes on the evidence were strongly negative. Despite the negative recommendation, the FDA granted accelerated approval for aducanumab, now branded Aduhelm, while requiring Biogen to do a confirmatory clinical trial over the next nine years. Really incredibly, it did not even limit approval to patients similar to those in the clinical trial, who had mild disease and confirmed amyloid plaques. Instead, it put no restrictions on its use. There was zero evidence that aducanumab was effective in patients with advanced Alzheimer’s disease, but the drug cleared the drug for these patients, too.
Little Uptake, and a Quick Exit
In June 2021 the House Committee on Oversight and Reform announced it would investigate Aduhelm’s FDA approval and its pricing. They pointed to the broad approval labeling and the decision to approve based on a surrogate endpoint in an array of criticisms it levied at the regulator.
Uptake of Aduhelm, given the controversy and persistent questions about efficacy was slow after approval. Clincians were skeptical. More importantly, many private insurers simply refused to cover the drug. As I noted above, the Centers Medicare & Medicaid Services announced it would only fund the drug when patients take part in a clinical trial.The European Medicines Agency rejected the drug outright. In December 2021, the manufacturer lowered the annual cost of the drug from $56,000 to $28,200. It had no effect. While Biogen did launch the clinical trial that the FDA mandated as part of its approval, sales were dismal. In February 2022, Biogen’s financial statements revealed only $3 million in revenue for all of 2021.
In January 2024 Biogen announced it was discontinuing Aduhelm. Only 2,500 people are currently taking the drug worldwide, and they can continue to receive the drug until November. This was expected (by Biogen at least) to be a multi-billion dollar drug, considering the list price and how prevalent Alzheimer’s disease is. Biogen says they’re turning their focus to Leqembi, which it has partnered with Eisai to market. They have relinquished the marketing rights back to Neurimmune, the company that discovered the drug, and terminated the clinical trial the FDA had mandated.
So where does this leave patients with AD and their families? Given there was no evidence aducanumab actually worked, the approval was premature and may ultimately have doomed the drug. How this drug’s approval influenced the FDA’s perspective on the newer Alzheimer’s drugs is not clear, but the data for those looks more promising. Whether those benefits are meaningful is perhaps an open question, and one which will be debated and hopefully studied carefully.

Tonsillectomy Indications and Complications
Steven Novella on January 11, 2012
Link
Tonsillectomy remains a common surgical procedure with over half a million cases in the US per year, the most common surgical procedure in children. The indications and effects of tonsillectomy remain a matter of research and debate, as is appropriate. It is also a subject of popular misinformation and alarmism.
A recent article by Seth Roberts raises many of the issues with tonsillectomy, but also reveals the pitfalls of non-experts trying to understand the clinical literature and the effects of bias on evaluating a complex medical question. Throughout the article Roberts displays a persistent bias toward downplaying the benefits and exaggerating the risks of tonsillectomy, while accusing the medical establishment of doing the exact opposite. The purpose of this post is not to defend the practice of tonsillectomy but to review some of the relevant issues and explore how bias can affect an assessment of the evidence.
Indications for Tonsillectomy
Roberts tells the story of Rachael who was offered tonsillectomy for her son and so did some research on her own. She looked on Pubmed (a good place to start) and found a Cochrane review from 2009.
The Cochrane Review that Rachael found (“Tonsillectomy or adeno-tonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis”) was published in 2009. It describes four experiments that compared tonsillectomy to the care a sick child would otherwise receive. All four involved children like Rachael’s son, and all four had similar results: Tonsillectomies had only a small benefit. (Contrary to what Rachael was told.) During the year after random assignment to treatment — the point at which some children had their tonsils removed, other children did not — children whose tonsils were removed had one less sore throat than children who were not operated on (two instead of three for children like Rachael’s son).
Roberts fails to mention that the benefit described above – one fewer sore throat – was for the mild group only. For those who had a more severe sore throat history, the review found greater benefit:
For more severely affected children adeno-/tonsillectomy will avoid three unpredictable episodes of any type of sore throat, including one episode of moderate or severe sore throat in the next year.
In addition there were fewer sore throat days, 17 with tonsillectomy compared to 22 without, even including the sore throat days from the surgery. One of the main points of Roberts’ article is to criticize the reviewers for omitting information from their review, but while discussing that very point he is omitting information stated plainly in the article abstract.
I find this to be a common source of bias in evaluating medical interventions – conflating the risk/benefit in low risk or severity groups with higher severity groups. Also, Roberts commits other common non-expert fallacies in evaluating the potential risk vs benefit of a therapy, narrowing the field of indications and potential benefits. In his article Roberts assumes that the only indication as a preventive measure for tonsillectomy is for recurrent sore throats. This is certainly a common indication, but not the only one. Tonsillectomy is also performed for acute abscess in the tonsils.
Further, there are complications from tonsillitis that go beyond merely have frequent sore throats, including dysphagia (difficulty swallowing) and sleep apnea (airway obstruction during sleep). In fact these are major considerations in deciding who should get a tonsillectomy.
Published guidelines reflect these additional factors that Roberts ignored – only doing tonsillectomy on severe cases and considering other issues like dysphagia and sleep apnea, and recommending medical management and watchful waiting in less severe cases. Roberts accuses physicians of ignoring relevant information about tonsillectomy, but he ignores published practice guidelines that look much more deeply into the issue than is reflected in his analysis.
Risks of Tonsillectomy
After downplaying the benefits and oversimplifying the indications for tonsillectomy, Roberts then goes on to exaggerate the risks. He seems to take the approach of listing any possible hypothesized risk as if it is established. The links he uses to defend each risk he cites does not support the claims he is making. Once again he is led to the conclusion that doctors are ignoring the risks and morbidity from tonsillectomy, while those alleged risks have not been established.
For example, he lists Hodgkins disease with links to evidence for an association with tonsillectomy. He does link to one article from 1972 and disputes the association, but did not link to a 1987 review that found no association between Hodgkins disease and tonsillectomy. As far as I can see this was the last word on the issue. Roberts still gets to list Hodgkins disease as a scary increased risk from tonsillectomy without fairly representing the state of the evidence.
He also lists variant Creutzfeld-Jacob disease, and links to two articles which do not establish a higher risk of developing the disease from tonsillectomy. Rather, the issue is about whether prion disease has an affinity for the tonsils, and whether tonsillar biopsy can be used for diagnosis. The correlation is about the natural history of prion disease, not a cause and effect from having a tonsillectomy. A deeper reading into the literature is needed in order to see this. Roberts, however, simply searched for tonsillectomy and complications and listed everything he found. In none of the cases is a cause and effect established. He wonders why doctors do not list all of the complications he found – that’s why.
The underlying issue is the effect of tonsillectomy on the immune system. Roberts engages in very simplistic reasoning – the tonsils are part of the immune system, removing them therefore compromises immune function and is a bad idea. He ignores the fact that those tonsils that are removed are unhealthy, and perhaps they have become counterproductive to immune function. From the practice guidelines linked to above here is a summary of the current thinking:
With chronic or recurrent tonsillitis, the controlled process of antigen transport and presentation is altered due to shedding of the M cells from the tonsil epithelium. The direct influx of antigens disproportionately expands the population of mature B-cell clones and, as a result, fewer early memory B cells go on to become J-chain–positive IgA immunocytes. In addition, the tonsillar lymphocytes can become so overwhelmed with persistent antigenic stimulation that they may be unable to respond to other antigens. Once this immunological impairment occurs, the tonsil is no longer able to function adequately in local protection, nor can it appropriately reinforce the secretory immune system of the upper respiratory tract. There would therefore appear to be a therapeutic advantage to removing recurrently or chronically diseased tonsils. On the other hand, some studies demonstrate minor alterations of Ig concentrations in the serum and adjacent tissues following tonsillectomy. Nevertheless, there are no studies to date that demonstrate a significant clinical impact of tonsillectomy on the immune system.
What are the alternatives?
The other display of flagrant bias in the article, reflecting, in my opinion, the successful marketing of “alternative” medical thinking, is Roberts’ endorsement of the naturopathic approach to chronic sore throats. While decrying the lack of evidence-based practice on the part of medical doctors (while not understanding or properly reflecting the evidence), he then offers as an alternative that is blatantly not evidence-based. The naturopath, of course, offered nutritional and herbal treatments. Roberts is correct only in that such interventions are lower risk and less permanent than a surgical procedure, so the threshold of evidence efficacy can be lower, but that does not justify making non-evidence-based recommendations.
He mentions vitamin D. Here the evidence is preliminary and mixed, looking for a correlation with vitamin D levels and chronic sore throats. One study found:
There is no difference between the serum vitamin D level and receptor gene polymorphism among children with recurrent tonsillitis and healthy children. But vitamin D insufficiency is more prevalent in children with recurrent tonsillitis group (18%).
That’s pretty thin. Vitamin C was also raised. Roberts blames Linus Pauling for giving vitamin C a stigma among scientists. This may be true, but it’s quite irrelevant. There have been many studies of vitamin C and infections, and the bottom line is that there is no proven benefit. The same is true for multivitamins.
The naturopath also offered powdered larch bark. Here is a summary of the current evidence there:
Larch arabinogalactan is approved by the US Food and Drug Administration (FDA) as a food additive and fiber supplement. However, available scientific evidence does not support claims that larch bark is effective in treating cancer or any other disease in humans. Early laboratory evidence suggested that larch arabinogalactan may stimulate the immune system. However, a more recent study in mice contradicts this finding. Further studies are needed to identify other uses for larch in humans.
Conclusion:
The point of this post is not to thoroughly review the research and make recommendations regarding tonsillectomy. That is not my area of expertise, and panels of experts have already done that. The point, rather, was to use this question, and Roberts’ article, as an example of how bias and lack of expertise affects how we view the evidence. Several common errors in looking at clinical questions were made here, and I find frequently – taking a simplistic approach to disease and treatment mechanism, failing to consider severity as an indication for a treatment, failing to consider all relevant outcomes when assessing potential benefit, and using different criteria of evidence when assessing alternatives.
I do think that health consumers should avail themselves of information that is available to the public, but it is not easy to do so. Pubmed is a good place to start, but for the non-expert I would also recommend finding practice guidelines or summaries of the evidence prepared for the non-expert. It is also a good idea to use the information found as a basis for a conversation with a real expert, rather than as a means of replacing expert opinion with a “Google University” opinion.

What Is Type 3 Diabetes?
Steven Novella on April 3, 2024
Link

I’m always wary of new medical terms that seem to be used and promoted prematurely, when still in the hypothesis phase. It seems like an obvious way to bias any thinking about an alleged phenomenon – just label it as the hypothesis, as if it is already a conclusion. Calling symptoms that may follow a lyme infection “chronic lyme disease” implies something that has never been proven.
That was my reaction when I first heard of “Type 3 diabetes”. It didn’t help that it was from a video by such a dubious source as Mark Hyman in which he says, “Scientists now call Alzheimer’s disease Type 3 Diabetes.” Really? I didn’t get the memo.
The underlying idea is a valid research question. Preliminary studies have found that neuronal insulin resistance may be playing a role in the dysfunction and degenerative processes of Alzheimer’s disease. For quick background – insulin is a hormone that allows cells to transport glucose from the blood into the cell to use for energy. Type 1 diabetes results from a decreased ability to create insulin, likely due to an autoimmune disease which destroys the cells of the pancreas that create insulin. Type II diabetes results mainly from insulin resistance, which is partly genetic and partly due to lifestyle factors. Insulin resistance means that it take more insulin for cells to get enough glucose, so people with Type 2 diabetes may actually have increased insulin levels (although the pancreas may then get burned out and not be able to keep up with this increased demand for insulin).
The idea of Type 3 diabetes is that the neurons of the brain have insulin resistance. They are unable to maintain their high demand for glucose, which compromises their function. The brain is a very glucose-hungry organ, so it is plausible that it would be disproportionately affected by insulin resistance.
But biology is complex, and evolution tends to use what’s already there to achieve multiple ends. So it’s not surprising that insulin may have multiple effects in the brain. As a recent review summarizes:
However, emerging evidence from human and animal studies indicate that insulin influences cerebral bioenergetics, enhances synaptic viability and dendritic spine formation, and increases turnover of neurotransmitters, such as dopamine. Insulin also has a role in proteostasis, influencing clearance of the amyloid β peptide and phosphorylation of tau, which are hallmarks of Alzheimer’s disease. Insulin also modulates vascular function through effects on vasoreactivity, lipid metabolism, and inflammation. Through these multiple pathways, insulin dysregulation could contribute to neurodegeneration.
Sounds pretty compelling. Does this mean, as Hyman says, that Alzheimer’s disease (AD) is type 3 diabetes? No so fast. The history of Alzheimer’s research has been one of finding all sorts of clues as to pathological processes associated with AD, that turn out to be just part of the picture. No one process that we have discovered so far has been shown to be the one factor that is causing and driving the disease.
It turns out, when neurons are under some kind of metabolic stress and start to degenerate, there are a lot of downstream effects. Neurons start misbehaving in lots of ways – almost every way we choose to investigate. I have been in neurology long enough to have heard a dozen hypothesis that seemed like we have finally found the one true cause of AD, only to not pan out.
Is it inflammation? Perhaps disrupted axonal transport is the culprit. Genetic variants that correlate with abnormal protein folding seems to be critical. What about oxidative stress, or neurotoxicity? We know a lot about what is happening in AD, and build up of beta amyloid and abnormal tau proteins are certainly playing a key role. But even there, we are now just getting interventions in the form of monoclonal antibodies that seems to modify disease progression (if modestly) by targeting amyloid, with clinical trials of those targeting tau on the way. But again – are we treating the true cause of AD or just one important component of disease progression?
It’s not surprising that glucose metabolism is also abnormal in AD, and that the complex effects of insulin are compromised. Again – most of the cellular functions we look at in AD turn out to be abnormal, at least in a subset of patients.
For now it is reasonable to conclude that it is a good idea to prevent prediabetes or diabetes with good lifestyle habits. It is also good to carefully control blood glucose and insulin resistance in people with these conditions or who are predisposed. This is already the recommendation, so nothing has changed. At most there is one more downstream negative consequence to diabetes that can be improved by good diabetes control.
We can say the exact same thing about hypertension. There is a strong link between high blood pressure and AD risk. There is also a lot of research into the mechanism that connects the two. For now, the best recommendation is to have good blood pressure control – which is already a good idea and standard medical advice. Are scientists now calling Alzheimer’s disease “hypertensive brain”?
AD remains horrifically complex and only partially understood. It is likely a variable set of metabolic processes that have a common final pathway of pathology. There are a lot of risk factors and processes that play a role. At this point it seems like folly to think that there is one true cause of AD.
Insulin resistance seems like it is one of the many things that plays a role in AD pathology. In the short term this reinforces existing advice on preventing and treating diabetes. Perhaps basic research into the mechanisms of insulin’s role in AD may lead to some specific treatments. But it is silly to say that AD should now be known as Type 3 diabetes – unless you are trying to reinforce a simplistic medical narrative by massively overemphasizing the role of diet in every disease.

DIY Diabetes Treatment
Can DIY medicine work?
Steven Novella on November 17, 2021
Link

Recently The Lancet Diabetes and Endocrinology published a consensus statement on the use of do-it-yourself (DIY) closed-loop automated insulin delivery (AID) systems – “Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals“. (The full article is available free but requires registration to access.) The issue is worth exploring because it raises a host of issues relevant to SBM, involving the relationship between scientific evidence, professionalism, regulation, and self-care.
The specific practice at issue here is the increasing use among those with Type 1 diabetes of DIY AID systems – open-source software to control insulin pumps connected to glucose monitors. Continuous glucose monitoring involves a small sensor wire inserted under the skin that can measure glucose levels in interstitial fluid. This is covered by a patch so that it can be worn continuously, even in the shower. Systems typically provide a glucose measure every five minutes 24 hours a day. When glucose monitoring is connecting to an insulin pump and controlled with a computer algorithm that is called a closed-loop system (or colloquially an artificial pancreas).
There are commercial systems available that are tested and approved. However, they are also quite expensive, and there are many people with Type 1 diabetes who cannot afford or do not have the insurance to cover these systems. As a result, in recent years a community of people with diabetes have developed open-source software that can control the insulin pumps based on data from the continuous glucose monitor. Open-source software is free for anyone to use and update, it is crowd-sourced without any central control. Because it is free it has made AID systems available to thousands of patients who could not afford a commercial version. Many of these systems run on smart phones, and have a higher level of control and customization that their commercial counterparts.
The emerging question for professionals has been – what are the ethics and legal considerations of patients using unapproved AID systems, and what are their professional responsibilities as their doctors? This is the purpose of this international statement – it essentially supports the DIY community and encourages physicians to work with and support their patients who use open source AID devices. This is very clarifying for physicians in this situation, but the statement is also very open about the limitations and trade-offs here.
First and foremost – there is a distinct lack of scientific evidence for the safety and efficacy of DIY devices, specifically there are no double-blind placebo-controlled trials. There are real-world observational studies which support the safety and efficacy of these devices. The obvious solution here is to do more studies, but this field is a moving target. Which DIY system do you study and which version? These systems are constantly being updated and customized, so a well-controlled study is essentially impossible. The same is true, however, or many medical treatments, and we often have to be content with lesser standards of clinical evidence, such as open-label treatment (you can’t double-blind surgery, for example).
These DIY systems are also not a panacea. While they make closed-loop systems more available, specifically to those who cannot afford commercial systems, they are still highly selective in who benefits. Adopters need to have a certain level of technical savvy. They will have to do all updates and customization themselves, and there is no centralized support structure. There is a DIY community of support, however.
Essentially, the recommendation of the international panel of experts authoring this paper is that physicians should not work against the DIY community, but rather work with and support them. In this specific context the recommendation makes sense, but it definitely had me thinking about the broader implications for the practice of SBM in an increasingly digital and DIY world. This is also an extension of a broader discussion we have had within SBM about the following dilemma – when it comes to paraprofessional or non-professional medical interventions that are clearly not science-based, do we push for full regulation and banning, or emphasize reform and collaboration? We have not arrived at any consensus on this question, because I don’t think it has one clear answer. It is very context-dependent, with strengths and weaknesses in each approach.
Ultimately the question may be taken out of our (meaning the medical community’s) hands. Perhaps this is part of the evolution away from the old paternalism model of health care. I was educated within the paradigm of the cooperative model, where patients are given fully informed consent and are partners in the clinical decision-making. The role of the physician is not so much to make decisions as to provide information and offer options. In practice this also varies considerably depending on the situation. For chronic medical conditions, however, the cooperative model is not only preferred – it is essential. Patients need to become partners in their own care.
This is hugely complicated, however, by the existence of unregulated over-the-counter snake oil, and unscientific pseudoprofessionals and gurus whose practice seems to be based on giving the worst and most unscientific advice possible. Further, there is a wealth of health misinformation on social media, and entire ecosystems built on conspiracy theories and antiscientific notions. This makes helping patients treat themselves feel more like throwing them to the sharks. But like it or not, this is the world in which we are now practicing.
Which brings us back to this core dilemma. I think the only answer is to take an individualized hybrid approach. Some practices and products just need to be regulated. There is no legitimate role, for example, for homeopathy, which is 100% magical snake oil. There is no way to work with a patient to manage their illness with homeopathy, and the only advice a science-based practitioner can give is that it is worthless and not recommended at all.
At the other end of the spectrum are over-the-counter products and lifestyle choices that are highly evidence-based. The role of the practitioner here is to educate their patients about these options and their optimal use, to monitor outcomes, and help their patients manage their own illness with these options, along with those requiring prescriptions or procedures.
In between there is a vast gray-zone. There are products like CBD and Kratom that are drugs, even powerful drugs, with all the risks and benefits that implies. Kratom is essentially an addictive opioid-like drug that is available over-the-counter. There are many practices like intermittent fasting, ketogenic diets, deep-tissue massage, even hot-yoga that have some rationale, but often come with claims that go way beyond the evidence and have some safety concerns.
The modern physician needs to be aware of all these things, and be able to work with their patients to help them navigate these options, while minimizing risk. It would be simpler and easier if all medical interventions were regulated and controlled, but that world never existed and is getting farther away, if anything. We essentially have no choice but to collaborate with the DIY medicine model to some extent. In this way we may be able to make it a bit more science-based, and at least have more of an open discussion with our patients so that they can make better decisions. We also need to better study these options, not to promote them but to understand their risks and benefits better. Meanwhile we need to push for better regulations, to at least reduce the extent to which the market is flooded with fraudulent, harmful, and useless products and services.
        ◦ The DIY AID treatments are a good example of when this model can work. In fact, it shows how we can leverage the open-source community to improve the care of our patients and bring cutting edge technology to those who would otherwise not be able to access it.

Generic GLP-1s are here (for some)
Will approved generic versions of Ozempic eliminate the grey market for compounding?
Scott Gavura on September 10, 2026
Link

GLP-1 drugs have redefined the term “pharmaceutical blockbuster”. Already a USD$79 billion global market, continued growth is expected and sales could reach USD$190B in a decade. But while there is great enthusiasm for these products, cost has limited uptake, especially as insurers have been reluctant to take on coverage beyond their original intended use for diabetes. Earlier this year I noted that one market was about to face serious disruption: Generic semaglutide was about to arrive in Canada. Well, the generics have arrived, but GLP-1 sales continue to set new Canadian records.
There seems to be more public awareness of GLP-1 drugs than possibly any other drug on pharmacy shelves. Semaglutide sales took off during the early years of the pandemic. Before the pandemic (2019), Canadian sales were $126 million. By 2025, they had reached $2.9 billion. Ozempic is the version of semaglutide that’s labelled for diabetes. Wegovy is labelled and packaged with larger doses and is approved for weight loss. The delivery mechanism differs, as does the dosing, but both contain semaglutide as their active ingredient.
Not all GLP-1 options are the same
Given a choice between a generic drug and a compounded drug, the generic wins on almost all fronts. Compounding is the process by which a pharmacy can create a customized drug product that addresses unique patient needs, such as an allergy or dosage form requirements. But importantly, compounded drugs are not subject to regulatory approval, and finished products are not reviewed for safety, efficacy, or quality. Risks of harms are consequently higher with compounded products. Compounding serves an important need for patients who need a drug or dosage form that isn’t commercially available.
Compounding GLP-1s was an issue on both sides of the border. I’ve blogged previously about the widespread proliferation of compounding in the United States that started when there was a genuine shortage of GLP-1 drugs (compounding is legally permitted under these circumstances).
The FDA has moved to shut down GLP-1 compounding outside the narrow legal exceptions that once permitted it, sending waves of warning letters out to telehealth providers and compounding pharmacies. Under U.S. law, “503A” pharmacies may compound patient-specific prescriptions, while “503B” refers to outsourcing facilities permitted to compound medications in larger quantities for healthcare providers and institutions. Both may compound products that contain the same active ingredient as FDA-approved drugs when those drugs appear on the FDA drug shortage list. Semaglutide and tirzepatide were compounded on a large scale because Wegovy, Ozempic, Zepbound, and Mounjaro faced supply shortages due to overwhelming demand. These provisions were intended as a temporary response to supply disruptions, not as a permanent substitute for approved medicines. There is no longer any shortage of these products.
The FDA announced this past May that it proposes not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List, concluding that the evidence did not demonstrate a clinical need for outsourcing facilities to compound these drugs from bulk active ingredients. While the comment period has closed, the final determination is still pending. If finalized, it will eliminate the principal 503B bulk-compounding pathway that has supported much of the large-scale telehealth GLP-1 compounding market in the United States. And that will eliminate lower-cost (but higher-risk) versions of these products.
Compounding has also been occurring in Canada, too. In 2025, Health Canada issued a position statement on compounded GLP-1 drugs, raising concerns similar to those raised in the USA:
In general, compounding of sterile preparations is a high-risk activity and should only be considered in exceptional circumstances. A compounded drug might be appropriate if a patient’s medical need cannot be met by an approved drug, or in the case where an approved drug is not commercially available, as in the context of a shortage.
Compounding is a legitimate part of the practice of regulated healthcare professionals however it must not be used to bypass the federal drug review and approval system.
and
While there may be some unique case-by-case scenarios in which a patient would need a customized GLP-1 receptor agonist therapy, Health Canada is concerned about the lack of scientific evidence (or justification) to support the use of semaglutide with other active ingredients in products sold as compounded GLP-1 receptor agonist therapy. For example, Health Canada is aware that some pharmacies have been preparing and selling injectable semaglutide with pyridoxine (vitamin B6). However, Health Canada is not aware of any scientific evidence to support this addition to address an unmet therapeutic need.
Health Canada indicated it was taking regulatory action and even issued a recall for two compounded products. Regulators in Canada and the USA clearly shared similar concerns about these “grey market” products.
But there’s been a big change in Canada now. The Canadian patent for semaglutide lapsed on January 4, 2026, based on what may have been an oversight by Novo Nordisk. This allowed generic manufacturers to enter the Canadian market, the first of any G7 nation. To secure approval, manufacturers are required to demonstrate to regulators that their products are bioequivalent (behave the same way in the body) as the reference product. Generic drugs are held to the same manufacturing and quality standards as the reference drug product, and that must be proven to the regulator. If you’re using an approved generic, you can be confident that the drug will provide comparable effectiveness and product quality as the reference drug product.
The first semaglutide generic arrived in April 2026 – earlier than many anticipated. Others have followed, with additional brands on the way. More brands equals more competition, which is expected to push the price down (currently generic semaglutide is about $100 per month) even further. Novo Nordisk hasn’t walked away – they appear to be offering coupons to discount the net price of Ozempic for consumers, so they don’t lose the entire market to the generics. Generic sales have been modest so far: Apotex sold about $15 million of its version by June 30, and Dr. Reddy’s just $1 million, against $1.49 billion in brand Ozempic sales alone in the same half-year. Brand Ozempic is on pace for a record year in 2026, even with generics on shelves.
While generic sales look trivial compared to brand products, this is influenced by the late arrival of both generic brands during the reporting period. Time will tell who will ultimately capture the market in Canada.
Only one path to genuinely lower prices
GLP‑1 drugs are highly effective therapies, and there’s a huge potential market and demand for these treatments. They are generally well tolerated and are having meaningful, population-level effects on obesity. High prices created an illicit grey market in both Canada and the USA. A path to lower prices now exists in Canada, in a way it doesn’t yet in the US. Whether that actually displaces the grey market, or just adds a third option alongside brand and compounding, is still an open question with only a few months of sales data to go on.

Doves, Diplomats, and Diabetes
Harriet Hall on April 16, 2013
Link
In the past I have criticized evolutionary medicine for its tendency to rely on unverifiable “Just-So Stories,” but a new book has helped me appreciate what the best kind of evolutionary thinking can contribute to our understanding of medicine. Doves, Diplomats, and Diabetes: A Darwinian Interpretation of Type 2 Diabetes and Related Disorders by Milind Watve investigates diabetes from an evolutionary perspective, suggesting how it might have originated, why it persisted, and how it is related to survival advantages. Watve develops well-reasoned hypotheses that can be tested by examining their expected consequences. He believes it is impossible to understand metabolism without understanding behavioral ecology, and he makes a good case.
A reassessment of the evidence concerning Type II diabetes (T2D) reveals a number of paradoxes. Elevated blood glucose is the defining feature of T2D but controlling it doesn’t prevent all the complications of diabetes, and it doesn’t appear that elevated blood sugar could produce all the pathological changes of diabetes. Insulin resistance is believed to be central to a cluster of deadly diseases in humans, but in other animals it has no adverse effects on health and even increases lifespan. Studying diabetes from an evolutionary perspective can shed light on such paradoxes.
Insulin resistance leads to type II diabetes and coronary heart disease. It is associated with obesity and is thought to have developed as a response to periodic starvation, but a close examination of the evidence really doesn’t support that interpretation. Instead, it may be a socio-ecological adaptation that mediates (1) a transition in reproductive strategy to a smaller number of offspring with larger investment in each, and (2) a transition from a relatively more muscle-dependent lifestyle to a more brain-dependent lifestyle (stronger to smarter, soldier to diplomat).
There is a mass of complex information in this book that I can’t hope to master. It runs 428 pages and is exhaustively referenced. I hesitated to write about it because I don’t think I can do it justice. I can only hope to present a simplified summary to whet the appetite of interested readers.
Old paradigm: Type I diabetes is a primary deficiency of insulin. Type II diabetes is a relative insulin deficiency. It begins with insulin resistance that leads to increased production of insulin (hyperinsulinemia); eventually the pancreatic beta cells wear out and can no longer produce enough insulin to compensate for the increased insulin resistance. Then blood sugar rises and that causes inflammatory changes with damage to blood vessels, eyes, kidneys, and heart. Obesity is thought to be a primary cause (along with a genetic predisposition), and as the incidence of obesity has increased, the incidence of diabetes has increased.
New paradigm:
     1.  A plurality of behavioral strategies can exist in a population of animals, and a prominent dichotomy is between the hawks and the doves, between the soldier (physical strength and aggression) and the diplomat (cognitive abilities and social manipulation). The number of individuals following each strategy varies with environmental and social conditions.
     2.  Behavior affects physiology. Numerous physiological adaptations support the different behavioral repertoires, and the diplomat option is accompanied by a divestment from muscle, an increase in visceral fat, elevated cholesterol, elevated insulin, and insulin resistance.
     3.  Increased levels of insulin, cholesterol, leptin, and cortisol produce aggression suppression, physical risk aversion, and enhanced cognitive functions.
     4.  Aggression anticipates injuries, and the soldier’s body prepares for wound healing; the diplomat’s body puts its resources elsewhere, and therefore becomes more susceptible to factors that tend to impair wound healing such as low-grade chronic inflammation and deficiency of many growth factors.
     5.  Crowding in a population affects reproductive strategies, aggressive behavior, etc.
     6.  Most of the complications of diabetes are due to growth factor deficiency, changes in immune response, oxidative stress, and angiogenesis dysfunction. Hyperglycemia aggravates these effects but is not the underlying cause.
     7.  Beta cell degeneration is not due to the pancreas “wearing out” but to factors that may be reversible. Other body functions increase their response in the face of increased demand; they don’t “wear out” and stop responding. Something is going on here that we don’t understand.
     8.  Insulin resistance can be decoupled from the mechanisms listed in 6, and it can promote health and longevity. It is not central to the pathology of diabetes.
     9.  The rate of glucose transport from the brain capillaries affects plasma glucose levels. The key to glucose homeostasis is most likely to be found in the brain.
     10.  Obesity is not central to T2D but is only a risk factor. It is associated with suppression of soldier behaviors, with two-way causality.
     11.  Insulin sensitivity and insulin secretion respond to a large number of signaling molecules including sex hormones, endorphins, myokines, and many others. It’s fiendishly complicated.
     12.  T2D is not primarily or mainly about insulin and glucose homeostasis.
     13.  Glycemic control is not sufficient to prevent all the complications of diabetes.
     14.  The pathophysiology of T2D originates from brain and behavior rather than from diet and energy imbalance.
     15.  T2D is potentially curable.
What about obesity? Fat has multiple functions in the body. Obesity is an adaptation that favors survival through various mechanisms rather than the simplistic explanation of energy storage to buffer against periods of starvation. Rather than obesity causing insulin resistance or insulin resistance causing obesity, there is likely a behavioral syndrome that precedes both; neuroendocrine processes driven by specific behavioral strategies may initiate pathways leading to obesity and T2D and the associated pathologies. Relative obesity is more important than absolute obesity: in countries where obesity is less prevalent, people become diabetic at lower BMI.
Watve introduces the concept of “behavioral deficiencies,” for instance of aggression, agility and rapid action, adventure, injury proneness, exposures to sun, weather, plants, microbes, and animals. He suggests that such behavioral deficiencies contribute to various diseases including cancer, skin disorders, hormonal dysfunctions, osteoporosis, chronic fatigue syndrome, depression, and various inflammatory conditions. He suggests that the typical exercise prescriptions are grossly inadequate, and that exercises should be designed specifically to supplement specific behavioral deficiencies. Competitive sports probably do more good than treadmills.
Unfortunately the book is very expensive and is not likely to reach many of those who would benefit from it. The list price is $209, and $159 for the eBook version. I didn’t know it or its author even existed until Watve e-mailed me out of the blue and kindly sent me the pdf. Its extensive references cover a broad gamut of scientific disciplines. I don’t feel qualified to judge how credible his hypotheses are, and I wish experts in the various fields could read the book, all put their heads together, and critique it more intelligently than I could hope to. I would love to see some of his research proposals carried out.
I wrote an article on “Bad Books” where I said:
There are two kinds of science book: one aims to educate the public by explaining the current state of evidence and the consensus of the scientific community. The other has an agenda: it uses (and mis-uses) science to persuade readers to believe something that the authors believe but that the scientific community as a whole has rejected.
This book doesn’t fall into either category. I don’t know whether its conclusions are correct, but I do know that its approach is unimpeachable. It epitomizes the best of scientific thinking. It doesn’t go beyond the evidence. It recognizes where the evidence is insufficient and how better evidence could be obtained by the proposed studies.
Watve is a professor of biology at the Indian Institute of Science Education and Research in Pune, India. His home page says:
I specialize in not specializing. I used research more as a tool in education and tried to motivate undergraduates to identify novel problems and use a variety of tools to handle them including modeling, simulations, observations, surveys, meta-analysis, field experiments as well as lab experiments…there is a common theme that runs through all the work, the connecting thread being evolutionary biology.
He challenges his students to question everything they read in their textbooks and to examine the evidence behind the accepted wisdom. In the case of diabetes, the underlying evidence was marked by a number of flaws, paradoxes, anomalies, and contradictions. That eventually led to the present book. He located thousands of published studies from various fields and tried to evaluate the data with a fresh eye. He also had access to data from many unpublished studies. He located some fascinating evidence that directly contradicts the standard textbook story of T2D.
The best thing about this book is its humility. Instead of bragging that he has found “the answer,” he raises more questions. He suggests hypotheses that might better explain the known facts, and proposes specific experiments to test those hypotheses. He says the new paradigm answers more questions than the old one but is far from complete. He begs researchers to carry out the necessary experiments. He invites criticism from readers. He even includes an epilogue entitled “I May be Wrong After All!!” He is interested in finding the truth rather than vindicating his own ideas.
He says:
I keep the possibility open that I have actually got into a thinking trap from where it is really difficult to get out. But I would like someone to try and convince me that it is so. I tried doing it myself and it did not work…the possibility remains that I have made erroneous arguments out of inadequate knowledge of the field. I would be glad to correct myself if anyone points out specific problems in my way of thinking.
These are the words of a true scientist and a wise man. Whether or not you agree with his ideas, you have to respect Milind Watve’s approach. He sets a stellar example for every scientist and critical thinker to follow.

OPTHOMOLGY


Eye Drops for Dry Eyes
I could have chosen a prescription eye drop for my dry eyes. I decided not to. Here’s why.
Harriet Hall on May 4, 2021
Link

Dry eyes can have many causes: disease, medications, environmental irritants, or just age. Tear production tends to decrease as we get older. My husband (age 80) and I (age 75) were both diagnosed with dry eyes by an ophthalmologist and he instructed us to use lubricant eye drops as often as every hour if needed to maintain comfort. This helps, but it’s cumbersome to use the drops every hour. Well-meaning friends advised me to try prescription cyclosporine eye drops (Restasis and others). After looking at the evidence, I decided not to. Here’s why.
A Cochrane Review of topical cyclosporine in 2019 concluded:
Despite the widespread use of topical [cyclosporine A (CsA)] to treat dry eye, we found that evidence on the effect of CsA on ocular discomfort and ocular surface and tear film parameters such as corneal fluorescein staining, Schirmer’s test, and TBUT is inconsistent and sometimes may not be different from vehicle or artificial tears for the time periods reported in the trials. There may be an increase in non-serious, treatment-related adverse effects (particularly burning) in the CsA group. Topical CsA may increase the number of conjunctival goblet cells. However, current evidence does not support that improvements in conjunctival mucus production (through increased conjunctival goblet cells) translate to improved symptoms or ocular surface and tear film parameters. All published trials were short term and did not assess whether CsA has longer-term disease-modifying effects. Well-planned, long-term, large clinical trials are needed to better assess CsA on long-term dry eye-modifying effects. A core outcome set, which ideally includes both biomarkers and patient-reported outcomes in the field of dry eye, is needed.
This is far from a strong endorsement. They noted that “Artificial tears were used as adjunctive to study medication in all but five trials”.
The Medical Letter reviewed cyclosporine eye drops in 2003 shortly after Restasis was approved by the FDA. The rationale? Dry eye disease is thought to be caused by cytokine-mediated inflammation of the ocular surface with infiltration of T-cells into the lacrimal glands, and cyclosporine has anti-inflammatory and immunomodulating effects. FDA approval was based on two identical randomized, double blind trials involving 877 patients. Cyclosporine was found to be slightly more effective than the vehicle alone in increasing tear production, relieving blurred vision, and decreasing use of artificial tears. Only “slightly” more effective. Transient burning and stinging were reported, but there were no systemic effects. The dose is one drop in each eye twice daily, and the cost is estimated to be $6 a day, or $180 a month. The Medical Letter concluded, “Ophthalmic cyclosporine (Restasis) may improve symptoms and increase tear production in some patients with dry eye disease, but more convincing data are needed. Since blood levels are usually undetectable, this ophthalmic preparation should be safe, but it is expensive.”
Fish oil is endorsed by the American Academy of Ophthalmology, but the evidence is scanty. A randomized double-blind study of fish oil found that the fish oil group had no better outcomes than those who got placebo.
Conclusion: I decided to pass
Considering the cost and the less-than-ringing endorsements, I decided to stick to my lubricant eye drops.

CDC Reports Fourth Death Blamed on Contaminated Eye Drops
An outbreak of deadly ocular infections, which have cost some people their vision and even their life, has been traced to contaminated eye drops.
Clay Jones on May 26, 2023
Link

Plenty of medicine cabinet staples can kill you. In fact, some are quite well known for causing serious health problems. If I was told about someone dying because of a drug purchased over-the-counter at a local convenience store or pharmacy, I would put my money on acetaminophen. That particular drug, which is extremely safe when used appropriately for fever and/or pain, even in newborn infants, manages to put 2,600 people in the hospital and kill about 500 of them every year in the United States when too much is ingested. I certainly wouldn’t have thought of eye drops.
But here we are. At deadly eye drops.
In February, the FDA issued a recall of two brands (EzriCare, Delsam Pharma) of OTC artificial tear lubricant eye drops after the CDC had reported an outbreak of infections across 12 states. The outbreak had affected consumers who had used these products from May of 2022 through January 2023. The 55 reported cases known at that time involved infections of the eyes, with some resulting in permanent vision loss, as well as the respiratory and urinary tracts. One unfortunate victim had even died from a bloodstream infection (sepsis) with the bacteria that had contaminated these products.
Last week, the CDC released an updated report identifying a total of 81 cases across 18 states (CA, CO, CT, DE, FL, IL, NC, NJ, NM, NV, NY, OH, PA, SD, TX, UT, WA, WI). These cases include 18 with permanent loss of vision, 4 of which required complete surgical removal of an eye. Finally, the death toll now sits at 4 people who simply wanted relief from dry eyes.
The bacterial contaminant in question is a particular strain of Pseudomonas aeruginosa (VIM-GES-CRPA) that is extremely resistant to even very broad spectrum antibiotic treatment. Essentially, every antibiotic I’ve ever heard of is ineffective. Normally I would caution readers to take that with a bit of a grain of salt, because I am only a simple country pediatric hospitalist, but this bacterial is seriously resistant.
Bacteria isolated from 5 of the patients were found to be susceptible only to cefiderocol, a drug that was approved in the United States in 2019 as a last ditch treatment for certain highly resistant bacterial strains, Pseudomonas aeruginosa being one of them. Sadly there is already significant resistance being reported to this antibiotic around the world. One other antibiotic, a combination of aztreonam and avibactam, was found to inhibit growth on an agar plate at certain concentrations in some of the isolates, which does not always equate to being a successful treatment approach because human and bacterial physiology is highly complex and at times unpredictable.
These cases represent the first time that this particular combination of antibiotic resistance genes has been found in combination in the United States. Both genes result in the production of enzymes, in this case a Verona integron-encoded metallo-β-lactamase (VIM) and Guiana-Extended Spectrum-β-Lactamase (GES), that break down antibiotics before they can cause any damage to the bacteria. And they are easily spread to non-resistant strains via plasmid transfer, so the risk of them taking hold here should be taken very seriously.
You know it’s bad when the CDC is talking about bacteriophages as a potential treatment. These are viruses that that target and kill specific bacterial species, or even a unique strain within a species, which can be a good or bad thing. Certain bacteria only become pathogenic, with release of harmful toxins, after being infected by a phage. Phage-encoded toxin production is largely behind diseases such as cholera, diphtheria, and botulism, for example. Phages can also serve as vectors for transferring antibiotic resistance genes between bacteria.
Phages have been used to treat bacterial infections in the past, typically only when approved for compassionate use in extreme circumstances. The process of finding the right phage can be lengthy and we have not worked out how to consistently get phages where they are needed in the body. And that is just the tip of the iceberg when it comes to the challenges inherent in this type of treatment, which is still in its infancy despite having been discovered a century ago.
The CDC has already announced that the University of California at San Diego’s Center for Innovative Phage Applications and Therapeutics and the Yale Center for Phage Biology and Therapy have completed the first step and identified a phage active against the bacteria implicated in the current outbreak. That is good news, but hopefully it won’t come to that. The best means of preventing additional infections and spread of the genes associated with such extreme antibiotic resistance is to avoid using these products.

First Whole Eye Transplant
A whole eye transplant did not restore vision, but is still an important advance.
Steven Novella on November 15, 2023
Link

At first this may sound like tabloid exaggeration or even wholesale fabrication, but it is essentially true – surgeons at NYU Langone Health have performed the world’s first whole eye transplant. The critical question that this fact immediately raises is – was vision restored? The answer is no, but that does not mean this isn’t an important step forward, and the details are interesting.
The patient is a 46-year-old military veteran from Arkansas who was injured on the job by a high-voltage exposure. As a result of the injury he lost his left arm above the elbow, his nose, mouth, left eye, and left cheek. The injury occurred in June of 2022. Since then he has had multiple reconstructive surgeries.
In May 2023, as part of this reconstruction, he underwent a partial face transplant from a deceased donor. Face transplants themselves are rare, with only 19 ever being done in the US, and only the fifth by the lead surgeon, Eduardo D. Rodriguez, MD, DDS. The surgery took 21 hours to complete.
The decision was made to perform a whole eye transplant at the same time, to replace his left eye which was damaged and had to be removed because it was causing serious pain. This was felt to be low risk, because the patient was already receiving a face transplant from the same donor and would have to be on immunosuppressing drugs to avoid rejection anyway. The operation itself was considered successful, but the real question is the long term fate of the transplanted eye.
There are two basic questions – how long and how well will the eye biologically survive, and will any function be restored. Regarding the first question, the transplanted eye has exceeded expectations. The surgeons were hoping the eye would survive for at least 90 days. So far it has survived over five months. The cornea and retina are getting blood supply. The eye is plump and retains its fluids. Overall the eye is healthy.
There are also two aspects of function to consider. One relates to the restoration of the muscles around the eye. These were also reconnected, although I could not find any mention if the muscles themselves were donor muscles or patient muscles. In any case, so far no movement of the eye has been restored. Also, the muscle that raises the lid is not demonstrating any function, so he cannot open or blink the eye. According to reports, however, the team has detected some flicker of activity in the muscles, just not enough to actually move the eye or the lid.
Of course the big functional question is, will vision be restored to any degree? When the damaged eye was removed the surgeons cut the optic nerve as close to the eye as possible, to facilitate potential later transplant. When the donated eye was transplanted the connected the ends of the optic nerve. They also took bone marrow from the donor and converted the cells into adult-derived stem cells. During the transplant they injected these stem cells at the point of connection of the optic nerve. The hope was that this would make it more likely for the two ends of the optic nerve to grow together.
There really wasn’t an expectation that this would work. It seems this was more of a – do it and let’s see what happens – approach. The entire surgery (the whole eye transplant part) should be considered exploratory. Again, the very low threshold for success was considered the eye itself surviving for 90 days. It has passed that. Everything else is gravy. In this way the transplant is considered to be cosmetic, rather than functional.
How big a deal is the qualified success of this surgery? From a transplantation perspective, I think this is a significant milestone. It is the first successful whole eye transplant, able to restore blood flow and result in a long term healthy eye. This is a necessary step toward a future where functional eye transplants are possible. But obviously it is not sufficient. And arguably, functional restoration is by far the more difficult task.
Unlike peripheral nerves, the optic nerve is actual considered part of the central nervous system, and it lacks the capacity to regenerate. So the optic nerve, on its own, will not regenerate and form a new connection between the eye and the brain. Apparently, just putting a patch of adult-derived stem cells on the optic nerve is not enough to provoke regeneration. However, central nervous system regeneration, including optic nerve regeneration, is an active area of research. It is no inconceivable that in the future we will be able to coax the optic nerve to fully regenerate. But we cannot yet say how long it will take to develop this capability. It could be decades off.
Eye muscle restoration is also a difficult task, but easier than optic nerve regeneration because the nerves and muscles that move the eye are peripheral, and do have some capacity to regenerate. Although it has not yet happened in this patient, this is not entirely new.
Still, the “holy grail” of eye transplantation remains the regeneration of the optic nerve. Once this technology has been achieved (which again, could take decades) that would open up exciting possibilities. Whole eye transplants that are fully functional could restore vision to many people.
The next question, however, will then be – how will the brain adapt? How well will the brain be able to map to the new connections to the transplanted eye? Generally when nerves regenerate, they don’t go back to exactly where they were before. This doesn’t matter much if you are connecting a large muscle. It does matter when nerves to fine muscles, like those in the face, regenerate. The optic nerve is exquisitely mapped to the visual cortex, and remapping may take a long time and be only partial. In other words, even if optic nerve regeneration were possible, the degree of functional recovery remains to be seen.
The ability to regenerate the optic nerve also opens the door further to prosthetic functional eyes. A robotic eye that is essentially a digital camera with a brain-machine interface to a functional optic nerve is theoretically possible. If this technology advances sufficiently, it make be preferred to a donor biological eye. There is no issue with rejection. Also, the robotic eye may be able to use AI to map its signals to the brain, rather than requiring the brain to map to the new pattern of incoming signals.
And since we are speculating about future technology, we can also envision a future in which eyes can be grown from a patient’s own cells, essentially cloned eyes. This removes the need for a donor, and also removes the problem of rejection and the need for immunosuppressive drugs. While this is also an area of research, it also likely lies decades in the future.
For now whole eye transplants should be considered cosmetic, with any functional implications exploratory. Still, this is an important step and does make possible a potential future of functional eye transplants.

Anti-VEGF treatment of Macular Degeneration: Science-Based Success
Let’s celebrate some good science with a story about some evidence-based treatments for macular degeneration!
David Weinberg on October 25, 2013
Link
Science-Based Medicine authors tend to focus attention on practices that misuse or ignore the tools of science. This is not a criticism. As a daily reader and occasional contributor, I recognize that shining a light on pseudoscience is a critical part SBM’s mission. It is what brings me back day after day. Sometimes, however, it is nice to highlight what real science and real evidence can do.
In my world of treating patients with retinal disease, a revolution has taken place over the past few years. The most aggressive form of macular degeneration has been transformed from a relentlessly progressive, disabling disease to one which can be tamed with medication. Now, patients diagnosed with exudative macular degeneration can expect stabilization and even improvement in vision.
It is a story worthy of a Hollywood movie. Start with a reluctant hero; add controversy, Wall Street, politics, and most important of all, a happy ending.
Background: Age-related macular degeneration
Age related macular degeneration (ARMD) is the leading cause of irreversible legal blindness among adults in the industrialized world. In the United States nearly 2 million people are estimated to have more advanced forms of macular degeneration. But this is just the tip of the iceberg. Over 7 million Americans have earlier forms of ARMD with lesser degrees of vision loss and a lifelong risk of progression to advanced disease. These numbers are expected to rise dramatically as the population ages.

The retina lines the inner wall of the eye like wallpaper, and functions like the film in a camera. The cornea and lens, in the front of the eye, focus light on the retina. The brain interprets the signals from the retina as vision. The macula is the anatomic and physiologic center of the retina. It is, quite literally, the center of your visual world. It is responsible for the sharpest, most detailed vision and needs to be healthy for reading and other detailed visual tasks.
ARMD occurs in two forms, or stages, referred to as “dry” and “wet”. Most patients have the dry type. In the early stages, patients usually have no symptoms, and the lucky ones will never experience noticeable vision loss. Over time, there is often slow anatomic and functional deterioration of the macula. Patients may experience a variety of symptoms including, blurriness, loss of contrast sensitivity, distortion, and blind spots in or near the center of their vision, but the progression tends to be quite gradual, over many years.
Wet (or exudative) disease is the most feared form of ARMD. Only a minority of patients develop wet ARMD, but those that do often experience a rapid, catastrophic loss of vision over a period of weeks or months. The defining event in transformation from dry to wet ARMD is the growth of abnormal blood vessels within the macula. These blood vessels cause bleeding, swelling, and scarring.


Patients with ARMD comprise a large part of my practice. They are typically in or approaching their retirement years. As the disease progresses they experience loss of activities that give them pleasure such as reading, watching television, and using the computer. They also face loss of activities that give them independence such as driving and handling their own financial affairs.
Additional educational material about macular degeneration can be found here, and here.
Treatments for wet ARMD have evolved over the decades. First there was laser treatment. This strategy used laser energy to coagulate or “burn” the abnormal blood vessels. The laser created a lot of collateral damage and resulted in blind spots in the patient’s vision, but these tended to be more stable the than damage created by the growing blood vessels. Only a small minority of patients were eligible for this treatment, and the rate of recurrence was quite high.
The next treatment was photodynamic therapy or “cold laser”. This treatment consisted of the administration of an intravenous photosensitizing dye, followed by low intensity laser. This combination caused much less collateral damage than a traditional laser, but the results were far from spectacular. On the average, treatment slowed down, but did not halt the progressive vision loss. Only a small minority of patients experienced improvement in vision. Furthermore, certain large subsets of patients did not respond favorably to treatment at all.
A reluctant hero, and a new era
The hero of our story is a physician/researcher named Judah Folkman. David Gorski wrote an appropriately admiring obituary when Dr. Folkman died in 2008. If you are not familiar with Dr. Folkman, and want an in-depth biography of a consummate practitioner of science-based medicine, read his story.
Dr. Folkman was a bit of a maverick. He chose to create a new field of research, a field that was not taken very seriously by his contemporaries, at least not at the beginning of his career. His attitude was maverick, but his work ethic was not. He started from scratch, by creating and refining his own models. He worked meticulously, behaved humbly, and spoke cautiously. He was a mentor to many young investigators who passed through his laboratory, and an inspiration to countless others.
Dr. Folkman did not set out to create a treatment for macular degeneration. It is doubtful that this disease was even on his radar when he launched his research career. His goal was to find new treatments for cancer. Folkman recognized that solid tumors required a blood supply to grow. He reasoned that if he could understand how tumors recruited new blood vessels, he might be able to use that knowledge to treat cancer. His early work was met with much skepticism. Eventually his work was recognized and emulated. The field became known as “angiogenesis”. Folkman’s lab became an incubator for young investigators to launch their own careers.
Much of angiogenesis research was identifying biologic compounds that stimulated the growth of new blood vessels, and also searching for others that stopped new vessels from growing. Because the eye contains avascular structures, it was used as a model for experiments in Dr. Folkman’s lab. Like cancer, macular degeneration (and several other blinding eye diseases) resulted from unwanted blood vessels growing in the wrong place at the wrong time. Researchers in eye disease recognized the relevance of angiogenesis research to eye disease, and several launched their careers in Dr. Folkman’s laboratory.
It wasn’t just academics who jumped on the angiogenesis bandwagon. Pharmaceutical companies recognized the potential for drugs that could inhibit the growth of blood vessels. The main target was cancer, but the possibilities treating eye diseases did not escape some of the companies.
In 1989 scientists at the biotech company Genentech isolated a family of compounds that appeared to be critical in how the body (and cancers) regulate the growth of new blood vessels. They became known as Vascular Endothelial Growth Factor (VEGF). In later research (by several investigators), it was discovered that VEGF is produced in the human eye, and is found at higher concentrations in diseases for which new blood vessels grew. In animal models, VEGF was both necessary and sufficient for neovascularization to occur. It was a reasonable hypothesis that if the action of VEGF could be blocked, the growth of new blood vessels in diseases like wet ARMD could be arrested.
The race is on
The race was on to develop a drug targeting VEGF for eye diseases. The first company to successfully develop such a drug was a start-up called Eyetech. The first disease they studied was ARMD. The drug was called pegaptanib, later sold as Macugen. Pegaptanib is from a class of compounds known as aptamers. Aptamers function much like antibodies. Antibodies are made of proteins, aptamers are made of nucleic acids. Pegaptanib was designed to bind to VEGF. The idea was that pegaptanib would act like a sponge, and soak up VEGF so it could not bind to its receptors, and thus neovascularization could be arrested.
Eyetech navigated clinical trials rather quickly and the studies were favorable. Patients treated with Macugen ended up with better vision than controls. FDA approved the drug in December 2004.
Although Macugen was a huge step forward, and established proof of principle that VEGF blockade was a valid strategy in the treatment of ARMD, the result were not the “home run” we had hoped for. Like photodynamic therapy, Macugen slowed down the progression of wet ARMD, but like photodymanic therapy, the trend was still for progressive loss of vision. Only a small proportion of patients actually enjoyed an improvement in vision.
Meanwhile, the scientists at the biotech company Genentech were working on their own VEGF-binding drug for ARMD. Their drug, ranibizumab was an antibody fragment. Antibodies are proteins that are part of the immune system. Two regions of each antibody bind to foreign material such as bacteria, viruses, or other molecules. Antibodies are fairly specific regarding the materials to which they bind. Genentech eliminated much of the non-binding portions of an antibody directed against VEGF. By making the molecule smaller, they hoped that the drug would be better able to penetrate into the tissues of the eye.
Even in phase 1 and 2 studies, ranibizumab showed great promise. The phase 3 data were finally presented at a meeting in July, 2005. The results were impressive. There were two phase 3 studies, each treating a different subset of wet ARMD patients. In both studies, patients treated with ranibizumab fared better than controls; not just a little better, but much better. For the first time, the average patient’s vision improved by a significant amount. Very few patients lost vision.

The table displays data from the phase 3 study comparing ranibizumab (Lucentis) to photodynamic therapy (PDT). Points on the chart represent the mean change in vision over the 24 months of the study. Note that patients treated with PDT (the usual care for patients when this study was done) lost vision over the course of the study. Patients treated with Lucentis had sustained improvements in vision. The average patient treated with Lucentis ended up able to read letters less than half the size of the average patient treated with PDT.
Patients would have to wait one more year for Lucentis to be approved by the FDA.
You’re going to do what to my eye?
So far, I haven’t mentioned the way anti-VEGF drugs like Macugen and Lucentis are given. The technique is called “intravitreal injection.” The vitreous cavity is a space that occupies about 4/5 the volume of the eye. It is filled with a transparent gel called vitreous. It has been known for many years that many drugs can be injected safely into the vitreous cavity via hypodermic syringe and a very fine needle. The vitreous acts as somewhat of a drug reservoir. There are advantages to intravitreal injection. It can be difficult to achieve therapeutic drug levels in the eye through conventional routes. By injecting the drug into the eye, high concentrations can be achieved in the target tissues, with minimal exposure or toxicity to the rest of the body. Although it sounds barbaric, patients seem to tolerate these injections very well. It is routinely done in the office, and most retina specialists now do dozens of these injections each week. If you are not squeamish about such things here is a video of an intravitreal injection.
In the clinical trials, patients treated with Macugen received injections every 6 weeks. For Lucentis, injections were given every month. That’s right, patients submitted themselves to an experimental needle in the eye eight to twelve times per year. In the real world, strategies are being explored to try to reduce the number of injections necessary to achieve good results, but repeated injections are still required for most patients.
The shot heard ’round the world
In July 2005, at the very same meeting at which the phase 3 ranibizumab data were presented, was another paper which changed the world. Phil Rosenfeld, MD, PhD, a well-known and respected physician from the University of Miami, presented a case series of patients he had treated with intravitreal injections of bevacizumab (Avastin). The case series was small, and uncontrolled, but the results were intriguing. The drug appeared to work, and work well, even in patients who had failed to respond to other therapies. Bevacizumab is an anti-VEGF antibody which had been FDA-approved to treat colon cancer. It was also a product of Genentech and sold under the name Avastin. Avastin was actually the parent compound of Lucentis. Most of the nonbinding parts of the Avastin antibody were removed to create Lucentis.
What happened over the next few months is legendary. Doctors and patients had seen the phenomenal data for Lucentis. The drug vastly outperformed all known treatments; but Lucentis was not yet FDA-approved, and thus unavailable to them. The data for intravitreal Avastin were tantalizing. A few doctors went home and tried using Avastin as an off-label treatment for their patients. The results surpassed anything they had ever used. Word spread quickly. More and more physicians tried Avastin, and liked the results they were seeing. The treatment became quite prevalent world-wide.
Sticker shock!
Lucentis was finally FDA approved in 2006, nearly 1 year after the data were presented. The wholesale price: $1,995/dose. Remember, in the clinical trials Lucentis was dosed monthly. Some patients needed injections in both eyes! Medicare will generally pay 80% of the cost of drugs administered in doctors’ offices. Unless the patient had good supplemental insurance to pick up the other 20%, they carried a significant personal financial burden.
In contrast, Avastin was cheap. Although fairly pricey as an intravenous treatment for cancer, the amount of drug needed for an intravitreal injection was so small that each dose was inexpensive. Compounding pharmacies were willing to dose out the drug in pre-filled syringes for a small fee. Even with these added costs, each dose of Avastin cost approximately $50.
Based on the solid data of safety and efficacy, and the stamp of approval from the FDA, many physicians adopted the use of Lucentis. Other doctors had become quite comfortable using Avastin and saw no reason to switch. This was fueled, in no small part, to anger over the high price of Lucentis. Although Avastin and Lucentis had not yet been compared in a head-to-head trial, many doctors perceived that the two drugs were equally effective, and felt it was irresponsible to use the one that was 40 times the cost of the other.
Corporate shenanigans
The situation was unprecedented. Genentech had created Lucentis, a spectacularly effective and expensive drug for wet ARMD. This was a win for patients and stockholders, but sales were undercut by competition from a cheap, off-label competitor. Ironically, the cheap competition was their own drug, Avastin. The availability of cheap Avastin significantly impacted the sales of Lucentis. The great Avastin vs. Lucentis debate was born. One was more likely to read news about macular degeneration treatments in the business section of the newspaper than the science or medicine sections.
The New York Times reported a secret program instituted by Genentech that provided financial incentives to high-volume prescribers of Lucentis. The contract physicians signed to participate in the program stipulated that the agreement was confidential.
Genentech also announced their intent to stop selling Avastin to compounding pharmacies, a move that would shut down access of most physicians (and patients) to the less-expensive option. Genentech said the move was out of concern for the safety of patients. Ultimately, they backed down from their decision under heavy pressure from professional organizations of ophthalmologists.
The showdown
The Avastin vs. Lucentis debate went on for many years. The financial ramifications were of importance to patients as well as Medicare and other payers. The economics of the standoff were summarized by Phil Rosenfeld (the same man who introduced the world to intravireal Avastin) in testimony before the Senate Special Committee on Aging. There were physicians firmly entrenched on each side. Surveys and Medicare records showed that use of Avastin was slightly more prevalent than Lucentis by a ratio of approximately 6:4. Lucentis users had the backing of high-quality randomized clinical trials, and the imprimatur of the FDA. Avastin users did not have the highest quality studies to back up their choice, but they were confident that their treatments were as safe and effective as Lucentis and fiscally more responsible.
It was clear that a head-to-head Avastin vs. Lucentis study was needed. The National Eye Institute (NEI) of the National Institutes of Health decided to sponsor such a study, titled: “Comparison of Age-Related Macular Degeneration Treatments Trials” (CATT). The coordination of all the government agencies responsible for overseeing and paying for the study proved daunting. Putting the regulatory and financial puzzle pieces together delayed the start of the study for over a year. The leadership of the study expressed their frustration negotiating the political minefield in an editorial. It makes for interesting reading.
And the winner isn’t…
The one and two year results of the CATT study were published in 2011 and 2012, respectively. The overall conclusion was that, for all practical purposes, Avastin and Lucentis were equally effective. But, there was a catch; there were an increased number of adverse events in the group treated with Avastin.
When given intravenously in cancer studies, VEGF-blocking drugs cause hypertension, and increase the risk of thromboembolic events (strokes and heart attacks). The small doses given in the eye were felt to be at low risk. However, after intravitreal injection, the systemic exposure to Avastin is slightly higher than Lucentis, theoretically imparting a greater risk of thromboembolic events. It turned out there were no differences between the drugs for mortality or thromboembolic events. The excess adverse events in the Avastin group did not follow an easily identifiable pattern. The meaning of these safety data are the subject of much debate and further investigation.
A new kid on the block
Even before the final Avastin vs. Lucentis data were announced, the world became more interesting and more complicated. A new drug, aflibercept, was approved by the FDA to treat macular degeneration in November 2011. This was brought to market by another biotech company, Regeneron. The drug is sold as “Eylea”. In the pivotal phase 3 trials, Eylea was compared to Lucentis. For the first 3 months, Eylea was dosed every month, just like Lucentis. After the third dose Eylea was given every other month. With this reduced dosing schedule, patients treated with Eylea did just as well as patients treated with monthly Lucentis.
The price-tag for Eylea: $1850/dose, less expensive per dose than Lucentis, potentially with fewer doses. Even with the reduced dosing schedule it is still far more expensive than Avastin.
Epilogue
The availability of anti-VEGF drugs for exudative macular degeneration has completely transformed the expectations of patients with wet ARMD. Patients who have developed wet macular degeneration within the past 8 years are much more likely to be able to read, drive, knit, paint, watch TV, golf, write a check, and recognize their grandchildren, than those who preceded them.
But that is not the end of the story. These drugs are also proving effective for the treatment of a growing list of eye diseases including one of the greatest scourges to good vision: diabetic retinopathy. Stay tuned.

Macular Degeneration, Genes, and Grandma’s Vitamins: To test or not to test?
Is genetic testing necessary to optimize treatment for patients with a potentially blinding eye disease? The stakes are high and the answer depends on which of the two feuding, financially-conflicted groups you believe. In the end, the best evidence wins!
David Weinberg on March 30, 2018
Link

A study published in 2001 reported the finding that antioxidants and zinc supplements slow the progression of age-related macular degeneration (AMD). Based on this study, eyecare providers routinely recommend these supplements to patients with AMD. Since then we have learned a great deal about the genetics of macular degeneration. Genes play a major role in the risk of developing AMD and in the progression of AMD. Numerous genes have been identified.
A group of investigator has published research promoting the assertion that the standard combination of antioxidants and zinc may result in sub-optimal outcomes for AMD patients with specific genetic fingerprints. If their assertions are true, genetic testing would be necessary to ensure that patients are receiving the optimal combination of supplements. A second group of investigators has performed their own analyses, criticized the methods of the first group, and vociferously challenged their recommendations. This debate has become quite contentious, and played out in numerous articles, counter articles, and letters to editors.
This debate has tremendous public health implications. The prevalence of AMD is so high that even small incremental changes in outcome affects the lives of millions of patients. It is also in interesting case study in critical analysis of conflicting opinions. In this post I will drill into the arguments on both sides and try to find the best answer based on the available data.
Background: What is age-related macular degeneration?

The retina lines the inner wall of the eye like wallpaper, and functions like the film in a camera. The cornea and lens, in the front of the eye, focus light on the retina. The retina send information to the brain via the optic nerve. The brain interprets the signals from the retina as vision. The macula is the anatomic and physiologic center of the retina. It is, quite literally, the center of your visual world. It is responsible for the sharpest, most detailed vision and needs to be healthy for reading and other detailed visual tasks.
ARMD occurs in two forms, or stages, referred to as “dry” and “wet”. Most patients have the dry type. In the early stages, patients may have no symptoms. Over time, there is often slow anatomic and functional deterioration of the macula. Patients may experience a variety of symptoms including, blurriness, loss of contrast sensitivity, distortion, and blind spots in or near the center of their vision, but the progression tends to be quite gradual, over many years.
Wet (or exudative) disease is the most feared form of ARMD. Only a minority of patients develop wet ARMD, but those that do often experience a rapid, catastrophic loss of vision over a period of weeks or months.
Chances are you know someone with AMD. If so, it is likely that an eye-care professional has recommended they take nutritional supplements to slow the progression of the condition. If you are a regular reader of SBM, you know that aside from overt nutritional deficiencies, vitamin supplements have generally exhibited no health benefits. AMD may be an exception.
AMD is a serious public health concern, with a substantial global burden. The prevalence is estimated to be 8.69% among older adults; substantially higher among those of European descent. By the year 2020 it is estimated that globally nearly 200 million individuals will have macular degeneration, increasing to 288 million by 2040.

Recent advances have led to effective pharmacotherapy for exudative AMD. Although highly effective, this form of treatment is expensive, inconvenient, and uncomfortable for the patient. Patients with AMD live in fear of loss of vision and resulting loss of independence. Sadly, the fears become reality for many. The fear of vision loss prompts some patients to seek dubious and dangerous treatments. The American Academy of Ophthalmology has more information on AMD.
Nutritional supplements and macular degeneration: the AREDS Studies
In 1991, the Age-Related Eye Disorders Study Group (AREDS) reported a randomized, placebo-controlled clinical trial demonstrating that patients with age-related macular degeneration derived benefit from taking a combination of antioxidants and zinc. Compared to placebo controls, patients taking the antioxidants and zinc were less likely to progress to advanced stages of AMD. A second study, AREDS 2, published in 2013 resulted in some modification of composition of the antioxidants recommended for patients with macular degeneration. These two studies have become canon in the ophthalmologic literature, and inform clinicians’ recommendation for their patients with macular degeneration.
Genetics and macular degeneration
Macular degeneration is a disease influenced by a complex interaction of genetic and environmental factors. Twenty or more genes have been identified that influence the incidence and progression of macular degeneration, but two seem to be the most influential: Complement Factor H (CFH) and the Age-Related Maculopathy Susceptibility 2 Gene (ARMS2). The expression of these genes interacts with each other and with behavior/environmental factors such as age, smoking, diet, and BMI.
Everyone receives one copy (or allele in gene-speak) of the CFH gene from their mother and one from their father. Similarly they receive one allele each of the AMRS2 gene from their mother and father. Each allele may be the normal variant or may be a variant conferring additional risk of AMD. Each individual carries 0, 1, or 2 “risk alleles” for the CFH gene and 0, 1, or 2 risk alleles for ARMS2.
Pharmacogenomics and macular degeneration
Pharmacogenomics is the study of how genes influence an individual’s response to drugs. Pharmacogenomics is part of a movement branded as personalized medicine, or precision medicine, with the promise of being able to customized therapies based on the unique characteristics of each individual patient. In some fields of medicine, such as oncology, pharmacogenetics is increasingly important is making therapeutic decision. Based on the known genetic influences on macular degeneration, it is entirely plausible that a patient’s genetic profile might influence their response to treatment, including nutritional supplements. A group of researchers set out to test this hypothesis, and published a provocative and potential very disruptive study (Awh et al 2013).
The debate begins: Genotype influences response to AREDS supplements
The AREDS study was a publicly (National Institutes of Health) funded study. A subset of patients for the study had blood drawn and banked for future research. The study data, and the material from the genetic bank, were made available to independent researchers. Awh and collaborators obtained specimens and performed genetic analysis on a subset of 989 patients from the original AREDS study.
Awh’s analysis suggested that various combinations of CHF and ARMS2 risk factors influence response to supplements, to that extent that patients with certain genotypes may be harmed by the nutritional supplements recommended based on the AREDS studies. The authors of the paper recommended individual genetic testing of patients with macular degeneration to inform supplement recommendations.
The debate continues: Genotype does NOT influence response to AREDS supplements
The leadership of the AREDS study was quick to respond. A response article by Chew et al. attempted to discredit the Awh et al. study and presented a contrary analysis. Since the publication of that response, there has been a fierce controversy, played out in the literature, with articles, counter-articles, letters to the editor, and various editorials.
Yes it does!
Awh et al. published another article providing additional analysis on their first article. One of the criticisms of their first paper was lack or statistical significance for differing responses among the 9 genotypes. This time they sorted the 9 genotypes into 4 categories, and now were able to show statistically significant outcomes that differed from the original AREDS study results. They doubled down on their recommendation of individual patient genotyping to guide nutritional supplement advice.
Does not!
Chew et al. replied with a new analysis. They performed genetic analysis on an additional 526 patients from the AREDS study. The recreated the categories used by Awh et al., and found that this new group did not behave at all like Awh’s larger group. The group analyzed by Chew et al did not replicate the results of Awh, et al. Chew’s patients looked much more like the overall AREDS study population.
And so on…
The two camps continued to argue their interpretations of the data in letters and response letters to the editor and at high profile meetings.
Agree to disagree? Let’s look at the evidence
Here we have 2 groups. Each group has done its own analyses and reviewed the analyses of the other. Based on exactly the same information they have come to opposing conclusions. The Awh group feels they have convincingly demonstrated that genotype is necessary to make optimal supplement choices for patients with AMD. Chew and colleagues assert that the data are not sufficient to override the recommendations of the AREDS studies. How could this have happened? How could two groups of scientists reach such disparate conclusions based on the same data? Who is right?
Conflicts of interest
Conflicts of interest are common in research, and do not necessarily connote any impropriety in the conduct or interpretation of a study. Journals generally have strict rules about the disclosure of potential conflicts of interest for papers they publish. It is worth noting these disclosures when critically reviewing research. The first paper by Awh et al. has 5 authors. Awh, the first author discloses he is a consultant, member of the Scientific Advisory Board, equity owner, and patent holder for a company called ArcticDx. Another author is listed as consultant to ArcticDx, another is employee, equity owner, and holds patents for ArcticDx, and another is consultant and member of the Scientific Advisory Board for ArcticDx.
ArcticDx is introduced thusly on its website:
Welcome to ArcticDx Inc., a molecular diagnostic company with a focus on commercializing genetic discoveries in human healthcare. The company has a High-Complexity Genetic Testing Laboratory in Grand Rapids, Michigan. Arctic Medical Laboratories is CLIA and CAP certified and provides laboratory services to doctors nationally and internationally.
Among the genetic tests offered by ArcticDx are two relevant to AMD. MaculaRisk is a genetic test aimed at predicting the risk of progression for patients with AMD. And then there is VitaRisk:
Vita Risk is a pharmacogenetic test designed to aid in the selection of appropriate eye supplement formulations for a patient diagnosed with intermediate Dry Age-related Macular Degeneration.
The conflict of interest is clear. Part of ArticDx’s business depends on selling a genetic test. The rationale for the test is the assertion that different genotypes need different permutations of nutritional supplements.
The counter-analysis written by Chew et al had nine authors. Three of the authors reported patent royalties (of uncertain relevance) via the university for whom they work. One of these three also disclosed that they had provided consultancy services to a pharmaceutical company (with no obvious relevance to the issues under consideration). Another author reported patent royalties for AMD testing through a different university. The study was supported by the National Institutes of Health (NIH). It was disclosed that:
The NIH holds a royalty-bearing license issued to Bausch & Lomb for the Age-Related Eye Disease Study Supplement.
In other words, the NIH collects royalties from the company that markets and sells supplements recommended by the AREDS studies. If fewer patients receive the AREDS-recommended supplement combination, the NIH could lose revenue generated by their royalty agreement with Bausch and Lomb. None of the authors would profit directly from this arrangement, but two of the authors, including the first author (Dr. Chew), are employees of the National Eye Institute of the NIH.
Dr Ferris reported holding a patent for the Age-Related Eye Disease Study (AREDS) formulation with Bausch & Lomb.
Although not an author in any of Chew’s studies referenced so far, Frederick Ferris III, MD is a high-ranking official at the National Eye Institute, and Dr. Chew’s supervisor. He was integrally involved in the AREDS studies and has personally received royalties from Bausch & Lomb. His conflict of interest is disclosed on relevant AREDS publications on which he is an author.
A summary of the various financial conflicts is summarized in this article, which also hints at the animosity between the individuals on the two sides of the debate.
Conflicts of interest may raise red flags, but in the end, research findings stand or fall based on their own merits. In the next section I will take a deeper dive into the research methods for the various studies relevant to this debate.
More about AREDS
The strongest evidence of benefit of nutritional supplements for AMD came from the Age-Related Eye Disorders Studies (AREDS). The results of AREDS were surprising but generally persuasive. The first AREDS study was a multi-center randomized, placebo-controlled clinical trial. There were four treatment groups. Group 1 received antioxidants (Vitamin C, Vitamin E, and ß-carotene). Group 2 received zinc. Group 3 received antioxidants and zinc. Group 4 received neither antioxidants nor zinc. Each group received placebo versions of the supplements they were not assigned.
At baseline, patient fundus photos were graded and assigned a category of macular degeneration (a measure of severity). The endpoint was development of “advanced AMD.” For patients entering with category 3 or worse macular degeneration, the group assigned to antioxidants and the group assigned to zinc both had results numerically better than placebo. The group receiving antioxidants AND zinc did the best, surpassing the placebo group by a statistically significant margin.
In the chart below, each line represents the proportion of patients in a treatment group who progressed to a more advanced stage of macular degeneration at consecutive points in time. A shallower slope in the line means that patients in that group progressed at a slower rate, and therefore represents a more favorable outcome. Note that patients in the antioxidants plus zinc group had slowest rate of progression to advanced AND, therefore the best outcome among the treatment groups.

The AREDS 2 study had a very complicated design, but when the dust settled, the only change to the AREDS recommendation was the substitution of lutein and zeaxanthin for ß-carotene. This was largely due to a known increase in the risk of lung cancer among smokers and former smokers taking ß-carotene.
The AREDS studies are not without their critics (possibly a subject for another SBM post), but the results have been widely accepted among eyecare professionals. Recommendation of AREDS-based nutritional supplement of antioxidants plus zinc has become standard of care for patients with AMD.
The case for genetic testing
Awh round 1
In their first paper, Awh and colleagues performed a genetic analysis on a subgroup of 989 patients from the first AREDS study and segregated them by genotype for CHF and ARMS2. This produced nine distinct genotypes. The analyzed a variety of interactions between genotype, AMD progression, and response to dietary supplements. The main conclusions of the paper arise from the figure and table below. The patients are sorted into groups based on the number of risk alleles for CHF (columns) and ARMS2 (rows).


Based on these data the authors concluded:
In this analysis, patients with no CFH risk alleles and with 1 or 2 ARMS2 risk alleles derived maximum benefit from zinc-only supplementation. Patients with one or two CFH risk alleles and no ARMS2 risk alleles derived maximum benefit from antioxidant-only supplementation; treatment with zinc was associated with increased progression to advanced AMD. These recommendations could lead to improved outcomes through genotype-directed therapy.
Criticisms of study
Awh and coauthors did an unplanned subgroup analysis on a non-random sample of patients in the AREDS study. They further subdivided this sample into smaller groups based on genotype. These reasons limit the authority of these data for making therapeutic recommendations. It can be useful to perform analyses like this as a means of generating hypotheses to be confirmed or rejected based on additional research.
By dividing 989 patients into 9 genotype groups, they create small sample sizes. The genotype groups had as few as 10 patients. 5 of the 9 groups had fewer than 70 patients. The patients in each of these groups had been randomized among four treatment groups, creating even smaller samples. When slicing and dicing patients into this many small groups, one is almost certain to find that some groups deviate from the pattern of the original population. These variations could be due to true differences, but could be due to chance alone. Note that in the table above they list the “best Age-Related Eye Disease Study Treatment.” The “best treatment” conclusions are based on observation of trends but no statistical justification is reported. The numerous subgroups and lack of any statistical analysis render these data uninterpretable for making clinical decisions.
Awh round 2
In response to criticisms of the first paper, they published a second. This one introduced some additional analyses of the same data. They sorted the 9 genotypes into 4 groups. I have taken the liberty of annotating the figure from the first paper to show how they have sorted the genotype groups for the second paper. The authors describe these as “natural genotype groupings.”

Analyzing for outcomes for each of the 4 genotype groups,


The authors conclude:
The benefit of theAREDS formulation seems the result of a favorable response by patients in only 1 genotype group, balanced by neutral or unfavorable responses in 3 genotype groups.
Based this conclusion they doubled down on the recommendation of customizing nutritional supplements based on individual patient genotype for ARMS2 and CFH.
Criticisms of the study
This remains an unplanned analysis of a nonrandom sample of patients from a larger clinical trial. This sample was further subdivided into genotypes. All these factors justify caution in generalizing these data. However, by sorting nine genotypes into four categories, they have generated large enough sample sizes to squeeze out some results that appear to be statistically significant. Are these analyses valid? Are the conclusions justified?
Chew and co-authors clearly do not think so. They published an analysis of a new data set and critique of the Awh study. They performed genetic analysis on a sample of 526 unique patients from the original AREDS study (referred to as the “residual cohort” in the paper and in the figure below). Although their sample size was smaller, they argued that if Awh’s findings were real, an independent sample from the same study population should exhibit similar trends, and if they did, it would serve as validation of Ahw’s analysis. In fact, when grouped and analyzed in the same way, Chew’s outcomes were much different than Awh’s, and were much more reminiscent of the results of the original AREDS study. This is clearly displayed in the following figure.
In the figure below, bars rising above the horizontal line indicate that the treatment group did better than placebo, whereas bars below the horizontal line indicate the group did worse than placebo. The height of each bar reflects the magnitude of the difference from the placebo group. The analysis on the left side of each box depicts Awh’s data and the analysis on the right side of each box depicts Chew’s analysis.

Note that in genotype group 1, Awh’s analysis showed that the patients receiving antioxidants had the best outcomes (in contrast to the AREDS 1 study). In Chew’s analysis (residual cohort), patients randomized to antioxidants plus zinc had the best outcomes, just as they did in the AREDS study. In Genotype group 2, Awh showed that patients receiving any supplements did worse than placebo. This could be a serious concern, but Chew showed that patients receiving antioxidants, or antioxidants plus zinc did better than placebo, as in the original AREDS study. In Chew’s analysis, contrary to Awh, no genotype group was disadvantaged by being randomized to what became the AREDS-recommended formula of antioxidants plus zinc. Chew and coauthors proclaimed:
One should not deprive patients of a therapy that has been proven to have significant public health impact on the basis of a statistically flawed, not replicated retrospective analysis of existing data.
Who is right?…Experts weigh in
I have looked the data and the arguments of both sides, and I agree with Chew and coauthors. Awh’s findings are provocative but not persuasive. Various experts and professional organizations have communicated the same sentiment via editorials and letters to the editor. This includes a leading biostatistician and epidemiologist, a prominent ophthalmic geneticist, and a genetics task-force from the largest organization of American retina specialists. Clearly, the consensus of expert opinion does not accept Awh’s recommendation for genotyping of patients to inform selection of supplements for macular degeneration.
But Awh’s results were statistically significant!
In Awh’s first paper he and coauthors took a non-random sample from the study and further subdivided into nine genotypes. The data looked provocative, but not backed up with statistical analysis. In Awh’s second paper, he sorted the nine genotypes into four categories (genotype groups), and was able to generate some statistically significant analyses to reinforce the conclusions from their first paper. This is problematic for a couple of reasons. First of all, this remains an unplanned retrospective analysis of a non-random subgroup from a much larger study. This raises many cautionary flags. In the next step they reassembled the nine genotypes into larger “genotype groups.” It is important to note that the composition of these groups was defined after they had seen the data for each genotype. This is an enormous red flag. Why is this important? Imagine you have 20 cards to sort into four poker hands. You have the flexibility to sort any card into any hand. If the cards are face down, every hand would have an equal probability of being the winner and you would not know the outcome of the game until you turned the cards over. If you begin with the cards face-up and you were so-motivated, you could control the position of the winning hand every time.
Look again at this figure showing the way Awh et al. sorted genotype groups for their analysis.

The sorted nine groups into four categories. Category 2 contains only one genotype group. Categories 1 and 4 have two genotype groups each. Category 3 has four genotype groups. There are hundreds of ways nine items can be sorted into a distribution of 1:2:2:4. But it is more complicated than that. They could have sorted into categories of 1:2:3:3, or 2:2:2:3, etc, each with hundreds of permutations. Why not three categories…3:3:3, 2:3:4? There are literally thousands of ways they could have sorted the nine genotypes into genotype groups. If the investigators had a pre-specified hypothesis that sorting the genotypes in one particular way would yield a particular outcome, then confirmed that outcome with data, their conclusions would have much more credibility.
Even with random data, if you split the data into small groups then, with full knowledge of the data, creatively sort these into larger categories, one can often (if so motivated) “find” a pattern. This is somewhat analogous to gerrymandering in the drawing of voting districts. In a rare (and refreshing) display of academic snark, Chew et al. demonstrated this point. They “proved” that patients born under the signs Cancer or Aries had negative outcomes in the Awh cohort, but good outcomes in the Chew cohort.
However, despite the methodological weaknesses and the expert consensus against Awh’s recommendations, some have been persuaded by them.
A fresh look at stale data!
Awh et al. and Chew et al. voluntarily submitted their data to be distributed to three prestigious groups of academic statisticians (the identities of the statistics teams were disclosed in the publication, but not to Awh et al. or Chew et al. at the time of analysis). The teams worked independently and used different methods to explore the data from the two groups. After performing their analyses, the groups collaborated to write a report (currently “in press” but available online). Remember these statisticians were not just critiquing the analyses of the two feuding groups, they were performing independent analysis of the actual data provided to them by the two groups of investigators. The results could hardly be less ambiguous and is thusly summarized in the abstract of the paper:
We found errors in the data used to support the initial claim of genotype–treatment interaction. Although we found evidence that high-risk patients had more to gain from treatment, we were unable to replicate any genotype–treatment interactions after adjusting for multiple testing. We tested 1 genotype claim on an independent set of data, with negative results. Even if we assumed that interactions in fact did exist, we did not find evidence to support the claim that supplementation leads to a large increase in the risk of advanced AMD in some genotype subgroups.
They concluded:
Patients who meet criteria for supplements to prevent AMD progression should be offered zinc and antioxidants without consideration of genotype.
Case closed!(for now)
The evidence for pharmacogenomic selection of supplements for patients with AMD failed to persuade experts in the field and more importantly failed statistical validation by independent expert statistical teams. In this author’s opinion this debate should be considered settled, unless more persuasive data emerges.

Mast Cell Activation Disorder – Yes, It’s Real
Mast Cell Activation Disorder is real, but there are a large number of fake diagnoses out there. How do you tell the difference?
Steven Novella on May 31, 2017
Link

I have been asked several times about Mast Cell Activation Disorder (MCAD) by people who think there are red flags that maybe this is a made-up disorder. As I will review below, it is a legitimate and interesting disorder. What is more interesting, from an SBM perspective, is why people would question the diagnosis.
It appears to be a situation of, the quack who cried fake diagnosis. The educated and skeptical public cannot trust apparent experts when they say that a diagnosis is real because there are so many fake diagnoses (and fake experts) out there. This results in real disorders by real experts being doubted because the diagnosis is complex and may share some superficial features with ones that are not real.
Here’s a quick guide to help at least know when to be suspicious of a claimed diagnosis.
Not all diagnoses are created equal
It is first important to understand that medical scientists use different kinds of labels to designate clinical entities. Not everything that is a diagnosis has the same status. The most solid clinical labels refer to pathophysiological diseases. These are clear diseases in which a specific anatomical, infectious or functional pathology has been identified. If you have Type I diabetes, your pancreatic islet cells have been damaged, probably by inflammation, and can no longer produce insulin. Insulin, in turn, has specific effects in the body, mainly transporting glucose into cells so it can be used for energy. A lack of insulin therefore causes increased blood sugar levels while cells are starved for sugar.
Pathophysiological diseases have specific causes and specific effects. They can also generally be diagnosed with objective laboratory tests, and often have specific clinical signs. Our knowledge of specific diseases varies, and some are more heterogeneous than others, but there is no doubt that they are real diseases.
There is also a more fuzzy category of diagnoses, which we may refer to as disorders. The main difference between a disease and a disorder is that we do not understand the pathophysiology. There may not be one specific cause, and therefore there may not be any clear objective test to make the diagnosis. Migraine is a perfect example – there is no doubt it is a real phenomenon, but there is no objective laboratory test to establish it. There is also no one cause for migraine, and the presentation is variable with several subtypes.
Disorders like migraine are usually diagnosed clinically – if you have enough symptoms then you meet the diagnostic criteria. Without clear pathological findings, however, we need to be really careful when establishing such a disorder. Are the symptoms specific or vague? Are there plausible mechanisms? Does the diagnosis predict anything about prognosis or response to treatment?
The third category of diagnostic labels is syndromes. (The term “syndrome” can also refer to a suite of effects from a specific genetic mutation, but that is a different use of the term.) A syndrome is a constellation of symptoms and features that tend to occur together. We don’t even know yet if it is real, if it is one or more disorders, and what the pathophysiology might be. Often such clinical syndromes are just placeholders so that scientists have a common language while researching possible causes and treatments.
We need to be able to discuss and explore syndromes, disorders, and diseases to do research and to treat patients in the absence of definitive knowledge. Problems arise from confusing the different categories – treating a syndrome as if it is a disease, or denying a disorder because we don’t understand the pathophysiology.
Examples along the spectrum
The differences between these categories is perhaps best explained by examples. I have already given diabetes mellitus and migraines as an example of a disease and a disorder respectively. Here are some other common and often controversial diagnoses so we can see where they fit along this spectrum.
Chronic Lyme disease is claimed by some to be a pathophysiological disease, but that designation is premature and probably wrong. The claim is that some people can have a chronic infection with the Lyme spirochete that is reduced by antibiotic treatment but not eliminated. The notion of a chronic infection that cannot be eradicated is plausible, there is just no evidence to support chronic Lyme disease specifically as real. Alleged sufferers do not have any specific signs or symptoms, but rather any of a long list of non-specific symptoms (fatigue, fogginess, achiness, etc.). The diagnosis is largely based on special pleading – atypical clinical syndrome with seronegative tests and an atypical response to treatment. It is essentially Lyme disease without the Lyme disease. The label also doesn’t predict anything, including response to treatment.
Fibromyalgia is a good example of an alleged disorder that is more commonly accepted within mainstream medicine but is also dubious. It is supposed to be a disorder of chronic myofascial pain without a specific identifiable cause. I think fibromyalgia is fine as a placeholder syndrome label. There are patients with chronic myofascial pain without a known cause, and it’s reasonable to give them a syndrome label while we try to sort out what’s going on. The problem is that the label is often used as if it is an established disorder or even disease.
When the diagnostic label was first created it included the criteria that there would be specific trigger points that were especially painful. However, clinicians mostly ignored the trigger points and used the diagnosis as a garbage pail for anyone with unexplained chronic achy pain. So eventually they just dropped the trigger point criterion, now it is officially a garbage pail diagnosis.
Again – such labels are useful, such as “fever of unknown origin” or even “chronic fatigue syndrome” as long as it is understood we are just describing the presentation without making any claims to a specific disease or disorder. Patients with fibromyalgia do not have a specific disease. They have a symptom that needs to be further diagnosed if possible.
Mast cell activation disorder
MCAD, as I stated above, is an actual pathophysiological disease. It is caused by various mutations that alter mast cell function. Mast cells are part of the immune system. They release histamine and other immune mediators. MCAD is often associated with specific skin lesions, which provide a diagnostic sign. It is also possible to measure histamine levels or in some cases identify known mutations.
The reason MCAD may be confused with a dubious diagnosis is that it is very heterogeneous. This is because mast cells exist in every organ in the body and therefore MCAD can have a long list of possible symptoms, depending on the organs involved. In this way it is like lupus, which is a chronic auto-immune disease that can affect any tissue in the body. Also, mast cells release hundreds of immune mediators, and only a small number of them can be measured with commercial lab tests. Further, there are many possible mutations that have not yet been identified.
So it is possible to have MCAD with negative laboratory testing. Still the diagnosis would be based upon some specific findings and does predict response to treatment with antihistamines and mast cell membrane stabilizing drugs.
Exploitation
The whole notion of varying diagnostic labels and our knowledge of specific diseases and disorders is extremely complex, as you might imagine. Unfortunately this means that the situation is ripe for exploitation by charlatans and dubious practitioners. It is easy to make a fake disorder out of non-specific symptoms, and explain away the absence of definitive diagnostic testing, and then prescribe some placebo treatment. When careful scientific testing demonstrates that the alleged syndrome is not real, the charlatans just claim there is a conspiracy, that their suffering patients are being ignored, that mainstream medicine is too closed-minded and in the thrall of the convenient villain of the day. That villain can vary as needed, from Big Pharma, to the insurance industry, to a specific specialty protecting their turf.
The harm from this is extensive. Patients given fake diagnoses are often then given fake, worthless, or even harmful treatments, often at great expense. They are also kept from pursuing their real underlying diagnosis or more practical treatments.
Further, as we see here, the existence of fake experts and fake diagnoses creates a lot of confusion in the general public. They don’t know what to trust and whom to believe. That, I think, is partly the point – to destroy the very nature of expertise. Without legitimate experts, then anything goes. Your snake oil is as legitimate as the best science-based medicine.

Pegcetacoplan, a new treatment for macular degeneration
FDA approves a new treatment for macular degeneration: the good, the bad, and the disappointing.
David Weinberg on June 6, 2023
Link

In February 2023, the US Food and Drug Administration (FDA) approved a new drug for the treatment of age-related macular degeneration (ARMD). The drug, pegcetacoplan (commercial name Syfovre™), is produced by Appelis Pharmaceuticals. This is the first drug approved for treatment of dry macular degeneration. Among eyecare specialists, enthusiasm around this event has been mixed.
There is uncertainty about which patients should be treated with this new drug, and who will benefit. The context is analogous to a pair of drugs recently approved for Alzheimer’s disease. Aducanumab (Aduhelm) was FDA approved for treatment of Alzheimer’s disease. The clinical trials were initially ceased due to futility. Despite a “no” vote by a panel of experts the FDA granted approval based on post hoc analyses of a biomarker (reduction of amyloid beta plaque) without demonstrating a benefit in any clinical measure. The approval of this drug was controversial and discussed in more detail by Scott Gavura and Steven Novella.
Lecanumab (Leqembi) was also approved for Alzheimer’s disease. Compared to placebo, the drug slowed progression of dementia, but there were safety concerns and per Steven Novella, the slowing of the clinical course over the 18 months of the clinical trial were “modest.”
In terms of persuasiveness, the clinical trial data for pegcetacoplan for age-related macular degeneration fell somewhere between the 2 drugs for Alzheimer’s disease. Pegcetacoplan met its primary study endpoint and clearly modified the progression of ARMD, but like aducanumab, did not demonstrate a benefit in any measure of visual function. Like lecanumib, there are safety concerns.
About Macular Degeneration
In a previous SBM article I gave a background explanation of ARMD, with a focus on wet (or exudative) ARMD
Dry ARMD is the most common form, and patients with dry ARMD live in fear of developing the more rapidly progressive wet (or exudative) form. Wet AMRD is not the dismal relentlessly progressive disease it once was. I previously wrote about new treatments that have revolutionized and dramatically improved outcomes among patients with wet ARMD. These treatments are inconvenient because they require repeated injections of medication into the eye, but they are quite effective in stabilizing or improving vision. Since that article appeared on SBM two new drugs have been approved by the FDA for treatment of wet ARMD.
The vast majority of patients have dry ARMD. Dry ARMD tends to progress much more slowly than the wet variant, but is a threat to vision, nonetheless. There is a gradual deterioration of the structure and function of tissues in the macula. Among patients with dry ARMD those that develop a variant called geographic atrophy suffer the greatest loss of vision. In geographic atrophy, regions of the macula undergo profound loss of structure and function. These atrophic regions correspond to blind spots (scotomas) in vision. The zones of geographic atrophy enlarge over time. Because the blind spots are in or near the center, they are highly consequential in visual function.
Intravitreal injection
The route of drug delivery for the most effective treatment of wet ARMD is by intravitreal injection. This is a procedure performed in the office under local anesthesia. A small needle is inserted through the white part of the eye, into the vitreous. A small volume of drug is injected. It is tolerated surprising well by patients, and has a low rate of serious adverse effects. Pegcetacoplan for treatment of dry ARMD is delivered in the same way.
A video depicting intravitreal injection is linked here (not for the squeamish).
Pegcetacoplan: the good
Pegcetacoplan is a complement inhibitor. Complement is part of the immune system and the complement pathways are known to be involved in the pathophysiology of macular degeneration. The design of the pegcetacoplan clinical trials targeted geographic atrophy.
Patients entering the phase 3 trials had geographic atrophy at study entry. They were randomized to receive: pegcetacoplan every month, pegcetacoplan every other month, or sham treatment.
Through 24 months pegcetacoplan at both dosing frequencies decreased the growth of the geographic atrophy compared to sham treatment. This has rightly been hailed as a major victory…the first first drug definitively demonstrated to slow the progression of dry ARMD. The FDA looked favorably on these results and approved pegcetacoplan injection (commercial name Syfovre™) to be sold for treatment of geographic atrophy.
Pegcetacoplan: the bad
Wet macular degeneration is the rare, but most feared form of AMRD. Anti-VEGF drugs, delivered by intravitreal injection have revolutionized treatment of wet ARMD, but these treatments are inconvenient, uncomfortable, and expensive. Compared to sham-treatment, eyes treated with pegcetacoplan every other month were roughly twice as likely to develop wet ARMD. Eyes treated monthly were roughly four times more likely to convert. This is a serious disadvantage. Prior to the availability of effective treatment for wet ARMD this would have been an intolerable adverse effect. It is still highly undesirable. We are trading the hope of decreasing the risk of vision loss from geographic atrophy with increasing the risk of another vision threatening form of macular degeneration, wet ARMD.
If a patient develops wet ARMD while treated with pegcetacoplan, they can continue intravitreal injections with pegcetacoplan every 1-2 months, but they must also begin treatment with an intravitreal anti-VEGF drug, usually initiated with monthly intravitreal injections, and sometimes requiring monthly treatment for life.
Pegcetacoplan: the unfortunate
The results of the phase 3 clinical trials leading to FDA approval of pegcetacoplan for macular degeneration are not yet available in a peer-reviewed article. It is always uncomfortable to advise patients on a new treatment with incomplete information. Information is limited that which has been presented at meetings, and in press releases. In addition to the increased risk of exudative ARMD there are more disappointing features.
In a large clinical trial like this, the sponsor identifies a primary endpoint. This is the measurement on which success or failure is defined. The endpoint for pegcetacoplan clinical trials was an anatomic one: change in size of geographic atrophy (GA). From a study design perspective, GA size is a nice variable. GA is easy to measure using standardized imaging techniques. Changes are relatively easy to quantify. Measurements can easily be blinded to patient treatment assignment and managed at a centralized reading center. Pegcetacoplan at both dosing intervals decreased the rate of growth of GA compared to sham treatment.
Patients are less interested in anatomic endpoints and more interested in outcomes reflecting visual function: how will this treatment affect/protect my vision? Measures of visual function would be things like visual acuity, field of vision, contrast sensitivity, reading speed, etc.
None of the visual functional endpoints reported by the sponsor, so far, have shown a significant benefit for the drug vs sham treatment. In addition there are always secondary endpoints in the analysis plan. It is safe to infer that no secondary endpoints measuring a functional visual outcome achieved statistical significance. If they had, those particular result would have been highlighted in the current reports. Given a clinical trial of this size (over 1258 patients) and duration (2 years) the inability to demonstrate a tangible benefit to patients is disappointing.
The Buzz
I understand why the FDA approved this drug. It achieved its primary efficacy endpoint. It is the first entry addressing a major unmet medical need.
The press reports accompanying the approval of this drug has included many breathless endorsements declaring a “breakthrough” and providing “hope” to patients.
Despite the enthusiastic hype there have been some skeptical voices. These have mostly been confined to peer-to-peer conversations and QA sessions at meetings, but few have made their way into print.
Demetrios Vavvas, MD, PhD Professor of Ophthalmology at the Harvard School of Medicine stated he will not be offering the drug to any patient:
“So if a patient comes in and asks you, ‘Will I see any benefit?’ the answer is no. There is no improvement in any symptoms or quality of life or any functional index that was tested.”
The Bottom Line
This was an important and path-breaking study. It provided proof of principle that pharmacologic intervention could influence the progression of a blinding form of dry macular degeneration, It validated the complement pathway as a target for intervention. There are numerous other drugs in the pipeline.
But, does this particular drug, as administered in these clinical trials, provide sufficient benefit to justify the cost, inconvenience, and risk? In my opinion, the available evidence has not answered this most-critical question.
I expect this drug to be heavily marketed to physicians and to potential patients.
Faced with ambiguous data like these, educating patients and providing informed consent is a true challenge. How do I, in the limited time allowed in a clinical encounter, explain a treatment that attenuated the progression of the disease, but did not result in a functional benefit, and…by the way…doubled to quadrupled the risk transformation to a more aggressive (but treatable) form of the disease.
The way I have explained this to patients goes something like this: “…Some of the people received eye injections with the drug and some did not. After 2 years, the pictures looked better in the patients that received the drug, but they did not see any better. They were also more likely to develop an aggressive form of macular degeneration that requires more eye injections“
There are undoubtedly patients who will choose to proceed. For example, if I was a patient that had experienced loss of vision in one eye due to geographic atrophy, I might roll the dice and begin treatment in the other eye.

Pegcetacoplan (Syfovre™) for macular degeneration: an update
SBM’s guest contributor and ophthalmologist, Dr. David Weinberg, provides an update on the phase 3 trials of pegcetacoplan for macular degeneration. The results are still disappointing.
David Weinberg on January 11, 2024
Link

Eighteen years ago the Food and Drug Administration (FDA) approved the first anti-VEGF drug for wet Age Related Macular Degeneration (ARMD); a treatment that transformed wet ARMD from a relentlessly progressive, disabling condition to a manageable one. A major limitation of anti-VEGF medications is that they are relevant for a minority of patients with ARMD. Only about 15% of patients with ARMD develop the wet (or exudative) form. A safe and effective treatment for the more common dry form of ARMD remained an unmet medical need. Last year the FDA approved pegcetacoplan (Syfovre™), Apellis Pharmaceuticals), the first treatment for dry ARMD. Specifically, pegcetacoplan was approved for geographic atrophy, the most destructive variant of dry ARMD. Like the available treatments for exudative macular degeneration, pegcetacoplan is delivered by intravitreal injection. In this article I hope to address the question of whether or not this new treatment satisfies an unmet medical need.
Apellis, the company behind pegcetacoplan, has launched a low-key advertising campaign. You may have seen the ads — the PSA-style TV commercials themed “GA won’t wait” featuring spokesperson Henry Winkler. It is a “raising awareness” infomercial that introduces the abbreviation “GA” as an abbreviation for geographic atrophy. The name of the drug is never mentioned, but viewers are advised to see a doctor if they experience certain symptoms. The address to an informational website is given.
I wrote a previous SBM article entitled: A new treatment for macular degeneration: The Good, The Bad, and The Disappointing. In that article I explained that preliminary reports disclosed an anatomic advantage, but no functional benefit for treated eyes. Treated eyes were also more likely to progress from dry to wet macular degeneration. At that point there was no published report of the phase 3 clinical trials. Since then there have been some emerging safety concerns, as well as publication of the phase 3 data.
The phase 3 studies
The FDA approval of pegcetacoplan was based on a pair of nearly-identical phase 3 clinical trials called OAKS and DERBY. A published report appeared in The Lancet, October 2023, linked here. (Probably behind a paywall for most of you).
In both studies, eyes were randomized to receive intravitreal pegcetacoplan every month, intravitreal pegcetacoplan every other month, or control (sham injection). The success of pegcetacoplan was based on the measurement of geographic atrophy (GA) from specialized retinal photographs. The primary endpoint was the growth rate of GA in the treated eyes compared to sham-treated for 12 months.
In the OAKS study, both monthly and every-other monthly doses demonstrated statistically-significant benefit for the predefined 12-month endpoint of GA growth. In the DERBY study, neither dosing regimen achieved a statistically significant benefit vs sham for the same endpoint, but did achieve statistical significance at 24 months (a secondary endpoint). Failure for one of two pivotal trials to achieve a primary endpoint could spell trouble for regulatory approval of a new drug, but the FDA approved pegcetacoplan for GA in February 2023.
Further Details
The drug did not (and was not expected to) reverse the damage from geographic atrophy. All groups progressed, but based on specialized photographs, treated eyes progressed more slowly. After one year a reduced growth rate of GA (the primary outcome measure) was demonstrated in one of the two phase 3 studies and after two years in both studies. This anatomic endpoint can demonstrate that the drug is having a biologic effect on relevant tissues, but it does not prove that patients are benefiting in any meaningful way. Patients care about functional endpoints: Will treatment result in better vision compared to no treatment?
In order to test the hypothesis that pegcetacoplan confers a visual advantage, the designers of these clinical trials included multiple functional measures as secondary endpoints. There were five prespecified secondary outcomes intended to measure and compare visual function for treated vs sham eyes. These outcomes were reported for the combined data of the OAKS and DERBY studies. Because there were 5 functional endpoints, each tested for 2 dosing regimens, there were 10 comparisons. None of these revealed a statistically-significant functional advantage for eyes treated with pegcetacoplan. With the power of the combined data from two phase 3 clinical trials and 10 comparisons with sham control, they failed to demonstrate any functional benefit for eyes receiving the experimental treatment. Not a strong endorsement for a meaningful benefit to patients.
We can add 2 additional analyses to the 10 described above. The Lancet paper also reported a pair of post hoc analyses. Post hoc means that an analysis was not planned at the design stage, but created after the data were seen. There may be legitimate reasons for performing post hoc analyses, but the results must be interpreted in context and viewed with appropriate skepticism. Post hoc analyses are ripe fruit for p-hacking. In these analyses, they compared the number of blind spots near the edge of the geographic atrophy at baseline and after 24 months. This analysis was statistically significant for the every-other month dosing, but not for the monthly dosing regimen.
Including the planned and post hoc functional outcomes, there were 12 statistical analyses, and only 1 result meeting the traditional threshold for statistical significance. With 12 analyses, the likelihood of finding at least one false positive would be about 46%, even if the treatment was completely ineffective. Considering that the one positive result was for a post hoc analysis makes it even less persuasive.
Bad news
Eyes receiving the drug experienced some disadvantages. They were 2 to 4 times more likely than sham-treated eyes to progress to wet (exudative) macular degeneration. Wet macular degeneration is the rarer but more rapidly progressive form of ARMD making this a decidedly undesirable side-effect. There were other adverse events over-represented in the treated eyes and patients, including a higher mortality rate.
More bad news
Shortly after the approval of pegcetacoplan The American Society of Retina Specialists began to collect reports of patients whose eyes developed inflammation and retinal vasculitis after pegcetacoplan injection. By mid-July they had received a half dozen reports. By the end of July the number had increased to 21, with some patients suffering severe vision loss in the affected eye.
Known-knowns
Here are things we know: In a pair of large phase 3 clinical trials, eyes treated with pegcetacoplan did not experience any demonstrable functional benefit. The hope is that, given enough time, functional outcomes will catch up with the photographic evidence of efficacy, but this remains speculative.
We also know that in those trials eyes treated with pegcetacoplan were 2 to 4 times more likely to transition to the more rapidly progressive wet ARMD. There were some other less frequent, but equally troubling excess adverse events in the treated subjects. Since the drug was approved, some patients have experienced complications resulting in severe vision loss.
Known-unknowns
For pegcetacoplan there are important unknowns: Will functional benefits be demonstrated in future studies? Why weren’t cases of vasculitis and severe vision loss seen in the clinical trials? How common are these complications in the real world? How likely is random patient to suffer severe vision loss after treatment?
Is pegcetacoplan “safe and effective” for treatment of geographic atrophy
In the judgement of the FDA, pegcetacoplan favorably modifies the progression of geographic atrophy with an acceptable safety profile. This, in turn, allows Apellis to sell the drug for use in patients.
A balance between hypothetical benefits and real risk creates a problematic risk/benefit ratio. The lack of functional benefit and excess adverse events led some colleagues to voice aversion to this new treatment. This point/counterpoint article summarizes the pro and con arguments voiced after the approval of pegcetacoplan. The “con” side of the argument bears the provocative title: “An Exciting Game Changer for Everyone Except the Patient.”
As a clinician, my role is to provide case-by-case advice about the relative safety and efficacy of options available to my patients. For pegcetacoplan, the available data have not provided convincing evidence of a benefit that is meaningful to most patients. On the flip-side, there are harms that are real, but not fully quantified.
In addition to arguments of safety and efficacy are assessments of “value.” The cost of each dose is $2,316 (accessed 12/18/2023) repeated every month or every-other month. Add to this the procedure-related expenses and inconveniences.
Not all regulatory agencies are following the example of the FDA. European regulators are predicted to deny approval of the drug.
There is not a medical need for a treatment that results in better-looking retinal photographs. There is a medical need for a treatments that benefit patients’ vision and quality of life. Until confronted with more-persuasive evidence, I maintain that a treatment with demonstrable safety and efficacy for treatment of dry age-related macular degeneration remains an unmet medical need.

A Bionic Implant to Restore Vision
A new technology may allow patients to recover vision for conditions that were previously thought irreversible
David Weinberg on November 13, 2025
Link
Can a bionic retinal implant paired with high-tech glasses restore sight in patients with age-related macular degeneration? An article in a recent issue of the New England Journal of Medicine described an attempt to do so (the article is behind a paywall for most of you).
The results were encouraging, but preliminary.
Age-Related Macular Degeneration
Age-related macular degeneration (ARMD) is the most common cause of irreversible vision loss in older Americans. Severe vision loss can occur via two main pathways. The wet form of macular degeneration is the result of abnormal blood vessels growing under the retina. This form can progress rapidly. There are now several drugs that, when injected into the eye, can significantly reduce the vision loss in wet ARMD. 
Dry ARMD is the more common form. Among patients with dry ARMD, geographic atrophy (GA) is responsible for the most severe vision loss. I wrote 2 previous articles here and here about Pegcetacoplan (Syfovre), a new treatment for geographic atrophy that, in my opinion, was approved despite lackluster data from the clinical trials. Subsequently, a second drug, avacincaptad pegol (Izervay), has been FDA-approved with similarly dubious clinical trial results.
None of the medical treatments for GA are capable of restoring vision that has already been lost.
About the retina
The retina is the light-sensing tissue of the eye. It lines the inner wall of the eye like wallpaper. The macula is a specialized region of the retina, and corresponds to the “straight-ahead” portion of vision. It contains the highest density of photoreceptors. The macula is selectively damaged by ARMD.
https://www.researchgate.net/figure/Anatomy-of-the-human-retina-The-human-retina-is-located-in-the-back-of-the-eye-and_fig1_388033611 [accessed 28 Oct 2025]. Labels modified for clarity.
The above figure is a simplified “wiring diagram” of the retina. Light enters the eye and traverses the retina from the top of the figure to the bottom. When visible light interacts with the retina, the photoreceptors (rods and cones) are activated. The photoreceptors transduce light energy into electrical signals. The photoreceptors pass the electrical signal on to the bipolar cells, which pass the signal to the ganglion cells. The ganglion cells have long extensions (dendrites) that form the optic nerve and travel all the way back to the brain.
Geographic Atrophy: when things go wrong
In the geographic atrophy form of ARMD, the photoreceptors and retinal pigment epithelial cells in the macula die. This is a progressive condition resulting in blind spot(s) in or near the center of the visual world of the patient. These can greatly impact the ability to perform tasks such as reading, driving, recognizing faces, and navigating through daily activities. Currently available medical treatments for geographic atrophy aim to slow down the growth of geographic atrophy, but are unable to reverse it.
Toward a bionic retina
The device described in the NEJM article is called the Photovoltaic Retina Implant Microarray (PRIMA). “Photovoltaic” refers to the process of converting light into electrical signals. Solar panels are the most prevalent examples of photovoltaic devices. The PRIMA device is surgically implanted under the retina in regions where the photoreceptors are missing. This, in theory, allows the PRIMA device, when exposed to light, to produce and transfer electrical impulses to the bipolar cells, simulating the function of photoreceptors. The bipolar cells then stimulate the ganglion cells, which communicate with the brain via the optic nerve.
Image of eye with geographic atrophy before and after implantation of PRIMA device. The PRIMA has been surgically implanted beneath the retina within the zone of geographic atrophy. From: Holz, F. G. et al. Sub-retinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. N. Engl. J. Med. (2025) doi:10.1056/nejmoa2501396.
The photovoltaic implant is only one link in the system. The patient must also wear high-tech eyeglasses that capture images and convert those images to infrared light. That light is projected onto the implant, which powers the electrical stimulation of the bipolar cells. The signal is passed on to ganglion cells, then to the brain via the optic nerve. Since infrared light activates the PRIMA chip, but not the photoreceptors, the creators of the implant explain, this system allows the patient to use the PRIMA system without interfering with the native vision from healthy portions of the retina. 
From: How a tiny retinal implant is helping people regain their sight
Photo of the glasses paired with the PRIMA implant. Glasses consist of a front-facing camera, a pocket processor, and a rear-facing infrared projector.
The Clinical Trial
The study was a multi-center open-label study without an external control group. The primary endpoint was a “clinically meaningful” improvement in vision at 1 year post-implant compared to baseline. Clinically meaningful was defined by a pre-specified proportion improvement in central visual acuity (measured size of letters that could be read). 
Results
38 participants received the implant and 32 were assessed at 12 months.
The good
81% of the participants evaluated at 12 months met the threshold for clinically meaningful vision improvement. The average improvement in vision was impressive. After one year, participants could read letters about 1/3 the size they could see before the implant.
The bad
The surgical procedure to implant the PRIMA is not trivial. There were 26 serious adverse events, mostly related to the surgery. Most of these resolved spontaneously or were successfully treated. It is likely that with greater experience and refinement of the procedure, adverse event rates will decrease.
The uncertain
The study included a questionnaire to measure vision-related quality of life. Such surveys are now standard in many clinical trials. The data from the quality of life surveys are reported in a Supplementary Appendix to the article. Different domains were tested (eg, emotional, mobility, reading, overall). The results were not impressive. None of the domains achieved statistically significant improvement.
The authors point out that the study was not powered to detect changes in quality of life. This is true, however, given the substantial improvement in vision among the participants, one might have expected larger responses in quality-of-life activities such as reading and mobility. This raises concern that the changes in vision measured under the conditions of the clinical trial may not translate directly into meaningful gains in real-world activities. Further research will undoubtedly explore this question.
Summary
This study demonstrates proof of concept of a technology that may allow patients to recover vision for conditions that were previously thought to be irreversible. This is an exciting study that will surely stimulate further research.  The real-world impact of this technology, as well as longer-term safety and efficacy studies should be explored. 


Do We Need “Evolutionary Medicine”?
Harriet Hall on July 3, 2012
Link
3 years ago I wrote an article critical of “evolutionary medicine” as it was presented in a new book. Recently a correspondent asked me if I thought another book, Why We Get Sick: The New Science of Darwinian Medicine, by Randolph M. Nesse, MD and George C. Williams, PhD, was a more reasonable approach to the subject. It was published in 1994 and got good reviews from respected scientists like Richard Dawkins (“Buy two copies and give one to your doctor.”) and E.O. Wilson (“bringing the evolutionary vision systematically into one of the last unconquered provinces…”). I was able to obtain a copy through interlibrary loan.
The book was interesting and gave me some things to think about, but it didn’t convince me that “Darwinian medicine” is a new science, that its existence as a separate discipline is justified, or that its unique approach offers any real practical benefits for improving medical care.
Why do we get sick? A simplistic view of evolution holds that it systematically eliminates any factors that decrease fitness for survival. So why does disease persist? Why didn’t we evolve to be “fit” enough to never get sick? Because evolution is not a straightforward process.
Evolution is complicated. There are countless “design flaws” in the human body. For instance, we are subject to choking because of the crossed anatomy of our respiratory and digestive systems. Nesse and Williams point out that it would be more sensible to relocate the nostrils to somewhere on the neck, but that just ain’t gonna happen. Evolution is limited by pre-existing patterns and has to make compromises. Historical accidents result in developments that are far from optimum. A useless or even a harmful gene may be perpetuated because it is linked with a beneficial gene. We are in an arms race with pathogens: we evolve defenses and they evolve ways to overcome those defenses. Natural selection made us fit as small groups of hunter-gatherers on the plains of Africa. We are specifically adapted to Stone Age conditions. We face very different environments today where our evolved traits can be counterproductive.
Who are the fittest? Fitness doesn’t mean fitness for the individual’s welfare, but fitness for propagating the individual’s genes. After the individual has reproduced, diseases of old age don’t affect evolutionary fitness except in minor, indirect ways. (Grandparents past reproductive age can contribute to the survival of descendants by helping with childcare and providing accumulated knowledge and wisdom.)
Nesse and Williams differentiate between proximate and evolutionary explanations: heart attacks are caused by cholesterol deposits in the arteries, but they want to know why evolution shaped us to deposit cholesterol, crave fat, over-eat, etc. I want to know, too; but I’m not so certain that knowing will reduce my chances of a heart attack.
Are evolutionary explanations just pseudoscientific equivalents of Kipling’s Just-So Stories? They argue that they are not. They give the example of morning sickness. It has been hypothesized that the nausea, vomiting, and food aversions of early pregnancy are beneficial because they protect the vulnerable fetus from dietary toxins. This would predict that morning sickness preferentially results in avoidance of foods most likely to harm the fetus. This is a testable prediction and there is some evidence to support it; but there is no way to prove that this is the true explanation or the only one. They suggest that suppressing morning sickness might increase the risk of congenital defects. But there is no evidence for that. They recommend that women “respect their nausea” and remember that it may be beneficial. (It would likely decrease your survival prospects if you said that to your wife while she was throwing up for the umpteenth time!) They admit that relieving suffering is important too, but they recommend that any anti-nausea medicine should be carefully evaluated to make sure it doesn’t cause any harm. Of course, we already do that for all medications used during pregnancy. I fail to see how evolutionary thinking adds anything to the care of pregnant women. In fact, I can see how it might result in unnecessary worry and suffering.
They suggest that sexual reproduction is an advantage because the genetic variations increase survival when a population faces an infection. As supporting evidence, they cite studies showing that asexual reproduction is more frequent in species and habitats with fewer parasites. Maybe. Correlation doesn’t prove causation.
They speculate that schizophrenia must persist in our genomes because it offers some advantage that balances the severe costs. They even have a creative hypothesis about why we sleep.
Most mammals can make their own vitamin C; humans can’t. The authors tell us that when humans switched to a high fruit diet rich in vitamin C, it allowed our biochemical machinery for making it to degenerate. Maybe. If so, nice to know. But so what? We still need exogenous vitamin C.
Even the most plausible evolutionary explanations may or may not be the true story. We can base predictions on them and test those predictions, but that can only provide circumstantial evidence. We can never know for sure whether our Just So Story is true or whether some other accidental factor was responsible.
Should we treat fevers? Fever probably evolved as a defense mechanism: it may do something towards helping fight off the infection. Evolutionary thinking makes us ask why we developed this adaptation and whether it is wise to interfere. But do we need evolutionary thinking for this? Doctors have already questioned the need to lower a fever, recognizing that it is not the fever but the infection that needs to be treated, that fever itself doesn’t do much harm, and that lowering a fever might have adverse effects in some cases. I’ve read many discussions of those points, and nowhere did they mention wondering about why we evolved to have fevers. I don’t see that evolutionary thinking adds anything useful to the discussion. Fever is what it is, and we can study it and deal with it without speculating about how it came to be that way.
Why are wisdom teeth a problem? Modern children frequently need orthodontia and surgery to remove wisdom teeth. They propose a possible explanation: we don’t chew enough. In the Stone Age, food required more jaw exercise. Today softer foods result in deficient use of jaw muscles, which results in poorer development of jawbones so there is less room for all the teeth. They suggest that many dental problems might be avoided if children chewed more gum or engaged in prolonged vigorous biting competitions.
This is nothing but silly, far-fetched speculation. You’ve got to give them credit for imagination; but if this is the kind of thing “Darwinian medicine” produces, we can do without it.
There is a disconnect in their logic. They say
For instance, if we hypothesize that the low iron levels associated with infection are not a cause of the infection but a part of the body’s defenses, we can predict that giving a patient iron may worsen the infection — as indeed it can. Trying to determine the evolutionary origins of disease is much more than a fascinating intellectual pursuit; it is also a vital yet underused tool in our quest to understand, prevent, and treat disease.
We can ask if something acts as a defense. We can ask whether something is a cause or effect. We can ask whether something does more harm or good. We can ask all these questions about how something works without necessarily needing to ask why it evolved to work that way.
Evolutionary thinking is already an integral part of medicine and an essential element of all biology. E. O. Wilson’s description of medicine as “one of the last unconquered provinces” simply is not true. Doctors regularly think about evolution and study its effects. The evolution of drug resistance in bacteria is the best-known example but there are many others. For instance, we think that sickle-cell anemia has persisted because it only affects those who inherit the gene from both parents, while those with only one copy of the gene (heterozygotes) have an increased resistance to malaria. G6PD deficiency causes hemolytic anemia but also offers protection against malaria.
But consider this: malaria is a credible explanation, but we can’t prove that it is the real one. Some other factor that we have not considered might be the true explanation, and malaria resistance might be a coincidence. And the malaria explanation is intellectually satisfying to those who ask “why” but it has had no practical impact on diagnosis or treatment.
They want anyone faced with a problem of medical importance to ask “what is its evolutionary significance?” But they have not demonstrated to my satisfaction that systematically asking that question improves the progress of modern medicine.
So why do we get sick?
    • We have genes that make us vulnerable. They may be new mutations, or genes that haven’t been eliminated because their effects occur too late in life to affect reproductive fitness, or genes that have unappreciated benefits that outweigh their costs, or genes that only have harmful effects in novel environments.
    • We are exposed to factors that did not exist in the environment in which we evolved.
    • Design compromises.
    • The arms race with pathogens.
    • Unfortunate historical legacies.
They think every discussion of a disease should ask questions based on each of these factors, starting with the question “which manifestations of the disease are actually defenses?” Is the runny nose of a cold a host defense, a means the virus uses to spread itself, or both? That’s a good question, but it can be answered without any need for evolutionary speculations.
They propose special separate funding for studies of evolutionary hypotheses, and they accuse medical science of ignoring evolutionary thinking and even showing an antipathy to it.
Conclusion
I’m sorry, but I just don’t “get it.” Am I missing something? Am I just a contrary curmudgeon? Evolution is already an essential part of all science. Medical scientists already understand evolution and apply its principles appropriately. I didn’t see a single example in their book of any significant practical development in medical care that would not have occurred in the general course of medical science as it is commonly practiced, without any need for a separate discipline of “Darwinian medicine.” Evolutionary explanations, whether true or speculative, may satisfy our wish to understand “why,” but I can’t see that they have much objective usefulness. Instead, they have produced at least one major annoyance: a movement that preaches to us how we ought to revert to the supposed diet of our ancestors (the Cave Man Diet, etc.).

Thumbthing Worth Reading
Harriet Hall on October 2, 2012
Link
I intended to read Sam Kean’s new book The Violinist’s Thumb: And Other Lost Tales of Love, War, and Genius as Written by our Genetic Code just for fun. I was expecting a miscellany of trivia loosely gathered around the theme of DNA. But I found something much more worthwhile that I thought merited a book review to bring it to the attention of our readers. Kean interweaves entertaining stories into a somewhat disjointed but nonetheless valuable history and primer of genetics. The title refers to Paganini, whose DNA created the unusual joint flexibility that facilitated his unprecedented feats of virtuosity on the violin.
Kean details the discovery of genes, chromosomes, and DNA; not only with the well-known players (Mendel, Watson, Crick) but with more obscure researchers, weird fruit fly studies, womanizers, scientists who fought against the growing consensus, those who unraveled the complexities of how our cells read the genetic code, those who took some very wrong turns, and the complex politics that plagued the human genome project. His vignettes make the scientists come alive.
Along with the basics about inheritance and the G-T-A-C code, we learn about endosymbiosis, the incorporation of viral DNA into the human genome, jumping genes, viral DNA manipulation of host behavior, the complications introduced by the development of the X and Y chromosomes, how a person’s environment can alter the expression of genes in their children and even their grandchildren (epigenetics), gene reassortment, how genes are read and mis-read, how DNA ties itself in knots that have to be unraveled by canny proteins called topoisomerases, why identical twins are not truly identical, why we have fewer chromosomes than any other primate, how the box gene organizes development in the embryo, and how “junk” DNA is proving to be anything but.
Along the way, we learn about a couple who shared their house with 689 cats, an oddball piece of math (Zipf’s law) that applies to both linguistics and DNA coding, an unlucky man who fled Hiroshima after the bombing only to be bombed again in Nagasaki, explorers who died of vitamin A poisoning from eating polar bear liver because humans lack the genes that polar bears have evolved to protect themselves, a Russian scientist who tried to create a human/chimp hybrid by inseminating women with chimp sperm either with or without their consent, the postmortem peregrinations of Einstein’s brain tissue, the origin of funny names for genes like sonic hedgehog, and Darwin’s mysterious lifelong health problems.
We learn how DNA illuminates human history and evolution. The rate of mutation is steady enough to serve as a clock. In a bottleneck after the eruption of a monster volcano, the population of humans dropped precipitously, perhaps even as low as 40 adults. Because of that, we have far less genetic diversity than chimps and gorillas, even though our current population is 7 billion and theirs is only 150,000.
Gene sequencing is getting cheaper every day. We can only speculate what the future may bring. We may eventually have the technology to eliminate genetic defects in individuals and to direct the evolution of our species.
Kean’s colorful cast of characters is unending. We meet Craig Venter, the midwife toad, Stalin, Dolly the sheep, Toulouse-Lautrec, Neanderthal cannibals, a Cyclops, King Tut, and Kim Peek, the inspiration for “Rain Man” whose abnormal brain could perform astounding feats of reading and memory but couldn’t handle simple tasks of daily living. We meet a Victorian zoophagy enthusiast who thought moles were the worst-tasting animal until he ate a bluebottle fly.
A Lesson About Personal Genomic Testing
I was particularly interested in Kean’s experience with testing his own DNA because it illustrated some of the concerns that both Scott Gavura and I have raised.
When his results were reported, the company gave him the option to not learn his risk of specific diseases. He opted not to know his risk of Parkinson’s, a disease he particularly dreaded because he had bad memories of his grandfather’s deterioration from it. When he read about Craig Venter publishing everything about his genome, he was inspired by that example to unseal his own results. He was relieved to learn he had no increased risk for Parkinson’s after all. His emotional relief was only minimally impacted by his rational understanding that “no increased risk” didn’t mean “no chance” of getting Parkinson’s. Later the company announced updates to the old results based on new scientific studies. A new study had looked at the DNA in a different spot on the genome and it showed he had a slightly greater than average risk of developing Parkinson’s. He felt as if he had been condemned, pardoned, and then condemned again.
His reaction was tempered by what he had learned during research for this book:
    • Parkinson’s is complex, affected by many genes.
    • Any one gene probably contributes very little.
    • Slightly higher was defined as just 20%.
    • Parkinson’s only affects 1.6% of men. (If the baseline risk is 1.6% and his risk is 20% higher, that would only raise it to 1.92%.)
    • The new study was classified by the company as “preliminary.”
    • Preliminary results are subject to amendments and reversals.
In short, genetic testing shows probabilities, not certainties. It seldom leads to useful preventive actions and it can lead to unnecessary anxiety or false reassurance for those who don’t know enough about genetics to appreciate the limitations of the findings. Scott Gavura said it well:
Our access to genetic information currently exceeds our understanding of what that information actually means.
Conclusion
Thumbs up to The Violinist’s Thumb. You will learn things you didn’t know and you will be heartily entertained in the process.

Product B: Here We Go Again
Harriet Hall on November 25, 2014
Link

“Telomeres shorten each time a cell divides. In most cells, the telomeres eventually reach a critical length when the cells stop proliferating and become senescent. But, in certain cells, like sperm and egg cells, the enzyme telomerase restores telomeres to the ends of chromosomes. This telomere lengthening insures that the cells can continue to safely divide and multiply. Investigators have shown that telomerase is activated in most immortal cancer cells, since telomeres do not shorten when cancer cells divide.” — National Institute of Aging
New health products are constantly appearing on the market in such numbers that I can’t hope to keep up. Product B was new to me. I was introduced to it by a doctor who said a family member was “quite enthusiastic” about its potential to “lengthen telomeres and thereby address a myriad of health issues.” Of course, I immediately asked “What exactly are they claiming Product B does?” and “Do they have evidence that it actually does what they claim?” Their website didn’t provide satisfactory answers.
Product B is described as “a powerful blend of complex botanicals and vitamins uniquely designed to offer superior telomere support for youthful aging.” It is sold as part of a multilevel marketing (MLM) scheme. Because it is classified as a dietary supplement, FDA regulations only allow them to make “structure and function” claims, so the claims are deliberately nebulous. Basically, they seem to be saying that short telomeres are bad (they cause aging and disease), telomerase is good because it makes telomeres longer, and Product B is an effective way to increase telomerase; therefore Product B prevents disease and retards aging. But these assertions are questionable, and the website doesn’t offer any credible evidence of clinical efficacy for any single health issue, much less a myriad of them. Or any evidence of safety, for that matter.
Oh, good grief! It’s sold by the Isagenix company. Talk about déjà vu! Isagenix keeps coming back to haunt me; it even generated my favorite insult ever: “Dr. Harriet Hall is a refrigerator with a head.” You can read the three articles I wrote about Isagenix here, here, and here.
If I am a refrigerator, at least I try to be a fair one. I wasn’t going to reject the claims out of hand just because Isagenix made them. I spent quite a bit of time searching the Internet for information, and I even wrote the company to ask directly for their evidence. They didn’t bother to reply.
One thing puzzled me right off the bat. Was there a Product A that I had somehow missed? Why did they name this “Product B”? That doesn’t impress me as a savvy marketing choice. Couldn’t they have thought up something catchier like “Telomiracle”? I couldn’t help wondering what the B might stand for and my mind quickly associated the words bogus, blarney, business, baloney, bunk, bullshit, blunder, basura (Spanish for garbage), barbaridad (Spanish for stupid thing), and blague (French for joke). It made me think of second choice, as in “plan B.” What does it make you think of?
Pardon the digression. It makes no difference what they call it. “A rose by any other name…” All that matters is what it is and whether it works.
What’s a telomere?
Every chromosome has a telomere, a repeated sequence of nucleotides at the end of the DNA strand. It is a disposable section that carries no genetic information. For vertebrates, the nucleotide sequence is TTAGGG; this repeats from 300 to several thousand times according to the species of animal. Telomeres are sort of like the aglet, that little hard piece on the end of a shoelace that keeps it from unraveling. They protect the end of the chromosome and keep it from losing important genes or sticking to other chromosomes.
When cells divide, each strand of DNA is copied. The enzymes that carry out that job don’t actually make a perfectly identical copy: when they get to the end of the DNA strand, they are unable to copy all the way to the very last nucleotide, so every time a cell divides, the DNA is shortened. Some of those TTAGGG’s are lost. When enough of them are lost, the cell is kaput. The Hayflick limit is the number of times a cell can divide before it becomes incapable of dividing further, typically 40-60 times for human cells in cell culture in the lab. If your cells stop dividing, you die.
Telomerase is a reverse transcriptase enzyme that has its own RNA. It serves as a template to make more TTAGGG sequences and add them to the telomere, reversing the usual shortening process. Telomerase is active in cells that can’t afford to stop dividing: embryonic cells, the testicular cells that produce sperm, and stem cells; but it is not found in most adult body cells. So the hypothesis is that if you could make the telomerase gene express itself in somatic cells, the telomeres might not shorten with age, the Hayflick limit might be over-ridden, the aging process might be stopped in its tracks, and we might overcome natural death and become immortal. So far, this hypothesis is only a dream.
Telomerase is not always a good thing
There’s a downside: encouraging telomerase might be dangerous. Cancer is characterized by unregulated growth, and telomerase is active in 90% of human malignancies. We don’t want cancer cells to live forever. Drugs that reduce telomerase activity are being investigated as cancer treatments. So if Product B really increases telomerase activity, that might not be such a good thing. We might fall from the frying pan of the aging process into the fire of more cancers.
The role of telomerase in aging is still controversial. Short telomeres could be just a sign of cellular age rather than a cause. In at least one species of seabird, they are neither: telomeres become longer with age.
The Product B website says “Almost every known disease can be attributed to the shortening of telomeres.” That is demonstrably false. Well, maybe they “can be attributed” by someone who is willing to make false attributions; but there is no evidence that short telomeres actually “do” cause almost every known disease. In fact, it has not been conclusively established that they cause any disease. There are correlations, but science is still trying to tease out causation.
Questionable information
The website doesn’t provide much in the way of scientific evidence, but it provides the usual testimonials and a couple of slick video presentations. Aging is a complex subject not well understood by science, and the science of telomeres is still in its infancy. They grossly oversimplify and misrepresent the science with sound bites like “We age because our cells age, and our telomeres get shorter.” They say we are born with 10,000 telomere bases, and when we get down to 5,000 bases we begin to die of old age. No, it’s not that simple.
The videos feature William H. Andrews, “a world-leading researcher on telomeres.” They call him “the principal discoverer of RNA and protein components of telomerase.” I was unable to verify that. He is not listed as one of the authors of this study that identified the protein composition of human telomerase.
Elsewhere on the web I learned that Andrews started out trying to develop a pharmaceutical drug that would activate the telomerase gene. He tested thousands of compounds in vitro; some of them worked but were toxic. After his research funding dried up, he met John Anderson, a “nutritionist” with decades of experience in formulating nutritional products. Anderson persuaded him to stop trying to develop a pharmaceutical drug, to just bypass the FDA and market a diet supplement instead. Together, they formulated a diet supplement product and accumulated lots of testimonials about more energy, sounder sleep, feeling younger, etc. Andrews says:
I have never seen so many anecdotal testimonies for any product ever. [He has obviously led a sheltered life!] I am a pharmaceutical scientist by training. I believe in double blind placebo controlled studies. I believe that placebo effects occur but I have just never seen this many testimonials before. I strongly believe something is happening but I am not going to make any claims until the clinical studies are done.
Sound familiar? Maybe he’s not making any claims, but the Isagenix company is certainly managing to get the Product B message across to its customers despite the required FDA disclaimer. I’d bet that most of their customers believe they are buying a product that will lengthen their telomeres, retard aging, give them lots of energy, and make them feel and look younger.
What’s in Product B?
You can read the list of ingredients here. Basically, it’s a mixture of four vitamins with a proprietary blend of some 30 herbal products such as thistle, horny goat weed, ginseng, and green tea. Most of these have never been shown to have any effect on telomerase.
This 2012 review article covered “Pharmaceutical Regulation of Telomerase and Its Clinical Potential.” They report that a commercially developed telomerase activator molecule, TAT2, derived from the root of Astragalus membranaceous has been found to transiently activate telomerase in the lab in T lymphocytes that were not proliferating. They say it “could” prove useful, but “more work needs to be done to determine mechanism of action and safety.” Neither TAT2 nor Astragalus are ingredients of Product B.
In Table 1 of that review, they list all the phytochemicals that are known to regulate telomerase. There are only 2 known telomerase activators and 7 known inhibitors. Several of the inhibitors are among the ingredients of Product B, which is being sold to activate telomerase. Something doesn’t add up. I can’t see any rationale for the particular kitchen sink of ingredients in Product B. It seems like they just threw in a little of everything anyone had ever suggested might be good for you.
The review concludes:
Pharmaceutically inhibiting telomerase may prove an important option in cancer therapy in conjunction with traditional chemotherapeutics. Conversely, the activation of telomerase could be useful to treat age related diseases and HIV/AIDS patients where lymphocytes have stopped proliferating. However, the long-term effects of regulating telomerase either positively or negatively are unclear.
William Andrews was one of the authors of this study that tested the Astragalus derivative TAT2 as part of a complex dietary supplement protocol. It activated telomerase in vitro, and in vivo it produced a decline in senescent toxic T cells and killer cells, mainly in subjects who were seropositive for cytomegalovirus (CMV). Mean telomere length did not increase, but they interpreted the results as positive because there was a reduction in the percentage of short telomeres. This was an uncontrolled pilot study by researchers who had a declared financial interest in the product, and it gives us no useful information about clinical benefits. William Andrews was one of the authors and he also served as a subject. The financial disclosure statement reports that he is founder and president of a company that develops therapeutics for inducing telomerase expression and that the study was partly financed by his company.
A single study of Product B
But TAT2 is not in Product B. I found only one study that actually tested Product B. It was a randomized, placebo-controlled double blind study but was small (only 43 subjects) and was presented at a conference but has not yet been accepted for publication in a peer-reviewed journal. It found that Product B increased catalase activity by 30% in red blood cells. That doesn’t tell us much. Why did they measure catalase instead of telomerase levels or telomere length? One of the authors explained, “There is yet to be a direct measure of telomeres that is reliable enough for an accurate measurement of telomere length for obtaining statistical significance in a clinical trial.”
That sounds to me like a poor excuse. It can’t be that difficult to measure telomere length, since so many studies have done it; after all, that’s how we learned that telomeres shorten with age. And I know there is an accurate method to measure telomerase: the TRAP method (Telomeric Repeat Amplification Protocol) that most researchers accept and that has been used in many other studies.
Isagenix is not the only company selling products targeted at telomeres. “America’s number one anti-aging pioneer,” Dr. Al Sears sells UltraEssence, described as a “reliable telomere support supplement.” And the Geron company sells Imetelstat to inhibit telomerase and treat cancer.
Conclusion
There are lots of proposed anti-aging remedies, and there are even Longevity Clinics, but as far as I know, no treatment has yet been proven to slow the aging process or extend the human lifespan. There are only preventive measures to reduce the risk of premature death and to improve the likelihood of staying healthy while you age (exercise, weight control, smoking cessation, vaccines, screening tests, seatbelts, treating high blood pressure, etc.).
I wouldn’t go so far as to call Product B a scam, but it certainly is not supported by good scientific evidence. It is based on bold extrapolations from basic research along with speculation, unwarranted assumptions, and wishful thinking. There are lots of products out there with similarly unproven claims, for instance Protandim, which I wrote about here, here, and here.
My Plan A: remain skeptical of Product B and wait for Evidence E.

Misleading Ad for Apeaz
An ad for Apeaz in Discover Magazine is misleading. Its active ingredient may provide some temporary relief of pain, but the claims in the ad are overblown. It is not a new blockbuster drug or an anesthetic.
Harriet Hall on January 29, 2019
Link

I saw a full-page ad in Discover Magazine for Apeaz, a “New blockbuster arthritis drug” in the form of a cream. Almost everything in the ad was wrong. The active ingredient is methyl salicylate, which is not new, is not a blockbuster, and cannot replace disease-modifying treatments. That was bad enough, but it went downhill from there.
The claims
    • New Arthritis Painkiller Works on Contact and Numbs Pain in Minutes.
    • Uses the strongest approved dose of an anesthetic drug.
    • Anesthetics are highly regarded by physicians in the medical community.
    • Numbs the nerves that cause relentless joint pain.
    • It numbs the nerves right below the skin but also apparently reaches the arthritic joint itself (!?)
    • Rapid relief that lasts for hours and hours
    • Offers impressive advantages over traditional medications:
        ◦ Faster action
        ◦ None of the negative side effects of oral medications
        ◦ The chemicals in pills can tear the delicate lining of the stomach, causing ulcers and bleeding.
        ◦ Lower cost: less than $2 a day
    • An FDA drug [sic] with approved claims for the pain relief of the following conditions:
        ◦ Temporary pain
        ◦ Strains
        ◦ Athletic injuries
        ◦ Simple back pain
        ◦ Sprains
        ◦ Muscle stiffness/pain
        ◦ Wrist, elbow, shoulder, hip, knee, ankle, foot, muscle or joint pain
The active ingredient
Methyl salicylate, a relative of aspirin, is a nonsteroidal anti-inflammatory drug (NSAID) also known as oil of wintergreen. It is the active ingredient in many over-the-counter remedies like Bengay. It acts as a counterirritant, which (along with rubbing the painful area as it is applied) tends to distract patients from their pain. It is well absorbed and then is metabolized into salicylic acid which has some analgesic and anti-inflammatory properties, but there’s no rigorous research to support its use for pain.
Evidence?
The ad says, “Published pre-clinical animal studies have shown that the other ingredients in Apeaz can also prevent further bone and cartilage destruction.” What other ingredients? It contains menthol and camphor, but the study I found called them “inactive ingredients”.
It was a 2009 study in a mouse collagen induced arthritis model that “shares a number of clinical, histological and immunologic features with RA (rheumatoid arthritis).” The researchers explained that the active ingredient of Apeaz is methyl salicylate and that it also contains the “inactive ingredients” glucosamine sulfate, menthol, camphor and methyl sulfonyl ethane. They reported finding downregulation of both inflammatory and autoimmune components of the disease. They said:
Treatment with Apeaz™ completely abrogated joint swelling and destruction of cartilage and bone as demonstrated by histopathology and X-ray analysis of joints. In addition, Apeaz™ reduced the levels of inflammatory cytokines in the joints of arthritic mice. Our data suggest that Apeaz™ could be a viable candidate as a DMARD [Disease Modifying AntiRheumatic Drug] for RA.
That is preliminary, speculative, and the suggestion is not warranted. Mice are not humans, and the induced model in mice is not the same as RA in humans. Apeaz has not been studied in human clinical trials.
Silly mistakes
    • “Getting to the source of you [sic] pain”
    • They offer a special hotline for discounted pricing that will be available at 6:00 AM “today” and will only be open for the next 48 hours. Don’t they realize that Discover is a monthly magazine? One wonders how “today” is supposed to be interpreted. The day of publication? The day a subscriber receives a copy? Would it apply to readers who picked up an old copy in the dentist’s waiting room?
    • This is the initial public release, but they claim “thousands of consumers” have already experienced the “guaranteed” Apeaz relief. How could that be? And they don’t mention any guarantee.
    • Calling it an “anesthetic” is a real stretch, if not an outright lie. While Apeaz may produce a mild numbing sensation, it is not an anesthetic by any scientific definition of the word.
Fake news
The ad might be confused with a news story. It carries a byline: “By David Watson, Associated Health Press.” There is no such organization and no such person. These ads are typically published in daily newspapers, which explains the confusion about “today”. The newspaper ads have the same wording and the same warning not to wait because supplies may run out. But they do have a different toll-free number to call. And the newspaper ad also advertises a companion product, ArthriVarx, which supposedly works on the inside to cushion the joints while Apeaz is working on the surface pain. But wait! Didn’t they say Apeaz reaches the joints?
Believing the ads could harm patients
This product has not been tested in humans. Patients with rheumatoid and other inflammatory types of arthritis can be treated with DMARDs which are proven to reduce the chance of permanent joint damage, disability, and deformity; and DMARDs are more effective when started early in the course of the disease. Patients may not know what type of arthritis they have. It would be unfortunate if patients with RA relied on Apeaz and delayed getting effective treatment.
Shame on Discover!
Discover Magazine claims to be “Science for the Curious”, and the issue that this ad appeared in featured the top stories of 2019 in medicine. Publishing ads like this undermines their scientific message and lends a false prestige to non-scientific claims. Topical application of wintergreen oil may provide some temporary relief of pain, but questions remain:
    • How well does it work?
    • How does it compare to other treatments?
    • How many customers who would benefit from proven DMARDs will use Apeaz instead and become needlessly crippled with permanent joint damage?
There are no answers to these questions, because the necessary controlled scientific studies have not been done.

Do custom-compounded pain creams actually work?
Pharmacy-prepared pain creams are widely used for different types of pain and injuries. They may be expensive, but do they work better than a placebo?
Scott Gavura on February 7, 2019
Link

It wasn’t that long ago that most prescriptions were custom manufactured, or compounded. A pharmacist combined raw chemicals into different dosage forms like capsules, tablets, liquids, and creams. Compounding allows complete customization of a prescription — from a new strength of a capsule, to a liquid form of a tablet, to creams with combinations of ingredients that can be completely individualized. With the proper equipment, sterile products like injectable drugs can be made in pharmacies.
These days, commercial manufacturers supply most drug products, and the need for in-pharmacy compounding has dwindled. For these products, regulators like the FDA ensure product uniformity, purity, potency, efficacy, and safety standards for consumers. You can be assured that any product approved by the FDA has gone through a barrage of manufacturing tests and multiple clinical studies. However, any retail pharmacy is still capable of providing compounded prescriptions. Some pharmacies specialize in this practice, calling themselves “compounding pharmacies” and aggressively promote the service. Organizations like the Professional Compounding Centers of America, provides training, formulations (recipes), and raw ingredients to compounding pharmacies. To pharmacies and pharmacists, compounding is a business opportunity and a way to differentiate yourself from the competition. But the enthusiasm can outpace the evidence, and there may be a lack of evidence that compounded products really are safe and effective. Now a new clinical trial raises questions about a very popular compounded product: pain creams.
While compounded pharmacy products can address important patient issues (e.g., allergy, requirement for a liquid dosage form, etc.) the fact that they undergo significantly less scrutiny than FDA-approved products has raised concern for some time. The negligence that occurred at the New England Compounding Center killed 64 people from fungal meningitis that was a consequence of shoddy manufacturing standards. Evidence standards can also be questionable, as I’ve pointed out before, where compounding pharmacies have a symbiotic relationship with advocates for practices like “chelation”, used in circumstances where the benefits are unproven.
Treating chronic pain
Chronic pain is the most common cause of long-term disability and can occur as a consequence of diseases like cancer. Despite the societal burden of pain, there are few truly effective (and risk-free) medical options. Opioids are often used but with mixed results and legitimate concerns about addiction. Non-steroidal anti-inflammatory drugs (NSAIDs) can be effective for some forms of pain, but their side-effect profile is considerable. I’ve written before about topical NSAIDs which despite my initial skepticism do have some evidence of effectiveness for osteoarthritis and acute pain and fewer side effects compared to NSAID pills.
Given the positive clinical trials from commercially-manufactured products like Voltaren cream, and recognizing the limitations of other treatment options for chronic pain, it is perhaps no surprise that there has been growing interest in preparing other products for topical use for the treatment of pain. Compounding pharmacies will manufacture multiple products marketed for the treatment of pain. Muscle relaxants or drugs like ketamine and lidocaine can be prepared for topical use. Sometimes multiple ingredients are compounded into a single cream. In the paper we’re about to discuss, the authors, who are affiliated with a US military treatment facility, note that the Department of Defense’s health system drug program was spending $6 million per day on compounded medications in 2015, an amount that has been growing over time. Soaring expenditures and a lack of efficacy data led to the current study, which sought to examine if these expensive, customized products actually work.
The study
This study is from Robert E. Brutcher and colleagues at the Walter Reed National Military Medical Center, entitled “Compounded Topical Pain Creams to Treat Localized Chronic Pain“, published in the Annals of Internal Medicine in February, 2019.This was a double-blind, randomized, parallel study of 399 patients that compared three different compounded pain products versus placebo. Participants were from an academic military treatment facility and had to be 18-90 years old, with localized pain on a pain scale of 4 or more on a 1 to 10 scale, that had lasted more than 6 weeks. More than 40% were active duty personnel. Patients were randomized to one of three products (active or placebo) based on the type of pain they were experiencing and the assessment of the treating physician.
    • Nociceptive pain (pain typically caused by injury or inflammation): The active treatment was 10% ketoprofen, 2% baclofen, 2% cyclobenzaprine and 2% lidocaine.
    • Neuropathic pain (pain due to nerve injury): The active treatment was 10% ketamine, 6% gabapentin, 0.2% clonidine, and 2% lidocaine.
    • Mixed pain: The active treatment was 10% ketamine, 6% gabapentin, 3% diclofenac, 2% baclofen, 2% cyclobenzaprine, and 2% lidocaine.
Creams were compounded in a typical pharmacy compounding base (carrier). The concentrations of active ingredients were based on previous trials and commonly marketed compounded formulas. Creams were applied to the affected area 3 times per day.
The primary outcome of interest was the average pain score one month after treatment. A positive response was deemed to be a reduction in pain score of 2 (scale of 1-10) and a score above 3 on a 5-point satisfaction scale. There were a number of secondary outcomes, and patients with positive-reported outcomes were followed for 3 full months.
The results
The (compounded) drugs don’t work. All patients improved slightly, but the change in pain score at 1 month, and at 3 months did not differ significantly between the drug and placebo for all three pain groups. There were also no differences in functional improvement or satisfaction with the product. The placebo was as effective as the “active” treatment.
Both the active treatments and the placebos were generally well tolerated and there were no differences overall in side effects, with the exception of slightly more skin irritation reported in the active treatment group.
The implications
This study found no evidence that 3 different compounded pain creams have any effect on different forms of pain. This study is consistent with some other research but is also at odds with some randomized trials that have shown effectiveness for products like topical NSAIDs for conditions like knee osteoarthritis. Limitations of this study include the variety of medical conditions included, which might miss effectiveness in a specific type or location of pain (e.g., knee osteoarthritis). Overall, this trial gives important information that should lead health professionals and consumers to question the effectiveness of compounded pain creams.

ust How Addictive Are Opioids?
There is an opioid epidemic, with increasing overdose deaths from both prescription drugs and illegal drugs. Just how addictive are opioids? It appears they are safe when used appropriately, but there is a high risk of abuse, and they are deadly when misused, especially OxyContin.
Harriet Hall on January 22, 2019
Link

We are in the midst of an opioid epidemic. Prescription opioids are being over-prescribed and misused. People have become addicted when taking opioids prescribed for them by doctors for acute, chronic, or post-surgical pain; or when inappropriately taking meds prescribed for others; or when buying illegal drugs on the street. Many prescription drug addicts switch to heroin because it is easier to get, and heroin overdoses are also on the rise. More than 11 million people abused prescription opioids in 2016. 42,000 Americans are dying every year from opioid overdose, 40% from prescription opioids. For comparison, 33,636 Americans die of firearm injuries, 37,133 from traffic accidents, and 480,000 from cigarettes every year. President Trump has declared opioid addiction a national Public Health Emergency.
According to New York Magazine’s Intelligencer, “No other developed country is as devoted to the poppy as America. We consume 99 percent of the world’s hydrocodone and 81 percent of its oxycodone. We use an estimated 30 times more opioids than is medically necessary for a population our size.” 
Are the drug companies to blame?
27 states have sued Purdue Pharma, the creator of OxyContin, accusing them of two things:
    • False advertising
        ◦ They downplayed the dangers and exaggerated the benefits.
        ◦ They misrepresented newer, stronger opioids as less addictive.
        ◦ They failed to disclose information they were aware of from their clinical trials.
        ◦ They claimed that because of the time-release formulation, OxyContin posed a smaller risk of abuse and addiction than other, shorter-acting opioids.
        ◦ They promised 12-hour relief based on a flawed initial study, but follow-up studies showed that for up to 95% of patients, it didn’t last that long.
    • Producing and distributing the pills on a massive scale.
        ◦ In some areas, more bottles of OxyContin were sold than there were people.
        ◦ This despite the fact that they knew there was a high risk of abuse.
        ◦ They knew the drugs were being diverted onto the black market, yet they failed to monitor usage or do anything to stop it.
In a 2007 case, Purdue and three executives pleaded guilty to criminal charges. Purdue paid $600 million and the three executives paid $19 million, $8 million, and $7.5 million in individual fines.
An article in The Atlantic asked, “Did Free Pens Cause the Opioid Crisis?” It described the aggressive marketing tactics of the drug companies and cited a study showing that while prescriptions decreased across the country in response to much-publicized abuse, “among physicians who continued to receive gifts from opioid makers, prescriptions continued to see a modest rise.”
Opioids can be used responsibly or irresponsibly
A report by the Surgeon General says:
there are certain populations who rely on prescription opioids and are taking them responsibly under the care of a trusted provider. These include, but are not limited to: individuals in hospice care; individuals who are undergoing cancer treatment; people who recently experienced a traumatic injury; or those with long-term disability and chronic pain…Opioid pain medications are generally safe when taken for a short time and as prescribed by a health care professional, but because they produce euphoria in addition to pain relief, they can be misused.
A Cochrane review found that:
OxyContin is one of the most commonly abused prescription drugs. The drug’s controlled-release formula provides chronic pain relief for up to 12 hours. Many people bypass the time-release action by crushing and snorting OxyContin, or by dissolving the tablets in water and injecting the solution. This allows the user to achieve the full effect of the drug all at once.
The addiction process
The Surgeon General’s report said:
Well-supported evidence suggests that the addiction process involves a three-stage cycle: (1) Binge/Intoxication, the stage at which an individual consumes an intoxicating substance and experiences its rewarding or pleasurable effects; (2) Withdrawal/Negative Affect, the stage at which an individual experiences a negative physical and emotional state in the absence of the substance; and (3) Preoccupation/Anticipation, the stage at which one seeks substances again after a period of abstinence. This cycle becomes more severe as a person continues substance use and as it produces dramatic changes in brain function that reduce a person’s ability to control his or her substance use.
A study that compared therapeutic use to street use found that:
CNCP [opioids prescribed for chronic non-cancer pain] patients started therapy in the low dose range for oral morphine (</=60 mg/day) and most (83%) did not move into a higher dose range once adequate levels of analgesia were attained. Street users started smoking heroin intermittently, before daily use. Most escalated their dose by increasing the amount used and by switching from smoking to injecting. Unlike CNCP patients, street users demonstrated patterns of compulsive drug use, social problems and intoxication. Only 3/31 (9.5%) pain patients that discontinued opioid therapy reported withdrawal symptoms on abstaining from the drug compared to 35 (89.5%) of street users.
Definitions
Not all individuals who abuse drugs are addicts. Drug abuse is defined as the habitual taking of addictive or illegal drugs. Drug dependence is defined as experiencing withdrawal symptoms when the drug is withdrawn. Withdrawal symptoms can be avoided or managed by gradually reducing the dose. Addiction is a chronic relapsing brain disorder characterized by compulsive drug seeking.
Just how addictive are opioids, anyway?
It’s very difficult to get a straight answer to that question.
Many websites ask “Why is OxyContin so addictive?” or say it is a “highly addictive drug.” But even they admit that “very few people who take OxyContin as prescribed become addicted to the drug.” There are animal studies, but no well-designed controlled human studies. And there are many possible confounders.
The confusion started in 1980, when a letter published in The New England Journal of Medicine said addiction is rare (less than 1%) in patients treated with narcotics. It was widely cited and believed, and Big Pharma relied on it for their advertising. But it was only a one-paragraph letter about data collected from records of hospitalized patients in highly regimented settings and it was misrepresented and misused to justify widespread outpatient use.
The experience of the Viet Nam war seemed to confirm that opioids were not very addictive. About 15% of servicemen became addicted to heroin while stationed in Viet Nam. 95% of them stopped using it and did not resume when they returned stateside.
A systematic review of studies found a prevalence of drug abuse, drug dependence, and drug addiction in the range of 3.2-18.9% but said there is little evidence that addictive behaviors are common within the chronic pain population.
A study published in 2011 found that:
Although preclinical measures of opioid antinociception, tolerance, addiction and dependence need to be interpreted with caution, overall they appear to have good predictive validity for human responses to opioids. The primary problem in making this connection is the lack of randomized controlled human studies.
A better question
While we don’t have a straightforward answer to “just how addictive are opioids?” especially OxyContin, the available evidence seems to point to this: when taken as directed, opioids are not especially addictive. In practice, OxyContin is more addictive than other drugs because of the way it is abused.
The drug itself is only part of the problem. Psychological factors, socioeconomic factors like joblessness and hopelessness, mental illness, drug company misinformation, doctors who overprescribe, patients who share their prescribed meds with others, and patients who disregard instructions are also to blame.
So a better question is not “how addictive?” but “what can we do to prevent addiction and overdose?”
What can be done to stop the opioid epidemic?
There have been many suggestions: alteration of opioid formulations to make them less subject to abuse, better monitoring of prescription and addiction rates, early identification of drug abusers, better treatment programs for addicts, better insurance coverage, supplying first responders with naloxone to reverse overdoses, programs to educate doctors, better identification of risk factors, and more.
We know many of the risk factors for addiction: a family history of addiction, a personal history of alcoholism or other substance abuse disorders, mental illness (especially major depression), etc. A combination of five risk factors is known to increase the risk of dependence by a factor of 56.36. Doctors can check for risk factors, prescribe with caution, prescribe smaller quantities, and closely monitor patients for abuse and for suicidal potential. They could also try to find out if the patient is part of a high-risk peer group and is exposed to drug abusers and illegal drugs.
Success will require a joint effort of doctors, patients, families, drug companies, legislators, and the media. Fingers crossed.

What are the risks of touching fentanyl?
There is the widespread belief that simply touching fentanyl can be fatal. This assumption isn’t supported by science or evidence.
Scott Gavura on July 21, 2022
Link
Fentanyl is a powerful opioid analgesic that initially was brought to the market in the form of transdermal patches, intended for the treatment of severe chronic pain. It is also used in the hospital environment as an injectable drug for anaesthesia and acute pain. Fentanyl is a synthetic drug, based on the morphine molecule, that is 50-100x more potent than morphine on a milligram-to-milligram basis. Fentanyl rapidly penetrates lipids (fat tissues) and once it’s in the bloodstream, quickly reaches the brain and other organs with a short duration of action.
Fentanyl is now infamous because it has entered the illegal drug supply and become a major driver of opiate overdoses and deaths. When used illegally, it is typically supplied as tablets or as a powder. Because so little fentanyl is required for a “high” compared with other drugs, it may be deliberately combined with or sold as other drugs, sometimes with fatal results. Even potentially fatal doses are too small to be tasted or otherwise easily detected.
Fentanyl, like all opioid drugs, works by binding to opioid receptors in the body. In addition to euphoria, it reduces respiration. Overdoses slow breathing, leading to hypoxia, and the accumulation of carbon dioxide. When there is insufficient oxygen to the brain, coma, brain damage, or death can result.
With the recognition that only small doses of fentanyl can be fatal, there have been multiple reports of law enforcement officers that have fallen ill or fainted from simply touching fentanyl. While toxicologists have questioned these stories and pointed out that skin contact is fentanyl is not itself sufficient to cause an overdose, there are multiple stories about “overdoses” attributed to skin contact. (See the Slate article “The Viral Story About the Cop Who Overdosed by Touching Fentanyl Is Nonsense“.) Yes, fentanyl patches do demonstrate that it can be absorbed by the skin, but they work slowly, and are specifically formulated to push the drug across the skin barrier. A specialized transdermal formulation is essential, because skin is normally an effective barrier against a variety of toxins. Transdermal patches, including fentanyl patches, must adhere to the skin and not be removed for some time in order for the drug to diffuse across the membrane and accumulate in the upper layers of the tissue, where it eventually becomes available to the blood stream. Fentanyl is estimated to take 20 minutes just to penetrate the skin and be detectable in the blood. With a fentanyl patch, it will take 1-3 days for steady absorption rates to be achieved.
A case report of inadvertent skin exposure
As a clever pharmacist who found a way to turn an accident into a paper, Ryan Feldman recently wrote up his personal exposure to a very large dose of fentanyl liquid. (Spoilers: He was fine):
Never thought I’d BE a case report, but here we are🤷
Outcomes from confirmed fent exposure are needed to fight misinformation, & sometimes in science accident=opportunity😅
Our article (w/ @BenWWeston!) in🧵 below. Hope it does some good!#FOAMed #MedEd #Twitterx #MedTwitter https://t.co/8Mc6UdxiB3
— Ryan Feldman PharmD DABAT (@EMPoisonPharmD) June 22, 2022
Feldman’s paper describes how he became an unwitting case study. He was disposing of a container of fentanyl solution, but accidentally spilled it on his hand, wrist and forearm. He had a cut and some abrasions on his exposed hand, so the skin was not in optimal condition. One minute after this exposure to approximately 380mcg, he washed the area soap and water. Despite this exposure and skin contact with a very large dose of the drug, a medical exam was normal. He had no signs of opioid exposure and resumed work.
Ultimately, the exposure and absorption of a drug like fentanyl will be based on the area of the body exposed, and the dose that one is exposed to. As the authors point out, this case study should provide reassurance to those concerned about accidental skin exposure.
There is the widespread belief, particularly among first responders, that even brief skin contact with fentanyl can cause overdoses and death. Occupational exposure to opioids is a real concern to this group. Toxicologists have suggested that reported reactions, like fainting, may be psychogenic rather than a result of any actual toxicity. This case study provides more reassurance about ungloved contact with fentanyl. In the event that there is transient skin exposure to fentanyl, no meaningful absorption is anticipated. Simply wash the affected area with soap and water as soon as possible.

The (Cold) Drugs Don’t Work
The FDA continues to permit the inclusion of an ineffective ingredient in hundreds of cough and cold products.
Scott Gavura on March 30, 2023
Link

I’ve been blogging semi-regularly for almost 15 years and whenever I feel like I’m “blogged out” with nothing more to say, I inevitably find a topic that I’ve missed or forgotten to blog. When I read this post and then this paper about the dubious justification for the sale of a common cough and cold ingredient, I was frankly embarrassed that I hadn’t already written about it – years ago. Because the ineffectiveness of some cough and cold products is something everyone should be aware of.
We all suffer from coughs and colds. Surprisingly, while there are dozens of brands and formulations of cough and cold remedies on pharmacy shelves, they all use combinations of the same core handful of ingredients. And the evidence supporting some of these products is very, very weak. In the case of phenylephrine, included to treat “congestion”, it’s widely considered ineffective. Yet the FDA and regulators around the world continue to allow this ingredient to be included in cold products, as if it has medicinal benefits. Considering the evidence, this seems unwarranted.
What is phenylephrine?
In 1976, the FDA concluded that three medicines were safe and effective for the treatment of nasal congestion caused by colds, allergies, and sinusitis: phenylpropanolamine, pseudoephedrine, and phenylephrine. Almost 25 years later, phenylpropanolamine was withdrawn from the market after use was associated with strokes. Pseudoephedrine is an effective decongestant that is chemically very similar to methamphetamine, a addictive and controlled drug that subject to abuse. Pseudoephedrine does not share the same stimulant properties as methamphetamine, though it can cause jitteriness, mild tremors, and insomnia. However, because pseudoephedrine can be used to manufacture methamphetamine, the over-the-counter sale of cough and cold products that contain this ingredient are not permitted. Sales were moved “behind the counter” in the US, with the requirement for the customer to produce photo identification and the requirement for the pharmacy to maintain a log of all sales, tracked by customer name and address.
When pseudoephedrine was moved behind the counter, manufacturers of cough and cold products either had to accept a much smaller market for their (effective) product, or…pivot.

Some companies reformulated their products to contain phenylephrine instead, the last remaining non-prescription ingredient that the FDA had approved for congestion. Phenylephrine is from a category of drugs called alpha-1 agonists, that stimulate alpha-1 receptors that are present throughout the body, including the nasal passages. It is used as a nasal spray but more commonly as a oral product take to treat nasal congestion. There was a problem with FDA’s approval, however. There was little convincing evidence phenylephrine, when taken orally, was effective.
The evidence against phenylephrine
Phenylephrine is a poorly-absorbed drug (i.e., it has low bioavailability). Most of the drug is broken down during the absorption process and after passing through the liver. Only an estimated 38% of a dose actually reaches the bloodstream (compared with 90% for pseudoephedrine). In clinical trials, phenylephrine has been compared to other decongestants in a randomized controlled trial of 20 patients (way back in 1971) and found to be no more effective than placebo in reducing airway resistance. Another trial compared single doses of four different decongestants against placebo in 88 patients with congestion. It also found that phenylephrine was no more effective than placebo. In a review of the data that the FDA had considered, that review noted that for the 10mg dose, 4 studies showed efficacy and seven showed no difference from placebo. The authors concluded that a systematic review did not support the FDA’s decision. Other trials conducted since that time (like this one in 2009) are supportive of the conclusion that the 10mg dose is ineffective.
The fact that we are relying on trials conducted in the 1970’s pretty much tells us what we need to know about phenylephrine. Given how poorly it is absorbed, there is the question of whether simply giving bigger doses will work – and it turns out it may. However, the 10mg dose is what’s available in US cough and cold products – and the best evidence shows that this drug is effectively a placebo at that dose. I will point out that the manufacturers of the consumer products that contain this ingredient continue to write their own papers suggesting that there is evidence of efficacy.
The FDA is petitioned…and is finally acting
In 2015, pharmacy professors Randy Hatton and Leslie Hendeles of the University of Florida College of Pharmacy filed a citizen’s petition with the FDA, asking it to remove phenylephrine from the monograph of over-the-counter cold remedies, noting the absence of a decongestant effect at the approved dose of 10mg. They noted that since the FDA’s Nonprescription Drugs Advisory Committee had called for more research in 2007, four studies had been conducted, and none of those studies demonstrated that phenylephrine was more effective than a placebo. This petition is supported by the American Academy of Allergy, Asthma and Immunology:
The low bioavailability of pharmacologically active oral PE explains the lack of nasal therapeutic efficacy and cardiovascular effects. It is extensively metabolized in the gut mucosa causing insufficient systemic PE levels to produce vasoconstriction of nasal and other blood vessels. Available data do not support whether a dose greater than 40mg of oral PE would be effective or safe. Furthermore, the American Academy of Allergy, Asthma & immunology and the American College of Allergy, Asthma & Immunology in their role as patient advocates have concluded that keeping oral phenylephrine over‐the‐counter does a disservice to patients who might be prone to taking higher doses than recommended due to lack of effect and/or delay their visit to their primary care clinician or a specialist who could help resolve their symptoms.
Ineffective drugs don’t deserve stamps of approval
Professors Hatton and Hendeles reiterated their call for the FDA to take action in 2022, and finally the FDA may act this April:
The committee will discuss the adequacy of efficacy data available for oral phenylephrine as a nasal decongestant and whether oral nasal decongestants phenylephrine hydrochloride and phenylephrine bitartrate should be reclassified as not ‘Generally Recognized as Safe and Effective’ (GRASE) due to lack of efficacy.
Why the approval has persisted so long is puzzling from an evidence perspective, but perhaps it was sensible to the FDA. Phenylephrine is safe at the 10mg dose, and withdrawing the drug might raise more questions about why this drug was permitted in cough and cold products, for decades, without clear evidence of effectiveness. Until that time, remember that the only available non-prescription oral decongestant that has been shown to actually be effective is pseudoephedrine. Ask your pharmacist if pseudoephedrine is right for you.

Medicine Must-Haves: A Pharmacist’s Guide to Your College Student’s First Aid Kit
A pharmacist recommends medications for a basic first-aid kit.
Scott Gavura on August 28, 2025
Link
Sending a child off to college or university is a milestone filled with excitement, anxiety, and – if you’re a pharmacist – a bit of overthinking about their medicine-related needs. (Just me?) Beyond the usual concerns, like roommates, buying a refrigerator, and moving across the country, there is less obvious but still important question – how do we set our kids up for independence, medicine-wise? While most young adults are generally healthy, the reality is that minor injuries, stomach upsets, headaches, and allergies don’t disappear at school, and they won’t have their parents around to help them. A well-selected first aid kit can help students effectively treat minor issues. It’s also worth noting which medicines are best avoided because they are ineffective, have side effects, or should be used only on the advice of a health care professional. Here is one pharmacist’s guide to medicines to consider for a basic/minimalist medicines kit for students. And it’s not just students – I have the same medicines on hand for when I travel (pictured above).
The Disclaimers
Before diving into my recommended medications, it’s worth noting a few key considerations and limitations. First, this list focuses on pharmaceuticals; items like bandages and thermometers are worth considering in a first aid kit, but they’re not part of this discussion – there are plenty of guides you can find on what to include. Second, each student’s health needs and medical history will be different. Allergies, chronic conditions, or sensitivity to certain medications should always guide what goes into a medicines kit. If unsure, check with a licensed health professional who knows their health history. I am not your pharmacist, so what I’m suggesting here is general information that does not reflect what might be most appropriate considering specific medical circumstances. With these points in mind, here are the medicines this pharmacist would generally recommend, and those best left at home. I’ll divide this into categories.
Pain and Inflammation
Most first aid kits should include acetaminophen, typically 325 mg or 500 mg tablets. These are effective pain relievers and are generally very safe when taken at recommended doses. They also have the advantage of not irritating the stomach. The main limitation of acetaminophen is that it does not treat inflammation. For other types of pain, or pain that doesn’t respond well to acetaminophen—such as minor injuries—an anti-inflammatory drug like ibuprofen 200 mg is my preferred choice. It’s widely available, easy to dose (1–2 tablets at a time), and effective for both pain and inflammation. An anti-inflammatory alternative to ibuprofen would be naproxen which has the advantage of less frequent dosing, but at the expense of more stomach and digestive complications, especially with prolonged use.
Digestive Issues
For common stomach problems, a few well-chosen medications can be very helpful and will be appreciated if they are accessible. Antacids like Tums (essentially calcium carbonate) provide quick relief for occasional heartburn or acid discomfort. For longer-lasting control, products that reduce stomach acid, such as famotidine (preferred over ranitidine because of safety concerns) can be useful for heartburn or stomach upset. There is also omeprazole, a proton pump inhibitor, but I don’t recommend it for first aid, because it takes days to reach peak effectiveness. If you need to take either product regularly, it should be on the advice of a physician.
For diarrhea, loperamide (Imodium) can be a lifesaver. It can help quickly get symptoms under control and allow your student to stay on schedule. While fine for occasional use, it should not be used if there’s a fever or blood in the stool, since loperamide treats the symptom rather than the underlying cause of the diarrhea. I recommend loperamide over any other antidiarrheal because of how quickly it works.
Allergies and Allergic Reactions
An antihistamine such as loratadine or cetirizine is a good choice for students who experience seasonal allergies, insect bites, hives, or other mild allergic reactions. These medications generally do not cause drowsiness (though cetirizine is more sedating than loratidine), making them convenient for busy active students. I do not recommend diphenhydramine – it causes drowsiness and is not more effective than the non-sedating antihistamines for common allergic reactions.
Topicals
Topical medications can help with minor skin issues. A mild non-prescription corticosteroid cream, such as 1% hydrocortisone, is useful for relieving irritation from insect bites, mild rashes, or other skin irritations. It’s generally safe for short-term use on small areas. However, avoid topical antihistamines – they are not effective.
For minor cuts, scrapes, or burns, a topical antibacterial ointment like bacitracin or a triple-antibiotic ointment can help prevent infection while the skin heals. Used sparingly, these products are typically well-tolerated.
What to Leave Out
Not every medication belongs in a student’s first aid kit. There are several I do not recommend.
Narcotic-containing products, such as codeine-based pain relievers or cough syrups, should be avoided entirely. These products carry risks of dependence, sedation, and are unnecessary for most minor pain.
Most over-the-counter cough and cold products offer limited benefit and can cause unwanted side effects, especially multi-ingredient formulations that combine decongestants, antihistamines, and pain relievers. These can be confusing to dose and often contain unnecessary or ineffective ingredients.
Drugs to promote sleeping (non-prescription) are not recommended. While it is popular, I do not recommend melatonin because of the lack of evidence and questionable manufacturing standards.
Herbal supplements. All of them. If you’ve read any of my posts for the past 15 years you’ll know why.
Conclusion
A thoughtfully stocked first aid kit won’t solve every health issue, but it can empower young students to manage common problems confidently and safely. The essentials I’ve suggested here reflect a minimalist, practical approach, one that I use myself when traveling. You can fit all these products into a small bag or box. Tip: When you pack the kit, note the earliest expiry date, write it on a label, and attach that label to the outside of the kit. A little preparation now can save stress and anxiety down the road, and gives students and their parents more peace of mind.
What did I miss?


Stocking Your Home First Aid Kit: A Pharmacist’s Guide
A well-stocked home first aid kit saves time, stress, and urgent trips to the pharmacy.
Scott Gavura on September 11, 2025
Link
My home first aid kit. The savvy reader will be able to guess its vintage.
My post a couple of weeks ago on what medicines to send with your college student struck a chord with some of you. The comments were full of thoughtful additions and stories, and they made me realize that while we may think about “student kits” or “travel kits,” many of us haven’t put the same care into having a well-stocked kit at home.
I keep a compact (but still portable) kit of medicines and first aid materials that sits in a cupboard in my house (pictured above) with everything we need handy, in one place. There’s nothing like a feverish child in the middle of the night, a stinging caterpillar dropping on your neck, or (and this actually happened) swallowing a bee mid-run to remind you that even if the pharmacy is nearby, having essential medicines, organized, and on hand is important. It’s also handy to have it ready to go for disaster planning.
With that in mind, here’s a short, sensible list of medicines and supplies I think every household should keep in a home first aid kit.
Disclaimers
Like my last list, this list focuses on over-the-counter drugs but I’ll include some important non-drug products I recommend. Second, consider this a list as a starting point to build your own kit around – consider medications, chronic medical conditions and medication sensitivities to assemble something that suits you and your family. Lastly, remember that this is general information: I am not your pharmacist and I don’t know your medication history. I’m not giving you personal advice. I’m also not giving you dosing information. Read the package insert for each medication carefully. If you need advice, speak with a registered and licensed health professional, like your pharmacist. With these points in mind, here are the medicines this pharmacist would generally recommend.
General Considerations
A few general tips:
Wherever possible, and especially for medicine you use infrequently, choose medicines that come in unit-dose or blister packaging—individually packaged and labelled tablets. They are more compact in your first aid kit, and assuming you are storing your first aid kit properly, will not expire before the printed expiry date. A regular bottle may be more practical for medicines you access more frequently.
I am a fan of single-ingredient medicines versus combination products, with two or more ingredients. This allows you to match the medicine you take to your needs, and reduces the risk of accidentally combining duplicate ingredients.
Consider dosage forms. If you have children or family members with difficulty swallowing, you may want to have solid and liquid (and even chewable) versions of some products.
Buy generic when you can. Brand products are typically more expensive than the comparable generic. Generic drugs in most countries are tightly regulated and as safe and effective as their brand equivalents. If you are ever unsure, ask the pharmacist if they can recommend a generic equivalent.
Don’t forget your pets. Pets are part of the family and may have their own medicine requirements. Label specialized pet medicines clearly.
Store your kit carefully, away from temperature extremes. As you build your kit, note expiry dates on a sheet of paper. Put a label or sheet with the earliest expiry date somewhere visible as a reminder.
Suggested Medicines
Pain and Inflammation
In most cases the go-to analgesic is acetaminophen, either 325 mg or 500 mg tablets. It is an effective pain reliever and is generally very safe when taken at recommended doses. (Do not exceed 4000 mg per day.) Acetaminophen has the advantage of not irritating the stomach. The main limitation of acetaminophen is that it does not treat inflammation. For other types of pain, or pain that doesn’t respond well to acetaminophen—such as headaches or minor injuries—an anti-inflammatory drug like ibuprofen 200 mg is a good option. It’s widely available, easy to dose (1–2 tablets at a time, ideally with food), and effective for both pain and inflammation. An anti-inflammatory alternative to ibuprofen would be naproxen which has the advantage of less frequent dosing, but at the expense of more stomach and digestive complications, especially with prolonged use. You probably need only two products (acetaminophen + an anti-inflammatory) on hand for pain and inflammation, but you may want a few different dosage forms (such as chewables or liquids) if you have children or family members who have difficulty swallowing. I’ll cover topical analgesics below.
Digestive Issues
For common stomach problems, a few well-chosen medications can be very helpful. Antacids like Tums (calcium carbonate) provide quick relief for occasional heartburn or acid discomfort. (One commenter two weeks ago noted a preference for non-calcium antacids, like Gaviscon, so experimenting before an urgent situation may be worthwhile.) I also keep a bottle of bismuth subsalicylate tablets (Pepto-Bismol) in my first aid kit for general and acute stomach upset issues as well.
For longer-lasting relief, products that reduce stomach acid, such as famotidine (preferred over ranitidine because of safety concerns) can be useful for heartburn or stomach upset. There is also omeprazole, a proton pump inhibitor, but I don’t recommend it for your first aid kit, because it takes days to reach peak effectiveness. If you need to take either product regularly, it should be on the advice of a physician.
For diarrhea, loperamide (Imodium) can be a lifesaver. It can help quickly get symptoms under control. While fine for occasional use, it should not be used if there’s a fever or blood in the stool, since loperamide treats the symptom rather than the underlying cause of the diarrhea. In that case, you need medical advice. I recommend loperamide over any other antidiarrheal because of how quickly it works.
Coughs, Colds, and Allergies
For cold symptoms like congestion, pseudoephedrine is the only effective oral decongestant available over-the-counter. Depending on what country you live in, you may have some hoops to jump through to purchase it. Phenylephrine is also sold as a decongestant but it is not effective. Decongestant nasal sprays are also effective but I see them as optional for a first aid kit unless you want decongestant on hand and can’t use pseudoephedrine.
An antihistamine such as loratadine or cetirizine is a good choice for insect bites, hives, or other mild allergic reactions. These medications generally do not cause drowsiness (though cetirizine is more sedating than loratadine), making them convenient. I do not recommend diphenhydramine – it causes drowsiness and is not more effective than the non-sedating antihistamines for common allergic reactions. I described the approach to treating seasonal allergies earlier this year. Nasal corticosteroids are very effective but from my perspective less useful in a first aid kit unless it’s something you already use regularly. Avoid topical antihistamines – they are not effective.
Dimenhydrinate (brand name Gravol) is an antihistamine that is more commonly used for nausea and motion sickness. I keep this in my first aid kit and it’s handy, especially if you travel with your kit. It can cause drowsiness.
Topicals
Topical products can make your kit more versatile. Here’s what I’ve personally found helpful to have on hand, based on my own trial and error over the years.
Aloe vera gel – Optional but sometimes handy. Provides symptomatic relief for minor burns or sunburns.
Antiseptic wipes – Compact and useful for cleaning minor cuts and scrapes.
Topical antibiotic ointment (bacitracin or a triple antibiotic) – Helps prevent infection in small wounds. Use sparingly.
Antifungal cream or powder (e.g., clotrimazole) – Helpful if you or family members are prone to athlete’s foot or fungal rashes.
Hydrocortisone 1% cream – This is usually the maximum strength available without a prescription. It reduces irritation from insect bites, mild rashes, and skin inflammation. Safe for short-term use on small areas.
Topical pain relievers (menthol-based rubs, lidocaine gels) – Can provide temporary relief for sore muscles or minor injuries.
Sunblock (travel size) – Always useful if you’re caught without it.
Special Situations
Naloxone (Narcan) kits are worth keeping on hand for suspected opioid overdose whenever opioid exposure is a possibility. It can be truly lifesaving.
COVID-19 tests – Worth considering, especially for high-risk individuals who may require treatment with COVID therapeutic drugs if they become ill.
Epinephrine auto-injector (Epipen) – If you have a family member with anaphylactic allergies, they’re already carrying an Epipen. Keep an extra in your first aid kit.
Non-Drug Supplies
Medicines are only part of a good first aid kit. A few non-drug supplies make it much more useful:
Thermometer – A reliable digital thermometer is essential.
Bandages – Adhesive bandages in a variety of sizes, plus gauze pads and medical tape for larger cuts or scrapes. Blister treatments like hydrocolloid bandages and moleskin are essential, in my opinion.
Elastic bandage – For sprains or to secure dressings.
Tweezers and scissors – Tweezers for splinters or ticks (or a dedicated tick remover), scissors for cutting tape or bandages.
Gloves – Disposable medical gloves are compact and handy.
Masks – A few surgical or N95-style masks can help manage illness or unexpected exposure.
Oral rehydration salts or electrolyte powders – Useful during illness, heat, or after intense activity.
Keyring flashlight – For power outages or night-time emergencies.
Basic first aid manual – Even a short guide can be helpful in stressful situations. I don’t want to rely on my phone in an emergency.
Conclusion
    • A well-stocked first aid kit won’t cover every situation, but it will save you from late-night pharmacy runs and give you peace of mind. Start with the basics, tailor it to your household and your unique medication and health needs, keep updating it based on what you learn, and check it regularly so everything is current and ready to use. Let me know what’s in your own first aid kit at home and what I missed.

Dual Sympathetic Reset for PTSD
Dual Sympathetic Reset is being promoted as a treatment for PTSD prior to any convincing clinical evidence.
Steven Novella on January 10, 2024
Link

Can we treat psychological disorders by treating the physical symptoms of the disorder? That’s an interesting question, but it is a complicated matter to scientifically demonstrate a confident answer. Some therapists are bypassing the science and specifically endorsing such an interpretation for an “emerging” treatment for post-traumatic stress disorder (PTSD) – Dual sympathetic reset or block.
“Emerging” is in quotes for that is often a euphemism for a treatment that lacks sufficient evidence to demonstrate efficacy. When a treatment is described as “emerging” it seems to me that two things are being acknowledged. The first is that the treatment is unproven, or else it wouldn’t be an emerging treatment, it would be an established or proven treatment. The second is an assumption – that future evidence will support it. It’s similar to the optimistic use of the word “yet”, as in, this treatment has not been proven “yet”. That implies that it will be.
Language matters, and a neutral and more scientific approach would be to call it exactly what it is – experimental. If a treatment has not yet been studied scientifically, then it’s “untested”. It is important to recognize that experimental treatments, in the end, may not work – that’s why we are doing experiments. In fact, most experimental treatments do not ultimately work. This is a fact critical to science-based medicine.
Most such treatments have supporters who treat scientific research as a mere inconvenience, a box that needs to be checked on the inevitable path to widespread use. They often give away their bias by stating that the treatment is being studied to show “that” it works, or “how” it works rather than “if” it works. “If” a treatment works is the only important question until you demonstrate scientifically that it does.
When discussing that scientific research you also have to keep a lookout for similar euphemisms. The research for treatments that have not yet been adequately demonstrated to work is often called “encouraging”. My concern here is not so much that it’s not true – positive preliminary evidence is encouraging – but rather that “encouraging” is often presented as “inevitable” when in reality most preliminary encouraging research turns out to be wrong.
I also find it problematic when explanations are offered to explain “how” a treatment works (often with the phrase “thought to” – the treatment is thought to work through this mechanism) before we know if they work. I find it especially problematic when hand-waving explanations are given that are based on metaphors or simplistic neuroscientific notions.
The risk here is that an emerging treatment with encouraging preliminary evidence and semi-plausible mechanism of action will be prematurely adopted, creating a group of providers who now have a vested interest in the treatment, and patients convinced by what may be nothing more than placebo effects. This becomes a self-sustaining ecosystem that can thrive in the absence of scientific evidence. Research is then steered into pragmatic studies that are not designed to actually test efficacy. When evidence for lack of efficacy emerges, it is dismissed.
I have concerns that this is exactly the path that Dual Sympathetic Reset for PTSD is taking. Promoters are talking about the treatment as if it is fully established. The idea is to use a dual sympathetic block (dual sympathetic reset), a nerve block procedure involving the stellate ganglion, to treat anxiety and PTSD. This is an established procedure for some types of facial pain. The claim is that people who suffer from PTSD are hypervigilant and have an exaggerated startle response because their sympathetic “fight or flight” system is stuck in the on position. Blocking the stellate ganglion can “reset” or “reboot” the sympathetic nervous system back to its normal function.
That’s a nice story, but it is completely unproven. I find it a bit simplistic. It is also a setup for maximal placebo effects – an invasive procedure that may have some symptomatic relief. It is not surprising that the vast majority of “studies” of this treatment are little more than case reports or case series – purely anecdotal.
A 2023 review of the published evidence concluded:
“Despite the encouraging results, we remain cautious in interpreting the benefit of the technique due to the lack of sufficient standardized clinical trial data, heterogeneity in reported results, and the potential for bias in reporting. Future studies should focus on evaluating and addressing the technique’s effectiveness, safety, tolerability, and indications.”
Another review found only two randomized placebo controlled trials for dual sympathetic blocks for PTSD, one study was positive and the other study was negative. Both studies were small and should be considered preliminary.
Clearly what is needed is registered trials with randomized, double-blind, placebo-controlled design and with the power and rigor to address the main question of efficacy. I can be convinced there is a useful clinical effect here (even if I would not jump to the simplistic “reset” explanation) with that level of evidence, if it reliably replicates. But we are no where near that threshold of evidence.
Language used by responsible professions should reflect reality – this is an experimental treatment, and it should be treated that way. That means it should only be used with proper informed consent indicating its experimental nature, and ideally within the context of a clinical trial. What we are mostly seeing instead is the treatment being promoted as if its efficacy is established, based entirely on anecdotes.

Generic Drugs and Global Deception
Generic drugs are supposed to be equivalent to brand-name drugs, but all too often they are defective. Katherine Eban’s book shows that corrupt overseas manufacturers have committed intentional global fraud. The system is broken and the FDA lacks the power to correct abuses.
Harriet Hall on September 3, 2019
Link

I always thought generic drugs were the best choice. They were tested and proven to be equivalent to the brand name originals and cost much less. But I never imagined that some of the data the FDA relied on had been doctored as part of a global pattern of deception. The book Bottle of Lies: The Inside Story of the Generic Drug Boom by investigative journalist Katherine Eban is an eye-opener. The unfortunate truth is that generic drugs can’t always be trusted: some of them are ineffective or even deadly.
When brand-name drugs come off patent, less expensive generic equivalents can be marketed. Prior to 1984, there was no clear pathway for a generic drug to be approved in the US. Senator Orrin Hatch sponsored legislation to get generics approved through an Abbreviated New Drug Application. All the company had to do was show that the generic was bioequivalent and performed similarly in the body. The first company to file its generic application would win the right to market its product exclusively for 6 months at close to the brand-name price before competitors could jump in and slash the price.
The FDA has a worldwide reputation as the “gold standard” for regulatory bodies. It regulates about one-fifth of the US economy, safeguarding public health by ensuring the safety of food, drugs, medical devices, pet food, and veterinary supplies. It has had an admirable track record, for instance when it refused to approve thalidomide. But the generic drug revolution exposed some serious flaws in the system. By 2005, the number of foreign manufacturing sites regulated by the FDA exceeded the number of sites in the US. American drugs are no longer made in America, and the FDA lacks the resources to properly regulate them.
AIDS drugs used to cost $10,000-15,000 a year in the West, but Cipla was soon offering the same drugs to Doctors Without Borders for $1 a day in the rest of the world. The Ranbaxy company in India agreed to sell the drugs for 38 cents a day. They won FDA approval, but a company employee, Dinesh Thakur, discovered an appalling culture of deceit and eventually became a whistleblower despite threats to his career and his family. Thakur found that Ranbaxy submitted false dossiers to the FDA, invented data, altered or discarded records, faked dissolution studies, and cheated in every possible way. Astoundingly, the company’s head of analytical research told an auditor “It is not in Indian culture to record the data while we conduct our experiments.” Their manufacturing standards boiled down to whatever the company could get away with. In India, “you could almost always make a problem go away, whether through strategic payments or the threat of force.”
The FDA aimed to inspect every facility making drugs for the US market every two years, but by 2009 the number of overseas facilities had skyrocketed to over 3,000. The FDA lacked resources and the actual rate of inspections was closer to once per decade. Inspections of foreign plants were announced ahead of time, losing the surprise element and facilitating Potemkin village-like cover-ups by the company. Language barriers were a problem, but clever investigators were still able to find clues in computerized records. They learned not to let the companies show them the facilities but to demand to go wherever they wanted. There was bias and coercion, and orders were often given to downgrade findings prior to release. A secret report within the company revealed such incriminating information that the cover page carried the warning “Do not give to the FDA“. (But the FDA got a search warrant for the company’s New Jersey facilities and obtained the offending document as part of their haul.) The whistleblower’s information showed that the top executives of India’s biggest pharmaceutical company had committed intentional global fraud. Such widespread corruption was so hard to believe that his information was distrusted, and he had to hire a lawyer to protect himself.
The companies were creative about explaining away discrepancies and missing data. They showed a blatant disregard for the law and lied to the inspectors’ faces. They said it was a cultural thing. They knew they could get away with it. Eban says, “it seemed that Ranbaxy was better at making excuses than it was at making drugs.” There was great pressure to make cheaper drugs available to the public, and sometimes it seemed that Ranbaxy was too big or too important to fail. Ranbaxy had manufacturing plants in 11 countries and sales in 125 countries. There were political concerns, with fear of damage to international relations. The FDA had no police power, no jurisdiction in foreign countries. The worst they could do is impose an Application Integrity Policy (AIP) to halt all review of a company’s applications pending review by outside auditors. For various reasons, they found it difficult or impossible to invoke that penalty.
Eban is a skilled storyteller. Instead of a dry recital of facts, her book is an intriguing mix of thriller, mystery, science, psychology, soap opera, and suspense. The short chapters maintain interest so the reader will want to know what happens next. She tells how Ranbaxy deceived the Japanese company that wanted to buy it, gave inspectors contaminated water and food to make them sick, bugged their hotel rooms, and engaged in every kind of skullduggery. She describes regulatory efforts, Congressional inquiries, bribery, and deaths caused by inferior drugs.
Joe Graedon, co-author of the syndicated column The People’s Pharmacy, initially told his readers they could trust generic drugs, but changed his tune when he became aware of the evidence of harm. For instance, there was an epidemic of bad reactions to contaminated heparin from China, organ transplants failed when tacrolimus generics produced inconsistent blood levels, and cardiac drugs dumped overdoses into the bloodstream by dissolving too fast. A generic version of the statin drug Lipitor was found to contain tiny shards of blue glass, never adequately explained. Defective drugs were supposed to be destroyed, but often the company just resold them in another market. Africa became a dumping ground for defective drugs, and Africans died. An American doctor working in Rwanda coined the term “The Lazarus Effect:” dying patients suddenly recovered when switched from a generic to a brand-name drug.
There were reports of bad odors and foreign objects in generic pills, from eyelashes to insects. A woman in New Jersey was about to take her daily capsule for high blood pressure when she saw a flash of movement. A small, centipede-like bug was stuck halfway inside the capsule and was wriggling to free itself. There were sporadic regulatory successes: Ranbaxy pled guilty and paid heavy penalties, but the responsible executives were not punished and moved on to wreak havoc at other companies.
Conclusion: the FDA system for regulating generics is broken
One might hope that exposure of these problems would lead to solutions, but the problems remain. The FDA didn’t even learn its lesson about surprise inspections. In 2016, they agreed to stop unannounced inspections and to notify India’s companies in advance.
I get my medications from the Department of Defense system, which consistently chooses to stock the least expensive generic version. Now I’m worried. If you’re not worried, I urge you to read Eban’s book.

Geopolitics and Drug Shortages
The war in Iran is challenging pharmaceutical supply chains and revealing strains in the system.
Scott Gavura on March 26, 2026
Link

I’ve been writing about drug shortages at this blog for almost 15 years. My most recent entry was in April 2020, when a major global health crisis was disrupting access to medicines and putting essential drugs into short supply. But over the past week I’ve been reading new columns about current events and their anticipated effects on the worldwide distribution of medicines. Some are predictable but some are less obvious. But the impact has been similar: Systems optimized for efficiency are vulnerable to disruption. The effective closure of the Strait of Hormuz and of several Mideast airports are exposing a reality of pharmaceuticals today: Efficiencies have built fragility into supply chains.
What’s happening now?
The Iran conflict has obviously created fuel supply issues, which are getting most of the headlines. But countless other essential products pass through this region, and it’s affecting the global distribution of medicines. Commercial activity through the Strait of Hormuz is running at a fraction of pre‑conflict levels, and air cargo rates are surging as Gulf airport capacity has plummeted. To be clear, I have not yet seen any widespread drug shortages on account of this disruption, but it could be because of existing inventory buffers: many manufacturers hold months of stock, and national/regional/local purchasers may also keep some inventory on hand.
The current state is not yet a crisis, but it is revealing strains. It echoes pandemic-era supply issues and illustrates that efficiencies in the system do not cope well with disruptive change. In the pandemic, the primary issue was lockdowns affecting manufacturing of active pharmaceutical ingredients (APIs) and their distribution. Today, it’s distribution bottlenecks and cost shocks. Both reveal system fragility. It is already being seen in how care is being delivered in conflict‑affected regions. In The Lancet, Mark Lawler of Queen’s University Belfast, notes that global cancer care is still recovering from disruptions caused by the pandemic, and this conflict could threaten quality care:
In many countries, cancer systems were already under pressure from financial constraints and the lingering impact of COVID-19. “Conflict layers an additional shock onto systems that are already fragile, and that can tip them over the edge”, Lawler said. Among the most immediate threats is disruption of medicine supply. “Even a short interruption in supply routes can quickly mean patients are not getting treatment at the time they should, or only receiving part of their treatment.” Because several cancer therapies must be administered on strict schedules, delays can have direct consequences for outcomes. “Quite quickly you can move from a system that is coping to one under severe strain, and that is when the cracks begin to appear”, Lawler added.
The importance of the Gulf
A less obvious vulnerability is not where drugs are made, but how they move. The Gulf—particularly Dubai—functions as a global pharmaceutical transit hub and has a disproportionate effect on the worldwide distribution of pharmaceuticals. As Think Global Health notes:
Dubai is central in this network. Its primary air-cargo airport—the world’s eleventh largest as of 2024—functions as a major pharmaceutical re-export hub, where medicines arrive, are warehoused, and then are shipped globally. CEVA Logistics, DHL, and DP World—Dubai’s pharmaceutical supply-chain logistics giants—have significantly grown the emirate’s pharmaceutical and health-care distribution footprint by expanding re-export and cold-chain capacities. They also capitalize on proximity to the Jebel Ali Free Zone, whose container port is the ninth largest in the world.
Dubai’s air-cargo capacity is almost 4 million tons annually. Considering the conflict-driven drop in the region’s cargo capacity, and that pharmaceuticals account for 4% of global air freight, the emirate could lose out on processing more than 10,000 tons of pharmaceutical air freight this March. These airspace disruptions are also spilling over into global-health emergency supply-chain response, and the World Health Organization’s (WHO) Dubai hub operations are currently on hold.
Which drugs are vulnerable?
Three categories of drugs seem to be at highest risk of supply shortages, based on their characteristics.
    • Temperature‑sensitive medicines: Vaccines, insulin, and drugs like biologics must be stored within a narrow temperature range throughout transit to avoid accelerated spoilage. Delays, and even worse, potential temperature variations increases the risk that drug quality may be compromised – an unacceptable situation for medicines that can be lifesaving.
    • Short‑shelf‑life and high‑value products: Some drugs already have short shelf lives. Disruptions to their distribution may mean that medicines, when they arrive at their destination, must be used quickly or will expire before they can be used. The longer supply interruptions exist, the greater likelihood of impact.
    • Generic drugs: Generic medicines make up a huge volume of current pharmaceutical markets, and are the backbone of hospitals and public insurance programs. Their low prices and cutthroat price competition have pushed margins low, and as I noted in past posts, consolidated production to fewer places worldwide. Because generics are already produced with thin margins, with manufacturing consolidated to a small number of facilities worldwide, spikes in energy and shipping costs may push some manufacturers to cut or exit low‑profit lines, or raise prices significantly. Either will cause supply issues and price spikes, which means purchasers need to find substitutions, implement rationing or even look at compounding.
The consequence of efficient systems
The current disruption is a reminder that drug shortages are not random failures. They are predictable outcomes in a system optimized for cost and efficiency, with little margin for error when shocks, geopolitical or otherwise, appear. Recognizing that is the first step toward building more resilient supply chains and more honest conversations about the trade‑offs between low prices and reliable access for patients. A more resilient system will not be as efficient, and that likely means higher costs.
When shortages make the headlines, they’re often treated as isolated, one‑off issues. Current events highlight that shortages are the consequences of supply chains with few redundancies that wrap around the world. No nation is immune, and the solution requires rethinking incentives, infrastructure, and visibility, not just rhetoric about “resilience” and “sovereignty”. Like I wrote almost fifteen years ago, no one “owns” the supply issue, and there is no single cause of medicines shortages. The challenge is building accountability for drug supply throughout this complex pathway. If we are unwilling to change this system, we are implicitly accepting drug shortages as a permanent feature of it.

Smart Drugs Are Here
Steven Novella on April 1, 2026
Link

There is a quiet revolution going on. While so much media attention is being spent on debating the risks vs benefits of raw milk, the latest outrages from the systematic dismantling of quality science at the CDC and other federal agencies, and by the tsunami of terrible medical science being pushed on social media, science-based medicine marches on. Public awareness of recent medical advances is limited, while so much of their attention is dominated by snake-oil peddlers, science deniers, and rank pseudoscience. Further, trust in authoritative medical information has taken a serious hit due mostly to all this misinformation.
Meanwhile – monoclonal antibody-based medicines are transforming almost every medical discipline. Targeted immune therapy is transforming cancer treatment. And CRISPR and other genetic technologies are ushering in an age of treatments for genetic illnesses. I think it’s important that as we highlight the dangers and false claims of scam medicine, we also showcase the real progress being made by scientific medicine. The contrast is stark.
So here is one more modern medical technology to be aware of – smart drugs. The idea behind smart drugs is to have increased control over where drugs go in the body, down to the cellular level. In classic pharmacology, what I learned in medical school and practiced most of my career, drugs are distributed in different compartments in the body. Some essentially bathe every cell in the body, while others are kept out of the central nervous system; some distribute more in water and others in fat tissue. But basically, drugs just diffuse throughout the body according to their chemistry, even if there is just one specific cell type that is the intended target of their action.
This “dumb” aspect of drugs is a major contributor to their side effect profile. This is perhaps most true when it comes to chemotherapy – powerful drugs that are highly toxic to cells. Because we are dealing with potentially deadly cancers, a high side effect profile is still worth it, and we use drugs that are optimized to be more deadly to cancer cells than they are to healthy cells, pushing the safe dosing to its limits.
But that was yesterday – today we rely more on targeted therapies like immune therapies that target the host’s own immune cells against their specific cancer. There are also smart drugs, which use a technology called antibody–drug conjugates (ADCs). These use monoclonal antibodies to target a biomarker on a target cell, such as a biomarker of a specific type of cancer. They then deliver a package of drug to cells with those biomarkers. This allows for concentration of the drug on the target cells with lower concentrations reaching healthy cells.
But ADCs have some limitations. They are large (on the molecular level) and so do not penetrate that deeply into solid tumors. They also can carry a limited amount of drug. They are not as selective as we would like, so there is still some off-target drug delivery. But still – ADCs are smarter than traditional drugs that just diffuse through tissues unguided.
But now a recent study points the way toward a significant advance – going from merely smart drugs to programmable drugs. This is a proof-of-concept study, so we are not ready for the clinic yet, but the technology is moving fast. Instead of antibody-drug conjugates this technology uses DNA-drug conjugates (DDCs). This is how it works.
DNA strands are used to target desired biomarkers and deliver their payload to the desired cells only, such as cancer cells. However, these DDCs can target multiple biomarkers at once, giving them much higher specificity than ADCs. A DNA initiator strand is split between these biomarkers. When the correct combination of biomarkers are close enough together on the cell surface, the split DNA strands come together in a hybridization chain reaction. This initiates endocytosis into the cell, delivering the package of drugs.
These split DNA strands can act as logic gates that make this system highly modular and programmable. In other words, they can be programmed so that the drug is delivered only when both biomarkers are present. But they can also be programmed to deliver the drug when other combinations of criteria are met – either/or, both, neither, etc.
There are several advantages over existing ADCs (in addition to being more programmable and modular) – they are smaller and can penetrate deeper into solid tumors, they can deliver more drugs, and they have a higher specificity. They can be used to deliver immune therapies in addition to drugs. They also tested mechanisms for amplifying the drug delivery, resulting in even higher concentrations of the desired drug at the desired cells, by a hundredfold.
This technology, while ideal for chemotherapy delivery, is not limited to treating cancer. It can potentially be used to target any drug to a specific cell type, which can result is greater effectiveness with fewer side effects at much lower total doses and therefore toxicity. This also allows for truly personalized and targeted pharmacological treatments.
The main limiting factor at this point is that the unmodified DNA used in the DDCs is not very stable in plasma, which limits its utility. This is a technical issue that will have to be worked out before DDCs are ready for the clinic, but this sounds like a very solvable issue.
This technology could have wide-ranging implications for the safety and effectiveness of modern medicine. The idea of just bathing the entire body in a drug in order to affect just one cell population may one day seem hopelessly crude (let’s hope). Also, many potential drugs are extremely effective, but fail because of off-target toxicity. They just don’t have a safe dose range. But if we could use a tiny dose that concentrates 100 times only on the target cells, they could become safe and effective treatments.
Keep in mind – we already have smart drugs. This technology could give us smarter drugs. And even if this specific technique does not work out, researchers are working on many paths to this same outcome. Little by little our drugs are getting smarter and this is quietly transforming medicine.
I just hope people notice among all the noise of pseudoscience and denialism.


Revolutions in Drug Delivery
New medicines are getting better. But so is our ability to get them where they need to go.
Scott Gavura on June 4, 2026
Links

Drug innovation is typically framed in terms of action: new targets, new molecules, new mechanisms of action. But some of the most consequential advances in drug treatment today are not solely about what a drug does – they are about how the drug behaves in the body. Surviving long enough in the bloodstream, reaching the right organ, releasing a treatment at the right moment: these are engineering problems, and solving them can be as difficult as finding the drug itself.
A cluster of recent approvals and late-stage trials results makes this visible. The therapies I want to discuss today span different diseases entirely: HIV prevention, bleeding disorders, cardiovascular disease – but share a common thread: Each works in large part because someone solved a delivery problem that was blocking the medicine from reaching its potential.

Lenacapavir: Convenient and Effective HIV Prevention and Treatment
Pre‑exposure prophylaxis (PrEP) is a preventive approach for HIV infection. It involves HIV‑negative individuals taking medication regularly to reduce their risk of acquiring HIV. PrEP uses antiretroviral drugs – the same types of drugs used to treat HIV infection – to prevent infection by blocking viral replication. It is intended for people at increased risk of HIV, such as those with HIV-positive partners, multiple sexual partners, or who share injection equipment.
To be effective, the drug must already be present in the body at an effective level to successfully prevent the establishment of an infection when HIV exposure occurs. The most common approach to PrEP is daily dosing of an antiviral medication. The challenge with the usefulness of PrEP it depends on consistent daily adherence.
Lenacapavir is one of the most consequential recent advances in HIV treatment and and prevention. Its innovation is not just incremental: it introduces a new drug target, a distinct pharmacologic profile, and a fundamentally different dosing paradigm.
Most existing HIV drugs target viral enzymes, such as reverse transcriptase, integrase, or protease. Lenacapavir targets the viral capsid—the protein shell that surrounds and protects the virus’s genetic material. The capsid plays a critical role at multiple stages of the viral life cycle, and disrupting it interferes with HIV replication in several ways.
Its pharmacologic properties are also unusual. Lenacapavir is highly potent, and when administered by subcutaneous injection, it has a long tissue half‑life. As a result, therapeutic drug levels can be maintained for months after a single dose. This enables dosing as infrequently as twice per year – dramatically different that daily oral PrEP.
Clinical trials show that lencapavir provides very high levels of protection against HIV infections and is superior to daily oral PrEP, and eliminates the need for strict daily pill compliance. In that sense, lenacapavir represents a different kind of advance: not just a more effective drug at the molecular level, but a pharmacologic solution to a behavioral limitation. By reducing the need for a daily patient habit, it has the potential to meaningfully expand the impact of HIV prevention. The remaining constraint is no longer scientific, but economic. In the United States, lenacapavir is priced at ~$28,000 per year, an unimaginable cost to many, especially in countries where PrEP is most needed.
GalNAc-siRNA: The Molecular “Address Label”
siRNA (small interfering RNA) is a tiny molecule that helps turn off specific genes in a cell. If you think of DNA as the master set of genetic instructions in the cell, and mRNA as a copy of one instruction used to make a protein, then the siRNA stops the mRNA from accomplishing its task. It finds the matching mRNA sequence and recruits cellular machinery that destroys it, silencing the gene before a protein can be made.
A useful analogy is that if you think of DNA as a cookbook, then mRNA is a copy of a recipe from that cookbook. siRNA shreds the recipe, so that the meal is never prepared. The cookbook (DNA) remains unchanged, but the siRNA ensures that particular reciped (protein) is never made.
siRNA is tremendously exciting because it can turn off specific genes. The medical challenge has been getting siRNA into the correct cells. RNA is rapidly degraded by enzymes in the bloodstream. It also cannot easily cross cell membranes, can trigger immune responses, and has no built-in mechanism to selectively enter specific cells. Injecting unmodified siRNA into the bloodstream is like mailing a letter with no envelope and no address, and hoping it reaches the correct recipient.
This is where N‑acetylgalactosamine (GalNAc) comes in. GalNAc is a sugar molecule that binds specifically to ASGPR receptors found in high abundance on hepatocytes (liver cells). When siRNA is chemically linked to GalNAc and injected into the bloodstream, these receptors bind the GalNAc and internalize the siRNA into the cell. The address matches, and the siRNA is delivered to the intended destination.
GalNAc-siRNA is an exciting platform for very targeted treatments where hepatocytes (liver cells) are involved. It’s the same delivery vehicle, but the payload is different. This means multiple drugs that treat different diseases can use the same architecture. Two examples:
Fitusiran for hemophilia: In hemophilia, the body is missing or has reduced levels of key clotting proteins (factor VIII in hemophilia A, factor IX in hemophilia B). This results in impaired clot formation and an increased risk of prolonged or spontaneous bleeding.
Rather than replacing the missing clotting factors, fitusiran reduces the production of antithrombin, an anticoagulant produced in the liver, using siRNA-mediated gene silencing. This shifts the balance of the coagulation system toward clot formation.
Because this mechanism acts independently of factor VIII or IX, fitusiran does not rely on replacing those factors. As a result, one drug can be used to treat both hemophilia A and hemophilia B.
In phase 3 trials, fitusiran reduced annualized bleeding rates by approximately 90% compared with traditional treatments, with many patients experiencing no bleeding episodes.
Lepodisiran for elevated Lp(a): Lipoprotein(a), or Lp(a), is a cholesterol-containing particle in the blood with levels that are largely determined by genetics. High Lp(a) levels are associated with an increased risk of cardiovascular disease (e.g., heart attack and stroke). Lp(a) is not meaningfully lowered by standard cholesterol treatments, such as statins, and until recently there have been no targeted therapies to address it.
Lepodisiran is an siRNA therapy designed to reduce the production of Lp(a) at its source in the liver. It targets the mRNA for apolipoprotein(a) in hepatocytes—the key component required to assemble Lp(a). Using a gene-silencing approach, lepodisiran recruits the cell’s RNA-silencing machinery to degrade this mRNA, preventing the protein from being produced. With less apolipoprotein(a) available, the liver generates substantially less Lp(a), lowering circulating levels.
A single injection of lepodisiran reduced Lp(a) levels by about 94%, with effects that persisted for up to a year. A phase 3 cardiovascular outcomes trial is underway.
Conclusion
Each of these examples represents a recognition that the gap between a promising molecule and an effective medicine can be often a delivery problem. Finding a drug that works in a test tube or animal model is challenging enough. Ensuring it survives in the bloodstream, reaches the right cells, acts for long enough to matter, and doesn’t harm you in the process is another challenge entirely. Design and delivery issues have received less attention – but that’s changing. The GalNAc platform alone has dozens of candidates in development targeting other liver-expressed genes. Depot formulations like lenacapavir’s are being explored for other conditions where adherence is a structural barrier to treatment. The molecules are innovative. Increasingly, so are the envelopes we’re delivering them in.


How the “Don’t take this medication with grapefruit juice” warning originated
How a chance discovery by one scientist improved the safety of consumers worldwide.
Scott Gavura on September 29, 2022
Link

Medical knowledge is the accumulation of aggregated learning, research, and observations. Research can be systematic, but discoveries can be also be serendipitous. I was thinking about serendipity and pharmaceuticals when I heard that Canadian pharmacist/pharmacologist David Bailey had recently died. Bailey made an unexpected discovery about drug metabolism and how food can profoundly affect the delivery of drugs into the body. 
In the early 1990s I was completing a hospital residency program in London, Ontario. My residency supervisor told me about a surprising finding made by a PhD researcher who had been working with the pharmacy department. David Bailey was trying to determine if the absorption of a new antihypertensive medication, felodipine, was affected by alcohol. This was a double-blind test, so Bailey needed to mask the alcohol. He tried different liquids, but ultimately found grapefruit juice was the most successful beverage. The results were surprising. He found that felodipine levels dramatically exceeded predicted levels, which was hypothesized to have potentially been caused by an interaction between the felodipine and the grapefruit juice – a drug-food interaction which had not been previously identified.
Bailey’s next experiment was on himself. He took a dose of felodipine and drew blood levels. The next day he took the same dose, with grapefruit juice. He could soon feel the effects of rapidly lower blood pressure, and the blood levels of felodipine confirmed that something odd was happening. A subsequent small clinical trial (now with almost 800 citations) showed that this effect was substantial, reproducible, and appeared to be limited to grapefruit juice (orange juice had no similar effect). Until this point, no serious interactions between drugs and food had been shown.
The grapefruit-drug interaction that had been discovered was the pivot for Bailey’s entire research career from that point onwards. Bailey had grown up as an exceptional track and field athlete and was the first Canadian to run a sub-4-minute mile. As a pharmacist and then PhD researcher, he didn’t plan to spend his career exploring drug-food interactions. But after this discovery, he turned his research lens on this phenomenon. His team in London went on to study this phenomenon extensively.
How does grapefruit juice affect drug metabolism?

The body has a number of mechanisms to deal with unwanted chemicals that might be ingested. Drug metabolism is the conversion of a drug to an inactive form that can be excreted, usually in the urine. The most common pathway for drug metabolism is what’s called “cytochrome P450“. One enzyme, called cytochrome P450 3A4 inactivates many drugs we consume. This enzyme is found in cells that line the small intestine and colon, as well as the liver. This means that for drugs that we take orally, a substantial percentage of the dose taken may be eliminated in the intestines and then the liver. In the case of felodipine, the drug Bailey had first studied, the bioavailability (amount available to the body to have a drug-like effect) is only 15% of the dose actually consumed. Because it has low bioavailability, anything that affects the action of the 3A4 enzyme may change the amount of felodipine that reaches the bloodstream.
Furanocoumarins are compounds produced by grapefruits (and limes, Seville oranges, and pomelos) possibly as a predator defense. When ingested, they can permanently inhibit CYP3A4 by binding to the enzyme itself, inactivating it. Once inactivated, the enzyme cannot metabolize ingested drugs, leading to greater levels of drug in the bloodstream when the drug is taken orally. The body needs to replace the enzyme in order for activity to be restored.
Grapefruit eater/drinker? Check your medications!
Several dozen drugs have subsequently been shown to be potentially affected by grapefruit. Characteristics include oral dosage form, low natural bioavailability, and metabolism by the 3A4 enzyme. When grapefruit juice is taken with these medications, it can be the equivalent of taking 20x the dose. You can find lists online – or just ask your pharmacist if you’re a grapefruit eater/drinker and you take prescription medicines.
David Bailey died last month at age 77. If you ever receive a prescription with a sticker cautioning against taking grapefruit, give thanks to Bailey for his accidental discovery 30 years ago.

The Polypill Comes of Age
The polypill is effective for secondary prevention of cardiovascular disease. By combining drugs in a single pill, it improves convenience and compliance.
Harriet Hall on September 20, 2022
Link

The polypill, not polypharmacy. Polypharmacy is the use of multiple medications by a single patient, which is sometimes appropriate and necessary, but can be ill-advised and result in medication interactions and complications. The polypill was first recommended 20 years ago. When the striking ability of statins to reduce the risk of cardiovascular disease was first recognized, one tongue-in-cheek proposal was to add statins to the drinking water. Of course, that scattershot approach didn’t make sense; the dose could not be controlled and would have resulted in over-medicating low-risk patients who didn’t need treatment while under-medicating those who did. And some people don’t drink tap water.
In their original proposal, Wald and Law coined the term polypill to describe a fixed-dose combination of medications to prevent cardiovascular disease. Their proposal was two-fold. They said that giving a polypill to everyone over the age of 55 would reduce cardiovascular events by more than 80%. And they proposed using a fixed-dose combination instead of individually prescribed medications.
A heated debate ensued over who should be treated, and unfortunately it over-shadowed the idea of using a fixed-dose combination, a strategy that has been shown to improve compliance by simplifying the treatment regimen. Re-focusing the debate on secondary prevention removed the objections about giving medication to those who don’t need it, since it has been shown that giving medication to everyone with established cardiovascular disease improves outcomes.
Numerous studies have now shown similar or even improved risk factor control with the polypill as compared to usual care. But previous trials were underpowered and unable to demonstrate the effect of polypills on cardiovascular outcomes. Hence a new study, the SECURE trial, reported in the September 15, 2022 issue of The New England Journal of Medicine, along with an informative editorial by Thomas Wang.
SECURE stands for Secondary Prevention of Cardiovascular Disease in the Elderly. It was an open-label, multinational, randomized, controlled trial comparing a polypill-based strategy (aspirin, atorvastatin, and ramipril) to usual care according to current European Society of Cardiology guidelines for secondary prevention in patients with recent myocardial infarction. 2,500 elderly patients were followed for 3 years. Major cardiovascular events occurred more frequently in the usual care group than in the polypill group (12.7% compared to 9.5%). This was despite high rates of evidence-based therapies in the usual care group (97% were on statins). The safety of the polypill strategy was again confirmed.
Six different formulations of the polypill were available for physicians in the trial to choose from, with 2 different doses of atorvastatin and 3 different doses of ramipril. 95% of patients were also taking a second antiplatelet drug. Should that be added to the polypill to reduce the pill burden even further?
Conclusion: A good idea whose time has come
After 20 years, the polypill’s role in secondary prevention is clear. It improves compliance and outcomes. Some barriers remain, including a lack of commercial interest, but it seems to me a clever marketing campaign could create a blockbuster new drug for some lucky company.

Fixed Dose Combination Drugs: Consensi Is a Bad Example
Consensi combines two drugs for high blood pressure and osteoarthritis. That doesn’t make sense, and it costs $12,000 a year more than taking the individual components.
Harriet Hall on April 21, 2020
Link

Combination drugs, or fixed dose combinations (FDCs), combine two or more active ingredients in a single dosage form. One company added LSD to their birth control pills so you could take a trip without the kids. OK, that’s just a joke, but the FDA has approved a new FDC, Consensi, that is almost as laughable.
There are good reasons to combine drugs. HIV/AIDS patients used to have to take a complicated regimen of pills, some as often as five times a day. Now all they need is a single once-daily pill that combines two to four anti-retroviral drugs. Oral contraceptives combine two hormones, estrogen and progestin. There are numerous FDC blood pressure pills; for instance, a beta blocker may be combined with a diuretic. The Parkinson’s drug carbidopa/levodopa combines those two ingredients to increase the availability of levodopa to the brain and to reduce side effects. The two antibiotics trimethoprim and sulfamethoxazole are combined in products like Bactrim and Septra because they act together synergistically against bacteria. The four anti-tuberculosis drugs isoniazid + rifampin + ethambutol + pyrazinamide are combined in a single pill.
There are good reasons for combining these drugs. Combinations simplify treatment, improve patient compliance, reduce prescribing errors and inadequate regimens, and may reduce drug supply management problems and cost. Studies have shown that these combinations are safe and effective, and there is plenty of evidence that FDCs improve compliance. Patients appreciate the convenience and the reduced co-pays (for one pill instead of two). But not all combinations make sense.
Sometimes drugs are combined for reasons other than therapeutic benefit. Drug companies create FDCs as a way to extend their proprietary rights, increase prices, and improve marketability. It is much less costly for them to combine existing drugs than to develop new ones. The FDA does not usually require additional studies before approving a combination product as long as there are good data on the components and no concerns about safety issues.
For the period 1990 through 2013, the FDA approved a total of 131 prescription FDC products. 13 have been discontinued because of poor commercial performance or the development of a better product. 117 had two active components, 12 had 3, and 2 combined 4 components. A polypill with 5 components (3 anti-hypertensive drugs plus a statin and aspirin) showed promise on initial testing, but never took off.
The big question is whether a combination offers advantages that outweigh the disadvantages. There is no way to adjust the amount of one component. The FDC may contain more or less of one component than is ideal for an individual patient. If adverse reactions occur, it’s hard to know which component is responsible. Patients may be over-treated when they might have responded to a single component.
There are lots of rational combination drugs with advantages that outweigh the disadvantages. But there are also irrational combinations that beggar the imagination.
The FDA recently approved Consensi, a combination of treatments for two very different diseases. It contains amlodipine, a common drug used to treat high blood pressure, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), used to relieve the pain of osteoarthritis. It comes in 3 strengths with varying doses of amlodipine, but all formulations contain the same amount of celecoxib: 200 mg. The company website says “ConsensiTM is under patent protection in the U.S. until 2030 and will be the only NSAID whose labeling indicates a reduction of blood pressure and consequent risk reduction of heart attack, stroke and death.”
The Medical Letter recently reviewed Consensi. Their conclusion:
There is no good reason to use the fixed-dose combination…The cost of the combination is much higher than the cost of the two components taken separately, and continued daily use of celecoxib can result in serious adverse effects, including renal and cardiovascular toxicity. Elderly patient should minimize their use of any NSAID, including celecoxib.
The cost for 30 days of treatment with Consensi is $1,287. Generic amlodipine alone costs $1.10. Generic celecoxib alone costs $34.40. Consensi is available at Costco with a free coupon for a reduced price of $1,104.13. Consensi carries a boxed warning of the risk of serious cardiovascular and gastrointestinal events.
The Coeptis and Kitov companies have entered into an agreement for commercialization under which Kitov will receive millions of dollars in royalties, milestone, and reimbursement payments.
Conclusion: An irrational product
It doesn’t make sense to combine these two ingredients for such very different diseases. How many patients have both diseases and would benefit from Consensi?
High blood pressure is seldom controlled on a single anti-hypertensive drug. In the best possible scenario, if a patient happens to have high blood pressure that is already well-controlled with amlodipine alone and also happens to have osteoarthritis that is already well-controlled with 200 mg of celecoxib alone, it would be more convenient to take one combination pill than two single pills. But does that convenience justify an added cost of over a thousand dollars a month, over $12,000 a year? I don’t think so! Patients might argue that they don’t have to pay for it, that insurance pays; but if insurance expenses go up, someone has to pay, and it ultimately impacts all of us.
Thumbs down!

Sex and Racial Bias in Cardiac Care
Sex and racial biases in cardiac care partly reflect cognitive biases that can be corrected with education.
Steven Novella on May 4, 2022
Link

One of the core principles of SBM, and one of the features that distinguishes it from EBM, is that it considers not just clinical evidence but the full range of scientific evidence in addition to metacognition – principles of logic and critical thinking. Critical thinking includes not just basic logic but also understanding of informal logical fallacies, heuristics, and cognitive biases. These principles apply not just in evaluating the scientific literature, but also in clinical decision-making – the best science does not help if we do not apply it properly when dealing with an individual patient.
This is why a proper medical education should include direct confrontation of the various cognitive biases and how they can adversely affect our clinical decision-making. Most of this occurs as implicit “pearls” of clinical wisdom, but I think it’s better to teach them as explicit formal critical thinking. For example, it’s one thing to teach medical students about the pitfall of giving too much weight to diagnostic “zebras” (rare but enticing diagnoses). It’s another to teach them explicitly about the representativeness heuristic (evaluating probabilities based solely on apparent similarity to type and ignoring the base rate) and all the various forms it may take. Deeper still, it’s important to teach students about the complex relationship between intuitive and analytical thinking in the various stages of decision-making.
Beyond falling for a statistically rare diagnosis, the representativeness heuristic may also cause clinicians to delay or ignore a likely diagnosis because of what are considered “atypical” features (demographic or symptomatic). It is now increasingly recognized, for example, that women receive less aggressive cardiac care simply because they are women. Why does this happen? Doctors learn that a “typical” heart attack patient is male, older, with crushing chest pain, shortness of breath, and diaphoresis (sweating). That is the essence of the representativeness heuristic – thinking about which features are typical, rather than how predictive each feature is. Being female, in the right clinical setting, is not very predictive that a patient is not having a heart attack, at least not enough that standard of care should be ignored or delayed. Yet that is exactly what happens.
Another layer of bias is that the “typical” suite of signs and symptoms of an acute heart attack were developed by studying men, long treated as the default or standard in medicine. Women tend to present a little differently, with a more varied location and type of pain, and may not have chest pain at all. This is considered an “atypical” presentation of a myocardial infarction (MI), but it isn’t. It’s atypical for men, but perfectly typical for women. Even considering this presentation “atypical” is itself a bias.
Yet another layer of bias is the notion that women are “protected” from MI because of their biology. While this is true, relative to men, it has limited relevance when dealing with an individual patient. Statistically women will get an MI 7-10 years later than men, but it is still the leading cause of death in older women. The fact that men have an even higher risk of MI is actually irrelevant. When a patient is presenting with possible symptoms of an MI, their demographic risk relative to another group does not matter. But it creates another bias against accurately assessing the risk of the individual. This is yet another cognitive bias, where we tend to consider magnitude relative to other things rather than intrinsically.
All of these biases have an effect. It is now well-established that women receive less aggressive preventive, diagnostic, and acute cardiac care than men. Adding to this is a recent study looking at the treatment of women presenting to the ER with possible MI:
Women were less likely than men to be triaged as emergent (19.1% versus 23.3%, respectively, P<0.001), to undergo electrocardiography (74.2% versus 78.8%, respectively, P=0.024), or to be admitted to the hospital or observation unit (12.4% versus 17.9%, respectively, P<0.001), but ordering of cardiac biomarkers was similar.
Other studies have looked specifically at the time delay from first symptom to definitive treatment for acute MI. The primary delay seems to be the time from first medical contact to hospital arrival, which was delayed by 28 minutes on average. Essentially women were treated with less urgency when making that first call about their symptoms.
Racial biases also exist in the delivery of medical care. This is one of those phenomena that the more you look for it, the more you find it. In the cardiac treatment study above, they also found:
People of color waited longer for physician evaluation (HR, 0.82 [95% CI, 0.73–0.93]; P<0.001) than White adults after multivariable adjustment, but there were no racial differences in hospital admission, triage level, electrocardiography, or cardiac biomarker testing.
It is reassuring that the treatment was the same, but race did seem to be an independent predictor of the delay in initiation of care. Twenty-five years of research, however, have demonstrated consistent differences in treatment and outcome. The causes are distinct from sex difference, but follow the same themes of systemic and individual biases. One systematic review lists these possible causes:
    • Some black patients may decline state of the art treatments or fail to seek out care because they are less informed about symptoms, medications, and treatment related to heart disease than their white counterparts.
    • Black patients may be less likely to trust the health care system based on their perception of discrimination and knowledge of historical atrocities like the Tuskegee Experiment of Untreated Syphilis in Negro Males.
    • Physicians caring for black patients may be overwhelmed by the volume of patients and the severity of disease at presentation, and underperforming with regards to following evidence-based treatments.
    • Unconscious bias with regard to race (“white preference”) and frank racism may result in physicians being selective in applying medical and procedural therapies.
    • Black patients may be overrepresented at hospitals that underperform with regards to high-quality, evidence-based cardiac care.
    • The physician workforce in the USA does not reflect the nation’s patient population, potentially exacerbating all of the above and depriving many patients of culturally sensitive, compassionate care from individuals with whom they have something in common and whose recommendations they may be more likely to follow.
In order for physicians to be advocates for their patients we need to confront these biases that can lead to worse medical outcomes for our patients. Systemic and societal issue are of course very tricky to deal with and are more of a generational project. Individual clinician biases, however, can yield fairly quickly to data and education. We now have extensive research describing the problem. One solution is to incorporate not just these individual cases, but the deeper principles of critical thinking into standard medical education.

Swearing to Treat Pain: Helpful Approach or Just Another Distraction
Pain is a complicated problem and something that we will all experience in our lives. Is swearing a helpful way to reduce pain, or is it just another distraction? Maybe it’s both.
Clay Jones on May 13, 2022
Link
Last week I strained a muscle in my upper back and neck, likely my trapezius. For several days I had pain and stiffness that restricted turning my head and made sleeping difficult to say the least. I’ve had acute back and neck injuries before, as will roughly 80% of humans thanks to walking upright with spinal bones better suited for our arboreal ancestors, but this was one of the worst ones I’ve experienced yet.
Pain is one of the more complex health problems we face. There is currently no reliable means of measuring pain objectively. No blood test or imaging modality exists that might help me know if a patient is in pain or how much pain they are in. Instead I must rely on observing behavioral cues or, when a patient is old enough and capable of answering questions, I can ask them how bad their pain is using a variety of tools, none of which are very helpful.
The experience of pain is fairly unique to each individual. As they say, one person’s 5 out of 10 pain is another’s 10 out of 10. The specific factors that influenced my personal experience of pain over the past week or so aren’t easily quantifiable and largely exist in my brain, even though acute tissue injury was clearly the inciting event. Previous experiences with pain, cultural beliefs, and personal attitudes played a role, as did any subconscious fear of prolonged suffering or anxiety over the potential for loss of function. But this is just the beginning when it comes to biopsychosocial factors that might have influenced not only my experience of pain but also how I might describe that experience if asked.
This is not to say that the degree of tissue injury doesn’t correlate with the amount of pain someone might experience. A gunshot wound to the abdomen will naturally hurt more than a paper cut. There are clearly instances where I can reliably assume that there will be severe pain, and even pain that might last for an extended amount of time, and tailor my medical management accordingly. But it is often not clear.
How much should a generic unit of pneumonia hurt? How about a migraine, a broken arm, or an ear infection? There are a seemingly infinite number of injuries and medical maladies that result in a spectrum of pain severity such that it is challenging if not impossible, or just plain wrong, to make assumptions. And chronic or functional pain, which often lasts long after any potential tissue injury has resolved, ratchets up the complexity by orders of magnitude.
Another important factor in an individual’s perception of pain is their susceptibility to distraction. Our brains, through myriad subconscious processes, raise or lower the intensity of our pain based on numerous variables. For clarification (I hope), imagine the following two scenarios:
Scenario 1
A 40-year-old woman develops anterior chest pain soon after turning in for the night. Her father had died last year from a sudden and unexpected heart attack which initially presented with chest pain. The woman had similar chest pain a month ago and felt ignored by the emergency department physician who told her that it was just heartburn and to take an antacid. She had recently read an article online that discussed heart attacks in women and how there can be delays in diagnosis and appropriate medical care. In the emergency department, she rates her pain as 10 out of 10 and expresses that it is unbearable.
Scenario 2
A 40-year-old woman develops anterior chest pain soon after turning in for the night. Her family history is benign, and she has always been healthy except for occasional episodes of heartburn that she treats with an antacid. She recently read an article online that discussed common benign conditions that can mimic a heart attack. She spoke with her mother, a retired cardiologist, about the pain and rated her pain as 3-4 out of 10. She takes an antacid and watches an episode of her favorite television program. After an hour, she feels much better and goes to bed.
As I stated earlier, there is no objective means of quantifying pain. But what if I told you that in this thought experiment there was, and that each of these women with heartburn had the same amount of pain as determined by measuring some fictional serum biomarker? What would explain the difference in how they experienced and expressed their pain when asked?
The woman in the first scenario was, understandably, more worried about her chest pain. She was afraid of the repercussions of missing a life-threatening condition and her previous experience left her feeling as if her concerns were dismissed by the medical system. Her brain likely perceived the situation as more of a threat and responded by turning up the volume on her pain, so to speak, without any conscious awareness or control.
The woman in the second scenario had a very different background. There was no recent loss of a loved one and she had a history of heartburn so was likely able to reassure herself that this wasn’t any different than all those other times when an antacid did the trick. She was even able to bounce her pain off an expert that she trusted and who likely provided additional reassurance. Because her brain hadn’t assigned a high threat level to her pain, distraction was an easy and helpful intervention. Before she knew it, the pain was gone and she was able to avoid a trip to the emergency department.
These scenarios are necessarily simplistic. There are countless biopsychosocial factors at play when it comes to pain, and I could never come up with two short stories that cover all or even a quarter of them. My goal was simply to highlight how the potential psychosocial variables can be just as important as the biological ones, if not more so.
Distraction, such as when the woman in scenario 2 watched a television program that she enjoys, can be a very effective means of reducing acute and chronic pain in many people. This is particularly true during brief episodes of procedural pain, like a vaccination or a finger stick. And there are countless ways to achieve distraction, though not all approaches will work for all people. Some people won’t respond to any non-pharmaceutical interventions, while others react like it’s legit magic, which is of course based on yet more complex psychosocial influences.
In March, Archives of Physiotherapy published a “Viewpoint” by physical therapist Nicholas Washmuth and psychologist Richard Stephens that discusses the potential for harnessing the pain relieving, and performance enhancing, powers of swearing. It’s just another form of distraction and unlikely to work via any unique mechanism, but it’s still a quick and interesting read. It is available in full online, which is nice for a change, but I’ll briefly break it down.
In the introduction, the authors point out the power of words to change how we think, feel, and perform, comparing them to drugs. That’s true in the general sense, though words do have limits. They won’t replace insulin, after all. Still it’s a good point. They endorse a biopsychosocial approach to physical therapy, which is great. Failure to recognize the importance of how we think, and the role of environment, fails the patient every time.
They give a brief historical perspective on swearing and set the scene for why it might serve as a powerful distraction because of its shocking nature. As evidence of potential downsides to swearing, they mention the risk of social isolation and cite a study which found an association between swearing and depression in women with rheumatoid arthritis or breast cancer, but only when swearing around other people. I didn’t read that study, but I would be curious to know if it addressed the possibility that depressed people are just more likely to start swearing in public rather than the other way around.
The authors then switch gears and list positive attributes associated with swearing. They claim that swearing has been found to be a sign of intelligence, honesty on a personal and societal level, and perhaps even creativity? Yeah, no shit.
The most important point made in their introduction is that the power of swearing, as well as the potential for negative repercussions, is largely dependent on the context of the situation and on an individual’s prior experience. Someone will likely find swearing to be more emotionally arousing if they have learned, through negative feedback from people around them, that swearing is “bad” and should be avoided or at least used sparingly. Of course, according to the authors, this is only about 10% of the adult human population. The rest of us apparently curse like sailors.
The authors caution that swearing shouldn’t be incorporated into a treatment plan without a specific goal in mind, such as reducing pain or relieving stress. They further warn that swearing might be less helpful a tool if used in a formal or public setting, though they admit that swearing can help to bring people closer together in certain situations by engendering a more relaxed social environment. Swearing could, by extension, help to foster a better therapeutic alliance between physical therapist and patient, which might help to address psychosocial factors related to the perception of pain.
You’re probably wondering if anyone has actually designed a study looking into the potential pain reducing benefits of swearing. The Viewpoint authors surely wouldn’t waste our time with mere conjecture! They discuss a study where subjects placed their hands into ice water while repeating either a swear word or a more socially acceptable word. Subjects in the swearing group kept their hand in the ice water for 40 seconds longer on average and also waited longer before admitting that they felt any pain while their hand was submerged. Not surprisingly, subjects who used swear words more frequently experienced less of an effect.
All of this is consistent with simple distraction, which the authors admit is the most likely mechanism behind any apparent reduction in pain associated with swearing. They give some helpful tips for readers:
     1.  Use a swear word that you would use if you banged your head accidentally.
     2.  When in doubt, just use “shit” or “fuck”.
     3.  Use an actual swear word rather than one that is made up to merely sound naughty.
     4.  Don’t direct your swear at your physical therapist or any present individual.
     5.  Limit non-therapeutic swearing in order to preserve any potential benefit for reducing pain.
The authors point out that swearing might not be for everyone because there are some potential negative consequences. They also recommend that patients should work with a trained clinician to determine if they might be a good candidate. Finally, they remind the reader that it’s probably best to keep the swearing private or at least to a group of trusted friends.
If it sounds like I’m giving this paper a hard time, I am…a little. Swearing to help reduce pain is a bit of a silly concept, but it is a potential distraction and might help alleviate some kinds of pain in certain circumstances. But it is a cumbersome means to achieve that end, and there are better and perhaps more productive approaches.
Even if we assume some benefit, the biggest weakness with swearing is the loss of effect with repeated use. Once the novelty has worn off, then the patient is just saying a word that has no power. Other distraction techniques don’t have this issue. But if you think swearing helps, whether to reduce pain, alleviate stress, or just to impress your friends, family, and co-workers, go for it.

Are Muscle Relaxants an Effective Adjunct for Treating Acute Low Back Pain? Yes and No
The journal American Family Physician left me confused about adding muscle relaxants to analgesics for acute low back pain. One article says it isn’t effective, but another article in the same issue says it is.
Harriet Hall on August 17, 2021
Link

For 22 years, American Family Physician (the journal of the American Academy of Family Physicians) has been publishing an annual review of the top 20 research studies of interest to family physicians, identifying original research that is most likely to change and improve primary care practice and that represents POEMS (Patient Oriented Evidence that Matters). I was interested to read in the July 2021 issue that muscle relaxants are not reliably effective adjuncts for treating acute low back pain. The full text is available online.
Confusingly, that evidence was contradicted by another article in the same issue on Pharmacologic Therapy for Acute Pain that said “muscle relaxants may be useful for acute low back pain”. It gave a top A rating to the evidence, based on systematic review and multiple randomized controlled trials.
So which is it? Are muscle relaxants effective adjuncts for treating acute low back pain or not? They conveniently provided references for both statements, so I was able to go to the sources they relied on.
The evidence provided to support the “No” conclusion was a single study by Friedman et al. published in the Annals of Emergency Medicine in 2019. The title was “A Randomized, Placebo-Controlled Trial of Ibuprofen Plus Metaxalone, Tizanidine, or Baclofen for Acute Low Back Pain“. It found that “Adding baclofen, metaxalone, or tizanidine to ibuprofen does not appear to improve functioning or pain any more than placebo plus ibuprofen by 1 week after an ED visit for acute low back pain”.
A review on The NEJM Journal Watch called it a high quality study and commented that it was no surprise, since it corroborated previous studies showing a lack of evidence for the effectiveness of muscle relaxants for this condition. In another study, diazepam (another drug commonly used as a muscle relaxant) was also no better than placebo.
The evidence provided to support the “Yes” conclusion consisted of twice as many references, but only two studies. One of the studies must be disregarded because it was not actually a study and was only a clinical practice guideline for neck pain, not low back pain. The other was a Cochrane systematic review by van Tulder et al. It evaluated muscle relaxants alone and in various combinations with analgesics for acute low back pain. For muscle relaxants + analgesics vs. placebo + analgesics, it found six studies suitable for evaluation.
Of the six studies they identified for acute LBP, five were considered to be high quality (Berry 1988b; Corts Giner 1989; Hingorani 1966; Sirdalud 1998; Tervo 1976) and one was a low quality trial (Borenstein 1990). Five trials evaluated non‐benzodiazepines and only one trial benzodiazepines (Hingorani 1966). All are described in the Cochrane review. For some endpoints, there was no statistical difference; for others they found modest improvement. They questioned the clinical importance of the improvement. Overall, they claimed to have found “strong evidence that non‐benzodiazepines are effective for acute LBP”. You can read the results of each study on the Cochrane website and judge for yourself. They concluded that “Muscle relaxants are effective in the management of acute and chronic non‐specific low back pain, but the adverse effects (most often drowsiness and dizziness) require that they be used with caution”. They mentioned a Danish report that reached a negative conclusion, “Muscle relaxants, for example diazepam, should play no role in the treatment of back pain. The possible positive effects are greatly overshadowed by the risk of physical and psychological dependency, even after short term usage”. I queried PubMed and didn’t find the results very helpful.
Conclusion: Maybe yes, maybe no
I am disappointed that AFP provided mixed messages and less-than-impressive scientific evidence. I am left wondering whether adding muscle relaxants to analgesic treatment of acute low back pain is worthwhile. I am skeptical. In the absence of more convincing evidence, I would be hesitant to prescribe muscle relaxants for adjunct treatment.

Platelet-Rich Plasma (PRP) Injections: Lots of hype, no convincing evidence
Platelet-rich plasma injections are advertised as an expensive cure-all for sport injuries. The evidence, however, is consistently negative.
Scott Gavura on October 17, 2019
Link


Like many people who are physically active, I have had my share of sports injuries, which seem to occur more frequently and last longer as I get older. Trying to fight against the inevitability of ageing is hard work, and no matter the activity, minor injuries seem to follow. Achilles injuries plagued my running. An intercostal strain from barbell training disrupted my sleep for weeks. And those newly aching elbows? Apparently I’m now getting some sort of tendinopathy. More trips to the physiotherapist. Sports medicine is quite possibly the worst area of medicine for pseudoscience, and it is difficult, if not impossible, to find a clinic that is pseudoscience-free. One service that is commonly offered and is seemingly very popular are injections of “platelet-rich plasma” or PRP. PRP is touted as an effective treatment for musculoskeletal injuries, where vials of your own blood are centrifuged and the platelets are injected back into you. PRP may be expensive, but does it work?
What is PRP?
Platelets are small cells in the blood that promote blood clotting. When you cut yourself and it clots, that’s your platelets working. Without platelets you would bleed to death. When platelets reach the site of a tissue injury they release chemical signals and growth factors to promote cell healing and recovery. Platelet-rich plasma is plasma (the liquid component of blood) with a concentrated amount of platelets. When vials of blood are spun rapidly in a centrifuge, the red blood cells, being more dense, separate. There are different methods to extract and separate out the platelets, but the final product will contain several times the normal concentration of platelets. This is then injected back into the injured area. PRP is a general term and there is no standardized product or manufacturing process that is used consistently by clinics that offer PRP. Moreover, as the evidence shows, there is no one method that has been clearly shown to be more effective than other forms. The variety of manufacturing processes complicates the evaluation of clinical trials. Like clinical trials of herbal remedies, the lack of standardization and consistency means that clinical trials may be complicated by slightly different “versions” of PRP.
What does the evidence tell us?
Surprisingly, no one has blogged about PRP at this blog since way back in 2009. (Isn’t it remarkable that SBM is still going strong 10 years later?). Val Jones noted at the time:
Without any clear evidence of benefit beyond placebo, platelet-rich plasma (PRP) is now being marketed aggressively as a cure-all for sports injuries. And at about $300 per injection (the NYT reports $2000/treatment), there’s plenty of money to be made.
She reviewed the literature and found it lacking, noting almost no published research on tendon injuries, and small trials in other conditions which were unconvincing. So what’s happened in ten years? In order to keep this blog post at a reasonable length, I’ll cite the evidence from the most comprehensive and current reviews that I could find.
The Alberta College of Family Physicians has an excellent Tools for Practice publication which answer clinical questions comprehensively. They recently published a summary of the evidence of PRP for Achilles tendinopathy, lateral epicondylitis (tennis elbow), and rotator cuff tendinopathy (the most common cause of shoulder pain). They restricted their search to randomized, placebo-controlled trials with patient-relevant outcomes measured. They noted:
Chronic Achilles Tendinopathy: Three RCTs comparing PRP to saline injections found no significant differences in pain, function, return to sport or patient satisfaction after 6, 12, and 24 weeks. They cite a meta-analysis which noted:
PRP injection with eccentric training did not improve VISA-A scores, reduce tendon thickness, or reduce color Doppler activity in patients with chronic Achilles tendinopathy compared with saline injection. Larger randomized trials are needed to confirm these results, but until or unless a clear benefit has been demonstrated in favor of the new treatment, we cannot recommend it for general use.
Chronic Lateral Epicondylitis: Two RCTs of PRP vs. saline found no difference at 12 or 24 weeks.
Rotator Cuff Tendinopathy: Two RCTs compared PRP to plasma or dry needling, finding no difference in pain or disability scores.
The review concludes:
The best quality evidence shows no difference in pain, function or return to sport between platelet-rich plasma, dry needling, or saline for patients with Achilles tendinopathy, lateral epicondylitis, or rotator cuff tendinopathy.
When it comes to summaries of the literature it is worth seeking out multiple reviews, to further minimize the risk of bias. Fortunately there is a 2014 Cochrane summary of PRP (called PRT, or platelet-rich therapy) for musculoskeletal injuries included a literature search up to 2013. It notes the following:
The quality of the evidence is very low, partly because most trials used flawed methods that mean their results may not be reliable. The trials also used different ways of preparing and applying the platelet-rich plasma. We were only able to pool data for our primary outcomes (function, pain, adverse events) for a maximum of 11 studies and 45% of participants.
And:
When we pooled the limited data that was available for all these conditions, we found very weak (very low quality) evidence for a slight benefit of PRT in pain in the short term (up to three months). However, pooled data do not show that PRT makes a difference in function in the short, medium or long term. There was weak evidence that suggested that adverse events (harms) occurred at comparable, low rates in people treated with PRT and people not treated with PRT.
And they concluded:
Overall, and for the individual clinical conditions, there is currently insufficient evidence to support the use of PRT for treating musculoskeletal soft tissue injuries. Researchers contemplating RCTs should consider the coverage of currently ongoing trials when assessing the need for future RCTs on specific conditions. There is need for standardisation of PRP preparation methods.
Is PRP safe?
There is the widespread belief that because PRP are your own cellular materials, injected back, that there are no risks to the treatment. Setting aside any sterility risks and the risks of infection that accompany any injection, PRP side effects tend to be minor and include pain, bleeding, bruising, and swelling. However, earlier this year Health Canada published a policy position paper, noting the following risks with autologous cell therapies (which include treatments like PRP injections):
With the exception of donor-derived infections and anti-donor immune responses, autologous cell therapy products present the same risks to patients as their allogeneic counterparts, including:
    • the potential introduction of bacteria or viruses;
    • between-patient cross contamination, for example if equipment is not properly sterilized;
    • risks resulting from processing activities and exposure to processing reagents; and
    • the stimulation of unwanted immune reactions, ectopic tissue and/or tumour formation.
From a clinical perspective, cell therapy products have unique absorption, distribution, metabolism, and elimination characteristics compared to other drugs, and have the potential to persist in recipients for a prolonged period of time. This prolonged exposure, relative to the duration of exposure to most drugs, carries the potential for both long-term benefits and long-term risks. Indeed, a number of serious adverse events have been associated with use of autologous cell therapies and strategies to mitigate these risks are needed.
But I’m injured! Is there anything to PRP worth pursuing?
Despite the enthusiasm and aggressive marketing, there are few well-controlled and rigorous clinical trials of platelet-rich plasma. These highest quality trials are consistently negative. It could be that the variety of manufacturing practices and administration techniques are confounding clinical trials, and that there is something actually worth still pursuing. No research has yet shown that to be the case. But it’s far more likely that what we see with PRP are simply placebo effects – the non-specific positive expectations initiated by health practitioners who are charging you a large sum of money for an injection (of cells!), backed by their personal assurances, patient testimonials, and glossy advertising. Until there is convincing evidence to demonstrate otherwise, there is little reason to accept the risk of PRP, regardless of your injury.

Crizanlizumab for Sickle Cell Crisis
Monoclonal antibodies to prevent sickle cell crises represents the promise and difficulties of high tech medical treatment.
Steven Novella on March 2, 2022
Link

Crizanlizumab is a monoclonal antibody treatment to reduce the risk of a sickle cell crisis. You can tell because the name ends in “mab”. There are a lot of “mab” drugs coming onto the market in the last few years. One might be tempted to think that this is a new technology, but it was first developed in 1975. There was a long road of development from the first monoclonal antibodies to the current crop of treatments, and it is a good reflection of the relationship between cutting edge science and medicine.
Crizanlizumab
Crizanlizumab is FDA approved for the treatment of a sickle cells crisis and is given as a monthly IV infusion. Like all mabs, it is an expensive treatment, and this remains a limiting practical factor for monoclonal antibody treatments. However, clinical trials show that regular treatment is efficacious in reducing sickle cell crisis by about 60% – “The median rate of uncomplicated crises per year was 1.08 with high-dose crizanlizumab, as compared with 2.91 with placebo.”
Sickle cell disease is a genetic disorder of hemoglobin which can cause red blood cells to become stiff and misshaped, going from a flexible coin shape to a rigid sickle shape. This can then lead to the formation of clumps of red blood cells which block blood flow, resulting in a painful sickle cell crisis. Having almost two fewer hospitalizations for sickle cell crisis per year could make crizanlizumab treatment cost effective.
Crizanlizumab is a “humanized anti-P-selectin monoclonal antibody” that binds to the protein P-selectin on platelets and the inside walls of blood vessels (endothelium). This blocks and disrupts an interaction among platelets, red blood cells, sickling red blood cells, and the endothelium to reduce the formation of clots that block blood flow and precipitate a sickle cell crisis.
While this is all interesting medical science, why am I bothering to write about it here? I think it’s an excellent representation of many of the realities we face with modern medicine, and it is a useful example of how the relationship between science and medicine works.
Monoclonal antibodies
The history of monoclonal antibodies is a good example of the complex relationship between scientific advance and the practice of medicine. Essentially these are antibodies that are designed and grown in cells. They are “monoclonal” because they are literally all clones of each other – one clone – so they are identical. Antibodies are “Y” shaped proteins (at least the IgG type) produced by the B-cells of our immune system. They have two binding sites that are highly variable, with each antibody having a specific shape that will fit onto a specific target (called an antigen).
Monoclonal antibodies were first made by injecting a mouse or rat with the protein we want to make antibodies against, then recovering the resulting B-cells from their spleen. These B-cells were then fused with an immortal myeloma cell, to make a hybridoma. These immortal cells could be cultured indefinitely in vitro and will continue to produce the desired antibodies. This technique was developed in 1975. This traditional technique is still used, but there are more modern techniques as well. Bacteriophages can be used to create monoclonal antibodies entirely in vitro. This method is cheaper and faster, and also does not require immunizing an animal and so antibodies against toxic substance can be made.
The first monoclonal antibody treatment was licensed in 1986 – a treatment for acute kidney transplant rejection. However, use was limited because of side effects, mainly stemming from an immune reaction to the monoclonal antibodies themselves, a human anti-mouse antibody response.
It took many more years to develop the technology to the point that monoclonal antibodies could be used routinely as a medical treatment. This is the reason for the “humanized” label when describing crizanlizumab – monoclonal antibodies need to be improved so that they are more human and don’t provoke and immune response of their own. By 2014 there were 30 monoclonal antibodies FDA-approved for use, including for transplant rejection, cancer, chronic infections, and heart disease. Now there are over 100 monoclonal antibody treatments, including treatments to prevent migraines and now sickle cell crises.
Reductionist science
Monoclonal antibodies are a good representation of the power of reductionist science. They require an understanding of how biology works at a fundamental level in addition to translating that knowledge into specific clinical applications. While this gives us powerful tools, we also have to recognize the downsides.
First, developing high-tech medical treatments takes time. Monoclonal antibodies are really only coming into their own in the last decade, four decades after they were first developed. There is a tendency to overestimate short term technological advances, and so when new scientific developments are made the press and enthusiasts will often tout their amazing potential. The public is left with the impression that a medical revolution is just around the corner. This leads to inevitable disappointment.
Further, not all new scientific developments pan out as a treatment. Most, in fact, don’t. Early hype that does not put a medical scientific advance into proper context, however, also sets the stage for exploitation and pseudoscience. We have been seeing that for the last two decades regarding stem cells. Early hype about stem cell technology was similar to hyping monoclonal antibodies in the 1970s. In fact, its probably worse, in that stem cell technology is even more tricky, and it seems now that it is going to take much longer to translate into medical treatments. Stem cells may be more of a treatment for the second half of this century. Meanwhile, a host of fraudulent and predatory stem cell clinics have popped up, exploiting the premature hype.
Another reality we have to face is that monoclonal antibody treatments, like most high-tech medical treatments, are expensive. In fact, technology is by far the number one driver of rising health care costs. Sometimes, as with sickle cell disease, even expensive treatments can be cost effective if they reduce hospitalizations, which are themselves very expensive. But often they simply add a new costly treatment. The monoclonal antibodies targeting CGRP receptors and antigens are highly effective treatments for the prevention of migraine headaches but they cost up to $8,000 per year. They improve quality of life and may also reduce lost productivity, but overall they increase the cost of managing severe migraine, which is the primary limiting factor on their use.
In the end we just have to decide as a society how much health care we are willing to pay for. But also we can make choices about how to target our research and development, and perhaps prioritize cost effectiveness as a practical matter.
Despite the fact that high-tech medical treatments come with trade-offs, most people feel they are worth it, especially if they or a loved-one is a beneficiary. Also, no one would argue that they are a replacement for simpler interventions, or basic healthy lifestyle choices. We also have to confront issues of equity of access. But it is better to live in a world with them than without them.

New Drugs for Sickle Cell Disease: Small Benefit, Large Price
The FDA has approved two new drugs to treat sickle cell disease. They don’t do much, and they are prohibitively expensive.
Harriet Hall on June 30, 2020
Link

Sickle cell disease is a serious genetic disorder, an abnormality of hemoglobin that is inherited in an autosomal recessive pattern, where both parents have to pass on the defective gene. The red blood cells take on a sickle shape and obstruct small blood vessels. In areas where malaria is prevalent, sickle cell hemoglobin can improve survival from malaria, but where malaria is absent it only causes harm. Patients develop painful crises that often require inpatient management and opioids; they develop acute chest syndrome with pulmonary infiltrates; and they may develop avascular necrosis with the death of bone. They are anemic, with low levels of hemoglobin. They can develop complications including bacterial infections, strokes, gallstones, spleen malfunction, and even infarction of the penis. Life expectancy is reduced: 42 years for males and 48 years for females.
Current treatments include hydroxyurea, blood transfusions, bone marrow transplants, and allogeneic stem cell transplants from a matched sibling donor. The disease can be cured if the patient can switch to producing normal hemoglobin in place of the defective form. Research is ongoing, with trials of umbilical cord blood transplants and gene therapy.
While awaiting a cure, Big Pharma has stepped up to the plate with new drugs, but it has struck out. It gained FDA approval to market two new drugs, Crizanlizumab (Adakveo) and Voxelotor (Oxbryta). The Medical Letter recently reviewed these two drugs, and the news was not good. Crizanlizumab is a monoclonal antibody that binds to a protein expressed on the surface of endothelium, inhibiting adhesion, increasing microvascular blood flow, and reducing vaso-occlusion. Voxelotor inhibits the polymerization of sickle hemoglobin.
The evidence from clinical studies
Crizanlizumab was tested in 198 patients in a double-blind trial of patients who had 2-10 sickle cell related pain crises in the previous year. The annual rate of pain crises was 1.63 with crizanlizumab and 2.98 with the placebo. Statistically significant, but not very impressive. It is given by IV infusion over 30 minutes every four weeks, and a year’s treatment costs $122,571.30.
Voxelotor was evaluated in the double-blind HOPE trial of 274 patients who had 1-10 vaso-occlusive crises in the previous year. The primary endpoint was an increase in hemoglobin of >1.0 g/dl at week 24. 33% responded to the 900 mg dose, and 51% responded to the 1500 mg dose, compared to 7% with the placebo. The Medical Letter pointed out that “Whether voxelotor decreases the frequency of sickle cell crises and incidence of multiorgan failure and death remains to be determined.” Voxelotor tablets are taken orally once daily. The cost for a year’s treatment is $126,739.70. Numerous adverse effects were reported with both of these drugs.
Were you underwhelmed by the evidence and overwhelmed by the cost? I was. So was The Medical Letter. Their conclusion:
In clinical trials in patients with sickle cell disease, crizanlizumab-tmca (Adakveo), which prevents vaso-occlusion, reduced the number of painful vaso-occlusive crises and voxelotor (Oxbryta), which inhibits polymerization of sickle hemoglobin, increased hemoglobin levels, but clinical data are limited and both drugs are prohibitively expensive.
High drug prices are a problem
        ◦ This is another in a long list of new drugs that offer small benefits at large prices. Is it worthwhile to pay for them? How much is one fewer sickle cell crisis a year worth? Are the drug companies actually going to make a large profit on them? They are not covered by Medicare and have only temporary approval from some insurance companies. Science can give us information about the efficacy of these drugs, but difficult decisions will have to be made by society as a whole and by individual patients whose willingness to take risks may not match their financial resources. There will be cost-benefit analyses, and factors like poverty and racial bias will have to be considered. And prices are high not only for new drugs, but for older, life-saving drugs like insulin and epi-pens whose price has risen beyond many patients’ ability to pay. I don’t have any solutions, but I have a lot of concerns.a

“Mystery” Illness in Colombia
Steven Novella on September 24, 2014
Link

It looks like we can file this one under “here we go again.” A small town in Colombia, El Carmen de Bolivar, has seen more than 200 girls hospitalized with a mysterious illness since May of this year. The symptoms include dizziness, headaches, and fainting. So far, all of the girls hospitalized have been found to be healthy and were quickly released from the hospital without discovering any specific disease or pathology.
Unfortunately I have to depend on news outlets to provide information about this case, and most are skimpy on details. However, taking what is being reported, the case has all the features of mass psychogenic illness. Specifically, the cases are clustering in a small community, which is typical for typical for episodes of mass delusions. The symptoms being reported are all subjective and the kinds of symptoms that can result entirely from psychological stress. I have seen no reports of objective clinical findings, such as fever, rash, abnormal laboratory findings, strange lesions, or objective findings on exam.
Doctors who have examined the patient feel that the presentation is consistent with psychogenic illness. I have discussed this at length previously. A psychogenic illness results from the physical manifestation of psychological stress. This is always partly a diagnosis of exclusion, meaning that other causes of the presenting symptoms need to be ruled out. However, it is more than just a diagnosis of exclusion, as there are sometimes clinical features that can be positively demonstrated to be psychological rather than physical. The ultimate test of the psychogenic diagnosis is that patients should improve with support and encouragement.
From a practical clinical point of view, once a specific treatable illness has been ruled out (it may not be possible to prove a negative, that no biological illness is present, but it is possible to rule out any known and treatable condition), then it makes sense to focus on symptom management and quality of life. Further, all chronic illnesses can have a psychological component. Being chronically ill can cause stress, anxiety, and depression which in turn can disrupt sleep, cause muscle tension, and result in further physical symptoms.
Therefore, once demonstrable, treatable pathology has been ruled out, a physician can remain agnostic toward the true underlying cause of the symptoms, and shift focus to managing quality of life, including stress management, treating anxiety and depression, and improving sleep and other lifestyle factors.
There are a few pitfalls that can happen along the way, however. Patients or their family may be frustrated at the lack of a specific pathophysiological diagnosis and will therefore continue to seek a specific diagnosis and treatment. There are certainly cases where a specific diagnosis was missed and only later properly diagnosed. Therefore it is reasonable to seek a second or even third opinion regarding an unusual illness. Also it’s important to make sure you have seen an appropriate specialist. However, this can turn into an endless and counterproductive adventure in doctor-shopping, with endless “million-dollar workups.”
Even worse, desperate patients seeking an acceptable diagnosis may run afoul of a fringe or alternative practitioner who will happily provide a dubious diagnosis and offer to treat.
In some cases, patients may find themselves the focus of media attention. Journalists looking for a “dog bites man” narrative are likely not to put the story into a reasonable perspective, but rather spin a tale of a desperate patient being dismissed by an uncaring medical establishment, perhaps with a brave maverick doctor willing to step in and save the day. An alternate narrative can turn the case into a “mystery illness” and then stoke fears of a possible environmental cause that can be putting the entire community at risk.
These are the cases that may catch fire and turn into a mass psychogenic illness. Now, with social media, mainstream media is no longer necessary. Posting one video on YouTube or Facebook may be enough to fan the flames. Of course, in a local and tight-knit community, no media is necessary, as fears can spread the old-fashioned way, by word of mouth.
The Colombia case seems to one of the local spread variety. This is case often described as a “community panic” – in this case there is widespread fear among the community that the Gardisil vaccine is to blame. All of the patients with symptoms are girls, and it is reported that they all recently received the Gardisil vaccine (however, I find it unlikely that 100% did, and we are given no authoritative information that this claim is true). Some parents are already convinced it is the vaccine, and the claim is being irresponsibly spread by some media outlets.
There has already been an investigation (at least preliminary), and there does not appear to be any connection to the vaccine. It is reported that 2.9 million women in Colombia alone have been given the Gardisil vaccine, and there is no indication of any similar reaction.
The story is very similar to the LeRoy New York story from 2012. In that case 20 children (all but one girls) came down with a “mystery illness” characterized by twitching. Activists came out of the woodwork to exploit the case to promote their pet ideology. Anti-vaxxers, as with this case, immediately blamed Gardisil. Some environmentalists (most famously, Erin Brockovich) blamed toxins in the soil. Brockovich argued it was from a chemical spill from 1970. Alternative practitioners were happy to offer their fake diagnoses – one patient being diagnosed and treated for chronic Lyme disease.
Now, two years later, the dust has settled on the LeRoy case. No toxins or environmental factors have been identified. No doctor has been able to document any previously-missed pathology. The neurologist who treated 15 of the patients also reports that they are completely or mostly better with nothing but reassurance. It’s possible that the initial case was a genuine case of Tourette’s syndrome, but then triggered a psychogenic reaction in the other cases.
Conclusion
We will have to wait for more details to emerge regarding the Colombia case, but as of now it seems like a classic case of mass psychogenic illness. There hasn’t been as much of a media feeding frenzy so far as there was with the LeRoy case, but now that the story is getting some international attention that may change.
Media attention in such cases is largely counterproductive – helping to spread symptoms, spread unfounded fears, and promote fringe theories. I am not saying it is wrong to report such stories at all, but care should be taken to put them into a proper context and to avoid spreading unnecessary fear. Media reporting so far has at least contained some skepticism. Most reports include the following:
Meanwhile, Health Minister Alejandro Gaviria is criticizing hyped coverage by the media for stirring panic, saying concerns about their vaccine, which has been applied to 2.9 million women in Colombia, are baseless.“On one side we have the weight of scientific evidence and on the other are opinions and moral prejudices,” he told W Radio on Wednesday, adding the cervical cancer claims the lives of more than 3,000 women every year in Colombia.
I do think it’s important to properly report such cases, and to do appropriate follow up. There hasn’t been nearly as much reporting about the follow up of LeRoy, for example, as there was for the initial occurrence. It would be good for the public to know that in that case, the experts were correct and the psychogenic illness hypothesis was largely demonstrated to be correct. Further, speculations about environmental toxins and vaccine fears proved baseless.

Medical Science in 2024
What medical breakthrough are likely in the near future?
Steven Novella on January 3, 2024
Link

Happy New Year to all our SBM readers.
It’s fun to look back and look forward when the calendar year ticks over. Last year was a huge year for medical science. I think the two biggest medical science news stories of 2023 were new treatments for Alzheimer’s disease (AD) and the first regulatory approval of CRISPR-based gene therapies.
There are now three drugs with various stages of approval that are disease modifying in AD. There is still some skepticism about the real-world net clinical effect of these treatments – they are not a cure, nor do they stop progression, and the amount of benefit may be modest – but they represent a milestone for two advances. One is that all three drugs are monoclonal antibodies. I wrote in June of last year how this is a bit of a revolution in therapeutics that has been rolled out with little public fanfare. New monoclonal antibody products just started appearing, with almost every medical specialty now having new and powerful treatment options. The reason why these three AD drugs have succeeded when many similar chemical drugs failed may be because the monoclonal antibody approach is just more powerful.
Second, these drugs are a proof of concept that some version of amyloid is not just a marker for AD but is, to some extent, driving the disease. That is a notable breakthrough, even if the effect is modest. Amyloid build up is certainly not the entire picture of AD, but it is an important piece and a legitimate therapeutic target. 
In November I wrote about the first regulatory approval for a CRISPR-based treatment – to treat sickle cell disease and beta thalassemia. These are truly effective treatments. Again, these are not a “cure” but come pretty close. The gene therapy allows for the production of fetal hemoglobin, which is free of the disease-causing mutation in these conditions. This type of treatment is the low-hanging fruit for gene therapy, because we know how to access the bone marrow where the target cells live, but it points the way to a future with many gene-based interventions.
What will be the big medical science news items of 2024? I don’t know, and that’s exciting. Generally new breakthroughs do not come out of nowhere. The amyloid-based treatments and CRISPR treatments referred to above were years in the making, and we saw them coming. But we still never know how the research is going to turn out. They could have been a bust, or encountered some tricky obstacle like a horrible side effect. Disappointment in medical research is common, and nothing is inevitable.
Twenty years ago stem cell therapy was supposed to revolutionize medicine. They are still an important medical technology – but the stem cell revolution never occurred. Perhaps it still will one day, and it is common for new medical technologies to take a lot longer than we initially hope. There are many labs working around the world on stem cell research. It would therefore not be totally surprising if some stem cell breakthrough were announced. But it’s not inevitable.
We can extrapolate from existing research, and look forward to potential breakthroughs that we know are in the works, even if we cannot predict the outcome of research with total confidence. I don’t expect a stem cell breakthrough in 2024 – the stem cell revolution seems to be still a ways off – but I do hope I get surprised.
An easier prediction is that there will be more gene-based therapies coming, and we may see one or more in 2024. CRISPR technology, which gives us the ability to quickly and cheaply make precise alterations to the genome, is still advancing and is already quite powerful. Changing or inserting a gene is one thing, but therapeutic applications require other technologies. One big obstacle is targeting the appropriate cells, which requires a vector. We have options, but they are imperfect. A breakthrough here can be a sudden game-changer. l
Another challenge for gene therapy is dosing. Let’s say a disease would benefit from the insertion of a gene that produces a therapeutic protein. Instead of giving a drug to a patient on a regular basis, you simply give their body the ability to make it for themselves. Perhaps it’s replacing a defective protein. But there is no easy way to regulate how much of the therapeutic protein the body makes – there is no way to control the dosing.
Already this year there is study published showing a potential solution. The researchers included in the RNA gene for the therapeutic protein a polyA sequence, which is a stop signal, right at the beginning of the gene. This effectively stops the gene from being expressed – no protein production. But they also include right next to the polyA sequence a receptor for a small molecule, in this case the drug tetracycline. When tetracycline binds to the receptor it blocks the polyA signal and turns on protein production. Therefore we would control the dosing of the therapeutic protein simply by the dosing of tetracycline, an already approved drug.
Simply put, DNA and RNA are the digital code for life, and we now have a high level of control over that code. It’s always hard to predict timing, but I do expect that gene therapies are going to be increasingly in the news in the coming years.
It’s also easier to predict incremental advances than true breakthroughs. I anticipate more monoclonal antibody treatments on a regular basis. I also expect more incremental advances in brain machine interface technology and therapeutics that involve electrical or magnetic brain stimulation.
My biggest prediction for 2024, which is actually just a hope, is for something truly surprising, an advance beyond the predictable incremental grind that typifies most of science. The only thing I can be reasonable sure of is that if one does occur you will read about it here.

Melanoma: A Pseudoepidemic of Skin Cancer Prompts New Screening Recommendations
There appeared to be an epidemic of melanoma skin cancer, but it seems to be a pseudoepidemic caused by overdiagnosis. Screening everyone with skin exams does more harm than good and can no longer be recommended.
Harriet Hall on February 2, 2021
Link


In the January 2021 issue of The New England Journal of Medicine, H. Gilbert Welch, Benjamin Mazer, and Adewole Adamson published a “Sounding Board” article entitled “The Rapid Rise in Cutaneous Melanoma Diagnoses“. There appeared to be an epidemic of melanoma, but their careful examination of the evidence revealed it to be a false alarm, a pseudoepidemic. Based on their findings, they recommend that the practice of doing skin examinations to screen for skin cancer be stopped, except for those at substantially high risk.
Melanoma was once rare, but its incidence has increased rapidly and is now 6 times as high as it was 40 years ago. Curiously, this increase is limited to cutaneous melanoma. There has been no increase in noncutaneous melanoma, which has a common cell of origin.
Welch et al. set out to explain this puzzling discrepancy. They had two starting hypotheses: that skin lesions were more accessible to diagnosis, or that the skin was subject to some exposure to which noncutaneous sites were not.
The obvious candidate exposure is ultraviolet exposure from the sun or tanning beds; but the evidence for a relationship between UV radiation and melanoma is mixed, and most of the data come from case-control studies which are subject to recall bias: patients with cancer tend to report more exposure than controls. Total sun exposure carries a 1.34 relative risk of melanoma; chronic sun exposure, a 0.95 relative risk; intermittent exposure, 1.61; sunburn, 2.03; ever having used a tanning bed, 1.2; frequent use of a tanning bed, 1.42; and first use of a tanning bed before the age of 35, 1.59. In short, not a particularly strong association. In the worst possible case, if everyone in the population had been sunburned, we would expect to see a much lower incidence than the 6X increase that was observed.
They found evidence that the increased incidence was due to increased diagnostic scrutiny rather than to UV exposure. During the same time period, almost twice as many Medicare beneficiaries were getting biopsies. The diagnostic criteria are subjective. They found evidence that pathologists have tended to lower thresholds for diagnosing melanoma, and smaller lesions are being biopsied.
Their most compelling argument is that the rise in melanoma diagnoses was not accompanied by a rise in melanoma deaths.
Conclusion: There is no epidemic, but there is a problem of over-diagnosis
They point out “the economic disruption caused by Covid-19 obliges clinicians to protect people from the financial stress of needlessly being turned into a patient”. It gives us an opportunity to change course, to focus on education rather than on screening. Screening everyone for skin cancer does more harm than good and should be stopped.

Acetaminophen: Still the pain reliever you should trust?
Scott Gavura on October 10, 2013
Link
Recently ProPublica and This American Life (TAL) released the results of an investigation into acetaminophen, the active ingredient in Tylenol. TAL devoted an entire episode to the issue, and ProPublica has published several stories on acetaminophen’s toxicity, how it can cause harm, and how it is regulated.
The investigation summarizes the key “Takeaways” as follows:
    • 150 Americans die per year from accidental acetaminophen overdoses
    • The safety margin (safe dose vs. toxic dose) with acetaminophen is small
    • Both the FDA and the manufacturer, McNeil, have known about the toxicity for years
    • For over 30 years the FDA has failed to implement measures to reduce the risk of harms it knew existed
    • The manufacturer has taken steps to protect consumers but has also opposed other safety measures
While Tylenol is a single brand out of hundreds of prescription and non-prescription products that contain acetaminophen as an active ingredient, it is the brand most closely associated with the chemical. Amazingly for a drug that has no patent and lots of competition, Tylenol products are estimated to make up half of all non-prescription acetaminophen sales in the US, a testament to the power and effectiveness of marketing. (It’s also a clear refutation to alt-med arguments that unpatented products can’t be profitable, or aren’t of interest to the pharmaceutical industry.) While much of the focus of the investigation centers on the corporate behavior of Tylenol’s manufacturer, McNeil, (a division of Johnson & Johnson), it is important to keep in mind that no single company is responsible for acetaminophen sales and marketing.
Before diving into the investigation and its findings, a review of the pharmacology and toxicity of acetaminophen will help with the context. (More detail, if you’re interested, is contained in a prior post.) Acetaminophen is a drug that has analgesic (pain relief) and antipyretic (fever-reduction) actions. Unlike non-steroidal anti-inflammatory drugs (NSAIDs) like acetylsalicylic acid (ASA, aspirin), ibuprofen (Advil) and naproxen (Aleve), acetaminophen has no effect on prostaglandin synthesis – so it is not an anti-inflammatory. This lack of anti-inflammatory action gives it a completely different side effects profile. Unlike NSAIDs, acetaminophen is unlikely to cause gastrointestinal ulcers, blood disorders, or kidney problems, all common with NSAIDs. Nor does acetaminophen increase the risk of cardiovascular events such as heart attacks and strokes, like some NSAIDs. Compared to NSAIDs, acetaminophen also has few interactions with other drugs, so it can safely be used for pain relief in those on multiple medications, or with other medical conditions where other pain relievers might have unwanted effects. Acetaminophen is not a narcotic, and provides a non-addictive alternative for managing chronic pain issues. It can also be used during pregnancy, and while breastfeeding. Finally, at the recommended dose, acetaminophen is almost completely free of significant side effects. This can be contrasted with NSAIDs, that cause a considerable number of drug-related hospitalizations each year. The problem with acetaminophen appears when an excessive dose is taken. And in that situation, acetaminophen is much worse than any NSAID.
The body eliminates acetaminophen through the action of liver enzymes that converts the base drug into substances (metabolites) that are easier to for the kidneys to filter and excrete. In overdose situations, this system fails catastrophically. We are physiologically able to safely metabolize a small amount of acetaminophen at a time – about 4,000mg in a 24 hour period for adults is generally considered the safe upper limit. The two main metabolic paths are sulfation and glucuronidation. These paths can be exhausted and overwhelmed in overdose situations, which is when other enzymes take over. N-hydroxylation creates a chemical compound that causes liver damage. In the diagram below: blue is good, and red is bad (note, paracetamol is acetaminophen):
The toxicity of acetaminophen has been recognized since at least 1966. As I’ve discussed before, acetaminophen poisonings are a significant public health issue. The acetaminophen poisoning antidote is a universal feature of emergency rooms – overdoses are that common. The raw numbers are huge: poisonings from this drug alone result in 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths per year. [PDF] This makes acetaminophen responsible for more overdoses, and overdose deaths, [PDF] and acute liver failure, than any other drug product.
Poisoning from acetaminophen will usually take one of two forms:
    • the one-time ingestion of a massive dose (e.g., a suicide attempt)
    • the prolonged ingestion of a dose that exceeds the body’s ability to eliminate the drug safely
Between the two, massive single overdoses are much easier to manage medically. An antidote (acetylcysteine) does exist, which can save an individual’s liver, and their life, if given within 8 hours of an overdose. Poisoning due to chronic ingestion, which are often unintentional, are far more difficult to manage. The early signs of liver damage are not obvious, and can mimic flu-like symptoms. Once hepatic damage has started, the antidote’s effectiveness drops. In severe cases, a liver transplant is required.
It’s the second form of overdose, the inadvertent poisonings, that are understandably the focus of the ProPublica/TAL investigation. Let’s examine the “takeaways” in order. The first is the number of acetaminophen deaths, which they claim at 150 per year in the USA. While The Poison Review disagrees with the show’s methodology and its fatality calculations, the FDA’s own estimate was 458 deaths (from all causes) per year in the period 1990-1998. Case reports collected over the past several decades attest to the fact that unintentional poisonings do occur regularly, although the distinction between deliberate and inadvertent overdoses isn’t always clear, especially when the poisoning is fatal. So while there is some legitimate controversy over the actual numbers, there is no question that accidental poisonings do occur.
TAL/ProPublica’s second “takeaway” is that acetaminophen has a narrow safety margin. Again, it is well established that massive overdoses are fatal unless treated promptly. What is less clear is when liver toxicity becomes an issue with acetaminophen use. The normal maximum dose for adults is 4,000mg per day, and toxicity is felt to be unlikely from a single dose of 7.5-10g. What’s not clear is whether modestly but consistently exceeding the 4,000mg/day maximum is likely to cause harm, or if 4,000mg/day may be too much for some. Case reports suggest that even repeated daily doses of 5,000mg/day to 7,500mg/day have been associated with liver damage. That’s obviously concerning, as modestly exceeding the maximum dose could easily and inadvertently occur from ignoring the dosing instructions, calculating the wrong dosage (particularly in children), or taking two products that both contain acetaminophen.
Acetaminophen is unquestionably toxic in overdose, and potentially harmful at or above the maximum recommended dose. So does that mean that NSAIDs are always preferable? Not necessarily. Massive overdoses of anti-inflammatory drugs are, on balance, less harmful than acetaminophen. Deaths from acute overdose of NSAIDs are rare. What is more insidious and problematic with NSAIDs is the side effect profile I described above. What’s worse, NSAIDS have the potential to cause significant harm, even when dosed appropriately. The Propublica/TAL reports don’t elaborate on the full toxicity profile of the NSAIDs, which implies they are safer – a potentially misleading comparison. Comparing acetaminophen’s toxicity with NSAIDs isn’t an apples-to-apples comparison, and it can’t be quantified. Which is worse in overdose? Acetaminophen. What’s more likely to cause harm at normal doses? NSAIDs. Which is the safest for any given person? It depends. This is the crux of the issue, and I’ll come back to this later. Considering 28 billion doses of acetaminophen were consumed in 2005, this suggests the overwhelming majority of acetaminophen users are not encountering toxicity and poisoning problems with their use.
This isn’t to say that we should accept 150-400+ deaths per year as an acceptable cost of making a drug available, if there are ways we can minimize overdoses, especially the unintentional ones. The third “takeway”, that the FDA has been aware of this issue for years, should not be a surprise. The toxicity of acetaminophen has been understood since the 1960s by health professionals and regulators alike. The population-level harms are well documented in the medical literature. What’s relevant is whether the regulator acted appropriately to address this information. This is the investigation’s fourth takeaway, and where the most effective points in the investigation are made. The FDA has been discussing various measures to enhance various aspects of acetaminophen’s labeling for an astonishing 30 years, with very little to show for it. Recommendations have been drafted, formal advice has been provided, and the FDA has repeatedly deferred making substantive labeling, packaging, or regulatory changes that have the potential to reduce the risk of accidental poisoning. The investigation does a good job describing some of the major changes recommended, and why they are warranted.
The TAL episode describes the tragic death of an infant who died of an overdose due to a dosing error, caused by confusion between different brands of Tylenol liquid. Two formulations for pediatric use have traditionally been available – a concentrated version for infants, dispensed with a dropper, and a less concentrated version for children, dispensed with a spoon or oral syringe. In the case described, the parents were given dosing instructions for Tylenol based on the children’s version of the drug. The parents gave the same volume of the infant formula, resulting in an overdose. The baby suffered liver failure and eventually died of acetaminophen poisoning. This tragic, preventable death sets up TAL and Propublica for a discussion of both manufacturer and regulator behavior, and how the actions (and inactions) of both parties may have been factors in these deaths.
The FDA tightly regulates what drug manufacturers can say about the drugs they sell. Before any manufacturer of over-the-counter drugs can change the dosing instructions on its label, it must obtain FDA approval. And that approval can take years, TAL/Propublica discovered. Unless you’ve ever tried to give Tylenol to an infant, you may not know that Tylenol products sold in the USA do not contain instructions for dosing children under the age of two. The instructions indicate that consultation with a physician is required. There’s no therapeutic reason for this – dosing instructions for this age group are listed on Tylenol bottles sold in Canada, for example. McNeil has been asking the FDA to approve a label change for years, arguing that specific instructions will reduce the likelihood of simply guessing the dose, potentially raising the risk of overdose. The FDA has just recently agreed, and this label change is coming, which should reduce the risk of wrong doses.
One step that McNeil could have done, TAL/Propublica argues, would have been for McNeil to remove one version of its Tylenol liquid, which would eliminate the risk that one product could be accidentally substituted for each other. But McNeil didn’t act. A recent change approved by the FDA will mean the two products will continue to exist – but at the identical concentration, so substitutions won’t carry the same risk. (Interestingly, both products, at two different concentrations, continue to be sold in Canada.) This isn’t the only issue the investigation finds with McNeil. The website includes a much longer list of McNeil’s actions that appear to put business interests ahead of safe use: It has repeatedly fought labeling changes that would put it at a competitive disadvantage to its competitors in the pain reliever marketplace. It fought the FDA’s modest public service campaign to warn about the risks of acetaminophen overdose. And it never disclosed to the FDA its own (ultimately abandoned) work to develop a safer formulation of acetaminophen.
In fairness to McNeil however, it needs to be reiterated that Tylenol is just one brand of acetaminophen liquid among hundreds of acetaminophen products on the market. Without the FDA compelling the entire market to change its labeling or packaging, it’s unlikely that a single manufacturer (albeit the biggest) would act alone. And it’s not clear that different manufacturers, each selling their own concentrations of acetaminophen liquid, would actually create a safer marketplace for consumers. For these types of changes to be truly effective, there needs to be a coordinated approach that applies to all manufacturers – one that only the FDA could have mandated. But it didn’t, for years.
So what are we ultimately left with? Balancing access against patient safety has no single correct answer. There are no risk-free strategies – even shifting use of acetaminophen to substitute drugs, like NSAIDs, could have unforeseen negative consequences. The Propublica/TAL investigation succeeds in raising the toxicity profile of acetaminophen among the public. I hope it will encourage consumers to follow the directions carefully, and to double-check the ingredients and doses of the acetaminophen products they use. It has also shone a bright light on the FDA’s regulatory inertia, which may compel more decisive and timely action to improve labeling, which may in turn reduce accidental overdoses. Where the investigation is weaker is in describing the relative risk of acetaminophen compared with its substitutes, which may leave consumers with the erroneous impression that NSAIDs are safer and more appropriate for pain relief and fever reduction. My personal take is that acetaminophen, when used appropriately, is an exceptionally safe medication, with several substantial advantages over NSAIDs. But I also agree that there’s a lot more that can and should be done to improve the public’s capacity to use this medication safely. Ultimately as a health professional I’m an advocate for appropriate regulation and marketing that gives consumers the information they need to make informed and safe decisions about their own care.

Tylenol May Not Be As Safe and Effective As We Thought
Harriet Hall on February 18, 2014
Link
I’ve always thought of Tylenol (AKA acetaminophen in the US and paracetamol in the UK) as one of the safest drugs around, with essentially no side effects when used as directed. But it has been in the limelight lately. Several SBM articles have addressed it here, here, and here. We know there is a risk of liver damage and death with acetaminophen overdose or accidental ingestion (458 deaths a year in the US). Since it is included in many other products (painkillers, cold and cough remedies, etc.) consumers may not realize how much they’re taking. The FDA has addressed this problem, and reformulations and lower daily dose recommendations are being implemented; but there is still no guarantee that consumers will realize that their “non-aspirin pain reliever,” pain pills like Vicodin, and many cold, sinus, and cough remedies have the same ingredient as Tylenol.
We have gradually become aware of other dangers not associated with overdose. Acetaminophen has been associated with kidney damage (especially with long-term use), gastrointestinal symptoms, and cardiovascular events. Combining the recommended dose with alcohol ingestion can lead to liver failure. It can also interact with some other drugs, for instance isoniazid. Allergic reactions can occur, and 7% of patients who are allergic to aspirin or NSAIDs also react to acetaminophen. It is excreted in breast milk, but in very low concentrations. The manufacturer’s professional product information includes detailed listings of reported reactions, drug/drug interactions, and safety studies in patients with various diseases. There is no need to adjust dosage for the elderly or for those with liver or kidney disease. For most patients, including those with chronic disease, acetaminophen is the pain-reliever of choice due to its low risk. But recently a draft recommendation from the UK’s NICE (National Institute of Health and Care Excellence) has warned us against using it, at least to treat the pain of osteoarthritis.
NICE warns against using it for osteoarthritis
Osteoarthritis is the “wear and tear” arthritis that most of us develop as we age. It is distinguished from inflammatory types of arthritis like rheumatoid arthritis. For inflammation, NSAIDs (non-steroidal anti-inflammatory drugs), steroids, and other drugs are helpful; but the initial treatment for the pain of non-inflammatory osteoarthritis has traditionally been acetaminophen. Last summer, NICE issued a warning against prescribing acetaminophen for osteoarthritis, saying they were “extremely concerned” about serious side effects. This advice was part of their draft for updated guidance on osteoarthritis. The report can be downloaded here.
It is exhaustive, with over 600 pages, and filled with tables listing the pertinent scientific studies and assessing the quality of evidence and the likelihood of bias.
It warns of the potential side effects of paracetamol and says it has “limited benefit.” When used, it should be the “lowest effective dose” for the “shortest possible time.”
It cites a very definite trend from observational data linking paracetamol at increasing doses to cardiovascular (fatal/non fatal MI, stroke, heart failure), gastrointestinal (upper and lower) and renal adverse events. The Guideline Development Group “felt that the increase in renal adverse events with long-term cumulative doses of paracetamol particularly would be a surprising finding for most clinicians and wishes to highlight this issue.”
NICE based its concerns mainly on these studies:
    • A US study published in the journal Circulation showed use of NSAIDs or paracetamol at high frequency or dose is associated with a significantly increased risk for major cardiovascular events.
    • A 2010 UK study of 1.2m general practice records in 2010 found a 28% increase in mortality with paracetamol and a 50% increase when used in combination with ibuprofen, compared with those not using the drugs. This compared with a 12% increase in the ibuprofen group. The study also shows a 36% increase in the risk of upper gastrointestinal events, 14% increase in heart attack and a 20% increase in renal failure risk with paracetamol use.
    • A 2010 Osteoarthritis Research Society International review of evidence for various analgesics in osteoarthritis concludes there is accumulating evidence to suggest high-dose paracetamol may have upper gastrointestinal side effects. It also finds ‘some evidence’ to suggest mild loss of renal function in women following long-term consumption of high doses. (Osteo Carti 2010;18:476–499)
    • A 2011 study by University of Nottingham researchers showed an increased risk of reduced hemoglobin after 13 weeks treatment with ibuprofen or paracetamol alone, with the risk doubling when the drugs are taken in combination.
Other recommendations
The guideline also recommends that glucosamine and chondroitin products should not be offered to manage osteoarthritis as the evidence on their clinical effectiveness is very limited and uncertain.
It recommends against acupuncture for osteoarthritis, because most studies showed no difference between sham and true acupuncture, and the studies showing a benefit were of lower quality.
It also recommends that osteoarthritis can be diagnosed clinically if the patient is 45 or over and has activity-related joint pain with either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes. X-rays and other tests are not necessary.
How critics reacted
There was an uproar. Experts and organizations, including the British Society of Rheumatology, wrote to NICE to protest, saying that there was no new evidence to support the draft guidance and that it would impact self-management of pain and might increase the use of opiates.
The UK medicines regulatory body (MHRA) contradicted NICE, saying there was no new evidence to support the advice not to use paracetamol regularly for OA.
An article in Pulse generated a lot of unfavorable comments from clinicians, mostly aimed at the lack of alternatives. Here is a sampling:
    • “So what exactly is left then?”
    • “I’ll refer you to the appliance department for a piece of wood. You can chew on it if the pain gets too much. Trust me, it’ll be better for you, I’ve read the NICE guideline.”
    • “So now it’s official that we are to place defensive medicine over and above patient care. Nice one, NICE.”
    • “Without suggesting any alternatives these guidelines are utterly useless.”
    • “Here we go the reality check on the safest ever claimed medicine is no longer “SAFE” so what next?”
NICE responds to criticisms
NICE listened, and last week they made a dramatic U-turn that completely reversed the guidance of the first draft. The revised draft recommends GPs continue to use paracetamol as a first-line analgesic option in osteoarthritis. It said NICE was also “aware of an ongoing review by the MHRA of the safety of over-the-counter analgesics. Therefore NICE intends to commission a full review of evidence on the pharmacological management of osteoarthritis, which will start once the MHRA’s review is completed, to inform a further guideline update.”
Conclusion
This controversy can serve as a reminder to us all that Tylenol is not as harmless and not as effective in relieving pain as we would like to think. Still, when an analgesic is required, it’s safer to try Tylenol first than to bypass it for other more effective analgesics with worse side effects. Some might even consider it a “pseudo-placebo” – an effective drug that may not really do much, but that we can justify offering to the patient along with all the non-specific effects of the doctor/patient encounter, seeking to maximize placebo effects and avoid the use of more dangerous drugs. We can also keep in mind that not every pain has to be treated with medications. We can offer safe non-drug treatments like distraction, comfort measures, exercise, massage, and other safe modalities.
Tylenol is a good reminder that any drug that has effects has side effects; we can’t trust any drug to do only what we want it to do: it will do whatever it can do.

Tylenol Ramblings
Mark Crislip on October 21, 2025
Link
This was an extremely difficult post to write. I live in war-ravaged Portland, Oregon, and it is like World War II here. Think Berlin at the end. Nothing but chaos, death and destruction. A burning hell hole. I sit in my cellar, the walls shaking from the brown bombs and artillery. Using the light from the burning house next door to see the text. I will upload this to Starlink using an old 300 baud modem, powered by the fading battery of an abandoned Cybertruck. Thank you, Mr. Musk. At least we will soon have National Guardsmen in the city who will certainly be able to stem the Red tide. But if I don’t survive this hellscape, remember, Keep Portland Weird.
I was never much of a fan of acetaminophen, either personally or professionally. As a clinician I was rarely responsible for pain control of patients. And I have long been of the learned opinion that, with a few exceptions, treating fever is either a waste of time or counterproductive.
My early clinical experience with acetaminophen was as a resident with Tylenol overdoses. I took care of one or two a year, and since it was slow, it was a particularly awful way to die. The pattern was consistent: someone would swallow a bottle of acetaminophen as a gesture. Nothing would happen, and a day or so later would show up in the ER, chagrined and embarrassed but wanting to make sure they were OK. They were not. Acetaminophen had killed their liver and they would go on to die of liver failure, usually over the course of a week and regretting it to the end. Did not make me a Tylenol fan.
Personally, I never found acetaminophen did anything for pain, especially compared to NSAIDs. It did not even have a placebo effect that I could tell. A great big nothing burger.
It is a drug that is so ubiquitous that I cannot ever remember either being taught about it in medical school or elsewhere. Acetaminophen is. It requires no further explanation.
Then my total knee replacement, a most unpleasant experience. Not really painful, I needed no narcotics after 48 hours, just uncomfortable and limiting. But I was told to take Tylenol around the clock, as it would make me more comfortable and would potentate the oxycontin should I need some. So I did, despite my opinion that acetaminophen is worthless. I try and do what I am told, since my medical knowledge outside of ID is sketchy at best. The doctor who treats themselves has a fool for a patient and an idiot for a physician.
But I wondered. How efficacious is acetaminophen for pain? What kinds of side effects outside of killing the liver and kidney could I expect?
Pain
Searching PubMed with acetaminophen and pain results in 10,805 hits. Slightly more than I want to read. So this screed will, by necessity, be targeted.
I was curious how acetaminophen was found to be a pain killer. Pain wounder. Pain annoyer. It appears that acetanilide is an old analgesic. Investigations into its metabolism in the 1940s revealed that acetanilide is metabolized to acetaminophen, the sort of kind of perhaps maybe active molecule.
I guess they assumed that, since acetanilide was an analgesic, so was acetaminophen. But when I look for anything that resembles proof of analgesia, for acetanilide, I cannot find much. There is a series of cases from 1889 that concluded
Allowing for the fallacies in estimating therapeutic effects where reliance has almost solely to be placed on the statements of patients, these results are satisfactory, and justify the hope that exalgene may take a useful and important place among the remedies by which pain is relieved. Its analgesic power is not a very powerful one, but it has the enormous advantages of being free from the disturbance and inconveniences that are associated with the action of nearly all other pain-subduing agents and for the dangers inseparable from the use of the more powerful of these agents.
The more things stay the same, the more things stay the same. And I love the style of these old medical journals.
Acetanilide was also used as an antipyretic for diseases like typhoid fever back in the day, and fevers can be uncomfortable with myalgias and headache. I wonder if the supposed analgesic effect of acetanilide was more a side effect of fever relief.
But it was assumed for a long time that acetaminophen was an analgesic based on little to no clinical data.
In 1948 there was a study, the details I cannot get, that showed acetaminophen increases pain threshold to thermal injury. Acetaminophen use for pain started in 1950, but the first clinical trial of acetaminophen monotherapy (the 50s and 60s were big on polypharmacy) I could find was in 1967.
I came across this title from 1965: On treatment of the “pain” symptom in obstetric and gynecologic pathology. I like that pain was in quotes. Oh, those hysterical females and their “pain.”
But if you wander the Pubmeds, the conclusion you will come to is that acetaminophen is the worst of all the analgesics, depending on the pain treated. Barely better than or equal to placebo.
One nice summary from 2016 suggests
    • Paracetamol at doses between 500 and 1000 mg is in the least effective quartile of drugs for treating acute postoperative pain.
    • Paracetamol 1000 mg has modest efficacy in migraine and tension-type headache.
    • Paracetamol at doses up to 4000 mg daily is ineffective in back pain.
    • Paracetamol at doses up to 4000 mg daily is practically ineffective in arthritis. Though marginally better than placebo, paracetamol has little chance of achieving clinically meaningful benefit in osteoarthritis.
    • No review evidence that paracetamol works for dysmenorrhoea, neck pain, rheumatoid arthritis or cancer pain.
Migraine seems the best use. Which is odd. There are many types of pain, so why would acetaminophen be most efficacious against migraine?
I found two studies (one, two) using oral acetaminophen alone vs. placebo and both studies demonstrated efficacy. One even showing acetaminophen was “highly effective.” But both studies were run by the makers of Tylenol. Now that does not automatically invalidate the study, but pharma-funded studies often have better results than independently funded studies.
Studies sponsored by pharmaceutical companies were more likely to have outcomes favoring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons).
My rule of thumb, pulled out of thin air, was to whack 30% off the results of all pharma sponsored studies. So “highly effective”? Meh. I see a bit of hype.
IV acetaminophen, which should act faster, but
The results indicate, that 1000 mg intravenous acetaminophen is not superior to placebo in treating severe acute migraine attacks.
This study was paid for by an unrestricted grant from Bristol Meyers Squibb, the makers of IV acetaminophen but run by university hospitals. So I lean towards the idea that acetaminophen is likely overrated for migraine treatment.
As an aside, it looks like Bristol Meyers Squibb, makers of Excedrin, and McNeil, makers of Tylenol, have battled over which product is superior.. Whose OTC pain reliever will reign supreme? Not Tylenol.
I was curious about its efficacy for total knee replacement pain. Pain, at least from my experience, is not experienced as a single entity. Acute or chronic, all the pain I have had hurts in different ways. With the knee replacement I have at least 4 different and qualitatively distinct pains. But the team was adamant that I take Tylenol round the clock and I try and do what I am told.
So the data?
All over the map, but unimpressive. For example, one meta found
Our meta-analysis results indicated that compared with a control group, intravenous acetaminophen was associated with reductions in total morphine consumption and visual analogue scale (VAS) score at postoperative day (POD) 3. However, there was no significant difference in morphine consumption at POD 1 or in VAS at POD 1 or POD 2. Moreover, there was no significant difference in the length of hospital stay.
Not the kind of pain relief I would have found impressive, although I would note that the length of stay in these studies was 3 days. So also not applicable to my knee replacement, as I spent the night and was discharged by noon the next day, less than 24 hours from the end of my surgery. And I needed no oxycontin for pain after 36 hours, so also not applicable; at least to me.
And another found decreased narcotic use all three days post-op:
Additional intravenous acetaminophen to multimodal analgesia could significantly reduce pain and opioid consumption after total joint arthroplasty with fewer adverse effects.
But a more recent double-blind study found
acetaminophen to preoperative preemptive multimodal analgesia did not decrease postoperative morphine use or ameliorate pain relief.
Which is consistent with the overall literature on acetaminophen and pain: it does little to nothing.
Side Effects
48 hours post-op, I was only taking the Tylenol. And I noticed that I felt like crap an hour after the dose: headache, slight nausea, sweating and a general malaise that faded until the next scheduled dose. It turns out these symptoms are common with acetaminophen, so I stopped it. The symptoms resolved and there was zero change in the various pains in my knee. The acetaminophen was doing squat.
I do not mention my experience with acetaminophen as any sort of proof. The plural of anecdote is still anecdotes, not data. And the pleural of infection is empyema. I do so to note that my experience is consistent with the literature: acetaminophen is next to worthless as a pain reliever. It is no better than acupuncture for pain relief. Its role in pain control would be like that of acupuncture: when there is nothing to offer that is effective, at least you pretend to do something to treat the pain. Which brings us to pregnancy.
Pregnancy
You have a pregnant person with mild to moderate pain. Headache. Sprain. Migraine. Well, migraine is not so mild to moderate. What are you going to offer? Not a lot of options. So it’s acetaminophen. Which is as close to doing nothing as doing something will allow. Because patients are not fond of being told there is nothing to do, it will get better on its own. So acetaminophen it is. Safe and unlikely to be effective but with the added benefit of multiple side effects.
Kind of an odd place to be: yes, based on the medical literature, I can defend this drug as safe for your fetus, but for you it offers little to no efficacy and a fair number of toxicities. I might as well suggest acupuncture. Same operative characteristics for pain and I can find no reports of acupuncture harming the fetus. Why would it, outside of an amazing poorly placed needle?
I suppose you could try and educate the patient, but I suspect that will go nowhere. I think the literature is clear that, with a few exceptions, treating a fever at best does nothing to alter the course of infection and, at worst, leads to more prolonged disease and complications. Fever relief only makes the patient more comfortable. I have been saying don’t treat fevers for decades and made zero impact whatsoever on the treatment of fevers. Hell, when my kids were febrile, my wife gave them Tylenol, completely ignoring me.
Like treating a fever, I would wager using Tylenol for pain is too ingrained in society to be amenable to change. Unless you want to use fear based on fictions to alter behavior, and I am not a fan of lies as a motivation technique. A pity, as
Besides, as the vilest Writer has his Readers, so the greatest Liar has his Believers; and it often happens, that if a Lie be believ’d only for an Hour, it has done its Work, and there is no further occasion for it. Falsehood flies, and the Truth comes limping after it; so that when Men come to be undeceiv’d, it is too late; the Jest is over, and the Tale has had its Effect…
So acetaminophen will continue to be the most commonly used ineffective drug for pain.


How to Choose a Doctor
Harriet Hall on March 20, 2012
Link
From an e-mail I received:
As a proponent of SBM, and a someone who places a high value on reason, logic and evidence, I would like to find a physician who shares this mindset.
He went on to ask how he could go about finding one.
Another correspondent was referred to a surgeon by her primary physician, and the surgeon inspired confidence until she started talking about using homeopathic arnica pills to improve healing post-op. How she could determine the technical competence of this surgeon? Was acceptance of homeopathy a reason to shed doubt on her judgment in other areas? Should she seek a second opinion?
I get a lot of inquiries about how to find a good doctor. I don’t have a good answer. I thought it might be useful to throw out some ideas that have occurred to me and hope that readers will have better ideas and will share their experiences about what has or hasn’t worked.
What Do We Want in a Physician?
    • We want a doctor who is knowledgeable and technically competent.
    • We want one who exercises good judgment.
    • We want one we can trust not to use quack diagnostic tests or quack remedies.
There are a lot of other considerations. Do you like him? Does he act like he cares about you as a person? How’s his bedside manner? Does he explain things well? Does he encourage questions? Is he authoritarian or does he treat the patient as a partner in making decisions? Is his office conveniently located? Is he booked up months in advance? Is he on your insurance plan? Is he available in an emergency? Is he reachable by phone or e-mail?
If it’s a straightforward technical matter like setting a broken bone, personalities may not matter; but in other cases (a difficult diagnostic puzzle, a chronic disease, or a psychological issue) they may matter a great deal. Sometimes through no fault of their own, a patient and doctor are simply not a good fit for each other for developing a good doctor/patient relationship. Perhaps the doctor reminds the patient of an uncle who abused her; perhaps the patient reminds the doctor of his wimpy, hypochondriacal cousin. Perhaps they have different political opinions, different religions, or different cultural backgrounds with different world views. I know an atheist who walked out of a doctor’s office when she found out he was a Christian.
What kind of doctor?
As a family physician, I’m partial to a board certified family practice doctor (FP) as primary physician; as a general rule, the FP mindset tends to be more comprehensive and practical than that of internists or specialists. A urologist sees a lot of prostate cancer and is more likely to insist on PSA screening; an FP is more likely to weigh all the pros and cons and involve the patient in deciding whether to screen. (Of course there are exceptions.)
Consider other options besides MDs. In the US, DOs pass the same licensing exams and are trained in the same residency programs as MDs and can be considered equivalent. Physician assistants and nurse practitioners tend to be more “interested” in routine patients; many of them work in group settings with ready access to doctors when needed.
How To Find One
I have no experience in choosing a doctor. I’ve always been arbitrarily assigned to one in the military health care system. But let’s say you’ve just moved to a new city and want to find a primary physician. How could you go about it? I don’t know, because I’ve never had to do this, but here are some ideas that have occurred to me:
     1.  Word of mouth. Ask friends, relatives, neighbors, and co-workers about their doctors.
     2.  Ask your previous doctor. If he doesn’t know anyone in your new area, he might know someone who does.
     3.  Use the Internet. Social networking sites, forums, sites that rate doctors, lists of licensing board disciplinary actions and malpractice lawsuits, the websites of doctors and the groups they work for, etc.
     4.  Nurses know things. If you can find a nurse who works in a local hospital or medical center, who has had experience working with lots of different doctors, she may have a good sense of which ones are better than others, and she might have heard some pertinent grapevine gossip.
     5.  Call the doctor’s office and ask if the receptionist or nurse knows if the doctor ever recommends CAM or refers to CAM providers.
     6.  Check to see if the doctor’s group includes CAM providers or advertises “integrative” medicine.
     7.  Ask about credentials: training, board certification, hospital privileges, etc. If you are contemplating surgery, ask about the doctor’s and the hospital’s volume and complication rates for that operation.
     8.  Interview the doctor. Make a new patient appointment and tell the doctor you want to ask some questions to see if you and he are a good fit. Ask how he goes about deciding when to adopt a new drug and whether he gets his information from drug reps. Ask what he thinks about CAM. If you have a medical problem, ask what experience he has had with that problem. Watch to see if he washes his hands.
     9.  If for any reason you don’t feel comfortable with a doctor, don’t hesitate to look for one you feel more comfortable with.
     10.  If you have any doubts about a recommended treatment, it can never hurt to get a second opinion.
     11.  Ask if the doctor reads SBM. If he answers yes, that’s a good sign! If he answers no, maybe you can get him to start reading it.
Maybe I’ve been unusually lucky. In the military health care system, I’ve been treated by MDs, DOs, PAs, NPs, and even a clinical pharmacologist; some of them were military officers, others were civilians employed by the military. I’ve seen multiple specialists in the military system and when appointments were not available in the system I’ve been referred out to civilian doctors, both primary care and specialist. None of them ever mentioned homeopathy, acupuncture, chiropractic, or energy medicine. When they talked about questionable areas, they always acknowledged that the evidence was inconclusive. The surgeon explained the biology and the statistics and then asked me to choose between breast biopsy and watchful waiting. The retinal specialist gave me a brochure about a new vitamin mixture that I “might” want to consider as a possible preventive measure for macular degeneration, but she wasn’t selling it herself or even recommending it, and she said so far there was no real evidence for prevention but only for slowing progression of established disease.
I know the medical profession includes a significant number of charlatans, of individuals who don’t really understand science, and of gullible, misguided swallowers of the Kool-Aid. But in my own anecdotal sampling of the medical profession, I haven’t come across a single health care provider who would not be acceptable to patients who are “proponents of SBM, and who place a high value on reason, logic and evidence.” I’m guessing a doctor picked at random would be more likely to agree with SBM than with Mercola. I’m hoping our readers will comment and offer practical suggestions about how best to avoid the minority of duds.

When To See a Doctor
Harriet Hall on March 6, 2012
Link
Two weeks ago I wrote about the demise of the traditional annual physical for healthy adults who have no symptoms.
The First Step: Identifying a Symptom
People who do have symptoms should see a doctor. They should have appropriate evaluations that may or may not include a partial or complete physical exam. One problem is that people may not be able to decide what qualifies as a significant symptom. Could the heartburn actually be a heart attack? Is the fatigue a normal result of exertion, or could it be a sign of something serious? Could my headache be a sign of brain tumor, or should I just take an aspirin? My spouse says I’ve been snoring more: could that be a sign of sleep apnea? What if I just “don’t feel right”?
This is a real dilemma, because minor transient symptoms are a normal part of life. Some of them are due to trivial conditions that spontaneously resolve; some are sensations due to the normal functioning of the body. Some people are more aware of these sensations than others. Paying attention to them tends to make them worse. Some people barely let these minor sensations intrude on conscious thought; others fixate on them and obsess about them. There is a spectrum of human reactions ranging from the stoic denier to the hypochondriac.
One of my classmates in medical school did a research project where he had healthy volunteers keep a detailed diary of every annoying bodily sensation. When you pay close attention and write them all down, it’s amazing how much you can notice. Today my ankles were a bit sore for about 5 minutes after I exercised, my nose itched, my eyes felt dry, I had a brief twinge of lower back pain, I felt a bit lightheaded when I stood up suddenly, I woke up twice during the night, my weight was up a pound from yesterday, just now my left knee felt like it was going to give way, my shoulders ached a bit after I sat too long at the computer, I noticed a new red bump over a knuckle, and now that I think of it I have a bit of a mild headache… you get the idea. If I were depressed, anxious, or under stress, it might be tempting to fixate on some of these symptoms and magnify them in a search for a physical scapegoat to explain my psychological distress. As it happens, I’m not at all worried about these trivial symptoms and I’m not going to waste any time thinking about them. As a doctor, I have a knowledge base that gives me reasonably good judgment about when to worry; but I could hardly expect the average layperson to have as good judgment. 
We don’t want patients to bother doctors every time they have a loose stool or a pimple. Useful criteria are to see if a symptom persists or becomes more severe or frequent over time. But how much is too much? And should you go to the emergency room or can it wait for a routine appointment?
There are lots of “When should you see a doctor?” and “What are signs of cancer?” and “Are you having a heart attack?” guidelines on the Internet and in books. Many health care institutions have hotlines patients can call to talk with a nurse for guidance. These are useful but not foolproof.
The Second Step: Dealing Appropriately with the Symptom
Once a symptom is reported to a doctor, another problem arises: the doctor may not respond appropriately. Sometimes instead of improving health outcomes, both CAM and mainstream providers only create more suffering. If a provider spends a great deal of time with a patient asking detailed questions, it may just raise more alarms in the patient’s mind. It may make them more observant of all those normal bodily sensations. The doctor asked if I ever get short of breath; now that I know to watch for that, I’ve been paying more attention and I’ve noticed that I do get a little short of breath sometimes. The homeopath asked me about my dreams and said dreaming about robbers is one of the things listed in his book that helped him choose the remedy he prescribed for me; should I start keeping a dream diary to help monitor my health? The chiropractor asked if my baby nursed more from the left or the right breast; should I have kept better track? Did I inadvertently cause a subluxation in my baby’s spine? The naturopath asked me about every detail of my diet; today I ate a piece of fried chicken and now I feel really tired; was it because of the chicken? The integrative medicine specialist asked about a lot of things unrelated to my chief complaint, things that I hadn’t even known I should be concerned about, and then recommended a whole list of diet supplements; I couldn’t afford to buy them all and now I’m worried that I may develop cancer without them; my bowel movement today was an unusual color: could that be a sign of cancer?
A minor symptom can escalate into the perception of a serious problem with the collusion of a provider. An overzealous doctor may embark on a cascade of unnecessary tests that not only worry the patient but can lead to physical harm from biopsies or exploratory surgery. A more judicious provider can minimize the concern, reassure the patient that the symptom is not a sign of anything serious, encourage the patient’s coping skills, and get him thinking about his strengths and the ways in which his health is good.
CAM providers even invent new pseudo-diseases to worry about and treat: an example is the solanine toxicity syndrome I wrote about three weeks ago. Or they frighten patients by diagnosing real and serious diseases on the basis of unvalidated tests, as Dr. Gorski described in his post yesterday.
To Comfort Always
The motto of good medicine is “To cure sometimes, to relieve often, to comfort always.” The motto of CAM might be “To cure never, to relieve sometimes, to comfort always.” CAM specializes in the comfort; science-based medicine specializes in the cure. There are a lot of things science can’t cure and doesn’t promise to cure; CAM can’t cure anything but promises to cure everything, and even to make you healthier than healthy. As practiced in our high-technology, hectic, demanding modern medical settings, science-based medicine brings trauma patients back from the brink of death and transplants organs, but sometimes skimps on the comfort. In the patient’s perception, comfort may be more important than cure. We can do better.
Recently a friend called me about something that had him really worried. He had been exposed to an immigrant with TB and AIDS, and the health department wanted to test him and all his family members for TB. He thought he was contagious, confined himself to the house for fear of infecting others, and dreaded the results of the test, thinking the disease was devastating and possibly fatal. I was able to reassure him that his exposure was probably not close enough or long enough to be a significant risk, that he wasn’t contagious, that TB was curable, and that if the test was positive it wouldn’t mean he had active TB but only that he was at risk of developing it and would need to take isoniazid pills for a few months as prophylaxis, as I did when my skin test converted in 1975. I can’t cite any randomized controlled trials to prove the benefit of our conversation, but I doubt if anyone would question the fact that I gave him comfort based on my knowledge of medical science.
I can’t help but wonder what the average chiropractor or naturopath would have said to him. I have encountered chiropractors and natural hygiene advocates who would have told him to refuse the TB test and not to worry, because TB germs don’t cause disease. Others might have started him on a regimen of diet, supplements, maintenance adjustments, or other treatments to protect his health.
When should you see a doctor?
In my opinion, if you are concerned about anything or even have any questions about your health, you should never hesitate to consult a science-based health professional. This doesn’t necessarily mean a formal appointment with a doctor: a telephone or Internet contact with a physician assistant, nurse, or other member of the health care team might suffice. Even minor worries take their toll. For me, the most rewarding thing about practicing family medicine was being able to reassure the worried well and those with overblown worries about minor illnesses. No questions are silly questions: it’s only silly not to ask.

Re-thinking the Annual Physical
Harriet Hall on February 21, 2012
Link
Please note: the following refers to routine physicals and screening tests in healthy, asymptomatic adults. It does not apply to people who have been diagnosed with diseases, who have any kind of symptoms or signs, or who are at particularly high risk of certain specific diseases.
Throughout most of human history, people have consulted doctors (or shamans or other supposed providers of medical care) only when they were sick. Not too long ago, the “if it ain’t broke don’t fix it” mindset changed. It became customary for everyone to have a yearly checkup with a doctor even if they were feeling perfectly well. The doctor would look in your eyes, ears and mouth, listen to your heart and lungs with a stethoscope and poke and prod other parts of your anatomy. He would do several routine tests, perhaps a blood count, urinalysis, EKG, chest-x-ray and TB tine test. There was even an “executive physical” based on the concept that more is better if you can afford it. Perhaps the need for maintenance of cars had an influence: the annual physical was analogous to the 30,000 mile checkup on your vehicle. The assumption was that this process would find and fix any problems and insure that any disease process would be detected at an early stage where earlier treatment would improve final outcomes. It would keep your body running like a well-tuned engine and possibly save your life.
We have gradually come to realize that the routine physical did little or nothing to improve health outcomes and was largely a waste of time and money. Today the emphasis is on identifying factors that can be altered to improve outcomes. We are even seeing articles in the popular press telling the public that no medical group advises annual checkups for healthy adults. If patients see their doctor only when they have symptoms, the doctor can take advantage of those visits to update vaccinations and any indicated screening tests.
The physical exam itself
The physical exam of a healthy, asymptomatic adult is unlikely to reveal any significant abnormality (1) that would not have been detected eventually when symptoms developed and (2) whose earlier detection and treatment would reduce morbidity and mortality in the long run.
A directed physical exam is sometimes indicated in patients with risk factors for specific conditions. A Pap smear is indicated in most women, but not every year, and the accompanying pelvic exam is likely a waste of time.
For healthy adults between the ages of 18 and 65, The American Academy of Family Physicians (AAFP) recommends only these components of the traditional physical exam:
    • For men, a blood pressure measurement.
    • For women, a blood pressure measurement and a periodic Pap smear.
They have other recommendations including vaccinations, counseling, and screening tests; but none of those require a physical exam.
Because they are so unproductive, routine physical exams are very boring to most physicians. My least favorite chore as an Air Force physician and flight surgeon was doing the required physicals. The system had some really idiotic requirements: for instance, the flight physical required a measurement of pulse rate after exercise, but there was nothing in the regulations that said what readings were considered abnormal or what actions to take if they were!
I heard about one doctor who had to do a lot of exams of healthy young men at a recruiting center and dreamed up a way to make it more interesting. He challenged himself to identify patients with situs inversus. This is a condition where the internal organs are on the wrong side (i.e. heart on the right, appendix on the left). It’s disqualifying for military service, probably because of the implications for battlefield trauma care. He soon held a record for the most diagnoses of situs inversus and was asked how he did it. He explained that he simply looked for men whose right testicle hung lower than the left and subjected those patients to a more intensive evaluation!
Screening tests
We are increasingly questioning screening tests that were formerly recommended. The annual chest x-ray, tine test, and urinalysis are long gone. The recommended age limits for mammography have changed. Routine PSA testing is being discouraged. A recent study suggested that a woman whose DEXA scan shows normal bone density or mild osteopenia need not be rescreened for 15 years.
We don’t need to examine all the published literature on screening tests, because the U.S. Preventive Services Task Force (USPSTF) has done all the work for us. They continually update recommended screening tests for different age and risk groups based on the latest studies. There are other organizations in the US and elsewhere that make similar recommendations but that may differ to some degree in different countries. In general, a specialty organization is likely to recommend more screening in its particular area of interest, based on a different focus in interpreting the same published evidence. The American Academy of Family Physicians, with a broader perspective, generally follows USPSTF recommendations.
The early detection myth
There is a general perception, among the public and among doctors, that there’s no such thing as a bad screening test, that early detection is important, that knowing is always better than not knowing. If something is wrong with you, you need to know because, if you find a problem in time, it can be treated effectively to prevent morbidity and mortality. If you get a checkup and everything looks OK, you can breathe a sigh of relief and relax. Unfortunately this is all wrong.
A recent book explains why: Overdiagnosed: Making People Sick in the Pursuit of Health, by Drs. H. Gilbert Welch, Lisa M. Schwartz, and Steven Woloshin. It’s a comprehensive explanation of how test results make people sick and why visiting a doctor can be hazardous to your health. I reviewed it in an earlier article here on ScienceBasedMedicine.org. Please read that link and then come back.
Welch et al. commented
…some people may feel safer having their potential problems diagnosed and treated. For some, that may make the treatment side effects and hassle factors seem worth it… [but] the sense of being safer is likely an exaggerated view of the reality.
For a healthy, asymptomatic patient, the physical exam with the laying on of hands and stethoscope and other rituals is pretty much meaningless. If nothing is found, it can produce false reassurance. If something is found, it is not likely to prolong the patient’s life and it has a significant likelihood of leading to harm from unnecessary treatment or from a diagnostic cascade of tests, unnecessary surgeries, unnecessary expense, and unnecessary worry.
Re-inventing the check-up
Doctors are not punished for overdiagnosis, but they are punished for failing to diagnose. We mustn’t let fear of lawyers interfere with our good judgment. The annual physical is obsolete.
On the other hand, there is a good argument for a periodic visit with a healthcare provider without the ritual of the physical exam. It’s helpful to have a systematic way of ensuring that the screening tests recommended by the USPSTF get done. An annual visit would be an opportunity for a preventive medicine interview and advice about a healthy diet, exercise, and other lifestyle factors. While an objective benefit has not been proven by any controlled studies, it can only be helpful for a doctor to get to know his patients before they get sick, for a patient’s history to be documented in a chart, and for patients to develop a relationship with a doctor they can trust. Instead of just rejecting the annual physical, maybe we ought to reinvent it.
Anyway, what’s so special about “annual?” The human body can’t read the calendar. A year is only a convenient way to jog the memory. Who’s to say that 365 days is better than 340 or 390 for any given purpose? In the absence of solid data, a range of suggested intervals might be more appropriate.
Welch et al. point out that health is more than absence of disease; it’s also a state of mind. They recommend health promotion efforts that lead people to feel more resilient, both physically and emotionally. Ironically, pursuing health requires not paying too much attention to it.

Is the Annual Physical Unnecessary?
Harriet Hall on April 26, 2016
Link

I was approached by The Wall Street Journal to write an article for their Big Issues in Health Care debate series. The subject was “Is the annual physical unnecessary?” I was to take the “yes” side and an internist was to take the “no” side. I wrote the following article. The editor wrote me a couple of times with questions. The internist pointed out the value of preventive medicine, developing a personalized healthcare plan, and developing a meaningful doctor-patient relationship. I said I wholeheartedly agreed, but I thought those goals could be accomplished just as well (arguably even better) with a periodic health maintenance interview or consultation. I pointed out that the traditional “physical” exam with stethoscope, routine lab tests, etc. provides no further advantages and can be counterproductive, with false positive or harmless findings leading to unnecessary worry, further testing, and expense. I said there was nothing magical about the interval of a year. I don’t know what the optimum interval would be; that could be studied. I suspect it would vary with the patient’s age, medical conditions, risk factors, and other considerations, and might be left up to the judgment of patient and doctor deciding together.
Finally I got an e-mail with apologies, saying they had decided not to continue with the debate because the internist and I agreed on too many important details. While I understand that stirring up a fight is good for selling newspapers, I think it’s a much better thing when people on two sides of a debate reach an agreement. It reassures me that they are converging on the truth. So I thought it would be worthwhile to publish my article here on SBM.
Annual physicals are wasteful and lead to overdiagnosis
The annual physical is obsolete. Routine physicals don’t reduce mortality or morbidity and can no longer be recommended for asymptomatic adults. They waste resources and can sometimes lead to harm.
People used to consult doctors only when they were sick. The routine annual physical originated in the 1940s. The idea was that if healthy people with no symptoms saw a doctor every year, diseases could be detected early and treated before they could cause any harm. It seemed like a good idea at the time.
The annual physical was never clearly defined. Depending on the doctor, it might include vital signs; eye/ear/throat exams; palpating necks, breasts, testicles, and abdomens; inserting fingers into vaginas and rectums; updating immunizations; and various tests like Pap smears, stool guaiacs, complete blood counts, urinalyses, chemistry panels, TB tine tests, mammograms, chest x-rays, EKGs, and others.
The interval of a year was arbitrary, based on calendric convenience rather than on any scientific rationale. There was a risk that routine exams would give false reassurance of health and lead patients to minimize the significance of new symptoms or delay reporting them until the next annual physical.
By the 1980s, doctors had begun to question which components of the annual physical were worthwhile. Little by little, practices changed. Annual CBCs, urinalyses, TB tine tests, and chest x-rays were found to be useless and were dropped. Pap smears and STD screening were proven worthwhile, but the routine pelvic exam with speculum and bimanual palpation was not.
The physical examination of a healthy, asymptomatic adult is unlikely to reveal any significant abnormality (1) that would not have been detected eventually when symptoms developed and (2) whose earlier detection and treatment would reduce morbidity and mortality in the long run.
It is very rare for a finding on a routine physical to save a life. Far more often there are false alarms and minor findings that would never have caused harm. These can lead to diagnostic cascades and dangerous invasive procedures. In many cases early diagnosis doesn’t change final outcomes, but only puts people in the “sick” category for a longer period. The United States Preventive Services Task Force (USPSTF) is an invaluable clearing house for up-to-date evidence about which preventive health measures improve outcomes, which do more harm than good, and which can neither be recommended nor discouraged because there is insufficient evidence.
The preventive services recommended by the USPSTF have been proven to reduce morbidity and mortality, but they don’t require an annual physical exam by a doctor. There are arguments for components of the physical exam that don’t affect mortality but that provide subjective benefits. It’s an opportunity for patients to ask questions they wouldn’t consider important enough to make an appointment for, to get to know the doctor before illness strikes, to review current meds, to educate, and to reassure patients about minor health worries. But those same opportunities can be provided without an annual physical exam.
By the 1980s, most medical organizations were no longer recommending an annual physical. Instead, they recommended periodic (not necessarily yearly) screening, counseling, and selected components of a physical examination only as indicated by the individual patient’s history and review of symptoms. It’s called a health maintenance visit. Another feasible alternative is to take advantage of illness appointments to update the recommended preventive measures. Most preventive screening tasks can be delegated to auxiliary personnel, leaving more time for doctors to interact meaningfully with patients. It’s time we stopped meaningless rituals like perfunctorily applying stethoscope to chest once a year.
Addendum
The Medicare Initial Preventive Physical Examination (IPPE) might serve as a useful template. It consists of a review of the patient’s medical and social history, risk factors, functional ability and level of safety, end-of-life planning, and a physical exam consisting of height, weight, blood pressure, visual acuity, and “other factors deemed appropriate based on the beneficiary’s medical and social history and current clinical standards.”

Low Dose Aspirin for Primary Prevention
Steven Novella on November 19, 2014
Link


A new study published in JAMA sheds further light on a controversial question – whether or not to prescribe low-dose aspirin (81-100mg) for the primary prevention of vascular disease (strokes and heart attacks).
Primary prevention means preventing a negative medical outcome prior to the onset of disease, in this case preventing the first heart attack or stroke. Secondary prevention refers to treatments given to patients who have already had their first heart attack or stroke in order to reduce the risk of subsequent events.
The evidence strongly supports the efficacy of aspirin for the secondary prevention of both heart attacks and strokes. Aspirin has two effects which likely contribute to this protective effect. First, aspirin is an anti-platelet agent – it reduces the stickiness of platelets, which are cell fragments in the blood that clump together to stop bleeding. They can also clump together around an ulcerated cholesterol plaque on an artery, forming a thrombus, resulting in blockage or embolus (the clot traveling downstream) and causing either a heart attack or stroke.
Other anti-platelet agents, such as clopidogrel, are also effective in preventing stroke and heart attack.
Of course, platelets exist for a reason, and blocking their action increases the risk of bleeding or can make bleeding worse when it occurs. Therefore determining the optimal dose and target population are important to maximize the benefit of aspirin or other anti-platelet agent while minimizing the bleeding risk. 
A second mechanism of aspirin which likely contributes to its protective effect is that it is an anti-inflammatory. Inflammation likely contributes to atherosclerotic disease. This anti-inflammatory effect may also provide protection for diseases other than vascular disease. For example, there is some evidence that aspirin may also be useful in the prevention of certain types of cancer. However, as with primary prevention, any potential benefit is small compared to the burden of the disease, and has to be carefully weighed against side effects.
So, while it is the standard of care to prescribe daily aspirin or an equally effective drug to patients who have had a vascular event, it remains somewhat controversial whether aspirin should be given for primary prevention, and if so, in which populations.
A 2009 systematic review of aspirin for primary prevention concluded:
Aspirin reduces the risk for myocardial infarction in men and strokes in women. Aspirin use increases the risk for serious bleeding events.
A 2013 review concluded:
We have found that there is a fine balance between benefits and risks from regular aspirin use in primary prevention of CVD.
That about sums up the situation – a fine balance. This means that we are trying to find slight advantages by studying very large populations and following them for many years. Perhaps, in the right patient population (those with a certain risk), we might eke out a small outcome advantage. In the US we tend to prescribe aspirin for primary prevention in high-risk populations, those with high cholesterol, hypertension, and diabetes, for example.
On this background comes the new study from Japan. They followed 14,464 patients for up to 6 years, but with a mean follow up of 5 years. Half received aspirin and half received no aspirin. This was an open-label trial with no placebo. Study outcomes were adjudicated by a blinded multidisciplinary expert panel.
The study, which was for primary prevention but in high-risk patients, found that the incidence of non-fatal heart attacks were reduced by about 50% in the aspirin group and non-fatal strokes by about 40% in the aspirin group. However, fatal events were not reduced. Further, when all cardiovascular outcomes were combined, there was no statistically significant difference between the groups.
These results, in my opinion, keep the waters just as muddied as they were previously. Proponents of aspirin use in high-risk patients can point to the reduction in heart attacks and stroke, while critics can point to the lack of overall decrease in events, and to the lack of effect on survival.
It is also reasonable to ask if this Japanese population can be generalized to other populations. While the Japanese diet and therefore risks have been increasingly Westernized over recent decades, they continue to have lower overall risk than in the West (heart disease mortality rate is 1/3 to 1/5 that in the US). Lower risk means lower benefit from prevention.
Conclusion
While this recent study failed to show an overall benefit from low dose aspirin for the prevention of vascular events, it did show a benefit for the reduction in non-fatal heart attacks and strokes. Further, it is not clear if the study population can be applied to Western populations, especially since there is such a fine line between risk and benefit with this treatment.
In terms of the stakes of this question, you can look at it in one of two ways. From the individual perspective, the balance between risk and benefit for aspirin for primary prevention is slight. Aspirin will have a small statistical effect on overall health risk and may not have any net effect on survival.
From a population-based perspective, however, given the total burden of heart attacks and strokes, even a small statistical decrease in risk may translate into a large number of prevented events.
With this new study I think we are left in the same situation as before. Aspirin (or other anti-platelet or blood thinning treatment, as appropriate) should be used for secondary prevention of vascular disease – heart attacks and stroke. It should be considered for primary prevention in patients who are at risk for vascular disease, but an individualized decision should be made based on various factors. We cannot make, however, a blanket recommendation for aspirin for primary prevention.

Is Midstream Urine Collection Necessary?
There’s considerable evidence that the standard procedure for urine specimens, with cleansing and mid-stream collection, may not be necessary. Is it time to change?
Harriet Hall on January 26, 2021
Link

In November 2020, I reviewed Paul Offit’s book about when doctors refuse to believe evidence. I have just become aware of another example. The evidence for diagnosing urinary tract infection (UTI) by the gold standard – clean catch mid-stream urine collection – is lacking, but it is still universally recommended. I get my medical care at Madigan Army Medical Center; the lab there instructs women to wash hands, cleanse the area with two towelettes, then to hold the labia apart and collect a midstream urine sample. Some labs even recommend removing underwear and sitting facing the back of the toilet. Is all that rigmarole really necessary?
What does the scientific evidence show?
A 1981 study by Immergut et al. published in Urology was titled “The myth of the clean catch urine specimen“. It concluded:
Urine specimens obtained from unprepped ambulatory females who voided into an unsterile disposable plastic cup showed a 95-per cent correlation with a catheterized specimen collected from a prepped patient through a sterile cystoscope. From these data, it appears that the midstream urine specimen and its unpleasant collection routine can be eliminated. We have found that specimens collected at any time during voiding in unsterile disposable plastic cups result in reliable urine cultures.

A 2000 study found that in young, outpatient women with symptoms suggestive of a urinary tract infection, the midstream clean-catch technique does not decrease contamination rates.
A 2011 multicenter study in Italy confirmed that mid-stream collection was the most accurate.
A 2012 study of urine samples from children found that contamination rates were much higher for clean catch specimens than for specimens obtained by catheter or suprapubic aspiration.
A 2013 article in Urology Times argued that mid-stream urine samples have limited value in diagnosing cystitis because they don’t accurately represent the bacterial content of the bladder.
A 2015 study found that contaminants resulted in false-positive cultures and over-diagnosis of UTIs in women without infection and was common regardless of collection technique.
A 2016 study found that the contamination rate for midstream urine collection in women was reduced from 40% to 25% when instructions were illustrated.
A 2018 article in Emergency Medicine News said, “Contrary to popular belief, multiple studies have shown no difference in bacterial contamination rates when comparing clean-catch samples against non-clean-catch samples”. It recommended careful consideration of other factors like the patient’s symptoms and markers like nitrites, leukocytes, and blood.
A 2019 study in Scandinavia found that diagnosis of urinary tract infections was more accurate for mid-stream than for first-void specimens.
Another 2019 study questioned the use of midstream urine cultures, showing that false negatives were common and diagnosis was more accurate with genomic testing and with simply going by symptoms.
A 2020 study compared initial-stream to mid-stream samples and found that a biomarker for kidney disease was more accurately detected by mid-stream samples.
A systematic review in 2016 found that the diagnostic accuracy of midstream urine collection from men compared to straight catheterization or suprapubic aspiration was high, but the overall strength of the evidence was rated as low. For children and infants, high quality evidence showed larger reductions in the odds of contamination in favor of midstream collection with cleansing over other methods of collection. For women, they concluded that midstream collection with cleansing is recommended, but no recommendation for or against is made for midstream collection without cleansing.
Conclusion: Questions remain
The evidence is conflicting. Clean-catch mid-stream samples may not be necessary. And anyway, patients often fail to follow the instructions and there are caveats about how the results are interpreted. I see no harm in continuing to recommend mid-stream samples. But it seems pretty clear that the cleansing routine is unnecessary and could be abandoned. The full routine has been standard practice for so long that doctors are reluctant to give it up. Maybe it’s time to reconsider.

Surgery Under Hypnosis
Steven Novella on June 18, 2014
Link
The BBC recently reported that a Guinean singer, Alama Kante, sang through her surgery in order to protect her voice. The reporting is unfortunately typical in that it emphasizes the seemingly amazing aspects of the story without really trying to put them into proper context. Specifically, the story emphasizes that hypnosis was used during the surgery, since Kante could not be placed under general anesthesia and still be able to sing, reporting:
“The pain of such an operation is intolerable if you are fully awake. Only hypnosis enables you to stand it,” he was reported as saying by to French publication Le Figaro.
“She went into a trance listening to the words of the hypnotist. She went a long way away, to Africa. And she began to sing – it was amazing,” he said.
Reports of major surgery being performed using self-hypnosis or hypnosis instead of anesthesia crop up regularly, because of the obvious sensationalism of such stories. I reported a similar case from 2008, for example. At least in this case the news report gave the critical piece of information, often missing entirely from such reports:
The Guinean singer, who is based in France, was given just a local anaesthetic and hypnotised to help with the pain during the operation in Paris.
She was given a local anaesthetic. Local anesthesia, when properly done, can completely block all pain and sensations from the relevant area. Why was hypnosis even necessary, then? Perhaps it wasn’t, but hypnosis, self or otherwise, can be useful as a means of calming anxiety or distracting a patient from the procedure. Even with local anesthesia, a patient may still feel pulling and poking and this can cause anxiety.
Hypnoanesthesia might be a useful adjunct for surgical procedures where the patient is awake. The literature is not clear. But it is important to note how some define hypnoanesthesia – as “hypnosis, local anesthesia and minimal conscious sedation.” It isn’t certain what role hypnosis is playing when both local anesthesia and conscious sedation are given. In this case the BBC report did not mention conscious sedation either way, so we don’t know if the hypnosis had any pharmacological help.
It is also not uncommon for patients to medicate themselves prior to surgery, by taking some of their prescription pain or anti-anxiety medication.
Published research looking at hypnoanesthesia has been mixed, plagued by poor methodology and not carefully separating out hypnosis and an independent variable. Those that do have a higher tendency to be negative.
It should also be noted that hypnosis doesn’t really involve putting people in a “trance,” even though that word is commonly used (as with the current BBC reporting). Hypnoanesthesia is mainly a form a deep meditation, which can be self-induced or guided by another. The person is still awake and alert, and not what people might imagine from movies or television as “in a trance.”
This can be a useful technique for distracting patients from the procedure and any uncomfortable sensations and reducing anxiety. Such techniques are as old as medicine itself. Every medical student learns how to distract patients from a painful procedure, engage them in small talk, and to calm their anxiety. This is just good bed-side manner. Hypnosis or self-hypnosis is just a formalized way to do this, without clear evidence that it is superior.
The theme of mainstream reporting on surgery with hypnosis, however, generally paints a very different picture, for sensational effect – that of a patient in a trance while surgery is being performed on them with little or no anesthesia. This is a fiction.
The other aspect of this story reported for sensational effect was that the patient, Kante, sang during the critical parts of the surgery to “save her voice.” The surgery was on the parathyroid gland. The risk with such surgery is damage to either the superior laryngeal nerve or recurrent laryngeal nerve (RLN), which can cause hoarseness or loss of voice.
While the incidence of temporary or permanent paralysis of the RLN is quite low, 1-4%, it is a serious complication when it occurs. The greatest risk is from bilateral RLN injury, which can compromise breathing.
Monitoring the function of the RLN during surgery is not a new idea, and there are numerous studies looking at this technique. This involves stimulating the nerve and measuring a response (so that patients can be under general anesthesia). RLN stimulation is not perfect, but does highly predict RLN damage from surgery. It does not prevent the damage from occurring, however. Its primary use is to detect RLN damage on one side before proceeding to surgery on the other side, in order to prevent bilateral damage (on both sides).
Kante’s procedure apparently is unique in that singing was used to detect damage to the RLN, rather than nerve stimulation. It’s not clear if this was at all useful in preventing damage to the RLN, just demonstrating that damage had occurred.
Conclusion
This story is of a singer who had parathyroid surgery under local anesthesia and didn’t suffer a complication that occurs 1-3% of the time and could have damaged her voice. News reporting focused on the two aspects of this story that may have had little or no impact on the procedure, the hypnosis and singing as a way of detecting damage to the RLN.
It is not clear if hypnosis is at all beneficial, but it is plausible that hypnosis during procedures in an effective strategy of relaxation and distraction (although not necessarily more effective than any other method).
Singing during the surgery to monitor the RLN seems like little more than a gimmick. There is already a method in place to directly monitor RLN function and detect damage. It is also not clear if such monitoring reduces the incidence of damage to the RLN, or just predicts it.
The BBC, however, did not let educating their readers about all the relevant facts get in the way of telling a compelling narrative.

Point-of-Care Ultrasound: The Best Thing Since Stethoscopes?
Harriet Hall on March 25, 2014
Link
A bit of good news for a change: a “Perspective” article in the New England Journal of Medicine describes how point-of-care ultrasound devices are being integrated into medical education. The wonders of modern medical technology are akin to science fiction. We don’t yet have a tricorder like “Bones” McCoy uses on Star Trek, but we are heading in that direction, and the new handheld ultrasound devices are a promising development.
The stethoscope has become iconic, a symbol of medical expertise draped proudly around the neck by doctors and other medical personnel. Before it was invented, doctors could only try to listen to a patient’s heart by direct application of ear to chest. In 1816, Laennec interposed a tube of rolled paper between ear and chest, and the stethoscope was born. It quickly became an essential tool, allowing us to hear the distinctive murmurs produced by different heart valve abnormalities, to take blood pressures, to detect the wheezing of asthma or the collapse of a lung , to hear the bruits caused by atherosclerotic narrowing of blood vessels, to detect intestinal obstructions by listening for borborygmi (I love that onomatopoeic word!).
The stethoscope allows us to hear sounds produced by the body, but sound also allows us to see inside the body. Diagnostic ultrasound has a multitude of uses. With prenatal sonograms, we can determine the sex of a fetus, watch it suck its thumb, and even take its picture for the family album. With echocardiography we can evaluate heart valves, see fluid accumulation in the pericardium, observe the thickness and motion of the heart wall, and even quantify the efficiency of the pumping process. Ultrasound lets us see clots in blood vessels and stones in the gallbladder, evaluate abdominal organs, detect cysts, screen for carotid artery narrowing and abdominal aortic aneurysms, and guide needles into the body for therapeutic and diagnostic purposes.
Modern imaging methods allow us to see abnormalities in the living patient that were once only detectable on autopsy. Because of this, medical autopsies are no longer so useful and their rates have declined drastically although forensic autopsies are still required by law. It’s really amazing what we can see with CT scans, MRIs and ultrasound. I recently had an echocardiogram and my mind was boggled as I looked into my own heart and watched the valves open and close. I developed a new respect for my heart as I watched the organ pumping away, working assiduously to keep me alive, with never a moment’s rest. The visual experience was impressive, but perhaps even more impressive was the way the technician was able to precisely measure the thickness of the ventricular wall and quantify the ejection fraction, measuring the amount of blood that was being pushed out of the ventricle with every heartbeat.
Instead of writing an order for technicians to do these tests, doctors now have the option of using ultrasound technology themselves as part of the physical exam at the bedside or in the office. Several US medical schools are offering ultrasound training as early as the first year, even in orientation programs. Ultrasound is used in classes of anatomy, physiology, and physical diagnosis, and eventually on clinical rotations. Harvard has students performing ultrasounds on each other. Mt. Sinai is issuing hand-held ultrasound units to all internal medicine interns.
Studies have shown that first year medical students using these devices are better at detecting cardiac abnormalities than cardiologists (75% vs. 49%) and better at judging liver size than specialists palpating the liver. In the future, ultrasound may well become a standard part of the physical exam. The stethoscope was an extension of the doctor’s sense of hearing, and ultrasound extends the doctor’s senses in far more versatile ways.
Providing these devices to students may not be an unalloyed good. Proper use requires extensive training. False positives and negatives will occur. Students will rely on technology and neglect other diagnostic skills like palpation and auscultation. Full conventional ultrasound studies will still be needed for confirmation and further detail.
Consider this criticism:
Notwithstanding its value, I am extremely doubtful because its beneficial application requires much time, and gives a good deal of trouble both to the patient and the practitioner.
No, that wasn’t criticism of ultrasound, it was an 1829 comment about the stethoscope. Old dogs (and old docs) are slow to learn new tricks, and any new-fangled technology is bound to meet with some resistance. The real question is whether its use will improve medical practice and patient outcomes. It seems logical that it will, but that premise, like any other, will have to be evaluated by controlled scientific testing. I am optimistic.
Developments in scientific medicine are far more awe-inspiring than anything alternative medicine has to offer. Invisible acupuncture meridians and chiropractic subluxations can’t compete with watching your own heart valves open and close.
Reality is a lot more satisfying than fantasy.

Constipation Myths and Facts
Scott Gavura on October 27, 2011
Link
When it comes to health issues, bowels are big business. Bowel movements are part of everyday life, and we notice immediately when our routine changes. Constipation, from the Latin word constipare (“to crowd together”) is something almost everyone has some experience with. In most cases, it’s an occasional annoyance that resolves quickly. For others, particularly the elderly, constipation can be a chronic condition, significantly affecting quality of life.  Depending on the question and the sample surveyed, prevalence seems to vary widely.  It’s estimate that there are 2.5 million physician visits per year in the USA, and the costs of management are estimated at about $7.5 billion annually. It’s not a trivial issue.
One of the biggest challenges in interpreting both individual patient situations, as well as the literature overall, is understanding what’s defined as “constipation”. One person’s regular routine may be another person’s constipation. From my dialogue with patients, personal definitions seem to vary. Some panic after a single missed bowel movement, while others may be unconcerned with daily (or even less frequent) movements. What’s the optimal frequency? It depends. Infants may be 3x/day. Older children may be once daily. Adults may be daily or less frequently.  The literature generally, though not consistently, defines constipation as a delay or difficulty in bowel movements ( usually less than 3 per week) lasting two weeks. Symptoms can include infrequent, painful bowel movements, straining, and lumpy or hard stools.  When these problems last for more than three months, it’s termed chronic constipation. When constipation is accompanied by other symptoms like bloating, diarrhea, and abdominal pain, it may be termed  irritable bowel syndrome (IBS).
There are multiple causes of constipation. It may be a consequence of other illnesses (e.g., high/low thyroid, diabetes, cancer, and neurological diseases like multiple sclerosis). Drugs, both prescription and over-they-counter, can also cause constipation.  Primary or idiopathic constipation is a diagnosis of exclusion, after other causes have been ruled out.  If there are no signs of a more serious underlying condition, treatments can be considered.
Many have firmly-held opinions about their colon and their bowel movements: what’s normal, and what’s not. And there are equally strong opinions about the causes of, and solutions to, constipation. But despite the ubiquity of constipation and the firmly-held opinions on treatments, there’s a sizable chasm between practice and evidence.  This is an area with crappy (sorry) data, and it’s hard to sort out what are true treatment effects. But an absence of evidence isn’t evidence of absence, so we’re challenged to make the best decisions possible, despite a disappointing evidence base. Here are some common statements I’ve encountered, and an evidence check on their veracity.
The colon is the root of all illness
Colonic dysfunction as constipation has been described as a cause of disease since at least the 16th Century BC. It’s been a recurring medical motif as long as medicine has existed, starting with ideas of internal putrefaction, and later, once germ theory arrived, became a worry about autointoxication. This theory proposed that unnamed “toxins” were being absorbed from the bowel and causing systemic disease.  Now discredited in science-based medicine, these ideas continue to manifest today, largely in the realm of CAM with its warnings to “detox”, irrigate our colon, and indulge in other ritualistic “cleansing” practices. So today the colon continues to be blamed for all manners of illness, including eczema, cancer, high blood pressure, allergies, and more. There’s no evidence  to substantiate these claims.
I need to have a bowel movement at least every “X” to avoid toxins/allergies/chronic disease/certain death
This argument is an extension of beliefs about the necessity of bowel movements to avoid systemic disease. Interestingly, over hundreds of years, there’s always been the idea that constipation is a modern disease, one of urbanization and civilization: dietary changes, the busy pace of life and a lack of exercise.  So if you don’t feel constipated, you aren’t. Bowel habits can be evaluated on their own merits. As long as they’re not painful or hard, there is no ideal frequency. In the absence of constipation, the flushing of the colon, or the use of laxatives or other purgatives is at best unnecessary, and at worst, potentially harmful.
A lack of fibre can cause constipation, and fibre supplements are effective constipation treatments
The granddaddy of fibre cereals, All Bran, appeared on the market in the 1900s as a treatment for the diagnosis of the day,  autointoxication of the colon. Since then, fibre has held a special place in the armamentarium of health professionals and CAM advocates alike: It’s not only natural, but nature’s little broom, right?
Fibre, from cereal or other foods, serves multiple purposes in the bowel. It adds bulk to the stool and can increase the frequency of bowel movements. But there is a lack of correlation between dietary fibre intake, and the risk of constipation. And in patients given fibre supplements, the response in patients with chronic constipation is erratic. Fibre, particularly bran and other insoluble fibres causes gas formation, which can limit acceptance. Soluble fibres, like psyllium (Metamucil) are better tolerated.
Studies suggest that that low fibre diets may be a a contributing factor to constipation in a subset of patients, who may  respond to higher fibre diets. Consequently, Fibre supplements may be useful in some patients with mild or occasional constipation. But in more severe cases of chronic constipation, fibre can actually aggravate symptoms,and does not appear to be an effective therapy.
Drinking more fluids can help reduce the risk of constipation
The idea that consuming more water will result in softer, easier to pass stools hasn’t been substantiated when studied in patients with chronic constipation. Studies in the elderly have also failed to reveal an association between increased fluid intake and constipation. Constipated children, randomized to consume different amounts of fluid, didn’t experience any changes in stool frequency, consistency, or ease of defecation. Unless there’s evidence of dehydration, consuming extra fluid on its own is unlikely to make any difference in cases of constipation.
Exercise can help constipation
In most patients with constipation, this statement is true. There’s an established relationship between our activity level and our bowel habits, giving us the luxury of sleeping several hours without interruption. There seems to be a relationship between exercise levels and incidence of constipation, though across several studies, it’s not clearly a causal relationship. And in cases of vigorous exercise (e.g., running) there is clearly evidence of a significant increase in activity. While it’s not possible to do a truly randomized, double-blind trial, the evidence available supports the use of  physical exercise can be helpful for modest constipation, but it does not seem to be effective for severe cases.
Stool softeners are effectiveStool softeners (e.g., docusate sodium (Colace)) are among the most popular products prescribed for the prevention or treatment of constipation. They’re often a reflex prescription that accompanies narcotic prescriptions, because constipation is a frequent side effect of narcotic drug use, mainly due to effects on transit time through the colon. Stool softeners are essentially soap, and the theory is that they make the stool easier to pass. Despite their widespread use, there’s no good evidence that docusate sodium or docusate calcium are effective for the treatment of constipation. I find it quite fascinating that docusate sodium is one of the active ingredients in Corexit, last seen being dumped in large quantities into the Gulf of Mexico to disperse the Deepwater Horizon oil spill. Presumably the evidence is better for that indication.
Natural or synthetic, the drugs don’t work
Before treating constipation, getting an understanding of symptoms, other medications, and other illnesses is important. In cases where reversible factors  have been ruled out, drug therapy may be warranted. Despite the lack of good evidence, dietary and lifestyle changes usually precede drug therapy. In cases that don’t respond or resolve on their own, medications are next. Broadly, categories of treatments include bulk-forming products, stool softeners, osmotic agents, and stimulant laxatives.  Products available are a mix of naturally-derived and synthetic products. Some of the most popular laxatives are naturally-derived. The strange smell of Senokot tablets gives a clue to its origin: They’re senna glycosides, a product of the senna plant. The naturally occuring glucosides it contains are colonic irritants, stimulating colon contraction. Metamucil is psyllium seed husks, which swell into a gelatinous mass in the stomach, carrying water and bulk to the colon. Most of the other fibre supplements are naturally-derived as well.
The other commonly used products are synthetically derived. Milk of magnesia, despite its natural sounding name, is a suspension of magnesium hydroxide.When consumed, most of the magnesium isn’t absorbed, and it pulls fluid with it (via osmotic pressure) when it’s shunted to the colon. Polyethylene glycol (PEG) works this way, as does lactulose, a non-digestible sugar. The cathartics taken before endoscopy are all osmotic agents, too.
Bisacodyl (Dulcolax) is another popular over-the-counter product. A stimulant laxative like senna, bisacodyl stimulates colon contraction.
Despite the number of products, and prevalence of constipation, the evidence base for drug treatments is weak. There’s little head-to-head evidence that has pitted on treatment against another. So we’re largely left to make inferences from poor studies on different populations. The best evidence (which is still pretty weak) exists for the osmotic agents like PEG. Some evidence exists for psyllium, but it’s underwhelming. There’s evidence for lactulose as a treatment, as well. An excellent systematic review from the Oregon Evidence-Based Practice Center summarizes the evidence base in greater detail.
Probiotics can be effective for constipation
Probiotics, covered in depth by Mark Crislip already, are live microorganisms administered with intent of a therapeutic effect. If you like yogurt that does double duty, you’ll probably see brands that include Bifidobacterium and Lactobacillus, and, depending on your national regulator, there may be vague health claims about intestinal “wellness” on the label. The idea of probiotics for constipation is at least plausible, as probiotics have the potential to disrupt the colon’s bacteria ecosystem – if only to a very limited extent, as Mark noted in his post.  For constipation, their effectiveness hasn’t been demonstrated though. A systematic review published in 2010 examined the data supporting their use in adults and children.  Five high quality trials were identified and the results were unimpressive:
Data published to date suggest that adults with constipation might benefit from ingestion of B. lactis DN-173 010, L. casei Shirota, and E. coli Nissle 1917, which were shown to increase defecation frequency and improve stool consistency. However, in some cases, even if there was a significant difference in results, their clinical relevance is unclear.
Their conclusion:
Until more data are available, we believe the use of probiotics for the treatment of constipation condition should be considered investigational.
Overall, not encouraging. And little reason to recommend their use. That’s the opinion of some regulators, too. The European Food Safety Authority has largely rejected general health claims for probiotics.
Taking laxatives continuously is dangerous and leads to tolerance and then dependence
This is a common myth, but not substantiated by fact. [PDF] As a pharmacist I see a lot of chronic laxative use – some appropriate, and some clearly inappropriate. Something that was planted in my head in pharmacy school was the warning that chronic use would lead to dependence, and a near-certain risk of constipation if their use was suddenly stopped.  The warning is primarily with the stimulant laxatives, which have been believed to affect nerve conduction and muscle damage, largely based on anecdotal evidence. Microsope examination of colon tissue in chronic laxative users reveal some differences from normal subjects. But whether these changes are caused by stimulant laxatives, or are a product of an underlying disorder, is unclear. The best evidence we have suggests that risks of of most  laxatives, when used to treat constipation, at recommended doses, is probably small.  Risks seem restricted to patients with severe symptoms on high doses of stimulant laxatives.  Notably, because laxatives are generally not even absorbed, there is no risk of them directly causing nervous system effects. Consequently, there’s no risk of a actual addiction, through there’s no question that they can be misused. Misuse beyond the treatment of constipation can be problematic, potentially leading to electrolyte disturbances.
Children are little adults
False. Constipation is children is common, and it causes distress to parents, too. I’ve spoken with parents of infants only weeks old, already set on giving their child a suppository because the “regular” bowel movement is hours late. In infants, parents often ask me about iron-free formulas, thinking the iron may be causing constipation. However iron-fortified formulas haven’t been shown to be more constipating that iron-containing formulas. So switching to an iron-free formula may have no effect, and introduce the challenge of ensuring adequate iron intake.
The most common cause of constipation in children is functional constipation – constipation without an intrinsic cause, usually caused by children deliberately delaying or avoiding bowel movements, usually due to a painful past movement. Delaying causes further constipation, and further pain with bowel movements. Functional constipation is the cause of almost all constipation in children. Constipation that’s accompanied by abdominal pain, nausea, anorexia, or vomiting needs a physician examination to rule out other causes.
Despite its frequency, constipation in children rarely lasts and generally doesn’t require medication. Which is good, because there’s little evidence to demonstrate that laxatives are effective in children. A systematic review published earlier this year summarized the evidence base. Like treatment for adults, the data are limited. Because of the lack of evidence, dietary changes, while also not well supported by evidence, should precede any drug therapy. Acute treatments should be followed with longer term strategies to prevent further episodes. While the effectiveness of fibre for the treatment of constipation in children hasn’t been demonstrated, encouraging fibre-rich fruits or vegetables as a first step may plausibly help, and have numerous other health benefits as well.
Conclusion
Constipation is is common condition, yet there’s little high quality evidence to guide our actions. Myths about constipation further complicate treatment strategies. In the absence of high quality evidence, it would seem most conservative to carefully evaluate each situation for potentially causal factors, and introduce the treatments backed by the best evidence only after core dietary and lifestyle factors have been implemented.

Breathing Easy: Treating Allergic Rhinitis
Spring is a miserable season for those with seasonal allergies. There are effective drug- and non-drug measures that can control most symptoms effectively.
Scott Gavura on May 8, 2025
Link
It’s spring in the northern hemisphere, and for millions, it’s a miserable time. Sneezing, nasal congestion and itchy eyes – and it’s probably not something infectious, but more likely the symptoms of allergic rhinitis (sometimes called seasonal allergies). Allergic rhinitis can impair quality of life, work productivity, and even sleep. Stemming from a recent request, I wanted to catch up on allergic rhinitis, discuss environmental triggers, and review the range of treatment options, both drug and non-drug.
Prevalence and Mechanism
Allergic rhinitis is triggered when the immune system reacts to otherwise harmless airborne substances, such as pollen, dust mites, mold spores, or pet dander. Allergic rhinitis affects both children and adults, with global prevalence estimates ranging from 25% to 40% depending on the region and age group. The prevalence is increasing, which is attributed in part to climate change causing longer pollen seasons and higher pollen counts.
Beyond discomfort, allergic rhinitis imposes a significant burden through reduced quality of life, increased absenteeism from work or school, and increased healthcare costs. It also frequently coexists with or can can worsen other respiratory conditions, such as asthma.
Allergic rhinitis is a “Type I” hypersensitivity reaction, mediated by immunoglobulin E (IgE). Upon initial exposure to an allergen, the immune system becomes sensitized, producing allergen-specific IgE antibodies that bind to mast cells in the mucus membranes in the nose. Subsequent exposures cause these sensitized mast cells to rupture, releasing histamine, leukotrienes, and other proinflammatory mediators. This causes the classic allergic symptoms—nasal congestion, sneezing, runny nose and itchy skin – often within minutes. A later phase, driven by eosinophils, can cause the inflammation to last for for hours or days.
Causes, Triggers and Risk Factors
Allergic rhinitis is typically triggered by airborne environmental allergens. Seasonal allergens include pollens from grasses, trees, and weeds, while year-round (perennial) triggers tend to be from indoor exposures to substances such as dust mites, mould spores, pet dander, and (shudder) cockroach droppings. Genetics plays a substantial role: Individuals with a family history of atopic disease (such as asthma, eczema, or allergic rhinitis) are significantly more likely to develop allergic rhinitis. Living conditions, tobacco smoke exposure, and early-life microbial exposures (e.g., farm living) may also influence susceptibility.
Diagnosing Allergic Rhinitis
Assessing allergic rhinitis ideally involves a clinician who will perform a physical examination, evaluate symptoms, and document their history. It usually presents with sneezing, runny noses, nasal congestion and nasal itching. Eye itching, tearing and pain may also be present as well, and is called allergic conjunctivitis. Symptom timing, duration, and association with triggers should be identified. Allergic shiners (dark discolouration under the lower eyelids) is a common sign. A physician will typically try to understand symptoms, triggers, seasonal effects, environmental effects, and family history. Allergic rhinitis is usually suggested if triggers are identified. When symptoms are severe, usual treatments fails, or the diagnosis remains unclear, allergy testing (usually skin prick tests) can be helpful.
Non-Drug Strategies
Non-drug strategies are central to allergic rhinitis management, especially in mild cases. Start with following local pollen forecasts, if pollen is a cause. Allergen avoidance is ideal in theory, but not always feasible. You cannot eliminate pollen or even dust mites from your life, but you can reduce exposure with masking, air filters (home and car), and mite-proof bedding covers. Nasal saline irrigation with low volume liquids (e.g., saline nasal sprays) or large volume liquids (e.g., neti pots) have been shown to be effective, reducing symptom severity. They are also safe, as long as distilled/previously boiled or otherwise sterilized water is used. Artificial tears and cooling eye compresses may provide some relief to itchy eyes. Finally, allergen immunotherapy, either subcutaneous (SCIT) or sublingual (SLIT) is the only disease-modifying option, which can reduce the long-term symptom burden and medication use through gradual desensitization.
Drug-based Strategies
There are dozens, probably hundreds of products to treat allergies on pharmacy shelves, and some treatment options require a prescription. The choice of product is usually guided by severity of symptoms, their frequency, and patient preferences. What follows is a high level summary of the major treatment options for adults – this is not individual advice. For brevity, it doesn’t address factors like other medications, medical conditions, or circumstances like pediatric uses, pregnancy or lactation. A qualified health professional should be consulted who can provide recommendations that consider patient factors and preferences. Just because many medications to treat allergies do not require a prescription does not mean that these products are free of side effects, or can be combined with other medications safely.
Intranasal steroids – The “second generation” drugs like ciclesonide, fluticasone, or mometasone are preferred treatments and are very effective for moderate to severe allergies. These steroids may offer an advantage over “first generation” products (e.g., beclomethasone, budesonide, flunisolide and triamcinolone) in that very little of the drug is ultimately absorbed into the bloodstream and available to the rest of the body (where steroids can have negative, unwanted effects). Steroid nasal spray typically require a prescription, but that will vary by products and country. To prevent allergies, they need to be started 1-2 days before anticipated exposure. Effectiveness may take days to weeks to evaluate. Technique for administration matters, and it can vary by product – ask your pharmacist. For persistent allergies, intranasal steroids may need to be used regularly. Often when symptoms are controlled, doses can be reduced – sometimes to every-other-day or just when needed. Intranasal steroids are felt to be superior to antihistamines, particularly for treating nasal congestion.
Antihistamine nasal sprays – These products contain ingredients like azelastine or olopatadine. They are effective for those that do not want steroid sprays, and have the advantage of being effective if used immediately before allergen exposure, taking effect in about 15 minutes.
Antihistamines are also found in combination steroid-antihistamine sprays which have the benefit of acting rapidly and in a complementary way to provide additional benefit when single products are not effective.
Oral antihistamines – “Second generation” antihistamines such as cetirizine, fexofenadine or loratidine are popular owing to their non-prescription status and long history of use. Oral antihistamines effectively reduce itching, sneezing, and runny nose, as well as eye itchiness, but are less effective for nasal congestion compared with steroid sprays. They are less sedating and just as effective as the older “first-generation” antihistamines. These older antihistamines, such as chlorpheniramine or diphenhydramine have been used for decades and continue to be used despite the availability of much safer and tolerable “second generation” products. Contrary to marketing, no antihistamine has been shown to be demonstrably better for a specific allergen than another. If one antihistamine does not work however, another may be effective and switching may be necessary to find a product that work.
Decongestants – In the USA you can’t easily access pseudoephedrine (the OG and most effective oral decongestant) but topical sprays that contain ingredients like oxymetazoline are effective and can provide quick relief. However, a problem with decongestant sprays is that they can cause rebound congestion if used regularly for more than a few days. Phenylephrine is marketed as a decongestant and may still be found in products – its efficacy is indistinguishable from placebo. Depending on where you live, decongestants may be combined with antihistamines, but are not preferred products unless it’s been shown that combined use provides relief over antihistamines or decongestants alone.
Alternatives to Conventional Medicines
There are highly effective non-drug and drug-based therapies for allergic rhinitis. Evidence for other alternatives (“natural” or otherwise) is limited. Local/raw raw honey has been promoted as “natural immunotherapy” yet the evidence is not consistent or impressive. Acupuncture has been promoted, yet there is adequate evidence presented and discussed at this blog to show that acupuncture’s effects seem to placebo effects. There are interest in herbal remedies and some have been studied in clinical trials, but there are concerns about the quality of evidence, and overarching concerns about the standardization and manufacturing consistency of these products. Overall, given the effectiveness of non-drug therapies like saline sprays and rinses, it’s possible to address some cases of allergic rhinitis without medication (or alternative medicines) at all.
Practical, Individual Approaches
Allergic rhinitis may be considered a “minor” ailment but it can have extensive and prolonged negative effects on ones quality of life. A combination of avoidance, exposure minimization, and an evidence-based use of drug and non-drug measures can bring symptoms under control for many. While self-treatment may be effective, the assessment and advice of health professionals can be valuable in identifying causes and finding the right treatments. Ultimately, the most successful approach will always be a personalized one—tailored to individual triggers, preferences, and lifestyle, and utilizing evidence and available approaches to find what works.

Botulinum Toxin: A tale of medicine, beauty, and danger
When used responsibly botulinum toxin is very safe, but patients should be especially vigilant about cosmetic treatments done outside a medical setting.
David Weinberg on February 10, 2025
Link
Recent headlines introduced Manhattan aesthetician, Joey Grant Luther, accused of injecting his clients with counterfeit Botox. He was arrested, but only after several patients experienced significant complications, some requiring hospitalization.
Clients experienced adverse reactions such as: double vision, difficulty chewing, difficulty swallowing, palpitations, and slurred speech. Luther complained to his supplier that clients were experiencing complications from “contaminated” product. However, the complications experienced by Luther’s clients are typical for excess or off-target dosing of the active ingredient.
Layers of illegality
There are several layers of alleged illegality in this story:
    • The imported drugs were not approved for use or sale in the US.
    • Botox is an FDA regulated drug and can only be given by a provider with appropriate licensing.
    • Mr. Luther had no license to give prescription medication.
    • He knew the product was counterfeit but explicitly promoted it as the real thing.
    • He continued to use the illegal product even after he was aware of the adverse effects on his clients.
Mr. Luther is facing serious charges, and potentially serious jail time.
According to the US Attorney’s Office of the Southern District of New York:
LUTHER, 54, of New York, New York, is charged with one count of wire fraud, which carries a maximum sentence of 20 years in prison; one count of dispensing of a misbranded drug while held for sale, which carries a maximum sentence of one year in prison; one count of holding counterfeit drugs for sale and for dispensing, which carries a maximum sentence of 10 years in prison; one count of receiving misbranded drugs in interstate commerce and delivery or proffered delivery thereof, which carries a maximum sentence of three years in prison; and one count of smuggling, which carries a maximum sentence of 20 years in prison.
Botulinum toxin is sold in various formulations under various brand names in US and abroad. The most common is “Botox,” a registered trademark of Allergan. The product used by the Mr. Luther was allegedly a counterfeit drug mislabeled as Botox. The various brands/formulations are approved for a variety of therapeutic and cosmetic indications. For most of this article I will ignore the differences between the various formulations and tradenames and use the generic term “botulinum toxin.”
Clostridium botulinum, the villain and hero of the story
Clostridium botulinum is an anaerobic bacterium notorious for producing a potent neurotoxin. Eating food contaminated with Clostridium botulinum can cause widespread muscle weakness/paralysis, a condition known as botulism. Botulism can cause death due to paralysis of the respiratory muscles.
Muscle contractions are activated by nerves. Nerves activate muscles via the neurotransmitter acetylcholine. The culprit in botulism is a class of proteins, hereafter referred to as botulinum toxin. These toxins prevents release of acetylcholine from these nerves. In the absence of acetylcholine, the muscle is unable to contract, thus botulinum toxin causes muscle weakness or paralysis. Botulinum toxin is incredibly potent, possible the most potent toxin known. The effects of botulinum toxin are prolonged but temporary, lasting weeks to months.
Under the proper conditions, Clostridium botulinum bacteria produce spores. The spores themselves are not toxic, but are very difficult to kill. If food is not sterilized properly and stored in low-oxygen conditions, the spores can germinate into bacteria and produce botulinum toxin. If the infected food is consumed, the toxins cause possible fatal botulism. Prevention of botulism is the reason preserved foods must be properly prepared, and why you should never consume food from “bulging” cans.
Medical use of botulinum toxin
A truly innovative physician named Alan Scott deserves most of the credit for the medical use of botulinum toxin. Dr. Scott, an ophthalmologist, was interested in treating a condition called strabismus, or misalignment of the eyes. Each eye is moved back-and-forth and up-and-down by 6 muscles. For a variety of reasons, the eyes can become misaligned. Dr. Scott understood that botulinum toxin weakened muscles and reasoned that if he could strategically weaken some of the eye-movement muscles he might be able to bring the eyes into alignment.
What Dr Scott and a small group of collaborators achieved with limited time and resources was remarkable. The toxin was provided by an outside scientist. Dr. Scott developed processes to manufacture, and assay a stable formulation of the toxin. He performed appropriate animal studies. He set up a small scale production facility utilizing Good Manufacturing Practice with colleague Dennis Honeychurch.
The extraocular muscles targeted for treatment with botulinum toxin are small, and difficult to see without surgical exposure. In parallel with the development of the drug, Dr. Scott developed a technique for localizing the muscle using electromyography and injecting the drug with the same needle, obviating the need for surgical exposure. The first human was treated for strabismus in 1997, with good results. The first case series was published in 1980. Dr. Scott produced the drug under the name “Oculinum.” For years he manufactured the drug and provided it to colleagues for a nominal fee. Clinicians found other uses for the drug.
Expansion of botulinum toxin usage
In addition to strabismus, Dr Scott recognized the potential use for a treatment called essential blepharospasm. Patients with this condition develop uncontrollable, forceful closure of the eyelids and facial muscles around the eyes, which can be a physically and socially disabling condition. As Dr Scott predicted, the condition responded very well to treatment with botulinum toxin. This paved the way for the use of the drug for a variety of conditions related to dysfunctional muscle contraction.
Due to the rigors and liability of manufacturing and distributing the drug Scott sought, and initially had difficulty in finding, a partner pharmaceutical company. Ultimately, a then small drug company, Allergan, saw the potential of the drug and bought the company from Dr Scott. Dr. Scott died in 2021.
Global market
The global market for botulinum products was valued at $8.14 billion in 2023 and growing. The products are produced by multiple companies under a variety of names. Products using botulinum toxin are FDA approved for a variety of indications including strabismus, blepharospasm, muscle spasticity, chronic migraine, and axillary hyperhidrosis (excess armpit sweating). The global market for botulinum products also has a large market for aesthetics. Just over half of the market is for therapeutic use and the remainder for aesthetic indications.
Misuse of botulinum toxin
Botulinum toxin is no joke. The lethal dose is miniscule.
When used responsibly botulinum toxin is very safe. Because of extreme potency and potential for off-target muscle paralysis, careful control of dosage and injection technique is critical. Unfortunately, due to recklessness or cluelessness, some have used these products frivolously.
In the hands of Manhattan aesthetician Joey Grant Luther, the excess complications could have been due to mislabeled concentration of the counterfeit Botox, poor technique by the untrained, unlicensed provider, or both.
There have been other similar abuses. In 2004, a physician in Florida overdosed himself and 3 others This particular physician had lost his license due to previous infractions. He purchased botulinum toxin sold for laboratory-use-only and, despite warnings from his assistant, he treated himself and 3 others for cosmetic uses with enormous over-doses. Concentrations measured in their blood were 21 to 43 times the estimated lethal dose. Further details were revealed in a 2006 report. Fortunately, they all survived due to medical care including administration of antitoxin, and protracted hospitalization with “prolonged mechanical ventilation.” In other words, these patients were paralyzed to the extent they could no longer breathe and would have died if not supported with a ventilator.
Buyer beware
In 2024 Centers for Disease Control reported 19 people in 9 states with “harmful reactions” after treatment with counterfeit drug or by “unlicensed or untrained individuals and/or in a non-healthcare setting…” Nine were hospitalized.
A later CDC report provided further guidance. Patients were encouraged to investigate the credentials of providers, and advised to inquire whether or not the product is the FDA approved version obtained from a reliable source. Patients were urged to seek urgent medical attention if they experience symptoms of unintended muscle weakness, including: blurry or double vision, drooping eyelids, difficulty swallowing, difficulty breathing, or muscle weakness. I would add a caution that patients should be especially vigilant about cosmetic treatments done outside a medical setting, such as a spa or at-home treatment.


DIY Botox: Why Self-Injecting a Neurotoxin Is a Terrible Idea
DIY Botox is popular on TikTok, but injecting an internet-sourced neurotoxin into your face is a gamble that can can lead to serious harms.
Scott Gavura on January 15, 2026
Link

TikTok continues to demonstrate that it’s a tremendous source of poor health advice. The growing trend of DIY at-home use of botulinum toxin has become a real public-safety problem. In late 2025 the U.S. Food and Drug Administration issued warning letters to 18 websites illegally selling unapproved versions of botulinum toxin (know by its brand name, Botox), noting “adverse events associated with unapproved and misbranded botulinum toxin products, including botulism symptoms.” These products, marketed online and often purchased via social media, bypass the controls that exist for licensed medical drugs – and have been linked to serious health harms. State health authorities like the California Department of Public Health are warning consumers that counterfeit and improperly administered products have caused hospitalizations and other serious reactions when used outside regulated healthcare settings. And it’s not just sketchy providers. People are injecting themselves, trained only by TikTok videos.
Botox is no ordinary cosmetic
David Weinberg covered the key points of botulinum toxin in his excellent post last year. It’s worth repeating: Botox is not a cosmetic in the ordinary sense. It is a prescription drug whose active ingredient is one of the most potent neurotoxins known. It works by blocking nerve signaling to muscle – which may be fine if you want to relax a frown line, but it’s bad when you paralyze an eyelid, your throat, or the muscles that are helping you breathe. The narrow margin between “useful” and “harmful” is what makes this drug so different from fillers and other skincare products that people may be used to experimenting with. When someone orders a vial online and injects it without training, sterile technique, or any reliable way to verify what is really in the syringe, they are taking tremendous risks with their health and gambling with a powerful neurotoxin.
Risks of DIY self-injection
The risks of DIY botulinum are significant, and fall into three broad categories. First is the product itself. Much of what is sold online as “Botox” or “botulinum toxin” appears to be unapproved, counterfeit, or manufactured without the quality controls that apply to legitimate, regulated prescription drugs. There is no assurance that a product that is purchased online in this way will be sterile or free of contaminants. Importantly, even if the vial contains real botulinum toxin, its strength may not match what the label claims. This links to the second issue: dosing. Botulinum toxin injection is measured in biological units. Small differences in concentration will translate into large differences in effect. Experienced injectors rely on standardized products and precise dilutions. None of that is assured with internet-purchased products. Third is placement. Facial anatomy is not intuitive. Injecting a few millimeters too deep or too close to the wrong muscle can lead to eyelid droop, facial asymmetry, trouble speaking, or difficulty swallowing. And these are the milder outcomes. If enough toxin diffuses beyond the target area, it can cause the same generalized weakness and paralysis that make botulism poisoning a medical emergency.
Botox has moved beyond sketchy spas and into true DIY territory. The FDA warning letters were not aimed at fly-by-night estheticians, but at online vendors openly shipping injectable products claiming to be botulinum toxin directly to consumers. These sites market themselves as affordable, convenient alternatives to clinic-based care, often with slick packaging and dosing charts meant to look medical and legitimate. Social media then completes the pipeline, with TikTok and Instagram referral links and videos showing viewers how to mix, draw up, and inject these drugs at home.
Why the appeal?
So why are people willing to take these risks? Social media plays a big role, but cost does too. In-office Botox is expensive, has to be repeated every few months, and involves consultations and appointments. Online sellers promise to simplify all that. For a fraction of the cost of a clinic visit, you’re offered what looks like the same drug, shipped directly to your door. And influencers give you the confidence that self-injecting a neurotoxin look safe and normal. When your feed fills with Botox posts, now it looks like an easy way to save some money while reducing the signs of aging. Everyone else seems to be doing it!
What gets lost in that logic is how lopsided the tradeoff actually is. When Botox is used in legitimate medical and cosmetic settings, it comes from regulated manufacturers and is administered by people trained in anatomy and dosing. This makes a potentially dangerous drug relatively safe for use, even for cosmetic purposes. Strip it away to the internet and DIY and you’re multiplying your risk to an unknown degree. You’re taking an unknown substance of unknown strength and injecting it into tissue that is millimeters away from the nerves and muscles that let you see, speak, swallow, and breathe. No amount of online confidence or anecdotal success stories changes these facts or reduces the risk.
The uncomfortable truth is that DIY Botox only looks like a clever hack if you ignore what Botox actually is. This is not skincare or self-care. It is the self-administration of a prescription neurotoxin, obtained from an unregulated supply chain and injected without the training or safeguards that make its use tolerable in medical settings. That some people have apparent success with it does not make it safe. It just means the odds happened to be in their favor. For everyone else, the consequences can range from disfiguring to life-threatening, No discount internet-sourced mystery vial is worth that gamble.


Hope, Evidence, and Hard Questions in Duchenne Muscular Dystrophy
Scott Gavura on November 20, 2025
Link
I’ve been reflecting on the disappointing outcomes and the reaction to Sarepta Therapeutics’ recently announced clinical trial results for its Duchenne muscular dystrophy treatments, AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen). The tension is evident: Families want treatments that benefit patients, while critics note the evidence reveals a different story. Duchenne muscular dystrophy is a relentless disease. When a company suggests it has a therapy that could alter its trajectory, hope naturally follows. Hope is meaningful to families. But when the data fail to match those expectations, it forces difficult questions about how we develop and evaluate therapies for rare diseases and what it truly means for a treatment to help.
Duchenne, Sarepta, and the Importance of Hope
Duchenne muscular dystrophy (DMD) is a rare, progressive genetic condition that primarily affects boys. Caused by mutations in the dystrophin gene, DMD leads to severe muscle weakness and degeneration. It typically appears in early childhood and results in loss of ambulation, breathing complications, and eventually cardiac or respiratory failure. Despite decades of research, there is no cure and no treatment that meaningfully changes the overall disease trajectory.
Sarepta as company has roots that date back to the 1980s, but has spent over a decade developing treatments for DMD, becoming both a source of hope and a subject of controversy. Families are eager for breakthroughs. Sarepta has pursued therapies built around “exon skipping”, a genetic technique designed to help cells “skip over” faulty instructions in a gene. Exon skipping is meant to help cells bypass a faulty section of the dystrophin gene, so they can produce a shortened but partially functional version of the protein, similar to what is seen in milder forms of muscular dystrophy. It is not a gene repair strategy, and it does not correct the underlying mutation, but it aims to give muscle cells some of what they are missing. For families facing a disease with so few options, the possibility of even modest benefit is meaningful.
Conditional Approvals
Sarepta’s therapies reached the market through the FDA’s accelerated approval pathway, which allows drugs for serious or life-threatening conditions to be approved on the basis of a surrogate marker or other endpoint that is expected to predict a meaningful benefit. In DMD, the FDA has relied on dystrophin-related biomarkers as surrogate endpoints. This biomarker is considered reasonably likely to predict clinical benefit because dystrophin is essential for muscle integrity, and its absence causes DMD. If a therapy can increase dystrophin levels, it may help stabilize muscle function over time.
Because a surrogate is only a proxy, and is not itself clinically meaningful, companies are required to run confirmatory trials to show that patients actually experience meaningful improvements in strength or mobility. Accelerated approval is meant to balance access with evidence, but it also shifts the uncertainty onto patients and families. Yes the drug is available, but its efficacy is not clear. When the follow-up trials fail to confirm benefit, as we’ve now seen with ESSENCE, it raises difficult but important questions about how much confidence we should place in early signals, and how much risk is acceptable when choices are so limited.
The ESSENCE Trial
The FDA granted accelerated approval to VYONDYS 53 in 2019 and AMONDYS 45 in 2021, on the basis of the drugs’ abilities to increase dystrophin levels in muscle. ESSENCE was the trial developed to meet the FDA’s expectations of showing actual clinical benefit. ESSENCE was a large, randomized, placebo-controlled study that followed boys with DMD for about two years and the primary endpoint was a practical measure of mobility: how quickly a child could climb four steps. This outcome was chosen because it reflects a real and important part of daily life for patients and families living with DMD. Patients were randomized to either weekly injections or placebo for 96 weeks. ESSENCE was meant to answer the central question behind the entire exon-skipping treatment strategy: do dystrophin increases lead to meaningful benefits?
The Results and the Reaction
When Sarepta released the ESSENCE results, the findings were disappointing. The trial failed to meet its primary endpoint: boys receiving AMONDYS 45 or VYONDYS 53 did not improve their ability to climb four steps in a way that reached statistical significance (p = 0.309) compared with placebo. The measured difference was small, showing only a small numerical improvement (0.05 steps/second) in stair-climbing speed. Sarepta attributed much of the underperformance to COVID-19 disruption, noting that excluding patients whose trial participation overlapped with the pandemic yielded a more favorable trend (0.11 steps/second, p ≈ 0.09) – which was still not statistically significant. Analysts were quick to point out these limitations, noting that confirmatory trials are meant to provide clarity—not rely on re-cut data to find a signal. The drugs were well tolerated, however, and serious adverse effects were rare.
What This Means for Patients and the Families
For families living with DMD, these results will be disappointing. But the ESSENCE findings mean that the expected functional benefits of AMONDYS 45 and VYONDYS 53 have not yet been show to be real, despite several years on the market and thousands of doses given. This confirmatory trial highlights the challenge with accelerated approvals based on surrogates. Families want hope, but it may not bear out. A clear understanding, grounded in evidence, is essential, not to diminish that hope, but to sustain it.
Evidence Gaps and Rare Diseases
What has unfolded with ESSENCE is not unique to Sarepta. Companies often rely on surrogate markers, like dystrophin levels, not because they are perfect predictors of benefit, but because they are measurable. But they may not bear out into outcomes that are meaningful. The failure reflects the reality that rare-disease science is difficult, and basing an approval on an unproven surrogate is risky. The challenge is finding ways to push innovation and access forward without lowering the bar so far that ineffective treatments are used for years. Keep in mind that drugs can also cause harmful side effects – although that doesn’t seem to be the case with these drugs. Finally, we need to balance early, promising evidence with a commitment to follow-through with good research and ensure that the drug does what we want it to do.
I’m going to quote from Matthew Herper, writing in Forbes back in 2013 about Sarepta, because this is an evergreen paragraph in drug development:
This same story happens again and again in the drug industry: A new medicine seems to show promise in a terrible disease. Patients and investors become excited, lobbying the Food and Drug Administration to approve it quickly or the company to make the medicine available and bidding up the drug maker’s stock price to dizzying highs. And then, too often, it turns out that the wonderful cure was just a mirage and that the FDA was right in its slow, deliberate pace – that the agency did its job of making sure the treatment actually helped patients before allowing a drug company to charge a very dear price for it.
Where DMD Research Goes From Here
The ESSENCE trial is a setback to DMD, no question. But it points where work is needed. Better biomarkers are essential – ones that reliably predict meaningful functional outcomes rather than serving as hopeful (but faulty) proxies. As gene therapy and other emerging therapies continue to advance, regulators and developers will need to remain cautious about balancing access based on unproven surrogates against the need for real outcomes. The need for treatments for DMD remains as important as ever.
    • 

First Pig Lung to Human Transplant
Steven Novella on August 27, 2025
Link
In the midst of all the controversy surrounding the science of healthcare, certain technologies continue to progress in the background, with the promise of transforming the practice of medicine. One of them is the development of genetically modified animals as a source for organ transplants.
I most recently wrote about this earlier this year, specifically about an experiment to transplant a pig heart into a baboon infant. The goal is to provide a bridge until the infant is old enough to receive a permanent heart transplant. Now Chinese surgeons have transplanted a pig lung into a brain-dead patient as a preliminary exploration of the viability of this approach.
The ability to transplant organs from a living or dead human donor into a human patient was transformative for modern medicine. Since 1988, in the US alone, about 800,000 people have had their lives saved or significantly improved (such as coming off of dialysis) with organ donation. But the technology still faces significant challenges.
The biggest medical challenge is rejection. Organs have to be carefully matched between donor and recipient in order to minimize the attack by the host’s immune system against the “foreign” tissue that has been transplanted. This often requires a lifetime of anti-rejection medication, which contributes to a major practical limitation of organ transplantation – it’s very expensive. Another significant practical limitation is the availability of organs for transplant. There simply is not enough to go around, and many people die on the waiting list for an available organ.
In my opinion, the best high tech solution to these challenges is genetically modifying animals to be human organ donors. Pigs are good candidates for many organs because their size and anatomy is very compatible with humans. A transplant from another species is called a xenograft, and these are especially challenging because the immune attack (without modification) would be very robust and lead to certain failure. As I discussed in my last article, other options, such as 3D printing organs, growing organs outside of animals, and mechanical organs, are very far away from realization.
Genetically modifying animals, which still has a way to go scientifically, is the best hope for creating an almost limitless supply of transplantable organs. Not only would this meet the need of those on the existing waiting list, it could allow for the lowering of the threshold for who gets on the list. If supply were not an issue, we could use transplants to treat more and more diseases and conditions. Your organ is causing you some trouble? Here’s a new one.
The technology leverages our rapidly advancing genetics knowledge and techniques. CRISPR and other techniques allow for rapid and relatively cheap genetic modification and experimentation. The main goal of research is to identify all the genes that would need to be modified so that the organ recipient’s immune system does not detect the donated organ as foreign.
In the current study, for example, six genes were edited in the pig donor to limit rejection. The recipient was monitored for 216 hours, during which time:
“Antibody-mediated rejection appeared to contribute to xenograft damage on postoperative days 3 and 6, with partial recovery by day 9. Immunosuppression included rabbit anti-thymocyte globulin, basiliximab, rituximab, eculizumab, tofacitinib, tacrolimus, mycophenolate mofetil and tapering steroids, with adjustments made during the postoperative period based on assessments of immune status.”
So there was some early signs of rejection, with partial recovery by the end of the monitoring period. And- the recipient was also receiving a heavy dose of anti-rejection drugs. This was definitely a preliminary study, really just paving the way for more details experiments. Two other details worth noting:
Lungs are the most difficult organ to transplant from an immune perspective. This is because lungs have robust immune responses because they are constantly exposed to the outside world. Obviously many invading organisms gain entry through the lungs, so it is often a first line of immune defense. Immune incompatibilities can therefore be a special problem.
Second, this study did not evaluate the function of the lung. Only one lobe was transplanted, and the other lobe was left intact, so the researchers did not determine if the transplanted lung functioned and could sustain the host. So again – this is very preliminary. At most this study tells us that the organ was not immediately rejected, nor cause significant graft vs host disease. This likely means that the modified genes had some impact.
Let’s say this technology reaches its ultimate goal, what would that world look like? That would mean that scientists have identified all the genes necessary to prevent any form of immune rejection in either direction (the host rejecting the transplant and the transplant attacking the host).
I also have to point out that genetic modification like this has two basic forms. First, the genetic change can render the pig an immune blank slate, meaning that they are a universal donor, without any of the proteins or targets that would provoke an immune attack. The second would be to match the animal’s immune system to the specific intended recipient. Likely we would see some combination of these strategies – genetic changes to humanize the pig’s immune factors, perhaps tailored to specific types (such as blood type), and if necessary with specific changes to align with an intended recipient.
Also, this kind of modification is not an all-or-nothing situation. The more thorough and successful the genetic modification, the lower the risk of rejection and the lower the need for anti-rejection drugs. Ideally, we could achieve zero rejection with no need for any immune suppressing drugs. j
In that ideal situation, organ transplantation might become far more routine. Not only would there be essentially no waiting list (transplants on demand), but the list of conditions for which transplants make sense would grow. This could significantly extend life expectancy and quality of life. It might also significantly reduce healthcare costs, by eliminating the need for lifelong treatments and costly hospitalizations.
It is hard to know how long it will take and how close we will get to this ideal situation. But this is definitely a technology to watch. There is no theoretical reason why such an ideal organ supply is not possible. Genetic technology continues to advance at a rapid pace, and all we need is incremental advances to achieve this goal. There are no fundamental breakthroughs or brand new technologies needed, just continued improvements in existing tech.

Breakthrough Heart Xenotransplantion from Pig
In a first, a bioengineered pig heart is transplanted into a human donor, indicating we are on the threshold of a game-changing option for organ transplantation.
Steven Novella on January 12, 2022
Link

The public is mostly numb to claims for “scientific breakthroughs” because the term is so highly overused. Every incremental advance is deemed a breakthrough, and often false claims of breakthroughs are used to market highly dubious products and treatments. It is also often difficult to know when an advance is truly a breakthrough, meaning that it will change the world in some significant way. We can only really know in retrospect. But I am going to go out on a limb and declare this incremental step at least a significant milestone, if not a genuine breakthrough.
On January 7, David Bennett, 57, received a heart transplant from a bioengineered pig. This is a technology that we have been anticipating for years, and it is not ready for prime time yet, but the first such bioengineered xenotransplant in a living recipient definitely crosses an important line. There is a high probability, in my opinion, that this is a first “test-tube baby”-type moment.
The pig heart was provided by a company called Revivicor. They made news last summer when they provided a slightly genetically engineered pig kidney (one gene was altered) to connect to a human recipient. In this case the recipient was braindead and the kidney was just hooked up to their blood supply, not implanted. This is best considered a pre-clinical study, mainly to determine if the kidney would be immediately rejected. It wasn’t, and it seemed to work, filtering blood and making urine. But this safety test lasted only 54 hours.
The pig heart that Revivicor supplied to David Bennett has had ten genetic modifications: four genes were silenced, three to reduce rejection and one to limit growth after transplantation, and six human genes were inserted, all to reduce rejection. The modifications essentially are used to make the pig’s immune system more like a human’s, so that the organ recipient’s body will not vigorously reject them. The strength of immune rejection depends greatly on how close a genetic match the donor and recipient are. Even within the human species, genetic matching is critical. Crossing the line to a different species (the definition of xenotransplantation) is guaranteed rapid rejection. With these genetic modifications, the goal is to at least make the pig donor’s immune markers closer to that of a human.
Bennett, however, also is receiving an experimental anti-rejection drug which will suppress the part of his immune system responsible for rejection. The drug was developed by Kiniksa Pharmaceuticals, co-developed by Muhammad Mohiuddin, M.D., director of the University of Maryland School of Medicine’s cardiac xenotransplantation program, who did the surgery. Further, Bartley P. Griffith did the surgery and had to develop the technique of adapting the pig heart anatomy to the human vascular system. So this one operation is a triple experiment – testing the viability of the genetically modified pig heart, a new anti-rejection drug, and the surgical techniques used to adapt a pig heart to a human. The FDA gave emergency use authorization for the entire procedure based on their compassionate use program on December 30st.
Part of the reason the FDA cleared the experimental treatment is that Bennett had a terminal cardiac arrhythmia and was being kept alive on a heart machine. He had exhausted his treatment options and is not a candidate for a human donor, so his options were this experimental procedure or death. What does his treatment, if successful, mean for the future of xenotransplantations?
This research is being done because there is a great unmet need for organ transplants. In the US alone more than 100,000 people are on the waiting list for an organ, and 17 of them will die every day before they can get that organ. The ability to simply make or grow organs, therefore, would be a game-changing technology. Of all the possibilities, such as mechanical hearts, 3D printed organs, and cloning, the technology that seems to have the greatest chance of success is bioengineering non-human donors. Several companies are working on this technology, not just Revivicor. For example, Harvard geneticist George Church cofounded a company, eGensisis, also developing bioengineered pigs for organ transplantation, although they are apparently not as far along as Revivicor.
And obviously this technology is still highly experimental, but the learning curve is steep. CRISPR and other genetic modification technology allows this research to be done many times more rapidly than even in the recent past. The heart that Bennett received is just “pig heart 1.0” and it is likely we will see more elaborately engineered non-human organs in the future, further reducing organ rejection. It’s even theoretically possible that such genetic tinkering can go beyond making humanized donors, to tweaking the genetics to be a match for a specific donor. In the end bioengineered organs may be superior to human donated organs.
For now such transplants will remain in the realm of experimental use, like in cases such as Bennett where all other options have been exhausted. But once the technology is established well enough (which will take years of research) they will likely be approved for general use. That will be the day that this technology completely changes the world of organ transplantation. From there incremental improvements will only make the technology better. Essentially, the approach of bioengineering non-human organ donors allows transplantation science to ride the wave of rapidly advancing genetic technology.
        ◦ There will likely be the usual pushback from predictable ideological groups. Some will question the ethics of growing animals as donors. But we already grow over 100 million pigs every year to slaughter for food, growing even a million extra to save lives hardly feels like an ethical line. There will also likely be the usual luddite response that such treatments are not “natural” or violate some natural code. I predict these objections will have as much of an effect as protests against in-vitro fertilization. Once xenografts start literally saving lives, demand for this technology will overwhelm criticism.

Pig Heart Xenografts for Infants
Steven Novella onMay 7, 2025
Link
Organ transplant is a potentially lifesaving medical intervention, but there is a critical lack of donor organs. Even in a wealthy country like the US, there are about 100,000 people on the waiting list for an organ transplant, but only about 23 thousand organs become available each year. About 6 thousand people die each year while on the waiting list.
For this reason researchers are looking for alternatives. For the heart, which is essentially a pump, mechanical hearts have been in development for years but the technology is very challenging as they tend to be destructive to blood cells. The record so far is living over 7 years with a mechanical heart, so we are making progress. Other organs, like livers and kidneys, don’t have mechanical alterantives.
Growing organs is another approach, but the challenge here is getting an organ to develop properly outside the environment of a developing organism. Yet another approach is printing organs with stem cells. So far, this approach requires a “scaffold” on which to print the stem cells, and these are obtained from donated organs that are denuded of cells, so this really does not solve the problem of limited donor organs.
In my opinion the best approach that is most likely to succeed is growing organs for transplant in genetically modified animals. We could genetically modify a pig, for example, so that it has an essentially human immune system. This would make a xenograft (transplant from another species) more like an allograft (transplant from the same species). In fact, with enough genetic modification, we could significantly reduce the chance of rejection and therefore the need for immunosuppressive treatment. It may even be possible to grow a pig with an individual’s immune system, not just a human immune system, to produce an organ specific to them.
While this approach is advancing nicely, we are not there yet. However – the longer people can survive on the transplant waiting list, the more likely they are to get a transplant and survive long term. Therefore, while we are developing these approaches as an ultimate solution they can still serve a purpose today. A recent study shows the potential here.
Researchers created a genetically modified pig to be compatible with a baboon recipient. Specifically they wanted to transplant the heart into an infant baboon. Infants are a special challenge for heart transplants, especially those who need transplants because they have an anatomically different heart, such as a single ventricle. Mechanical hearts often don’t work as well in these infants because they are not as adaptive moment-to-moment to demand for blood flow to the lungs and body. These infants do not survive long with mechanical hearts.
In the study 14 baboon recipients survived for several months with the transplanted modified pig heart, with one surviving for 21 months. In one case they were also able to then replace the pig heart with an allograft from another baboon, showing this is possible.
The idea here is to use these genetically modified xenograft hearts to buy time for infants on the transplant waiting list until a compatible human heart is found for them. If we can consistently achieve survival time to several years that would allow many more infants to survive until they get their permanent transplant.
And of course, it is possible for this approach to ultimately work so well that a modified pig heart could be their permanent transplant. With sufficient genetic modification, such transplants might not even need immunosuppression treatment.
The process, such as that used by one biotech company, Revivicor, who is developing this technology, is to genetically modify skin cells taken from a pig. The make genetic edits to reduce the size of the organs to be more compatible with a human recipient, to reduce blood clotting, and to reduce rejection. Then then use the DNA from those cells to insert into embryos where the DNA was removed, to clone the pigs. At this point they have 10 genetic modifications in the cloned pigs.
How close are we to having people on the donor waiting list get modified pig organs? Still years away, but ideally not that many. The company is looking for FDA approval to start human trials soon. If all goes well, we could be 5-10 years away from this being a medical reality.
Of course, this approach is not without its ethical controversy (which goes back to Baby Fae, the infant who received a baboon heart xenograft). Some have raised concerns over creating animals specifically to be sacrificed. However, we raise billions of animals to be slaughtered for food, and this is arguably a better purpose. I know this is not an answer for those who oppose raising animals for food, but while this is legal and accepted it is inconsistent to oppose raising animals for organ transplantation.
Another concern raised is that these organs might be a disease vector. This, of course, is where regulation comes in. Revivicor claims its animals are all raised with the highest ethical standards, and in a disease-free environment. This certainly can be a condition of FDA approval.
This approach can potentially save many lives, improve quality of life for organ recipients, and save the system a tremendous amount of money. The potential advantages are so large, I don’t see the ethical concerns being a significant barrier. Many of us likely know someone who died on an organ transplant waiting list (I do). When facing your own death or the death of a loved-one, people will accept this alternative. Eventually it will become routine, like IVF (which was originally opposed on ethical grounds).
We should also consider the ethical advantages of this approach. Having a virtually unlimited source of donor organs eliminates or significantly reduces many ethical problems, such as the equitable sourcing and availability of donor organs for those on the waiting list. In my opinion this technology is a massive net positive, one that we should embrace and if anything accelerate.


Ivermectin to Control Malaria — A Cluster-Randomized Trial
Another use for Ivermectin from last week’s NEJM
Tim Noonan on July 31, 2025
Link
Malaria causes about 1/4 billion new cases of disease and about 600,000 deaths every year. 3/4 of the deaths are children under 5 years old. The July 23, 2025, NEJM has a free full text article showing use of ivermectin to prevent malaria and potentially save a lot of lives. This should appeal to ivermectin proponents, since hundreds of thousands of lives could be saved by an effective intervention.
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on treated persons, can reduce malaria transmission is unclear.
We conducted a cluster-randomized trial in Kwale, a county in coastal Kenya in which malaria is highly endemic and coverage and use of insecticide-treated nets are high. Clusters of household areas were randomly assigned in a 1:1 ratio to receive mass administration of ivermectin (400 μg per kilogram of body weight) or albendazole (400 mg, active control) once a month for 3 consecutive months at the beginning of the “short rains” season. Children 5 to 15 years of age were tested for malaria infection monthly for 6 months after the first round of treatment. The two primary outcomes were the cumulative incidence of malaria infection (assessed among children 5 to 15 years of age) and of adverse events (assessed among all eligible participants).
What about DDT?
Why can’t we just DDT the mosquitoes away? Surely, Dire Straits could have a Concert for DDT, singing that, I waaaant my DDT. The problem is resistance to DDT. Mosquitoes are not cooperating with plans to exterminate mosquitoes. Researchers have known about this DDT resistance for a while:
Insect resistance to dichlorodiphenyltrichloroethane (DDT) emerged in the 1940s, with the first conclusive study being conducted on the Culex molestus mosquitoes in 1947 in Italy. Insecticide resistance was also reported among Anopheles sacharovi mosquitoes in Greece in 1951 [23]. In 1955, it was reported in the An. gambiae species in Nigeria [24]. Thereafter, resistance has been reported in more than 500 insects, 50 of which transmit malaria parasites in humans [21, 25].
That simple solution is not an effective long-term solution, so the much more complex approach of medical intervention is currently needed. Genetically modified mosquitoes could be effective, but the technology is newish and opposition to this will be tremendous, even if there is abundant evidence of safety.
Take ivermectin
Ivermectin is an endectocide, a drug that is effective against endoparasites and ectoparasites, and is used in mass drug administration to treat onchocerciasis and lymphatic filariasis and to reduce their transmission. Through the Mectizan Donation Program established by Merck, more than 4.6 billion ivermectin treatments have been distributed safely since 1988 to populations in regions where malaria is endemic.6 Ivermectin can also kill malaria vectors that feed on treated persons.7 Thus, mass administration of ivermectin has been suggested as a potential strategy to reduce malaria transmission driven by mosquitoes that are either resistant to insecticides or evade them through behavioral changes.8 To address public health needs and guide the development of new malaria vector-control tools, the WHO produced the preferred product characteristics for endectocides in 2016 and updated it in 2022; one target characteristic that was considered to be of potential value to public health was a 20% reduction in the incidence of clinical malaria or infection.9,10
Our primary research question was whether mass administration of ivermectin, given in three monthly doses of 400 µg per kilogram of body weight at the start of the short rainy season (which typically spans from October through December), would result in a relevant reduction in malaria transmission in an eligible population and have an acceptable safety profile.11
From the Protocol supplementary material in PDF (page 125/266):
The study will be open label but outcome assessor-blinded. Participants in the ivermectin and control arms will receive products that differ in aspect and numbers. Participants will be informed that they are taking one of two antihelminthics. The sponsor and the study statistician will remain blinded to the assignment of each cluster group. All unblinded DSMB [Data and Safety Monitoring Board] reports will be prepared by an independent statistician.
Why?
From the Protocol supplementary material in PDF (page 110/266):
Given the use of albendazole in the control group, fully blinding the study would require a double-dummy approach with placebo-ivermectin and placebo-albendazole tablets. Ivermectin is only available in 3 mg tablets and it is dosed by body weight. This results in a relative high pill-burden with up to 13 tablets for heavier adults (see table 1). Adding placebo pills would further increase this burden. It is for this reason that the study is open-label but assessor blinded.
Screening
Pregnancy tests were required prior to dosing to minimize the possibility of embryonic/fetal harm from a drug with an uncertain pregnancy risk. Participants also had their skin checked for signs of other parasitic diseases. An added benefit is that other parasitic diseases are expected to be decreased by this public health intervention. Treatment for malaria was administered right away, when any of the children tested positive for malaria, regardless of whether the participants had symptoms.
Dosing
A finger stick blood test was used to detect malaria and to check drug levels. The dose of ivermectin was larger than currently given in Kenya, but within limits approved for use in the Netherlands and Germany. The repeated dosing of ivermectin and albendazole are more frequent than recommended anywhere, but calculations of elimination rates were expected to decrease the amount of drug remaining in the blood, at the time of the next dose, to less than 1% of the maximum blood level by the time the next dose would be given. Toxicity was not expected to be a significant risk, but was screened for. The safety results of the study did not show problems that any reviewers attributed to the increased doses of the study drugs.
From page 110/266 of the Protocol supplementary material in PDF. Table 1.
This dosing table seems as if it is encouraging a higher dose than is reasonable, but the displayed numbers are only the highest dose for that weight range. The doses are all multiples of 3 mg tablets. The highest per kg dose listed is for the 31-40 kg participants, the dose is 484 µg per kg for the lightest patients in that weight range. These are the only weight group receiving 5 tablets (15 mg ivermectin). 15 mg ranges from 375 µg per kg for the 40 kg participants up to 484 µg per kg for the 31 kg participants. Breaking up tablets to get more precise dosing was probably considered impractical.
This was during the rainy season. Transportation was by motorbike and bicycle, so the niceties of a hospital lab, or even the niceties of a watertight vehicle, were not available at the time of dosing. All of the participants were weighed, apparently using portable scales. The scales were cleaned and placed on a flat surface, at the time of dosing for an accurate weight.
Controlling Contamination
Contamination: a state of heterogeneous or impure roll out of the intervention in any given cluster or group of clusters. This implies a risk of over- or under estimating the effect size. Given that the maximum recorded dispersal of Anophelines in East Africa is 661 meters [42], contamination risk will be assessed by calculating the mean proportion of households with equal assignment in a 1 km radius around every core household. For control households only ivermectin-treated households within this 1 km radius may cause contamination. For ivermectin-treated households both control and non-participating households may cause contamination (Figure 7).
Why do the researchers worry about contamination? If the intervention affects the health of the mosquitoes that bite participants in the ivermectin group, the ivermectin is expected to harm those mosquitoes. Less healthy mosquitoes are less likely to spread malaria to participants in the control group (participants receiving albendazole) and less likely to spread malaria to the non-participants. Non-participants are part of the calculation of the efficacy of the intervention, if the possibility of contamination is not controlled for.
Having non-participants, who benefited from the intervention, but are not part of the intervention group, included in the calculations benefit from the intervention makes the intervention appear less effective. Since the rate of malaria among the non-participants is calculated using all of the people counted in the cluster, there would be contamination of the results. The clusters are arranged with a buffer area to prevent that beneficial effect to non-participants from affecting the statistical results from contamination by that bias. There is no actual contamination of non-participants by ivermectin. Each participant takes several tablets to get their monthly dose. This dose would be much more than a mosquito could carry to the next person they bite, even if the mosquito bit the study participant when the study participant’s blood concentration of ivermectin was at its highest.
From page 120/266 of the Protocol supplementary material in PDF. Figure 5.
What were the results?
A total of 84 clusters comprising 28,932 eligible participants underwent randomization. The baseline characteristics of the participants were similar in the trial groups. Six months after the first round of treatment, the incidence of malaria infection was 2.20 per child-year at risk in the ivermectin group and 2.66 per child-year at risk in the albendazole group; the adjusted incidence rate ratio (ivermectin vs. albendazole) was 0.74 (95% confidence interval [CI], 0.58 to 0.95, P=0.02). The incidence of serious adverse events per 100 treatments did not differ significantly between the trial groups (incidence rate ratio, 0.63; 95% CI, 0.21 to 1.91).
26% lower incidence of malaria infection is not a huge percentage, but malaria kills a lot of children. A small percentage of a lot of people is still a lot of people. Yet, even saving the lives of a hundred children would be great. This public health intervention could save tens of thousands of lives and prevent millions of cases of malaria. Malaria is not the only medical condition that could be made less harmful with this intervention.
Mass administration of ivermectin would be a drug-based approach to vector control that leverages a mechanism of action that is distinct from that of the currently used insecticides in public health programs. This innovative method not only enhances vector control but provides potential collateral benefits in areas in which neglected tropical diseases, such as scabies and diseases caused by soil-transmitted helminths and filariae, are also endemic,37-39 particularly if existing delivery systems are leveraged for the distribution of ivermectin.40,41
This trial provides evidence to support the use of ivermectin as a complementary strategy for malaria control and prevention in areas where malaria is mesoendemic and transmission is perennial.
Why should we care?
Kenya is on the equator, so they do not have the kinds of seasons we are used to outside of the tropics, yet. Maybe this intervention will help to avoid making malaria endemic in America again. Currently, almost all cases are due to travel to places where malaria is endemic, but there have been occasional cases transmitted within the United States. Both malaria and yellow fever (caused by a virus, not a parasite, but also transmitted by mosquitoes) used to be right at home in the United States. Since these diseases are not foreign to the United States, the environment may support their return. A wall won’t keep mosquitoes out. Screwworms are another problem a wall won’t solve. The plan to stop the spread of screwworms by dropping sterile flies from aircraft in the Darién Gap in Panama is no longer working.
Public health measures are becoming more important, so we should be investing more in research on public health.
The trial was conducted in accordance with the principles of the Declaration of Helsinki, . . .
That is the beginning of a paragraph describing the ethical requirements the researchers met. The concern some might raise is that the active control group is not receiving an inert placebo. They are receiving an effective intervention. Depriving research participants of effective treatment is prohibited by ethical standards, such as the Declaration of Helsinki. People who understand science and ethics recognize that depriving research participants of a safe and effective intervention is causing harm. Causing harm to one group of research participants, for no expected benefit, is no longer allowed.
Science improves by learning from the mistakes of scientists. This is why the United States Public Health Service Study of Untreated Syphilis in the Negro Male at Tuskegee and Macon County, Alabama, 1932 -1972 is notorious. Research participants were deprived of a safe and effective intervention for no benefit to the research participants.
Starvation is at its lowest level due to advances made by scientists, including Fritz Haber, whose discovery enabled the large-scale production of synthetic fertilizers, feeding billions and preventing global famine. Then again, Haber also came up with a method for poisoning soldiers on the battlefield and another method for poisoning prisoners in extermination camps. Haber was not exactly altruistic, but he did save many times more lives than he helped to kill – and Haber was one of the most harmful scientists ever.
The Declaration of Helsinki and its predecessor the Nuremburg Code, were implemented to prevent those types of abuse.
Science – and scientists – save lives
To paraphrase the fictional Dr. Ian Malcolm, “Your anti-science propagandists were so preoccupied with whether or not they could spread Fear, Uncertainty, and Dread, they didn’t stop to think if they should.” That is not what is meant by people using the original quote, but it highlights the problem of pretending that competent scientists do not already study the safety of interventions in many ways before these interventions even leave a laboratory. But the safety of every intervention is studied at every step along the way, beginning with animal studies all the way up to final approval, and it continues to be monitored after approval.
The people usually quoting the mathematician from Jurassic Park would have us believe that these forms of preventive medicine are going to kill us all, because scientists are the problem. But opposition to science is the real problem.
Opposition to science doesn’t stop scientists from saving lives, but this opposition can decrease the benefits of science. Regulation is what helps people to do science well, even when it seems as if everything and everyone is trying to coerce scientists toward irresponsible behavior. Public health interventions treat people who are healthy, or not as sick as they could be without public health interventions. These public health interventions are intended to prevent harm, but the irrational human brain does a horrible job of assessing the relative risks of a possibly severe medical condition and a probably very safe medical intervention.


Science vs. Hype: The Unproven Promise of NAD+ IV Therapy
Two new papers and renewed safety concerns for this popular (yet unproven) therapy.
Scott Gavura on July 16, 2026
Link

Nicotinamide adenine dinucleotide (NAD) and its reduced form (NADH) therapy are dietary supplements that are promoted widely to support and treat a variety of conditions, from jet lag all the way to serious illnesses like Alzheimer’s disease and Parkinson’s disease. Back in 2021 I looked at the evidence base for this supplement. At that time I concluded that the evidence was weak and unconvincing, leaving this product unproven for any use. Now there’s a few new papers that helps us get a better picture of the potential value of this popular supplement.
What is NAD/NADH?
Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in every cell. It exists in oxidized (NAD+) and reduced (NADH) forms, and plays a central role in cellular metabolism and energy production. NAD is synthesized from niacin (vitamin B3), nicotinamide, and tryptophan through multiple biochemical pathways. Because NAD is involved in many cellular processes and has been thought to decline with aging and some diseases, there has been growing interest in its potential therapeutic and anti-aging effects. This is because research has suggested that NAD+ levels fall as people age, and that measuring NAD+ in blood could be a way to track aging or health status.
Back in 2021 the primary pitch for NAD was “cures cravings”. Today, the marketing seems to have shifted to “reverses aging,” with Hailey Bieber (who says shes “never gonna age”) and Kendall Jenner as the influencers. The claims have progressed. How about the evidence?
New Evidence for Long-Standing Questions
A new systematic review by Cory Gallagher and Owoturo Oluwaseun Emmanuel, published in February 2026 in Ageing Research Reviews, gives us a comprehensive summary of the current evidence base. It included 113 intervention studies: 33 in humans and 80 in rodents. In animals, NAD-boosting interventions often improved metabolic, mitochondrial, inflammatory, vascular, and sometimes performance outcomes, but the results were inconsistent across models and endpoints. In humans, oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) usually increased blood or cellular NAD-related markers, which shows the supplements reach their biochemical target. However, improvements in meaningful outcomes were mixed: Some trials found small benefits in specific measures, while many found no clear effect on physical performance, insulin sensitivity, arterial stiffness, sleep, or other wellness outcomes. Nearly all of the trials were rated as having some risk of bias. Importantly, the review found no eligible controlled outcome trials of intravenous, intramuscular, or subcutaneous NAD itself for anti-aging or wellness indications. The authors concluded that NAD augmentation does seem to have biochemical effects, but the evidence that it works as an anti-aging therapy in people remains inconclusive. Interestingly, while the bulk of the (limited) evidence is for oral supplementation, the biggest hype is around expensive intravenous use, where there is virtually no clinical trial evidence.
The discussion section of the paper argues there could be biological constraints on NAD when given intravenously. NAD+ is a large, polar dinucleotide and so is not expected to cross cell membranes intact. Moreover, extracellular NAD+ is rapidly broken down into nicotinamide and ADP-ribose before any uptake can happen. The authors reference a small pilot study from 2019 that infused NAD+ intravenously and found early plasma clearance with a metabolite pattern consistent with this extracellular breakdown. The authors argue that any cellular uptake, if it does occur, is likely due to the retention of these NAD+ metabolites.
Overall I found the systematic review interesting, but not conclusive. While it’s not a “gold standard” (I likely need to retire that phrase, given it’s been co-opted) systematic review given the lack of registration, the declared conflict of interest, and other issues, the overall conclusions seem reasonable considering the evidence assessed:
In summary, oral NAD⁺ precursors (most commonly NR and NMN) consistently demonstrate biochemical target engagement in humans and appear generally well tolerated in the short term, but evidence for clinically meaningful anti-aging or wellness benefits remains heterogeneous and inconclusive across outcome domains. Preclinical studies provide broad biological plausibility yet do not reliably predict human efficacy. Evidence supporting parenteral NAD⁺ delivery for anti-aging/ wellness outcomes is currently absent among eligible controlled outcomes trials, and mechanistic considerations further underscore the need for rigorous pharmacokinetic/pharmacodynamic and clinical efficacy studies. Future trials with longer follow-up, standardized clinically meaningful endpoints, and prespecified analyses in appropriately selected populations are needed to define whether NAD⁺ augmentation offers measurable healthspan benefits and to clarify the role, if any, of parenteral approaches.
Is the premise for supplementing unjustified?
In another fascinating and informative paper published in May 2026 in Nature Metabolism, by Maria M. Trętowicz and colleagues, researchers measured NAD+ levels in blood samples from seven different groups of people using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). They first developed and validated a methodology to distinguish between genuine biological differences in samples, and expected degradation due to handling/storage/freezing. They then looked at seven cohorts of patients large enough to detect actual differences, considering the sensitivity of the tests. If whole-blood NAD+ really does decline with age, or responds to lifestyle interventions, the effects should have been detectable here.
They researchers found that blood NAD+ levels were surprisingly stable. They did not consistently decrease with age, and they did not change meaningfully in response to lifestyle interventions such as diet or exercise programs. However, NAD+ levels did increase when people took nicotinamide riboside (NR), a supplement designed to raise NAD+ levels. This is a critical point – the analysis was able to detect supplementation, when it occurred.
The consistency of these findings across the different cohorts raises an important question: If whole-blood NAD+ does not decline with age when measured under rigorous conditions, why have other, earlier studies suggested otherwise? This research suggests that those findings (and conclusions) could be an artifact of sample collection and storage, and not our biology. If correct, this calls into question the entire premise for administering NAD+ and it could explain why NAD supplementation doesn’t seem to show any meaningful treatment effects.
Manufacturing considerations
Because there are no FDA-approved commercial NAD+ intravenous formulations manufactured by traditional pharmaceutical companies, any consumer receiving an NAD+ infusion is receiving a compounded product. These are typically prepared by 503A compounding pharmacies or 503B outsourcing facilities, which operate under very different regulatory standards and quality control oversight than standard drug manufacturers.
This creates a challenging “buyer beware” environment. In 2024, the FDA issued a safety reminder warning that some compounders are utilizing cheap, food-grade NAD+—which is only intended for oral supplements—to manufacture sterile IV injections. When non-sterile, food-grade ingredients are injected into the bloodstream, they carry a high risk of microbial and endotoxin contamination. This is not a hypothetical hazard; the FDA has documented adverse event reports of severe chills, violent shaking, and vomiting requiring medical intervention—all classic signs of endotoxin poisoning. In 2025, the FDA issued a Class I recall for NAD+ for injection manufactured by GenoGenix LLC, following the detection of endotoxins.
In medicine, we routinely accept sometimes meaningful risks and potential side effects when a treatment or intervention has a critical, demonstrated therapeutic benefit. Accepting these same, highly preventable contamination risks for an expensive, unproven “wellness” treatment is far more difficult to justify.
Conclusion
The main takeaway from this newer research is that it raises questions about the whole rationale for monitoring and supplementing at all. It could be that blood NAD+ levels may not be a useful marker of aging or lifestyle-related health changes, despite claims to the contrary. It could also be that raising levels with supplementation has no meaningful medicinal or therapeutic effects. While this research alone doesn’t rule out the idea of NAD supplements, it does give us greater reason to question the relevance and usefulness of this supplement. Compared to where we were in 2021, I’m even more skeptical of the therapeutic potential for NAD.

Statins

Statins: The Impact of Negative Media Reports and the Risks of Discontinuing Treatment
Harriet Hall on December 29, 2015
Link
The evidence is clear: statin drugs are effective in reducing the rate of heart attacks and death in people who have already had a heart attack as well as in people who are at high risk of having one. Some people refuse to believe that evidence; they are statin deniers, similar to the climate change deniers and AIDS deniers (and there are even germ theory deniers!) who manage to disregard the strong evidence that proves their opinions wrong. The deniers demonize statins, cherry-picking studies to minimize the benefits and exaggerate the side effects.
A new study found that negative media reports about statins were correlated with patients discontinuing statin therapy. It also found that discontinuing statin therapy was correlated with an increase in heart attacks and death. 
Statins work
I discussed the new guidelines for statin therapy in a previous post. I won’t repeat what I said there except to emphasize that the recommendations were made by a panel of experts who reviewed all the published evidence and arrived at a consensus. Panels of experts can be wrong, but if a denier is going to reject their consensus, he needs to come up with stronger evidence than the evidence the consensus was based on. The statin deniers don’t have that kind of evidence; they just re-hash studies that the experts knew about and took into consideration.
Criticisms of statins
There are some legitimate concerns. The effect size of statin therapy is not large; for every patient who benefits, a number of patients take them without benefiting (the number needed to treat or NNT varies with the individual’s overall risk status). Like any other effective drug, statins can cause side effects. And there are ways to reduce cardiovascular risk without drugs. (The guidelines emphasize other risk-reduction strategies, but if lifestyle changes don’t reduce the overall risk score enough, adding a prescription for statins is in order.) Some patients may rely on the protection of statins and be less motivated to lose weight, exercise, and stop smoking. Inappropriate prescription is a problem; some over-eager enthusiasts have even suggested statins should be added to the public water supply!
Then there are philosophical objections. There will always be room for informed patients to reject statin treatment for their own personal reasons. They may feel that the chance of benefit is too small to warrant the even smaller risk, they may not want to spend the money, they may know someone who had a serious adverse reaction to the drug, they may have ideological objections to solving problems with pills, they may have trouble swallowing pills, or they may have idiosyncratic reasons of their own that are hard for the rest of us to understand. Patient autonomy is the foundation of medical ethics; no one is going to force patients to take statins against their will. Science can’t tell people what they should do; it can only quantify the risks and benefits of doing it vs. not doing it.
The new study: methods
The new study was done in Denmark. That country’s Civil Registration System records births, emigration, immigration, and deaths for 100% of the population. Denmark also has a Registry of Medicinal Products Statistics that records data for all prescribed drugs, allowing the researchers to identify patients who were started on statins but did not continue getting them. The researchers examined the data on 100% of the individuals in Denmark who filled prescriptions for statins between 1995 and 2010. They excluded patients who started using them prior to 1995, those who started statins before the age of 40, those who took other cholesterol-lowering drugs, those who got more than 120 pills in the first dispense, and those who emigrated or died within 6 months of the first dispense. They were left with 583,349 patients who continued getting statins and 91,551 who didn’t. They did a nested 5:1 matched study to compare patients in the discontinuation group to patients in the continuation group, matching them for various characteristics in order to rule out possible confounders. They examined a number of factors that might have contributed to early statin discontinuation.
For the media analysis, they searched the Danish Infomedia database. It includes all news stories from Danish newspapers, magazines, radio, television, websites, and news bureau feeds, with dates of publication and textual transcriptions. The researchers found and read 1,931 transcripts and rated 110 as negative, 1,090 as neutral, and 731 as positive.
The effects of the media on statin use
They found a small but significant correlation between statin discontinuation and negative news stories. They calculated the odds ratio (with 95% confidence interval) for early statin discontinuation. After negative media stories appeared, the odds of discontinuation were 1.09 (1.06-1.12); for neutral stories 0.98 (0.96-1.01); for positive stories 0.92 (0.90-0.94).
Statin discontinuation increased risk of heart attack and death
In the nested study comparing continuers to discontinuers, those who stopped taking statins were more likely to have a heart attack, with an odds ratio of 1.26 (1.21-1.30), and more likely to die, with an odds ratio of 1.18 (1.14-1.23).
Discussion: Limitations and denial
This study adds to the evidence that negative media stories can have an impact on medication use and on patient welfare. After the results of the Women’s Health Initiative study were publicized, the use of hormone replacement therapy (HRT) dropped and the rate of breast cancer dropped. After reports of a higher suicide risk in adolescents taking antidepressants, the prescription rate dropped and the rate of suicide increased, presumably because the drugs had actually been preventing suicides.
The correlation between negative media reports and statin discontinuation is small and is not that impressive. Correlation doesn’t mean causation; there is no way to know whether a patient had actually read the stories. We shouldn’t ever go by the results of a single study. The authors themselves pointed out the limitations of their study and warned that “great care should be taken in the interpretation of the present results.”
For me, the real importance of this study was the finding that patients who were prescribed statins had a greater risk of heart attack and death if they stopped taking them than if they continued. This should come as no surprise. We had good evidence that statins reduce the risk of heart attacks and death; it would have been surprising if the data had shown unchanged or reduced risk with discontinuation.
Statin deniers are already trying to discredit this study; among other things, they have accused the second author of bias because he declared that he received consultancy fees and honoraria from pharmaceutical companies. The study is far from definitive about the effects of the media, but it reinforces the already abundant evidence that statins are effective. The deniers don’t want to hear that message.

Statin Side Effects
How bad are the side effects of statin use? A recent article on the subject suggests that they are not bad, comparable to the base rate in the population.
Harriet Hall on March 8, 2016
Link

A recent article in The New England Journal of Medicine by Andrew L. Mammen, MD, PhD, reviewed statin-associated myopathies. Reading his article prompted me to revisit the subject of statin side effects.
It can no longer be disputed that statins statistically benefit patients who have cardiovascular disease or who are at high risk of cardiovascular disease. But there are still disputable issues. Which patients should be treated? The recent treatment guidelines have been widely criticized. And the actual magnitude of the benefit is small, although we know the benefits are greater for patients at higher risk. It has been argued that as many as 99% of patients who take statins will take them unnecessarily, risking side effects for no benefit. The problem is that we can’t identify which patients those are. Until we learn more, we are stuck treating the many to help the few. As with any medication, there are risks to be balanced against the benefits. What do we really know about the side effects of statins?
Lots of anecdotes, conflicting evidence
It’s very hard to pin down the truth. The Internet is full of anecdotal reports of devastating side effects from statin drugs, including cancer, dizziness, depression, anemia, acidosis, pancreatitis, cataracts, heart failure, hunger, nausea, sleep problems, memory loss, ringing in the ears, “a sense of detachment,”… the list goes on. When symptoms such as these have been evaluated in controlled studies, they have not been shown to occur more often with the drug than with placebo.
In clinical practice, 10-25% of patients experience muscle problems; but scientific studies tell a different story. In a recent (2014) systematic review they found that mild muscle problems occurred in approximately equal numbers of persons treated with statins and those given placebo. The reviewers commented, “This small difference probably reflects a high background rate of nonspecific muscle problems in both groups that could not be distinguished from statin-associated myalgia because most clinical trials did not use a standard definition for statin myalgia.” There are many insiduous causes of body pain, and it’s hard to tease them apart.
I have written about the large JUPITER trial with 18,000 subjects. I pointed out that in that study:
The rate of reported side effects was similar for both the rosuvastatin and the placebo group. Muscle side effects including rhabdomyolysis have been a great concern of statin critics, but in this study there was no difference between the statin and placebo groups and there was only one case of rhabdomyolysis and that was in a 90-year-old subject with febrile influenza, pneumonia, and trauma-induced myopathy. Some critics have claimed that statins cause cancer, but in this study there were fewer new diagnoses of cancer and significantly fewer cancer deaths in the rosuvastatin group (p=0.02). The only adverse finding was a higher rate of physician-reported diabetes in the rosuvastatin group; but there was no significant difference in blood glucose levels between the groups.
What about diabetes?
Most experts have concluded that the benefits of statins outweigh the concerns about diabetes. Treating 255 patients with statins for 4 years led to 1 extra case of diabetes mellitus, whereas 5.4 cardiovascular events were prevented. Therefore, although the risk of diabetes mellitus is higher in patients receiving statins, statins ultimately benefit cardiac health in people with established heart disease or risk factors for heart disease.
Muscle problems, from minor to serious
When patients report mild muscle problems like myalgias (muscle pain), reducing the statin dose or switching to another statin usually seems to solve the problem. Supplementation with CoQ10 has been recommended to prevent or improve statin-induced myopathy, but a recent meta-analysis of randomized controlled trials found no benefit. More serious muscle problems do occur. One in 10,000 patients develops rhabdomyolysis with serious muscle damage, weakness, and elevated levels of creatine kinase (CK). The problem almost always resolves spontaneously when the drug is discontinued. But there is also a much more serious statin-associated autoimmune myopathy that is estimated to occur in 2 or 3 of every 100,000 patients. It may develop soon after the drug is started, or it may not develop until after years of treatment. Patients notice muscle pain and weakness, and have difficulty rising from a chair, climbing steps, or lifting heavy objects. The weakness usually persists or worsens even if statins are discontinued. The weakness is usually mild-to-moderate, but severe cases have been reported.
Diagnosis is confirmed by extremely high levels of CK, electromyography, muscle biopsy showing necrosis of muscle cells, and the presence of autoantibodies against HMG-CoA reductase. But the same autoantibodies can also be found in patients who have never taken statins. The mechanism is not known, but there may be a genetic predisposition and/or environmental triggers. Some patients with mild weakness recover without treatment, but in most cases immunosuppressive therapy is necessary, with drugs like prednisone, methotrexate, and immune globulin. When full strength is achieved, the drugs can be tapered, although relapses are possible. Sometimes strength returns while CK levels remain high, and sometimes weakness persists after CK levels have normalized.
Dr. Mammen concludes:
For the overwhelming majority of patients, statins have a good side-effect profile. Only in those in whom markedly and persistently elevated muscle-enzyme levels develop should the very rare side effect of statin-associated autoimmune myopathy be considered. Confirmation of the diagnosis with a test for anti–HMG-CoA reductase autoantibody should lead to the discontinuation of treatment with statins and the initiation of immunosuppressive therapy. Fortunately, when this disorder is recognized and treated, patients with statin-associated autoimmune myopathy usually have very good outcomes, with marked improvements in muscle strength.
Conclusion: The tension between anecdotes and data
        ◦ It’s hard to know what to think about all the anecdotal reports of devastating side effects. There could conceivably be small subsets of the population that are uniquely susceptible. I suspect that some people are quick to blame statins for any new symptom they have, and that statins aren’t always responsible. On the other hand, the scientific studies (especially those funded by drug companies) may not always search diligently enough to identify all side effects, especially mild ones that patients may not think to report because they attribute them to getting older. I think patients deserve to know the evidence for benefits and the verified side effects, especially the small but serious risk of statin-associated autoimmune myopathy. Individuals will continue to disagree about the level of risk they are willing to tolerate for a potential benefit. After reviewing everything I could find about the risks, I have personally chosen to continue taking a statin, but I think it can be reasonable for others to choose differently based on the currently available evidence and their own risk factors.

Statins for everyone? Not so fast.
Scott Gavura on April 7, 2016
Link


People love the idea of preventive medicine. Preventing a disease, before it occurs, seems intuitively obvious. But when it comes to taking medicine to prevent a disease before it occurs, people tend to be much less comfortable. Not only are there the concerns about the “medicalization” of healthy people, there are good questions about benefits, risks, and costs. Cardiovascular disease will kill many of us, so there’s been decades of research studying how to prevent that first heart attack or stroke. But even if you’re born with good genes and do everything possible to prevent heart disease (e.g., don’t smoke, exercise regularly, eat a healthy diet, moderate your alcohol, and keep your weight down) you’re still at risk of heart disease. And if you have one or more risk factors for disease, your lifetime risk goes up dramatically. Once you’ve had your first heart attack or stroke, the effectiveness of medical therapy is clear. Drug therapy with medication like the “statins” class of cholesterol-lowering drugs reduces deaths from cardiovascular disease. Given their unambiguous effectiveness, and the high likelihood that many of us will eventually have cardiovascular disease of some sort, the idea of “pre-treating” otherwise-healthy people with drug therapy to possibly prevent that first event has been held out as a potential public health strategy. There’s new evidence that tests this hypothesis, and the results are surprising. 
One polypill to medicate them all?
Preventing a disease before it occurs is called primary prevention. So-called “lifestyle” approaches to primary prevention of cardiovascular disease are always the preferred approach: Changing behaviors may be low cost, are simple, and can be safe. Smoking control efforts are probably the best example of such an approach – reduce population levels of smoking, and you’ll see decreases in cardiovascular disease. Medications have been proposed as a secondary approach to disease prevention. The polypill concept has been around for some time. The idea is to bundle one or more low-dose medications into a single pill, with the objective of changing lifetime risk factors. In someone that’s otherwise well, convincing them to take multiple medications, daily, for a lifetime is not likely to be acceptable to many. The polypill could theoretically prevent cardiovascular disease through multiple methods (e.g., by targeting blood pressure and/or blood lipids), and (it’s hoped) reduce overall risks. One of the key ideas of the polypill concept is that it should not require close monitoring that is burdensome to patients and physicians. The patient should be able to take it daily and essentially go about their life as they always have. The more monitoring, and the greater the side effects, the lower the likelihood that anyone is going to be willing to take any medication for a lifetime, especially when they’re not actually sick yet.
If we were going to build a polypill, we’d probably look for drugs with a track record of reducing deaths in cardiovascular disease. Drug like aspirin (ASA), the statins, beta-blockers, and hypertension drugs like ACE inhibitors and angiotensin receptor blockers (ARBs) would be likely candidates, as they reduce the risk of death in people who have already had their first heart attack or stroke. Last week there was a widely-reported study of a polypill published. The trial, called “HOPE-3”, examined the use of statins and blood pressure drugs to prevent heart disease. This massive study of 12,705 people was co-sponsored by a pharmaceutical manufacturer (Astrazeneca, makers of Crestor) and the Canadian Institutes of Health Research, the primary government funder of health research in Canada.
What did the HOPE-3 trial try to answer?
HOPE-3 was a clinical trial designed to test the real-world effectiveness of a polypill. It studied a diverse population (29% Chinese, 29% Hispanic, 20% white, 20% South Asian or other Asian, 2% black, and 2% “other”.) This was a double-blind, placebo-controlled trial that randomized 12,705 people into one of four groups: rosuvastatin 10mg+placebo, rosuvastatin 10mg+candesartan 16mg & hydrochlorothiazide (HCTZ) 10mg, candesartan & HCTZ + placebo, or placebo+placebo. This slide, via the investigators, illustrates:
This design allowed the individual evaluation of the cholesterol-lowering “statin” drug, the blood pressure drugs, and the combination of three drugs. The trial was designed to mimic “real life” as much as possible. Entry in the trial wasn’t based on blood pressure or lipids. There were no dose adjustments after you started the trial. Men had to be aged 55 years of age or older, and women, 65 years of age or older. Participants had to be free of cardiovascular disease but have at least one risk factor (besides their age) such as:
    • An increased waist-to-hip ratio
    • Smoker
    • Low HDL (the “good” cholesterol in the blood)
    • Dysglycemia (abnormal blood sugar levels)
    • Mild kidney dysfunction
    • A family history of heart disease
You were excluded from the study if you had clear cardiovascular disease already, if there were medical reasons you couldn’t take the drugs, or if you already had kidney dysfunction or low blood pressure causing symptoms. The study took place in 28 countries – but not the United States, interestingly. The first coprimary outcome was a composite of death due to cardiovascular disease, heart attacks and strokes. The secondary primary endpoint added resuscitated cardiac arrest, heart failure, and revascularization to the first outcome.
Because of the 2×2 design, there are three trials published, and they’re currently available free from the New England Journal of Medicine:
“Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease” (Lonn et al.)
“Blood Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease” (Yusef et al.)
“Blood Pressure and Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease (Yusef et al.)
Before getting to the results, I want to look at the adherence. Specifically, how many stayed on therapy? Primary prevention is treatment when you’re not ill, so there’s likely to be little real-world acceptance of any medication that people don’t stick with, especially when the treatment is for life. Somewhat surprisingly, for all the complaints that you may hear about the side effects of drugs, these treatments were very well tolerated, with little difference from placebo. Again, a slide from the trial group illustrates:
While more people taking statins had muscle pain or weakness (5.8% vs. 4.7%), (classical statin side effects), there was no difference in discontinuation rates for this reason. Overall, the drug therapies were well tolerated, and the results show that more people stayed on triple drug therapy than those on a double placebo. One notable area where there was an excess of harms was in surgery for cataracts, where those taking statins had more surgery than those on placebo (3.8% vs. 3.1%).
Does HOPE-3 give hope?
On to the results, and this is where the study gets really interesting. There are three papers here and I’m not going to recite all the findings. I’ll focus just on the primary endpoint, and you can look at the PDFs above for the others. Treatment with a statin reduced cardiovascular events by a relative 24% with an absolute reduction of 1.1%. Overall, the anti-hypertensives did not reduce the risk of cardiovascular events at all – but there were differences depending on whether or not you had hypertension when you entered the trial. Combined statin + antihypertensive treatment was no better than statin alone. And in all three active treatment groups, there were no differences in “all cause” mortality (i.e., death for any reason).
The study was most clear when it comes to primary prevention with statins: Rosuvastatin offers meaningful benefits to those at intermediate risk of cardiovascular disease. There were fewer deaths and fewer strokes. This finding was independent of the cholesterol levels when patient started the trial. You “set it and forget it”, and the strategy largely worked. Importantly, the results show the benefits of using statins based on risk factors for disease, rather than the traditional approach of looking at lipid levels to guide decisions.
What about blood pressure control? The third of patients with the highest levels of blood pressure did benefit from taking the dual drug therapy. In the middle third, there was no benefit. And in the bottom third, blood pressure lowering caused harm. Some of the criticisms raised have included the low doses of the medication used, the duration of the trial, or the choice to use hydrochlorothiazide instead of chlorthalidone, a similar drug that has better evidence of benefit. It could be a combination of factors. The takeaway from this trial is that (unlike what we learned with statins and cholesterol) if there’s no high blood pressure, then you shouldn’t take medication to lower your blood pressure. In patients with high blood pressure, already on medication, and at intermediate risk of cardiovascular disease, then adding a statin is an option that may be worth considering, as it will add meaningful (though small) benefits over lowering blood pressure alone.
Put statins in the drinking water?
One of the key results from this study is that while statins offer real benefits, those benefits are, from a population perspective, modest. If statins provide a 1% absolute benefit over 5 years, then we must treat 100 people for five years to benefit one person. I calculated the cost in Canada to be about $135 per year for 10mg a day of generic rosuvastatin. I understand that the same drug and dose in the United States, where there’s no generic available, will cost about $3,600 per year. Using the Canadian costs, that means it will cost approximately $67,500 to prevent one major cardiovascular event. It’s estimated that three-quarters of men over the age of 55 and women over the age of 60 could be eligible for statins based on this data. While statins are not tremendously expensive, they are not free, and a decision to put millions on statins means resources not spent in other areas – potentially other measures that improve overall live expectancy, such as focusing on the social determinants of health.
Primary prevention with statins is lifelong therapy. Before undertaking it, one needs to consider the expected benefits (they are real, but modest), and the potential for harms and side effects (relatively small, but not zero). It’s possible (though not proven) that the lifetime benefits of statins may be larger, as the follow-up in this trial was just over 5 years. Perhaps more than any other type of medical treatment, primary prevention mandates a close consideration and respect for a patient’s own preferences. Some may be willing to take medication to reduce the likelihood that they will have a cardiovascular event. Others in the exact same circumstances may opt not to. There is not right or wrong answer. With HOPE-3, we now have good data to inform those discussions.

New Study Finds that Statins Prevent Cardiovascular Deaths
A new meta-analysis shows that statin drugs are effective at preventing cardiovascular events and death, especially in patients with a baseline LDL cholesterol >100.
Steven Novella on April 18, 2018
Link

The widespread use of statin drugs remains a little controversial despite the fact that the science is fairly clear. Statin drugs work by lowering bad cholesterol (low-density lipoprotein, or LDL) in the blood. Higher LDL cholesterol is associated with increased deposition of fat on arterial walls, leading to an increased risk of heart attacks, strokes, and death.
We have, therefore, a fairly solid mechanism of action for what should be an effective preventive treatment. We also have good clinical evidence showing that statin drugs actually work – they reduce vascular events and all-cause mortality.
There remain, however, a couple minority opinions that are progressively marginalized by the evidence. There are statin and cholesterol “skeptics” (really deniers, at this point) who think the cholesterol theory of vascular disease is wrong. There are also those who believe that statin drugs work, but not by lowering cholesterol. Rather they work through an anti-inflammatory effect. This view has also been contradicted by evidence.
New evidence
A new meta-analysis published in JAMA supports the current consensus on statin treatment and adds some details and further weight to the evidence. The study, “Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering,” as the name implies, focused mainly on the relationship between baseline LDL levels and the effectiveness of statin treatment. Here are the key findings:
In this meta-analysis of 34 randomized clinical trials that included 270 288 participants, more intensive LDL-C–lowering therapy was associated with a progressive reduction in total mortality with higher baseline LDL-C levels (rate ratio, 0.91 for each 40-mg/dL increase in baseline level); however, this relationship was not present with baseline LDL-C levels less than 100 mg/dL. There was a similar relationship for cardiovascular mortality.
This is a meta-analysis, with all the strengths and weaknesses that implies. The primary strength is the amount of data – 270,288 participants. The overall quality of the evidence was also high. Of course, a meta-analysis is only as good as the studies it includes. Combining data from different studies also introduces new potential biases, such as study selection bias, or potential confounding factors in how data is adjusted so that it can be combined. But these are general concerns. I don’t see anything in this study that raises any flags.
The results demonstrate a feature of a legitimate treatment that we like to see – a dose response effect. In this case we have a double dose-response effect. Higher doses of statins were more effective than lower doses of statins. Also, statins were more effective in patients with LDL >100 than in patients with LDL <100, and the dose response effect was only statistically significant in those with LDL >100.
These results also support the LDL hypothesis, the notion that it is the LDL cholesterol itself that raises the risk of vascular disease. So all the ducks appear to be in a row. Statin drugs lower LDL cholesterol, high LDL is associated with heart disease, statin treatment lowers heart disease, stroke, and mortality, and there is a nice dose-response curve.
At this point the effectiveness of statin drugs, and the cholesterol hypothesis, are not in serious question (although fringe critics remain).
The remaining controversy
Medicine, however, is a complex business. There is often a bottomless pit of more and more refined clinical questions we can ask. The remaining question have to do with – who gets treated with a statin when, and how does it fit into an overall plan to minimize the risk of vascular disease.
Looming in the background of the public debate on the topic is the specter of “Big Pharma.” There are legitimate concerns about the tendency of pharmaceutical companies to oversell the benefits of their drugs, while glossing over the risks and expense. Statins get a lot of attention because they are “blockbuster” drugs, with sales in the billions.
However, just because a drug is profitable, that does not mean it is not a good idea. In this case independent scientific study has clearly established that statins are safe and effective. Anti-pharmaceutical conspiracy theories are just poisoning the debate at this point. Generally they are counterproductive, tainting legitimate watchdog criticism with pseudoscientific conspiracy mongering and scaring people away from effective treatments.
The legitimate debate focuses now on where to draw the line – who gets treated.
Of course, the first-line treatment for high cholesterol should be diet and exercise. No one doubts this. Maintaining a lean body mass, regular exercise, and not smoking are the most effective ways to prevent heart disease for most people.
Unfortunately, lifestyle interventions are not very effective. This is not because they don’t work, it’s because it is very difficult to remain compliant over the long term. Obviously we should still make a huge effort to optimize lifestyle factors. But it is not reasonable to argue that we should do this instead of medication treatment.
The best approach is to institute both lifestyle interventions and medication treatment in appropriate patients. Then, if they are successful at lowering their cholesterol with diet and exercise you can always decrease or stop the drugs later. In the meantime, the patient is getting effective prevention. Otherwise you are missing an opportunity to prevent disease while waiting for something that is probably not going to happen for most patients.
Finally we need to consider who gets treated. This is really the only remaining controversy, because there is no clear correct answer. There are some populations who clearly benefit from and need statin treatment. These include secondary prevention – treatment after a vascular event has already occurred. Also in patients with inherited high cholesterol. Diet alone will absolutely not work in this population. They need medication management.
This brings us to primary prevention, preventive treatment in the general population who have not had a vascular event. Do we put it in the proverbial drinking water? Do we give it to everyone over 50? Where do we draw the line?
At this point the recommendation is to make individual decisions (not give them to everyone) based on overall risk. The higher the risk, the higher the benefit of preventive treatment. This is where the current study is most useful. It supports the routine use of statins for primary prevention in patients with an LDL >100.
There are also formal guidelines, based on expert reviews of the evidence. The current recommendations are:
    • Use statins in “Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater.”
    • May use low to moderate dose statins in “Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 7.5% to 10%.”
    • And cannot recommend routine treatment in “Adults 76 years and older with no history of CVD.”
This is a common approach – stratify treatment by baseline risk. The higher the risk, the more aggressive the treatment.
The current meta-analysis supports the consensus that statins are effective and should be used in appropriate patients for prevention of cardiovascular disease. Statins clearly save lives. It is important for this clear message to get out to the public, because many people who should be on statins are not. This message needs to cut through all the noise and false controversy over statins that is common online.
Bottom line – if you are 40 or over see your primary care doctor and address the issue of all treatments for cardiovascular disease prevention, including statins. Don’t be scared off from a potentially life-saving preventive treatment because of false controversies.

Can statins make you an asshole?
Can statins have rare but significant effects on behavior? A case study.
Scott Gavura on February 6, 2020
Link

Today’s topic is a real question from a colleague who was concerned medications are making her father, a curmudgeon all his life, even more cranky now that’s he’s started taking a statin. My reflex response was “no”, as statins are not generally associated neurological side effects. However, rare side effects are reported to all types of drug therapies, so is was it truly impossible?
What are statins?
“Statins” are a class of drugs that reduce LDL cholesterol. There are a lot of brands on the market, and your choice may vary by country: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. There is more in common than different about the statins, so I’ll refer to them as a class of medications.
There’s two general uses for statin therapy: primary prevention (avoiding a first heart attack or stroke), and secondary prevention (using a statin in someone that has already had a heart attack or stroke, to reduce the risk of another cardiovascular event). There is good evidence that statins reduce the risk of heart attacks and strokes, when used for both primary and secondary prevention. Much of the debate on the usefulness of statins has focused on the absolute benefit when used in lower-risk groups. This is a fair question that has been discussed on the blog before (most recently by Steven Novella in 2018), and not something I want to get into today. What is not in question is that statins have been proven to reduce the risk of heart attacks, stroke, and death.
Why would I want to take a statin?
There are no symptoms to high LDL cholesterol. Lowering cholesterol won’t make us feel better today. The only reason to take a drug that targets cholesterol is because we expect it to lower the risk of heart disease: heart attacks, strokes, and death. The benefit of statins is proportional to the underlying risk. There are tools online to estimate your underlying risk of cardiovascular disease. Once you know your underlying risk, you can use online decision aids that outline the expected benefit from statins. Statins, in general, tend to give a relative risk reduction of 20-30%. So if your ten-year risk of a cardiovascular event is 1%, you’re looking at an absolute reduction in risk by 0.2-0.3%. Once your 10-year risk of a cardiovascular event reaches about 10%, guidelines and health professionals tend to recommend statin therapy, as it would be expected to reduce your absolute risk by 2-3%. Regardless of the underlying risk, a decision to take a statin comes down to a willingness to accept some side effects (which tend to be minor) in exchange for an expected future benefit. It is an individual decision, and there is good evidence to inform us of the expected benefits.
What are the normal side effects of statins?
Statin are generally well-tolerated drugs. Compared to a placebo, the most common side effects that are directly attributable to statin therapy are muscle-related side effects. Perhaps because of their widespread use, there are significant nocebo effects attributed to statins. Muscle aches, soreness and stiffness occur in about 2-11% of people, and muscle-related symptoms are the most common reason people stop their therapy. A careful investigation is recommended in order to identify if the reported effects are truly due to statins.
How statins actually cause these effects is still not well understood. There appears to be a genetic component, and the likelihood may vary with the choice of statin. It is usually diagnosed based on patient reports, along with a trial of discontinuation and treatment restart. There is interest in using supplements (coenzyme Q10, vitamin D) to reduce these effects, but the evidence isn’t there to support routine use.
What about other effects?
So now we get to the crux of the question – can statins cause other side effects, including effects on the central nervous system? Here is where clinical trial data is helpful, but more limited. Despite the muscle-related effects, people on a statin are no more likely to discontinue therapy, compared to a placebo. Statins do rarely seem to cause liver problems, but the risk is comparable to placebo. Negative effects on the kidney have been reported, but are also very rare.
When we look at central nervous system effects, there is evidence to demonstrate that statins are not associated with an increased risk of depression or suicide. Beyond trials, we need to look at case reports and other summaries that collate adverse events that could be vanishingly infrequent. When it comes to statins, that have now been taken by millions of people, some case reports have emerged that suggest that statins could be causing central nervous system effects.
A case series in 2004 reported on six individuals with irritability and short temper on statin therapy. In all six cases, symptoms resolved with discontinuation. In four of the six, symptoms reappeared with restarting statin therapy. The authors of the paper commented:
Statins have vitally important cardiovascular benefits, and the findings presented here do not suggest that prescribing practices should be modified. Nonetheless, it is essential that a full understanding of risks as well as benefits be sought, so that if significant adverse effects occur (even if rare), the possible connection to drug can be recognized, and reasoned risk-benefit assessments can adjudicate whether treatment should be continued or modified. In the context of the larger literature, additional numerous reports we have received of more modest manifestations of irritability on statins that resolve with discontinuation and recur with reintroduction, and the widespread use of statin cholesterol-lowering drugs, the possibility of rare but serious adverse personality and behaviour effects of statins should not be dismissed.
More generally there are some studies that have looked at post-operative delirium (association is unclear) and also memory loss (association is also unclear). In general, the approach to management is usually the same: Discontinue the statin, wait a few weeks, observe, and then restart the statin. If the effect seems to be related to the statin, sometime switching to a different statin may help.
Is it the statin? Probably not.
It is important not to dismiss any possibly adverse event as potentially related to medication. However, evaluations need to consider plausibility and also the evidence base. In the case of statins making one into a curmudgeon, my advice to my colleague was that it was probably not the statin. However, if she truly felt that the behaviour was extraordinary and worthy of continued investigation, that a complete medication review was warranted, in addition to a comprehensive medical examination to look for other causes. Ultimately, decisions to take medications like statins rely on a personal decision regarding expected benefits versus the willingness to accept side effects. Given this is always a personal decision, having the evidence available is essential to informed decision-making.

“New vaccine replaces statins?” Not So Fast!
News reports suggest new drugs may replace statins. PSCK9 inhibitors are useful, but only along with statins in high risk patients not controlled on statins alone, or for patients who can’t tolerate statins. They’re not about to replace statins.
Harriet Hall on September 5, 2017
Link


Are statins obsolete? Are new drugs more effective and free of side effects? The headlines sound too good to be true:
“New cholesterol drug with no side-effects to replace statins… a new vaccine could replace statins.”
“New cholesterol fighting drug may replace old treatment.”
“New drug cuts ‘bad’ cholesterol by 60% on average, reducing heart attack risk.”
“The new drug for people who suffer side effects from statins.”
“Drugs that replace statins but without the side effects approved for use by the NHS.”
As usual, many of the headlines are misleading. Evolucumab and other new PCSK9 inhibitors are effective, but they’re not exactly going to replace statins. The devil is in the details, and the details bring up several concerns.
What is PCSK9?
PCSK9’s long name is proprotein convertase subtilisin/kexin type 9. It is an enzyme, the 9th member of a family of proteins that activate other proteins. PCSK9 binds to the LDL receptors on the liver and keeps them from recycling to remove more LDL particles from the blood; hence, PCSK9 raises LDL cholesterol levels in the blood. Blocking PCSK9 lowers LDL blood levels.
A new class of drugs, PCSK9 inhibitors, are human monoclonal antibodies that bind to PCSK9 and keep it from binding to LDL receptors on the liver, leaving more receptors available to remove LDL cholesterol from the blood. Since antibodies are destroyed by digestion, they can’t be used orally: they must be injected subcutaneously once or twice a month. Evolucumab (Repatha) was approved in 2015. It costs $14,300 per year.
The FOURIER study
Evolocumab had been shown to lower LDL cholesterol levels by 60%, but did it also reduce the rate of cardiovascular events? The FOURIER study, recently published in The New England Journal of Medicine, was designed to answer that question.
    • Randomized, double-blind, placebo-controlled multinational trial
    • 1,242 sites in 49 countries
    • 27,564 patients between the ages of 40 and 85
    • Subjects were all high-risk. They had clinically evident atherosclerotic cardiovascular disease and additional risk factors. Their LDL was 70mg/dL or higher or HDL was 100 or higher while they were on an optimized regimen of statins. 5.2% were also taking ezetimibe, a drug that decreases cholesterol absorption in the small intestine. 92.3% were also taking antiplatelet therapy, 75.6% beta-blockers, 78.2% ACE inhibitors or angiotensin-receptor blockers (ARBs).
    • Median duration was 26 months
Results:
    • Evolucumab lowered LDL cholesterol levels by 59% from baseline levels, to a median of 30mg per deciliter.
    • It reduced LDL to 70 or lower in 87% of patients, 40 or lower in 67%, and 25 or lower in 42%
    • Reductions of 21-27% in myocardial infarction, stroke, and cardiovascular revascularization
    • The benefits increased over time
    • No reduction in rate of hospitalization
    • It reduced cardiovascular events but didn’t save lives; there was no reduction in cardiovascular deaths.
    • Safety: the drug and placebo groups had the same rates of adverse events except that injection-site reactions were slightly more frequent in the evolucumab group.
Interpretation
This study was not about using evolucumab alone, but about adding it to an optimized statin regimen in patients who are at high risk. The results may not be applicable to lower risk patients or to patients treated with evolucumab alone.
Relative risk figures like 21-27% can be misleading when the numbers are small. It is more meaningful to look at absolute risk and the NNT (number needed to treat). 74 of these high-risk patients would have to be treated for 2 years to prevent one incident in the composite outcome of cardiovascular death, heart attack, or stroke.
There was concern that evolucumab might affect cognitive function. That concern was put to rest by a study that showed no difference in cognitive function between evolucumab and placebo groups over a 19-month period. The FOURIER study confirmed the safety of the drug: it found no increase in any adverse events compared to placebo, other than mild injection site reactions.
Current treatment guidelines recommend prescribing statins according to risk status and not worrying about the LDL levels achieved. The FOURIER study suggests that there is additional benefit to lowering LDL levels to well below any previous target levels. It will be interesting to see whether official treatment guidelines will change accordingly.
Cost and inconvenience are big concerns. Evolucumab must be injected once or twice a month, and it is very expensive: $14,300 a year. Generic statins cost much less, about 1% of that ($12 a month or less), and they come in convenient once-a-day pill form.
Many patients on statins complain of muscle pain, but their pain is not always caused by statins. In some placebo controlled studies, the incidence of muscle pain was no higher than with placebo. If statin-related muscle symptoms do occur, they can often be managed by reducing the dose or switching to another statin (unless the rare complication of rhabdomyolysis occurs). And evolucumab can cause muscle pain too. Myalgias occur in 4% of patients and musculoskeletal pain in 3.3%, and there are a number of other side effects. Stopping statins and switching to evolucumab might not be the best idea. We don’t yet have studies comparing evolucumab to statins.
In contrast to the positive headlines, one said, “A new drug to replace statins? Don’t believe the hype.” It says it’s not a statin replacement and would only be appropriate when diet and statins haven’t lowered LDL enough.
Other options
Alirocumab (Praluent) is another PCSK9 inhibitor that was shown in a post-hoc analysis to reduce the risk of cardiovascular events. It was the first PCSK9 inhibitor approved by the FDA. It was approved for the treatment of familial hypercholesterolemia and for use along with statin therapy in adults whose cholesterol is still too high after diet and maximally tolerated statins. Like evolucumab, it costs around $14,300 a year.
Another PCSK9 inhibitor, inclisiran, appears to maintain its effectiveness longer and might decrease the number of injections to 3 or 4 a year. The NNT? They estimate that 17 high-risk patients would have to be treated for 5 years to prevent one heart attack or stroke.
Vaccines are being investigated and have shown promise in animal studies, but human trials are only just beginning.
Canakinumab is a human monoclonal antibody targeting a cytokine. It has anti-inflammatory effects and has been approved for the treatment of rheumatologic disorders. Treatment of atherosclerosis has focused on reducing cholesterol levels, but inflammation is involved and statins have an anti-inflammatory effect in addition to their effect on LDL cholesterol levels. The CANTOS trial was a randomized, double blind, placebo-controlled study of patients with a history of a heart attack who had elevated levels of C-reactive protein, a marker of inflammation. Canakinumab reduced inflammatory markers but not cholesterol levels, and it significantly reduced the incidence of recurrent cardiovascular events. This supports the inflammatory hypothesis of cardiovascular events. Canakinumab causes side effects: there was a higher incidence of fatal infection and sepsis, and a reduction in platelet counts. But it also has beneficial side effects: it improves other inflammatory conditions like arthritis and gout. And it significantly lowers the mortality from some cancers. It appears to reduce the occurrence of lung cancer by 67% and death from lung cancer by 77%. It costs $64,000 a year, which some consider a bargain for a drug that prevents lung cancer in high-risk patients
Conclusion: PSCK9 inhibitors are effective but not likely to replace statins
In my opinion, there is a place for limited use of PSCK9 inhibitors, but only in patients who are truly unable to tolerate statins, or along with statins in high risk patients whose cholesterol is not well controlled on statins alone. Other potential treatments for atherosclerosis are promising, but still investigational. Statins have a proven track record; they remain the treatment of choice.

Statin Side Effects Revisited
Patients on statins frequently report muscle pain and other side effects, but controlled studies have shown side effects are not more frequent than with placebo. Why this discrepancy? A new study sheds some light.
Harriet Hall on January 19, 2021
Link


Something strange is going on. People who take statins frequently discontinue them because of side effects, but blinded trials have shown no excess of symptoms compared to placebo. The most commonly reported side effect is muscle pain, but patients also commonly report headaches, dizziness, feeling sick, feeling unusually tired or physically weak, digestive system problems (constipation, diarrhea, indigestion and farting), sleep problems, and low blood platelet count. Less common complaints are memory problems, hair loss, pins and needles sensation, flu-like symptoms, pancreatitis and stomach pain, skin problems like acne and rash, and sexual problems such as loss of libido and erectile dysfunction. Rarely reported side effects include muscle weakness (myopathy), loss of sensation or tingling in the hands and feet (peripheral neuropathy), and tendon problems.
Incidence and management of myopathy
1.2 patients develop myopathy for every 10,000 person years, and the average incidence per 10 000 person years for atorvastatin, pravastatin, or simvastatin is 0.44 (0.20 to 0.84) and for cerivastatin is 5.34 (1.46 to 13.68). Symptoms can begin anywhere from one week to four years after starting statins. Management starts with measuring creatinine kinase (CK) and thyroid-stimulating hormone. If the CK level is more than 10 times the upper limit of normal, statin therapy is usually discontinued but another statin can be prescribed or there can be a repeat challenge with the original statin. Further studies may include muscle biopsy. Coenzyme Q10 has been recommended to reduce the risk, but its usefulness is unclear and more studies are needed.
Rhabdomyolysis is a serious condition that can lead to brown urine and kidney failure and is potentially life-threatening. With treatment, many patients recover. Death is rare: by one estimate, 0.15 deaths per million statin prescriptions.
Report in The NEJM
A letter to the editor published in the November 26, 2020 issue of The New England Journal of Medicine tried to shed some light on the subject. It reported an attempt by researchers in the UK to assess the side effects of statins in an N=1 three-group randomized double-blind trial of statins, placebo, or no treatment. The subjects were 60 patients who had discontinued statin therapy because of side effects that occurred within 2 weeks of starting the statin. The primary endpoint was the nocebo ratio, the ratio of symptom intensity produced by the placebo compared to the statin. Patients reported symptom intensity daily through a smartphone app. The mean symptom intensity was 8.0 during the no-tablet months, and 15.4 during the placebo months, and 16.3 during statin months. 90% of the symptom burden was also elicited by the placebo, and half the trial patients were able to successfully restart statins.
This was reported in a letter to the editor; it was not a gold-standard peer-reviewed study. But it is consistent with other reports suggesting that statin therapy is not the cause of most reported side effects.
Conclusion: Statins are vindicated
This study adds to the evidence that many or most of the reported side effects are not actually due to the statin therapy. That helps explain the discrepancy between patient reports and the data from controlled studies. It helps confirm that statins are safe.
Disclosure: I take a high-dose statin because I have had a stroke and high-dose statins are strongly recommended for anyone with a history of stroke, to reduce the risk of recurrence. It has worked well to markedly reduce my blood cholesterol. I have not noticed any side effects and I’m not worried.

Review Recommends High Dose Statins
Steven Novella on July 30, 2025
Link
The exact role of different types of dietary fat and the best approach to prevention in cardiovascular disease has been somewhat controversial. However, the level of controversy among experts is much less than that being generated in the public by outliers and contrarians. Since cardiovascular disease remains a major source of morbidity and mortality, it’s important for the public to be kept up to date as the science progresses. We now have decades of research that have explored many of the nuances in this area and can make some solid recommendations.
A recent review helps clarify where we are in terms of treating cholesterol for the primary (before an event has occurred) and secondary (after an event has occurred) prevention of vascular disease, including heart attacks and strokes.
One of the issues that may have previously been controversial is the role of LDL (low density lipoprotein – the “bad” cholesterol) in vascular disease. But we now have enough evidence to confidently say that LDL does lead to increased clogging of the arteries which contributes to the risk of heart attacks and strokes. Further, lowering LDL is effective in reducing vascular risk. And further still, medications, such as statin drugs, that lower LDL are both statistically and clinically effective in reducing vascular events and prolonging survival.
They point to the published evidence which shows that statin drugs are more effective than any other current intervention at lowering LDL, and therefore should be considered first line therapy. As always, this should be combined with lifestyle changes, which are independently effective. However, it’s often difficult to get patients to comply with lifestyle change, and they can take a long time to take effect, and so immediate use of statins should be done in the meantime.
They point out that 40% of the American public have so-called metabolic syndrome (a combination of obesity, hypertension, and insulin resistance) and only 21% get sufficient exercise every day. Also, lifestyle changes are effective even in people who are already on statins.
They further recommend that statins should be started at high dose. Often we start medications at the low end of the dose range in order to assess for tolerance and effectiveness and then titrate up the dose as needed and as tolerated. This is a good generic approach. However, they point out that the evidence clearly shows that statins, such as rosuvastatin and atorvastatin, are more effective at the higher dose, and people tend to stay at the dose they are initially prescribed. Therefore, at a population level, prescribing high doses initially may be more effective.
Given the evidence, other interventions should be considered adjunctive or secondary. There is good evidence for aspirin in secondary prevention, for example, but for primary prevention the evidence is less clear and individual decisions need to be made.
The authors are less enthusiastic about newer drugs, such as ezetimibe and evolocumab. The evidence for their efficacy is not as strong and the overall benefit may be less than statins. They worry that these newer drugs are being overused, perhaps because of their novelty, when the older statins are supported by more robust evidence.
What about HDL – omega 3 fatty acids or good cholesterol? Evidence for the efficacy of omega 3 remains fairly weak, which the authors suspect is because of the widespread use of statins obscuring any benefit. There is possibly one exception – the REDUCE-IT trial showed that icosapent ethyl reduced major cardiac events by 25%.
As always, the purpose of this article is not to make personal medical recommendations, but rather to educate the public about the state of the science. Consult your physician for individual recommendations. There is a lot of misinformation on social media and in the public about dietary fat and cholesterol-lowering medications. It’s good to know that the science has continued to chug along, and an increasingly clear picture has emerged. LDL is a risk factor for vascular disease. The evidence supports a heart-healthy diet, regular exercise, control of blood pressure, avoiding smoking and limiting alcohol. Further, drugs that lower LDL are clearly effective. The benefits of supplementing HDL are less clear.
Like all medications, statin drugs may have side effects, but not necessarily. Don’t be scared off of trying them if it is clinically appropriate to do so. If you have not discussed managing your vascular risk factors with your doctor, now is a good time to do so. 


The Cholesterol Wars Continue
Steven Novella on October 1, 2025
Link
As a first approximation it seems that the purpose of social media is to misrepresent medical information and to promote wellness gurus who basically have no idea what they are talking about. Part of the problem is that medical science is often complex, and the short attention-span format of social media often favors simple clean narratives. So “wellness influencers” dominate while genuine science communicators struggle to keep up.
Take the story of cholesterol. This has been challenging for medical scientists because it turns out to be very complex. Quickly, here is what we know. Cholesterol is a lipid (a fat) that is linked to lipoprotiens in the blood – this is the LDL and HDL particles. Cholesterol is very much a necessary biomolecule, used in hormone production, cell membranes, vitamin D, and bile acids. However, cholesterol can also build up on the inside of artery walls, causing plaques, inflammation, and increasing the risk of heart attacks and strokes.
That’s the simple part, and it is essentially correct, but the story gets complex. Based on that model it was originally recommended to restrict dietary cholesterol. But then it was found that dietary cholesterol does not translate to increased serum cholesterol, so the restrictions were not helpful. However, then we discovered that a certain subpopulation of superabsorbers do need to restrict their total dietary cholesterol.
Further, keeping a low LDL to HDL ratio is more important that total cholesterol. High HDL is protective, within limits, while low LDL is highly protective. While much of this is based on observational data, we also have data from studies looking at treating cholesterol, finding that treatments, like statins, reduce all-cause mortality, reduce cardiovascular death and events, and that they work for both primary prevention and in those with a prior cardiovascular event.
It is also clear that cholesterol biology is highly genetic. About 40-50% of the risk for high cholesterol and its contribution to CVD is genetic, while 50-60% is lifestyle.
While this overview is the current consensus based on lots of evidence, there is enough complexity in the data to have reasonable debate about some of the finer details. There is also plenty of fodder for unscrupulous wellness gurus to cherry pick and mispresent that data to confuse the public and promote their own brand and snake oil.
Here is a good example – they are discussing this 2023 Swedish study looking at extreme longevity. The study found: “Higher levels of total cholesterol and iron and lower levels of glucose, creatinine, uric acid, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, and total iron-binding capacity were associated with reaching 100 years.”
The presenter in this video is making a very simplistic – and almost certainly wrong – claim, that the study supports the notion that cholesterol is an unalloyed good, and that higher cholesterol levels are good for your health.
First, we have to recognize that this is an observational study. As I often repeat, observational studies do not establish cause and effect because they are not controlled. There are many possible confounding factors. This is especially true to general outcomes like survival – which is rife with confounding factors.
In this study the authors conclude that the correlation with reaching 100 years of age among those with extreme longevity is likely a result of genetics. This is supported by some additional data looking at the children of centenarians. In other words – if you have a genetic tendency for longevity this may come with a tolerance of higher cholesterol. For example, people who have a risk of dying of cardiovascular disease as a result of high cholesterol have already been weeded out of this cohort.
The authors also point out that this data could mean that normal values for biomarkers may change as we age. This, of course, is often true – biology changes as we age. I should also point out that the subjects of this study did not have high cholesterol. Their total cholesterol was mostly in the normal range. But those who reached 100 were slightly higher than those who did not. There is no reason to think this tells us much about having high cholesterol in your 40s and 50s.
The bottom line is that this is an observational study with a likely very complex set of confounding factors. There is definitely a lot of survivor bias in the data – people who live into their 90s and beyond are not a representative population, and many factors have biased who remains alive at this age. Genetics is likely the overwhelming factor in this data, telling us something about the biology of people who live to extreme age.
What this data absolutely does not do is call into question the consensus that high total cholesterol and especially LDL cholesterol during middle age is a significant risk factor for cardiovascular disease, that it results from a roughly even mix of genetic and lifestyle factors, and that lifestyle and medication intervention to lower cholesterol reduces the risk of death and heart disease.


Are Cardiac Calcium CT Scans Useful?

Steven Novella on November 5, 2025
Link

My doctor recently recommended that I get a cardiac CT calcium scan to help stratify my risk of cardiovascular disease (CVD). So of course I was interested in how good this scan is, because diagnostic tests to assess risk, especially in those who are asymptomatic, can be tricky. I was happy to discover that the short answer is – yes. These tests are very helpful in stratifying risk of coronary events, even in young patients, those without a prior cardiac event, and those with otherwise high traditional CVD risk factors. (I had a good test outcome if you are interested – an Agatston score of zero.)
It’s a good opportunity to review the role of diagnostic testing, and other factors, in stratifying risk of disease or medical events, and further the role of stratifying risk in determining the best treatment. Treatments in medicine, as we have discussed many times, is all about risk vs benefit. No treatment is risk-free, and interventions come with cost, inconvenience, and opportunity cost. Some may also be invasive or have significant side effects. Therefore we always want to determine, as much as possible, which population will have the greatest benefit to risk ratio, and where the point is where those lines cross. Only with certain nutrients do we literally or metaphorically “put it in the water”.
Cardiac events are notoriously difficult to predict. Harriet wrote in 2008 about cardiac CT angiograms, and hit most of the salient points. CT angiograms look at stenosis or blockage in the coronary arteries, and questioned at the time whether or not CT angiograms predicted future events or made a significant difference in treatment or outcome. This is because stenosis of the coronary arteries, while it is one piece of relevant information, by itself is not a great predictor of the future risk of heart attacks.
This may seem counterintuitive, but makes sense in the context of how most heart attacks occur. One way is for plaque to build up on the inside wall of a coronary artery until it simply blocks blood flow completely, infarcting coronary tissue. But this is rarely what happens. Such blockages would occur slowly, over years, resulting in collateral blood flow to compensate for the slow decrease in flow through the original artery. Literally new small arteries grow to bypass the blockage.
Much more often the cause of a heart attack is an ulceration of the plaque – the plaque breaks down through inflammation, causing platelets to clump at the site causing a sudden thrombus (blood clot) which blocks flow. This is why antiplatelet drugs, like aspirin, are helpful in reducing the risk for such events. Plaques that are ready to ulcerate have calcium in them (oversimplified but true enough). So cardiologists developed a technique for imaging calcium in the coronary arteries. They then did the hard work of real medical science – studying if and how useful such scans are.
The CT scan for calcium in the coronary arteries was first introduced in 1990. This was followed by 30 years of research, exploring every aspect of this test. In 2018, the cardiovascular society cholesterol guidelines recommended a calcium scan to help determine if someone should go on statin drugs to reduce their cardiovascular risk. Use of this san has increased since then. Also, the technology itself has improved over time. The current standard is multidetector ECG-gated CT, which is fast, does not use any contrast, and uses significantly less radiation exposure than older scans. So the risk and inconvenience has gone down while evidence for benefit has piled up.
That evidence has shows multiple things. First and foremost, the degree of calcium in your coronary arteries is a strong and independent predictor of future risk of coronary events. It is independent of age, of other traditional risk factors (cholesterol, weight, smoking, and family history), and of prior events. It is better than any other single predictive factor, and as good a predictor as having a prior event (which has always been the best predictor of future events).
This does not mean that everyone should get one. One common question for instructors to ask students, to help them learn clinical decision making, is – how will this affect your management? You want to order this test? Will it affect anything that you do? For CT calcium scans the main utility seems to be determining statin therapy. There are different ways to measure calcium, but the dominant method is now the Agatston score, which measures visible calcium deposits of a certain threshold. A score of 0 means very low risk, 1-100 is low risk, 101-300 is moderate risk, and >300 is high risk.
Further, we can use these scores, combined with other risk factors, to make informed decisions about statin use. If the score is 0 then statin use can be deferred, unless someone has very high cholesterol. Low risk you can probably wait and repeat the scan in 3-10 years, with moderate risk it is probably a good idea to go on statins but not absolutely necessary, and for high risk, statin therapy is highly recommended. This is always coupled with lifestyle interventions.
Therefore, cardiac calcium scans are a well-researched diagnostic tool, developed based on our basic understanding of the mechanism of most heart attacks, with high predictive value and high clinical value in individualizing preventive treatment. The technology itself has also evolved to make it a quick, easy, and low risk study.
This history of this diagnostic tool also shows nicely how science-based medicine works. After the scan was developed, it did not immediately go into widespread use. Doctors were skeptical of its utility, and asked every possible question about what it did and did not predict, and eventually developed an evidence-based recommendation for how it can be incorporated into the total care of patients.
This stands in stark contract to many “alternative” or pseudoscientific medical interventions, where a diagnostic or therapeutic intervention is developed, often out of whole cloth based on some hand-wavy justification, and then widely adopted without any real assessment of its safety and utility. Never do you see three decades of careful research before use is cautiously recommended.


A closer look at penicillin allergies
While many people believe they may be allergic to penicillin, few actually are. The consequences may be serious.
Scott Gavura on June 15, 2017
Link
(While Scott takes a summer break from blogging, here’s a slightly refreshed older post that may be new to many:)
Allergies are taken seriously by health professionals. As a pharmacist, when I’m dispensing a medication, it’s my responsibility to ensure that the medication is safe and appropriate for the patient. Asking about allergies is a mandatory question for every new patient, and it’s essential to double-check allergy status when drugs like antibiotics are prescribed, as reported allergies are common. Penicillin is one of the oldest antibiotics still in use despite widespread bacterial resistance. Multiple versions of penicillin (like the amoxicillin pictured above) have been developed to change its effectiveness, or improve its tolerability. And other classes of antibiotics (e.g., cephalosporins) share some chemical/structural features with penicillin. Collectively, these antibiotics are widely used for both routine and serious bacterial infections. Unfortunately, allergies to penicillin are commonly reported. Statistically, one in ten of you reading this post may believe that you’re allergic to penicillin. Yet the actual incidence of anaphylaxis (a serious allergic reaction) to penicillin is estimated to be only 1 to 5 per 10,000. So why do so many people believe they’re allergic to penicillin? Much of it comes down to how we define “allergy.”
Adverse events, reactions, and allergies
There are a number of confounders when it comes to evaluating allergies. A big one is terminology. While different groups vary in their definitions, the term “adverse drug event” typically means that an undesirable event has occurred, but isn’t causally linked to the consumption of a drug. In contrast, “adverse drug reaction” is usually reserved to where a causal link to the drug has been established, or is fairly certain. Adverse drug reactions can occur under completely normal use of a drug. And they’re not uncommon, as I’ve pointed out before. An allergic reaction to a drug is an adverse drug reaction that is mediated by an immune response. If there is no immune response, it’s not an allergic reaction. So if you take codeine or morphine and it makes you drowsy and constipated, that’s not an allergic reaction—that’s an effect of the drug. Erythromycin (and drugs of this type) commonly causes stomach upset, so if you vomit, that’s not an allergy either. So, to sum:
Penicillin allergies
Within that box of adverse reactions we’re calling “drug allergies” there are a number of methods of classifying the different immune responses. The most common way is to split events into immunoglobulin E (IgE)–mediated (immediate) reactions, or non–IgE-mediated (delayed) hypersensitivity reactions. The IgE-mediated reactions are the ones we might immediately think of when we hear “penicillin allergy”: flushing, itchy skin, wheezing, vomiting, throat swelling, and even anaphylaxis. These reactions can occur immediately to a few hours after a dose. The non-IgE-mediated reactions are delayed, and can be mild or severe, ranging from serum sickness to the horrific (but fortunately rare) Stevens-Johnson syndrome.
Skin rashes (morbilliform eruptions) are non-IgE reactions commonly reported with penicillin therapy, though their relationship to the penicillin itself isn’t clear. Rashes that appears several days after starting therapy (or even after finishing a course of antibiotics) may be due to a poorly-understood relationship between the antibiotic and any concurrent viral infection. These rashes are not itchy. With subsequent exposure to penicillin (or a related drug) the rash can reappear. These types of reactions do not mean that one cannot receive penicillin again, however.
It’s the structure of the penicillin molecule itself that triggers allergic reactions. Both the “parent” drug and any iterations created through metabolism can induce allergic responses. Analogs of penicillin, with different molecular side chains, can trigger selective sensitivity in some. So one could have an allergic reaction to amoxicillin or ampicillin, but be able to tolerate penicillin.
Testing for allergies can be important
Determining if you’re actually allergic to penicillin is important to sort out, as not all reactions mean penicillin cannot be administered again. Skin testing is the standard for testing for IgE-mediated allergies, and needs to be performed under medical supervision, usually by allergy specialists, in settings where access to resuscitation medication is available. Given the unreliability of memory, skin testing is the standard when there’s any doubt at all about the type of prior reaction. Skin testing is the best method of testing for anaphylaxis allergies to penicillin, and is best performed when you don’t currently need antibiotics. In cases of the severe non-Ig-E type reactions, there’s no rechallenge attempted, and those patients should never receive penicillins again.
So if you think you’re allergic to penicillin, but are not certain of the type of allergy you have, testing is something worth thinking about, and discussing with a health care professional. Without it, you’re setting yourself up for a lifetime of risk and consequences of the avoidance of penicillin. People considered penicillin-allergic will typically receive more broad-spectrum antibiotics, which may have more side effects, be more expensive, and in some situations, less effective. And given IgE-mediated allergy can wane over time, even significant childhood reactions may not manifest as adult allergies—but only testing can determine this for certain.
Formal evaluations of penicillin allergies support this approach. A paper in the Journal of Allergy and Clinical Immunology describes a prospective evaluation of children that presented to an emergency room with a delayed-onset rash from penicillin. Eighty-eight children were enrolled over two years. At the time of enrollment, they were screened for viruses. Each child returned to the hospital two months after their initial visit, where they underwent skin (patch and intradermal) as well as blood evaluations for allergy. They all had an oral challenge with the original antibiotic, too. After evaluation, none had a positive skin test, 11 children (12.5%) had an intradermal reaction, and only six (6.8%) had the rash recur after an oral challenge. Within the group that had a positive oral challenge, two had intradermal-negative, and one was intradermal-positive. Most of the children had tested positive for viral infections, too.
The authors concluded that penicillin allergies are overdiagnosed, and viral infections may be a factor leading to rashes and over-diagnosis. The authors recommended oral challenges, rather than skin, intradermal, or blood tests for all children that develop delayed-onset rashes during treatment with penicillins.
Conclusion: Penicillin allergy is less common than people think
While penicillin allergies can be real, and can be serious, only a small percentage of people that consider themselves allergic actually cannot receive penicillin. Avoiding penicillin can mean using antibiotic alternatives that are less effective, more expensive, and have greater side effects. For this reason, confirming a penicillin allergy with a physician is warranted—before an antibiotic is needed. After all, unless it’s necessary, you don’t want to end up with Mark Crislip standing over your hospital bed, being asked what his second choice of antibiotic is going to be.

G-Spot Discovered? Not So Fast!
Harriet Hall on May 1, 2012
Link
Is this the G-Spot?
The press release proclaims “Study Confirms Anatomic Existence of G-Spot.” The study itself is titled “G-Spot Anatomy: A New Discovery.” It was just published in The Journal of Sexual Medicine. The author, Adam Ostrzenski, is an “internationally renowned gynecologic surgeon” with multiple degrees (MD, PhD, Dr Hab) and many peer-reviewed articles listed in PubMed.
The G-spot, or Gräfenberg Spot, is an area on the anterior wall of the vagina that can be stimulated to produce sexual excitement, stronger orgasms, and maybe even female ejaculation. Its existence is questionable. Wikpedia has an extensive article explaining the controversy and the published evidence, pro and con, with links to the original sources. You can read more than you ever wanted to know about it there, so I won’t bother trying to repeat it here. A 2012 review of the G-spot literature concluded: 
Objective measures have failed to provide strong and consistent evidence for the existence of an anatomical site that could be related to the famed G-spot. However, reliable reports and anecdotal testimonials of the existence of a highly sensitive area in the distal anterior vaginal wall raise the question of whether enough investigative modalities have been implemented in the search of the G-spot.
Dr. Ostrzenski claims to have found the G-spot and taken its picture (above). Believers in Bigfoot and the Loch Ness monster have pictures too. They even had “Bigfoot hair” that later turned out to be synthetic wig fibers. Ostrzenski’s “proof” is no more credible than theirs.
The Study
This “discovery” was based on dissecting out the pictured structure in the cadaver of one (yes, only one !) 83 year old woman who died of head trauma. The dissection was performed in Warsaw, Poland, but I will scrupulously refrain from making any Polish jokes. The author declared it was a G-spot based on visual inspection of the specimen alone; he said it was an 8.1 mm sac-like structure with a head, body, and a rope-like tail that disappeared into surrounding tissues. After excision, it could be stretched to 33 mm. He said the walls of the structure “resembled fibroconnective tissues and resembled erectile tissues.” Both? Apparently he didn’t even bother to take the most obvious, rudimentary next step of examining slices of the specimen under a microscope (with appropriate staining) to determine what kind of tissue it was. One wonders if he even preserved the specimen in formalin so histological study might still be possible. And he doesn’t tell us whether he had tried to find it in other cadavers and failed before this “success.”
Visual inspection of one autopsy specimen? How could he possibly know what it was that he had found? Is this a G-spot structure or something else? During embryological development of the genitourinary system there are structures that form and are reabsorbed: could this be a left-over remnant of that process? Could it be a tumor? A variant of normal anatomy having nothing to do with sexual response? Something else? Why didn’t he look for it in a second autopsy (or, preferably, a whole series) before rushing into print? And even if he could document the existence of a never-before-described anatomical feature, wouldn’t it take something more than simple observation to determine that it was the G-spot?
A Big Oops
In the discussion section of his article, Ostrzenski makes an embarrassing mistake: he claims that the G-spot gene has been identified and has been already incorporated into a GeneChip microarray. That struck me as odd. How could they have identified a gene for a structure whose very existence was in doubt?
The reference Ostrzenski provides for this claim doesn’t support it. In that reference, G-spot does not mean what he thinks it means. By “G-spot” they don’t mean anything to do with vaginal anatomy: they mean DNA probes containing a contiguous run of 4 or more guanines (base pair nucleotides). They make that clear in the second sentence of the abstract. He read carelessly, and his foolish mistake should have been caught by his editors and peer-reviewers. If I thought to question it and look it up, why didn’t they?
Even If It Isn’t Real, It’s Profitable
Whether or not the G-spot exists, you can buy a sex toy, a curved vibrator, specially designed to stimulate it. And there is even a plastic surgery procedure called G-spot amplification to enhance its sensitivity. The ACOG has spoken out against this operation. Guess who performs and teaches this surgical procedure, along with a number of other questionable vaginal procedures?
Yep, Ostrzenski himself.
The Hype Begins
CBC News, Science Daily and other news outlets promptly proclaimed “G spot anatomy found.” The very day this study was released, I got a PR e-mail announcing it, proclaiming that the existence of the G-spot had been proven, and offering me an interview with a doctor who would explain “how the discovery of the G-spot will change sex for men and women.” A doctor who, incidentally, does not inspire my confidence because she also happens to prescribe bioidentical hormones and practice anti-aging medicine. The Huffington Post wasn’t so sure this study would settle the debate but commented that 
perhaps knowing it and understanding it goes beyond anything you can dissect or measure. It’s an untouchable pathway to bliss and the cosmos, making it something so much more.
Conclusion
In short, this published study is a junk-science travesty perpetrated by a researcher who has a vested interest in proving there is a G-spot so he can justify operating on it. No one deserving the name of scientist would claim to have discovered a new normal anatomical structure based on a visual inspection of one specimen with no further investigation. The author, the editor of the journal, and the peer-reviewers should all be ashamed of themselves.
Further Thoughts
In contrast to the vaccine/autism manufactroversy, there is a legitimate controversy about the existence of the G-Spot. We don’t have enough evidence to confidently conclude either that it does or doesn’t exist. At this point, I wouldn’t even venture an opinion.
I would argue that it really doesn’t matter very much. Clearly, some women respond to anterior vaginal stimulation, others don’t. This might have other explanations: conditioning, suggestion, experience, variations during embryologic development, the ability of any highly innervated area to trigger orgasm in some individuals, or other factors.
Women might think not being able to find their G-Spot means they are defective. Pursuing the elusive G-Spot might engage men in fruitless hunting expeditions when they could be finding other ways to please their partners and concentrating on spontaneous enjoyment rather than prescribed techniques.
Poor men! They have a hard enough time just finding the clitoris.

Progeria
The first drug to treat Hutchinson-Gilford Progeria, a rare and uniformly fatal rapid aging disease, has been approved by the FDA. It can prolong the life of these children by 2.5 years, but it is very expensive.
Harriet Hall on December 8, 2020
Link

Big Pharma marches on. While vigorously pursuing COVID-19 vaccines that will benefit everyone in the world and should bring them large profits, they haven’t forgotten rare diseases that only affect a few. On November 20, 2020, the FDA announced that it had approved a new drug to treat progeria, a rare genetic disease. The drug is called Zokinvy (lonafarnib). It is manufactured by Eiger BioPharmaceuticals, Inc. It was given Orphan Drug status and a Rare Pediatric Disease Priority Review Voucher. It is indicated to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older.
What is progeria?
You may never have heard of progeria unless you happen to have seen the HBO documentary Life according to Sam. You can “meet the children” and read their life stories and see their photos here. It is a “rapid aging” disease, where children have the appearance of old people, develop many but not all of the diseases associated with old age (atherosclerosis but not cataracts or osteoarthritis), and die prematurely, usually by age 13 of heart attacks or strokes. The oldest survivor died at age 29. A patient with progeria was presented to us in medical school; her distinctive appearance is seared on my memory and I will never forget her. I didn’t realize until just now what a privilege it was to meet her. They told us it was a rare disease, but they didn’t explain that only a very few people had been diagnosed with it (18 in the entire country today, probably fewer back then).
Hutchinson-Gilford progeria syndrome is rare. The Progeria Research Foundation has been searching for undiagnosed cases. It has identified 179 cases in 53 countries, only 18 of them in the US. Progeria is genetic but not hereditary. It is caused by a sporadic mutation in a gene and it seldom recurs in families.
The symptoms
These children appear normal at birth. By the age of 18-24 months it becomes apparent that something is not right. They do not grow normally, are short in stature, lose all the hair from their scalp and body, and have a small face with a pinched, beaked nose and a shallow, recessed jaw. They have prominent scalp veins and lack body fat. They develop many conditions that usually only appear in the elderly: decreased vision, scleroderma, kidney failure, heart attacks, strokes, heart failure, stiff joints, hip dislocations, and other problems. Their mental and motor development are not affected. They have normal or even above-normal intelligence. Patients with progeria have graduated from college and women with progeria have become pregnant and have delivered normal babies.
It was hoped that studying these patients would lead to a better understanding of the aging process, but that hasn’t panned out. The defect has been identified as a single-letter misspelling (technically a “single nucleotide polymorphism” or SNP) in a gene on chromosome 1 that codes for lamin A, a protein that is a key component of the membrane surrounding the cell’s nucleus. This SNP results in progerin being produced instead of lamin A, but researchers don’t yet understand how that leads to the changes of rapid aging.
What is Zokinvy?
The new drug, Zokinvy, is a farnesyltransferase inhibitor that helps prevent the buildup of defective progerin or progerin-like protein. It is dosed by height and weight and comes in two strengths. The capsules are given twice daily. It’s not cheap. A year’s treatment may cost $650,000.
The most common side effects include nausea, vomiting, diarrhea, infections, decreased appetite, and fatigue. A full list of reported side effects can be found here. It is contraindicated if the patient is taking strong or moderate CYP3A inhibitors and inducers, midazolam, or the cholesterol-lowering medications lovastatin, simvastatin, and atorvastatin. Some patients developed lab test abnormalities, and eye toxicity was seen in animals, so periodic lab tests and eye exams are recommended.
The new drug is not a cure, and the evidence is not gold-standard
Approval was based on its demonstrated effectiveness in 62 patients from two single-arm trials that compared it to matched, untreated patients from a separate natural history study. Patients treated with Zokinvy lived an average of 3 months longer than untreated patients through the first 3 years of the study, and an average of 2.5 years longer through the maximum follow-up time of 11 years. This is not the kind of rigorous evidence we usually demand before a drug is approved. It’s small, with a historical comparison group, and is not placebo-controlled or double-blinded. Orphan drugs are allowed to meet less rigorous standards, and in this case there is no other FDA-approved treatment for progeria and the condition is uniformly fatal. Most patients die of cardiovascular disease by the age of 13. So in this case, relying on lesser quality evidence is probably justified.
Conclusion: A welcome but expensive treatment for a rare disease
Children with Hutchinson-Guilford progeria are intelligent, personable, and cherished by their families. I think most families would gladly spend what they could to keep them alive 2.5 years longer. But the cost will be prohibitive for most families, and it’s not yet clear how health insurance companies and government will respond.

Vyleesi: New Drug for Hypoactive Sexual Desire in Women
New drug to treat hypoactive sexual desire in women, Vyleesi, is not very effective and has several drawbacks. It is NOT Viagra for women.
Harriet Hall on July 23, 2019
Tweet

The FDA has approved a new drug, Vyleesi (bremelanotide) that has been hyped as “female Viagra”. It is no such thing. Viagra is used to treat erectile dysfunction in men who have sexual desire but are unable to perform. Vyleesi is used to treat women who don’t have sexual desire but want to. That is a real problem for some women, but the new drug is far from an ideal solution. It’s not very effective and is problematic in other ways.
Vyleesi is a drug marketed for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD has been estimated to occur in up to one-third of adult women, but most estimates are much lower. It is defined as:
the persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity with marked distress or interpersonal difficulty not otherwise accounted for by a general medical or psychiatric condition…[it] may be primary or secondary, lifelong or acquired, or generalized or situational.

Distress is critical for diagnosis; some women have a low libido or even a total absence of interest in or desire for sex but are not bothered by it. Some people can best be categorized as “asexual”.
What is Vyleesi?
Bremelanotide is based on a compound that was first studied as a possible tanning product. It activates melanocortin receptors. The mechanism of how it could work to improve sexual desire is unknown. It was approved by the FDA following two clinical trials. It’s not for sale just yet, but it will probably be available in September. There is not yet any information on pricing or reimbursement. One prediction is that it may cost $50-75 per dose, with an anticipated average of four doses per month. Its long-term effects have not been studied.
It must be injected under the skin of a woman’s abdomen or thigh at least 45 minutes before she anticipates sexual activity. Use is limited to once in 24 hours and eight times per month. It is not indicated for post-menopausal women. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The company website lists numerous warnings and precautions. Its safety in pregnancy has not been studied; patients are advised to use effective contraception and to stop Vyleesi if they suspect they might be pregnant. It transiently increases blood pressure and decreases heart rate. A whopping 40% of users reported nausea; 13% required anti-emetic therapy. Focal hyperpigmentation occurred in 1% of patients. Besides nausea, the most common adverse reactions (<4%) included flushing, injection site reactions, headache, and vomiting. It may slow gastric emptying and interfere with absorption of oral medications.
There have been two phase 3, randomized, double-blind, placebo-controlled trials. They have not yet been published, but the results are reported on the company website. Both studies showed a statistically significant increase in self-reported sexual desire and a significant decrease in self-reported distress. But the effect was modest. 25% of users reported an increase of sexual desire compared to 17% of those who got placebo. And there was no significant difference in the number of satisfying sexual events.
Other options
There is one other FDA-approved drug for HSDD: flybanserin, sold under the brand name Addyi. It is a tablet that must be taken regularly, once a day. It costs $426 for a month’s supply. It has not been widely adopted. It can’t be used with alcohol because it can interact to cause hypotension and syncope, and providers have to be specially certified to prescribe it. In clinical trials, the benefits were statistically significant but not impressive. After adjusting for placebo, only around 10-12% of subjects reported even minimal improvements in sexual desire, and it did not improve the ability to orgasm or the quality of sex.
Counselling, cognitive behavioral therapy, and the drugs buproprion, buspirone, and testosterone (used off-label) have also been tried for HSDD with limited success.
Is hypoactive sexual desire disorder even a legitimate diagnosis?
The diagnostic category of HSDD has been criticized on several grounds. It is poorly defined and may have more of a social function than a medical one. It may be a diverse group of conditions and may have many causes. The requirement that it causes distress may be problematic. The parameters of normality are not yet well understood. HSDD has been accused of medicalizing sexuality and pathologizing normal variations.
Conclusion: Not very effective, and problematic
I don’t see a great future for Vyleesi. The restrictions and adverse effects are cause for concern, especially the 40% incidence of nausea. Patients have to plan for injection 45 minutes before sex, and then it only increases desire without increasing the number of satisfying sexual events. How often can women plan sex 45 minutes ahead? What about spontaneity? Why would a woman want to take something that makes her horny but doesn’t lead to satisfaction?
Women who have low libido and want to raise it don’t have any really good options, especially if they are past menopause. The FDA-approved drugs are only for premenopausal women who meet certain criteria. They are not very effective, the risks are substantial, and I predict that not very many women will choose to use them.

TENS for Pain Relief: Does It Work?
TENS units are used to relieve pain and for other indications. The evidence is not impressive.
Harriet Hall on July 21, 2020
Link

I was first introduced to TENS by physical therapists during my training. They made it sound like a wonderful way to relieve pain, and I was expecting to hear more about it. As the years passed, I heard it mentioned less and less. I wondered why.
TENS stands for Transcutaneous Electrical Nerve Stimulation. TENS units are devices that produce electrical currents for therapeutic purposes, usually for pain relief. They are used in physical therapy clinics, and there are many brands of portable stimulators for home use. These are typically battery-powered and have electrodes that attach to the skin with gel pads. The evidence is mixed. There are positive clinical studies but also negative studies and there is controversy over when to use TENS and what settings to use. It is not the treatment of first choice for any condition.
In ancient history electric fish and eels were reportedly used to relieve pain, but that was before anyone understood what electricity was. Development of today’s TENS device is attributed to a 20th century American neurosurgeon. It has been used to treat many conditions, including acute and chronic pain from temporomandibular joint dysfunction, migraine, postoperative pain, childbirth, dysmenorrhea, cancer, knee osteoarthritis, diabetic neuropathy, phantom limb syndrome, muscle knots, endometriosis, multiple sclerosis, injuries, fibromyalgia, and carpal tunnel.
TENS units have also been used for erotic stimulation. No comment.
How does it work?
It works by both peripheral and central mechanisms. It was found to release endogenous opioids in the brain, but endogenous opioid release has also been implicated in the placebo response. The duration of pain relief may be up to 24 hours, but for some patients the pain returns as soon as they switch off the device.
Contraindications and safety
Pregnancy, epilepsy, heart problems, and pacemakers are generally considered contraindications, although it is used in pregnancy to treat labor pains. TENS is generally safe, although contact dermatitis and allergic reactions have been reported, as have fainting and nausea. They recommend not using TENS units while driving or operating heavy equipment. Habituation might lead to reduced effectiveness or even to increased pain. Applying the electrodes to some locations is contraindicated: over the eyes, transcerebrally, on the front of the neck, internally, on broken skin and wounds, through the chest, over the spinal cord, and over a tumor.
What does the evidence show?
There have been many studies of TENS for treating various kinds of pain, and there have been many systematic reviews and meta-analyses. Numerous organizations have reviewed the evidence and issued statements. I can’t cover them all here, but I’ll provide some examples to give you a sense of the scope of the evidence.
Medical News Today said “Due to a lack of high-quality research and clinical trials, researchers have not yet determined whether TENS is a reliable treatment for pain relief”.
The American Academy of Neurology issued guidelines saying TENS is not recommended for chronic low back pain because research shows it is not effective. They also commented that TENS can be effective in treating diabetic nerve pain, but said more research is needed.
Medicare covers part of the cost of rental of TENS units for acute post-operative care for up to 30 days, and purchase of TENS units for chronic pain lasting at least 3 months. It must be medically necessary and prescribed by an authorized provider.
Aetna considers it experimental and investigational for most conditions, and will only pay for its use in acute postoperative pain and certain types of chronic, intractable pain.
A 2014 review found inconsistent evidence but concluded “Systematic reviews suggest that TENS, when applied at adequate intensities, is effective for postoperative pain, osteoarthritis, painful diabetic neuropathy and some acute pain conditions”.
A 2020 study found TENS superior to placebo for postoperative pain relief.
A 2020 meta-analysis based on four studies found TENS somewhat effective for tinnitus.
A Cochrane review found conflicting effects of TENS for the pain of rheumatoid arthritis.
Another Cochrane review was unable to assess the effectiveness of TENS for phantom limb pain and stump pain because they found no randomized controlled trials to evaluate. A 2015 Cochrane update found “tentative evidence” that TENS was superior to placebo for acute pain, but found that the studies had high risk of bias and there was incomplete reporting.
A 2018 meta-analysis of 12 RCTs concluded “These results suggest that TENS does not improve symptoms of lower back pain, but may offer short-term improvement of functional disability”.
In PainScience, Paul Ingraham reviewed the evidence for TENS and found that the systematic reviews were mostly negative or inconclusive. He concluded:
it probably mostly doesn’t work much better for most pain than an aspirin, and it’s not much good for anything else except maybe some relaxation or gently exercising muscles in rehab…it probably works well enough for some patients to be worth trying if you’re desperate…but keep your expectations low
He considers it a form of sensation-enhanced placebo.
Conclusion: Inconclusive evidence
I have to agree with Paul Ingraham that there is some evidence for using TENS for some pain conditions, but that it doesn’t appear to be very effective for anything else.
I agree that it may be worth trying for patients who are desperate, but they should keep their expectations low. Or they could try standing on an electric fish, as reportedly used in ancient times. TENS is undoubtedly more convenient than electric fish, although it would not be as acceptable to those who want “natural” remedies.

Your gout, your fault?
Is gout a consequence of lifestyle choices? Or is it mainly genetics?
Scott Gavura on December 13, 2018
Link


You or someone you know may have experienced gout before. It’s excruciatingly painful, debilitating, and not an event that anyone wants to repeat. Diet and alcohol consumption are regularly cited as causes of gout, and it’s widely believed that gout is a something you bring upon yourself, usually as a result of an indulgent lifestyle. This belief has been around for centuries – as long as gout has been documented. Gout used to be a status symbol – only those with enough wealth (and food) might be lucky enough to have a gout attack.
But what effect does diet really have on gout? While specific foods are undoubtedly aggravating factors, it’s also been known for some time that there is a genetic component to gout. However, the relative contribution of genetics vs. dietary choices is not as well understood. A new paper suggests that the impact of dietary choices on the causes of gout may be small, and that your genetics, not your diet, may be the primary factor influencing your risk of gout. So if you’ve had a gout attack, must you change your diet permanently? That’s the question that this new paper attempts to answer.
What is gout?
Gout is a consequence of excessive uric acid in the blood. Uric acid is produced by the body as a part of metabolism, and it is normally eliminated in the urine. Uric acid is only poorly soluble in blood, and when it crystallizes out of the blood (as urate) and into joints or the skin, it causes the condition known as gout. The big toe is affected in about half of cases, and it appears like a sudden case of inflammatory arthritis, causing swelling and pain.
Treating gout, once you have it, focuses on reducing pain and inflammation. Gout attacks will eventually go away on its own, but medication will reduce pain and hasten resolution. The non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used, as are steroids, and colchicine, whose natural source (autumn crocus) was used to treat inflammation and swelling as far back as 1500 BCE. Most people need to treat a gout attack for about a week before symptoms resolve.
There are several factors that are associated with gout. Sex (males more than females), increasing age, race/ethnicity, and genetics – which we’ll come back to.
Once you’ve had one gout attack, you’re at risk of another. The focus then shifts to prevention. Lowering the blood level of uric acid is the goal, and that can be accomplished primarily through medication (a topic for another post) and lifestyle changes, which shift the balance of uric acid production (via the liver) and uric acid elimination (via the kidneys). Weight loss in the obese reduces uric acid levels. Medications can lower uric acid levels, which may be part of a long-term strategy to reduce urate deposits in the body. The other major intervention tends to be dietary changes, with the focus on reducing the consumption of foods that increase uric acid levels.
The relationship between diet and gout risk has been implicated for centuries. Through anecdotal observation, consumption of red meat, shellfish, alcohol, sugary beverages, and alcohol have been linked to a raised risk of gout. Dietary interventions, like the DASH diet and the Mediterranean diet have conversely been linked to reduced uric acid levels.
Despite dietary interventions and weight optimization, some people remain more at risk of gout, because of non-modifiable risk factors. This brings us to this new paper, which examines the relative contribution of diet and genetics to uric acid levels in a healthy population.
The latest study
This new paper is entitled “Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts“, was published in The BMJ, and is from Tanya J Major and colleagues. It was a meta-analysis, or a study of studies, of five different studies. The objective was to examine the relationship between diet and serum urate levels, evaluating the relative contributions of diet and genetics to serum urate. In total the researchers had data on over 16,000 individuals (mainly of European ancestry) who did not have gout and were not taking drugs that would affect uric acid levels. Participants had uric acid levels measured along with dietary data and other demographic factors that might affect gout risk. Genetic risk factors were also identified. The primary measure was average serum urate levels and the variance in serum urate levels.
Diet and urate levels
Fifteen foods were found to be significantly associated with serum urate levels in the total, male, or female cohort.
Increased serum urate levels
    • Beer
    • Liquor
    • Wine
    • Potatoes
    • Poultry
    • Soft Drinks
    • Meat (beef, pork, lamb)
Decreased serum urate levels
    • Eggs
    • Peanuts
    • Cold cereal
    • Skim milk
    • Cheese
    • Brown bread
    • Margarine
    • Non-citrus fruit
The paper breaks down the differences between the males, females, and the full cohort, as well as the association with different diet scores. Here is the full table, which you’ll need to enlarge to view.

What’s remarkable is how modest the dietary effects are on serum urate levels, individually and in total:
Individually, the 14 food items associating with serum urate in the full cohort explained 0.06% to 0.99% of the variation in serum urate levels, and summed they explained 3.28% of the variation (table 1). All 63 food items, when summed, explained 4.29% of variation in serum urate levels (supplementary materials, table S5). Food groups (fruit, vegetables, meat, and dairy products) explained between 0.16% and 0.52% of variation in serum urate levels (supplementary materials, table S5). Unadjusted by the genetic risk score, the DASH diet score explained more of the variation in serum urate levels in the full cohort (0.28%; table 2) than the Healthy Eating (0.15%), Mediterranean (0.06%), or data driven (0.16%) diet scores, but each diet score explained less variation in serum urate than the most strongly associated individual food items (table 1).
Emphasis added.
Genetics had a much larger effect, and when you consider genetics, the food effects themselves are smaller:
In contrast, 30 genetic variants previously associated with serum urate levels at a genome wide level of significance in Europeans additively explained 8.7% of the variance in serum urate levels in the full cohort (excluding the NHANES III study; supplementary materials, table S8). A weighted serum urate genetic risk score constructed from these 30 variants,14 unadjusted by any dietary score, explained 7.9% of the variance (table 2). When included in models with the dietary scores, the percentage variance explained did not substantially change in the full, male, and female cohorts (maximum difference of 0.04%; table 2). The percentage variance explained by the dietary scores after adjustment for the genetic risk score fluctuated from a −0.09% difference for the data driven diet pattern in the male cohort to a +0.13% difference in the Mediterranean diet score in the male cohort (table 2). Genome wide estimations of serum urate heritability explained 23.9% of variance in serum urate levels in the full cohort (excluding the NHANES III study). The heritability estimates were 23.8% in the male cohort and 40.3% in the female cohort. Only the DASH diet score showed any evidence for an interaction with the weighted genetic risk score, and only in the female cohort (P=0.04); for all other interactions the P value was ≥0.21 (supplementary materials, table S9).
Emphasis added.
An accompanying editorial to this paper notes that these findings replicate the results of previous studies, but also note that correlations identified between potatoes, peanuts and margarine are new, and require confirmation.
There are several limitations to this study. The biggest limitation is the problem with food frequency questionnaires which are notoriously unreliable, and which differed slightly between the different studies that made up the meta-analysis. Secondly, this was a study in healthy patients, not patients that have gout, so a closer examination in those with gout is essential. This was also a group of patients who were mainly of European ancestry, living in the United States, so how far these findings can be generalized is not clear. It’s also important to note that this study doesn’t look at the impact of modifying diet on the risk of gout attacks, or whether specific foods can trigger gout in predisposed individuals.
Genes over diet?
Individual food choices contribute no more than 1% of an effect on serum urate levels, and diets overall appear to have very little influence. Genetic factors, conversely, are strongly correlated with urate levels and overall are responsible for over 20% of the variation in urate levels. While this is not a study of patients with gout, or a comparison of dietary changes vs. medication management, it does give further weight to the need for medication to help manage uric acid levels. This study should also give some reassurance to patients and health providers that, like so many other medical conditions, “blaming the patient” for their circumstances is harmful and wrong.

Making Waves or Just Noise? A Look at Shockwave Therapy
Scott Gavura on April 24, 2025
Link
I’ve been a runner—on and off—for over 25 years. For years, my goal was qualifying for the Boston Marathon. But I was never quite fast enough for my age group. At one point, I figured if I could just hold my best marathon time for another 20 years, I’d eventually “age into” a qualifying time. Unfortunately, my musculoskeletal system has other plans. Every time I increase my training intensity or distance, something breaks down. Usually, it’s Achilles tendinopathy—the bane of every runner’s existence.
Extracorporeal Shockwave Therapy (ESWT) is commonly offered as part of rehabilitation programs. Introduced in the 1980’s it is a non-invasive treatment used for a wide number of musculoskeletal disorders, including plantar fasciitis, Achilles tendinopathy, and rotator cuff disease. Through the delivery of acoustic waves to targeted tissues, ESWT is thought to to stimulate and accelerate healing and reduce pain. Despite widespread use, the efficacy of ESWT is not clear, with mixed results in clinical trials Given I’m currently limping and cursing my Achilles, I felt it was a good time to review the evidence and controversy associated with ESWT, so I’ll be better prepared when it’s offered to me at my next physiotherapy appointment.
What is ESWT?
ESWT delivers pressure waves (“shock waves”) using a handheld device applied to the skin. Compared to the more common ultrasound, ESWT is lower frequency, but higher energy. Shock wave therapy is used to (effectively) treat kidney stones, and it’s changed that surgical procedure into a treatment that doesn’t require an incision. The idea with ESWT seems to be that it stimulates healing by creating controlled microtrauma: promoting increased blood flow and cellular repair. The therapy has also been proposed to “reset” pain signaling pathways, leading to a decrease in perceived pain. It has also been suggested ESWT can disrupt chronic inflammation, encourage tissue repair, and even break down calcific deposits, particularly in tendons and fascia. However, the mechanism of action – if there is one – is not well defined, nor has it been proven.
How ESWT is used
ESWT is commonly used to treat musculoskeletal injuries. These include plantar fasciitis, Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis (tennis elbow), calcific tendinitis of the shoulder, and even stress fractures. Treatment protocols vary depending on the condition, but generally involve a series of sessions over weeks during which focused or radial shockwaves are applied to the affected area. Energy levels or “doses” start low and are increased as tolerated. The non-invasive nature of ESWT, coupled with its relatively low risk profile, has made it an appealing option for both clinicians and patients seeking alternatives to surgery.
Evidence For and Against ESWT
Given ESWT is so widely available from health care professionals, it would be reasonable to assume that there is a good evidence base for the therapy – but that is not the case. While there are some positive trials, there are also negative trials and the overall body of evidence is surprisingly poor.
A 2008 trial found that radial ESWT significantly improved pain and function in a randomized controlled trial in 245 patients with chronic plantar fasciitis compared to placebo. The UK National Institute for Health and Care Excellence (NICE) has cautiously endorsed ESWT for plantar fasciitis and Achilles tendinopathy, stating that while evidence is limited, it supports its use under certain protocols. Additionally, some evidence supports its use in non-union fractures and patellar tendinopathy, though these indications are less well studied.
Despite some promising results, the overall evidence base for ESWT is inconsistent and often methodologically weak:
The Cochrane Collaboration looked at ESWT for rotator cuff disease and concluded that, with moderate certainty, it does not improve pain and function compared with placebo. The review noted small sample sizes, a variety of treatment protocols, inconsistent outcome measures, and short follow-up durations.
A 2024 scoping review of ESWT evaluated methodological and reporting qualities of published systematic reviews on tendinopatihes. It included 18 systematic reviews and noted the overall methodological quality was “critically low”, with only 16% of studies having a low risk of bias.
A 2024 systematic review and meta-analysis examined the effects of ESWT on rotator cuff tendinopathy. It include 16 randomized controlled trials with over 1000 patients. It concluded ESWT significantly improved pain and function compared to control groups. However, the authors noted that the evidence is currently limited and “further research and clinical trials may be required”.
A 2024 critical overview analyzed eight systematic reviews and meta-analyses on ESWT for knee osteoarthritis. It concluded the methodological quality of these reviews was generally unsatisfactory, with only 3 out of 49 outcome indicators assessed as moderate quality, with the rest rated at low or very low quality, suggesting that the reliability of the results of systematic review and meta-analyses is compromised by the poor quality of the included studies. ​
Friend-of-the-Blog Paul Ingraham has an extensive article on ESWT, reviewing far more articles. He noted “bizarre lack of quality research”, which does not substantiate the hype about this therapy. Moreover, the mechanisms of action remain poorly understood, and there’s ongoing debate over whether the observed benefits are due to the shockwaves themselves or placebo and contextual effects (I’m looking at you, acupuncture).
Side Effects
ESWT seems to be generally well tolerated, but it can cause pain at the application site as well as bruising, skin blistering, edema, and skin and nerve irritation. Exacerbation of symptoms has been reported. More serious adverse events are rare, through there are case reports of Achilles rupture following tendinopathy treatment. There is general advice to avoid anti-inflammatory drugs after treatment – not because there is any evidence against this but NSAIDs are thought to have a negative impact on tissue healing. ESWT is not recommended in a number of clinical conditions (e.g., patients with clotting disorders, pregnancy) or in certain locations (e.g., over growth plates in children, around gas-filled tissues). The poor research quality may mean that short- and longer-terms harms have not been described.
Pseudo-Quackery?
ESWT is big business in rehabilitative and sports medicine. It’s expensive and potentially painful, but the benefits have not been clearly established. While there is published evidence to support some uses, the broader evidence base has significant methodological limits, conflicting results, and a lack of high-quality, long-term studies. How ESWT works remains unclear. Its benefits maybe driven more by placebo, hype and hope than by a true physiological effect. Until there is better evidence, clinicians and patients alike should look at ESWT cautiously. As for me, I’m not planning on ESWT for my Achilles pain. Boston will have to wait – as long as I’m still running in my sixties, I may have a chance.
    • 

An Alternative to Appendectomy: Antibiotics
Harriet Hall on August 18, 2015
Link


My title doesn’t refer to alternative medicine, it refers to an alternative within medicine: treating appendicitis with antibiotics instead of surgery. You may be surprised to learn that patients with appendicitis don’t always automatically need an appendectomy. A recent randomized controlled trial in Finland compared surgery to medical treatment.
History of appendicitis treatment
There is an excellent, detailed history of appendicitis available online, complete with anecdotes illustrating its importance. The appendix was not mentioned in early anatomical studies, probably because they were done on animals that didn’t have an appendix. The organ was first described in 1521. The existence of appendicitis (called “typhlitis” until 1886) was gradually recognized during the 19th century, and by the end of that century surgical removal of the appendix had become the standard treatment. Walter Reed, the yellow fever researcher for whom the Army hospital was named, died of a ruptured appendix. King Edward VII’s coronation was delayed while he underwent a life-saving appendectomy.
Appendectomy predated antibiotics, and it was believed that appendicitis would invariably progress to perforation. Once antibiotics were available, doctors experimented with treating appendicitis with them instead of with surgery, starting as early as 1956. The published trials had limitations, so the new study was done to try to get a more definitive answer to the question of whether the antibiotic approach was as effective as the surgical approach.
The study
They enrolled 530 patients age 18-60 with uncomplicated acute appendicitis confirmed by CT scan. They originally screened 1,379 patients; 849 of those were excluded because they didn’t meet the inclusion criteria. 337 had complicated appendicitis, 351 had other findings on CT, 18 were outside the prescribed age range, 116 refused to participate, and 27 were rejected for other reasons. Patients were randomly assigned to antibiotics or to surgery using the open operative approach.
In the group assigned to surgery, one patient did not get the surgery because his symptoms resolved before surgery could be performed (demonstrating that spontaneous remission can occur). The other 272 patients assigned to surgery had successful surgery and were cured. In the antibiotic group, 70 of the 256 antibiotic-treated patients (27%) eventually underwent surgery either during the initial hospitalization (15%) or during the 1-year follow-up period. The study failed to show that antibiotic treatment was non-inferior to surgery: their predetermined criteria of non-inferiority was that fewer than 25% of patients treated with antibiotics would later need surgery; in this study, 27% did. They looked at some secondary outcomes: the length of hospital stay during the original hospitalization was shorter in the surgery group but patients in the surgical group took more days of sick leave (19 days vs. 7 days). 55 patients in the antibiotic group had to be re-admitted, accumulating even more hospital days. The overall complication rate was greater in the surgical group (20.5% vs. 2.8%), but the surgical complication rate for the patients in the antibiotic group who eventually needed surgery was lower (7%) than in the surgery group (20.5%).
They concluded that “most” patients (73%) treated with antibiotics did not need later surgery, and those who did had no significant surgical complications.
Criticism of study
A commenter on the PubMed site pointed out that non-inferiority trials to answer this question are not in the best interests of patients. They assume that avoiding appendectomy is an advantage, they allow too large a margin for failures, and they don’t compare the overall benefits of both approaches (they didn’t address the risks and complications of surgery).
Previous research
A 2011 Cochrane review called the evidence for antibiotics “inconclusive” and the quality of studies low to moderate, and concluded that surgery was still the treatment of choice, while antibiotics might be used in specific patients or conditions where surgery is contraindicated.
A meta-analysis published in the British Medical Journalin 2012 looked at complications, efficacy of treatment, length of stay, incidence of complicated appendicitis, and readmissions. It concluded:
Antibiotics are both effective and safe as primary treatment for patients with uncomplicated acute appendicitis. Initial antibiotic treatment merits consideration as a primary treatment option for early uncomplicated appendicitis.
In 2014, a systematic review covering 900 patients found fewer immediate complications with antibiotics (18%) than with surgery (25%) but more subsequent failures. After one year of follow-up, only 63% of patients treated with antibiotics were asymptomatic and had had no complications or recurrences.
A more recent meta-analysis published earlier this year found that the antibiotic approach caused harm. The rate of major complications with antibiotics (10.1%) was significantly higher than the rate of major complications with appendectomy (0.8%). They calculated a number needed to harm (NNH) of 10.7, and a risk ratio of 7.71. In other words, one out of every 10.7 patients treated with antibiotics would have complications, and they were 7.71 times more likely to have them than patients treated with surgery.
Other considerations
In the past, diagnosis of appendicitis was problematic. Not every patient had the classic symptoms of right lower quadrant pain and acute tenderness over McBurney’s point. And not every patient with classic symptoms had appendicitis. Historically, the accuracy of diagnosis was only around 80%. A lot of normal appendixes were removed, and that was considered unavoidable: better to remove a few normal ones than miss the ones that would perforate and kill the patient without surgery. Fortunately, modern imaging techniques allow a much more reliable diagnosis today. The accuracy of ultrasound is between 71 and 97%. The accuracy of CT scanning is between 93 and 98%, but it does have disadvantages (cost, radiation exposure, complications from contrast media).
Most of the studies involved open appendectomy. Since 1993, a safer procedure has been available: laparoscopic appendectomy. Its advantages include a smaller incision, less pain, fewer infections, shorter hospital stay, and quicker recovery. Its disadvantages include increased cost and longer operating times. It is not suitable for every patient: there are contraindications such as a perforated appendix or dense adhesions from previous surgeries. It is much more widely available in the US than in other countries.
Surgery solves the problem once and for all, providing peace of mind. Antibiotics can have side effects. Patients who eventually need surgery after antibiotic treatment are exposed to unnecessary worry, suffering, repeat hospitalization, time off work, etc. I’m not a lawyer, but I wonder if patients who had complications following antibiotic treatment might successfully sue their doctors for not following the standard of practice.
Antibiotics may be the better option for some patients, but we don’t yet have any reliable way to identify which patients those are. And it’s clearly not for everyone. In this study, only 530 out of the original 1,379 patients screened were considered eligible for antibiotic treatment.
Alternative medicine alternatives for appendicitis
Here’s what integrative medicine guru Dr. Andrew Weil has to say:
While there is no alternative to surgery as a treatment for appendicitis, you should request an intravenous (IV) drip of high doses of vitamin C during the operation. High levels of vitamin C speed the healing of surgical wounds. If there’s time (since surgery for appendicitis usually is done on an emergency basis, there may not be), make a tape of healing statements to be played while you’re under anesthesia. A study conducted at Beth Israel Hospital in New York showed that patients who heard taped positive affirmations while they were under anesthesia required 50 percent less postoperative medication than a control group. After surgery, you may be able enhance the healing process with healing touch therapy such as Therapeutic Touch and Reiki, two forms of energy medicine.
There are websites that offer home remedies in lieu of treatment by doctors. Among other questionable remedies, drinking a quart of buttermilk a day is recommended to treat chronic appendicitis and consuming small quantities of green gram (mung beans) thrice daily is recommended to treat acute appendicitis.
A naturopath claims to have cured several cases of appendicitis with a regimen of high dose IV vitamin C, constitutional hydrotherapy, thymus extract, and an herbal tincture.
An acupuncture website recommends palpating the appendix point on the lower leg to diagnose appendicitis. It says complications can occur during a surgical operation, but there are no complications of not having one. That’s wrong-headed. The complications of not having surgery include rupture, peritonitis, and death.
What about chiropractic? According to chiropractic theory, appendicitis should not develop if the spine is in proper alignment. On a chiropractic forum, a second-year chiropractic student answered the question “Can chiropractic help appendicitis” by saying “HELL NO!!” but claimed that chiropractors are trained in detecting appendicitis. A chiropractic website has an account of curing appendicitis with prayer.
Homeopathy offers many treatment suggestions. One website says “Every case of appendicitis needs professional evaluation by an experienced homeopathic physician before deciding if it is suitable for surgery or homeopathy.”
Needless to say, none of these alternative treatments have been scientifically tested, and most of them are highly implausible. In my opinion, patients who rely on them instead of treatment by a mainstream doctor are risking their lives.
Was I wrong?
The recent study was brought to my attention by a reader. He remembered a SkepDoc column in Skeptic magazine where I wrote that we didn’t need to do randomized controlled trials to test appendectomy, and he thought this new study proved me wrong. I’m always happy to admit it when I am wrong, because it means I have learned something. But in this case I am not persuaded that I was wrong. My point was that we don’t need to do RCTs for things that are well established like the usefulness of parachutes when jumping out of airplanes. The efficacy of appendectomy for appendicitis is well established, and the new study did not question it. In fact, they used appendectomies as the gold standard fallback when antibiotics failed. The study did not question whether appendectomy worked; it was only asking if antibiotics might also work and if surgery might be avoided in some cases. By analogy, there is no need to do an RCT asking if parachutes work, but there might be a reason to do an RCT someday if someone invents a contraption, perhaps with some kind of wings and high-tech bubblewrap, that might offer equal or better protection.
Conclusion: A valid choice that must be made by patients
I think most people would want the most effective treatment for a potentially fatal disease, and if they chose a less effective treatment they would need to have a very good reason to do so. The Cochrane review found that the effectiveness of surgery was 97.4%, antibiotics 73.4%. If I had appendicitis, I would choose surgery because I would want to be sure the problem had been dealt with and would not recur. But the evidence shows that antibiotic treatment is a valid alternative for patients who are unable or unwilling to have surgery.

Appendicitis: Surgical vs. Medical Treatment
Surgery or antibiotics for appendicitis? This new study can help with the decision.
Harriet Hall on November 24, 2020
Link

The standard treatment for appendicitis has long been appendectomy, the removal of the appendix. The successful use of antibiotics instead of surgery was first reported in 1956 by Dr. Coldrey in the British Medical Journal, and since then there have been several randomized trials of antibiotics in adults, but they have all suffered from flaws. They excluded important subgroups like patients with appendicoliths (“stones” in the appendix) and the sample sizes were small. Questions remained about applicability to the general population. More than 95% of patients with appendicitis still get an appendectomy. The COVID-19 pandemic has prompted doctors to reconsider many aspects of health care delivery. The CODA trial (Comparison of Outcomes of Antibiotic Drugs and Appendectomy) was reported in The New England Journal of Medicine on November 12, 2020. It included patients with appendicoliths and it recognized that not all patients prioritize the multiple outcomes related to appendicitis care in the same way. This large, pragmatic, non-blinded multicenter randomized comparative effectiveness trial found that antibiotics were noninferior to surgery. But an accompanying editorial advised, “proceed with caution”.
Study design
1,552 American adults with appendicitis were randomly assigned to get either an appendectomy or a 10-day course of antibiotics. Diffuse peritonitis was one of the criteria for exclusion from the study, but evidence of perforation on imaging studies was not, unless complications were observed. Antibiotics were initially given intravenously for 24 hours, followed by oral antibiotics for 10 days. 47% of patients in the antibiotic group were treated as outpatients. The primary outcome was 30-day health status as assessed with the European Quality of Life- 5 Dimensions (EQ-5D) questionnaire. Secondary outcomes were an eventual need for appendectomy in the antibiotic group and complications at 90 days. Outcomes were compared for patients with and without appendicoliths. Decisions about which antibiotics to use or when surgery was needed for a patient in the antibiotic group were left up to the treating doctors.
Results
Some people refused to be randomized; only 39% agreed to randomization. An appendicolith was seen on imaging in 27% of patients. Quality of life: the 30-day EQ-5D results were the same in both groups. At 90 days, 29% of patients in the antibiotic group had required appendectomy. Patients in the antibiotic group who had an appendicolith were more likely to eventually need an appendectomy: 41% compared to 25% who didn’t have an appendicolith. Most appendectomies were performed laparoscopically. Complications were more common in the antibiotic group (8.1 vs. 3.5 per 100 participants); but only in those with an appendicolith (20.2 vs. 3.6 per 100 participants). The rate of serious complications was higher in the antibiotic group than in the surgical group (4.0 vs. 3.0 per 100 participants). More patients in the antibiotic group required hospitalization for any reason, including for appendectomy (24% vs 5%). Patients randomized to surgery missed more days of work (8.73 vs. 5.26). Patients in the antibiotic group had more visits to the Emergency Department and spent more time in the hospital. There were no deaths in either group. Another consideration was the identification of unsuspected neoplasms: nine were found in surgical specimens, but there is no data on whether early detection improved outcomes.
In an accompanying editorial, Dr. Danny Jacobs urges caution. He would recommend surgery for uncomplicated cases and he thinks most providers would agree. But he acknowledges that the advantages of the antibiotic option may be greater during public health emergencies like the COVID-19 pandemic. He mentions the dreadful health care disparities in our society and the adverse impact of social determinants, structural bias, and racism. He recommends that individual characteristics, preferences, and circumstances be taken into consideration. The effects of racial or ethnic group, location, insurance status, and socioeconomic status may affect quality of life and could lead to poorer outcomes.
Conclusion: Much to think about
There were patients with appendicitis long before surgery was feasible and before antibiotics were developed. And not all of them died. Some lucky individuals recovered with no treatment of any kind. Not treating is no longer a serious option for most people except perhaps for the few who believe in faith healing, but which option is best for the individual patient? There are many factors to consider, but at least now we have more information to go on. For one thing, this new study tells us the presence or absence of an appendicolith can make a difference. And we can involve patients in more realistic informed consent.

Ian Harris on “Surgery, the Ultimate Placebo”
Ian Harris explains that more than half of commonly performed surgical operations may be placebos. Adequate studies using a blinded control group are essential.
Harriet Hall on October 27, 2020
Link

Ian Harris, a Professor of Orthopaedic Surgery at the University of New South Wales in Sydney, Australia, wrote a book titled Surgery, The Ultimate Placebo. I haven’t read the book, but I watched his excellent YouTube video lecture on the subject. It is an eye-opening evaluation of commonly performed surgical operations that have been tested and shown to be no more effective (and arguably worse) than placebo, or that have never even been tested. He covers the history of sham surgery studies, talks about placebo effects, and explains why so many surgeons ignore the evidence and continue to do ineffective operations. In the process, he provides a valuable education in critical thinking.
His introduction to skepticism at age 18 was a documentary on television where dowsers were subjected to an elegant controlled test by James Randi and Dick Smith. They buried ten pipes and challenged dowsers to determine which pipe the water was flowing through. When they knew which pipe was active, the dowsers all identified it correctly; but when they didn’t know, they were only right 12% of the time. He was impressed by how a simple test could easily refute a claim.
When he watched the same documentary again recently, he was impressed by the reaction of dowsers when shown that dowsing didn’t work. He recognized it as the same reaction he was seeing in surgeons when their operations were tested and shown not to work. They made up excuses, hypotheses about why the experiment might not have given the results they expected, and said they wouldn’t give up doing the operation, “because it works”.
In the early 20th century, a common operation for heart disease was internal mammary artery ligation. It seemed obvious that it worked: patients felt better. In 1939, a sham surgery experiment showed that an equal number of patients got better if the surgeon just made an incision but didn’t ligate the arteries. Surgeons heeded the evidence and stopped doing that operation.
He takes us on a historical tour of surgical operations that have been tested and shown not to work. Surgeons often reject the evidence and make up rationalizations as to why it might not have worked in those studies, but they remain convinced that it does work in their hands. When they refuse to stop doing that operation, their excuses sound just like those of the dowsers. They insist on continuing to do the operation “because it works” (in their experience). Billions of dollars are being wasted on hundreds of thousands of operations that have been shown not to work or that have never even been tested to see if they work better than doing nothing.
False analogies and faulty reasoning
Theory often says an operation should work, but biological plausibility means absolutely nothing unless tests can show that it really does work. Dr. Harris says “You can make up a biologically plausible mechanism for anything you want.”
The parachute analogy says you don’t need a randomized controlled study of parachutes to find out if they work. Dr. Harris says he has seen it frequently invoked, usually for procedures that are later shown to be rubbish.
Comparative effectiveness studies are done comparing two different methods of something like steroid injections for back pain, but they don’t tell us whether either of them work. They would be better called comparative ineffectiveness studies. The first step should have been to use a control group and compare steroid injections to no injections.
Perceived effectiveness
Perceived effectiveness is a combination of two things: the treatment’s specific effects plus its placebo effects.
There are shortcuts in thinking that all humans are hard-wired to take. They assume correlation means causation, and they fall for the post hoc ergo propter hoc fallacy (assuming that if B follows A that must mean that A caused B). These shortcuts in thinking often lead to errors. Improvement might be due to something other than the surgery, like the natural history of the disease, regression to the mean, or concomitant treatments.
Improvement can be perceived by the patient (sometimes it is a false perception due to placebo factors or misinterpretations) and/or by the doctor, due to factors like measurement error, reporting bias, confirmation bias, etc. Doctors rate the effectiveness of their treatments higher than their patients do. The perception of the doctors is wrong; they consistently overestimate the benefits and underestimate the harms of their treatments.
Treatment is not always needed
He tells the story of Archie Cochrane, for whom the Cochrane Collaboration of systematic analyses was named. As the only doctor in a POW camp in World War II, he was responsible for 10,000 prisoners, many suffering from open wounds, dysentery, typhoid, and other serious diseases. His requests for doctors and medicines were denied by his German captors, who said doctors were superfluous. In six months, only 4 prisoners died, each of them shot while trying to escape. The rest all got better, without treatment.
Harris’ story distorts the truth, but it serves as a vivid illustration of an important fact: recovery often occurs without any treatment. Cochrane’s experience led him to question much of what was being done in the name of medicine. Patients were kept in bed for a week after a heart attack not because of any evidence, but just “because it makes sense”. Cochrane did a controlled study and found that bedrest was actually harming people.
Surgery often acts as a placebo
Harris covers the many factors that affect a patient’s response to a placebo. A systematic review found that placebo was just as effective as surgery in over half of the cases studied, and all of the recent trials comparing surgery to placebo have found that surgery was no better than placebo.
He demolishes all the arguments surgeons give for continuing to do these operations that have been tested and shown not to work. The real reason is that they continue to believe the procedure is effective, just as the dowsers continued to believe they could find water with a forked stick. Tradition and personal experience triumph over science and reason.
Science is just a systematic way to reduce error. Imperfect, but better than any other way. Blinded trials are the least biased way to determine effectiveness.
Ethical concerns
Some people object that doing sham surgeries is unethical. Placebos are unethical in clinical practice for treating an individual, but not in research where they are essential to finding the truth and balancing harms and benefits for large groups of people and for preventing future harms. Surely, it’s unethical to perform ineffective surgeries. On Science-Based Medicine, we are constantly questioning the ethics of selling dietary supplements with claims that have never been properly tested. Some herbal medicines might be harmless, but surgery always carries a risk of infection, tissue damage, and adverse effects. And it is expensive: millions of dollars are being wasted worldwide on procedures that expose patients to risk for no possible benefit.
Conclusion: Evidence is essential
He concludes by saying we should treat new surgical procedures like new drugs, and only pay for those that are part of a trial to find out if they work. Most surgical procedures being done today have not been subjected to blinded trials.
Advice to patients: it’s OK to ask for a second opinion, and you should always ask your surgeon for the evidence showing the benefits and risks of the procedure, and what you can expect to happen if surgery is not done.

The Apple Heart Study
A recent study involving the Apple Watch raises some interesting points about modern clinical trials. It also has some implications and conclusions about screening for atrial fibrillation (a. fib).
Christopher Labos on December 12, 2019
Link

The Apple Heart Study, recently published in The New England Journal of Medicine, is perhaps one of the largest studies of the modern era. It enrolled over 400,000 patients to evaluate the Apple Watch and test it in “real world” settings to see whether it was effective in diagnosing arrhythmias. Any new tech gadget invariably gets a lot of media coverage and the size and scope of the Apple Heart Study is objectively impressive, but the results of the study are slightly more nuanced than some headlines suggested.
First, how does this impact clinical trials?
While people use the term “game-changer” far too much in medical journalism, we should acknowledge that the Apple Heart Study was a massive undertaking and used a radically different approach to study recruitment. It enrolled over 400,000 patients, which is a huge trial. While not the largest in clinical trial ever done (the March of Dimes was able to launch a study of 1.3 million children to test Jonas Salk’s polio vaccine in 1953), it is still impressive. The Apple Heart Study also recruited patients “virtually” by leveraging the power of the Internet. Rather than recruiting patients through their physicians or via a physical testing center, they recruited them through a downloadable app, which means patients could enroll in the study from home, without actually visiting any specific site. Enrolling 400,000 patients in 9 months, as this study did, is no mean feat, and would not have been easy using traditional recruitment methods. Given how difficult it is to recruit patients into clinical trials, this type of Internet-based study recruitment might be something we will be seeing more of in the near future.
But the scale of the study obscures some downsides. Since patients had to already have their own Apple Watch and iPhone, and had to download the app to participate and record the data, the patient population skewed towards the young, the wealthy, and the healthy. In the study over half of the participants were under 40 and only 6% were over age 65. With our ageing population demographic, that was not quite a representative sample.
As a consequence of the young age of the participants, very few patients actually had an irregular heartbeat during the trial. This is not entirely surprising since heart disease becomes more common with age (age is arguably the most important risk factor for heart disease). In fact, only 0.5% of the people enrolled in the Apple Heart Study ended up receiving an alert from their watch. Sadly, most people seem to have ignored these alerts. The study protocol required people to go get a proper heart monitor (in this case an ECG patch they would wear for 7 days to determine if they actually had an arrhythmia). But only about one in five people who got an alert from their phone actually complied. In the end, only 450 people submitted their ECG patches for analysis, which makes the Apple Heart Study fairly small by most measures.
This loss to follow-up is perhaps not totally surprising. Downloading an app on your phone is easy, but making a doctor’s appointment is hard, or at the very least, time consuming. So many of these young, and presumably otherwise healthy individuals, probably just ignored the alerts from their Apple Watch or looked into it with their own physicians without notifying the study personnel.
Unfortunately, loss to follow-up is a major problem in clinical trials. Usually, the staffs of clinical trials spend a great deal of time and effort following up with patients and making sure they follow through on the research protocol. However, with this type of “virtual recruitment” it simply wasn’t possible. To what extent this loss to follow-up affected the results of the Apple Heart Study is hard to say. Perhaps the Apple Watch study would have done better with more data points for researchers to analyze, or perhaps it would have done worse if more healthy people with no other problems were thrown into the mix. The most interesting aspect though, is that if “virtual recruitment” is going to be the future of clinical trials, then we need to work out how we are going to deal with the problem of people deciding to drop out.
Now on to the study itself.
What were they actually testing?
At its core, the Apple Heart Study was trying to do something that is quite difficult. It was trying to prove that population screening for atrial fibrillation is a good idea.
Atrial fibrillation is a very common arrhythmia that affects 2.7 million Americans and increases the risk of stroke. To prevent this rather severe complication, many patients with atrial fibrillation (or a. fib for short) are given blood thinners. There has been considerable research over the years looking into who should get blood thinners. In brief, anyone with risk factors for stroke (advanced age, having diabetes, high blood pressure, heart failure or a previous stroke) is generally prescribed these medications.
But screening for atrial fibrillation is not as easy as it seems. Screening implies testing a large number of symptom-free individuals to find a previously undiagnosed disease. And screening is a low yield activity that can generate many false positives. To understand why, consider the following theoretical scenario. Imagine a population of 1 million where about one thousand people have a.fib.
	Have a.fib	Do not have a.fib	Total
Total	1,000	999,000	1,000,000
Now imagine we give all these people an Apple Watch to try and detect a.fib. Let’s assume for the simplicity that the Apple Watch is 99% accurate in its analysis. This means that for the 1,000 people who have a.fib, we will correctly identify 990 of them, and miss 10.
	Have a.fib	Do not have a.fib	Total
Apple Watch detects a.fib	990		
Apple Watch does not detect a.fib	10		
Total	1,000	999,000	1,000,000
Now for the 999,000 people who did not have a.fib, we will correctly identify the heart rhythms as normal for 99% of them, or 989,010 individuals. It will also make an error with 1% of them and think 9,990 are having an arrhythmia when they are not.
	Have a.fib	Do not have a.fib	Total
Apple Watch detects a.fib	990	9,990	
Apple Watch does not detect a.fib	10	989,010	
Total	1,000	999,000	1,000,000
So the Apple Watch will record atrial fibrillation in 990+9,990 = 10,980 patients and call 989,020 patients as normal.
	Have a.fib	Do not have a.fib	Total
Apple Watch detects a.fib	990	9,990	10,980
Apple Watch does not detect a.fib	10	989,010	989,020
Total	1,000	999,000	1,000,000
In this fictitious patient population, you can be pretty certain that if your Apple Watch calls your heart rhythm normal, then it is probably normal. Only 10 of the 989,020 people who were recorded as having normal heart rhythms were misdiagnosed. In other words, there are few false negatives.
	Have a.fib	Do not have a.fib	Total
Apple Watch detects a.fib	990
(true positives)	9,990
(false positives)	10,980
Apple Watch does not detect a.fib	10
(false negatives)	989,010
(true negatives)	989,020
Total	1,000	999,000	1,000,000
But its positive predictive value (PPV) is somewhat low. Of the 10,980 patients where the Apple Watch alerted its users to an abnormal rhythm, only 990 had a.fib in our example and the rest were false positives. Its PPV is actually 990 ÷ 10,980 = 9.01%. In other words, when detected a.fib we were only right 9% of the time.
Again, this was theoretical example to illustrate a point. But it’s useful to see what would happen if we took our same scenario but tested it in another population of one million people where atrial fibrillation was more common. In this population, where 10,000 people (or 1% of the population) have atrial fibrillation we can reconstruct the same table we did above.
	Have a.fib	Do not have a.fib	Total
Apple Watch detects a.fib	9,900	9,900	19,800
Apple Watch does not detect a.fib	100	980,100	980,200
Total	10,000	990,000	1,000,000
In this case, the negative predictive value is still quite high. If the Apple Watch does not detect a. fib then the patient likely does not have it. Only 100 of the 980,200 people with normal recordings were misdiagnosed. The negative predictive value is still over 99%.
But the PPV has improved. Of the 19,800 people in whom a.fib was detected, there were 9,900 who did actually have a. fib. This means that a positive reading from the watch is correct 50% of the time.
What we can see from these two hypothetical examples is that the usefulness of the test improves when you test it in a population where more people have the disease. We unfortunately cannot reconstruct a table like this for the Apple Heart Study because only the people with abnormal notifications went on to get further testing to confirm the arrhythmias. But what we do know from the main result of the paper is that of the people who got an abnormal alert from their Apple Watch (and who followed the protocol to get further cardiac monitoring) only 34% had a confirmed atrial fibrillation on subsequent monitoring. In other words, the positive predictive value was 34%. What’s interesting is that for people under the age of 40, who made up most of the population, the positive predictive value was only 18%.
Why the Apple Watch did so poorly is not hard to see. Atrial fibrillation is a very common arrhythmia but it is very unusual to get it at a young age. About 9% of people over age 65 have a.fib, while only 2% of people under age 65% have it. For people under 40, who were half the study population, a.fib is quite rare.
So what does the Apple Watch study mean?
The Apple Watch clearly works and is obviously an improvement over the previous generation device where the Positive Predictive Value was only 8% in one of their study cohorts. That means it was generating false positives 92% of the time. The problem with the Apple Watch and screening for a.fib is that the Apple Watch is invariably bought and used by young, otherwise healthy individuals in whom a.fib is rare and in whom the Apple Watch will generate many false positives. The other problem is that it’s not clear what to do with short episodes of atrial fibrillation in young people. Even if you do make a diagnosis of atrial fibrillation, you wouldn’t necessarily give someone blood thinners if they were young and had no other risk factors. Also, most people would only give someone a diagnosis of atrial fibrillation if the arrhythmia lasted for more than 30 seconds, which is the definition used in this study. What to do with people who have brief episodes that last only a few seconds is less clear.
The problem with the Apple Watch is not its technology, it’s how we use it. Because even good tests and good technology fail if you use it on the wrong group of people.

An Owner’s Manual for the Heart
Harriet Hall on January 24, 2012
Link
In writing about science-based medicine, we give a lot of attention to medicine that is not based on good science. We use bad examples to show why science is important and how it is frequently misapplied, misinterpreted, misreported, or even wholly rejected. It’s a pleasure, for a change, to write about a straightforward example of the best of science-based medicine in action. The book Heart 411 is such an example.
The medical literature is a jungle of conflicting and complicated studies. It’s difficult for novices and even for sophisticated non-specialists to navigate. It’s useful to have experts as guides who can apply their knowledge, experience, and judgment to analyze the data and put everything into perspective. I can’t imagine anyone more qualified as guides to “matters of the heart” than the authors of this book. Heart surgeon Marc Gillinov and cardiologist Steven Nissen practice at the Cleveland Clinic, which has been ranked as the number one heart hospital by U.S. News & World Report for the last 15 years and is currently ranked 4th best hospital overall. They have treated more than 10,000 heart patients over 30 years of clinical practice and have also done extensive research and published hundreds of articles in peer reviewed journals. Their book contains everything they would like their patients to know about the prevention, diagnosis, and treatment of heart disease. It amounts to an owner’s manual for the heart. 
They begin with a valuable explanation of different levels of evidence and how to spot flaws in clinical studies, covering everything from surrogate endpoints to publication bias. They go on to cover risk factors old and new, the role of cholesterol, weight, diet, exercise, how tests are done and when they are not indicated, stents vs. surgery, heart failure, arrhythmias, sex differences, children, and predictions about future advances in the field. I was amused by one chapter title: “Vitamins and supplements: Trick or treatment?” recalling the title of Singh and Ernst’s book.
The book is a goldmine of information. Here is a sampling of just a few of the items that caught my eye for one reason or another:
    • Only 20% of our cholesterol comes from diet; the liver manufactures the other 80%.
    • Forget about special lipid tests: the standard lipid panel tells you all you need to know.
    • Statins are incredibly useful but some are more effective than others.
    • Red yeast rice is a “natural” alternative to prescription statins that is risky because dosage is uncontrolled and 1/3 of products contain chemicals that are toxic to the kidneys. 
    • A “low fad” diet is best for weight loss; calories matter, not the proportions of macronutrients. The Ornish, Esselstyne and Pritikin diets are not recommended: they explain why.
    • Saturated fats in the diet contribute to heart disease; studies showing otherwise are flawed because they only compared high fat diets to other unhealthy diets.
    • The first coronary angiogram was an accident.
    • Cardiac catheterization via the wrist is safer than via the groin, but only 10% are done by that route in the U.S. compared to 60% in Europe.
    • Chelation for heart disease is nothing but “a wallet biopsy” and is dangerous.
    • Stents do not prevent heart attacks; they only limit damage from heart attacks in progress.
    • Surgical checklists save lives: make sure your surgeon uses them.
    • A normal heart ejects at least 50% of the blood from the ventricle with each heartbeat; but some patients function well with an ejection fraction as low as 10%.
    • One type of LVAD (left ventricular assist device) pumps the blood continuously, so these patients do not have a pulse!
    • Mixing supplements with prescription drugs is as dangerous as mixing drinking and driving.
    • If vitamins and supplements are going to be used as medicines, they must be tested using the same rigorous standards we use for prescription drugs.
    • The data on fish oil are questionable. If you’re going to take it, they recommend a specific brand: Carlson Super Omega 3.
    • They disagree with the American Academy of Pediatrics and would not use statins in children under the age of 13 even if they are at high risk from familial hypercholesterolemia.
    • The deficits of so-called “pump brain” after open heart surgery are probably not attributable to the pump.
    • Eliminating cardiovascular disease would increase life expectancy by 7 years, compared to 3 years from eliminating cancer
    • Although existing studies are not definitive, the evidence indicates that the Mediterranean diet is probably the best diet for heart health.
The book validates what I had previously written about heart disease, statins, diet, weight loss, and other subjects. I was reassured to know I’d gotten those things right, but I also learned a number of new things from it. They clarified one point I had been wondering about. Why do cardiologists tell patients to limit their egg intake when most of our cholesterol is manufactured in the liver? They explain that there are good reasons to restrict cholesterol and saturated fat in the diet, even for patients on statins: the contribution of diet is small but still significant, and a low fat diet permits a lower dose of statins, minimizing the risk of side effects.
The stress is on prevention: they estimate that 90% of heart attacks are preventable. They would be glad to be put out of business. They say
Don’t worry about us; we will gladly hang up our scalpel and stethoscope if we can find a better way to lead you to a heart-healthy life.
The book was written for the general public but is equally appropriate and informative for doctors and scientists. The promotional material says “If you have a heart, you need this book.” Even if you don’t “need” it, I certainly think you would find it worthwhile, whether you are a layman or a doctor treating heart patients.

The Monoclonal Antibody Revolution
Monoclonal antibodies are the medical scientific breakthrough you may never have heard of.
Steven NovellaonJune 7, 2023
Link

If you ask the general public or members of the press what the most exciting or powerful medical developments have been in recent decades they will likely mention things that are more hype than reality. Stem cells, antioxidants, superfoods, and magnetic therapy might get a mention. CRISPR will also likely get mentioned, and this is a genuinely exciting technology, but still in its infancy as a therapeutic tool. l doubt many non-experts would put at or near the top of their list monoclonal antibody therapeutics, even though this technology has been quietly revolutionizing medicine in the last decade.
Even as a physician its possible to have not noticed the scope of change that has occurred. There are new monoclonal antibody (mAb) products in my subspecialty, but it takes time to notice that every subspecialty seems to have them. What’s going on?
The first monoclonal antibody was created in 1975, and the first therapeutic product was licensed in 1986. Yet mAbs are only now coming into their own as a mature medical treatment. The basic technology involves the isolation of a single B cell, the type of cell in the immune system that makes antibodies. Antibodies are proteins that have two binding sites with variable affinity for another protein or substance, called an antigen (a target binding site for an antibody). Normally an immune response involves producing lots of B cells with variable antibodies, a sort of “shotgun” approach to immunity. This blankets possible antigens, and then gets more specific as the immune system learns how to better target the invading organism or substance. Such an immune response is called polyclonal, or many-cloned, because many different types of antibodies are produced.
A monoclonal antibody, or single clone, involves isolating a single B cell (which makes one specific clone of antibodies) and then reproducing it, so that you can make a lot of a single clone of antibodies. The initial technique for doing this was injecting an animal, such as a rat, with an antigen in order to produce an antibody response, then isolating a single B cell that produces an antibody against that antigen. This B cells is then hybridized with an immortal B cell, taken from a cancer such as myeloma, but one that does not produce antibodies of its own. You then hopefully have an immortal B cell that creates the antibodies you want. You then culture that cells for mass production.
The basic technology existed almost 50 years ago, so why are we only now seeing so many mAb therapeutics? Because I am glossing over a lot of complexity. First, you have to select a B-cell that produces an antibody with the desired affinity that does not also cross-react with other proteins you don’t want (causing side effects). Also, because an animal is used, there are non-human protein sequences on the mAbs that can trigger their own immune response, an immune reaction against the mAbs themselves. One workaround for this was to partially humanize the mAbs, joining the part of the antibody with the desired affinity to a human antibody base. It also took decades to develop the technology to the point where it was cost effective to mass produce mAbs as a pharmaceutical product.
The technology to mass produce human or humanized mAbs with the desired affinity is also only half of the equation. You also need to identify a therapeutic target – what are you going to target the mAbs against. This requires research into the mechanisms of specific diseases. Of course this was already happening. Essentially now, when a therapeutic target is identified, pharmaceutical companies can develop traditional drugs that chemically react with the target, and/or they can develop mAbs with affinity for the target.
Essentially we crossed a fuzzy threshold where mAb technology has progressed to the point that it is medically and economically feasible to quickly develop and mass produce mAb products. This technology also allows for a level of personalized medicine. You can identify specific targets on an individual patient’s cancer and then target that. To put recent progress into perspective, in 2014 there were 30 mAbs approved by the FDA (and this is after they already started to take off) and the global market was estimated at $30 billion. In 2022 it was estimate at $188 billion, and is growing fast. As of December 2022, the FDA has approved 153 mAbs, and there are 140 products in late stage development.
As a therapeutic choice there are positives and negatives to mAbs. First, they are not chemical drugs, so they don’t interact with other drugs, and they don’t have to be processed by the liver or eliminated by the kidneys like many other drugs. They can also be highly specific in their affinity, which can reduce the side effect profile. Because they are proteins they are given as injections or IV infusions. This has both advantages and disadvantages. Getting a self-injection once a month, for example, may be preferable to many people than taking a daily pill. This also can improve compliance. However, some people are needle-phobic.
Perhaps the biggest disadvantage of mAbs is that they are expensive. Even though the cost has come way down, it may still cost thousands of dollars per year for mAb treatment. While the therapeutic potential is great for patients, we are potentially adding billions of dollars to already high health care costs. Insurance companies are pushing back, and it is often challenging to get approval for new mAb therapies. To some extent this makes sense – we need to practice cost effective medicine, and it does not make sense to replace a drug that costs a couple hundred dollars per year with one that costs 6-7 thousand per year for a small incremental improvement. Costs are likely to come down as technology and mass production improve, but mAbs are likely to remain relatively expensive for years. In a way, it’s a good problem to have, but it still is a serious issue.
Monoclonal antibodies are a fascinating technology that has been around for a long time but is just now really coming into its own as a therapeutic tool. They show the power of scientific medicine, but also the challenges, and how long it can take to go from new discovery to have a large impact on the practice of medicine. I find it interesting that attention and media hype is often aimed in the wrong direction. Perhaps the mAb “revolution” was too slow, or too diffuse, to make sexy headlines. The story of mAbs also stands in contrast to many hyped but not legitimate treatments – new treatments do not come out of nowhere. They have a long history, and involve the work of countless scientists and organizations working over decades. Understanding and appreciating real scientific developments makes it easier to recognize the fake ones.

Air Dryers vs Paper Towels
Which hand drying method is the best, air or paper towel? The answer is more complicated than you might think – but do wash your hands.
Steven Novella on October 24, 2018
Link
This seems like an almost comically mundane topic, but it is one we face on a regular basis, and can be extremely important in certain environments. Which method of drying hands is superior – hot air dryers, paper towels, or the newer jet air blades (which blow room temperature but fast air)?
I was reminded of this issue while traveling recently in the UK. Almost without exception, all public bathrooms I visited had hot air blowers, often with self-congratulatory signs indicating that these were the environmentally friendly option. Always the skeptic, I suspected that the issue was likely far more complicated than that, and it is.
First we need to define our question, specifically what criteria will we use to determine which method is superior. I found studies looking at several criteria: effectiveness of hand drying (including compliance), carbon footprint, cost, the degree to which bacteria and viruses are deposited on the hands during the drying process, and the degree to which bacteria and viruses are spread from the hands to the environment.
I also found that many studies were sponsored by either the paper towel industry, or the air blower industry, with entirely predictable results favoring their products or maligning their competitors.
Another layer of complexity is the assumptions made during the comparison. Not all air blowers are created equal, and some are more efficient than others. Also, paper towels can vary in thickness, and be made from recycled paper or be recyclable or not. The method of paper distribution also affects the average amount consumed by each user. Further, the source of electricity affects calculations of the overall carbon footprint.
Cost and carbon footprint
The consideration of cost is less important from a medical perspective, but often is what drives decision-making. Here there is a clear and consistent answer – paper towels are more expensive than either hot air or jet air dryers. Estimates of course will vary according to the relevant variables I listed above, but on average paper towels cost 2-3 times as much per month as hot air blowers, and 10-20 times as much as an air blade. In one comparison, for example, paper towels in a heavy use environment would cost $1,460 per year, while an efficient air blade just $48 per year. Up front costs are higher, but they pay for themselves within a few months of heavy use.
For many companies, that is the end of the comparison. For those interested in minimizing carbon footprint, the answer is similar. Paper towel vs hot air blowers are about the same. They overlap in carbon footprint depending on the relevant variables, so no clear winner there.
However, air blades have a lower carbon footprint than both, when doing a thorough lifetime analysis. Air blades have about one-third the carbon emissions per drying than the other two methods.
Effectiveness and hygiene
Here is where comparisons get fairly complex, although there does seem to be a reasonably clear answer. Unfortunately, the answer is completely flipped from the cost and carbon footprint comparison – with paper towels being the clear winner.
A 2012 systematic review found that paper towels dry hands more quickly and more thoroughly than the air dryers available at the time. They concluded:
This review found little agreement regarding the relative effectiveness of electric air dryers. However, most studies suggest that paper towels can dry hands efficiently, remove bacteria effectively, and cause less contamination of the washroom environment. From a hygiene viewpoint, paper towels are superior to electric air dryers. Paper towels should be recommended in locations where hygiene is paramount, such as hospitals and clinics.
This and other studies also show:
Also, air dryers that are used in many washrooms allow for only one user at a time and each person could take up to one minute to dry their hands. This is not convenient and often leads to avoidance or incomplete drying. In several studies, on average people spent just 22.5 seconds drying hands, and 41% wiped their hands unhygienically on clothes.
You might consider this an intention to treat analysis – if people aren’t compliant, it doesn’t matter how effective the intervention is. The authors of the review also point out that wet hands spread bacteria much more efficiently than dry hands, so just having more complete dryness is a significant advantage.
So here the bottom line appears to be that paper towels dry hands more quickly and effectively, and people use them more. With air dryers, people are more likely to incompletely dry their hands, or not dry them at all.
Air jet manufacturers would argue that their newer products are faster, solving the problem, but that remains to be seen in careful studies. The question, however, is a bit of a moving target as technology advances.
Recent attention has been paid to a number of studies looking at the spread of bacteria onto or from the hands during the drying process. Here the clear winner is also paper towels. A 2014 study found:
Jet air and warm air dryers result in increased bacterial aerosolization when drying hands. These results suggest that air dryers may be unsuitable for use in healthcare settings, as they may facilitate microbial cross-contamination via airborne dissemination to the environment or bathroom visitors.
A lot of attention was focused on a 2015 study that found that jet dryers spread 1,300 times more bacteria than paper towels. This study was criticized (mainly by Dyson, the maker of jet dryers) for being contrived – it used gloved subjects and exposed them to high amounts of bacterial contamination. It was more of a proof-of-concept study than real world study.
Regardless, there is a nice consensus of research that hot air blowers spread more bacteria and viruses from and onto user’s hands than paper towels, and jet dryers even more. As the authors note, this “suggests” that air dryers are less hygienic, but I could not find any studies looking at actual infection rates.
Bottom line
Given all of this, what is the best current decision regarding hand drying method in public spaces? The answer is – it depends. It depends upon your priorities.
If your major goal is minimizing carbon footprint or personal cost, than air jets are the way to go. If you want to maximize customer service, than it seems that most people prefer paper towels, given that they use them more and avoid or minimize their use of air dryers in high percentages. You can also provide both options and let patrons decide, depending on their preferences and current needs.
If, however, your primary goal is hygiene, which is the case in hospitals and other healthcare settings, then paper towels are the current clear winner. They dry hands faster, more completely, and minimize the spread of bacteria to the environment and cross contamination. Since hospitals are notoriously loaded with resistant infectious bacteria, this is clearly an important goal.
There are other considerations, however. Focusing on drying method ignores the issue of how hands are cleaned in the first place. There is clear evidence that washing hands thoroughly with soap is critical to good hygiene. If soap is used, then there is essentially no significant bacteria left to spread to the environment.
Further, hospitals generally use sanitizer, which contains alcohol and is self drying. The CDC recommends either washing with soap, or using a sanitizer with at least 60% alcohol to minimize bacteria. Some studies show that high alcohol content hand sanitizers are superior to hand washing for reducing bacteria, in fact. (Although hand washing is better for removing dirt.)
So wash your hands, use soap or sanitizer, and use whatever method is available to dry them effectively. Don’t let your hands drip dry, and don’t dry them on your clothes.

Everlywell: At-Home Lab Tests That Don’t Make Sense
EverlyWell offers 34 at-home tests for everything from IgG tests for food sensitivities to a Sleep and Stress test. Most of them make no sense and are likely to mislead customers.
Harriet Hall on June 4, 2019
Link

Here we go again! First I wrote about Theranos, then SmartJane, and now EverlyWell. More companies are jumping on the at-home testing bandwagon; apparently the convenience and the message of do-it-yourself empowerment appeal to enough customers to generate big profits. But most of these tests are not medically indicated and are more likely to mislead customers than to improve their health.
EverlyWell advertises “Lab testing made easy. Results you can understand.” They offer tests so you can learn about yourself. They say,
For each test, our medical team curates the biomarkers we think are the most useful and applicable to providing the health insights you care about [often they think wrong]. … Our tests are generally the same tests that your physician orders, and are supported by independent, peer-reviewed research.
I beg to differ. Some of the tests are tests that your physician would selectively order as part of a diagnostic workup for symptoms, but most of them are not supported by research as appropriate for screening purposes.
The two tests that they seem to be pushing are the Food Sensitivity Test and the Heart Health Test.
The Food Sensitivity Test
They actually offer two different food sensitivity tests. For $159 they measure IgG reactivity to 96 foods. For $249.99 you also get a saliva-based DNA test that looks for five specific genes that they think affect metabolism and absorption of certain foods and nutrients. Both tests are unreliable and not indicated.
The science of genetic testing has not yet advanced to the point that it is able to direct appropriate dietary changes for individuals. And testing for only five genes makes no sense: the expression of genes is affected by other factors and by genes they don’t test for or even know about.
As for IgG testing, the American Academy of Allergy Asthma and Immunology (and Scott) calls it a myth. They explain,
It is important to understand that this test has never been scientifically proven to be able to accomplish what it reports to do. The scientific studies that are provided to support the use of this test are often out of date, in non-reputable journals and many have not even used the IgG test in question. The presence of IgG is likely a normal response of the immune system to exposure to food. In fact, higher levels of IgG to foods may simply be associated with tolerance to those foods.
The Choosing Wisely campaign recommends against IgG testing for allergy. And our own Scott Gavura has spoken out against it after thoroughly reviewing the rationale and the evidence (or rather the lack of evidence).
The Heart Health Test
For $79, this fingerstick test measures total cholesterol, HDL, Direct LDL, Triglycerides, hs-CRP and HbA1c. Reputable science-based sources acknowledge the heart health implications of cholesterol and diabetes but they do not recommend screening for triglycerides or CRP. Experts stress the importance of blood pressure, weight, smoking, and exercise, none of which are addressed by EverlyWell. Along with the Heart Health test results, EverlyWell promises to offer guidance in the form of suggestions to jumpstart a healthier lifestyle, but those suggestions apply to everyone and do not depend on test results. You would be better off consulting your own physician who can evaluate all your risk factors, put them into perspective, advise you, and provide treatment like statins when indicated.
Other tests
They offer an astounding array of 34 tests. Some of them might make sense in some settings (HIV, HbA1c, Lyme disease test, thyroid tests, etc.) but your doctor should decide which ones to order. They should not be used indiscriminately as screening tests or just to satisfy idle curiosity. Some of them make no sense at all. I won’t try to cover them all, but here are some highlights:
STD Test – Male
For $199 they test a urine sample and a finger prick blood sample for chlamydia, gonorrhea, hepatitis C, herpes type 2, HIV, syphilis, and trichomoniasis. How does the validity of their tests compare to standard lab test results? We have no way of knowing. They claim to use certified, top-quality labs and reassure customers that:
Each partner lab we choose to work with is CLIA-certified (Clinical Laboratory Improvement Amendments). This means they have to meet high standards to obtain both state and federal certifications and submit themselves to regular inspections.
That’s not enough to reassure me. I’d like to know their false negative and false positive rates. Remember that Theranos had a 35% false negative rate on their syphilis tests.
If you test positive, “you’ll have the opportunity to connect with our independent physician network and may receive treatment.” May receive treatment? Wouldn’t it be better to consult your own physician who can not only order appropriate tests and interpret them but can treat you?
Heavy metals
For $199 they will test blood and urine for arsenic, mercury, cadmium, bromine, selenium and iodine. One woman’s testimonial says they found only a high cadmium level. She is worried and wants more information. I easily found some more information. Cadmium toxicity is seen mainly with high occupational exposure. A population study found that “Environmental cadmium exposure was associated with a [slightly] increased risk of all-cause, cancer, and cardiovascular disease mortality among men, but not among women” (which makes me question the validity of the results). Higher cadmium levels are associated with a modest increase in the risk of developing diabetes. There is cadmium in cigarettes; cigarette smokers have higher levels of cadmium. There is no treatment other than avoidance of exposure. Cadmium testing is not recommended as a screening test; since the prevalence of cadmium toxicity is so low, the false positives would far outnumber the true positives and would only cause unnecessary worry.
Breast milk DHA test
For $69, they will test your breast milk for DHA to “ensure that you have adequate DHA in your diet to supply your growing baby with the DHA that he or she needs”. Breastfeeding mothers should eat a healthy diet, but there is no need for this test, and no evidence that testing does any good.
Sleep and Stress Test
For $249, this tests fluctuations of “three vital hormones needed for a restful night’s sleep”: cortisol, cortisone, melatonin, and creatinine. Note: creatinine is not a hormone but is included as a control to make sure the other test results are accurate. Again, there is no need for these tests, and no evidence that testing does any good.
The research
They say they conduct original research, but the page listing “our studies” is a laughingstock. They list a grand total of three studies, all of them presentations or planned presentations at conferences, none of them controlled studies, none published in a peer-reviewed journal. They all amounted to simply collecting data from their customers:
     1.  “Women Aged 50 and Older Have a Significantly Lower Early Morning Urinary 6-Sulfatoxymelatonin (MT6) Level than Women Under age 50 in a Consumer-initiated At-home Sleep Test.”
     2.  Among women who took the Women’s STD panel test, 21% of women received at least one positive STD result.
     3.  STD results in men (they don’t even bother to describe this one).
Conclusion: designed for profit, not for health benefits
EverlyWell’s tests don’t make sense. Most of them are not medically indicated, and in the few cases where a test might be indicated, patients would be better off consulting their physician. Some of the tests, like IgG for food sensitivities, are known to be useless and are contraindicated. Others are questionable and not supported by evidence. The scientific community has carefully evaluated the evidence and listed recommendations for screening tests, and EverlyWell’s tests don’t qualify as rational screening tests. They may find a few true positives but are far more likely to find false positives.
I can foresee the fallout. Customers will be unnecessarily worried. They will wonder why their doctors didn’t do those tests. They will take the EverlyWell results to their doctors and the doctors will be left to pick up the pieces, to reassure them, to convince them that they don’t have a disease and that the test results don’t mean anything for their health. People will commit themselves unnecessarily to a restrictive lifelong diet that eliminates many of their favorite foods. Some good might come of it if customers are frightened into adopting a healthier lifestyle, but on the whole, I think these tests are likely to do far more harm than good.
This is marketing, not science. It benefits the company, not the customers. Caveat emptor.

Experts slam CAM lab tests, call for better regulation
Experts review the evidence and find that common CAM lab tests have “little or no clinical benefit” and are “a potential risk to patient safety.” Regulatory reform is urgently needed to protect the public.
Jann Bellamy on March 14, 2019
Link

Experts in pathology recently published a review of the evidence for CAM laboratory tests commonly used in the U.S., the U.K., and Australia. Their article, published in the Annals of Clinical Biochemistry: International Journal of Laboratory Medicine (article behind paywall), notes that CAM practitioners, such as naturopaths, “promote and sell a wide range of tests, many of which are of dubious clinical significance.” Some “have little or no clinical utility and are widely discredited.” Others are legitimate lab tests used for unvalidated purposes. The term “CAM testing” is used in the article to describe both types of tests; collectively, those with “little or no clinical benefit that represent a potential risk to patient safety.”
In my view, the authors have contributed an extremely important addition to the medical literature, for three reasons. First, there is far too little in the mainstream medical literature exposing the risks of CAM practices and CAM practitioners like chiropractors, naturopaths, and acupuncturists. Second, the article handily collects the most popular CAM lab testing scams into one convenient reference. Third, it serves as pushback to the infiltration of integrative medicine in the medical literature (also here and here), which treats CAM practitioners as valuable additions to the healthcare team, conveniently eliding the risks posed to patients by their pseudoscience, including dubious diagnostic tests, which, as the article points out,
are often accompanied by extensive clinical interpretations which may recommend, or be used to justify, unnecessary or harmful treatments.
Testing may be “particularly appealing” to CAM practitioners and their unwitting patients for several reasons, according to the authors, two of whom are with the departments of clinical biochemistry in London hospitals; the third is a retired Australian pathologist.
    • It adds “an element of science” to the office visit. Patients are aware that conventional medicine relies on diagnostic testing and may erroneously assume CAM testing gives them the benefit of a scientific approach.
    • Testing produces data to support a diagnosis, however bogus. CAM tests are “often ordered as large profiles of multiple analytes,” increasing the possibility of getting “abnormal” results purely by chance. CAM practitioners can then build a narrative around these “abnormal” results, especially with chronic conditions (such as chronic fatigue syndrome and fibromyalgia) without a definitive cause and with limited treatment options.
    • CAM practitioners make money by selling further testing, dietary supplements, or other treatments based on the “abnormal” lab results.
    • CAM practitioners can claim they are offering a unique service unavailable from conventional physicians. This is appealing to patients “with unexplained symptoms for which there are a limited range of evidence-based investigations and treatments available.”
The authors note that there are now labs around the world devoted solely to CAM testing. Some of these operate outside of any regulatory program, others are fully accredited to the same standards as established clinical labs. These labs often promote themselves as environmental, nutritional, natural medicine, or other CAM, specialists. Some sell directly to the public; others require a “health professional” to order a test but will actually accept orders from unlicensed naturopaths and nutritionists, who may order tests inappropriately or misinterpret the results. Some labs issue reports recommending therapies for the “abnormalities” detected by their testing.
The article offers a useful primer on how lab tests are evaluated per the American Association of Clinical Chemistry (AACC) framework (emphasis added):
Analytic validity of a test defines its ability to measure accurately and reliably the component of interest. . . .
Clinical validity defines the ability to detect or predict the presence or absence of an accepted clinical disease or predisposition to such a disease. . . .
Clinical utility refers to the likelihood that the test will lead to an improved outcome. What is the value of the information to the individual being tested and/or to the broader population?
Ethical, legal and social implications (ELSI) of a test. Issues include how the test is promoted, how the reasons for testing are explained to the patient, the incidence of false-positive results and incorrect diagnoses, the potential for unnecessary treatment and the cost-effectiveness of testing.
Their framework is essential to understanding the, in my view, tragically inadequate regulation of lab tests in the U.S., which directly contributes to the explosion of dubious lab tests now made available directly to consumers and via naturopaths, chiropractors, so-called “integrative physicians”, and the like. We’ll return to this topic, including draft legislation to address this regulatory gap now circulating in Congress, in a moment.
SCAM testing
The authors reviewed the evidence for over a dozen common CAM lab tests, noting “there are many others not covered in this review.” As is appropriate for a scientific journal and expert review, their analysis is at times highly technical. As a layperson, my summary of their analysis will not be, and I’ll add a few comments of my own.
Live blood cell analysis (or LBA, also known as dark-field video analysis, nutritional blood analysis)
LBA is done is real time, with the practitioner “interpreting” cell morphology and the presence of meaningless features in a sample of “live” blood viewed under a dark field microscope and displayed on a video monitor. The test can supposedly diagnose any number of diseases, from nutritional and energy “imbalances” to cancer. Merely describing this test should be sufficient for all but the most credulous to dismiss it as nonsense, but the authors actually found two studies of LBA. Big surprise: They showed the test lacked reliability, sensitivity, and specificity.
Interestingly, the authors note that labs performing LBA in the U.S. must be CLIA-certified for high complexity testing, which, according to a federal regulatory agency, is “virtually impossible” for a facility offering LBA. In other words, anyone performing LBA is very likely in violation of the certification requirement, which is exactly what the feds found in a 2001 audit of labs offering LBA.
SBM’s Mark Crislip did his own analysis of LBA and found it wanting as well. Yet, in 2014, the Washington State Board of Naturopathy declared that the Bolen Blood Procedure (which is either the same or a very similar type of blood analysis) was within the scope of naturopathic practice.
Leukocytotoxic tests: Bryan’s test, ALCAT test, MELISSA test
Bryan’s Test for allergies, a blood test, was found in controlled studies to have very poor correlation with known allergens, a high-false positive rate, and poor reproducibility, within-individual and inter-operator.
The manufacturer of the ALCAT test, a commercial, mechanized cytotoxic test, “supplies panels of hundreds of foods, environmental chemicals, food colorings, molds, herbs and some drugs.” Studies have found “no credible evidence” to support the test and several medical organizations internationally, including the American Academy of Allergy, Asthma and Immunology, have recommended against using ALCAT for the diagnosis of food intolerance or allergy.
MELISA is an assay used primarily for metal sensitivity and Lyme disease. Researchers independent of the commercial lab providing the test report that “MELISA is so non-specific as to be of no clinical utility.”
Food intolerance testing using food antigen-specific IgG4 antibodies
The authors found that food intolerance or sensitivity testing is widely available direct to consumer (DTC), often as a panel, some containing over 200 food components and often with an interpretive report recommending excluding foods from one’s diet. Advertising suggests that the test can identify foods responsible for a variety of symptoms, including “bloating, abdominal pain, fatigue, depression, irritable bowel and skin complaints.”
As SBM’s Scott Gavura explained (also here) IgG4 antibodies indicate food exposure, not sensitivity or intolerance. As these authors point out, there is no evidence that IgG4 testing is beneficial in determining food intolerance or food allergy, and dietary exclusion based on testing “would result in considerable overtreatment and potential harm from unnecessary dietary restriction, especially in children.” This is why, they note, many professional organizations recommend against IgG4 testing for clinical purposes.
Nevertheless, just last week, the Florida Association of Naturopathic Physicians newsletter touted IgG testing for food “sensitivity” as it can lead to “chronic health problems, including ADHD, digestive disorders, and persistent infection.”
Hair analysis for trace elements and minerals
This is a quack favorite, employed by naturopaths and functional medicine practitioners.
The authors of this journal article note that quantitation of trace elements in hair is usually offered for individuals with nutritional or toxicological concerns and test reports “often include detailed interpretation highlighting nutritional deficiencies or heavy metal toxicities and further investigations that may be required” and “recommending unnecessary treatments.”
The method is fraught with numerous difficulties, including, according to the CDC, variable collection procedures, sample preparation, and methodology; lack of standards; sample contamination; poor understanding of the biological processes underpinning element incorporation into hair; lack of reference ranges; and lack of correlation between element levels and target tissues. There are also questions over conflicts of interest because many CAM laboratories work in collaboration with CAM practitioners who sell treatments on the basis of “abnormal” hair test results. In sum, there is “little evidence to support the use of hair element analysis in routine nutritional or toxicological assessment.”
Antioxidant status
CAM laboratories commonly offer assessments of antioxidant status, ranging from a single analyte, such as reduced glutathione, to panels of vitamins or tests for total antioxidant status . . . [They] may claim that free radicals cause or aggravate many ailments, such as cancer, Alzheimer’s disease, heart disease, chronic fatigue syndrome (CFS) and dementia.
While free radicals may have a role in many conditions, the authors say the appropriate question is whether there is any clinical utility in measuring antioxidant status. As it turns out, the answer is “no” according to the only paper they could find addressing this question.
Even though this bogus testing is used to sell antioxidant supplements,
no regulatory authority has approved any antioxidant supplement for the treatment of any condition . . . [and there is] no evidence to support the use of antioxidant supplements in the primary or secondary prevention of chronic diseases or mortality. Supplementation with beta-carotene, vitamin A, and vitamin E may actually increase mortality.
Urine kryptopyrrole
Marketing of this test suggests it is useful in the diagnosis of many conditions, including bipolar disorder, schizophrenia and depression, but this review found no evidence in the mainstream, peer-reviewed literature that it is useful in any of those conditions or any other clinical purpose for that matter.
Mitochondrial function: neutrophil ATP profile
This test, according to the article, is marketed with the claim that its “ATP profile” correlates with physical disability in CFS and is “used to tailor unconventional therapies.” It is based on a study that has never been independently replicated or validated.
Candida testing
This is a popular CAM scam we’ve covered here on SBM. As the this article explains, CAM practitioners claim that low-level colonization with Candida can cause symptoms such as fatigue, muscle weakness, depression, and bloating, a “theory” that is widely discredited. Testing patients with non-specific symptoms “carries a high risk of false positive or clinically irrelevant results.” In addition to unnecessary supplements and dietary modifications, treatments include potent antifungal agents, which has resulted in “severe iatrogenic complications.”
Post-chelator challenge testing [PCCT]
Yet another CAM favorite and the subject of SBM posts (also here and here). As this article explains, agents that bind metallic elements from the body’s tissues (chelators) increases the excretion of these elements in urine. “In-house” laboratory assays, which have not been cleared by the FDA for clinical use, will show elevated metallic elements (e.g., mercury) which are then interpreted by practitioners “as an indication for ‘detoxification,’ sometimes involving powerful chelating agents that can have serious side effects and have caused a number of fatalities.”
Laboratories offering PCCT frequently report post-challenge metal excretion levels against reference intervals derived from unprovoked individuals. This inevitably leads to at least one ‘elevated’ results and opens the door to potential misinterpretation. So far as we are aware validated reference intervals and cut-offs for clinical toxicity do not exist for samples taken post-chelation.
The article points out that, despite being uniformly criticized by health professionals, toxicologists, and regulatory agencies, PCCT remains widely available, especially in the U.S.
Secretory IgA
Secretory IgA (sIgA) tests using stool and saliva samples are promoted by CAM practitioners “to assess immune health with claims that abnormal results may suggest autoimmune disease, asthma, allergy, infection, inflammatory bowel disease, dental caries and many other conditions.” (This includes the Florida Association of Naturopathic Physicians, which recommended IgA testing in its aforementioned monthly newsletter.) The stool test is also advertised as an alternative test for celiac disease. Yet, there is no convincing evidence, according to this review, that sIgA testing is useful diagnosis of any condition.
Testing using sIgA is likely to lead to further unnecessary investigation, anxiety and possibly inappropriate treatment, such as dietary exclusion. Screening for [celiac disease] using sIgA carries a significant risk of missing a potentially serious diagnosis.
Adrenal stress profile
Saliva samples, collected by patients several times during the day (“collection and sampling handling instructions vary significantly”), are analyzed for cortisol and DHEAS. The test results are often interpreted by CAM labs as adrenal dysfunction and used by CAM practitioners
to support the medically-unrecognized diagnosis of adrenal fatigue . . . [and] claim this poorly-defined adrenal dysfunction is caused by chronic physiological or psychological stress, resulting in a variety of non-specific symptoms. There is no consensus on criteria for diagnosis or recommended treatments, though the diagnosis is often used to justify the prescription of nutritional supplements. . . There are no published data validating the adrenal stress profile for the investigation or diagnosis of any condition.
You can find Scott Gavura’s posts on “adrenal fatigue” here and here.
Possible regulatory reform in U.S.
In sum, the authors of this excellent review say,
The common factor in all these tests is the lack of evidence for clinical validity and utility as used in CAM practice. This should not be surprising since this is true for CAM practice in general.
Indeed.
They find that inadequate regulatory oversight of CAM lab testing in the U.K., Australia and the U.S. is a big cause of the problem and should be remedied. (Of course, I would add that inadequate regulatory oversight of CAM practitioners is a big cause of the problem and should be remedied.)
Here in the U.S., the FDA abandoned its efforts to effectively regulate the use of laboratory-developed tests (LDTs), that is, tests developed and performed at a single laboratory, with all samples sent to that particular lab for testing. Many of the CAM lab tests fall into this category, which has been, and still is, only lightly regulated. While this is an oversimplification, as it now stands, LDTs are required to show only analytical validity, but not clinical validity or clinical utility. And I see no evidence that any CAM lab test manufacturer or marketer has ever thought about the ethical, legal and social implications of their tests, if they even know this consideration exists as part of the AACC framework.
Instead, the FDA, apparently realizing that it lacked the necessary authority to fully address the regulatory issues raised by the exponential growth in lab testing, turned to Congress for a remedy. This resulted in the drafting of a bill, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018, which would overhaul regulation of all in-vitro diagnostic testing, including LDTs. The VALID Act draft, which has bipartisan support, is now circulating in Congress.
Needless to say, stakeholders in the lab industry are not fully on board with a broad reworking of the lab testing regulatory scheme and, due to their lobbying, the draft will undoubtedly undergo substantial revision. We’ll have to wait to see what effect, if any, these efforts will have on CAM testing. In the meantime, CAM practitioners will continue to bamboozle patients into unnecessary and possibly dangerous therapies based on the results of dubious lab tests, which can themselves cause injury.

CHRONIC FATIGUE SYNDROME

IOM Recommends Replacing CFS with SEID
The Institute of Medicine has proposed replacing the terms chronic fatigue syndrome and myalgic encephalomyelitis with systemic exertion intolerance disease (SEID).
Harriet Hall on March 3, 2015
Link
Chronic fatigue syndrome (CFS) is a controversial diagnosis that has also been called myalgic encephalomyelitis (ME or ME/CFS), post-viral fatigue syndrome (PVS), chronic fatigue immune dysfunction syndrome (CFIDS), Iceland disease, “yuppie flu”, and many other names. A new report from the Institute of Medicine (IOM) says that none of those names really fit the disease and recommends it be re-named systemic exertion intolerance disease or SEID.
ME/CFS is thought to affect as many as 2.5 million Americans. The cause remains unknown, but in many cases it appears to have been “triggered by an infection or other prodromal event, such as immunization, anesthetics, physical trauma, exposure to environmental pollutants, chemicals and heavy meals, and rarely blood transfusions.” Some doctors question its very existence and interpret the symptoms as imaginary or psychological.
The IOM examines the evidence base
At the request of several government agencies including the NIH and the FDA, the IOM convened a committee of 15 experts to examine the evidence base for ME/CFS. They reviewed over 9,000 published studies and heard testimony from patients and advocates. Before publication, an additional 15 experts were asked to provide peer review. The full text of the report is available free online.
Few people will want to read the entire 304 pages, but dipping into it will give you a sense of the complexities of the issues, the rigor of their investigation, and the judgment that went into their recommendations. The section on history is particularly worthwhile.
They concluded that there was good evidence that ME/CFS is a real entity:
ME/CFS is a serious, chronic, complex, multisystem disease that frequently and dramatically limits the activities of affected patients.
They consolidated the published evidence to determine which symptoms were most representative of the disease, and they proposed new diagnostic criteria based on the best available evidence.
Problems with diagnosis
When CFS was first recognized as a new entity, it was thought to be associated with Epstein-Barr virus (EBV) and was called chronic EBV syndrome. When the relationship with the virus didn’t hold up, it was re-named chronic fatigue syndrome and a working definition was established for the purposes of research. That working definition was not originally intended for clinicians to use in diagnosing individual patients, but it was quickly adopted for that purpose without any formal validation.
Diagnosis has always been problematic: more than 70% of patients reported seeing four or more doctors before receiving a diagnosis. There have been at least 20 sets of diagnostic criteria or case definitions. One of the most commonly used is the Fukuda case definition, which requires prolonged fatigue that persists or relapses for 6 months or more, plus four or more of the following: impaired memory or concentration, sore throat, tender cervical or axillary lymph nodes, muscle pain, multi-joint pain, new headaches, unrefreshing sleep, and post-exertion malaise.
The problem with these definitions is readily apparent. Most of the criteria are subjective and not easily quantified. How much fatigue? How do you distinguish between physical fatigue and psychological fatigue? How much impairment of concentration? Everyone experiences fatigue and memory lapses; when does it become pathological? Even tenderness of lymph nodes relies on subjective patient reports and depends on how hard you press on them. Individuals with major depression, hypochondriacs, and the worried well might report enough of these symptoms to qualify. This is a very fuzzy area, and there is considerable overlap with other diagnoses like fibromyalgia, Gulf War syndrome, somatization disorder, etc. If we are going to study the condition, we want to make sure we aren’t studying a mixed bag of other conditions. In one study, 33.7% of healthy controls fulfilled the Fukuda definition.
New diagnostic criteria
The proposed diagnostic criteria for ME/CFS diagnosis requires that the patient have the following three symptoms:
     1.  A substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities, that persists for more than 6 months and is accompanied by fatigue, which is often profound, is of new or definite onset (not lifelong), is not the result of ongoing excessive exertion, and is not substantially alleviated by rest, and
     2.  Post-exertional malaise,* and
     3.  Unrefreshing sleep*
At least one of the two following manifestations is also required:
     1.  Cognitive impairment* or
     2.  Orthostatic intolerance
* Frequency and severity of symptoms should be assessed. The diagnosis of ME/CFS should be questioned if patients do not have these symptoms at least half of the time with moderate, substantial, or severe intensity.
A new name
They say the name “chronic fatigue syndrome” has done a disservice to many patients, and the name “myalgic encephalomyelitis” fails to describe the major features of the disease. They propose renaming it “systemic exertion intolerance disease,” a name that they think more fully captures the full scope of the disorder.
Problems with diagnostic categories
Unexplained symptoms are common and frustrating. Doctors have always been puzzled by patients who complained of fatigue and a variety of associated symptoms without any identifiable pathological cause. Today’s CFS patients would once have been diagnosed with neurasthenia, a diagnosis that has been abandoned. “Fad” diagnoses wax and wane in popularity as both patients and doctors strive to give unexplained symptoms a satisfying name.
The same constellation of symptoms might be variously diagnosed by different mainstream and alternative medical providers as CFS, fibromyalgia, chronic Lyme disease, Gulf War syndrome, post-traumatic stress disorder (PTSD), multiple chemical sensitivity, environmental sensitivity, candidiasis, and any number of fake diseases. However the symptoms start, they quickly become complicated by deconditioning. As patients exercise less, they become less able to exercise. Muscles atrophy with disuse, endurance declines. Confirmation bias sets in. The sick role becomes a self-fulfilling prophecy. Whatever the underlying pathology, the degree of suffering is affected by psychological factors. It is devilishly difficult to sort out the physical from the psychological and to know how best to help these sufferers. Current treatments are not very effective.
When does a group of symptoms become a syndrome or a disease? We do our best to divide human suffering into categories and apply labels, but in the absence of valid diagnostic tests and pathophysiologic explanations, we are working in the dark. At this point, we don’t have conclusive evidence, we only have the best educated guesses of experts based on the limited evidence we do have.
Conclusion
Whatever we call it, I think it is inevitable that until we have a better understanding of this condition (or conditions?) it will be over-diagnosed by some doctors, some patients will self-diagnose inappropriately, and research will continue to be problematic. Anything we can do to make the diagnosis more precise will be welcome. The IOM proposals are a step in the right direction.

Treating Chronic Fatigue Syndrome with Cognitive Behavioral Therapy and Graded Exercise Therapy: How the PACE Trial Got It Wrong
The PACE trial found that cognitive behavioral therapy and graded exercise therapy were effective treatments for chronic fatigue syndrome and could produce recovery in 22% of patients. It seems they got it wrong.
Harriet Hall on April 4, 2017
Link


Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), and the recently-suggested IOM term systemic exertion intolerance disease (SEID), is characterized by long-term fatigue and a host of other symptoms that impair the patient’s ability to function. It sometimes develops after a flu-like illness, but can also come on gradually with no apparent antecedent. The cause is unknown. There is controversy about the diagnostic criteria, and treatment has not been very successful. Between 8-63% of patients improve during follow-up, but fewer than 10% of adult patients return to pre-illness levels of functioning.
A 2001 review in the Journal of the American Medical Association (JAMA) found that cognitive behavioral therapy (CBT) and graded exercise therapy (GET) were the most promising treatments, but the evidence was mixed and the supporting studies had methodological inadequacies. They warned that positive results on subjective measures in these studies did not mean the participants had actually improved their physical capacities. The PACE trial was designed to look for better evidence.
The PACE trial
The PACE trial was published in The Lancet in 2011.
641 patients meeting Oxford criteria for CFS were randomized to four groups:
     1.  Specialist medical care alone (SMC): explanation of CFS, generic advice such as avoiding extremes of activity and rest, specific advice on self-help, and symptomatic pharmacology.
     2.  SMC plus adaptive pacing therapy (APT): helping the patient achieve optimum adaptation to the illness by planning and pacing activities.
     3.  SMC plus cognitive behavioral therapy (CBT): based on the fear avoidance theory that regards CFS as reversible and says fear leads to avoidance of activity, which interacts with physiological processes to perpetuate fatigue.
     4.  SMC plus graded exercise therapy (GET): based on the theory that CFS patients suffer from deconditioning that is reversible with systematic gradual increase in physical activity.
Primary outcomes were rated by subjects who filled out standard questionnaires to assess fatigue and physical function.
Results
Percentage of subjects with improvement in fatigue from baseline:
     1.  SMC: 65%
     2.  APT: 65%
     3.  CBT: 76%
     4.  GET: 80%
Percentage of subjects with improved physical function from baseline:
     1.  SMC: 58%
     2.  APT: 49%
     3.  CBT: 71%
     4.  GET: 70%
Adverse events were monitored and serious deterioration did not vary significantly between groups.
Recovery?
A second PACE report was published in 2013 in Psychological Medicine. It claimed that 22% of subjects treated with CBT or GET recovered, as defined by a score within the range of mean plus or minus one standard deviation of a healthy person’s score.
Together, the two PACE reports concluded that CBT and GET, when added to SMC, were safe and effective treatments for CFS, with a moderate effect size; and with those treatments, a substantial number of patients could achieve recovery from CFS.
Criticism of the PACE study by patients
There was an extensive reaction from patient and advocacy communities. CFS patients were offended by the suggestion that their symptoms were psychological: they knew there was a large body of research indicating that CFS was a biological condition. CFS patients could not accept the results of the study, because in their experience, even mild exertion could increase all the other symptoms of the disease, and they knew that their exercise tolerance varied from day to day. They knew that starting low and building slowly simply wouldn’t work for them. They had learned to rest as soon as they felt tired.
There was evidence to support them. A 2011 study compared CFS patients to normal controls on two maximal exercise tests done 24 hours apart. There were no significant differences on the first test, but the CFS patients had significantly worse performance on the second test, indicating an atypical recovery response and protracted malaise in CFS.
One patient, Julie Rehmeyer, pointed out the problem with subjective reports:
But the subjective reports from patients seemed suspect to me. I imagined myself as a participant: I come in and I’m asked to rate my symptoms. Then, I’m repeatedly told over a year of treatment that I need to pay less attention to my symptoms. Then I’m asked to rate my symptoms again. Mightn’t I say they’re a bit better — even if I still feel terrible — in order to do what I’m told, please my therapist, and convince myself I haven’t wasted a year’s effort?
Criticism of the PACE study by scientists
Dr. David Tuller, writing on the Virology blog, identified several major flaws:
    • 13% of subjects already met the criteria for “recovery” at the start of the study.
    • In the middle of the study, subjects were given a newsletter including glowing testimonials about how the treatments had helped patients.
    • During the trial, the researchers deviated from the protocol. They changed methods and relaxed the criteria for “recovery.”
    • They violated their own protocol by failing to tell prospective participants about their conflicts of interest: connections to government and insurance interests.
Tuller quoted several top researchers who agreed that the study was fraught with indefensible methodological problems. Comments included statements like “I’m shocked that The Lancet published it” and “It’s a mass of uninterpretability.”
The struggle to access the trial data
Critics pushed for an independent review of the trial data. They submitted dozens of freedom-of-information (FOI) requests for PACE-related documents and data. The National Institutes of Health (NIH) and the Institute of Medicine (IOM) chimed in, and experts said the deconditioning hypothesis was flawed and untenable. The authors claimed they were being persecuted by patients and advocacy groups. They had received death threats and a phone threat of castration, and one had been stalked by a woman who brought a knife to one of his lectures.
When the trial data were finally made available (only after long persistence, many FOI requests, and a court order), an independent group did a preliminary analysis of “recovery” from CFS using individual participant data. It found that the previously reported recovery rates had been inflated by an average of four-fold. Re-analyzing the data according to the published trial protocol revealed that the recovery rate was 3.1% for SMC alone, 6.8% for CBT, 4.4% for GET, and 1.9% for APT. These differences were not statistically significant.
Fiona Godlee wrote in an editorial in the British Medical Journal (BMJ) that when there is enough doubt to warrant independent re-analysis, “Such independent reanalysis and public access to anonymised data should anyway be the rule, not the exception, whoever funds the trial.”
The authors of the re-analysis said,
The PACE trial provides a good example of the problems that can occur when investigators are allowed to substantially deviate from the trial protocol without adequate justification or scrutiny. We therefore propose that a thorough, transparent, and independent re-analysis be conducted to provide greater clarity about the PACE trial results. Pending a comprehensive review or audit of trial data, it seems prudent that the published trial results should be treated as potentially unsound, as well as the medical texts, review articles, and public policies based on those results.
An open letter calling for the article to be retracted went unheeded. The original open letter to Psychological Medicine was reposted with a total of 142 signatories.
An article in the Journal of Health Psychology includes an impressive number of references and concludes:
Science is not always plain sailing and sometimes the voyage is across an angry sea. A recent clinical trial of treatments for chronic fatigue syndrome (the PACE trial) has whipped up a storm of controversy. Patients claim the lead authors overstated the effectiveness of cognitive behavioural therapy and graded exercise therapy by lowering the thresholds they used to determine improvement. In this extraordinary case, patients discovered that the treatments tested had much lower efficacy after an information tribunal ordered the release of data from the PACE trial to a patient who had requested access using a freedom of information request.
Conclusion: A flawed study with lessons to be learned
Studies like the PACE trial can have a strong impact on patient care, and flawed studies can result in harm to patients. Conventional peer review is obviously not enough: the effective peer review in this case came after publication. Numerous flaws were found that should have been addressed before publication. Critics called for the study to be retracted; so far, it hasn’t been. This unfortunate episode can serve as a wake-up call and it points out the value of freely sharing raw data with other researchers. Good scientists want to know if they are wrong. They want to have their work scrutinized and should be willing to share their data without the requesters having to resort to a court order.
ADDENDUM: The tribunal that finally resulted in the release of the data found that the researchers’ claims of death threats were false. Their complete report is available online.


A New Test for Chronic Fatigue Syndrome?
Steven Novella on November 26, 2025
Link

The headline reads, “Breakthrough blood test finally confirms Chronic Fatigue Syndrome.” As you might imagine, the story is far more complicated than that. Let’s start with some background of chronic fatigue syndrome, also called myalgic encephalomyelitis (ME/CFS).
As the name implies, it is a syndrome, meaning a collection of symptoms with a typical natural history – CFS is characterized by severe debilitating fatigue not relieved by rest, difficulty thinking, dizziness, chronic pain, and poor tolerance of even moderate exertion. Sometime we see this following a severe infection, especially encephalitis (brain infection). It is possible that CFS is related to long COVID.
The primary challenge in dealing with CFS is that we do not know its ultimate cause, there is no specific treatment, and there is no objective test to confirm it. The diagnosis is based on having the constellation of symptoms chronically without another diagnosis that can be the cause (so it is partly a diagnosis of exclusion). The symptoms are also what we call nonspecific, meaning that they can occur with a host of different conditions.
Patients with CFS often have depression and/or anxiety. This creates a diagnostic dilemma – are the physical symptoms caused by severe depression, or is the depression secondary to chronic debilitating symptoms? Perhaps they are comorbid – they reinforce each other without one being the ultimate cause.
Patients who suffer from CFS also have the burden of not having a definitive diagnosis. It is challenging to communicate the complexity of the syndrome and how we approach it clinically without sounding dismissive. For example, you should ask questions about anxiety and depression, but patients can interpret this as dismissing the physical symptoms as psychological. And some practitioners are skeptical that CFS is a specific illness.
Research provides some tantalizing clues, but no definitive answers. This is often because a syndrome has multiple overlapping causes, which is likely the case here. But there is some evidence for autonomic and immune dysregulation, mostly involving the brain.
The current study is an attempt to gather more information about what might be going on in CFS. It is a genome-wide association study – they are looking at lots of genomes of people with clinical CFS compared to the general population looking for any correlation. They found:
“We recruited 21,620 ME/CFS cases and performed genome-wide association studies (GWAS) for up to 15,579 cases and 259,909 population controls with European genetic ancestry. In these GWAS, we discovered eight loci that are significantly associated with ME/CFS, including three near BTN2A2, OLFM4, and RABGAP1L genes that act in the response to viral or bacterial infection.”
This is interesting research, but it is extremely premature to call this final confirmation of CFS or that there is now a test for it. First, I must point out that this is a preprint, so it has not yet been peer-reviewed. It is also a preliminary look at the data. Even if it holds up, it’s basically a fishing expedition, looking at a vast data set for any correlations. Those correlations would need to then be confirmed with a new set of data before we can say they are likely meaningful.
The study also has a major omission – they did not compare patients with CFS to patients with other diseases, only to healthy controls. It’s possible, for example, they the correlations they found are nonspecific, and could be present in many chronic illnesses, or perhaps they are just a sign of altered immunity or even a predisposition to depression.
So we are still along way from confirming that these correlations are real and then determining if they are specific to CFS, and then determine what they actually mean.
We would then want to determine if these markers mean anything clinically. For example, does a positive test predict anything about the prognosis, or response to a specific treatment, or perhaps the genetic risk of family members. Until we close the loop in this way – showing that the correlation connects to a cause or causes of the disease and tells us something useful like who should be treated and how – we can’t be sure if the correlation is real and meaningful.
Initially such a test, if the correlation holds up, may be used only to give patients a label – we would divide patients with CFS into test positive and test negative. This is useful for further research, but not for clinical management. Patients would likely find it useful to be test positive in that it would mitigate the stigma of being dismissed as not having a real illness. But this might also exacerbate this issue for patients with clinical CFS who are test negative.
What we have here is a potential new puzzle piece in the complex story of CFS. It needs to be confirmed, and if so then there needs to be lots of follow up research to know what it all means. I suspect we are still 10-20 years away from an actually useful clinical test of CFS based on these findings (if they pan out).
    • 

Rituximab for Chronic Fatigue Syndrome: Jumping the Gun
Harriet Hall on January 8, 2013
Link
Now that the XMRV myth has been put to rest, patients with Chronic Fatigue Syndrome (CFS) are no longer jumping the gun to demand anti-retroviral treatments. But they are jumping the gun in new ways, based on very preliminary data coming out of Norway.
A correspondent in Norway wrote to tell me patients from Norway with myalgic encephalitis/chronic fatigue syndrome (ME/CFS) are travelling to the US to have Dr. Andreas Kogelnik in San Francisco treat them with IV infusions of rituximab, apparently to no avail. A course of treatment costs over $6000, not to speak of travel and other expenses.
What is Rituximab?
It’s a chimeric monoclonal antibody against the protein CD20, and it destroys B cells. It is used to treat diseases with excessive, overactive, or dysfunctional B cells such as some lymphomas, leukemias, transplant rejection, and some autoimmune disorders, notably rheumatoid arthritis. It is expensive (several thousands of dollars per infusion), must be given IV, and can cause serious adverse effects including infusion reactions, reactivation of infections, and cardiac arrest.
Using it for CFS is not based on any clear scientific rationale, but only on a few observations of patient improvement and on speculation about a possible cause of CFS that might explain the observations. It has certainly not been established that CFS symptoms can be attributed to B cell abnormalities.
A Patient’s Story
A blogger in Canada has chronicled her experience at great length. She has been travelling to San Francisco for treatments, and she believes she is enrolled in a pilot study. A quote from her blog:
The treatments I would receive are not considered a clinical trial, but a pilot study because clinical trials are tightly regulated and operated. It needs a lot of work from investigators to establish guidelines and procedures, obtain approval from ethic boards, etc.
When questioned, she elaborated:
a pilot study is not a registered clinical trial. It’s a one person trial. It gives the opportunity for the physician and researcher to gain experience with the drug and to refine the protocol associated with its administration. The goal for this is to move forward with a very formal and well controlled clinical trial.
She is hopelessly confused about what constitutes a pilot study. I can’t tell whether she was misinformed or simply misunderstood what she was told, but it raises questions about informed consent. She had worked as a chemo nurse and had been involved in phase 1 studies of new drugs so she should know better.
She says Kogelnik told her he was in touch with the Norwegian researchers (see below) every two weeks; she got the impression that he was collaborating closely with them on pilot studies. But my Norwegian correspondent contacted those researchers and they told her that while they are in touch with Kogelnik now and then, they only have general discussions about ME and immunology. He has told them he is doing some kind of study; but they have never seen the protocol, don’t know how many patients are enrolled, and are concerned that he hasn’t officially registered his study.
The blogger has made multiple trips from Canada to San Francisco. The Genentech Foundation apparently pays for the drug under a patient assistance program if the patient can document 2 refusals by insurance, but the trips and special lab tests cost her around $6000 for the year. She vividly describes the difficulties of traveling with her symptoms, arranging for wheelchairs and oxygen, etc. She says travel makes her sicker.
She has come to hate the term CFS because of its associations. She prefers to call it ME. Now she says Kogelnik has changed her diagnosis to CVID (Common Variable Immune Dysfunction), but it seems to me neither her symptoms nor his treatment match very well with that diagnosis. Perhaps she means chronic fatigue immune dysfunction syndrome (CFIDS), which is essentially a synonym for CFS. She suggests that he is using a different diagnosis because it is more acceptable to insurance companies and regulators and helps to justify what he is doing.
Her B-cells were effectively eradicated by the drug, but she got worse instead of better. She says:
I have known to expect worsening of my symptoms. Dr K warned me about it….Dr K think that it takes about 3 months to start feeling durable effects of Ritux and they seem to taper the dose down as they go.
Here’s her protocol.
Rituximab induction: Day 1 and Day 15. Dose #3 at Week 8 (I got mine at Week 9). Dose #4 at Week 24. Dose #5 at Week 44 and Dose #6 at Week 60. Pretreatment for each infusion with Tylenol, IV Benadryl, and Phenergan (to reduce the risk or severity of infusion reactions).
Despite her initial enthusiasm, the drug has not helped her. In fact she has developed various new symptoms and abnormal liver function tests, but she refuses to attribute any of these to the treatment.
I am getting resigned that I may not respond from Rituximab- but then I guess if it happens, that’s totally fine too. I hope that this process can be of help to research, notably finding out who responds and why, and who doesn’t and why.
This is particularly sad, since she was not treated as part of a controlled study that might have actually accomplished those goals. She was merely a guinea pig in an irresponsible uncontrolled experiment.
What Is the Evidence?
An initial observation. Fluge and Mella observed that a patient with CFS had an unexpected, marked recovery of CFS symptoms lasting for 5 months during and after cytotoxic chemotherapy for Hodgkin’s disease. They reasoned that the improvement was probably related to her treatment with methotrexate, a drug known to induce immunomodulation in part through B-cell depletion.
A small case series. So they decided to try depleting B-cells with rituximab in the original patient plus two others. This was published as a case series in 2009. The treatment was 2 IV infusions given 2 weeks apart, with a maximum dose of 1000mg. 2 of the 3 patients were also given oral methotrexate for recurrent symptoms.
All three patients, with 7–10 years of CFS disease duration, had substantial relief of all symptoms related to CFS after rituximab intervention. Patients 1 and 2 had a marked symptom improvement after approximately 6 to 12–16 weeks, followed by slowly increasing symptoms (yet still a benefit 6 months after treatment). Patient 3 had slight symptom improvement from 6 to 26 weeks after treatment, thereafter a major recovery of all symptoms lasting until 40 weeks after treatment, followed by a gradual worsening the following month.
One randomized controlled trial. Their next step was to do a randomized, double-blind, placebo-controlled comparison of rituximab to IV saline. 2 infusions were given 2 weeks apart to 30 patients. All patients were pre-treated with cetirizine, paracetamol and dexamethasone to minimize the risk of reactions.
They are calling it a positive study; but for their primary end-point (effect on self-reported CFS symptoms three months after intervention) the results were actually negative. They continued to observe the patients for secondary endpoints, and other secondary endpoints were added to the protocol mid-stream. They found a significant difference between the groups at 6-10 months after treatment.
They characterized this as:
significant, though generally transient clinical responses, with CFS symptom improvement in two thirds of the included patients.
Of the patients on rituximab, 10 had a major or moderate response lasting from 8–44 weeks; the other third failed to respond. Two patients in the placebo group had a major or moderate response.
The study design could have been better. There were some significant differences between the patient characteristics in the two groups, and it doesn’t appear that they questioned patients to see if they could guess which group they were in (i.e., whether blinding was adequate).
More studies in progress. They announced:
Based on new pilot patient experiences [what does this mean? Are they, too, confusing pilot studies with anecdotal evidence?] we have now started two new open-label phase-II studies investigating Rituximab treatment with two infusions two weeks apart (as in the present study) followed by maintenance Rituximab infusions at 3, 6, 10 and 15 months, to further explore this treatment principle in CFS (ClinicalTrials.gov, NCT01156909 and NCT01156922).
Strangely, both of these studies are open-label, with no control group and no blinding. What were they thinking?
What Is Kogelnik Doing?
Kogelnik founded the Open Medicine Institute to facilitate electronic information sharing in a community-based process. It is crowd-sourcing private funds. It has great plans for research, but as yet no studies have been registered at ClinicalTrials.gov. As far as I have been able to determine, he is offering individual patients treatment outside of any legitimate study. I don’t know how he is representing this to his patients, but at least one medically trained patient believed she was participating in a pilot study Kogelnik was doing in collaboration with researchers in Norway. I have no way of knowing whether the misunderstanding was on her part or his.
Some of this reminds me of Burzynski’s deceptive tactics, but Kugelnik is no Burzynski. I’m willing to believe he is sincerely trying to help patients who have no other options. But I think he’s on the wrong track. The way to really help these patients is to insist on providing the drug only in the context of well-designed clinical studies to establish once and for all whether rituximab treatment is effective. Jumping the gun is not scientifically or ethically justified.
Don’t expect anyone to try to stop him. Rituximab is an FDA-approved drug for other indications, and it is not illegal to prescribe the drug off-label. Offering experimental treatments to patients is not illegal. Medical boards have disciplinary power: the infamous Dr. Mark Geier, chemical castrator of autistic children, lost his license for “almost total disregard of basic medical and ethical standards,” but that kind of medical board action is the exception to the rule. Similar malfeasance (Dr. William Rea, for example) has typically been ignored or punished only with a mild slap on the wrist. Even Burzynski has not lost his license. In the absence of regulatory action, the only remedy would be a lawsuit if a patient died or was seriously harmed by the treatments.
Conclusion
So basically, the evidence consists of one case report (involving a different drug!), a case series of 3, and one preliminary controlled study with 30 patients showing a 2/3 response that was delayed and transient. Preliminary studies serve to justify further studies but they are not sufficient to justify forging ahead with offering the treatments in clinical practice. All too often, attempts to replicate preliminary studies fail, and initially promising results are discredited by larger, better studies. XMRV was a prime example of that.
The protocol in the studies was 2 IV infusions 2 weeks apart. The protocol that Kogelnik is using (treatments 2 weeks apart, then at 8, 24, 44 and 60 weeks) doesn’t correspond to the published study or even to the Norwegian studies in progress.
In my opinion, what he is doing is not based on acceptable evidence and is not ethical. He is indulging in irresponsible, uncontrolled experimentation. He is knocking out a vital part of his patients’ immune systems (B cells produce antibodies to fight off infections) with little understanding of what he is accomplishing, of whether it addresses some basic underlying causal mechanism of CFS, or of what the possible long-term consequences might be. By jumping the gun he is putting patients at risk; exposing them to considerable cost, discomfort, and inconvenience; and by running around the track prematurely by himself, he is missing out on the real race to understand and treat patients diagnosed with CFS/ME/CFIDS.

Chronic Fatigue Syndrome: Rituximab Revisited
Harriet Hall on January 19, 2016
Link

Three years ago I wrote about an experimental treatment for chronic fatigue syndrome (CFS): rituximab (brand name Rituxan). I was concerned that doctors who offered it, like Andreas Kogelnik, were jumping the gun by offering it before the evidence was in, and that they might be putting patients at risk.
A correspondent who has been following the CFS forums asked me to revisit this issue. She sent me links to forum posts indicating that Dr. Kogelnik is treating CFS patients with the drug, that they are not being enrolled in clinical trials, that information about results is not available, and that at least one patient may have developed a life-threatening side effect. I want to stress that I don’t have any evidence that those statements are true. These are only posts on a forum, and I have no way to verify the information. I tried to get more information from Dr. Kogelnik’s clinic, but was unsuccessful. Nevertheless, even if everything in those forum posts is false, I think the issue is serious enough to bring it to the attention of the public again. My purpose is to provide accurate information about rituximab and to get people to think about the principles involved, not to make claims or accusations or cast any blame.
What is rituximab?
Rituximab is a monoclonal anti-CD20 antibody. It destroys B cells that have the CD20 antigen on their surface. B-cells are an important component of the immune system, and depleting B-cells makes patients more vulnerable to infections. Rituximab is licensed only for a few specific indications such as B-cell lymphomas and refractory rheumatoid arthritis, although it has been prescribed off-label for a number of other autoimmune diseases. If it works in CFS, that would support the hypothesis that CFS is an autoimmune disease (though this is far from a clearly-supported hypothesis, as the primary defining characteristic of CFS is exercise intolerance).
Side effects can be deadly
Rituximab is marketed with black box warnings about a number of serious side effects that can cause death and disability. It is given intravenously; infusion reactions are common, and severe infusion reactions have been fatal. Infusions require premedication and special safety precautions. Infusion reactions occur in up to 50% of patients, usually with the first dose; they typically develop within 30 minutes to 2 hours but can be delayed for up to 24 hours. Severe mucocutaneous reactions can also be fatal. Hepatitis B virus can be reactivated. Fatal bacterial, fungal, and viral infections can occur. It can cause cardiac arrhythmias, renal toxicity, bowel obstruction and perforation, and many other side effects.
One of the most serious side effects is progressive multifocal leukoencephalopathy (PML). It is a rare and usually fatal disease caused by the JC virus. Up to 58% of the general population has been infected with this virus, and a third of the adult population has a persistent asymptomatic infection. It only becomes a problem when the immune system has been severely damaged. PML is a demyelinating disease similar to multiple sclerosis but much worse. The symptoms vary with the location of lesions in the brain; they can include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. The prescribing information for Rituximab warns that if any new neurologic symptom develops during treatment, the drug should be stopped and the patient should be evaluated for PML. There is no treatment. It is usually fatal within a few months. Survivors are left with permanent neurologic disabilities. A recent study found 231 confirmed cases of PML with rituximab and suggested it occurs far more often than has been recognized.
The evidence to date
When I wrote about this before, the evidence for rituximab in CFS boiled down to a case series of three, and one small randomized controlled trial in 2008. That RCT was negative for the primary end-point of self-reported symptoms at 3 months but 2/3 of the subjects showed a delayed transient improvement after 6-10 months of followup. The protocol in that study was not the same as the protocol Dr. Kogelnik was using.
At the time I wrote, there were two more studies pending, both open label and without a control group. One of those is still ongoing. The other has been completed. It found an improvement in self-reported fatigue scores in 64% of patients. It took an average of 23 weeks to see improvement. 14 patients had a “major response” lasting an average of 105 weeks; 4 had a “moderate response” lasting 69 weeks. 18 of the 28 subjects were the same individuals who had participated in the 2008 randomized study. Adverse events included two allergic reactions, two episodes of neutropenia, and eight transient symptom flares. One major responder dropped out after 32 months when he experienced a full relapse. Since there was no control group, it’s hard to judge what these results mean.
By the time that study was published, July 2015, the researchers had embarked on a randomized, double-blind, placebo-controlled study, and they were also conducting a small open-label study on patients with very severe symptoms. Two out of their four severe patients had experienced “a slight beneficial effect” but they had classified all four as non-responders. They warned that the treatment is experimental and they said:
We do not encourage the use of rituximab for ME/CFS outside of approved clinical trials, and this is especially important for the group with very severe disease.
All the Rituximab/CFS research has been done by a single group of researchers in Norway. I find that a bit worrisome. Their results will be more convincing if they can be replicated elsewhere.
A totally disabled patient
Whitney Dafoe was a world-traveling photojournalist until 2009 when he started to develop crushing fatigue, dizziness, GI problems, joint pain, and weight loss (down to 115 pounds on a 6 foot 3 inch frame). According to a news article his disease has now progressed to where he can no longer talk, read, eat solid food, or use the Internet, and rarely gets out of bed. Dr. Kogelnik was the one who made the diagnosis of CFS. Whitney’s father, Ronald Davis, is a researcher affiliated with Kogelnik; the research seems to be mainly focused on identifying possible biomarkers for CFS and looking for an etiology.
Whitney is featured in a video that also features Dr. Kogelnik and his Open Medicine Institute. He posts as “Whit” on the Phoenix Rising forum. In December 2012 he was able to write an articulate, coherent post. He apparently was started on rituximab by Dr. Kogelnik in January 2013 and rapidly went downhill. By April he posted “Can’t read much now…”
In September he posted a disjointed message saying he was worse since starting rituximab, and complaining of throat swelling, apnea, and sleeplessness. He says “CFS also wrse[sic]. I can’t talk. Can’t type/text enough to communicate. Haven’t had a conversation with someone in 8 months…”
By November 2013 he was no longer able to post for himself. He had his caretaker post “I am now 99.99% bedridden and can’t go to a dentist. I have serious sleep apnea that wakes me up in the night unable to breathe, and seriously disturbing my sleep…” According to more recent posts, he can’t tolerate his sister being in the room or even his partner who used to lift him from bed to stretcher; the only people who can care for him are his parents.
I want to stress again that I don’t have all the facts, but I can’t help but wonder if this unfortunate young man might have developed cognitive and other neurologic problems due to PML triggered by the rituximab. If nothing else, I think we can assume that the rituximab didn’t help him. He thinks it made him worse, and he may be right.
Comments on Kogelnik from other patients
The following are quotations from posts on the Phoenix Rising forum and I want to stress that the information in them is unverified. On the other hand, I have no reason to doubt their veracity. Please take them with the grain of salt that they deserve. Note: ME stands for myalgic encephalomyelitis, an alternate name for CFS that some people feel is more appropriate.
    • I am surprised they haven’t published a retrospective chart review of all ME/CFS patients they’ve treated with rituximab at this clinic. I suspect this hasn’t happened because the outcomes with this treatment are abysmal in the real world outside of the Norwegian trials and no one would be prepared to hand over $40k once they saw the numbers.
    • I do not believe it is a research study and it is offered to anyone that they feel is a good candidate (who is then informed of all the potential risks.)… they are charging $40k for a treatment whose efficacy has not been adequately established in ME/CFS and they have not published their outcomes despite having treated an unknown number of patients with RTX. Even a small case series would be useful so people can have some peer-reviewed information before parting with 40 grand.
    • the reason I started this thread is because no where on PR or anywhere else I searched could I find one single person who went to OMI and got Ritux and had a significant recovery or remission. Everyone failed or only had a short response. It could be that most of these people don’t know of or aren’t active on any ME forums like PR, but it just seemed weird to me because 67% is an impressive efficacy rate and I would’ve expected to see more.
    • I am a health care professional, and he attempted to push me into studies I was not interested in after risks discussed. One of drugs carried risks of death with weird virus causing movement disorder. Side effect RARE – but no thanks! Clearly he had ego involved in wanting to publish this. Does not respect the importance of patient’s role in making decisions within the context of informed consent.
Conclusion: Rituximab for CFS is, at best, experimental
The evidence that rituximab may be an effective treatment for CFS is preliminary. It must be considered an experimental treatment at this point. I can only speculate about what Dr. Kogelnik is doing, because he has not been very forthcoming with information. In interviews he talks about organizing trials, but so far he mainly seems to be trying to collect better information on CFS patients rather than putting rituximab to a fair test. He has published nothing on rituximab; PubMed lists only two studies he did on valganciclovir. I searched for his name on clinicaltrials.gov and all I found was a study on vitamin D. If he is indeed treating patients outside of clinical trials, I think that’s a very bad idea. Rituximab is a very dangerous drug: its side effects can be fatal. I don’t know for sure if Whitney was harmed by the drug; but if he wasn’t, it’s only a matter of time until someone is harmed. I hope patients will carefully consider the risks and the preliminary state of the evidence before they spend a lot of money ($40,000?) on a therapeutic trial of rituximab. I understand the desperation and the wish to try “anything” that might relieve their suffering, but clinical trials are the only way to find out if this treatment really works. If patients are treated outside of clinical trials, their experience doesn’t help advance the scientific knowledge needed to help other patients.
I hope the advice of the Norwegian researchers will be heeded: not to use rituximab outside of approved clinical trials, especially on patients with very severe disease.

Health and Wellness Coaching: cautious optimism and some concerns
Jann Bellamy on June 9, 2016
Link
The National Consortium for Credentialing of Health & Wellness Coaches (NCCHWC) and the National Board of Medical Examiners (NBME) signed an agreement last month for the launch of a national certification for individual health and wellness coaches in the U.S. According to a joint press release, the agreement is a landmark in the efforts of a dedicated group of individuals who have been working for years to establish professional practice and educational standards for health and wellness coaching.
What is “health and wellness coaching?” According to NCCHWC’s website:
Health and Wellness Coaches partner with clients seeking self-directed, lasting changes, aligned with their values, which promote health and wellness and, thereby, enhance well-being. In the course of their work health and wellness coaches display unconditional positive regard for their clients and a belief in their capacity for change, and honoring that each client is an expert on his or her life, while ensuring that all interactions are respectful and non-judgmental.
This includes, according to a Job Task Analysis, helping the client set her own health and wellness goals and then helping her get there through various techniques, such as behavior tracking and providing “basic healthy lifestyle recommendations by credible sources.”
Again according to the press release, both the NBME and the NCCHWC,
envision a professional community that is dedicated to high quality and continuous improvement and an advocate for the development and certification of high-quality coaching skills across healthcare, academia, and industry.
Beginning next year, health and wellness coach training programs will have to meet certain standards for accreditation by the NCCHWC. They must have qualified faculty who hold graduate degrees in a health field, described as “MPH, MSW, MD, PhD, MSN, DrPH, etc.” Students must complete minimum hours in both clinical and classroom training, including “Healthy Lifestyle Basics,” with a curriculum based heavily on the CDC’s “robust, evidence-based website that provides valuable resources for the coaching process.” After this, the candidate will have to pass the certification exam administered by the NBME.
I am cautiously optimistic that this endeavor could turn into a positive contribution to improvement in the nation’s health. Physicians could refer patients with, for example, chronic diseases and weight problems, to certified health and wellness coaches. The coaches could help these patients set and meet goals to improve their health. In fact, I have thought about (and meant to write a post about), science-based alternatives to the false claims of CAM providers that they somehow hold the key to health promotion and disease prevention. Health coaching could become an evidence-based tool in the health care armamentarium and actually help patients avoid turning to CAM.
Some qualms
That said, I see trouble on the horizon for this nascent field. With all good wishes and great hope for their success as a positive addition to the science-based health care field, I feel compelled to offer some friendly advice.
To their credit, some big names in “integrative medicine” (“IM”) were involved in getting health and wellness coaching to this point in its evolution toward professionalization. These include Karen Lawson, MD, ABIH, University of Minnesota Center for Spirituality and Healing, a member of the Academic Consortium for Integrative Medicine, and David Eisenberg, MD, who was apparently involved in negotiating the deal between NCCHWC and the NBME. I also heard a mention of Dr. Oz in one of the videos explaining the organization’s formation. (The video was from 2014, hopefully before he was disgraced by Sen. Clare McCaskill for supplement shilling.) Others from Integrative Medicine programs are also on the Board of Directors and Council of Advisors, as is someone connected to the American Holistic Nurses Association.
We at SBM (myself included) have often been quite critical of so-called Integrative Medicine (formerly known as “CAM”) which we see as an excuse to lower the evidence standards for medical practice, in part by incorporating quackery like homeopathy and reiki. We have also criticized IM for their championing of “CAM providers,” who don’t feel any allegiance to science and evidence at all, such as naturopaths. One of our gripes has been the fact that IM co-opts exercise and diet as its own. In fact, evidence-based diet and exercise advice, including referring patients to other professionals, such as Registered Dietitians and physical therapists, have long been a part of “conventional” medical practice. I don’t back down from any of those criticisms one bit.
I hope the NCCHWC will think long and hard about its association with “integrative medicine.” If health and wellness coaching is trying to establish itself as an evidence-based profession, then tying your future to an ideological movement in medicine that lowers the bar for evidence is not the best solution. For example, the website of Dr. Lawson’s own University of Minnesota Center for Spirituality and Healing contains an uncritical description of craniosacral therapy, an egregious form of quackery. It refers patients to an article with a lame excuse for why controlled trials of craniosacral therapy cannot be done, a form of “special pleading” typical of pseudoscientific practices. It also contains a link to the Upledger Institute, which teaches and promotes this form of pseudoscience. This is moving medicine back into the 19th century, not moving it forward.
Even integrative medicine’s most ardent proponents admit that integrative medicine has no set definition and that there is much about it we do not know, such as:
    • Whether IM really offers the best of conventional medicine and CAM.
    • Whether IM produces better outcomes.
    • Whether IM is effective in the area of prevention, including obesity and cardiovascular risk.
    • Whether IM has anything to offer preventive medicine.
    • Whether future IM research will yield beneficial results.
    • Whether IM has a positive impact on utilization clinical preventive services, smoking cessation, diet, and physical activity.
    • Whether IM is cost effective.
Is that a movement you want to be associated with as you work to establish your credibility? It may well be that those who promote IM have the best of intentions, but, as Peter Rosenbaum, MD, wrote in an article critical of the “CAM” being offered to children with cerebral palsy,
Good intentions are no substitute for good evidence.
I wholeheartedly agree.
Let me mention another cause for concern. Right now, some health and wellness coach training organizations have received what is called “Transition Phase Approval” from the NCCHWC. This means they are authorized to train coaches during a transitional phase while the NCCHWC gets its full program up and running. Sometime next year, more stringent requirements will be in place for training programs and all must apply and be accredited (even those with Transition Phase Approval) every three years.
I see some organizations on the Transition Phase Approval list that give me pause. While I do understand the need for a transitional program to get things started, one would hope that more stringent requirements would bring these programs under greater scrutiny and allow NCCHWC to reassess their qualifications for accredited status. A few examples:
Integrative Women’s Health Institute: Offers some highly questionable advice on women’s health issues. (For example, if your testosterone is too high and you have PCOS, eliminate dairy and sugar and use lots of cinnamon, among other things.)
Functional Medicine Coaching Academy, Inc.: This is another outlet for the Functional Medicine brand, now helmed by Mark Hyman, MD, which includes courses in practicing so-called functional medicine as well as an outpost at the Cleveland Clinic. The most measured thing I can say about functional medicine is that there is insufficient evidence for its underlying principles (which are themselves pretty vague) as well as no evidence that it improves health outcomes.
Institute for Integrative Nutrition: I mention this website as an example of a training outfit that provides insufficient evidence about its program to permit an appropriate evaluation by a potential student. There is no information on, for example, cost, faculty, financial aid, or curriculum available without having to contact the company. I suggest that NCCHWC require all accredited schools to provide this type of information in a standardized format on their websites, as is common with colleges. I am also concerned about faculty who promote their own particular “brand” of nutrition, as opposed to evidence-based information.
The choice is yours
I think evidence-based health and wellness coaching offers a wonderful opportunity to improve the nation’s health, one patient at a time. NCCHWC’s association with the NBME and incorporating CDC recommendations in its curriculum are steps in the right direction. But health and wellness coaching is a rich target for those who want to promote their personal brand of “wellness” or incorporate pseudoscience into their training and practice regimens. An early effort on the part of NCCHWC to guard against these inroads would go a long way towards establishing itself as a credible and valued addition to health care.

Colonoscopy: More Misinformation from Mercola
Harriet Hall on January 5, 2016
Link
Joseph Mercola, D.O., runs the website mercola.com which is full of misinformation, advocates all kinds of questionable alternative treatments including homeopathy, and discourages vaccination and other aspects of conventional medicine.
Like Dr. Oz and Andrew Weil, he is more dangerous than easily recognizable quacks in that he combines some good medical information with egregious misinformation, and readers who know he is right about the good information are likely to wrongly assume everything else he says must be equally true. He’s right about some things, but the safest course is to assume that anything on his website is false unless you can verify it as true by consulting other sources that are reliable. I tried to verify the information in his recent article on colonoscopy. I found outright errors along with fear-mongering and bias.
What Mercola says about colonoscopy
The webpage is headed by a video that tells us:
    • There are 3 options for colon cancer screening: colonoscopy, sigmoidoscopy, and annual fecal testing for occult blood (FOBT). Doctors decide patients should have colonoscopy rather than informing them of the other options and giving them a choice. [Patients deserve to have enough information to give informed consent, and it is true that doctors seldom take the time to discuss all the pros and cons with patients, but many patients are content to trust the doctor’s judgment and don’t want to hear all the confusing details. And none of that is an argument against colonoscopy itself – HH]
    • Colonoscopies are not used as much in other countries. [Of course they aren’t. In other countries they are not as readily available and the high cost is a consideration. That doesn’t mean doctors in other countries think colonoscopy isn’t advisable – HH]
    • Colonoscopies are profitable; doctors get paid by the procedure. [That doesn’t mean they aren’t the best choice. And colonoscopies are recommended just as often in DOD health facilities and other systems where doctors are not paid more for doing more procedures – HH]
    • They are expensive because the AMA sets the prices. [False! The AMA doesn’t set prices for anything, and the price varies widely according to geographic location and other factors – HH]
    • PCPs recommend them because they get financial kickbacks. [No, PCPs recommend them because they know the evidence supports them – HH]
The video is by Dr. Michael Greger. I don’t consider him a reliable source. I wrote about another of his videos here.
Both Greger and Mercola make these claims:
    • “1 in 350 colonoscopies end up doing serious harm.”
    • “The death rate is about 1 for every 1000 procedures.”
I questioned those numbers and looked for reliable sources.
What the evidence says
I found a position statement of the American Society for Gastrointestinal Endoscopy that includes a thorough discussion of all the complications of colonoscopy. Based on a review of published data, they estimate the colonoscopy-specific mortality as 0.007%. They provide citations.
I found the supporting documents that the USPSTF used to develop its recommendations. Figure 1 shows the proportion of serious complications as 0.00277.
Faulty reasoning
Under “risks of colonoscopy” and “false positives” Mercola mentions that 30-40% of men treated for prostate cancer were treated unnecessarily. That is a risk of indiscriminate screening for prostate cancer; it has nothing whatsoever to do with colonoscopy. He doesn’t tell us what the false positive rate is for colonoscopy. As a matter of fact, colonoscopy is the gold standard for finding out if the results of other colon cancer screening tests are false positives (or negatives). If you have a positive fecal occult blood test, the next step is colonoscopy. And of course no discussion of risks is meaningful without putting those risks into perspective with the lives saved and other benefits. He fails to do that.
He spends a lot of time discussing the proper sterilization of colonoscopes. He claims that colonoscopes and sigmoidoscopes are impossible to clean! That’s demonstrably untrue. It goes without saying that the instruments should be properly cleaned between patients. The reported incidence of infection with endoscopy is very low, around 1 in 1.8 million procedures, and the CDC has published guidelines for disinfecting endoscopes that should prevent even those cases.
He recommends using peppermint oil. Indeed, PubMed lists a couple of studies showing benefits from peppermint oil instilled into the colon. There is a single double-blind study showing that taking it orally facilitates colonoscopy by reducing spasm; it was a small study with only 33 patients in the peppermint oil group. It sounds promising, and might be worth trying, but the study will have to be replicated and confirmed before peppermint oil can be recommended as a standard part of the colonoscopy prep. So he’s not “wrong” about peppermint oil, but the impression he gives of its benefits goes beyond the actual evidence.
Near the bottom of the page, Mercola asks “Should you have routine colonoscopies starting at age 50? To his credit, he admits that visual inspection is the most reliable way to check for colon cancer, and that colonoscopy can remove precancerous polyps and could save your life. But he prefaces these facts with this inanity:
I’m 61 and I’ve never had a colonoscopy and have no plans of ever getting one. While I believe they can be valuable as a diagnostic tool, I feel confident that with my diet (which includes daily amounts of raw turmeric) and lifestyle it’s highly unlikely I would develop colon cancer.
That’s wishful thinking, not science. There is some preliminary evidence that certain dietary interventions may be effective in modestly reducing the risk of some cancers, but they don’t eliminate the risk. The Natural Medicines Comprehensive Database states there is insufficient reliable information to rate the effectiveness of turmeric in colorectal cancer prevention (and I’ve discussed the lack of good evidence for turmeric as medicine before). It is foolish to refuse colonoscopy based on such scanty evidence.
Mercola influences a lot of people, and the overall impact of this article is negative. It will likely persuade a lot of his readers to forgo a potentially life-saving procedure. You can see from the comments on his website that many of his readers reject not only colonoscopies but mammograms, public health measures like vaccination and fluoridation, and sometimes even conventional medicine as a whole.
Mercola is untrustworthy
His website is featured on Skeptoid’s recently updated list of the top 10 worst anti-science websites:
Moving up from #6 on our previous list to #3 this time is the sales portal of anti-vaccine activist Joseph Mercola. Since our last episode, he’s received at least one more warning letter from the FDA (to add to his ever-growing collection) for failing to test whether some of his supplement products actually contain the advertised ingredients. To drive his estimated $7 million in annual sales, Mercola parrots a staggering array of long-debunked unscientific claims: that genetically modified crops are harmful, that microwaving food makes it poisonous, that cell phones cause cancer, that AIDS is caused not by HIV but by a diet lacking in his products, that organic food is a superior substitute for medical care, and that using sunscreens other than the all-natural version he sells is the true cause of skin cancer.
Among Skeptoid’s 10 anti-science websites, 5 are medical websites. NaturalNews is ranked as number 1, and Dr. Oz, the FoodBabe, and Deepak Chopra follow Mercola at 5, 7, and 8 respectively.
Mercola features on other lists of untrustworthy websites including FatFighterTV and Quackwatch.
Mercola is notorious on the Science-Based Medicine website. A 2009 article by Joseph Albietz listed 9 reasons to completely ignore Mercola. David Gorski wrote about him here, here, and here. And Steven Novella has written about him on the Neurologica blog.
Mercola is also featured in The Skeptic’s Dictionary and his Wikipedia article has links to numerous other sources criticizing him.
As if we didn’t already have enough evidence that Mercola is untrustworthy, it has just been revealed that his Organic Daily Face Cleanser (with his name emblazoned on it) contains pesticides and a carcinogen!
Conclusion: Mercola’s discussion of colonoscopy is incomplete and misleading
I reviewed the evidence for colonoscopy here. Briefly, colon cancer screening is clearly beneficial for those over 50, and there are pros and cons to each of the three recommended screening methods. The FOBT has more false positives and negatives and the false positives require further evaluation with colonoscopy, sigmoidoscopy only examines part of the colon, and colonoscopy allows for gold-standard visualization of the entire colon and biopsy of suspicious lesions but it involves more risks, inconvenience, and cost than the other options. I will repeat what I said before: “if you are approaching the age of 50, you have a decision to make: not whether to be screened, but which screening test to choose.”
Mercola’s discussion of colonoscopy is incomplete and misleading. It is one more example among many that he is not a reliable source of science-based medical information. Visiting his website could be hazardous to your health.

Hypnotherapy For Pain and Other Conditions
Steven Novella on April 25, 2012
Link
Hypnotherapy is the use of hypnosis as a medical intervention, usually for the treatment of pain and other subjective symptoms. It remains controversial, primarily because the evidence for its efficacy is not yet compelling, but also because it is poorly understood. This situation is not helped by the fact that it is often characterized as an “alternative” therapy, a label that can “ghettoize” an otherwise legitimate treatment modality.
What Is Hypnosis?
Any meaningful discussion of hypnosis, or any other phenomenon, needs to start with a specific, and hopefully operational, definition. If we cannot define hypnosis then it becomes impossible to meaningfully discuss it. The problem of definition plagues the science dealing with many so-called alternative therapies, such as acupuncture. Good science requires controlling for specific variables, so that we can determine which variables are having what effects. If we don’t know which variables are part of the operational definition of a specific therapy, then we cannot conduct proper studies or interpret their results.
For example, with acupuncture, in my opinion the only meaningful definition of this procedure is the placing of thin needles into specific acupuncture points in order to elicit a specific response. Research has shown, however, that acupuncture points do not exist, that placing needles at specific points is not associated with a specific outcome, and even that sticking needles through the skin (as opposed to just poking the skin superficially) does not correlate with outcome. When these variables are isolated they do not appear to contribute anything to efficacy, therefore one might conclude that acupuncture does not work. Research into acupuncture, however, often does not adequately isolate these variables from the therapeutic ritual that surrounds acupuncture, or even mixes in other modalities, such as electrical stimulation.
Psychologically-based therapies all suffer from this potential failing as well. It is difficult to separate the variables that are specific to a treatment from the non-specific elements of the therapeutic interaction.
What, then, are the variables specific to hypnosis that make it an identifiable intervention? This is not clear, but we can start with a definition of hypnosis based upon our current understanding. Hypnosis, first of all, is not what happens on stage for the purpose of entertainment. It is not about making people act like a chicken. It is also not a deep sleep or trance-like state. Hypnosis, however, is believed to be a specific state of consciousness. We experience different states of consciousness all the time, defined by differences in alertness and focus of attention. Hypnosis, rather than being a sleep-like state, is actually a state of heightened alertness. Attention, however, is focused (usually on the hypnotist or something they are using as a focus of attention). In this state subjects are more responsive to social cues and suggestion.
The above description of hypnosis is fairly superficial, and is still a matter of ongoing debate. There are conflicts between the conceptual definition of hypnosis (what we think is going on in the brain) and the operational definition (how we define it experimentally). Some researchers suggest that the operational definition is simply increased suggestibility following a hypnotic induction procedure. Even this stripped down definition has problems as it is not clear if hypnosis depth scales are just measuring baseline suggestibility, rather than a hypnosis effect.
My understanding of the current state of the research is that the hypnotic induction procedure may place subjects in a state in which they are focusing their conscious attention and are more receptive to unconscious processing of information (suggestibility). Beyond this there are many theories as to what is going on in the brain, but at present we simply do not really know and much more research is needed. There is no consensus as to the theoretical model of hypnosis. This makes clinical research into hypnosis difficult.
Hypnosis as Therapy
Regardless of the conceptual definition of hypnosis, if we have a standardized operational definition then we can study its effects. Systematic reviews of hypnosis for specific indications, however, generally observe heterogeneity of operational definition of hypnosis across trials. In other words — there often is no consistent operational definition of hypnosis and this makes it difficult to interpret study results. This is another way of saying that clinical research often does not adequately control for variables that allow us to isolate something that can meaningfully be called “hypnosis.”
This is all another way of saying that effects seen from hypnosis may all be either placebo effects or non-specific effects from the therapeutic interaction, rather than a specific response to hypnosis itself.
A systematic review of hypnosis for fibromyalgia pain, for example, found that:
The significant effect on pain at final treatment was associated with low methodological and low treatment quality.
CONCLUSION: Further studies with better treatment quality and adequate methodological quality assessing all key domains of FMS are necessary to clarify the efficacy of H/GI in FMS.
Studies used variable definitions of hypnosis and control of what exactly was being delivered, and poor study quality correlated with positive outcome — a trend that always calls into question whether or not there is a real effect present.
Other systematic reviews of hypnosis for pain control generally find positive effects, but they do not always carefully assess for methodological quality (such as for cancer pain). A systematic review of hypnosis for labor pain also found positive effects, but also cited methodological limitations in the research.
The major limitation of much of this research is that it does not adequately control for the effects of relaxation, cognitive therapy, expectation, or the introduction of a novel therapeutic intervention — all phenomena that may “come along for the ride” with hypnotherapy but not be specific to hypnotherapy. In other words — is hypnotherapy a necessary component of a positive therapeutic effect or is it an unnecessary ritual by which other non-specific elements have an effect? Some researchers are trying to tease apart these variables, but that constitutes a minority of the clinical research on hypnotherapy.
Conclusion
My personal current summary of the clinical research is that there is a suggestion of a positive effect from the specific operational elements of hypnosis (specifically increased suggestibility) for the treatment of subjective symptoms, like pain and nausea, that are amenable to suggestibility. However, the research has not yet adequately isolated this variable and therefore more research of better methodological quality is necessary to definitively answer this question. Until then hypnotherapy will remain controversial.
The more basic question as to what hypnosis is also is in an early stage of research, although there do seem to be some promising conceptual theories. The use of fMRI and other techniques may help define hypnosis from a neuroanatomical perspective, and this may further aid in understanding what hypnosis actually is.
Meanwhile, I find it counterproductive to lump hypnosis in with the broad and poorly defined category of “alternative” therapies. A recent article on hypnotherapy, for example, contained this quote from a practitioner:
“You can think of it in the same general healing family as acupuncture, massage [or] Chinese herbs,” he said. “All of these are kind of nonmainstream or alternative or holistic treatments. But they are gaining much more respect and popularity every year in our country. These are things they’ve been doing in China or India for thousands of years.”
You can see how this approach causes only confusion. Hypnotherapy has not been used in China or India for thousands of years, and has absolutely nothing conceptually in common with any of the modalities mentioned. The only possible connection among these various treatments that would put them into a common “alternative” group is the lack of scientific support or the confusion of placebo effects for specific effects. This is exactly what I meant by the “ghettoizing” of hypnotherapy.
It would be unfortunate for this to happen. I would rather see hard scientific research to better define hypnosis and its therapeutic potential.

NSAIDS AND ASPIRIN


Aspirin Risks and Benefits
Steven Novella on January 18, 2012
Link
A new review published in The BMJ once again opens the question of the risks vs benefits of daily aspirin as a prevention for heart attacks and strokes. The reviewers looked at nine randomized trials involving over 100,000 patients and found that aspirin is effective in reducing heart attacks and strokes, but also increases the risk of gastrointestinal bleeding and that in some patients this risk outweighs the benefit.
This is an old and enduring controversy, and one with significant public health ramifications. Aspirin is an anti-platelet agent – it inhibits platelets, the cell fragments in the blood that are the first line against bleeding, from aggregating (clumping together). Platelets aggregate in order to quickly stop bleeding from damaged veins or arteries. But they can also aggregate around cholesterol plaques in arteries, causing a large thrombus (blood clot) that can block off the artery, or that can break off and lodge in a downstream artery (an embolus) and cause a stroke or heart attack.
By inhibiting platelet aggregation daily aspirin reduces the risk of forming a thrombus or embolus, and thereby reduces the risk of heart attack or stroke. Of course, the real story is always more complex than our straightforward explanations. There is some research to suggest that the anti-inflammatory effects of aspirin may also be important to their role in reducing vascular risk. The relative contribution of anti-platelet and anti-inflammatory effects have not been fully teased out. Further, the anti-inflammatory effects of daily aspirin may have non-vascular benefits, like reducing the risk of some cancers.
By inhibiting the normal function of platelets, however, aspirin also increases the risk of bleeding. Patients taking regular aspirin will often notice that they bruise easily, or bleed for a long time from minor cuts (such as cuts from shaving). In fact these symptoms can be used as a rough guide to how much of an anti-platelet effect an individual patient is getting from their dose of aspirin. Sometimes we will cut back on the dose of aspirin, for example, if patients have excessive bruising. The real concern is not about simple bruising, however, but of significant bleeding. Aspirin can cause or exacerbate gastric ulcers, and if they bleed they will bleed more severely because of the blood-thinning effect of the aspirin. Also, if a patient does have a stroke that stroke is more likely to bleed, and that bleeding is likely to be more severe. Also, patients taking aspirin who suffer trauma are likely to have more severe bleeding from that trauma.
In other words – taking daily aspirin has both risks and benefits. Researchers have for years tried to figure out exactly what the relationship is between aspirin risks and benefit at specific doses of aspirin and in specific populations of people. What is not controversial is that daily aspirin is effective for secondary prevention of heart attacks and strokes. Secondary prevention means (in this case) people who have already had a heart attack or cerebrovascular event (stroke or transient ischemic attack – TIA). There is still some dithering about dose (81mg per day vs 325mg per day), but overall the benefits outweigh the risks.
The enduring controversy is over aspirin for primary prevention, in those who have not already had a vascular event – a heart attack or stroke. The risks of aspirin are generally the same in these two groups. Risk of bleeding complications increases with age, but is not significantly different in the primary vs secondary prevention groups.
What is different is the benefit of aspirin. As a general principle the benefit of any preventive intervention increases as the incidence of the disease or event it is meant to prevent increases. Aspirin has increased benefit for secondary prevention because the population of people who have already had an event are at higher risk of having a subsequent one than those who have never had a vascular event. Heart attacks and strokes are relatively uncommon in people who have never had such an event, and so the benefit of aspirin, while significant as a relative decrease in risk, is very minor as an absolute reduction of risk in the low risk population.
The question is – where do the lines of risk vs benefit cross? This is the question the recent study sought to illuminate.
What they found is that for primary prevention those taking regular aspirin were about 30 percent more likely to have a serious GI bleed. So-called “all-cause mortality” was not different in the aspirin vs no-aspirin groups. Aspirin reduced the risk of heart attacks and strokes (more heart attacks in men and more strokes in women) but less than the increase in GI bleed.  For every 162 people taking regular aspirin, one nonfatal heart attack was prevented but there was an increase of about two GI bleeds.
When translated to the general population we are talking about millions of heart attacks, strokes, and bleeds over several years in the US alone, so the public health consequences are huge. In other words, obsessing over small percentage differences has a big effect when translated to the overall population.
This review is not the final word on this question. It leaves us with the same bottom-line conclusion that we had prior to this review (it is a review, so the studies it looked at were already taken into consideration in forming guidelines). That is – for primary prevention aspirin use should be individualized. When looking at the general primary prevention population the risks seem to outweigh the benefits, but perhaps there are subpopulations that are at high risk for a stroke or heart attack in whom aspirin would be a net benefit. It is difficult to study subpopulations for this question because we need very large numbers to get statistically significant results (because the base risk is so low).
But – for those who have diabetes, high blood pressure, high cholesterol, or a strong family history of heart attack or stroke, the benefit of daily aspirin may still outweigh the risks. This means if you were placed on aspirin by your doctor and you have one or more of the above risk factors, this latest study should not make you stop taking aspirin – although you might want to revisit the question with your doctor to see if their recommendations for you have changed.
Official recommendations are to individualize the decision whether or not to use aspirin for primary prevention based upon age, risk of bleeding, and risk factors for vascular disease.
This is a question, with many sub-questions, that was an interesting controversy when I was in medical school two decades ago, has been the subject of ongoing research since then, and researchers continue to refine the data on this question finer and finer. It is an excellent example of evidence-based medicine at work. It is also an example of the real process of individualized medicine -making treatment recommendations based upon the history and risk factors of the individual patient. It further demonstrates the attention and effort that science-based medicine dedicates to preventing disease and morbidity. All of this stands in direct contrast to the propaganda of those who oppose science-based medicine.

An aspirin a day to prevent heart attacks, strokes, and cancer?
Taking an aspirin a day has always been controversial when it comes to preventing disease before it occurs. Now a task force is recommending daily use under some circumstances. Do the benefits really outweigh the risks?
Scott Gavura on September 24, 2015
Link


Despite the remarkable advances in medicine over the past 20 years, cardiovascular disease and cancer will still kill half of us. Beyond the deaths, millions survive heart attacks, strokes and cancer, but many are left with disability and a reduced quality of life. While lifestyle changes can improve our odds of avoiding these diseases, they do not eliminate our risk. Finding ways to medically prevent these diseases before they occur, a term called “primary prevention”, is a holy grail in medicine. Primary prevention can be a tough sell, personally and medically. It means taking medicine (which may cause side effects) when you’re well, with the hope of preventing a disease before it occurs.
The US Preventative Services Task Force (USPSTF) released draft guidelines on the primary prevention of cardiovascular disease and colorectal cancer last week. The USPSTF is now recommending daily aspirin in some age groups who have at least a 10% risk of cardiovascular disease in the next 10 years. This isn’t the first guideline that’s recommended aspirin for primary prevention of cardiovascular disease, but it is the first major guideline to endorse aspirin to prevent colorectal cancer. Given these recommendations will apply to millions of people, they have attracted considerable controversy. Is this strategy going to reduce deaths and disability? Or are we about to start “medicalizing” healthy people inappropriately?
Why take Aspirin?
Aspirin or acetylsalicylic acid (ASA) has a long history of use with origins in a natural remedy, where willow bark was used as medicine as far back as 3000-1500 BCE. The active ingredient in willow is salicin which, after being isolated, was modified chemically in an attempt to improve the side effect profile. The ASA chemical structure was invented in 1899 by the pharmaceutical company Bayer, which still retains the right to the trademarked brand name “Aspirin” in some countries. ASA is generic, inexpensive, and one of the most widely used drugs in the world.
The analgesic and pain-relieving effects of ASA are well known. At high doses, ASA can be used to treat inflammatory diseases like rheumatoid arthritis. ASA appears to reduce the risk of heart attacks and strokes through mild anti-inflammatory effects as well as anti-platelet effects (reducing their “stickiness”). The effectiveness of ASA in preventing cardiovascular disease was demonstrated back in the 1980s, with considerable research occurring since then on the optimal dose and conditions for use. The role of ASA in the prevention of a second heart attack or other cardiovascular “event” after the first one has occurred is now well established. In this population, the benefits tend to greatly outweigh the risks, and daily ASA therapy is standard treatment. As supporting evidence has emerged, there has been growing enthusiasm for its use in primary prevention, with some guidelines now (cautiously) endorsing its use. Steven Novella reviewed the evidence in a past post, noting that the potential benefit, being small, needs to be weighed against the real risk of side effects.
How ASA prevents colorectal cancer isn’t clear, but it does appear to work. It may be due to its effects on inflammation, possibly reducing the formation of tumors in the colon, but its effects on platelets have also been proposed.
What did the USPSTF do?
The USPSTF commissioned three systematic reviews and a decision analysis model to develop its recommendations. Using benefit and harm data, they estimated overall benefits to different groups. The model started by assuming a population that was not already taking non-steroidal anti-inflammatory drugs (NSAIDs), and with no risk factors for gastrointestinal bleeding. They used a risk calculator to predict the 10-year risk for a heart attack, stroke, or other death due to heart disease. They then considered the likelihood of benefit (cardiovascular events and cancers avoided) versus the risk of harms (e.g., gastrointestinal ulcers, and strokes caused by bleeding in the brain), and how that changed over time. The effects were modest but for some groups, a net benefit was found. ASA can reduce the risk of heart attacks and strokes by about 22%, although effects on all-cause mortality (any reason for death) are more modest (6% based on pooled data). Data on the effectiveness in reducing the risk of colorectal cancer was also observed. However, it takes 10 years or more before a benefit is seen – which can be up to 40%, with a 33% mortality benefit. The longer your life expectancy, the greater chance you have to experience benefit.
The net benefits and risk were then summarized for different age groups.
What are the expected benefits of daily ASA consumption?
Decisions about risks and benefits are ultimately personal ones. In this case, you must weigh your perceptions about the benefit of avoiding colorectal cancer, heart attacks and ischemic strokes against the risks of harms from ASA. The USPTF concluded there was sufficiently good evidence to conclude with “moderate certainty” that the benefits outweigh the risks for those aged 50-59 who are not at an elevated risk of bleeding:
The USPSTF recommends low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults ages 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.
They were also supportive, but with somewhat less confidence, of daily ASA used in those aged 60-69:
The decision to use low-dose aspirin to prevent CVD and colorectal cancer in adults ages 60 to 69 years who have a greater than 10% 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to use low-dose aspirin.
I’m under 50 or over 70 years old, why did the USPSTF say the evidence was “insufficient”?
The USPSTF concluded the evidence was insufficient to assess benefits and harms of primary prevention if you are younger than 50 or over the age of 70.
In those under the age of 50, the risk of cardiovascular disease is lower and the expected benefits have not been well studied. Given the lower risk, the harms likely outweigh any expected benefits. People with shorter life expectancy are less likely to obtain an overall benefit from ASA therapy. That’s why the USPSTF was more supportive of starting ASA in those aged 50-59.
Evidence of benefit in older (>70 years) is also lacking. While the risk of cardiovascular disease is much higher, so is the likelihood of harm from ASA. There is also less expected benefit in terms of protection from colorectal cancer in this age group. Consequently, any decision to treat requires a careful evaluation of expected benefits and potential risks.
Why do I need to take ASA for 10 years? Is there any benefit to taking it occasionally?
The overall benefits of ASA are due to effects on cardiovascular disease and cancer. The evidence suggests you need to take ASA daily for at least 10 years before there’s a meaningful benefit on your risk of colon cancer, which is an important contributor to the overall benefit of the therapy.
What’s the proper dose of ASA for primary prevention?
There’s no clear evidence supporting any single dose. The 81mg tablet is widely available and used regularly. There’s no persuasive evidence that enteric-coated tablets or “buffered” tablets reduce the side effects of ASA. One tablet daily is the usual dose.
What are the possible risks of daily ASA therapy?
The biggest risk of ASA treatment is gastrointestinal (GI) bleeding. The risk of a GI bleed increases with age. Any other conditions or medications that raise that risk (e.g., history of GI ulcer) need to be considered in the overall decision. There is also the risk that the benefits will be reduced if the medication isn’t taken. A decision to start ASA to prevent disease should be considered a 10 year commitment. Sticking with daily medication use can be challenging, particularly when you’re not actually ill.
I don’t want to take ASA, what can I do to reduce my risks?
You can dramatically reduce your risk of cardiovascular disease through lifestyle changes:
    • Don’t smoke
    • Maintain a healthy body weight
    • Exercise regularly
    • Eat a healthy diet
You can also add to this:
    • Prevent and treat diabetes, high blood pressure and high cholesterol, using the best evidence
Do as many of these as possible and you will significantly reduce your risk of cardiovascular disease.
There’s less evidence to suggest that lifestyle changes can prevent colorectal cancer, but a healthy diet and the advice above will probably be helpful. Screening programs are effective, and should be considered at the appropriate age (usually age 50).
Praise and criticism
Taking ASA for primary prevention requires a close evaluation of known risks and expected benefits. The new USPSTF guidelines try to clarify the place in therapy. Probably the biggest argument against primary prevention with ASA is the fact that there is limited randomized data that’s examined this specific question. This has led to different interpretations of the evidence. As recently as May, the FDA denied a request from Bayer to approve the marketing of Aspirin for primary prevention. Some criticize the guidelines for their complexity, suggesting that some may consider self-medicating without implementing more important (and effective) lifestyle changes or accessing screening programs.
What’s the bottom line?
Given the risks, is the evidence strong enough to recommend ASA for primary prevention? For those in the 50-69 age group, there is likely to be a modest, but real benefit. But this benefit comes with some risks. On an individual basis, the incremental benefit needs to be considered in the context of everything that you’re doing to prevent cardiovascular disease and cancer. Calculate your own cardiovascular risk. Think about what you personally value, your own lifestyle choices, and the risks you’re willing to accept. Then speak with your primary care provider about your preferences.

Anti-inflammatory drugs and heart attacks: How real are the risks?
A new study provides more evidence that anti-inflammatory drugs like naproxen and ibuprofen cause small but real increases in the risk of heart attacks.
Scott Gavura on May 18, 2017
Link

Many of us are familiar with the non-steroidal anti-inflammatory drugs (NSAIDs) like Advil, Motrin and Aspirin. They’re among the most versatile and arguably well-loved drugs in our medicine cabinets. They offer good pain control, reduce inflammation, and can treat fever effectively. We give NSAIDs to infants, continue them in adulthood for the aches and pains of modern life, and take them regularly, often at prescription-level dosages, in our later years for the treatment of chronic conditions like osteoarthritis. An astonishing 17 million Americans use NSAIDs on a daily basis, and this number is expected to keep growing as the population ages.
Surprisingly, while drugs like ASA (aspirin), naproxen and ibuprofen don’t require a prescription, they have a long list of serious side effects. Not only do they cause stomach ulcers and bleeding by damaging the gastrointestinal mucosa, there are cardiovascular risks, too. It was the arrival (and departure) of the drugs Bextra and Vioxx that led to a much better understanding of the potential for NSAIDS to cause cardiovascular toxicity. It is now clear that these effects are not limited to the “COX-2” drugs: All NSAIDs seem capable of raising the risk of hearts attacks and strokes.
Now a new meta-analysis published in The BMJ suggests that the risks of heart attacks and strokes could be raised after only one week of taking an anti-inflammatory drug regularly. How does this change how we should use them?
NSAIDs 101
NSAIDs all work in the same way, blocking the cyclooxygenase (COX) enzyme, responsible for the production of prostaglandin messenger substances that cause pain, inflammation and fever. This mechanism of action is also responsible for the extensive list of side effects, a consequence of COX enzymes being distributed throughout the body. NSAIDs cause a startling amount of harm. They have been linked to about 30% of drug-related hospital admissions, and it’s estimated that 12,000-16,000 Americans die annually as a result of gastrointestinal bleeding caused by NSAIDs. The risks of gastrointestinal toxicity are significantly increased in the elderly, in those on high doses of NSAIDs, and when combined with other drugs (e.g., steroids) that suppress normal stomach protection. Fortunately these side effects can be prevented with drugs like proton pump inhibitors.
The other well-known side effect is cardiovascular disease, and the evidence is now quite clear that NSAIDs increase the risks of heart attacks and strokes.
There are two main subtypes of COX enzymes (conveniently, COX-1 and COX-2), and the affinity of a particular NSAID for the different COX enzymes has been thought to be the main factor influencing the degree of cardiovascular risk. The COX-2 inhibitors like Vioxx had fewer effects on COX-1 in the gastrointestinal tract, reducing side effects, but effects on COX-2 are more closely linked with increases in events like heart attacks and strokes. These effects may be a consequence of interference with the beneficial effects of concurrent low dose ASA, direct negative cardiovascular effects, and/or worsening of fluid balance, leading to heart failure. What hasn’t been clear is how quickly a user of NSAIDs may face an increased risk of a harmful cardiovascular event .This new paper starts answering that question.
Despite the headlines you may have seen, this analysis from Bally and colleagues is a systematic review, and not a new clinical trial. Published in The BMJ, it’s entitled “Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.” The fact this uses individual patient data (IPD) is notable. Most meta-analyses pool the results of trials. IPD meta-analyses pool and analyze the raw patient data from different trials. If that sounds cumbersome, that’s because it is. Cochrane considers IPD meta-analysis the “gold standard” of systematic review methods.
The researchers set out to examine the characteristics and time course of heart attacks (myocardial infarction) with the use of NSAIDs. Datasets were searched for observational studies of large healthcare databases that compared the risk of myocardial infarction in NSAID users and non-users, and that allowed for an analysis by time window. They also had to provide adequate detail about the NSAIDs consumed. Given the restrictive criteria, only a small number of possible trials could be used. The researchers eventually used data sets from Quebec, Saskatchewan, Finland, and the United Kingdom, totaling over 61,000 patients who had heart attacks. The NSAIDs of interest were celecoxib, the three commonly used NSAIDs, (diclofenac, ibuprofen, and naproxen), and rofecoxib (Vioxx). With all this data they created categories of use that sorted patients according to when they took an NSAID, what their dose was, and how long they took it. The index date was the date of hospital admission for a heart attack:
With these types of studies there’s a huge potential for confounders, or factors that influence the observed relationship. The list of possible confounders the researchers generated was extensive (and I won’t detail it here, plus other aspects of the review, in the interest of space). For the analysis, they studied the results of the four trials, but also the pooled patient data. They used a Bayesian framework to make probability statements about the risks in different time periods.
The results: Significant elevations in risk
In total there were 61,460 cases and 385,303 controls. Between the four trials included, the populations differed significantly. This study found that there was a relative risk increase of 20-50% overall, with what appears to be a 75% increase in risk for ibuprofen and naproxen, and over a 100% risk increase for rofecoxib (Vioxx). The risk of heart attack appears to increase almost immediately (and decrease over time after the last use of an NSAID). There was also a dose effect observed, with higher NSAID doses appearing to correlate with greater risk. Interestingly, risk didn’t continue to increase beyond a month of therapy. That is, there appears to be greater risk of heart attack if an NSAID is used beyond one month. There were some small but modest differences between the NSAIDs studied. Notably, naproxen appears equally harmful to other NSAIDs, while celecoxib (Celebrex) appears no more harmful than the other NSAIDs.
There have already been some criticisms raised in the rapid responses, which seems to focus on the apparently immediate onset of risk with NSAIDs, which some feel may be related to reverse causation, in that these patients may have been taking NSAIDs for the pain of a (subsequently-diagnosed) heart attack. It should also be noted that non-prescription use of NSAIDs is no considered in this paper, as that data was not available. Given the widespread use of non-prescription NSAIDs, it’s really not clear to what extent this may have influenced the findings.
Absolute versus relative risk: Beyond the headlines
While the risks found in this analysis appear to be real, it’s essential to recognize that these are relative risk increases, not absolute risk increases. If your underlying risk is low, then the incremental risk is low. This paper does not report absolute risks. The authors suggest using a risk calculator like the Framingham Risk Score to estimate the 10 year risk of coronary heart disease, and use that finding as a guide to place this research in context. They note:
Without use of NSAIDs, one could expect that the number of cases of acute myocardial infarction will be fewer than 1 case per year per 100 persons in those at low risk (less than or equal to 10% over 10 years), 1 to 2 cases per year per 100 persons in those at intermediate risk (10-20% over 10 years), and greater than 2 cases per year per 100 persons in those at high risk (>20% over 10 years).
Assuming an increase in the relative risk of acute MI of 20 to 50% across NSAID doses and durations studied in the IPD meta-analysis, the number of excess acute myocardial infarctions associated with use of common NSAIDs might range from fewer to 0.2 to 0.5 case per year per 100 persons in those at low coronary risk or < 0.2-0.5% annually (< 2 to 5 cases per 1,000 persons per year) up to 0.4 to 1 or more cases per year per 100 persons in those at high coronary risk or > 0.4 to 1% annually (> 4 to 10 cases per 1000 patients per year). Hence the absolute percentage increase of excess MIs due to NSAID exposure is likely to range from 0.2% to 1% annually.
Emphasis added.
Treating pain: Between a rock and a hard place?
It’s important to remember that this new paper doesn’t change what we’ve known for some time: If your baseline risk of a heart attack or stroke is low, then NSAIDs raise your risk only slightly. However, given the fact NSAIDs are taken so casually, the apparent rapid escalation of risk should concern anyone with a modest- to high-risk of a heart attack who might not normally have worried about several days of high-dose NSAID use (say, for an acute injury). What this analysis shows is that there’s an apparent rapid increase in risk.
Overall, these findings reinforce the fact that we lack safe and effective treatment options for chronic pain control. With the opioid epidemic killing thousands across North America, there’s more awareness than ever of the risks of using narcotic analgesics for acute or chronic pain. However, many patients with chronic pain may be older, or have risk factors for cardiovascular disease, and shouldn’t be on NSAIDs. Given the modest and even questionable effectiveness of acetaminophen (Tylenol) for many types of chronic pain, there are few effective medical options remaining. I’ve written before about topical NSAIDs which appear to lack the toxicity of oral products. They may be a reasonable alternative for those that want to minimize their risk, or are seeking treatment alternatives.
Use with caution
With the populating aging, the need for effective treatment options for conditions of age, like osteoarthritis, will continue to grow. It’s now clear that indiscriminate use of opioids have been a public health disaster. What’s less obvious, but also causing substantial harms, are the NSAIDs. This well-done individual patient data systematic review provides useful data to health professionals and consumers alike: The risk of harm from taking an NSAID, even products like ibuprofen or naproxen, is low, but increases quickly with use. Regular usage of the NSAIDs studied, beyond a week or more, is associated with a modest (but real) increase in the risk of heart attack. NSAIDs provide good pain relief and can decrease inflammation. But they have the potential to cause significant harm, which increases with dose, duration of use, and the underlying risk. Use them if you need them, but only if you need to, at the lowest dose possible, and for the shortest duration possible.

Anti-inflammatory drugs: A closer look at the risks
Scott Gavura on March 15, 2013
Link
If science-based medicine reflects the application of the best evidence, then we should expect practices to change when new data emerges. In the long run that’s generally true, and the progressive gains we’ve seen in the management of disease reflect this. But in the short run, change can be maddeningly slow, and there are many areas of medicine where we could be doing a better job of applying what we already know to improve outcomes and reduce harms. One area where this is obvious is drug treatments, which can provide remarkable benefits but are also sources of significant harms.
Somewhat problematically, the real world is often the setting where the full extent of harms from treatments are identified. Bringing new drugs to market means tradeoffs: Do you demand larger and longer clinical trials to get as much information as possible about a drug before it’s sold? Or do you approve based on more preliminary, potentially weaker evidence, to meet (potentially) important patient need? There is no set formula or right answer to this questions – it’s ultimately a value judgement exercised by regulators like the FDA, who decide which drugs are allowed for sale (the benefits are assumed, overall, to exceed the harms) or removed for sale (when the opposite is felt to be the case).
Once a decision is made to allow a drug for sale, the evidence on risk and benefit continues to emerge, sometimes from continued clinical trials, possibly from adverse drug reactions, and occasionally from epidemiological studies that are conducted to better understand the overall safety and efficacy of treatments. In general, once a drug is on the market the threshold for removing it is fairly high. For example, I suspect a drug that taken in overdose can cause liver failure and is the leading cause of liver transplants would probably not be approved if developed today, even if acetaminophen (paracetamol, or APAP) is an effective pain reliever and safe at appropriate doses.
Tylenol is far from the only drug with significant benefits as well as significant harms. Nowhere are trade-offs between risks and benefits more apparent than with the non-steroidal anti-inflammatory drugs (NSAIDs). Some, like ibuprofen (Advil, Motrin), ASA (Aspirin), and naproxen (Naprosyn, Aleve) are available without prescriptions in some countries, while about a dozen more including celecoxib (Celebrex) and diclofenac (Voltaren) are usually prescription-only.
NSAIDs are among the most widely used drugs, starting in infancy for pain and fever, right through to the elderly where they are standards for treating osteoarthritis and other muscle and skeletal conditions. NSAIDs all work in the same way, blocking the cyclooxygenase (COX) enzyme, responsible for the production of prostaglandin messenger substances that cause pain, inflammation and fever. The mechanism of action is also responsible for the extensive side effect list, a consequence of COX enzymes being distributed throughout the body. Ulcers are the most well-known effect and hospitalization secondary to gastrointestinal bleeding from NSAIDs is common. Fortunately these side effects can be prevented with drugs like proton pump inhibitors. The other well-known side effect is cardiovascular disease, and NSAIDs seem to increase the risks of heart attacks and strokes. There are two main subtypes of COX enzymes (conveniently, COX-1 and COX-2) and the affinity of a particular NSAID for the different COX enzymes seems to be the main factor influencing the degree of cardiovascular risk. The COX-2 inhibitors like Vioxx had less effects on COX-1 in the gastrointestinal tract, reducing side effects, but effects on COX-2 were linked with increases in events like heart attacks and strokes. Importantly, other NSAIDs interfere with the beneficial effects of ASA (aspirin) on platelets that can give protective effects against cardiovascular disease.
Now in a world that responds quickly to new evidence we’d expect to see a shift away from the NSAIDs with the worst side effect profiles and towards more use of those with the best side effect profiles. After all, no NSAID has been shown to be clinically more effective than another in trials, although individual responses can vary. But the most toxic NSAIDs are still used widely, as was noted recently in a paper published in PLoS Medicine, entitled, Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries by Patricia McGettigan and David Henry. NPR’s headline was perhaps a more succinct summary of the key finding, which was World’s Most Popular Painkiller Raises Heart Attack Risk. It’s important to note that this paper doesn’t present any previously unpublished information about NSAID safety, but it does an effective job of illustrating the disconnect between medical evidence and medical practice.
The authors start by summarizing the known risks of cardiovascular events with NSAIDs in a handy table:
There’s a lot here. The columns summarize the risks of NSAIDs identified by trials, and the rows show the different drugs studied. The relative risk is reported – that is the degree to which the baseline (or underlying) cardiovascular risks were observed to increase as a result of that particular NSAID. Rofecoxib (Vioxx), now withdrawn, has a clear risk of 1.27 to 1.45 x versus non-users. What’s remarkable is what the NPR headline hints at. The risks from diclofenac, the most popular NSAID in the world, is at least as high as Vioxx: A 1.39-1.69 relative risk. That is, cardiovascular events are 40-70x more likely among users of diclofenac compared to non-users.
Let’s put the relative risk in context. The actual increase in risk to anyone is dependent on the baseline risk. A young, otherwise healthy make or female would have a small underlying risk of a cardiovascular event. So the incremental risk from taking any NSAID, even one like Vioxx, is still tiny. But the risk changes in patients with multiple medical conditions who are already at high risk of heart attack or stroke. A relative risk increase of 40% could imply a significant increase in the absolute risk. So the relevance of this controversial debate about NSAIDs really depends on the underlying risk.
So if diclofenac is the worst, which NSAID is best? The data suggest the risk with naproxen is similar to non-users of NSAIDs. Why naproxen is the least toxic is unclear, but it may be because of its high affinity for COX-1 which may give it antiplatelet effects that are actually beneficial. The data are pretty consistent – if you’re worried about minimizing cardiovascular risk, naproxen looks like a much safer choice than the other NSAIDs. Beyond naproxen, celecoxib (Celebrex) and ibuprofen have a dose-dependent elevation in relative risk that does not seem to be significant at the lower doses typically used.
The second part of the paper is an examination of the worldwide use of NSAIDs, based on a basket of countries representing a range of incomes. Countries studied included Australia, England, Canada and thirteen Asian and South-Asian countries. The United States was not included in the survey, and there’s no explanation why. Based on an analysis of prescriptions and sales, diclofenac is the most widely used NSAID, and diclofenac plus etoricoxib (not available in North America, but with a similar risk profile to Vioxx) make up one-third of all NSAIDs used. The authors note that the World Health Organization’s recommended list of “essential” drugs still includes diclofenac, despite a risk profile that is equivalent to Vioxx.
If you’re looking for a good example of the disconnect between research and practice and the avoidable harms, this is it. Despite the risks of diclofenac being known for at least a decade, worldwide it’s still widely used and enormously popular. Whether due to slow-to-change physician prescribing or to other factors, like over-the-counter purchases, it’s clear that something is blocking the switch. The authors argue that regulators should withdraw diclofenac, a blunt instrument that would certainly reduce use. While this action would be a negative for those that have found diclofenac to be the most effective NSAID, it would almost certainly reduce the incidence of heart attacks and strokes in those countries where it’s used indiscriminately.
Topical NSAIDs
In the United States and in other countries, diclofenac is also sold as Voltaren cream or “Emulgel,” a topical product that you apply directly to the site of pain. It’s marketed for both short-term and chronic pain conditions. I admit to having dismissed topical NSAIDs as placebos when I first heard of them, believing that oral delivery was essential for getting meaningful amounts to the side of action. I was wrong. Not only do topical NSAIDs work, they are quite effective and preferable to oral NSAIDs for some conditions (especially superficial musculoskeletal problems, like arthritis or tendonitis). The main advantage of topical NSAIDs is the reduced exposure of the rest of the body to the product, which reduces the side effect profile. Given the toxicity of NSAIDs is related in part to the dose, it follows that topical treatments should have a better toxicity profile. Consequently, the cardiovascular risks of topical diclofenac, even in those with a high baseline risk of disease, should be negligible with the topical forms.
Conclusion
All NSAIDs are hazardous, but but some have higher toxicities than others. For occasional and long-term use, products like ibuprofen and naproxen are safer and as effective as other NSAIDs. Diclofenac remains a popular NSAID despite the evidence that it causes heart attacks and strokes in rates similar to that of Vioxx. There’s little rationale for allowing its continued sale, and there’s good justification for withdrawing it from the market worldwide. Until practices change or regulators act, this will remain another example of the gap between evidence and practice, a gap that’s likely resulting in thousands of avoidable deaths each year.

The evolving story of the harms of anti-inflammatory drugs
Scott Gavura on July 23, 2015
Link
Owing to summer vacation, today’s post updates a 2011 post and a 2013 post with some new information.
Anti-inflammatory drugs are among the most well-loved products in the modern medicine cabinet. They can provide good pain control, reduce inflammation, and eliminate fever. We give non-steroidal anti-inflammatory drugs (NSAIDs) in infancy, continuing through childhood and then adulthood for the aches and pains of modern living. It’s the later stages of life where NSAIDs are used most frequently, usually in the treatment of joint disease like osteoarthritis, which eventually affects pretty much everyone. Over 17 million Americans use NSAIDs on a daily basis, and this number will grow as the population ages. While they’re widely used, they also have a long list of side effects. Not only can they cause stomach ulcers and bleeding by damaging the lining of the gastrointestinal tract, cardiovascular risks are also significant.
It was the arrival (and withdrawal) of the drugs Bextra (valdecoxib) and Vioxx (rofecoxib) that led to a much better understanding of the potential for these drugs to increase the risks of heart attacks and strokes. And it’s now well-documented that these effects are not limited to the “COX-2″ drugs – almost all NSAIDs, including the old standbys we have used for years, raise the risk of heart attacks and strokes.
Natural origins
ASA (acetylsalicylic acid, better known as aspirin) is the prototypical NSAID. ASA traces its origins back to willow bark, a natural source of the chemical salicylate. All NSAIDs work the same way, interrupting the production of inflammatory and pain-related hormones called prostaglandins. Since ASA’s introduction in 1897, more than two dozen chemically-related drugs have been developed. They’re now among the most commonly used drugs used worldwide. If you believe the marketing, you may think there are vast differences between the NSAIDs in terms of efficacy and safety. But the evidence show that NSAIDs are similarly effective at the population level, though individual response, and toxicities, can vary between drugs. Currently available NSAIDs differ in their side effect profile based on the way they work at a molecular level. The discovery of different forms of what are called “cyclooxygenase” enzymes led to interest in developing drugs that targeted COX-2 (at sites of inflammation) rather than COX-1 enzymes. COX-1 enzymes regulate normal cellular processes including protecting the lining of the stomach and blood clotting. Inhibit COX-2 rather than COX-1, the thinking went, and you could get the anti-inflammatory action of traditional NSAIDs without serious gastrointestinal side effects. Traditional NSAIDs (e.g., Advil) are considered “unselective” NSAIDS. To minimize GI side effects, manufacturer’s developed more “selective” NSAIDs that preferentially inhibited COX-2. “COX-2” drugs like Celebrex (celecoxib) provide comparable pain relief to a traditional NSAID, like Naprosyn (naproxen) but with a lesser risk of causing stomach ulcers and bleeds. However, as the Vioxx debacle demonstrated, COX-2 inhibitors had a significant prothrombic (i.e., blood clotting) effect – with devastating cardiac consequences (e.g., heart attack and stroke).
The risks of NSAIDs
Prescription drugs can cause harm. They can even hospitalize. While we may think nothing of popping a few Advil now and then, NSAIDs have been linked to about 30% of drug-related hospital admissions, and it’s estimated that 12,000-16,000 Americans die annually as a result of gastrointestinal bleeding caused by NSAIDs.
Stomach bleeding and ulcers are an expected side effect of the way NSAIDs work – their effect on prostaglandins. The lining of the gut is weakened, and stomach and duodenal ulcers result. Even very low doses of ASA have been documented to have measurable effects on the mucosal lining of the gastrointestinal tract. The risks of gastrointestinal toxicity are significantly increased in the elderly, in those on high doses of NSAIDs, and when combined with other drugs (e.g., steroids) that suppress normal stomach protection.
The cardiovascular risks of NSAIDs became well documented following the worldwide withdrawal of Vioxx and international examinations of the cardiovascular risks of the entire category of drugs. Data have now emerged to convincingly establish that most NSAIDs (except ASA in low doses) are associated with an increased risk of cardiovascular events. Vioxx alone is estimated to have caused as many as 140,000 heart attacks over the five years it was sold in the US. Chronic (routine) consumption of NSAID drugs is linked to small but real increases in heart attacks and stroke. These effects may be a consequence of interference with the beneficial effects of concurrent low dose ASA, direct negative cardiovascular effects, and worsening of fluid balance, leading to heart failure.
When it comes to cardiovascular risks, not all NSAIDs are the same, and the US Food and Drug Administration (FDA) has met regularly to review emerging data since the Vioxx/Bextra withdrawal. The FDA also asked Pfizer to examine celecoxib’s safety compared with ibuprofen and naproxen in what became known as the PRECISION trial (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen) that launched in 2005. As of 2015 there are over 24,000 participants enrolled, however the rate of cardiovascular events has been lower than expected, limiting any conclusions about the differences in cardiovascular harms. The trial wasn’t expected to conclude until the end of 2015 [PDF], and that date has since been revised to 2016.
The most recent FDA meeting was in 2014. It resulted in an FDA announcement earlier this month that strengthened their warning on the use on non-aspirin NSAIDs and the risk of heart attack and stroke. If you’re interested in the details of the FDA’s review, there is a nice open-access summary in Drug Safety, but here are a few highlights of some of the data examined:
    • A 2011 network meta-analysis examined traditional NSAIDs, like naproxen, ibuprofen, and diclofenac, as well as the COX-2 selective NSAIDs, like celecoxib and rofecoxib. It concluded “Although uncertainty remains little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. Naproxen seemed least harmful. Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug.”
    • A 2011 Danish observational study examined NSAID use in those with cardiovascular disease and concluded that even short-term use of NSAIDS raises the risk of heart attack and death. It recommended against short- and long-term use of NSAIDs in this group.
    • A 2013 network meta-analysis of trials concluded that the cardiovascular risks of diclofenac and high-dose ibuprofen are comparable to the COX-2 drugs, and noted that naproxen is associated with less risk than other NSAIDs.
Given the latest data, the FDA has now announced the following for over-the-counter and prescription NSAIDs (excluding ASA):
    • The risk of heart attack or stroke can occur as early as the first weeks of using an NSAID. The risk may increase with longer use of the NSAID.
    • The risk appears greater at higher doses.
    • It was previously thought that all NSAIDs may have a similar risk. Newer information makes it less clear that the risk for heart attack or stroke is similar for all NSAIDs; however, this newer information is not sufficient for us to determine that the risk of any particular NSAID is definitely higher or lower than that of any other particular NSAID.
    • NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease. A large number of studies support this finding, with varying estimates of how much the risk is increased, depending on the drugs and the doses studied.
    • In general, patients with heart disease or risk factors for it have a greater likelihood of heart attack or stroke following NSAID use than patients without these risk factors because they have a higher risk at baseline.
    • Patients treated with NSAIDs following a first heart attack were more likely to die in the first year after the heart attack compared to patients who were not treated with NSAIDs after their first heart attack.
    • There is an increased risk of heart failure with NSAID use.
So for the individual consumer, when do the risks outweigh the benefits of NSAIDs? Ultimately this comes down to an individual consideration of reasons for use, risk factors, and expected benefits. When used for treating short-term conditions, the increase in risk for those without cardiovascular disease appears to be very low. While the data seems pretty convincing that naproxen is associated with less cardiovascular risk, the FDA did not make a definitive statement to this effect. In those with a low risk of cardiovascular disease, there doesn’t appear to be much difference between ibuprofen and naproxen when taken occasionally. In those that need to take an NSAID for a longer period, naproxen (versus the other NSAIDs) looks like a safer choice from a cardiovascular perspective.
Topical NSAIDs: The evidence
Over the past two decades, evidence has emerged to demonstrate that topical versions (e.g., over-the counter gels) of NSAIDs are well absorbed through the skin and reach therapeutic levels in synovial fluid, muscle, and fascia. Given the cardiovascular harms of NSAIDs seem to be dose-related, do topical versions provide comparable benefits with less harm? A 2012 Cochrane Review provides the most recent summary of the evidence for chronic pain, concluding that there is good evidence that topical NSAIDs (like diclofenac) provide similar pain relief to oral NSAIDs (for knee and hand osteoarthritis) with reduced gastrointestinal side effects. The reviewers note that there is a lack of long-term safety data for topical NSAIDs, and consequently there is a lack of evidence on the associated cardiovascular risks. (This is owing to their relative rarity compared with gastrointestinal side effects.) A 2010 Cochrane review also reports positive findings about the use of these products in the treatment of acute pain conditions. Forty-seven trials were included in their analysis that considered topical NSAIDs for strains, sprains, and overuse-type injuries. Compared to placebo, topical NSAIDs were evaluated to be more effective, with fewer side effects. Given the systemic absorption of NSAIDS like diclofenac is lower with topical versions, the toxicity we associate with oral NSAIDs should be lessened, too. There’s little evidence to demonstrate that topical NSAIDs are effective for some types of pain, like back pain, headache, or neuropathic pain. But based on what’s now known about the cardiovascular toxicity of NSAIDs, it’s likely that topical products provide a superior risk/benefit perspective over the oral NSAIDs (at least for some pain/joint conditions).
What about Tylenol?
As Harriet Hall noted last year, while acetaminophen (paracetamol) is widely used for the treatment of pain, the evidence for its efficacy is modest. As long as it is given in appropriate doses, however, there’s no evidence that suggests that Tylenol is associated with the cardiovascular risks of NSAIDs. However, it seems reasonable to continue to use acetaminophen before trying NSAIDs for conditions that require pain relief but not anti-inflammatory effects.
Conclusion: NSAIDs are convenient, effective, and safe, but not harmless
While NSAIDS may be conveniently purchased in large quantities from your neighbourhood drug store, don’t let the ease of access imply these products are harmless, especially if used inappropriately. Everyone that takes an NSAID raises their risk of cardiovascular and gastrointestinal harm to some extent. Consequently, the safest strategy is to take the lowest effective dose for the shortest duration of time. Those with pre-existing cardiac conditions or risk factors should check with their primary care provider before taking NSAIDs, to determine if non-NSAID alternatives may offer a better balance of benefit vs. risk.
While the evidence comparing NSAIDs is still somewhat murky, naproxen seems safest amongst the non-prescription oral NSAIDs. Topical NSAIDs also appear to be useful alternatives to regular oral NSAID use. Among the prescription NSAIDs, it’s somewhat of a mystery that oral diclofenac remains licensed and in use as a prescription drug despite the evidence that it causes heart attacks and strokes in rates similar to that of Vioxx.
The lesson in the NSAID–cardiovascular story is the impact and need for good evidence. All drugs, even those with life-changing benefits, may have serious albeit rare unintended consequences. The evolving safety evidence on NSAIDs is a constant reminder of the challenge of balancing risks and benefits in the absence of good evidence.

Do anti-inflammatory drugs effectively treat spinal pain?
While anti-inflammatory drugs are commonly used to treat back pain, a new review suggests that they may not provide meaningful benefits to most people.
Scott Gavura on February 9, 2017
Link


Most scientific presentations begin with a PowerPoint slide showing all of the speaker’s conflicts of interest. Not all conflicts of interest are financial. Some can be personal. My conflict of interest today is that I’ve suffered from occasional back pain, on and off, for years. And when I’ve had acute pain, I’ve taken non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil). And while I’ve never found them to be miracle drugs, I did believe that they were providing some degree of pain relief, albeit with risks. Earlier in my career, I learned just how toxic these drugs can be. Working 12-hour shifts, always on my feet, led to some debilitating back pain. I took NSAIDs daily, for weeks. I was eventually diagnosed with a stomach ulcer. Since that time, I’ve found regular exercise seems to keep the back pain at bay, most of the time. And I’m pretty cautious about taking ibuprofen anymore. But I still use it occasionally, assuming that the potential for benefit outweighed any short-term risk. Now there’s a new study that suggests that the benefits of NSAIDs for spinal pain may be even more modest than I (and others) may have been led to believe. And it’s generating new questions about the best approach to spinal pain.
The ubiquity of spinal pain
Spinal pain, whether it’s low-back pain or neck pain is a common cause of disability and among the most common reasons for physician consultation. While most cases of acute pain are self-limiting and will resolve over time, they can be very debilitating, and I find as a pharmacist that people are willing to do or try just about anything if they think it will help them get back to normal function. Despite how common spinal pain is, the causes are poorly understood, and in most cases, never identified. While heat, ice, physical therapies, and spinal manipulation are sometimes sought out for acute spinal pain, self-managed therapy often starts (and ends) with analgesics and anti-inflammatory drugs. They are the mainstay of therapy. But do they deserve to be?
NSAIDs are among the most widely used drugs in the world, starting in infancy for pain and fever, right through to the elderly where they are standards for treating osteoarthritis and other muscle and skeletal conditions. NSAIDs all work in the same way, blocking the cyclooxygenase (COX) enzyme, responsible for the production of prostaglandin messenger substances that cause pain, inflammation and fever. The mechanism of action is also responsible for the extensive side effect list, a consequence of COX enzymes being distributed throughout the body. Ulcers are the most well-known effect and hospitalization secondary to gastrointestinal bleeding from NSAIDs is common. Fortunately these side effects can be prevented with drugs like omeprazole. The other well-known side effect is cardiovascular disease, and NSAIDs seem to increase the risks of heart attacks and strokes. Given they’re used so frequently for spinal pain conditions, understanding their risk and potential benefit is essential. That’s what a new study set out to document.
This new paper is entitled “Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis,” and was published in the Annals of the Rheumatic Diseases. The advantage of a systematic review is that it can give more precision and accuracy to a specific clinical question, pulling together the results from multiple smaller trials into a comprehensive analysis. A systematic review looks at all the evidence on a topic, eliminating the risk of arbitrarily “cherry picking” the trials that point to a specific or erroneous conclusion. The risk of a systematic review is that it can be a GIGO scenario, as ultimately the review’s usefulness is a function of the types of studies that went into it. There can be good and bad aspects to these types of reviews, which I’ll come back to.
The investigators (Gustavo C. Machado and colleagues) cast a “wide net” looking for studies – they used fairly broad criteria. They searched the major databases for randomized controlled trials, published in peer-reviewed journals, comparing NSAIDs with placebo for spinal pain. Trials had to include those with neck or back pain, with or without “radicular” pain (radiating pain). They included acute (short-term) and chronic (long-standing) spinal pain, and including any type of NSAID as well as any formulation (oral, injectable and topical forms were included). They excluded patients with serious spinal conditions or other conditions (e.g., cancer) and they also excluded pain management after surgery. All non-randomized trials, guidelines, and observational studies were excluded. I’m not going to describe the data extraction and trial quality assessment process. I am not a methodologist, but the process described looks consistent with other systematic analyses.
Measuring pain and pain relief

One of the challenges in measuring pain, especially in clinical trials, is that there’s no objective marker. We rely primarily on visual analogue scales (0-100) or asking patients to rate their pain (“How does your pain feel on a scale of 0 to 10”). The image above is an example of a scale that might be used. An important question when using a pain scale is determining what constitutes a “meaningful” difference. This often comes up in the discussion of alternative medicine where a very weak (but statistically significant) difference is shown in some measure, which is cited as “proof” that the intervention (e.g., acupuncture) “works”. We use the term “clinically important” or “clinically relevant” to try to distinguish between changes that are meaningful to patients, and those that are likely not. For example, if you rate your pain a 70 today and a 66 tomorrow, that’s not likely to be clinically meaningful. In this analysis, a difference of 10 points (on a 0-100 scale) is what the authors specified they considered the smallest worthwhile effect.
The results
After searching and screening, only 35 randomized trials were found, a number I found disappointingly low given how frequently NSAIDs are used for the spinal pain. Most of the trials were for oral products, but five looked at intravenous or topical treatments. Twenty-two trials examined low back pain, split evenly between studies of acute and chronic pain. Eleven trials looked at sciatica and only two looked at neck pain only. Amazingly, the median treatment duration in the trials was seven days. While there were a relatively small number of trials, they were of generally high quality. Overall, the researchers assessed that there was a low risk of bias in the results.
Efficacy
The pooled analysis found moderate-quality evidence that NSAIDs do reduce pain in the short- and intermediate-term, compared with placebo, with mean differences in pain scores of -7.7 and -9.2, respectively. The number needed to treat to obtain clinically significant pain relief effects was calculated at 6 for short-term pain, and 5 for intermediate-term pain. There were also real effects on disability with a short term decrease of -6.1 and intermediate-term effects of -8.1. Given the mean difference between the groups was less than 10 for all measures, the authors noted that these differences were not expected to be clinically important. There were no studies reporting medium- or long-term effects of NSAIDs on spinal pain. Figure 2, which I’ve reproduced below, shows that there’s undeniably a real effect from NSAIDs, with some studies showing substantial effects. At issue is the extent to which we should consider the overall effectiveness to be clinically meaningful:
Safety
Twenty-one trials were included in the safety analysis, where the median treatment duration was 7 days. There were no differences noted in “any event” adverse events reports between NSAIDs and placebo. However, when looking specifically at gastrointestinal effects, there were more adverse events reported in the NSAID group, with a relative risk of 2.5 compared with placebo. This isn’t surprising. I’ve blogged before about the overall safety profile of NSAIDs, which wasn’t the subject of this study.
Use of “rescue” medications
It’s not uncommon in pain trials to look at the use of other analgesics as a proxy for the effectiveness of the treatment. The use of “rescue” analgesics was studied in a pooled analysis of 4 trials, and while there was a modest (yet statistically significant) reduction (-0.4 tablets/day) in the NSAID group, the authors comment that this is “arguably not clinically significant.”
Secondary analyses
The authors sliced and diced the studies and found:
    • Trials with the lowest risk of selection bias had larger effects (mean difference -11.2)
    • COX-2 drugs (like Celebrex) had larger effects than the “nonselective” NSAIDs (mean difference -13.4 vs -7.7)
    • There were slight differences in the effects of the different dosage forms (topical MD -13.2, oral MD -8.5, injectable MD -9.5)
Conclusion: NSAIDs reduce pain…somewhat
NSAIDs reduce spinal pain. This effect is observed across different drugs and even with different dosage forms. The effects are modest, however, and the overall usefulness is not as obvious as we’d like. Translating the effect size into a number needed to treat, the authors calculated that for every 5-6 people that take NSAIDs for spinal pain, only one will derive clinically meaningful benefits. This is at the expense of a slight increase in the risk of short-term gastrointestinal adverse effects. There are some limitations in the analysis which are driven by the underlying data. Remarkably, despite how common spinal pain is, there’s a startling lack of good evidence to inform our decision-making. There were few trials on neck pain and none on whiplash. While there’s better evidence with low back pain, the short-term nature of the trials leaves open the question about the benefits (if any) of extended usage.
What this paper also reinforces is that we lack proven safe and effective medical treatment options for spinal pain. There’s little evidence that acetaminophen (Tylenol) has any meaningful effects for back pain. Opiate analgesics are not preferred owing to their side effect profile and the risk of dependency. And now we have an analysis suggesting that the effectiveness of NSAIDs is more limited than we might expect. The toxicity of NSAIDs must be considered too. Everyone that takes an NSAID raises their risk of cardiovascular and gastrointestinal harm to some extent. Consequently, the safest strategy is to take the lowest effective dose for the shortest duration of time. Given the maddening “black box” of spinal pain, where the underlying cause is often not understood, perhaps it’s not surprising that there is no panacea to be found in anti-inflammatory drugs.

Another way ibuprofen can kill us?
Scott Gavura on October 6, 2016
Link


Do you ever take ibuprofen? Naproxen? Cold medication with an anti-inflammatory ingredient? The non-steroidal anti-inflammatory drugs (NSAIDs) are among our most well-loved medications. We start giving them in infancy, for fever, and continue use through to adulthood for everyday aches and pains. But it’s our later stages of life when we really ramp up the use, and daily consumption becomes common for conditions like arthritis. While they may be easily accessible and included as ingredients in thousands of consumer products, NSAIDs have a long list of potentially serious side effects. Not only can they cause stomach ulcers and bleeding by damaging the lining of the gastrointestinal tract, they can also increase the risk of fatal cardiovascular disease. Now there’s new research that looks at the relationship between NSAIDs and heart failure, a condition where the heart cannot pump adequately and appropriately. The study, “Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study” resulted in some fairly dramatic, alarming headlines:
Headlines like this suggest that NSAIDs are killing us indiscriminately, which may make you wonder how so many of us manage to have lived this long. And while The Daily Mirror got the facts wrong, they quoted from a well-conducted study. There is a real risk of heart failure from NSAIDs. But context is everything.
From natural origins, dozens of drugs
All NSAIDs act in a similar manner, interrupting the production of inflammatory and pain-related hormones called prostaglandins. Since the introduction of acetylsalicylic acid (ASA or Aspirin) in 1897, more than two dozen chemically-related drugs have been developed. And while your individual results may vary with each NSAID, research shows there isn’t much of a difference overall in how effective they are. However, the risks and side effect profiles of the different NSAIDs can differ, in some cases significantly. Most of us are familiar with the gastrointestinal side effects, which led to the development of the “COX-2” NSAIDs, intended to reduce those effects. The cardiovascular risks of NSAIDs were poorly understood until the worldwide withdrawal of the COX-2 Vioxx (rofecoxib), which triggered multiple studies of the cardiovascular risks of all of the NSAIDs. Multiple confirmatory studies have now clearly established that most NSAIDs (except ASA in low doses) are associated with an increased risk of cardiovascular events, like heart attacks. And over time, further studies have been done to identify if NSAIDs cause other negative effects. Which brings us to this paper.
Do all NSAIDs cause heart failure?
The relationship between NSAIDs and heart failure has already been identified in other studies. NSAIDs can more than double your underlying risk of heart failure. But in most of us, our underlying risk of heart failure is low, so the increased risk is trivial and largely irrelevant. Sensibly, current treatment guidelines recommend caution in those at risk of heart failure, and avoidance of NSAIDs in those with confirmed heart failure. The relative risk of the different NSAIDs is less well understood, so this study examined the type of NSAID used, and the dose.
This new study was a large, sophisticated analysis of NSAID users in five countries. It was a case-control study that identified those who had been prescribed an NSAID (note: not casual users) and then looked to see if they were subsequently admitted to a hospital for heart failure. The rates of hospital admission for heart failure were compared to up to 100 other controls, who didn’t take an NSAID, but otherwise were matched (e.g., same age/sex) to the NSAID users.
The analysis described is quite complex given the multiple datasets and limitations of each. The analysis looked at each NSAID, as well as the prescribed daily dose.
The findings
The study found over 16,000 cases and matched them to 1.2 million controls. The average age of was 77 in the treatment group and 76 among controls, with about 45% men. The bottom line from this study is that all NSAIDs are not the same. The degree of risk seems to vary quite significantly. In this diagram, anything that straddles the line is statistically non-significant. Any drug that is over to the right is associated with a statistically significant increase in heart failure. The rarely-used NSAID ketorolac almost doubles the heart failure risk (which is what The Daily Mirror quoted), while ibuprofen is associated with less risk: a 20% relative risk increase. And surprisingly, Ketorolac, etoricoxib, and indomethacin all cause more heart failure than the withdrawn rofecoxib (Vioxx). Interestingly, celecoxib (Celebrex) doesn’t appear to raise the risk of heart failure at all.

The composite (overall) result in in the bottom line, showing that current users of any NSAID have a 20% higher risk of heart failure than past users.
What does this mean to me?
This new evidence gives more support and context to our understanding of how NSAIDs can harm. NSAIDs do raise your risk of heart failure, although some are worse than others. However, if your underlying risk of heart failure is low, then occasional NSAID use is not a concern. As your risk of heart failure increases, your risk of experiencing harm from an NSAID increases, too. So do the risks outweigh the benefits? Ultimately this comes down to your individual factors: your reasons for use, any risk factors for disease you may already have, and the expected benefits. When used on a short-term basis by those who are not at risk of heart failure, the potential harms are slight. So don’t use NSAIDs indiscriminately, but don’t panic, either.

Salonpas
Salonpas is an over-the-counter topical NSAID used to treat pain. It’s probably safe and might be worth trying for minor pain, but the effect is small and the advertising is more hype than substance.
Harriet Hall on December 22, 2020
Link

Do you get annoyed when the media keep repeating the same commercials? I do. And recently I’ve been particularly annoyed by ads for Salonpas for pain. They make strong claims, but they don’t divulge the kind of details I want to know. What the heck is Salonpas, anyway? And where did that silly name come from?
What is Salonpas?
Salonpas is a suite of products sold over the counter in the form of patches, sprays, and gels. Most of them contain methylsalicylate and menthol, but some contain capsaicin, camphor, and lidocaine. A handy list of their products and ingredients can be found on Wikipedia. Two of their methylsalicylate/menthol patches are the only pain relief patches approved by the FDA. The company claims theirs is the strongest-labeled topical NSAID on the market; but as far as I could determine, there have been no studies comparing Salonpas to other topical products like diclofenac. The name means that the salicylate passes through the skin into the body. The company, Hisamitsu, did its own randomized trial and found that subjects using Salonpas reported significantly more relief (approximately 40% more) than those using a placebo patch. The study was said to be double-blinded, but was it really? It’s difficult to devise appropriate controls and to create double blind conditions, since both wintergreen oil and menthol cause skin irritation and both have distinctive odors. I could not find any replications or any studies by independent researchers.
First-line therapy?
The Arthritis Foundation recommends topical NSAIDs for joint pain relief, but the only one they mention is diclofenac, approved by the FDA in 2007 and available as gels, liquids, and patches. The advertising for Salonpas says “Two prestigious medical societies now recommend that physicians use topical NSAIDs, like Salonpas Pain Relief Patch LARGE, to treat acute pain from non-low back musculoskeletal injuries.” Both the American Academy of Family Physicians and the American College of Physicians recommend topical NSAIDs as first-line therapy. That’s true, but misleading. An article in American Family Physician says “Topical diclofenac and ketoprofen are slightly more effective than placebo for relieving chronic pain associated with osteoarthritis in adults.” They specify topical diclofenac and ketoprofen but do not mention other NSAIDs. The joint guidelines are questionable, since they also recommend acupressure. The quality of the studies varies, and the effect size is small.
Not for children
An FDA report says “To fulfill the PREA Postmarketing Requirement, a pediatric clinical study was conducted for Salonpas Pain Relief Patch and Salonpas Arthritis Pain topical patch and found them to be ineffective in this population. As a result, a pediatric labeling change was approved on March 29, 2013, for Salonpas Pain Relief Patch and Salonpas Arthritis Pain topical patch to note “Children under 18 years of age: Do not use; this product has not been shown to work in children.”
Is it an NSAID?
Salicylic acid is classified as a non-steroidal anti-inflammatory drug (NSAID), but topical methylsalicylate (wintergreen oil) is usually not, although it is metabolized in the body to salicylic acid. Wintergreen oil is probably more properly classified as a rubefacient. Rubefacients cause reddening of the skin, with dilation of capillaries and increased blood flow. The evidence for their efficacy is limited, and it has been speculated that when they relieve pain the effect is partly due to rubbing the skin. We instinctively rub painful areas; rubbing may work as a distraction or produce a pleasurable feeling that helps counteract the painful feeling. There are few trials of rubefacients, and better trials showed little difference from placebo.
According to the knowyourOTCs.org website, these brands contain methylsalicylate:
    • BENGAY®
    • Deep Heating®
    • Flexall®
    • Icy Hot®
    • LISTERINE®
    • Salonpas®
    • Satogesic®
    • THERA-GESIC®
Side effects
Side effects are usually minor, such as redness and skin irritation, but Salonpas might cause an allergic reaction. It should only be applied to unbroken skin and should not be used on children. It can interact with warfarin and certain other drugs to increase the risk of bleeding. There have also been reports of serious skin injuries and chemical burns.
Conclusion: More hype than substance
Salonpas may provide some degree of pain relief and is usually safe. Its effects are not very strong and the evidence is weak. It’s probably worth trying for minor injuries and other aches and pains before resorting to potentially more harmful remedies like oral NSAIDs or opioids. Is it a better choice than other topical over-the-counter products like BENGAY? We have no way of knowing, since there have been no head-to-head comparison studies.

Osteopenia: When Does Decreased Bone Density Become a Disease Requiring Treatment?
Osteoporosis is routinely treated with bisphosphonates to prevent fractures. A new study suggests that osteopenia should be treated too. But questions remain.
Harriet Hall on January 8, 2019
Link


Bisphosphonate drugs have been shown to increase bone density and prevent fractures in postmenopausal women with osteoporosis (remember Sally Field in those ads for Boniva?) but what about women with milder decreases in bone density (osteopenia)? Can the drugs prevent osteoporosis and/or fractures in patients with osteopenia?
A recent study published in The New England Journal of Medicine set out to answer that question. “Fracture Prevention with Zoledronate in Older Women with Osteopenia.” was a 6-year randomized, placebo-controlled, double-blind trial of 2,000 women age 65 or older with osteopenia (defined as a T-score of -1.0 to -2.5). Subjects received four IV infusions of either zoledronate or saline at 18-month intervals. Those who got zoledronate had significantly fewer vertebral and non-vertebral fragility fractures. But there was no significant decrease in hip fractures. They estimated that the number needed to treat (NNT) to prevent one (non-hip) fracture in one woman was 15.
While it is disappointing that the treatment had no effect on hip fractures, these are nevertheless impressive results, and the NNT is better than for many of our other standard treatments. Does this mean we should identify all older women who have osteopenia and treat them with IV zoledronate every 18 months to prevent fractures? I think it is too soon to jump on that bandwagon. There are a lot of unanswered questions.
Is osteopenia a disease that needs treating?
Osteopenia is defined as lower than average bone density; it is a risk factor for developing osteoporosis. It can be considered a normal consequence of aging, affecting over half of women older than 50. What defines a disease? Many lab values like estrogen and testosterone levels decrease with age; when do they become a disease that needs treating? The majority of women with osteopenia will not go on to develop osteoporosis, and not all those with osteoporosis will have fractures. Hip fractures are devastating, leaving many women bedridden and shortening their lives; but two thirds of vertebral fractures are asymptomatic. Is it reasonable to lump them together?
Fragility fractures are fractures that occur from a fall from a standing height or less. An article in The BMJ pointed out that fragility fractures are not always osteoporotic fractures; we may be overdiagnosing bone fragility in the quest to prevent hip fractures.
In 2008, The BMJ published the article “Drugs for pre-osteoporosis: prevention or disease mongering?” Not long after, the drug manufacturer Merck was accused of inventing the disease osteopenia in order to sell its drug Fosamax. I wrote about that controversy in 2010.
How is it diagnosed?
Dual Energy X-ray Absorptiometry (DEXA) is the test most commonly used to measure bone mineral density (BMD) and to diagnose osteoporosis. It involves a low dose of radiation.
BMDs are given a T-score, a standard deviation-based comparison to the BMD of a healthy 30-year-old of the same race and sex.
Bone Density (BMD)	T-Score	Prevalence (%)*
Normal	+1.0 to -1.0	20
Low (osteopenia)	-1.0 to -2.5	52
Osteoporosis	-2.5 or more	28
*in white women older than 50
These categories were arbitrarily assigned by the World Health Organization (WHO) and were meant to be a tool to measure the emergence of a problem in a population. They were not meant to diagnose individuals, but they are being used that way. The definition of osteopenia starts when the bone density is one standard deviation below the average for a young woman. Some women diagnosed with osteopenia may just be on the low end of the normal spectrum. These scores have been interpreted to mean that half the population has a disease they need to worry about.
The emphasis has been on women. If men’s bones are compared to the BMD of a 30-year-old white man, nearly half of all middle-aged men would be diagnosed with osteopenia, but their risk of hip fractures is much lower than for women. And in a Merck study, the prevalence of osteopenia varied from 28% to 45% depending on the machine being used.
Bone density doesn’t capture a poorly understood factor known as bone quality, which declines with age. Given the same bone density, an 80-year-old woman is at much greater risk of a fracture than a 50-year-old.
Other risk factors for fracture
Other risk factors include:
    • Gender (women are at higher risk, especially after menopause)
    • Race (Asian and Caucasian women have higher risk)
    • Family history can increase risk by 50-85%
    • Age (BMD decreases by 0.5% every year after age 50)
    • Lifestyle choices (poor diet, excessive alcohol or caffeine, lack of exercise)
    • Bone structure and body weight (petite and thin women at greater risk)
    • Smoking
    • Other medical conditions
    • Certain medications
The FRAX tool takes many but not all of these risk factors into consideration then estimates the 10-year probability of hip fracture or major osteoporotic fracture.
Recommendations for screening and treatment
The USPSTF recommends screening for bone density in women age 65 and up and in postmenopausal women younger than 65 who are at increased risk of osteoporosis. It does not recommend screening men.
The National Osteoporosis Foundation recommends treatment for postmenopausal women and for men over 50 who have:
     1.  Prior hip or vertebral fracture
     2.  T-score of −2.5 at the femoral neck or spine, excluding secondary causes
     3.  T-score between −1.0 and −2.5 at the femoral neck or spine and a 10-year probability of hip fracture ≥3% or a 10-year probability of major osteoporotic fracture ≥20%
     4.  Clinicians’ judgment in combination with patient preferences indicate treatment for people with 10-year fracture probabilities above or below these levels.
The first two are diagnostic of osteoporosis. Number 3 is based on osteopenia. The last item is important. The clinician can consider other relevant details like the degree of trauma associated with a prior fracture, the patient’s exercise history, family history, the patient’s willingness to accept the risks, financial considerations (each infusion costs $1,200), whether the patient engages in activities where falls are likely, etc.
Questions about the new study
In the first place, it is never wise to let a single study guide clinical practice, since there are so many things that can go wrong in research. It would be reassuring to have other studies with similar findings.
According to The Medical Letter, the FDA has approved IV zoledronic acid every two years to prevent osteoporosis in women with osteopenia. Approval was based only on improvements in BMD; until this new study, there was no available evidence for a reduction in fractures.
The new study found a reduction in fractures, but there was no reduction in hip fractures, the fracture of most concern. Why wouldn’t an improvement in bone density have the same effect on all fractures anywhere in the body?
The study participants had a T-score of -1.0 to -2.5 at either the total hip or the femoral neck on either side. Some subjects were “at the interface between osteopenia and osteoporosis.” If they had a T-score of less than -2.5 in the spine or at the hip/femoral neck on one side they were not excluded. This muddies the findings. I wish they had excluded everyone with even a single finding of a T-score below -2.5. And it raises the question of which BMD measurement is the most reliable for screening.
Which bisphosphonate?
Bisphosphonates are recommended as first-line treatment for osteoporosis. There are several to choose from. Some have been shown to reduce the risk of vertebral and hip and other nonvertebral fractures in osteoporosis; ibandronate has only been shown to reduce the risk of vertebral fractures. Drugs other than zoledronic acid (Zoledronate, brand name Reclast) have not been shown effective for osteopenia. There have been no head-to-head trials comparing different bisphosphonates. Oral bisphosphonates require special precautions; patients must fast overnight, take the drug with 6-8 ounces of plain water, avoid ingesting anything other than plain water for 30 minutes, and remain in an upright position for 30-60 minutes. IV versions are more acceptable to patients.
What are the risks?
A number of side effects have been reported with bisphosphonates, including vision problems, cough, headache, muscle pain, GI disturbances, jaw osteonecrosis, long-bone fractures and atrial fibrillation. IV infusions have caused reactions (flu-like symptoms and more), usually with the first infusion; these reactions can sometimes last for months. There have been no long-term follow-up studies.
What have other studies of bisphosphonates found?
In a randomized, double-blind, placebo-controlled trial of patients who had surgical repair of a hip fracture, a yearly injection of zoledronic acid reduced the incidence of new clinical vertebral fractures from 3.8% to 1.7%, of new nonvertebral fractures from 10.7% to 7.6%, and of deaths from any cause from 13.3% to 9.6%. The incidence of hip fractures was reduced, but the reduction was not statistically significant. Only 41-42% of subjects had a T-score of -2.5 or less.
The majority of fractures occur in women with osteopenic T-scores because there are far more women in that group. The fracture rate rises progressively with decreasing BMD scores. The number needed to treat (NNT) to prevent one fracture was reportedly much higher for osteopenia (>100) than for osteoporosis (10-20). This article went on to say it is not advisable to treat patients based on T-scores alone.
The NNT website got very different results for bisphosphonate treatment of women without prior fractures. NNT: no fractures were prevented. NNH: a small number were harmed. They got their data from the Cochrane Database of Systematic Reviews. They say, “…in those without very low BMD or fractures no study has demonstrated a true benefit.” And they point out flaws in the positive studies reviewed by Cochrane: for one drug there was only a single study, subgroup analyses were used, and the fractures were diagnosed by x-ray and may not have been clinically significant.
Conclusion: Useful, but not for everyone
Bisphosphonates are undeniably useful for patients with osteoporosis, but it has not yet been established which patients with osteopenia will benefit. The NNT website warns:
serious side effects such as atypical fractures and osteonecrosis of the jaw and gastrointestinal, musculoskeletal, and other side effects leading to disproportionate discontinuation have been increasingly linked to use of these drugs in the long term. These side effects should strike a note of caution and should firstly be discussed with any woman considering bisphosphonate therapy, and secondly be a warning against initiating this therapy in patient groups who have not been proven to benefit.
As I said in my 2010 article,
Sally Fields sends a panacea message rather than saying this is a drug with pros and cons that only offers partial protection and doesn’t benefit every woman who takes it, and that shouldn’t automatically be prescribed to everyone diagnosed with osteopenia by an arbitrary test.
Bottom line: patients are complicated individuals, and knee-jerk one-size-fits-all cookbook prescriptions are not justified. We should look at clinically significant benefits, not just test results. For statins, we don’t just want improved cholesterol levels, we want to see fewer heart attacks, strokes, and deaths. For bone density, we don’t just want improvements in T-scores; we want to see fewer osteoporotic fractures, particularly fewer hip fractures. Questions remain; more research will be useful in guiding clinicians.

Evenity for Osteoporosis
Hip and wrist fractures are a common result of osteoporosis. A new drug, Evenity, reduces the risk of vertebral fractures, but it doesn’t significantly reduce the risk of non-vertebral fractures. Other drugs do.
Harriet Hall on February 16, 2021
Link

I recently got an email from a woman who is 70 years old and is being treated for osteoporosis. Her rheumatologist had recommended Evenity injections (romosozumab) after she had failed to improve with Fosamax, Reclast or Prolia. When she read a newsletter by Al Sears, MD, she became confused and didn’t know what to think. She asked for a consultation and wanted to know my fee. I told her I am retired and no longer see patients, but I offered to look into Evenity and evaluate the research on its safety and efficacy.
Evenity (romosozumab) is an anabolic sclerostin inhibitor that stimulates bone formation and decreases bone resorption. It requires monthly injections. It carries a black box warning about increased risk of heart attacks, strokes, and cardiovascular death. There are many drugs available to treat osteoporosis. They were reviewed in The Medical Letter in the July 13, 2020 issue (#1602, subscription required). In clinical trials, Evenity was more effective than alendronate in reducing vertebral and clinical fractures and more effective than teriparatide in increasing hip bone mineral density. They concluded that it could be considered for initial treatment of women at very high risk of fracture.
Dr. Sears’ newsletter said that the FDA had rejected Evenity two years earlier, because it provided only a modest improvement in reducing bone fractures and because clinical trials had shown it increased the risk of heart attacks, strokes, and cardiovascular death. Why did it decide to reverse course and approve the drug now? He claims it was because the Big Pharma company’s existing osteoporosis drug’s patent was about to expire and they would lose billions in profits when it went generic, so they needed a new money-maker. Evenity was their solution; it would cost $22,000 a treatment.
His information is questionable. According to the company’s website, the list price is $1,825 per month, and financial assistance is available. (I don’t know where he got the $22,000 figure; he doesn’t tell us.) And the FDA doesn’t base its approval on a company’s desire for profits. In this case, it based its approval on a re-submitted application for a narrower patient population: postmenopausal women with osteoporosis who carry a high risk of fracture, or patients who have failed or are intolerant to existing osteoporosis therapies. Natalie Grover has a better description of what actually happened.
Sears says for years he has been warning patients to stay away from these “bone-building” drugs. He says they don’t work, and there are safer alternatives.
He explains osteoporosis as a result of an imbalance between the osteoclasts that break down bone and the osteoblasts that deposit new bone. He says the bisphosphonate drugs kill osteoclasts so they can’t remove more bone. They do that, and your bones become denser, but the denseness is made up of old bone and old calcium (what?). He says the osteoblasts won’t make new tissue if the old tissue is still there, so your bones become brittle and more prone to fracture. They look strong on a scan, but in reality they are weak and fragile. These drugs cause the exact thing they are supposed to prevent: broken bones. (Really? But weren’t they approved by the FDA because studies showed they reduced the incidence of fractures?) The reference he cites is “Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate” by Lenart et al. published in 2008 in The New England Journal of Medicine. It was not a peer-reviewed study, but only a letter to the editor. It reported on 15 patients who had “low energy” fractures occurring in a fall from a standing height or less. They found a unique radiographic pattern of cortical thickening in 10 of the 15 patients; those patients had been taking alendronate for longer (7.3 years) than the 5 patients who lacked that pattern (2.8 years). They called for additional studies. Sears’ description of this reference is simply wrong. He says it was a study of women taking alendronate who “had experienced some sort of fracture” and that 65% had the same rare fracture of the middle of the thigh bone, a place where people rarely get a fracture. That’s such a completely false misrepresentation that I found it hard to believe that Dr. Sears had actually read the article and understood it.
A 2020 study by Black et al., “Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates” was subsequently published in The New England Journal of Medicine. It said bisphosphonates were effective in reducing hip and osteoporotic fractures, but that concerns had been raised over atypical femur fractures in women taking the drugs. They followed 196,129 women for ten years; 277 women had atypical femur fractures. The risk increased with the duration of bisphosphonate use, rapidly decreased after bisphosphonate discontinuation, and was greater in Asians than in Whites. In their conclusion, they stressed that the absolute risk of atypical femur fracture remained very low as compared with reductions in the risk of hip and other fractures.
The advantage of Evenity is that it works more quickly than other drugs. It is intended for short-term use – 12 months – to reduce risk in patients with imminent risk of fracture, to be followed by an antiresorptive drug such as Prolia. Unfortunately, it does not reduce the risk of non-vertebral fractures (hip and wrist, which are the most consequential complications of osteoporosis). Other drugs (Tymlos and Forteo) reduced the risk of non-vertebral fractures by 43-53%, while Evenity showed only a non-significant reduction of 25%. Both Tymlos and Forteo require daily dosing compared to Evenity’s once-a-month injections, and both of them also carry black box warnings – for osteosarcoma – but these are based on animal studies and not verified in humans.
Side effects of Evenity
In addition to the black box warnings, the company’s website lists these other risks of Evenity treatment: serious allergic reactions, low calcium levels, osteonecrosis of the jaw bone, and unusual thigh bone fractures. But they say the most common side effects are joint pain and headaches.
What does Dr. Sears recommend?
He dismisses prescription drugs, claiming that there are safer alternatives. He offers the “Big 3” bone strength boosters: vitamin D3, boron, and vitamin K2, which he calls “bone glue.” He cites references, but they are far from convincing and don’t say what he seems to want us to think they say. And of course, there are no controlled clinical studies comparing drugs to Dr. Sears “Big 3” for preventing osteoporotic fractures.
Who is Dr. Sears?
Should we believe Dr. Sears? He is an MD, but he says a lot of things that don’t make sense. He misrepresents the references he cites so badly we can only wonder if he actually read them. He practices integrative medicine and bills himself as America’s #1 anti-aging authority. Integrative medicine is a mish-mash of ideas that are based on science and ideas that are not. As Mark Crislip famously said, “If you integrate fantasy with reality, you do not instantiate reality. If you mix cow pie with apple pie, it does not make the cow pie taste better; it makes the apple pie worse.”
Conclusion: Sears is not a credible source of information
IMHO, my correspondent can safely disregard the statements in Dr. Sears’ newsletter that confused her. She would be better off trusting the advice of a science-based rheumatologist who is familiar with her case.

Innovations in Blood Transfusions Will Save Lives
Stored blood quickly loses its effectiveness, so how can we improve the situation?
Henry MIller on March 11, 2025
Link

Blood transfusion is one of the cornerstones of modern medicine, used in a spectrum of situations from traumatic injuries to chronic illnesses that impair red blood cell production. About every two seconds, someone in the U.S. needs blood. Yet, beneath the surface of this life-saving practice is a largely ignored issue that jeopardizes its efficacy: the quality of stored blood.
The science of blood transfusion seems simple but is deceptively complex. Although donors supply millions of units each year, the process of storing and using this blood is fraught with challenges. One critical concern is a phenomenon known as “blood storage lesion,” a combination of biochemical, mechanical, and functional changes that occur in red blood cells (RBCs) after they are collected and stored. Although these changes are invisible to the naked eye, their effects can be clinically significant.
The Invisible Problem with Stored Blood
To understand why blood storage lesion matters, we need to consider the unique biology of RBCs. Packed with a protein called hemoglobin, these specialized cells evolved to onload lung oxygen and then deliver oxygen efficiently to tissues. However, this finely tuned system works best when RBCs are actively circulating in the body; once donated and stored, their ability to function begins to degrade rapidly.
Within hours of storage, RBCs undergo significant biochemical changes. Levels of ATP (a chemical that maintains the biconcave disc shape of RBCs) and 2,3-DPG (a molecule that increases oxygen offloading of hemoglobin) plummet by up to 90% within the first few days. Mechanical changes also occur: Cell membranes lose flexibility and become “sticky,” impairing their ability to squeeze through tiny capillaries and circulate. Oxidative damage further compromises cell function, increasing the likelihood of rupture. The rate and severity of these changes vary depending on the donor, adding another layer of complexity to the phenomenon.
The Clinical Implications of Aging Blood
The risks posed by stored blood are not hypothetical. A 2022 Danish study suggested that “transfusing exclusively older RBC units stored for >1 or 2 weeks increases the 28-day recipient mortality and risk of thromboembolism or death compared with transfusing fresher RBC units.” This raises critical questions about the safety and effectiveness of current blood storage practices.
For years, researchers believed that the storage lesion developed gradually, and that blood stored for seven days was nearly as good as fresh blood. However, more recent studies indicate that the most critical damage occurs within the first few days of storage. This has profound implications for how we assess blood quality, because based on flawed assumptions about how damage accumulates, many clinical studies have underestimated the risks of using stored blood.
Part of the problem is that the tests to measure oxygen offloading, ATP levels, and DPG levels are time consuming and complicated, so they are rarely used. Thus, the efficacy of stored blood is assumed but not measured.
A Technological Revolution in Blood Transfusion
If stored blood loses its effectiveness so quickly, how can we improve the situation? Enter new diagnostic and therapeutic technologies designed to mitigate the effects of storage lesion.
The effectiveness of the transfusion of RBCs depends not only on blood flow but also on oxygen unbinding from hemoglobin and oxygen diffusion through the RBCs. Thus, the usual therapeutic strategies of packing the red cells with oxygen (breathing oxygen gas) and increasing blood flow (with drugs) do little to improve oxygen delivery to the body’s tissues, which is dominated by oxygen offloading.
A breakthrough innovation is FlowScore, a tool developed at the University of Oxford, UK. A “flow-cytometric proxy of the functional quality of blood,” it allows clinicians to assess the quality of stored blood quickly. The developers summarize its value thusly: “By evaluating how effectively red blood cells can unload oxygen to tissues, FlowScore provides a much-needed metric to determine whether stored blood is safe to use — or whether it requires rejuvenation.”
FlowScore can be measured with a device already available in most blood facilities. A hematological flow cytometer measures various physical and chemical properties of blood cells and is already widely used in clinical and research settings to analyze cells in a fluid suspension. These devices can be used to measure FlowScore with only a software upgrade. Given its ease of use, arguably, FlowScore should be measured for all blood units transfused.
For older blood with a low FlowScore, how can we “rejuvenate” blood? By restoring ATP and 2,3-DPG levels, as well as repairing oxidative damage, the FDA-approved rejuvesolR solution containing phosphate/inosine/ pyruvate/adenine (PhIPA) pharmacologically replenishes those key metabolic reserves. Combined with more efficient blood handling devices, PhIPA could significantly improve clinical outcomes for the millions of patients receiving transfusions.
The Road Ahead: Making Transfusions Safer
The implications of these advances are enormous. Recent studies show that rejuvenated RBCs have better survival rates and enhance heart, kidney, and lung function in transfusion recipients.
Together, FlowScore and PhIPA are likely to reduce morbidity and mortality by reducing complications like Transfusion-Related Acute Lung Injury (TRALI), one of the leading causes of transfusion-related deaths. In short, these integrated technologies — spanning diagnostic, therapeutic, and automated blood preparation — can establish new standards for blood storage and transfusion. These innovations promise not only to reduce morbidity and mortality but also to lower the overall demand for blood donations — a critical benefit in an era when blood supplies are often stretched thin.
While transfusions save countless lives every year, it’s time to rethink how we manage and use stored blood. The medical community, blood banks, and policymakers must work together to address the risks of aging blood by implementing these emerging technologies. Doing so will not only make transfusions safer but also ensure that this life-saving intervention is optimally effective.


PUBLIC HEALTH

Messaging and Public Health
Steven Novella on March 5, 2014
Link
Affecting public health has a few components. It includes providing a safe environment at home, at work, and in public spaces. It involves protecting the food and water supply from pathogens and toxins. Perhaps the most challenging component, however, is affecting people’s behaviors. Humans are complex psychological animals, and simply providing information to facilitate a rational decision may not always have the intended effect.
Those in power wishing to protect the public from themselves can simply pass laws that coerce people into safer behavior, such as seat belt laws and helmet laws. This approach amounts to outlawing certain unhealthy choices. There is also the “nudge” approach where the unhealthy choice is not outlawed, but the healthier choice is facilitated or made the default choice so that people have to work harder if they still wish to make the unhealthier choice for themselves.
Short of passing laws to force or nudge people in the right direction, the default approach to improving healthy behaviors is to provide information via either public service announcements or warning labels. How effective, however, are such measures? 
A recent survey (all the usual caveats about the limitations of surveys apply) looked at various methods for increasing the intent of parents to vaccinate their children. This was a survey, not a measure of actual vaccine compliance, but the results are sobering nonetheless. 1,759 parents were surveyed:
Parents were randomly assigned to receive 1 of 4 interventions: (1) information explaining the lack of evidence that MMR causes autism from the Centers for Disease Control and Prevention; (2) textual information about the dangers of the diseases prevented by MMR from the Vaccine Information Statement; (3) images of children who have diseases prevented by the MMR vaccine; (4) a dramatic narrative about an infant who almost died of measles from a Centers for Disease Control and Prevention fact sheet; or to a control group.
The results were no what we would have hoped:
None of the interventions increased parental intent to vaccinate a future child. Refuting claims of an MMR/autism link successfully reduced misperceptions that vaccines cause autism but nonetheless decreased intent to vaccinate among parents who had the least favorable vaccine attitudes. In addition, images of sick children increased expressed belief in a vaccine/autism link and a dramatic narrative about an infant in danger increased self-reported belief in serious vaccine side effects.
None of the four messaging styles had a positive effect, they just had different kinds of negative effects. Most interesting, telling parents who tended to be anti-vaccine to begin with that the MMR vaccine is not linked to autism reduced their belief that MMR causes autism, but at the same time reduced their willingness to vaccinate a hypothetical future child from 70% to 45%.
Just like in the movie War Games, it seems the only way to win this game is to not play at all. The authors caution that, given vaccination rates overall are already quite high, any messaging about the safety of vaccines has a greater potential to inadvertently reduce vaccine compliance rather than increase it further.
The authors further speculate that the paradoxical result is due to the parents digging in their heels and being motivated to defend their initial vaccine negativity. This is consistent with other research (nicely summarized here by Chris Mooney) indicating that people will tend to react to new information that contradicts their existing beliefs by clinging to them even more tightly. The new information motivates them to think of other reasons to support their initial belief, in addition to reasons to dismiss the contradictory information. In the end they may be even more convinced of their original position.
The situation reminds me of the parable of the sun and the wind who decided to compete to see who could get a man to remove his coat. The wind tried to blow the coat off, but the harder it blew the harder the man held onto his coat. The sun then had its turn – it simply shined down on the man until he became warm and took off the coat.
In public messaging, we have to be more like the sun than the wind. A successful campaign would get people to want to engage in the healthier behavior, and perhaps even think it was their idea all along. Yes, this is psychological manipulation (just like all politics, by the way). Rational people have a knee-jerk negative reaction to the notion of such manipulation. We want to live in a world where giving people information is enough for them to make rational decisions, but that is not the world in which we live.
One approach, therefore, is benign psychological manipulation – making the healthy choice seem more desirable. One such approach is called social norming. This approach essentially leverages peer-pressure by telling people that most people do not engage in unhealthy behaviors, or do engage in healthy behaviors. It would therefore have been interesting if the above survey had a fifth group who were simply told – “most parents protect their children from infectious diseases by vaccinating them.” This is not deceptive, it is entirely true, but it is selected to coerce with positive peer pressure.
Such social norming campaigns are especially effective when people believe that an unhealthy behavior is more common than it actually is. Giving them correct information about actual prevalence of the behavior does seem to reduce the unhealthy behavior whereas warning people about the dangers of a behavior may just foster further belief that the behavior is more common than it is, which can actually increase the unhealthy behavior.
Conclusion
Public health campaigns have the potential to significantly increase the health of the public and reduce the cost of health care. We should not make naive assumptions about the efficacy of such campaigns, however. Like any other intervention, they will be most effective if they are evidence-based.
What the evidence is telling us so far is that public messaging can easily backfire if human psychology is not taken into account. Further, basic human psychology can be leveraged to have very successful public information campaigns.
There is, however, another approach. A public that had greater scientific literacy coupled with greater critical thinking skills would be more likely to respond rationally to simple information. This is not just an assumption – there are studies that show that skeptics are more likely to engage in analytic cognitive thinking and make fewer logical errors in their reasoning. Skeptics are also more likely to engage their inferior frontal gyrus, which is involved in cognitive inhibition.
In other words, when confronted with new information it is possible to inhibit the automatic response to defend one’s existing beliefs, and to engage in the hard work of analytic thinking and metacognition. A greater emphasis on teaching such critical thinking skills would therefore create a populace that is better prepared to receive future messaging about healthy and unhealthy behaviors.

Science-Based Public Service Announcements
Steven Novella on April 24, 2013
Link
Changing behavior is difficult. It is also an increasing priority for health care. We have entered a period of history when lifestyle choices have a dominant impact on health and longevity. People are no longer dying young of incurable infectious diseases in significant numbers. Rather they are surviving long enough to die from their bad habits.
Further, health behaviors are having a huge impact on the overall cost of health care. So the motivation is greater than ever to impact public health by influencing behavior. Yet, we are not very good at doing this.
It’s not that we’re not trying – it’s simply that having a large influence on people’s day-to-day behavior is remarkably difficult. There is ongoing research looking at how to effectively change behavior at the individual and public level, but it is complex, often conflicting, and new techniques at best yield only marginal gains.
The default method for changing behavior has been education – explain to people what the risks are of certain behaviors and the benefits of changing. I tell patients every day, for example, the risks of smoking and why they should quit. Of course, they all already mostly know everything I tell them. I try to use the latest techniques, like motivational interviewing and social norming. I ask them what their health goals are, and explain that quitting smoking will help them achieve their goals, and I have many other patients who can do it.
But – the effectiveness of individual counseling is extremely low. A recent review concludes:
Physician brief counseling and trained health professionals’ intensive counseling (individual, group, proactive telephone) are effective with abstinence rates between 2.1% and 17.4%. Only practical counseling and motivational interview were found effective intensive interventions. The clinical effect of smoking cessation counseling is low and long term cessation rates uncertain.
Obviously individual counseling alone is not going to be enough, even with intense innovative techniques. Public health interventions are also needed. There are two general types of public health interventions, mass public education (such as public service announcements, PSAs), and regulation that is designed to make it more difficult to engage in unhealthy behavior.
The latter does seem to have an effect. Taxes on cigarettes, for example, are effective (although tobacco companies try to offset taxes with lower prices). Banning smoking in certain public locations is also effective. Attention is now turning to similar regulations to reduce obesity, such as the infamous proposed ban on large drinks in New York City. There are regulations on tobacco advertising, and on packaging.
The overall goal of such regulation is to minimize enticements for unhealthy behavior, and to make the behavior as inconvenient as possible.
What about PSAs? How effective is it to have commercials of the famous “this is your brain on drugs” type? Recent research has been looking at how to fashion PSAs for maximal impact. One recent study looked at 71 subjects exposed to ads with either strong content or weak content, flashy editing or plain editing.
Encouragingly, they found that having a strong message was the more important variable. If the PSA had a weak message then it did not matter if the editing was boring or flashy. If the PSA had a strong argument then it was effective even with plain editing, but more so with flashy editing. The study used fMRI to image subjects watching the PSA and found that strong messages engaged the decision-making part of the frontal lobes. They also monitored subjects a month later for urine nicotine metabolites and found the strong messages were associated with a decrease.
What this seems to indicate is that you have to grab people’s attention and deliver a persuasive message. What is still lacking from this research, however, is long term follow up.
Other research also indicates that the “scared straight” approach has limited long term utility. The strong message may benefit from the incremental gains offered by techniques such as motivational interviewing (engaging the viewer’s goals) and social norming (essentially peer pressure).
ConclusionIt seems that it would be highly cost effective to invest research dollars into improving the technology of altering public health behavior. There is no simple answer to this complex problem. No matter how you look at it, it’s very difficult to have a significant impact on such behaviors.
Likely any successful campaign will involve multiple components, individual counseling, PSAs, and regulations, each with an incremental effect but with an overall significant effect.
So far the most effective methods seems to be those that make it easier to engage in healthful behaviors and difficult to engage in risky behaviors. People still have choice, but the easy default choice is the healthy one.

Dr. Joseph Ladapo’s assault on public health in Florida: Will it be coming to the federal government next year?
The Florida Department of Health, run by Surgeon General Dr. Joseph Ladapo, just released guidance on COVID-19 vaccines based on antivax tropes. Is the federal government next?
David Gorski on September 16, 2024
Link
The number of developments worrisome for the future of public health in this country have been coming so fast and furious that I can’t keep up with them on a weekly posting schedule here at SBM. I had hoped to write about something other than COVID-19 and vaccines, but unfortunately, there’s been another development in the past few days. That’s after last week, when I noted that former President and Republican nominee for President Donald Trump had cozied up to Robert F. Kennedy, Jr., who’s been a rabid antivax loon for nearly two decades now (at least), leading them both to come up with a riff on Trump’s “make America great again” (MAGA) slogan, namely “make America healthy again” (MAHA). Let’s just say that it wasn’t the greatest slogan—MAHA?—and RFK Jr.’s plan was a mixture of the not-bad (e.g., concern about regulatory capture) with the absolute bonkers (e.g., giving half of the NIH budget to research into “holistic” therapies) and, tellingly and conveniently enough, mentioned absolutely nothing about vaccines. It’s as if RFK Jr. and Trump both thought that we would totally forget about RFK Jr.’s two decades of antivax fear mongering and conspiracy theories. Now, hot on the heals of that disturbing news, it’s difficult for me not to take notice of the recently issued Updated Guidance for COVID-19 Boosters for the Fall and Winter 2024–2025 Season from the Florida Department of Health, currently run by COVID-19 contrarian and now arguably antivax physician Dr. Joseph Ladapo, discouraging the use of mRNA-based COVID-19 vaccines for older people (and that’s not all) based on misrepresented science and antivax tropes.This guidance was sent by email last Thursday to all licensed healthcare providers in the state of Florida.
Before I discuss just how off-base this “guidance” is and what it says about the danger to public health in this country, I can’t help but note that Dr. Jonathan Howard just posted a good summary of what I’m talking about when I point to the fact that RFK Jr. has been appointed honorary co-chair of Trump’s transition team, should Trump win in November. What, exactly, “honorary co-chair” means or entails is unclear, but what is clear is that RFK Jr. has managed to achieve considerable influence in the Trump campaign and will likely himself score a major cabinet position, the most likely position being Secretary of Health and Human Services, a truly horrifying prospect given that he would then have control over the Centers for Medicare & Medicaid Services (CMS), the FDA, the CDC, and the NIH are parts of HHS. Of course, for this to happen, Republicans would also have to retake control of the Senate, given that the chances that a Senate controlled by Democrats would ever confirm someone like RFK Jr. for HHS, speculation has thus already begun as to who, if Trump wins, might score leadership positions in these government agencies critical to medicine and public health. Jonathan and I have speculated that contrarian physicians like Drs. Vinay Prasad, Scott Atlas, Jay Bhattacharya, and, yes, Joseph Ladapo might be up to head the FDA, CDC, and the like. (I think it less likely that someone bonkers will be appointed to the NIH, but that could just be wishful thinking if Trump retakes power and RFK Jr. becomes HHS secretary.)
This brings us back to Dr. Ladapo. If you want to see the direction that the federal government will likely take if Trump becomes President again and RFK Jr. oversees the appointment of federal officials overseeing public health agencies, such as the FDA Commissioner and CDC Director, look no further than Florida, where COVID-19 contrarianism, hostility to public health, and outright antivax misinformation have taken over the Department of Health of a large state.
“Updated guidance”? More like the same old misinformation
So let’s look at what the updated guidance regarding COVID-19 boosters for the winter season says. I note that, almost certainly (for reasons that I will discuss shortly) Dr. Ladapo had a great deal of influence in these guidelines. They begin with a dog whistle to antivaxxers:
The Florida Department of Health (Department) is reminding health care providers of the importance of remaining up to date with current literature related to COVID-19 vaccines and boosters, and the importance of providing patients with informed consent.
Remember, whenever you see someone hostile to vaccines invoke “informed consent,” what they virtually always really mean is something that, over the years I’ve referred to as “misinformed consent” or, more recently, “misinformed refusal.” What do I mean by those terms? I mean that, under the seemingly unobjectionable cloak of a bedrock principle of medical ethics, informed consent, what is really being fed to you is at best a biased—and at worst utterly incorrect or made-up—summary of the evidence designed to portray vaccines in the worst possible light and falsely imply that the risks outweigh the benefits. Trying to produce misinformed refusal in an audience is, of course, a tactic not limited to antivaxxers. Quacks use it too, to frighten you away from conventional medicine.
Now comes the spin designed to provoke misinformed refusal, first the semi-reasonable but painted in the worst possible light:
On August 22, 2024, the United States Food and Drug Administration (FDA) approved and authorized updated versions of mRNA vaccines from Pfizer-BioNtech and Moderna. The FDA approved the vaccine for people 12 and older and provided emergency use authorization for children 6 months to 11 years old. The stated target of these boosters is the Omicron variant which is not causing a significant number of infections.
The most recent booster approval was granted in the absence of booster-specific clinical trial data performed in humans. Furthermore, this booster does not protect against the currently dominant strain, accounting for approximately 37% of infections in the United States. There are currently limited data to inform whether these boosters offer any substantial protection against the virus and subsequent circulating variants. Although randomized clinical trials are normally used to approve therapeutics, the federal government has not required COVID-19 vaccine manufacturers to demonstrate their boosters prevent hospitalizations or death from COVID-19 illness.
Notice the methodolatry, defined as the profane worship of the double-blind randomized clinical trial (RCT) above all other forms of evidence and devoid of context regarding whether an RCT would be feasible or practical. Basically, when you see someone invoking RCTs regarding updated vaccines to target variants, you are very likely looking at methodolatry that weaponizes EBM against public health and vaccines to sow doubt and mistrust. The implication is that large RCTs need to be done when updating a vaccine to target the predominant strains of a virus in circulation, when in fact the practice adopted for COVID-19 vaccines is similar to what we have long done with influenza vaccines.
It is, of course, true that if the experts picking the strains to include in the yearly update to the seasonal influenza vaccine pick wrong, which has occasionally happened in the past, the efficacy of the vaccine will be disappointingly low, compared to years when they prognosticate accurately regarding the strains expected to circulate that season. One can argue how accurately scientists have chosen the strain of SARS-CoV-2 to include in this year’s update to the vaccine, but Dr. Ladapo’s argument goes beyond that to imply that the strains chosen have resulted in an ineffective vaccine. Moreover, one might even question whether everyone needs a yearly COVID-19 booster, as Dr. Paul Offit did last year, but that’s not what Dr. Ladapo is doing here either. Worse, as you will see, in contrast to what Dr. Offit was arguing, namely that boosters should be targeted to those at highest risk for severe disease and death from COVID-19, what Dr. Ladapo appears to be doing is discouraging the use of mRNA vaccines in that very population, in addition to young people who, as antivaxxers have long deceptively argued, are at such low risk that vaccines are unnecessary.
That’s why I contrast the spin that Dr. Ladapo’s department places on the situation, which is to imply that a mismatch means that the vaccine won’t work, to a more sober assessment from a less “contrarian” scientist, Andy Pekosz, PhD, a professor in Molecular Microbiology and Immunology, who contributed to an article published by the Johns Hopkins Bloomberg School of Public Health, What to Know About the Updated COVID Vaccine for Fall, Winter 2024–25:
As in previous years, there are mRNA vaccines—one from Moderna, one from Pfizer—and a protein-based vaccine, from Novavax. One nuance this year is that the mRNA and protein-based vaccines target different—though closely related—variants.
The updated mRNA COVID vaccines from Moderna and Pfizer are based on the KP.2 strain, one of the FLiRT variants that have been spreading since early spring. These variants and their sub-variants have caused the majority of infections during this summer’s COVID wave. The protein-based Novavax vaccine is based on the JN.1 variant, which accounted for the majority of COVID infections in the first few months of 2024 and is the parent strain from which KP.2 and other currently circulating variants branch from.
At the end of the day, laboratory experiments show that all of the updated vaccines available this season can recognize circulating COVID variants and therefore should be similarly effective in reducing your chance of becoming severely ill from COVID infection or needing to be hospitalized.
As you can see, Dr. Ladapo is trying to persuade you that the new vaccines are likely to be ineffective because they supposedly target the “wrong” strains of SARS-CoV-2 compared to the strains that are currently circulating, when in fact the strains are very similar, meaning that vaccinating against one will likely provide adequate protection against the other related strains. Indeed, that is exactly the rationale cited by FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) in making its recommendations to manufacturers:
The committee unanimously voted to recommend a monovalent JN.1-lineage vaccine composition. Following the vote, the committee discussed considerations for the selection of a specific JN.1 lineage SARS-CoV-2 strain (e.g., JN.1 or KP.2) and expressed a strong preference for JN.1.
During this meeting, the advisory committee was informed of the manufacturing timelines, and they reviewed the available data. These data included information on the circulation of SARS-CoV-2 virus variants, current vaccine effectiveness, human immunogenicity data of current vaccines against recently circulating virus variants, the antigenic characterization of circulating virus variants, animal immunogenicity data on new candidate vaccines expressing or containing updated spike components, and preliminary human immunogenicity data on JN.1 candidate vaccines.
Based on the totality of the evidence, on June 6, 2024, FDA initially advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States beginning in fall 2024 should be monovalent JN.1 vaccines.
FDA has continued to monitor the circulating strains of SARS-CoV-2. Based on the most current available data, along with the recent rise in cases of COVID-19 in areas of the country, the agency has further determined that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 Formula) is the KP.2 strain, if feasible. This change is intended to ensure that the COVID-19 vaccines (2024-2025 Formula) more closely match circulating SARS-CoV-2 strains. FDA has communicated this change to the manufacturers of the licensed and authorized COVID-19 vaccines. The agency does not anticipate that a change to KP.2 will delay the availability of the vaccines for the United States.
I can see here from this why Moderna and Pfizer based their vaccines on the KP.2 strain and Novavax stuck with the JN.1. It’s simple logistics. Because the vaccines by Moderna and Pfizer are mRNA-based, it’s way easier for them to change the sequence of the template used to make the mRNA to be included in the vaccine and quickly ramp up manufacturing than it is for Novavax, whose vaccine uses recombinant protein as the antigen, which takes longer to make because there are the additional steps of making and purifying the protein product to be packaged in the vaccine.
Let’s look at the final “guidance” here, and then in the next section I’ll point out the antivax tropes used to come up with the “guidance”:
Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use of mRNA COVID-19 vaccines. Any provider concerned about the health risks associated with COVID-19 for patients over the age of 65 or with underlying health conditions should prioritize patient access to non-mRNA COVID-19 vaccines and treatment.
You read that right. Dr. Ladapo is advising against the use of any mRNA vaccines, period. I kid you not. He’s advising against them for everybody and only grudgingly saying that they might be used in older people and those with underlying chronic health conditions, you know, those who have been known since the beginning of the pandemic to be among the populations at the highest risk for severe disease and death from COVID-19, but only after prioritizing “patient access to non-mRNA COVID-19 vaccines and treatment.” WTF? Seriously, all treatments for COVID-19 are “non-mRNA,” because only the Moderna and Pfizer vaccines are mRNA-based, not any treatments for COVID-19 that I’m aware of. One wonders if he’s implying that doctors should encourage the use of ineffective treatments like ivermectin, but I could be reading too much into it. Maybe.
Now let’s look at the rationale cited. You will recognize several common antivax tropes. Indeed, Dr. Ladapo made it very clear that he’s conspiracy mongering in his post on X, the hellsite formerly known as Twitter, in which he accuses public health authorities of “gaslighting” the public regarding vaccines and dons the mantle of being all about The Real Science:
@CDCgov & @US_FDA are gaslighting Americans with their new, unproven COVID-19 boosters, and recommend them for 6 month-old babies!We say bring data, acknowledge serious safety concerns & acknowledge the many people who believe they’ve been injured by these vaccines.See my…
— Joseph A. Ladapo, MD, PhD (@FLSurgeonGen) September 13, 2024
“Acknowledge serious safety concerns”? You mean the minor or nonexistent safety concerns that antivaxxers have been flogging for nearly four years? and the “many people who believe they’ve been injured by these vaccines”? You mean like the ones who have been fooled into thinking that their cancers—excuse me, “turbo cancers”—were caused by the vaccine?
Seriously, even though this “guidance” seems semi-reasonable if that’s all you read, Dr. Ladapo can’t help but give the game away when he’s on social media. Also note how he says at the end, “See my latest guidance.” Not “see the Florida Department of Health’s latest guidance,” but “see my latest guidance.” You can see why I refer to this document as being all Dr. Ladapo and refer to it as his. I’m just taking my lead from the crank himself.
How not to justify “updated guidance”
Right before the “guidance” in bold, Dr. Ladapo suggests that “they” are either hiding evidence or at least not providing sufficient evidence to assuage the fears of the public (fears that, I note, have been stoked by antivaxxers) over “serious safety concerns”:
Additionally, the federal government has failed to provide sufficient data to support the safety and efficacy of COVID-19 boosters, or acknowledge previously demonstrated safety concerns associated with COVID-19 vaccines and boosters, including:
    • prolonged circulation of mRNA and spike protein in some vaccine recipients,
    • increased risk of lower respiratory tract infections, and
    • increased risk of autoimmune disease after vaccination.
Later in the “guidance,” Dr. Ladapo claims as a risk:
Elevated levels of mRNA and spike protein from the mRNA COVID-19 vaccine persist among some individuals for an indefinite period, which may carry health risks.
I’ve discussed concern number one above, the “prolonged circulation of mRNA and spike proteins” in “some” vaccine recipients. I note that the word “some” is doing a lot of heavy lifting there. For example, the half-life of the mRNA for spike protein used in the Pfizer and Moderna vaccines is on the order of a few days, with the spike protein being detectable for at most eight weeks in “some” patients. While it is true that one study oft-cited by antivaxxers found vaccine mRNA fragments in the blood as long as 28 days after vaccination, I note that this was mostly mRNA fragments, meaning that the mRNA would not be expected to generate further spike protein. Indeed, the authors speculated that this finding might have been due to slow leakage of the lipid nanoparticles out of the injection site. In any event, contrary to what antivaxxers claim, neither the modified mRNA nor the spike protein coded for by that mRNA persist long term in the human body, and there’s no evidence that their observed persistence is unsafe.
As for the last two? Regarding the claimed increased risk of lower respiratory tract infections associated with COVID-19 vaccination, I note that no studies were cited, unlike the other concerns later in the document. I do remember studies showing an increase in other infectious diseases associated with the lifting of COVID-19 restrictions after the vaccines became available, such as this one from Israel. However, you know what increases your risk of subsequent lower respiratory infections? That’s right, COVID-19 does, and the risk increases with each reinfection. As for the last one, there is no robust evidence linking COVID-19 vaccination to any autoimmune diseases, later in the “guidance” Dr. Ladapo claims:
The mRNA COVID-19 vaccine may be associated with an increased risk of autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis, and psoriasis.
But what did that study actually conclude? Not exactly what Dr. Ladapo tried so much to imply above:
We report that the risk of developing most AI-CTDs did not increase following mRNA vaccination, except for systemic lupus erythematosus with a 1.16-fold risk in vaccinated individuals relative to controls. Comparable results were reported in the stratified analyses for age, sex, mRNA vaccine type, and prior history of non-mRNA vaccination. However, a booster vaccination was associated with an increased risk of some AI-CTDs including alopecia areata, psoriasis, and rheumatoid arthritis. Overall, we conclude that mRNA-based vaccinations are not associated with an increased risk of most AI-CTDs, although further research is needed regarding its potential association with certain conditions.
See what I mean?
Many among the rest of the “risks” come straight out of the fever swamp of COVID-19 antivax nonsense. I’ll start with some of the most egregious before moving to the just exaggerated, starting with—you guessed it!—”turbo cancer” and the claims that the mRNA vaccines “permanently alter your DNA”:
Potential DNA integration from the mRNA COVID-19 vaccines poses unique and elevated risk to human health and to the integrity of the human genome, including the risk that DNA integrated into sperm or egg gametes could be passed onto offspring of mRNA COVID-19 vaccine recipients. 
Oh, no! The vaccines are going to corrupt our DNA! Actually, no they are not, and the study cited by Dr. Ladapo above was an infamous one by Kevin McKernan, who has done his best to torture science to demonstrate that somehow, against all of what we know about molecular biology and what it takes for DNA to integrate into the genome, that nasty and supposedly “massive” DNA contamination from the vaccine is affecting your DNA. It’s not, and I discussed that very study in gory detail a long time ago. It’s utter nonsense. That Dr. Ladapo would cite such ideologically motivated horribly bad “science” to support his “guidance” should tell you all you might want to know.
But let’s look at some more claims:
    • “The mRNA COVID-19 vaccines present a risk of subclinical and clinical myocarditis and other cardiovascular conditions among otherwise healthy individuals.”
    • “The mRNA COVID-19 vaccine may be associated with an increased risk of postural orthostatic tachycardia syndrome (POTS).”
Here’s the interesting thing. As anyone who’s paid attention to the real issue of an elevated risk of myocarditis after vaccination with the mRNA vaccines knows, that risk occurs primarily in young people, in particularly young men, who nearly all make a full recovery, not the over-65 population who are most at risk of severe disease and bad outcomes if they catch COVID-19. As Dr. Paul Offit put it regarding Dr. Ladapo’s attempt to frighten everyone, including older people, away from the mRNA-based vaccines:
“It’s just such a dangerous game he plays,” said Offit, who has served on the FDA’s independent vaccine advisory committee. “You only have a roughly 1,000 times greater likelihood of dying [from Covid] if you’re over 65 than if you’re under 18.”
“The mRNA vaccines are remarkably safe,” he added.
As for POTS, yes, there is a small increased risk of POTS after vaccination, but the risk of POTS is much higher after COVID-19; specifically a recent study in Nature Cardiovascular Research concluded that COVID-19 infection is associated with a five-fold greater risk of POTS than COVID-19 vaccination. I can’t help but notice how Dr. Ladapo cited this exact study but failed to mention this or that the odds ratio for post-vaccination POTS was 1.10, quite low. Funny that. Actually, no, it’s not funny. It’s predictable given that Dr. Ladapo is an antivax crank.
I also can’t resist letting Dr. Peter Hotez also chime in:
5/n Covid vaccination protects heart health https://t.co/xbxGpap4hw
— Prof Peter Hotez MD PhD (@PeterHotez) September 13, 2024
In other words, Dr. Ladapo is either lying by admission or just plain lying, although one does have to allow for the possibility that he’s a true believer and his ideology has blinded him to what the totality of evidence shows.
Finally, there’s this:
Throughout the pandemic, studies across geographic regions found that the mRNA COVID-19 vaccines are associated with negative effectiveness after four to six months. As efficacy waned, studies showed that COVID-19 vaccinated individuals developed an increased risk for infection.
I can’t help but note that the first study cited concluded:
Effectiveness against COVID-19 hospitalization and death was 70–80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.
Moreover, the findings of “negative vaccine efficacy” are likely an artifact of biases related to measuring the true versus observed levels of infection in some observational studies in which exposure and testing of individuals vary based on vaccination status, as this commentary describes:
Different sources of bias produce negative VE by influencing either (1) the true levels of infection or symptomatic infection by vaccination status (e.g., by differences in exposure) or (2) the observed levels of infection or symptomatic infection by vaccination status (e.g., by differences in testing) (Figure 1). Although the biases related to (1) cause true underlying (symptomatic) infection differences that exist even given perfect sampling, biases related to (2) cause a perception of differences that do not reflect the real (symptomatic) infection levels present in the population. Although both categories of bias are important to discuss in the broader context of VE studies, their relevance for a specific study will depend on the type of VE being measured. The biases related to (1) and (2) can both influence VE measurements of infection and symptomatic infection; the biases related to (2) are less likely to play a role when measuring VE against severe outcomes (e.g., intensive care unit admission, intubation, and death) because testing for these outcomes is unlikely to differ across vaccinated and unvaccinated individuals [14].
I recommend reading the whole commentary, as it points out how these biases can give a false appearance of “negative efficacy,” and this figure is worth looking at too, as it summarizes the issues:
One notices that antivaxxers always cherry pick these studies and ignore the overall totality of the evidence, which shows that COVID-19 vaccines are safe and effective and reduce your chance of severe disease that can result in death. It’s no surprise that Dr. Ladapo does the same thing. Nor is it any surprise that he implies that the following will help as much or more than the vaccines:
Improving habits and overall health help manage and reduce the risk of heart disease, type 2 diabetes, and obesity, risk factors for serious illness from COVID-19.
The State Surgeon General and the Department continue to encourage Floridians to prioritize their overall health by:
    • Staying physically active,
    • Minimizing processed foods,
    • Prioritizing vegetables and healthy fats, and
    • Spending time outdoors to support necessary vitamin D levels.
This is the same sort of false dilemma that antivaxxers have long used. Sure, you’ll be healthier if you stay physically active and prioritize healthy eating, although staying outside is a two-edged sword if you don’t also avoid excessive sun exposure that can increase your risk of skin cancer. As for all of this supposedly reducing your risk of COVID-19, this is a trope that COVID-19 contrarians were spewing before there was even a vaccine, when, for instance, Dr. Aseem Malhotra attacked Krispy Kreme for providing free doughnuts to frontline healthcare workers in the UK and claimed that “metabolic optimization” could cure COVID-19. Everything old is new again. Too bad most people, including many of my colleagues, don’t recognize that.
Florida public health pseudoscience: Coming soon to the federal government?
When Florida Governor Ron DeSantis first appointed Dr. Ladapo as Florida’s Surgeon-General and therefore the person in charge of the Florida Department of Health and the state’s entire public health apparatus, many of us were justifiably alarmed, an alarm that has been totally validated by his performance since his appointment. After all, Dr. Ladapo was a founding member of America’s Frontline Doctors, which made a name for itself in that horrible first summer of the pandemic by touting hydroxychloroquine as a miracle cure for COVID-19 and later turned to telehealth grift selling prescriptions for ivermectin to cure COVID-19, and a signatory of the Great Barrington Declaration, the document published by contrarian scientists brought together by a right-wing think tank to advocate a social Darwinist “let ‘er rip” approach to the pandemic with poorly defined “focused protection” for those most at risk for severe disease and death from the pandemic.
Moreover, this “updated guidance” is far from the first time that Dr. Ladapo has tried to mislead using the usual denialist techniques of cherry picking evidence and even outright misrepresenting it. Last year, he was busted for altering a Florida Department of Health study for lying with statistics to make it look as though the vaccine was more dangerous than COVID-19 for men under 40. Earlier this year, consistent with its inclusion in this “guidance,” Dr. Ladapo was parroting McKernan’s bad science that massively exaggerated the problem of DNA contamination of the vaccine.
Given the recent developments in which Donald Trump has cozied up to RFK Jr. and (apparently) promised him a cabinet-level position in his administration, should he win in November, it’s very easy to foresee what will happen to medicine, public health, and science in general if Trump becomes President again. You need look no further than Florida, except that it could even be worse than Florida. After all, Dr. Ladapo isn’t the only doctor hostile to vaccines and public health science who would likely find a leadership position in a second Trump administration. There is ample reason to be afraid, very afraid.

Update on the Zika Virus
Steven Novella on February 10, 2016
Link
A new word has been added to the public’s vocabulary – the Zika virus. It seems we have one more infectious agent to worry about. Here are the facts as we currently understand them regarding the recent Zika epidemic, and also some rumors and conspiracy theories that need debunking.
Zika virus
The Zika virus (of the viral family Flaviviridae, an Arthropod-Borne or arbovirus) is spread through Aedes mosquito bites, the same mosquitoes that also spread dengue fever, West Nile, and yellow fever. The infections themselves are usually mild, causing fever, rash, joint pain, and conjunctivitis. Many of those infected (about 80%) may even have a subclinical infection, meaning they do not notice any symptoms.
According to the World Health Organization:
Zika virus is diagnosed through PCR (polymerase chain reaction) and virus isolation from blood samples. Diagnosis by serology can be difficult as the virus can cross-react with other flaviviruses such as dengue, West Nile and yellow fever.
Although the primary infection is mild, the infection can have complications. There is one case report of Guillain-Barre Syndrome (GBS) following a Zika infection. GBS causes inflammation of the lining of nerves resulting primarily in weakness with variable recovery. This does not appear to be a huge risk, but something to monitor.
The bigger concern is if a pregnant women becomes infected. There are numerous reports of poor pregnancy outcomes, mostly microcephaly, in women who have been infected with Zika while pregnant. Microcephaly means small head, and results from poor brain development (more on this below).
There is currently no treatment for a Zika infection (other than usual supportive care if necessary). There is also no vaccine, although efforts are already underway to develop one.
Zika was first identified in Uganda in 1947. It spread throughout Africa, and then spread to Southeast Asia in the late 20th century. Recently it has also spread to South America and Mexico, with Brazil being a particular hot spot.
There are as yet no cases of locally acquired Zika in the US. There have been a few cases of people returning from travel to South America with a Zika infection. It is possible for Zika to become endemic in the US.
The virus can spread wherever there are Aedes mosquitoes, which exist throughout the Americas except for Peru and Canada. Interestingly, these mosquitoes were previously localized to the tropics and subtropics, but have been spread as invasive species by human activity – paving the way for later viral infections.
Zika is in the news now because its pace of spread has dramatically increased. It is no longer a “slow” pandemic, but rather is spreading rapidly.
Microcephaly
The Zika infection itself is mild, in fact it is less of a problem than the flu. However, what has caused such great concern is the apparent association between Zika outbreaks and a condition known as microcephaly.
At this point the connection is still a correlation without proven causation, but the Zika virus being the cause is likely and it is reasonable to assume this is the case unless evidence proves otherwise.
Brazil is the center of the microcephaly concerns. According to reports, drawing from a CDC study published in January:
Public health officials in Brazil are investigating more than 4,000 cases of suspected microcephaly, and have confirmed more than 400. Prior to the Zika outbreak, Brazil saw on average 163 cases annually of microcephaly over the past five years, according to WHO. In 17 of the new cases, the presence of Zika was identified in the mother or the baby.
A study of 35 Brazilian babies born with microcephaly during the Zika outbreak reported by the CDC Jan. 29 added strength to the suspected connection.
The mothers of all 35 infants had lived in or visited Zika virus-affected areas during pregnancy, the report said. Twenty-five infants had severe microcephaly, and 17 had at least one neurologic abnormality.
In addition to the spike in cases of microcephaly in areas of Zika infection, the cases themselves are unusually severe. Microcephaly experts have examined the brain scans of some of the cases, and found:
“These children have a very severe form of microcephaly,” Dobyns said. “The brain is not just small, it’s small with malformations of the cerebral cortex and calcifications. It has the appearance of a very severe, destructive injury to the brain.”
There is also evidence that the brains in severe cases have actually shrunk. These findings all point to severe brain injury as a result of the infection. These children are going to have severe lifelong neurological impairment.
While the connection between Zika and the spike in microcephaly needs to be absolutely confirmed, the evidence so far is very compelling, and other likely causes so far have been ruled out.
What to do?
As there is no treatment or vaccine for Zika, basic precautions are necessary. This mostly involves limiting mosquito populations and avoiding exposure. Mosquitoes breed in standing water, even small puddles or containers with water. Eliminating any standing water is therefore an important measure.
Ponds and lakes can also be sprayed. In the US, the CDC embarked on a campaign to eliminate malaria in the South through control of mosquito populations, and they were successful. So it is possible to reduce mosquito populations to such a degree that infections cannot spread – although malaria is not a virus, which may be more difficult to control.
Meanwhile, those living in areas with the mosquitoes can use repellent, keep their windows closed, use mosquito nets, and take other measures to avoid being bitten.
The WHO and CDC are advising pregnant women not to travel to areas where there is currently an outbreak of the Zika virus. They are also suggesting that women who live in an area of an active outbreak might want to delay pregnancy, although they acknowledge this is a very personal decision.
Conspiracies
Of course, no news story is wasted by the conspiracy theorists. There are already a number of rumors and conspiracies about the Zika virus, all apparently made up out of whole cloth.
Some anti-vaccine and medical conspiracy sites are blaming vaccines for the cases of microcephaly, specifically the Tdap vaccine given to pregnant women. There is no evidence for these claims.
In fact, there have been a number of safety studies showing no increased risk of adverse events in children of women receiving the Tdap vaccine during pregnancy.
Another popular conspiracy theory is that the virus is being spread by genetically modified mosquitoes. This theory fails on multiple levels, but perhaps the single biggest failure is that the genetically modified mosquitoes are all male, and male mosquitoes do not bite. The males are nectar feeders, and only the females feed on blood.
There are also a number of conspiracy theories that the outbreak of Zika is a hoax, or was created on purpose for some nefarious reason. These are Illuminati-level grand conspiracies and are not even coherent enough to directly address.
The big picture
The public has had to deal with a series of new serious infections emerging in the world. Prior to 1980 no one had ever heard of HIV. This infection emerged as a world-wide pandemic fairly quickly, and literally changed the practice of medicine. Now we take for granted that we live in a world with HIV.
More recently the H1N1 flu emerged as a new strain, although fortunately did not turn out to be as virulent as feared. Still, we had to adapt, and now the annual flu vaccine targets the H1N1 strain routinely, in addition to the predicted circulating strains.
We have been hearing about the avian influenza (bird flu) for a number of years. This is an extremely virulent form of the flu that primarily affects birds and is a threat to the poultry industry. There are individual cases of humans being infected, but currently this virus is not spread from person to person. The fear is, however, that one or more strains will make the full transition to the human population and we could see a serious pandemic.
There have been serious pandemics in the past. Perhaps the most famous was the flu pandemic of 1918, which killed between 20-40 million people (more than World War I).
Fortunately the WHO and CDC are doing their job. They are on top of such outbreaks – that’s why we hear about them. The CDC is confident that if Zika reaches the US directly (so far it is just isolated cases of people coming from Zika areas), that they can contain the spread.
Outbreaks, epidemics, and pandemics are just part of the reality of having a large world-wide population. The Zika virus is just the latest example, and there are certain to be others. It is not fearmongering (as some conspiracy theorists suggest) to warn about emerging infections and to encourage people to take basic precautions.
Because the Zika virus is spread by mosquito, we can significantly reduce its spread by reducing mosquito populations and protecting against being bitten by mosquitoes. Meanwhile scientists are working on a vaccine.
Our greatest defense against the persistent reality of infectious diseases is science and information. Our greatest threat, more than the virus itself, is ignorance and misinformation.

Zika virus, microcephaly, and calls to bring back DDT (Rachel Carson revisionism edition)
In response to the Zika virus threat, predictably the same group of anti-environmentalists are urging that we bring back DDT and “Spray, baby, spray!” To make their questionable case, they overstate the benefits of DDT, downplay its risks, and engage in some major historical revisionism regarding the legacy of Rachel Carson.
David Gorski on February 15, 2016
Link

If there’s one thing I’ve learned over the last decade-plus of blogging about medicine and alternative medicine, it’s that any time there is an outbreak or pandemic of infectious disease, there will inevitably follow major conspiracy theories about it. I saw it during the H1N1 pandemic in the 2009-2010 influenza season, the Ebola outbreak in late 2014, and the Disneyland measles outbreak last year, when cranks of many stripes claimed that either the outbreaks themselves were due to conspiracies (usually, but not limited to, conspiracies to promote the “depopulation” vaccination agenda of—who else?—Bill Gates) or that nefarious forces were seizing on the outbreak to take away our freedom. The second thing I’ve learned is that inevitably people will try to impose their ideology on to the disease and try to use outbreaks to push their own ideological agenda. Indeed, the Ebola outbreak, for example, was rapidly seized on by politicians to promote quarantines and to halt immigration from the affected countries. This year, the biggest infectious disease-related story thus far is the Zika virus outbreak in Brazil that has been linked to microcephaly and other birth defects, and it’s a case of the same stuff, different year.
The Zika virus is a mosquito-borne flavivirus related to dengue virus and transmitted primarily by Aedes aegypti mosquitoes. On the surface, this virus would appear to be relatively benign, with 80% of those infected by it remaining asymptomatic, while the other 20% suffer from what is usually a self-limited, relatively mild illness characterized by fever, rash, arthralgias (joint aches), and conjunctivitis. In the grand scheme of things, after decades of being endemic in many tropical areas Zika virus infection probably didn’t seem so bad and didn’t appear to be much of a public health priority in the regions where Aedes aegypti mosquitoes live, mainly tropical regions in South and Central America, Africa, southeast Asia, and the Pacific islands. Then came the evidence that prenatal infection might cause microcephaly, and everything changed. Not surprisingly, conspiracy theories galore arose with social media speed, as did the ideologically motivated overselling of proposed solutions, such as bringing back DDT to combat the mosquito carrying the disease.
I don’t feel the need to go into a lot of detail about the various conspiracy theories and quack ideas that have sprung up over the last couple of months, given that Steve Novella, Tara Smith, and a certain friend of the blog have deconstructed these in detail already. I was just grateful that homeopaths hadn’t discovered Zika virus yet (at least until they did—crap). Suffice to say that the main conspiracy theories come from the anti-GMO fringe, who claim that the outbreak was caused by genetically modified mosquitos released by the British company Oxitec (it wasn’t) and antivaccinationists, who blame either the maternal Tdap vaccine or congenital rubella syndrome from the MMR vaccine for the birth defect (again, neither caused it). Then there’s a crank claiming either that the Zika virus isn’t real or that it doesn’t cause microcephaly and that in reality the whole “scare” is a covert op to sell vaccines and/or hide the real culprit: pesticides. This last one debunks itself. Sadly, none of this kept George Takei from buying into a “study” that was basically a greatest hits of Zika virus conspiracy theories:
If this study bears out, we shall have much soul-searching to do indeed.
Posted by George Takei on Sunday, February 14, 2016
Et tu, George?
Of course, it is amusing to me that the cause and solution to the Zika virus health crisis would be pesticides. But is there even a crisis? Let’s examine the evidence before deciding whether it’s appropriate to unleash the white powder known as DDT.
Zika virus and microcephaly
Before embarking on a discussion of the reaction thus far to the Zika virus health crisis, it’s important to ask: What’s the evidence for a link between Zika virus and microcephaly? Microcephaly literally means “small head” and is characterized by an abnormally small head and brain with delayed brain development. But does Zika virus cause microcephaly? As Facebook relationship statuses like to say, it’s complicated. The existing epidemiological evidence is suggestive but by no means a slam dunk for inferring causation, and some have even questioned whether the number of cases of microcephaly has really increased as much as initially thought, further muddling the question and contributing to the “Zika virus didn’t do it” conspiracy theories.
Steve did a fine job of summarizing the evidence linking Zika virus infection and microcephaly. It’s a good, digestible summation, but unfortunately for him events are moving so fast that, shortly after his post went live, the CDC published a report in the MMWR, Notes from the Field: Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses — Brazil, 2015, and the New England Journal of Medicine published a case report that adds to the very suggestive evidence of a link between maternal Zika virus infection and microcephaly.
The MMWR paper describes the result of Zika virus assays developed by the CDC for testing formalin-fixed, paraffin-embedded (FFPE) tissue samples (this is what pathologists routinely do to fix any tissue removed during biopsies or surgery). In December, the CDC tested tissues from two newborns with microcephaly who died within 20 hours of birth and two miscarriages (fetal loss at 11 and 13 weeks). They all came from the state of Rio Grande do Norte in Brazil, and all four mothers had had clinical signs of Zika virus infection, complete with fever and rash, during the first trimester of pregnancy but had no signs of active infection at the time of delivery or miscarriage. Tissues subjected to testing included brain and other autopsy tissues from the two newborns, a placenta from one of the newborns, and products of conception from the two miscarriages.
These tissues were subjected to reverse transcription-polymerase chain reaction (RT-PCR) directed at the gene for the nonstructural protein 5 and envelope genes with commonly-used methods for RT-PCR. Tissues were also subjected to immunohistochemistry (using antibodies to identify specific proteins in tissues) using an anti-Zika virus antibody. This is what the CDC found:
For both newborns, significant histopathologic changes were limited to the brain, and included parenchymal calcification, microglial nodules, gliosis, and cell degeneration and necrosis. Other autopsy tissues and placenta had no significant findings. Tests for toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and HIV were negative in the two mothers who experienced miscarriages. Placental tissue from one miscarriage showed heterogeneous chorionic villi with calcification, fibrosis, perivillous fibrin deposition, and patchy intervillositis and focal villitis, while tissue from the other miscarriage had sparsely sampled normal-appearing chorionic villi.
This report describes evidence of a link between Zika virus infection and microcephaly and fetal demise through detection of viral RNA and antigens in brain tissues from infants with microcephaly and placental tissues from early miscarriages. Histopathologic findings indicate the presence of Zika virus in fetal tissues. These findings also suggest brain and early gestational placental tissue might be the preferred tissues for postmortem viral diagnosis. Nonfrozen, formalin-fixed specimens or FFPE blocks are the preferred sample type for histopathologic evaluation and immunohistochemistry, and RT-PCR can be performed on either fresh frozen or formalin-fixed specimens. To better understand the pathogenesis of Zika virus infection and associated congenital anomalies and fetal death, it is necessary to evaluate autopsy and placental tissues from additional cases, and to determine the effect of gestational age during maternal illness on fetal outcomes.
In other words, the brains showed evidence of cellular degeneration and necrosis (cell death), and the placenta from one of the miscarriages had evidence of inflammation. The importance of these findings is that it shows that the Zika virus can infect the fetus when the mother is infected and that it appears to favor infecting the brain. Obviously, only four individuals are not enough to draw any sort of generalizable conclusions about prenatal Zika virus infection, but these results do provide evidence for biological plausibility of the hypothesis that prenatal Zika virus infection might be causing an outbreak of microcephaly.
Further adding evidence of both biological plausibility and a potential link is the case report published online last week in the NEJM. This report describes the case of a 25-year-old previously healthy European woman in Ljubljana, Slovenia who had worked as a volunteer in Natal, the capital of Rio Grande Do Norte state in Brazil since December 2013. She became pregnant near the end of February 2015 and became ill during her estimated 13th week of gestation with a high fever, a rash, musculoskeletal pain, and eye pain. Infection with Zika virus was suspected, but no diagnostic testing was performed. Ultrasound at 14 and 20 weeks showed normal fetal growth and anatomy. The patient ultimately returned to Europe around her 28th week, and a 29 week ultrasound examination showed fetal anomalies. Another ultrasound at 32 weeks showed intrauterine growth retardation, a head circumference less than the second percentile for gestation, along with abnormalities of the brain, including calcifications. The pregnancy was terminated, and the fetus showed prominent microcephaly, with almost complete agyria (lack of the normal folds on the surface of the brain). Other abnormalities included inflammation and evidence of a viral infection in the neurons.
A detailed family history failed to find any genetic syndromes, and other causes of microcephaly were ruled out. The brain tissue was subjected to next-generation sequencing, and:
A complete ZIKV genome sequence (10,808 nucelotides) was recovered from brain tissue. Phylogenetic analysis showed the highest identity (99.7%) with the ZIKV strain isolated from a patient from French Polynesia in 2013 (KJ776791) and ZIKV detected in Sao Paolo, Brazil, in 2015 (KU321639), followed by a strain isolated in Cambodia in 2010 (JN860885, with 98.3% identity) and with a strain from the outbreak in Micronesia in 2007 (EU545988, with 98% identity).
And:
The complete genome sequence of ZIKV that was recovered in this study is consistent with the observation that the present strain in Brazil has emerged from the Asian lineage. The presence of two major amino acid substitutions positioned in nonstructural proteins NS1 and NS4B probably represents an accidental event or indicates a process of eventual adaptation of the virus to a new environment. Further research is needed to better understand the potential implications of these observations.
In other words, the virus isolated from this microcephalic fetus appears to have come from Asia. It also appears to have two mutations in nonstructural proteins, the significance of which are unknown. Again, this is not slam-dunk evidence that Zika virus causes microcephaly, given that it’s only one case. (For instance, something else could have caused the microcephaly and at the same time made the fetal brain more susceptible to infection.) Even so, it adds to the accumulation of evidence linking Zika virus to microcephaly.
Still, there remain many questions, such as why there haven’t been outbreaks like this before, given that Zika virus has been endemic in many areas since at least the 1950s and there have been outbreaks of Zika virus before in Africa, southeast Asia, and the Pacific Islands, as well as several countries in Central and South America where Zika virus outbreaks are currently being reported. Yet, despite how widespread the virus is, there haven’t been reports of increased incidence of microcephaly before this. Clearly, there are many unanswered questions that will require large scale epidemiological studies to answer. In the meantime, taking precautions and developing a vaccine are reasonable interventions.
Since Zika virus is mosquito-borne, prevention is impossible without mosquito control in the affected areas.
Enter DDT
It was at this point that I couldn’t help but note an argument that was popping up in certain spheres about the Zika virus and how to control its vector. For instance, Gil Ross of the American Council on Science and Health (ACSH), an organization I’ve discussed before that apparently never met a pesticide it didn’t like, posted an article entitled “Stopping Zika Virus in Its Tracks, by Unleashing DDT,” while Josh Bloom of the same organization wrote a very pro-DDT article that might as well have been entitled “DDT is good for you.” Meanwhile, Dr. Jane Orient, whom we’ve also met before, executive director of the American Association of Physicians and Surgeons (AAPS), an organization that we’ve also encountered before, published an article in WorldNetDaily entitled “Zika Virus: What Should We Do About It?” It was this passage from Dr. Orient’s article that got me thinking and made me decide to write about DDT:
Travel restrictions would greatly harm the economy of Latin American countries, especially as Brazil is preparing to host the Olympics. Of course, there is no screening at all of illegal entrants to the U.S. The key public health measure is mosquito control. Mosquito-borne diseases, after a time when it was thought that even malaria might be wiped out, began increasing worldwide when the U.S. banned the most effective public health weapon of all time: DDT. If Zika causes rethinking of this disastrous decision, even though other deadly threats like malaria have not, it will save millions of lives – and even help us win the war on bed bugs.
The damaged babies are a terrible tragedy. How can we prevent more? Instead of waiting for some future vaccine against a virus that may prove innocent, we could stop transmission now with effective mosquito control in affected areas. We could also immediately stop deliberately exposing women who might be pregnant to medicines or vaccines without thorough safety testing.
I can’t help but note that in her article Dr. Orient embraced antivaccine claims that Tdap and/or the MMR vaccine was causing the microcephaly, while insinuating that the whole thing might be trumped up as a means to promote an agenda that includes combatting anthropogenic climate change, loosening restrictions on abortion in Central America, keeping immigrants out of our country, and, of course, letting loose the DDT if it turns out this Zika virus-microcephaly thing is real.
Of course, it’s easy to pick on Dr. Orient; she’s a bona fide crank who denies even the concept of a scientific consensus and runs an organization that resembles a cross between a mini-AMA and the more extreme elements of the John Birch Society. Besides, just because she’s a crank doesn’t mean she might not be right on this one issue. Also, she’s not the only one pushing to bring back DDT. A quick Google search about DDT and Zika virus brings up a slew of articles with titles like “Zika Virus Shows It’s Time to Bring Back DDT: Our most effective tool has been banned,” “WHO Says Zika Virus a Global Threat; Health Experts Push to Lift DDT Ban,” “The Experts Want To Unleash DDT To Fight The Zika Virus,” “Physician: Lifting DDT Ban Could Stop Mosquito-Borne Zika Virus,” and “To Combat Zika, Bring Back DDT.”
One can’t help but also notice that there is one thing nearly all of the publications and persons calling for a return of DDT share, and that’s a certain political orientation, something made a bit clearer in titles of other pro-DDT articles written about the Zika virus outbreak, such as “DDT might have stopped Zika, but environmentalists chose mosquitos over people” and “Mass Murders and Radical Environmentalists,” the latter of which seriously argues that environmentalists, through banning DDT, have killed more people than Hitler and Stalin, concluding with the utterly unhinged and reprehensible statement that the “title of ‘Greatest Mass Murderer of all Time’ goes to the late Rachel Carson and all of her radical environmentalist followers.” Yes, Rachel Carson is the target of most pro-DDT ire, a typical title being a little less histrionic; e.g., “Zika Virus: Rachel Carson’s Deadly “Good Intentions” Legacy Continues.”
Basically all these articles argue that, if only we would let loose with the “excellent powder” of DDT, Zika virus would no longer be a problem, frequently with the claim that the only thing preventing us from doing this are those pesky environmentalists, starting with Rachel Carson over 50 years ago! But do they have a point? Not really, at least not a particularly good one. Their narrative, in which Rachel Carson inadvertently led to the deaths of tens of millions because her book persuaded the US, having eradicated malaria within its own borders, to ban the tool we used to do it so that poor countries couldn’t do the same and in which all we have to do is to bring back DDT to defeat malaria and other mosquito-borne illnesses like Zika virus, is simple and attractive. Unfortunately, because it ignores a lot of nuance, it is also mostly wrong.
Rachel Carson, Silent Spring, and DDT
Dichlorodiphenyltrichloroethane (DDT) is a colorless crystalline organochloride that is also tasteless and almost odorless and has been used for many decades as an insecticide, particularly for eliminating disease-carrying mosquitos. It was first synthesized in 1874 by a German graduate student in chemistry, Othmar Zeidler, under the supervision of Adolf von Baeyer. Not much was done with it until 1939, when Swiss chemist Paul Hermann Müller discovered its insecticidal properties. After that, DDT soon was in widespread use during World War II to control malaria and typhus. After the war it was used as an agricultural pesticide, and its use skyrocketed. Because DDT was such an effective pesticide with such apparently low toxicity to humans and animals, in 1948 Müller won the Nobel Prize in Physiology or Medicine for his discovery.
There’s no doubt that DDT was incredibly effective—at first—and cheap too. In 1955, the World Health Organization initiated its Global Malaria Eradication Program that relied largely on DDT for mosquito control and rapid diagnosis and treatment to reduce transmission. The program was very successful—again, at first. Unfortunately, failure to maintain the program and the development of resistance to DDT (evolution in action!) conspired to roll back or even completely reverse early victories.
It was in the middle of this history that Rachel Carson published her book Silent Spring in 1962. The book was a powerful indictment of what Carson saw as the overuse of DDT and other pesticides, which she termed “biocides,” mainly because such chemicals almost never limit their toxic effects to just the intended organisms. In the book, she documented a number of adverse effects of DDT and other pesticides on the environment and human health. Specifically, Carson blamed DDT and pesticide use for thinning of birds’ egg shells and declining bird populations, as well as described it as potentially carcinogenic based on animal studies. She described how DDT entered the food chain and accumulated in the fatty tissues of animals, and how one of DDT’s greatest advantages as a pesticide, its ability to persist where it is sprayed and remain toxic to insects for long periods of time, was also what contributed to its potential harmful effect to the environment and humans. Much of what she found has stood up, although in fairness it must also be noted that Carson did vastly overstate how carcinogenic DDT is, although the science at the time did provide enough reason to be alarmed.
Despite this indictment, contrary to popular belief, it was not a book that was just about DDT, nor was it a book that called for the outright banning of DDT or other pesticides. Indeed, Carson was at pains to point out that she did not advocate banning DDT or pesticides. At one point she wrote:
It is not my contention that chemical insecticides must never be used. I do contend that we have put poisonous and biologically potent chemicals indiscriminately into the hands of persons largely or wholly ignorant of their potentials for harm.
Which was really hardly arguable at the time, because it was largely true. In fact, I doubt there are too many environmentalists today who would argue with this. She was also correct about the evolution of resistance:
No responsible person contends that insect-borne disease should be ignored. The question that has now urgently presented itself is whether it is either wise or responsible to attack the problem by methods that are rapidly making it worse. The world has heard much of the triumphant war against disease through the control of insect vectors of infection, but it has heard little of the other side of the story—the defeats, the short-lived triumphs that now strongly support the alarming view that the insect enemy has been made actually stronger by our efforts. Even worse, we may have destroyed our very means of fighting.
Yes, those last two sentences refer to exactly what happened: Mosquitos developing pesticide resistance in the face of too-zealous use of DDT and other pesticides, which she later described explicitly:
The whole process of spraying seems caught up in an endless spiral. Since DDT was released for civilian use, a process of escalation has been going on in which ever more toxic materials must be found. This has happened because insects, in a triumphant vindication of Darwin’s principle of the survival of the fittest, have evolved super races immune to the particular insecticide used, hence a deadlier one has always to be developed and then a deadlier one than that. It has happened also because, for reasons to be described later, destructive insects often undergo a “flareback,” or resurgence, after spraying, in numbers greater than before. Thus the chemical war is never won, and all life is caught in its violent crossfire.
It’s easy for us in 2016 to forget just how heavily pesticides were used in the 1940s-1960s and therefore conclude that Rachel Carson was unduly alarmist. However, back in the day, governments engaged in aerial insecticide spraying campaigns over farms, forests, cities and suburbs. Farmers routinely applied high concentrations of insecticides, and the residential use of these chemicals was common in everything from shelf paper to aerosol “bombs” designed to clear out a house of insects. Aerial residential and forest sprayings were often carried out whether the residents affected wanted them or not. You can get an idea from this late 1950s film called Goodbye, Mr. Roach:
It’s not for nothing that the 1950s were called the golden age of pesticides. In other words, pesticide use in Rachel Carson’s time was incredibly indiscriminate by today’s standards.
Influence and backlash
Silent Spring was an immediate sensation beginning before the book itself was published. That’s because parts of Silent Spring were serialized in The New Yorker in June 1962 and then later published as a book that September. Advance sales totaled 40,000, and October Book-of-the-Month sales hit 150,000. By the time Carson died of metastatic breast cancer in April 1964, a million copies had been sold. The book was also hugely influential, particularly after Carson appeared on a CBS Reports television special, The Silent Spring of Rachel Carson, which was broadcast on April 3, 1963. An hour long special, it featured investigations by Eric Severeid interspersed with an interview with Carson, now visibly ill from her breast cancer, and interviews with experts, particularly scientist Robert White-Stephens, a spokesman for American Cyanamid, wearing black-rimmed glasses and sitting among beakers in a lab, trying to refute Carson. The response was overwhelmingly positive, as White-Stephens came off as loud and wild-eyed, while Carson appeared calm—anything but the hysterical woman her opponents had portrayed her as.
Not surprisingly, the attacks began very early. Although predictably many of these attacks did come from the chemical industry and scientists sympathetic or linked to it, there was also a very Cold War flavor to the criticism. Carson’s warnings were often portrayed as, in essence, an attack on American values. She was not infrequently referred to as a Communist and attacked in misogynistic terms, for example in a letter to The New Yorker after serialization of Silent Spring:
Miss Rachel Carson’s reference to the selfishness of insecticide manufacturers probably reflects her Communist sympathies, like a lot of our writers these days. We can live without birds and animals, but, as the current market slump shows, we cannot live without business. As for insects, isn’t it just like a woman to be scared to death of a few little bugs! As long as we have the H-bomb everything will be O.K.
“We can live without birds and animals”? WTF? Believe it or not, this is how a lot of Americans thought over 50 years ago.
This accusation being a Communist was echoed by former Secretary of Agriculture Ezra Taft Benson in a letter to former President Dwight Eisenhower in which he said that Carson was “probably a Communist.” Elsewhere she was accused of being radical, unscientific, hysterical, and disloyal. Much was made of calling her a “spinster” because she was unmarried. David Hecht noted that initially criticism of Carson involved mainly scientists concerned with defending their vision of science from what they perceived as the threat embodied in Carson’s ecological perspective and that the “legion of critics” attacking her defended DDT by making it emblematic of technological progress, suggesting that her condemnation of it derived from a philosophy antithetical to the modern world.
Despite all this, it’s not for nothing that Carson’s book was credited with sparking the modern environmental movement. Silent Spring became part of popular culture. By the early 1970s, public opinion had shifted. This wasn’t entirely due to Carson’s work, of course, but there’s no denying that her book was very influential. Ultimately, the EPA held seven months of hearings in 1971-1972 where the evidence for and against DDT was presented, and in the summer of 1972, William Ruckelshaus, the EPA’s first Administrator, announced a ban on DDT use in the US for most uses, although he did not ban its manufacture or sale overseas and there was an exception for public health; e.g., malaria control. Indeed, the US continued to manufacture and export DDT until the mid-1980s. In the following years, agricultural use was banned in most developed countries. Most recently, the Stockholm Convention on Persistent Organic Pollutants took effect in 2004 and restricted DDT use to vector control. Specifically, the convention exempts public health use within WHO guidelines from the ban. Today, approximately 3,000 to 4,000 tons of DDT are used each year for vector control, usually application to the inside walls of homes to kill or repel mosquitos, a technique known as indoor residual spraying.
Rachel Carson revisionism to DDT’s rescue!
Now that the World Health Organization has declared the Zika virus to be a “global public health emergency,” calls to bring back DDT by lifting the ban are, predictably, coming fast and furious. A few are somewhat reasonably nuanced. Most are nowhere near nuanced. For instance:
The Zika virus outbreak is the latest batch of blood on the dirty hands of Rachel Carson and the entire environmental movement which puts mosquitoes ahead of people. There was a time when we beat insect-born [sic] diseases through simple and easy methods that worked.
That method? DDT of course. Of course, if anyone thinks that controlling mosquitos was ever “simple and easy,” even in the era of maximal DDT spraying, well, I have a bridge I think that person just might be interested in buying. Here’s another:
Rachel Carson died in 1964, but the legacy of Silent Spring and its recommended ban on DDT live with us today. Millions are suffering from malaria and countless others are contracting the Zika virus as a result of the DDT ban. They were never given the choice of living with DDT or dying without it. The World Health Organization should recognize that DDT has benefits, and encourage its use in combating today’s diseases.
If you’ve read Merchants of Doubt by Naomi Oreskes and Erik Conway, you’d be aware that there has been a renewed concerted effort to discredit Rachel Carson, which is what I mean when I refer to “Carson revisionism.” Over the last 20 years or so, the story of Rachel Carson has been subjected to historical revisionism by the very same people who tried to deny the science demonstrating the harmful health effects of tobacco and who more recently have spearheaded anthropogenic climate change denialism.

This revisionism involves a narrative in which, because of the anti-pesticide and anti-DDT fervor ignited by her book that led to the banning of DDT in the US, and, if you believe the narrative, in the rest of the world, millions died of malaria whom DDT could have saved. Key components of the narrative are predictable: DDT is the only hope of controlling Zika virus. There wouldn’t be so many people dying of malaria if only those damned Rachel Carson environmentalists would let governments unleash DDT. After the DDT ban, malaria came roaring back, and now Zika virus is uncontrollable. DDT is harmless (or its adverse effects were grossly exaggerated.) Environmentalists care more about birds than people, and not lifting the ban will lead to a Zika virus pandemic. Oh, and liberals and environmentalists want to keep DDT banned as a population control measure because it was too effective.
Indeed, in a speech railing against climate science, dismissing secondhand tobacco smoke as harmless, and characterizing environmentalism as a “religion,” late author Michael Crichton, whom I’ve discussed before, characterized the DDT ban as having “caused the deaths of tens of millions of poor people, mostly children, whose deaths are directly attributable to a callous, technologically advanced western society that promoted the new cause of environmentalism by pushing a fantasy about a pesticide, and thus irrevocably harmed the third world.” In his novel State of Fear, Crichton even had one of his characters (a sympathetic one) say, “Banning DDT killed more people than Hitler.” He even put the death toll at 50 million. Sure, it was just dialog in a novel, but it’s clear from interviews (and the speech quoted above) that Crichton believed it. Tellingly, the plot of State of Fear involved eco-terrorists plotting mass murder to publicize the dangers of global warming. No wonder Chris Mooney described the novel as “pure porn for global warming deniers.”
There’s only one problem with the revisionist narrative promoted by Crichton before his death and still being promoted by conservative free market-friendly think tanks like the Heartland Institute and the Competitive Enterprise Institute. Although Rachel Carson was certainly not correct about everything (for instance, the evidence linking DDT and cancer turned out to be fairly weak, even over 50 years later, although not, as her critics claim, nonexistent), nonetheless this revisionist narrative is demonstrably a false one promoted by the likes of not just Crichton but Steve Milloy of Junk Science fame, who never met an anti-environmentalism myth he didn’t like, DDT included. The “Rachel Carson killed more people than Hitler” myth is basically a zombie myth that won’t die.
For example, one claim frequently made in defense of DDT is that in Sri Lanka, DDT dramatically decreased the incidence of malaria, such that when the spraying stopped only a handful of people suffered from the disease, but that from 1968 to 1970, malaria came roaring back to infect 1.5 million because Sri Lanka could no longer use DDT. In Merchants of Doubt, Oreskes and Conway point out that this doesn’t tell the whole story, namely that Sri Lankans did use DDT when malaria came roaring back in 1968 but it couldn’t control the mosquitos because resistance had developed; in fact they used ever greater amounts of it, to no avail. They had to switch to malathion, a pesticide to which their mosquitos hadn’t yet developed resistance.
In reality, DDT use peaked before Silent Spring and DDT use was decreasing because mosquitos were developing resistance, just as Rachel Carson had been concerned about. Sadly, it’s a myth that skeptics who should know better not infrequently fall for, sometimes people I never would have guessed as being susceptible to such messages.
Is there a role for DDT in controlling Zika virus?

Rachel Carson revisionism aside, it must be conceded that it is not entirely unreasonable to examine all the tools in our armamentarium and ask if there might be a role for DDT in controlling Aedes aegypti. However, the answer to such a question must be grounded in a scientifically-supportable and balanced understanding of the risks versus the benefits. My main reason for discussing Rachel Carson revisionism is because it represents a certain kind of antiscience that, because of ideology, vastly exaggerates the benefits of DDT and other pesticides while all but denying any potential harm. In the 1960s, the ideology behind attacks on Carson linked DDT with “progress” and the American way, while painting her as an enemy of modernity and science itself, a hysterical woman (who was probably a Communist) who would set back American agriculture to the inferior level of the Soviet Union at the time. Since the late 1990s, that ideology has been a certain free market belief system that chafes at any regulation of business, particularly regulation rooted in environmental concerns. Some of those of this ideological bent have latched on to DDT as an example of overweening government regulation spurred by a environmentalists who in their view don’t care how many people die of malaria, as long as the birds are saved (unless, of course, they are killed by wind turbines, which, in this view, is acceptable to these parodies of environmentalists).
Obviously, this view rests on a Panglossian view of DDT in which it is virtually perfectly effective and safe, even though nothing really is. Perhaps the most balanced discussion of the risks and benefits of DDT for mosquito control was published ten years ago in The Lancet by Walter Rogin and Aimin Chen, who concluded that there was sufficient evidence of health problems to be concerned. In particular, they noted that exposure to DDT at amounts that would be needed for effective malaria control might cause preterm birth and early weaning, abrogating the benefit of reducing infant mortality from malaria, while at the same time noting that the evidence for a link between DDT and human cancer was tenuous at best. Rogin and Chen then note that DDT can be very effective in eliminating mosquitos, but that there are a number of problems that are not so easily overcome that demonstrate the problems of using DDT just for malaria control:
However, the effectiveness of DDT can be compromised by insecticide resistance and social resistance to DDT indoor spray. Because of the irritating, excito-repellent nature of the DDT residue, some mosquitoes tend to leave before they have absorbed a lethal dose, or tend to avoid entering the house or resting on the wall at all. By the end of Global Malaria Eradication Campaign, some mosquito species had developed resistance to DDT, especially in India and Sri Lanka. In 1968, high amounts of resistance to DDT in Anopheles gambiae was reported in Upper Volta (now Burkina Faso); shortly thereafter, DDT had no effect on mosquito mortality, biting frequency, or resting in houses in trials undertaken in Togo and Senegal. In the 1980s when DDT was judged to control the resurgence of malaria in Zanzibar after the DDT spraying programme finished in 1968, resistance was found in A gambiae ss and A arabiensis. In 2002, 2 years after DDT residual spraying was reintroduced in KwaZulu-Natal to control the increase of malaria cases, resistance was recorded in A arabiensis, although A funestus was still susceptible to DDT. Social resistance to DDT indoor sprays occurs because bedbugs are resistant to DDT, and DDT leaves stains on walls, which residents then replaster. In practice, the efficacy of DDT spraying for vector control depends on the coverage of spraying, mosquito species, and resistance to DDT. Climate—especially rainfall, temperature, and latitude—could affect the stability of transmission, and thus also affect DDT efficacy. WHO points out that DDT spraying is “most effective in reducing the overall malaria burden in unstable transmission areas, areas with marked seasonal transmission peaks and disease outbreaks, and highland areas”.
In other words, DDT is no panacea, and its effectiveness very much depends on local conditions and the strategy used, not to mention the specific insects being targeted.
Indeed, there is reason to believe that letting loose the white powder would likely be far less effective than the pro-DDT apologists would lead you to believe because Aedes aegypti is particularly difficult to control. DDT is effective without mass indiscriminate spraying against many strains of the Anopheles mosquitos that spread malaria in part because of this:
Goldman said the pesticide is effective against the Anopheles mosquito, a night-biter that spreads malaria indoors while people are sleeping.
In many developing countries, DDT has proven effective when sprayed on the indoor walls of buildings.
“Basically the anopheles likes to rest on a wall surface between feedings and thus is poisoned by the DDT that is on the walls,” Goldman said.
“Also there are insecticide impregnated bed nets — usually with pyrethroids, and, infrequently, with DDT — to guard against malaria transmission while sleeping. Bed nets also are very effective.”
But the mosquito that transmits Zika is not the anopheles but another genus known as the Aedes, which also transmits dengue and chikungunya viruses, according to Goldman.
Aedes mosquitos bite outdoors, during the day, she said. Spraying walls with DDT won’t help.
Aedes mosquitos, in contrast to the Anopheles mosquitos, thrive in urban environments and tend to breed in close proximity to human populations, in particular in trash or discarded tires. They require a very tiny amount of water to breed, and their eggs can stay viable for a long time without water, ready to develop again once rains return. These characteristics make it relatively impervious to outdoor spraying, whatever the insecticide. Even though the mosquitos only survive two weeks and don’t fly very far, Dr. Thomas Frieden, director of the CDC, has likened them to the “cockroach of mosquitoes,” who “lives indoors around people and hides in dark places.” All of this means that spraying will be much less effective than it would be against Aedes. It could even backfire. How?
By doing this:
But according to Joe Conlon, a technical adviser to the American Mosquito Control Association and a former entomologist with the U.S. Navy, using DDT to control Zika is a terrible idea. “DDT seems like a silver bullet, but it isn’t.” First of all, the mosquitoes might be resistant to DDT. Conlon says the Latin American countries where Zika is blooming now used DDT heavily in the 1960s to kill off the Aedes aegypti, which also carries diseases like dengue and yellow fever. It worked, but the mosquitoes in the region developed robust resistance to the pesticide, which may still be lingering in the population. DDT resistance lasts a long time, he says, because the chemical persists in the environment so long. If you spray a wall with DDT today—a method commonly used because mosquitoes are known to rest on walls a moment after having a blood meal—it could still be coated by DDT in 20 years. The mosquito population continues to be bombarded by the chemical, so the resistance shows up in every subsequent mosquito generation.
And even if the mosquitoes aren’t already resistant, they will be. It only takes a “few generations” of mosquito to develop resistance, and when an Aedes mosquito’s life span is about 10 days, that’s not long at all. Conlon speculates mosquitoes could develop resistance within a year. “What’s even worse, resistance to DDT can stir cross-resistance to the other pesticides we use, like the pesticide we use to treat bed nets, to fight malaria.”
And that’s what bothers me so much about how ideologues have dragged DDT into the Zika virus debate. It distorts the debate that should be occurring, which is not a question of choosing environment or birds over humans or vice versa. That is a false dichotomy and the wrong question to be asking. Rather, deciding how to combat the Zika virus involves balancing one set of risks and costs, human, environmental, and financial, associated with different methods of mosquito control versus the risks and costs in human terms of a virus that hasn’t (yet) been conclusively demonstrated to be causing microcephaly. Add to that the consequences of bringing back DDT, which could reinvigorate resistance among mosquitos carrying malaria, and there are some real potentially bad consequences.
This is a situation where there is a lot of uncertainty involved, and all the available options are imperfect. Bringing back DDT could well be the most imperfect option of all.

Heat A Growing Public Health Problem
Heat related deaths are on the rise. What can we expect?
Steven Novella on August 16, 2023
Link

Heat is the number one environmental cause of death in the US – greater than cold, storms, hurricanes, floods, or tornadoes. Worldwide there are about 5 million deaths per year related to extreme heat or cold, four and a half million from cold and half a million from heat. This ratio is slowly shifting, however, due to global climate change. There are fewer cold related deaths, but more than offset by greater numbers of heat related deaths in recent years. We can expect this trend to continue for at least the next 2-3 decades, depending on how successful our efforts are to mitigate climate change.
Most heat-related deaths occur during weather events known as heat waves. In 2022 Europe experienced severe summer heat waves, and a recent study estimates this resulted in almost 62,000 heat-related deaths. Heat waves are getting more frequent, more intense, lasting longer, and with a longer heat wave season. In addition, rising global temperatures are also increasing humidity due to increased evaporation and because warmer air can hold more water vapor. This has significant health effect because the heat index, the effective temperature felt by the body, depends on both the temperature and the humidity.
Humidity is critical because one of the ways the body sheds excess heat is through sweating. When sweat evaporates on the skin it carries away some heat. But as humidity increases, this method of heat loss becomes less and less effective, until it does not work at all. Heat is also lost through radiation, convection and conduction. Conduction of heat is through direct contact with cooler objects. Convection works through air or water moving across the skin, carrying away heat. Radiation carries heat away through infrared rays, without needing direct contact with anything physical. We lose about 60% of our heat through radiation, but this is not something that is easily modifiable.
The body primarily uses evaporation to regulate temperature because that is the one variable it can control through sweating. Blood flow regulation can also bring more blood and heat to the skin to allow for greater convection. However, when air temperatures rise convection becomes less efficient, just as when humidity rises, evaporation becomes less efficient.
The National Weather Service heat index chart shows the impact of humidity on how dangerous high temperatures are. For example, at 40% humidity, you get into the danger zone at 98 degrees F, but at 80% humidity the danger zone begins at only 88 degrees. At 94 degrees you get into extreme danger, where heat stroke is “highly likely”. The highest heat index (effective temperature) this year reached 153 degrees in the Middle East, which is at the limit of human survivability.
What is heat stroke? Heat stroke occurs when the body is no longer able to shed as much heat as it is creating, due to decreased effectiveness of evaporation and convection. When this point is reach, heat accumulates in the body causing body temperature to rise rapidly. Within 10 minutes of reaching this point, body temperature can increase to 106 degrees F. This high temperature causes confusion, can lead to loss of consciousness, and can cause seizures. Heat exhaustion can also occur, which results when the body is depleted of water and electrolytes due to excess sweating. This, in turn, can lead to syncope (fainting) and muscle cramps.
High body temperatures caused by heat stroke can damage most organs, the brain, heart, kidneys, and muscles especially. Death due to heat stroke most often occurs because of cardiac effects. Children, elderly, and those with underlying heart conditions are most susceptible to death due to heat stroke. Repleting water and electrolytes can be critical, but the most important treatment is to reduce body temperature. This requires getting into a cooler environment immediately.
While global climate change is global, it refers to average temperatures. Not everywhere is affected the same. Heat related deaths, for example, are concentrated in Europe, southern Asia, and sub-saharan Africa. But as global temperatures rise, the number of locations around the world susceptible to dangerous heat waves is increasing, as is the number, duration, and intensity of those heat waves. This means the number of people living with the threat of dangerous heat waves is increasing. Some parts of the world may simply become uninhabitable during certain times of the year.
The primary mitigating technology for extreme heat is air conditioning. However, this uses a lot of energy, which ironically can worsen global warming due to increased carbon-intensive energy demand. Also, heat waves can lead to spikes in demand for energy for air conditioning which can stress existing systems. A power outage during a heat wave can be deadly as millions of people may suddenly lose access to air conditioning.
What all of this means is that heat related deaths are a large and growing public health concern. Researchers have found that already about a third of heat related deaths are attributable to climate change (would not have happened without climate change). This proportion is going to rise significantly.
Another study attempted to project heat deaths in the US as a function of climate change. They found that climate change mitigation can have a significant effect. With aggressive mitigation, essentially the best-case scenario, there would be no significant change in heat-related deaths in the US. With the worst case scenario high levels of warming, annual deaths from heat can rise by 97,000. With an average projected warming, deaths would still rise by 36,000. This is for the US alone, with numbers much higher globally. Where we fall in that range is entirely up to the policy decisions we collectively make regarding climate change.

The Health Costs of Fossil Fuel
Steven Novella on May 22, 2024
Link

Imagine if we could save over 8 million lives per year globally through public policy. Many of these preventable deaths are in younger people and fall disproportionately on the poor and disadvantaged. This is the estimate of a recent observational and modelling study on the effects of air pollution (fine particulate and ozone pollution). Of these death, over 5 million could be prevented by phasing out fossil fuel use.
This information is not new. There are studies going back decades, like this one from 1997, showing health benefits from improved air quality. In addition the research shows that these benefit are mostly linear – which means that, to whatever degree we decrease air pollution, there is a corresponding improvement in health. Benefits are also both global and local, so when a local community invests in improved air quality, they benefit.
The health benefits are not limited to preventing excess deaths. Air pollution, mostly from the combustion of fossil fuels, contributes significant to disease burden. This includes (but is not limited to) many forms of heart disease, asthma and other pulmonary diseases.
Of course, phasing out fossil fuel use will not be cheap or easy. It involves a massive change in many industries, and a huge corresponding investment in infrastructure. A full transition will take decades, and the stated goal of doing so by 2050, while possible, is considered ambitious. This is why it is also important to consider the healthcare costs of fossil-fuel caused air pollution.
One recent review of the published evidence by the Natural Resources Defense Council estimated the annual cost in the US alone of fossil fuel induced air pollution at over $820 billion. Estimate vary, however, with a 2023 study putting the figure at $77 billion. Another estimate put the global costs at $2.9 trillion. But we need to drill down on what we consider to be “costs”. There are direct costs and indirect costs.
The direct costs are mainly for healthcare for those affected, including medications, hospitalization, physical therapy, and other costs. This represents about $8 billion per year. The rest is indirect costs, mostly those due to premature deaths and lost productivity. Indirect costs include something called a VSL – value of a statistical life. This estimates the economic impact of a premature death.
There is no objective correct answer as to what the best method is to use – they just give different information. It is helpful to understand both direct costs and the likely total economic impact.
Most of the studies also emphasize that these numbers are likely to be an underestimate, because they only include the effects of air pollution itself. If you then also include the downstream effects of global climate change, the figures can climb much higher. For example, excess forest fires also release a lot of particulate matter into the air, worsening air pollution with all the downstream economic health costs.
There is also a quality of life issue that is difficult to model economically. What is the value, to us individually and collectively, of the improved quality of life from not having to deal with the negative health effects of air pollution? How much is avoiding a premature death, or not having to take a child to the ER for an asthma attack, worth?
The precise numbers and methods used to derive them can be endlessly debated, but across many studies it is clear that the direct healthcare costs of fossil fuel use is in the billions annually, for any large industrialized nation, and the hundreds of billions globally. The indirect costs are harder to objectively estimate, but even at the low end approach $100 billion nationally and trillions globally.
And again, I must emphasize, this is just considering the healthcare costs, not the costs of climate change, which also run into the trillions globally.
All this means at least two things, when considering the big picture. First, fossil fuel use is a clear public health issue. This means the medical profession should be, at least in general terms, advocating for policies that improve air quality, which should include phasing out fossil fuel use.
        ◦ Second, phasing out fossil fuels is a good economic investment. We should not think of measures that reduce fossil fuel use as an expense, they are an investment. Any money spent which effectively reduces fossil fuel use is likely to be repaid many times over. As a side benefit, we have improved health and quality of life.

The Healthcare Costs of Fossil Fuels
Steven Novella on July 23, 2025
Link

While the debate continues about the true impact of burning fossil fuels on the climate and what the optimal policy response should be, we need to make sure we do not neglect another aspect of fossil fuel use – air pollution and the effect is has on our health. There is a growing body of research showing a significant negative impact with accompanying price tag. Let’s take a look.
Burning fossil fuels releases sulfur dioxide, nitrogen oxides, particulate matter, carbon monoxide, and mercury into the atmosphere. The cumulative effects of these pollutants exacerbates respiratory illness such as asthma and COPD, increases the risk of cardiovascular disease and cancer.
A recent study confirms that these effects are not just theoretical, but can be directly measured. They looked at the rate of ED and hospital admissions for asthma and other respiratory illness for the three years prior to and after the closing of the Shenango coking plant located on an island in the Ohio River near Pittsburgh, PA. They found that after the closing there was an immediate 20% decrease in weekly respiratory ED visits, and a 41% decrease for pediatric asthma ED visits. This was following by a 4% decrease per month for the duration of the study. So there are both short and long term benefits to respiratory health.
What, then, are the health and financial costs of the global fossil fuel industry? It depends on what you count. The restrictive approach is to consider only the direct health effects of the air pollution itself. At the other end of the spectrum there are studies which also include the health effects of the resulting climate change. For example, you can include the health effects of the increase in forest fires estimated to occur due to climate change. Or the health effects of the increase in heat waves. Also, with any estimate of health costs there are different approaches. There are direct and indirect costs. The direct costs consider only healthcare expenses. Indirect costs consider things such as lost work days and also the value of lost life from premature death.
At the high end of estimates is a study by The Medical Society Consortium on Climate and Health, who estimated the annual cost to the US at $820 billion. This includes the direct effects of pollution and the resulting climate change. This does not include non-healthcare related costs. This does include 107,000 premature deaths each year. On average this costs each American $2,500 in increased medical bills anually. While it’s possible to quibble about the methods used and what exactly should be included, the estimate is not unreasonable when trying to account for the total societal cost. It is also likely an underestimate for the factors it’s including due to incomplete reporting.
If we consider just the direct healthcare effect of fossil fuel pollution and not the effects of climate change, one recent study finds:
“We find that air pollution in 2016 from the oil and gas sector in the US resulted in 410 000 asthma exacerbations, 2200 new cases of childhood asthma and 7500 excess deaths, with $77 billion in total health impacts.”
That is still a huge number. It is an externalized cost of the fossil fuel industry, one that we all pay. If we take a purely financial approach to this question, it’s clear that phasing out fossil fuels is a good financial investment. We could invest hundreds of billions of dollars per year in transitioning to a low carbon and low pollution energy infrastructure, and still come out ahead.
But of course this is not purely a financial situation. We are talking about the health of people, their quality of life, and avoiding premature death. We can estimate a financial worth of a human life, but not what it is worth to that person and those close to them.
    • 

Air Pollution and Public Health
Steven Novella on February 24, 2016
Link

Public health measures are those not aimed at individuals but at society as a whole, or subgroups within society. Physicians are charged not only with promoting the health of their own patients, but as a profession we (and health care professions in general) are charged with promoting the public health.
Public health measures, however, are highly likely to cross into politically charged areas. This should not deter the promotion of public health.
Issues that we deal with regularly involving public health include vaccination programs and laws surrounding vaccine requirements, fluoridation of public water supplies, helmet laws, and even gun laws. We have never, however, written about air pollution as a public health concern (except for dubious claims that air pollution is linked to autism).
The health risk of air pollution
Air pollution as a health risk is nothing new, but several recent studies are focusing attention on this issue. Recently the Royal College of Physicians produced a report in which they claim that 40,000 deaths per year in the UK can be attributed to poor air quality, both indoors and outdoors.
This has a significant societal cost in both premature death and financial cost, which they estimate at £20 billion per year. The primary negative health outcomes from air pollution relate to asthma and heart disease.
While they discuss a large number of sources of poor air quality, the two biggest contributors by far are cars and power plants.
Individuals can have an impact, especially on air quality in the home. They recommend making sure that any gas or solid fuel burners are kept in good repair, that the home is energy efficient, keep your house well ventilated, and be aware of the effect that products with strong scents can have on air quality.
The biggest impact, however, can only be had at a societal level.
A 2008 systematic review of the total societal costs of air pollution shows how complicated such calculations can be. However, they estimate that the direct medical costs for the US alone are in the range of $40 billion per year, with additional intangible costs of around $5 billion per year.
A recent analysis just published this year estimates the total societal cost for air pollution in the US in 2011 to have been $131 billion. The majority of these costs are from effects on public health. There was some good news in the report as well, the total costs are down from $175 billion in 2002. The authors cannot be sure of the cause of this decrease but speculate that it may be due in part to air pollution regulation.
The primary source of these costs according to the report is power generation, and specifically sulfur dioxide, but nitrogen oxides, ammonia, volatile organic compounds, and fine particulate matter were also important.
Air pollution and climate change
This is where the issue becomes highly political – one of the primary concerns of those who reject the scientific consensus on anthropogenic climate change is that proposed fixes would have a huge economic cost without a clear benefit. While that is not a valid reason to deny the scientific consensus, it may not even be a valid concern.
The health care costs of air pollution alone are likely to be greater than the cost of addressing air pollution. While carbon dioxide itself is not a direct health concern, energy production methods that release CO2 also tend to release pollutants that are a health concern.
Even if we ignore the political controversy over climate change, it would be cost effective as a society if we put a priority on shifting our energy production away from fossil fuels and toward renewable sources, and to shift our transportation away from gasoline-burning vehicles to zero-emission vehicles. Reducing CO2 emissions would be a massive side benefit, but not even necessary to make these measures cost effective.
Conclusion: Reducing air pollution helps your health, the economy, and the environment
Air pollution is a huge public health concern, costing tens of thousands of lives per year in a country the size of the UK, and conservatively costing tens of billions of dollars in health care costs and premature death. Worldwide the cost is in the trillions.
Addressing the main sources of air pollution, energy production and automobiles, is a public health concern.
From a practical point of view, however, it is critical to recognize that measures to reduce air pollution are cost effective. We don’t even have to make an economic trade off or sacrifice. Controlling air pollution is a win-win, saving lives and money.
Soaring health care costs is a major concern for every industrial nation. While there is no one solution to this complex problem, we can’t afford not to pick the low hanging fruit. The cost of health care is so great, in fact, that it may outweigh other sectors, such as the energy sector.
It may be politically advantageous to focus on the obvious win-wins in the climate debate. Reducing air pollution is cost effective when you consider the health costs to society, whatever your views on climate change. This could be a back door strategy for achieving political consensus on tackling air pollution, with addressing CO2 production as an incidental bonus.

The Health Effects of Air Pollution
Air pollution remains a grave threat to human health, but MAHA is doing nothing about it.
Steven Novella on January 28, 2026
Link

Attitudes toward fossil fuels are sharply and ideologically divided in the US. When asked in 2025 if we should prioritize developing renewable or fossil fuel 6 in 10 respondents favored renewables, but this is down from 8 in 10 in 2020 (according to Pew research). This decline is mostly driven by a flip in the attitude of Republicans, which went from 2/3 favoring renewables to 2/3 favoring fossil fuel.
Further, attitudes (including recent changes in attitudes) toward fossil fuels are largely driven by concerns (or lack thereof) over climate change. While concerns over climate warming are legitimate, and reason enough to justify a transition to low-carbon sources of energy, the issue overshadows another important aspect of extensive fossil fuel use – the health effects of the resultant air pollution.
Burning fossil fuels are associated with a number of pollutants that have negative health effects – including tropospheric ozone, particulate matter, nitrogen oxides (NOx), sulfur dioxide (SO2), and carbon monoxide (CO). The negative health effects of these substances is well documented and includes exacerbation of asthma and other forms of chronic obstructive pulmonary disease (COPD), heart disease, increased risk of some types of cancer, developmental and neurological disorders.
A recent study, in fact, found a correlation between prenatal exposure to air pollution and worse cognitive development in infants. A 2020 systematic review also found a growing body of evidence for multiple developmental disorders being associated with prenatal and infantile exposure to air pollution.
A 2025 study found that in the US there are 91,000 premature deaths annually due to the health effects of air pollution. In addition they found: “10,350 PM2.5-attributable preterm births, 216,000 incidences of NO2-attributable childhood-onset asthma, and 1610 lifetime cancers attributable to hazardous air pollutants (HAPs).” According to the WHO, the number of premature deaths due to air pollution worldwide is 6.7 million per year.
We can also estimate the externalized health-related costs of burning fossil fuel. There are a number of ways to do this. Do we factor in the value of lives lost and lost productivity? Do we count the health effects of the resulting climate change, or only the direct results of pollution itself? We can also express this as total cost to society, the externalized health costs per kwH, or the cost per consumer. No matter how you slice it, the costs are high.
In a 2013 study, for example, the average US consumer paid $0.14-$0.35/kWh in increased health care costs for the electricity they consume due to the effects of pollution. The same study estimates that the total societal health-related costs of burning fossil fuel is $361.7-886.5 billion annually. This amounts to $2,500 per year in additional healthcare costs per family on average. A 2021 study found that if we include the effects of climate change on health, the total costs are over $800 billion and may exceed a trillion dollars per year. These numbers are slightly old and are likely worse today.
We have decades of data showing a consistent picture – air pollution from fossil fuel has a significant negative impact on health and a massive cost, to the individual and society.
It is also another way to reveal the absolute sham that is RFK’s so-called MAHA movement. RFK has softened his stance on climate change, was silent as the Trump administration rolled back environmental protections to limit mercury exposure, and has agreed with Trump to “keep his hands off oil and gas”. RFK Jr promised to make American healthy again, but he has mostly set about to destroy our vaccine infrastructure, which will definitely harm public health. His attempts to change the food pyramid and remove “toxins” from our foods is not evidence-based and likely will achieve nothing.
And, arguably, abandoning his alleged environmentalist roots and facilitating what the Trump administration is doing at the EPA, to expand fossil fuel use and slow down the transition to renewables, will have a negative effect on American health that will dwarf anything positive RFK might manage to do (if anything).


Do Helmets Prevent Head Injuries?
Harriet Hall on May 19, 2015
Link
A cycling enthusiast asked me about helmets. It seems compellingly obvious to me that a head impacting the pavement without a helmet is likely to sustain more damage than a head protected by a helmet. He challenged that, citing a BMJ article by Ben Goldacre that questioned whether the evidence showed that helmets do any good. He said I was making a non-evidence-based assumption and challenged me to actually look at the evidence, so I did.
Goldacre says there is a:
complex contradictory mess of evidence on the impact of bicycle helmets. Like most places where there’s controversy and disagreement, this is a great opportunity to walk through the benefits and shortcomings of different epidemiological techniques, from case control studies to modeling.
He proceeds to give a lesson in epidemiology. He points out that there are a lot of emotion involved, and that epidemiologic studies, because of their inherent imperfections, are probably not capable of resolving the debate.
There are basically two questions:
     1.  What is the effect of wearing a helmet for the individual?
     2.  What is the effect of a public policy that promotes or requires helmet use?
He shows why research has difficulty answering both of those questions, and covers some of the possible confounding factors:
    • If the controls are cyclists with other injuries, the analysis assumes that wearing a helmet doesn’t affect overall accident risk.
    • People who choose to wear helmets may be different from those who don’t (i.e., more cautious).
    • People who are forced by legislation to wear helmets may be different:
        ◦ They may not wear helmets correctly
        ◦ Their behavior may change through “risk compensation” (“I’m protected, so I can take more chances.”)
        ◦ Drivers may give larger clearance to cyclists without a helmet
    • Even if helmets have reduced injury rates, legislation might not have public health benefits overall, because of changes in cycling rates.
    • Regular cyclists tend to live longer because of the health benefits of exercise.
    • Reduction in risk is greater where crashes are more common, such as for children.
    • Legislation that compels compliance may selectively reduce cycling in the subgroup of cyclists who tend to cycle more slowly and have less equipment like helmets.
    • In countries like Denmark and the Netherlands, low injury rates without helmets are achieved through interventions like good infrastructure, legislation to protect cyclists, and a culture of routine non-sporty, non-risky cycling.
    • Risks and benefits are exaggerated or discounted due to political, cultural, and psychological factors.
Some other problems: studies focus on lives saved rather than injuries mitigated, and the documented effect of legislation is admittedly small. There is probably under-reporting of cycling accidents. Helmets may not prevent concussions; the scalp is protected from a direct impact but the brain is still vigorously jostled. Other measures including training may do more to mitigate injuries than helmets.
I reviewed relevant studies in PubMed and systematic reviews.
Here is an impressive list of cycling helmet safety studies.
Systematic reviews have shown efficacy.
Impact simulations have verified that helmets reduce impact to the head.
Individual studies reach varying conclusions; but overall, I interpret the existing body of evidence as showing that the science of protection is clear: helmets offer a significant benefit. The advisability of helmet laws is an entirely different question. The impact of legislation has not been as impressive as hoped, and decisions about laws are not made simply on the basis of science. Those decisions can (and should) be informed by science, but ultimately they depend on societal attitudes and other factors.
Physics and common sense
We don’t need to do randomized controlled studies to know that parachutes save lives or that it’s a good idea to suture wounds and immobilize broken bones, and we shouldn’t need randomized controlled studies to know that helmets are protective. The principles of physics and a little common sense tell us that helmets must provide some protection, even if the degree of that protection can be disputed. If you personally had the choice of hitting your head on the pavement with or without the protection of a helmet, which would you choose? It seems to me to be a no-brainer. (If nothing else, a helmet would prevent skin abrasions and contamination of wounds with dirt and gravel.) We have long accepted the wisdom of using helmets in a variety of sports, from show jumping to football. Construction workers use hard hats. Soldiers wear helmets in combat. Eggs are sold in protective containers rather than dropped individually into shopping bags; the principle is the same. It seems to me that the reaction against helmets for cycling is more emotional than evidence-based. Helmets clearly offer at least some degree of insurance for the individual. Whether individuals should be compelled by legislation to protect themselves is another matter entirely, a decision that I am willing to leave to others.

Picking Cherries in Science: The Bio-Initiative Report
Lorne Trottier on February 15, 2013
Link
by Kenneth R. Foster & Lorne Trottier
Science-based medicine is great, but it all depends on how you evaluate the scientific evidence. A bad example is the BioInitiative Report (BIR), an egregiously slanted review of health and biological effects of electromagnetic fields (EMF) of the sort that are produced by power lines, cellular telephones, Wi-Fi, and other mainstays of modern life. When first released in 2007, the BIR quickly became a key document used by anti-EMF activists in their various campaigns. Early in January 2013, the BIR appeared in a major update, to extensive media coverage.
The BIR concerns possible biological effects and health hazards of electromagnetic fields in two very different frequency ranges: at extremely low frequencies ELF’s of the sort emitted by power lines and appliances, and at radiofrequencies (RFs) of the sort that are transmitted by mobile phones, Wi-Fi and a host of other technologies. Both ELF and RF fields (which are subsumed under the more general EMF) are part of the electromagnetic spectrum, which includes infrared energy, light, ultraviolet energy, as well as X-rays.
ELF and RF fields are nonionizing, in that the energy of their photons is far too low to break chemical bonds, an effect that makes ionizing radiation such as X-rays so hazardous. Fields from power lines are at 50 or 60 Hz or cycles per second; those from mobile phones and other RF communications and broadcasting systems are in the range of hundreds or thousands of MHz (megahertz or million cycles per second). Simple physics tell us that a photon of 1GHz frequency has an energy of 6 millionths of an electron volt (eV), while the average thermal energy of a molecule is 0.03 eV and the ionization energy of a chemical bond is on the order of 1 eV
There are, of course, well-established hazards from excessive exposures to ELF and RF fields, which are mainly associated with electric shock (ELF) and excessive heating of tissue (RF). Such problems, however, require exposure to fields at vastly higher levels than anything that would be encountered in ordinary life. Most countries around the world have adopted roughly similar exposure limits that are designed to protect against these known hazards.
The possibility that the electromagnetic fields at much lower exposure levels can be bad for you has been a matter of public concern for many years. Countless public, scientific, and legal battles have been waged about possible health hazards produced by fields from power lines, cellular base stations, broadcasting facilities, and other technologies, despite the fact that public exposures from such technologies are invariably far below government exposure limits.
In response to such concerns, government and other agencies have funded many studies over the years. Thousands of scientific papers have accumulated on biological and possible health effects of ELF and RF fields, going back to the mid 20th Century and even before.
In many respects this scientific literature is uneven and confused. The studies vary widely in quality, biological endpoint, and relevance to health. The literature is filled with low-quality fishing expeditions in search of effects (as opposed to studies that tested hypotheses). Many of these studies were one-shot experiments, that were not followed up or even repeated by the investigators themselves. Many studies have obvious technical flaws, typically poor dosimetry (determining how much exposure the preparation actually received in an experiment) or poor temperature control (heating is a necessary consequence of RF exposure and most biological reactions are sensitive to temperature). Many of the reported effects were small, close to the level of background variability and small compared to potential artifacts (and hence difficult to identify reliably), with no particular relevance to health. The literature suffers badly from publication bias — researchers are more likely to report having found an “effect” and less likely to publish no effect studies. As might be expected, the literature abounds with reports of “effects”, many of which are simply artifacts from poorly conducted experiments.
At the opposite end of the quality spectrum are a number of well-done, massively funded studies that follow the lines of standard toxicological assays or epidemiology studies, which were designed to provide reliable evidence in assessing possible risks from ELF or RF fields. The results of these studies have been overwhelmingly negative, failing to document adverse (or any) effects of exposures at levels below current safety limits that are in effect throughout most of the world.
Expert reviews
This massive literature has been reviewed by numerous expert groups, who, with the exception of the BIR as described below, have consistently failed to find clear evidence for health hazards from ELF or RF fields at levels below international and U.S. limits. Luc Verschaeve (Univ of Antwerp), a noted Belgian health expert in this field, has reviewed more than 30 recent expert reviews. His review is available online.1 Links to over 30 of these expert reviews by the health agencies of virtually every industrialized country can also be found at EMFandHealth.com. Readers of this article are invited to review the findings of these reports.
But the science is hardly clear-cut. Some effects have been reported at levels below international safety limits from specialized exposure conditions, that health agencies regard as having some level of consistency. For example, several independent studies have reported minor changes in brain wave activity associated with use of a mobile phone handset. The effect has no clear health significance, and it is still an open question whether it is directly caused by exposure to RF fields or some other factor associated with exposure.
The second, and politically more inflammable, issue is whether EMF exposure is linked to cancer. The International Agency for Research on Cancer (IARC, a part of the World Health Organization) has classified powerline magnetic fields and RF energy from mobile telephone handsets as “possible carcinogens” (class 2B in the IARC terminology). This is based on weak epidemiological evidence that children living in homes near power lines, or long-term users of mobile phones, have a slightly increased risk of, respectively, leukemia and brain tumors. Thus, in IARC’s scheme of things, the evidence is sufficient to raise suspicions that a problem might possibly exist, but not enough for the agency to conclude that the fields actually (or even probably) do cause cancer.
While acknowledging the epidemiology data, health agencies have generally found them to be unpersuasive for several reasons. The studies report small increases in risk, close to statistical variability. While the increases may be “statistically significant” (unlikely to be due to chance), it is difficult to rule out possible errors or biases in the studies, of which there are many in epidemiology. The general lack of supporting evidence from the animal cancer tests showing no effect, and lack of generally accepted mechanism by which RF or ELF fields can cause any biological effects at the low level exposures considered here (apart from heating) are other stumbling blocks.
Two additional comments are in order. First, the epidemiology studies were simply not adequate to reliably detect small increases in risk after long term exposures to cell phones or powerline fields. Most of the cell phone-brain cancer studies determined exposure simply by asking subjects about their previous use of cell phones. (What reader can say for sure how much he or she used a mobile phone a year ago, much less in the distant past?).
Furthermore as we indicated in a previous article on SBM, since the IARC ruling on cell phones, three recent studies on brain cancer incidence rates have appeared. The studies show no change in incidence rates in the U.K., U.S., and Israel over the past decade despite the tremendous increase in use of cell phones. While one might argue that there is not enough time for a real effect to appear (cancer can take years to develop), the fact remains that the data are inconsistent with epidemiology studies by a Swedish group that supposedly gave the strongest indication of a link between brain cancer and use of cell phones and strongly influenced IARC’s 2B classification in the first place. In the long run we will all be dead, but there is little indication so far that it will be from use of mobile phones. It is for all these reasons that the World Health Organization issued Fact Sheet 193 following IARC’s ruling which stated the following: “A large number of studies have been performed over the last two decades to assess whether mobile phones pose a potential health risk. To date, no adverse health effects have been established as being caused by mobile phone use.”
The same scenario has been in play for the 40 years in which one of us (KRF) has been involved with the issue. Activists on the issue typically present long lists of effects from exposure to ELF or RF fields. They imply that these fields are biologically active at all levels of exposure, and by presumption are hazardous to your health at even very low exposures. Health agencies, in response, sponsor massive reviews that find no convincing evidence for any health hazard at exposure levels below international exposure limits, even as they point to inconsistencies in the data and argue for more research. Making lists of reported effects, and conducting a proper weight-of-evidence assessment of potential health risks, are two very different things.
Excluding bias
Scientific research on health, either concerning the effectiveness of treatments or possible health risks, is invariably subject to differing interpretations even by well-intentioned reviewers. To improve the reliability of assessments, agencies generally insist on detailed protocols for admitting and evaluating evidence. The definitive Cochrane Reviews, for example, has a lengthy handbook that guide its assessments of the effectiveness of medical interventions. The manual points out, for example, “in order to minimize the potential for bias in the review process, these judgments [about effectiveness of medical interventions] should be made in ways that do not depend on the findings of the studies included in the review”.
For its own part, the World Health Organization has published a set of guidelines for the assessment of the health risks of EMF: “All studies, with either positive or negative effects, need to be evaluated and judged on their own merit, and then all together in a weight-of-evidence approach. It is important to determine how much a set of evidence changes the probability that exposure causes an outcome. Generally, studies must be replicated or be in agreement with similar studies. The evidence for an effect is further strengthened if the results from different types of studies (epidemiology or laboratory) point to the same conclusion”. 
Enter the BioInitiative Report (BIR)
The latest (2012) version was released on the BioInitiative website early in January 2013. This massive 1479 page report contains 28 sections, incorporating in toto the original 2007 version together with new sections. It was prepared by a group of 29 individuals, most of them scientists who have long held controversial positions on health effects of electromagnetic fields. Two individuals (Carpenter and Sage) wrote the introductory and concluding sections. One of them, Cindy Sage, is not a scientist but a long time activist on the issue who runs a consulting firm on hazards of EMF exposure. Sage, the organizer of the BioInitiative project, also contributed sections on the inadequacy of current exposure limits and other topics.
As might be expected from a compilation of separately authored chapters done at two points in time, the BIR is inconsistent in approach and content. The 2007 chapter by David Gee (European Environment Agency) says almost nothing about EMF but is largely taken from a separate paper that discusses “late lessons from early warnings” about, for example, the tragedy of Diethylstilbestrol (a drug that was supposed to prevent miscarriage but later was found to cause birth defects in children whose mothers had used the drug). Many pages consist simply of abstracts copied from the original papers or from Pubmed (which may raise fair-use issues). Several chapters discuss the idiosyncratic theory of Blank (retired from Columbia University) that DNA is a “fractal antenna”, a theory that has received no independent scientific support, much less general acceptance by the scientific community. Nevertheless, his theory is repeatedly cited throughout the BIR as being somehow related to a mechanism by which weak RF or ELF fields can damage DNA. A relatively balanced section by Fragopoulou and Margaritis (University of Athens) offers a detailed review of “omics” studies that search for effects of ELF or RF exposures using techniques of modern molecular biology. This section emphasizes the difficulty of drawing reliable conclusions from such work, and concludes merely that changes in protein expression that some studies report following EMF exposure “might potentially explain human health hazards”. But here again, the evidence is mixed and inconsistent among studies, and the endpoints studied are difficult to relate to health.
Given the structure of the BIR, there is no way to tell how many of the 29 authors of the various sections agree with the conclusions and recommendations of the report itself — or with each other for that matter. Indeed, Henry Lai, one of the authors in the BIR, recently wrote:
I don’t think the BioInitiative Report came up with any unanimous conclusion. Each author wrote his/her chapter and the opinion in each chapter is that of the authors alone. There was no communication and discussion among the authors on the preparation of the Report. As a matter of fact, I don’t personally know some of them.
Moreover, Sage and Carpenter, authors of the introductory and concluding sections, clearly have their own political axes to grind. In a recent letter they emotionally attacked the World Health Organization and a major standards setting group (The International Commission on Nonionizing Radiation Protection, ICNIRP). The overall impression is that the BIR has been structured to give scientific support to Sage’s activist ideas.
Indeed, the BIR presents many alarming health claims. EMFs at ordinary environmental levels, the reader is told, are linked to autism, Alzheimer’s disease, several forms of cancer, genetic damage, neurological problems in children whose mothers used mobile phones, hypersensitivity reactions to EMF (with symptoms similar to those of allergies), among many others. Readers who are looking for reasons to fear electromagnetic fields will find plenty of material in the BIR to justify their concerns.
Cautionary limits and the end of wireless communications
The latest BIR (or at least the two individuals who wrote the concluding sections) proposes “cautionary” limits of 0.3 to 0.6 nanowatts (billionths of a watt) per square centimeter (nW/cm2) for exposure to RF fields – this is over 100X lower than the 2007 edition. This is roughly a million times below limits in effect in the US and most other countries at frequencies used by mobile telephone systems, Wi-Fi and other technologies.
As an example of another source of radiation, ordinary sunlight (one of the many forms of EMF) has an energy density of about 100 mW (milliwatt or a thousandth of a watt)/cm2, which is more than 100 million times stronger than the proposed BIR limit for RF energy. Sunlight contains little RF energy, but about half of the solar energy that hits the earth is in the infrared part of the spectrum, which is just above the radiofrequency region considered by the BIR.
Depending on how these limits would be implemented (a matter not discussed in the BIR), their implications might be profound. All urban areas have many places where RF signals from cellular base stations, television and radio broadcasting facilities, public safety communications systems, and other useful technologies will exceed these limits – sometimes by a very large factor. Signals from Wi-Fi devices, mobile phone handsets, cordless phones, and many other useful devices would also exceed the limits, as would transmissions from the police car driving through your neighborhood, and energy leaking from your kitchen microwave oven – the strongest RF source in most households. Radar for air traffic control would be ruled out by the recommendations. Assessing compliance with the proposed BIR limits would certainly create a lot of work for Sage Associates Environmental Consultants, and undoubtedly for legions of lawyers as well.
Cherry picking
Selective attention to data, colloquially known as “cherry-picking” or more technically as confirmation bias, is a failure in reasoning that affects all aspects of life. Recent U.S. presidential candidate Mitt Romney recently fell victim to confirmation bias by allowing himself to be convinced by the results of (evidently) skewed Republican polls that he was about to win the election.
To guard against confirmation bias, good expert reviews incorporate safeguards to ensure that all relevant data, supportive or not of the hypothesis being tested. Thus the Cochrane Review, cited above, says “judgments [about effectiveness of medical interventions] should be made in ways that do not depend on the findings of the studies included in the review”. A review that focused only on studies that report positive outcomes of a drug (for example) and ignored no-effect studies would surely have biased and unreliable conclusions.
The authors of the BIR commit exactly this error with EMF bioeffects studies, by speculating at length about possible implications of studies reporting effects of EMF while saying little about studies that failed to find effects. Rather than taking a “weight-of-evidence approach” to put all the studies together in a coherent picture, most authors simply listed numbers of studies reporting effects (of whatever nature at whatever exposure level) in comparison with those that found none.
An egregious example is connected with a long table near the beginning that lists reported biological effects from RF energy at low-intensity levels. The authors (at least the two authors who wrote the summary sections) based their cautionary recommendations on the lowest exposure levels used in studies that reported effects – regardless of the health significance of the effects, the scientific credibility of the studies, and presence of contradictory evidence.
And here is where the cherry picking comes in. The table only includes lists of studies reporting effects, some at vanishingly small exposure levels. Studies that did not report effects, or which could not confirm studies that earlier had reported effects, are conspicuously missing.
For example, one of the effects at the lowest exposure levels was reported in 2000 by David de Pomerai (University of Nottingham) and colleagues2 (see p. 106 of the PDF). In that study, exposure to low-level microwave radiation caused nematodes (a kind of worm) to express heat shock proteins. (Heat shock proteins are “expressed” or produced by the body as a way of adapting to temperature changes, an effect that can be observed at even slight temperature increases). Not mentioned is the fact that de Pomerai retracted the paper in 2006 after he had discovered that the earlier results were an artifact due to inadequately controlled temperature.3
The BIR also fails to discuss the high quality follow up studies (including one by de Pomerai and colleagues4) that found that RF exposure levels far above those used in the earlier studies did not induce heat shock proteins in a different nematode. Health agencies in their reviews have paid little attention to the expression (or non-expression) of heat shock proteins induced by RF exposure, in part because of lack of a robust and repeatable effect and in part because of the difficulty in separating the effects of simple temperature change from any specific effect of RF. Also, one might question the relevance of a small biological effect reported in nematodes in response to mild heating to human health.
A further example: the BIR concludes: “One study reports that RF at levels equivalent to the vicinity of base stations and RF- transmission towers is genotoxic and could cause DNA damage” (see P 73 of the PDF), citing a 1998 paper by Phillips (University of Colorado) et al.5 In fact, this study reported both increases and decreases in damage to DNA after very low-level exposures. One might equally cite the study as showing a protective effect of RF exposure at low exposure levels.
More importantly, this 15-year old study is not supported by later work. A careful review in 2012 by Vijayalaxmi (Univ of Texas) of 88 studies found no clear evidence of genetic damage in cells produced by RF exposure, even though the exposure levels varied by more than a million.6 Some studies reported effects, and some did not. Most of the reported effects were within the range of “spontaneous levels reported in a large data-base” and may have been unrelated to the RF exposure. By focusing on the one positive (actually, mixed) report by Phillips et al., the authors imply that RF exposures at levels produced by wireless base stations are genotoxic, a conclusion that is not supported by many later studies and a more careful analysis of the literature.
The BIR dismisses the apparent lack of consistency among studies with the rhetorical statement: “some experts keep saying that all studies have to be consistent (turn out the same way every time) before they are comfortable saying an effect exists” (see P20 of the PDF).
To our knowledge, no expert report in this field requires such absolute consistency, which would be impossible to achieve in real experiments in any event. Instead, health agencies look for different lines of evidence to point to the same phenomena across studies, together with other criteria such as potential health relevance.
For example, the authoritative World Health Organization (WHO) Environment Health Criteria document for ELF Fields7 says, with respect to cancer risk assessment, “For laboratory studies, priority should be given to reported responses (i) for which there is at least some evidence of replication or confirmation,(ii) that are potentially relevant to carcinogenesis (for example, genotoxicity), (iii) that are strong enough to allow mechanistic analysis and (iv) that occur in mammalian or human systems.”
This concern for confirmation is related to a fundamental requirement of science, that knowledge be generalizable. A study whose results cannot be generalized to other situations or yields no predictions that can be successfully tested by others, lacks external validity and is useless scientifically.
The BIR tries to have it both ways: it extrapolates from unconfirmed (or unconfirmable) laboratory studies to make dire predictions of health significance of RF exposures to humans. In effect it assumes that the results are generalizable from laboratory studies in cells or animals to human health. At the same time it dismisses the reluctance of health agencies to consider reports of biological effects that cannot be independently confirmed, which is to say that they cannot even predict results in similar laboratory experiments by other scientists.
Bad reviews
The BIR has long been criticized by health agencies for slant. In its devastating review of the original 2007 version,8 the Health Council of the Netherlands concluded:
“In view of the way the BioInitiative report was compiled, the selective use of scientific data and the other shortcomings mentioned above, the Committee concludes that the BioInitiative report is not an objective and balanced reflection of the current state of scientific knowledge. Therefore, the report does not provide any grounds for revising the current views as to the risks of exposure to electromagnetic fields.”
The same weaknesses are still present in the 2012 version, which moreover does not address the criticisms of the Health Council of the Netherlands or other expert groups.
It takes only a glance at Verschaeve’s article1 to realize how far out of line the BIR is with assessments of the issue by mainstream agencies. Of the more than 30 reviews that he considered, all but one did not “consider that there is a demonstrated health risk from RF-exposure from mobile telephones and other wireless communication devices.” The single exception was the BioInitiative report, which Verschaeve judged to be by far the weakest of the group of reports that he considered.
Conclusion: A mixed and contradictory body of evidence
Ultimately, the question reduces to the quality of judgments on what is, by all accounts, a mixed and in places contradictory scientific literature. This confusion may conceivably be the result of a small “signal” (a real but weak biological activity of ELF or RF electromagnetic fields at typical environmental exposure levels). But alternatively, it may also reflect the fact that science is difficult and often unreliable when searching for small effects in the face of a multitude of potential experimental artifacts.
It would require a more careful and balanced assessment than provided by the BIR to distinguish between these possibilities, or to fairly assess the potential health consequences of any effects from low-level exposures to electromagnetic fields in the environment, assuming that any can be definitely established.
The web page for the latest edition of the Bio-Initiative Report has been completely redesigned. The page is dominated by pictures of natural landscapes: retreating glaciers, wetlands, coral reefs, etc. that have nothing to do with the subject matter of EMF fields. They appear to be trying to associate themselves with legitimate concerns about the environment and climate change. But the analogy with climate change is the exact opposite of the impression they are trying to make. The consensus of the vast majority of climate scientists is that human caused climate change is real. Only a small minority of climate scientists is opposed to this consensus. In the case of EMF and health, the overwhelming majority of scientists see no good evidence for health effects. The BIR represents the views of a small minority.
The first edition of the BIR was widely quoted by activist groups, but had no significant effect on public policy. The “cautionary” recommendations of the latest 2012 edition of the BIR, which are more than 100 times lower than the previous one, are made without clear scientific justification and at levels that would all but eliminate broadcasting and wireless technology. Perhaps they are hoping to gain more attention with such an extreme position. It will certainly excite the activists but it is unlikely to influence public policy any more than the first edition did.
Individuals can choose in whom to place their trust. However, governments, including health agencies, have an obligation to use the best available advice about matters of importance to the health of their populations, and the BIR falls short by a huge margin. As in U.S. presidential elections, cherry picking can lead to disastrously bad judgment.
About the authors
Kenneth R. Foster is a professor of Bioengineering at the University of Pennsylvania: http://www.seas.upenn.edu/~kfoster/kfoster.htm
Lorne Trottier is co-founder of Matrox, a manufacturer of specialized video and graphics boards www.matrox.com. He maintains the website EMF and health (www.emfandhealth.com), which provides more information on this issue
References
     1.  L. Verschaeve, Evaluations of International Expert Group Reports on the Biological Effects of Radiofrequency Fields. (2012). In Wireless Communications and Networks – Recent Advances, Dr. Ali Eksim (Ed.), ISBN: 978-953-51-0189-5, InTech, Available from: http://www.intechopen.com/books/wireless-communications-and-networks-recent-advances/evaluations-of-international-expert-group-reports-on-the-biological-effects-of-radiofrequency-fields
     2.  de Pomerai D, Daniells C, David H, Allan J, Duce I, Mutwakil M, Thomas D, Sewell P, Tattersall J, Jones D, Candido P. Cell biology – Non-thermal heat-shock response to microwaves Nature 405; 2000. PubMed
     3.  Retraction notice. Nature 440: pg 437, 2006.
     4.  Dawe AS, Nylund R, Leszczynski D, Kuster N, Reader T, De Pomerail DI. Continuous wave and simulated GSM exposure at 1.8 W/kg and 1.8 GHz do not induce hsp16-1 heat-shock gene expression in Caenorhabditis elegans. Bioelectromagnetics 29:92-99; 2008. PubMed
     5.  Phillips JL, Ivaschuk O, Ishida-Jones T, Jones RA, Campbell-Beachler M, Haggren W. DNA damage in Molt-4 T-lymphoblastoid cells exposed to cellular telephone radiofrequency fields in vitro. Bioelectrochem Bioenerget 45; 1998. PubMed
     6.  Vijayalaxmi, Prihoda TJ. Genetic damage in human cells exposed to non-ionizing radiofrequency fields: A meta-analysis of the data from 88 publications (1990-2011). Mutat Res -Genet Toxicol Environ Mutag 749: 1-16; 2012. PubMed
     7.  WHO, Extremely Low Frequency Fields Environmental Health Criteria Monograph No.238, Geneva 2010. http://www.who.int/peh-emf/publications/elf_ehc/en/index.html
     8.  Critical Review of the BioInitiative Report, from the Health Council of the Netherlands http://www.gezondheidsraad.nl/sites/default/files/200817E_0.pdf

Health Effect of Wind Turbines
What are the health effects of living close to wind turbines? The answer is, probably not much, but definitive data is elusive.
Steven Novella on June 6, 2018
Link

The renewable energy debate can be complicated, as there are many variables in terms of all of the energy costs for the entire lifecycle of each energy source, the problems of intermittent energy, and the complex effects on the environment. Focusing on the direct health effects at least deals with a specific question for which there is some published evidence.
The health effects of polluting forms of energy has been estimated in various publications, and is staggering. A 2011 study found that in the US alone the health costs of air pollution were about $131 billion. A UK study attributes 40,000 deaths in the UK per year to air pollution. So, from a public health perspective, there is good reason to phase out fossil fuels, especially coal, as they are highly polluting forms of energy.
But we do have to consider the overall health effects of any energy production with which we replace fossil fuels. Wind turbines have come under criticism for various reasons, including killing birds and bats, being an eyesore, reducing quality of life, and negative health effects from the noise and infrasound they generate. None of these claims hold much water, but let’s take a closer look at the health effects.
Wind turbine syndrome
The most plausible health concern from proximity to wind turbines is that their noise can disturb sleep. Chronic sleep disturbance is a clear health risk, and so if this is true it would inform minimum safe distances between wind turbines and residential areas. Another concern is that the constant noise or even light flickering caused by the moving blades are a source of stress, which is its own health risk. Less plausible is the claim that some people are sensitive to the infrasound created by wind turbines, which cannot be heard but can have an effect none-the-less.
Here is what reviews of the published evidence have found so far:
A 2013 review concluded that there is some evidence that infrasound (sound of too low a frequency to hear) can affect the vestibular system, and so WTS is at least plausible.
A 2014 systematic review of possible WTS concluded:
Exposure to wind turbines does seem to increase the risk of annoyance and self-reported sleep disturbance in a dose-response relationship. There appears, though, to be a tolerable level of around LAeq of 35 dB. Of the many other claimed health effects of wind turbine noise exposure reported in the literature, however, no conclusive evidence could be found. Future studies should focus on investigations aimed at objectively demonstrating whether or not measureable health-related outcomes can be proven to fluctuate depending on exposure to wind turbines.
A 2015 review concluded:
In conclusion, there is some evidence that exposure to wind turbine noise is associated with increased odds of annoyance and sleep problems. Individual attitudes could influence the type of response to noise from wind turbines. Experimental and observational studies investigating the relationship between wind turbine noise and health are warranted.
There was also a large Statistics Canada study looking at data through 2013 which found:
Statistics Canada study found no direct link between residents’ distance from wind turbines and sleep disturbances (as measured by sleep assessments and the Pittsburgh Sleep Quality Index), blood pressure, or stress (either self-reported or measured via hair cortisol).
Data limitations
The major limitation on all these studies of possible effects of living near a wind turbine is that they are observational. Obviously you cannot randomize people to live near a wind turbine. There is also no way to blind subjects to their proximity. Some of the data is based on surveys, which introduces an element of selection bias.
But even the more rigorous studies are largely subjective. There is good reason to suspect that confounding variables may be dominant here. A 2014 study reviewed psychological factors which have been shown to influence reports of health effects from wind turbines. Subjects were more likely to report negative symptoms if they found wind turbines annoying, if they thought they were an eyesore, and if they did not gain any economic benefit from them.
A 2017 Australian study found that one’s political view toward wind turbines largely determine how symptoms and alleged health effects are interpreted – specifically, are they caused by proximity to wind turbines.
Plausibility
How plausible is a direct biological effect from wind turbines (as opposed to a psychological effect from annoyance)? There is some evidence to suggest that infrasound can have an effect on the vestibular system of sensitive individuals. This, however, has not been directly correlated with the existence of symptoms.
One objective question to answer is – how loud are wind turbines? This depends on the exact model and, of course, how fast the wind is blowing. But existing models in use generate about 105 decibels (about as loud as a lawnmower) at the source. The intensity of this sound drops off with distance. At 100 meters the noise is down to about 50 decibels, which is as loud as a medium-sized window air conditioner. At 300 meters the noise is at 40 decibels, which is as loud as a typical refrigerator. (In the decibel scale, which is logarithmic, a change in 10 decibels in a loudness factor of 10, so 50 decibels is 10 times louder than 40 decibels.)
Wind turbines are placed at least 300 meters distant from residential areas. It is definitely interesting that there is no “air conditioner syndrome” despite the fact that air conditioners generate 10 times as much noise as the closest possible wind turbine. Since most homes in developed countries are likely have a refrigerator, the existence of a wind turbine 300 meters away should not add much to the background noise.
Conclusion: Semi-plausible, mostly subjective
The existing evidence indicates that concerns over a wind turbine health syndrome are only semi-plausible. Further, the evidence does not support any objective measure of negative health effects (like blood pressure), but does show an effect on subjective symptoms. However, these results are questionable for two main reasons – they are subject to bias, and tend to correlate with negative political or personal attitudes toward wind turbines.
Unfortunately the evidence is not of sufficient quality to end debate on the question. Further study will help, but also will likely not resolve the debate, because we cannot gather gold-standard blinded and controlled data.
        ◦ Technological advances are diminishing the problem, however, as newer models of wind turbines are quieter than older models. It seems prudent to prioritize this feature of the technology as it further advances. But given that much of the opposition to wind turbines is political, more study and technological advances will probably not eliminate it.

Don’t Text and Drive
Steven Novella on June 12, 2013
Link
We accept certain risks for the benefits of modern society. We pump explosive gas into homes, we run wires with potentially fatal electrical currents through our neighborhoods, and we ski at breakneck speeds down mountains for fun.
We also allow people to operate vehicles weighing thousands of pounds at speeds that are potentially deadly if a mishap occurs. In 2011 there were 32,367 motor vehicle deaths in the US (10.4 per 100,000 population). Interestingly, this is down quite a bit from previous years. As a percentage of population the highest motor vehicle death year was 1935, with 34,494 deaths, or 27.1 per 100,000. The highest absolute number of motor vehicle deaths was in 1970, at 52,627.
The number of deaths has been mostly trending down since 1996, which is interesting because over this same period of time cell phone use has risen tremendously. There are various reasons for the decreased in fatalities – helmet laws, seatbelt laws, cracking down on drunk driving, increased car safety, and intermediate drivers licenses for new drivers to name a few. These trends have probably obscured any increase in car accidents from using portable communication devices while driving.
Recent laws have addressed this risk by requiring device users to use only hands-free devices. However, the evidence clearly shows that hands-free device use (talking or texting) is just as dangerous as using a hand-held device.
The problem is not that your hands are occupied, but that your mind is occupied. While talking on a cell phone you are distracted from scanning the road and will have slower reactions to unexpected obstacles. Information processing is the limiting factor.
A recent University of Utah study examined drivers with various levels of distraction. They found:
– Tasks such as listening to the radio ranked as a category “1” level of distraction or a minimal risk.
– Talking on a cell-phone, both handheld and hands-free, resulted in a “2” or a moderate risk.
– Listening and responding to in-vehicle, voice-activated email features increased mental workload and distraction levels of the drivers to a “3” rating or one of extensive risk.
Contributing to this problem is the illusion of multitasking – people believe they can do more than one mental task at the same time, but we can’t. We simply switch back and forth between tasks, further using mental resources to manage this switching. This results in what psychologists call interference -a decrease in performance in any task when distracted by extraneous information or performance of a simultaneous task.
Younger drivers are particularly cavalier about multitasking while driving – something that can be addressed with driver education. This is important because younger drivers are also less experienced and are already a higher accident risk.
The implications of existing research are clear – to minimize accident risk, do not use mobile devices while driving. Do not be lulled into a false sense of safety by hands-free devices. Minimize distractions while driving – it really does take your full attention, even if it doesn’t feel like it.
Hopefully, technology will get us out of this problem it has gotten us into. Computer-assisted driving technology is advancing rapidly. Google’s driverless car (a bit of a misnomer, as there is always a driver behind the wheel) is now able to drive on city roads, and can go miles between driver interventions. Computers have one extreme advantage over humans – they are not distracted, they do not get tired or lose their attention.
Computer-assisted driving seems like the perfect solution. It will be years before such technology becomes standard, however, so in the meantime – don’t text and drive.

The cost of repealing mandatory motorcycle helmet laws
David Gorski on January 18, 2016
Link

It’s a seldom mentioned aspect of my professional history that I used to do a lot of trauma surgery in my youth. I did my residency at a program that included a county hospital with a busy trauma program where I saw quite a bit of vehicular carnage and an urban hospital (which has since closed) where I saw a fair amount of what we in the surgery biz call gun and knife club action. During my time as a PhD student, I moonlighted as a flight physician for the local helicopter rescue service, Metro Life Flight, where I took care of patients with everything from cardiac disease requiring transfer to the Cleveland Clinic to near-drownings during the summer at the Lake Erie resorts, particularly Put-in-Bay, to obstetrical transfers (which terrified me) to, of course, the unfortunately copious run-of-the-mill vehicular trauma. I saw the sort of tragedy that could result. Then, in the late 1990s, as I did research for my surgical oncology fellowship in Chicago, I also moonlighted as a trauma attending at a local suburban level II trauma center.
At that point, I realized that trauma was not my thing, as I couldn’t see myself at my present advanced age doing the sort of physically and emotionally demanding work that required fast decisions. It stressed me out too much; which is part of the reason why I went into surgical oncology in the first place. However, I have an appreciation for those who do do trauma. I also realize that trauma is, in a way, the “purest” form of surgery in that it involves taking a body broken by mechanical forces and trying to repair it, all the while keeping the patient alive until the repairs can heal. I will, however, miss the enjoyment I get hearing presentations on tree stand falls during hunting season.
I don’t mention my youthful flirtation with trauma surgery so much because I think it’s something so fascinating that I must tell it. (If that were the case, I’d have been mentioning it much more frequently in my blogs and social media than I have before.) Rather, it lets you know why I was so distressed when this story was forwarded to me a few days ago. It’s a Reuters report entitled “Injuries soar after Michigan stops requiring motorcycle helmets“:
In the three years after Michigan repealed a mandatory motorcycle helmet law, deaths and head injuries among bikers rose sharply, according to a recent study.
Deaths at the scene of the crash more than quadrupled, while deaths in the hospital tripled for motorcyclists. Head injuries have increased overall, and more of them are severe, the researchers report in the American Journal of Surgery.
Senior author Dr. Carlos Rodriguez decided to do the study after noticing an abrupt change in the trauma unit at Spectrum Health Hospital in Grand Rapids, where he works.
The first week after the law was repealed in April 2012, he told Reuters Health, “I just could not help but notice the number of patients that had been in motorcycle crashes with no helmet on, which was enormously different in number and volume than we had experienced the weekend before.”
Yes, those of us in the trauma biz not-infrequently refer to motorcycles as “donorcycles” (as in organ donation) because of the head injuries that they cause, and nothing facilitates turning a motorcycle into a true donorcycle like not wearing a helmet. Indeed, motorcycle riding is associated with a 27-fold higher risk of death per billion miles traveled than driving an automobile.
Those of us who are skeptics might wonder whether Dr. Rodriguez was experiencing that very human cognitive shortcoming known as confirmation bias, wherein we hairless apes tend to notice and remember occurrences that fit in with our preconceived beliefs and to be less attuned to and forget occurrences that would tend to falsify those beliefs. We all do it, even skeptics. The main difference is that skeptics and scientists know that they do it and try to compensate by looking for objective evidence against which to test their hypotheses and beliefs. This is what Dr. Rodriguez did, and the result was a paper presented as an abstract over the summer at the Midwest Surgical Association meeting and then published online first last month in The American Journal of Surgery as a paper entitled “Repeal of the Michigan helmet law: the evolving clinical impact“.
Not surprisingly, the finding that repealing motorcycle helmet laws results in more fatalities and brain injuries is about as “Well, duh!” a result as I can imagine in that it’s incredibly predictable based on what we know. However, these studies, it seems, still need to be done because, as biologically (and physically) plausible as the hypothesis that wearing a helmet decreases the risk of serious or fatal head injuries in the event of a motorcycle crash is, data are nonetheless required.
Motorcycle helmet laws: The Michigan experience
In 2012, the Michigan legislature repealed the state’s motorcycle helmet law, a law that had been on the books for 35 years. In its place, the new law allowed riders 21 years old and older who have passed a motorcycle safety course within the last two years to forego wearing a helmet. One additional requirement, which was basically an explicit acknowledgement that this law was going to lead to a lot more deaths and severe injuries, is that helmetless riders must carry an additional $20,000 in medical insurance. This was, of course, almost certainly grossly inadequate, as Michigan AAA pointed out, but was in fact a concession to reality, however weak.
The Brain Injury Association, AAA, trauma doctors, and other groups promoting highway safety appealed to Governor Rick Snyder to veto this misbegotten piece of legislation, as his predecessor Governor Jennifer Granholm had done to two prior bills before. Governor Snyder didn’t listen and signed the bill anyway. After a fight that had lasted decades, advocates of “freedom” had finally won based on arguments like this:
Vince Consiglio, president of American Bikers Aiming Toward Education of Michigan, called the law a useless holdover from bygone days.
“Helmet laws have done nothing to improve safety or reduce fatalities or the cost of insurance,” Consiglio said in a statement. “I want to extend our gratitude to all the legislative officials and Governor Rick Snyder, who courageously supported freedom in the face of an onslaught of baseless and emotional arguments perpetuated by our opponents.”
These claims are, of course, demonstrably false. Indeed, this statement reminds me a lot of the arguments that antivaccinationists make when they claim that vaccines don’t decrease mortality from infectious disease, that business interests are what keep vaccine mandates in place, and that their opponents make “emotional” arguments against loosening vaccine mandates. There’s also a massive case of projection here, given that arguments from anti-helmet law groups like ABATE rely heavily on appeals to “freedom,” much as antivaccinationists and quacks rely on appeals to “health freedom” and accusations of “doctored statistics,” again, very much like the antivaccine movement.
So now that the helmet law has been on the books for nearly four years, there are actually data to look at. In the introduction to the study, Dr. Rodriguez’s notes that one year after the repeal his group had published the early clinical impact due to this legislative change, noting that although fatality rates didn’t increase in hospitalized patients, crash scene fatalities increased significantly, as did intensive care unit stay, mechanical ventilation time, and cost of stay, which was roughly 50% higher. Looking at this pilot study, what struck me was how much the fatalities at the scene increased after the change in law – a more than five-fold jump.
The most recent study by Dr. Rodriguez’s group is a followup to that first pilot project. Basically it’s a retrospective cohort study examining a seven month period before the repeal from April to November 2011, which was compared to the same seven month period in three years after the repeal. They also collected Michigan State Department of Transportation data to determine fatalities within the western Michigan area covered by Spectrum Health Butterworth Hospital. Looking at the two cohorts, before and after the law change, the most striking differences are two. First, the percentage of unhelmeted riders involved in crashes increased from 8% to 29%, which is in line with an observational study of Michigan riders that found only 73% of them wearing helmets after the law change. Second, the percentage of crash scene fatalities increased from 14% to 63%, though the absolute numbers in this last comparison are small.
Other findings included a higher hospital mortality in unhelmeted patients compared to helmeted (10% vs 3%, p=0.04); a higher injury severity score (19 vs 15, p=0.004); a higher abbreviated injury score (AIS) for head injuries (2.2 vs. 1.3, p<0.001); a lower Glasgow coma score (GCS), which is a measure of consciousness in which a low score is worse (12.6 vs 14.0, p=0.009); percentage of patients requiring the ICU (55% vs. 31%, p=0.001); and percentage of patients requiring mechanical ventilation (24% vs. 12%, p=0.01). It was also noted that a higher proportion of unhelmeted riders were intoxicated in the univariate analysis, but that alcohol intoxication was not a significant independent predictor for any of the dependent variables.
Overall, these two studies are a good first attempt at determining the effect of the repeal of motorcycle helmet requirements in Michigan, except for individuals under 21, and its results are not in the least bit surprising, as the authors note in their conclusion when they characterize their findings as “not surprising” and as reflect “existing literature on the subject.” One potential shortcoming is that it would have been useful to examine more motorcycle seasons before the change in the law. Similarly, as the authors note, their hospital’s catchment area includes only western Michigan and not the entire state.
So how do we reconcile this finding with the relatively low motorcycle fatality rate observed in 2014? It’s hard to tell. Fatality rates and crash rates fluctuate year to year based on a number of factors. None of this stopped ABATE from making an astoundingly numerically challenged statement:
ABATE’s president, Vince Consiglio, noted that “helmets don’t prevent accidents … in Michigan, there’s more people killed wearing helmets than without.”
He sounds even more like an antivaccine activist, doesn’t he? After all, that’s basically the same argument antivaccine activists make when they point out that most victims in measles or pertussis outbreaks are vaccinated, ignoring the fact that vaccines aren’t 100% effective and that if you calculate risk of disease, the unvaccinated face a 23-fold increased risk of, for example, pertussis compared to the vaccinated.
Unfortunately, getting crash statistics out of the Michigan website is maddening because there isn’t an easy year-to-year comparison that I could find. Instead I had to manually extract scads of data for each year from 2005 to 2014, the first and last years for which data are published on the website, in order to put together a quick and dirty spreadsheet to look at the numbers. The first thing one has to note is that, for whatever reason, the number of motorcycle crashes in 2014 was the lowest in at least ten years (I know, I went back to 2005), and not by a little. In 2014, there were 2,860 motorcycle crashes; the year with the next lowest number was 2011, with 3,104 crashes. So of course the number of fatalities were down. Just for yucks, I looked at the percentage of fatalities over the years, comparing the period from 2005 to 2011 (before the helmet law change) to the period from 2012-2014 (after the helmet law change, except for the first three months of 2012). Guess what? The percent of fatal motorcycle accidents averaged 3.3% from 2005 to 2011; from 2012 on, it was 3.8%, a 15% increase. Is that real? Is it something that will be sustained? I don’t know. In comparison, the percentage of injuries remained roughly the same, 74% from 2005 to 2011 compared to 73% from 2012 on. The disparity between deaths and injuries could be explained by a shift to higher injury severity scores, as found by Rodriguez, or by confounders that are not available in the raw data tables I looked at. Regardless, based on what we know thus far, it is incorrect to argue that motorcycle fatalities are decreasing, as ABATE does. That is not the correct metric. Sure, in raw numbers, they are down, but so is the total number of motorcycle crashes, with 2014 being a year with an unusually low number of motorcycle crashes. As a percentage, motorcycle fatalities are up 15% since enactment of the law.
Even so, the finding of this study is plausible, based on what we already know, and it suggests that the problem might be getting worse. Certainly a study from the University of Michigan also suggests that there’s a problem.
Motorcycle helmets versus injury and death
I’ve compared anti-helmet law activists to antivaccine activists mainly because there is a depressing similarity in the quality and types of arguments they use, which largely rely on cherry picking data and innumeracy. However, there is a fairly large difference between the issue of school vaccine mandates and the issue of mandatory motorcycle helmet laws, which is that unvaccinated children endanger many others while those who don’t wear motorcycle helmets endanger mainly themselves. The consequences of many unvaccinated children include disease outbreaks and increased morbidity and mortality. The consequences of having anywhere from 30-40% of motorcyclists not wearing their helmets (which is around how many opt out in states without mandatory helmet laws) include more motorcyclists who die or who survive and suffer severe traumatic brain injury. Thus, the arguments for motorcycle helmet laws are even more prone to revolve around “freedom” arguments than school vaccine mandate laws are to invocations of “parental choice” and “freedom.”
In my reading, I discovered some rather interesting history behind motorcycle helmet laws. Motorcycle helmets, it turns out, were worn by racers as early as 1920, but a more interesting tidbit is that motorcycle helmets were more widely worn during World War II as a result of the work of Hugh Cairns, a consulting neurosurgeon to the British Army, who first became concerned about helmet use after he treated T. E. Lawrence – a.k.a. Lawrence of Arabia—for a fatal head injury suffered during a 1935 motorcycle accident. He later published several landmark papers using clinical case reports to show how helmets mitigated the severity of traumatic head injuries after crashes of military motorcyclists.
In the 1960s, after two postwar decades during which the motorcycle evolved into a symbol of freedom and masculinity in the US, the federal government got involved:
The 1966 National Highway Safety Act introduced drastic and unwelcome changes to US motorcycle culture. The law, which was introduced after the 1965 publication of Unsafe at Any Speed, Ralph Nader’s scathing indictment of the US auto industry’s vehicle safety standards, included a provision that withheld federal funding for highway safety programs to states that did not enact mandatory motorcycle helmet laws within a specified time frame. This provision was added after a study showed that helmet laws would significantly decrease the rate of fatal accidents. The National Highway Safety Act was passed without debate on the helmet law provision.11 Adoption of this measure drew upon a broader movement within public health to expand its purview beyond infectious disease to “prevention of disability and postponement of untimely death.”
As a result, between 1966 and 1976, nearly every state passed helmet laws in order to avoid losing federal highway dollars. Oddly enough, the biggest holdout was the state of California, where arguably motorcycle culture was at its most intense, and as a result motorcycle clubs and organizations had developed into a powerful anti-helmet law lobby. Over time, the influence of these groups grew throughout the country. In 1975, Congress revised the National Highway Safety Act to remove the tie between federal road funding and motorcycle helmet laws. Thus began a series of unplanned natural experiments in public health epidemiology showing the effect of these laws:
During the next 4 years, 28 states repealed their mandatory helmet laws. The consequences of these repeals were most succinctly expressed in the September 7, 1978, Chicago Tribune headline “Laws Eased, Cycle Deaths Soar.” Overall, deaths from motorcycle accidents increased 20%, from 3312 in 1976 to 4062 in 1977. In 1978, NHTSA administrator Joan Claybrook wrote to the governors of states that had repealed their laws and urged them to reinstate the enactments. She cited studies that showed motorcycle fatalities were 3 to 9 times as high among helmetless riders compared with helmeted riders and that head injury rates had increased steeply in states where helmet laws had been repealed. “Now that some states have repealed such legislation we have control and experimental groups which when compared show that one of the rights enhanced by repeal is the right to die in motorcycle deaths,” opined an editorialist in the June 1979 issue of the North Carolina Medical Journal.
For those concerned about public health, the unfolding events were viewed with alarm. In the June 1980 issue of the American Journal of Public Health, Susan Baker, an epidemiologist and director of the Johns Hopkins Injury Prevention Center, compared the situation to one where “scientists, having found a successful treatment for a disease, were impelled to further prove its efficacy by stopping the treatment and allowing the disease to recur.”
In contrast:
In Europe, meanwhile, where helmet laws were being enacted for the first time, studies were showing an opposite effect. In Italy, where a compulsory motorcycle helmet law went into effect in 1986, a group of researchers compared the accidents in 1 district (Cagliari) during the 5 months before and the 5 months after the law’s enactment. They found a 30% reduction in motorcycle accidents and an overall reduction in head injuries and deaths.
Nothing has changed in 30 years, it would appear. If there’s one finding that has been consistent about these laws, it’s that, whenever a state mandatory helmet law is repealed, inevitably studies come out a few years later showing an increase in head injuries, death, and medical costs in that state. There is also a strong correlation between repeal of universal helmet laws and a subsequent increase in motorcycle-related death, traumatic brain injury, and disability. Indeed, a 2009 study of more than 70,000 patients from the National Trauma Databank revealed that mortality among helmeted motorcyclists was 3.8% compared to 6.7% among unhelmeted motorcyclists. Those states with partial and no helmet laws had significantly higher mortality than those with universal helmet laws. Its authors concluded, “Unhelmeted motorcycle crash patients suffer more severe brain injuries, consume more resources, and have the worst payor mix. Society bears a large financial burden for these uninsured unhelmeted patients. There is a survival advantage for helmeted patients.” In addition, a cross-sectional study looking at national discharge data found that patients hospitalized after a motorcycle crash in states without universal helmet laws are “more likely to die during the hospitalization, sustain severe traumatic brain injury, be discharged to long-term care facilities”. There are plenty of other studies showing exactly the same thing across a number of states and countries, so much so that there is a very strong consensus that motorcycle helmet laws save lives.
Moreover, there is growing body of evidence that it is universal helmet laws that save lives. What we in Michigan now have is what is known as a “partial coverage statute,” because it still mandates helmets for riders under 21. Such laws are not enough and, in fact, tend to produce results indistinguishable from what is observed in states with no mandatory helmet law at all. For example, a 2007 analysis found that universal helmet laws are associated with a 31% decreased fatality rate among motorcyclists 15-20 years of age. The reasons why this might be true are not fully known, but some have suggested that in states with partial coverage statutes, enforcement is virtually impossible:
While an unhelmeted rider is very conspicuous in a state with universal coverage, enforcement is far more problematic under partial coverage, leading researchers to assume that a partial coverage statute is virtually unenforceable (Branas and Knudson, 2001, National Highway Traffic Safety Administration [NHTSA], 1980, National Highway Traffic Safety Administration [NHTSA], 2002 and Sass and Zimmerman, 2000). Empirical justification for treating a partial coverage law as indistinct from no law is supported by the simple correlational study by Sosin et al. (1990) and a small difference in observed helmet use between partial and no law states (NHTSA, 2004).
Whatever the reason, at the very least, partial coverage laws are not as effective as universal coverage and may not be effective at all. That’s where we are in Michigan now.
Personal freedom versus evidence
In a free society, we are faced with questions that balance individual freedom and risk. Which direction we choose to go in depends not just on evidence, but on our values. Public health imperatives can make powerful arguments for limiting certain types of freedom, such as the “freedom” to send one’s unvaccinated children to school to endanger other children by facilitating outbreaks of vaccine-preventable diseases. When the person who suffers as a result of invoking his freedom is no one other than himself or herself, it’s a little harder to use a public health imperative as a rationale for limiting the freedom not to wear a motorcycle helmet, but not impossible. After all, if not wearing a helmet results in a much higher risk of traumatic brain injury and death, with attendant much higher medical costs, then an argument can be made for requiring helmet use. At the very least, society can invoke the very arguments used by anti-helmet activists to invoke personal responsibility. It can require unhelmeted cyclists to pay more for vehicle and health insurance and impose penalties on those who lie about their helmet use in order to avoid paying extra. Michigan’s law does some of that, but not nearly enough. Even its requirement that unhelmeted riders carry an additional $20,000 in insurance, as paltry as it is, has been criticized as a “windfall” for the insurance industry—which, by the way, was very much opposed to Michigan’s repeal of its mandatory helmet law, because it knew what the toll would be.
Here’s the problem. If the debate over universal mandatory motorcycle helmet laws were an honest one, it would boil down to this. We know that repealing mandatory helmet laws will lead to an increase in unhelmeted riders from around 5-10% to around 30-40%. (One study estimates only 58% now wear helmets in states without mandatory helmet laws.) We know that not wearing a helmet greatly increases a rider’s chances of dying or suffering severe traumatic brain injury in a crash, which means an additional 20-35% of riders will subject themselves to that increased risk. We can therefore estimate fairly reliably how many more riders will die, how many more will suffer severe traumatic brain injury, and how much more money they will cost. Let those advocates of “freedom” simply make the argument on those terms and say, “We believe our freedom not to wear a helmet is worth this cost in human lives, disability, and money.” Then let the chips fall where they may. One can almost admire Robert Ford, chairman of Massachusetts Freedom First, an auto group that had earlier led a successful campaign to repeal the state’s seat belt law, for the purity of the argument he made in the late 1980s against helmet laws, as horrible as that argument was from a public health perspective:
We do not want to be told how to behave in matters of personal safety. We do not want to be forced to wear seat belts or helmets because others think that it is good for us. We do not want to be forced to eat certain diets because some think that it too may be good for us, reduce deaths and medical costs, and make us more productive citizens. We do not want to be forced to give up certain pastimes simply because some may feel they entail any amount of unnecessary risk.
This is the argument. It’s not one that we frequently hear in so unvarnished a form. Instead, we have groups like ABATE denying the mountains of evidence that helmet laws save lives using the very same techniques beloved of denialists of all stripes, be they anthropogenic climate change, evolution, or vaccine efficacy denialists, referring to helmets as “self-protection equipment with questionable benefits” and scientific evidence supporting helmet use as “DOCTORED statistics, the misrepresentation of facts, and outright lies used by the safety-crats to support their position.” These arguments are used to convince legislators that there will be no cost involved in repealing motorcycle helmet laws. If those favoring repeal of mandatory motorcycle helmet laws were really in favor of personal responsibility and freedom, they’d happily admit the danger of what they’re doing in the public debate over these laws and insist on provisions forcing motorcyclists who choose to go helmetless to pay the true cost of their decision.
I won’t hold my breath waiting for that.

E-cigarettes: The growing popularity of an unregulated drug delivery device
David Gorski on August 19, 2013
Link
This post is not about vaccines (for a change).
However, I deem it appropriate to mention that one of the topics that I blog most frequently about is vaccines and how the antivaccine movement pushes pseudoscience and quackery based on its apparently implacable hatred of vaccines. (You’ll see why very shortly.) It seems almost as long as my interest in the topic since I first noticed that the antivaccine movement acquired its very own celebrity spokesperson in Jenny McCarthy, who at least since 2007 has been promoting outrageous quackery and pseudoscience associated with her antivaccine views. To her, vaccines are chock full of “toxins” and all sorts of evil humors that will turn your child autistic in a heartbeat and in general “steal” your “real” child away from you the way she thinks vaccines “stole” her son Evan away from her. Indeed, among other “achievements,” she’s written multiple books about autism in which vaccines feature prominently as a cause, led a march on Washington to “green our vaccines” and has been the president of the antivaccine group Generation Rescue for the last few years. None of this stopped ABC from foolishly hiring her to join the regular cast on The View beginning in a few short weeks.
Because I occasionally check on what Jenny McCarthy is up to, I noticed a couple of weeks ago that she had been hired to be a celebrity spokesperson for blu™ e-cigarettes. Here she is, hawking the blu™ Starter Pack:
Particularly odd to me is how the ad has Jenny McCarthy hawking blu™ e-cigarettes as a “sexy” way to smoke. She points out dramatically that, now that she is single, being a smoker is a big problem because, apparently, smoking itself is a big turnoff to a lot of men and she hates interrupting dates to have to go outside to catch a smoke. If you believe the commercial, blu™ e-cigarettes have completely revitalized Jenny McCarthy’s love life, apparently in the wake of her breakup with Jim Carrey a couple of years ago. Oddly enough, I didn’t see any mention of blu™ cigarettes as what I had frequently been told that e-cigarettes are meant for: To help a smoker quit smoking through nicotine replacement plus the behavioral queues of smoking. No, this ad portrayed e-cigs strictly as a “safer” and less offensive way to smoke. Like Matt Carey, I also could not escape the irony of the woman who rails against “toxins” in vaccines and described her struggles trying to stop smoking when she was pregnant now shilling for a device designed to be used to inhale a toxic substance (nicotine) into one’s lungs. On the other hand, she has in the past raved about how she absolutely “loves” Botox; so maybe it’s not so difficult to understand.
Jenny McCarthy’s decision to shill for an e-cigarette company “inspired” me to think that now is a good time to do a post on the evidence base behind e-cigarettes. After all, it’s been three and a half years since the topic has been covered here on SBM, last time by Steve Novella. In particular, I thought it a good time because I have been bombarded with huge amounts of e-cigarette spam e-mail lately. I’ve also noticed that a certain organization that represents itself as defending the public against health scares by countering them with science, namely the American Council on Science and Health (ACSH), is very high on e-cigarettes, even going so far as to praise Jenny McCarthy for being on the right side of science for a change. A quick search of the ACSH website for e-cigarettes reveals hundreds of posts about them, all uniformly either praising e-cigarettes as the greatest thing since sliced bread for “safer smoking,” harm reduction, and as an aid to smoking cessation or chastising anyone that has anything bad to say about them or any government entity that seeks to ban or tightly regulate them. Indeed, Gilbert Ross, MD, the executive and medical director at the ACSH, has even written posts for Forbes in which he accuses regulators who would restrict or ban e-cigarettes as being out to kill American smokers, a message echoed on the ACSH’s own website, in which apparently European Union regulators share the same homicidal urges towards European smokers that American regulators apparently exhibit towards theirs.
Rhetoric like what I saw in the articles to which I linked above tend to raise a huge red flag to me warning me that someone is laying down heapin’ helpin’s of grade-A BS. However, I don’t know for sure that that’s the case; it might not be. Maybe ACSH is right. On e-cigarettes, I have been and remain agnostic. After all, it’s not implausible to speculate that e-cigarettes might be a useful strategy to assist smokers in quitting as just another nicotine delivery system, nor is it implausible that they could be a safer means of “smoking” than cigarettes. On the other hand, let’s face it. E-cigarettes are, without a doubt, drug delivery devices designed to administer nicotine in a vapor, virtually identical in concept to nicotine inhalers already used for smoking cessation, but smaller and looking very much like cigarettes, making them more convenient and socially acceptable for use outside of the home. Yet, as of this writing nicotine inhalers are regulated by the FDA as a drug/device combination, while e-cigarettes are not. As a result, I view e-cigarettes as being in the same category as supplements. They are unregulated, and proponents make specific health claims for them, primarily (1) that they are safer than cigarettes and (2) that they are effective smoking cessation tools. This leads to the only question that matters to me in a health issue like this: What does the science show? The disappointing answer: Not a lot one way or the other.
E-cigarette facts and history
The effects of tobacco smoking result in enormous morbidity and mortality, through the various cancers caused by smoking, most prominently lung cancer, as well as chronic obstructive pulmonary disease (COPD), and cardiovascular disease resulting in heart attacks, limb loss, and strokes. Consequently, reducing harm from tobacco is a major public health challenge, and smoking cessation would result in an enormous decline in premature death and disability. Indeed, if smoking prevalence were reduced to zero, lung cancer, heart disease, and COPD prevalence would plummet. Various nicotine-delivery systems, such as nicotine patches and nicotine inhalers, have proven to be useful aids to smoking cessation.
E-cigarettes are the most common variant of a class of medical devices known as electronic nicotine delivery systems (ENDS), whose purpose is to vaporize nicotine, along with other substances used to affect the vapor consistency and flavor, and deliver it to the lungs of the user. Indeed, quite a bit of effort goes into making the vapor look like smoke, as can be seen in the video above. Each device typically consists of a tube made of plastic or other material in which there are housed a rechargeable battery, electronic controls, and an electronic vaporization system. Cartridges containing the liquid mixture to be vaporized are attached to the tube, and puffing on the e-cigarette results in the production of vapor, which is inhaled. Frequently, there is a light at the end of the tube that lights up when a puff is taken to simulate the lit end of a cigarette. One notes from Jenny McCarthy’s commercial that in the case of blu™ e-cigarettes this light is blue, for reasons that escape me.
Although Herbert Gilbert invented a device similar to what we know as electronic cigarettes in 1963, it was never marketed, and the first generation of e-cigarettes as we know them today was developed by a Chinese pharmacist, Hon Lik, in 2003 and patented soon thereafter. They were first introduced into the Chinese market in 2004 and reached the international market by 2006. It didn’t take long for a variety of manufacturers to start making them and promoting them as a “healthy alternative” to smoking or as an aid to smoking cessation. In a relatively short period of time, selling e-cigarettes has become big business; it’s been estimated that e-cigarette sales could reach $1.7 billion this year. That’s still a fraction of the $80 billion a year tobacco industry, but it’s a rapidly growing one. Moreover, many e-cigarette companies are owned by tobacco companies, something the ACSH applauds; for example, blu™ is owned by Lorillard.
According to e-cigarette manufacturers, the vapor inhaled from e-cigarettes does not contain tar or many of the toxic chemicals found in real cigarette smoke. The chemical mixture vaporized is typically composed of nicotine, propylene glycol, and other chemicals. Not all e-cigarettes use propylene glycol as the vaporizing agent (for example, blu™ e-cigarettes use vegetable glycerin instead), although many do, along with flavors designed to make the vapor more pleasant and attractive, such as menthol, vanilla, cherry, coffee bean, chocolate, apple, and, yes, various kinds of tobacco. This proliferation of flavors has led to concerns that e-cigarettes are attractive to children and could facilitate getting them hooked on nicotine or even serve as a “gateway” to real smoking.
Through a quirk of a ruling based on the 2009 Family Smoking Prevention and Tobacco Control Act, as long as manufacturers do not make health claims for them the FDA cannot regulate e-cigarettes as drug/device combinations, even though that’s what they clearly are. This is why you don’t see ads touting e-cigarettes as a smoking cessation aid, but rather as a “healthy alternative” to smoking. Here’s what happened. Between 2008 and 2010, the FDA quite reasonably determined that e-cigarettes are unapproved drug/device combinations. In response, Sottera, Inc., an e-cigarette manufacturer, challenged the FDA in court, and the U.S. Court of Appeals for the D. C. Circuit ruled in Sottera, Inc. v. Food & Drug Administration in 2010 that a jurisdictional line should be drawn between “tobacco products” and “drugs,” “devices,” and combination products. The court further ruled that e-cigarettes and other products made or derived from tobacco can be regulated as “tobacco products” under the act and are not drug/device combinations unless they are marketed for therapeutic purposes. For reasons that are unclear to me, the FDA declined to challenge the ruling, but retains the power under the Tobacco Control Act to add categories to the tobacco products it regulates after going through procedural steps that include a public comment process. As a result, the FDA plans to propose draft regulations for e-cigarettes this fall and put them out for public comment. Until such a time as the FDA finalizes regulations, however, e-cigarettes are unregulated by the FDA, although some states have banned them in public places, much as cigarette smoking is banned in public places in many states. This quirk of U.S. law has been the proverbial camel’s nose in the tent that opened the way for the currently booming e-cigarette business.
Are e-cigarettes safer than cigarettes?
Since the main claim being used to sell e-cigarettes right now is that they are safer than tobacco-containing cigarettes, that’s the first claim that needs to be examined. If you look at e-cigarette advertising, it’s hard not to feel a sense of déjà vu with respect to past tobacco company ads, complete with appeals to “freedom” (Jenny McCarthy’s ad uses that, among other common advertising ploys, such as the implication that you’ll have more sex if you use this product), celebrity endorsements (McCarthy again), and appeals to sophistication, freedom, equality and individualism. All of this is coupled with, of course, appeals to health, such as this ad for South Beach Smoke:
Indeed, e-cigarette advertising has been characterized as the “Wild, Wild West,” something out of Mad Men, and the “next great frontier” for ad agencies. It’s not hard to see why.
As I said earlier, it is not implausible that “vaping” (as inhaling e-cigarette vapor is commonly known) might be safer than tobacco cigarettes. After all, they don’t contain the tar and combustion products that cigarette smoke does, although most of them do contain the nicotine. There are nicotine-free e-cigarette cartridges for those who want the experience of smoking but not the nicotine. To me that seems like drinking decaffeinated coffee, something I’ve never been able to understand, but maybe that’s just me. Be that as it may, there really is a dearth of evidence one way or the other regarding the safety of e-cigarettes. The evidence that is out there, from my perusal of it, is of almost completely uniformly low quality. Particularly lacking are long-term studies of e-cigarette use, obviously because they’ve only been on the market for less than a decade and only skyrocketed in popularity beginning around five years ago. For instance, Odum et al pointed out that:
Most e-cigarette data on safety and efficacy are derived from the surveys of current or past e-cigarette users.14-18 The surveys have reported successful reduction in smoking and benign side effects, such as dry mouth, throat irritation, dry cough, vertigo, headache, and nausea (Tables 1). Most survey participants were male and from the Unites States, Europe, and Canada. Respondents were typically recruited by posting links on e-cigarette or smoking cessation Web sites and/or sending e-mails with survey links to consumers of ecigarettes[sic]. One survey18 recruited subjects by handing out questionnaires at an e-cigarette enthusiast meeting. Many of these surveys14,15,17,18 provided only descriptive analyses to understand the usage patterns and opinions of e-cigarettes along with baseline demographics such as previous quit attempts. One survey16 found a statistically higher amount of throat burning in current smokers versus former smokers and in e-cigarettes with nicotine versus e-cigarettes without nicotine. No differences were found for the side effect of dry mouth/throat.
I perused PubMed for data on e-cigarette safety, and I was appalled at the low quality of the studies out there. For instance, here are two more recent surveys compared to the review article I cited above. They tell us little or nothing more. Even surveys reporting adverse events are not particularly helpful. This Internet forum survey, for instance, has a built-in selection bias. Even though it tells us that there are a wide variety of reported effects from e-cigarettes, including cough, headache, panic, nausea, tremor, fatigue, reflux, throat and mouth irritation, burning, dermatitis, and elevated blood pressure, it’s hard to tell what the true prevalence of such reported symptoms are. Not surprisingly, given the uncontrolled nature of these studies, they showed that smokers generally liked e-cigarettes, think they help them decrease or quit smoking, and don’t cause any significant problems. It’s simply amazing how little hard data there are published. Moreover, most of these studies were prone to selection bias because they tended to recruit subjects from visitors to e-cigarette manufacturer websites and e-cigarette enthusiast blogs, and recall bias was certainly a concern given that these studies had no independent verification of smoking cessation. In other words, these surveys are pretty much useless.
In 2009, the FDA was concerned about the content of e-cigarettes and undertook an analysis of two leading brands of e-cigarette cartridges and found that one out of the 18 cartridges contained 1% diethylene glycol, an ingredient in antifreeze that is toxic to humans. Also noted were “certain tobacco-specific nitrosamines which are human carcinogens” in half the samples tested. Other findings included:
    • Tobacco-specific impurities suspected of being harmful to humans—anabasine, myosmine, and β-nicotyrine—were detected in a majority of the samples tested.
    • The electronic cigarette cartridges that were labeled as containing no nicotine had low levels of nicotine present in all cartridges tested, except one.
    • Three different electronic cigarette cartridges with the same label were tested and each cartridge emitted a markedly different amount of nicotine with each puff. The nicotine levels per puff ranged from 26.8 to 43.2 mcg nicotine/100 mL puff.
    • One high-nicotine cartridge delivered twice as much nicotine to users when the vapor from that electronic cigarette brand was inhaled than was delivered by a sample of the nicotine inhalation product (used as a control) approved by FDA for use as a smoking cessation aid.
These findings have been disputed. For instance, it has been pointed out that the tobacco-specific nitrosamines found by the FDA are present in e-cigarette vapor are present at much lower concentrations than in cigarette smoke and comparable to what is found in nicotine patches. Given that the only chemicals found in e-cigarettes that raise significant health concerns are tobacco-specific nitrosamines and diethylene glycol (believed to be a contaminant from the use of non-pharmaceutical grade polyethylene glycol), from the standpoint of the vapor, e-cigarettes probably are safer than regular cigarettes. A recent technical report from Igor Burstyn of Drexel University reports that the levels of contaminants e-cigarette users are exposed to are “insignificant, far below levels that would pose any health risk.” However, although it’s referred to in various places as a “study,” it really isn’t. It’s a review article, and it wasn’t even a peer-reviewed article, simply a “technical report” posted at the Drexel website and touted by press release. It was also funded by Consumer Advocates for Smoke-free Alternatives (CASAA), a group that promotes “reduced-risk” alternatives to cigarette smoking, including e-cigarettes. To be honest, given the funding source of this review and its lack of publication in a peer-reviewed journal — one blog comment hilariously states that the study “has been made public for peer review. As CASAA promised when fundraising, the researcher would not keep the study results a secret from the public during the review process” — I’m less than impressed, for obvious reasons. And for shame, ACSH, for promoting this piece of propaganda! If you think I’m being too hard on ACSH, then just imagine what its reaction would be if a supplement company pulled this sort of stunt, publishing a “technical report” that’s not peer-reviewed and promoting it.
Other studies have evaluated the effects of e-cigarette use on various measurable endpoints, such as plasma nicotine levels, heart rate, and expired carbon monoxide concentrations, but these were all short term studies using surrogate endpoints. Another study comparing tobacco cigarettes and e-cigarettes found that e-cigarette vapors produced smaller changes in lung function than tobacco smoke, but resulted in similar levels of nicotine in the blood as measured by the metabolite cotinine, while another study supports the observation of at least some adverse physiologic changes due to e-cigarette vapor. Specifically, use of an e-cigarette for 5 minutes was found to cause an increase in impedance, peripheral airway flow resistance, and oxidative stress among healthy smokers. On the other hand, this increase was small, and it is unclear what its clinical significance may be.
Given that e-cigarettes are too new for long-term studies to have been done, harm from the vapor can’t be ruled out, but it’s not unreasonable to provisionally conclude that it probably is less than tobacco smoke. The problem is that that’s a really low bar to clear, given how incredibly harmful tobacco-containing cigarettes are known to be, and says nothing about whether e-cigarettes are acceptably safe. The other problem, of course, is that that rigorous, well-conducted, long-term studies on e-cigarette safety are basically nonexistent. All we can do is extrapolate from surveys, chemical analyses, and generally low-quality data, and there’s a lot of uncertainty in doing so.
Are e-cigarettes effective smoking cessation aids?
The vapor is not the only issue with respect to e-cigarettes, though. They are, after all, intended as nicotine delivery devices, oddities in the law here in the US notwithstanding that classify them as tobacco products even though they contain no tobacco. Although manufacturers are not allowed to make the claim that e-cigarettes are useful smoking cessation aids, promoters of e-cigarettes as a harm reduction strategy, like the ACSH, are not nearly so shy about trumpeting such claims far and wide, even to the point of claiming that attempts to ban or strictly regulate e-cigarettes will “kill smokers,” presumably by robbing them of their one and only chance to quit smoking. It’s massive hyperbole, of course, because data are so lacking, and these are the claims that set my skeptical antennae a-twitchin’.
So what about nicotine? One concern the FDA reported was a highly variable nicotine delivery rate per puff from cartridge to cartridge of the same brand. (One notes at least one other study citing variable nicotine content in e-cigarette cartridges.) That suggests poor manufacturing processes and lack of standardization that are concerning. In addition, e-cigarettes appear to deliver less nicotine compared to FDA-approved nicotine inhalers, as measured by peak plasma concentrations after 10 puffs. According to manufacturers, these cartridges generally contain between 6 and 26 mg of nicotine, although there are cartridges on sale that contain as much as 45 mg of nicotine. In comparison, a typical cigarette generally delivers approximately 1 to 3 mg of absorbed nicotine. However, e-cigarette cartridges are not meant to be the equivalent of one cigarette; so a one-to-one comparison is difficult, as a typical cartridge is the equivalent of up to a pack of cigarettes, as many as 350 puffs.
When I perused PubMed looking for studies on the efficacy of e-cigarettes as a smoking cessation aid, I was no longer surprised to note an extreme paucity of them. There are to date no randomized double-blind controlled trials. Zero. Zip. Nada. In fact, I could find only two studies that weren’t in my opinion such dreck that they weren’t worth bothering to mention, and the larger and better designed of the two was essentially negative. First, there was a randomized, single-blind study by New Zealand researchers with a cross-over design in which subjects who smoked more than 10 cigarettes a day for at least one year who weren’t trying to quit used either a nicotine inhaler, a no-nicotine e-cigarette, a 16 mg nicotine e-cigarette, or their own cigarettes for a nine hour period. The results? The 16 mg e-cigarette and the nicotine inhaler produces a similar reduction in the desire to smoke compared to the no-nicotine e-cigarette. It was a small study, of course, and only looked at short-term surrogate outcomes. As such, it says little about the use of e-cigarettes as a smoking cessation aid other than that they might be useful.
More recently, there was a larger study of a similar design from an Italian group published in PLoS ONE. It was larger study (300 smokers) looking at three different strengths of a popular e-cigarette in Italy. Group A (n = 100) received 7.2 mg nicotine cartridges for 12 weeks; Group B (n = 100), a 6-week 7.2 mg nicotine cartridges followed by a further 6-week 5.4 mg nicotine cartridges; Group C (n = 100) received no-nicotine cartridges for 12 weeks. Subjects underwent nine visits during which cigarette use and exhaled carbon monoxide levels were measured. Interestingly, declines in cigarettes/day use and eCO levels were observed at each study visit in all three groups with no clear consistent differences between study groups in rates of smoking cessation and declines in cigarette use. There was no difference in adverse events either, including dry cough, mouth irritation, shortness of breath, throat irritation, and headache. In other words, it was a negative study, but that’s not how it was spun. Not surprisingly, the authors argued that e-cigarettes are useful adjuncts to smoking cessation.
My interpretation? There was no real control group, and this study suggests that it doesn’t matter whether there is nicotine in the e-cigarette or not. Moreover, there’s no way of knowing whether there was selection bias, and 40% of subjects didn’t show up for their last visit. From my perspective, the Hawthorne effect, in which the simple process of observation results in improvement in behavioral studies regardless of the intervention tested, could potentially account for this result. That’s why appropriate control groups are so essential. (I bet that if there were a no-intervention “observation only” group and a nicotine patch control group, there would have been a significant decline in smoking in those groups as well.) Sadly, the authors didn’t even mention that possibility.
As I said before, the question of whether e-cigarettes are a useful smoking cessation aid is a question that cries out for a decent randomized, double-blind controlled trial and a trial comparing them to conventional methods currently used for smoking cessation. As anyone who’s ever smoked or dealt with smokers know, smoking cessation is an incredibly difficult nut to crack. Even the treatments that work don’t work all that well. As far as e-cigarettes go, the best I could find was a proposed protocol from investigators in New Zealand for a randomized double-blind, placebo-controlled trial:
Design: Parallel group, 3-arm, randomised controlled trial. Participants: People aged ≥18 years resident in Auckland, New Zealand (NZ) who want to quit smoking. Intervention: Stratified blocked randomisation to allocate participants to either Elusion™ e-cigarettes with nicotine cartridges (16 mg) or with placebo cartridges (i.e. no nicotine), or to nicotine patch (21 mg) alone. Participants randomised to the e-cigarette groups will be told to use them ad libitum for one week before and 12 weeks after quit day, while participants randomised to patches will be told to use them daily for the same period. All participants will be offered behavioural support to quit from the NZ Quitline. Primary outcome: Biochemically verified (exhaled carbon monoxide) continuous abstinence at six months after quit day. Sample size: 657 people (292 in both the nicotine e-cigarette and nicotine patch groups and 73 in the placebo e-cigarettes group) will provide 80% power at p = 0.05 to detect an absolute difference of 10% in abstinence between the nicotine e-cigarette and nicotine patch groups, and 15% between the nicotine and placebo e-cigarette groups.
Which is what is desperately needed, a head-to-head comparison between e-cigarettes with nicotine, without nicotine, and nicotine patch alone. I hope these investigators succeed in getting this trial going and that it produces clearly interpretable data. This is a question that needs to be answered.
The bottom line
E-cigarettes started out as a promising idea that turned into a product that got away “into the wild,” so to speak, before being adequately studied. Originally conceived as a safer way for a smoker to get his nicotine fix, e-cigarettes have evolved into a fad driven by claims that they are much safer and promoted as such by e-cigarette companies and now by the big tobacco companies that are frantically buying up e-cigarette companies and/or introducing their own brands. Because, through a quirk in US regulatory law, they are currently unregulated, which has led to a proliferation of many, many brands of variable design and reliability. Although short term studies of e-cigarettes appear not to have found any evidence of significant harms, there are currently no solid long term data regarding the effects of inhaling the vapors produced by e-cigarettes. A recent review concluded that the vapors are likely safe, but did so based on primarily on a review of chemical analyses of e-cigarette vapor. A more recent analysis finds some toxic chemicals in e-cigarette vapor but at much lower levels than in tobacco smoke. Again, however, there are no long term epidemiological or observational data in actual humans using e-cigarettes.
Given that e-cigarettes are being touted as a replacement for smoking and thus presumably for long term use rather than short term use as a tool to quit smoking, this is a rather glaring problem. Moreover, we don’t know yet whether long term use of nicotine delivered in this manner is safe. Nicotine is, after all, an addictive drug whose use results in vasoconstriction, increasing heart rate and blood pressure, as well as inducing a combination of free radical production, vascular wall adhesion, and a reduction of fibrinolytic activity in the plasma that might be an indication of contributing to atherosclerosis. It might be safe delivered this way. It might not. We don’t know.
Despite all the uncertainty, on the one side we see anti-tobacco activists proclaiming e-cigarettes to be potentially harmful and gateway drugs to children leading to the use of real tobacco, while on the other side we see e-cigarette promoters (and I do count ACSH among that group) making concreted, absolutist statements that e-cigarettes are safe and effective aids to smoking cessation. The evidence base is such that both are overstating their cases, although I tend to conclude that the e-cigarette apologists are overstating their case more, given the apocalyptic rhetoric of regulators killing smokers. The hypocrisy of some of the rhetoric is astounding, attacking apologists for unregulated supplements for promoting them, while simultaneously blasting critics of…unregulated e-cigarettes! Meanwhile harm reduction advocates tout testimonials and selection bias-laden surveys as “evidence” that e-cigarettes definitely help smokers quit. Quite frankly, I don’t get it. Would the same people accept such low quality evidence in support of, say, supplements? Surveys routinely show that people love their supplements and believe them to improve their health. Accepting such low quality evidence for the efficacy of e-cigarettes is the same thing as accepting survey data as evidence for the efficacy of supplements, and it distresses me how many are either unable or unwilling to understand that.
I can understand provisionally concluding that e-cigarettes are safer than cigarettes (they likely are), but the evidence that e-cigarettes are an effective aid to smoking cessation is currently slim to non-existent, much less any evidence that they are more effective than nicotine patches or inhalers, as is sometimes claimed. Making definitive statements about the safety or efficacy of e-cigarettes is not an evidence-based stance. An evidence-based stance towards the question of whether e-cigarettes are an effective smoking cessation aid is, “We don’t know yet. Rigorous studies are desperately needed.” At least, that’s my story, and I’m sticking to it. As I said early on in this post, when it comes to e-cigarettes, I have been and remain agnostic, particularly in light of the massive advertising and promotional campaigns designed to sell them. To me, today, that is the correct science- and evidence-based stance. Show me some decent evidence, and I will change that stance.
I wonder whether the same can be said of some of the advocates attacking and promoting e-cigarettes.

Vape Nation: Vaping Is Bad, Kids
The Surgeon General declared youth e-cigarette use to be an epidemic, but many vaping communities online downplay the risks. What does the evidence show?
Braden MacBeth on March 29, 2019
Link

Surgeon General Jerome M. Adams issued an advisory on December 18th, 2018 declaring E-cigarette use among youth to be an epidemic. Looking at the numbers Dr. Adams cites from the National Youth Tobacco Survey, it’s not hard to see why. According to Dr. Adams’s report, 1 in 5 high school students and 1 in 20 middle school students currently use E-cigarettes. That makes E-cigarettes about as popular among today’s teens as Fortnite; let that sink in. A lot of these E-cigarettes are appealing to high school students because they come in come in candy flavors, they don’t carry the same stigma as smoking, and it’s easy to get them hooked because they contain nicotine. It’s very easy for people to rationalize their vaping addiction because at least they aren’t smoking cigarettes. Today I want to explore the health risks of E-cigarettes, how E-cigarettes companies market themselves, and worrying trends in E-cigarettes.
Vaping vs. smoking, a false dichotomy
E-cigarettes started out being marketed as a “healthy” alternative to cigarettes when they hit the market in 2006. E-cigarettes are generally regarded as safer than traditional cigarettes but they have a lot of the same health risks, in addition risks of their own. Environmental Health Perspectives published a study in 2016 looking at the chemicals in the E-cigarette fluid, and of the 51 tested, 39 contained diacetyl. Diacetyl is a chemical flavoring typically used in popcorn as a butter-like flavoring. Diacetyl has been found to cause severe lung disease consistent with bronchiolitis obliterans in an investigation by the National Institute for Occupational Health and Safety. Bronchiolitis obliterans or “popcorn lung” causes irreversible lung damage, and can result in chronic cough and shortness of breath. Diacetyl isn’t the only chemical in E-cigarette vapor to be concerned about however.
The New England Journal of Medicine published a correspondence titled “Hidden Formaldehyde in E-Cigarette Aerosols” in 2015. What researchers found was that if the coil in the device overheats it can cause formaldehyde to be formed by the breakdown of propylene glycol. The researchers concluded that due to the increased inhaled formaldehyde intake the cancer risk could be as much as 5 times higher than the risk associated with long-term smoking. There was a significant limitation to the study however; their estimate was conservative because the researchers did not collect any gas-phase formaldehyde. According to the responses to the publication however, users should be able to detect the change because of an unpleasant burning taste described as a “dry puff”, and the risk of releasing formaldehyde was only associated with an overheated coil. I am unable to find any studies without serious conflicts of interest backing such a claim. I also found evidence that E-cigarettes can create formaldehyde emissions even through normal use according to a 2018 publication in Toxins.
E-cigarette also have risks that cigarettes don’t have such as device malfunctions; they can catch fire or explode. On February 4th, 2019 a Fort Worth man’s E-cigarette device exploded and dissected his left internal carotid artery, killing him. In 2018, a man in St. Petersburg, Florida was killed by a projectile wound to the head and burns covering 80% of his body when his E-cigarette exploded. A study published in The BMJ estimates that there were 2,035 E-cigarette explosion and burn injury related emergency department admissions between 2015 and 2017. While cigarettes are obvious fire hazards, I don’t recall any reports of deaths from exploding cigarettes recently.
The liquid used to refill E-cigarettes also presents significant health hazards not present in normal cigarettes. Nicotine can be absorbed transdermally, presenting a significant risk to children or pets if they were to come into contact with E-cigarette refill liquid. A lot of E-cigarette refill packages come in eyedropper-like packages, which are not childproof, and look like something in which you would store candy flavorings. In addition, lot of E-cigarette flavors come in sweet, fruit flavors that kids will want to get into. Poison control centers have handled over 3,000 E-cigarette-related cases in 2018.
E-cigarettes obviously contain nicotine, which is one of the most addictive drugs sold over-the-counter. Nicotine can harm the development of children’s brains, particularly the development of the cerebral cortex and hippocampus in adolescents. Nicotine exposure during pregnancy has also been shown to harm fetal brain development. Smokers who switch from tobacco to nicotine-replacement therapy may still be at significant risk for acute cardiovascular events compared to those trying to quit tobacco altogether. Even without all of the other chemicals in cigarettes, the nicotine in E-cigarettes can still presents serious health risks, especially to adolescents.
It can be argued that E-cigarettes are safer than traditional cigarettes because there are fewer harmful chemicals in the vapor compared to traditional cigarettes, but I think it’s a bit of a stupid question to ask which is safer. It’s like asking what kind of knife a serial killer is gonna use to carve out your eye balls; does it really matter? Not smoking or vaping is far healthier than doing either one. However, “It’s safer than smoking”, is the rationale that people will use to justify their habit. While research to analyze the long-term effects of E-cigarette use is on-going, the evidence we have now is more than enough to conclude E-cigarette use can have negative long-term health consequences. Why wouldn’t E-cigarettes have long-term health risks? When has recreationally inhaling a laundry list of chemicals on a regular basis ever gone well?
Harm reduction or gateway drug?
E-cigarettes companies still market their products as a safe alternative for smokers to switch to so they can quit entirely. However, the evidence shows that E-cigarettes aren’t a useful smoking cessation tool, and kids will readily switch from E-cigarettes to regular cigarettes. There is a large body of research examining if E-cigarettes help smokers quit; they don’t. A systematic review and meta-analysis published in The Lancet in 2016 reviewed 38 studies investigating if E-cigarettes could be used to aid smoking cessation. It found that the odds of someone quitting were 26% lower if they used E-cigarettes. It was also found that the odds of a smoker quitting if they switched to E-cigarettes were the same whether they intended to quit smoking or not. Despite the research clearly showing that E-cigarettes don’t work as a smoking cessation tool, E-cigarette companies will still market them as if they are.
More recent studies have been investigating whether or not E-cigarettes can act as a gateway to smoking in middle and high school students. A 2016 study in JAMA surveyed 3,396 high school students about their smoking habits. Students who stated that they vaped were twice as likely to start smoking, and their smoking habits reflected their vaping habits. The newest study published in JAMA on February 1st of this year used data from the Population of Tobacco and Health Study and follow-up surveys. Based on the 6,000 students surveyed it was found that prior E-cigarette use was associated with a three-times higher risk of cigarette use. The association between E-cigarette and later smoking was stronger in youth in the low-risk group. Vaping advocates online like to claim that E-cigarettes are hurting the tobacco industry. The reality is, E-cigarettes are helping to create a new generation of smokers.
Vape Nation
Tobacco use among children has been dropping steadily for close to four decades, until cigarette use among high school students jumped 1.6% from 2017 to 2018. It’s clear that the explosion of E-cigarette usage is the cause. But what caused the explosion in vaping? It all comes down to viral marketing, the most viewed videos that appear when searching vaping were created in the past two years exactly when the vaping trend began to take off. A lot of social media personalities, whose main audience is teenagers, vape on-stream or make vaping content. Vape companies know this and have tried to make deals with gaming streamers whose main audience is teens, whether they vape regularly on stream or not. Two popular Twitch.tv streamers, Gothalion and ProfessorBroman said on Twitter that vape companies contacted them about potentially promoting their products on stream. Both streamers are well known for being stand-up guys, and never would’ve taken such a deal. Other YouTubers, such as FaZe Rain, vape regularly and have made videos glorifying vaping, and the videos aren’t even age-gated by YouTube. I think it’s pretty clear that vaping didn’t start as a trend through television, movies, or news how we would typically expect trends like this to start. Vaping has been growing as a trend through social media sites like YouTube, Twitch, and Facebook. It’s important for parents to monitor what and who their kids are watching online. YouTubers and Twitch streamers have a lot of influence on kids. Understanding how vaping got to be such a big trend is important if we’re going to tackle this problem.
Worrying product trends
It’s interesting to browse vaping forums or listen to people talk about their vaping habits. Smokers typically stick to one particular brand of cigarettes and rarely switch. However, E-cigarette users have been shown to be more involved with their vaping habit, modifying product features or switching brands frequently. Just look at the difference in content between the smoking and vaping subreddits. It’s clear that the novelty of different vape products is a big selling point for vapers and they’re much more likely to use a variety of different flavors, brands, and even vape fluids with different drugs in them.
The buying habits of vapers isn’t just worrying because the chemicals in vape liquids vary from brand to brand, but vape companies make vape liquid with entirely different drugs in them. One company called InhaleHealth sells electronic cigarettes that allow users to take B12 and melatonin supplements through vaping. You might be thinking I just googled for hours to find the weirdest vape products I could find. I only know these exist because I’ve seen them sitting on the front counter at Sheetz for close to 6 months. There is no evidence that these products are more effective than just taking the associated dietary supplements, or that taking those supplements is necessary in the first place. It’s not just dietary supplements either; cannabis vapes are a growing trend where cannabis is legal. While it’s no surprise that people want to vape cannabis recreationally, companies are marketing CBD oil E-cigarettes as if they have health benefits. CBDOilReview.org claims:
Vaping CBD oil is one of the preferred methods to ease side effects of diseases, illnesses, and ailments including Leukemia, all types of Cancers, stress, anxiety, joint pain, seizures, inflammation, sleep apnea, high blood pressure and the list goes on. There are many benefits to CBD vape oil. However, the effectiveness of CBD helping with these conditions (and many others)
By their own admission, CBD oil has not been scientifically proven to treat any of those conditions. Who is CBD oil preferred by to treat those conditions? I would guess it’s the company selling CBD oil.
E-cigarette companies are big tobacco
E-cigarette companies are terrified of government regulation, whether it be safety regulations or laws that control where vapers are allowed to vape. Right-wing think tanks will criticize the FDA whenever they attempt to regulate the E-cigarette industry, claiming that regulations will do more harm than good. All of the arguments against regulation of the E-cigarette industry follow the same exact pattern. First, they will claim that E-cigarette usage hasn’t actually risen a significant level; which is obviously wrong. Then they will argue that regulations of the vaping industry claiming that it will increase smoking rates because E-cigarettes are an effective smoking cessation tool. Both claims are patently false, but it’s what lobbyists for the E-cigarette industry, which includes some doctors, will claim when talking to legislators.
Remember that response I talked about to the correspondence in the NEJM about formaldehyde in E-cigarette aerosols? There was a particularly interesting letter to the editor from Joel Nitzkin and Konstantinos Farsalinos in response. Both reported conflicts of interest in their letter to the editor. Farsalinos reported that that some of his studies on electronic cigarettes were performed with unrestricted funds provided to the Onassis Cardiac Surgery Center by FlavourArt and Nobacco, two E-cigarette companies. Dr. Nitzkin reported receiving partial funding for some of his tobacco policy work from the R Street Institute, an anti-regulation conservative think tank. Fortunately, in the conflicts of interest section neither had any more conflicts of interest to report; it’s hard to have more conflicts of interest than that.
In the letter, the two papers they cite are written by Farsalinos himself in the International Journal of Environmental Research and Public Health. That journal came up frequently when I was researching fake disorders for my Afflicted article; it’s a predatory journal. Farsalinos even has his own blog where he criticizes even the most well-designed studies as “research malpractice” when their findings show vaping isn’t safe. Dr. Stanton Glantz, director for the Center for Tobacco Research Control & Education, ripped apart both studies published by Farsalinos. Dr. Glantz compared Farsalinos’s research to earlier cigarette company-inspired studies that concluded it was toxicologically impossible for secondhand smoke to cause any disease. Despite the glaring conflict of interest issues, vaping websites will parrot Farsalino’s findings as if they are cutting-edge, scientific fact.
The main author of the response in the NEJM correspondence, Joel Nitzkin, also has a history of being cozy with the vape industry. Dr. Nitzkin has a long history of writing letters to state legislatures decrying proposed legislation that would regulate the vape industry. He argued that regulation would cause E-cigarette users to switch to traditional cigarettes, despite evidence to the contrary. Nitzkin even makes the ridiculous argument that tobacco control organizations are in partnership with the pharmaceuticals industry. His argument to legislators reads more like a sales pitch for E-cigarettes or a conspiracy theory on a vaping forum than a doctor trying to inform legislators about public health problems. As ridiculous an argument as it may seem, E-cigarette enthusiasts will argue online that any regulation imposed on the E-cigarette industry is a win for the tobacco industry, which is rather disingenuous. The argument implies that E-cigarette companies are somehow different from tobacco companies. The largest E-cigarette company, Juul, took a 12.8 billion dollar investment from Altria. Altria is a tobacco conglomerate that owns some brands you might have heard of such as Marlboro, Copenhagen, Skoal, and Middelton’s. Regulation of the E-cigarette industry is not a win for tobacco industry because E-cigarettes are not smoking cessation tools, and the E-cigarette industry is very much intertwined with the tobacco industry.
Conclusion: Scourge of the past
For the first time this century, underage cigarette usage is on the rise and it seems clear that the explosion of vaping is responsible. E-cigarettes are not an effective smoking cessation tool but they’re still marketed that way. E-cigarettes are probably healthier than cigarettes but they’re still not healthier than not using E-cigarettes or tobacco cigarettes. Public health organizations, regulatory agencies, and state governments are trying to take action, but they’re meeting substantial resistance from E-cigarette companies and their favorite doctors claiming that any action against the vape industry somehow benefits the tobacco industry. Fortunately, the government has been pretty on the ball. The Surgeon General has a great website where parents and teens can get the facts about E-cigarette use among teens and the risks. The FDA issued a final ruling in May of 2016 that deemed E-cigarettes and their accessories subject to regulation as tobacco products, and E-cigarette manufacturers were given a deadline to start complying with the new FDA regulations. Many of those regulations have come into effect over the past year, and there are many more about to come into effect this year. E-cigarette manufacturers are now required to submit a list of ingredients in their products, and sellers are not allowed to display advertisements for E-cigarette products without a warning label. Stores that modify E-cigarettes, or mix and prepare nicotine e-liquids may be considered manufacturers of tobacco products and subject to associated regulations.
That’s all great news but we still need to address the problem that these products still appeal to middle and high school students. The campaign against underage smoking has been undoubtedly one of the most successful public health campaigns of all time. From 1976 to 2015 the rate of smoking amongst 12th grade students dropped from 28.8% to 5.5%. Smoking went from being marketed as something only cool people do to being banned from advertising on television and radio outright, and found generally repulsive by most people. Vaping has managed to escape both the stigma and regulations around the tobacco industry and we need to fix that. E-cigarettes have a lot of the same risks as other tobacco products but none of the stigma. There have been a lot of good ads targeted at teens against vaping made by the FDA that get the salient points across quickly and clearly while presenting vaping in a negative light. However, some ads such as those from TobaccoFreeCA and TruthInitiative are not effective messaging, and almost amount to advertising for the vape industry. Effective messaging should talk about the health risks of vaping, including harming brain development, cardiovascular health, and addiction; not how popular vaping is in schools using weird puppet skits.
We need good messaging to win teens over because the vaping community has a lot of nonsense on the internet. For every action the FDA takes against the vaping epidemic, you can find a youtuber with at least one hundred thousand subscribers criticizing the FDA using the same nonsense arguments vape lobbyists use. Vaping is bad, kids. Anyone that says otherwise is wrong. The evidence shows that vaping won’t help smokers quit, but will help create new ones. Vaping might be healthier than smoking, but is nowhere near as healthy as not smoking or vaping. The vape industry is using the same slimy political tactics tobacco companies used in the past to promote their products to children and protect themselves from regulation. Hopefully we can get some progress on this issue so I won’t have to worry as much about someone assaulting my ears by vaping over Discord; that’s my last wish.

Vaping is Bad: Respiratory Illness, Banning Flavors, and Bad Behavior
Recent reports on the impact of vaping-associated respiratory illnesses are raising concerns about flavored e-cigarettes, and vaping in general. Adding to the problems are some rather draconian measures being implemented by some schools to “protect” students.
Braden MacBeth on September 27, 2019
Link


About six months ago I talked about the health risks of vaping, and the youth vaping epidemic in my post “Vape Nation: Vaping is Bad, Kids“.> Today I want to follow up by looking at the outbreak of vaping-related pulmonary illness, the flavored e-cigarette bans, and finally what I think is bad behavior on the part of public school administrators in response to the youth vaping epidemic.
Vaping related respiratory illness
Over the past month or so there has been an explosion of respiratory illnesses related to vaping. New cases are being reported so quickly I’ve had to change my numbers three times now and I’ve been working on this post for less than two weeks. Things really kicked off on August 16th when the CDC announced they were investigating a surge in unexplained respiratory illnesses with 94 cases in 14 states being reported. A week later public health officials announced that a patient in Illinois who was hospitalized for an unknown vaping related illness had died, and the number of cases had grown to 193 in 22 states. The week after that the number of reported cases nearly doubled to 354 cases. As of September 6th there have been over 450 cases reported to the CDC and 5 documented deaths. As of the 26th, here has been 805 cases in 48 states and 12 deaths.
So what’s going on? It’s difficult to say for certain, the investigation is still ongoing and the peer-reviewed case reports in medical journals and by state health officials don’t seem to be in complete agreement. According the New York State Department of Health, all of the 34 cases the Wadsworth center found that patients had used at least one cannabis containing product and each patient used at least one product containing Vitamin E acetate. Research published in the NEJM reported similar findings on September 6th, 83% of the 53 patients used THC-containing products. Unfortunately, it’s very hard to pin down any exact product because both reports state that patients used a variety of vaping products.
A common thread between the two reports is that both mention the brand ‘Dank Vape’ by name, and 60% of the 41 patients extensively interviewed used products with that name. There have been many people claiming that illegal or counterfeit THC-based e-liquids are to blame. I didn’t see any hard evidence for this at first but recently on the 13th there was an illegal vape cartridge operation that was busted by the cops in Wisconsin on Sunday. The searches uncovered 31,000 unfilled cartridges and 98,000 unfilled cartridges. The packaging is similar to the products public health officials in New York warned about. At this time there’s no confirmation from public health officials that this operation was responsible for the outbreak of the unknown vaping related illness, but it seems possible considering the first cases started popping up in Wisconsin and Illinois. That said, the best way to keep yourself safe from this illness is not to vape.
Banning flavors
On Wednesday September 4th, Michigan Governor Gretchen Whitmer ordered a ban on most flavored e-cigarettes. This ban should come into effect within the next for week and remain active for the next 6 months and she can reissue the ban for another 6 months. While the legislative branch could undo it, it’s probably not going to happen. As you can imagine, this was a pretty unpopular move at least in the eyes of online vaping communities and generated a fair amount of my favorite vape liquid: tears. The president of the American Vaping Association had this to say:
This shameless attempt at backdoor prohibition will close down several hundred Michigan small businesses and could send tens of thousands of ex-smokers back to deadly combustible cigarettes
Considering that 16% of high school students are using these products at least once a month, I would feel pretty shameless in my attempt to address that issue too. But will it cause thousands of ex-smokers back to regular cigarettes? I have my doubts. The ban does not apply to tobacco flavored e-cigarettes, which I assume would be acceptable to anyone who switched to e-cigarettes from tobacco cigarettes. Obviously this was a wildly unpopular move if the outrage on Twitter and Reddit is representative (it’s not), but one with legal precedent so it’s unlikely to be reversed. Will it actually combat the current trends in youth e-cigarette use? We can probably make a reasonable guess based on how the banning of flavored cigarettes affected youth smoking rates. In 2009 under the newly passed Family Smoking and Tobacco Control Act, the FDA banned cigarettes that contained flavors other than menthol and tobacco (obviously). In 2017 there was a study published in The American Journal of Preventative Medicine looking at the association between the 2009 ban and adolescent tobacco use. Banning flavored cigarette use resulted in a 17% decrease in youth cigarette smoking, in addition to a 54% decrease in the number of cigarettes smoked by youth smokers. However, it was found that youth switched to either menthol cigarettes or other flavored tobacco cigarettes such as cigars or pipes. Overall there was a 6% decrease in youth tobacco use.
It’s pretty common to hear public health officials say that companies are enticing kids with candy- and fruit- flavored nicotine products, but is there any evidence for it? In 2007, the World Health Organization put out a 117-page long report on the scientific basis of tobacco product regulation. I think their findings regarding flavored tobacco products on page 38 are pretty relevant:
     1.  The tobacco industry maintains that it supports youth smoking prevention and that it has put a stop to the targeting of young smokers. However, the evidence suggests that tobacco manufacturers continue to target young and inexperienced smokers with increasingly sophisticated products and marketing, in particular with flavoured tobacco products.
     2.  Youth targeting through marketing and product modifications influences youth smoking behaviour.
     3.  The use of new flavour technologies raises further questions regarding the practices of the tobacco industry, particularly given the current lack of regulation
According the research the WHO cites, 20% of young smokers report using flavored cigarettes, while only 6% of smokers over the age of 25 report using flavored cigarettes. The report also raises concerns about the safety of flavorings as many are largely unregulated, which very much applies to e-cigarettes today. The report concludes by recommending that tobacco manufacturers be required to disclose flavoring agents in tobacco products, disallowing manufacturers to imply flavored cigarettes have reduced health risks, barring tobacco manufacturers from introducing new flavored products, and that states should regulate flavoring agents. Ultimately, it’s clear that flavored nicotine products in e-cigarettes encourage kids to try e-cigarette products and experiment with different flavors while getting hooked on nicotine. Regulating flavored e-cigarette products would be a good way to tackle the youth vaping epidemic and on Wednesday, President Trump announced a plan to ban the sale of non-tobacco flavored e-cigarettes.
Bad behavior
The youth vaping epidemic has been the talk of the town in schools for a while now, and there are good and bad ways to respond to that. Unfortunately many schools have taken the wrong approach, and I think it’s important to talk about it. There have been many reports of schools, installing ‘vape’ sensors in bathrooms, removing bathroom stalls, and even implementing drug tests for students to test them for nicotine if they want to participate in extracurricular activities.
First things first, I’m skeptical that ‘vape sensors’ work very well, and I believe they would lead to many false positives. Using smoke detectors as a model, most e-cigarettes will not set off smoke detectors and the sensors would have to be highly sensitive. These devices presumably work by photoelectric and/or ionization sensors. Photoelectric sensors work by shooting a beam of light across the chamber, when smoke enters the chamber it causes the light to scatter and enter another chamber that triggers the alarm. Ionization sensors work by a thin layer of radioactive particles sitting between two electric plates that causes ions to flow between them. When smoke enters, it disrupts the flow of ions and the alarm triggers. As you can imagine, photoelectric sensors would be basically worthless because the vapor from e-cigarettes isn’t as thick and dissipates very quickly, so unless the student blows directly at the device, it probably won’t trigger. It’s unlikely that ionization sensors will detect a student vaping in a timely manner, or at all, because the chemicals from the vapor would have to reach the sensor in a concentration high enough to trip the alarm.
I’ve searched for a fair amount of time, and I’ve been unable to find any good discussions about how well they work. The best endorsement I could find was from a Chicago high school administrator saying “they were starting to work after a streak of false positives”, but he really didn’t confirm that they had successfully caught students vaping in the bathroom with them. One Palo Alto high school student reported that he was interrogated by school administrators after one of the devices randomly triggered. I was unable to find any information about the detection capability of the most popular device, the Fly Sense by Soter Technologies. Performing a simple test and writing a report would be a very easy thing to do. The company that makes it was founded in 2017, and the only coverage they’ve received is by outlets that do sponsored content frequently. The only demonstrations of their device I’ve seen have been people exhaling an e-cigarette directly at the device to trigger it. In my opinion these devices are likely ineffective, a waste of money, and an invasion of student privacy.
According to a survey conducted by TruthInitiative, 9% of school administrators said they had removed stall doors in the restroom. School administrators: could you from a purely PR perspective…not do that? Bathrooms are meant to be a private place to…you know…go to the bathroom. Nine percent of students report being bullied while in the restroom, a number I can only reasonably infer would increase when you remove any amount of privacy that students have while in the bathroom. It’s a well-established scientific fact that children ages 12-16 are actually the worst, please do not give them the opportunity to lower the bar. There is no evidence that removing the bathroom stall doors discourages students from vaping in the bathroom; why would it? Anyone can smell that someone is vaping in the bathroom.
Some schools have begun requiring students to submit to random drug tests if they want to partake in extracurricular activities. So any in addition to whatever schools are already spending, it’s going to cost more. Firstly, whenever you give someone a medical test there is always the possibility you will get a false-positive result. Secondly, have been studies showing that teens that participate in school sports are less likely to smoke or drink alcohol than kids who didn’t. While correlation doesn’t necessarily imply causation, I think we can imply causation fairly comfortably in this case. Do you know what kids aren’t doing when they’re participating in school clubs and playing sports? Drinking, vaping and trying drugs.
In a similar vein, some schools are punishing students caught vaping at school by suspending them. Using marijuana as a model, there have been studies showing that students suspended for violating drug policies at school were more likely to continue to use marijuana. In a study published in The American Journal of Public Health it was found that students who attended schools with suspension policies were 1.6 times more likely to use marijuana than schools that used different policies. So what’s the better way forward here? The study also showed that schools with counseling and abstinence-based policies were associated with lower marijuana use. It seems pretty reasonable that following the researchers’ recommendations of using abstinence messages, enforcing non-use policies, and adopting a remedial approach for policy violations rather than use of suspensions is the best way to tackle the vaping problem in schools.

Negative Health Effects of Vaping
Steven Novella on July 15, 2026
Link

When vaping was first introduced it was marketed mainly as a safer alternative to smoking and as a potential smoking cessation method. But increasingly people who have never smoked are vaping, and now the concern is that vaping is more of a pathway into smoking than one out of it.
According to the CDC, about 30% of all adults who vape have never used other tobacco products, but among young adults aged 18-24 the figure is 61.4%. Most vaping products contain nicotine, which is highly addictive, especially to the adolescent brain. Most users establish their habit in adolescence. The industry is now specifically targeting young users with flavored products and influencer campaigns.
Vaping is offered as a safer option compared to combustible tobacco, and it probably is safer than smoking, but that does not mean that it is safe. There are fewer carcinogens in vaping than in tobacco smoke, but there are some. There hasn’t been enough long term research yet to know the overall risk, so we cannot say definitively, but there is evidence of increased lung cancer risk and cancer markers in even young people who vape. Further, combining vaping and smoking has an increased cancer risk compared to smoking alone.
Smoking, however, has other health risks other than cancer, specifically cardiopulmonary risks. How do these compare? A 2020 narrative review concluded: “Overall, vaping has been found to cause similar effects as smoking on lung function and cardiovascular function.”
However, this is an area that requires more research, and there is a recent study to fill this gap. The study looks at 75 healthy young adults 18-30: 25 people smoked but never vaped, 25 people vaped but never smoked, and 25 who never smoked or vaped. The groups were otherwise similar in terms of lifestyle risk factors and overall health.
The subjects “underwent an incremental cycle exercise test with standard metabolic, cardiorespiratory, blood lactate and sensory measurements. Brachial artery flow-mediated dilatation (FMD) was assessed using Doppler ultrasound. Blood samples were collected to assess vascular inflammatory markers.”
And they found:
At peak exercise, both E-cigarette users and C-cigarette smokers had lower exercise capacity, oxygen uptake, and ventilation compared to controls…; all p<0.05). Furthermore, E-cigarette users and C-cigarette smokers demonstrated decreased exercise ventilatory efficiency, with higher ventilation, blood lactate, dyspnoea ratings, and leg discomfort during submaximal exercise compared to controls. E-cigarette users and C-cigarette smokers showed lower FMD compared to never-smokers (p<0.05), which was inversely associated with vascular cell adhesion molecule-1 and thrombospondin-2.
Basically, both smokers and vapers had about a 15% decreased exercise tolerance compared to non-users. They had decreased lung capacity and oxygen uptake, and increased blood lactate during exercise. Increased lactate is a sign that the muscles are not getting enough oxygen during exercise.
The vape that is inhaled is not just water vapor. Vapes heat a liquid into an aerosol that typically contains nicotine, propylene glycol, vegetable glycerin, and artificial flavorings. When heated, these chemicals break down into heavy metals, carcinogens, and volatile organic compounds. This causes inflammation, and even low levels of chronic inflammation can have negative effects.
The research to date, including this latest study, supports the conclusion that vaping is not safe. It has similar cardiopulmonary effects to smoking and less but still significant carcinogenic effects. Vape that contains nicotine is highly addictive, especially to adolescents. In fact, vaping fluid can have significant nicotine – one vape pen can have as much nicotine as 20 cigarettes.
The FDA now approves 45 vaping products. In May of this year they approved fruit-flavored products that are specifically attractive to young users. Such products are targeted at creating new young users who will become addicted long term.
We had made a lot of progress reducing smoking and the diseases that tobacco products cause. But now we are at risk of losing all those gains due to the rise of vaping, which is hooking new users and leading to multiple product use, including nicotine pouches.
Going forward, we need more comprehensive regulation before a new generation of users is hooked on these unhealthy products. The Lung Association has: “urged FDA to reconsider its decision to authorize kid-friendly e-cigarette flavors and not authorize any flavored tobacco products moving forward, including mint or menthol.” I agree with this. Kid-friendly products should be banned, as should all advertising aimed at youth, including influencer campaigns.  


Smoking: The Good News and the Bad News
Harriet Hall on March 12, 2013
Link
The principles we espouse on Science-Based Medicine are vitally important, but some of the subjects we address are not so important in the big scheme of things. Homeopathy and electrodermal diagnostic devices don’t actually harm very many people. For today’s post, I’m going to follow the Willie Sutton rule and go where the money is, so to speak.
Smoking is the leading preventable cause of death. No prospective double blind randomized controlled studies have been done, or ever could be done; but a mountain of evidence converging from many avenues has established the health dangers of smoking beyond any doubt. Hill’s criteria of causation have been amply fulfilled. Smoking causes 90% of all deaths from lung cancer and chronic obstructive pulmonary disease (COPD). It increases the risk of coronary heart disease, stroke, several types of cancer, infertility, stillbirth, sudden infant death syndrome (SIDS), osteoporosis, and premature skin aging (wrinkles). The dangers of second-hand smoke have been amply documented, and where smoke-free laws have been passed there has been a drop in the incidence of heart attacks and of emergency room visits for children with asthma.
Two new studies published in The New England Journal of Medicine reinforce what we already knew and offer both good news and bad news. 
Historical Notes
Back in 1604, King James I of England had a poor opinion of smoking. He said it was:
A custom loathsome to the eye, hateful to the nose, harmful to the brain, dangerous to the lungs, and in the black, stinking fume thereof, nearest resembling the horrible Stygian smoke of the pit that is bottomless.

He didn’t have any scientific evidence to go on, and neither did scientists until well into the 20th century. In the early 1900s, doctors promoted cigarette smoking. Ads featured doctor endorsements like “good for your health” and “more doctors smoke Camels.” Celebrities, Santa, even babies appeared in tobacco ads. The evidence of harm gradually accumulated, and the tide turned in 1964 with the Surgeon General’s report on smoking and health. Public attitudes changed, and the health hazards of smoking are now widely recognized, but the allure of cigarettes and the addictive properties of nicotine have kept the custom alive.
One New Study
A new study by Jha et al. found that smoking causes 25% of deaths among both men and women smokers between the ages of 35 and 69. Three times as many smokers die compared to nonsmokers. Smokers lose at least one decade of life expectancy. It’s hard to understand why anyone would knowingly begin using an addictive drug that would cut their life short by 10 years, but there’s something attractive about cigarettes that apparently overrides better judgment. Between 1965 and 2010 the prevalence of cigarette smoking in the US dropped from 42% to 19%, but it changed little from 2004 to 2010.
It’s a global problem. Most of the world’s smokers live in low- and middle-income countries. It is estimated that smoking will kill about 1 billion people in the course of the 21st century. That’s bad news.
The good news is that if smokers stop smoking before the age of 40, their risk of death will drop by 90% compared to those who continue to smoke. [Clarification: smokers’ life expectancy is 10 years less than that of non-smokers. If they stop smoking before the age of 40, their life expectancy will improve to only one year less than that of never-smokers.] It’s never too late to stop, but the benefits diminish with age. Smokers who stop at age 45-54 gain 6 years of life, and those who stop at age 55-64 gain 4 years of life.
Another New Study
A second study by Thun et al. looked at trends in smoking-related mortality over different time periods and found that:
The risk of death from cigarette smoking continues to increase among women and the increased risks are now nearly identical for men and women, as compared with persons who have never smoked. Among men, the risks associated with smoking have plateaued at the high levels seen in the 1980s, except for a continuing, unexplained increase in mortality from COPD.
For women, the relative and absolute risks of death from smoking have risen to parity with men for lung cancer, COPD, ischemic heart disease, and stroke. “You’ve come a long way, baby” but now maybe you will wish you hadn’t. As the authors point out, “women who smoke like men die like men.” And it appears that women have more difficulty quitting than men.
They corroborated the findings of the Jha study that smokers are 3 times as likely to die. [Clarification: over the 10 year period studied, all-cause mortality was at least three times as high among current smokers as among those who had never smoked.] More than two thirds of all deaths among current smokers in the older age groups are associated with smoking. The rate of COPD in nonsmokers has declined, but it continues to rise in smokers. The reason for that rise is not clear. They speculate that changes in cigarette design (less irritating tobacco blends, paper that dilutes the smoke, etc.) may have led to easier and deeper inhalation.
What Can Be Done?
Smoking is the leading preventable cause of death. What can we do about it? Prohibition wouldn’t work any better than it did for alcohol. But legislation to raise taxes on cigarettes, prohibit sales to minors, and restrict smoking in public places can have an impact. Warning labels on cigarette packages increase public awareness but don’t persuade many smokers to quit. Smoking cessation programs using nicotine replacement, drugs, hypnosis, incentives, and social interventions don’t have a very high long-term success rate. But there is hope: three-quarters of ex-smokers report having quit on their own without assistance of any kind.
Over 68% of smokers say they want to stop. . Advice from a health professional increases quit attempts and increases use of effective medications which can nearly double to triple rates of successful cessation. The US Preventive Services Task Force (USPSTF) recommends (Grade A recommendation) that clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products. But less than half of smokers who saw a health professional in the last year reported receiving advice to quit. That’s shameful. It means doctors were treating lesser problems while ignoring the greatest modifiable threat to their patients’ health. Surely we can do better.

Smoking Cessation
Smoking is the leading cause of preventable disease and death. There are effective pharmacological and non-pharmacological methods to help people stop smoking.
Harriet Hall on August 28, 2018
Link

Conventional medicine is often accused of ignoring prevention, just letting preventable diseases develop, and then only treating symptoms. And the Science-Based Medicine blog is often accused of ignoring the flaws of conventional medicine and addressing things in alternative medicine that are not very important in the overall scheme of things. So this week I will address something that is undeniably important: smoking, the leading cause of preventable disease and death in the United States. I will show that conventional medicine is working diligently to prevent harm from smoking, although success rates remain low.
I subscribe to the American Academy of Family Physicians’ continuing medical education program FP Essentials. Each month they publish a monograph on a topic important to family physicians; the January 2018 monograph was on lung cancer. They give prevention priority: the whole first section (a quarter of the monograph) is devoted to Smoking Cessation. They review the scientific evidence for drugs and other methods intended to help patients stop smoking.
Not just lung cancer
The lifetime risk of lung cancer for smokers is estimated to be as high as 32% but smoking also causes harm in a lot of other ways.
The CDC fact sheet on the health effects of cigarette smoking is daunting. Smoking is the cause of 90% of deaths from lung cancer, but that’s only a small part of the harm it does. The CDC reports that:
    • One in five deaths in the US are caused by smoking.
    • Smoking causes more deaths than AIDS, illegal drugs, alcohol, motor vehicle injuries, and firearm-related injuries combined.
    • More than 10 times as many U.S. citizens have died prematurely from cigarette smoking than have died in all the wars fought by the United States.
    • Smoking increases the risk of coronary heart disease by 2 to 4 times.
    • Smoking increases the risk of stroke by 2 to 4 times.
    • It increases absenteeism from work and health care utilization and cost.
    • It causes emphysema and bronchitis and exacerbates asthma.
    • Smokers are 12-13 times more likely to die of COPD.
    • It causes other cancers including bladder, blood, cervix, colon, esophagus, kidney, larynx, liver, oropharynx, pancreas, and stomach. If nobody smoked, one of every three cancer deaths in the US would not happen.
    • It increases the risk of stillbirth and preterm delivery, sudden infant death syndrome (SIDS), osteoporosis, diabetes, and many other health problems.
Smoking even endangers the health of nonsmokers. Since 1964, approximately 2,500,000 nonsmokers have died from health problems caused by exposure to secondhand smoke. And in 2014, smoking-related fires caused 570 deaths, 1,140 injuries, and $426 million in property damage.
Screening for tobacco use
As of 2015, 15% of US adults were current smokers. 68% of smokers want to quit, and 55% have tried to quit in the previous year. The U.S. Preventive Services Task Force (USPSTF) recommends that physicians ask patients about tobacco use at every visit, advise them to stop, and provide behavioral and pharmacological interventions to help them stop. It recommends the use of the “5 A’s” framework:
     1.  Ask every patient about tobacco use
     2.  Advise all users to quit
     3.  Assess willingness to quit
     4.  Assist with attempts to quit
     5.  Arrange follow-up
I don’t have any data on how many physicians are actually following these guidelines, but my impression is that most of them are. I have seen a lot of different doctors in various specialties in recent years, and at every appointment I was asked if I smoke (usually not by the doctor in person, but by a questionnaire or by auxiliary personnel), even though my medical record documents that I have never smoked.
Behavioral and other nonpharmacologic therapy
The AAFP lung cancer monograph lists these nonpharmacologic methods and assesses the published evidence for their effectiveness:
    • Acupuncture – no consistent evidence of effectiveness
    • Cellphone apps – no evidence available
    • Cellphone text message programs – cessation rate increased from 5.6% to 9.3%
    • Exercise – benefit found in some studies, not others
    • Financial incentives – increase cessation rates while in place
    • Hypnosis – insufficient evidence
    • Pamphlets – small increase in cessation rate
    • Quitlines – small increase in cessation rate
    • Group therapy – doubled cessation rate
    • Individual therapy – more effective than minimal behavioral intervention
Pharmacotherapy
Nicotine replacement (with gum, patches, lozenges, inhalers or nasal spray) has been shown to increase cessation rates by 50-70%. The number needed to treat (NNT) for one additional person to quit smoking is 15. Combining a constant delivery system (transdermal) with a faster-acting delivery method has been shown to be 50% more effective than either system alone. The gum is the least expensive, at $3 for 100 pieces.
Bupropion SR (Wellbutrin) is an antidepressant that is approved by the FDA as an adjunct for smoking cessation. There are generic versions available. The number needed to treat (NNT) for one additional person to quit smoking is 22. There are adverse effects like insomnia and dry mouth. A month’s supply costs around $20 with coupons.
Varenicline (Chantix) is a partial nicotinic acetylcholine receptor agonist that works by binding to nicotine receptors and displacing nicotine. It reduces cravings and nicotine withdrawal symptoms. It is more effective than bupropion: the NNT is 11. Combining it with nicotine replacement is not more effective than using it alone. Side effects that have been reported include nausea and nightmares. A 30-day supply costs around $287. It is approved by the FDA for 12 weeks of treatment, and if treatment is successful, it can be used for another 12 weeks.
E-cigarettes or electronic nicotine delivery systems have been used by smokers to help them stop smoking by replacing cigarettes. They have nicotine, but they don’t have all the other harmful ingredients in tobacco. There is weak evidence of their effectiveness for smoking cessation, but the long-term safety has not been established, and the AAFP feels there is not enough evidence to recommend their use. There is concern that these devices may be creating nicotine addiction in adolescents.
Anti-tobacco policies
Governments and institutions have tried to reduce smoking through taxes, advertising bans, graphic warnings, mass media campaigns, and banning smoking in workplaces and public locations. There is weak evidence to support institutional bans, and strong evidence that legislative bans reduce harms from second-hand smoke. It has been estimated that if the legal age were raised to 21, it would prevent 50,000 deaths. The Surgeon General estimates that every 10% increase in the cost of a pack of cigarettes reduces consumption by 3-5% in adolescents and young adults.
These policies have been effective. 42% of Americans smoked in 1965. Today it is down to 15%.
Conclusion: Good news and bad
The bottom line: Every doctor (with the possible exception of some sociopaths) would rather help patients stop smoking than care for them throughout a long illness and death from lung cancer or other smoking-related condition. Mainstream medicine cares deeply about prevention and is doing its best to prevent the harmful health consequences of smoking. Doctors can screen for smoking, advise against smoking, and offer effective aids to smoking cessation, but they can only do so much. The individual smoker is ultimately responsible for his or her own behavior.
The bad news is that outside of a smoking cessation program, 95% of attempts to quit smoking fail. There may be many attempts and relapses before final success. The good news is that there are more ex-smokers than smokers.
According to the World Health Organization, “Tobacco is the only legal drug that kills many of its users when used exactly as intended by manufacturers.” Think about it.

Smoking Cessation and the Affordable Care Act
Harriet Hall on January 13, 2015
Link

Smoking is the leading preventable cause of death. Each year it kills more than 5 million people around the world, 480,000 in the US alone. And for every person who dies, about 30 more have serious illnesses caused by smoking. On average, smokers die 10 years earlier than nonsmokers. Anyone who is concerned about preventive medicine must consider smoking cessation a priority. Fortunately, the Affordable Care Act (ACA) has taken a step in the right direction.
The ACA’s provisions
The Affordable Care Act requires health plans and health insurance to cover tobacco-use counseling and interventions without cost sharing or prior authorization. It requires screening of all patients for tobacco use and covering at least two attempts to quit each year. For each quit attempt, it authorizes four tobacco-cessation counseling sessions, each at least ten minutes long (including telephone, group, and individual counseling) and any FDA-approved tobacco-cessation medications (whether prescription or over-the-counter) for a 90-day treatment regimen when prescribed by a health care provider. In a separate provision, it requires that states not exclude FDA-approved cessation medications from existing Medicaid programs. These provisions should encourage providers and patients to increase their smoking cessation efforts.
It also allows some insurers to charge smokers premiums that are up to 50% higher than premiums for nonsmokers. That could be a double-edged sword: it could either encourage people to stop smoking to save money, or it could encourage them to lie about their tobacco use.
The harms of smoking
Tobacco was first used by shamans in the Americas to induce trances and later for ceremonial uses like the proverbial peace pipe. It developed a bad reputation as soon as it was introduced to Europe. King James I of England, who was born a scant 74 years after Columbus’ first voyage, wrote a treatise against it, saying that smoking was:
A custom loathsome to the eye, hateful to the nose, harmful to the brain, dangerous to the lungs, and in the black, stinking fume thereof, nearest resembling the horrible Stygian smoke of the pit that is bottomless.
The fact that tobacco is hazardous to health should not be news to anyone. But smokers might be surprised to learn just how long the list of hazards is. Smoking harms nearly every organ in the body. It is estimated to cause 87% of lung cancer deaths, 32% of coronary heart disease deaths, 79% of chronic obstructive pulmonary disease (COPD), and ⅓ of all cancer deaths, including cancers of the bladder, blood, cervix, colon, rectum, esophagus, kidney, ureter, larynx, liver, mouth, throat, pancreas, stomach, trachea and bronchus. Smokers have an increased risk of diabetes, rheumatoid arthritis, tuberculosis, peripheral vascular disease, cleft lip and palate, infertility, low sperm count, premature birth, ectopic pregnancy, low birth weight, miscarriage, macular degeneration, cataracts, sudden infant death syndrome (SIDS), osteoporosis, and rheumatoid arthritis. Smoking causes diminished overall health, increased susceptibility to infections, increased self-reported poor health, increased absenteeism, and increased health care utilization and cost.
A while ago there was a picture in the news of a woman who was complaining about air pollution from traffic as she smoked a cigarette. Anyone who is concerned about environmental toxins should be particularly concerned about tobacco smoke. Do all those advocates of “detox” realize that there are over 70 known carcinogens in tobacco smoke and that their detox regimens do nothing to reduce their risk? Do those who fear radiation from nuclear power and radon realize that smoking exposes the lungs directly to radioactive Polonium 210, which is 250,000 times more toxic than hydrogen cyanide? Second-hand smoke kills innocent bystanders and puts some of those it doesn’t kill in the hospital; for example, it is responsible for an estimated 7,500 to 15,000 hospitalizations for respiratory diseases every year for children under the age of 18 months.
Smoking has benefits, too
There are exceptions to everything. We are fond of pointing out that drugs that have effects are likely to have side effects too; conversely, things that are toxic are also likely to benefit some physiologic process in a human system that is so bewilderingly complex. There are reports that smoking benefits a few conditions to a small degree, including gum disease, Parkinson’s, Alzheimer’s, ulcerative colitis, and several others. This pro-smoking webpage claims that no studies have shown an increased risk of Alzheimer’s in smokers. That’s wrong: smoking is a recognized risk factor for Alzheimer’s and it was trivially easy to find a systematic review in PubMed that shows it increases risk.
The pro-smoking organization says:
The benefits of smoking tobacco have been common knowledge for centuries. From sharpening mental acuity to maintaining optimal weight, the relatively small risks of smoking have always been outweighed by the substantial improvement to mental and physical health.
In my opinion, and in the consensus of mainstream scientists, they got that exactly backwards. Any benefits pale in comparison to the documented harms.
Smoking cessation interventions
It’s hard to compare the success rate of different interventions in different studies because of different definitions of what constitutes success. Remember what Mark Twain said:
Giving up smoking is the easiest thing in the world. I know because I’ve done it thousands of times.
Whether they found it easy or difficult, lots of people have succeeded in stopping, either on their own or with assistance. Former smokers now outnumber current smokers. Behavioral support and medication can approximately quadruple the chances that a quit attempt will be successful.
A 2008 systematic review of reviews found evidence for the effectiveness of these approaches:
    • Group therapy (odds ratio 2.17)
    • Bupropion (OR 2.06)
    • Intensive physician advice (OR 2.04)
    • Nicotine replacement therapy (OR 1.77)
    • Individual counseling (OR 1.56)
    • Telephone counseling (OR1.56)
    • Nursing interventions (OR 1.47)
    • Tailored self-help interventions (OR 1.42)
These findings are robust: the confidence intervals ranged from a low of 1.26 to a high of 3.45. They found that an increase in price increased cessation rates by 3-5%, and comprehensive clean indoor laws increased quit rates by 12-38%. They did not include data on varenicline, which had just recently come on the market.
The FDA has approved five nicotine replacement products and two prescription drugs (bupropion and varenicline) and has approved the combination use of nicotine patches and bupropion. Varenicline appears to be more successful than bupropion, but not more successful than nicotine replacement. Both drugs have troublesome side effects, including reports of suicide with varenicline. They are expensive and are meant for short-term use only.
It’s hard to know just how effective these drugs are; results vary considerably from study to study. In one study where subjects were treated for 24 weeks, the abstinence rate at 24 weeks was 70.5% for varenicline, but it was 50% for placebo. In other words, it was about half again as effective as a sugar pill. And the abstinence rate after one year was 44% for varenicline versus 37% for placebo. Varenicline is only FDA-approved for up to 12 weeks. In another study where subjects were treated for just 12 weeks, the abstinence rate at one year was 23% for varenicline and 10% for placebo. Reports of placebo group responses of 10% and 50% are worrisome; the response of placebo groups in clinical studies is typically around 1/3. Markedly higher or lower percentages suggest something else may be going on, like one or more unrecognized confounding factors that may have influenced results.
A number of other prescription drugs have been tried off-label, with varying results. Alternative treatments have not been proven effective. Cochrane reviews of acupuncture and hypnosis were not favorable. Acupuncture:
Although pooled estimates suggest possible short-term effects there is no consistent, bias-free evidence that acupuncture, acupressure, or laser therapy have a sustained benefit on smoking cessation for six months or more.
Hypnotherapy:
We have not shown that hypnotherapy has a greater effect on six-month quit rates than other interventions or no treatment. There is not enough evidence to show whether hypnotherapy could be as effective as counseling treatment. The effects of hypnotherapy on smoking cessation claimed by uncontrolled studies were not confirmed by analysis of randomized controlled trials.
“Doctors don’t do prevention” is a lie
This is a common complaint we hear from alternative medicine advocates, especially from naturopaths. It is so wrong it hardly deserves an answer. Doctors are the ones who invented prevention, who have always known it’s better to prevent disease than to treat it, who actually have evidence-based ways to prevent disease.
Some chiropractors claim they can prevent disease by keeping the spine in alignment with maintenance adjustments; some acupuncturists claim they can prevent disease by eliminating blockages in the flow of qi; some naturopaths claim they know more than doctors about what causes disease and how to prevent it. But there’s not a shred of evidence that any of these claims are true. In fact, there is evidence that alternative providers are worse at prevention: their patients are less likely to be vaccinated than patients of MDs.
It’s instructive to google “naturopathy” and “smoking cessation” and see what the naturopaths are up to. They do a lot of the same things doctors do: counseling, behavioral modification, identifying triggers and ways to avoid temptation. But instead of evidence-based treatments, they rely on things like homeopathy (the homeopathic remedy Tabacum is said to be very effective), traditional acupuncture, ear acupuncture, laser stimulation of acupoints, herbal remedies (including lobelia, hyssop, ginseng, valerian, skullcap, and lung yin tonic to prevent dryness), diet advice, detoxification, guided imagery, drinking large amounts of filtered water with lemon, etc. I could not find any evidence that naturopaths are any more effective than other health care providers in helping smokers stop smoking, or in keeping people from starting to smoke in the first place. They pride themselves on their imagined expertise at prevention, but they haven’t even been able to demonstrate that their methods are effective against the major preventable cause of disease.
You might blame doctors for not doing enough to discourage smoking, but you can’t deny that doctors are trying. Every time I go to an appointment I am asked if I smoke, even though my medical record documents that I have never smoked. Instead of criticizing doctors, perhaps it would make more sense to criticize the patients who don’t follow their doctors’ advice. Thanks to the ACA, it should be easier for patients to follow that advice.
Conclusion
We can anticipate that the provisions of the ACA will have an impact on smoking cessation rates. The size of that impact remains to be seen. I am cautiously optimistic. The effort is certainly worthwhile. If we had to choose a single preventive intervention to improve the health of an individual patient or of society as a whole, there could be no better choice than smoking cessation.

Anti-Smoking Laws – The Proof of the Pudding
Steven Novella on March 7, 2012
Link
One consistent theme of SBM is that the application of science to medicine is not easy. We are often dealing with a complex set of conflicting information about a complex system that is difficult to predict. That is precisely why we need to take a thorough and rigorous approach to information in order to make reliable decisions.
The same is true when applied to an individual patient. Often times we cannot make a single confident diagnosis based upon objective information. We have to be content with a diagnosis that is based partly on probability or on ruling out other possibilities. Sometimes we rely upon a so-called “therapeutic trial” to help confirm a diagnosis. If, for example, it is my clinical impression that a patient is probably having seizures, but I have no objective information to verify that (EEG and MRI scans are normal, which is often the case) I can help confirm the diagnosis by giving the patient an anti-seizure medication to see if that makes the episodes stop, or at least become less frequent. Placebo effects make therapeutic trials problematic, but if you have an objective outcome measure and a fairly dramatic response to treatment, that at least raises your confidence in the diagnosis.
We can apply the same basic principle on the population level. If a public health intervention is addressing the actual cause of one or more diseases, then we should see some objective markers of disease frequency or severity decrease over time. Putting fluoride in the public water supply decreased the incidence of tooth decay. Adding iodine to salt decreased the incidence of goiter. Fortifying milk with vitamin D decreased the incidence of rickets. However, removing thimerosal from the childhood vaccine schedule did not reduce the incidence of autism (or the rate of increase in autism diagnosis). That is because calcium deficiency causes rickets, but thimerosal (or the mercury it contains) does not cause autism.
In public health there is also the equivalent of placebo effects – confounding factors in epidemiological studies. So studies need to be interpreted with caution. But if we see a consistent signal – a consistent association between a treatment and a decrease in disease incidence or severity, then our conclusion becomes more and more confident.
We are beginning to see this consistent signal with anti-smoking laws and a decrease in diseases that previous evidence suggests is increased by smoking or exposure to second-hand smoke. A recent study published in PLOS Medicine looked at the incidence of preterm birth and low birth weight in Scotland following legislation that came into effect on March 26, 2006 banning smoking in public places. Prior to the legislation preterm and low birth weight were trending up. The study found a statistically significant drop of about 10% beginning January 1, 2006, with a slight reversal two years later. They interpret these results as an anticipatory effect – smokers trying to quit in anticipation of the legislation, with some smokers failing and going back to smoking over the next two years. This conclusion is supported by the spike in nicotine patch prescriptions in January of 2006.
Further, the reduction in preterm birth and low birth weight was found among current smokers as well as never smokers. The decrease among never smokers suggests a second-hand smoke effect.
Epidemiological studies are always difficult to interpret, as I stated above, and this study is no exception. The strength of this study is that it was very thorough, looking at all pregnancies in Scotland over the study period. But there are many confounding factors, one of which pointed out by the researchers is the fact that smoking status was self-reported, and the introduction of legislation may have affected willingness to self-report smoking. Since all pregnancies were looked at, however, this would not have affected the overall decrease in these outcomes reported.
The significance of this one study is enhanced by the fact that it is part of a trend in studies showing a decrease in diseases that prior evidence suggests are worsened by smoking, following smoking bans. A study of acute myocardial infarction (AMI) in Massachusetts found a decrease of 7.4% following a statewide ban on smoking in public places. It is also significant that the decrease occurred in towns that did not have a prior local smoking ban, but not in towns that did. The effect was therefore also likely attenuated by the prior existence of local smoking bans.
A 2009 review and meta-analysis concluded:
Using 11 reports from 10 study locations, AMI risk decreased by 17% overall (IRR: 0.83, 95% CI: 0.75 to 0.92), with the greatest effect among younger individuals and nonsmokers. The IRR incrementally decreased 26% for each year of observation after ban implementation.
Using the same Scotland cohort following the 2006 ban, a study has also found a decrease in hospital admissions for asthma:
After implementation of the legislation, there was a mean reduction in the rate of admissions of 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7 to 21.8; P<0.001). The reduction was apparent among both preschool and school-age children.
Overall the data show that smoking bans reduce second hand smoke exposure, smoking, and adverse health outcomes associated with smoking. There is a fair degree of consistency in the data, and this consistency is growing as more studies are being published. We have appeared to cross the fuzzy threshold where we can conclude with a fair degree of confidence that banning smoking in public places works. In the interest of public health, reducing health care costs, and child safety, the totality of evidence strongly suggests that we should strengthen bans on smoking in public places and apply them universally.
Meanwhile, concerns that such bans would economically harm bar and restaurant owners have not been born out in the evidence. A Minnesota study, for example, found a slight increase in revenue following smoking ban laws. It seems more people are willing to go to bars if the experience does not necessarily involve being exposed to intense levels of second-hand smoke.
Smoking ban laws have passed the test of the “therapeutic trial”. Combined with the totality of evidence for the risks of smoking and second-hand smoke, this strongly supports such bans as effective public health measures.

The 4-Day Work Week and Health
There may be a strong public health argument to make for the 4-day work week.
Steven Novella on February 22, 2023
Link

There has been increasing interest recently in rethinking the standard 5-day work week. Specifically, would moving to a 4-day work week model be better overall, and what would the trade-offs be? A recent UK study adds to the research with a large study involving 61 companies in various industries, around 2,900 workers, over a six-month period. The results are very encouraging.
This kind of research is obviously difficult. It cannot be blinded, for example. Also, many of the personal outcomes measures are self-reported – subjects might have a motivation to present the 4-day work week in a positive light. There may also be an observer effect, where any change, no matter what it is and in which direction, might be followed by a positive self-report or even productivity.
With that in mind, the results of the study are still informative. They found:
The trial was a resounding success. Of the 61 companies that participated, 56 are continuing with the fourday week (92%), with 18 confirming the policy is a permanent change. Some of the most extensive benefits of shorter working hours were found in employees’ well-being. ‘Before and after’ data shows that 39% of employees were less stressed, and 71% had reduced levels of burnout at the end of the trial. Likewise, levels of anxiety, fatigue and sleep issues decreased, while mental and physical health both improved.
The most objective outcome was that revenue for the companies did not go down. In fact, in went up on average by 1.4%, with higher growth than the same period in the previous year. It’s also important to note that companies were able to choose their own method of reducing work hours – closing down on Friday, staggering days off, shifting hours seasonally, and even making the shorter schedule contingent on maintaining productivity. This result is consistent with previous research, which generally shows no decrease in productivity and significant increase in employee satisfaction.
While more and longer research is still necessary, so far it seems that going from basically a 5-day work week to a 4-day work week does not create any significant decrease in overall productivity. Mostly people compensate by working more efficiently – having shorter and more focused meetings, wasting less time, and finding productivity aids. They also took fewer sick days. But recently there has been a move to frame the question in terms of public health. The results of this study support that framing, but let’s take a close look.
The big effect is that many employees, as noted above, report less stress. Stress is a tricky outcome to deal with because it is so subjective, but is also plausibly results in physiological stress and worse sleep, which have objective physical outcomes. In the current study they found:
We found improvements in fatigue, with the average fatigue score falling from 2.56 to 2.12 (on a scale of 1-4, from never to daily), and 46% of employees reported a reduction in fatigue (with only 14% reporting an increase). The prevalence of insomnia and general sleep problems declined significantly. 40% saw a reduction in sleep difficulties, whilst 45% saw no change and only 15% saw increases.
Improvements in sleep is an objective outcome with broad health implications. It’s easy to see how this might be the case. Just having one more day a week to potentially sleep in can have large sleep benefits. But also, as the study found, increases in leisure and family time, the ability to do “self-admin” tasks during the week (which frees up weekends more) can reduce overall stress and allow more time for sleep. Many of the subjects reported that the reduced schedule gave them more time to “turn off” when they were at home, which also improved their sleep quality.
So far what we can say from the research is that there are two fairly consistent and strong signals in the data – productivity is not generally reduced by going to a 4-day work week model, and employee mental and physical well-being is enhanced. Again, this needs confirming research, but at least we can be fairly certain that the reduction will not be significantly harmful to companies, and may have significant benefits. This is enough to justify more broad adoption while progressing to the next stage of research (like going from a phase 2 to a phase 3 clinical trial).
There are other potential benefits as well, justifying further adoption and research. Fewer days of commuting means less time in cars and in traffic. This can save money and reduce CO2 emissions, while reducing overall traffic and further reducing stress. Many of the subjects report they will use their extra time to shop, which is positive for the economy. More satisfied employees also translated to less turnover. Reduced need for child care is also a potential money-saver.
We should note that the 5-day work week was not chosen based on any evidence. The 40 hour work week was mandated by regulation (although work hours have been increasing due to gig work, contract work, and other ways of getting around the regulations). There is likely some optimal balance between hours of work and increased productivity per unit of time. What the research is showing is that the 4-day work week may be closer to optimal than the 5-day work week. There is no reason, other than history, to consider the 5-day work week the default, and no scientific reason why the burden of evidence is entirely on the 4-day week. If we simply compare the two, the 4-day week seems to be superior.
But also, this study further showed that flexibility is likely to be very important, and perhaps just as important as the total number of hours. Different industries have different needs, as do different employees. There appears to be a significant potential for gain by reducing the total number of work hours within a framework of flexibility and enhanced efficiency.

Delaying School Start Times for Sleep Deprived Teens
Clay Jones on October 10, 2014
Link
In August of this year, a new policy statement from the American Academy of Pediatrics was published which tackled the widespread problem of insufficient sleep in our adolescent population. They even went so far as to label insufficient sleep as “one of the most common, important, and potentially remediable health risks in children.” The statement, which gave a number of recommendations on how to address the problem, made the news rounds primarily because of the call for schools to delay start times until at least 8:30 AM.
I wrote about pediatric sleep in March for a post on the potential link between some sleep disorders in children, specifically nightmares and night terrors, and the development of psychosis. Those claims are suspect but please read that post for a review of what sleep is, why we need it, and what can go wrong with it in children of all ages. For this post, my focus will be on adolescent sleep specifically, and on the role of delaying school start times in improving a variety of health parameters.
What are the common adolescent sleep challenges?
The typical modern teenager faces a variety of challenges to consistently obtaining a full night’s sleep, which is considered by most sleep experts to be in the 8.5 to 9.5 hours per night range. This doesn’t mean that every teenager will fall apart if they only get 7 hours of sleep each night, but sub-optimal sleep can adversely affect school performance in many, and even lead to long-term health problems in some children who establish such a pattern during these pivotal years. Hold that thought for now, however.
One obvious reason for insufficient sleep in teenagers, at least it is likely obvious if you have one of your own or have ever spent more than two minutes near one, is technology. Most older children have electronic media in their rooms, if not attached to their bodies in the form of a smart phone. 24-7 access to the internet and social media is a commonly-cited impediment to sleep onset. The increasing availability and popularity of energy drinks containing absurd amounts of caffeine among adolescents likely also plays a role as both a coping strategy for daytime fatigue resulting from insufficient sleep, and as a cause of it. In fact, I think I’ve just come up with the topic for my next post.
In addition to poor sleep hygiene and the intake of stimulants, the final impediment to a full night’s sleep addressed in the AAP statement is much more insidious. From a biological perspective, among the many changes that a child undergoes with the onset of puberty is an alteration of the internal circadian rhythm and sleep drive. Most adolescents gradually shift towards favoring staying up later and subsequently sleeping later. Even without the influence of social media and caffeine, teens often have difficulty falling asleep before 11 PM and waking before 8 AM. With chronic insufficient sleep, a teen may not feel truly alert until after 10 AM. Again, there is variability between individuals but this affects the vast majority of even healthy teenagers.
It is the combination of multiple factors, such as those discussed above, but also including the need to wake up earlier on weekdays for school, that leads to a buildup of daytime fatigue. Many teenagers will thus sleep later on the weekends or holidays. While this is a manifestation of their underlying biological sleep preference, it is also driven by sleep pressure accumulated during the week. Attempting to catch up on the weekends doesn’t actually solve the problem and may make it harder for teens to adjust sleep cycles over the long haul.
Again, this problem exists in almost all healthy teenagers. But many medical conditions, and the treatments for them, also negatively impact sleep. Poorly-controlled asthma is probably the most well-known sleep-disrupting diagnosis because symptoms like cough and wheeze are often worse at night and can occur frequently. Some children with asthma present with persistent nighttime cough and interrupted sleep as their primary complaint. The effect on parental sleep and well-being is also well known. Anxiety and stress related conditions are also common in the adolescent population, and these can both cause and be exacerbated by poor sleep. Not surprisingly, the socioeconomic milieu in which children find themselves in impacts the quality of their sleep as well, with kids in low-income families having the toughest time.
How common is insufficient sleep in adolescents?
According to the technical report that accompanied the AAP policy statement, the concern that teenagers are not getting enough sleep is based on solid epidemiological data, and is likely even underestimated because self-reporting tends to overestimate actual hours slept. With that in mind, the National Sleep Foundation Sleep in America Poll revealed that 3 out of 4 kids average less than 8 hours of sleep each night by senior year. This poll, and other studies presented in the report, uncovered the fact that most teens feel tired at school with many reporting episodes of falling asleep in class. Furthermore, most teens feel the need to compensate with stimulants and extra weekend sleep. Unfortunately, also per a number of surveys, parents are largely unaware of these issues and believe that their teenage children are getting the recommended amount of sleep.
How does insufficient sleep harm adolescents?
The list of potential harms from insufficient sleep in the adolescent population is large and varied, and includes both immediate and long term effects. The AAP report highlights three categories of negative effects: Physical health and safety, Mental health and behavior, and School performance. I’ll highlight some of the major potential consequences in each.
Obesity and long term cardiovascular events like heart attacks and stroke have been linked to insufficient sleep starting in the teenage years. More acute is the major issue of “drowsy driving” and the risk of motor vehicle accidents, with 50,000 fatigue-related accidents occurring each year involving a driver under the age of 25. Increased consumption of caffeine, and potential associated toxicity, is clearly linked to poor sleep, but use of prescription stimulants that have been diverted from their intended indications is also a concern, although evidence is lacking at this time.
Teenagers with chronic inadequate sleep are more likely to have anxiety conditions and depression. They are also at risk for difficulties with impulse control and self-regulation, increasing risk-taking behaviors. Poor sleep can also interfere with the ability to process stress, which can exacerbate the likelihood of illness and maladaptive coping strategies. And not surprisingly, adequate sleep plays an important role in cognitive function, memory and attention. Poor sleep thus can interfere with academic success, increase missed days of school and lead to higher rates of dropping out.
What can we do about insufficient sleep in adolescents?
The AAP’s big push is for schools across the country to delay start times to at least 8:30 AM. This isn’t a new concept, with some experts and parent groups calling for a return to later start times since the early 1990’s, but it still represents an important advance in advocating for adolescent health. The report provides compelling evidence of benefit, evidence that is available because over 200 school districts have already made such a change in the United States and later start times are more common in other countries. This study even looked at the opposite, following 40 students who were forced to transition to starting school an hour earlier.
The available research is more than adequate to answer some of the questions that have historically been raised. At the onset of the “Start School Later movement“, evidence was lacking regarding school performance benefits. It’s quite clear now, however, that students benefit across the board. Rather than simply staying up later in response, significant numbers of kids will increase their average sleep into the recommended range. Other outcomes that have now been shown to improve in multiple studies include decreased self-reports of fatigue and improved academic performance such as improved grades and higher reading and math scores.
When 18,000 high school students in Minneapolis had their start time shifted over an hour later, they got more sleep, called in sick less often and had fewer dropouts. We also have data showing improvements in mood and motivation, and even a decrease in car accidents. If only looking at the evidence of benefit, it truly appears to be a no-brainer.
But things are rarely so simple. The current most common school start times, usually somewhere in the 7 o’clock hour, may have only been in vogue for a few decades, but they are well established at this point. And although many school districts have successfully made a change, the logistics to consider are considerable. Historically, calls for making school start times more physiologically appropriate have fallen on deaf ears, primarily because of concerns regarding expense, transportation and loss of time after school for athletic and club activities, student jobs and homework. Some parents also depend on older children to watch younger siblings in the afternoons, which would be difficult if school ends later in the day.
Unfortunately there aren’t any studies investigating these concerns in districts that have shifted start times. So I am personally a bit hesitant to come down too hard on the districts that are dragging their feet. This change may be more or less reasonable depending on the community, but I do feel strongly that this should be taken seriously and the feasibility looked into. The AAP statement points out that many communities have come up with creative solutions these concerns, and that there is at least anecdotal evidence that many of the fears haven’t materialized.
Conclusion
Sleep is an important concept across the spectrum of age, and insufficient amounts can have a variety of negative health effects. This is perhaps even more critical a concern in the adolescent population. A growing body of evidence continues to reveal the damage that poor sleep can cause in teenagers, just how common the problem is and the unfortunate lack of awareness among parents and caregivers. And patterns of behavior learned during this pivotal period of development may be setting teens up to have health problems years down the road.
There are many ways to chip away at the problem of inadequate sleep, such as setting reasonable limits on the use of technology and educating teenagers on other ways to improve sleep hygiene, such as avoiding excessive intake of energy drinks and other highly caffeinated beverages. There is also a substantial literature in support of pushing the start of school days back in order to allow for extra sleep on weekdays. This change may come with some challenges, but it is almost certainly worth a potentially-difficult transitional period.

Sleep Duration and Health
Poor sleep is a genuine concern, but the results of a new cohort study are complex to interpret.
Steven Novella on October 19, 2022
Link

Good sleep is important for health and optimal function. That much is pretty clear from the totality of sleep research. Lack of sleep also exacerbates many chronic conditions, can be a trigger for things like migraines and seizures, and correlates with poor cognitive function and memory. Having good sleep habits, and good overall sleep is therefore an important lifestyle factor for health and function.
A new study adds to this data by showing a correlation between decreased sleep duration and chronic illness in older adults (>50), but the data is complex. Most mainstream outlets oversimplified the outcome of the study in a way similar to this BBC headline: “Five hours’ sleep is tipping point for bad health“. This is ultimately a misunderstanding of how statistical significance works, but let’s review the study itself: “Association of sleep duration at age 50, 60, and 70 years with risk of multimorbidity in the UK: 25-year follow-up of the Whitehall II cohort study“.
The Whitehall II cohort study follows a group of UK civil servants starting in 1985. The strength of this data set is the long duration, several decades, and size (it started with 10,308 individuals). These are large numbers for a study, but not really for an observational study such as this. Experimental studies where some variables are determined typically involve 50-100 individuals at the low end, with larger studies in the hundreds and rare very large studies in the thousands. Observational studies come in various types but they look at people in the world without determining specific variables. Observational studies can have tens of thousands to millions of individual subjects, depending on their methods, and can also follow subjects for long periods of time.
It is generally difficult to make causal conclusion from observational studies, which can only determine correlations by themselves. We can say, for example, that some potential risk correlates with a negative outcome based on observational data, but we cannot say it causes it because subjects were not randomly selected to be exposed or not to the risk. There are therefore multiple confounding factors and possible causal relationships.
So while this is a decent-sized cohort study, it is not a particularly large one, and since it is observational we have to be on the look out for possible confounding factors. Let’s look at what they found:
Compared to 7-hour sleep, sleeping ≤5 hours at age 50 was associated with an increased risk of a first chronic disease (1.20, 1.06 to 1.35; p = 0.003) and, among those who developed a first disease, with subsequent multimorbidity (1.21, 1.03 to 1.42; p = 0.02). Sleep duration ≥9 hours was not associated with these transitions. No association was found between sleep duration and mortality among those with existing chronic diseases.
Multimorbidity simply means two or more diseases out of the 13 chronic illnesses they tracked. Therefore, sleeping less than 5 hours a night had an increased risk of developing chronic illness but not of dying when compared to those who sleep 7 hours a night. This does not mean that 5 hours is a “tipping point,” it just means that the results did not become statistically significant until this point. It is possible, even probable, that the risk of association is continuous. That is how the researcher plotted their data, although they did not have very much resolution as they broke down sleep duration into one hour increments.
You may also wonder why <5 hours is compared to 7 hours. That’s because 7-hour sleep duration had the lowest morbidity association. The relative risk curves are actually U-shaped, with increasing risk for 8 hour and >9 hour sleep durations (although did not reach statistical significance primarily because of the small numbers of subjects in the >9 hour category). The U-shaped risk curve is interesting, and may suggest a strong possibility that at least some of this risk association has a reverse causality – chronic illness causes poor sleep, rather than the other way around. This cannot be excluded by this study.
In fact clinicians often think of poor sleep as “comorbid” with specific chronic illnesses – they likely worsen each other, and it is difficult to tease out the specific cause and effect. For example, poor sleep can exacerbate weight gain, and being overweight can worse sleep quality.
Another issue is that the sleep duration was mostly self-reported, with some data from subjects wearing sleep trackers. Sleep duration is not the only measure of overall sleep benefit. It’s possible that some of the long sleepers are staying in bed for 9 or more hours because their sleep quality is very low.
What about the fact that in this study (because of how it was conducted) short sleep duration preceded the development of chronic illnesses? This does not preclude confounding factors. Poor sleep can be an early symptom of a chronic illness. This is true for some neurological diseases, like dementia and Parkinson’s disease, for example. Also, other factors may cause poor sleep and chronic disease, such as being overweight, lack of physical activity during the day, or chronic conditions not on the list followed by this study.
There are a few take-aways from this study and other sleep research. First, given the totality of data it is reasonable to conclude that poor sleep is a risk factor for many chronic illnesses, exacerbates many symptoms and can impair function. None of my criticisms of this study or its reporting change that. For any individual, optimizing their sleep quality is likely to have health benefits.
For many of these lifestyle risk factors that are difficult-to-impossible to control for in an experimental setting, and therefore we have to do our best with observational data, we tend to take a practical approach. This gets back to the “comorbid” approach – I cannot necessarily tease apart the exact lines of cause and effect, so essentially we treat everything in hopes of reducing the complex of comorbidities – optimize sleep and lose weight and treat the depression, for example.
Also, if your sleep duration or quality is poor, or you do not feel rested in the morning, see your physician. This can be a primary sleep disorder, a risk factor, or it can be a symptom of an existing chronic illness. Either way, poor sleep is just as important to discuss with your health care provider as other chronic symptoms.
Further – observational data is complex, with many possible arrows of causation and confounding factors. Be skeptical of simplistic reporting about correlations found in such studies. This study does not show that 5 hours of sleep is a “tipping point” for chronic illness. It shows a complex correlation between mostly self-reported sleep duration and the risk of developing certain chronic illnesses, and provokes as many questions as it answers.
Follow up research can include more objective measures of sleep duration and quality, higher resolution data, larger cohorts with a more representative sampling, and gather data that can help address some of the possible causal relationships. But no single study is going to answer such complex questions. The relationship between sleep and chronic illness is one of those questions that will take dozens of high-quality studies to flesh out. This study is a good addition to the overall data, but we have to recognize its limitations.

Firearms as a Public Health Crisis
Steven Novella on June 26, 2024
Link

The US Surgeon General, Vivek Murthy, recently put out a 40 page report titled: “Firearm Violence: A Public Health Crisis in America.” The report is entirely informational, without any policy force, but Murthy is hoping it will have the same long term cultural effect as the Surgeon General’s warning about the health risks of tobacco.
I wrote about this exact issue in 2018, and the conversation has not changed at all since then. The core question is – is gun violence a public health issue? The answer to this question, I argued, is an unambiguous “yes”. The medical profession has an absolute interest in and significant role to play in public health, and the health of the public is affected by many factors, not just disease.
Smoking is an excellent example. This is a behavior deeply rooted in culture, and yet has a significant negative health impact that is a legitimate target of the medical profession. Perhaps the best analogy to gun violence is car safety. There is a tremendous amount of research into car related deaths and injuries, and how best to mitigate them. This has lead to seatbelt laws and car seat laws for children.
Murthy’s stated hope, perhaps overly optimistic, is that the report will help shift the conversation on gun violence away from the current political deadlock to one of public health and safety. Part of this strategy is to simply focus on the numbers, which are sobering.
But of course, they were in 2018 also. I wrote: ” In 2016 in the US there were 15,592 deaths involving guns (not including suicides, which average around 22,000), including 346 mass shootings, 732 children, and 3,234 teens.”
Since then the numbers have gotten worse. According to the report: “The age‑adjusted rate of firearm‑related homicide increased by 62.5% from 2012 (3.8 per 100,000) to 2022 (6.2 per 100,000), with an absolute increase from 11,622 to 19,651 deaths over the same period.” Gun violence is now the leading cause of death in children and teens (surpassing car accidents), with deaths in 1-19 year olds at 4,603 in 2022.
The report also points out that death is only one outcome. For each person killed by a firearm there are about two people who are injured. In addition there are the loved-ones of those killed, and those who have witnessed gun violence or been threatened with violence. The report notes that in a recent survey 54% of Americans have experienced some form of negative firearm-related incident.
The raw numbers is the one thing about which there seems to be broad agreement. Unfortunately gun violence has been made part of the political culture wars, and any discussion of gun safety is portrayed as a violation of the second-amendment rights of gun owners. The NRA, for example, was quick to criticize the report by saying that it is “an extension of the Biden Administration’s war on law-abiding gun owners.” That is the exact frame that Murthy is hoping to change.
Previous examples of pushing back against treating gun violence as a public health issue include the Dickey Amendment – A 1996 congressional appropriations bill stipulated that “none of the funds made available for injury prevention and control at the Centers for Disease Control and Prevention [CDC] may be used to advocate or promote gun control.” This effectively chilled any research into gun violence by any federal agency. This de facto policy has since been reversed and federally funded gun violence research has resumed.
Another example are the various states, most notably Florida, that tried to ban physicians from talking to patients or parents of their patients about gun safety at home (so-called “gag laws”). The Florida law was struck down by a federal appeals court as violating the first amendment rights of physicians. But explicit in these gag laws was the claim that gun safety is not a legitimate medical issue.
It is a good thing these laws were struck down. A survey recently released by the CDC found that: “Of respondents with a loaded firearm and a child or adolescent aged ≤17 years in the home, 25.2%–41.4% reported that a loaded firearm was kept unlocked.” We see in this one study the need for federally funded research into gun safety and the need for physicians to talk to their patients about gun safety at home.
At the very least I hope the report moves the conversation on gun safety forward and helps establish a couple of important premises. First, gun safety is a legitimate medical and public health issue. Second, we need more data, and research is a good thing.
But further, exploring ways to make gun ownership more safe, and funding research to explore and better understand the issue should be viewed as non-partisan, even apolitical. Of course, science is used to inform policy, but the science itself should be objective, and viewed that way. Suppressing research and professional discussion is completely unacceptable.

Docs v. Glocks: government regulation of physician speech
Jann Bellamy on January 21, 2016
Link

A few years ago, an Ocala, Florida, pediatrician, as part of a routine visit, asked a patient’s mother whether she kept firearms in the home. She refused to answer, feeling the question constituted an invasion of her right to privacy. The pediatrician then terminated the relationship and told the mother she had 30 days to find a new doctor for her child. In another incident, a mother reported she was separated from her children while medical staff asked them whether their mother owned firearms. And, according to a Florida legislator, he was told to remove firearms from the home during an appointment with his daughter’s pediatrician.
Complaints to Florida legislators about these and similar incidents prompted the introduction of a bill that would have, among other things, criminalized any
verbal or written inquiry by a . . . physician, nurse, or other medical staff person regarding the ownership of a firearm by a patient or the family of a patient or the presence of a firearm in a private home . . .
As finally passed by the legislature and signed by Governor Rick Scott, the 2011 Firearm Owners Privacy Act subjects physicians to disciplinary action for making “verbal or written inquiry” into a patient’s firearm ownership when the physician does not “in good faith believe” such inquiries are “relevant to the patient’s medical care or safety of others.” The Act included amendments to the Florida Patient’s Bill of Rights and Responsibilities, adding similar provisions. (The Act also applies to health care facilities, but here we will discuss only its effect on physicians and their patients.) Physicians may not enter any information regarding firearm ownership into the patient’s medical record if they know this information is not “relevant to the patient’s medical care or safety, or the safety of others.” They may not “discriminate” against a patient “based solely on the patient’s Second Amendment right to own firearms or ammunition.” Finally, physicians must refrain from “unnecessarily harassing” a patient regarding firearm ownership during an examination.
Shortly after Gov. Scott signed the Act into law, several physicians filed suit in federal district court challenging its constitutionality (Wollschlaeger v. Governor of Florida). The controversy was dubbed “Docs v. Glocks,” a term widely adopted by the media. Similar legislation has been introduced in at least 12 other states.
The Act, the physicians said, was an unconstitutional infringement on their First Amendment right to freedom of speech and was unconstitutionally vague because they were not fairly put on notice as to what they were expected to do to comply with the Act. (We’ll mostly focus here on the First Amendment issues.)
According to their complaint, the new law had caused them to change their practices in several ways. Previously, and in accordance with the American Medical Association’s policy guide’s suggestion that such questions were important to child safety and public health, these physicians had variously inquired about gun ownership as part of routine patient questionnaires, asked patients whether they owned firearms if there were other risk factors present (e.g., depression), and discussed firearms as part of routine preventive counseling. (The American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Physicians all recommend providing counseling and guidance on firearm safety as well.) All of these activities were viewed by the physicians as consistent with good medical practice.
After the Act, these physicians stopped asking firearm-related questions, in questionnaires or orally, either routinely or when the patient seemed upset by the inquiry, or stopped discussing firearm safety altogether, although some continued to do this by framing the inquiry in hypothetical terms not specific to the patient’s circumstances.
The U.S. District Court for the Southern District of Florida agreed with the physicians and prohibited enforcement of the law. The state appealed. In three separate opinions, all citing different grounds for its decision, a three-judge panel of the U.S. Court of Appeals for the 11th Circuit upheld the Act over the vigorous dissent by one of the panel’s judges. We’ll return to those decisions shortly.
Government limitations on physicians’ speech
Over the past several years, federal appellate courts have addressed similar First Amendment challenges to laws that restrict physicians’ speaking to patients, either by forbidding them from discussing certain subjects or by compelling physicians to give patients legislatively-scripted information. In both situations, physicians may find the legislature’s requirements medically questionable. A key issue in these cases is the degree of deference the courts give to the states in deciding if the state’s restrictions violate the physician’s First Amendment right to free speech.
When the government tries to regulate the content of a person’s speech, as opposed to regulating the time or place where it occurs, the law is subject to strict scrutiny by the courts in determining its constitutionality. Under strict scrutiny, the court will find the government’s regulation invalid unless the state can demonstrate that it is justified by a compelling government interest and is narrowly drawn to serve that interest. This is the most demanding standard of review and courts rarely find content-based restrictions constitutional. Restrictions aimed at particular speakers or particular viewpoints are also highly disfavored by the courts.
Some types of speech are entitled to less protection, such as commerical speech, which is protected as long as it is truthful. Courts apply an intermediate level of scrutiny in these situations and content-related speech restrictions will be upheld only if the state can show the law directly advances a substantial government interest and that the law is drafted in a way that will achieve that interest.
Note that none of these categories of speech are actually mentioned in the First Amendment nor are the standards for court review. All of this is case law developed by the courts because, the U.S. Supreme Court decided long ago, the courts are the final authority in determining the constitutionality of government actions. Note also that the parameters of each level of scrutiny are stated in very broad terms, leaving plenty of room for interpretation. Of course, all of these cases present particular facts, and it would be impossible to fashion some bright-line test of constitutionality.
The appellate courts have been all over the board in deciding challenges to physician-patient communications, sometimes referred to more broadly as “professional speech.” The Ninth Circuit Court of Appeals upheld a California law banning so-called “sexual orientation conversion therapy” (SOCT) by finding that the therapy, although spoken, was simply a form of treatment, not unlike surgery. Thus, the therapy was really conduct, not speech at all, and therefore unprotected by the First Amendment. The Third Circuit also upheld a New Jersey law banning SOCT. The court decided the physician’s speech, in the form of therapy, was entitled to some level of First Amendment protection, but found that the ban was a permissible restriction on professional communication between a physician and patient, applying an intermediate scrutiny standard.
The Fourth Circuit also found intermediate scrutiny of professional speech appropriate and struck down a state law forcing physicians to display ultrasounds to patients seeking abortions, as well as to convey certain scripted information those patients. Conversely, the Fifth and Eighth Circuits upheld similar laws passed in Texas and South Dakota, respectively, reasoning that limitations on physician speech are part and parcel of the state’s power to regulate medicine and that restrictions are valid as long as they are “truthful, relevant and non-misleading,” applying the same standard used to review commercial advertising. The Texas law requires a physician to perform an ultrasound on a patient seeking an abortion so she can hear the fetal heartbeat and to explain the ultrasound’s results. Even though none of this is medically necessary, the court found it meets the “truthful, relevant and non-misleading” test. On the same grounds, the Eighth Circuit let stand a South Dakota law requiring physicians to tell a patient seeking abortion that she
has an existing relationship with that unborn human being and that the relationship enjoys protection under the United States Constitution . . . [and] that by having an abortion, her existing relationship and her existing constitutional rights with regards to that relationship will be terminated.
Again, medically unnecessary, but truthful, relevant and not misleading, and therefore constitutional.
I imagine your agreement, or lack thereof, with these decisions may be influenced by how you feel about gun control, abortion rights and SOPT. That is a natural response. However, any decision by an appellate court is binding precedent for all district courts within its circuit, and for that appellate court’s later decisions (unless overturned). Thus, it is important to keep in mind that the same rationale is going to apply to a later case where you may have an entirely different view of the issue under consideration.
The “Docs v. Glocks” case
Remarkably, the 11th Circuit, presented with the physicians’ challenge to Florida’s law, issued three separate opinions based on three different standards of review. (Again, this was a two-judge majority of a three-judge panel, over a vigorous dissent by the third judge.)
There was notable firepower on both sides of the argument in the form of amicus briefs. (These are briefs filed by non-parties who are interested in the outcome of the case.) On the physicians’ side is the AMA, the American Academy of Pediatrics, numerous other physician groups, the American Public Health Association, the ACLU, suicide-prevention groups and Children’s Healthcare is a Legal Duty. The American Bar Association is among these as well, because of the implications for state attempts to restrict another form of professional speech: attorney-client communications. The National Rifle Association is the heavy hitter on the other side, filing a brief in support of the state.
In the first opinion, Wollschlaeger v. Governor of Florida I, decided in 2014, the court found that, because the law restricts only speech by a physician in the context of the physician-patient relationship, but irrelevant (at least in the court’s view) to medical care, it was totally exempt from First Amendment protection. As the dissent pointed out, Florida’s ban silenced doctors on a single topic to prevent them from communicating a message unpopular with the legislature to their patients, thereby scoring a home run of sorts by putting aside not only the courts’ traditional hostility toward content-based restrictions on speech, but also toward restrictions aimed at particular speakers and particular viewpoints.
The physician-appellees petition for rehearing, and, in the second opinion, Wollschlaeger II, issued in July, 2015, the court held that the First Amendment was implicated after all. But, finding that the law survived the intermediate scrutiny standard required for restrictions on professional speech, the court upheld the law again.
The court then asked the parties to file new briefs discussing the implications of a recently-decided Supreme Court case. Although the case wasn’t directly on point, the court thought it might possibly require a less forgiving standard than intermediate scrutiny. Upon further consideration, but without deciding that strict scrutiny was indeed required, the court found that, if it were, the law’s restrictions on physician speech were nevertheless constitutional. This decision, Wollschlaeger III, was issued in December.
The physicians have filed a petition for rehearing by the full 11th Circuit. Whether the full court hears the case or not, the U.S. Supreme Court may eventually agree to consider the matter because of the conflicting decisions among the appellate courts.
Criticism of Wollschlaeger
One commentator, constitutional law professor Eugene Volokh, posting on the Volokh Conspiracy blog (carried by the Washington Post), disagrees with the court’s analysis, calling it “quite wrong.” This is of some significance because Volokh is an avid supporter of the Second Amendment. I imagine his is an early exemplar of what will become widespread criticism of the case from across the spectrum. (He also criticized the first two opinions, as did others in legal academia: Duke, Case Western, Harvard, Cardozo, and the University of Pittsburgh all have critical articles in their legal literature.)
Prof. Volokh provides a helpful summary of just how much the Docs v. Glocks law, as interpreted by the 11th Circuit, impinges on physician-patient communications.
    • A doctor can’t ask all patients whether they own guns, “even if the doctor believes that this information would indeed be useful in giving general advice about safe gun storage, the supposed dangers of any gun ownership, and the like.”
    • “[A]sking patients about gun ownership and entering that information into the medical record requires that the information be ‘relevant to the patient’s medical care or safety, or the safety of others.’ And, according to the panel majority, ‘relevant’ here [and in situations described below] means relevant based on ‘some particularized information about the individual patient, for example, that the patient is suicidal or has violent tendencies.'”
    • Doctors can “turn away patients for refusing to answer questions about guns” so long as the questions are “relevant” but can’t “turn away patients for answering the questions with ‘yes, I own a gun.'”
    • Doctors are banned “from unnecessarily harassing a patient about firearm ownership during an examination.” This means “that a doctor ‘should not disparage firearm-owning patients, and should not persist in attempting to speak to the patient about firearm ownership when the subject is not relevant . . . to medical care or safety.'”
So how are these restrictions justified by a compelling state interest narrowly tailored to its purpose? Volokh finds they aren’t. I agree.
The first “compelling” reason is protection of the Second Amendment right to keep and bear arms. But wait, as Prof. Volokh points out, stating the obvious, the Second Amendment, like the First, Third, Fourth, and so on, is a restriction on the government, not private individuals. And even if it did apply to private action, the physician can’t do anything to interfere with the patient’s constitutional right to keep and bear arms, no matter how annoying her questions might be.
The court’s rationale for this restriction on a private citizen’s speech is the “imbalance of power” between physician and patient. That, the court says, means the patient could be dissuaded from exercising his constitutional rights. But, as Prof. Volokh says, persuasion and dissuasion are exactly the sort of activity that is protected by the First Amendment. He finds equally unconvincing the court’s view that the restrictions are permissible because the patient is a “captive audience.”
And what’s next? He asks: Can the Florida legislature now prohibit questions that implicate other constitutionally protected rights?
“Are you sexually active?” “Are you using contraceptives?” “What kinds of contraceptives are you using?” “Do you want to have children at some point?” “Have you ever been pregnant?” “How many sexual partners have you had in the past year?” “Are you engaging in anal sex?” “How much television do your children watch?” “Do your children play violent videogames?”
Prof. Volokh concludes by echoing a point I made earlier. The 11th Circuit’s opinion, he says,
can apply to a wide range of situations where the government can claim some supposed tension (however indirect) between constitutional rights, some “power imbalance” between speaker and listener, or some “vulnerability” or “captivity” of the listener. If not reversed, it will set a dangerous precedent for speech far outside the gun debate.
Closer to the SBM home, my concern about legislative bodies making medical judgments is reinforced by state laws promoting politically-favored messages not necessarily consistent with evidence-based medical practice. (I do not include the SOCT bans in this category. There the legislature’s judgment was medically sound.) As we’ve discussed a number of times on SBM, legislators sometimes wander far outside the boundaries of science in making decisions affecting healthcare: Legislative Alchemy, the 21st Century Cures Act, non-medical vaccination exemptions, and “Right to Try” statutes. Physician questioning about gun ownership is, in my view, based on a reasonable judgment that discussing it is, at least arguably, a medically sound preventive medicine practice. Yet, the court, in requiring “relevancy” to a specific patient’s medical care based on a “‘some particularized information about the individual patient” effectively overrules the physician’s judgment. The same is true of state laws requiring physicians to make scripted speeches containing medically irrelevant information. Perhaps we need a constitutional “right to science” to protect the public against scientifically unsound legislative decisions.

Gun Violence as a Public Health Issue
Gun violence is a serious public health issue in America but is not getting the research that it deserves. This needs to change.
Steven Novella on February 21, 2018
Link

Just about the only thing that everyone agrees on when it comes to gun violence is that it’s a problem in the US. The numbers are sobering:
Those countries all also enjoy low rates of gun violence, but the U.S. has the 31st highest rate in the world: 3.85 deaths due to gun violence per 100,000 people in 2016. That was eight times as high as the rate in Canada, which had 0.48 deaths per 100,000 people — and 27 times higher than the one in Denmark, which had 0.14 deaths per 100,000.
The countries with a higher rate of gun deaths tend to be war torn, or failed states with powerful criminal organizations. In 2016 in the US there were 15,592 deaths involving guns (not including suicides, which average around 22,000), including 346 mass shootings, 732 children, and 3,234 teens.
And that is where any significant agreement ends, on the raw numbers. Significant majorities of Americans agree with certain measures, such as background checks and banning certain accessories, like bump stocks which allow semi-automatic weapons to fire more like a fully automatic weapon. But for various reasons these majorities do not translate into political will.
There is wide disagreement about the causes of our out-of-proportion gun violence and what measures will have a beneficial effect. This is not unusual – there is wide disagreement about most important issues. One way to see our way through conflict and paralysis is with objective scientific information. This will never convince the true-believers (witness anti-vaxxers) but can marginalize them and empower the evidence-based majority to take action.
What I want to discuss here is not what the current scientific evidence says (that is a complex topic for another post), but simply advocate for doing scientific research on gun violence in the first place. If ever there were a debate that needed an injection of objective facts, this is it.
The Dickey Amendment
As summarized in a recent JAMA article:
A 1996 congressional appropriations bill stipulated that “none of the funds made available for injury prevention and control at the Centers for Disease Control and Prevention [CDC] may be used to advocate or promote gun control.” Similar restrictions were subsequently extended to other agencies (including the National Institutes of Health), and although the legislation does not ban gun-related research outright, it has been described as casting a pall over the research community.
What Congress did was reduce the CDC budget by the exact amount spent on gun violence research. This was clearly intended to intimidate the CDC by directly threatening their funding. The tactic worked, the CDC got the message, and effectively all research into gun violence at the CDC stopped. The JAMA article also researched the results of this policy:
Compared with other leading causes of death, gun violence was associated with less funding and fewer publications than predicted based on mortality rate. Gun violence had 1.6% of the funding predicted ($1.4 billion predicted, $22 million observed) and had 4.5% of the volume of publications predicted (38 897 predicted, 1738 observed) from the regression analyses. Gun violence killed about as many individuals as sepsis. However, funding for gun violence research was about 0.7% of that for sepsis and publication volume about 4%. In relation to mortality rates, gun violence research was the least-researched cause of death and the second-least funded cause of death after falls.
Some have argued that the CDC (Centers for Disease Control) has no business researching gun violence because being shot is not a “disease.” This argument does not hold water, however, and seems deliberately concrete. The CDC researches all threats to the health of Americans, and being shot dead is a significant risk to health. The CDC also researches deaths from car crashes, and how to mitigate those deaths, for example. And as stated above, the restrictions on research extend to other agencies, like the National Institutes of Health.
Gun violence is estimated to cost $229 billion dollars a year to our society ($8.6 billion in direct costs and the rest from indirect costs). Reducing gun violence is therefore likely to be cost effective, and certainly a cost of this magnitude to our society warrants proportionate research.
A recent national survey finds that 55% of Americans support research into gun violence. While it is good that a majority supports research, it is a disconcerting that 45% of Americans do not support researching gun violence.
The scope of medicine
The fact is that all forms of injury and trauma are considered well within the scope of medicine, uncontroversially so. Doctors, and by extension those involved with public health, consider all risk factors and threats to health. This includes many things that have nothing to do with disease, but relate to safety from violence or trauma.
Parents cannot take their newborn infant home until they demonstrate that they have a proper car seat. We know what constitutes a proper car seat from research into the effects of various designs and behaviors on the risk of death or injury from an accident.
Physicians must also consider the role of domestic violence in the presentation of their patients. Physicians are encouraged, for example, to ask as a routine question, “Do you feel safe at home.” We are trained to look for signs of domestic abuse and to protect vulnerable populations.
Taking a thorough history from a patient can be very intrusive – we ask about their diets, their daily habits, their relationships, their home situation, their socioeconomic situation, their personal and intimately private behaviors, even behaviors that are illegal. We do this because all of this information is potentially important to the health of our patients. We also do it within a professional covenant that we will use that information only for the benefit of our patients, and with the strictest confidence (legally protected privilege).
Why, then, should gun use, or the presence of a gun in the home, be singled out for special exception? Yet in 2011 Florida passed a law prohibiting doctors from asking their patients about access to guns in the home. This law was recently struck down by a federal appeals court for violating the first amendment rights of doctors.
We shouldn’t fear information
There are some clear steps we can take together as a society. Doing basic research into a clear problem, with resources proportional to the size of the problem, should be uncontroversial. The Dickey Amendment should simply be repealed. Even Jay Dickey, before he died, regretted sponsoring the Bill:
Dickey, the congressman responsible for the amendment suppressing the CDC’s gun violence research, passed away last April. He had come to regret his role in the episode. In 2012, he coauthored a Washington Post op-ed with Rosenberg, the very CDC official he squared off against when passing the amendment. Together, they argued for more gun-violence research.
Science does not determine policy, but it does inform policy. We need more science to better inform our national debate about the growing problem of gun violence and mass shootings.
It seems that those opposed to researching gun violence want to be stuck in a paralysis caused by insufficient information. They can oppose any gun legislation by arguing that there isn’t evidence proving the legislation will work. If that standard were used for all legislation we would have a very different style of government in our country.
I strongly advocate evidence-based government, making law is like practicing medicine in this regard. It is, at best, an applied science, which means there are value judgments involved, and often we need to make decisions in the absence of perfect information. So we use the best evidence available, within the principle of first do no harm, and evaluate the outcome.
Even with our current state of knowledge we can make rational decisions about gun regulations based on logic, plausibility and available evidence, then evaluate the outcome and make adjustments.
But more importantly, we don’t have to be stuck with our current state of knowledge. We can and should conduct research into the causes and potential solutions to gun violence. It is a health problem for our patients, and it is a public health problem for our society. The medical profession has a legitimate interest in preventing gun violence, and our publicly-funded health research institutions should be giving this topic the priority it deserves.

AMA Decides Gun Violence is a Public Health Issue
Steven Novella on June 15, 2016
Link

On June 14th the American Medical Association’s (AMA) House of Delegates in Chicago, IL voted almost unanimously to adopt a resolution supporting the idea that gun violence is a public health issue. The resolution also called for lobbying Congress to eliminate the ban on research into the causes of gun violence. The AMA reports:
“With approximately 30,000 men, women and children dying each year at the barrel of a gun in elementary schools, movie theaters, workplaces, houses of worship and on live television, the United States faces a public health crisis of gun violence,” said AMA President Steven J. Stack, M.D. “Even as America faces a crisis unrivaled in any other developed country, the Congress prohibits the CDC from conducting the very research that would help us understand the problems associated with gun violence and determine how to reduce the high rate of firearm-related deaths and injuries. An epidemiological analysis of gun violence is vital so physicians and other health providers, law enforcement, and society at large may be able to prevent injury, death and other harms to society resulting from firearms.”
The resolution is aimed primarily at a congressional ban on research into gun violence by the Centers for Disease Control (CDC). I will discuss this ban further, but first let’s address the underlying issue. 
Is gun violence a public health issue?
According to the World Health Organization:
Public health refers to all organized measures (whether public or private) to prevent disease, promote health, and prolong life among the population as a whole. Its activities aim to provide conditions in which people can be healthy and focus on entire populations, not on individual patients or diseases. Thus, public health is concerned with the total system and not only the eradication of a particular disease.
Essentially, the field of public health tries to address systemic issues that affect the health of people in society. Public health includes safety, and concerns itself with safety measures such as avoiding accidental poisoning, requiring car seats for small children, and work-related safety. It also addresses issues of individual behavior that affect health, such as use of recreational drugs, and the calorie density of restaurant meals.
It seems ineluctable that gun safety and gun violence is a legitimate public health issue. Health care institutions addressing gun safety is also appropriate given the magnitude of the harm – about 30,000 Americans die from guns every year.
The CDC ban on gun violence research
The CDC has had a de facto ban on research into gun violence since 1996. The NRA accused the CDC of promoting gun control, resulting in Congress threatening to strip the CDC of its funding. In fact, a Republican congressman led a successful effort to strip $2.6 million from CDC funding, which was the amount the CDC spent on gun violence research the previous year. Congress defunded any gun violence research by the CDC with a clear threat to further defund the CDC if they did not comply.
The CDC reacted predictably – they interpreted these actions by Congress as a ban on research into gun safety and gun violence, and since 1996 there has been no such research at the CDC.
Following the Newtown shooting in 2012, President Obama, by executive Order, reversed the CDC ban. However, in the three years since this executive order the CDC has still not resumed any research into gun violence. The executive order essentially did not work – officials at the CDC are worried that any such research will threaten their funding, which is controlled by Congress rather than the President.
This fear is evident in the following report:
A Wisconsin delegate spoke of a conversation with US Centers for Disease Control and Prevention’s director [Tom Frieden, MD] in which gun violence came up. “He said ‘ stop we can’t have a conversation about this and don’t put it in a letter, stop,’,” the delegate said.
Congress still does not fund any gun violence research through the CDC. There have been bills proposed to reinstate funding, but none have passed.
This situation is the focus of the AMA resolution, to lobby Congress to fund gun violence research through the CDC and to end their standing threat to the CDC to cut off their funding if they start any gun research.
Pediatricians and guns
In a related issue, the Florida legislature passed a measure that would ban pediatricians from asking parents about guns in the home:
“We take our children to pediatricians for medical care — not moral judgment, not privacy intrusions,” [NRA lobbyist Marion Hammer] says.
NRA lobbyists helped write a bill that largely bans health professionals from asking about guns. Hammer says she and other NRA members consider the questions an intrusion on their Second Amendment rights.
“This bill is about helping families who are complaining about being questioned about gun ownership, and the growing anti-gun political agenda being carried out in examination rooms by doctors and staffs,” Hammer says.
The underlying issue here is the same – is gun violence a legitimate health issue? Pediatricians clearly think that it is, as much as wearing bike helmets, asking if they have child locks on their cabinets that may contain dangerous household products, use of a proper car seat, smoking in the home, water safety, etc.
The idea that a physician invades the privacy of their patient or their patient’s caregiver by asking personal questions is absurd. That is the very nature of the doctor-patient relationship, and why that relationship is privileged. Patients and their caregivers need to share personal and intimate information with their physicians, without judgement and without fear that this information will be shared without their permission.
That includes information about guns in the home. There is no reason to carve out gun questions as being exempt from the normal rules of the patient-physician relationship. This is similar to arguing that questions about recreational drug use violates a patient’s privacy, or questions about their sexual activity, or whether or not they intent to vaccinate their children.
Science should inform politics
The AMA is absolutely right to take a strong stand supporting research into gun violence as a public health issue. Regardless of where one stands with regard to the politics of gun control, it is hard to imagine how someone can legitimately be against scientific research to better understand the issue. Taking a stand against research, as the NRA has done, essentially is a statement that your ideology trumps scientific evidence. It also implies a desire to make up supporting claims without the risk of being contradicted by actual data.
Science must stand outside of politics in order to function optimally. Politics cannot be determined entirely by science, because there are subjective value judgments involved. People will make different compromises when it comes to safety vs personal liberty, for example. Seat belt laws are a perfect example.
Politics, however, should be informed by objective science, as much as possible. At least then we can make an informed decision about the implications of the specific compromises we choose.
Many politicians, however, seem unable to resist the urge to put their thumb on the scale of science. They want to break science to justify their political ideology, and this is a very destructive impulse.
The CDC is a government agency, one mission of which is to perform epidemiological research in order to inform policy decisions. Gun violence should not be exempt from this.
The AMA is not a government agency, and they have no regulatory power. They are a professional organization – for a profession that is dedicated to public health and the health of individual patients. They should be lobbying the government for laws that promote public health, based upon the best science available. In that light the recent resolution was clearly the correct move, and was long overdue.

The adverse health effects of the lunacy that is Daylight Saving Time
Daylight Saving Time has been around for over 100 years. Why does it still persist when there’s little or no evidence that it does what it was intended to do (save energy) and growing evidence of adverse health effects related to the twice a year time change? That’s a good question. It’s time to get rid of this antiquated practice.
David Gorski on March 12, 2018
Link

If you’re at all like me, today will be very painful for you, because it is the first day back to work after the switchover to Daylight Saving Time (DST). Given that the loss of an hour occurs overnight on Saturday, I can usually fake it through Sunday (either that, or sleep in without actually getting more sleep by getting up an hour later by the click than usual), but when Monday rolls around there’s no faking it. As I contemplated a topic to write about today, I searched the archives to see if we’ve ever covered the topic of Daylight Saving Time before on Science-Based Medicine (SBM). I was shocked to see that we have not, as far as I can tell. So I decided that it was time to remedy this situation, because DST is a practice that persists despite little evidence that it achieves its stated goal of decreasing energy use and growing evidence of harm to health and wellbeing. It’s also in the news more than usual this year because recently Florida passed a law that would allow it to observe DST year round—although there is a catch that will prevent Floridians from leaving their clocks set an hour ahead come November, when we all have to “fall back.”
Time zones: A solution necessitated by the railroads
Standardized time is actually a rather recent innovation. Before clocks were invented, people kept time using various instruments, such as sun dials, to observe the sun’s meridian passing at noon. After the invention of reasonably accurate chronometers and clocks in the 18th century, towns and cities set their clocks based on sunsets and sunrises. Not surprisingly, this produced wildly differing times between (and sometimes even within) cities and towns. However, before the 19th century, this was not a particularly pressing problem because, even though sunsets and sunrises occurred at different times in different parts of the country, travel times were so slow that it was barely noticeable, and most people didn’t routinely travel far enough that it even made a difference.
What made the big difference in the 19th century was, of course, the train. In the late 1800s, American railroads maintained many different time zones, and each train set its own clock. Calculating arrival times thus became a serious problem for people traveling by train. Add to that how every city in the US used a different time standard, leading to more than 300 local sun times. To try to compensate, railroad managers established 100 railroad time zones, but this was an unwieldy solution to the problem that didn’t address all the local time zones. Operators of the new railroad lines needed a new time plan that would offer a uniform train schedule for departures and arrivals. In 1883, four time zones were introduced for the continental US.
In 1884, at the behest of the President of the US, 41 delegates from 25 nations met in Washington, DC for the International Meridian Conference. At the Conference the following important principles were established:
     1.  It was desirable to adopt a single world meridian to replace the numerous ones already in existence.
     2.  The Meridian passing through the principal Transit Instrument at the Observatory at Greenwich was to be the ‘initial meridian’.
     3.  That all longitude would be calculated both east and west from this meridian up to 180°.
     4.  All countries would adopt a universal day.
     5.  The universal day would be a Mean Solar Day, beginning at the Mean Midnight at Greenwich and counted on a 24 hour clock.
     6.  That nautical and astronomical days everywhere would begin at mean midnight.
     7.  All technical studies to regulate and extend the application of the decimal system to the division of time and space would be supported.
The plan adopted was based on a plan devised in the late 1870s by a Canadian railway planner and engineer named Sir Sandford Fleming, who had outlined a plan for worldwide standard time in the late 1870s. The Meridian Conference established the time zones that are still in use today. It wasn’t until 1918, though, that Woodrow Wilson signed the Calder Act, which mandated standard time. But what about Daylight Saving Time?

Enter Daylight Saving Time
It’s frequently noted that the concept of Daylight Saving Time appears to have originated with Ben Franklin, who in 1784 published an essay, “An Economical Project for Diminishing the Cost of Light”, written to the editor of The Journal of Paris. In his essay, Franklin observed that Parisians could save on candles by getting out of bed earlier in the morning, making use of the natural morning light instead. Franklin’s suggestion appears not to have been serious, but rather a joke, and he didn’t actually suggest turning clocks ahead. In reality, DST was “invented” by New Zealand scientist George Vernon Hudson and British builder William Willett. In 1895, Hudson presented a paper to the Wellington Philosophical Society, in which he proposed a 2-hour shift forward in October and a 2-hour shift back in March. Although there was some interest in the idea, it was never adopted as policy.

It was during World War I that DST became a reality for much of the world. Germany and Austria adopted it first, the rationale being to save on fuel use for artificial lighting at home in order to make more fuel available to the war effort. Britain and many other countries in Europe soon followed suit, although after the war ended they reverted back to standard time and DST did not make a reappearance until World War II. But what about the US?

Remember the Calder Act? That same act that mandated the use of standard time in the US also mandated DST. As Real Clear Science notes, the first switchover to DST did not go well:
It didn’t go smoothly. In 1918, Easter Sunday fell on March 31, which led to a lot of latecomers to church services. Enraged rural and evangelical opponents thereafter blamed daylight saving for subverting sun time, or “God’s time.” Newspapers were deluged by letter writers complaining that daylight saving upset astronomical data and made almanacs useless, prevented Americans from enjoying the freshest early morning air, and even browned out lawns unaccustomed to so much daylight.
Within a year, the DST provision of the Calder Act was repealed, but that didn’t mean DST didn’t continue:
In 1920, New York and dozens of other cities adopted their own metropolitan daylight saving policies. The Chamber of Commerce spurred along this movement on behalf of department store owners, who had noticed that later sunset times encouraged people to stop and shop on their way home from work.
By 1965, 18 states observed daylight saving six months a year; some cities and towns in 18 other states observed daylight saving for four, five or six months a year; and 12 states stuck to standard time.
This wasn’t exactly ideal. A 35-mile bus trip from Steubenville, Ohio, to Moundsville, West Virginia, passed through seven distinct local time zones. The U.S. Naval Observatory dubbed the world’s greatest superpower “the world’s worst timekeeper.”
Amazingly, it wasn’t until 1966, when Congress passed the Uniform Time Act, that the system of six months of standard time, six months of Daylight Saving Time became the law of the land. During the OPEC oil embargo of 1973, the US conducted an experiment mandating the use of DST year round to save energy beginning in 1974. (I remember this well, because I remember that winter walking to school in the dark a lot.) The experiment only lasted one year, and back in 1975 everything went back to the system before. Then, in 1986, Congress amended the Uniform Time Act to have DST extend from the first Sunday in April to the last Sunday in October. Finally, in 2005, Congress passed the Energy Policy Act of 2005, which extended DST from the second Sunday in March to the first Sunday in November beginning in 2007. That is where DST in the US stands today.
This brings me back to the recently passed Florida law, HB 1013, or the “Sunshine Protection Act,” which is the logical extension of this seemingly relentless increase in DST. Basically, nothing will happen as a result of the law if it’s signed, because, although states have the power to opt out of DST (as Hawaii and most of Arizona do), they do not have the power to opt out of standard time year round. It would require a change in federal law for Florida’s law to take effect.
The health effects of Daylight Saving Time
I’m not going to discuss (much) the science of whether DST actually saves energy. Suffice to say that the actual energy savings are minimal, if any. The most frequently cited evidence for the energy savings due to DST is a 2008 report to Congress by the Department of Energy which showed that total electricity savings from the extended daylight saving period that began in 2007 amounting to 0.03 percent of electricity consumption over the year, which is a minuscule savings. In contrast, a California Energy Commission study after the extension of DST in 2007 found that the estimated weather- and lighting-corrected energy savings from the extended DST was 0.18%, but the confidence interval ranged from a ranging from a 1.5% savings to a 1.4% increase. Indeed, one reason that Arizona opts out of DST is because of the concern that any savings in energy used for lighting would be more than offset by more use of air conditioning. One study looking at energy use in Indiana after it adopted DST statewide in 2006 showed that DST was actually associated with at least a 1% increase in residential electricity use. Other studies corroborate this effect. At best, DST is a wash; at worst, it increases energy consumption.
More importantly, that lack of benefit in terms of decreasing energy consumption comes at a considerable cost, and that’s because the lost hour of sleep comes not from wakeful time, but rather primarily from resting hours. This results in many problems associated with sleep deprivation and disrupted Circadian rhythms.
Here’s an example. Multiple studies show that there are more motor vehicle collisions the Monday after the time change to DST. For instance, in 1996, Canadian researchers noted that the number of traffic accidents rose significantly:
The loss of one hour’s sleep associated with the spring shift to daylight savings time increased the risk of accidents. The Monday immediately after the shift showed a relative risk of 1.086 (95 percent confidence interval, 1.029 to 1.145; ξ2 = 9.01, 1 df; P<0.01). As compared with the accident rate a week later, the relative risk for the Monday immediately after the shift was 1.070 (95 percent confidence interval, 1.015 to 1.129; ξ2 = 6.19, 1 df; P<0.05). Conversely, there was a reduction in the risk of traffic accidents after the fall shift from daylight savings time when an hour of sleep was gained. In the fall, the relative risk on the Monday of the change was 0.937 (95 percent confidence interval, 0.897 to 0.980; ξ2 = 8.07, 1 df; P<0.01) when compared with the preceding Monday and 0.896 (95 percent confidence interval, 0.858 to 0.937; ξ2 = 23.69; P<0.001) when compared with the Monday one week later. Thus, the spring shift to daylight savings time, and the concomitant loss of one hour of sleep, resulted in an average increase in traffic accidents of approximately 8 percent, whereas the fall shift resulted in a decrease in accidents of approximately the same magnitude immediately after the time shift.
The observation that the number of crashes declines in the fall transition back to standard time is very compelling.
A more recent study in 2016 published in the American Economic Journal estimated that the impact of DST from 2002-2011 resulted in over 30 deaths at a social cost of $275 million annually and that this result is most consistent with sleep deprivation as a cause. Yet another study (this one from 2004) estimates that never changing the clock all year round would reduce pedestrian fatalities by 171 per year, or 13% of all pedestrian fatalities in the 5:00–10.00 a.m. and in the 4:00–9:00 p.m. time periods, and motor vehicle occupant fatalities by 195 per year, or 3%. A 2014 study from the University of Colorado Boulder found a spike in fatal automobile crashes during the six days following the shift to DST. The list goes on.
Risk on the road and sidewalk is not the only health risk from DST, though. For instance, there is evidence of a small but real increase in heart attacks. Swedish data suggest the risk of myocardial infarction to be significantly elevated for the first three weekdays after the transition to DST. A 2013 study in The American Journal of Cardiology found a similar result, with an increase in heart attack rates the Sunday after the shift to DST. Similarly, a recent University of Alabama study found that heart attacks increase by 10-24% on Monday following the shift to DST. A recent review of the literature published in European Review for Medical and Pharmacological Sciences concludes:
Transitions into and out of Daylight Saving Time (DST) may disrupt circadian rhythms and lead to sleep disturbance and deprivation. A first report observed an association between DST and acute myocardial infarction (AMI), especially after the spring shift and in women. We tried to identify and evaluate the possible association between DST and AMI, using the MEDLINE, EMBASE and Google Scholar electronic database (years 2009-2016), with regards to the searching terms ‘daylight saving time’, ‘daylight saving time’ plus ‘gender’, and ‘daylight saving time’ plus ‘acute myocardial infarction’. In total, 72, 10, and 6 studies were found, respectively. Overall, 6 studies, including a total of 87,994 cases, resulted to satisfy the searching request, and were included in the present analysis. All studies confirmed a higher occurrence of AMI in the spring shift, ranging from 4 to 29%, whereas only 1 study showed a higher occurrence of AMI in the autumn shift. By the way, in 5 studies providing separate analysis, the results by sex were not univocal. In fact, as for the spring shift, 2 studies did not show differences between men and women, 2 reported a higher frequency in men, and 1 in women. Regarding the autumn shift, only 1 study reported a higher occurrence of AMI in women. These results support the presence of an association between DST and a modest increase of AMI occurrence, especially for the spring shift, and with no definite gender specific differences.
My reading is that this is probably a real phenomenon. Not only is it plausible that the shift to DST could lead to an increased risk of a heart attack in the days following, but multiple epidemiological studies are pointing to the same conclusion: A modestly increased risk of heart attack in the days following the shift to DST.
There are other health effects as well. There are far fewer studies of the effect of the DST transition on workplace injuries, but there are reports indicating increased work-related injuries and accidents on the Monday following the DST transition. For instance, a 2009 analysis from Michigan State University of the National Institute for Occupational Safety and Health database of mining injuries for the years 1983–2006 found that on the Monday following the time change miners suffered more workplace injuries and injuries of greater severity, with a 5.7% increase in injuries and a 67.6% increase in days of work lost because of injuries. There was no increase or decrease in injuries on Mondays after the switch back to standard time. This same study found that the miners arrived at work with an average of 40 minutes less sleep the night before.
But that’s still not all.
There are a number of other adverse health consequences that have been linked to the DST transition. Consistent with an increased risk for myocardial infarction, a recent study found an 8% increase in the risk of stroke on the Mondays and Tuesdays following the change to DST in the spring. For another example, a 2008 study found higher male suicide rates the week after the switchover to DST, although it also found higher suicide rates after the fall shift back to standard time, suggesting that it’s sleep change, not sleep deprivation, that could be responsible. A more odd effect of the spring transition is an effect known as cyberloafing, which was identified in a 2012 study. Cyberloafing is just what you think it is: Loafing around on the Internet, social media, and the like, such as checking Facebook and Twitter, answering personal e-mail, or shopping online. The study couldn’t show causation, but the authors speculated that lack of sleep led to lack of focus and motivation.
Are the benefits worth the risks? Probably not
In fairness, it should be noted that not all health effects of the springtime transition to DST are bad ones. Perhaps the best example of a beneficial effect of the spring DST transition is that it is associated with more physical activity in children. In a 2014 study published in the International Journal of Behavioral Nutrition and Physical Activity, investigators examined data from 23,188 children aged 5-16 years from 15 studies in nine countries brought together in the International Children’s Accelerometry Database. Of these 439 were of particular interest because they contributed data from both immediately before and after the clocks were changed. Activity was recorded using Actigraph accelerometers and average physical activity level represented as accelerometer counts per minute, which was the primary outcome. Results were adjusted for confounders such as weather characteristics including daily precipitation, humidity, wind speed and temperature. The authors concluded that a later hour of sunset (i.e. extended evening daylight) was independently associated with increased daily activity across the full range of time of sunset. They also observed that it was in the late afternoon and evening that the duration of evening daylight was most strongly associated with hourly physical activity levels. The authors concluded that the increased activity, although modest, was not trivial.
Another example is that DST is associated with lower robbery rates because fewer potential victims are out after dark, with the authors of one study estimating that the 2007 DST extension resulted in $59 million in annual social cost savings from avoided robberies.
Of course, a number of industries benefit from a later sunset, such as the New York department store owners who in 1920 lobbied for DST in New York City. Tourism is a huge industry here in my home state, and there’s no doubt that resorts benefit. Indeed, the tourism industry is the reason why bills to end DST in Michigan never go anywhere. (Heck, bills to move the start dates of various public schools to before Labor Day, as they are in a number of states that I’ve lived in during my lifetime, rarely go anywhere because of power of the tourism industry in this state.) Certainly, the golf industry benefits by as much as $400 million a year.
Besides benefiting various tourism and recreation industries and maybe a small benefit in terms of increased physical activity in children (there’s only been one study that I’m aware of finding that), who benefits from DST? The answer is, as far as I can tell, no one, and even these benefits come at too high a cost in health and energy use. As we are learning, sleep is important, and Americans, being chronically sleep deprived year round, are especially vulnerable to even minor disruptions in sleep, such that even a disruption as seemingly minor as the spring transition to DST and its associated “loss” of an hour can have ripple effects on health that we have been beginning to appreciate over the last decade or so. That’s why I’m with Jon Oliver when he asked: “How is DST still a thing?”
Not only is the transition to DST associated with a growing number of adverse health effects, but DST doesn’t even do what it was advertised to do 100+ years ago: Save energy. We at SBM advocate for science-based medicine and science-based health policy—actually, science-based policy in general. DST fails in every way to be science-based. It should have been scrapped decades ago, in favor of either year round standard time or DST, no clock changes ever necessary.
Now excuse me while I cyberloaf and take a cat nap at my desk. Fortunately for my patients, I have no cases today or tomorrow.

Myopia Epidemic
Steven Novella on September 25, 2024
Link
Myopia, or near-sightedness, has been steadily on the rise over the last half-century. A recent systematic review updates the literature on the extent and nature of this epidemic. Let’s get straight to the findings and then discuss what this means.
The reviews includes: “276 studies, involving a total of 5,410,945 participants from 50 countries across all six continents.” The researchers find a steady increase in the pooled prevalence of myopia, increasing from 24.32% in 1990 to 35.81% in 2023. They further extrapolate that myopia prevalence may hit 40% by 2050.
These results are in line with other published studies, and are even conservative. Other estimates are closer to 50%. Going back further, although the data is not as good, in the 1950s the prevalence of myopia was in the 1-3% range. Prevalence also differs dramatically by region of the world, being much higher in Asia, especially China, with prevalence as high as 80% in some areas. What is the cause of this dramatic, long term public health outcome?
Researchers have long suspected the answer, but a big confirming clue came during the COVID 19 pandemic. There was a significant spike in myopia following the shutdown period.
Myopia is a structural problem of the eye, resulting from the globe of the eye being too elongated. It can also result from too steeped a curve of the cornea. This causes the image to be focused too far in front of the retina, making it difficult to focus in the distance. What factors can affect the shape of the eye as it develops?
Whenever we detect an increase in the incidence or prevalence of a diagnostic entity, we have to ask some basic questions. Is the incidence really increasing, or is is just an artifact of how we are gathering data? Are we looking for it more, or perhaps just better at diagnosis the condition? Has the diagnostic criteria changed? Is there diagnostic substitution – other diagnoses now being labeled with the one that appears to be rising? For prevalence, earlier diagnosis and longer survival would increase the number of people with the condition at any one time, even without an increase in incidence over time.
Or is the increase a genuine increase in the true incidence/prevalence. For myopia it seems that the increase is genuine. None of the other explanations are very plausible and there is no evidence they are playing a significant role. We often turn to demographics as a clue to causation. According to the new review:
“Notably, individuals residing in East Asia (35.22%) or in urban areas (28.55%), female gender (33.57%), adolescents (47.00%), and high school students (45.71%) exhibit a higher proportion of myopia prevalence.”
We also have the COVID spike as more evidence. What the evidence points to is that reduced exposure to sunlight contributes to myopia risk. Kids are spending less time outdoors, and more time in front of screens. This may have nothing to do with screen time itself, as the effect predates extensive screen time by children, and my be largely or entirely due to reduced exposure to sunlight. Similarly, more time spent outdoors by children reduces their myopia risk.
Why is the prevalence so much higher in China? This has been linked to urbanization, and cultural changes that put high pressure on students to spend a lot of time studying indoors.
What is the mechanism by which lack of time outdoors causes myopia? We don’t know, but there are theories. One theory is that sunlight triggers the release of dopamine which is important for eye growth. Lack of sunlight leads to lack of dopamine leads to abnormal eye growth. Another theory is that spending too much time focusing close up, and not enough time focusing in the distance, causes the abnormal growth of the eye.
Whatever the mechanism, the fix is simple (if not easy). Increased time outdoors reduces myopia risk, at least during development (probably not as adults). This means we have to get kids outdoors – as a public health measure. This may be challenging, especially in highly urbanized areas, but it is important. There are other benefits to being outside as well, including reduced risk of obesity and improved psychological health.
School schedules need to build in outdoor time. Schools themselves should be designed to provide outdoor space for students. An urban areas need to maximize parks and green outdoor spaces for children.
We have known about the connection between lack of sunlight an myopia for years, and yet prevalence of myopia continues. If we do not take action as a public health concern, it’s possible that by 2050 or soon after half the world will be myopic.

Zapping Antipsychiatry ECT Nonsense
These days people’s perceptions of electroconvulsive therapy have a fictionalized understanding of what it is, and its harms. The reality is quite different.
Braden MacBeth on July 25, 2019
Tweet

Electroconvulsive therapy (ECT) is an effective treatment for medication-resistant psychiatric disorders. It’s also considered controversial for some reason. Antipsychiatry’s rhetoric surrounding ECT can be heard pretty much anytime the topic comes up in discussion. ECT is often misrepresented in movies such as One Flew Over the Cuckoo’s Nest, The Snake Pit, Requiem for a Dream, and most recently Suicide Squad. There have been many studies on the public’s perception of ECT and these films are cited as a pretty big reason why ECT is perceived so negatively. ECT is often portrayed as a barbaric, painful treatment used to punish patients held against their will in an in-patient psychiatric wing. The anti-science antipsychiatry movement has played this to their advantage, and criticize ECT as it appears in the films as if that’s what ECT is really like. In films ECT isn’t done under sedation, it has horrific side effects, and is incredibly painful. In reality, ECT is nearly painless, has relatively rare side effects that are usually minor, and is incredibly effective. One thing that is consistent across all literature on ECT is that ECT incredibly effective when it’s indicated, but is underutilized because of the stigma.
One Flew Over The Cuckoo’s Nest was not a documentary
Probably the most prominent antipsychiatry organization is the Citizens Commission on Human Rights. While CCHR sounds like an innocuous humanitarian organization, the organization’s singular goal is to perpetuate falsehoods about psychiatry, and they’re bankrolled almost entirely by the Church of Scientology. CCHR has a 32-page handout on psychiatry’s “brutal treatments”. I knew I was in for a treat when the introduction highlights this quote:
Despite the general belief that ECT ceased to be administered with the death of Jack Nicholson’s character of McMurphy in One Flew Over the Cuckoo’s Nest, hundreds of thousands around the world are still subjected to it each year.– Jan Eastgate, President of CCHR
One Flew Over The Cuckoo’s Nest, released in 1975, it’s so old that the third year med student who saw the film in theaters is now the attending who writes “sub-internship level” on third year med student evaluations and then gives only gives them a pass for an evaluation grade. The book the movie is adapted from was published in 1962. The depictions of psychiatry in the book weren’t even accurate for the time; the majority of lobotomies were performed in the 1940s to 1950s for example. While lobotomies were absolutely horrifying, so were most other things during that time. The Civil Rights Act was passed 2 years after One Flew Over the Cuckoo’s Nest was published. The point is, your criticisms of medical procedures have to be relevant to how they are done today, not how they were more than 50 years ago. Many of the “criticisms” outlined in CCHR’s document are based on information or events from more than 50 years ago.
The majority of CCHR’s arguments against ECT are based on unverifiable testimonials, professionals who don’t represent mainstream psychiatry, questionable research, verifiable falsehoods, trash publications, and legitimate research taken out of context. So about par for the course as far as anti-science movements go. There are a number of outrageous claims made in the CCHR document such as research “revealing” that the death rate from ECT among the elderly receiving ECT is one in two hundred. Their source for this claim is The Practice of Electroconvulsive Therapy: Recommendations for Treatment, and Privileging but there’s published research in Neuropsychiatry citing the exact same manual stating that the ECT may pose less risk of complications in elderly patients compared to pharmacotherapy, and that depressed elderly patients may have a better treatment response to ECT than young adults. The actual mortality rate from ECT is about 2 in 100,000 procedures, less than other operations using general anesthesia.
Overstated risks, understated benefits
The CCHR pamphlet also quotes Dr. Colin Ross (yes, that Colin Ross), a psychiatrist from Texas:
…the literature shows there is a lot of brain damage, there is memory loss, the death rate goes up, the suicide rate doesn’t go down. If those are the facts from a very well-designed, big study, then you’d have to conclude we shouldn’t do ECT… The literature that exists strongly supports the conclusion that it isn’t effective beyond the period of time of the treatment and there are a lot of dangers and side effects and a lot of damage.
I would agree that if the literature showed that ECT was causing brain damage, severe memory loss, death, or provided no benefit psychiatrists shouldn’t perform ECT procedures, but that’s not the case. The literature shows the ECT is safe, effective and has very few side effects. To be fair Ross stated this in 2004, and a huge amount of research has been done since then, but even at that time the research didn’t support his statement. The NIH published a statement based on a Consensus Development Conference held in 1985 and it concluded that the risk of ECT was not different from that risk associated with short-acting barbiturate anesthetics. The complication rate for ECT was 1 per 1,300 to 1,400, and was effective for a number of psychiatric conditions if the patient was not responding to pharmacotherapy. While the study states “There is also objective evidence, based on neuropsychological testing, of loss of memory for a few weeks surrounding the treatment; such objective tests have not firmly established persistent or permanent deficits for a more extensive period, particularly for unilateral ECT”, this was in 1985 and ECT has been studied much more since then and has improved a great deal.
The risk of temporary memory loss is brought up nearly every time ECT is discussed, and the literature shows that temporary memory loss used to be a very common adverse effect from ECT. The memory loss from ECT is temporary in the majority of cases, and memory problems usually resolve after a few weeks. That said, ECT has improved a great deal and the risk of memory loss occurring is much lower, and the degree of temporary memory loss is much less severe. In an editorial published in JAMA Psychiatry in 2017, Dr. Harold A. Sackeim explains that negative adverse effects resulting from ECT are directly related to the time it takes to recover full orientation following a seizure. It turns out that the recovery time had mostly to do with the anesthesia techniques and the dosing of the stimulus (the electric current) used. In the 1980s dosing of the stimulus was administered on a sine wave, and the orientation recovery times averaged several hours. Sine wave stimulation isn’t used at all anymore and was replaced by brief pulse stimulation, which delivers quick pulses of electricity in 0.5-1.5 millisecond intervals. Brief pulse stimulation has recovery times of 45 minutes for bilateral and 30 minutes for right unilateral ECT. Ultrabrief stimulation administers an electrical stimulus on intervals less than 0.3 milliseconds long, and has far fewer cognitive side effects and much faster recovery times, 15 minutes for bilateral and 10 for right unilateral ECT. As a result of improvements to how the electrical stimulus is administered, the risk and severity of negative cognitive effects following an ECT treatment have been reduced drastically.
The most recent research clearly shows that ECT more effective, safer, and has fewer adverse effects than ever before, but is underutilized. A study published in JAMA Psychiatry in 2017 that tracked the outcomes of 162,691 psychiatric inpatients found that 30-day readmission rates for patients with severe affective disorders who received ECT treatments were nearly half compared to those who did not receive ECT (6.6% versus 12.3%). ECT is particularly effective at treating major depression with psychotic features; one study found that remission was achieved in 95% of 77 patients with major depression with psychotic features, and remission was achieved much earlier in treatment. A systematic review published in the Annals of General Psychiatryin 2013 concluded that ECT was “a highly efficient option for treatment of several psychiatric disorders, achieving high rates of success remission, with few and relatively benign side effects”. The evidence shows that CCHR is grossly overstating the risks of ECT while heavily downplaying its potential benefits.
Antipsychiatry political malarkey
While ECT has been proven to be safe and effective, many people in the public believe that ECT is dangerous because the representation of ECT in films is likely the only time they’ll ever see it. That makes them much more easily swayed by the antipsychiatry movement. Antipsychiatry organizations have convinced legislators to propose legislation attempting to ban or arbitrarily restrict the use of ECT. In Pennsylvania, representatives Tom Murt and Stephen Kinsey proposed H.B 1809 that would ban ECT for people under 16. Representative Kinsey’s reasoning for proposing the legislation seems rather questionable to me:
“While ECT remains a controversial treatment for adults, it’s deplorable when done on children who have no say on whether to agree to this brutal treatment,” Murt said in a press release. “Yet, kids are still being shocked today. This treatment can cause brain damage. To me, it’s a form of child abuse. The use of electroshock therapy on children is outright cruel and unacceptable,” Kinsey said. “The side effects of ECT can be debilitating even for adults. Children should not be forced to undergo a treatment that can have a lasting impact on their physical and mental well-being. ECT sends up to 450 volts through a person’s brain, inducing a grand mal seizure. The US Food and Drug Administration reports that these seizures can cause complications including heart attacks, difficulties breathing, confusion, permanent memory loss, brain damage and death.
ECT isn’t controversial in the medical community; ECT has been proven to be effective for severe psychiatric disorders in adolescents. The review published in The Annals of General Psychiatry also stated in its conclusion that “The majority of the studies in the scientific literature show the efficiency of ECT use in adolescents and consider this approach more efficient than psychopharmacotherapy isolated”. Relatively few adolescents in Pennsylvania receive ECT; according the Department of Health and Human Services three adolescents between the ages of 13 and 17 received ECT in 2014. Obviously while this legislation wouldn’t affect many people, the three adolescents who receive ECT are doing presumably receiving treatments at the recommendation of a psychiatrist and are benefiting from it.
It’s not just Pennsylvania either, a bill was proposed on January 24 of this year in Maine to attempt to prohibit the use of ECT on anyone under the age of 18, over 65, or pregnant women. What’s most interesting to me is that the majority of people who receive and benefit from ECT are over 65. According to CCHR’s own statistics, 65-year olds receive ECT at a 360% higher rate than 64-year olds, because that’s when they’re eligible to receive Medicare benefits. As I’ve already stated, research has shown the elderly patients respond better to ECT and can experience less side effects compared to pharmacotherapy. I’m unable to find any reason stated by the representative who proposed the bill, although no reason is what it boils down to anyway. Fortunately, the bill was shot down immediately by the Committee on Health and Human Services.
Conclusion: Cool not cruel
ECT is not like what’s shown in the films, it’s done under anesthesia, it’s low risk, it has rare and often benign side-effects. The antipsychiatry movement wants to make out ECT to be the same as it is in films, a painful procedure done to punish unmanageable, often poor patients. In reality, ECT is almost always done on a voluntary basis, and unfortunately ECT is very expensive making it prohibitively expensive for the majority of patients when it’s not covered by insurance. I’m not going to litigate whether or not it’s ethical for psychiatrists to treat patients involuntarily when done so in accordance with established law and the APA code of ethics, it is. ECT can be an invaluable resource for people suffering from psychiatric disorders that aren’t responding to other treatment modalities.
The antipsychiatry movement does not care about the evidence showing that ECT is safe and effective; the antipsychiatry movement is an anti-science movement after all. The antipsychiatry movement perpetuates so many myths about ECT that even state representatives start to buy into them. Many antipsychiatry organizations such as the Citizens Commission on Human Rights are funded completely or partially by the Church of Scientology. While the history and beliefs of the antipsychiatry movement and its entanglement with the Church of Scientology is something I’d like to explore more in the future, the bottom line is that ECT isn’t something to be afraid of. ECT has improved a lot over the decades and has been a lifesaver for many people. It would be nice if Hollywood portrayed it as such more often.

Flame Retardants Have Ignited a Flaming Controversy
Flame retardants are controversial: proponents say they reduce fire damage and save lives; critics say they don’t work, are poisoning our environment, and should be banned.
Harriet Hall on January 24, 2017
Link

Flame retardants are a controversial subject. Many fire departments and chemical industry sources praise retardants for reducing fire damage and saving lives. Critics say they do more harm than good and should be banned; they are concerned about the spread of manmade chemicals in the environment and the harm they do or might do to human health. Both sides have an agenda. As with other controversial subjects like circumcision and marijuana, it’s hard to find information that is free of bias and emotion.
The history of flame retardants
Note: my source for this section is an article from the New York Times website written in 2015
In the 1970s, Tris, or Tris(2,3-dibromopropyl) phosphate, was used as a flame retardant in children’s pajamas. When Tris was found to be a mutagen, the Consumer Product Safety Commission prohibited its use in sleepwear. The ban was struck down by the courts, but manufacturers voluntarily agreed not to use it in their products. A newer version, chlorinated Tris, was also voluntarily kept out of sleepwear; but it was widely used, along with other chlorinated and brominated flame retardants, in furniture. A California regulation, Technical Bulletin 117, required upholstery foam to withstand a small open flame for 12 seconds, and the same standards were adopted nationwide. Researchers found that the standard was unrealistic: the fabric covering catches fire first, and its flames can overwhelm the flame retardants in the foam.
There were increasing concerns about health. The retardants are not chemically bonded to the foam and they can escape into the environment and contaminate everything from household dust to rivers to mothers’ breast milk. Small children may be particularly vulnerable because they put almost anything into their mouths, and their nervous and reproductive systems are still developing. Studies found lower IQs in children exposed to flame retardants.
After flame retardants were introduced, the number of home fires declined by 50%, but this could have been partly due to the decline in smoking, the introduction of self-extinguishing cigarettes, changes in building codes, and the prevalence of smoke alarms. In 2012, the Chicago Tribune published a series of alarmist articles alleging that manufacturers had waged deceptive campaigns leading to the proliferation of toxic chemicals that don’t even work as promised. Shortly thereafter, California amended its standards, requiring furniture to resist, not an open flame, but a smoldering cigarette. With the new standards, some furniture is now retardant-free.
A new generation of chemicals, PFAS (poly- and perfluoroalkyl substances) that are found in many consumer products, are considered safe by the chemical industry, but environmental researchers are concerned, saying:
It’s likely they’re going to have some health effects, it just may take us a while to figure out what that is.
Those are not the words of a good scientist. Scientists ask if there are any health effects; they don’t decide ahead of time that it is likely that there are and then go out and try to identify them.
Under the Toxic Substances Control Act of 1976, the government can only act after a substance’s potential for harm has been demonstrated. No flame retardant has ever been banned outright by the government; but some have been voluntarily phased out by industry.
There is no scientific consensus that the levels encountered in homes have any impact on human health, but critics say that is only because these substances have not been adequately tested by independent researchers.
Opinions vary
The criticism of flame retardants is exemplified by an alarmist Mercola webpage: “Flame Retardants Do More Harm Than Good, Research Shows.” He claims they have been linked to infertility, birth defects, neurodevelopmental delays, reduced IQ and behavioral problems in children, hormone disruptions, and cancer. He says they “do not work,” and they actually release toxic fumes that are more likely to kill you than the fire itself. He says these chemicals are also poisoning pets and wildlife. He suggests that flame retardants are responsible for cancers in firefighters, even while acknowledging that firefighters are exposed to hundreds of other toxic, carcinogenic chemicals during all phases of firefighting. His references include rat studies, popular publications like newspapers, and unreliable source like Rodale. He talks about studies that show associations as if they showed definitive proof of causation.
The Cleveland Clinic warns that PBDEs, polybrominated diphenyl ethers, the most commonly used fire-retardant chemicals, have been linked to numerous health problems including thyroid disruption, early onset of puberty, cognitive problems, and delayed mental and physical development. While they acknowledge that flame retardants are associated with decreased burn injuries in children, they are concerned that the long-term effects of using these chemicals in pajamas, furniture, and other products has not been adequately studied. They recommend fire prevention as the best protection for your children, and of course that is true; but there is no way to guarantee that a fire won’t happen despite the best precautions, and to my mind protection with the safer kinds of fire retardants is valuable insurance.
Pro-retardant websites are full of video arguments by chemistry professors. They tell us we each have a 1/3 probability of having a fire in our house some time during our lifetime. Flashover occurs in 3 minutes; with flame retardants, heat release is reduced and flashover is delayed, giving you up to 10-15 minutes to get out after a fire starts. There is plenty of evidence supporting those facts, and many studies that were done by independent researchers rather than by industry. Anecdotes abound. In a recent Air France crash off the end of the runway, the plane was completely destroyed by fire, but all 353 people aboard had time to escape without injury because the plane interior was treated with flame retardants. When a school bus caught on fire in North Carolina, it was totally destroyed, but all 64 children had time to escape out the rear exit without injury. (Of course, we have no way of knowing for sure how many would have died in those cases without flame retardants.) They argue that flame retardants demonstrably save lives. They say if we stopped using them, more people would die. That may be true, but I’d feel better about it if we had better studies with good controls.
Our modern lifestyle depends on polymers and other flammable materials. Water comes in plastic bottles rather than glass. Your furniture is plastic rather than wood. You can sit on a comfortable cushion instead of a hard surface. Your car is plastic. Plastics are made of carbon, hydrogen and oxygen, and the bonds are weaker than in the materials they replace; they burn far more easily. Electrical and electronic equipment and composite materials also increase the risk. Flame retardants are widely used in furniture, transportation, homes, and offices to decrease the risk. A couch without flame retardants can burn down a house in 3 minutes. People worry about toxicity, but the toxicity of a couch without flame retardants may be much worse.
A government-commissioned study in the UK reported: “Both the number and lethality of furniture and furnishing fires rose before the introduction of the regulations and fell afterwards.” It also notes, “The reduction in the rate and lethality of furniture and furnishing fires was estimated to equate to 54 lives saved per year, 780 fewer casualties per year and 1065 fewer fires per year in the period 2003-2007.” This sounds compelling, but can we entirely rule out a post hoc ergo propter hoc fallacy? The numbers declined after the regulations were in place, but how can we know if they declined solely because of the regulations?
Mercola claims that the government is not conducting chemical testing to make sure flame retardants are safe before they are marketed. In reality, the EPA must approve the marketing of flame retardant chemicals. A few compounds have been identified as hazardous, but during a recent review, the EPA identified 50 flame retardants that they concluded were unlikely to pose a risk to humans.
The evidence
What biased people say about the evidence is often misleading. In the first place, flame retardants include a diverse group of chemicals, some more toxic and some more effective than others, and they can’t all be lumped together; we must specify which one we’re talking about and how it is used in products.
One study found 4-point decrements in IQ in children whose mothers showed exposure to one flame retardant, polybrominated diphenyl ethers (PBDEs). That particular compound is no longer used, but it can still be found in older furniture and in dust in the home. Scientific American reported that study and said it was in line with other studies but they pointed out that none of the studies had demonstrated a definitive cause-and-effect link in humans. Correlation is not causation, and confounding factors might have skewed the data.
Flame retardants unquestionably can reduce the risk of fires starting and of fires spreading, as demonstrated in video tests comparing the results of exposing products with and without flame retardants to an open flame. For instance these, on the American Chemistry Council website. Admittedly, this is a pro- industry organization that supports companies and fights government regulation. But I couldn’t find any non-industry videos showing anything that contradicted their findings.
Whose version can we trust?
The person I have come to trust the most on questions like these is Dr. Joe Schwarcz, chemistry professor at McGill University and director of its Office for Science and Society. He understands the chemistry, knows how to interpret the published evidence, is not influenced by anything but science and reason, and has the good judgment to put risks into proper perspective. In his book Monkeys, Myths, and Molecules, which I reviewed for SBM, he has a chapter on flame retardants. He reports that researchers have linked PBDEs to problems in the development of the nervous system, disruptions of the endocrine system, fertility issues, behavior problems, and decreased birth weight; but they only showed associations that were not sufficient to prove cause and effect, and as he points out:
No adverse effects have been noted in foam or electronic equipment recyclers or in carpet installers, despite these workers having higher blood levels of flame retardants than the average population.
A New Zealand study compared exposures in cars to the amounts shown to be risky in animal studies and concluded that flame retardants in car seats were not likely to cause adverse health effects. Gymnasts are exposed to high levels from the foam mats and pits in the gym. In one small study, gymnasts were found to have three times the blood levels of brominated flame retardants as the general population, but no actual health effects have been found in gymnasts.
The new test standard, for smoldering rather than open flame, has been opposed by the flame retardant industry. They claim that it will erode safety. Dr. Joe comments:
That’s debatable, as is whether a decrease in exposure to a few compounds with possible hormonal effects will have an impact on our health in a world where exposure to thousands of both synthetic and natural hormone mimics is common. Hopefully with the elimination of brominated flame retardants we won’t be going from that proverbial frying pan into the fire.
Conclusion: No clear answers
We simply don’t have clear-cut, compelling scientific evidence to guide us at this point. We know flame retardants retard flame, delay flashover, and allow more time for people to escape in laboratory demonstrations; but we don’t really know how much impact widespread flame retardant use and regulations will have on real-world fires. We have concerns about possible health effects, but as yet no compelling evidence that humans are actually being harmed. In the absence of good data, some people tend to invoke the precautionary principle and say we should avoid any chemicals that “might” be harmful. I tend to invoke “the poison is in the dose” principle. We are unavoidably exposed to low levels of a host of chemicals, both natural and manmade; and our body has evolved mechanisms for coping with them. Our laboratories have become good enough to detect the tiniest amounts of all sorts of chemicals in our blood, alarming us about levels that may have no significance for health. For instance, they have found tiny amounts of uranium in our blood; the amounts are too small to worry about, they are negligible in comparison to the higher exposure to background radiation we get from living in Denver or in a brick house. I prefer to wait for clearer evidence before I worry too much about potential harms from low levels of environmental contaminants that may or may not turn out to be significant hazards for human health. Of course, we should continue studying these issues and adapt our regulations and practices as new evidence becomes available.

Are Humans Cooling? Probably Not.
Are humans cooling? According to a recent study out of Stanford, yes we are…a bit. I’m skeptical of the findings, however, and even more so of the proposed explanations. More data is needed.
Clay Jones on January 24, 2020
Link

Fever is one of my favorite topics. Our body’s physiologic response to (usually) infection by raising its internal temperature is fascinating on many levels, in particular the fact that it is so misunderstood by so many people. This has resulted in a significant amount of “fever phobia” and countless unnecessary blood draws, antibiotic prescriptions, and doses of antipyretics. I discussed this in detail in one of my earliest posts for Science-Based Medicine back in 2012:
The occasional abnormal elevation in body temperature associated with infection is as much a part of the human condition as abstract thought or the desire to lose weight without exercise or cutting calories. Commonly known as fever, this powerful yet misunderstood physiologic response has been documented in a variety of animal species including fish, reptiles and of course humans. We have all had fever at least once in our lives, and probably several times. And many of us have undoubtedly spent a few anxious nights cradling febrile little ones, afraid more of the repercussions of the fever itself than the potential sequelae of the underlying cause.
Along those lines, fever is one of the most common reasons for parents to seek medical care for their children, with roughly a third of pediatric acute care visits related to it, as well as a frequent impetus for late night nursing calls to sleepy hospitalists. Actually only about half of after-hours calls are about fever but who’s counting. Unfortunately most medical professionals, including many pediatricians, have a poor understanding of the pathophysiology of fever, and their panicked approach to its management in many children involves unnecessary laboratory tests, imaging studies, and doses of broad spectrum antibiotics. It also adds to parental anxiety and helps to establish a vicious cycle as patients of over worried caregivers tend to undergo more aggressive evaluation and treatment.
I’ve been thinking about fever, or more accurately what is a “normal” body temperature, a lot over the past week. In order to determine what a fever is, after all, you have to have a firm grasp of what a fever isn’t…right? Well, to be honest, firm isn’t exactly how I would describe our grasp of normal human body temperature. Not that we are wholly ignorant. We have it down to a decent range that is good enough for clinical purposes, but there are numerous genetic, hormonal, metabolic, and environmental variables that make determining what temperature any one healthy individual should be at any given time virtually an impossibility. And the early data upon which most people still base their understanding of “normal” body temperature, particularly the myth of 98.6°F, is over 150-years-old.
On January 7th, a paper on this topic was published in eLife that caught my attention thanks to several news articles and a Stanford Medicine press release claiming that the average temperature of humans has been steadily decreasing over the past 150 years or so. Not only do the authors claim that humans (in the United States) have been getting cooler by about .03°C on average per birth decade, they suggest several possible explanations. Though they discuss the possibility that changes in resting metabolic rate (RMR) may have played a role, they believe that the most plausible factor is a population-level decrease in inflammation:
Economic development, improved standards of living and sanitation, decreased chronic infections from war injuries, improved dental hygiene, the waning of tuberculosis and malaria infections, and the dawn of the antibiotic age together are likely to have decreased chronic inflammation since the 19th century.
To explain temperature data from more recent cohorts, when presumably the above factors would not be an issue, they raise the possibility that widespread use of anti-inflammatory medications is causing the slow decline in body temperature over time. Also mentioned by the authors was the potential role of the advent of climate controlling technology such as air conditioning:
Thus, the amount of time the population has spent at thermoneutral zones has markedly increased, potentially causing a decrease in RMR, and, by analogy, body temperature.
In my opinion, it is premature for the study authors to float possible explanations for a decrease in average human body temperatures (in the United States). We should prove that there truly is a decrease, right? The authors believe they have done this but I’m not convinced.
In order to determine that human temperature, at least in a resource rich developed region, is decreasing, the researchers looked at three cohort populations obtained over the past 157 years which involved a total of over 600,000 individual measurements. Data from each has potential issues that would make it difficult to draw firm conclusions regarding temperature trends in my opinion.
     1.  The Union Army Veterans of the Civil War, 1860-1940 (UAVCW): 23,710 individual adults, 83,900 total measurements. Unknown measurement technique (oral versus axillary) with unknown precision. Unknown time of day. Unknown ambient temperature. All male. Average age around 60.
     2.  The National Health and Nutrition Examination Survey, 1971-1975 (NHANES I): 15,301 individual adults, 15,301 total measurements. Oral temperatures, unknown precision. Time of day not available with all measurements. Unknown ambient temperature. 61% women with unknown ovulation status. Average age around 40.
     3.  The Stanford Translational Research Integrated Database Environment, 2007-2017 (STRIDE): 150,280 individual adults, 578,522 total measurements. Digital oral temperatures with known precision. Time of day available but not ambient temperature. 60% women with unknown ovulation status. Average age around 50.
Using the power of math, the authors claim that they have accounted for numerous potentially confounding variables and, most importantly, the possibility that differences may be the result of improved measurement accuracy over the decades rather than changes in human physiology. When all was said and done, they determined that both men and women, regardless of ethnicity, experienced a similar steady decline in average body temperature:
We observed a steady decrease in body temperature by birth cohort for both men (−0.59°C between birth decades from 1800 to 1997; −0.030°C per decade) and women (−0.32°C between 1890 and 1997; −0.029°C per decade).
Okay, not so fast. When I first read the paper and the accompanying press release, as well as the media coverage, there were some red flags. First off, a quote from the lead author demonstrated a perhaps not-so-solid understanding of human evolution:
“Physiologically, we’re just different from what we were in the past,” Parsonnet said. “The environment that we’re living in has changed, including the temperature in our homes, our contact with microorganisms and the food that we have access to. All these things mean that although we think of human beings as if we’re monomorphic and have been the same for all of human evolution, we’re not the same. We’re actually changing physiologically.”
To be clear, even if the study findings are true, it absolutely does not represent an evolutionary change in average human body temperature in response to environmental pressure. We aren’t cooling down because of a genetic mutation that resulted in a survival advantage in…checks notes…a world with less disease and a more comfortable life. Americans are also taller, heavier, and longer lived than 150 years ago, again not because of evolutionary changes in our physiology in response to environmental survival pressure but because of better health and easier access to large quantities of calories.
In the introduction, the authors describe how the normal range of human body temperature was largely determined by the work of German physician Wunderlich who, starting in 1851, began recording the axillary temperatures of his patients. He eventually collected data from 25,000 subjects over 15 years, amounting to millions of individual measurements, and came up with the infamous and thoroughly unhelpful 98.6°F average temperature. That useless number became chiseled into the collective consciousness of humanity, though in reality Wunderlich was a pioneer in establishing a range of temperatures in healthy and ill patients, and his work helped to establish temperature as an important factor in many conditions. Though he wasn’t the first to measure human body temperature, he was one of the first physicians to fiercely promote the idea that it was a clue to certain ailments, particularly infection.
In Wunderlich’s day, we had a very limited understanding of human physiology and have since learned a great deal about the normal variations in temperature related to hormonal cycles (higher in the late afternoon, lower in the early morning) as well as to numerous other internal and external factors. The concept of one temperature being used as a guideline for what is normal was long ago rendered meaningless and clinically unhelpful, even if it has persisted as modern day medical folklore because of cultural inertia. I do use specific values for what is a fever, 100.4F/38C in a young infant for example, but even then I recognize that this is somewhat arbitrary, purposefully oversensitive, and only one component of my assessment of a child’s risk for a life-threatening infection.
A problem when comparing modern temperature data to those measurements taken in 1851 is the fact that they were almost certainly inaccurate, although they had come a long way from the days of Galileo and Santorio. While Wunderlich and his contemporaries were well past the days of documenting human temperatures of 118F, the thermometers at his disposal could hardly be expected to have precision to tenths of a degree such as we have today. The first practical medical thermometer, which was still pretty large by today’s standards, wasn’t even invented until 1867, which means that in 1851 Wunderlich would have been using something extremely cumbersome, along the lines of a foot long instrument that took 20 minutes to yield a result.
More recent data mentioned in the eLife paper, such as a 2002 compilation of 27 modern studies and a 2017 study involving roughly 250,000 individual measurements, have found a lower average temperature of 97.9F/36.6C. The consensus conclusion from these papers is not that we are cooler but that we have better thermometers and use more accurate, though still imperfect, techniques. Taking temperatures orally with digital thermometers, for example. The authors of the new study beg to differ.
In order to support a claim that adults have gotten cooler, the study authors compared results of the above described cohorts to each other, but also looked within each cohort to compare subjects over time based on the years that they were born. They argue that each cohort would have used similar measurement techniques, thus avoiding the potential for bias of improved measurement techniques. In their analysis, they are forced to make numerous assumptions that I believe are problematic.
To give one example, the UAVCW data did not include measurement technique at all, but it is safe to assume that it consisted of a mix of both oral and axillary temperatures. These techniques yield different ranges and have different risks of measurement error. As an argument in support of ignoring the possibility that this might have made the data unreliable for their purposes of making comparisons over time, the study authors claim that axillary temperatures in the earliest cohort would have, if anything, resulted in an underestimation of the cooling.
The authors cite two modern studies finding that axillary temperatures are on average one degree Celsius lower than oral temperatures, but this is cherry picked and based on modern thermometers rather than the crude oral thermometers that would have been available at the turn of the 20th century. Axillary temperatures are more consistently found to be lower than the gold standard of rectal temperatures, but even in that case the data is varied and there is no accepted conversion. Because of wide normal ranges and the possibility for measurement bias, such as improper technique, ambient temperature differences, etc, an axillary temperature can easily be higher than an oral temperature. Ambient temperature was also unknown in the UAVCW cohort.
In addition to not knowing the ambient temperature in any of the cohorts, another glaring problem is that the time of day is not known in either of the first two sets of data. The difference in temperature from morning to late afternoon can be as much as .5C. Without the ability to take this variable into account, it is hard to have much confidence in any comparisons. Time of day was available in the third cohort, which is also the most recent and involved modern digital thermometers, so it has the most reliable data. But there are still many variables that couldn’t possibly be controlled for, and it can’t really be used to make comparisons to the older cohorts.
But if we assume that the most recent cohort, which involved measurements taken between 2007 and 2017, has no measurement errors and we can account for all the confounding variables, I still don’t see how the proposed explanations for a cooling add up. If it’s related to a decrease in inflammation, cooling should have hit a steady state by now. Regardless, it’s one set of data and would need replication.
Conclusion: Skeptical but my mind is open
As I said above, I don’t buy the claim that humans, at least in the United States, are cooling over time. My first instinct when I saw the headlines was that it’s a pretty ridiculous concept and reading the paper didn’t change my mind all that much. But the data from the most recent cohort is interesting, and I’m open to more research looking into this claim even if I honestly can’t imagine what utility it will have. Certainly there is no clinical usefulness and the proposed explanations are rather implausible.
The bottom line is that measuring temperature in humans in fraught with error and bias. Because obtaining measurements from the pulmonary artery or distal esophagus is risky, and most adults would frown upon rectal temperatures, we are forced to rely on more peripheral measurement techniques that give us an idea of what a subject or patient’s core temperature is. No technique, and there are more than just axillary or oral approaches, is particularly reliable, and what is normal is a range of temperatures throughout the day rather than one “normal” temperature.

Reverse Ageing Hype
Steven Novella on January 1, 2014
Link
There are a number of annoying clichés of science reporting, prime among them being the need to make a connection from any research to a specific application. It must be deeply embedded in the journalism culture, or written in a handbook somewhere.
In medicine this means that any study that involves viruses or the immune system’s ability to fight off infection might lead to a cure for the common cold. Any study that has anything to do with cell function might lead to a cure for cancer. Almost any study of the brain might one day cure Alzheimer’s disease.
Add to this – any study that alters a metabolic parameter that changes with age might, of course, reverse the ageing process.
Such were the headlines about a recent study in Cell looking at mitrochondrial function in mice. Here is the summary: 
Mitochondrial dysfunction is a hallmark of aging, but its causes are debated. We show that, during aging, there is a specific loss of mitochondrial, but not nuclear, encoded OXPHOS subunits. We trace the cause to an alternate PGC-1α/β-independent pathway of nuclear-mitochondrial communication that is induced by a decline in nuclear NAD+ and the accumulation of HIF-1α under normoxic conditions, with parallels to Warburg reprogramming. Deleting SIRT1 accelerates this process, whereas raising NAD+ levels in old mice restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner. Thus, a pseudohypoxic state that disrupts PGC-1α/β-independent nuclear-mitochondrial communication contributes to the decline in mitochondrial function with age, a process that is apparently reversible.
They used the magic word, “reversible” – that means to the media, apparently, the fountain of youth.
The research itself is very interesting. Mitochondria certainly are vitally important to cell function and are implicated in a number of disease processes. The more we learn about the function, regulation, and ageing of mitochondria, the better.
One thing we have certainly learned over the last couple of centuries is that biochemistry and physiology are complex webs of interactions. Our bodies are Rube Goldberg machines, evolved over millions of years to work well enough. Our biology is like code that has been patched, upgraded, and expanded millions of times – it’s a mess.
Another meta-lesson from medical science is that pulling on one thread in the complex biological web rarely has simple or predictable outcomes. If one small change has a clear positive outcome without any downsides, we probably would have evolved that solution long ago. Rather, biological interventions tend to have complex outcomes with many side effects.
What the researchers have found here is one tiny slice of the regulation of mitochondrial function – lower levels of NAD+ with ageing contribute to the decline in mitochondrial function, and artificially raising NAD+ levels restores certain measured aspects of mitochondrial function.
Here is what we do not know – what are the net effects on cell function of prolonged increase in NAD+, what are the net health effects on the organism, are such effects sustained, what are the negative effects?
The researchers, of course, acknowledge this. Reporting on this news item, however, focuses on the potential to “reverse the ageing process” in gushing terms, before finally adding the usual caveats – far enough down that most people probably won’t read that far. The BBC writes:
Experiments showed that boosting NAD levels, by giving mice a chemical which they naturally convert into NAD, could reverse the sands of time.
One week of youth-medication in two-year-old mice meant their muscles became akin to those of a six-month-old in terms of mitochondrial function, muscle wastage, inflammation and insulin resistance.
The words “reverse the sands of time,” or “youth medication” did not appear in the study publication.
The researchers note that the mice did not demonstrate any change with the treatment. Their muscle strength did not increase, despite the reported changes to the muscle cells. In the final paragraph to the BBC article they quote Dr. Ali Tavassoli, from the University of Southampton:
This could be for one of two reasons. Either they need to treat for longer so that the changes occurring in the cells have time to affect the whole organism, or alternatively, the biochemical changes by themselves are not sufficient to reverse the physical changes associated with ageing in the mouse.
More experiments are necessary to see which of these cases are true.
Which do you think is more likely? I certainly hope that increasing NAD+ levels turns out to be an elixir of youth, but I won’t hold my breath. Whenever a study of an intervention fails to find an effect it appears to be obligatory for someone to point out that the lack of effect could be because the dose was too low or the duration of treatment too short. This is, of course, generically true, but doesn’t change the fact that no effect was seen.
Take a look at this headline from The Guardian:
Harvard scientists reverse the ageing process in mice – now for humans.
This article is not about the current research – it is from 2010 and refers to a study in mice involving telomeres. The study looked at mice who lacked the gene for telomerase, which cause premature ageing and organ damage. Some of this damage was reversed when these mice were given injections to reactivate telomerase. Restoring mice to something closer to normal physiology is hardly reversing ageing.
Again, deep in the bowels of the article they discuss the fact that humans are different from mice in important ways regarding telomerase. The enzyme is suppressed as we get older to help prevent cancer from forming and spreading. Reactivating telomerase to reverse aging would likely result in rampant cancer. That is what we call a non-trivial problem.
To be clear, I am not against research into life extension or methods for limiting senescence. These are likely to be useful avenues of medical research. When reporting on such research, however, I would prefer if it were put into a more realistic context.
Ageing is not one process – it is many complex processes. No single intervention is likely to have a significant impact on overall ageing. Interventions are likely to have unwanted consequences, and overall risk-benefit will need to be carefully studied (just like with all medical interventions).
The difference here is that we are not talking about compensating for a dysfunction, but enhancing normal physiological function. This is a much trickier game.

Is Ageing a Disease That Can Be Cured?
Steven Novella on October 19, 2016
Link

There is an ongoing debate that has come to the fore recently about the ultimate limits of human longevity. The ultimate goal of medicine is to optimize health, with the result of maximizing the duration and quality of life. This is accomplished through health promotion, disease prevention, and disease treatment.
There is no question that this approach has increased life expectancy, which is the number of years one can statistically expect to live. The longevity debate is about life span – how long could a human theoretically live if they enjoyed optimal health? What is the ultimate limit of the human biological system?
A recent study by Dong, Milholland, and Vijg concludes that we are already reaching the maximal human lifespan, which they calculate at about 115 years. They looked at two statistical trends. First they looked at the age of the oldest person to die in each country, and found that this age increased from 1970 to 2000, reaching an average of about 115 years. From 2000 to present, however, this figure has peaked, and in fact trended down slightly.
They also looked at the age that had the greatest annual increase in survival. If both life expectancy and lifespan were increasing then this number should be increasing. They found that this number was also increasing from 1920 to about 1980, but then plateaued at around 100 years, and has only slightly crept up since then (101 for men, 102 for women).
From this they conclude that modern medicine has been increasing lifespan, mainly over the 20th century, but that this increase has plateaued at about 115 years for the last two decades.
Some questions about your future
A number of questions are raised by this study. The first is – are the conclusions reliable? The publication is recent, and is still being debated, so only time will tell. There are those who doubt the statistical analysis itself, and others who doubt the implications of the analysis. No one study is ever definitive, and so the question remains open to further studies. Also, at best the study is showing a recent trend in the data and it is generally folly to extrapolate current trends into the future without limit.
Let us assume for the sake of discussion that the data in the current study is reliable and tells us something meaningful about human lifespan. The most pessimistic interpretation is that we are currently at the limit of lifespan. Life expectancy can still increase, getting closer and closer to maximal lifespan. We can also improve the health span, the age to which most people remain healthy, sharp, and functional.
The next question, and the real debate that has been sparked by this paper, is whether or not this current plateau represents a limit of current technology or a fundamental limit of biology. I suspect the answer is a combination of these two things, meaning it is a limit of biology within the context of our current technological approaches. However, it seems likely that new approaches to health and ageing will extend the limits of biology, but to an unknown extent.
A friendly wager with death
This debate has manifested in a friendly wager between two longevity researchers. Steven Austad believes that the first person to live to 150 years old is already alive (he said this in 2000). Jay Olshansky disagreed, he thinks that advances to increase life span to that degree will come too late for anyone currently alive. They have each placed $300 in a long term investment account, to be awarded to the victor of this bet, or (much more likely) their heirs.
I don’t have a bet with anyone, but my take on all of this is that we are reaching some fundamental limit with our current technology. Current interventions focus on disease prevention, disease treatment, and on lifestyle habits to promote health. These interventions reduce the risk and impact of disease, and seem to have slowed the ageing process somewhat. Remember, life span has increased from about 108 years to 115 years.
Causes, and cures, for ageing
Current interventions, however, do not even address many of the known factors that contribute to ageing. According to most ageing researchers:
Ageing is the progressive accumulation of molecular damage in nucleic acids, proteins, and lipids.
Damage occurs to all the major components of cells, perhaps most importantly to DNA. This damage is repaired, but repair processes are imperfect, so over the years damaged molecules accumulate. There are other specific factors, such as the shortening of telomere length, and the accumulation of waste products that are imperfectly cleared from cells.
So, while we may be pushing up against the limits of the current approach to health (mainly disease prevention and treatment) that does not necessarily indicate the limits of entirely new approaches.
We already have an idea of what some of those new approaches might be. The “brute force” approach is to use nanomachines to repair damage, clear out waste, extend telomeres, and essentially directly support the repair mechanisms of cells. There is ongoing debate about the feasibility of this theoretical technology, and also how far in the future we might expect to see anything like this.
Other approaches could include gene therapy. We are already starting to identify genes associated with reduced disease risk and increased longevity. Genetic manipulation is more likely to help those who are not yet born, but gene therapy can also be done in adults. Again, this technology, while theoretically possible, has encountered significant practical hurdles.
Other interventions being studied include calorie restriction and pharmacological approaches. These interventions show promise in animal studies, which raises another controversial question – how much do animal models really tell us about human longevity? There are reasons to be cautious in interpreting such evidence.
Perhaps the most promising approach would involve stem cells. Rather than repairing an old damaged cell, just replace it with a fresh young cell. Grow entirely new organs. You couldn’t just grow a new brain, of course, for then the result would not be you and that would be rather pointless. It is theoretically possible, however, to slowly replace neurons and glial cells from stems cells, without disrupting continuity.
The future
My ultimate conclusion is that we simply do not know the answer to all of these questions. It does seem likely that we are reaching the point of diminishing returns in terms of life span specifically with our current medical approaches. There is still a great deal of room for improvement in life expectancy and optimizing quality of life as we age.
New medical approaches are certain to come on line and some of those have the potential to push life span even further. But, all theoretical technologies that would be true game-changers in terms of longevity are an unknown amount of time in the future. These are complex technologies with significant hurdles to overcome. We also have no way of knowing how much they will extend life span. New problems of ageing may start to emerge as we push past 120 or 130.
We will only know these answers once we get there. For now, we can only make friendly wagers.

Aging: Is It a Preventable Disease?
David Sinclair says aging is a disease that can be prevented and treated, and there is no reason life must end. The evidence he presents from scientific studies is intriguing, but far from definitive.
Harriet Hall on November 12, 2019
Link


We are living longer, but not much better. The average lifespan has increased, but the limit has not. 95% of people are dead before 100, and almost no-one reaches 115. The years at the end of life are filled with suffering and illness. Conventional wisdom tells us we will all experience a decline as we age, and we will all eventually die. Ben Franklin said nothing is certain but death and taxes. But what if death is not certain? What if we could stay healthy and live forever? Science is investigating some intriguing clues suggesting that aging and death may not be as inevitable as we thought.
David Sinclair believes aging is a disease, the most common disease, and he believes it should be aggressively treated. His book Lifespan: Why We Age and Why We Don’t Have To was published in September 2019. A PhD professor and researcher at Harvard Medical School and cofounder of the journal Aging, he is well informed. He explains how recent scientific breakthroughs have reversed the effects of aging in animal models. He has applied many of the scientific findings to his own life.
No limits?
He says, “there are no biological, chemical, or physical laws that say life must end.” There are organisms that do not age. Bristlecone pine cells do not undergo any decline in function with age. In the freshwater polyp Hydra vulgaris there are no significant differences between the very young and the very old. Certain jellyfish known as “immortal jellies” are apparently capable of living forever. The Greenland shark is estimated to live over 500 years and doesn’t even reach sexual maturity until it is 150 years old. Imagine a prepubertal 150-year-old human! A perpetual teenager?
Longevity genes?
There is no single gene that causes aging, but science has identified more than two dozen “longevity” genes that have demonstrated the ability to extend average and maximum life spans in many organisms. They also make life healthier, and can be thought of as “vitality” genes. These genes are found in every organism: trees, yeast, worms, whales, and humans.
Sirtuins are epigenetic regulators. There are seven sirtuins in mammals. They mute the chronic inflammation that drives many chronic diseases like atherosclerosis, arthritis, and asthma. Studies in mice have shown that they improve DNA repair, boost memory, increase exercise endurance, and help the mice stay thin. Nicotinamide adenine dinucleotide, or NAD, is required by sirtuins. TOR (=Target of Rapamycin) is a complex of proteins that regulates growth and metabolism. AMPK (adenosine monophosphate-activated protein kinase) is a metabolic control enzyme that plays a role in cellular energy homeostasis; it responds to low energy levels.
Sirtuin-activating compounds have been identified, such as fisetin and butein. Resveratrol outperforms both of these. It is considered a calorie-restriction mimetic. It has been shown to protect against several diseases, to extend lifespan in several species, and to make human cells resistant to DNA damage in the lab.
NMN, nicotinamide mononucleotide, increases NAD levels. It has been shown to extend life and protect against various diseases in mice; it is still being investigated.
Metformin, the diabetes drug, impacts many diseases and extends life. It activates AMPK, makes more NAD, and turns on sirtuins and other anti-aging defenses.
Experimental evidence
He describes many fascinating experiments in organisms from yeast to mice. Some of his many examples:
    • Researchers were able to speed aging in mice:
We’d simply broken the mice’s DNA in places where there aren’t any genes and forced the cell to paste, or “ligate,” them back together. Just to make sure, later we broke the DNA in other places, too, with the same results. Those breaks had induced a sirtuin response. When those fixers went to work, their absence from their normal duties and presence on other parts of the genome altered the ways in which lots of genes were being expressed at the wrong time.
    • In another experiment, mice were given NAD to increase the activity of sirtuins. They became ultra-marathoners and exercised so enthusiastically that they broke the lab’s treadmill.
    • NMN has anecdotally restored fertility in aged women.
His hypothesis about the cause of aging
His extensive knowledge of research findings led him to this conclusion:
Whenever epigenetic factors leave the genome to address damage, genes that should be off, switch on and vice versa. Cells malfunction. Chaos ensues…aging is caused by overworked epigenetic signalers responding to cellular insult and damage.
He believes a loss of information is the singular reason why we age. Not just digital information, but epigenetic information that is analog rather than digital. He characterizes the genome as a computer and the epigenome as software. The genetic information is the same in every cell; the epigenome is what instructs a cell to develop into a kidney cell rather than a heart cell. His definition of epigenetics differs from the generally accepted one, which defines it as heritable phenotype changes that can be passed on to subsequent generations.
A bit of adversity or cellular stress is good for our epigenome because it stimulates our longevity genes. It activates AMPK, turns down mTOR, boosts NAD levels, and activates the sirtuins—the disaster response teams—to keep up with the normal wear and tear that comes from living on planet Earth.
Sinclair calls it hormesis, the idea that a low dose (of stress) can be beneficial while a high dose is harmful. I’m not entirely convinced that this concept is applicable to aging. Some reports of hormesis have been questioned; it is a real phenomenon, but it may not be common or important.
Smokers age people faster. Smoking causes DNA damage and keeps the repair crews working overtime, resulting in epigenetic instability and aging. Sinclair says non-smokers are bathing in DNA-damaging chemicals too. Even breathing can damage DNA through air pollution, and we are exposed to many DNA-damaging chemicals in plastics, dyes, solvents, pesticides, hydraulic fluid, many foods, background and medical radiation, etc.
Longevity genes are activated by stress, but stressors can activate longevity genes without damaging the cell, through exercise, intermittent fasting, low-protein diets, and exposure to hot and cold temperatures. These benefits can also be mimicked by a single pill. He has applied these concepts to his own life. He is doing those things and taking those single pills – several of them (see below).
He acknowledges that the research is preliminary: “It will take some time to sort out which of these molecules are best, when, and for whom. But we’re getting closer every day.”
According to Sinclair, nine hallmarks of aging have been identified:
     1.  Deregulated nutrient sensing
     2.  Loss of proteostasis
     3.  Altered intercellular communication
     4.  Telomere attrition
     5.  Mitochondrial dysfunction
     6.  Stem cell exhaustion
     7.  Cellular senescence
     8.  Epigenetic alterations
     9.  Genomic instability (DNA)
Addressing one of these might slow down aging. If you address all of them, you might not age. But we can’t be certain there aren’t more hallmarks that have not yet been identified.
Sinclair says,
There is nothing wrong with using the hallmarks to guide interventions. We can probably have a positive impact on people’s lives by addressing each of them. It’s possible that interventions aimed at slowing telomere deterioration will improve people’s long-term well-being. Maintaining proteostasis, preventing deregulation of nutrient sensing, thwarting mitochondrial dysfunction, stopping senescence, rejuvenating stem cells, and decreasing inflammation might all be ways to delay the inevitable. Indeed, I work with students, postdocs, and companies around the globe that are developing solutions to each one of these hallmarks and hope to continue. Anything we can do to alleviate suffering we should do…But we’re still building nine dams on nine tributaries…Together we can build a single dam – at the source.
His predictions
It may be possible to vaccinate against aging.
Once you recognize that there are universal regulators of aging in everything from yeast to roundworms to mice to humans . . .. and once you understand that those regulators can be changed with a molecule such as NMN or a few hours of vigorous exercise or a few less meals . . . and once you realize that it’s all just one disease . . .it all becomes clear: Aging is going to be remarkably easy to tackle. Easier than cancer.
Maybe the aging process can be reset, like removing the scratches that prevent a damaged DVD from being read. Experiments with stem cells and cloning are intriguing. Gene therapy shows great promise but there are ethical concerns. Genetic analysis and new technologies are making great strides.
if even a few of the therapies and treatments that are most promising come to fruition, it is not an unreasonable expectation for anyone who is alive and healthy today to reach 100 in good health.
But he acknowledges that scientific proof will require double-blind placebo-controlled trials.
The first part of the book provides valuable information about cutting-edge research. The latter part of the book descends into speculations and opinions about global warming, overpopulation, food security, GMOs, poverty, CRISPR, research funding, jobs, the cost of health care, euthanasia, and various other political and ethical issues.
The author’s personal regimen
The final chapter includes a brief subsection “What I Do.” He doesn’t say everyone should do what he does. He makes no recommendations for others except “Eat fewer calories”, “Don’t sweat the small stuff”, and “Exercise”.
But he argues that if he does nothing, he will age and die, so he has nothing to lose by trying unproven treatments, and he has personally chosen to do these things:
    • He takes a gram each of NMN, resveratrol, and metformin daily.
    • He takes vitamin D, vitamin K2, and 83 mg. aspirin.
    • He limits sugar, bread, and pasta intake, doesn’t eat desserts, and avoids eating meat from animals.
    • He skips one meal a day.
    • He gets frequent blood tests to monitor biomarkers; if not optimal, he tries to moderate them with food and exercise.
    • He stays active, goes to the gym, jogs, lifts weights, uses the sauna and then dunks in an ice-cold pool.
    • He doesn’t smoke.
    • He avoids microwaved plastic, excessive UV exposure, X-rays, and CT scans.
    • He tries to keep environmental temperatures on the cool side.
    • He maintains a BMI of 23-25.
He plans to fine-tune his regimen as research evolves. He acknowledges “It’s impossible to say if my regimen is working…but it doesn’t seem to be hurting.” He says he feels the same at 50 as he did at 30.
You could follow this or similar regimens all your life and never know for sure if it was helping; and if it was, which components of the regimen were responsible.
Conclusion: Intriguing, but no definitive evidence
The experimental findings in other organisms are very impressive, but there is no actual evidence that they can be applied to extend lifespan and healthspan in humans. Proving that will require long-term studies and careful teasing out of meaningful data from noise and possible confounders. In my opinion, it is premature to apply current preliminary research findings to treating humans. It’s possible that some of these measures could interfere with the others and that there could be unforeseen consequences.
I sincerely hope Sinclair will be proven right, that aging is a treatable and preventable disease, that the human lifespan has no limits, and that the elderly can be treated to maintain youthful standards of health and activity. But I’m not convinced by his arguments. I would have to see better evidence before I would embark on a regimen like Sinclair’s. Meanwhile, there are plenty of evidence-based actions we can all take to better our health, like exercising, eating a nutritious diet, avoiding tobacco, and controlling weight.

Cold reality versus the wishful thinking of cryonics
David Gorski on August 2, 2014
Link
We all seek immortality in some way. Death has been one of the prime terrors haunting us since humans first started realizing that every living thing dies and death is permanent. After all, no one wants to face the end of everything that one has been, is, and will be. Indeed, a key feature of many religions is a belief that death is not the end, that there is an afterlife where we will all live forever. In some religions, in the afterlife evil is punished and good rewarded. Even if, as seems most likely, death is simply the end, and the time after death is just like the time before we were born (or, more properly, before our first memories), something that seems relatively benign just thinking about it, emotionally we still don’t want it. Being human, I get it, particularly now that I’m on the wrong side of 50 and, unless I’m far more long-lived than my genes are likely to permit, have considerably less life to look forward to than the lifetime I’ve already lived. I also realize that the number of people who are remembered long after they are gone by anyone outside of their family and friends is exceedingly small—and even that memory fades rapidly among family members. As the succeeding generation dies off, direct memory of the generation that spawned it disappears. I get it. Fifty years from now, it’s likely that all that will remain of my existence will be some scientific papers and a faint memory held by my nieces and nephews and maybe, if I’m lucky, a few of my youngest readers.
I don’t, however, get cryonics.
Detroit, like many large cities, has a free weekly “alternative” newspaper, The Metro Times. This week’s issue features this cover:
Yes, it’s a cover story about cryonics. I had no idea that there was actually a budding cryonics industry around the Detroit area. Given the unfortunate decay of my hometown during my lifetime and the brutal winter we endured last year in southeast Michigan, the jokes write themselves. I’ll resist the temptation, however, other than that brief acknowledgment. I’m more interested in the article itself, “MI Cryonics Inst. freezes dead for ‘reanimation’: Souls on ice“. If there’s a movement that resembles religion in having faith in something that doesn’t have evidence to support it, the cryonics movement is it. The article opens by describing a facility in Clinton Township, a suburb north of Detroit, where the body count tops 100, not counting critters, and “nestled inside Wal-Mart sleeping bags, the bodies stand upside-down within 10-foot-high tanks resembling immense white thermos bottles”:
This is the Cryonics Institute, and the people in those tanks — “cryostats,” they’re called — after being declared dead, have had their bodies frozen in perpetuity in the belief that future science may be able to thaw them, cure their ills, and, just maybe, return them to youthful vigor. They’ve made a bet: that in a time yet to come, they’ll rise again, with “death” only a temporary and reversible embarrassment easily remedied by medical know-how.
It’s an expensive bet that is likely never to be won. What struck me most reading this article is the power of wishful thinking, which has led an industry to spring up catering to our most primal fears and desires: Fear of death and desire for immortality. Admittedly, it’s a relatively small number of people. The article itself estimates that worldwide the number of people being frozen after death is “in the low double digits” every year. Out of the billions of people on this planet and the more than 50 million a year who die worldwide, we’re looking at an infinitesimally small fraction of the population.
Be that as it may, there’s no doubt that the technology to freeze living mammals (which is what humans are) has improved greatly and continues to improve. Unfortunately, there remains that problem of revivifying the frozen meat that is sitting in all that liquid nitrogen. Basically, when a person dies, something killed him. It could be disease. It could be trauma. It could just be some unlucky transient malfunction of an organ, such as a sudden arrhythmia that might have been survivable if treated in time or that a person might have had periodically, asymptomatically, for years but that until a single fatal incident resolved on its own. It could just be old age, the “running down” of the body. Even if it were actually possible to revive a frozen body, whatever killed the person would still be there.
Believers handwave that problem away:
“We’re not trying to bring people back to life. We don’t believe they’re really dead; if dead’s final, then they weren’t dead,” says Dennis Kowalski, president of the Cryonics Institute, which claims to have 1,100 living members worldwide. Members pay yearly dues of $120, or $1,250 for a lifetime membership, then about $28,000 when actually frozen. (In comparison, the average adult funeral in the United States costs about $8,000.) For many, life insurance benefits cover the preservation costs.
And:
But death is a gray line, Kowalski says, and it’s always moving. What might have been terminal 150, 15, even five years ago is treatable today. Something as simple as CPR has saved countless lives; cardiac defibrillation — the “shock paddles” used to jump-start a stopped heart — has revived patients previously considered dead. What’s “dead” mean to medicine, other than a challenge? From that perspective, he says, a storehouse of frozen bodies is no more macabre than a heart transplant, a now-common medical procedure once considered grotesque.
It all reminds me of this classic cartoon:
The problem, of course, is that advocates of cryonics never seem to be explicit in step two.
You can see this from the utter nonsense of the example of defibrillation. CPR and cardiac defibrillation can save lives because a fibrillating heart is still alive. Indeed, the cardiac muscle cells are still contracting and have electrical activity; they’re just doing so in a disjointed way that doesn’t produce meaningful contractions of the muscle mass that can produce any pumping power. If you’ve ever actually seen a heart that’s fibrillating, you’ll notice that it’s lamely twitching. Boiled down to its essence, the idea of the electrical shock is to “reset” all the cells to allow the intrinsic electrical pacemakers of the heart to take over and get them contracting in unison again. A heart that’s just lying there is in asystole, which is a state that defibrillation can almost never reverse, so much so that cardioversion isn’t even recommended anymore in the ACLS algorithm for aystole.
That’s why the ability of these interventions to save life rapidly declines with time after cardiac arrest. Within minutes, the heart muscle cells, deprived of oxygen-rich blood, start really dying. Once they do, no amount of CPR or defibrillation will get them working again. Basically, as soon as the heart stops, heart muscle cells start dying, and the more of them that die, the less the chance of getting the heart started again. Before defibrillation, patients only appeared “dead” because death at the time was defined as no pulse, no breathing, and no heartbeat, and the technology to get the heart going again before irreversible damage to the heart muscle occurred didn’t exist. Even so, occasionally people would “wake up” in response to a sharp blow to the chest.
The problem of the dead heart, however, is minor compared to the problem of the dead brain. The brain is highly metabolically active and is thus exquisitely sensitive to interruptions in blood flow. As soon as the blood flow stops from a cardiac arrest, the brain starts losing cells, and it only takes a few minutes before severe and permanent brain damage occurs that rapidly progresses to brain death; i.e., the death of the neurons controlling the “higher’ functions. Sadly, many are the times that patients in cardiac arrest have been resuscitated, only have severe anoxic brain injury (injury due to lack of oxygen) or be brain dead. Granting the fantastical assumptions behind the cryonics movement, specifically that dead people can be frozen and then successfully revived, what about the brain? Everything that defines your consciousness and personality comes from the function of your brain.
Look at it this way. Memory is stored in the neural network somehow through poorly understood protein changes. Freezing usually involves the formation of crystals, which could easily disrupt those changes. If the brain could be frozen without those crystals, theoretically the information might still be there (assuming, of course, that the body was frozen before the brain turned to mush from hypoxic injury). However there remains the question of recovering that information, which inevitably results in cryonics advocates, in essence, appealing to magic in the form of super future technology, most often nanobots. That’s not even counting fixing the physical damage to the brain from hypoxia that occurs after the cessation of blood flow and the freezing process itself, given the number of connections between the many billions of neurons in a single human brain.
Once that’s gone (or irreparably damaged), you’re gone. I like the way they put it in Rational Wiki: “Once you’ve fixed the body cells and the brain paths, you have a recovered corpse. Your next task is to resurrect the dead.” Just count the number of beliefs that are nothing more than wishful thinking in this paragraph:
Right now, though, cryonics is more like an in-progress medical trial. Advances in stem-cell research, nanotechnology, and therapeutic cloning give Kowalski and other cryonicists hope, but he admits there are no guarantees. Today’s frozen people are already dead, or “deanimated,” as some prefer; tomorrow’s helpful scientists will not only have to successfully thaw their “patients,” but return them to life. (And reunite them with their pets, though some are frozen out of generosity, their owners simply hoping to give their beloved animals more life.) That’s assuming, fingers crossed, that they’ve been frozen in a recoverable way, without too much tissue damage, and that they’ve been carefully maintained. Once thawed, they’ll have to be treated for being “dead,” by whatever methods would make that possible. And who wants to wake up alone in the future in a body already ravaged by time? Better to hope that a new, youthful body is waiting for you.
And if wishes were fishes…oh, never mind.
But think about it. First of all, such technological breakthroughs, even in the unlikely event that they were possible, are likely many decades, or even hundreds of years, in the future. If you were frozen and then revived, everyone you know, everything you knew in your life, would be gone. In its place would be a society where you would have no idea how to function and might not even be able to speak the language, given how language evolves over that span of time. Imagine, for instance, being transported back to Shakespeare’s time (in England, of course) and trying to communicate. You wouldn’t know anything that would allow you to make your way in the world. You’d be a curiosity to be studied at best, a burden on society at worst, all of which ignores the question of whether some future society and scientists would even want to revivify a bunch of decades- or centuries-old bodies. They might want to do a few to prove it could be done, but after that each succeeding body would just be another burden. Sooner or later, the scientific interest would wane, as would the desire to devote resources to it.
But what about the science? Cryonicists often point to the widespread freezing of embryos for in vitro fertilization (IVF), and it’s true. That works very well, and the viability rate after thawing is quite high. Of course, for IVF, we’re talking about structures that are usually only eight cells. As a biomedical researcher, I know that it’s quite possible to freeze human cells for cell culture indefinitely and revive them with only relatively small percentages of cells dying. There’s a huge difference between freezing suspensions consisting of single cells or embryos consisting of a cluster of a few cells and freezing a large mammal like a human being. It’s often pointed out that there are cases in which humans have survived severe hypothermia and been revived after warming. Such cases are relatively uncommon (most still die), and I can’t help but note that in no cases that I’ve been able to find has a “human popsicle” (i.e., a human frozen solid) ever survived and been revived.
Let’s just put it this way. Even though some small animals, particularly cold blooded animals like frogs, can survive partial freezing and some insects can survive freezing, that doesn’t mean cryonics is feasible. Indeed, lacking examples of a single decent-sized mammal being successfully frozen and revivified, I have a hard time seeing the promise of cryonics being the least bit feasible. After all, if we can’t even freeze a living animal in liquid nitrogen and revive it, what makes one think we can freeze a dead human and revive him or her? Let’s just put it this way, the plausibility of cryonics doesn’t quite reach homeopathy-level, mainly because it doesn’t require violating well-accepted laws of physics, but that’s the only reason it isn’t homeopathy-level. When Michael Shermer is quoted in the article saying “It is not impossible for cryonics to succeed; it is just exceptionally unlikely,” from a scientific standpoint he is being exceptionally optimistic.
Perhaps what’s the worst about this is that people spend incredible amounts of money, which could be used to make their lives now better or be passed on to their heirs, chasing immortality. Cryonics is not, as its advocates say, an “ongoing medical trial”. Rather, those who choose to freeze themselves are more akin to the ancient Pharaohs, who spent enormous resources constructing elaborate tombs, so that they will one day rise from the grave and live again. Instead, they are found thousands of years later and end up in museums around the world.

If You Think Doctors Don’t Do Prevention, Think Again
Harriet Hall on August 9, 2016
Link


One of the common criticisms we hear from alternative and integrative medicine proponents is that doctors don’t do anything to prevent illnesses and have no interest in prevention. They claim that doctors are only trained to hand out pills to treat existing illnesses. Sometimes they even accuse them of deliberately covering up cures and wanting to perpetuate illnesses like cancer so they can make more money by treating patients. Nothing could be more absurd. Every reputable doctor would rather prevent illnesses than treat them. In his book Heart 411, cardiologist Steven Nissen even said he would be glad to see his specialty become obsolete: “Don’t worry about us; we will gladly hang up our scalpel and stethoscope if we can find a better way to lead you to a heart-healthy life.”
Doctors own prevention. They invented it, from vaccines to clean water to preventive screening tests. Mainstream medicine was responsible for the greatest preventive achievement in history: the smallpox vaccine campaign succeeded in preventing anyone from ever getting smallpox again. I defy you to comb through historical records and find any doctor who ever said “Let’s stop vaccinating for smallpox so we can make more money treating its victims.”
Prevention is one of the six fundamental principles of naturopathy. Alternative practitioners pride themselves on prevention, but they don’t actually do a very good job of it. In fact, there is evidence that their patients are less likely to get immunizations and some of the standard preventive screening tests recommended by the USPSTF. Instead of rigorously implementing evidence-based preventive strategies, they tend to offer other speculative, untested recommendations.
Preventing Zika virus infections
The current Zika crisis is a case in point. Doctors are doing prevention. Mainstream medicine has responded with mosquito eradication programs, effective mosquito repellents, travel advisories, and public information campaigns. Two experimental vaccines have already been proven effective in mice, and human trials are already underway.
Meanwhile, what are the CAM folks doing? Recommending things like these:
    • Treating clothes with essential oils.
    • Natural mosquito repellents like lemon eucalyptus oil, lavender and garlic.
    • Eating vegetables rich in vitamins A and C and taking a daily Arogyam Pure Herbs Madhuparni tablet.
    • Home remedies that they claim will cure Zika infection naturally:
        ◦ Diatomaceous earth or clay.
        ◦ Homeopathic Eupatorium Perfoliatum
        ◦ Papaya leaf juice
Mike Adams of Natural News warns:
If the Zika virus spreads into a devastating pandemic, it will only be because natural cures that already exist in nature are being systematically suppressed or criminalized by our corrupt, criminally-run medical police state system.
No, I don’t think so!
Bottom line: doctors are doing real prevention; non-doctors are doing bogus prevention.
The medical literature
Anyone who thinks doctors don’t do prevention must not be reading medical journals. Much of the medical literature addresses prevention rather than treatment. A recent review article in the American Family Physician, the journal of the American Academy of Family Physicians, is a good example. The title is “Diet and Physical Activity for Cardiovascular Disease Prevention” and its six pages and 36 references contain not a single mention of statins or any other drugs. It provides evidence-based recommendations to follow a DASH or Mediterranean diet and to get at least 150 minutes of moderate-intensity aerobic activity, 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination each week.
What do naturopaths recommend for cardiovascular disease prevention? They may make the same evidence-based diet and exercise recommendations, but they also recommend non-evidence-based interventions like avoiding dairy, eating organic whole foods, taking vitamins and arginine, and using herbal dietary supplements like gingko and hawthorn. Some recommend CoQ10, omega-3 fatty acids, green tea, pomegranate, magnesium and potassium. And others add cinnamon, ALA, lutein, and plant sterols.
There are pragmatic studies claiming that the addition of naturopathic care to standard care decreases cardiovascular mortality, but pragmatic studies can’t determine effectiveness. Many of those studies are flawed and not properly controlled. They fail to distinguish between the effects of intensive counseling and the effects of the natural remedies they added. And those natural remedies are all over the map, so it is impossible to meaningfully compare studies or to determine which elements actually worked. I have seen no evidence that a patient under the care of a typical naturopath is any less likely to have a heart attack than the patient of a typical mainstream clinician.
What the critics really mean
When they claim “doctors don’t do prevention,” what they really mean is that they don’t think doctors spend enough time advising patients about things like exercise and diet. They seem to think doctors should take a detailed diet history from each patient and provide detailed personalized recommendations for what to eat at each meal. But that is not the job of doctors; that is the job of dietitians. Doctors understand the principles of good nutrition and provide general advice, but refer patients to dietitians for the nitty-gritty details.
Critics often have an exaggerated idea of what diet and lifestyle measures can accomplish. Only about a third of cancers are preventable by diet. Some people believe that if you eat right you can’t possibly get sick, and a recent commenter on this blog claimed that even genetic diseases could be reversed in three years by proper diet! They are wrong.
The critics cite anecdotes about patients who say they were given prescriptions with nary a word about preventive measures: for instance, statins to prevent cardiovascular events but no advice about weight loss, exercise, or heart-healthy diet. That may happen, but I suspect it is the exception rather than the rule.
I question the reliability of patients who claim their doctor never once mentioned smoking, weight loss, exercise, or diet. Memory is fallible. Studies have shown that 40-80% of medical information provided by healthcare practitioners is forgotten immediately, and half of the information that is remembered is incorrect. And surely people are less likely to remember advice that they didn’t want to hear.
The official guidelines for statins have been widely criticized, but the critics rarely acknowledge this paragraph from the report:
It must be emphasized that lifestyle modification (i.e., adhering to a heart healthy diet, regular exercise habits, avoidance of tobacco products, and maintenance of a healthy weight) remains a critical component of health promotion and ASCVD risk reduction, both prior to and in concert with the use of cholesterol-lowering drug therapies.
We can do better
Instead of “doctors don’t do prevention,” a more valid criticism would be “doctors don’t do as good a job of prevention as they might.” That is something doctors acknowledge and are already constantly working on, looking for effective ways of getting patients to understand and retain information and effective ways of improving compliance. And doctors don’t carry the responsibility for prevention alone. As with horses, doctors can lead patients to water but can’t make them drink. Doctors can encourage their patients to exercise but they can’t stand over them with a whip and make them get up off the couch. Doctors can lead patients to a healthy diet but they can’t follow them around 24/7 and slap their hand away if they reach for a slice of pecan pie instead of a piece of fruit.
Saying doctors don’t do prevention is a vile, ignorant canard. Showing how they could do better would be helpful, constructive advice.

Health Benefits of the Weekend Warrior
Steven Novella on December 11, 2024
Link

I tend to view skeptically science reporting that leans heavily on simplistic concepts and flashy titles. However, “skeptical” does not mean “dismissive”. Mainstream reporting may focus on click-bait terms but that does not necessarily mean anything about the underlying science.
I have seen lots of recent headlines about the benefits of being a “weekend warrior” and decided to look at the primary research. The net benefits of getting most of your physical activity over the weekend, rather than spread throughout the week, are not intuitive. Being relatively inactive for 5 days a week may have it’s own negative health impacts. Also, trying to compensate for lack of time with increased intensity can have its risks. But at the same time, a “week” is an artificial construct, not a biological concept, and so perhaps averaging physical activity over this timeframe may be just fine.
Let’s look at the recent study prompting those headlines – Associations of “Weekend Warrior” Physical Activity With Incident Disease and Cardiometabolic Health. First I note that the “weekend warrior” meme comes from the researchers and is not an invention of the media. This does not mean it’s automatically a good thing – often researchers or press offices will use techniques to increase the visibility of their research and the media happily comply. But in this case I think it’s a benign shorthand for people who get most of their exercise on the weekend.
The study looks at “89,573 participants (62±8 years of age; 56% women) of the UK Biobank prospective cohort study who wore an accelerometer for 1 week between June 2013 and December 2015.” So this is a retrospective correlational study (even though the data comes from a prospective cohort study). It is not controlled or blinded. The advantage of these kinds of studies is that you can look at large numbers of subjects. The downside is that it is difficult to account for every possible confounding factor.
One apparent weakness is that subjects only had to wear an accelerometer (like a FitBit) for one week. We cannot assume this one week is representative of their long term activity.
They broke the subjects into three groups – <150 minutes of moderate or greater physical activity per week, >150 minutes per week but with 50% or more concentrated in two days on the weekend, and >150 minutes but spread out more evenly throughout the week. When compared to the inactive group, the weekend warrior group and the regular exercise group both showed a significant decrease in risk for >200 conditions assessed. The associations were strongest for cardiovascular disease. When compared directly to each other, there was no difference between weekend warriors and regular exercisers. There was also no difference when compared to those who got >230 minutes of exercise per week.
Taken at face value, this can be seen as good news. I think what this data is telling us is that being inactive is extremely unhealthy, and that any exercise is better than no exercise. First, moderate exercise is sufficient to see the health gains demonstrated in this study. This can include walking, doing housework, or pretty much anything where you are standing and moving around.
Further, the bulk of the benefits are seen with 150 minutes of exercise per week, regardless of how it is distributed. So if you can get out for a two-hour walk on a Saturday to supplement your daily physical activity of just going about your business, that can get you to the threshold. Or you can take a 30 minute walk in the evenings. This kind of physical activity can be achievable for most, even older, people.
It’s important that when making public health recommendations that we don’t make the perfect the enemy of the good enough. The notion of “regular exercise” may seem intimidating to many people, either because of their busy schedule, or because they have physical limitations. Often the concept of “exercise” is paired with imagery of people in their 20’s engaging in vigorous exercise. So it’s important to get the message out there that even modest amounts of moderate exercise (equivalent to walking) has demonstrable health benefits. Again, this can be framed as, an extreme sedentary lifestyle has health risks.
On the other hand, this research is not saying that there are no benefits to exercise beyond this minimum threshold. Resistance exercise can build bone and muscle, or maintain bone and muscle, which has huge impacts on quality of life for older adults. There are also aspects of “fitness” that go beyond disease prevention, which was the focus of this study.
One other general point to pull out of this study is that the benefits of lifestyle factors are often not linear. It is a cognitive bias in humans that we tend to default to linear assumptions (the so-called linearity bias). But the world is often not linear. In medicine this often manifests as the assumption that if a little is good, then more is better, and extreme amounts will have extreme benefits. This is the faulty logic behind megadosing vitamins.
Here we are seeing massive benefits when going from little to no exercise to moderate exercise, and then a relative plateauing of benefits beyond 150 minutes of moderate exercise per week. Other research shows continued increase in benefits (depending on the outcomes followed), such as this study of A-fib which found the benefits of exercise continued even to the >300 minutes per week group. But still, the steep part of the curve is at the low end.
This is often the case, and a good general approach to health – avoid extreme unhealthy lifestyles, pick the low-hanging fruit wherever possible. Most of the health benefits are likely to be found with just moderate good lifestyle choices, without the need for extreme routines or diets.
We can also take an “intention to treat” approach to lifestyle recommendations. Emphasizing extreme or difficult choices may cause many people to throw up their arms in defeat and do nothing. But emphasizing the benefits of just moderate choices are more likely to change behavior.


Biohacking Backfires: When Self-Tracking Can Harm
Is your fitness tracker helping or hurting your health?
Scott Gavura on June 19, 2025
Link
Here’s my own smartwatch helping motivate me.
Last week my Garmin smartwatch gave me an update after a week of strength workouts, bike commutes, and two runs: “Training Status: Unproductive.” Subjectively I had been feeling pretty good, fitting in so much exercise despite a busy week. And yet, here was my watch, crunching thousands of data points into a single demoralizing status. I felt unfairly judged. Or was the watch onto something? Was I really training ineffectively? Or are these devices that promise optimized training plans and inevitable personal bests actually counterproductive, especially when their feedback starts to affect our mood, motivation, and mental health?
25 Years of Wearables
I am not a Luddite when it comes to wearable technology. I was marathon running with a Polar heart rate monitor back in the early 2000s, with an awkward chest strap and no way to export the very limited data. At the time, this type of measurement was mostly reserved for serious athletes. Eventually I upgraded myself to a Garmin GPS that was absolutely massive – but it could track so much running data! But these devices were strictly for workouts only.
The first mainstream consumer tracker, the Fitbit, launched in 2009. Since then, wearable fitness devices have exploded in popularity, promising to help us “optimize” our workouts and our lives with real-time feedback on everything from heart rate and sleep quality to training load and stress levels. Millions of people now wear devices like Garmin, Fitbit, Oura and Apple Watch not just to count steps, but to establish training schedules, monitor our sleep “quality”, and track our recovery. The appeal is obvious: objective data, personalized recommendations, and a sense of “control” over our health. But as these tools become more sophisticated and prescriptive, questions have been raised: How accurate are these devices? Is the advice they provide evidence-based? And to some, could all this tracking and data do more harm than good?
The Optimizer’s Curse
For some users, wearables have shifted from helpful tools to relentless performance auditors. Reddit is filled with posts from people who feel anxious when their heart rate spikes unexpectedly, guilty for missing step goals, or demoralized by poor “sleep scores” despite feeling well-rested. A recent article in Vox, entitled, I covered my body in health trackers for 6 months. It ruined my life. describe one person’s negative experience:
In the six months I spent hooked up to every health tracker I could find, feeding my morbid curiosity, I drove myself slightly crazy. Each hit of dopamine I enjoyed by getting good scores on a health-tracking app was offset by long periods of self-doubt that came from not fully understanding how to make sense of the torrent of data without my doctor’s help. I also became obsessive — checking the apps was the first thing I did in the morning and started occupying hours of my day.
That’s the contradiction embedded in this cutting-edge technology: It can often lead to panic rather than peace of mind.
In some cases, wearables encourage healthier behaviors, motivating people to move more, sleep better, or pay closer attention to how their body responds to training. But for others the constant stream of biometric data can lead to anxiety, self-doubt, and stress. When a device tells you your body is underperforming, even if you feel fine, who do you believe?
What the Evidence Says (So Far)
There is research that shows wearables can lead to modest improvements in health behaviors, at least in the short term. And the evidence base is growing. Most clinical trials and systematic reviews have focused on chronic disease management, cardiovascular health, physical activity, and psychological well-being.
Wearable smartwatches are associated with improvements in physical activity, self-management behaviors, and some surrogate health outcomes. A 2024 systematic review of smartwatch interventions found positive effects on outcomes such as foot ulcer recurrence, depression severity, healthcare utilization, lifestyle changes, medication adherence, unplanned hospital readmissions, atrial fibrillation diagnosis, and goal attainment for emotion regulation. The most used smartwatch was the Apple Watch. However, the review noted that the number of high-quality studies is actually quite limited, with only moderate quality: most studies were small and of short duration.
Other studies have found that using fitness trackers is associated with increased daily step counts and higher physical activity levels. A few randomized trials have shown small benefits for weight loss or cardiovascular risk factors. Direct impact on measurements like blood pressure or cholesterol are not as consistent. Effects are often modest, and long-term adherence tends to decline over time. While wearable technology shows promise for improving certain health behaviors and intermediate outcomes, persuasive evidence for long-term clinical benefit is still lacking. As “they” say, more research is required.
Effects on Mental Health
While wearables may support healthier behaviors, their psychological effects are more complex. For some, tracking activity, sleep, or recovery provides structure and motivation, potentially reducing stress and improving self-efficacy. Wearables are now being studied for monitoring and early detection of depression, anxiety, and stress. It’s hoped the devices can support self-management, and reduce psychological distress.
However, there is also evidence of wearables being associated with overuse or obsessive tracking. In some, wearable data may contribute to health anxiety, compulsive tracking behaviors, and even negative or maladaptive compensatory behaviors (e.g., disordered eating). Data overload, and the potential for misinterpretation of health data may negatively impact mental health, particularly in those that may be vulnerable. Obsessively checking heart rate, sleep scores, or recovery status may aggravate stress, especially when the reports provided seems at odds with subjective experience. While there are lots of anecdotes online, the negative consequence of wearable technology have been understudied.
Tools and Not Judges
While writing this post, a friend of mine went into atrial fibrillation, and it was his smartwatch that alerted him to it. He was assessed at the hospital and when he converted back to normal sinus rhythm, his watch notified him first. He even sent me the ECG his watch had recorded. Thinking back to my early 2000s Polar heart rate monitor with such limited functionality, I’m amazed how far this technology has progressed. Much of it s genuinely impressive, and in some cases, even possibly lifesaving. But as wearable devices become more advanced, we still need to think critically about what they tell us. These devices can be helpful tools when thoughtfully integrated into our broader health goals. They may be crunching our data, but they aren’t infallible. And if the feedback begins to affect our well-being or mental health, it’s worth stepping back and remembering who’s supposed to be in charge.

In Pursuit of Patient Safety
James Thomas on August 8, 2016
Link

[Editor’s note: With Dr. Gorski enjoying a vacation to recharge his batteries, we present a second offering from contributor James Thomas. Enjoy!]

Advocates of CAM* (Complementary and Alternative Medicine) have long argued that mainstream medicine is a dangerous undertaking using toxic drugs and invasive interventions that often do more harm than good, while the various quackeries huddled under the CAM umbrella are said to use natural interventions that aid the body in healing itself. A recent BMJ article naming medical errors as the third leading cause of death in the United States was trumpeted as proof of that claim and predictably enough unleashed a maelstrom of pearl-clutching commentary from the CAMsters. David Gorski has already deconstructed the ‘medical error is the third leading cause of death’ argument comprehensively. Rather than re-till that ground, I will use this essay to examine the allied accusation that medicine has little interest in the actual inherent dangers of medicnie, and less interest still in addressing those dangers. 
Make no mistake about it, medicine sometimes uses powerful drugs, deeply invasive procedures, and blasts of ionizing radiation. The patients for whom these interventions are used are ill, often desperately ill, and those interventions may be all that stand between the patient and chronic disability or an early and unpleasant death. Sometimes interventions fail, sometimes there are failures to rescue, sometimes diagnoses are wrong, sometimes errors are made. But medicine is not blind to errors when they occur and devotes substantial resources to preventing them. Contrary to the tale of indifference spun by the CAM community, the story of safety and quality improvement efforts in medicine is vast, far more than can be told in an essay of a few thousand words. So rather than sketch out broad outlines of quality initiatives throughout medicine I have chosen to tell the story as it played out in a single medical specialty.
The dawn of anesthesia
Surgery has existed in one form or another for several thousand years. It appears that one of the earliest surgical interventions was amputation, described in writing perhaps first in the Sushruta Samhita in the first millennium BCE. Trepanning too has a long history with some archeological evidence of the practice in India some 4,000 years ago. And legend has it that Julius Caesar was delivered in the first Cesarean section, though that account is almost certainly apocryphal. All of these interventions have been around for millennia, all invited sepsis, and all were unquestionably painful.
Modern surgical anesthesia dates only from the middle of the 19th century, but efforts at controlling surgical pain can be traced at least as far back as pre-Islamic Iran where cannabis and camphor were said to be used perioperatively. Alcohol was also widely used, as was opium. In the first century, the emperor Nero’s surgeon recommended the root of Atropa mandragora – a source of atropine – boiled in wine. In the 18th century it was recommended that tobacco smoke be introduced to the rectum, supposedly giving rise to the expression ‘blowing smoke up one’s ass.’
But pain control is not anesthesia.
In 1845 the New York Daily Tribune published a detailed account of an amputation. The operation took place at New York Hospital, a five-acre nest of low brick buildings, located on what is now Lower Broadway. The patient was a young man, cradled tenderly the whole time by his father and at the same time held firmly – and brusquely – in place by the attendants. As the surgeons – there were two – made their cuts, the boy’s screams were so full of misery that everyone who could left the room. The first part of the operation complete, the young man watched “with glazed agony” as the chief surgeon pushed a saw past the sliced muscles, still twitching, and listened as the blade cut through the bone in three heavy passes, back and forth. That was the only noise in the room, for the boy had stopped screaming.
— Fenster, 2001, Ether Day
Just a year later in 1846, the first surgical anesthetic using ether was demonstrated by the American dentist William Morton** at Massachusetts General Hospital. News of the advance spread like a prairie fire.
New and Valuable Discovery. We noticed yesterday the discovery of a new preparation by Dr Morton which is intended to alleviate the sufferings of those who are forced to undergo painful operations in surgery and dentistry, as well as to facilitate the work of operators (surgeons). The effect of this new discovery is to throw the patient into a state of insensibility and while unconscious any operation can be performed without occasioning pain. We are told by a gentleman of the highest respectability that he witnessed an experiment of the use of this most extraordinary discovery at the rooms of Dr Morton one evening this week. An ulcerated tooth was extracted from the mouth of an individual without giving him the slightest pain. He was put into a kind of sleep, by inhaling a portion of this preparation, the effects of which lasted for about three quarters of a minute, just long enough to extract the tooth. This discovery is destined to make a great revolution in the arts of surgery and surgical Dentistry.
—Boston Evening Transcript, October 1, 1846
Surgery would no longer be a test of the patient’s ability to withstand pain, nor the surgeon’s ability to withstand inflicting it. After witnessing one of Morton’s surgeries employing ether, Oliver Wendell Holmes Sr. suggested the word ‘anesthesia,’ from the Greek ‘anaisthesis’ (insensate), for the process of rendering a patient unconscious during painful procedures. The seed of a new medical specialty had been planted.
Ether as an anesthetic was joined by another agent a year later when Scottish obstetrician James Y. Simpson began using anesthesia during childbirth. Simpson had begun with ether but was disturbed by its persistent odor and its tendency to irritate the bronchi. He experimented on himself and his associates with, among other agents, acetone, benzene, and, the one he found most suitable, chloroform.
As an interesting historical aside, Calvinist clergy in Simpson’s native Scotland objected to Simpson’s use of chloroform arguing that the pain of childbirth should be endured with patience and fortitude. One wonders if the exclusive maleness of the Calvinist clergy might have had some bearing on their position. In any event, that issue dissipated when in 1853, Queen Victoria assented to chloroform during the birth of her eighth child.
It is difficult from the perspective of the twenty-first century to comprehend just how momentous the advent of surgical anesthesia was. Surgery had been a race to complete the procedure in the shortest possible time. The pain was unimaginable. The difficulties of performing surgery on a writhing, screaming patient were monumental. Yet as important a breakthrough as anesthesia was and despite all of the benefits it brought, there were concerns about patient safety from the beginning. In 1861, Lente wrote:
Greater or less danger is inseparable from the administration of every powerful agent in the Materia Medica, however cautious and skillful the practitioner by whom it is employed; nor can we reasonably expect that an agent, so powerful as in a few minutes to render the body insensible to the pain of a torturing operation, shall be entirely exempt from risk. By what means, then, can we reduce this risk to its minimum? One tells us that it is to be effected by the use of his inhaler; another by his; another by some peculiar arrangement of the sponge or towel so as to insure a due admixture of atmospheric air, or by regulating the successive doses of the agent. But still the fact stares us in the face that the number of deaths is not diminished. [emphasis added]
In these early days the administration of anesthetics was fairly crude. Ether or chloroform was dripped onto a sponge or towel inside a usually glass vessel with a mouthpiece on one end and an opening to room air at the other.

The patient would inhale through the mouthpiece, drawing room air across the sponge where it would mix with ether fumes. There was no supplemental oxygen, only room air, and the inspired concentration of ether varied with tidal volume, ambient temperature, the size of the sponge and its saturation. As transformative as it was for patients facing surgery, anesthesia was risky business.
Lest the general public who may read this may take alarm and exaggerate the dangers of ether, let me say at once that the deaths are estimated in various statistics as being only one death in 4533 administrations in America (Gwathmey), one in 5112 in Germany, one in 16,302 in Great Britain, and even only one in 50,000 (Rovsing).
– W. W. Keen, M.D., LL.D. 12/2/1915
That it was considered acceptable, even laudatory, that 1 in 4,500 anesthetics resulted in death should be some indication of the horrors and dangers of surgery without anesthesia.
Keen went on to say:
In this city and this hospital my topic – The Dangers of Ether as an Anesthetic – may at the first blush seem ungracious. But our profession ever seeks the unvarnished and untarnished truth. To recognize that there are dangers is the first step in eliminating them. When life is at stake ignorance is not bliss. Forewarned is forearmed.
There were certainly plenty of dangers to recognize. From the perspective of modern pharmacology, ether is a relatively safe anesthetic agent as it exhibits minimal cardiac and respiratory depression. But overdose was always a concern in those early days when ether was dripped on a handkerchief or given with a crude inhaler. Moreover, ether is associated with laryngospasm – a constriction of the vocal chords that can occlude the airway and lead to asphyxia. Nausea and vomiting are common after ether anesthesia and the potentially lethal aspiration of vomitus was an ever-present danger. But overdose, “over-inebriation” as it was then known, was the greatest concern.
[The patient was] inhaling, in the continuous way that was at first supposed to be essential to protracted insensibility, through a glass glove of ether, and long after insensibility was manifested. The operation was far from completed, when a bystander happened to feel the pulse. There was no special reason for doubt, inasmuch as the patient was, in general appearance, like all former thoroughly etherized patients. The pulse proved to be barely perceptible, and the patient to be etherized almost beyond recovery. The bystander, after repeated observation of other cases, published the fact, then first observed, that in ether anaesthesia the pulse stood as a beacon between safety and danger, between harmless inebriation and fatal narcotism. This was the discovery that ether was not dangerous; because this showed that its danger gives warning, and is under control. (Clarke & Bigelow, 1876, p. 179)
The ‘bystander’ in this recollection was the eminent surgeon Henry J Bigelow, the author of the article quoted. In the first days of ether anesthesia, monitoring of the patient’s vital signs was entirely incidental. With Bigelow’s observation came the first introduction of rigor in the delivery of anesthetics. Monitoring of patients’ vital signs moved from observation of pallor and lip hue to structured records noting times, conditions, and basic vital signs. In the early days of the 20th century, blood pressure readings joined heart and respiration rate in the patient record.
Anesthesia developed rapidly. Nitrous oxide, not as effective an anesthetic as ether or chloroform, was nonetheless an important adjunct (and unlike ether and chloroform is routinely used to this day). Early attempts to employ it were limited by the expense of equipment and technical expertise necessary to produce it in sufficiently pure form. Eventually nitrous oxide was compressed and bottled, making its use inexpensive and ubiquitous. Oxygen too was compressed and bottled and new and better anesthesia equipment was developed that allowed the clinician to establish flows of oxygen, nitrous oxide, perhaps other gases, and eventually the vapors of one or more inhalation anesthetics.
The importance of supplemental oxygen and equipment to deliver it can’t be overstated. The air we breathe is mostly nitrogen mixed with about 21% oxygen. Less than 21% oxygen and the gas is considered hypoxic. Breathing hypoxic mixtures for more than brief intervals can lead to brain damage and even death, and indeed was a significant cause of death from early anesthetics.
When an anesthetic mixture relies on atmospheric air, it begins limited to 21% oxygen. As other agents such as nitrous oxide and anesthetic vapors are added, the oxygen percentage is reduced, as is the total amount of oxygen inhaled. But with the advent of bottled oxygen and equipment to mix it with the other gases, the inspired oxygen concentration could easily be maintained at or above 21%. By 1917 the basic form of the modern anesthesia machine began to take shape.
For all of its charms, ether was not entirely benevolent. Many people suffered significant vomiting during recovery and, as mentioned earlier, laryngospasm during anesthesia. Chloroform, an alternative, had a narrow window between anesthetic efficiency and death and a nasty propensity for triggering heart arrhythmias. The search for better anesthetics yielded cyclopropane, a compressed gas like oxygen and nitrous oxide, making it easy to incorporate into anesthesia machines. As one early user observed:
My conception of anaesthesia with older gases is that we administer the gas, plus enough oxygen to keep the patient alive and in good condition. With cyclopropane, on the other hand, we administer oxygen with just enough of the anaesthetic gas to keep the patient asleep.
Cycloprane became increasingly popular in the 1930s and, with better monitoring, better anesthesia machines, better drugs, and better anesthetists, the death rate was less than 1 per 1,000 surgeries. You will note that this appears to be a higher mortality rate than at the dawn of anesthesia when it was perhaps 1 in 4,500. But by the late 1930s, much longer and more invasive surgeries were being performed meaning that patients were kept anesthetized for much longer periods, and much better records of fatalities were being kept. In any event, anesthesia remained a dangerous undertaking.
Risk of overdose and hypoxia were bad enough, but ether, chloroform, and cyclopropane share a characteristic beyond being effective anesthetics – they are all highly flammable, and exceptionally so in the presence of high oxygen concentrations.
A Spanish family brought their twelve-year old boy to the hospital, his lung condition making an operation necessary. The operation was proceeding normally when through a cause we were never able to trace, the glowing cautery set light to the ether vapour used as the anaesthetic. The violent explosion that followed, was repeated almost immediately as an oxygen cylinder blew up. The patient was killed on the spot, the sister and the assistant were injured, and I lost one ear-drum.– Ferdinand Sauerbach
Almost anything would trigger a fire or explosion: candles before electric lighting was widespread, switching electric lights on after they came to use, hot irons used for cautery, even static electricity caused by rolling an anesthesia machine across a floor. The situation only grew worse with the advent of medical electronics. By the early 1960s Electronics for Medicine (E for M) introduced the ORM-1 EKG monitor for operating rooms. Real time intraoperative electrocardiography was a revolutionary addition to the surgical suite but the monitor had to be built inside a sealed metal housing to prevent sparks from triggering explosions. The elaborately-housed ORM-1 was affectionately called the ‘torpedo.’ The Wood Library Museum of the ASA declined my request to use their photograph of an ORM-1 in this essay but you can see it here.
Despite hypoxia and overdose and fires and explosions, surgery with anesthesia was vastly more attractive than surgery without it. As anesthesia progressed from an ether-soaked rag to the modern anesthesia station, the driving force was physicians who were not content with the status quo ante of anesthetic care. Patient monitoring progressed from the observation that the patient hadn’t died, to a detailed patient record with contemporaneous recording of vital signs and drugs administered. New anesthetic drugs were developed that weren’t flammable. A range of pharmaceuticals emerged that anesthetists used to induce anesthesia, regulate circulatory system activity, paralyze muscles, and control postoperative pain. By about 1980 the anesthesia mortality rate in first world countries was less than 0.35 per thousand, half the mortality rate just thirty years earlier.
A paradigm shifts
From one perspective, a good deal of science can be seen as a reactive enterprise: an observation is made that triggers further exploration. The very practice of anesthesia began that way. The observation that surgery was too excruciating to last more than a few minutes led to the search for the first anesthetics. Observations of shortcomings of early drugs led to exploration for better ones. Observations of the dangers related to equipment led to better equipment and more equipment. Improvements in the ‘stuff’ of anesthesia were accompanied by improvements to the practice of anesthesia, to greater professionalism in that practice. All of these were driven by the desire to make anesthesia better and safer, but that drive was based on observations of deficiencies that occurred so frequently that they demanded address.
During the Second World War, a psychologist named John C. Flanagan was tasked with developing tests to identify candidates suitable for combat missions. This led to his study of human behaviors and their consequences in specific activities and, in 1954, publication of The Critical Incident Technique. Today Flanagan’s work informs everything from aviation safety to quality control in manufacturing.
Twenty-five years later, Jeffrey Cooper, a biomedical engineer at Massachusetts General Hospital, and his colleagues used this technique to study how human factors contributed to anesthesia errors. The perspective was beginning to change from reaction, to an accumulation of instances of some deficiency, to an organized program to identify the behaviors that impact – positively or negatively – anesthesia outcomes. The Critical Incident Technique would come to drive innovations in training, equipment design, even equipment to be used during the administration of anesthesia. Here was a tool that would help to prevent anesthesia problems before they had accumulated into a body of tragedies that triggered efforts to correct. The science was moving from reactive to proactive.
This is not to say that Cooper’s work was immediately embraced. The human factors that The Critical Incident Technique studies explicitly questioned were the behaviors of anesthetists, saying in short that the face in the mirror brushing her teeth might be a big part of the problem. That is a difficult proposition for someone with years of training and a deep commitment to professionalism to accept.
On April 22, 1982, ABC television’s news magazine 20/20 aired “The Deep Sleep: 6,000 Will Die or Suffer Brain Damage” and it rocked the anesthesia world:
If you are going to go into anesthesia, you are going on a long trip and you should not do it, if you can avoid it in any way. General anesthesia is safe most of the time, but there are dangers from human error, carelessness and a critical shortage of anesthesiologists. This year, 6,000 patients will die or suffer brain damage.
– 20/20
Anesthesiology was facing a malpractice insurance crisis in the 1970s and 80s. Anesthesiologists accounted for about 3% of physicians and about 3% of malpractice claims, but a whopping 12% of liability insurance payouts. Some anesthesia mishaps were minor, for instance a tooth chipped because of poor laryngoscope technique. But generally, anesthesia mishaps were likely to result in death, nerve, or brain damage. Many anesthesiologists were arguing for tort reform to limit malpractice payouts and to blunt malpractice insurance costs. But visionaries in the field held that the practice of anesthesia could be made very much safer.
Ellison “Jeep” Pierce, MD, had developed an interest in patient safety in 1962 when, as junior faculty at Harvard, he was assigned to give a lecture to residents on “anesthesia accidents.” He maintained his interest over the years, compiling a fat file of clippings and notes and in 1983, while first vice president of the American Society of Anesthesiologists, led that organization to create the Committee on Patient Safety and Risk Management with the goal of better understanding the causes of anesthesia mishaps. Richard Kitz, an anesthesiologist at Mass General, grasped the importance of Pierce’s Committee and suggested to him an international meeting on patient safety. That meeting, the International Symposium on Preventable Anesthesia Mortality and Morbidity, led to the creation in 1985, of the Anesthesia Patient Safety Foundation. Unique in its time, APSF brought together a broad range of stakeholders including nurses, regulators, manufacturers, attorneys, and others with the express goal that “no patient shall be harmed from anesthesia.” Not beholden to any one particular institution, APSF was free to explore controversial subjects and to follow research wherever it led. Perhaps most importantly, it cultivated a culture of patient safety that grew to permeate the practice of anesthesia.
Kitz, the anesthesiologist who suggested the symposium, was the chair of Jeffrey Cooper’s department at Mass General. The Critical Incident Analysis that Cooper championed, along with root cause analysis, became important tools in understanding adverse anesthesia outcomes and building strategies to minimize them. As the underlying causes of anesthesia mishaps became clear, new monitoring devices for inspired oxygen, oxygen saturation in the blood (SAO2), and changes in carbon dioxide content of respired gases (EtCO2) became standard equipment wherever general anesthetics are delivered. Simulators were developed that allowed clinicians to develop specific techniques for managing, for instance, difficult intubations and for practicing critical event management. Programs such as the Closed Claims Project continue to explore anesthesia mishaps for lessons that can improve anesthesia safety.
In 1999 the Institute of Medicine released To Err Is Human: Building a Safer Health System. The report notes the focused attention of the anesthesia community:
Patients who died during surgery requiring general anesthesia have been the focus of many studies over the last few decades. Anesthesia is an area in which very impressive improvements in safety have been made. As more and more attention has been focused on understanding the factors that contribute to error and on the design of safer systems, preventable mishaps have declined.45–48 Studies, some conducted in Australia, the United Kingdom and other countries, indicate that, today, anesthesia mortality rates are about one death per 200,000–300,000 anesthetics administered, compared with two deaths per 10,000 anesthetics in the early 1980s.49 The gains in anesthesia are very impressive and were accomplished through a variety of mechanisms, including improved monitoring techniques, the development and widespread adoption of practice guidelines, and other systematic approaches to reducing errors.50″
Today organized efforts to improve outcomes and safety can be found in nearly every medical specialty. There are federal agencies such as the Agency for Health Care Research and Quality and independent organizations such as the National Quality Forum, all working to make medicine safer and more effective. But apparently this deep commitment to patient safety is not shared by the CAM community. I tried to find similar organizations or at least organized efforts within naturopathy, chiropractic, and acupuncture, but came up empty. Perhaps my google-fu needs work.
Conclusion: Science is hard, worthy work
We take from this a number of important lessons. The advent of etherization and the dawn of anesthesia transformed surgery from a race against time for the surgeon and a gruesome and blood-curdling exercise in surviving unimaginable pain for the patient, to a largely painless procedure offering the surgeon ample time to explore, dissect, and repair a variety of problems. But with that incredible discovery came a set of quite specific risks, each requiring careful study and concerted effort to abate. A single discovery can have a major impact, but in the wake of that discovery new questions arise and in exploring those questions new insights are gained and new discoveries are made. That is how science works.
A common refrain of quacks and their enablers accuses science of ‘not knowing everything.’ And it doesn’t. Science is not a destination, it is a process. Scientists do not make a discovery, declare victory, and go home. Each insight adds a pixel or two to a very large and complex picture. Each one suggests new questions and new avenues of exploration. But that ‘science doesn’t know everything’ is not the same as science not knowing anything. Science knows vastly more than any other system of physical knowledge has ever devised. In particular, medical science learns more in any given month than all of the various medical quackeries combined since the beginning of recorded history.
We can also take the lesson that there is much more to science than the occasional strokes of genius. Many in the quack community paint themselves or their gurus as solitary mavericks with earth-shattering discoveries that confound narrow-minded scientists. They never are. Ernst T. Krebs, a serial failure at all things academic, was held as a maverick genius for ‘discovering’ Laetrile, once proposed as a cure for cancer. It wasn’t. Stanislaw Burzynski has been glorified as a maverick genius by film maker Eric Merola and a legion of hopeful cancer sufferers for his “revolutionary” anti-neoplaston therapy to cure cancer. He isn’t. Even the most generous would not have termed Morton a genius. His genius was not in discovering ether (first synthesized in 1540). His genius was not in recognizing that inhalation of ether rendered one insensible (the recreational use of ether for that purpose, so-called ether frolics, had been around since the 18th century). His genius was not even in using ether as an anesthetic. Others including Horace Wells, Charles Jackson, and Crawford Long either used ether for that purpose or discussed its potential as an anesthetic. William Morton’s genius, if indeed any could be claimed, was in advocating for ether’s use as an anesthetic, demonstrating its efficacy in that role, and tirelessly lobbying the US Congress to recognize him – and compensate him handsomely – as the discoverer of etherization, a goal he never achieved.
Science is not so much dependent on the flash of brilliance of lone mavericks as it is on the combined effort of thousands of scientists and technicians, each working alone or in groups in pushing back the darkness a millimeter at a time. Some labor an entire career with their contributions only understood by a handful of others. But in aggregate, those millimeters multiplied by the thousands at work keep science moving at an astonishing pace. And when individual flashes of brilliance translate into huge leaps of scientific advancement, it is important to remember that those leaps would not be possible without the careful work of all those who laid the foundations. The story of anesthesia, its discovery, and its long, slow evolution to the incredibly safe and effective science it is today, stands in testament to some of those thousands, most of whose names we will never know much less remember.
The last lesson is that quacks are wrong when they claim that physicians don’t treat the whole (hol?) patient. Early etherization revolutionized surgery, but that revolution came with some costs. Physicians and scientific researchers developed better equipment to deliver better anesthetics, better monitoring to assure safer anesthesia delivery, and better incident analysis to assure continuous improvement of both the quality and the safety of anesthesia. The ‘symptom’ of surgical pain was ‘cured’ by etherization in 1846. Yet science-based medicine continues to refine the anesthetic experience to deliver the best and safest outcome for the whole patient.
The story of the commitment of medical science to safe and effective treatments is vast. Today’s essay chose anesthesia as the exemplar of the history of and continuing commitment to better health care. Oncology or surgery or radiology or any of dozens of other disciplines would have served just as ably.
Imagine that the only anesthesia available for removal of an appendix or even an impacted wisdom tooth is acupuncture. Imagine that leukemia can only be treated with vitamin C infusions and homeopathic nostrums. Imagine radiology used only to image subluxations that are imagined to impede the nerves and result in liver disease or kidney disease. This would be medicine without science. Some of this was medicine without science just a century ago. The embrace of quackery by institutions great and small, quackademic medicine, means some of this is considered medicine today and perhaps more of it will be considered medicine tomorrow. This should not be the legacy we leave. This is yet another reason why science-based medicine matters.

Author’s Note: The history of anesthesia’s march from decidedly mixed blessing to nearly universally safe and effective care could easily fill a substantial book replete with interesting – sometimes eccentric – characters and compelling, occasionally hair-raising, stories. Seventy-five thousand words would probably do it. But for blog essays, I try (and here have failed) to keep to a limit of 1 Gorskon (1 Gorskon = approximately 4,000 words). So the narrative has necessarily skipped like a flat stone over still water, touching only a few high spots to illustrate the main argument and carry us to the conclusion.
I am deeply indebted to Robert K. Stoelting, MD for sharing a prepublication chapter of Quality and Safety in Anesthesia and Perioperative Care and for his generous suggestions of other resources for this essay. Dr. Stoelting is the author of several textbooks including the classic Handbook of Pharmacology and Physiology in Anesthetic Practice. Dr. Stoelting is the soon-to-retire president of the Anesthesia Patient Safety Foundation.

*I will not use the newly preferred term of Integrative Medicine as it is little more than an Orwellian distortion of language meant to obscure rather than to elucidate. What is to be integrated is the unproven, the disproved, and the nonsensical. Stripping away these integratees leaves the proven and that is not in need of integration with anything else. The proven is science-based medicine.
**In fact there is good evidence that Crawford Long, MD, used ether anesthesia in his Georgia surgical practice beginning in 1842, but Long didn’t publish and history generally credits Morton.

Human Sex Determination: Psychic Sperm and the Gambler’s Fallacy…..
Clay Jones on July 19, 2013
Link
Carl Sagan supposedly once said that randomness is clumpy. Those three words have become one of my favorite go-to quotes, particularly when teaching residents and medical students who are often overly impressed with improbable runs of similar diagnoses or exam findings. I love this quote because it is so simple and yet reveals so much about our experience with observing the natural world. Sagan’s ability to offer up insightful nuggets of rational thought, even if he didn’t actually produce this gem, was unmatched and his efforts to bring science and reason to the public have been sorely missed. If you haven’t read any of Sagan’s works, I highly recommend The Demon-Haunted World: Science as a Candle in the Dark.
If you have a coin, and a few hours to kill, record the results of a long run of flips and you’ll see what Sagan meant about the nature of randomness. You will inevitably observe clusters of heads or tails that might seem improbable, but eventually the outcomes will average out to about half of the flips being heads and half resulting in tails. The more trials that you perform, the closer the outcomes will approach 50% for each possible result, assuming you aren’t gaming the system by using a trick coin.
I don’t think that very many people would argue with the fact that on average a coin flip is random chance, although there are still people out there who think that the Earth is flat and that Justin Bieber is a reptilian humanoid. But because of a deeply rooted cognitive bias, the gambler’s fallacy, we frequently fail at recognizing that randomness is clumpy. We accept the established overall odds, but our acceptance wavers in the face of short runs that go against our expectations. This error in logic can lead to the belief, for instance, that after five heads in a row there is a higher than 50% chance that the next flip with land on tails as if to magically even things out.
In my line of work as a pediatric hospitalist, I frequently experience other healthcare professionals making this mistake in a variety of circumstances. There is a known likelihood of bacteremia when an infant less than 28 days of life is evaluated for fever, for example. Despite this, it is common for physicians and nurses to lament, upon seeing fever as the triage chief complaint, that they are due for this life threatening infection after a number of recent febrile neonates have had negative blood cultures.
The cognitive bias which results in this commonly employed logical fallacy is, as is often the case, the result of an inappropriately employed mental shortcut. These shortcuts, known as heuristics, can be very helpful but sacrifice accuracy for efficiency of thought. In the case of the gambler’s fallacy, the representative heuristic is to blame. If someone is aware of the fact that a result has a known frequency of occurring, they often mistakenly make the assumption that short runs will be representative of long runs. They believe that a run of ten or twenty should be equally split between heads and tails in the same way that a run of a million would be. But, once again, randomness is clumpy and short runs often have surprisingly unbalanced results.
A concept that is very closely related to this is the clustering illusion. Humans excel at failing to appreciate how variable a small sample of a larger population of random or almost random events can be. We see a streak or a cluster, rather than a random clump, and assign more meaning to them than they deserve. This phenomenon can be seen at play in sports when we determine that a player has a “hot hand” but more notoriously in bogus disease clusters.
Cries of cancer clusters are common in the media. Cancer Alley, a stretch of the mighty Mississippi between Baton Rouge and New Orleans, is one such cluster that achieved widespread coverage in the late 1980’s but has largely been shown to be an illusion. There is even a Wikipedia page specifically on cancer clusters.
I recently had a somewhat heated exchange with a relative of a friend on Facebook. My friend, a mother of three boys, was expecting her fourth child and had not yet found out whether this baby was a boy or a girl. She expressed her desire for a girl and her uncle commented that the new baby would almost certainly be female because the odds were highly in favor of such an outcome. While it is true that the odds of having 4 boys in a row are somewhat low at 1 in 16, this was a classic example of the gambler’s fallacy. I responded, an argument ensued, and nobody went home happy.
So what were the odds of my friend’s child being a girl? There are two ways to approach this problem with one of them being right and one feeling right to many people because of the representative heuristic. Readers of Science-Based Medicine should of course know that what feels right on a gut level is often completely wrong. First though, some basics on the determination of sex in humans are in order.
Unlike alligators, the sexes of which are determined by the temperature an egg is exposed to at a critical period of development, whether a human infant is born as a male or female is determined by genetics. The sex of most mammals, humans included, is determined by an XX/XY system that most of you are probably fairly familiar with even if you don’t remember all the specifics.
Modern humans, individuals with genetic syndromes aside, have a genome which consists of 23 paired chromosomes. The two that determine an individual’s sex are, not surprisingly, called sex chromosomes. Females generally have two X chromosomes (XX) and males have both an X and a Y chromosome (XY). It is widely considered that human zygotes are inherently on the path towards being female at conception and that, if present, a single gene located on the Y chromosome alters this course resulting in male offspring…usually. Sex determination is very complex and there are certainly instance where the genotype (XX or XY) doesn’t match the phenotype (outward appearance) but these are quite rare and beyond the scope of this post.
Most cells in the human body are identified as diploid, which means that they contain the above-mentioned 23 pairs of chromosomes. Well, this isn’t entirely accurate, as most cells in and on the human body are bacterial and they can have up to 4 chromosome copies depending on the growth conditions at the time. But we’ll keep moving.
Reproductive cells like sperm and ova, known as gametes, are haploid in that they only contain one set of the 23 human chromosomes. This makes sense because they will combine to form a diploid zygote at conception. The female ovum always contains an X chromosome. It is the male sperm which ultimately will determine sex because an individual sperm can carry an X or a Y chromosome. Which, if any, sperm fertilizes the impatiently waiting ovum is a crapshoot and it works out to a roughly 50/50 split between male and female embryos.
Of course there is some nuance to this. There is the possibility of a minor influence by environmental factors, or factors inherent to sperm carrying X versus Y chromosomes, which may lead to a slightly increased chance of male versus female offspring in some women, or a slightly higher rate of male or female births across some populations, but these differences are not meaningful. And unless you are making use of gender selection via technology, such as with IVF, the myriad other means of encouraging the birth of a preferred sex will not alter the outcome. And studies looking at large numbers of families have shown conclusively that even in the case of families with long runs of male or female children, the chance that a subsequent child will be male or female remains pretty close to 50/50.
So in the case of my friend with 3 boys and a baby on the way, the likelihood of having another boy was 50%, not 6.25%. And the chance of finally having a girl was 50%. But let’s further explore the notion so strongly argued by my friend’s relative, that the sex of previous children impacts the sex of future children. As I have already explained, there is a perfectly reasonable cognitive bias to blame for this fallacious logic, the misuse of the representative heuristic. But for argument’s sake let’s assume that he was right.
What would the mechanism for this phenomenon be? How would past results impact future results of a seemingly random process like sex determination? Could the male “apparatus” somehow be affected by the owner being cognizant of the sex of his mate’s prior children, thus initiating a physiologic process that selects an X- or Y-chromosome-carrying champion to breach the defenses of the female genital tract and fertilize the ovum in a more controlled fashion? Or could the female genital tract somehow alter conditions such that an X or Y chromosome might have a higher chance of success? None of this makes sense.
Or maybe something supernatural is going on? We should keep an open mind, right? If you believe in a higher power then I guess you have your answer. Perhaps there is a mysterious effort underway by a technologically advanced observing alien race to manipulate the human species but still attempt to maintain at least the appearance of randomness over multiple pregnancies? Or is this some diabolical scheme where sentient sperm must act to prevent our awareness of a grand conspiracy which only works if there is a roughly equal number of male and female offspring? Are they psychic and able to probe the inner recesses of the male mind or simply plugged into the nervous system via nanotechnology? We may never know the answer but there is something I do know: don’t anthropomorphize gametes, they hate that!
Oh, and it was a girl.
One last interesting tidbit. Right now the world is on the edge of its seat waiting to see what the sex of Prince William and Duchess Kate’s baby will be. There actually is some evidence to support that it will most likely be a little girl. Morning sickness seems to serve as a predictor for having a female infant, but not just any morning sickness. A study out of the department of epidemiology at the University of Washington found that women with severe hyperemesis gravidarum that required hospitalization were 50% more likely to have a girl. But obviously this would only be helpful after the sex has been determined.

Disparities in Regional Health Care Costs
Steven Novella on March 21, 2012
Link
In 2009, during the “Obamacare” debate that was dominating the news, Atul Gawande wrote an article in the New Yorker that was widely praised and cited, including by president Obama himself. The article is a thought-provoking discussion of why some communities in the US have much higher health care costs than other regions. I took two main conclusions from the article.
The first is the success of the Mayo model – organizing care as a team approach. The idea here is to pool optimal expertise in the care of each patient. Greater expertise leads to “more thinking and less testing,” as Gawande puts it. I agree with this. It takes expertise to be comfortable not doing a test. Often testing is ordered because a physician does not feel secure in their diagnostic assessment.
The second main conclusion was the McAllen model, a town in Texas that has double the average Medicare costs per capita in the country. Gawande concluded that these increased costs are likely do to the culture of medical practice in the region, leading to greater unnecessary care and procedures. He wrote:
The Medicare payment data provided the most detail. Between 2001 and 2005, critically ill Medicare patients received almost fifty per cent more specialist visits in McAllen than in El Paso, and were two-thirds more likely to see ten or more specialists in a six-month period. In 2005 and 2006, patients in McAllen received twenty per cent more abdominal ultrasounds, thirty per cent more bone-density studies, sixty per cent more stress tests with echocardiography, two hundred per cent more nerve-conduction studies to diagnose carpal-tunnel syndrome, and five hundred and fifty per cent more urine-flow studies to diagnose prostate troubles. They received one-fifth to two-thirds more gallbladder operations, knee replacements, breast biopsies, and bladder scopes. They also received two to three times as many pacemakers, implantable defibrillators, cardiac-bypass operations, carotid endarterectomies, and coronary-artery stents. And Medicare paid for five times as many home-nurse visits. The primary cause of McAllen’s extreme costs was, very simply, the across-the-board overuse of medicine.
Is that, however, a necessary conclusion from that data? The data support the conclusion that McAllen (the highest cost region) uses many more medical procedures than El Paso (the lowest cost region), but does that necessarily equate to “overuse” of medicine? Evidence does not support the conclusion that the population in McAllen is sicker than El Paso, but it is also possible that El Paso simply underdelivers care.
This is a very important question as we grapple with the rising costs of health care. There are many possible sources for this rising cost, including: increased availability of expensive technology, the aging population, defensive medicine and tort costs, public health problems such as obesity, overuse of medical procedures, poor access to care leading to delayed treatment or inefficient treatment, and the use of ineffective or worthless treatments (i.e. just about everything considered CAM). To make a significant difference and stem the rising tide of health care costs we probably have to address all of these issues.
However, it is estimated that about half or more of the rise in health care costs are due to advances in medical technology, and that this technology offers reasonable value. The core problem of health care costs may simply be that we have the technology to deliver more care than we can afford to. Combined with an aging population and a culture of individualism that often demands the most aggressive care for every person, that explains a large piece of the rising cost. It is not clear what the potential for savings is from increased efficiency and avoiding unnecessary care (although obviously we need to work towards greater efficiency).
Let’s get back to the question begged by Gawande – is the increased use of procedures in McAllen due to overuse? A recently published review of the literature does not support this conclusion. Keyhani et al performed a systematic review of the literature and came up with only five relevant articles comparing the overuse (not just use) of medical procedures in different regions. Here are the results:
Five papers examined the relationship between geographic variations and overuse of healthcare services. One study in 2008 compared the appropriateness of coronary angiography (CA) for acute myocardial infarction in high-cost areas versus low cost areas in the Medicare population and found largely similar rates of inappropriateness (12.2% vs. 16.2%). A study in 2000 using national data concluded that overuse of CA explained little of the geographic variations in the use of this procedure in the Medicare program. An older study of Medicare patients found similar rates of inappropriate use of CA (15% to 17% vs. 18%), endoscopy (15% vs. 18% 19%), and carotid endarterectomy (29% vs. 30%) in low-use and high-use regions. A small area reanalysis of data from this study of 3 procedures found no evidence of a relationship between inappropriate use of procedures and volume in 23 adjacent counties of California. Another 2008 study found that inappropriate chemotherapy for stage I cancer was less common in low-cost areas compared with high-cost areas (3.1% vs. 6.3%).
They make two conclusions from these results. One is that there is insufficient data to really answer this question definitively – only five studies. We therefore need to conduct further research into this important question. But, what evidence we do have does not support the conclusion that regional differences in utilization of medical procedures are due to overuse. Differences in overuse were slight and simply did not explain the disparity in health care use and costs in the regions compared. Their review suggests that Gawande’s assumption may not be warranted. It suggests, at the least, that the story is more complicated.
Conclusion
Like any complex issue the answer is probably “all of the above.” In other words – the problem of rising health care costs has many causes all of which need to be addressed if we are going to have a significant impact. We need to be realistic about the potential of addressing each contribution, however. It is tempting to blame the culture of medicine and overuse of procedures, because that is entirely fixable. I also completely agree with Gawande that optimizing health care to take maximal advantage of expertise and specialists is a good way to go. Specialty care is generally more cost effective.
We probably, however, will have to face the uncomfortable truth that a major contribution to rising health care costs is that we simply have the technology to deliver more care, and people want this care. This leads to the further conclusion that one primary mechanism to constrain health care costs is to ration care – something no one wants to do, and for which there is little political incentive to address. For example, one obvious way to ration expensive health care is to limit futile end-of-life care. We currently lack an efficient mechanism to enforce rational decisions about the utility of very expensive care for individuals who are very likely at the end of their life due to a catastrophic illness or event. Most of the time the physicians and families get together and do make reasonable decisions, but sometimes this does not happen, and millions of dollars of futile health care can result. Any possibility of addressing this issue, however, was killed during the “Obamacare” debate by the dismissing of this issue as “death panels.” This very important issue then became politically untouchable.
Another potential way to address the driving of health care costs by advancing technology is to adjust our research priorities. It is now reasonable to ask whether or not we should fund research that has the potential to make small incremental improvements in outcomes with expensive treatments or procedures. Perhaps we should give priority to research that has the potential of replacing an expensive treatment with a cheaper alternative, or prevent the need for the expensive intervention. Cost effectiveness is already a factor taken into consideration, but it can be given higher priority. Adjusting research, however, will take decades to have a significant impact.
One conclusion, I think, is clear. Whatever the ultimate solutions turn out to be, our best chance of getting there is to follow the science and evidence. This not only applies to medical practice, but the meta questions about the strategic organization and deliver of health care itself.

Motivation to Exercise in Mice
A new study in mice shows a connection between gut microbiome and willingness to exercise. Could this discovery lead to improved motivation to exercise in humans? Possibly, but we don’t yet know if humans share the same pathway.
Harriet Hall on January 10, 2023
Link

A study from the University of Pennsylvania, published in Nature on December 14, 2022 reported a gut-to-brain pathway that increases exercise performance in mice. They were trying to determine why some mice did more voluntary exercise on a wheel than others. The most important difference turned out to be the presence of certain gut bacteria, Eubacterium rectale and Coprococcus eutactus. They produce fatty acid amides that stimulate CB1 endocannabinoid receptors on gut-embedded sensory nerves, which increases dopamine levels in the ventral striatum of the brain, a critical node in the brain’s reward and motivation network. Giving the mice broad-spectrum antibiotics to get rid of gut bacteria reduced their performance by half. The researchers concluded that the extra dopamine reinforces the desire to exercise.
An article in Science Daily speculates about possible implications for humans if further studies can confirm the existence of a similar gut-to-brain pathway in humans. Research is ongoing. In The Scientist, evolutionary scientist Theodor Garland, Jr. praised the study but cautioned:
…analyzing motivation in humans is more complicated than it is in mice: a person’s incentive to exercise is based on many more factors, including external ones such as their social environment and influence from family or friends, than is a mouse’s. ‘We don’t go and give our mice pep talks…’
Various websites mentioned this study, highlighting the potential consequences for increasing the motivation to exercise in humans and speculating that this new data might explain the mechanism of the “runner’s high.” Could we eventually learn to tweak the gut microbiome to improve people’s motivation to exercise? An article on frontlinegenommics.com speculates even further: “Apart from possibly offering cheap, safe, diet-based ways of getting ordinary people running and optimizing elite athletes’ performance, the exploration of this pathway might also yield easier methods for modifying motivation and mood in settings such as addiction and depression.”
Psychology Today chimed in with the headline “Not Motivated to Exercise? Your Gut Microbes May Be to Blame“. It’s nice to have something to blame.
We know exercise has health benefits, but we also know how hard it can be to stay motivated to exercise. Facilitating motivation to exercise would have public health benefits and has long been a focus of study. Previous research had found that the dorsal medial habenula controls the desire to exercise in mice. The brain circuits underlying motivation are complex, as shown in this interactive graphic. An article on BetterUp describes various types of internal and external motivation and shows how you can use the types of motivation to your advantage. Various studies like this one have looked at motivation in specific situations like older patients with osteoporosis.
Will this mouse study have implications for humans? Does your microbiome determine whether you are a couch potato or a gym bunny? Will we be seeing fecal transplants to encourage exercise? Will doctors be influenced to avoid prescribing antibiotics for elite athletes? For everyone? Will we all be encouraged to take probiotics to promote motivation to exercise?
There’s one thing that bothers me about all this. It smacks of inappropriate anthropomorphizing. Mice are like humans in some ways, but very different in others. I don’t think mice are capable of “motivation” to exercise in the same sense as humans are. Motivation has a large mental component, involving mental capabilities that mice lack. Humans may be motivated to do something unpleasant or boring with the hope of future rewards. They may exercise to lose weight or to develop the level of fitness needed to compete in a marathon, or to earn accolades from another person like a trainer, coach, or exercise partner. They plan ahead, have goals, and think about the future; mice don’t. Mice run on wheels because of an innate drive, just as sled dogs have an innate drive to run. Sled dogs are not “motivated” to win races; I doubt if they even understand the concept.
I would be delighted if this research led to more enjoyment of exercise for humans, but it is too soon to speculate. The first step is to find out if the same pathways exist in humans.

Move
For most people, common health goals are best approached with as simple a strategy as possible. This avoids cognitive overload and non-compliance. Get the basics right, as there are diminishing returns from increasingly arcane details.
Steven Novella on February 14, 2018
Link

It is far healthier to move more than to move less. Simple advice, but extremely useful.
However, there is an industry of medical advice, which is definitely a double-edged sword. The average person now has more access to useful medical information than at any time in our history, and it is expanding every day. At the same time, there is more medical misinformation which may be causing more harm that the useful information is resulting in good.
Misinformation takes many forms. Sometimes the information is ideological, sometimes it is specifically for marketing purposes. Often the information itself is the product, in which case there is an incentive to make the information seem special, privileged, and particularly valuable.
The problem for the purveyors of information is that everyone potentially has access to the same data, the same published studies, and the same consensus of expert opinion. There is genuine value in expertise, rigorous scholarship, and talented science communication. That, however, is hard work. It’s far easier to just take a marketable narrative and package it up as if it is a special insight into secret information, what “they” don’t want you to know. Then brand it cleverly, and even better tie it to the personal brand of a guru.
When information is the product, you want more product to sell, so there is an incentive to make the information needlessly complicated. There are always tons of details to focus on. If you are a researcher or an expert, knowing these details is important. However, for the average person what they really need is a distilled version they can apply to their daily life.
Perhaps the most obvious context that demonstrates this principle is diet. The diet and weight loss section of Amazon, for example, has over 70,000 books. Meanwhile, what the average person needs to know about diet can fit into a single sentence – eat a variety of food and eat plenty of fruits and vegetables. If you have specific dietary needs, you may need a paragraph or two.
Meanwhile, weight loss is math. With less than a page of information, you can roughly determine your daily calorie needs. You can also estimate the caloric content of the common foods you eat. Then do the math. That is 99% of weight management – portion control, estimating caloric intake, maintaining caloric output. There are thousands of books obsessing about the 1%, with dubious benefit. All it really does is distract people from the 99%.
The real trick of weight loss is the psychological aspect of it – developing patterns of behavior that will help you control caloric intake, and identifying and mitigating any counterproductive behaviors. Maybe now you are up to a medium-length article.
There is not enough useful information (again, for everyday application) to fill a single book, let alone 70,000. Information overload is harmful. In medicine we refer to the “intention to treat” model. I can give a patient a rigorous highly tweaked treatment regimen that will optimize every variable, but if it is too complicated and onerous for most people to comply with, so what. They are likely to abandon it. However, I might be able to give them a simple regimen that is 95% optimal and easy to comply with – that will result in better outcomes.
And again, for emphasis, I am not saying that there isn’t a genuine expertise in nutrition or that nutritionists developing specific programs for patients is not necessary or useful. They are experts and that is their job. They are also potentially dealing with complex medical situations. What I am saying is that the average person does not need a degree in nutrition to eat healthy.
Getting to the single word title of this post, for most people all they really need to know about exercise can be summarized in one word – move. What the scientific literature shows is that it is better to move more than to move less. For most people, with the common goal of just being healthy, that is really all you need to know. Exercise is really good for your health.
But since there is so much complex information out there, with elaborate recommendations, let’s expand a bit. As with diet, we can summarize what most people need to know very briefly. Try to move every day. Stand rather than sit, walk rather than ride, take the stairs occasionally. If you have a sedentary job, get out of the chair as much as possible to move around.
For most people, moderate exercise will fit their goals. Get your heart rate up for at least 20-25 minutes at least 3 times a week. More is better. Do some exercise against resistance to maintain bone and muscle mass. And don’t overdo it. Don’t try to be athletic, or do anything extreme. Moderate exercise is generally safe and effective. Further, know your limits. If you have a bad joint or bad back, don’t overuse it. If you have any concerns, consult your doctor.
Of course, many people have goals other than basic health. They do want to be athletic, or to body build, or to engage in extreme sports or exercise. The thing to know here is that the more intense your exercise regimen, the greater the risks. Then you do need to know what you are doing, and at some point prior to engaging in such exercise (extreme endurance, heavy lifting, high impact, etc.) you should work with a coach, trainer, physical therapist, or other expert who can show you proper technique.
But for basic health, there is no magic exercise, you don’t have to obsess about the details, and there is no piece of equipment that is a game-changer. Just move.
What is important is that you build activities into your day that are convenient and enjoyable. Again – this is an intention to treat analysis. The higher the barrier to engaging in the activity, or the less you enjoy it, the less compliant you are likely to be. For both dieting and physical activity, doing it with others also seems to help. We enjoy social activity, it keeps us focused, and you can encourage each other.
Information overload is a real problem in our complex society. One way to deal with it is to recognize the general principle that for many things (using representative numbers) 5% of the information will get you 95% of the result, while 95% of the information will get you the last 5% of the result. In other words, there is diminishing return from more and more detailed information.
So you are better off mastering the 5% of the information, making sure you have that straight, and getting 95% of the benefit with simple lifestyle choices that are as easy as possible to comply with. Stop wasting your time, money, and effort chasing the last few percentage points of benefit, because you are likely to actually lose ground by being distracted from the more basic concepts which are the ones that really matter. The cognitive overload will also take a toll in general on other efforts in your life.
Take an “intention to treat analysis” approach to life. If you want to be healthy don’t listen to the gurus, don’t buy special “superfoods” or exercise equipment, don’t buy endless self-help books. Eat a variety of food, plenty of fruits and vegetables, don’t overeat, get plenty of sleep, don’t smoke, avoid excess – and move.

The Data Is In – Exercise Is Good For You
Steven Novella on February 4, 2026
Link

Many times in my career I have sat across from a patient who expressed that they are getting serious about their health, and then rattle off a list of things that they are doing to improve their health – all mostly worthless. I do not blame them – they are victims of a self-help, supplement, and wellness industry that has completely mislead them. A typical list might include: eating only organic, avoiding GMOs, taking daily vitamins, eating low-carb, and using a sauna (or perhaps cryochambers). Sometimes they throw in fully magical interventions, like feng shui or reiki. In short, they invest a lot of time and money into interventions that will not make them more healthy, and distract them from the things we know will.
If you want to improve your health and longevity the data suggests there are five things that are of primary importance (in terms of lifestyle) – eat a well-rounded balanced diet, get sufficient quality sleep, don’t smoke, limit alcohol intake, and exercise regularly. Obviously, getting good medical care is also very important. Get regular checkups (including for dental health), and address any specific health issues you have, including mental health.
The good news is – there is not mystery to good health. The lifestyle factors I list above are the 99 percenter, meaning that together that have the overwhelming largest effect on your health. So stop worrying about the 1%, there is no magical “superfood” our there, no hack, and no secret. Focus on doing the things everyone already knows they should do.
The other good news is that small changes can make a measurable difference. I’m going to focus on exercise for the rest of this post, since that is the one that seems to take the most effort, and the one factor that my patients seemed to struggle with the most. First, exercise is not just about “getting into shape”, or being strong or athletic. It is about basic health, and this includes your brain health.
This evidence has been building for decades, but a recent study shows how much benefit there can be to even a little bit of regular exercise:
“Existing guidelines from most national and global health organizations call for at least 150–300 minutes of moderate physical activity each week, or 75–150 minutes of vigorous activity, for healthy adults, sometimes alongside activities to strengthen muscle and bone. Although those guidelines remain good goals to aim for, newer studies suggest that meaningful health benefits emerge with much less exercise.”
It’s important to get this message out. Many people hear the fact that 150-300 minutes of moderate activity is recommended each week. This seems like a lot: 22-45 minutes every day. This messaging can have an unintended consequence, that people either feel like this is unattainable for them, so do nothing, or they make big plans, join a gym, buy a stationary bike, and then end up doing nothing. When people think a task is intimidatingly big, they procrastinate or don’t do it at all.
It is therefore good to know that any physical activity you do is better than doing nothing. Start small, start slow, and then build from there. Doing a little bit of physical activity, even for a few minutes, has measurable benefits. The flip side of this is that long periods of sitting or doing no physical activity is harmful to your health. Just getting up and doing a chore, or just walking a bit, to break up your sitting is good.
More good news – exercise is beneficial at any age. So it is never too late. Do little chores for yourself, like making a cup of tea or getting the mail, rather than have someone do it for you.
We tend to buy devices and services to make our lives easier, and this can make sense. Our time is valuable, and often it’s just more efficient to pay a properly equipped expert to do something than to do it ourselves. But perhaps we should hold onto some chores simply for the exercise. Why pay someone to mow your lawn while you go to the gym (or sit on the couch). If you’re too busy working, it makes sense, but if you are just trying to save yourself physical work, it may not. Or if mowing the lawn is not your thing, take up a hobby that has a physical component, like gardening.
There are several components to exercise that it helps to be aware of – cardio, resistance, and stretching. All are beneficial in different way. Cardiovascular exercise is anything that gets your heart rate up and burns calories, even a little. This could be just walking. Brisk walk if you can. Resistance exercise is anything that works your muscles against resistance, like lifting weights. This builds bone and muscle, and helps preserve bone and muscle as we age. Strength is also critical to functionality, which helps us move and do more, so there is a positive feedback.
Stretching is often neglected, but has an independent correlation with longer lives and greater functionality. Just doing a few minutes of basic stretching can be helpful.
So if you want to improve your health, live longer and maintain your function into older age, the data is clear. Move. Do anything, but try to get your heartrate up, do some resistance and stretching. Do a tiny bit every day, make it part of your routine, and then do a little more. Do something fun that you enjoy, do it with a partner, or at least do something that is convenient. You don’t have to spend a lot of money or buy fancy equipment. You don’t have to join a gym.
And you certainly don’t have to buy any self-help books, expensive supplements, wellness gadgets, or have someone manipulate your chi.


No evidence IV vitamin drips can treat infertility
There is no evidence IV vitamin drips can help treat infertility
Scott Gavura on May 25, 2023
Link

Infertility is remarkably common: The World Health Organization estimates 1 in 6 adults will experience infertility at least once in their lives. While it may not be discussed openly, infertility can have substantial psychological, financial and medical consequences. Defined formally as the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse, infertility can be caused by dysfunction with the male or the female reproductive system.
Despite the magnitude of the issue, solutions for the prevention, diagnosis and treatment of infertility – including assisted reproductive technology such as in vitro fertilization (IVF) – remain underfunded and often inaccessible to many due to high costs, social stigma and limited availability. This has led to a huge industry related to “supporting” those with infertility, often with questionable treatments and practices. Because of the frustration and even desperation that can be a consequence of infertility, individuals may be more open to “alternative” approaches that promise results but may not be backed by good evidence.
I recently learned that the IV vitamin infusion industry markets itself directly as a treatment for fertility. While I blogged about IV vitamins almost exactly a decade ago (have I been here this long?) I thought it might be worth re-examining this practice and the level of evidence.
What are IV Vitamin Drips?
Intravenous vitamin injections, initially made popular by celebrities, are widely available and may be offered by naturopaths and sometimes medical doctors. Yes, there is an established medical role for injectable vitamins, though it’s no energy-boosting cure-all – they’re used to replace what we should obtain in our diet. As a hospital-based pharmacist I used to prepare sterile bags of total parenteral nutrition (TPN), a mixture of vitamins, carbohydrate, protein and fat that completely replaced the requirement to eat. TPN is effective, but not without risks, and far less preferable than getting your nutrients the old fashioned way – by eating them. There’s also the routine use in medicine of injectable vitamins like B12, or iron, all of which can be science-based when used to address true deficiencies, or to manage specific drug toxicities. And there is the therapeutic use of high-dose minerals like intravenous magnesium for acute asthma attacks. But there is no medical justification to infuse vitamins into a vein when you can more appropriately obtain those nutrients in your diet.
Intravenous vitamin drips which you can pay for with a credit card are effectively glorified versions of $0.20 vitamin pills. Advocates claim vitamin injections can benefit serious conditions like cancer, Parkinson’s disease, macular degeneration, fibromyalgia, depression, and that ongoing obsession, “detoxification”. They’re also touted as helpful for preventing illness, too. Despite the hype and endorsements, there is no credible evidence to suggest that vitamin infusions in those that are capable of eating are either necessary or offer any meaningful health benefit. They are a marketing creation – not a medical product.
Why IV Vitamin Drips for Fertility?
Why IV vitamin drips for fertility? One clinic claims:
Benefits of IV Therapy:
    • Eliminate toxins that could be further impeding fertility.
    • Create an internal environment optimal for conception.
    • Detoxify your body.
    • Restore vital vitamins and nutrients.
    • Reduce inflammation.
    • Protect your cells from damage.
    • Enhance your immune system.
    • Treat nutritional deficiencies.
Numerous studies indicate that increasing body levels of Glutathione can improve sperm, egg and embryo quality. Glutathione is the building block of our Fertility IV Blends since oxidative stress and inflammation have been associated with reduced egg and sperm quality and Glutathione is the body’s master anti-oxidant. Trace elements such as zinc, copper, selenium and magnesium are essential for reproductive health and also included in all of our blends.
These products are also targeted directly at men too, like the “sperm booster” this clinic offers:
Sperm is highly sensitive to oxidative stress. The production of excessive amounts of free radicals contributes to the mechanism behind male factor infertility by promoting sperm cell dysfunction. Our radical revive will help your body clear excessive free radicals + promote optimal sperm production.
I was not able to find any published evidence to support claims that IV infusions of vitamins, minerals or other products have any meaningful effects on fertility – for men or women. Moreover, at over $100 per infusion and recommendations that you receive these infusions weekly until conception, they can create a significant cost burden to those that may believe these products are effective.
In 2019, the UK-based “wellness company” Get A Drip withdrew its £250 “fertility drip” after experts said it was exploitative. The British Pregnancy Advisory Service (BPAS) said that it “lacked any evidence base, was pitched at an exploitative price and playing on the fears and anxieties of women who may be struggling to conceive.” They also noted
Katherine O’Brien, associate director of communications and campaigns at BPAS, said the fertility drip offered an unproven “quick fix at an extortionate cost”.“There is no evidence that an IV drip of any combination of vitamins can improve a woman’s fertility,” she said. “In promising hope to women at a very desperate time, we are concerned that, aside from providing no real benefit, these drips may be causing real damage to women’s emotional wellbeing.”
Preying on Anxiety and Fear
Infertility can be stressful and understanding treatment options can be confusing. That’s why it’s important to turn to reputable sources that aren’t simultaneously trying to sell you something. While prenatal vitamins are recommended by women’s health organizations and public health organizations (in particular, folic acid supplementation), I was unable to find any organization that recommends vitamins (or other supplements) administered intravenously to those trying to conceive. I was also unable to find any evidence that IV vitamin drips have any demonstrated value to support conception or can affect infertility at all. Unfortunately, these products appear to little more than exploit fears and offer false hope at significant cost, with no demonstrated benefit.

Does “therapeutic ultrasound” actually work?
Ultrasound, a commonly used rehabilitation technique, may offer little benefit.
Scott Gavura on October 27, 2022
Link


A few years ago I suffered a fairly severe ankle sprain. After a physician’s assessment to rule out any broken bones, intensive physiotherapy was recommended and I booked several visits at my local clinic. The recovery process seemed to be relatively straightforward, with lots of assessments and exercises. On a few visits, I was offered ultrasound, which I accepted (I declined the offer of acupuncture). I was told ultrasound would help my ankle heal faster. At the time, it felt a bit like this was a mechanism that allowed the physiotherapist to multi-task multiple patients, but I accepted what was recommended in the hope of getting my ankle back to “normal” or whatever I could expect after this type of injury.
A family member recently suffered a bad ankle sprain and is now seeing a physiotherapist (this time I tried to find one that didn’t offer acupuncture). Digging out my old ankle braces reminded me of my recovery and rehabilitation process, and I thought back to the ultrasound experience. Was that time spent with the machine actually helpful? I did some research to understand just what benefits ultrasound may offer a bad sprain or other acute musculoskeletal injuries. With a shout-out to Paul Ingraham’s detailed, excellent and amazingly comprehensive own resource on ultrasound, what follows is my take on this physiotherapy mainstay:
What is “therapeutic ultrasound”?
Ultrasound when used in the physiotherapy context is different from the imaging modality. Imaging ultrasound sends and receives sound waves with a transducer to generate images of internal body structures. Therapeutic ultrasound, which I’ll just call ultrasound, was invented in the 1940s (apparently by Germans who were killing fish while developing sonar), and these devices are now FDA approved. The proposed mechanism is that ultrasound generates sound waves that stimulate changes in the tissues and cells. A wand generates the sound waves at frequencies of 0.7-3.3 MHz (million cycles per second), which are far above the audible hearing range (15-20,000 Hz). The use of ultrasound gel ensures solid contact with the skin itself. The transmission of the sound wave into the body causes the underlying structures oscillate or vibrate. The vibration is thought to break down scar tissue and potentially even cause gas bubbles to form, which is thought to promote healing. Sound energy, once absorbed, can even cause heat generation, which is the intended effect in some circumstances. Internal heating is thought to improve circulation and consequently promote healing. Beyond the frequency, the power level may be varied, and treatment may be “pulsed” or continuous. Pulsed therapy delivers treatment in intervals, and is typically used when the intent is not to heat tissue. The practitioner may also move the wand continuously around in a small area, which is believed to reduce the risk of unwanted tissue heating in any one area.
There is a variant of ultrasound called shock wave or extracorporeal shock wave therapy (ESWT) which is a more intense form of the treatment that’s also used by physiotherapists and rehabilitation specialists. Originally developed to treat kidney and gall stones, ESWT is much more expensive that regular therapeutic ultrasound, and is purported to provide “more” pain relief that plain vanilla ultrasound. ESWT devices are approved by the FDA for plantar fasciitis and lateral epicondylitis. I will leave ESWT aside for now, because it’s less common and the efficacy of the product for musculoskeletal conditions is unclear.
Ultrasound is used in medicine but more widely in rehabilitative medicine, and particularly by physiotherapists. It is commonly used for soft tissue injuries including sprains and tendinopathies, but also stress fractures and even to promote wound healing. Given how ubiquitous ultrasound machines are, it is reasonable to expect that they are clinically proven to offer benefit. The evidence, however, is not impressive.
What is the evidence for “Therapeutic Ultrasound”?
Despite the potential for ultrasound to heat tissue, it should be reasonably simple to test ultrasound devices for efficacy in blinded studies. Yet despite the ease at which it could potentially be evaluated, and how widely it is used, the number of high-quality, randomized placebo-controlled trials is small. Here are summaries of the systematic and narrative reviews I could find evaluating ultrasound for musculoskeletal injuries:
Robertson (2001), “A Review of Therapeutic Ultrasound: Effectiveness Studies”, 10 of 35 trials met quality criteria.
There was little evidence that active therapeutic ultrasound is more effective than placebo ultrasound for treating people with pain or a range of musculoskeletal injuries or for promoting soft tissue healing.
Desmeules (2014), “The efficacy of therapeutic ultrasound for rotator cuff tendinopathy: A systematic review and meta-analysis”, 11 RCTs.
Therapeutic US did not provide greater benefits than a placebo intervention or advice in terms of pain reduction and functional improvement. When provided in conjunction with exercise, US therapy is not superior to exercise alone in terms of pain reduction and functional improvement.
Shanks (2010), “The effectiveness of therapeutic ultrasound for musculoskeletal conditions of the lower limb: A literature review”, 10 studies.
This literature review found that there is currently no high quality evidence available to suggest that therapeutic ultrasound is effective for musculoskeletal conditions of the lower limb.
van den Bekerom (2011), “Therapeutic ultrasound for acute ankle sprains” (Cochrane Review), 6 trials, 606 participants.
The evidence from the five small placebo‐controlled trials included in this review does not support the use of ultrasound in the treatment of acute ankle sprains.
Page (2013), “Therapeutic ultrasound for carpal tunnel syndrome” (Cochrane Review), 11 studies including 414 participants.
There is only poor quality evidence from very limited data to suggest that therapeutic ultrasound may be more effective than placebo for either short‐ or long‐term symptom improvement in people with CTS…More methodologically rigorous studies are needed to determine the effectiveness and safety of therapeutic ultrasound for CTS.
Ebadi (2014, updated 2020), “Therapeutic ultrasound for chronic low back pain (Cochrane Review)”, 10 RCTs involving a total of 1,025 participants with chronic LBP.
The current evidence does not support the use of therapeutic ultrasound in the management of chronic LBP.
Peris Moya (2021), “Ultrasound improves motor distal latency on patients with carpal tunnel syndrome: systematic review and meta-analysis”, 8 trials of 2,069 patients.
The use of ultrasound on patients with carpal tunnel syndrome seems to improve motor distal latency.
Qing (2021), “Effect of Therapeutic Ultrasound for Neck Pain: A Systematic Review and Meta-Analysis”, 12 trials, 705 patients.
Therapeutic ultrasound may reduce the intensity of pain more than sham or no treatment, and it is a safe treatment. Whether therapeutic ultrasound in combination with other conventional treatments produced additional benefits on pain intensity, disability, or quality of life is not clear.
Luo (2022), “The effect of ultrasound therapy on lateral epicondylitis: A meta-analysis”, 13 studies, 442 patients.
The ultrasound therapy is helpful to relieve pain for LE patients, but no such benefit could be found for grip strength. However, it has no significant advantage against other conservative treatments like rest and brace.
Smallcomb (2022), narrative review, “Therapeutic Ultrasound and Shockwave Therapy for Tendinopathy”.
Despite mixed outcomes, all three therapies show potential as an alternative therapy with lower-risk adverse effects than more invasive methods like surgery. There is currently insufficient evidence to conclude which ultrasound modality or settings are most effective. More research is needed to understand the healing effects of these different therapeutic ultrasound and shockwave modalities.
The medical resource Up-To-Date only discusses ultrasound therapy in a discussion of tendinopathy:
…evidence supporting its efficacy in treating tendinopathy is lacking, and that there is no convincing evidence ultrasound is beneficial for tendinopathy of the knee, elbow, Achilles, or rotator cuff.
Conclusion: Despite popularity, little evidence to show effectiveness
The rationale for ultrasound therapy is based on the (plausible, but unproven) idea that vibrating injured tissue is better than not vibrating it. Given it has been in use for decades, and given possibly thousands (or tens of thousands) of patients receive ultrasound treatments every day, it seems reasonable to expect that it would be well studied and its use would informed by good evidence. Surprisingly and disappointingly, there is a lack of good information to show the benefits of ultrasound, and consequently its role in the treatment of musculoskeletal injuries remains unclear.

New Blood Pressure Guidelines: Why Are Previously Normal BPs Now Classified as High Blood Pressure?
Under the new blood pressure guidelines, more people are classified as having high blood pressure; but the treatment emphasis is on lifestyle changes, not medications.
Harriet Hall on December 19, 2017
Link

The American Heart Association and the American College of Cardiology recently released new guidelines for the diagnosis and treatment of high blood pressure. The highlights are reported here. Previously, high blood pressure (HBP) was classified as 140/90 mm Hg or above. Under the new guidelines, more people are now being diagnosed with HBP, not because their blood pressure has changed, but just because the definition has changed.
The new categories are (systolic BP in mm Hg and diastolic BP in mm Hg):
    • Normal: <120 and 80
    • Elevated: 120-129 and <80
    • Hypertension stage 1: 130-139 or 80-89
    • Hypertension stage 2: ≥140 or ≥90
But that doesn’t necessarily mean that all the newly diagnosed people are going to be treated with drugs. The guidelines include these recommendations for treatment or follow-up:
    • For normal BP: evaluate yearly, encourage healthy lifestyle changes.
    • For elevated BP: recommend healthy lifestyle changes and reassess in 3-6 months.
    • For hypertension stage 1: Assess 10-year risk of heart disease and stroke and…
        ◦ If risk is <10%, start with healthy lifestyle recommendations and reassess in 3-6 months.
        ◦ If risk is >10% or if the patient has known cardiovascular disease, diabetes, or chronic kidney disease, recommend lifestyle changes and prescribe one BP-lowering medication and reassess in a month and…
            ▪ If BP has reached goal, reassess in 3-6 months.
            ▪ If goal is not met, make changes to medication and follow monthly until BP is under control.
        ◦ For hypertension stage 2: recommend healthy lifestyle changes and 2 BP medications of different classes; reassess in 1 month for effectiveness and…
            ▪ If goal is met, reassess in 3-6 months.
            ▪ If goal is not met, change meds and continue monthly follow-up until goal is met.
Alarmist headlines warn that nearly half of US adults will be classified with high blood pressure. The percentage of adults with high blood pressure was 32% under the old guidelines; now it is 46%. But note that healthy lifestyle changes are first and foremost for all categories. By one estimate, the new guidelines will increase the number of women on anti-hypertensive medications by only 1.3% and men by 2.5%.
The recommended lifestyle changes include a heart-healthy diet (such as the DASH diet, reduced salt, and potassium-rich foods like bananas, potatoes, avocados, and dark green leafy vegetables), weight loss, stopping cigarettes, cutting back on alcohol, and increasing physical activity. Specific suggestions are included. They also address ways to more accurately measure BP, screening for “white coat syndrome,” special provisions for people with various existing health conditions, and management of hypertensive crises.
The new guidelines are not a plot by Big Pharma to increase prescription drug sales, nor are they a conspiracy of doctors who want to get paid for more visits. They are a well-thought-out effort by experts to improve health outcomes for their patients. People with a systolic blood pressure of 130 have twice the risk of cardiovascular events as people with a blood pressure of 120. The committee that formulated the guidelines based them on an extensive systematic review of the published evidence, which experts interpreted as showing that lowering systolic BP to <130 could be expected to significantly reduce the risk of several outcomes including heart attack, stroke, heart failure, and major cardiovascular events.
Conclusion: Prevention before pills
I’m sure this will generate a lot of controversy, just as the new cholesterol guidelines did. A family doctor, Kenny Lin, has already spoken out on Medscape. He pointed out that there was only one primary care physician on the expert panel. He said:
Cardiologists have the luxury of only needing to be concerned with cardiovascular disease, but the vast majority of my patients with hypertension have comorbid chronic conditions and take several medications. Adding one more anti-hypertensive drug means more potential side effects, medication interactions, and costs to the patient and the health system.
In my opinion, the new guidelines are a welcome advance. They represent a carefully thought out consensus of a task force of experts based on the best available evidence, and following them should reduce the number of heart attacks and strokes. As with other guidelines, they are only meant as general guidelines for the population as a whole, and clinicians can and should modify them as needed for the individual patient, based on many other considerations including the ones Dr. Lin pointed out.
Critics of mainstream medicine like to say that doctors don’t care about prevention and they just automatically hand out pills. These new guidelines are evidence that doctors do care very much about prevention and they don’t just hand out pills.
Addendum: after I wrote this, the AAFP decided not to endorse the new guidelines, but to stick with the earlier recommendations from 2014.

Signos Sells a Continuous Glucose Monitor, But Not to Diabetics
Signos is asking customers to pay for the privilege of testing their glucose monitoring system.
Harriet Hall on May 17, 2022
Link

You may have seen the commercials for FreeStyle Libre devices. Continuous glucose monitors (CGMs) are intended to help improve management of diabetes in patients whose diabetes is not under good control, and also for patients who hate having to keep pricking their finger for blood tests. A small, wearable sensor samples levels of blood glucose in the interstitial fluid (a proxy for blood glucose levels) at frequent intervals. The results can be read on a smart phone. It can alert patients to spikes or drops in the glucose levels, and it can help patients understand how diet, exercise, stress, sleep, and other factors affect blood glucose levels, so they can make appropriate adjustments to their diet and lifestyle.
Now there’s a new kid on the block, Signos. It sells a system with a continuous glucose monitor and support. But it’s not for diabetes. In fact, if you have diabetes you are ineligible. They are selling it for weight loss! And for energy and general health. They advertise: “Discover how your body responds to what you eat, and make small changes to hit your health goals”.
A prescription is required. Signos will help you get a prescription based on your answers to an online questionnaire. The Signos app will provide suggestions and online support.
Annoying and deceptive marketing practices
There is a button on the home page of their website to “request access.” You must answer a series of personal questions and you are warned that there is a long waiting list.
I answered the questions to see what would happen. I was then asked to choose my plan: 6 months for $149 a month, 3 months for $199 a month, or 1 month for @299 a month (marked down from $499 a month). All plans included “AI-powered weight loss insight, digital telehealth assessment, a best-in-class CGM for the duration, and FREE shipping”. The two longer-commitment plans also offered access to an in-app Nutritionist. When I chose the 6-month option, it said the 6-month subscription was $895 without a promo code. If there was a promo code, I didn’t see it. I didn’t subscribe. Shortly after I answered their questions, I received an email from Signos. It said “You’re in, Harriet! We’ve opened up 500 spots this week, so grab yours now. Your spot will be reserved for 72 hours.” A follow-up email arrived the next day, saying “Remember: We hold your spot for 72 hours. Time is ticking.”
The science behind Signos
A tab promises to reveal the latest scientific studies that show the effectiveness of Signos. It lists some studies that speculate about what they hope will be accomplished by Signos, but no studies that look at the actual effectiveness of the system. I thought the information they provided was deceptive, farcical, and insulting. They don’t have any evidence yet! They readily confess “Signos is in the process of conducting research on the feasibility of CGM use for weight loss”.
What that means is that they are hoping to recruit 20,000 customers to be their guinea pigs for a study that is registered in ClinicalTrial.gov and is estimated to be completed by November 1, 2026. The stated purpose of the study is “to collect three years of CGM data to show how efficacious the Signos program is in helping people lose weight, improve body composition, and promote overall wellness”. That’s a misstatement. The data may show “IF” the Signos program helps people lose weight. But without an appropriate control group for comparison, it won’t even show that.
According to ClinicalTrials.gov, “the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness”. How can they provide customized recommendations if they don’t even know if the program works?
Conclusion: An untested system
They appear to have great hopes for the Signos program, but marketing Signos now is really jumping the gun. The hopes are not yet supported by any credible evidence, and they have the chutzpah to expect their customers to provide the evidence for them. And to pay for the privilege! I think that’s unconscionable.

Another ADHD Denier
John Rosemond, a self-help columnist, denies the science of ADHD with the usual invalid and outdated arguments.
Steven Novella on May 17, 2017
Link

Attention Deficit Hyperactivity Disorder (ADHD) is real. As I discussed at length in a post two months ago, while the diagnosis is a clinical one, that is no different than many uncontroversial medical diagnoses. It is based on solid neuroanatomical correlates, clearly established dysfunction and harm, and standard treatments improve outcome.
Still it remains a popular target for contrarians or those who, in my opinion, want to appear edgy and controversial by going against conventional science. Because diagnosing and treating ADHD often involves prescribing medication to children, there is an obvious emotional hook as well.
Mostly, however, denial of ADHD is based largely on naivety about clinical medicine. Often the criticism comes from psychologists who misunderstand the nature of diseases and disorders in medicine. This time the attack comes from John Rosemond (Wikipedia), a psychologist who has actually been arguing against the reality of ADHD by his own account since the 1980s. He apparently has not updated his views in the last thirty years, despite the fact that the science of ADHD has progressed significantly.
Rosemond is definitely at the far end of the spectrum when it comes to denying ADHD. He writes:
Cancer, high cholesterol, influenza, measles, and a broken bone are realities. Using various tests, physicians can prove their existence. No one has proven the reality of ADHD, oppositional defiant disorder, or bipolar disorder of childhood. They are constructs.
Just to be clear: I am not saying ADHD is over-diagnosed; I am saying it does not exist. It is a fiction.
What he is doing is establishing a false dichotomy. On the one hand we have “real” diseases, such as broken bones, cancer, and infections. They all have demonstrable pathology, abnormal anatomy, altered cells, or foreign invaders. Everything else is not real – it is a construct and a fiction.
This is a common tactic of denialism. Establish a false dichotomy based on arbitrary rules that are designed to exclude whatever it is you wish to deny. Creationists, for example, deny evolution by claiming that “real” science involves experiments in the lab and observations of things happening right now, not inferences about what might have happened in the past. If you can exclude all history as part of legitimate science, then evolution is excluded as a matter of definition. Of course, this is not a valid argument because we can form testable hypotheses about what happened in the past and then test them with observations and experiments.
And yes, the comparison to creationism is both apt and completely fair. Rosemond would arbitrarily exclude from “real” medicine all disorders, all clinical “constructs”, and all syndromes. There are a lot of babies he is throwing out with what he thinks is bathwater.
My favorite example is migraine headaches. Millions of people suffer from migraines. They have a characteristic natural history, typical symptoms, risk factors, lifestyle factors, and response to treatments. There is also no demonstrable pathology with most migraines. It is a clinical diagnosis made in exactly the same way as most psychiatric diagnoses, such as ADHD. You need to have a certain number of symptoms from a list of possible symptoms, with other causes being excluded.
There is no laboratory or imaging test for migraine. It exists entirely as a clinical “construct.” There are plausible neuroanatomical correlates, however, just as there is with ADHD. In short ADHD is as real as migraines. Rosemond’s arguments for why he thinks ADHD does not exist all apply to migraines as well.
Rosemond also states in the article:
ADHD and other childhood behavior disorders were inventions of the psychological-psychiatric-pharmaceutical industry.
Perhaps he thinks that migraines are an invention of the neurologist-headache-pharmaceutical industry. This is yet another feature common to denialist strategies – imply a sinister conspiracy to fake the alleged phenomenon based on assumptions of cui bono. If someone benefits from the science, then the science is fake. Treating migraines is a multi-billion dollar industry. The cancer industry, which Rosemond appears to have no problem with, is even bigger. Those who argue that “they” are hiding a cure for cancer use the same argument, that the “cancer industrial complex” benefits from current treatments and so are hiding a cure.
Global warming deniers use the same strategy, with perhaps the least convincing cui bono argument I’ve heard, that climate researchers are faking the whole thing to goose their funding.
Rosemond also relies on a false argument from authority, citing Jerome Kagan for support of his views. But Kagan’s views on ADHD, which I have already thoroughly demolished in my previous article on the topic, are just as flawed as Rosemond’s.
Finally, Rosemond tries to argue that because mainstream psychiatrists refuse to debate him, he must be onto something and they must not be able to defend their views scientifically. This, yet again, is a common denialist strategy, which we have seen from creationists to HIV deniers. Public debate is a very problematic venue for hashing out complex scientific topics. Such a venue favors those with rhetorical polish and a simple emotional opinion to push. It does not favor scientists who have to correct misconceptions with dense scientific research.
Rosemond wants to accuse psychiatrists of drugging children and then watch them try to explain the neuroanatomical correlates of executive function.
Further, scientists do not necessarily have expertise in pseudoscience, denialism, the public understanding of science, or the nuances of critical thinking (they should, but often don’t). Understanding the science is often not enough to stand toe-to-toe with an experienced crank.
I, however, have no problem debating pseudo-scientists. I publicly invite Rosemond to either write a response to my criticism here, or to come on my podcast, the SGU, so I can explain to him why he has been wrong for the last three decades, and give him an opportunity to explain to me why all of neuroscience is essentially flawed.
Finally, I want to point out that Rosemond is not only applying a double standard to ADHD vs other noncontroversial medical diagnoses, but he is also applying a double standard to his own advice. He is primarily an advice columnist. He has written books, such as, John Rosemond’s Fail-Safe Formula for Helping Your Child Succeed in School. His website is full of columns that are based on his personal experience and his philosophy, with a noted paucity of citations from actual published research.
He unfairly criticizes the science of ADHD, while substituting his own home-spun advice which seems to be little more than his personal beliefs.
Rosemond appears to be part of the child-rearing self-help industrial complex, benefiting from poorly sourced advice and bashing mainstream psychology because they are the very experts who can call him out on his BS.

Dry Drowning
What is dry drowning, and should we worry?
Harriet Hall on July 7, 2020
Link

Parenting websites have been alarming parents about the possibility that their children might experience dry drowning or delayed drowning, with warnings like these:
a child can seem fine after getting out of the water, but start to have trouble breathing an hour—or even 24 hours—later.
Your child is in the pool, she swallows a bit of water and goes on playing—but a few hours later, she’s in the hospital on life support.
The Scary Mommy website warns parents that:
Not all instances of drowning happen right away. Sometimes your child may go under water or unintentionally swallow water while swimming, and then only experience symptoms of drowning hours or days later. And yes, sometimes these symptoms – especially if not addressed right away – can lead to fatalities.
Another website reports:
The phenomenon of “dry drowning” first gained national attention in 2008 through the tragic story of John Jackson, who was a 10-year-old boy with autism and ADHD. John accidentally inhaled some water while swimming in a pool. At the time, he coughed for a bit, but then calmed down. As the day went on, however, he started to seem a bit off—he had two poop accidents in his pants and he was overly tired, eventually putting himself to sleep earlier than usual. When his mom checked on him later, he was unresponsive and, ultimately, died.
This was not technically a case of “dry drowning,” and the child had other health problems that may have contributed to his death.
The CDC tells us “drowning kills more children 1-4 than anything else except birth defects,” so water safety is a serious concern for parents; but so-called “dry drowning” is rare. Parents have been frightened by inaccurate, alarmist messages.
What is dry drowning?
The idea originated when a small percentage of autopsies found no water in the lungs of people who had obviously died because of submersion in water. When water first enters the airway, it can trigger a spasm of the larynx, preventing water from going beyond and entering the lungs. Even a small amount of water in the lungs can destroy surfactant and lead to pulmonary edema. It is the lack of oxygen that causes harm, not the water itself.
Drowning requires going under water; it is not caused by just swallowing water or playing in water. “Dry drowning” is not accepted medical terminology, and it is used inappropriately by the media. Other unacceptable terms are “near drowning”, “secondary drowning”, and “delayed drowning”. A World Congress on Drowning and numerous professional organizations have agreed that the medically appropriate terminology is:
    • Fatal drowning
    • Nonfatal drowning with injury
    • Nonfatal drowning without injury
A 2017 article in Emergency Medicine News reported:
Earlier this month a young child died following days of vomiting. He had been in shallow water in a Texas dike about a week before his death. The story was picked up as an alleged case of a rare condition called dry drowning or secondary drowning…The media accounts went viral, spreading significant fear in parenting communities and among those learning about these alleged conditions from the news or social media…Unfortunately, there is significant misinformation in the media reports of this case, and we hope this evidence-based discussion of drowning and the best practice medical care of drowning patients will help set the record straight.
The authors go on to urge the media to use proper medical terminology and to abandon the terms near, dry, wet, delayed, and secondary drownings. They emphasize that anyone with respiratory symptoms after being in water should seek medical care, and they point out that “There has never been a case published in the medical literature of a patient who received a clinical assessment, was initially without symptoms, and who later deteriorated and died.”
Conclusion: “dry drowning” is a myth
        ◦ Rather than worrying unnecessarily about “dry drowning”, parents should worry about prevention. They should be encouraged to practice water safety, to include adult supervision, swimming lessons, life jackets and flotation devices, fences around home pools, and learning CPR.

The Marvelous Dr. Mütter
Harriet Hall on December 23, 2014
Link

The Mütter Museum in Philadelphia has a marvelous collection of human bones, surgical specimens, monsters in jars, and medical memorabilia. It holds attractions for everyone, from the jaded medical professionals who thought they’d seen it all to the coveys of youngsters who compete to point out the grossest items to their friends, from the student of history to the connoisseur of the macabre. There is an enormous megacolon said to look like a sandworm from Dune, a plaster cast of the famous Siamese twins Chang and Eng along with their actual preserved conjoined livers, a collection of bizarre swallowed objects, an iron lung, a tumor removed from president Grover Cleveland’s jaw while he was in office, a shocking assortment of deformed fetuses…the list goes on.
I knew about the museum and greatly enjoyed visiting it, but I didn’t know anything about Dr. Mütter himself until I read a delightful new book by Cristin O’Keefe Aptowicz , Dr. Mutter’s Marvels: A True Tale of Intrigue and Innovation at the Dawn of Modern Medicine. I learned that the good doctor was every bit as marvelous as his museum, and the book took me on a fascinating trip back to the medicine of the early 1800s that made me better appreciate all that modern medicine has accomplished.
Mütter’s world
Thomas Dent Mütter was born in 1811 into a world without anesthetics, antibiotics, x-rays, or sterile precautions; a world where wide-awake patients were held down by strong men and operated on by surgeons in street clothes with ungloved hands, in rooms lit only by candles, lamps or daylight, with no pain relief other than perhaps a swig of brandy. A world where doctors operated as swiftly as possible while their patients screamed in agony, where there was little aftercare, and where wound infections were called “laudable pus” and considered an essential part of the healing process. A world where much wrong information was accepted as truth, and quackery ran rampant.
Abortion was not the controversial subject it is today, because there was no way to diagnose pregnancy before “quickening” occurred. Human life was believed to begin when the mother could feel the baby moving, not at conception.
Infection and germ theory
Infectious disease was rampant. In Philadelphia alone, with a population of around half a million, cholera killed 1,012 people in 1849, smallpox killed 427 in 1852, yellow fever 128 in 1853, scarlet fever 433 in 1852, dysentery 558 in 1852, and typhus 205 in 1848. Malaria and tuberculosis were a constant presence, and people thought of terrible illnesses as an unavoidable fact of life. The germs that caused infectious diseases had not yet been discovered, and civic leaders were only beginning to suspect there was a connection between sanitation and disease. Religious leaders spoke of poverty as the wages of sin and fought against using public money to clean up poor neighborhoods.
The germ theory of disease was still far in the future. Oliver Wendell Holmes had published a convincing paper with an analysis of cases that inescapably demonstrated that puerperal (childbed) fever was carried by doctors from patient to patient, but doctors were unwilling to admit that they were to blame. In one three-month period, 77 obstetrical patients of a single doctor contracted puerperal fever, and 15 of them died. An esteemed professor of obstetrics was brought in to investigate, and he waved off any notion that the doctor could be responsible, saying the large number of cases was only because he had such a large practice. It boiled down to the same kind of controversy we still see today, where clear scientific evidence is rejected in favor of unreliable experience and opinion. When will we ever learn?
Surgical speed and brutality
Surgeons prided themselves on the speed of their operations. One surgeon’s “joy at amputating a patient’s leg at the thigh in less than three minutes was hindered greatly when he realized he had also inadvertently sawed off the patient’s testicles.” Another managed to kill the patient, cut off his assistant’s fingers, and slash the coattails of a spectator who promptly dropped dead of fright, achieving a record surgical mortality of 300%.
Early anesthesia
In 1846, ether anesthesia was first demonstrated at Harvard. Mütter was quick to appreciate its potential and to start using it, but there was widespread opposition among his colleagues. In the early days of anesthesia the learning curve resulted in quite a few overdoses and deaths. Surgeons argued that surgery without anesthesia was less likely to kill the patient, and obstetricians cited the Bible as proof that childbirth was meant to be painful. One doctor said anesthesia was of the devil; he refused to sanction its satanic influence, and opined that “men should not be prevented from passing through what God intended them to endure!” Some even argued, without any evidence, that anesthesia would hamper the patient’s ability to heal. Aptowicz describes a hilarious incident where a professor tried to demonstrate the dangers of ether by showing that it would kill a sheep, only to have his lecture disrupted when the “dead” sheep baahed and stood up.
Patients didn’t embrace anesthesia at first either. Surgeons had once been feared as sadists who delighted in their patients’ pain, but with anesthesia there was a new perception of surgeons as ghouls who knocked you out and sliced you open in disturbing new ways while you were unable to defend yourself.
E.R. Squibb spent over a year developing and testing a new apparatus to improve the standardization of ether production; instead of patenting it, he published his research and made it available to the world for free. A surprisingly humanitarian move for a man who went on to found one of the major pharmaceutical companies. (Dare I suggest that Big Pharma is sometimes motivated by more than just profits?)
No women in medicine yet
There were no women doctors in Mütter’s world. When the Woman’s Medical College was established, the Pennsylvania Medical Society issued a scathing statement against women practitioners, saying it was offensive that they wouldn’t restrict themselves to treating other women, and that women’s nerves were too delicate for the work. The Society even went so far as to expel members who taught women doctors or consulted with them in any medical capacity.
Mütter’s surgical innovations
As a professor of surgery in Philadelphia, Mütter’s innovations and accomplishments were unprecedented; he was far ahead of his time. In early feats of plastic surgery, he repaired cleft lips, deformities from burn scars, disfiguring tumors, and other cases that most surgeons wouldn’t dream of touching. He was a major contributor to the development of skin flap techniques in plastic surgery; in one memorable case he used a flap of skin still attached to its blood supply on the patient’s back and brought it around to the front of the her neck to replace the scar tissue that had tethered her chin to her chest after a burn injury. After the operation, she was able to turn her head, close her mouth, and blink her eyes for the first time in two decades. In an era of open fireplaces, hearthside cooking, and bulky, flammable female clothing, such burn injuries were common in women. Aptowicz vividly describes the disabilities those patients endured. They were unable to show themselves in public, and they felt their lives were not worth living, so they were willing to risk death and suffer agonizing pain in experimental operations.
Mütter was not a reckless advocate of surgical intervention. He seldom agreed to operate on patients with breast cancer. Due to modesty, women usually had far advanced cancer before they sought treatment, and operating on them was only likely to cause pain, suffering, infection, and a poor quality of life while doing nothing to improve survival.
He didn’t have the advantage of germ theory, but he instinctively practiced a cleanliness that greatly reduced the risk of infection, and he instituted post-operative hospital care in an age when most patients were sent home in a carriage immediately after the operation. His bedside manner was remarkable for his era: he spent a great deal of time with patients, explaining procedures and convincing them that he truly cared for them. He criticized his peers for treating patients as cases rather than as human beings (a complaint we unfortunately still hear today). He deplored paternalism and stressed the duty of the physician to give an honest prognosis so patients could prepare for death instead of being deceived by false hope.
Although raised in the slave-holding South, he employed only free men as servants, and believed there were no biological differences between the races under the skin. He spoke out about the dangers of disunion in the days before the Civil War, which he didn’t live to see.
Mütter’s legacy
Mütter had a big impact on medicine through his students, too. Several of them fought in the Civil War. Jonathan Letterman served in the Union Army where he became the father of battlefield medicine, developed an effective Ambulance Corps, and originated the concept of triage. Robert T. Coleman became the highest-ranking medical officer in the Confederacy. Henry W. Willoughby made history by serving as assistant surgeon to the first African American troop. Others had distinguished careers, worked with Florence Nightingale in the Crimea, treated Phineas Gage (the railroad worker who survived an iron bar driven through his skull by an explosion), and contributed to legislation that improved the supply of bodies to medical schools for anatomy classes. Another, William Goodell, applied Mütter’s hygienic principles to the practice of obstetrics and was responsible for a series of 2,444 deliveries with only 6 deaths.
It’s interesting to speculate what Mütter might have gone on to accomplish had he not died at the early age of 48 after suffering for years from conditions that could have been successfully treated today (gout that crippled his hands and sometimes kept him from operating or even writing, and what may have been tuberculosis). He knew he was dying. He had become one of the country’s leading surgeons, had developed many new surgical procedures, and had educated more than a thousand young doctors; but he wanted more for his legacy. He donated his extensive collection of specimens and teaching aids to the College of Physicians of Philadelphia, where it became the basis of his eponymous museum.
I have a new hero.

DENTISTRY

Is Dentistry Science Based?
A recent article in The Atlantic claims that dentistry is not science-based. Is it right? Nah.
Grant Ritchey on May 17, 2019
Link

In today’s social media laden climate, it is de rigueur for people to instantaneously react and become simultaneously defensive and offended when any of our sacred cows are challenged. It’s part of the human condition and we can’t help ourselves. We dentists had the opportunity to feel assaulted a couple of weeks ago when an article in The Atlantic by Ferris Jabr entitled “The Truth About Dentistry: It’s much less scientific—and more prone to gratuitous procedures—than you may think” was published. Dentists worldwide were summarily outraged, and vast hordes of people who for some reason aren’t fond of dentists collectively pointed their virtual fingers at us and virtually screamed “AHA! WE KNEW IT!!”
So I suppose the purpose of this post is to “unpack” the article and attempt to objectively assess the claims put forth therein. Moreover, I would like to give a superficial overview of what science-based dentistry is, with some excellent links and other resources should you want to dive in further. I will try my best to not be too defensive and to lay out my case objectively. We’ll see how well I do.
The Atlantic article
I don’t want to spend a whole lot of time criticizing the parts of the article with which I disagreed; not only will that appear to be very defensive on my part (which, if you recall, I promised I’d try not to be), but primarily because it was covered really well in other posts by my friends and colleagues Dr. Alan Mead and Dr. Chip Payet. If you read their pieces, you’ll get a sense of how Mr. Jabr perhaps misrepresented the issue a bit in some areas. Dr. Payet really picks apart the positives and negatives about the article, and deftly explains why certain areas of dental research can be so difficult to undertake. Dr. Mead’s article addresses Mr. Jabr’s piece from a journalistic perspective – that it perhaps is a bit sensationalistic and hyperbolic, and framed in such a way to get a lot of ‘clicks’ which is the goal of many publications these days, even if accuracy and fairness are sacrificed in the process. As for me, I feel that it was a bit heavy handed and focused too much on the evil doings of one derelict unethical dentist who did horrible things to his patients – causing pain, costing them significant and unnecessary costs, and violating the sacred trust that all health care professionals strive to maintain with the people in their care. What that rogue criminal dentist did was tangential to the real question “How scientific is dentistry?”
Because I don’t want to leave all of the heavy lifting to Al and Chip, I’ll give a couple of examples of where Mr. Jabr went a bit overboard, resorting to a bit of fear mongering as well as simply getting a few things wrong. When he discussed one of “Dr. Evil’s” patients, he said “she was born with one tooth trapped inside another…” which isn’t really a thing in dentistry. I suspect that perhaps a tooth was congenitally missing in this case, or perhaps didn’t erupt properly and remained impacted. When a procedure was described thus: “He also chiseled out her bridge…” I have to smile a bit because most dentists I know rarely, if ever, use a chisel when doing fillings, crowns, and bridges. This, in my opinion, was simply the author’s way of casting an evil and greedy light on the procedures done by that evil and greedy dentist. To generalize from the one to the all is a bit disingenuous, and I say this with no offense taken and not being defensive.
I also bristled when the article stated:
A multitude of factors has conspired to create both the opportunity and the motive for widespread overtreatment in dentistry. In addition to dentistry’s seclusion from the greater medical community, its traditional emphasis on procedure rather than prevention, and its lack of rigorous self-evaluation, there are economic explanations.
This accusation paints all dentists as greedy and uncaring, who only want to do expensive treatment on their hapless, powerless victims. Contrary to his erroneous assertion, the emphasis in modern dentistry is on prevention, but keep in mind that we are not in control of our patients’ risk factors and lifestyle choices. To accuse us thus is akin to accusing cardiac surgeons of only being procedure-oriented and not preventive. Primary care physicians from cradle to grave, as well as specialists, ceaselessly attempt to educate their patients on preventive care – good diet, adequate sleep, exercise, not smoking, etc. But what their patients choose to do with that information is up to them. Those of us in the “body repair” business are simply there to try to pick up the pieces once the damage has been done. To paint us all as moneygrubbers who only do procedures if they’re profitable is a bit disingenuous and unfair.
That being said, Mr. Jabr does rightfully mention the science (or lack thereof) of the six month recall that is standard in dentistry. I wrote about that very subject last year, and while not scientifically rigorous, that doesn’t mean it’s wrong or that we are trying to mislead our patients. I wish he would have been “fair and balanced” in this area but again, his angle was to portray dentists as non-scientific greedy predators.
Dentistry and science
Is dentistry scientific? That’s the crux of this blog post and I hope I can lay out a solid case for the affirmative. I do believe that dentists are more than tooth carpenters and gum gardeners, and while Mr. Jabr points out that dentists only have four years of post-graduate education and training (unless one pursues a specialty), he failed to inform his readers about what our education entails. I won’t bore you with the details, but please indulge me while I bore you with the details.
    • To be accepted to an accredited dental school in the United States (standards are similar in other countries), one must pass the Dental Admissions Test (DAT), which tests the applicant’s knowledge in such topics as biology, general chemistry, organic chemistry, reading comprehension, perceptual ability, and quantitative reasoning.
    • While a Bachelor’s degree is not required, most dental students do have a Bachelor’s degree, usually in a science field such as biology or biochemistry.
    • Once in dental school, our basic science education mirrors the training found in medical schools, encompassing anatomy, physiology, immunology, embryology, histology, pathology, pathophysiology, microbiology, biochemistry, neuroanatomy, and so on. In fact, when I was in dental school (University of Oklahoma), we took our basic science courses with the medical students. So I do think it’s fair to say that we have a decent scientific and medical foundation.
    • In order to practice dentistry, we must pass a comprehensive board exam which reviews our knowledge in the basic sciences and dental topics, followed by completing work on live patients. To maintain our licenses, we must complete significant numbers of hours of continuing education each year.
Dental research in the 21st century is vast and varied, from improving the materials we use for fillings and crowns, to advances in technology, to Buck Rogers type stuff such as creating new teeth from stem cells, genetic testing and therapies, and other amazing biotechnologies. Yegane Guven wrote an excellent review on the scientific basis of dentistry, areas of current and future research, and how this is translated into dental education and practice.
Evidence-based dentistry
On this blog and elsewhere, distinctions have been made between the terms “evidence-based medicine (EBM)” vs. “science-based medicine (SBM).” The same differences and debates could be made in the realm of dentistry, but for us the term “evidence-based dentistry (EBD)” is more widely utilized, therefore I will be using EBD in this post with the understanding that I am applying the concepts and philosophies of SBM to the topic. The American Dental Association itself has an arm called The Center for Evidence Based Dentistry, which is an excellent resource for dentists and non-dentists alike. They host workshops and training for dentists and others in the dental field, helping us to apply the best scientific evidence into our clinical practices for the benefit of the patients we serve as well as the public at large.
According to the website, EBD can be defined as:
an approach to oral healthcare that requires the judicious integration of systematic assessments of clinically relevant scientific evidence, relating to the patient’s oral and medical condition and history, with the dentist’s clinical expertise and the patient’s treatment needs and preferences.
One of the best in depth discussions I have read on EBD is an article by Afrashtehfar and Assery, and for those of you who want to do a deeper dive on the subject, I highly recommend reading it.
This EBD triad of care encompasses the necessary components of what constitutes the standard of care for dentistry: the best scientific evidence, the needs and preferences of the patient, and the clinical expertise of the practitioner. If any aspect of this approach is violated (as it most certainly was in the Atlantic article), then the entire system of quality ethical care breaks down. An important point to make is that in medicine, dentistry, and every other area of health care, we rely on the “best available scientific evidence.” Science (including medicine and dentistry) progresses sequentially, in fits and starts, building upon previous knowledge. Therapies and procedures that are in use today may be overturned tomorrow if sufficient evidence dictates it. This is the strength, not a weakness, of the scientific process.
Conclusion: Maybe you’re defensive!
How did I do? Did I come across as offended or defensive? I really tried not to, but if I did, I apologize. What I do hope is that you, dear reader, have come away with a better understanding about the practice of dentistry as it takes its rightful place under the larger umbrella of Science Based Medicine.
What can you as a dental consumer do to ensure that you are receiving appropriate dental advice and treatment so that you don’t become a victim of an unethical practitioner like the dentist in the Atlantic article? The good news is that if you are a frequent reader of this blog, you are probably 99% of the way there. You have learned the tools of science and critical thinking and are able to apply them in your daily life. That being said, here are some other steps you can take:
    • “Patient friendly” websites such as the Center for EBD (discussed above), the Cochrane Library, and PubMed are excellent places to research current evidence and guidelines in dentistry and other fields.
    • Never hesitate to ask your dentist or hygienist to explain all of your options (including the option of no treatment at all), what the risks and benefits of a procedure are, all costs, and the experience and expertise of the provider. If you don’t understand the treatment, ask questions until you do. If you feel that you are being “sold” on any treatment, it is advisable to get a second (and maybe even third) opinion.
    • Seek advice from objective science based dentists on social media, dental schools, or other platforms. We are always willing to help demystify dentistry and give general advice to people who contact us.
    • Keep reading Science Based Medicine and other blogs who promote a science based worldview and foster critical thinking.
It was a tragedy that the dentist in The Atlantic article took such wanton advantage of his patients. Fortunately, situations like this don’t happen very often, but there are charlatans out there in all walks of life, so to arm oneself with the tools of critical thinking is one of the best defenses against such mistreatment in the dental office and elsewhere.

The Wisdom of Third Molar Removal
In the Olden Times (ten or so years ago), the indication for third molar (aka “wisdom teeth”) removal was the presence of wisdom teeth. Now, oral surgeons are rethinking things.
Grant Ritchey on April 24, 2020
Link

These are unprecedented times. I’m not going anywhere with that statement; I just think that in these unprecedented times, we all need to make a point to say it every chance we get, just like they do in all the commercials.
Which leads us to the topic at hand – wisdom teeth. For most of us, once we reached the mid- to late teenage years and just when our zits were starting to clear up, we were told by our dentist that it was “time to have your wisdom teeth out.” Although we probably just sat there nodding obediently, inside we were asking “Why do I have to have my wisdom teeth out? They aren’t hurting anything.” But the following summer we dutifully acquiesced and had them out. It was a rite of passage.
Wisdom teeth and tonsils used to have a lot in common, not the least significant of which was the attitude by dentists and physicians that if they were in your head, they needed to come out no matter what. Like the old adage “don’t ask a barber if you need a haircut,” it was common knowledge that if you asked an oral surgeon if you needed your third molars out, the answer was a predetermined affirmative.
Nowadays, the research is showing that wisdom teeth may not have to be summarily extracted; indeed, some may be maintained in a healthy state throughout one’s life. After all, just as with any medical procedure, there are risks as well as benefits associated with third molar removal, and these must be carefully weighed in deciding what the best course of action should be. There are a lot of moving parts here, and I’ll try not to get too bogged down with minutiae, but let’s visit the wonderful world of wisdom teeth, shall we? My goal is not to make you an expert on third molar pathosis and treatments, but to give you the tools necessary to make an informed choice for yourself or family member if the need arises.
Very brief fundamentals
The “normal” human mouth contains 32 permanent teeth: 8 incisors in the front, 4 canine teeth (aka “eye teeth”) behind the incisors, 8 premolars (or bicuspids), and 12 molars. The first and second molars are usually referred to as the “6 year molars” and “12 year molars,” respectively, and the average ages of eruption should be apparent by those nicknames. The eruption schedule for wisdom teeth is more variable; typically they erupt between ages 17 and 21, but can come in significantly earlier or later than this. However, unlike their 28 predecessors, by the time the wisdom teeth erupt there often isn’t enough room for them to come in normally, which can cause the issues for which they are famous. Humans living before 10,000 years ago, as well as many contemporary indigenous people, had (and have) plenty of room for all 32 teeth, in contrast to today. There are many interesting hypotheses for why this has happened, but that discussion is for another day. If you’re interested in going down that wormhole, you can read a couple of fine articles here and here.
A fortunate minority of people today will have enough room for their wisdom teeth to erupt normally, but for just about everyone else, lack of space and other factors can cause a number of issues ranging from mildly annoying to very serious and painful to even life threatening in rare cases. What are these potential problems, you may ask?
Potential problems
Space will not permit me to list all of the possible diseases associated with third molars, so I will focus on the three most prevalent issues we see in the dental office that leads to wisdom tooth removal – pericoronitis, caries (i.e. tooth decay) and related disease, and caries on the distal (backside) of the adjacent second molar. Please note that almost all of the problems associated with wisdom teeth occur in the lower jaw, and I have and will refer to the operators who remove said teeth as oral surgeons, the dental specialists who handle these sorts of things, but be aware that many general dentists also extract third molars.
Fig. 1
     1.  Pericoronitis – Pericoronitis (“peri-” = around, “coron-” = the crown of the tooth, “-itis” = inflammation) is inflammation around a partially erupted tooth (See Fig. 1). When a tooth isn’t fully erupted, a flap of tissue lies atop the crown (or top) of the tooth. Bacteria, food debris, and other bugaboos can get under this flap, where it is almost impossible to adequately clean. This can lead to swelling, pain, bone loss, and infection (abscess).
     2.  Caries and related disease – Even in the rare instance where a wisdom tooth comes in straight and perfect, it’s still difficult to reach with a toothbrush, floss, and other cleaning aids. Consequently, it is more susceptible to tooth decay and associated problems, such as pulp (nerve) inflammation or necrosis, which could result in a dental abscess.
     3.  Fig. 2
Caries on the distal of the adjacent second molar. Because of the aforementioned difficulty in keeping the area around third molars clean, tooth decay can also form on the tooth in front of the wisdom tooth, especially if the wisdom tooth is impacted. In Fig. 2, on your left (the patient’s right), you can see where a cavity (dark shadow) is starting (arrow) on the 2nd molar due to the presence of the impacted third molar. On the other side, the angular impaction has caused severe bone loss on the distal (backside) of the second molar (other arrow). Even after the wisdom tooth is removed, there is a significant chance that the patient will lose the second molar as well. As an aside, even though the upper wisdom teeth are unerupted, because of the shape of the upper jaw and the angulation of the teeth, they are unlikely to cause a problem.
Obviously, when a patient presents with any of the above issues (or any other issue which is causing pain, swelling, or altered function), it’s usually recommended to extract the affected offenders. What about the 18-year-old with asymptomatic partially or fully impacted wisdom teeth that aren’t showing any signs of pathosis? Should they be prophylactically removed to prevent future problems? Should they be left alone and closely monitored? How are these decisions made?
Third molar surgery and its potential complications
No effective dental treatment is risk free, and while the risks of third molar extractions are low, they are still very real. When the determination is made to extract one or more wisdom teeth, the typical informed consent form will list the following possible risks and complications:
    • Post-operative infection or inflammation
    • Swelling, bruising, and pain
    • Damage to adjacent teeth or fillings
    • Drug reactions and side effects from anesthesia, including death
    • Persistent bleeding requiring more treatment
    • Possibility of a small fragment of root or bone being left in the jaw intentionally when its removal is not appropriate (such fragments may work their way partially out of the tissue and need to be removed later)
    • Delayed healing (dry socket) necessitating several post-operative visits
    • Damage to sinuses requiring additional treatment or surgical repair at a later date
    • Fracture or dislocation of the jaw
    • Damage to the nerves during tooth removal resulting in temporary, or possibly partial or permanent numbness or tingling of the lip, chin, tongue, or other areas.
Pretty intimidating, right? Of course, any serious and long-lasting unforeseen complications arising from third molar surgery are rare, but every patient must be informed nonetheless. But when there is evidence of disease, the decision to treat is fairly straightforward. But what if there isn’t evidence of disease?
Get ’em out or leave ’em in?
As I mentioned above, prophylactic third molar removal was much more prevalent in the past, and while that number is decreasing, it is still a common procedure. That said, the research does show that many asymptomatic wisdom teeth, even when they are impacted, do not have to be removed preventively. Many factors weigh into the decision of whether to get ’em out or leave ’em in. They include (but are not limited to:
    • The predicted risk(s) of removal vs. retention
    • Optimal timing of treatment
    • Costs associated with treatment
    • Medical and dental confounding factors
    • The desires of the patient
The American Association of Oral and Maxillofacial Surgeons (AAOMS) have issued a position statement to address these concerns. It reads:
Predicated on the best evidence-based data, third molar teeth that are associated with disease, or are at high risk of developing disease, should be surgically managed. In the absence of disease or significant risk of disease, active clinical and radiographic surveillance is indicated.
Seems pretty straightforward, doesn’t it? If the wisdom teeth are causing problems, get ’em out; if they aren’t, leave ’em in. As the old saying goes “If it ain’t broke, don’t fix it.” Sadly, the human body doesn’t work that way, and just as asymptomatic hypertension can lead to heart attacks and strokes, dentists can’t predict when a wisdom tooth is likely to cause an issue and when it isn’t. In general, wisdom teeth can be monitored clinically and radiographically over time if they are asymptomatic, they aren’t causing (or likely to cause) damage to adjacent teeth, if they are completely impacted and fully encased in bone, and (if erupted or partially erupted) the patient can demonstrate a high level of oral hygiene. Contrary to popular belief, the eruption of wisdom teeth do not cause post-orthodontic crowding. Teeth that would be considered for prophylactic removal would be those likely to cause damage to adjacent teeth, if the tooth is partially erupted and likely to develop pericoronitis, if the tooth is non-functional (i.e. it doesn’t participate in chewing or other oral functions), if there is an overlying removable prosthesis (such as a partial denture or full denture), if removal is necessary for other restorative procedures, or if the presence of the wisdom tooth is causing orthodontic problems.
These decisions become more important as one ages because the risks of third molar surgeries increase. Healing is slower, quality and density of the jawbone can change, and other confounding medical and pharmacological issues (heart disease, hypertension, diabetes, prescription medication concerns, etc.) can be present. In the UK for example, guidelines for the prophylactic removal of third molars were implemented on the NHS in 2000, resulting in a significant drop in that procedure. Sounds like a good thing, right? However, between 2003 and 2012, there was a 97% increase in secondary issues related to wisdom teeth, primarily due to caries. We can conclude therefore that the net effect of prophylactic removal vs. monitoring over the long term remains to be seen.
Conclusion: It depends
Like many areas in medicine and dentistry, the proper management of disease is not clear cut. Third molars are no different. Because each person presents with their own unique situation, each case must be worked up and managed on an individual basis. What has changed, however, is the philosophy of automatically removing all wisdom teeth, regardless of how they present and what the potential risks of future disease might be. Anyone who is considering having their third molars removed would be well-advised to have an in-depth conversation with their oral surgeon about risks of taking them out compared with leaving them in, as well as the possible selective removal of the problematic teeth while leaving the low risk teeth behind. Many wisdom teeth can remain healthy and function perfectly throughout a person’s lifetime.

he Six Month Dental Recall – Science or Legend?
The evidence to support dental cleaning every six months is…less than ideal, but it still may be a good idea for many people.
Grant Ritchey on February 23, 2018
Link

“OK Mrs. Splanchnic, everything looks good. We’ll see you again in six months.” Dentists and dental hygienists all over the world repeat this phrase countless times each and every day. Sometimes however, our patients don’t get off so lucky; they will have to come back to have some procedure done – perhaps a filling, a crown, or (if they’re really unlucky) a toxic root canal. But if you are one of those people who have been told “see you in six months,” did you ever stop to consider why we say that to you? Why six months? Is it by coincidence or some grand design of nature it conveniently works out that 90% of people’s teeth just happen to get grungy enough to clean precisely at that six month mark? Are we just greedy and looking for ways to drag patients back in in order to fund the second Jacuzzi in our Gulfstreams? Or is there an evidence-based rationale for this time honored protocol?
Gather ‘round and settle in folks, because we have a lot of unpacking to do. And if you’re expecting some cut and dried science based answers, boy are you going to be disappointed!
First off, some basics
Prevention is the hallmark of modern healthcare. Despite claims by ideologically driven individuals accusing physicians, dentists, and “Big Pharma” of wanting to keep people sick because we can make more money by treating the disease, this is assuredly not the case. In dentistry, prevention takes many forms: from encouraging people to brush and floss, to eating a healthy diet (especially one low in cavity promoting carbohydrates), to the fluoridation of toothpastes, mouthwashes, and community water supplies.
In the dental office, prevention typically takes the form of the semi-annual examination and dental prophylaxis (or “prophy” if you want to use the cool lingo), also known as “The Check Up,” “The Six Month Recall,” or just “A Cleaning.” To keep it simple and consistent for the purpose of this article, I’m going to refer to it as the “Examination and Prophy” or E&P. Please note, Dude, that this is not the preferred nomenclature; it’s just the one I’m going to use here because I’m too lazy to think of anything better.
The E&P looks a little bit different in each office, and all of these steps aren’t done in every office at every appointment, but the basic components of the preventive dental appointment consist of:
    • Review and update medical and dental history
    • Blood pressure screening
    • Oral cancer examination
    • Examination of the teeth and periodontal tissues (i.e. gum tissue and supporting bone). This includes a visual examination for signs of dental caries (cavities), other problems with the teeth (chips, broken fillings, etc.), looking for signs of inflammation and infection, and periodontal probing, which measures the depth of the gum pocket. Just as in golf, the higher the number, the worse off you are.
    • Radiographic exam. The content and timing of dental x-rays can vary and are customized to the needs and disease susceptibility of the patient. The dental team weighs risk vs. benefits when taking dental x-rays, keeping radiation exposure to a minimum using the ALARA (As Low As Reasonably Achievable) Principle. And no, dental x-rays don’t cause meningiomas or pose any significant risk to health. We do, however, go out of our way to make the x-ray packets (or sensors) as pointy and gaggy as possible. You’re welcome.
    • We also do some specialized exams, depending on circumstances. If you are wearing a denture or a partial denture, for example, we’ll check those out. Kids with retainers, patients with sleep apnea or TMJ appliances, patients who are bleaching their teeth, etc.- we’ll review them as well.
    • Then comes the actual prophylaxis (cleaning). This is the fun part where we scrape your teeth with metal hooks and/or use a power washer/jackhammer device to remove the calculus (tartar) and biofilm (plaque) from your teeth, followed by polishing them with sand.
    • Application of a topical fluoride agent, when indicated.
    • Usually at the end of the appointment, the dentist will come in and review all the findings and radiographs, make any necessary diagnoses, and recommend treatment, if indicated. If everything looks nice and healthy, he or she will say “OK, Mrs. Splanchnic, we’ll see you again in six months.” Which is awkward if your name is Mr. Glorb, but we dentists aren’t very good with names.
The legend of the six month recall
As the story goes (and it’s fairly well documented, so I do believe it is legit), the “scientific” basis of the twice a year cleaning came not from bespectacled dentists in the lab or in the clinic, meticulously studying the issue with experimental groups, control groups, and double-blinding; no, it was actually the fabrication of an advertising genius named Claude Hopkins in the early 1900s. Mr. Hopkins was the ad wizard who boosted Schlitz beer’s sales by claiming that Schlitz cleaned their bottles with “live steam” (failing to mention that all of the other brewing companies did too).
One day, a friend of Mr. Hopkins’ approached him with a new product, a minty, foamy toothpaste called Pepsodent. At the time, toothbrushing was rare; fewer than 7% of households had a tube of toothpaste (or can of tooth powder, as the case may be) in their medicine cabinets. Dental decay at the time was such an enormous public health issue that the U.S. Army declared it to be a national security risk during World War I. Hopkins agreed to launch an advertising campaign, and within five years he turned Pepsodent into one of the most famous brands on earth by associating brushing one’s teeth with health and beauty. Soon everyone, including Clark Gable and Shirley Temple, were promoting that “Pepsodent Smile.” “You’ll wonder where the yellow went when you brush your teeth with Pepsodent!” Within ten years of being introduced, an estimated 65% of households had a tube of Pepsodent in their medicine cabinet.
After World War II, Pepsodent – still the leading toothpaste brand – created a new marketing catchphrase: “Use Pepsodent every day – see your dentist twice a year.”Sadly, until that time, very little was being done in preventive dentistry. Most people did not have their teeth cleaned regularly and they would wait until something hurt or broke before they sought care. Cavities were painfully drilled out with a belt-driven slow speed handpiece (usually without anesthetic) and large amalgam fillings were placed. Root canal therapy was rarely done, implants were years away, and if a tooth was painful, it was summarily extracted. Dentures were the rule in people over sixty years old, not the exception like it is today.
Pepsodent helped to change all that. Behind the strength of its brand and the popularity of its product, its marketing slogans helped make toothbrushing a ritual in homes and embedded the importance of seeing a dentist for preventive care into the psyche of the American consumer. By the 1960s and 70s, other preventive measures appeared on the dental stage, namely the widespread addition of fluoride into toothpastes and municipal water supplies, and pit and fissure sealants, resin coatings applied to the grooves in the biting surfaces of back teeth where tooth decay is most likely to form. Tooth decay rates plummeted, and when cavities did occur, they tended to be smaller and easier to restore. Improvements in equipment (namely the high speed handpiece) and materials improved the quality of care as well. In the 1970s the insurance companies got into the dental game, covering many dental procedures. They soon learned that if they covered preventive care, their costs would be lowered down the line, so most dental insurance plans began paying for two cleanings per year, which further encouraged this interval. How did the insurance companies arrive at the six month figure? Insert shrug emoji here. My hypothesis is that they bought into the Pepsodent narrative.
The actual science behind the six month recall
OK, so now we’ve established and accepted that the six month recall is the cornerstone of modern preventive dentistry. It’s taught in dental and dental hygiene schools worldwide and is practiced almost universally. It’s been elevated to the level of dogma, handed down on stone tablets from the dental gods on Mt. Sinai. So what does the science say? If you’ve read some of my previous Science Based Medicine posts or have listened to the podcast I co-host with fellow Science Based Medicine contributor Clay Jones, it won’t surprise you to learn that the science behind the six month recall is pretty lame, just like a lot of research is in dentistry.
Insert sad trombone sound here.
I suppose at this point I should discuss what evidence actually does exist to support or refute the health benefits of a six month recall schedule. This is the Science Based Medicine blog after all, and they’re paying me big shill bucks to write this piece. Better give them what they want.
There are some research papers, including meta-analyses, that cover the recall interval as it pertains to various outcomes. A 2007 Cochrane Review by Beime, et. al. concluded that:
There is insufficient evidence from randomised controlled trials (RCTs) to draw any conclusions regarding the potential beneficial and harmful effects of altering the recall interval between dental check-ups. There is insufficient evidence to support or refute the practice of encouraging patients to attend for dental check-ups at 6-monthly intervals.
Across the pond, a 1977 Lancet article by Sheiham concluded:
Persons having dental examinations at intervals longer than 6 months were not at a disadvantage. They did not have more severe dental caries or periodontal disease than those attending at intervals of 6 months. Neither was there any evidence that an interval of more than 6 months would affect the prognosis for orthodontic treatment. Oral malignancies are rare in British populations, and routine 6-monthly screening to detect oral malignancies is unreasonable.
And in the British Dental Journal (2003), Davenport et. al. in a systematic review stated:
There is no existing high quality evidence to support or refute the practice of encouraging six-monthly dental checks in adults and children.
Insert embarrassed emoji here.
Are you starting to get the picture? Let’s press on and see what else is out there.
Another Cochrane Database Systematic Review by Riley et. al. (2013) concluded pretty much the same thing as everyone else, saying:
There is no evidence to support or refute the practice of encouraging patients to attend for dental check-ups at six-monthly intervals. It is important that high quality RCTs are conducted for the outcomes listed in this review in order to address the objectives of this review.
Studying whether recall intervals of varying lengths would have an effect on dental caries, Patel, et.al. summarized:
The authors conclude that the evidence for using a one-recall-interval-fits-all protocol to reduce caries incidence was weak. Studies that addressed the impact of recall interval on caries incidence were methodologically weak. The evidence was not strong enough to support using any specific one-recall-interval-fits-all protocol for all patients.
As you can see, there isn’t a lot of good data to support our recommendation for the routine six month cleaning. Part of it has to do with the quality and quantity (or lack thereof) of good dental research. Perhaps if a really robust and powerful study was done, it would support the six month recall. But then again, it might not. The other aspect to consider is that there are so many variables that each patient brings to the table, how could we even think a “one size fits all” approach would be appropriate in the first place? Factors such as age, diet, smoking, medical cofactors (e.g. diabetes), oral hygiene effectiveness, medications, genetics, socio-economic status, etc. all play into this mystical and complex algorithm. So what is a conscientious, science based dental patient to do?
Confused emoji.
Conclusion: Um…it isn’t not science based…
Warning: You are being redirected from the Science Based Medicine website to the Opinion Based Dentistry website.I’ll repeat: What is a conscientious, science based dental patient to do?
Despite the lack of clear evidence in this area, I do believe some rational and logical recommendations can be made. First, I’ll describe what I and most of my science based colleagues do in our practices, and while we won’t be able to back up our rationale with solid evidence (see blog post above), I believe that it falls within the realm of biological plausibility and common sense. My medical colleagues are in the same boat in many areas: what is the appropriate interval for colonoscopies? Mammograms? There are guidelines to be sure, but it’s not a precise science.
Most of my patients are on a six month recall. There, I said it. Why? Because like it or not, that’s what patients expect, that’s what insurance pays for, it is an appropriate interval which keeps the majority of our patients mostly healthy, and I take comfort knowing that if a patient is in the early stages of gum disease or tooth decay, we can identify it early. I call this the Dental Recall Heuristic®, a “shortcut” algorithm which employs a practical method not guaranteed to be optimal or perfect, but sufficient for our immediate goals. Admittedly, I can’t back up our policy with rock solid science, but it’s the best we can do with the information we have. It might not be completely science based, but it isn’t not science based.
Many of our patients require a more frequent recall interval to maintain their oral health. Almost always these are patients with ongoing periodontal disease, and more frequent debridements and removal of plaque is often indicated to prevent progression of the disease. Some need more extensive periodontal treatment with a specialist. Conversely, some of our patients only need to be seen annually. Yes, a minority of our patients just have “good teeth.” For some in this hallowed demographic, it’s because they work really hard, brush and floss constantly, eat well, follow our advice, and help old ladies cross the street. Most in this category, however, are just lucky. They hit the nature/nurture lottery. They abuse their teeth just as much as the next guy or gal and aren’t that great at brushing or flossing, but for some reason they are decay and gum disease resistant. They don’t need to be seen every six months; it would confer very few benefits to them. I need to point out that we don’t make any money on these selfish people who only think of themselves. Some choose to have their teeth cleaned because they like it when their teeth don’t feel fuzzy, but that’s their choice, not our recommendation.
So circling back to what is appropriate for those dental consumers who are reading this post, here’s what I would recommend. If you are a “typical” dental patient, in the humpy middle part of the dental Bell Curve – i.e. you don’t get that many cavities, and while your dental hygienist may nag at you for not flossing enough, otherwise he or she says your gums are in “pretty good shape” – then go every six months. Just like changing the oil in your car regularly, it’s a good habit and it will help keep you in a state of dental health for your entire life. If, however, you have a history of periodontal disease, tooth loss, bleeding gums, deeper pocket depths (e.g. >3 mm), then it may be in your best interest to be seen more frequently. Discuss this with your dentist and/or dental hygienist to weigh the pros and cons for your particular situation. Don’t be afraid to ask questions, and your dental team should always be able to support their recommendations. Conversely, if you are a “golden child” like the ones I mentioned above – perfect teeth and gums, no issues, everything is happy happy clappy clappy – then you may be someone who can lengthen their recall interval to nine or even twelve months. Again, have the discussion with your dentist and/or dental hygienist.
On the other hand, if you’re not content to trust your oral health to Claude Hopkins’ ad campaign slogans, then I recommend some of the following resources to investigate the fascinating world of teeth and gums: The American Dental Association Center for Evidence Based Dentistry is a fantastic resource, easily searchable, and up to date; the Cochrane Database of Systematic Reviews; and of course PubMed.
Smart person emoji.
When there isn’t good evidence to support our claims or practices, we dentists are fond of saying “Dentistry is an art and a science!” This is one of those cases, but in the end, despite treading on shaky evidential grounds, it’s possible to maintain the health of your teeth and gums for a lifetime. So don’t forget to brush your dentist twice a day and visit your toothbrush once a year!

Do You Need Daily Treatment to Repair Damaged Enamel?
Does a toothpaste provide “next level” fluoride technology that you need to use every day? You know the answer.
Harriet Hall on November 30, 2021
Link
The commercial keeps airing on TV with annoying frequency. She’s a dentist, she wears a white coat, and viewers are expected to assume she is offering good advice. I find her voice irritating, but that would be beside the point if her information were accurate. It isn’t. She is providing inaccurate information invented by marketers to sell a supposed remedy.
Consumers may find her advice credible. They have come to expect successive improvements in preventive dental care. Instead of just cleaning teeth any old way, they were told to use a toothpaste with fluoride. Then they were told they must floss regularly. They were advised to make more frequent trips to the dentist (every 6 months instead of yearly or when problems arise). In that context, they might not be surprised to hear that they need daily treatment to repair damaged enamel. But they don’t.
What she says: We have to be able to repair our tooth enamel on a daily basis. With Sensodyne Pro-Namel Repair Toothpaste more vital minerals enter deep into the enamel surface (compared to a non-optimized fluoride toothpaste), giving you an opportunity to repair acid-weakened enamel. Use twice daily. It’s amazing. It will always be her go-to toothpaste.
What the BBB says: Two years ago, the BBB National Programs National Advertising Division recommended discontinuation of the commercial because it makes these false claims:
Express claims:
    • ProNamel toothpaste provides “next level” or “innovative” sodium fluoride technology, beyond the typical remineralization effect marketed for decades.
    • ProNamel toothpaste heals cracks “deep within the tooth [or enamel] surface”.
    • ProNamel toothpaste “repair[s] what has already been damaged”, including the cracks in teeth shown in the advertisement.
Implied claim:
    • The product demonstration falsely communicates that ProNamel toothpaste fills and heals cracked enamel.
The manufacturer, GlaxoSmithKline, said it would comply with the NAD’s recommendations, but the deceptive ads continue.
The reality
Once lost, tooth enamel will never grow back or be replaced (although admittedly there are experimental treatments under development that may someday be recommended for that purpose). The BBB complaint explained:
Exposure to acids from foods or drinks can weaken and destroy tooth enamel. Once enamel is lost it will never grow back or be replaced. Fluoride is a naturally occurring mineral that can be found in most toothpastes. While fluoride helps to repair and strengthen weak spots on existing enamel, it cannot repair or strengthen tooth enamel that no longer exists, including enamel that has been cracked, chipped or otherwise permanently destroyed.
The dramatization in the video conveyed a misleading message.
Established ways to maintain healthy enamel
    • Good oral hygiene, including brushing, flossing, and mouthwash
    • Avoid sugary foods and drinks
    • Fluoride (in water and/or in toothpaste)
    • Stop teeth grinding (bruxism)
    • Treat acid reflux
    • See your dentist regularly
Conclusion: Don’t believe everything you see on TV
        ◦ No, you don’t need a special toothpaste to repair damaged tooth enamel on a daily basis. Remember: TV commercials are designed to sell products, not to impart good science-based information.

Mercury amalgam fillings and you
Grant Ritchey on January 29, 2016
Link

Note this special guest post submitted by Maddaz A. Hatter, D.D.S. Thanks Dr. Hatter!
Also, on an almost-completely-unrelated note, skeptical dentist, haberdasher extraordinaire, and sometime-guest-blogger Grant Ritchey recently moderated debate between SBM regular Clay Jones, and pediatrician-who-has-yet-to-be-coerced-into-blogging-with-us Raymond Cattaneo, about the pros and cons of firing families who refuse to vaccinate according to the recommended schedule. I’m told Clay wins the debate through a swift blow to the throat, but it happens at the very end so you’ll have to listen to the whole thing! Located at the Prism Podcast via this tasteful and refined link.
In England during the 1700s and 1800s, felt hats – very fashionable at the time – contained trace amounts of mercury, and many of the workers in the hat factories that produced them succumbed to mercury poisoning over time. Symptoms of mercury poisoning include dementia and other neurological complications, from whence came the term “Mad as a Hatter.” We’ve known for quite a while that quicksilver in large enough quantities does not do a body (or brain) good.
This brings up a point. It seems that a recurring theme at Science Based Medicine is that we are always defending what legitimate health care providers want to put into a human body to prevent, cure, or manage disease, or to improve health or quality of life. Conversely, we critique those who want to put things in us that are of no demonstrable benefit or which may cause harm. To wit: vaccines – good, coffee enemas – not good. Fluoride (at appropriate doses) – good, colloidal silver – not good. This is an ongoing tug-of-war that will likely continue until our sun supernovas and consumes our planet, after which all arguments will probably be moot.
In the dental field, the two biggest battles we seem to continually wage deal with the safety of fluoride and the use of dental amalgam. Fluoride and fluoridation has been written about many times before on Science-Based Medicine. I have also discussed it several times on my podcast, The Prism Podcast, but I’ve never written about amalgam fillings before. Harriet Hall wrote an excellent SBM post on the matter way back in 2008, but after all these years it’s probably time to revisit the topic.
Amalgamology 101
Dental amalgam is the most commonly used filling material for decayed and broken teeth and has been for over one hundred and fifty years. While its use is decreasing due to more cosmetically-pleasing filling materials, concerns over toxicity, improved reimbursement from insurance companies for alternative materials, and other factors, it is still placed in over one billion teeth worldwide per year.
Dental amalgam contains approximately 50% mercury and is mixed with silver, copper, tin, and other metals to form a plastic (i.e. moldable) mixture which is then condensed into the cavity where it hardens. There has long been a concern that the mercury contained within a filling (although chemically bound to silver and other metals) could be released and cause a multitude of diseases and conditions, such as multiple sclerosis, Alzheimer’s disease, kidney disease, as well as a host of other maladies affecting every known body system. In fact, Norway, Sweden, and Denmark have banned its use due to concerns about environmental disposal and in Sweden, also for health concerns. The population of patients in which the greatest concern is expressed is pregnant women and children under the age of six, where toxic threshold levels may be lower than in adults. Countries such as the United States and Canada have not banned amalgam’s use in these groups, but have issued warnings for potential toxicity issues and uncertainties about its possible effects. The Food and Drug Administration (FDA) states: “There is limited clinical information about the potential effects of dental amalgam fillings on pregnant women and their developing fetuses, and on children under the age of 6, including breastfed infants”, while the Canadian Dental Association (CDA) says on their website: There is no scientific evidence of ill effects [on pregnant women or children], although mercury is known to cross the placenta.”
So, is dental amalgam safe to use in the expecting mother or young child? If there are uncertainties surrounding the effects of mercury on this susceptible population, is it ethical for a dentist to recommend dental amalgam as a filling material to his or her patients? What about everyone else? Are amalgam fillings a legitimate choice for restoring a tooth? Do the risks justify the benefits?
Dental amalgam: A brief history
Dental amalgam reportedly was first used by a man named Su Kung in China around 659 CE. More recently, in 1528, a German physician named Johannes Stokers recommended amalgam as a dental filling material. Fifty years later, in 1578, Li Shihchen chronicled a dental mixture of 100 parts mercury with 45 parts silver and 900 parts tin for filling teeth. It is unknown how well or how long any of these restorations lasted as there was little follow up care or record keeping at that time. Moreover, the means by which dental decay was diagnosed and removed was quite primitive by today’s standards. But there probably weren’t a lot of malpractice attorneys around then either, so why not try it out?
The next major historical reference to silver–mercury amalgam was recorded in 1826, when a Frenchman by the name of Traveau described a “silver paste” filling material, produced by mixing silver coins with mercury. In 1833, the Crawcours brothers in the US introduced their “Royal Mineral Succedaneum,” a fancy sounding name for a mixture of shaved French silver coins and mercury, mixed into a paste, and placed in the cavity. Up until that point, the most commonly used filling material was gold foil, which was hammered into the cavity with a mallet. It was (and is) a great filling material, but it was (and is) more expensive and more difficult to place than other materials and is thus rarely used nowadays. Dental amalgam was offered as an inexpensive, easy to place filling material in those days of primitive dentistry (the first dental school in the US did not open until 1840).
The controversy: Then and now
After dental amalgam was introduced in the US in the 1830s, many dentists at the time felt that it was an inferior material. The American Society of Dental Surgeons (ASDS), the only existing dental association at the time, labeled its use malpractice and required all of its members to sign a pledge vowing that they would not use the material. This led to the first “Amalgam War”, which raged until the 1850s. After the ASDS folded in 1856, and when the American Dental Association was founded three years later, there was no such ban on amalgam. Because of this tacit approval by the fledgling ADA, as well as advances in dental sciences and techniques in general, dental amalgam became more widely accepted as a filling material and has been used by nearly all dentists worldwide since that time. With very few exceptions, dental amalgam enjoyed nearly a century of unquestioned acceptance, with significant improvements being made in the manufacture, composition, and placement techniques occurring throughout that time period.
In today’s image-conscious society, patients typically want to have their teeth fixed with materials that look natural and realistic. Even so, amalgam will always have a place in the dentist’s arsenal. Amalgam is a useful filling material: it’s cheaper and in some situations longer-lasting than the alternatives. It possesses desirable properties that are especially valued in areas where dentistry is primarily cost driven, such as underserved regions of the world (including parts of the US), in charity clinics, prisons, teaching institutions, and so on. Dental amalgam is less technique-sensitive than composite fillings; it is more forgiving being placed under difficult circumstances or moist environments (for example, when the decay is below gum level or in an area that is difficult to access, such as a wisdom tooth). It requires less skill and training to work with, and can be placed faster than composite (tooth colored) fillings.
This invites the question: since mercury is a known neurotoxin, and since trace amounts of mercury leech out of fillings and find their way into the body, why is its use allowed at all? As with most questions concerning science and technology, medicine, and public policy, there are usually no clear-cut answers. There are too many variables to be controlled, too many risk vs. benefit equations to calculate. An attempt to discuss all possible scenarios whereby mercury’s role in pathological brain development and other neurological and physical issues vs. the use of mercury in commerce and medicine would be exhaustive and require a book, not a blog post. The decision tree in evidence-based dentistry is a complex interaction between the known scientific data, the care, skill, judgment, and experience of the dentist, and the circumstances and preferences of the patient.
A brief mercury primer
Mercury (atomic symbol Hg) can be (but shoudn’t be!) consumed in its elemental state (as a liquid or a vapor), in inorganic salts, and in organomercuric compounds (i.e. bound to carbon). Methylmercury (the organomercuric compound found in fish) is the most toxic and is absorbed through the digestive tract. The phase of mercury found in amalgam is elemental mercury (the liquid element that spills out of a broken thermometer), which is primarily processed in the lungs via inhalation, with very little being absorbed in the gastrointestinal tract. Exposure to mercury compounds can come from a variety of sources; chief among them is fish consumption, but can also occur from environmental exposure, exposure to spills (e.g. a thermometer or light bulb breaking), or from dental amalgam. Symptoms of mercury toxicity include profuse sweating, pink or red skin, desquamation (sloughing) of the skin, ataxia (poor coordination) and loss of balance, dysphagia (difficulty swallowing), other sensory deficits, confusion, peripheral neuropathy, and death.
Daily mercury intake
In the US, the FDA has established an acceptable daily intake for mercury of 0.4 micrograms per kilogram of body weight per day. Research shows that this amount of mercury, consumed for extended periods up to a lifetime, presents a negligible risk of adverse health outcomes in even the most sensitive human populations (pregnant women, developing fetuses, young children, or those with kidney disease, for example). The World Health Organization (WHO) has set a standard of 1.6 micrograms per kilogram of body weight per week, cumulatively less than the FDA figure. Although neither the FDA nor the WHO revise their recommendations downward for pregnant or nursing women, they do recommend reducing the amount and types of seafood in order to minimize mercury absorption and transference to the unborn or nursing child.
Much dental research has been done over the past twenty years in the area of dental amalgam and its effects upon human health. The medical scientific community is now in general agreement that patients with dental amalgam fillings are chronically exposed to mercury (a slight amount of mercury vapor is released from a filling during chewing, tooth grinding, etc.) and that the average daily absorption of mercury from dental amalgam is from 3 to 17 micrograms per day, which correlates to roughly 7-50% of the FDA’s acceptable daily intake (depending on body weight and other variables such as toothbrushing, number and size of fillings, clenching and grinding habits, gum chewing, etc.). To date, studies have shown no correlation between dental amalgam and birth defects or adverse health issues in patients with dental amalgam or in dental health care workers who are exposed to it on a daily basis. The FDI World Dental Federation, the world’s largest dental organization, released a policy paper which emphasized that there is no documented scientific evidence to show adverse effects from mercury in amalgam restorations except in extremely rare cases of mercury hypersensitivity. The American Dental Association’s Principle of Ethics and Code of Professional Conduct explicitly states: “removal of amalgam restorations from the non-allergic patient for the alleged purpose of removing toxic substances from the body, when such treatment is performed solely at the recommendation of the dentist, is improper and unethical.”
In the United States, amalgam is not regulated as a material by the FDA, but as a prosthetic device. Because of this classification, amalgam is not forced to undergo the same safety testing as is required for pharmaceutical products. In 2009, the FDA issued a ruling that reclassified mercury from a class I (least risk) device to class II (more risk) device. Because of this, a warning label must be enclosed in every package of dental amalgam that reads: “Dental amalgam has been demonstrated to be an effective restorative material that has benefits in terms of strength, marginal integrity, suitability for large occlusal surfaces, and durability. Dental amalgam also releases low levels of mercury vapor, a chemical that at high exposure levels is well-documented to cause neurological and renal adverse health effects.”
Amalgam removal to cure systemic disease
In the 1970s, a dentist by the name of Hal Huggins began advocating for the wholesale removal of amalgam fillings, claiming that mercury toxicity from them cause such illnesses as multiple sclerosis, Crohn’s disease, lupus, arthritis, leukemia, and many, many more. He subsequently lost his dental license for “‘deceptive yet seductive advertising” when conning his patients into replacing their amalgam fillings with other restorative materials, often at great cost to the patient. Since then, the anti-amalgam movement has gained strength and momentum, with entire organizations such as the International Academy of Oral Medicine and Toxicology (with their own journals and conferences) boasting thousands of members. Fortunately for the public, very few dentists are as zealous about removing amalgam fillings as Hal Huggins was, but there is a pervading belief among anti-amalgam dentists that mercury toxicity is a real and serious danger, and they are pushing for legislation to ban amalgam fillings. Dr. John Dodes authored an excellent review of the literature regarding the use of amalgam and the adverse health claims made by amalgam opponents and concluded that “(t)here are numerous logical and methodological errors in the anti-amalgam literature… (and) that the evidence supporting the safety of amalgam restorations is compelling.”
Informed consent in the use of dental amalgam
When choosing a dental material to use when restoring teeth, the dentist (in collaboration with his or her patient, and based upon the most current reliable scientific data) must identify which one will serve the patient best while reducing the probability of any untoward effects. Many factors come into play in this decision making process: the strength, durability, and longevity of the material, cost factors, cosmetic concerns, biological compatibility (i.e. low allergic or hypersensitivity potential), etc. In the case of dental amalgam, the following is accepted as being true: it is strong and durable, it is inexpensive when compared with other dental materials (gold, porcelain, composite), and it is not cosmetically appealing. In the area of health (although it has been shown to not cause medical problems) many patients have a concern in putting a known neurotoxin into their body, and this is a concern not to be taken lightly, especially in pregnant women and children.
When presenting options to a patient, the prudent dentist will objectively explain all risks and benefits, as well as costs, to the patient. Of course, the dentist can offer his or her professional opinion as to what the most favorable option would be, but ultimately the choice is the patient’s, and the dentist must respect this choice. For many, dental amalgam is an acceptable choice and an acceptable risk. For others, the choice and risks are unacceptable, and alternatives are then utilized. Children and women of childbearing age are of particular interest to the prudent dentist, as this subgroup (or the potential unborn child contained therein) is considered to have an increased risk of mercury toxicity if exposed. Further, what are the ramifications and ethical considerations of a mother consenting for her child (born or unborn)? Finally, the dentist must take into consideration the total environmental mercury intake of a person, not just that due to amalgam fillings. For example, if a person consumes a high quantity of fish and other mercury-rich foods, then even a “safe” level of dental amalgam could theoretically push the mercury burden to unsafe levels. Another dilemma in the decision-making process is the almost total absence of randomized controlled studies in this field; our only data come from less robust cohort studies. Even if these studies infer a minimal risk to the unborn or young child, the dentist may find it difficult to confidently assure the mother or father that placing dental amalgams in their child (or pregnant mother) is safe. If there are complications in childbirth, or if the child develops a neurological disorder, will the dentist be held liable?
Conclusion: Dental amalgams balance utility and safety
In the United States, Canada, and in many countries worldwide, citizens pride themselves on the qualities of autonomy, self-determination, self-direction, and freedom of choice, including those decisions involving health care. The regulatory agencies that govern amalgam use in North America (EPA, FDA, ADA, CDA, et.al.) make recommendations that are science based, using high quality research to evaluate the most current data on the safety of amalgam. Balancing the low risk of mercury exposure with the benefits to the general public of such a material is an on-going task, and one the various agencies revisit with regularity, making new recommendations and guidelines as the evidence warrants. To date, they have done an excellent job (in my opinion) with their recommendations, as retrospective studies are confirming their decisions as responsible and accurate; however the RCT “gold standard” studies remain forthcoming. For now, dental amalgam remains a safe and effective restorative material when indicated. If, in the future, studies definitively demonstrate harm being done, the new regulations and guidelines will change to reflect this. Evidence-based dentists will then change their protocols appropriately.

Note: Dental fillings do not actually contain plutonium.

Antibiotic Prophylaxis For Dental Procedures
Transient bacteremia (bacteria in the bloodstream) is common after dental procedures, but it rarely causes a problem. So, who needs antibiotic prophylaxis before a dental procedure? What procedures? What does the science say?
Grant Ritchey on June 30, 2017
Link

Did you know that getting your teeth cleaned can kill you?
Ok, that’s really not true (except in extremely rare, freak circumstances), but since today’s post is somewhat boring and unimaginative, I had to draw you in with what real journalists call a “hook”, and what hack writers like me call “click bait.” Looks like it worked.
Most of the time, a dental cleaning is a routine semi-annual event where you get to lie back, relax, and be made to feel guilty for not flossing often or well enough (even though we know it probably wouldn’t help a lot, anyway). The dentist or dental hygienist then scales the hard calculus deposits off of your teeth and polishes away the soft bacterial biofilm (formerly known as plaque), leaving your teeth feeling fresh and sparkly.
But did you know that even if your mouth is extremely healthy (i.e. your gums don’t bleed and you don’t have periodontal disease or cavities), even the most gentle dental cleaning forces untold multitudes of bacteria into your bloodstream, where they circulate throughout your body? Before you swear off dental cleanings forever though, keep in mind that this is almost always harmless; your immune system easily dispatches these invaders and you are none the worse for wear. However, for a small percentage of the population, these bacteremias (bacteria in the bloodstream) can be harmful and even deadly. Fortunately, we dentists have known about this connection for at least 80 years and have taken steps to reduce the risks of a lethal infection to almost zero. We do this by prescribing a dose of antibiotics prior to almost any appointment for those patients who are in a higher risk category of having a complication following a dental procedure. Having a dose of prophylactic antibiotics on board waiting for the bacteria to arrive helps to ensure that no infection will result.
As simple as that protocol might sound, it is much more complex and nuanced than that. In this blog post I want to unpack the concept of prophylactic antibiotic coverage for dental procedures: the pathophysiology of bacteremias, history of prophylactic antibiotic therapy, indications and contraindications, current guidelines, and the challenges we face trying to adhere to those guidelines.
The issue in a nutshell
As stated above, bacteria find their way into our bloodstream all the time, yet problems rarely occur. So you are probably asking: “why do we suddenly have to worry about it when we go to the dentist?” Excellent question, because as you know, we dentists are already trying to kill you with fluoride, mercury, and root canals. So it’s only logical that we would try to infect you by shoving germs through your gum pockets. It’s what we do.
There are two broad categories of patients who are perceived to be at a higher risk for an adverse outcome following a transient bacteremia: those with certain heart conditions or defects (particularly the heart valves) and those with artificial joints (knee or hip replacements, etc). Additionally, there may be situations in which antibiotic prophylaxis would be considered; for example poorly controlled insulin-dependent diabetics when surgery is performed, people living with HIV with very low CD4 counts, individuals with severe myelodepression (usually due to chemotherapy), or recent transplant recipients, including large organ or bone marrow transplants, to cite a few possibilities. In these unique (and fortunately rare) cases, the dentist, working in conjunction with the patient’s physician(s), will determine whether pre-medicating with antibiotics prior to a dental procedure is warranted.
Infective endocarditis (IE) is an infection of the lining of the heart chambers or valves with bacteria, fungi, or other organisms. IE occurs most commonly in people who have abnormal heart valves or had previous heart surgery. On rare occasions, it can occur in otherwise healthy people who have do not have a history of heart disease.
Here’s how a hypothetical case of infective endocarditis could occur following a routine dental procedure (in this case, the extraction of a tooth) in a patient with a defective mitral valve:
    • During an extraction there is a communication between the mouth and bloodstream. Bacteria (as well as other types of micro-organisms) enter the patient’s bloodstream. There are hundreds of species of bacteria, viruses, and fungi in the mouth, living in a delicate ecological balance. Most are harmless (or even beneficial), while others are responsible for causing such diseases as tooth decay, gum disease, strep throat, and a host of others. Mouths are messy.
    • These wayward bacteria then circulate in the bloodstream and adhere to the lining or valves of the heart, usually at a site of previous injury or surface irregularity or abnormality. In this example it’s around a leaky mitral valve (the valve through which blood flows from the left atrium into the left ventricle) where the flow is disrupted, creating eddy currents. Instead of being swept “downstream” like leaves in a fast-flowing stream, the eddies provide an opportunity for the bacteria to accumulate at or around the site of the defect.
    • The bacteria then grow on the valve surface, forming a small mass (called a vegetation) on the heart valves or lining. The valve or surface that is infected may then become secondarily damaged, causing Bad Things to happen.
    • A similar sequence of events occurs on patients who have a recently placed artificial joint – a hip or a knee, for example. Just like in the above example, instead of lodging in the heart, the bacteria are transported through the bloodstream to the site of the prosthetic joint, where they set up shop, leading to infection and the possible subsequent failure of the surgery.
A brief history and where we are today
In the pre-antibiotic era, dental infections could (and often did) kill people. In fact, in the 18th and 19th centuries, dental complications were the 5th or 6th leading cause of death, according to records from the time. For almost 100 years, the connection between heart valve defects and elevated cardiac risks from dental procedures has been known. In the 1930s, researchers first detected bacteremias caused by Streptococcus species following dental extractions, thus confirming the pathophysiology of IE. Early attempts to prophylactically manage these potential complications involved the use of sulfonamide antibiotics, anti-bacterial rinses prior to dental procedures, scaling and polishing teeth to reduce the bacterial load prior to extraction, irrigation of the extraction socket and cauterization of the gum tissue following an extraction, and many others. In one protocol suggested in the early 1940s, it was recommended that an autogenous streptococcal vaccine be obtained from a culture of the apical (i.e. root) area of the first tooth extracted, which was then to be administered before extraction of the following tooth. When penicillin became available following World War II, it became the antibiotic of choice for IE prophylaxis.
In 1955, the Committee on Prevention of Rheumatic Fever and IE of the American Heart Association (AHA) developed the first prophylactic protocol for use in patients with IE undergoing dental procedures. This protocol was recommended in patients with congenital or rheumatic heart disease who were undergoing dental extractions or other manipulations that affected the gingival tissues. The AHA panel stated that the aim of prophylaxis was to make high concentrations of the antibiotic available at the time of the manipulation and to maintain the presence of the drug in the bloodstream for several days in order to eliminate any bacteria that had adhered to the heart valves during the bacteremic episode. The recommended regimen was an intramuscular injection of a dose of 600,000 IU of aqueous penicillin and 600,000 IU of procaine penicillin dissolved in oil with 2% aluminum monostearate administered 30 minutes before the dental procedure. Alternatively (although less desirable), they proposed the oral administration of 250,000-500,000 IU (which is about 250ish milligrams) of penicillin 30 minutes before each meal and before bedtime, starting 24 hours before the dental treatment and continuing for 5 days afterwards, and with an extra dose of 250,000 IU of penicillin immediately prior to the procedure.
Since 1955, the recommendations for antibiotic prophylaxis for IE (also referred to as Subacute Bacterial Endocarditis (SBE) prophylaxis) have been revised nine times, the latest occurring in 2007. A general trend in the revisions has been twofold – a lessoning of the dosage of the antibiotic taken and eliminating conditions that require antibiotic premedication. Although the complications from a dentally-caused bacteremia can be severe, the evidence for the benefit of antibiotic prophylaxis is not all that robust. In fact, when the recommendations were last changed, Dr. Walter R. Wilson (the head of the committee which wrote the guidelines) stated:
We’ve concluded that if giving prophylactic antibiotics prior to a dental procedure works at all — and there’s no evidence that it does work — we should reserve that preventive treatment only for those people who would have the worst outcomes if they get infective endocarditis. This changes the whole philosophy of how we have constructed these recommendations for the last 50 years.
This, in my opinion, was a wise tack to take. If the evidence for benefit is scant, then why do it? On one hand, what’s the harm of one small dose of an antibiotic? That surely can’t do any harm, can it? Well, for the most part, no. One dose will not cause a “superbug” to evolve, nor will it significantly alter the microflora of the individual. That being said, a real concern is that, although rare, negative side effects can occur. A potentially fatal anaphylactic reaction to amoxicillin is possible, and has occurred on many occasions, so we cannot ignore the debit side of the risk to benefit ratio ledger. Other negative side effects (nausea, vomiting, interacting with other medications, etc.) can occur as well.
The current guidelines for dentists are as follows: for any patient, whether they have a cardiac defect or a recent joint replacement, a single oral dose of 2,000 milligrams of amoxicillin, one hour to their appointment, is prescribed. For those patients allergic to amoxicillin, clindamycin is usually prescribed instead.
So what’s the problem?
For the most part, there is no problem. Our patients who need premedication – for whatever reason – before they have a cleaning or a root canal or (heaven forbid!) an extraction, they take it, have the procedure, and return home uneventfully. In 31 years of practice, I haven’t killed anyone yet.
However, as a general dental practitioner, I am faced with a minor ethical dilemma on an almost daily basis, but to be fair I have to say that it’s almost always with the orthopedic physicians, not the cardiologists. I don’t want to throw my orthopedic pals under the bus, but I will say that, in my experience (cue worst phrase ever), they are the most difficult doctors to deal with regarding antibiotic prophylaxis. Here’s why: after a thorough review of the literature, the American Dental Association (ADA) determined that:
…[A] 2014 systematic review states, “In general, for patients with prosthetic joint implants, prophylactic antibiotics are not recommended prior to dental procedures to prevent prosthetic joint infection.”
In other words, there’s really not a problem with undergoing a dental procedure following joint replacement surgery (assuming no confounding factors such as uncontrolled diabetes or other immune compromises). Yet, most of the otherwise excellent orthopedic physicians I work with insist upon pre-medicating our mutual patients following joint replacement surgery – typically for two years, but often for life even though this protocol is not supported in the literature. I’m sure they just want to play it safe, or perhaps they continue recommending premedication because that’s what they’ve always done and old habits are hard to break.
Usually I comply with their edict, because it’s outside my legal scope of practice to call the shots for any medical procedure or condition. But if I am the one who prescribes the antibiotic at the behest of my patient’s physician (even if I know if it is contrary to current scientific evidence), what happens if the patient has an adverse reaction to the drug? Who is responsible? Me? The orthopedic doctor?
The problem is that bacteremias are caused every time you brush, every time you eat, and every other time you’re just sitting there. It’s not just confined to dental procedures. So why is the risk elevated only when you’re in my office? In an article published in the July 2016 issue of The Journal of Bone and Joint Infection, the authors state:
Transient bacteraemia occurs during daily oral hygiene activity (e.g., tooth brushing) and thus the cumulative risk for a haematogenous PJI (prosthetic joint infection) from tooth brushing is higher than that from a dental procedure. PJI after a dental procedure are rarely reported. On the basis of an epidemiological model, several thousand patients with artificial joints must receive antimicrobial prophylaxis to prevent a single PJI. Considering this ratio, the number of adverse events due to the antimicrobial compound exceeds the benefit of administering it by a large magnitude. Therefore, as a rule for the vast majority of cases, antimicrobial prophylaxis during dental procedures is not recommended. It is important that a patient has a good oral health status before joint implantation and that good oral hygiene is continuously maintained in patients with artificial joints.
In other words, prophylactic antibiotic therapy for patients with joint replacements is not indicated without extenuating circumstances. The risk of an adverse reaction to the antibiotic (statistically) far exceeds the risk of joint infection.
So, I suppose the purpose of this blog post is to inform our dear readers about the science of antibiotic prophylaxis prior to dental treatment; plus I want to issue a wake-up call to my physician colleagues to work with their dental allies to together determine what is best for their mutual patients and to follow the latest science based guidelines.
If you are a patient with a heart defect, please do your due diligence and consult with your cardiologist and dentist regarding the necessity of antibiotic prophylaxis. If you have had a joint replacement, also please do your due diligence and consult with your orthopedist and dentist regarding the appropriateness of taking an antibiotic prior to routine dental procedures. Ask for evidence and the most current guidelines regarding the best practice. Your health could be at stake.

Dental X-rays and Brain Tumors — Oh My!
Steve Hendry on May 11, 2012
Link
Fear sells, and the media loves it. If it’s scary, no matter how tenuous the link or inconclusive the study, you are going to see it on the news. How many times over the years have you heard that your cell phone might give you brain cancer, even though it never turns out to be true? Once such a claim is made, however, it becomes lodged into the public’s psyche and is accepted as true, even after refutations and retractions are published (see Wakefield, Andrew).
And so it is with x-rays. The latest scare du jour, a recent study out of Yale that claims to show a correlation between dental x-rays and intracranial meningioma — the most common brain tumor and usually benign — has been enjoying widespread attention in newspapers and on the evening news. We don’t know if it will be on Dr. Oz, because we can’t bring ourselves to watch that show, but we feel the chances are good. Other alt-medders will no doubt have collective woogasms over the story and will further incite fear and mistrust into the doctor-patient relationship. In fact, the Mercola website wasted no time in weighing in:
While this study does not necessarily establish causation between dental X-rays and tumors, previous research has also implicated dental X-rays in the development of thyroid cancer, and research clearly shows this type of radiation is not harmless…
Typical alarmist fear-mongering. When has any health care professional claimed that radiation is harmless? This is not cutting edge research; Wilhelm Röntgen, the discoverer of x-rays in 1895 and winner of the Nobel Prize in 1901 for his research in the field, advocated the use of lead aprons for protection from the ionizing radiation way back when. Further, trying to lump one study linking dental x-rays to meningioma to another study linking them to thyroid cancer is taking quite the kitchen sink approach. But if there are multiple alleged possible potential theoretical adverse effects from our dental death rays, it must be true, right?
Well, not so fast. We’re dentists, and unlike many knee-jerkers, we’ve actually read the study and would like to offer a little bit of insight into this before everyone panics. In fact, with respect to Letterman, we’d like to offer our Top Three Reasons Not To Panic:
1. The data is primarily anecdotal. The study authors reasoned that since actual data about people’s radiographic histories is hard to compile (people typically see multiple dentists over their lifetimes, and there is no central repository of radiographs taken), it would be acceptable for epidemiological purposes to simply interview people and ask them to recall what dental x-rays they’d had taken over the years since childhood. Claus et al. claim that people show accurate and unbiased recall of their x-ray histories suitable for drawing inferences decades later, but we have news for you. It is standard procedure for us, as dentists, to ask new patients what sorts of radiographs they’ve had in the last fews years (we will ask your previous dentist for copies to avoid taking them needlessly) and you people are terrible at remembering this sort of thing. Except for people who haven’t seen a dentist at all in years, it’s actually a bit unusual for a patient to accurately tell us what and when their last dentist took, even in the previous couple of years — we usually have to call your previous office to find out. Based on our daily reality, the idea that patients can recall what radiographs they’d had since childhood with epidemiologically useful accuracy seems implausibly optimistic, especially when considering that the sample population ranged from 20 years to 79 years old. This would require an accurate memory and reporting of radiographs taken as far back as the 1940’s and 1950’s in many cases, which we submit is not a valid assumption. In fact, the authors, to their credit, state:
Limitations of this study include the possibility of either under-reporting or over-reporting of dental x-rays by study participants. This is a difficult problem in epidemiology, because, unlike medical care, which (at least within cohorts of patients drawn from health maintenance organizations or similar entities) may be confirmed by a review of centralized medical records, dental care generally is obtained (even for a single individual) from numerous dentists, all of which are outside of a health maintenance organization or hospital-based setting, providing little opportunity for researchers to validate dental reports in a timely or cost-efficient manner. No national database of dental treatment exists within the United States; hence, researchers must rely on patient self-report, despite the potential for bias.
Let’s play a fun game. We’ll ask you, the astute and intelligent reader of the Science Based Medicine Blog, to recall your dental x-ray history for your entire life. Can you recall the exact dates when a full series of radiographs were taken? What about a panelipse? Corrected tomograms? Cone beam films? Individual films called periapicals? What about bitewing x-rays?
How did you do?
Not very well, did you? Well, don’t feel badly; we’re dentists and we wouldn’t be able to recall our own radiographic history from memory even if threatened with homeopathic hemlock! Asking meningioma patients if they remember having x-rays, and comparing with the memories of people not preoccupied with having brain tumors, is not only inaccurate, but also raises the obvious possibility of reporting bias by the study participants.
We are also concerned that the authors apparently did not survey for other potential confounding factors, such as tobacco history, diet, occupational exposures, etc., or if so, they were not disclosed in the paper. It might even be that having had dental x-rays is correlated with going to the dentist regularly, and that those people are also more likely to see a physician regularly and have a timely diagnosis of medical conditions like meningioma. Or perhaps people who live healthy lifestyles and thus have healthier teeth and gums require fewer dental x-rays over their lifetime. In this scenario, quantitative measurements of dental x-rays are an indirect indication of systemic health, and thus meningioma risk. Who knows, but the point is that there are a myriad of risk factors not considered in this study, and the one variable they attempted to measure was vague and nebulous.
2. The results defy dose response expectations The Yale study reports that meningioma patients are twice as likely than controls subjects to remember ever having had a bitewing x-ray (the most common film used in dentistry), and that more frequent bitewings were associated with increased risk. So far so good. But they found no significant correlation with full mouth series radiographs — a set of 16-20 dental x-rays. Please note that a full series of dental radiographs includes 2-4 bitewings, then adds 14-18 more! The take home message, if this were valid, is that a couple of cavity detecting x-rays may give you a brain tumor, but if your dentist takes an extra dozen or so films instead, you’ll be fine. Dr. Alan Lurie, president of the American Academy of Oral and Maxillofacial Radiology, said “That inconsistency is impossible to understand to me”, and he has a good point. “I think it is a very flawed study,” Dr. Lurie went on to say. As reported in the ADA News:
He (Lurie) characterized at least one outcome of the study—reflected in a table that related meningioma risk to types of dental X-ray examination—as “radio-biologically impossible.”
Said Dr. Lurie, “They have a table, Table 2, in which they ask the question, ‘Ever had a bitewing,’ and the odds ratio risk from a bitewing ranges from 1.2 to 2.0, depending on the age group. Then they asked ‘Ever had full mouth’ series, and the odds ratio risk from a full mouth series ranged from 1.0 to 1.2.
“That is biologically not possible because the full mouth series has two to four bitewings plus another 10 to 16 periapicals. A full mouth series, just to round things off, is 20 intraoral X-rays of which two to four are bitewings. They are showing that one bitewing has 50 to 100 percent greater risk than a full mouth series that has multiple bitewings plus a bunch of other films.”Explaining this gross internal discrepancy is difficult, as the epidemiologic and statistical methods are widely accepted, Dr. Lurie said. He attributes the perceived discrepancy in the data to possible recall bias in the patients involved in the study.
The study also found no correlation with cone-beam CT scans, increasingly used in dental implant treatment and providing the highest x-ray dose of any dental radiograph.
3. Lost in the background. Claus et al. point out that dental x-rays are the most common source artificial source of ionizing radiation, which is true, but omit the fact that they are among the least significant quantitatively. Data published in 2009 in the journal Radiology, puts this nicely in perspective:
Estimated collected effective dose from various sources, U.S. 2005 (thousand person-sieverts)
Natural background	720.0
Medical radiography	899.0
Nuclear medicine	231.0
Dental radiography	2.5
Nuclear power	0.1
Consumer products and misc.	39.0
Take note: in the race to blast the most radiation through your brain, nature is falling a bit behind your hospital, but your dentist can’t get within 2 orders of magnitude of it. That’s why you never see a Superhero (or a Godzilla) mutating out of a dental office to save (or destroy) the world. While hospitals and Mother Nature have veritable radiation bazookas at their disposal, we have but pea shooters.
The reason your dentist is actually such a poor choice for suicide by brain tumor is related not to frequency (what the authors of the study focused on) but to dose. Particularly with current trends toward digital x-ray equipment (which exposes patients to significantly less radiation than film x-rays), the actual radiation dose in a dental x-ray might surprise you (data from the Health Physics Society and from Randall Munroe’s superb infographic):
Dose in microsieverts
Dental bitewing	5
Dental Panorex	10
Daily background radiation	10
Airplane flight NY-LA	40
Chest x-ray	100
Lumbar spine	1500
Intravenous pyelogram	3000
Whole-body CT scan	10,000
Coronary angiogram	20,000
We hope this will help you understand why we roll our eyes when a physician reporter on NBC tells the audience that they should be really be refusing x-rays at the dentist. This is dangerous advice coming from someone outside of their field of expertise.
Medical radiation aside, an important question remains: when we all get several hundred μSv of background ionizing radiation through our bodies and brains per year — every year- it seems a bit odd that an extra 10 μSv, even once in your life, would significantly raise your risk of anything to the degree that the Yale study claims.
And One More Thing. We are really getting a bit tired of hearing everyone who publishes or pontificates about x-rays opine sagely that x-rays should only be used where necessary, as if they have invented the concept of radiation hygiene. This implies that physicians and dentists routinely take unnecessary x-rays. But this is not a new idea. Keeping radiation exposure As Low As Reasonably Achievable is a cornerstone of diagnostic radiography, and has been for decades. It’s called the ALARA Principle, and it has been taught to everyone who uses x-rays in Medicine and Dentistry for ages. If you go to your dentist (or your physician) and announce that you don’t want any unnecessary x-rays he or she is NOT going to say “no problem — we never really needed the ones we used to take!”. If he or she is any good, chances are that radiographs are prescribed (and that really is the correct term) because the diagnostic benefits of the bitewing or the angiogram vastly outweigh the risks. It’s good to discuss this with your healthcare provider, but bear in mind that doing many invasive procedures without the benefit of adequate diagnostic radiographs is often regarded as malpractice, and for good reason.
And One More One More Thing. We have devoted most of this blog post pointing out some of the flaws of this study and how it may have adverse effects upon your dental health. We would be remiss, however, if we didn’t point out that the fallout from studies such as these rests squarely upon the shoulders of irresponsible reporting by the media. In a desperate battle for viewers/listeners/readers, these stories are belched to the public uncritically, with fear being the primary angle. Rarely is equal time given to rational responses, and sadly, the personalities who spout the loudest are often physicians contracted with the news networks. This is unfortunate for many reasons; among them being that 1) as doctors, they should know better; they should read the article themselves and be able to interpret it correctly, and 2) their opinion is held in high regard by the public, making our job of discussing it with our patients that much more difficult. We can’t tell you how often we have heard from our colleagues the fallout we’ve received when the Great and Powerful Oz (a cardio-vascular surgeon) informed his disciples that one can effectively whiten one’s teeth with raisins and lemons. Not only is that patently false; it’s harmful to teeth, as putting something almost as corrosive as battery acid on one’s teeth is generally frowned upon in the dental community.. Stories such as these can often create a wedge in the relationship we dentists try so hard to establish with our patients.
Finally, dentistry is by necessity somewhat more reliant on routine radiographs than other health professions because we deal primarily with hard tissues subject to diseases that are often invisible without some radiographs. Keep in mind that tooth decay and periodontal disease are among the most prevalent diseases of the human race, and early detection and treatment are critical to good oral and systemic health. Without radiographs, we often cannot see decay until it reaches the nerve and kills your tooth, or the impacted wisdom tooth until it has damaged the tooth next door, or the asymptomatic abscess until it puts you in the hospital. Occasionally, we discover pathological processes, including the rare case of oral cancer long before they would manifest clinically. A timely x-ray, even in someone with no symptoms, could save a life. We as a profession readily accept the radiation burden in a bitewing or full mouth exam because of the obvious benefits for the well being of our patients. When we order any X-ray exam, we have made the determination that the benefit outweighs the risk and the risk of such exams are much less than those risks we commonly accept in daily life. We do not take this responsibility lightly.
So, do dental x-rays cause meningiomas? We have criticized the original article and the reporting thereof, but the fact remains that we don’t know. They might, of course, but unfortunately the article only gives us a smattering of data that may or may not be relevant. The signal to noise ratio contained in this study was too low to be of much use, and it’s hard to understand how higher-dose x-ray exams could be safer than the lower dosed single bitewings, or why far higher doses from other sources would not contribute to the same problem. Hopefully a more thorough study will be done to add to our body of knowledge and either confirm or refute the findings of the original article.
We do hope this has helped pull at least some of you back from the brink of a total freakout about your next dental visit. If you still need more dental fear, stay tuned — we hope to tell you soon about another dire threat from your dentist: silver amalgam fillings.
Dr. Grant Ritchey received his Bachelor’s degree in Human Biology from the University of Kansas in 1982, and his Doctor of Dental Surgery degree from the University of Oklahoma in 1986. He lives in Kansas City, is married, and has two grown daughters. Since 1986, he has maintained a general dental practice in Tonganoxie, Kansas, and was awarded a Fellowship in the Academy of General Dentistry in 1998. Currently, he is working toward his Masters in Education Degree from the University at Buffalo in the Science and the Public program, with an emphasis on the prevalence of alternative medical practices in dentistry.
Dr. Steve Hendry, BSc DDS FAGD, completed an honours degree in Genetics at the University of Western Ontario before deciding to be a dentist when he grew up. He spent summers working in a corn cytogenetics research lab through dental school. Since graduating in 1981, he’s maintained a general dental practice. Steve has always been fascinated and appalled at the scarcity of critical thinking skills in society and, increasingly in his own profession. He is particularly proud of having attained the status of “closed minded” in the eyes of some of his woo-friendly peers.

What’s in that tube?
With Science-Based Toothpaste on one hand, and “all natural homeopathic toothpaste” on the other, what’s the difference?
Grant Ritchey on February 24, 2017
Link
Today’s Science Based Medicine post will leave you foaming at the mouth. Not from excitement, organophosphate pesticide poisoning, or rabies, but because our topic today is toothpaste! You may find yourself asking “Why toothpaste?” followed by “Didn’t you bore us a while back with a post about flossing?” Indeed I did! We dentists aren’t the most titillating people around, so to us, brushing and flossing are really stimulating topics. We really should get out more often.
For years, I’ve seen adverts for “natural” toothpastes, and patients often ask me if such and such brand is better for them than Crest® or Colgate® since they read somewhere on the internet that fluoride causes[insert every possible illness imaginable here], or that sodium lauryl sulfate causes [insert every possible illness imaginable here], or that the little “plastic beads” found in some products, including some toothpastes are decimating our environment like some small scale dental Silent Spring.
But what really prompted me to write this article was a fun discussion I had with Myles Power and James Gurney on their excellent podcast The League of Nerds. Myles purchased a tube of “homeopathic toothpaste” as a joke to break the ice and get our conversation going. But after he examined it more closely, Myles – a chemist by training and trade – noticed some disparities between what was claimed vs. what the toothpaste actually contained, as well as some questionably-misleading labeling. This observation allowed the three of us to wander off into a more in-depth analysis of what these products are and how they can often make specious claims that can fool consumers that they are getting more health benefits from their toothpaste than are possible. Not long after that, another friend (and former guest on Clay Jones and my podcast) Lydia Finch Segebrecht sent me some absurd toothpaste ads that had popped up on her Facebook timeline and suggested that I write an SBM post about it. Voila!
Introduction to Dentifrice-ology
When we are at cocktail parties or dental conferences, we dentists refer to toothpaste as a dentifrice. We do this primarily to identify ourselves as members of our tribe and to solidify our social status therein, but also because we health care people think we have to have fancy sounding words for everything just to try to appear intelligent.
A dentifrice is defined as “A substance, such as a paste, powder, or liquid for cleaning the teeth.” Now that you know, you can put it in the “I’ll never use that word again” file. Some form of tooth cleaning substance has likely been used since prehistoric times, and while we don’t know exactly what was in them, it is believed that such things as ash, crushed oyster shells, bone, and even oxen hooves and other abrasive ingredients were used. While occasional cleaning concoctions are mentioned in history dating from around the 9th century CE and earlier, it wasn’t until the mid-1800s when dentifrices (in the form of tooth powders) were introduced to the public. It was during this time when soaps and other surfactants were added to the powder, followed by the introduction of tooth creams in the 1850s, and Colgate getting into mass production of their tooth cream in the 1870s. Grandma swore by peroxide and baking soda, or even brushing with pure, unadulterated Morton’s salt, but then again, Grandma was probably in dentures by the time she was 45.
Fast forward to 2017 and if you look on the toothpaste aisle of your pharmacy or grocery store, you’ll find a mind-numbing selection of toothpastes from which to choose. And that vast selection is but a small sampling of the choices you have online and in other venues such as health food stores and the like. Despite the plethora of choices, toothpastes have some basic ingredient characteristics in common. First I’ll discuss the basic formula for the majority of toothpastes, then I will lay out the case for “science-based toothpastes” followed by giving some examples of “alternative” or “natural” toothpastes and why they may not do what they claim to do.
So what’s in dentifrice toothpaste?
The four basic components of toothpastes are:
     1.  Abrasives – Abrasives serve an important role in toothpaste. But instead of oyster shells and oxen hooves, modern abrasives are gentler and typically include calcium carbonate, dehydrated silica gels and hydrated aluminum oxides. The goal of the abrasives in today’s toothpaste is to scrub the surface of the teeth without damaging your tooth’s enamel.
     2.  Flavoring – Artificial sweeteners (not decay causing sucrose!) and flavorings make the toothpaste palatable so people will be more inclined to brush for the proper amount of time. (People usually don’t brush for the proper amount of time, but at least the flavoring makes them more inclined to.)
     3.  Humectants – Humectants are chemicals that help retain the water in the toothpaste so you get that nice smooth gel consistency when you squeeze the tube. Sorbitol (also a flavoring agent) and glycerol are examples of humectants.
     4.  Detergents – Detergents are used to promote foaming and act as a surfactant to help clean the teeth. Sodium lauryl sulfate is the most common detergent.
These are the four main cornerstones of dentifrice chemistry. Sometimes sodium lauryl sulfate is removed because some people believe it is toxic or allergenic, but for the most part, almost all toothpastes contain these ingredients.
The fifth basic component of toothpaste, which I deliberately omitted, is fluoride. Fluoride is a mineral that is in most “mainstream” toothpastes, and as we all know, it plays a vital role in strengthening enamel and reducing the likelihood of getting a cavity. I omitted it because fluoride can be removed from toothpaste without noticeably affecting the characteristics of it. It is also the Mason-Dixon line between what I will call “Science-Based Toothpastes” vs. “Natural Toothpastes.”
So let’s discuss the concept of the Science-Based Toothpaste.
The American Dental Association Seal of Acceptance
A good place to start is with the American Dental Association (ADA) Seal of Acceptance. According to the ADA website:
When you see the ADA Seal, you can be sure the product inside has been scientifically evaluated to be safe and effective. In fact, to obtain the ADA Seal companies frequently are asked to meet higher standards than what is required by law. Not all products submitted for the Seal meet the ADA’s stringent requirements.
The ADA Seal is never sold. No profit goes to the ADA when a company earns the Seal. The ADA Seal is not an endorsement of a particular product; rather it is designed to help you know that claims made on the label say what they do and do what they say.
Science-based toothpastes often add one or more active ingredients to their product to accomplish a certain goal. Fluoride to reduce tooth decay, for example. Another example is the addition of tetrasodium pyrophosphate, which is in “tartar control” toothpastes. Tetrasodium pyrophosphate acts by removing calcium and magnesium from saliva, thus reducing calculus (i.e. tartar) accumulation on the teeth.
Which brings us back to the ADA Seal of Acceptance. If a toothpaste manufacturer decides to put some ingredient in their toothpaste and claims said ingredient confers some benefit, then the ADA requires that the manufacturer demonstrate those claims scientifically. For example, it’s not enough to put fluoride in toothpaste; to get the ADA Seal, it must be shown that the proper, stated amount and type of fluoride is present and that the toothpaste actually delivers that fluoride to the tooth surface.
All this is to say that most dentists advise their patients to purchase whatever toothpaste they want. Whatever tastes best, whatever the kids like, whatever is on sale – it doesn’t matter as long as it has the ADA Seal on it. That way we, as health care professionals, know that together we are helping our patients maximize their dental health, and that the consumer/patient is getting what he/she believes they are getting.
So, does this mean that all toothpastes without the ADA Seal of Acceptance are worthless and should be avoided at all costs? Actually, no. One thing to keep in mind is that most of the benefits of toothbrushing (and flossing for that matter) derives from the mechanical action of the brush, floss, or pick on the tooth, which physically disrupts and removes the biofilm (aka “plaque”). The suds and the taste, and yes, even the fluoride are all ancillary benefits to brushing. It’s more important that you brush with something – anything! – and do it well, than to not brush enough or effectively, no matter how much toothpaste you use.
Which leads me to my final section – the “alternative” or “natural” toothpastes. This is the Science-Based Medicine blog, by god, and we hate everything that doesn’t fit into our neat Science-Based Boxes, right? Anyone who isn’t science-based is an ignorant fool and should be ridiculed, right? Anyone who brushes their teeth with a “natural” toothpaste should suffer the consequences of tooth loss and putrefying gums, right?
Not so fast.
As I mentioned before, the brand or type of toothpaste is secondary to the importance of actually using your toothbrush properly and for the correct amount of time. I say this because I’m going to call out a handful of “natural” toothpastes below and shed them in a somewhat unfavorable light. But this isn’t necessarily because they are bad toothpastes, not at all. It’s because many of them make health claims that not only don’t pass ADA Seal of Acceptance muster, but they don’t even pass the sniff test for biological plausibility, much less passing any test of scientific validity.
Let’s take a look, shall we?
Toothpaste or woo-thpaste?
(Do you know how long I’ve been waiting to say woo-thpaste? I can now die happy.)
Anyway, let’s discuss some of the “natural” toothpastes out there. As many regular readers of the SBM blog already know, the term “natural” has been co-opted by alternative medicine people to imply and infer that natural is good, artificial is bad. It resonates with those whose ideology demands that one only ingests or imbibes substances that come directly from the earth and not indirectly synthesized in a laboratory. While evidence-based individuals are aware of this appeal to nature fallacy, many either are not familiar with the finer point of what it actually means, or they choose to not believe it.
Let’s begin with perhaps the most popular of the alternative toothpastes- Tom’s of Maine.
Tom’s is one of the “good guys” in natural products. The company was formed in 1970, and it appealed to the burgeoning natural movement of the 70s. They offer many oral health care products, and their “claim to fame” was that they manufactured a high-quality toothpaste that didn’t contain that awful fluoride neurotoxin. Of course we dentists bristled at that, but patients are free to purchase whatever they want to purchase. The admirable thing about this company is that they also manufactured toothpaste that contained fluoride (consumer choice), and they went through the arduous and not-inexpensive process of becoming ADA certified. So, despite holding themselves out to be a “natural” alternative to the Crests and Colgates of the world, they never made unwarranted claims or advertised themselves as anything other than what they were.
The next toothpaste on the list is the one that Myles brought up when he interviewed me on his podcast. This lil gem is called Bilka Homeopathic Toothpaste. Homeopathic toothpaste, you say? How can that be? Is it just a tube of water that had all the toothpasty stuff succussed right out of it? Well, Myles contacted the company, and they said “No, no, what we mean is that this is a good toothpaste to take if you are also taking homeopathic remedies.” OK then.
    • Toothpaste Bilka Homeopathy Lemon is a natural product created for people who prefer the natural-friendly way of life. It does not contain mint and fluoride or harmful-for-the-health colors and sweeteners. It contains xylitol – a natural ingredient, which protects the theeth [sic] from caries and plaque.
    • It is suitable for people using homeopathic remedies.
    • With pure natural lemon aroma.
    • Ingredients (INCI): Calcium Carbonate, Aqua, Sorbitol, Glycerin, Xylitol, Hydrated Silica, Xanthan Gum, Aroma, Sodium Lauryl Sulfate, Sodium Bicarbonate, 2-Bromo-2-Nitropropane-1,3 Diol, Limonene, Citral.
Notice the ingredients. Not a lot of “natural” stuff there, is there? This, of course, is marketing pure and simple. And bad marketing at that.
Moreover, they imply a lot of shady stuff. “Mint free!” Is mint bad for you? Why are they touting this as a benefit?
If you’re like me (or Lydia), you’ve gotten a rash of ads on social media about this miracle charcoal toothpaste that claims to:
    • detoxify your mouth
    • whiten teeth
    • “restores tooth enamel at the same time”
This toothpaste uses activated charcoal, and apart from the unsubstantiated claims listed above, its marketing ploy is to show (via viral videos) people from around the globe brushing their teeth with this black paste, which is shocking and effective in its approach. “How can brushing your teeth with this black crap be good for you? But it is!!” It’s that counter-intuitive thought that lodges the meme in one’s mind and makes one susceptible to the messages promoted above.
Conclusion: Toothpaste totally matters!
First off, I realize that talking about toothpaste isn’t like talking about chemotherapy or anything else in life that really matters. However, most of us reach for that tube of toothpaste at least once per day (and hopefully more!), and squeeze that concoction of fluoride, flavoring, humectants, detergents, and abrasives (from the bottom up for god’s sake!) onto our nylon bristles in order to stave off the ravages of tooth decay and gum disease, as well as to freshen our breath. Hopefully, this will shed a little light on what to look for when purchasing toothpaste, and to realize that while most “alternative” toothpastes confer no real benefits, some make outrageous claims which can be unethical, and flat out wrong.

Pulp Fiction
Are your root canals poisoning you? Probably not. Is an alternative dentist trying to sell you something? Probably.
Grant Ritchey on October 7, 2016
Link


As so often happens at Science Based Medicine, the inspiration for today’s post comes from a reader of the blog, seeking evidence-based advice and references after receiving conflicting (and perhaps even contradictory) information from other sources. On one hand, it saddens me when people get bad advice from health care professionals or elsewhere, whether it’s from their “regular” doctor, an “alternative” practitioner, or from Dr. Google; on the other hand, the fact that well-meaning patients are seeking out science-based recommendations through Science Based Medicine is encouraging and emphasizes the important role this blog serves.
The email that was referred my way was written by a man who is considering having a tooth extracted in the hopes that it will alleviate some general health issues he is having. He writes:
May I request that you write an article refuting the claims made in the book “Toxic Tooth — How a Root Canal Could Be Making You Sick”?
The purpose of my request is that I am considering getting a root canal pulled out.
After an initial back and forth where I told him that I’d look into it and to meanwhile not do anything hasty, he related his general symptoms (all correspondence reprinted with permission):
My personal information is I am a ** year old male, and I have a lot of fatigue. MDs are not able to tell me why. I have a TSH of 12. MDs are not able to tell me the root cause. I have Monocytes of 13, normal range is 4-13, this means I have an infection. This makes me wonder if maybe that root canal is the cause of that infection.
To translate (very superficially and simplistically): His TSH (Thyroid Stimulating Hormone) level is elevated. TSH is a hormone released from the pituitary gland and helps regulate the thyroid hormones which are involved in the body’s cellular metabolism. Normal values are in the 0.3–3.0 µIU/mL in an adult, and an elevated TSH usually means that the patient has an underactive thyroid (hypothyroidism). On rare occasions, it can indicate the presence of a thyroid tumor or other uncommon issues. His monocyte level is a bit elevated as well, which could mean the presence of a chronic infection or perhaps an auto-immune disease, but that lab value alone is not enough to make that call. But I’m just a dentist; what do I know? 
Could his fatigue and abnormal lab values be attributed to the presence of his endodontically treated tooth (i.e. a tooth that has had root canal therapy)? Let’s look into the science of it and come back to that question at the end of my article.
This particular fellow seems to have done some research. His email went on to give me a link to a Mercola article where the author of the aforementioned book was interviewed and claimed that root canal therapy consistently leaves bacterial by-products behind, resulting in chronic infection with serious systemic sequelae. To the lay person, these claims can be very convincing and seem frightening, and inadvisable decisions (such as having perfectly healthy teeth extracted) can result from believing these dubious assertions. I am very grateful this person emailed us with his inquiry. He isn’t feeling well, is presumably doing his due diligence (although I question that he only sent me links from alternative medicine sources and not from science based sources), and wants to make the right health care choices so that he can begin to feel better. But what is the right choice and why?
If you’ve ever sat in the dental chair with that lovely powder blue paper bib clipped around your neck and have been told you need a root canal, you know how sphincter-puckering that news can be. After all, root canal therapy is right up there with kidney stones, epidural-free childbirth, and bank bail outs in the pain and agony department, or so the story goes.
I am going to over-simplify and over-generalize here, so please forgive me. If you want greater detail on pulp (i.e. nerve) pathology and the intricacies about the procedure itself, you can read about it here. I just want to give you the basics so that you will have a context from which to understand the false and fraudulent claims that are being made.
Normal tooth anatomy
Before we can cover tooth pathology and subsequent treatment (as well as treatment options), we have to review the anatomy and physiology of a healthy tooth.

As you can see in the above diagram, the part of the tooth that you can see, called the clinical crown, is covered by enamel, an extremely hard, mostly inorganic material that protects the tooth and allows you to chew just about anything. Under this 1-1.5mm protective shell is the dentin (or dentine if you’re outside the US) which is softer and contains tubules that radiate outward from the pulp (or nerve). These tubules contain fluid and cellular extensions of the pulp. The core of the tooth is the pulp, which contains blood vessels, nerve tissue, and other cells. The part of the pulp that travels down the root to connect with the systemic nerves and blood supply is called the root canal.
If the nerve is irreversibly damaged (by tooth decay or trauma, for example), it will “die” and become necrotic. Eventually the space where the pulp used to dwell will be colonized by bacteria, causing the dreaded “abscessed tooth.”
Root canal procedure
Ok, now we find ourselves with an abscessed tooth. Again, there are other reasons and scenarios where endodontic therapy may be needed, but this serves as a good primer, as the process is pretty much the same in most situations. So you’re sitting in the chair, powder blue paper bib clipped around your neck, sphincter puckered, ready for the dreaded procedure.
In a nutshell, here’s what happens next: your tooth is numbed up, and your dentist prepares your tooth for the root canal by drilling out any decay and gaining access to the pulp chamber (the “core” where the live pulp used to be). Having gained access, your dentist will identify the canal(s) that traverse down the root and commence to cleaning and shaping them out with small metal files. These files are typically nickel-titanium these days, and can be either hand held or rotary files (i.e. in a handpiece). Think of them as specialized bottle washers that go down to the end of each canal to remove the necrotic debris, bacteria, and other gunk that’s in there. During the procedure, the dentist will irrigate the tooth and canals with a disinfectant, usually sodium hypochlorite (household bleach), to help remove the debris and kill any remaining bacteria that are present within the tooth. When all this is completed, he or she then seals the canals with a synthetic rubber-like material called gutta percha in order to prevent recurrence of the abscess. Sometimes antibiotics and/or pain medications are prescribed to assist with post-operative care.
Within a short period of time, the tooth feels normal again, and after being restored with a filling or crown, it can function normally with an excellent success rate, which is estimated at around 90% according to one systematic review.
What happens when a root canal goes south on you? Sometimes the tooth can fracture beyond repair, especially if it doesn’t have a crown on it (for most cases on back teeth; often front teeth don’t need crowns), resulting in extraction. In other situations, the tooth itself can become re-infected, causing a new abscess. This can be detected and diagnosed based upon clinical signs and symptoms, x-rays, and other diagnostic tests. When this happens, the tooth needs to be treated as quickly as possible to prevent pain, the spread of infection (including cellulitis and sepsis, both of which can be life threatening), and/or compromising the health of adjacent teeth. In many cases, these endodontic flare-ups can be retreated and the tooth be saved; other times the tooth is lost.
Risks, costs, and alternatives
Believe it or not, root canal therapy isn’t for everyone or every tooth. Like every medical and dental procedure, there are pros and cons, risks, and costs involved. First and foremost, root canals ain’t cheap. Fees vary, but you can expect to pay $800-1,500, depending on geographic location as well as which tooth it is (a single-rooted front tooth is easier to treat and thus less expensive than its multi-rooted wisdom toothed counterpart). Insurance often picks up a sizable percentage of the fee, so that can be factored in if you happen to have good dental insurance.
Some of the risks of endodontic treatment include:
    • If the damage is too extensive, the tooth may be not be able to be saved, even if the abscess is eliminated.
    • Although rare, it is possible for the files to perforate the side of the root, or a file may separate (break) inside the tooth. Both of these complications can be managed, but worsen the long term prognosis of the tooth.
    • Undetected fracture in the root can lead to failure of the procedure, resulting in the loss of the tooth.
    • Other rare complications such as an allergic reaction to materials being used, local anesthetic, etc.
Sometimes, a root canal isn’t practical, even if the prognosis is excellent. For example, if a tooth is in the very back of your mouth, and it has no opposing tooth to bite against, many people choose not to spend the time and money to save a tooth that is non-functional. If a patient has multiple other needs, or isn’t able or willing to maintain his or her dental work with good oral hygiene, good dietary habits, and regular preventive dental visits, then sometimes it’s not advisable to spend the time and money on a tooth that very likely will be lost in a short time anyway.
So what are the alternatives to root canal therapy? What happens if there is a fracture or an abscess, but the patient is either unable or unwilling to undergo root canal therapy, or if root canal therapy is contraindicated, or the prognosis is poor? Sadly, extraction is the only alternative in cases like this. Infections won’t spontaneously resolve, even with antibiotics, until the source of the infection is removed. This can be by just removing the dead, infected nerve with a root canal (as described above), or removing the whole tooth. We as dentists hate it when a patient loses a tooth, but sometimes that is the prudent thing to do, whether it is for biologic, pragmatic, or financial reasons.
The first option a patient has, believe it or not, is to do nothing. While for most people, most of the time, replacing a missing tooth is the best thing to do from a function, comfort, and cosmetic standpoint, it’s not necessary. Most people typically get by just fine with all, some, or none of their teeth. That being said, there can be consequences to not replacing a tooth, such as other teeth around the missing tooth shifting or tilting into the empty space.
If a patient wants to replace one or more missing teeth, there are three broad options that he or she can consider. Because this post isn’t about how to restore mouths, I’ll just give a brief overview with even briefer pros and cons of each:
    • Removable partial denture. Pros: cheapest option, no surgery or “grinding down” of other teeth. Cons: It’s a prosthesis, taken in and out. Not as strong, comfortable, or natural looking.
    • Fixed bridge. Pros: Natural looking (when porcelain or zirconium), “permanent”, strong. Cons: More expensive, you have to prepare (grind down) the teeth on either side of the space. More difficult to clean under.
    • Implant and crown(s). Pros: Natural looking, no preparing of adjacent teeth. Cons: More expensive, surgical procedure, more time consuming.
When a root canal becomes a woo-t canal
I apologize for that long and boring preamble, but it was necessary so that I could set the table for the rest of this article; namely to outline some of the fear-mongering and outright misinformation that some alternative sources (including dentists and physicians, sadly) are posting online and elsewhere. Unfortunately, because of the plethora of bad information as well as frequent cross referencing and circle-jerking type linking, often this pseudo-dental information pops up at the top of search engines, confusing the lay public and directing them down paths where they should not go. As a science based dentist who fights “Dumb Disease and Truth Decay” (thank you Evan Bernstein for that horrible, horrible pun!), I want to try to set the record straight and give sound dental information so that people (in concert with the advice and counsel of their dental provider) can make informed choices based upon sound scientific evidence and which are consistent with their values, wishes, and budgets.
The overarching theme when it comes to the “alternative” or “holistic” criticism of root canals comes down to the claim that no matter how well the root canal procedure is performed, there are still bacteria and bacterial toxins left in and around the tooth, which then ostensibly continues to infect the patient, causing a host of maladies, from heart disease to diabetes to cancer. One of the authors (Dr. Thomas Levy) of the above referenced book Toxic Tooth — How a Root Canal Could Be Making You Sick stated in an interview that “there can be few things as catastrophic as a root canal.” Considering that an estimated 15 million root canals are performed each year, I’m surprised that people who have had root canals (including me 20 years ago) haven’t all dropped dead. That doesn’t sound catastrophic to me. Unlike the way I described the root canal procedure above, Dr. Levy (a cardiologist, not a dentist) described the procedure as one where the “life force” of the tooth is removed and then is subsequently “embalmed.” Dr. Hal Huggins, the notorious “Father of Quack Dentistry” who lost his license for “gross negligence and other professional misconduct” for promising patients that taking out their amalgam fillings would cure their MS and other diseases, compares an abscessed tooth to a ruptured appendix. “If you have a ruptured appendix, are you going to fill it with wax and crown it?” asks Dr. Huggins incredulously. Even Mercola says that after a root canal, “(u)nder the stresses of oxygen and nutrient deprivation, these formerly friendly organisms morph into stronger, more virulent anaerobes that produce a variety of potent toxins. What were once ordinary, friendly oral bacteria mutate into highly toxic pathogens lurking in the tubules of the dead tooth, just awaiting an opportunity to spread.” The only thing this statement informs us of is Sloppy Joe’s total lack of even a basic understanding of microbiology or physiology.
Let’s talk about some of the main anti-root canal memes circulating around.
First, we’ll start off with a doozy that has been circulating around the World Wide Woo for some time. Several alternative medicine peddlers have this headline plastered across their pages:
97% of Terminal Cancer Patients Previously Had This Procedure
Of course, they are talking about root canals, and I don’t even know where to begin in trying to debunk this claim. NOTHING about it is even remotely accurate or true. (If you have a strong stomach and want to read the entire article, do so at your own peril by clicking here.) Suffice it to say that there is no scientific literature that even hints to this conclusion. In fact, one study showed that people who had a history of tooth decay and endodontic treatment actually had a reduced risk of head and neck squamous cell carcinoma, for what that’s worth. Allegedly, a “Dr. Robert Jones” studied this phenomenon, and his research is what is passed around and cross linked. The problem is, no one really seems to know who this mysterious Dr. Jones is or what his primary research says, if it was ever published. Searches on PubMed and Google Scholar yielded nothing. If any of our astute readers could let me know where to find him or his work, I’d greatly appreciate it! Even Snopes weighed in on it and seems as baffled as I am about it. I think we can all agree to dismiss this ludicrous claim out of hand; it’s not worth the virtual paper it’s written on.
The other two phenomena associated with root canals are not as far out as the above cancer scare association, and deserve mentioning. The first centers around the term NICO. No, I’m not referring to the German actress/model/singer who sang on the Velvet Underground’s amazing debut album; rather, I mean Neuralgia-Inducing Cavitational Osteonecrosis, which is decidedly less cool than the Velvet Underground. NICO is a small area of necrotic (dead) bone, which creates small spaces in the jaw. They are difficult to diagnose, can create atypical pain patterns, and tend to recur. While the cause of NICOs is still unknown, they are sometimes associated with old extraction sites, trauma, and have been linked with autoimmune and clotting disorders. That being said, the American Association of Endodontists (AAE) have stated in their position paper that “(d)ue to its indefinite disease characteristics with unclear etiology and pathogenesis, there have been growing doubts regarding whether NICO is a distinct disease entity.”
The reason I bring up NICOs is that, even if it turns out to be a real “thing,” the alt-medders have co-opted the term in much the same way as chiropractors have co-opted the term “subluxation”, which is a real thing in medicine, but is meaningless in the context of chiropractic philosophy. The anti-root canal faction uses NICOs as a reason to eschew and condemn endodontic therapies; they claim that most if not all root canals create NICOs, which then can “seed” the body with infection and toxins. They claim that they can detect NICOs by seeing them on x-rays or by use of some E-Meter-like device which purportedly can detect them. When found, a “biologic” dentist will want to remove the NICO by curetting out the lesion, then treating with some wonder poultice like ozone or colloidal silver, in addition to chelation therapy and IV vitamin C therapy. This is, of course, invasive, risky and expensive theatre with no proven benefit. Unproven treatments for non-existent pathologies. Any reader of the SBM blog will recognize that pattern, as it applies to so much to what alternative practitioners of all stripes do on a daily basis. Even Aetna weighed in on the matter and penned a rather thorough review of NICOs and basically said there was little evidence of their legitimacy, the methods of diagnosis were unproven and suspect, and treatments would not be covered due to their “experimental and investigational” status.
There are so many areas of this topic I could talk about and would like to talk about, but to do so would require a blog post of Gorski-esque dimensions, and I just don’t have that sort of attention span. So I’ll wrap this up with a discussion of the claim that bacteria from the mouth are a cause of many systemic diseases. Jumpin’ Joe Mercola claims that root canals can cause a veritable smorgasbord of problems, including, but not limited to: heart disease, kidney disease, arthritis, joint, and rheumatic diseases, neurologic diseases (including ALS and MS) and autoimmune diseases (including lupus). That’s quite a grocery list, and he even left out cancer! Despite the typical fear-mongering found on websites like this, the link between oral pathogens and systemic disease is a valid and science based observation, and warrants further discussion. Research is ongoing, but it does appear that there is a correlation between periodontal (gum) disease and such diseases as heart disease and diabetes. Whether this is a causative link remains to be seen, but we can’t dismiss this connection summarily as pure woo propaganda. The problem is that once again, the “woolistic” dentists have extrapolated research in one area (endodontics) into another area (periodontics), then have claimed that the bacteria from root canals travel to the coronary arteries to cause the formation of atherosclerotic plaque. This tortures the existing data and takes it to places it has no business being, and that brings me to my final point.
All of the claims made in the persecution of root canal therapy state or imply that a tooth which has undergone endodontic therapy is a cesspool of residual infection, but that’s not the case. If the procedure is carried out properly, however, the infection is for all intents and purposes eliminated; any bacteria or bacterial products which may remain fall well below the threshold for causing any sort of local inflammation or infection. And if that is the case, the likelihood of it causing any systemic diseases is very low indeed. To this end, the AAE has a web page outlining the literature on root canal safety which is thorough and informative. It addresses the issues we’ve discussed here as well as many more. Please give it a good looking over if you want good information.
Conclusion: Another patient led astray
Circling back to the email I received from the man inquiring as to the possible connection of his root canalled tooth to his feelings of fatigue and abnormal lab values. After exploring the literature, but admittedly without examining him or being privy to his lab tests, I can generalize my professional opinion thus:
    • If there is any correlation between his feeling of fatigue, his elevated lab values, and his root canal, then it is because his root canal is failing.
    • If his root canal was failing, it most likely would be symptomatic, with pain and/or swelling present. Any dentist could diagnose that situation, and an x-ray would most likely show evidence of pathology.
    • A healthy, successful root canal would not cause his issues.
    • Assuming his endodontically-treated tooth was done properly and is now healthy and functional, removing it would not improve his systemic status, and now he would be left with a missing tooth to show for it.
Obviously, I can’t diagnose him or give specific information, but based upon the current scientific literature combined with my 30+ years of experience, I can tell you with a high degree of confidence that he has been led astray by alternative practitioners. It is my hope that he and others like him will not fall for the scare tactics and poor science that these purveyors of woo peddle.

Preventing Tooth Decay in Kids: Fluoride and the Role of Non-Dentist Health Care Providers
Clay Jones on January 17, 2014
Link
The following post is a collaborative effort between myself and science-based dentist Grant Ritchey DDS. Dr. Ritchey is a co-host of the always excellent The Prism Podcast, most recently interviewing Dr. Robert Weyant and discussing how to teach critical thinking to dental and medical students. He can also be found on Twitter at @SkepticalDDS. Dr. Ritchey has written for SBM before on the topic of cranial osteopathy in dentistry.
As a pediatric hospitalist, I don’t deal with issues of dental health very frequently. Sure I see plenty of oral mucosal lesions, as occur during a primary herpes outbreak or a case of Kawasaki disease, but not many problems with the teeth themselves. I do admit a few dental abscesses here and there that need to be cooled down with IV antibiotics prior to definitive surgical drainage. And as a hospitalist that sees a fair amount of newborns, I also discover the occasional natal tooth. That’s when a baby is born with a tooth, usually a central mandibular incisor, having already erupted.
But as a pediatrician, I care deeply about the overall health of children and the network of caregivers that surround them. I guess you could say that I take a holistic approach, but I would prefer that you didn’t. Although we aren’t dentists, pediatricians recognize that oral health is integral to the well-being of a child and that many long-term dental maladies develop during the first two decades of life, often before the first tooth even appears. The most common, and one which non-dentist health care providers can have a major impact on, is the development of dental caries, or “cavities”.
Why not just let dentists take care of teeth?
Again, pediatricians are interested in every aspect of the health of their patients. Non-dentist health care practitioners that see kids also typically have access to them long before they ever see a dentist. The American Academy of Pediatrics (since 2003), American Academy of Pediatric Dentists and the American Dental Association all recommend that children be seen by a dentist at or near their first birthday, which leaves a lot of time for problems to develop. And pediatricians are often asked about dental health, particularly about fluoride and brushing.
It is critical in the first year of life for assessment of risk, and intervention in high risk patients, to be performed in order to prevent tooth decay. And it can be prevented. But there are a number of stumbling blocks that prevent children from receiving appropriate dental care. In many areas, dentists will not see young children, and the nearest pediatric dentist may practice a few towns over, limit what insurances they accept, or simply be too swamped to accept new patients. It is often very difficult for children of any age that are on Medicaid to find a dentist, and even when there is availability many parents don’t think of early dental care as a priority so they don’t make the appointment.
But some pediatricians are also to blame. Until 2003, the AAP did not recommend that most children first see a dentist until age three. And as with many aspects of medical care, there has been sluggish adoption of new recommendations by established practitioners. So the pediatrician and family doctor often find themselves providing dental care and education on cavity prevention.
What is dental caries and who gets it?
Simply put, caries is tooth decay. Often called a “cavity”, caries is actually one of the most common infectious diseases in humans, right up there with the common cold. In fact, it is the most common chronic disease in the pediatric age group. The process starts early, often in the first couple of years, and almost nobody is spared. Roughly 90% of us will have some degree of tooth decay during our lifetime. The other 10% must be on the Paleo Diet. I kid. Want an easy way to know if your diet is probably bogus? If it’s capitalized. Nobody capitalizes “the eat fewer calories” diet.
Breaking incidence down by age groups shows a steady increase in the prevalence of caries over time, which makes sense because a large portion of the risk is related to repeated exposure to cariogenic foods (sugar) and the bacteria that love them. The National Health and Nutrition Examination Survey (NHANES) III revealed that about a quarter of children ages 2 to 4 years were found to have decay in their primary, or “baby”, teeth. This increased to half of kids aged 6 to 8 years and roughly 60% of adolescents, with these being secondary, or “permanent”, teeth.
Rates of caries are higher, and it occurs much earlier, in the poor. Not surprisingly, it also tends to be worse. There are significant numbers of children out there not receiving any treatment for their dental decay, but poor children are considerably more likely to slip through the cracks.
But we are all at risk for the development of caries, even the most wealthy and privileged among us. But certainly some individuals are more prone to decay for a variety of reasons. As mentioned above, folks below the federal poverty line are more at risk and those above 200% of it are somewhat protected. The reason for these trends, though not completely understood, is likely the impact of the mélange (calm down Dune fans) of variables unique to groups, such as cultural practices, education, diet, hygiene and the availability (or lack of) dental care.
There are a number of additional risk factors which are child- or caregiver-specific. Kids who have had caries in the past are obviously more likely to develop it again. Children with visible dental plaque, who frequently expose their enamel surfaces to sugar, who don’t brush regularly and who have inadequate fluoride exposure are also at increased risk.
Remember that this is considered to be an infectious disease, and kids frequently swap oral flora with their parents. For this reason, I do not recommend spit cleaning a pacifier, but particularly if the caregiver has problems with caries. It appears that the worse off a caregiver’s mouth is, the more likely their child will develop decay, and this may be from spreading around cariogenic bacteria. This includes having multiple involved teeth and actual tooth loss. Modeling of behavior likely plays a big role as well. Parents who brush less than the recommended two times per day, or who express a lack of concern regarding oral health, teach their kids to do the same.
But it gets even more complicated because there is emerging evidence that genetics may contribute significantly to the risk of developing caries as well, perhaps as much as 50%. How the tooth is formed, the composition and flow of saliva, the affinity for ingesting high sugar foods and the immune response to the presence of cariogenic bacteria all likely play a role. Tooth decay truly is a complex, multifaceted process that clearly isn’t as simple as forgetting to floss every day or even the socioeconomic status.
The goal of dentists, and ideally all pediatric healthcare professionals, is to prevent the development of caries in the first place. And again, this is very possible. But as the numbers show, this rarely happens. Many of the risk factors listed above, which are more fully fleshed out by the American Academy of Pediatric Dentistry’s Caries risk Assessment Tool, are based on clinical findings or established habits and dentists are often playing catch up anyway. A great deal of damage has already been done by the time a child is seen in their office, with many children only referred to a dentist once there are complications.
Risk assessment ideally should take place before the first eruption of teeth, or very soon after, so that children at high risk for caries can be referred to a pediatric dentist, or at least one that will see an infant. Placing all children who live below 200% of the federal poverty level on the most intense caries prevention program is probably the easiest approach, but is likely not cost effective. Combining this with questions about the dental health of biological parents is probably the best means of flagging high risk kids. If done right, when the first teeth begin to appear sometime between five and eight months of age, true primary prevention can be initiated.
There are a few other risk factors for tooth decay which should prompt a referral to a pediatric dentist, if available. These include breast or bottle feeding past a year, use of a bottle at bedtime, visible plaque and enamel pits or defects. If there isn’t a dentist that will see a high risk child, which as you now know is fairly common, there are caries prevention strategies besides just education that can be implemented in the non-dentist’s office, the best for a variety of reasons probably being the application of a fluoride varnish. I’ll discuss this at length in a bit.
Why do we care about tooth decay?
Ultimately, untreated dental caries leads to loss of teeth. This is commonly seen as a minor inconvenience in children, with many unfortunately considering it to be a sort of rite of passage. In some communities I believe that a learned helplessness has set in, and the rotten teeth and subsequent telltale mouth full of silver crowns is accepted as inevitable. In my home town of Baton Rouge, this is an extremely common site. But although important for a variety of reasons (chewing, speech development, holding a space for adult teeth), those are typically primary teeth and will be replaced by an adult version. Loss of adult teeth is a much larger concern because we aren’t sharks. With rare exceptions, there are no more in the pipeline.
In children with untreated tooth decay, toothache is common with pain emanating from the tooth leading to thousands of emergency department and primary care practitioner visits each year. As untreated caries progresses, inflammation and infection of the gums (gingivitis) sets in, potentially followed by involvement of deeper tissues and surrounding bone (periodontitis). Or the tooth can just become loose, because the periodontal ligament is involved, and simply fall out. Finally, an abscess can form in the tooth or surrounding tissue that requires surgical intervention and sometimes admission to a hospital. Kids miss school. Parents miss work. All this costs money, but tragically this is still not the worst complication.
Here is a 2007 case where a child died because of untreated caries which apparently led to meningitis or a brain abscess. It’s difficult to tell from the article. But it highlights the issues I’ve raised very well. The author states that “Deamonte Driver’s life could have been spared if his infected tooth was simply removed– a procedure costing just $80.” While true, it’s important to point out that his life would likely also have been spared if he had been appropriately flagged as high risk and had a fluoride varnish applied by his pediatrician or family doctor, or perhaps even just counseling on better oral hygiene.
Tooth anatomy (Ritchey)
There is a large subset of children who see their pediatrician but don’t regularly see a dentist. And to dovetail with what Clay has already discussed, I think it would be worthwhile to briefly describe how fluoride works to reduce the incidence of dental caries, because fluoride is the best weapon in our arsenal against tooth decay and is something that can be understood and put into use by health care practitioners who didn’t go to dental school.
As we all learned in grade school and demonstrated in our 4th grade science fair projects, tooth enamel is the hardest substance in the human body. It is the translucent, whitish covering of the crown of the tooth, that part that is above the gum line. It averages a millimeter or so in thickness and protects the softer underlying dentin and pulp (nerve) tissues.
Tooth enamel is composed of approximately 96% minerals, with the rest consisting of water and a small amount of organic material. If you want to impress your friends at parties, you can nonchalantly drop that enamel is a crystalline structure composed of hydroxyapatite (HAP), arranged in parallel “rods” that extend from the external surface of the tooth toward the center. While this extremely hard hydroxyapatite structure allows us to chomp ice and have a dazzling smile, its Achilles’ heel is that it is susceptible to erosion from acids and mechanical forces (e.g. chewing, aggressive toothbrushing, etc.), in much the same way that acid rain and years of footsteps will erode the limestone steps of an old building. Once this demineralization occurs, it becomes a site where further bacterial colonization can occur, and when this happens, you have a cavity!
Role of fluoride
This is where fluoride comes in. Tooth enamel, when exposed to fluoride either systemically during tooth development or topically via toothpaste, fluoridated water, or professional application, becomes strengthened. The fluoride ion becomes incorporated into the hydroxyapatite crystalline structure to form a substance called fluorohydroxyapatite (FAP), which is significantly more resistant to acid attack and subsequent decay. Moreover, the presence of fluoride in saliva helps demineralized teeth absorb calcium and phosphate ions so that damage can actually be reversed, a process known as remineralization. Last, fluoride ions affect the bacterial plaque directly by interfering with a step in carbohydrate metabolism. This not only reduces the amount of acid the bacteria can produce, it retards the reproduction of bacteria, resulting in slower-growing plaque.
So, the bottom line is that fluoride is a triple threat in the fight against tooth decay, a veritable hat trick of protection. In fact, the Centers for Disease Control (CDC) has recognized water fluoridation as one of the top 10 public health achievements of the 20th century, right up there with vaccinations, birth control, and figuring out that smoking is not that good for you.
What’s the catch?
There’s a catch. There’s always a catch. Over the 100 years or so that fluoride has been investigated by dental researchers, it has been recognized that too much fluoride can have a negative effect on the teeth, and in extreme instances, bones.
The most common adverse effect of an excess of fluoride is dental fluorosis. During tooth development in children (essentially from gestation until age 8 or so), fluoride is incorporated into the enamel as it forms. Usually this is a good thing, as it strengthens the tooth as described above; however, if too much fluoride is present, it can disrupt the formation of enamel, resulting in cosmetic blemishes on the surface of some or all of the teeth. This can start with mild fluorosis, in which small, almost imperceptible white spots are found on a single or a few teeth. The spectrum then continues to moderate fluorosis (in which more teeth are involved and are more apparent), up to severe fluorosis, where the tooth becomes mottled and the stains are brown and quite unaesthetic. Severe fluorosis actually increases the risk of decay.
There is also a condition known as skeletal fluorosis, in which excessive environmental fluoride can become incorporated in the bones, resulting in pain, limited movement, and disfiguration. It must be emphasized that skeletal and severe fluorosis of the teeth do not occur as a result of any sort of community water fluoridation, or because of fluoride in toothpastes or professional fluoride treatments. They occur in areas with naturally occurring fluoride levels far in excess of what is safe, and are rare in the United States. In these areas, a defluoridation process must be undertaken to return the water concentration of fluoride to safe and optimal levels.
So what is a safe and optimal level of fluoride?
Great question! I’m glad you asked.
For decades the optimal level of fluoride in drinking water fell in the range between 0.7 parts per million (ppm) and 1.2 ppm, according to the American Dental Association (ADA). This has been adjusted according to region and was affected by temperature (less fluoride in hotter areas), water hardness, and other factors. But trends in water intake, and significant increases in bottled beverage consumption, have led to a recent recommendation to decrease fluoride levels in community water supplies to 0.7 ppm across the board.
How much water people drink these days depends less on regional temperature variations, and the intake of bottled beverages that contain fluoride has increased dramatically. If a product is made with fluoridated water, it’s no different than drinking fluoridated water from your tap. So in many areas without fluoride in the community water, more kids are getting some in other ways and this has equalized the relative risk somewhat when comparing communities. If not taken into account, this might make the benefit of a community water fluoridation program seem less impressive.
Not all ingested fluoride comes in the form of water or water based products. There is also fluoride-containing toothpaste, and then supplement drops that have historically been used in children living in areas with low levels in the drinking water. In an individual kid under the age of 8 years, it is recommended that the daily intake of fluoride be in the 0.05 to 0.07 mg/kg. That seems to be the sweet spot between too much fluorosis and too many cavities. Research has shown that these levels are extremely safe, minimize any untoward side effects such as fluorosis, and maximize the protective benefits of fluoride in tooth enamel.
Fluoride drops have gone out of favor for the most part. They require a prescription, are more expensive than fluoride-containing toothpastes and don’t provide the benefit of topical fluoride once teeth have erupted. They also increase the likelihood of developing fluorosis. In many countries, including the United States, fluoride toothpaste is recommended in young children, although how young it should be initiated has been debated.
Current recommendations in the US are to begin using a fluoride toothpaste to brush with the first tooth in high risk children, and to start at age 2 years when the risk of caries is low. Most experts recommend an amount equal to a grain of rice in young children with an increase to a pea sized amount from 2 years on with each brushing. In reality, starting all children in infancy would be fine considering that the amount of fluoride in a smear the size of a grain of rice would be below the level that would cause fluorosis even if completely swallowed twice a day.
Another recommendation, and one which I’ve found surprises many people, is to not have children rinse after brushing. But it makes perfect sense once explained. Young children don’t know how to rinse and spit anyway, so will actually swallow more of the toothpaste if an attempt is made. And when a child is old enough to do so, the act nullifies the benefit of having topical fluoride in the first place. If you must rinse, it is best to use a fluoride containing product, but many of these contain less than what is in a pea sized amount of toothpaste so the fluoride will still be diluted.
Does it really work?
The American Academy of Pediatric Dentistry published their Guideline on Fluoride Therapy, an excellent document summarizing the current research and recommendations on fluoride use. Their conclusions are as follows:
1. There is confirmation from evidence-based reviews that fluoride use for the prevention and control of caries is both safe and highly effective in reducing dental caries prevalence.
2. There is evidence from randomized clinical trials and evidence-based reviews that fluoride dietary supplements are effective in reducing dental caries and should be considered for children at caries risk who drink fluoride-deficient (less than 0.6 ppm) water.
3. There is evidence from randomized controlled trials and meta-analyses that professionally applied topical fluoride treatments as five percent NaFV or 1.23 percent F gel preparations are efficacious in reducing caries in children at caries risk.
4. There is evidence from meta-analyses that fluoridated toothpaste is effective in reducing dental caries in children with the effect increased in children with higher baseline level of caries, higher concentration of fluoride in the toothpaste, greater frequency in use, and supervision.
5. There is evidence from randomized clinical trials that 0.2 percent NaF mouthrinse and 1.1 percentNaF brush-on gels/pastes also are effective in reducing dental caries in children.
The fluoride controversy
Despite its 50+ years of study, and positive track record of proven benefits, there remains a strong anti-fluoride sentiment in many people. Won’t go into it too much here, as Steve Novella wrote an excellent article on the subject; however, suffice it to say that there is a small but active movement in the US and worldwide to put forth their agenda of the evils of fluoride. Evidently, Big Fluoride is attempting to sap and impurify our precious bodily fluids.
Their concerns primarily come down to four claims, all of which are unfounded:
1. Fluoride is a potent toxin. It’s even on the warning labels on toothpaste to call poison control if ingested while brushing!
2. Adding fluoride to community water sources amounts to forcing a medication on the public!
3. Individual choice is not taken into account. People who want it can just take a supplement!
4. Adding fluoride to community water leads to a variety of ill health effects, including lowering IQ, broken bones, joint problems, dementia and cancer!
Fluoride is a naturally-occurring substance in water everywhere, often at levels much higher than what is recommended in community programs. And it isn’t unique among many beneficial substances in the fact that excessive amounts can be harmful. But to compare the adverse effects of fluoride to these other substances, many of which have no safe level of consumption, is absurd. The safety data is abundantly clear. There is no credible evidence to suggest that fluoride lowers IQ, causes intellectual impairment, or increases the incidence of any cancer. The benefit far outweighs the risk of fluorosis.
Fluoride also isn’t being used as a medication to treat a disease but as a means of prevention on a population level. There is little difference between putting fluoride in the water and folic acid in bread. And yes, there is even potential toxicity from too much of that too. Relying on people who want to take fluoride to do so would be a disaster. Many people would be unable to obtain it and it doesn’t work as well as topical fluoride once the teeth have erupted.
What can non-dental health care providers do? (Jones)
I grew up in Baton Rouge, the capital of Louisiana and home of the LSU Fighting Tigers. I don’t live there anymore but I’m proud to call the state my home. I’m also very thankful for the existence of Mississippi and Arkansas, bordering states which do a great job preventing us from being the worst state in the union when it comes to health. Louisiana is behind in a number of parameters, not the least of which is the overall state of pediatric oral health. Oral health in general is abysmal in the Sportsman’s Paradise. An assessment by the Louisiana Department of Health in 2010 revealed that we met essentially none of the goals set out by the CDC’s Healthy People 2010 objectives for improving oral health.
Focusing on pediatric concerns, the numbers really do look bad. For instance, a full two thirds of third graders in Louisiana have had dental decay, with a little over 40% being untreated. Both of these issues are more than 10% more prevalent compared to the national average. This jibes with my personal experience practicing medicine in Baton Rouge for four years before my recent move to the Northeast. There are a lot of rotten teeth in Baton Rouge children, because Baton Rouge has yet to develop a community program to bring fluoride levels in drinking water up to the recommended amount. That and roughly 70% of the children are on Medicaid.
Pediatric dentists have several fluoride-containing options to address cavity prevention and treatment in individual patients. There are foams, gels, rinses and toothpastes containing higher amounts of fluoride than the OTC variety. Historically non-dentist providers did their best counseling parents and children on good oral hygiene and trying to make referrals. Now, in places like Baton Rouge and Houston, where a majority of children have dental caries and access to a pediatric dentist is spotty at best, some offices are beginning to apply fluoride varnishes in high risk kids.
Fluoride varnish is highly concentrated and applied like paint with a special brush. The coating releases fluoride when plaque is present and an acidic environment begins to develop. There is very good data showing this to be highly effective in children of any age. All they need is a tooth and no special preparation is necessary. It is also very easy to apply, doesn’t taste bad, is portable and well-tolerated. So it is perfect for use in clinics, even schools perhaps. Insurance, even Medicaid, will pay non-dentists for the application in many, but not all states. Hopefully this will change.
Fluoride varnish is technically off-label at this time when used to prevent caries, but is approved for use as a desensitizing agent and cavity lining. But it has been used effectively in many other countries for years. And there is good evidence in support of the current recommendations to apply the varnish at least twice yearly in high risk children. Of note, in England varnish is recommended twice yearly in every child, and three to four times per hear in those at high risk. So varnish works, but is it cost effective? There is the rub.
From available data, it does not appear that the application of fluoride varnish is cost effective if done in every child. This is unfortunate because even low risk children receiving optimal daily fluoride exposure still can get cavities, and varnish is extremely safe. But when an appropriate risk stratification is performed, and varnish applied to only those who are at high risk for caries, it very likely would be cost effective. There isn’t data to support that assumption that I could find at this time, however.
Another intervention, this time at the community level, is the implementation of classroom-based toothbrushing programs. There is actually very good evidence from other countries that this is effective, but none in the US so far. Supervised brushing is part of our Head Start programs by the way.
Conclusion: Tooth decay is not good, fluoride is
Tooth decay is extremely common and much more than a simply nuisance. There are significant possible downstream effects. All children are at risk for developing caries, but some are at high risk for a variety of reasons, many of which are likely genetic. Having someone assign risk early in life, when true primary prevention is a possibility, is ideal and the non-dentist pediatric health care professional is well suited to do just that.
In a perfect world, every kid would see a pediatric dentist around their first birthday, or earlier if they are high risk, but there are huge gaps in access. This is particularly a problem in children living below the federal poverty line. Pediatricians are great at educating parents on how to improve oral hygiene but that isn’t always enough. The application of fluoride varnish in the clinic is a great possible intervention in high risk kids, although it is unclear if it is a cost effective one. At the community level, supervised brushing with fluoride containing toothpaste in the classroom is almost certainly another great means of decreasing rates of tooth decay.
Finally, don’t be afraid of fluoride. It is one of the best public health measures every devised and is extremely safe. Despite the vocal minority of anti-fluoridation folks, and numerous websites touting all manner of bogus adverse effects, there is no evidence to support fluoride as a cause of cognitive impairment, dementia, or cancer.

Antifluoridation Bad Science
A new review of research out of Harvard University suggests fluoridating drinking water above the EPA limit is a bad idea – which we already knew.
Steven Novella on August 1, 2012
Tweet
There is a movement in the US to oppose a public health measure that is backed by impressive evidence showing it is safe and effective, as well as highly cost effective. For as long as the government has supported this health measure, there have been those opposed to it, claiming (against the evidence) that it is unsafe, ineffective, and represents a violation of personal freedom and the right to refuse an unwanted medical intervention. I could be talking about vaccines and the anti-vaccine movement, but in this case I am talking about the fluoridation of public water supplies and the antifluoridation movement.
This social debate (there isn’t much of a scientific debate) crops up in the news every now and then – mostly prompted by an antifluoridation activist or group making noise, or by a local referendum to block fluoridation in a community. Recently there has been a Harvard study making the rounds of social media, “Developmental Fluoride Neurotoxicity: A Systematic Review and Meta-Analysis.” The actual findings of the study do not show that there is any risk to public water fluoridation (if anything, they show that it is safe), but the study was seized upon by antifluoridation activists and distorted for their propaganda purposes. Unfortunately, the internet is now fertile ground for the spreading of propaganda.
The NYS Coalition Opposed to Fluoridation put out a press release distorting the findings of the study. Their press release (“Harvard Study Finds Fluoride Lowers IQ – Published in Federal Gov’t Journal”) was then printed as a science news item by many online news outlets. Reprinting press releases, without any editorial filter, is a cheap and easy way to add news-like content to your website. The Sacramento Bee, for example, published the press release under their “News” tab. Near the top of the page, in small print, they did put a disclaimer (which is better than most sites):
This section contains unedited press releases distributed by PR Newswire. These releases reflect the views of the issuing entity and are not reviewed or edited by the Sacramento Bee staff. More information on PR Newswire can be found on their web site.
That’s better than nothing, but I wonder how many people reading the press release will notice and read the disclaimer. In my opinion, a news outlet should not reprint press releases sent out from advocacy organizations clearly intended to promote an agenda. They especially should not print them under the banner of “News.” The disclaimer is not adequate. The spreading of this “news item” around Facebook and other social media demonstrates this.
Some background
Before I get to the study itself, let me review the basic facts surrounding fluoridation of public water supplies. In the 1940s and 50s in the US there were major studies looking at the role of fluoride in the health of teeth. It was first noticed that too much fluoride, which occurs naturally in many water supplies, can cause a darkening and pitting of the teeth, now called fluorosis. However, smaller amounts of fluoride are necessary for tooth health and can help reduce tooth decay. Fluoride can help remineralize the enamel of teeth, to reduce or even reverse destruction by acid-producing bacteria.
The turning point in terms of evidence came with the publication of a study in 1950 – Dr. H. Trendley Dean, head of the Dental Hygiene Unit at the National Institute of Health published the results of a study in Grand Rapids, Michigan in which fluoride was added to the drinking water of one community and not another. The study revealed a 50% decrease in dental cavities in the fluoridated community compared to the control. This and other evidence led to the recommendation to adjust the fluoride levels of local water supplies to about 1 mg/L (or 1 part per million, ppm). Some communities have natural levels of fluoride in the water at higher levels, and these are often reduced. The decision on whether and how to adjust fluoride is made at the municipal and local governmental level – not the Federal level. Therefore, some communities add fluoride while others do not.
Immediately after the recommendation was made and some communities started adding fluoride, the antifluoridation movement started. The primary motivation seems to be objecting to the imposition on personal freedom, seeing fluoridation as involuntary medication. Groups that oppose fluoridation, however, are typically not content to make the freedom argument, but rather also distort the evidence to argue that fluoridation is not safe or effective, despite the actual evidence. At the fringe there are also those who believe that the fluoridation of water is part of a dark government conspiracy to make us all into mindless slaves. (These conspiracy theories were famously lampooned in the brilliant movie Dr. Stranglove, when the character General Jack Ripper talks about the violation of his “precious bodily fluids.”)
The last 50 years of scientific research has only confirmed the safety and efficacy of fluoridation. A 2008 systematic review of this research concluded:
Fluoridation of drinking water remains the most effective and socially equitable means of achieving community-wide exposure to the caries prevention effects of fluoride. It is recommended that water be fluoridated in the target range of 0.6-1.1 mg/l, depending on the climate, to balance reduction of dental caries and occurrence of dental fluorosis.
For further background see the policy statement on fluoridation by the Institute for Science in Medicine (of which I and other SBM authors are members).
The Harvard study
The Harvard study is actually not a new study, but a review of prior research. Further, the studies reviewed did not involve water fluoridation programs. The review concludes:
“The results support the possibility of an adverse effect of high fluoride exposure on children’s neurodevelopment. Future research should include detailed individual-level information on prenatal exposure, neurobehavioral performance, and covariates for adjustment.”
“The possibility” of an effect justifying future research is not the same as concluding that there is an effect. But the problems with the way this review is being presented go far deeper. The implication being implied by anti-fluoride groups is that the fluoridation program in the US and elsewhere is putting children’s IQs at risk. This data, however, cannot be used to support that conclusion.
First it should be noted that almost all of the studies reviewed were conducted in China (one was conducted in Iran) – not in the US. China had a limited fluoridation program for a time, and has had no fluoridation of drinking water since 2002. So why, then, are most of the studies from China?
There are many rural areas of China that have naturally high levels of fluoride in the well water. The studies were largely looking at this exposure. Two studies looked at fluoride exposure from inhaling smoke from coal burning. So the question is – how do these levels of exposure relate to the amount of fluoride being added to water in the US (because toxicity is always all about dose)? There was a lot of variability across the studies, but generally the high fluoride groups were in the 2-10 mg/L range, while the reference low fluoride groups were in the 0.5-1.0 mg/L range (not including the coal burning studies, which had much higher fluoride levels).
The recommended fluoride level for fluoridated drinking water is 0.5-1.0 mg/L (similar in most countries – Australia, for example, uses 0.6-1.1 mg/L). The EPA set the upper safe limit at 4.0, with a secondary (voluntary) recommendation of 2.0. Areas with high natural fluoride actually have some of the fluoride removed from the drinking water.
In other words – fluoridated water in the US has the same level of fluoride as the control or low fluoride groups in the China studies reviewed in the recent article, and the negative association with IQ was only found where fluoride levels were much higher – generally above EPA limits.
Also – these studies were mostly epidemiological or ecological – they were not experimental studies (like the Grand Rapids study) in which variables were controlled in any way. It is possible, and even likely, that the high levels of fluoride exposure from natural or industrial sources (not deliberate fluoridation) also correlate with exposure to other contaminants, such as arsenic.
Conclusion: Your drinking water is still safe
There are many weaknesses to the epidemiological studies reviewed in the recent article – high heterogeneity, poor controlling for other variables, no indication of blinding of IQ assessments, and many others. But even taken at face value they do not indicate any association between lower IQ and the fluoride levels added to drinking water in the US. In fact, those levels of fluoride were used as the controls in these studies showing higher IQ. (There was a lot of variance of the effect size, but the net effect size on IQ in the meta-analysis was -0.45 standard deviations). Therefore, if anything, this review adds to the body of evidence for the safety of fluoridation.
This fact has not stopped anti-fluoridation groups from exploiting the review for their own propaganda purposes. Otherwise respectable news outlets are unwittingly collaborating in this anti-scientific propaganda campaign by lazily reprinting these press releases in their news sections – without any editorial filter.
The “fluoride wars” are likely to continue as long there is a fluoridation program. This is evidence that there is no public safety measure that is so effective, safe, and cost effective that there will not be those who vigorously oppose its implementation.

Fluoride: Still Not Poisoning Your Precious Bodily Fluids!
Grant Ritchey on September 14, 2014
Link
We dentists are an evil group of sociopaths. When we’re not trying to kill you or give you chronic diseases such as multiple sclerosis with our toxic mercury saturated fillings, we are advocating for the placement of rat poison/industrial waste (i.e. fluoride) in your water supply by our governmental overlords. What is up with us?
The problem is, we’re failing miserably. Even after more than 150 years of placing silver amalgam restorations in our patients, thereby saving untold numbers of teeth, reducing pain and suffering, and improving chewing ability for millions upon millions of people, there is still no evidence worth a damn that shows any correlation or causative effects for any known disease or condition. And with fluoride, after adjusting fluoride levels in municipal water supplies throughout the U.S. and in many places world wide for over sixty years, after adding fluoride to toothpastes and mouthwashes, and giving fluoride treatments to patients in our offices, the only nefarious result we have obtained is the significant reduction of dental decay with its concomitant savings of billions of health care dollars and untold pain and suffering for our patients. Man, we can’t do anything right.
Now, with the help of the American Academy of Pediatrics (AAP), there’s a new strategy.
Our new strategy is to recommend the use of fluoride toothpaste as soon as the first tooth erupts, which is typically around six months of age. On August 25th, the AAP issued new guidelines to that effect. To summarize their position, which echoes the positions of the American Dental Association (ADA) and the American Academy of Pediatric Dentistry (AAPD), the AAP stated:
    • Fluoridated toothpaste is recommended for all children starting at tooth eruption, regardless of caries risk.
    • A smear (the size of a grain of rice) of toothpaste should be used up to age 3. After age 3, a pea-sized amount may be used. Parents should dispense toothpaste for young children and supervise and assist with brushing.
    • Fluoride varnish is recommended in the primary care setting every 3–6 months starting at tooth emergence.
    • Over-the counter fluoride rinse is not recommended for children younger than 6 years due to risk of swallowing higher-than-recommended levels of fluoride.
Dentists, myself included, are pleased that the AAP issued these guidelines, both because of the content but also because getting this information out to pediatricians and other physicians, nurses, and allied health professionals is instrumental in the education of new parents and the dental health of the child. The opportunity for interaction between parent and doctor during the first six months of the child’s life is going to be much greater at the physician’s office during well (and sick) baby visits than at the dentist’s. Moreover, we dentists are rejoicing at the increased role that Primary Care Providers (PCP) are playing in the dental health education of children, an area long neglected in the past. They, not we dentists, are almost always the earliest contact point between child and dental health, both in the clinic and in public health programs. In fact, last January, two extremely intelligent and handsome Science Based Medicine authors wrote a blog post about this very subject. However, if you look back at that article, it described the old guidelines for fluoride use, which stated that a fluoride containing toothpaste should be used as soon as the first tooth erupts in high-decay-risk children, and at two years old otherwise. Now, as stated above, it is recommended that fluoride-containing toothpaste be used at tooth emergence on all children. When followed properly, the benefit to the child can be significant while lowering risks (namely dental fluorosis) to nearly zero. And to reiterate the recommendations, if you’re brushing your precious lil’ nipper’s first tooth, do not use a full fledged nurdle, but instead place a tiny smear no larger than a grain of rice on the toothbrush to minimize swallowing any excess toothpaste.
When the AAP made its recommendations a couple of weeks ago, I prepared myself for the outrage and pushback from the likes of Mercola and other associated Woomeisters. But to my surprise, there was almost no backlash, no indignation, no accusations of sapping and impurifying our precious bodily fluids by dentists and school and public health outreach programs. Oh sure, there were a few cries in the wilderness, such as the one from a Susan Posel at OccupyCorporatism.com, who goes on a random and somewhat irrational screed about fluoride being a neurotoxin, and sometimes “…fluoride, among other neurotoxins are causational to the onset of neurodevelopmental disabilities (NDDs).
The researchers identify a few NDDs [sic] as:
    • Autism
    • Attention-deficit hyperactivity disorder (ADHD)
    • Dyslexia”
Fortunately and to my delight, Aimee Ogden at Mommyish.com wrote a witty piece in support of the AAP’s position, complete with a game of Anti-Fluoride Bingo to play with the comments to her post. I will unashamedly and with gratitude steal her bingo card for use here so you readers can play along at home.
So there you have it. Although there are no epidemiological studies that demonstrate a causative link between professionally applied fluoride or fluoride-containing products and any of the above disorders (or any other disorders for that matter), this is the tack the anti-fluoridationists take. Perhaps they cite a study from industrial pollution, or from areas of the world that have many times the recommended concentration of fluoride naturally occurring in their water supply. But in the case of optimal fluoridation of municipal water supplies, the literature is clear: tooth decay is significantly reduced (30-60%, depending on demographic factors), period, with almost no adverse side effects other than cosmetic blemishes on teeth. That’s it. No lowered IQs, no neurotoxicity, no calcification of the pineal gland which, as we all know, is the seat of the soul. Consequently, before you feel the need to run out and detoxify yourself, either by eating turmeric, a spice alleged in the Pharmacognosy Magazine to mitigate the effects of fluoride toxicity, or any of the other detox remedies on the market.
So rest easy gentle readers. No matter how hard we try, we dentists aren’t very good at poisoning you people. In fact all those things we recommend to you actually are beneficial to your dental and overall health and have a long track record of success as well as reams of solid scientific evidence to back up their safety and efficacy. And kudos to the AAP for updating their fluoride recommendations to better protect our young children from dental decay, the number one malady affecting children.

Cochrane Review on Community Water Fluoridation
Grant Ritchey on July 3, 2015
Link

One of the overriding themes of the Science Based Medicine blog is to use rigorous science when evaluating any health claim – be it medical, dental, dietary, fitness, or any other assertion put forth with the intention of improving one’s health. Once the scientific evidence is evaluated as to efficacy, there are other criteria which must be taken into consideration, such as ease of administration, costs, possible adverse effects, and so on. Benefits have to be carefully weighed against risks to properly determine any appropriate course of action. For example, if a new pill is developed which is significantly better at , say, managing hypertension than existing medications, but it kills 10% of patients taking it, it obviously would not be the drug of choice. Conversely, if a proposed treatment, say homeopathy, is touted as being 100% safe with no side effects, but has absolutely zero benefits, it too would not be a recommended treatment. It’s a complicated and often ambiguous algorithm, and is imperfect due to the impossibility of attempting to quantify non-quantifiable values and qualities.
The perils and profits of fluoride
And so it is with the never-ending fluoride debate. Fluorosis is the major “risk” of fluoride ingestion, while decay prevention is the primary benefit (ignoring unsubstantiated claims by anti-fluoride groups of fluoride toxicity causing lowered IQ, chronic diseases, and other maladies). I’ve covered this topic before here and with Dr. Clay Jones here, but a new systematic review from the Cochrane Collaboration was recently released, its goal being:
…to assess the effects of water fluoridation (artificial or natural) for the prevention of tooth decay It also evaluates the effects of fluoride in water on the white or brown marks on the tooth enamel that can be caused by too much fluoride (dental fluorosis).
This marks the most comprehensive literature review to date on the subject, and instead of crystallizing our grasp on the effectiveness of community fluoridation programs, it has raised more questions than it answered. In this brief and admittedly superficial overview (cut me some slack; I had to work under a tight deadline while traveling!), I will attempt to unpack what the Cochrane Report says and means and, perhaps more importantly, what it doesn’t say and mean.
Review design
First things first: let’s look at the design of the systematic review. The consortium of Cochrane reviewers, possibly cloistered in a concrete bunker far beneath the Urals, searched through all of the major databases – The Cochrane Oral Health Group’s Trials Register, The Cochrane Central Register of Controlled Trials, MEDLINE via OVID, EMBASE via OVID, Proquest, Web of Science Conference Proceedings, and ZETOC Conference Proceedings . They searched the US National Institutes of Health Trials Registry (ClinicalTrials.gov) and the World Health Organization’s WHO International Clinical Trials Registry Platform for ongoing trials. From these sources, they found 4,677 references after eliminating duplicate search query results. For their inclusion criteria for tooth decay rates (also called dental caries), they included only prospective studies with a concurrent control that compared at least two populations – one receiving fluoridated water and the other non-fluoridated water – with outcome(s) evaluated at least twice, at separate times. For the assessment of fluorosis, they included any type of study design, with concurrent control, that compared populations exposed to different water fluoride concentrations. After applying these criteria to the large initial group of research literature, they winnowed it down to 155 papers that were suitable for evaluation. Twenty studies examined tooth decay, most of which (71%) were conducted prior to 1975. A further 135 studies examined dental fluorosis. Overall, it was a well-done, rigorous systematic review.
Results
FluorosisLet’s look at the results and conclusions, shall we? We’ll start with the fluorosis arm of the study, since it’s the easiest and most straight-forward. The researchers calculated that, in areas with a fluoride level of 0.7 ppm in the water (which is the current recommended concentration of community fluoride programs in the US), approximately 12% of the people evaluated had fluorosis that could cause concern about their appearance. And although the majority of the research articles (135 out of 155) were about fluorosis, the Cochrane Group still concluded that:
…(t)here is a significant association between dental fluorosis (of aesthetic concern or all levels of dental fluorosis) and fluoride level. The evidence is limited due to high risk of bias within the studies and substantial between-study variation.
So, for this part of the report, there is no real earth shattering news. At the recommended doses of fluoride, there is a small risk of fluorosis, harmless but potentially annoying cosmetically. We knew this already, and no new light was shed on the subject. However, what is of note here is that of the 135 studies – the best, most rigorous studies, mind you – the evidence was generally found to be not of high qualitative value. In fact, the authors stated “(o)ver 97% of the studies were at high risk of bias and there was substantial between-study variation.” Does that mean the research is wrong? No, it doesn’t, and the research probably isn’t wrong. The report merely speaks to the confidence one has in using said research for drawing any sort of definitive conclusions or making recommendations based upon it. It also speaks to what we Science Based Dentists have been screaming for years – that the quality and quantity of dental research at the population level is woefully thin and inadequate in many areas.
CariesWhich brings us to fluoride and dental caries. Here things get a little murkier, and the stakes are higher. After all, the entire raison d’être for the recommendation of fluoride by just about every dental, medical, governmental, and public health organization is to prevent cavities, the number one disease affecting the human species. If fluoride is shown to offer no protection against tooth decay, then its use cannot be justified, no matter how insignificant any side effect might be.
For this arm of the review, only twenty studies out of the original 4,677 search hits fit the criteria for evaluating the role of fluoridation and caries prevention. These studies too showed a high risk of bias, and even more problematic was that most of the studies included in the systematic review were done prior to 1975, before fluoride was used routinely in toothpastes, mouthwashes, and even topically in dental offices. At that time the city water supply was the primary source of fluoride. But since the pre-1975 studies and the post-1975 studies were merged into one meta-analysis, the confounding factor of fluoride sources other than municipal water obfuscate the significance of the results. Overall, community water fluoridation has resulted over time in a 35% reduction in tooth decay in primary teeth and a 26% reduction in permanent teeth. Moreover, fluoridation increased the percentage of children with no decay by 15%. These are very impressive numbers and attest to the vast reduction in pain, suffering, and dental health care expenses over every demographic group in society. That is why the Centers for Disease Control (CDC) has called fluoridation one of the Top Ten public health victories of the twentieth century.
But here’s the rub. Historically, it was thought that the benefits of fluoride occurred primarily via systemic ingestion, where it would be incorporated into the tooth enamel as it formed. Unfortunately, that is also the route by which fluorosis forms – a spanner in the works during tooth development. More recent research, however, has demonstrated that much (if not most) of the strengthening of the enamel is due to the topical effects of fluoride. Fluoride from toothpastes, fluoride varnishes, mouthwashes, and yes, even drinking water, “soaks” into the outer layers of enamel to make it more acid resistant and therefore less susceptible to dental caries. I hope that by now you can see why this systematic review is problematic in ascertaining if community water fluoridation programs are justified. Are the benefits we enjoy from fluoride primarily from toothpastes, professional dental applications, processed foods made with fluoridated water, or fluoride from community water supplies?
Despite the new report, fluoridation is still unanimously supported and endorsed by all of the major health organizations – the American Dental Association, American Academy of Pediatrics, American Association of Public Health Dentistry, the World Health Organization, the CDC, and so on. And while the pure benefits of water fluoridation aren’t as obvious due to widespread fluoride consumption by various other means, they are still important. For example, people living below the poverty line may not have access to good-quality fluoride toothpaste or professional dental fluoride varnish applications. Fluoridated water is a cheap and effective means to administer fluoride, and is non-discriminatory. Unfortunately, this too could not be substantiated in their report.
Ambiguity and qualifications
When you read the conclusions of the systematic review, the wording is much more ambiguous and non-committal in their endorsement of water fluoridation. To wit:
Although these results indicate that water fluoridation is effective at reducing levels of tooth decay in children’s baby and permanent teeth, the applicability of the results to current lifestyles is unclear because the majority of the studies were conducted before fluoride toothpastes and the other preventative measures were widely used in many communities around the world.
There was insufficient information available to find out whether the introduction of a water fluoridation programme changed existing differences in tooth decay across socioeconomic groups.
There was insufficient information available to understand the effect of stopping water fluoridation programmes on tooth decay.
No studies met the review’s inclusion criteria that investigated the effectiveness of water fluoridation for preventing tooth decay in adults, rather than children.
They sure said “insufficient information” a lot, didn’t they? If you weren’t a regular reader of Science-Based Medicine, you might read the report and conclude that the fluoride ship has sailed, that there is no longer a justification for putting fluoride in municipal water supplies. But since you are a regular reader, I’m certain the phrase “absence of evidence is NOT evidence of absence” immediately popped into your head. And that, dear reader, is (in my opinion) the crux of the review. Although it can be (and already has been) spun by the anti-fluoride crowd as evidence that fluoride isn’t effective, that’s not what the report says at all. Fluoride has a proven track record in the reduction of tooth decay. The main unanswered question (which the Cochrane Group hoped would be answered in this meta-analysis) is: to what degree of protection against dental caries does community water fluoridation currently confer? I think it can be assumed that if pre-1975 research papers were eliminated from the systematic review, and more recent high quality studies were available, the overall reduction in decay would be less than the pre-1975 levels. The authors state:
Our confidence in the size of effect shown for the prevention of tooth decay is limited due to the high risk of bias in the included studies and the fact that most of the studies were conducted before the use of fluoride toothpaste became widespread.
It’s this statement of limited confidence that has not only allowed the anti-fluoriders to seize upon it for their own aims, it has even led mainstream new sources to report on the report in such a way to mislead their readers. Newsweek’s headline, for example, reads “Fluoridation May Not Prevent Cavities, Scientific Review Shows“. Of course, this is irresponsible journalism, as that’s not what the review showed at all. But it does peddle false scientific information to its huge readership, which is regrettable for a news outlet of Newsweek’s caliber.
So until further research is in, you don’t have to attend anti-fluoride rallies or write a letter to your local newspaper calling for the cessation of community water fluoridation. It is still safe and effective, one of the best prevention values in health care. Each dollar that is spent on fluoridation reduces dental costs many fold, not to mention untold pain, suffering, loss of teeth, and loss of productivity.

Fluoride and IQ
The evidence continues to support that low levels of fluoride in drinking water are safe.
Steven Novella on November 1, 2023
Link

The anti-fluoride movement continues to make dubious claims about the safety of fluoride in public drinking water. They are also expanding into new social media platforms, like TikTok, where everything old is new again. These platforms give a second (or more) life to old debunked claims, which means we have to constantly be whacking these moles down again.
Recent anti-fluoride activism has been focusing on studies showing that high enough fluoride levels can be a neurotoxin. This tactic took off with the Harvard study back in 2012. The Harvard study still gets prominent mention in anti-fluoride posts, as if it’s still news, or somehow is being suppressed. The study was a meta-analysis of studies, mostly occurring in China. These were ecological studies comparing measures of IQ in children to see if there is a statistical correlation with fluoride exposure from drinking water. The study found a positive correlation, making it a permanent member of the anti-fluoride rhetoric.
However, details matter. The studies involved naturally-occurring fluoride in drinking water, not communities where the levels of fluoride were controlled (which is why they took place in China, that largely does not control fluoride levels). They found that communities with high levels of fluoride in the drinking water had lower IQs on average than communities with low levels of fluoride. But here is the critical point missed in a lot of reporting and in anti-fluoride propaganda – the low level communities had fluoride levels in their drinking water in the same range as fluoridated water in the US and other Western nations. Fluoridated water was the low-level control group that had the higher IQs.
Meanwhile, it should be pointed out that the association with lower IQs and very high levels of fluoride have not been definitely established. There are lots of confounding variables in the observational studies, and it takes some fancy statistics to tease out a small statistical effect. A New Zealand study, for example, found no association between IQ and fluoride once confounding variables were adequately taken into account.
A 2023 systematic review did find a correlation between fluoride levels and IQ, but generally found the quality of the evidence to be low.
The inverse association between fluoride exposure and IQ was particularly strong in the studies at high risk of bias, while no adverse effect emerged in the only study judged at low risk of bias.
So the one study deemed high quality showed no association, and meanwhile there seems to be a correlation between low quality (high risk of bias) and a positive effect. This pattern of evidence does not lead to high confidence. The one thing that all studies appear to agree with is that better studies are needed to settle the question.
But it is plausible that at high doses there may be a neurotoxic effect from fluoride. As always – toxicity is all about dose. What we need are studies that look carefully at the range of fluoride levels that are contained in managed municipal water. Instead we appear to be getting more of the same. The latest study to make the rounds in being presented with headlines such as: “Water Worry: Excess Fluoride Linked to Cognitive Impairment in Children.”
This study is similar to the China studies in that it takes place in a rural community, this one in Ethiopia, in which there is high levels of naturally occurring fluoride. This is also a pilot study, which the researchers hope will “spur further research”. The researchers broke the subjects into three categories based on fluoride levels, <3 mg/L, 3-8 mg/L, and 8-15.5 mg/L. The recommended level of fluoride in drinking water in the US is 0.7 mg/L. The WHO recommends level below 1.4 mg/L.
So once again the low fluoride level control group was in the range of fluoridated water, while the high level groups were very high. Even if we take these results at face value, they show us, if anything, managed fluoride levels are safe. But in reality they don’t tell us anything either way, because the data is not looking at a range of fluoride that covers deliberately fluoridated water.
The results are also not that compelling, even for a risk of high fluoride exposure. The researchers used three measures of cognitive function, a picture drawing test, a memory test, and a paired association learning test. The findings were inconsistent but there was an overall statistically significant trend toward lower performance at the higher fluoride exposure levels. But as you can see from this graph of some of the data, the noise level appears to be far greater than the signal. Just looking at the data (if the trend lines were not present) it would not be possible to discern a trend.
The effect, in other words, if it is real, does not appear to be clinically dramatic.
Of course, all potential neurotoxicity to the developing brain should be taken very seriously. Every IQ point is a precious human resource. For this reason we should err on the side of caution when it comes to potential toxicity. What the current data shows is that there is a potential of neurotoxicity from fluoride at high levels, significantly higher than in the drinking water. But the same data shows, if anything, the managed drinking water levels are safe. Further, the best quality evidence does not show any clinical effect.
What I think all this means is that current drinking water fluoridation levels (below 1.4 mg/L) are safe, and provide a significant benefit for dental health. But also, we need to conduct higher quality studies to show if there even is a real neurotoxic effect, and to zoom in on the levels in managed drinking water (rather than just using that range as the low-level control).
And, as always, the media needs to do a better job of reporting this data and putting it into proper perspective.

The Fluoride Dragon Cometh! Or does he?
Craig D Pearcey on September 18, 2016
Link


[Editor’s note: With no further ado, and with no introduction necessary, here is a second post from Craig Pearcey; Witness his science and despair, quacks of the world!]
First for the basic chemistry
There is one particular word that tends to get many CAM supporters very vocal and the conspiracists thinking about running for their home-made bunkers in a basement somewhere. It is the word “fluorine” or any of its analogues. However, before getting into their anti-fluorine claims, we need to briefly review it properties as both an element and in various molecular forms. Without this background it may be possible to make certain assumptions about fluorine that are baseless for a given molecular structure and application. It is this very type of error that the antivaxxers and many in the CAM field make in regards thimerosal – i.e. Ethyl(2-mercaptobenzoato-(2-)-O,S) mercurate(1-) sodium, methyl-mercury, and elemental mercury. All three have significantly differing chemical properties based on their molecular structure, but some individuals/groups continue to attribute the toxicity and chemical properties for elemental mercury to thimerosal (Ethyl(2-mercaptobenzoato-(2-)-O,S) mercurate(1-) sodium). Similarly, drawing conclusions on thimerosal toxicity from methyl mercury is equally flawed. In addition, in their instance in equating the three they refuse to provide any viable mechanism how thimerosal is converted into either elemental mercury or methyl mercury, or how they can be attributed the same chemical properties.
And now for fluorine chemistry
Fluorine is one of the halides (i.e. halogen), and is located in Period 2 (the second row of the periodic table), Group 17 / Group VIIa (the column second most from the right of the table). It has the highest electronegativity of any of the elements (i.e. a “love” for accumulating extra electrons) in the periodic table, and consequently is one of the strongest oxidants in nature. This strong oxidizing potential tends to make it dangerous to any living organism that comes into contact with it in it elemental form (typically as molecular fluorine – F2) due to its tendency to cause severe oxidative damage. Fluoride on the other hand, the anion of fluorine, is supplied in various forms for the prevention of cavities. These forms include sodium fluoride, fluorosilicic acid, and sodium fluorosilicate. As an anion, i.e. F–, its potential for oxidation is spent and it tends to form salts like sodium fluoride (NaF) with any cation in its immediate environmental. However, sodium fluoride is still toxic in small to moderate amounts (the lethal dose for a 70kg/154lb individual is 5-10 grams) and has a health warning of three on the NFPA 704 scale. In addition, sodium fluoride is also highly soluble in water. Lithium fluoride on the other hand, is far less water soluble and is typically associated with molten salts, and is used for (among other things) solar energy conduction in solar plants. Fluorosilicic acid (H2SiF6) and sodium fluorosilicate (Na2SiF6) are the acid and conjugate base of the same fluoridated silicon chemical species. Both are highly toxic (given by the NFPA 704 scale numbers of 3 and 2 respectively) and fluorosilicic acid is corrosive, including corrosive to glass. When elemental fluorine is chemically bonded to organics, its high electronegativity allows it to form strongly bonded associations with the organic backbone. This allows multi-fluoro-alkyls to have considerable thermodynamic stability, which lends them to multiple commercial and industrial uses (eg. high performance fire-retardants), particularly when multiple or complete hydrogen-fluorine substitution has been effected such as the various perfluor-alkyls and polyfluoror–alkyls (PFAS).
Turning Flint waters into a merry-go-round…
Given the prior discussion on heavy metals, it is appropriate at this point to move onto another issue Natural News writers often frequent – even though it does not include the topic of fluoride. Most recently, the writers of Natural News have published the an article entitled:- “City governments across America are poisoning children with lead and nothing is being done about it” in which they reference what is now known as the Flint Water Crisis. It is one of a number of articles in the similar vane in which they attempt to link the Flint Water crisis and the hazardously high lead levels in in Flint’s (Michigan) public water system to their unfounded claim of deliberate poisoning of the general US public with elevated levels of heavy metals in all US public and water drinking water. The whole story of the Flint Water crisis is known by most of the US public (though little known outside of the US) and has been extensively covered in the US press. In essence, the metropolitan of Flint changed over its water supply from the Detroit Water and Sewerage Department to the Flint River, but did not add the necessary corrosion inhibiters to the Flint river water supply. This resulting in hazardously elevated levels of lead in the public water supplied to Flint due corrosion / leaching of lead out from the old lead-pipe based public water system into the public water. The effects on the citizens of Flint, particularly the poorer, were severe with as many as 6000-12000 children experiencing health related problems. In addition to, that when the problem became openly known, there were attempts by certain individuals to hide evidence of negligence. At present, extensive efforts have been undertaken to address the problem, include the changing back to the Detroit Water and Sewerage Department water supply, replacing the old lead pipe-lines with something more modern and infrastructure upgrades. Legal action is also being presumed against certain individuals. In addition, the story of the Flint Water Crisis is still developing as these efforts are ongoing. In general, Natural News’ coverage thereof is within acceptable bounds until they move beyond the basic facts of the case. Once, the writers of Natural News attempt to link the events of the Flint Water Crisis to their broader conspiratorial claims of heavy-metal poisoning of the general US public, they move from a factual position to one of unsupported supposition. The general mountainous preponderance of Water Quality testing data/evidence in the US, by the EPA and others, does not support they preposition. In fact the avalanche of evidence actually supports the counter claim. This cannot be more clearly demonstrated than by the fact that Mr Adams’ own CWC laboratory results (a review of which was undertaken earlier) strongly suggests no heavy metal poisoning of the general US public , but overall; adequate to good quality drinking water instead.
RED-ALERT! PFAS invasion on the way …
With this background, it is appropriate at this juncture to mention three recent articles on the Natural News website as they illustrate the approach in regards the general topic of anything to do with fluorine by many CAM supporters and conspiratists. The first of these was written by Mr. Mike Adams (Health Ranger) and is entitled “Millions of Americans exposed to deadly, toxic chemicals in public water supplies… massive scientific investigation backs up Health Ranger findings“. In his article, Mr. Adams states:
The study comes on the heels of the Natural News nationwide water quality assessment effort which analyzed hundreds of water samples via ICP-MS instrumentation to determine that 6.7% of the U.S. water supply is contaminated with toxic heavy metals that exceed allowable EPA limits. Click here to read the results of my own study in the Natural Science Journal, the journal I launched to publish real science in the public interest (without corporate or government influence). My article explaining the illegal heavy metals contamination found in the U.S. water supply is detailed at this link.
This article was subsequently followed reasonably quickly by two further articles on Natural News regarding the same topic and are entitled “Millions of Americans at risk for cancer and other harmful diseases due to toxic tap water” and “California tap water most toxic in nation; Harvard study finds deadly industrial chemicals used to fight fires, insulate pipes and more“. All three articles refer to the same recent joint study undertaken by the Harvard T.H. Chan School of Public Health and the Harvard John A. Paulson School of Engineering and Applied Sciences in which the lead author, Xindi Hu, discussed the progressive emergent threat of PFAS in US public drinking water as part of her doctoral thesis. The author of the Harvard study used data supplied by the EPA’s Third Unregulated Contaminant Monitoring Rule (UCMR3) program and a brief review of part of the contents thereof indicates that the Harvard study itself was well designed and executed. However, it is clear from both the title and the quoted contents of Adams’ article that he is trying to ram through his claims of heavy metals poisoning of the US public via its drinking water on the coattails of Hu’s completely unrelated study. A prior debunking of Mr. Mike Adams’ prior claims around heavy-metal poisoning of US public and state water is available on Science-Based Medicine. The impression that all three articles attempt to produce is that the EPA is either neglectfully ignorant of the risks associated with PFAS contamination of the national water supply, or criminally inactive about it. However, neither impression is true as, firstly, the EPA has been aware of the risks associated with PFAS for some time as given by the EPA’s UCMR3 testing program used in the Harvard study and, secondly, they have instituted activities to deal with the threat. In other words, the EPA has not been caught suddenly by surprise, and they are already at work tracking and attempting to address the problem. Furthermore, the issue of PFAS is not just a US problem, as the three Natural News articles appear to imply, but a global problem. This is clearly evident in the considerable amount of work and investigation being undertaken by the UNEF under the UN Global Monitoring Plan on POPs. Data from these and many other sources show similar levels of PFAS’s in the ground water, fauna and populous of all EU countries as compared to the USA. A similar trend is also observed around the rest of the globe. Lastly, given Mr. Adams related claim, a final comparison of the maps provide for heavy-metal results and the EPA on PFAS clearly suggests that there is no significant correlation between Adams’ heavy-metal data and the EPA PFAS data. In the end, these three Natural News articles are nothing more than an attempt to appeal to authority to justify their unfounded claims of US public water heavy-metal poisoning using a good-quality study that is not at all related to their claims – a “guilty by association” approach.
Beware the dental hygiene!
In addition to these three articles on the Natural News website on PFAS, a pair of articles on fluoride and dental hygiene were also been published during the same period. As with the three on PFAS, the central theme has been the issue of the apparent toxicity of US state and national drinking water, but this time in regards the addition of various sources of fluoride with a view to improving dental hygiene. These articles include “Whiten your teeth naturally, without chemicals” and “How New Zealand is systematically poisoning its citizens with fluoride… while crushing local control over water safety” and if you are really curious about what Mr Mike Adams’ is actually think on the subject, you can find a whole category of articles on fluoride. Overall, the general tone given by Natural News is that the writers believe that the use of fluoride at any dosage level (even the smallest) is extremely toxic and harmful to any individual regardless of the method of delivery or the frequency of the dose. There are a few references on Natural News to dental fluorosis and skeletal fluorosis as well as frequent references to avoiding fluoride or filtering it out as given by the titles: “Water purification breakthrough revealed: AquaTru countertop water purifier removes 128 toxic chemicals, fluoride, heavy metals and more” and “Big Berkey beats ProPur gravity water filter for removal of heavy metals and toxic elements“. It is almost as though they are talking about high intensity radioactive contaminants like Cobalt-60 or Iodine-131. Most recently, the writers of Natural News have also published the an article entitled:- “How to prevent fluoride from destroying your brain” which refers to a study undertaken by Dr. Philippe Grandjean (Harvard School of Public Health) and Dr. Philip Landrigan (Icahn School of Medicine published) in the medical journal The Lancet (Neurology)- see abstract and full article. In their article, Natural News asserts:-
In 2014, the journal Lancet Neurology declared that fluoride is a developmental neurotoxin. A meta-analysis of 27 cross-sectional studies was lead by Dr. Philippe Grandjean of the Harvard School of Public Health, and Dr. Philip Landrigan of the Icahn School of Medicine. The study analyzed the effects fluoridation had on children across the world, though most were from China. What the researchers found was shocking. Exposure to elevated levels of fluoridation led to a decrease in IQ of about seven points, on average. Most of the water supplies in the studies had fluoride levels that would be permissible by current EPA standards, of less than 4mg per liter.
However, these views by the writers of Natural News are unsupported scientifically and have no basis in reality. The science behind the application of fluoride to teeth for good dental health has been extensively studied and is well established. Among the aspects covered by these studies is the chemical mechanics behind the conversion of hydroxyapatite to fluoro-hydroxyapatite in tooth enamel with fluoride application, as well as chemical/solubility equilibrium studies (Le Châtelier’s principle) and reaction kinetic studies associated hydroxyapatite deposition/re-deposition – including some more recent studies. The impact of dosage levels has also been well studied and from these studies, the appropriate and safe levels for fluoride application have been determined (0.7 – 1.2 ppm in drinking water). These studies have also shown that dental fluorosis and skeletal fluorosis only occur at high and extremely high levels respectively, typically at consumption levels one or more orders of magnitude above those proposed (i.e. 10 or even 100 ppm), at which point community water supplies would begin removing fluoride from the water. Thus, the claim by the Natural News writers that fluoride application at any dosage is dangerous is without any basis. In regards the Lancet study, the writers of Natural News appear to have quoted the Lancet study completely out of context. The language and structure of Natural News article suggests that its writers are attempting to create the impression that the Lancet article was sole about fluoride and its dangers, specifically in regards that added to US drinking water. However, the original Lancet article is actually a study that focuses on a large variety of known neurotoxicants (not just fluoride) and how they impact on cognitive development, with a specific emphasis on children. Some of the neurotoxins referenced in the article are Lead , polychlorinated biphenyls (PCB) , arsenic, toluene, manganese, chlorpyrifos, dichlorodiphenyltrichloroethane, tetrachloroethylene, and polybrominated diphenyl ethers. Fluoride is only mention twice in the article, once in table 2 and once in the abstract, however, it is not discussed at all in the article, including in the abstract. Thus, it is difficult to know the context of the fluoride (ie. the dosage level) that the article is referring to. A study of the sources sighted by Dr Gandjean and Dr Landrigan in the original article is more revealing. One of the sources referenced is an article published in the journal of Environmental Health Perspectives that deals with developmental delay in respect to fluoride dosage levels that are abnormally high as given by an article entitled:- “Developmental Fluoride Neurotoxicity: A Systematic Review and Meta-Analysis” . An extract from the articles abstract states:-
Conclusions: The results support the possibility of an adverse effect of high fluoride exposure on children’s neurodevelopment. Future research should include detailed individual-level information on prenatal exposure, neurobehavioral performance, and covariates for adjustment.
Lastly, the mention of 4.0 ppm (4.0mg/L) as the current EPA standard by the Natural News writers appears to be a break-down in understanding and general confusion around the NCR 2006 study (which was into the adverse impact of fluoride at the 2-4 ppm level) and the stipulated EPA specifications for fluoride in drinking water (0.7 – 1.2 ppm).
Further afield …
Two other claims that have been made by those in the anti-fluoridation camp are:
     1.  That the rest of the world is against the use of fluoride to dental hygiene entirely, and
     2.  That fluoride aids the uptake/release of heavy metals in the human body – thus aiding heavy metal poisoning.
In regards the rest of the world being against fluoridation, this is completely untrue as both the UN World Health Organization and EU European Food Safety Authority are strongly in favour thereof. This, then, raises the question as to why considerably more countries do not add fluoride to their drinking water than do. The answer is that the majority of the countries whom do not add fluoride to their public water use other methods to provide fluoride to their general public, such as fluoride in toothpaste, oral medications, and dental fluoride treatments typically involving pastes/gels. The reasons behind this are based more political and legal issues, not scientific or health ones. In regards higher heavy-metal uptakes/release by fluoride, the proponents hereof have not provided any viable scientific evidence for these claims, nor have they ever proposed a viable chemical mechanism for this. The single article they reference mentions only increased lead levels in the water supply to certain areas of Flint due to the increased corrosion of lead pipes via fluorosilicate.
Final words on PFAS and fluoride
So, in summary:
     1.  PFAS are a clear point of concern in the US, the EU and globally. Presently, the EPA and UN are carefully monitoring PFAS levels and working to address these concerns. However, for the Natural News writer to try link their unfounded claims of heavy-metal poisoning of the general US public via their drinking water with the PFAS study is completely without merit and inherently false.
     2.  The use of fluoride for dental health is well documented and thoroughly scientifically proven, provided the dosage of fluoride is maintain within the appropriate range. For the writers of Natural News to claim the use of fluoride at any dosage level, by any mechanism, and at any frequency, to be dangerous and damaging to public health, is totally unfounded and pure misinformation.
     3.  Although most of the world does not use fluoridation of water as a means of supplying fluoride to the general populous, they generally are in favour of fluoride application for oral hygiene and supply it in other forms.
     4.  The CAM and conspiracy camps have not provided a viable chemical mechanism to explain how fluoride worsens the uptake/release of heavy-metals by the human body to facilitate poisoning thereby.
An unrelated bit of fun chemistry
And now for something completely off topic and of interest in regards Period 2 chemistry. Being in Period 2, each fluorine atom processes only s and p-orbitals (i.e. electron shells), but no d or f-orbitals which gives fluorine some unique properties. Consequently, this is why (together with the number of protons in its nucleus against its size) fluorine has the highest electronegativity of all known elements. This lack of d and f-orbitals also tend to confer unique properties to all the other Period 2 elements such as boron, carbon, nitrogen and oxygen, ect. This unique s/p-only orbital property for carbon as well as its four-valence bonding capacity makes it the only element in the universe that can readily and easily form polymers and chains of endless length that are thermodynamically stable. Silicon, the next four-valence bonding element in the Periodic Table (Period 3), does not readily form long polymers due to it having d-orbitals which favour silicon-oxygen linkages. Consequently, silicon tends to form silanes and silicones polymers, but only to a given size due to steric hindrance of the polymer structure. It is for this reason that any possible extra-terrestrial life (if it exists) on any exoplanets (include those recently discovery by either radial-velocity or transit methods – see the Kepler satellite) will always be carbon based rather than silicon based (despite science fiction’s general enthusiasm for silicon based life-forms).

Some Data on Fluoride
Steven NovellaonNovember 6, 2024
Link

David Gorski wrote yesterday about the threat that a second Trump term holds for American health, specifically if he keeps his promise to give RFK Jr. some high level position over public health. Unfortunately, we have seen this movie before, although the sequel promises to be much worse. Putting a pseudoscientist, crank, conspiracy theorist, anti-vaxxer in charge of the organizations that are supposed to use scientific evidence to protect public health is horrifying to contemplate.
During the COVID pandemic we at SBM found ourselves spending much of our time addressing the tsunami of misinformation that was coming out of the White House. We will likely have our work cut out for us over the next four years and beyond. Since RFK Jr specifically stated one of his top priorities is to get local governments to remove fluoride from public water supplies, let’s start there.
Fluoride has been added to some public water systems since 1945, starting in Grand Rapids MI. Fluoride is naturally occurring in many water systems to various concentrations, and it was observed that locations with high fluoride levels had better oral health and fewer cavities. Adding small amounts of fluoride to water supplies that lack it has been, according to the CDC, one of the 10 greatest public health measures of all time.
The bottom line is that fluoridation works. It is cost effective, saving from $20 to $38 in oral health care for every $1 spent. It is especially important for lower income areas who may lack adequate dental care. Tooth disease also correlates with a number of other serious systemic diseases. Communities that stop water fluoridation consistently see subsequent rises in oral disease and cavities, especially among the poor.
The benefits of fluoridation are actually not controversial. They are very clear. Anti-fluoridation activists, like RFK Jr., focus on the alleged toxicity. He wrote recently:
“Fluoride is an industrial waste associated with arthritis, bone fractures, bone cancer, IQ loss, neurodevelopmental disorders, and thyroid disease.”
He gives away his conspiratorial mindset by repeating the anti-fluoride fear-mongering that fluoride is an industrial waste. This is mostly a myth and in any case is irrelevant. First, fluoride exists is many water supplies naturally, at about the optimal levels for safe oral health. In the ocean fluoride is present at about 1 part per million. Most of this comes from leaching from rocks and minerals that contain fluoride compounds.
Added fluoride comes in three main forms, sodium fluoride, hydrofluorosilicic acid (hexafluorosilicic acid) and sodium silicofluoride. These come from a variety of sources, including some from industrial processes. But the source does not matter at all – regardless of the original chemical, all types completely break down in water resulting on fluoride ions. Fluoride is an element, and a fluoride ion is a fluoride ion, regardless of its source. Trying to scare people by calling it “industrial waste” is anti-science and just playing on chemophobia.
In the US the EPA has set a maximum fluoride level in public drinking water (regardless of source) at 4.0 mg/L. The CDC recommends an optimal level of 0.7 mg/L for oral health (again, less than the concentration in the ocean and many natural water supplies). As we all know, toxicity is all about dose. So are there health risk at fluoridated levels? No.
Let’s start with bone health. Multiple reviews have found that at levels of fluoride added to water systems, there is no association with bone fractures or negative effects on bone health. A National Resource Council review found mixed evidence for a possible increase in bone fractures starting at 4.0 mg/L. For this reason the CDC recommends lowing the highest allowable amount and the EPA is reviewing their standards.
But keep in mind, in the US we only add fluoride up to 0.7 mg/L. The higher concentrations were studied because there are locations with high naturally occurring fluoride levels in the US. The question is – when do we remove fluoride from drinking water? This is not about adding fluoride, which is well below any safety concern.
What about bone cancer? There was a single study in 1990 that found possible evidence of increased osteosarcoma in male rats (but not female rats, or mice) associated with higher levels of fluoride exposure. This looks like a typical quirky result. Subsequent studies did not find this, and epidemiological studies have not found any association with increased bone cancer and fluoridation programs. f
Of course you can always cherry pick one study from over 30 years ago an ignore more recent and relevant data. This is also another hazard vs risk issue. Toxicology studies generally overcall toxic effects – they are often designed to find toxic effects. But that does not tell us much about actual risk. For that we need epidemiological data in humans, which in this case is negative.
I already wrote about fluoride and IQ. The quick summary is that in the studies touted by anti-fluoride activists that show a correlation with fluoride and lower IQ, they compared naturally high levels of fluoride (typically over 4 mg/L) to lower levels (in the range of fluoridation programs, 0.7 – 1.0 mg/L). So in the very studies cited, the fluoridation programs were associated with the higher IQ. Again, there is no evidence that fluoridation at levels deliberated added to public water carries any health risk.
But of course, as new data comes in we may tweak the guidelines to optimize benefit and minimize risk. The current recommendations, however, are based on the best current evidence available.
RFK Jr.’s recommendations are not based on the best science available. They are based on conspiracy theories, pseudoscience, and fearmongering. I guess that is what we can expect from the next four years. Buckle up.

May the Floss be with you?
Grant Ritchey on November 6, 2015
Link


I’m beginning this blog post under the assumption that the average Science Based Medicine reader is more intelligent, more motivated, and more health conscious than your typical Jane or Joe Blow. As such, most of you probably visit your friendly neighborhood dentist for cleanings and checkups twice a year just like the toothpaste manufacturers American Dental Association recommends. And if you’re like 99% of the patients my dental hygienists and I see in my practice, you get encouraged/chided/scolded to floss more. Because we all know no one flosses like they’re supposed to and that flossing is absolutely the best thing a person can do for his or her oral health, right? We even have posters that have witty quips like “Only Floss Those Teeth You Want To Keep!” Pretty clever, huh? You have to get up pretty early in the morning to be funnier than a dentist.
But how effective is flossing anyway? After all, it is the cornerstone of what we dentists preach to our patients to prevent cavities and gum disease (and evidently have since the Bronze Age), but does flossing really deliver the goods? We dentists are consistently voted as one of the most trusted professions, but can you trust our recommendations about flossing?
Well, I don’t want to come across as one of those conspiracy theory nuts, but this blog post could very well be titled “Things Your Dentist Doesn’t Want You To Know.” It turns out that flossing may not be as beneficial as we have been claiming all these years. But before you throw out the canisters of floss you’ve accumulated over the years (but never use), please stick with me until the very end of the article. After we take a look at the literature, there are some subtleties we need to unpack to get the full story about which oral hygiene practices are recommended.
The literature
Looking at the dental literature, one would think that good studies about flossing and brushing would be abundant, but this isn’t the case. Who knows why, but I assume that it’s one of those topics where efficacy was always presumed from experience – both the patient’s and the dentist’s. There is robust biological plausibility for brushing and flossing: bad bugs live on teeth, said bugs cause cavities and gum disease; therefore, make bad bugs go away and your dental problems will go away as well (to put it in Crislipspeak). Moreover, many of the studies that are published were done by dental product manufacturers, and they obviously have a vested interested in hawking their wares and demonstrating the superiority of their products over their competitors’.
In an attempt to crystalize the data on the matter, a couple of systematic reviews were done, one in the Journal of Dental Research, a high quality, peer reviewed dental journal, and the other by the Cochrane Collaboration, also a well-respected resource for such endeavors. Both of the reviews have been out for a while, but have recently popped up again in the lay press. And as you might be able to guess, much of the “science journalism” is misleading or downright wrong.
The first systematic review I will cover is “Dental flossing and interproximal caries: a systematic review” by Hujoel, et. al. In this systematic review, the investigators assessed the effect of flossing on interproximal (between the teeth) caries (tooth decay) risk. Toothbrushing doesn’t reach between the teeth, therefore flossing is the logical solution to preventing cavities there. The authors identified six trials involving 808 subjects aged 4 to 13. In one of the reviewed studies, children were professionally flossed every school day for 1.7 years, which resulted in a 40% reduction of caries risk. Professional flossings every three months for three years as well as self-performed flossing for two years did not statistically alter caries risk. Again, they looked only at tooth decay reduction, not gum disease. The take home message from this review is that:
     1.  Flossing when done by professionals five days per week works! That means if everything goes just right, if you know what you are doing (e.g., you are a dental hygienist or a dentist), you have good visualization of the teeth from outside the mouth, you are motivated and do the job regularly, you can in fact reduce caries. This is the definition of efficacy.
     2.  If you don’t do it five days per week but just occasionally (even if you are good at it) there is no benefit in terms of lessening your chances of getting a cavity.
     3.  If you ask people (adolescents) to do it themselves, they can not achieve a good result. Why? They probably can’t technically do it right, don’t do it often enough, or some other unknown reason. This is the definition of effectiveness.
     4.  So the conclusion for caries prevention is that flossing has some efficacy but not good effectiveness when left to patients to be the flosser.
OK, now that you’re all bummed out because you’ve been misled by your wonderful dentist and hygienist all these many years, let’s see if flossing confers any benefit in the prevention of periodontal (gum) disease over and above flossing alone. There has to be SOMETHING to this flossing thing, right?
In the Cochrane review, “Flossing for the management of periodontal diseases and dental caries in adults,” Sambunjak et. al. searched multiple data bases in all languages, going back to at least 1950, for studies which assessed the effects of flossing in addition to toothbrushing (as compared with toothbrushing alone) in the management of periodontal diseases and dental caries in adults. Even with these broad search criteria, only twelve studies involving 582 participants were included in the systematic review. Seven of the trials were assessed as “unclear risk of bias”, while the remaining five were at “high risk of bias.” Plaque and gingivitis were the measured outcomes of the studies. While there was not much difference in the amount of plaque found on flossers and toothbrushers vs. toothbrushers alone, there was a statistically significant decrease in gingivitis in the flossing group at one, three, and six months. While this is a good thing, keep in mind that gingivitis is merely inflammation of the gums: the redness, puffiness, and bleeding you see in gums that aren’t healthy. This is to be distinguished from periodontitis, which is when the infection actually penetrates into the jaw bone surrounding the teeth, causing tooth mobility and ultimately tooth loss. So while this systematic review did show benefit in gingivitis reduction, there was no real benefit in terms of outcomes like tooth retention or other quality of life issues. In a nutshell, the investigators concluded that “(t)here is some evidence from twelve studies that flossing in addition to toothbrushing reduces gingivitis compared to toothbrushing alone. There is weak, very unreliable evidence from 10 studies that flossing plus toothbrushing may be associated with a small reduction in plaque at 1 and 3 months.” They also pointed out that in this review, “(n)o studies reported the effectiveness of flossing plus toothbrushing for preventing dental caries” in adults.
To summarize, flossing might make your gums less puffy, and likely makes your mouth feel better without those hunks of shredded chicken stuck in that annoying space between your molars, but it really doesn’t do much in terms of any sort of disease prevention.
As a dentist, these reports are distressing to me, as our brushing and flossing screeds have always been the cornerstone of our oral health education, not only in our practices, but in public health and dental outreach programs as well. As a health care practitioner with a science-based outlook, however, I must accept the current evidence and realize that when I recommend brushing and flossing, it is for reasons other than caries and periodontal disease prevention. It’s tough to change a fundamental worldview like this, but change it I must.
That being said, I am still going to recommend that my patients brush and floss, and I’m pretty sure I will continue to brush and floss myself. Why? For one, it’s in our DNA. Just as salmon must return to their birth rivers to spawn, we dental professionals are compelled to drone on and on about brushing and flossing. We can’t help it. Second, floss is cheap, and there’s really no downside to doing it. Third, the reviews discussed above are statistical analyses, and despite the overall lack of proven efficacy on a population level, on an individual basis there will be people who may prevent disease by good oral hygiene practices. And finally, most people don’t want their mouths to taste and smell like the bottom of a birdcage. I will, however, make a point henceforth to not tell my patients that if they brush and floss more/better they won’t get as many cavities or have as many periodontal issues. Instead, I will focus on proven, science-based methods for disease prevention such as fluoride use, sealants when and where indicated, dietary counseling to reduce sugar consumption, smoking cessation to reduce periodontal disease risk, and the like.
But I digress
So now that we are all up to speed on flossing research, I’d like to turn my attention to how this research has been playing out in the lay press. As passionate as I am about a scientific worldview in medicine, dentistry, and practically all areas of life, I am equally passionate about science communication, science education, and science journalism. Having good scientific information is one thing; disseminating that information to the public (including policy makers as well as consumers) is another. Science communication is unfortunately all over the map quality wise. Science sections of newspapers and science editors in general are becoming dying breeds. For example, the above systematic reviews were reported in one notorious rag from the UK thus:
Flossing your teeth can be a waste of time – and do more HARM than good, leading dental expert claims!!
Pretty pathetic interpretation of the reports, in my opinion. Now, to be fair, the article itself isn’t too bad, but this headline is a travesty. Even the subheader says “Bad technique can push bacteria and plaque further into the gums” and “This can increase the risk of gum disease and cause painful damage.” Well no, not really, unless it is your habit to flog your gums like a rented mule.
Forbes, on the other hand, posted an accurate and humorous article entitled “Dentists Say You Need to Floss. Science Says You Don’t.” Excellent title, one I wish I would have thought of first. No sensationalism, no misleading headlines, just a well-written review of the material, as it should be.
I bring this up because I believe it is important to remain vigilant, not only in applying critical thinking and rationalism to the issues of the day, but also to note how that information is packaged and fed to the public. Often, people will not read past the headlines, and by contaminating good scientific information, these publications distort and mislead a public who needs high quality scientific information more than ever.
To floss, or not to floss? That is the question. Now that you are armed with the evidence, you can make the choice which is best for you. If you want to prevent tooth decay, you should focus on reducing your sugar intake, use a fluoridated toothpaste, and perhaps a fluoride mouth rinse. Whether you decide to floss or not depends on your desired outcome. For a fresh, debris-free mouth, yes, go ahead and floss away. If your desire is to prevent cavities or periodontitis, other methods are more effective.
Final note: I am deeply indebted to my friend Dr. Robert J. Weyant for his assistance and advice during my research for this blog post. Bob is a professor and associate dean for Dental Public Health and Community Outreach at the University of Pittsburgh School of Dental Medicine. He also is a longtime lecturer at the annual ADA Evidence-Based Dentistry Champion Conference, and is the host of the excellent ADA Science Podcast.

Dental Management Of Obstructive Sleep Apnea
Grant Ritchey on August 3, 2014
Link

[Editor’s Note: I’m pleased to announce that Grant Ritchey has agreed to join SBM as a regular. He’ll be writing about dental science and pseudoscience every four weeks on Sunday. (I swear, we’ll get up to seven day a week publishing if it kills me—or the other bloggers.) Grant will be starting with science, but I’m sure he’ll soon be discussing all the sorts of claims about dentistry and dental disease that are—how shall I put it?—less than science-based soon enough.]
Obstructive sleep apnea (OSA) is a sleep-related breathing disorder in which the airway is partially or completely blocked during sleep. Although little or no air is flowing, the person continues to attempt to breathe. Typically, cessations in breathing last longer than 10 seconds per episode, but can last over a minute and usually occur multiple times during sleep. This can lead to poor sleep quality and precipitous drops in blood oxygenation levels over an extended period of time. This potentially life-threatening condition is frighteningly prevalent, especially in adults over 40, and it is estimated that 80-90% of OSA goes undiagnosed, further compounding the problem.
When a person experiences multiple apneic episodes during the night, the brain responds by alerting the body, resulting in increased efforts to breathe, gasping, and arousal from sleep. These frequent waking events, combined with lowered oxygen levels, can lead to the signs, symptoms, and sequelae of obstructive sleep apnea. Typically, OSA sufferers snore loudly, then are silent for 10-30 seconds as the airway is blocked. This is followed by choking, snorting, or gasping sounds when their airway reopens.
This illustration shows the relationship between the oro-pharyngeal structures and the airway:
Signs and symptoms
According to the American Academy of Dental Sleep Medicine (AADSM) and others, the most common signs and symptoms of OSA are:
    • Unintentionally falling asleep during the day
    • General daytime sleepiness
    • Unrefreshed sleep
    • Fatigue
    • Insomnia
    • Waking from sleep with a choking sound or gasping for breath
    • Loud snoring
    • Bruxism (tooth grinding). This has been definitively shown in children; it is correlated in adults, but the literature is still inconclusive.
Prevalence
Data from the American Academy of Sleep Medicine (AASM) state:
    • OSA is most prevalent in middle aged and older individuals.
    • Approximately 2-5% of children exhibit OSA signs and symptoms, but it peaks at approximately 9% for girls and 7% for boys at around age 4 when the tonsils and adenoids are largest relative to head size.
    • Approximately 24% of men and 9% of women have obstructive sleep apnea.
As stated above, an estimated 80-90% of OSA remains undiagnosed. OSA in children is primarily due to enlarged tonsils and adenoids, which can impede air flow. As they mature, the tonsils and adenoids usually shrink in conjunction with the growth and development of the head and OSA rates plummet. In adults, sleep apnea is caused by other risk factors.
Risk factors
There are several risk factors that together or separately are predictive for sleep apnea. This list isn’t comprehensive, and a person may have several of these risk factors and not have OSA.
    • Overweight individuals
    • Men and women with large neck sizes (size 16-17 or larger)
    • Ethnic minorities
    • Children with enlarged tonsils and adenoids
    • Structural abnormalities of the head and neck (e.g. deviated septum)
    • Middle aged and older men; post-menopausal women
    • Smoking
    • People with a family history of OSA
    • People who suffer from allergies, rhinitis, and the like.
Diagnosis
The definitive diagnosis of obstructive sleep apnea is made on the basis of an overnight sleep study, monitored by a sleep technologist (when done in a sleep center) and interpreted by a sleep physician. The test, called a Polysomnogram, will chart a patient’s brain waves, heartbeat, and breathing during sleep. It also records arm and leg movements. Traditionally this has been in a sleep center (an “attended study”), but home sleep tests are becoming more common due to convenience and financial considerations. Of paramount importance is the total number of partial (hypopnea) or complete (apnea) cessation of breathing for greater than 10 seconds. Last, the sleep study will monitor the blood oxygen saturation level using a pulse oximeter.
Another thing a sleep physician will assess are any other medical considerations that may mimic or co-exist with OSA, including other sleep apneas (e.g. central sleep apnea, in which the cessation of breathing during sleep is due to a neurological problem, not an obstruction of the airway), medication side effects (many medications cause respiratory depression), substance abuse, or a mental illness (e.g. depression).
Once the sleep study is concluded, an index known as the Apnea Hypopnea Index (AHI), combined with the oxygen desaturation level, is created and a diagnosis is made. The number of apneas and hypopneas are averaged and a score is assigned. Roughly speaking, the classification is broken down as follows:
    • AHI < 5: Mild to no OSA
    • AHI 5-15: Mild OSA
    • AHI 15-30: Moderate OSA
    • AHI > 30: Severe OSA
Regarding oxygen saturation, at sea level normal waking blood oxygenation level is around 96-97%. This drops about 5% during sleep. Any blood oxygenation level under 90% is considered problematic; anything under 80% is considered severe.
Sequelae of obstructive sleep apnea
The following is a partial list of adverse effects of long-term OSA. When doctors start talking about the various issues associated with sleep apnea, it is tempting to assume that they think of OSA as a “One True Cause” of a plethora of illnesses. I assure you this isn’t the case. Just as a sedentary lifestyle can cause a breakdown in a wide ranging variety of body systems, so too can chronic hypoxia and interrupted sleep cycles. So please don’t read too much into it, but still appreciate the seriousness of the condition.
    • Increased heart rate – the lack of oxygen due to breathing cessation causes the heart to beat faster to supply oxygen to the body’s tissues.
    • Elevated blood pressure – the heart has to work harder to get oxygen to the tissues.
    • Increased risk of stroke and heart disease.
    • Impaired concentration and chronic drowsiness.
    • Reduced glucose tolerance and increased insulin resistance.
    • Mood changes, depression.
    • Disturbance of bed partner’s sleep cycle.
    • Erectile dysfunction.
    • Increased risk of motor vehicle accidents.
Treatment
After the proper diagnosis is made, OSA patients can be treated in various ways. The three broad classifications of treatment are:
PAP therapy: This has been the gold standard for treating OSA for over 30 years. PAP stands for “positive airway pressure” and it comes in many flavors, with the CPAP (continuous positive airway pressure) being the most popular and familiar. There are also BiPAP (bilevel positive airway pressure) and VPAP (variable positive airway pressure) machines, which deliver variable pressures of air. PAP therapy involves the delivery of pressurized air through a mask or nasal pillows in order to force the obstructed airway open to maintain adequate blood oxygenation throughout sleep. The advantages of PAP therapy are that there is a lot of good data attesting to its efficacy; the main disadvantage is that it is unwieldy and uncomfortable to wear and operate for most people.
Dental appliance therapy: Oral appliances can be used in many cases of mild to moderate OSA, and in severe cases where the patient is intolerant to PAP therapy. There are many makes and models of appliances, but the vast majority of them are variations on a theme in which upper and lower rigid mouthguards are worn which keep the mandible (lower jaw) postured forward in order to open the airway (see diagram below). I will discuss them in more depth later, but the main advantages of oral appliances are that they are more easily tolerated than PAP machines and are more convenient, especially when traveling. The disadvantages include they are not 100% effective, especially in more severe cases, and in some instances they can be uncomfortable to wear.
Surgery: Not used as often as the other two, there are different surgical techniques employed to open the airway. The most common is the uvulopalatopharyngoplasty (UPPP), in which excess tissue in the throat is removed, widening the airway space. Jokingly referred to as the “Roto-Rooter” approach, it is a fairly aggressive and uncomfortable procedure, and its success rate is marginal at best. Nasal surgeries to correct a deviated septum, genioplasty (tongue reduction), tracheostomy, orthognathic surgery (jaw advancement), and others are also employed. The main advantage of surgery is that it is permanent when successful, and the patient often doesn’t have to be married to a PAP machine or oral appliance for life. The disadvantages are obvious: surgeries are costly, can be risky, uncomfortable, and there is the potential of post-operative complications. Moreover, the efficacy and success rate for most surgeries pale in comparison to the other two alternatives, with the exception of the tracheostomy, which bypasses the obstruction altogether.
In children who are diagnosed with OSA, the removal of tonsils and/or adenoids is usually sufficient to treat the apnea. In the past tonsils and adenoids were usually removed only in cases of persistent infections, but fortunately pediatricians and otolaryngologists (ENTs) recognize the importance of managing children’s airways, even in the absence of infection.
Adjunctive therapies: There are other measures an OSA sufferer can take to help reduce the severity of their disease. In rare cases, the apnea may resolve completely after trying them. Among these therapies are losing weight, training oneself not to sleep on one’s back, medications for allergies, and others. One caveat is that there are many scam therapies out there that should be avoided: acupuncture, herbal remedies, and most of the other CAM therapies that promise to cure everything but don’t have any evidence to support their claims are foisted upon an unsuspecting public. Over the counter appliances are sold at retail stores, online, and on late night TV shows. They are usually marketed as “anti-snoring” devices because they cannot claim to treat an illness or disease, but don’t be fooled. Without a medical diagnosis and proper follow-up, it is impossible to determine if the person indeed has OSA, and if so, if the appliance is effective. Just because the snoring goes away, that doesn’t mean the apnea is gone. And no, I’m not a shill for Big Sleep. You get what you pay for.
More about dental management of obstructive sleep apnea
OK, now you’re a pseudo-expert on OSA, what the signs and symptoms are, how it’s diagnosed, and treatment options. Now I’d like to delve a little deeper into what “sleep dentists” do (note: sleep dentistry is only a special area of interest of some dentists, not a recognized specialty). Of course, as mentioned above, it all starts with a referral to a sleep center where a sleep study under the supervision of a physician is done and a diagnosis made. If the patient does not want to try PAP therapy, or if he or she has tried PAP therapy and found it to be intolerable, an oral appliance may be just what they need.
After an appropriate taking of a medical and dental history, an exam is performed to check for dental pathology or other issues. The polysomnogram is reviewed by the dentist, the patient is informed of the risks and benefits of treatment, and consent is given. The dentist will then take impressions of the upper and lower teeth, as well as registering the proposed initial jaw position so that the laboratory can properly fabricate the appliance. The models are then sent to the laboratory and are ready about 2-3 weeks later. When it returns, it is fitted properly to the patient and instructions are given. A follow-up study is performed (the patient is instructed to calibrate the appliance themselves, looking for silence and an improvement in fatigue), either at a sleep center or (as is more frequently happening) with a home sleep test to confirm that the appliance is effective. If it doesn’t resolve the apnea, the patient returns to the dental office for a reevaluation, and the appliance is adjusted to move the mandible further forward. At some point, a position is determined where the apnea is controlled and the patient is comfortable with the appliance.
I know what you’re thinking. What does that thing look like? The following illustration shows a representative appliance called a Somnodent (By way of disclosure, I have no financial interest in any product I discuss).
As you can see, this appliance fits over the upper and lower teeth. The “wings” on the lower appliance contact the upper extensions, which keep the lower jaw forward to maintain an open airway. There is a screw on each side that can be adjusted to bring the jaw further forward if necessary. After wearing the appliance for a while, the appliance is adjusted and calibrated, moving the jaw forward only as far as necessary to stop the apnea. Other proprietary appliances on the market have an adjustable “strut” connecting the upper and lower members, but the principle is the same for all of them.
Conclusion
Dentists can play a major role in the management of obstructive sleep apnea. We work in conjunction with sleep physicians and technicians to find the most successful means to control a patient’s OSA. Oral appliances have been shown to be very effective when used properly in the appropriate cases. They are not panaceas, however. In many cases, PAP therapy remains the treatment of choice. To learn more about OSA, follow the links given earlier in this post for the dental and medical sleep apnea organizations. In a recent podcast, I interviewed a prominent sleep dentist (Shameless Plug here), who goes into more detail than I was able to in this blog post.
Sweet dreams!

The Frenetic Frenum Freeing Frenzy
What problems do tongue-ties cause? Do all of them need to be clipped?
Grant Ritchey on August 20, 2021
Link

The human mouth is weird and wonderful. Known in Ancient Times as “The Gateway to the Soul”,1 the oral cavity serves many roles. The teeth chew our food and aids in digestion. The saliva buffers harmful acids, contains antibodies to help control harmful oral pathogens, and is chock-full of enzymes which begin the digestive process. The tongue is a keen sensory organ, full of taste buds and sensory nerves, to not only provide enjoyment from food and drink, but to also warn us against ingesting potentially toxic substances. Our tonsils stand as sentinels against antigenic invaders, mounting robust antibody responses before they can penetrate the body further. The mouth is the starting point of the alimentary canal, and the digestive tract could not function without it. Last, the mouth is an emotive and expressive feature, revealing our feelings through smiles, frowns, grimaces, and yawns.
While each of these facets of our oral anatomy deserve much attention and glory, I want to focus on an oft-neglected, yet very important structure- the humble frenum (plural frena). (Note: many people call it a “frenulum;” the two terms are identical and interchangeable. Potatum-Potatulum.) A frenum is described as a membranous fold of skin or mucous membrane that supports or restricts the movement of a part or organ, and is derived from the Latin word for “bridle”. There are several frena in the mouth; notably the lingual frenum, which is the band of tissue that you see when you lift up your tongue, and the labial frena, the most notable of which are located in front of your central incisor teeth when you pull your lips out and away from your teeth.
For most of us, these harmless little mouthstrings cause no problems at all, save for the occasional poke with a Dorito which can really smart. However, there are a few potential issues that overzealous frena can cause that I want to discuss. Moreover, the issues I will cover are often overdiagnosed and overtreated; thus care must be taken to determine the proper indications, prognoses, and potential sequelae for any proposed treatment.
We’ll examine the three most common frenal problems, the treatments, and review the quality of the evidence behind these treatments.
Maxillary labial frenum
Perhaps the most common of the frenalopathies2 involves the maxillary labial frenum, which is easily seen if you pull your upper lip up. When there is a prominent frenum which attaches low on the gingiva (gums) between the two front teeth, the resulting pull on that area can cause the front teeth to separate, creating a diastema, or gap (see photo below).
If the space is less than 2 millimeters, it often will close spontaneously as a child reaches adolescence, due to the eruption of permanent teeth as well as an upward (superior) migration of the frenal attachment. In these cases, no treatment is usually necessary. However, when the space is wider than 2 millimeters and/or the band of tissue is thick and fibrous, the space likely will not close spontaneously. Moreover, if the space is closed orthodontically, it is not uncommon for the space to reopen due to the pull of the frenum on the connective tissue fibers surrounding the teeth. In this situation, surgical intervention is indicated, and the frenum is clipped or, if necessary, the entire frenum is removed.
At this point, a digression is in order so that I may describe the treatments for the conditions described here. In short, all treatment involves some sort of cutting/excising of the frenum with an instrument: a metal blade (generally a scalpel or surgical scissors), electrosurgery, or laser. There are three general procedures:
     1.  Frenectomy: excision of the frenum left to heal by secondary intention (i.e. not sutured).
     2.  Frenotomy: simple cutting or incision of the frenum.
     3.  Frenuloplasty: excisions involving sutures releasing the frenum and correcting the anatomic situation.
Other, less common dental indications for maxillary frenum surgery would be if the frenum prevented a denture from fitting properly.
Mandibular labial frenum
Unlike the upper teeth, on the lower teeth, excessive pull by the frenum typically doesn’t cause spacing between the central incisors, but instead can cause severe gingival recession, which can lead to bone loss around the teeth and even tooth loss. It has been claimed that a strong frenum is a risk factor for tooth decay, but the evidence for this is weak. When the recession is only slight, a simple frenectomy is usually the treatment of choice; however in more severe cases, a frenuloplasty followed by a gingival graft to replace the lost tissue is often required (see before and after photos).
Lingual frenum
When the lingual frenum is mispositioned, it can restrict the mobility of the tongue. This is known as ankyloglossia, or “tongue-tie” Like with the other frena, this usually doesn’t cause any problems whatsoever; however, in more pronounced cases, it can have an effect on breastfeeding, speech, and jaw development and tooth position.
Breastfeeding – I’m just a dentist, not a pediatrician or Lactation Consultant, so I’m not going to weigh in too much on the indications for frenotomies on lingual frena. In some cases, the restriction of the infant’s tongue can reduce the quality of attachment to the breast or bottle as well as having a negative effect on swallowing. When this occurs, a quick and simple frenotomy (typically a quick snip with the scissors) does the trick, and the babe is back in the game. There is an excellent review examining the relationship between ankyloglossia and breastfeeding, which you can read here.
Speech – I’m just a dentist, not a speech pathologist, so I’m not going to weigh in too much on the role tongue-ties plays in speech. That said, the research is all over the map – some papers claiming that children with significant tongue ties have speech articulation issues than those who don’t, others claim little correlation, as the perception of speech articulation problems is highly subjective, and speech therapy is almost always done in conjunction with surgical correction, so benefits are difficult to ascribe.
Orthodontics – I’m just a dentist, not a…wait! I can actually field this one. Many dentists and orthodontists claim that ankyloglossia can adversely affect the growth of the mandible and cause shifting of the lower teeth, resulting in the need for orthodontic intervention, and there is some evidence that this is true. However, normal growth and development of the upper and lower jaws usually occurs in the presence of a tongue-tie, so the recommendation of surgical correction in conjunction with orthodontic treatment must be carefully weighed.
Other dental problems – Many dentists claim that tongue-ties in adulthood can cause such diverse issues as TMJ problems, headaches (including migraines), sleep apnea, “chronic fatigue”, speech issues, and many others. The scientific literature does not support any of these claims to a significant degree.
Fuzzy areas
Sadly, like with any medical or dental procedure, there is a risk of either outright fraudulent recommendations being made, or more commonly well-meaning practitioners who believe they are helping their patients, but are performing services that aren’t supported by the scientific evidence. When the patient is an infant or child, of course the parent wants to do almost anything and everything to help them, and are thus in a vulnerable position. There has been a tremendous uptick of frenum related diagnoses, especially in the dental and ENT communities. Weekend training courses in surgical correction of these disorders are everywhere, often sponsored by laser companies who claim that these “profit centers” will increase the practitioners income and will help the fancy expensive laser “pay for itself”. It can seem that in these cases, the indication for surgical correction of a frenum is the presence of a frenum. While the risks of these procedures are very low, they aren’t zero and they aren’t cheap. Recently, the concept of the “posterior tongue-tie” which is not due to a frenum at all, but merely the presence of a tight band of collagen fibers under the tongue which can’t be seen, only palpated. There is an ongoing debate in professional circles about whether this is even an anatomical or structural anomaly at all, and if so, what problems does it cause (and how). Without better research, it sounds a bit dodgy to me.
Conclusion: A real problem with fake solutions
Ankyloglossia and other aberrant frenum attachment issues are real and can have real consequences if not managed properly. However, with the significant rise in case diagnoses, as well as the number of health care professionals who are promoting treatments (which usually are not covered by insurance), one must be on guard and make sure that the decisions made are science based.

Footnotes:
     1.  No it wasn’t. I made that up.
I made that word up too.

Dr. David Villarreal’s “Holistic Dentistry:” Full of Holes?
Harriet Hall on April 21, 2015
Link


I get a lot of e-mails from publicists offering suggestions for articles and interviews with their clients. I quickly delete most of them, but one recently caught my eye. It said that patients travel from as far as Europe and Africa to have California “holistic dentist” Dr. David Villarreal remove the old silver fillings that are damaging their health. He has removed 20,000 of them in his 30-year career; removing fillings accounts for 75% of his practice. It said your dental fillings could be killing you – and not just the mercury in your “silver” fillings. Dr. Villarreal says that filling materials that are not compatible with your particular body chemistry can suppress immune responses, leading to a host of illnesses from frequent colds to autoimmune diseases to far worse conditions. He performs a blood compatibility evaluation to pick the right material for your body. He picks the right composite to maintain optimum health and help heal the immune system.
He says amalgam fillings are 50% mercury, the most toxic non-radioactive element on earth, more toxic than lead, arsenic or cadmium. He says heavy metal poisoning has been linked to MS, ALS, chronic fatigue, fibromyalgia, lupus, Parkinson’s, arthritis and many other autoimmune diseases. He says most European countries banned mercury fillings almost 40 years ago.
I’d heard similar criticisms of amalgam fillings before, but what really caught my attention was the description of his filling removal process. He wears special protective gear including a gas mask, and uses a special suction system, an ionizer in the room, and a mercury separator to ensure none gets into water systems or oceans. He drapes the patient, provides protective eyewear, and uses extra protective covering in the patient’s mouth. In addition to all that, a naturopathic doctor is on hand to administer intravenous vitamin C in order to help pull the heavy metals out of the system so they can exit the body as waste. This offsets any possible negative health consequences or withdrawal symptoms that may arise from the extraction of the heavy metals from the system. He practices “ozone dentistry,” purifying and sterilizing the tooth so it can be filled with a more healthful alternative. He says his patients report back that they have seen significant overall health benefits and often the elimination of specific conditions that they didn’t perceive were related to their teeth at all.
More information from his website
I didn’t know of any scientific evidence that would support his beliefs and practice methods. I went to his website, BioDental Healing, hoping to find out more. I didn’t find even a shred of evidence there. But I did find a few other things.
I found that he is a disciple of the late Hal Huggins, a notorious crusader against mercury fillings and root canals who believed mercury amalgams were responsible for a wide variety of ills (from mononucleosis to leukemia) and made extravagant claims for his methods (he got wheelchair-bound MS patients up and walking by fixing their teeth!). Huggins lost his license for gross negligence and the use of unnecessary and unproven procedures.
I found that he provides nutritional counseling.
I found that his clinic offers acupressure massage and other massage therapies to “help heal the disharmonies between internal organs and blockage to the circulation of Chi, or energy, through meridians.”
I found that he is the founder and formulator of an all-natural whitening toothpaste and mouth rinse line, called Estrella (the Spanish word for star).
The Meridian Tooth Chart
And then I found something that almost made me fall out of my chair: the Meridian Tooth Chart on his website. It explains that every tooth is related to an acupuncture meridian, which is connected to other parts of the body through an “energy highway.” This connection “is so apparent that an experienced dentist can often assess your overall health and wellness by reviewing your dental condition. If a person has a weak internal organ, the condition of the associated meridian tooth could make it considerably more problematic.”
The chart has two interactive features:
Click on an organ, for example the pancreas, and you will learn that it is related to teeth 2,3,5,12,21,22,27, 28, and 29. The “organ” bile ducts is related to teeth 11 and 22.
Click on a tooth, say the right front incisor, and you will see that it is related to:
    • Specific organs: kidneys, bladder, urogenital
    • Glands: pineal and epididymis (Is the epididymis a gland?)
    • Spine and spinal cord segments: L2,3, S3,4,5, coccyx
    • Sense organs: frontal sinus (Are the sinuses sense organs?)
    • Musculature: lower extremities
    • Joints: foot, sacrum and coccyx, knee (posterior)
    • Other relationships: conceptual connections, mental dynamics, vitality, hormonal capacity, emotional disturbances, impotence, sterility, creative genetic world (what do you suppose that means?), fear, sadness, instability, kidney functions, anger, depression, and moodiness.
Incidentally, an article on the DentalWatch website highlights the absurdity of these meridian charts. The author found more than 50 different versions on the Internet.
How do they know?
I wondered how the developers of the Meridian Tooth Chart figured out all those relationships. I e-mailed the BioDental Healing website to inquire. And I also asked them to identify some of the “many European countries” that supposedly banned mercury fillings 40 years ago. My own understanding, from information I found on the Internet, is that they are still in use throughout Europe. A European commission only very recently recommended phasing them out and suggested that a ban would be one way to reduce total environmental mercury exposure. Subsequently two countries, Norway and Sweden, introduced legislation that would ban mercury fillings, but that was for environmental reasons rather than because of any danger to patients from fillings.
They answered my questions about meridians with a link to a PDF filled with discussions of “energy”, ancient Chinese wisdom, and the activities of Reinhard Voll, a German doctor and engineer known for his development of Electroacupunture of Voll (the basis of a number of bogus devices that I have written about previously). To the skeptical eye, it is self-explanatory. It doesn’t even mention teeth!
Regarding the banning of mercury amalgams, they sent two articles, one a press release, the second an article from the notoriously unreliable Mercola.com. These sources say mercury fillings were banned in three (not “most”) European countries in 2008 (not 40 years ago).
I kept trying to pin them down. They finally admitted the 40 year claim was wrong; they said they were checking with their publicist as to why that claim was released and would get it re-worded to “a few countries.” My requests for information about the meridian tooth chart were first answered by links to copies of the chart on other websites, and eventually they admitted that there was nothing “scientific” about the meridian tooth chart but denied that they had ever claimed there was. Their excuse:
Our office has been careful to state that it is an alternative point of view and it is not scientific nor do we aim that it is a diagnostic tool. I have overheard the dentist state that the chart is a concept based on traditional Chinese acupuncture points.
Conclusion
One undeniably true statement on the BioDental Healing website is “we practice a type of unconventional dentistry.” Conventional dentistry is conventional for a very good reason: scientific evidence is the best guide to reality. Quackwatch recommends “Stay Away from ‘Holistic’ and ‘Biological’ Dentists.” I do too. I’m not going to provide a detailed critique of Dr. Villarreal’s beliefs and practices, because I would have to bite my tongue into bloody shreds to talk about it without using words I might regret. I think BioDental’s own words speak volumes, and I will leave it to my readers to check out the evidence for themselves.

Cranial Osteopathy in Dentistry
Grant Ritchey on October 17, 2011
Link
Editor’s note: Having just submitted a major grant on Friday and then having had to turn around and head to an NIH study section meeting today in Bethesda, I just didn’t have the time to produce something up to the usual standards of SBM for today. (And, being managing editor, I should know what’s up to the usual standards of SBM; what I started to write wasn’t it. Trust me on this.) Fortunately, Dr. Grant Ritchey and Dr. Steve Hendry, two skeptical, science-based dentists, did submit something up to SBM’s usual standards. Even better, since we’ve been having a number of requests for posts involving dentistry, it seemed like a perfect time to publish their first contribution to SBM and see how our readers like it. Maybe next time around, I’ll have them update the “state of knowledge” regarding amalgams.
Form follows function, as the old saying goes. Nowhere in the human body is this adage more fitting than in the oral cavity.  In less than two generations, the practice of dentistry has evolved from basic pain relief and function-based procedures (such as extractions and fillings), into today’s practices of complex cosmetic rehabilitation, orthopedic and orthodontic management of the teeth, jaws, and facial structures, replacing missing teeth with dental implants, and treatment of sleep apnea and temporomandibular joint (TMJ) disorders, to name but a few.   With such rapid progress, it is to be expected that for every science based advance made in our field, there are just as many claims that are either dubious in their evidential support or outright pseudo-scientific or anti-scientific nonsense.
In this article, we’ll be taking a look at the roles that health care practitioners such as chiropractors, osteopathic physicians, and physical therapists, are attempting to play in the dental field.  We will also see how well-meaning dentists have been trained in and apply their pseudo-scientific principles in their dental practices. In particular, we’ll be examining Cranial Osteopathy (also known as Craniosacral Therapy or Cranial Therapy) in the management of the dental patient, the purported benefits claimed by practitioners of cranial osteopathy, and the quality and quantity of evidence for this type of treatment in the scientific literature.
Basic Skull Anatomy
The human skull is made up of some eight cranial (head) bones and fourteen facial bones.  These bones help protect the organs of vision, hearing, taste, equilibrium, and smell. They also provide attachment for muscles that move the head, control facial expressions and chew our food.  At birth, the spaces between the cranial bones- called fontanelles – are wider and more elastic, allowing the infant to pass through the birth canal and later permitting brain growth in the first few years of life.  In humans the lateral fontanelles close soon after birth, the posterior fontanelle generally closes several months later, and the anterior fontanelle may remain open for three years.
By early childhood, the cranial bones become tightly interlocked in a zig-zag, zipper like pattern (illustrated nicely here) that renders them immovable in a macroscopic sense, although each suture (called a synarthrosis if you want to impress your friends at parties) has a very slight amount of flexibility- 10-30 micrometers on average (1 micrometer = 1/1000th of a millimeter or approximately 4/100,000ths of an inch).  These sutures fill the minuscule space between the cranial bones, essentially stitching them together with dense, strong connective tissue fibers called Sharpey’s fibers.
Tenets and Scope of Cranial Osteopathy
Cranial Osteopathy was invented by William G. Sutherland D.O. around 1900 when, while viewing a disarticulated human skull, he noted the way some of the skull bones were:  “…beveled… like the gills of a fish… indicating articular mobility… for a respiratory mechanism.”   Note that we said “invented” rather than “discovered,” as this discipline was indeed invented from whole cloth, based upon the happenstance similarity in the appearance of a skull bone and the gills of a fish, which he then superimposed on his 19th century osteopathic ideology.  (Imagine what he would have come up with had he instead noted the similarity between the uvula and the male genitalia!)  Sutherland claimed, and adherents of Cranial Osteopathy hold, that the cerebrospinal fluid (CSF) has an inherent rhythmicity, which he likened to the tides of the ocean.  He called this the “Primary Respiratory Mechanism (PRM)”, often referred to today as “Craniosacral Rhythms.”  According to Osteopathic principles, the PRM underlies all of life’s processes and begets vitality, form, and substance to all of a person’s anatomy and physiological processes.  Any disturbance in the natural flow of CSF could cause illness and conversely, practically any illness could be prevented or cured by the physical manipulation of the cranial bones, “freeing up” the functional flow of the CSF.   Towards the latter part of his life, Sutherland believed that he could sense a “power” which allowed corrections to occur from inside his patients’ bodies without having to provide any physical manipulations.  This has come to be known as “biodynamic craniosacral therapy” or “biodynamic osteopathy”.  See this overview of the scope of Cranial Osteopathy (“The Cranial Concept”) in their own words.
Of course, none of this imagery would be of any use without a therapy to sell, and osteopaths assert that they can fix what ails you through hands-on manipulation of your skull bones. As one practitioner’s website puts it:  “As incredible as this may seem, we feel the bones move, the membranes pull, the fluids fluctuate, and even the brain undulate”.  And woe unto the poor sap who suffers from a rigid-boned, lax-membraned, fluid stasisy, un-undulating brain!  Practitioners of Craniosacral Therapy or Cranial Osteopathy claim that they can detect this secondary CSF pulse with simple palpation and distinguish them from a regular vascular pulse.
Cranial manipulations are performed in a variety of different ways depending upon the condition being treated and the philosophy and training of the practitioner.  (See an overview of some of the techniques.)  Some of them include range of motion therapies similar to what a physical therapist would do; others involve the supposed manipulation and movement of the cranial bones, using only digital (i.e. finger) pressure with a very light force.
The Cranial Osteopathic Academy, a component society of The American Academy of Osteopathy (AAO), described it thus:
Treatment is typically very gentle. Tissues are supported and allowed to change. Usually very little force is used during treatment, but at times some force may be necessary. Diagnosis and Treatment are said to blend into one another. As tissues change the physician learns more about their nature. As the nature of the tissue dysfunction is better understood, the therapeutic response deepens.
Each patient’s experience is unique. Some patients sense only a gentle touch, while others feel their body change immediately. Some patients simply feel a deep sense of relaxation, and others feel nothing at all. Most patients feel a distinct change following the treatment.
Though Cranial Osteopathy is very gentle, patients can occasionally experience some discomfort during certain stages of the treatment. When this occurs, it is simply a part of the healing process. As the treatment progresses, the discomfort subsides.
Although physicians practicing Osteopathy in the Cranial Field will work anywhere on the body, they may find it important to diagnose and treat the head. Though styles of treatment may vary, the osteopathic physician will primarily focus on the body’s “mechanism” – the body’s natural striving for health and normal function.
According to Dr.Sutherland, within each patient there is great wisdom, an inner physician, a wise all-knowing force that is the source of all healing. In his own words: “Allow physiologic function to express its own unerring potency rather than apply blind force from without.”
Cranial Osteopathy and its variants make a number of imaginative leaps from histological starting points to therapeutic endpoints.  From the slight (micrometer) flexibility of cranial sutures, and the slight-but-measurable fluctuation in CSF pressures, practitioners infer that the brain and spinal cord undulate rhythmically “like a jelly fish, coiling and uncoiling” which is critical for health.
Dental Applications of Cranial Osteopathy
Gradual movement of teeth within bones, and gradual orthopedic movement of facial bones themselves, are familiar to all dentists who do orthodontics.  Dentists performing orthodontic treatment utilize various appliances to expand the palate (palatal sutures don’t normally fuse until adolescence) and move teeth within the jawbones.  Further, the treatment of TMJ disorders has typically been in the realm of the dentist, involves the articulation of cranial bones in the scope of treatment (the mandible and the temporal bone), so the Osteopathy belief system would seem a natural fit to dentistry, especially in these areas.  And sure enough, Osteopathy has colonized the dental profession. We’ve seen expensive dental continuing education courses with “Cranio-”, “Sacro Occipital Therapy” and “Chiro-” in their names that graft Osteopathic principles onto dentistry to create whole new, untapped disciplines to market.
Websites promoting these dental applications of Cranial Osteopathy claim to teach amazing new skills to dentists, including how to “free up” and move facial bones around, by hand, in minutes using only fingertip pressure.   Additionally, in almost every case, these dental courses provide a gateway to other, more garden variety forms of CAM: nutritional supplements, detox, immune system boosting,  nervous system balancing, and so forth. For the dentist, taking one of these courses is the first step in going “down a rabbit hole” into CAM-land – a metaphor that devotees enthusiastically embrace and frequently use.
An important point to reiterate here is that the emphasis in the dental application of cranial osteopathy is not merely to treat illness or facilitate the flow of the CSF as in “regular” osteopathy; it claims to actually bodily move the facial and cranial bones to more ideal positions to improve orthodontic and TMD outcomes.  Cases are shown where overall changes in facial structure and the occlusion (i.e. the bite) are alleged to have been changed by as much as a half of an inch or more by cranial manipulation alone.  Of course, these are case studies with little to no supplementary documentation (radiographs, CT scans, etc.) available for an objective reviewer to confirm the claims. We have yet to see a well-documented, objectively presented case study in the medical or dental literature which adequately demonstrates the validity of the treating practitioner’s claims, although one would think that after decades of the existence of their treatment modalities, such evidence would be plentiful, substantive, and readily accessible to the health care community.
Credibility as a Dental Treatment
For Cranial Osteopathy to be viable treatment, there needs to be good evidence anatomically and histologically that the sutures are indeed movable (by hand, no less) to a significant degree, and evidence that doing so is therapeutically beneficial.   Neither appears to exist. Although Cranial Osteopathy can provide a modicum of basic research to support its claims, it falls far short of what is needed to establish a scientific foothold in the dental-medical community. Osteopathic applications are woefully lacking in any substantive research but instead rely on anecdotal evidence as the foundation of its validity and applicability.  See the excellent overview of Cranial Therapy at Quackwatch.org.
Evaluating the literature, minute movements of the cranial bones appear to be possible (in the micrometer range as stated above) — but not the large rearrangements of bones that practitioners claim to make with hands-on manipulation.  It is dubious that a practitioner can feel distortions in cranial bones that the most sensitive neurophysiological instruments cannot.
Moreover, even if an Osteopathic therapist could detect abnormalities in the skull, there appears to be no credible evidence linking small movements at cranial sutures to beneficial health outcomes.  As a scientific principle, this is nothing more than wishful thinking and resembles faith healing more than evidence based medicine. The therapeutic claims, research protocols, treatment goals, and definitions of what constitutes solid medical evidence are as flexible as the cranial bones they purport to manipulate.
Cranial Osteopathic adherents predictably scold their critics as being closed-minded and unwilling to learn, or worse, a shill for the Dental Industrial Complex.  But we like the old adage about staying open-minded, but not so open that your brain falls out.  The really surprising (and disturbing) thing to us is the number of bright, conscientious, and highly-trained dentists we see being drawn to courses in Cranial Osteopathy, and in many cases buying into the smorgasbord of alternate-medicine courses offered as side dishes at the cranio-dental table. If there’s harm in the Cranio-dental movement, besides a lot of money wasted by dentists on dubious courses and by patients on dubious treatment, it may be that it seems to be a particularly attractive gateway to more bizarre alternate treatment philosophies – one that seems to appeal to surprisingly smart and educated dentists.   By granting dentists a license to practice, the public trusts us to apply evidential knowledge to the management of their dental problems. This implies that we must critically examine new hypotheses, decide if there is rational evidence for them, reject the pseudo-science, and apply the knowledge that sifts through for the benefit of the patients we serve.
Post Script:  This is our first article in what we hope will be many to come on dental-related topics.  We would love to hear from you, the fine readers of the Science Based Medicine Blog.  If there are topics you would like to see addressed, or if you have any questions, comments, or critiques, please feel free to email us.

(Dys-)Functional Medicine Comes to Dentistry
Grant Ritchey on August 28, 2015
Link


The great philosopher Deepak Chopra wrote: “I do not believe in meaningless coincidences. I believe every coincidence is a message, a clue about a particular facet of our lives that requires our attention.” So when SBM author extraordinaire Jann Bellamy emailed me last week with an article about so-called “Functional Dentistry” with the comment “Blog fodder?”, I looked it over with interest and then promptly filed it away in my brain along with other things that I might get around to doing but probably won’t. The very next day, Dr. Clay Jones – also an SBM bloggist extraordinaire – asked me if I’d mind pinch-hitting and write a blog post for his upcoming Friday morning time slot while he was away on vacation.
Coincidence?
Personally, I find it more plausible that Jann and Clay secretly conspired to have me write this article in order to lure me into a rage spiral, than the notion that The Universe was sending me a message about a particular facet of my life that required my attention. But we are at Point B now, are we not? Regardless of whether the first domino was pushed by The Universe or by Jann and Clay, I suppose it is now incumbent upon me to share with the SBM readership yet another way where pseudo-scientific practices and deceptive branding and marketing tactics have trickled down from medicine into dentistry.
In this blog post, I will review what Functional Medicine (FM) is, what is wrong about it and what is right about it (yes, there are aspects of FM that are legitimate, if not admirable), and how it has infiltrated (some say contaminated) the field of dentistry. I think you’ll find that, when you pull back the curtains, the reality of FM as a “new and improved” medical/dental paradigm is vastly embellished and overstated, and the Great and Powerful Functional Medicine Oz is really just an old geezer pulling the levers of spin and hyperbole and pushing the buttons of pseudo-science.
What is Functional Medicine?
Functional Medicine, according to the Institute for Functional Medicine’s website:
addresses the underlying causes of disease, using a systems-oriented approach and engaging both patient and practitioner in a therapeutic partnership. It is an evolution in the practice of medicine that better addresses the healthcare needs of the 21st century. By shifting the traditional disease-centered focus of medical practice to a more patient-centered approach, functional medicine addresses the whole person, not just an isolated set of symptoms. Functional medicine practitioners spend time with their patients, listening to their histories and looking at the interactions among genetic, environmental, and lifestyle factors that can influence long-term health and complex, chronic disease.
Functional Medicine has been covered thoroughly in SBM by the late Wally Sampson, and the not yet late David Gorski and Steve Novella, among others; consequently, I need not delve too deeply into it here. However, a cursory unpacking of the above definition reveals a recurring logical fallacy, namely the Unstated Major Premise or Unstated Assumption. When it is claimed that FM “…addresses the underlying causes of disease,” or “Functional medicine practitioners spend time with their patients, listening to their histories and looking at the interactions among genetic, environmental, and lifestyle factors that can influence long-term health and complex, chronic disease,” the unstated premise is that “regular” doctors don’t do any of these things; they must be only symptom-oriented, not preventive in their outlook, and don’t take all of a patient’s personal, medical, and social factors into consideration before arriving at an invidualized course of action. This, of course, is false, and is what any good physician will do. I know mine does, and he does not identify as a Functional Medicine physician. This dubious technique is employed by most if not all CAM providers in an attempt to set themselves apart from the crowd.
Where does FM get it right?
Where FM gets it right is that, from all appearances, FM physicians as a whole tend to leave more appointment time for the history and physical exams, and claim to do a more thorough genetic, environmental, and lifestyle evaluation of their patients than a typical primary care physician. Functional Medicine practitioners emphasize healthy lifestyles, good nutrition, exercise, good sleep habits, smoking cessation, and so on, in addition to the normal comprehensive physical examination and lab tests, which is a good thing. This, of course, typically comes at a cost, as FM patients often (but not always) have higher out of pocket co-payments due to some tests and fees not being covered by medical insurance. However, patients state that they feel they are heard by their FM health care team, and the chances of some illness or condition being overlooked potentially could be reduced with the extra time spent and tests performed (although this hasn’t been demonstrated). Patients don’t want to wait hours in their “regular” doctor’s reception room, only to feel as though they are herded like cattle into cold examination rooms, then to wait another eternity until their nurse or physician gives them the proverbial seven minutes of their time before scribbling out a prescription that treats a symptom only. And while I hope you see through my above Straw Man scenario, you can see where the perception of individualized, caring medicine would be appealing to a significant percentage of the population, particularly those who are proactive and preventive in their health care decisions, those who may have a mistrust of “mainstream” medicine, and the worried well.
They are also right when they point out that the incidences of chronic diseases (such as cancer, heart disease, diabetes) have risen and that the health care costs associated with these diseases are burdening health care systems in many nations. Further, many if not most of these chronic disease are lifestyle related (smoking, poor sleep hygiene, sedentary habits, poor diet, etc.) and are thus preventable. Again, this is just good medical practice, and not a recent innovation of Functional Doctors.
Another area where FM is winning in the marketplace of perception and image is that they have branded themselves as progressive, a new paradigm in medicine. They throw around such enticing buzz- words and phrases as “powerful new operating system”, “empowerment”, “biochemical individuality”, “high touch/high tech”, et. al. while demonizing “conventional” medicine by describing it as “doctor centered”, “disease oriented”, “expensive”, and an “acute care model.” This message is indeed powerful, and has resulted in the integration (pardon the pun) of FM into such esteemed institutions as The Cleveland Clinic and George Washington University, and others. Even in my neck of the woods, The University of Kansas Medical Center has an Integrative Medicine department, where they boast of such quackery as vitamin C infusions and neurofeedback, the latter of which promises to “rebalance your brain.” Yes, those exact words are on the official University of Kansas Medical Center website. Sigh. Well, at least my alma mater still has the best college basketball program in the world.
What is wrong with Functional Medicine?
What is wrong with Functional Medicine is that it often promotes many CAM practices which have been shown to be of questionable therapeutic value, or outright ineffective. Reiki, acupuncture, chiropractic adjustments, “detoxification” programs, the aforementioned vitamin C infusions (unless you’re a bescurvied 18th century sailor fresh off the boat), and many other CAM modalities are offered as “holistic patient centered” options (again, at a significant cost and not without risk). Individualized care based on biochemical and genetic markers have some merit in some situations, and I’ve no doubt that this will become more prevalent in the future as techniques improve and applications are demonstrated scientifically. For now, however, it is an idea whose time has not yet come on a broad scale, and it is disingenuous to state or imply otherwise.
The other area where FM is a bit misleading is in how they frame their message. As stated earlier, the concepts of treating the cause of disease instead of just the symptoms is the foundational basis of all health care. I’m sure that Mark Crislip, an infectious disease doc, actually tries to kill the bugs that cause his patients’ diseases; he doesn’t just treat the symptoms. Often, however, treating the cause isn’t possible. For example, with many auto-immune diseases, there is no cure for the underlying pathophysiology, therefore managing the patient symptomatically is the best modern medicine can do at the present time. Using deceptive rhetoric and logical fallacies to their advantage, they frame FM as cutting edge and (ironically) science based, while portraying the mainstream medical community as closed minded, archaic, and behind the times.
Functional Dentistry – Coming to a theatre near you
Not wanting to feel left out, some dentists who have for years called themselves “biologic” or “holistic” dentists decided that a cool new word would really help separate themselves from the “ordinary” dentists who recommend such poisons as fluoride and amalgam fillings. Originally, “alternative” was the word of choice, but over time it grew stale and was subsequently replaced by “complementary”, a kinder and gentler term that implied a sort of truce between science based medicine/dentistry and non-traditional practices. After a while, the term “integrative” became fashionable, as complementary and alternative medicine attempted to insert itself into mainstream medicine. Thanks to promoters like Mehmet Oz, Andrew Weil, Deepak Chopra, and Joltin’ Joe Mercola, integrate it did. Not only into university-based medical centers, as mentioned above, but into private medical and dental practices worldwide. Within the past couple of years, some dentists have seized upon the “Functional” moniker and have co-opted it for their own use. Mind you, for these dentists, there has been no change in philosophy or standard of care from when they were only bioholisticompleternative dentists, it is a marketing/branding term only, which they presumably hope will help their websites’ Search Engine Optimization.
To date there are no “official” Functional Dentistry organizations, although I wouldn’t be surprised if one was founded in the near future. However, many individual dentists’ websites blatantly ride FM’s coattails. One dentist’s website states:
Functional Medicine Based Dentistry is the application of the principles and practices of Functional Medicine with the practice of the art and science of Dentistry. Philosophical differences exist today between traditional Evidence-Based Dentistry and Biological Dentistry, which have an impact on all patients and their oral and systemic health. Functional Medicine believes that a patient’s history, physiology, and lifestyle are fundamental factors when evaluating a patient’s health. Examination and interpretation of a patient’s individual biochemistry and genetics can give clues and hence better understanding of a patient’s chronic disease.When we apply these concepts in the course of dental examination, diagnosis and treatment, the “one size fits all” philosophy of standard American dentistry becomes outdated and dentists transform from “molar mechanics” to true “physicians of the mouth.”(emphases in the original)
Just like in Functional Medicine, statements like the above are disingenuous and fairly drip with the Unstated Assumption fallacy. As a non-Functional dentist, I can honestly say that I too believe that a patient’s history, physiology, and lifestyle are fundamental factors when evaluating their oral health. In fact, I know of no dentist who believes otherwise. Further, “examination and interpretation of a patient’s individual biochemistry” is a bit vague; while there are some useful genetic and salivary tests (when indicated) that are available in dentistry, they shouldn’t necessarily be utilized routinely and indiscriminately as screening tools until the evidence justifies it. And last, there is no such thing as a “one size fits all” approach to dentistry. Every person, every mouth, every situation is unique, and every prudent dentist takes all of these factors into consideration when determining a course of action for a patient, involving them in their treatment decisions. This is in our code of ethics and is not the domain of any one particular brand of dentistry.
Conclusion: Choose substance over marketing
All that said, most “alternative” or “functional” dentists are very conscientious dentists who sincerely want the best for their patients. If your dentist claims to be “holistic” or “functional” or “biologic”, you may want to put your antennae up if you are a science-based consumer of health care, but don’t throw the baby out with the bath water and summarily reject him/her. He or she may be a fantastic, science based dentist who is merely adapting the cloak of Functional Medicine Based Dentistry because they believe they are indeed “whole person” centered, want to appear to be cutting edge and progressive, and to gain a marketing advantage on their competition. There’s nothing wrong with that per se. To that end however, never hesitate to ask for good evidence if your dentist recommends something that seems “non-traditional.” The Center for Evidence Based Dentistry is a great resource for patients and health care providers alike. By being aware of what labels are being employed by physicians and dentists, what these labels mean, and why they are being used will help health care consumers make sound, science based decisions for themselves and their loved ones.

Journal of the American Dental Association Falls for Tooth Fairy Science
Jann Bellamy on November 14, 2013
Link

Another venerable scientific journal has fallen prey to “alternative” medicine research. The Journal of the American Dental Association (JADA) has joined the New England Journal of Medicine and Annals of Internal Medicine, among others, with its publication of “A pilot study of a chiropractic intervention for management of chronic myofascial temporomandibular disorder,” in the October, 2013, issue.
And what “chiropractic intervention” is this? The Activator Method Chiropractic Technique (AMCT) as taught by Activators Methods International (AMI), which also conveniently sells its own line of Activator Instruments. (Practice-building seminar DVDs sold separately.)
What is this Activator Method? In short, it is a method of detecting and correcting subluxations (the chiropractic version, not the medical one). Thus, the underlying premise of this study was that subluxations could cause myofascial temporomandibular disorder (TMD) pain and that finding and vanquishing these subluxations could bring about pain relief.
Now, as regular readers of this blog know, vertebral subluxations are a figment of the chiropractic imagination. They do not exist, as we have pointed out many, many, many times. And here is where alternative medicine has it all over conventional medicine and dentistry. In alternative medicine, once you invent a non-existent condition you can proceed to invent all sorts of diagnostic techniques and remedies to treat patients with this condition. The AMCT is a perfect example of this. Conventional medicine and dentistry, on the other hand, are saddled with the scientific method, biological plausibility, having to discard therapies when studies no longer support their use, and all sorts of other persnickety limitations.
The Activator Method Chiropractic Technique is a complete diagnostic and treatment package. The diagnostic method is laughably nonsensical. Here, we turn for an explanation to SBM contributor and chiropractor Sam Homola, writing for Chirobase:
The AM system is based on a concept of “pelvic deficiency (P.D.)”—also called “functional short leg”—which proponents define as an “apparent” difference in length, not an anatomical difference. To determine where the alleged problem is located, the practitioner holds the patient’s feet in various prescribed ways while the patient lies facedown on an examining table. Other parts of the body may be tested in various other ways.
AMI sells these shoes for patients to wear during their leg length analysis to “ensure accuracy.”

Now, to the treatment itself, which is equally nonsensical “chiropractic gimmickry,” again quoting from Chirobase:
If any inequality or “imbalance” is found, the practitioner taps various points along the spine, pelvis, and/or elsewhere with a handheld, spring-loaded mallet [called an Activator] until the legs appear to be equal in length . . . Slight variations of hip position or normal spinal muscle tension are probably responsible for the “imbalances.”
Ironically, the Activator design was derived from a dental impactor. Here’s the Activator IV, used in the JADA study:

I’ve used a similar Activator, to great comic effect, in my talks to medical students on complementary and alternative medicine. They seem to enjoy passing it around and thumping each other.
Here’s the latest model, described on the website as “revolutionary not evolutionary.”

Climbing the stairway to FDA approval
Yet, the FDA has issued a 510(k) medical device clearance for the Activator Adjusting Instrument for “chiropractic adjustment of the spine and extremities.” How could that happen?
According to FDA records, Activator I (still for sale on the AMI website) was in use prior to the effective date of the federal law requiring pre-market approval. Such devices were grandfathered in under the law. After the law’s enactment, AMI applied for pre-market approval of its newer model, Activator II. It did so on the basis that II was “substantially equivalent” to I, as permitted by law. However, applicants must show that the device submitted for approval is similar in safety and effectiveness to the device already on the market. The required 510(k) summary submitted to the FDA cited a 1986 study published in the Journal of Manipulative and Physiological Therapeutics (JMPT): “Accuracy of Piezoelectric Accelerometers measuring Displacement of a Spinal Adjusting Instrument.” Unfortunately, I cannot access the full article or provide you with a link to this abstract, from which this quote is taken:
The impedance-head-equipped spring-loaded Activator chiropractic adjusting instrument had a low velocity when used on the patient and appeared to cause bone movement and a measurable EMG response.
According to the summary, this “demonstrate[s] the effectiveness of the instruments to cause vertebral movement for chiropractic adjustment at very low energy.” Note that there is no statement in the abstract about whether this “bone movement” actually did anything for the patient or even that its putative effect was measured at all.
But progress marches on, and eventually the Activator III appeared. Its premarket approval was based on substantial equivalency to Activator I and II, with no citation of additional studies of clinical effectiveness in the 510(k) summary. Activator IV apparently did not require FDA approval, or at least I didn’t find any evidence that AMI got it. That brings us to Activator V. This application was based on similarity to III and to two similar devices (FDA approved here and here) manufactured by other companies. Like the III application, the V didn’t cite any studies of clinical effectiveness, nor could it piggyback onto studies cited by the manufacturers of the two other devices, as they don’t cite any in their applications. There is now an Activator V-E, also approved, but unfortunately its summary does not appear on the FDA’s website. (V-E is not sold on AMI’s website.)
Thus, it appears that the evidence of clinical effectiveness of the Activators submitted by AMI to the FDA is less than convincing, even though the FDA requires it for approval. (21 CFR Sec. 807.92) Interestingly, by the time V was submitted for approval in 2007, there was a 2005 article in the JMPT reviewing the studies of clinical effectiveness of the Activator Method and validity of leg-length analysis. The authors concluded that studies of AMCT diagnostic measures “did not permit assertions concerning the validity of AMCT assessment procedures for the detection of supposed joint lesions [one of the many names chiropractors have invented for the invented subluxation] or targets for adjustive intervention.” Clinical trials of the Activator method itself led them to the conclusion that it “may be a clinically useful tool” although they admit that the handful of studies they rely on have insufficient controls (e.g., lack of a placebo, not blinded) and not enough participants to demonstrate much of anything. And the funny thing is one of the authors of this article is Arlen W. Fuhr, D.C., co-creator of the Activator Method, President of Activator Methods International and the contact person on each of the pre-market approval applications filed with the FDA. Why wasn’t his article cited to the FDA?
The Tooth Fairy visits the Journal of the American Dental Association
Of course, all of this is simply Tooth Fairy Science in the first place, that wonderful term coined by SBM’s own Harriet Hall. “Tooth Fairy science seeks explanations for things before establishing that those things actually exist,” according to the Skeptic’s Dictionary. Dr. Hall offers this example:
You could measure how much money the Tooth Fairy leaves under the pillow, whether she leaves more cash for the first or last tooth, whether the payoff is greater if you leave the tooth in a plastic baggie versus wrapped in Kleenex. You can get all kinds of good data that is reproducible and statistically significant. Yes, you have learned something. But you haven’t learned what you think you’ve learned, because you haven’t bothered to establish whether the Tooth Fairy really exists.
Speaking of tooth fairy science, let’s turn to the JADA article. The rationale for the study will sound familiar:
TMD can become a chronic problem lasting several years, and patients receive little help from traditional forms of treatment. Consequently, some patients may seek complementary and alternative (CAM) approaches to manage their TMD-related pain.
So, what to do? Should we expose chiropractors for ripping people off by telling them they have subluxations which may be causing their TMD pain and proceeding to “correct” those subluxations with little spring-loaded mallets? No, we study it because CAM is popular. (Actually, it isn’t.) And we study it with taxpayer money, in this case provided by NCCAM. No surprise there.
Do the authors cite any evidence that the Activator method is nevertheless effective for TMD in an attempt to justify this study, despite the lack of plausibility (which they never admit, of course)? Well, they cite a single case report and a prospective case series of 8 patients who were assessed at 6 weeks with no further follow-up. There was no blinding and no placebo control. I don’t know if this would normally justify a “prospective randomized controlled pilot trial” (as this study is described) of a medical or dental intervention, but perhaps some of you could comment.
Fifty-two (out of an original 80) completed the JADA study. Participants were divided into 4 groups which numbered between 11 and 14 in each group. They compared self-care and self-care plus either AMCT, sham AMCT or reversible interocclusal splint therapy (RIST). Self-care consisted of someone talking to the patient about TMD and suggesting such things as using OTC pain medications, jaw relaxation stretches, and reducing their stress levels.
Before I get into how AMCT was described, let me repeat Sam Homola’s explanation, because it should be fresh in your mind when you read what follows:
The AM system is based on a concept of “pelvic deficiency (P.D.)”—also called “functional short leg”—which proponents define as an “apparent” difference in length, not an anatomical difference. To determine where the alleged problem is located, the practitioner holds the patient’s feet [perhaps shod in AMI shoes] in various prescribed ways while the patient lies facedown on an examining table. Other parts of the body may be tested in various other ways. . . . If any inequality or “imbalance” is found, the practitioner taps various points along the spine, pelvis, and/or elsewhere with a handheld, spring-loaded mallet until the legs appear to be equal in length . . .
Of course, anyone with a background in medicine or dentistry would have his or her suspicions instantly aroused by such an explanation and likely seek further information. Or perhaps even toss the proposed article into the wastebasket. But let’s look at how the authors describe AMCT:
The AMCT protocol is a structured method of chiropractic treatment that involves the use of a series of biomechanical tests in determining how, where and when (or when not) to perform a mechanically assisted manipulation. These biomechanical tests involve well-defined joint or joint complex (motor unit) movements involving the area of examination. Each specific manipulation—called an “adjustment”— is given with a hand-held, springloaded instrument (Activator IV, Activator Methods International) that delivers a quick, shallow thrust. The AMCT protocol can include the entire spine and extremities, as well as the temporomandibular joint. The entire AMCT protocol has been described in detail elsewhere.
A “series of biomechanical tests?” Where is the description of functional leg-length analysis? Or the subluxations it supposedly uncovers? How about an explanation of the subluxations’ putative effect on TMD? Or what it is that this “quick, shallow thrust” is supposed to do?
And that description “in detail elsewhere?” The authors cite a chiropractic textbook written by the aforementioned Arlen W. Fuhr, a text which I expect resides exclusively in chiropractic school libraries and practitioner offices. A less obfuscatory explanation of ACMT can in fact be found in a source more readily available via medical libraries – the same 2005 article in the Journal of Manipulative and Physiological Therapeutics not cited to the FDA by AMI. (JMPT is indexed in PubMed.) Also not cited was a 2012 systematic review in the Journal of the Canadian Chiropractic Association (also indexed in PubMed), which found no difference in results between the Activator Method and manual therapy. Since none of the 8 studies were randomized clinical trials, all lacked a no-treatment or sham treatment group and were unblinded, no results could reliably be attributed to either treatment.
Had the JMPT article been cited, the peer reviewers would not only have discovered the obvious: the lack of validity, not to mention the underlying pseudoscience, of functional leg length analysis and lack of evidence of effectiveness (and, again, the pseudoscience) of the Activator Method. They would also have found a refreshingly honest admission by its authors: there is no evidence that the chiropractic subluxation exists in the first place.
Let’s imagine two scenarios here. First, the peer reviewers were misled by what was made to sound like a fairly innocuous procedure by using vague terms like “structured method of chiropractic treatment” and “biomechanical tests.” Part of me hopes this is the case, although I do think someone should have asked for more detail. And part of me doesn’t want to contemplate a second scenario: that more information was requested by the reviewers and a more straightforward explanation provided by the authors and that it informed them exactly what AMPT is.
And the results of the JADA study?
After going through an impressive amount of verbiage about subject selection, control groups, confidence intervals, baseline characteristics, and all the other accoutrements typical of Tooth Fairy Science, we learn there was no statistically significant difference between results in each group. But that’s ok because the study was simply looking at the “feasibility of conducting a full-scale RCT to evaluate the effectiveness of AMCT” although the next study, according to the authors, should be a comparative effectiveness study. An odd suggestion, as such studies are generally done to compare treatments that are effective. Otherwise, why would you do it?
However, I can’t say nothing useful was learned, although likely not what the researchers intended. First, for all of the hoopla we hear about patients preferring CAM practitioners for their more “holistic” approach, mean satisfaction with care was actually greater for the RIST and self-care-only groups than with the AMCT and sham-AMCT groups. Second, they report “subtle differences” between the chiropractor’s interaction with participants in the AMCT and sham AMCT groups. Actually, some of the differences (more fully explicated in a poster presentation by the authors) weren’t so subtle. The chiropractor talked more to one group than another, but which was which is not reported. And in the active AMCT group the median number of Activator device “clicks” was almost twice as many as in the sham group (42 clicks v. 22 clicks).
But what about the idea that CAM practices must be studied because, as the authors suggest, “some people may seek complementary and alternative approaches to manage their TMD-related pain.” True enough, “some people” do exactly that. “Some people” may seek crystal therapies or use biomats, or tape magnets to their jaws. Should we study those too? After all, they have no less plausibility than AMCT. Must we study every treatment anyone makes up? And does it matter why “some people” try these therapies? Does it matter that they seek them out because chiropractors are misleading them about AMCT’s effectiveness and taking their good money for a worthless treatment? Wouldn’t it be more useful to tell them this rather than spending money on implausible treatments that we know can’t possibly work? Do we think for one second that chiropractors will stop using AMCT because the studies don’t support its use? (Answer: they won’t.)
Which brings me to other troubling aspects of this study.
Why was this study approved by the University of Iowa’s Institutional Review Board (IRB)? I am certainly not an expert in bioethics, but it is my understanding that no trial should be approved that does not conform to the “World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects,” which states:
21. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation.
As well, ethical and legal principals require informed consent before a human subject agrees to participate in a trial. As Steve Novella said yesterday in his post on informed consent:
This principle is, in turn, based largely upon the principle of autonomy – people have the right to control their own lives, and one cannot have control without information.
The same is true for informed consent in the legal context, which is based historically on the tort of battery: no one can intentionally touch you without your consent. And to consent you have to know what you are consenting to.
So let’s review what we know about AMCT.
     1.  It is based on the “theory” that subluxations (chiropractic version) of the spine affect human functioning and can cause ill health. As chiropractors themselves admit, there is no real support for this “theory.” And whatever chiropractors think, as any responsible scientist will tell you (and as one neuroscientist in fact told me) the whole idea is nonsense.
     2.  These subluxations can be discovered by something called “functional leg length analysis,” which even a casual observer can see makes no sense (anatomical or otherwise) whatsoever.
     3.  That thumping the vertebrae or other articulation with a small, spring-loaded mallet will reduce the subluxation by moving it back into its proper location, an obviously dubious concept.
     4.  This “correction” of the subluxation will have a beneficial effect on the patient’s condition.
And how do we know this? Through information readily available via a search of literature indexed on PubMed. There are plenty of other journal articles with similar information, but articles on AMCT alone will tell you everything you need to know. As will Science-Based Medicine, for that matter.
Did the University of Iowa IRB have this information? I don’t know, but it was certainly easily available. Would this information be relevant to a person making a decision on whether to participate? Of course. Were the subjects told this? I doubt it. (And if anyone out there has the informed consent documents used in this trial, I would certainly love to see them.)
If I can figure all of this out with my 10th grade biology science education and an internet connection, why couldn’t the editors of JADA? Why couldn’t the University of Iowa IRB? Good questions.

The Sleep Bank
Clay Jones on May 10, 2013
Link
The following article is entirely made up. It’s satire. I am making fun of treatment modalities which are claimed by proponents to cure everything, from real medical ailments to fictional entities like “adrenal fatigue”. I am also poking fun at the state of medical reporting these days. If the concepts discussed seem similar to actual alternative medical practice, it is because a great deal of what goes on out there in the real world really isn’t distinguishable from purposefully outlandish fictional treatments made up by someone with a doctoral degree in Feng Shui from Thunderwood College.
The Sleep Bank: A scientific solution to fatigue?Jandine Odenkirk sits patiently in a room at a clinic located just blocks from her downtown Baton Rouge apartment, waiting for her doctor. Only instead of the typical sterile treatment room, uncomfortable examination gown and nervous pacing, Odenkirk is nestled in a warm bed, surrounded by soft lights and music. A doctor walks in, places a metallic band around her head and plugs the attached array of wires into a sleek black machine in the corner of the room. It immediately comes to life and within seconds a slow but steady stream of paper emerges which the doctor examines closely for irregularities or, as is usually the case, signs of improvement. The doctor smiles as he examines it. Her brain waves look much better today.
As you may have already gathered, this isn’t your usual medical practice. In fact, it is much more than that. Odenkirk is one of a growing number of patients whose lives are being changed for the better by the Baton Rouge Sleep Bank™, which is owned and operated by Dr. Mort Fishman, DS. Fishman, a Doctor of Sleepology™ certified by the Certification Division of the Correspondence College of Tampa, a subsidiary of Sleep Bank™, saw a great need for sleep banking in Baton Rouge. “I’m proud, not only to call such a fine city as Baton Rouge home, but also to be able to provide such a life-changing service,” Fishman explains while Odenkirk undergoes her hour-long treatment process. “Before I came here people literally didn’t even know that sleep banking existed!”Fishman has seen it all during his 5 years as a certified Sleepologist™. He says that fatigue is the number one cause of most medical complaints (See Table 1). Luckily, despite being ignored by more conventional doctors who only treat the symptoms of fatigue rather than the whole tired person, maverick scientists have been investigating treatment options for fatigue without the benefit of billions of dollars from the pharmaceutical industry because alternative treatments can’t be patented. Their tireless efforts eventually led to the discovery of sleep banking and ultimately to the patented process of Sleeptivation™, where banked sleep is transferred into the brain of a sleep-deprived patient.
“It’s simple really,” explains Dr. Fishman. “Most people are familiar with regular banks, where they deposit and withdraw money. Many people may even be familiar with milk banks or even cord blood banks. This is exactly like that except instead of breast milk for micropremies or stem cells for cancer patients, we bank sleep.”
Here’s how it works. Just like with blood or plasma donation, healthy volunteers take anywhere from thirty minutes to an hour of their time, usually on a weekend or day off, to come to the Sleep Bank™ and donate sleep. The process couldn’t be easier. Volunteers are hooked up to the same machine as Jandine Odenkirk only the large black knob on the front is turned to “In” instead of “Out”. Volunteers are not monetarily compensated for their donation for a very important reason. “Studies performed at Sleep Bank™ regional headquarters in Boulder were troublesome,” Fishman reveals. “They discovered that non-altruistic sleep donation increased the risk of sleep rejection by over a quartile! It wouldn’t be right to take that kind of chance.”
When a fatigued patient, like Jandine Odenkirk, comes in for a Sleeptivation™ session, they are treated as well as they would be at any expensive spa, conventional or medical. Aromatherapy and music therapy are integral to the process, which also includes a 5-minute light massage and a glass of wine. The knob on the machine is then turned to “Out” and the patient typically enters a relaxed state almost immediately, with most actually falling asleep. “Several studies have shown that the process of Sleeptivation™ is more effective if the patient is asleep during it, but that is where our understanding of this complex science becomes less clear.”
Odenkirk, a 45-year-old executive with a history of stress and anxiety disorders, isn’t concerned about the science. She reveals, “I’m glad that top minds are looking into these questions, but what really matters is if it works. And, in general, I can usually say that I feel somewhat more relaxed after the treatment.”
Sessions can last anywhere from thirty to forty-five minutes, but Dr. Fishman has on occasion allowed them to go longer. “We don’t practice cookbook Sleepology™ at the Sleep Bank™. Sometimes a patient just needs a few more minutes.”
Dr. Fishman, one of only ten certified Sleepologists™ in Louisiana, invites naysayers to check out the process for themselves. I asked a noted and anonymous local skeptical blogger, The Red Stick Skeptic, their thoughts on sleep banking and Sleeptivation™. “It sounds like a typical set up for being fooled into thinking that a treatment works, when all that is going on is the customer is getting a nap and a healthy dose of placebo,” Red Stick Skeptic bellowed curmudgeonly. “And I’m sure it isn’t free either!” The blogger declined the opportunity to try a session, most likely because of closed-mindedness.
To answer the question once and for all, I underwent a Sleeptivation™ session and couldn’t have been more impressed. As a dedicated investigative journalist who is lucky to get 2 to 3 hours of sleep each night, I know that sleep deprivation is a big problem, and sure enough I suffer from just about every symptom on Dr. Fishman’s list. After my hour of treatment, I felt relaxed and ready to face the rest of the day. I’d recommend it to anyone and everyone. Sleeptivation™ is the real deal.
(Sleeptivation™ costs $200 per half hour but there are less expensive rates when sessions are bought in bulk packages of 10, 20, or 50 sessions. The Baton Rouge Sleep Bank™ also offers an unlimited lifetime membership for $15,000. There is also an at-home system which can be rented for $500 per day or $2,000 per week. These fees do not include consultation with a certified Sleepologist™. High quality cotton tee-shirts, with the slogans “You Ain’t Been Vated, ‘Til You Been Sleeptivated™!” or “Perfect Health is 1% Perspiration and 99% Sleeptivation™!” are available for $20.)
————————————————————————————————
Table 1: Symptoms proven to be treated by Sleeptivation™*-fatigue-halitosis-fever-sluggishness-difficulty maintaining homeostasis-persistent production of saliva-tiredness-irritability-excess flatulence-difficulty abstaining from cocaine use-moodiness-continued regrowth of body hair despite repeated attempts at shaving it off-difficulty holding more than 5 to 9 objects in working memory-difficulty reading without one’s glasses or contacts-aching muscles-headache-nightmares-erectile dysfunction-digestive problems-weight gain-weight loss-aging-telomere degradation————————————————————————————————*According to the International Sleepology Institute™

Nobel Prize in Physiology or Medicine 2026
Steven Novella on October 7, 2026
Link

Each year I like to document the Nobel Prize in Physiology or Medicine here on SBM – it’s a great reminder of the power of science to transform medicine. There is nothing like it in so-called “alternative medicine”, which is still peddling basically the same snake oil and energy nonsense of previous centuries, just with updated marketing. This year the prize goes to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their work developing optogenetics. This is a great story about a powerful tool that allows us to create a functional map of the brain.
The story begins with Hegemann, who in the 1990s was studying the free-swimming algae, Chlamydomonas. The algae swim towards light, which anyone can reproduce by shining a light on a petri dish full of the green organisms. They have a small eyespot that can detect light, but Hegemann was fascinated with how quickly they were able to respond to a light signal. This led him to hypothesize that the algae may be using a different method for turning light into a signal that can affect their behavior than vertebrate eyes.
In vertebrate eyes there is a cascade of events, called phototransduction, starting with a photon of light hitting 11-cis-retinal attached to an opsin protein in cones and rhodopsin in rods. This causes a conformational change in the retinal, which activates the opsin, which activates G-protein transducin, causing its α-subunit to exchange GDP for GTP. Transducin then activates phosphodiesterase-6 (PDE6), which hydrolyzes cGMP, lowering its cytoplasmic level. This causes cGMP-gated Na⁺/Ca²⁺ channels to close, reducing the inward “dark current.” This causes the photoreceptor to hyperpolarize, reducing Ca²⁺ entry at the synaptic terminal and therefore reduces glutamate release onto bipolar cells.
Don’t worry about all those details – the point is, this takes time, 100-200 ms. When Hegemann attached electrodes to Chlamydomonas and shined a light on them, he was able to detect an electrical signal in half a millisecond – incredibly fast. This is simply too fast for anything like phototransduction, so he thought perhaps it must be the same protein that detects the light and creates the resulting electrical pulse. Now all he had to do was identify that protein.
A Japanese group had already mapped the DNA of Chlamydomonas and, of the genes identified, two had properties that might fit the bill. But this was now a bit out of the field of expertise of Hegemann, so he contacted Nagel for help and sent him the code for the two candidate genes. Nagel injected the genes into separate batches of frog eggs, which began to express the proteins. He could then study how the proteins functioned and was able to confirm Hegemann’s hypothesis. Both proteins, named channelrhodopsin-1 and channelrhodopsin-2, were ion channels that respond to light by opening up, allowing positive ions to flow through, and creating an electrical potential. Channelrhodopsin-2 was particularly powerful, creating an electrical signal in 0.2 milliseconds. They were able to incorporate the gene for this protein into human and hamster kidney cells and show that they become light sensitive.
This is where Deisseroth enters the picture. He is a physician and neuroscientist studying mental illness like schizophrenia. His early work in neuroanatomy was interesting, but he realized he needed a functional map of the brain if he was going to make real progress understanding these illnesses and conditions. He searched for a method to activate on demand a signal brain neuron, so that its connections and effects could then be studied and mapped. He heard about the work of Hegemman and Nagel and asked Nagel for the DNA of the Channelrhodopsin-2 protein, which he provided. Deisseroth started by incorporating the gene into rat neurons cultivated in a petri dish. At first he was concerned that introducing a foreign protein into the neurons might cause some injury, but they did fine. When Deisseroth exposed the modified rat neurons to light, they responded immediately by generating an electrical signal that could be propagated to other neurons. This was just the beginning of the work, however.
Deisseroth began to collaborate with Hegemann and Nagel and also other groups to develop this into a useful lab technique. They were able to identify other light-sensitive proteins, responding to different wavelengths of light. They were also able to genetically modify mice so that their neurons produced one of these proteins. In fact, they could do so for just one specific population of neurons. They then introduce a thin optic fiber into the brain of such a mouse – and now they have a switch they can use to activate those specific neurons. In some of his early work with this technique, Deisseroth was able to determine which neurons control the mouse whiskers, and also another group of neurons that wake up sleeping mice.
And with this work, the field of optogenetics was established. Now neuroscientists can tag specific neurons in living animals and then activate them at will, exploring the specific effects of these neurons in the living brain. This allows neuroscientists to develop a detailed functional map of the brain, and to test many hypotheses. The Nobel committee considers this a “transformative” technology for neuroscience, and I agree.
I also always like to use the Nobel prizes as an opportunity to highlight how cutting-edge science today is such a collaborative and often international effort. They can only give the prize to three individuals, and the three winners were clearly at the center of this advance. But they relied upon the work of other scientists from around the world, and collaborated with many people not only at their own institutions but in many others. This kind of research would not have been possible for a single team at a single university.

Science-Based Satire: Hiring a Doula for Dental Procedures
Clay Jones on April 8, 2016
Link


Suzy Flanders had always dreamed of having a natural tooth extraction without pain medications, sedation, or local anesthesia, just like in the Bible or on an episode of Keeping Up With Kardashians. “When the day finally came on April 1st 2011, and my dentist recommended the removal of an impacted third molar, I almost couldn’t believe it,” Flanders explained. “After reading everything I could find online and talking to a few trusted friends and family members, the right choice became clear. I had to do what was best for me and for my precious tooth.”
What she found in her research was the consistent recommendation to have someone present during the procedure that had been through the experience themselves. Many proponents of natural dental care endorse this practice because there is evidence that it helps to reduce the need for harmful medications that might prevent a quick return to normal activity. They also argue that a dental procedure is about more than just the removal of an abscessed tooth or the correction of malocclusion, it’s about experiencing what the procedure feels like and discovering what you are capable of achieving. Natural dental care patients learn to manage their pain and remain open to the excitement and exhilaration of the process, and often report feeling higher levels of satisfaction. After all, modern humans have been experiencing the beauty of natural dental pain for 250,000 years.
After discussing the idea with her husband Daniel, Flanders decided to seek out the services of a dental doula.
What is a dental doula?
Similar to doulas that attend the birthing of children or farm animals, the specific focus of a dental doula involves being present prior to and during a procedure in order to provide reassurance, support, and information. The dental doula that Flanders found served as a calming presence and a firm voice of support and encouragement throughout the extraction. “We really connected. She had been through it all herself after a rollerblading accident resulted in a fractured maxillary central incisor, so she knew the pain that I was feeling. I was able to focus on her voice and cling to it like a piece of floating driftwood during a powerful storm.”
Introspective data from across the nation has shown an increasing utilization of dental doula services over the past decade. According to the American College of Dental Doulas spokesdoula Kate Orberton, people are realizing that dental doulas empower patients and ease communication with dentists, orthodontists, and their support staff without giving dental advice. Orberton stressed that dental doulas are not a replacement for licensed oral health professionals.
First-time dental patients are especially vulnerable, according to Orberton. When a dental doula enters the room, they allow for the patient to relax and focus on blocking out the agony that they are about to experience. They are ready with helpful information and they encourage reasonable expectations. “We can tell the patient that they made the right choice and help them to focus on the benefits of that choice, between the intermittent shrieks and sobs.”
Are there downsides to using a dental doula?
The American Dental Association recently raised concerns over the increasing popularity of dental doula services. Although this hasn’t been studied specifically, some ADA members believe that there is a link between dental doulas and the rise in home dentistry. Though almost unheard of a few decades ago, currently about 1-2% of dental procedures are being performed at home by direct entry traditional mouth healers. Although in low risk patients, such as healthy children with an uncomplicated loose tooth, home dentistry is considered by many to be safe and effective, more complicated procedures should be performed under the care of a trained professional. Some dental experts argue, however, that even seemingly uncomplicated extractions have the potential to require higher levels of care.
Currently, no states require certification of competence for dental doulas or any form of licensure. Grant Ritchey, a natural dentist in Tonganoxie, Kansas, compares the current dental doula climate to the Wild West. “You don’t know what you are going to get unless you do your homework. Some dental doulas are excellent, some don’t know the oral cavity from a hole in their head. I know when a patient has made a good choice though. They all scream, but there is an underlying peace beneath the screams that reminds me of why I got into dentistry in the first place.”
What’s the bottom line on dental doulas?
A dental procedure, like the extraction of a diseased premolar, can be one of the most rewarding and meaningful experiences in a person’s life, but it can also be one of the most challenging. Patients who rate their procedures as positive on Yelp tend to express feelings of being in control. Dental doulas work for the patient, not the dentist or insurance company, which frees them from many constraints that interfere with the desired outcome. Dental procedures are about more than just fixing a tooth, they are about fulfilling a mouth’s destiny.
Fast forward to today and Suzy Flanders has now had three natural root canals in addition to the extraction, all with the aid of a dental doula. She is even considering a fourth root canal and is interested in having the procedure done in a warm water environment surrounded by koi and/or a dolphin. Because of her positive experiences with dental doulas, she says she would recommend them to anyone. “I will never forget when Dr. Ritchey handed me my extracted tooth, my husband on my right and my dental doula on my left, both enveloping me with gentle and relaxing energy.”

Science-Based Satire: Alternative Medical Adverse Events on the Rise
Are patients being senselessly slaughtered by poorly trained Reiki practitioners? Probably not. Okay, they aren’t…at least not directly. But Reiki is dumb and so is the belief that the power to manipulate human energy fields would be risk free. Here satire article is.
Clay Jones on December 1, 2017
Link

Isn’t it ridiculous that proponents of so-called alternative medicine rarely ever own up to the risks? Nothing in medicine is risk free. Nothing! But believers in pseudomedicine from acupuncture to Z Wave technology want to have their alkaline electric zucchini cake and eat it too.
Last time I wrote about a bogus energy healer who has scored a spot on the TLC schedule and some false legitimacy thanks to gullible academics at NYU. During a discussion on Twitter, I asked Goldsmith if there were any risks to manipulating a patient’s energy. Could he, I wondered, choose to unbalance their energy and cause symptoms. He didn’t respond, but it got me thinking.
What if energy healers, Reiki practitioners, and therapeutic touchers could use their powers for evil? What if they simply were having a bad day and gave someone gout? What if a novice trainee got in over his head? It’s absurd of course, but still.
That’s right! It’s time for more science-based satire.
Wait, alkaline electric zucchini cake?
Alternative medical adverse events on the rise according to new study
Bethesda, MD – A new report out of the National Center for Complementary and Integrative Health (NCCIH) is calling into question the safety of Reiki, a technique which was developed in Japan in the early 20th century as a way to manipulate innate human energy fields in order to improve health.
The report, which will be published in the upcoming issue of The Vitamin Shoppe’s Amazing Wellness magazine, reveals that the number of Reiki related deaths have increased by almost a quartile since the last assessment in 2007. Lead author Lance Unglesby, a Level IIB practitioner of Therapeutic Touch, estimates that as many as three to four thousand people and animals are injured each year at the hands of poorly trained Reiki practitioners.

Mittensby J. Ticklepaws III, shown here mere seconds before suffering catastrophic cardiopulmonary failure during a botched veterinary Reiki session
“Many of these deaths occur in July, when new Reiki trainees are starting programs all over the country,” Unglesby explains. “People go to a healer expecting to be healed. This is a crisis and something needs to be done about it.”
Featured in the report is 10-year-old Louisiana child Timmy C., a boy whose life was tragically cut short when he was brought to a Reiki training facility for help managing his ADHD, which had been diagnosed earlier that week by the lady who cuts his hair. Timmy’s mother describes in chilling detail how things turned from miracle to mayhem.
We had a coupon for a free session and I figured it couldn’t hurt, and at first it seemed to be working. The student meditated and then placed his hands over Timmy’s body. It was like a light came on in his eyes and I could just tell that his ability to focus was returning. But something went wrong. I heard the Reiki student muttering something about how this shouldn’t be happening. He called for help and two Master Teachers rushed in but it was too late.
Only after a full alternative medical autopsy was performed did an explanation for Timmy’s death emerge. Parish Coroner Frank Grimes DC, who performed the examination in the basement of his clinic, found a number of vertebral subluxations and a touch of adrenal fatigue, but the true cause of death only became apparent when he hooked Timmy up to an Electro Interstitial Scanning (EIS) system and found a complete absence of resonance. “If you had asked me what killed him before the exam, I would have absolutely said it had to be Acute Severe Subluxation Syndrome, because that is the cause of 99% of non-traumatic deaths. But Timmy was one of those one in a million cases.”
What Dr. Grimes discovered allowed him to piece together Timmy’s final moments. During Reiki therapy sessions, a practitioner sends his own healthy energy into the patient in order to correct imbalances. Unfortunately, the normal flow of energy reversed during Timmy’s session. While a well-recognized complication, and one that countermeasures have been developed for, such as counting backwards from ten or crossing the big and second toe of the dominant foot, the unskilled student working on Timmy was unaware of these techniques because he had not started chapter 4 (“Management of Energy Flow Reversal and Energy Stream Crossing Emergencies”) in his Clinical Reiki textbook.
Devoid of any human energy, his body became riddled with dis-ease and he died, right there in his mother’s arms. Sadly, had Timmy’s mother been trained in Emergency Energy Replacement (EER) she might have been able to save him. An investigation by local authorities revealed that the Reiki training facility did not meet safety code, as it did not have a functional automated energy delivery device (AEDD) on site.

Science-Based Satire: NASA Teams with NCCIH to Study Alternative Medicine in Space
Are NASA and the NCCIH working together to study reiki in space? It sounds plausible I know, but this isn’t even remotely true. It’s satire. Enjoy!
Clay Jones on April 6, 2018
Link

Washington, DC- Two federally funded scientific organizations tasked with the advancement of our understanding of the cosmos are teaming up for the first time to study alternative medicine in space.
“Frankly I’m surprised it took this long for the two agencies to get together,” National Center for Complementary and Integrative Health director Josephine Briggs MD explained. “Until now, we’ve been handicapped by our inability to study alternative therapies beyond the Karman line. How else can you explain so many years of negative studies?”
For nearly three decades, the NCCIH, formerly known as the National Center for Complementary and Alternative Medicine, has investigated a wide variety of natural healing practices and herbal remedies supported by tax dollars under the guidance of the National Institutes of Health. So far, despite trying really hard, they have had little if anything to show for their efforts. This failure to produce proof of efficacy didn’t sit well with some congressional leaders, like former Iowa Senator Tom Harkin.
Harkin, who in the early 1890s recovered from a viral upper respiratory infection with the aid of an elixir he bought from a travelling salesman in Des Moines, became a believer in alternative therapies. A century later, in 1992, he would be instrumental in the formation of the office that would become the NCCIH. Harkin was also the force behind this unprecedented collaboration with NASA.
The first NCCIH trial to be run with the assistance of NASA will take place on the International Space Station and study the use of an energy-based healing therapy known as Reiki as a treatment for space adaptation syndrome, a severe motion sickness commonly experienced by space travelers. Developed in 1922 by a Japanese monk, Reiki practitioners claim to tap into and manipulate a patient’s qi, the universal life energy that, according to Reiki practitioner and lead researcher Ben Kenobi, “Surrounds us and penetrates us, binding the galaxy together and activating natural healing processes while restoring physical and emotional well-being.”
Until now, evidence of any benefit from the practice has been lacking, leading some to question the existence of this elusive “force”. H. Solo, a member of the Corellian Skeptical Society, has even gone on record denying it entirely:
…I’ve seen a lot of strange stuff, but I’ve never seen anything to make me believe there’s one all-powerful force controlling everything. There’s no mystical energy field that controls my destiny or that can prevent or treat space sickness.
According to Briggs, space is the perfect environment for studying Reiki because it is far, far away from the many potential sources of interference on Earth, like overhead power lines, Wi-Fi and skepticism. “We are of course primarily interested in its healing ability, but I think we’d all love to see some Reiki Lightning.”

Science-Based Satire: Florida Authorities Report First Case of Mosquito-Borne Fentanyl Overdose
Can a mosquito bite result in a fentanyl overdose? Will police soon be fitted with wearable naloxone pumps? Can fentanyl be detected by a handheld electronic device? The answer…is no. This is merely more nonsense cooked up in the mind of someone who probably should stick to his day job.
Clay Jones on March 17, 2023
Link

Miami, FL – The first case of a fentanyl overdose caused by a mosquito bite was recently reported by the Miami Police Department, and local authorities are raising awareness of this potential new threat.

“I was handcuffing a suspect and saw the mosquito go straight from his arm to mine, MPD officer Corporal Chad Blaze explained. “I immediately overdosed, and I kept overdosing all the way to the hospital where I received care and was discharged home after an hour. The crisis was over, but I think on some level I’ll always be overdosing on some level…at least a little bit…on the inside.”
Corporal Blaze was saved by the quick action of the very man he was in the process of detaining for suspiciously waiting for a bus. Wince Jenkins, a Miami bartender who has been battling an addiction to painkillers since an unfortunate alligator attack in 2019, recognized the telltale signs of a fentanyl overdose and called for help. “That cop started breathing real fast and talking about how he has kids and how he didn’t want to die in the street like an alligator. I yelled for his partner and she called for an ambulance. They both looked really scared.”

Fentanyl, a synthetic version of drugs like morphine, codeine, and super codeine, is much stronger than naturally occurring narcotics. Some medical experts, like police toxicologist Mort Fishman, aren’t surprised by this case of a mosquito-borne fentanyl overdose. “This stuff is potent. It’s like heroin on crack, and then on steroids. And if my certificate of participation from the third best toxicology academy in Tampa means anything, anything at all, this won’t be the last time it happens around here.”
Several high profile cases of police officers requiring treatment with an opioid reversal agent have been reported across the country in recent years, with most not even being caused by mosquitoes. According to Corporal Blaze, the close physical contact required in policing is a major risk factor for developing an overdose when an officer is worried that fentanyl has touched their skin. “And you know it is happening more than what you see in the news. That’s why I can’t wait until I get my pump.”

The “pump” Blaze is referring to will likely be a game changer when it comes to fentanyl overdoses in the line of duty. Researchers at the American multinational biopharmaceutical company Emergent BioSolutions Inc. are close to the successful development of a wearable pump for the continuous infusion of naloxone, a lifesaving drug used to reverse the effects of an opioid overdose.
“Our initial target demographics are police officers and other first responders,” Emergent BioSolutions Inc. CEO Robert Kramer Sr. explained. “Essentially anyone at high risk of being really worried about coming into contact with fentanyl. But in light of recent news reports, we are considering expanding this to anyone who might also live near a mosquito.”
Not all experts are fully on board with the naloxone pump. Fishman and other police toxicologists are raising concerns over the possibility of officers having a false sense of security. “I want our boys in blue to feel safe when they’re protecting us from the evils of the world, like when fentanyl that looks like glitter is being used on kindergarten birthday party invitations or when black people are picking up their kids from soccer practice. I just don’t want them getting reckless because they feel invincible. Qualified immunity only works when they are violating Fourth Amendments rights, not when they are overdosing on fentanyl!”

Fishman believes that prevention is key to keeping officers and other first responders safe. That’s why he recommends all patrol cars carry and use a Fentascan portable fentanyl security system. “When it comes to this stuff, you just can’t be too safe. It’s everywhere and in everything. And it’s patient. It will wait until you make a mistake.”
An injection of reality
Yes, I did some fentanyl fear satire back in October and I apologize for the repetition. But this nonsense just refuses to go away. Since then there have been numerous cases of police officers blaming fentanyl for panic attacks and/or simply passing out. Here is a typical scenario from December of last year.
Why is this a problem? In a follow-up piece on the above claimed “overdose”, actual toxicologist and expert on fentanyl exposures Ryan Marino sums it up:
Overdoses are killing hundreds of Americans every day, and the biggest driver of our overdose crisis right now is fentanyl in street drugs,” Marino said. “So I mean, I think it is something that everyone should be talking about. But these myths that come up, unnecessarily scare people, distract from meaningful conversations and even prevent people from doing the things that are necessary to really stop overdoses.
Marino has been pushing back against this false narrative for years. In this article, he further points out that this simply isn’t how fentanyl overdoses work. Our own Scott Gavura also delved into this issue last July, concluding that no meaningful absorption occurs with transient skin contact and simply washing the area with soap and water is all that is necessary.
These myths increase the risk that someone in actual need of a reversal agent on the street might be allowed to die because of fear of a contact or inhalation overdose. They originated as DEA disinformation designed to increase funding but have had the unfortunate side effect of distracting from efforts that might actually help people reduce their risk of death from overdose. Some people are even facing additional charges, such as “assault with intent to kill” after an officer has a bogus fentanyl overdose.

Science-Based Satire: A Powerful and Ancient Practice is Revolutionizing Medical Venipuncture
Are experts in medical dowsing using medical grade rods to locate blood vessels to improve venipuncture success rates? No, they aren’t. That’s absurd and this is clearly satire. But dowsing for dead bodies might be accepted in a court of law near you, which is also absurd but not made up. Really.
Clay Jones on July 22, 2022
Link

Boulder, CO – In an effort to improve patient care by reducing the number of needle sticks needed to obtain IV access or to draw blood for testing, an increasing number of nurses have turned to an ancient method used for finding sources of underground water.
“Finding a suitable vein for drawing blood or placing an IV can be challenging, particularly in older or obese patients,” explained Hortense Samuelson, a nurse at the Mountain View Manor skilled nursing facility in Boulder and recipient of a practitioner certification in Medical Dowsing. “Since I began using medical dowsing to locate good veins, I can hardly remember any instances where I haven’t been successful in the first few tries.”

Dowsing, known historically as “water witching”, is a 600-year-old method of divination traditionally used to find groundwater. But over the years, dowsing practitioners have branched out into other areas. These days, dowsers can be found not only on farms finding new sources of fresh water, but also working with petrochemical companies on the hunt for new oil deposits and prospectors searching for hidden gold.
The addition of locating hard to find veins to dowsing’s repertoire was truly a no-brainer, and it originated in Boulder, right down the street from the Mountain View Manor skilled nursing facility. Since 2008, the Institute of Medical Dowsing (IMD) has offered certification to interested nurses and other healthcare professionals. The IMD is actively pursuing national accreditation of their Medical Dowsing Certification (MDC) with the National Commission for Certifying Agencies (NCCA) as well as credentialing from the Institute of Credentialing Excellence (ICE) for their Medical Dowsing Certified Practitioner (MDCP) program. They have successfully obtained approval from the National Acronym Approval Association (NAAA).
For those interested in a more advanced understanding of medical dowsing, the MDCP program consists of a rigorous weekend session designed to teach the knowledge of dowsing as it applies to a variety of medical areas, not simply phlebotomy. For instance, a certified medical dowser can also help locate hidden areas of inflammation or cancer. They can also be called upon to find lost articles of clothing or a patient’s car keys upon discharge from a facility.

How medical dowsing, and dowsing in general, works remains somewhat of a mystery. Proponents believe that their specially designed tools, often in the form of two L-shaped rods, allow for the detection of subtle energies or vibrations. One school of thought, in regards to medical dowsing, is that the metallic rods are drawn together when over a source rich in iron such as human blood.
A hit occurs when the two rods move over one another. Or they may point in opposite directions, forming a straight line and perhaps indicating a particularly long segment of blood vessel close to the surface. Sometimes the rods are prevented from moving by nearby interference, such as when there is a skeptical family member in the room or when the clinic had been built on iron-rich soil. But for a highly trained medical dowsing practitioner, the rods don’t always need to move in order to successfully locate an area of clinical concern or interest.
“I once worked on a man who, several years later, was found to have metastatic liver cancer right under where I remember getting a strong feeling as my rods passed over,” Samuelson revealed. “You don’t forget something like that. That’s why I trust my training and the scientific foundation it was built on.”
Critics have questioned the validity of dowsing, citing the failure to successfully find water under controlled testing conditions and an overall lack of scientific plausibility. But this type of negativity doesn’t concern Nurse Samuelson and other proud practitioners of medical dowsing. “I know it works because I’ve seen the results myself. And patients love it. At the end of the day, isn’t that what truly matters?”
Uncrossing the rods
I realize that medical dowsing sounds ridiculous, largely because it is ridiculous. This does not, as I’m sure readers of SBM know all too well, mean that there aren’t plenty of people out there who believe in it and support incorporating it into conventional medical practice. This is true despite the many controlled attempts to replicated dowsing success that have failed to show it works better than mere chance, and a highly plausible explanation for what dowsing practitioners experience known as the ideomotor phenomenon.
What inspired me to post this today, however, was a March 2022 article on dowsing in the field of forensics that I recently stumbled upon. The article features a highly respected program in the field of crime scene investigation:
Dowsing for the dead is not exactly endorsed by scientists or forensic experts. But it is a highlight for some students attending the National Forensic Academy, a 10-week training program sponsored by the University of Tennessee. Since the academy’s inaugural class 20 years ago, school administrators say, more than 1,200 crime-scene investigators from agencies in 49 US states and five foreign countries have attended the program, which currently costs students $12,000.
The featured forensic dowsing expert is a walking textbook in pseudoscience belief systems, even comparing himself to Galileo:
Cutting-edge scientists have always faced skepticism and even persecution, he says. “Galileo’s a great example. Remember what the church did to him when he said Earth was not the center of the universe?”
Though dowsing in the field of forensics is hardly mainstream, my jaw hit the floor when I read this:
In particular, some experts are distressed that a Vass trainee recently got witching results admitted as evidence in a Georgia murder trial. This could set a legal precedent and allow witching-based evidence to be used in other cases, says Chris Fabricant, a lead attorney for the Innocence Project, which works to exonerate wrongfully convicted prisoners. “The search for the truth is never advanced through junk science,” he says.
Sadly, I was able to confirm this and even found video of the testimony involving dowsing. It starts at 15:45 and involves a description of dowsing as well as a demonstration, in a court of law during a murder trial. The man even makes an excuse ahead of time in case his demonstration fails, claiming that a nearby cemetery could interfere with the rods. This is a completely uncontrolled test with a box of bones in clear view, so there was zero chance that the rods weren’t going to behave as desired by the so-called expert.

PEDIATRICS

Pediatrics & “CAM” I: the wrong solution
Jann Bellamy on November 17, 2011
Link
Oh no!  Not again! The venerable medical journal Pediatrics devotes an entire supplement this month to Pediatric Use of Complementary and Alternative Medicine: Legal, Ethical, and Clinical Issues in Decision-Making.
We sense from the very first sentence that we are in familiar territory:
Rapid increases the use of complementary and alternative medicine (CAM) raise important legal, ethical, clinical, and policy issues. (S150)
“Rapid increases”? And evidence of these “rapid increases?” None cited.
We do, however, see the same shopworn reference to popularity deconstructed elsewhere on SBM. What we learned by actually examining “the large 2007 US survey” which purportedly “revealed that ~4 in 10 adults and 1 in 9 children and youth used CAM products or therapies within the previous year”(S150) is that
…most hard-core CAM modalities are used by a very small percentage of the population. Most are less than five percent. Only massage and manipulation are greater than 10 percent. These numbers are also not significantly different from 10 or 20 years ago — belying the claim that CAM use is increasing.
We also find this definition of “CAM”:
a broad domain of healing resources …other than those intrinsic to the politically dominant health system of a particular society or culture in a given historical period. (S150)
I’m not sure what it takes to become “intrinsic” to the “politically dominant” healthcare system. If it includes being legal, licensed or covered by public and/or private insurance, that would appear to disqualify dietary supplements, chiropractic, acupuncture, homeopathy, homeopathic products and naturopathy as “CAM” in some, or in some cases all, of the American states.
There are four main authors, one of whom will be familiar to SBM readers: Michael H. Cohen, J.D., a character in Dr. Kimball Atwood’s revelatory opus on the “CAM” shenanigans at Harvard Medical School. Cohen’s pro-CAM proclivities have been nicely set out in our friend Orac’s recent post over at Respectful Insolence: “Misinformed Consent rears its ugly head in Pediatrics,” which takes on one of the Supplement’s articles: Informed Consent: Advising Patients and Parents About Complementary and Alternative Medicine Therapies. (S187-S192)
Another author is Sunita Vohra, M.D., M.Sc., a Canadian physician affiliated with the “Complementary and Alternative Research Education (CARE) Program,” at Stollery Children’s Hospital in Edmonton, Alberta, Canada.
The authors acknowledge the contributions of the Canadian College of Naturopathic Medicine (S153) and an “anonymous pediatric chiropractic reviewer” (S204).
Cohen and Dr. Vohra have ploughed this ground before: in 2007, as co-authors of “Ethics of complementary and alternative medicine Use in children,” in Pediatric Clinics of North America. Dr. Vohra also co-authored “The use of complementary and alternative medicine in pediatrics,” as part of the Task Force on Complementary and Alternative Medicine, Provisional Section on Complementary, Holistic and Integrative Medicine, also in Pediatrics.
If you have read those articles, there is nothing new here, except an expansion of post-hoc rationalization for the use of “CAM.” As with CAM efficacy/effectiveness research, CAM legal and ethical research builds on the unshakable premise that CAM — whatever CAM is — must be included in the health care armamentarium, and then scrambles to tell us why the evidence — in this case law and ethics in addition to scientific research — mandates this conclusion, a topic to which I will return in a subsequent post.
DANGER: “CAM” in use
In the first of ten articles comprising the supplement, the authors state they
examined current legal, ethical, and clinical issues that arise when considering CAM use for children and identified where gaps remain in law and policy. (S150)
As a springboard for this examination, they construct various scenarios in which a pediatrician or other physician must deal with the unfortunate presence of CAM in his patient’s case.
(In light of Dr. David Gorski’s Monday post, Defining what a ‘physician’ is, please be advised that that when I say “physician” I mean an M.D., or, in the U.S., a D.O., a definition which will remain consistent throughout my posts until further notice.)
What immediately strikes the reader of this series is the number of times the authors mention the lack of research supporting the use of CAM for pediatric patients. The articles are filled with statements such as:
    • Meeting [the need for ‘sound information’ about CAM practices] is made more difficult by the relative scarcity of pediatric research in the area. (S150)
    • This determination [of who should make treatment decisions] may be more challenging when considering CAM, because evidence may be lacking or less adequate than desired. (S152)
    • Relatively limited research on the efficacy and safety of CAM, especially in children, means that decisions must frequently be made in conditions of uncertainty. (S152)
    • [A suggested framework for advising patients about CAM] may be helpful when there is adequate reliable evidence but it is less helpful when evidence is lacking or limited, as is often the case with CAM. (153)
    • Information about the safety and efficacy of CAM therapies is increasing all the time, but there are still large gaps in knowledge. (S153)
    • [T]he lack of evidence about many CAM therapies and products can make assessing CAM options particularly difficult. (S153)
And that’s just the first four pages of text! (S150-S153)
Another curiosity is that the CAM used in hypotheticals designed to illustrate the authors’ points is described almost uniformly as ineffective and dangerous. Not curious in the sense that this would be unusual or surprising, but curious considering the authors’ recommendations, which we’ll get to later.
    • Jenny, an HIV-positive teen, takes (unbeknownst to her treating specialists) St. John’s wort for self-diagnosed depression. This results in the possibility that “a drug-herb interaction has led to her unstable indinavir levels and decreased CD4+ T-cell counts.” (S156-160)
    • Chris, who is 14 years old, is diagnosed with ulcerative colitis. His doctor recommends surgery and his parents agree that this is the best option, and all risks and benefits having been explained to both Chris and the parents. Chris, however, says he has “researched his condition and knows that other therapies, including homeopathic treatment, are available.” He is opposed to surgery and wants to consult a homeopath. (S161-S166)
    • Three-year-old Angela was diagnosed at 15 months with glycogen storage disease type IV and her gastroenterologist recommends a liver transplant. After initially agreeing to put Angela on a transplant waiting list, her parents want her taken off because “they have spoken with a Chinese medicine (TCM) practitioner, who recommended specific dietary treatment, mind-body imagery, and acupuncture.” (S176-S180)
    • The mother of Phoenix, age 24 months, doesn’t want him to get the MMR vaccination because “her chiropractor has discussed the issue of vaccination with her,” including the topic of vaccination safety. He discussed immune function as well and noted that treatments such as spinal manipulation and nutritional supplements, “although not an alternative to vaccination, may optimize her son’s natural immune function.” (S168-S172)
    • Lindy is a teen suffering from chronic recurrent headaches. After trying other treatments, her physician refers her to an acupuncturist. The acupuncturist uses unsterilized needles and she contracts acute hepatitis B. (S182-S186)
    • Michael, a 14-year-old, has “new-onset back pain with no known precipitating cause.” He goes to his mother’s chiropractor who concludes Michael has a “misaligned spine” and performs spinal manipulation on Michael twice a week for 6 weeks. Michael complains of increasing fatigue and pain, for which the chiropractor recommends nutritional supplements and relaxation techniques, having concluded that these symptoms are adverse responses to the manipulation. Michael then sees a pediatrician and is diagnosed with testicular cancer with lung and retroperineal nodal metastases. (S201-S205)
The point of these “case scenarios” is “to act as a practical anchor in the exploration of CAM policy issues and to illustrate the application of and shortcomings in existing guidance and intervention principals.” (S151) One of the purposes of these articles, the authors further explain, is to “act as a catalyst for policy development.” (S153)
A “job jar” for medicine
Their solution is to come up with a big “to do” list for pediatricians and other physicians who care for children. Here’s what the authors want you — the busy physician — and the larger medical community, including hospitals, to do:
     1.  “Be aware of research regarding CAM use for those conditions [you treat, especially chronic health conditions] to help prevent the potential harm of adverse reactions.” (S156)
     2.  If your patient insists on using CAM instead of “conventional” treatment, you “will need to closely monitor his condition by using conventional means.” As well, you should “attempt to ascertain whether there is evidence about its use for this condition, and assess the likely impact on his health.” (S164)
     3.  When referring a patient to a CAM practitioner, “the physician should also learn about the proposed treatment plan to ensure that it is what was anticipated when referring and does not include practices known to be unsafe or ineffective. In addition, he should monitor the patient conventionally and treat as appropriate.” (S184)
     4.  If the physician doesn’t want to refer a patient to a CAM provider he “should state his or her own view and reasons [and] refer the patient to another physician who may be more comfortable advising about the referral or to a regulatory authority [for the “CAM provider] or professional association [of CAM providers]. (S184)
     5.  “There is a moral imperative [!] to develop good evidence through research into CAM therapies to facilitate informed decision-making and informed consent.” (S152)
     6.  We must “incorporate more formal training about pediatric care into chiropractors’ education” to “reduce the risk of adverse events caused by delays in diagnosis or referral.” (S203)
     7.  “Patient and public education campaigns” need to inform dietary supplement consumers of risks and adverse effects of supplements. (S158)
     8.  Hospitals must institute credentialing for “CAM” providers. (S196-S198)
     9.  And finally, because there are “divisions between …CAM practitioners and some physicians about the merits and risks of vaccination …educational programs …about vaccines and the diseases targeted should be developed.” (S168, S171). This recommendation comes in spite of the authors’ acknowledgment that “neither evidence-based teaching nor presentations from polio survivors changed chiropractic students’ perceptions of immunizations.” (S170)
It’s all your fault
And why the list? Perhaps because in the illustrative scenarios created by the authors, it isn’t the lack of sound public policy and adequate regulation which allows these CAM disasters to happen. In several of the scenarios it’s your fault, dear physician.
Thus:
Who are the parents of Jenny, our HIV-positive teen, mad at about her dietary supplement — drug interaction? The government for failing to adequately regulate supplements? No. Sen. Orrin Hatch? No. Perhaps a supplement manufacturer for making overly broad claims about St. Johns wort? No. How about the manufacturer for failure to warn about drug interactions? Wrong again. They are mad at her HIV specialist because, according to the authors, although supplement — drug “interaction data are still scant, particularly from pediatric populations” the specialist who treats Jenny “should make special efforts to explore CAM use with patients during history-taking.” (S156-S158)
We next learn that this has caused the parents to lose faith in their daughter’s specialist which (the plot thickens) leaves them with “limited options” because “there may simply be no one else to provide care to Jenny.” Thus, “the onus is on her physicians to take the steps needed to begin rebuilding trust and, more broadly, to alter their practice to take the increasing prevalence of various forms of CAM use into account.” (S157) Indeed, the authors argue that “practitioners are legally obligated to inquire about the use” of supplements. (S157)
In the case of Lindy, who contracted hepatitis B from acupuncture needles, we see that it is the physician’s fault for failing “to check to determine if the practitioner is licensed by a trustworthy body, such as a professional college or regulatory body.” (S182) Well, at least, according to this vignette, Lindy’s chronic recurrent headaches “that have not been relieved by any of the medications her physician has suggested” seem to have disappeared after two weeks of acupuncture. (S182)
Then there’s little Phoenix, whose mother doesn’t want him vaccinated based on her chiropractor’s dubious advice. In the authors’ view, this simply requires “different and unique educational strategies” for chiropractors about vaccination because “one reason for this failure [of educational efforts] may be that educational programs have not addressed practitioners’ concerns, such as questions regarding safety of adjuvants and preservatives used in vaccine preparation.” (S170) An odd recommendation, seeing as how that very information is readily available to everyone else.
Jake, a six-year-old with medulloblastoma, in the case covered by Orac, suffers from chemotherapy-induced nausea and vomiting (CINV), which drugs either do not relieve or cause unpleasant side effects. His parents are also mad at their son’s oncologist because they learned on the internet about acupuncture for CINV and “are delighted to see that his nausea and vomiting are much improved after each acupuncture session.” Not only that, but “Jake begins to regain his appetite, gains weight, and generally has a better sense of well-being.” (S188)
The parents could be forgiven for attributing this positive effect to acupuncture, an effect that goes way beyond what the studies indicate would happen, even taking the most optimistic view of the authors’ evidence (S190),  which Orac reviewed.  We should be far less forgiving of the authors’ coming to the same conclusion when they state, in a different article following up on Jake’s progress:
We continue with the example of 6-year-old Jake’s success with acupuncture for chemotherapy-induced nausea and vomiting, described in the preceding article ….” (S194)
We’ll return to Jake’s “success with acupuncture” in the next post, when I’ll examine why the authors’ ethical, legal and medical arguments don’t support the their recommendations and offer “alternative” ideas about the locus of the solution to the CAM problem.
The authors are apparently of the view that these very serious problems with CAM — lack of evidence, incompetence of CAM practitioners and their overly-broad scope of practice, safety issues, intransigence to public health measures, ineffective treatments — are solvable if only the medical community would get off up its collective derriere and embrace CAM — monitor it, study it (post hoc), alert the public to its dangers, provide it with some additional education and training, overcome its resistance to proven public health measures, credential it, waive the usual level of evidence required to recommend therapies and forget plausibility as a basis for medicine.
They don’t ask for much, do they?

Pediatrics & “CAM” II: just wrong
Jann Bellamy on December 1, 2011
Link
In November, the journal Pediatrics published an entire supplement devoted to Pediatric Use of Complementary and Alternative Medicine: Legal, Ethical and Clinical Issues in Decision-Making. The authors purport to have “examined current legal, ethical, and clinical issues that arise when considering CAM use for children and identified where gaps remain in law and policy.” (S150) Their aim is to “illustrate the relevance and impact of identified [ethical, legal and clinical] guidelines and principles,” to recommend responses, identify issues needing further consideration, and thus “assist decision makers and act as a catalyst for policy development.” (S153)
Unfortunately, as we saw in Pediatrics & “CAM” I: the wrong solution, the authors’ solution for the “issues that arise when considering CAM use for children” consist, in the main, of placing a huge burden on the practicing physician to be knowledgeable about CAM, keep up with CAM research, educate patients about CAM, warn patients about CAM dangers, refer to CAM practitioners, ensure that CAM practitioners are properly educated, trained and credentialed, and so on.
Limit CAM? Not happening
Curiously absent are recommendations placing responsibility on those who profit from the sale of CAM products and services — the dietary supplement manufacturers, homeopaths, acupuncturists, and the like — whose actions are directly responsible for the deleterious effects on patients’ health detailed in the supplement articles and described in the earlier post.
Apparently the authors’ view is that there is no accommodation to CAM too onerous to ask the practicing physician or the patient to bear. Even though they plainly locate the problems they describe — a missed diagnosis, ineffective treatments, drug therapy interactions, poor advice — in the CAM services and products themselves, suggesting that these services and products be limited or eliminated never seems to cross their minds.
It is not as if they are unaware that regulation of CAM is less than ideal. In discussing credentialing of CAM providers, they suggest:
Hospitals should be aware of the scope of CAM providers’ practice authorized by legislation and ensure that therapies provided on-site comply with regulatory requirements. Uncertainty about safety or efficacy may affect decisions about the scope of practice permitted on site. Institutions may narrow CAM providers’ scope of practice in the hospital from that authorized by their governing statute. If there is not convincing evidence of efficacy for some part of CAM providers’ practices, some American health care institutions limit them to what is supported in the literature. (S197)
In other words, the authors know that while the safety and efficacy of “some” CAM practices is questionable, these practices are nevertheless permitted by CAM practice acts. Yet they fail to recommend that the problem be treated at its source, by limiting or removing the statutory authority to engage in those practices.
The authors also state “there is a moral imperative to develop good evidence through research into CAM therapies to facilitate informed decision-making and informed consent.” (S152) (They offer no suggestions as to who should pay for this research.) This “moral imperative” exists, according to the authors, because those who make treatment decisions for children, when considering CAM, may be confronted with situations in which “evidence may be lacking or less adequate than desired.” (S152)
Would it be too much to suggest that perhaps we simply not allow health care products and services where “evidence may be lacking or less adequate than desired”? That we as a society could require a plausible basis in science and maybe even a bit of evidence of effectiveness before allowing therapies and products to be used on actual patients, especially children?
Given the authors’ stated desire to inform public policy, one would assume they would make compelling arguments for their exoneration of all responsibility for CAM providers and sellers of CAM products. Perhaps we could respect the authors’ conclusions if they at least undertook this discussion and then argued against any limitations on CAM. But they do not. No matter how effectively their own examples demonstrate CAM’s untoward effects on patients and their families, they avoid any such discussion.
For example, in a scenario involving an HIV-positive teen, Jenny, whose undisclosed St. Johns wort use interferes with her drug treatment (S155-S160), there is no recommendation that the Dietary Supplement Health and Education Act be amended to require perfectly reasonable steps such as pre-market testing for safety and efficacy, or warnings on supplement labels of possible drug interactions. Instead, the authors conclude it is the physician’s responsibility to know of this possible interaction, to inquire about the patient’s supplement use, to recommend discontinuation of the supplement, to find another treatment for her self-diagnosed depression, and so on.
Likewise, in another hypothetical, the parents of three-year-old Angela want to use Traditional Chinese Medicine in lieu of her physician’s suggestion that she undergo a liver transplant for glycogen storage disease type IV, a rare genetic disorder. The authors’ solution to this dilemma is to have the physician treat the parents’ preference as a serious option and undertake research on TCM for glycogen storage disease type IV. As one might expect, “there are no specific data [about TCM] for Angela’s condition to help guide her.” (One is tempted to say, “Duh!”) Therefore, the physician should then “tell the parents what she has learned about the lack of evidence supporting the use of TCM for this condition.” (S178) If the physician decides a transplant is “the only reasonable choice” and the parents continue to refuse “conventional” treatment, “child welfare authorities will have to be involved.” (S178)
While the authors are willing to place this enormous burden on the practicing physician, there is no corresponding recommendation for TCM practitioners or policy makers. Would it not be perfectly reasonable to greatly reduce the scope of practice of TCM so that this sort of choice is removed from the realm of possibilities? (Perhaps the authors hold out the possibility that someday we’ll discover TCM cures glycogen storage disease type IV?) Why not recommend that TCM professional organizations enact a code of ethics which would prevent any TCM practitioner from ever suggesting TCM is an appropriate remedy for glycogen storage disease type IV? Why not preclude TCM practitioners from treating pediatric patients altogether, or only upon the recommendation of an M.D. or D.O.?
Similarly, in the case of fourteen-year-old Chris, who wants to see a homeopath instead of having surgery for ulcerative colitis (S161-S166), the authors never even explore the possibility that perhaps, as a matter of public policy, we should not license homeopaths nor allow the sale of homeopathic products, even while they admit that homeopathic products are not effective. (There is no discussion of why they can’t be effective.) No, their recommendation is:
The physician [after researching the issue] should share the lack of efficacy data and reassuring safety data about homeopathy with Chris. If he is [legally] able to make his own decisions, this will assist in ensuring that his consent is both properly informed and voluntary. If he insists on homeopathy, the physician will need to closely monitor his condition by using conventional means. (S164)
Policy solutions: wrong again.
The authors’ avoidance of placing any burden on those who profit from the sale of CAM goods and services could be excused if they were simply focusing on what practicing physicians might do when confronted with the unfortunate presence of CAM in their patients’ cases, leaving broader policy solutions for another day. However, that is not the case.
In only one instance out of the 10 articles comprising the supplement do the authors suggest that CAM providers themselves take responsibility for reducing the unfortunate consequences of their actions. In response to a case in which a chiropractor fails to diagnose testicular cancer in a teenage boy and fails to refer the boy to a physician when chiropractic proves ineffective for his symptoms, the authors recommend that “incorporating more formal training about pediatric care into chiropractors’ education could reduce the risk of adverse events cause by delays in diagnosis or referral.” (S203)
This is not a good suggestion, as essentially what they are asking is to make chiropractors capable of differential diagnoses for pediatric conditions, a skill that can’t just be tacked onto chiropractic education with a course or two. But at least it does raise the possibility that some responsibility for CAM’s ill effects lies with the CAM practitioners themselves and that they should do something about it.
Another suggested policy change — this as a solution to parents’ reluctance to have their children vaccinated — is a no-fault system of vaccine compensation. (S167-S174) Again, while credit is due for the rare suggestion that does not further burden the practicing physician, this is another bad idea.
The authors observe that “the need to establish a causal link between the vaccine and the harm suffered still limits eligibility” for compensation and propose “no-fault compensation in those rare instances when serious injury occurs” (S170) although this suggestion is truncated later in the article to “a no-fault compensation if a child should suffer a vaccine-related injury” (S171).
This proposal is curious, to say the least. First, in the U.S., there is already a no-fault administrative system for certain vaccines if the claimed side effect is one recognized by a statutory index and occurs within a specified time frame. If the criteria for one of these “table claims,” as they are called, is met, there is a statutory presumption of eligibility for compensation. If the claimed injury is “off table,” there is no presumption of causation and the claimant must satisfy a preponderance of the evidence standard to recover. However, instead of having to resort to the courts under traditional tort principles, cases are heard before Special Masters, with relaxed rules of evidence, assured payment to plaintiffs’ attorneys, and other plaintiff-friendly provisions.1
In any event, an exclusively no-fault system is simply inappropriate for putative vaccine-injury claims because of the speculative connection between vaccination and injury in many cases. The traditional tort system is meant to place financial responsibility for injury on the party who caused the injury instead of the injured party. No-fault systems are designed to eliminate the requirement that the injured party prove causation where there is an identifiable event in which the injury occurred — a car crash or an industrial accident, for example. In the no-fault vaccine injury system, the “table claims” are based on scientific evidence of a plausible connection between the vaccination and the injury, and thus fit a no-fault scheme.
In no-fault systems, certainty of recovery for the injured replaces the uncertainty of the fault-based tort recovery system. As a trade-off, insurers and their insureds benefit from the cost savings introduced when fault-based litigation is reduced or eliminated. In addition, costs are spread among all drivers, in the case of no-fault auto insurance, or, in the case of workers’ comp, all employers, thereby reducing the individual cost to any one driver or employer.
The authors want to extend this no-fault system to all vaccine claims. Presumably, any illness occurring at any time after any vaccination would subject the vaccine manufacturer to liability under the authors’ proposed no-fault scheme. The very reason the vaccine manufacturers themselves pushed for a statutory solution to the traditional tort system for adjudicating claims was that, in exchange for considerable concessions, an element of predictability would be introduced to the number of potential claims and the amount of liability. A no-fault system would reintroduce a huge element of unpredictability — chaos wouldn’t be too strong a term — into the vaccine injury compensation system, as there would be no way to predict the number of claims or the extent of injuries for which manufacturers could be held responsible. We would be back to where we started when the Vaccine Act was adopted in 1986, with only a handful of manufacturers producing vaccines, and those threatening to cease production.
Discussion ≠ Recommendation
As we’ve seen, the authors go to great lengths to accommodate CAM by creating a lot of extra work for the physician. At the same time, they avoid even suggesting any reasonable limitations on CAM practices and products or, for the most part, suggesting that CAM providers and sellers of CAM products themselves do anything to avoid the injuries they cause. We have also seen that they arrive at this solution, not by thoroughly discussing and then rejecting any limitations on CAM, but simply by avoiding discussion of such possibilities altogether.
But let’s give the authors one last chance: do they deserve credit at least for coming up with solutions that are compelled by their analysis of legal and ethical principles, even if their solutions avoid directly addressing the deficiencies of CAM? In other words, do they at least get some credit for effectively arguing for their conclusions? Again, no.
This is not to say that they don’t do a serviceable job of covering the basics in some of the articles. They do. There are decent discussions of the basic law of negligence, court intervention when parents refuse effective treatments for their sick children, malpractice, informed consent, hospital credentialing, the decisional capacity of children, and other subjects of interest to the practicing physician. The problem is, however, that their explication of these basics does not, in my view, compel the results they suggest.
For example, in discussing Chris, the teen who wants to forgo surgery for ulcerative colitis and see a homeopath, the authors review the law on decisional capacity of patients. (S163-S164) But nothing in that discussion requires the conclusion that the physician go to the trouble of researching the efficacy of homeopathy. Yet that is what the authors have the physician doing. (Helpfully, the authors tell us that “[t]here are few data regarding the use of homeopathy for irritable bowel disease to gauge potential efficacy.”(S164.))
Likewise, there is a discussion of hospital credentialing in another article (S194-S196), which leads to this suggestion:
It would be prudent for hospitals and health facilities to consider adopting a formal protocol and/or formal processes to establish what CAM therapies and products to allow or make available on-site, which kinds of CAM practitioners can provide them, under what conditions they may be provided, and how they will function and interact with patients, other health care providers, and the institution. (S196).
And exactly why would this be “prudent?” What in their discussion of credentialing leads to the notion that allowing CAM in the hospital is “prudent?” Nothing.
In one instance, the authors try to manipulate the law into compelling the physician to advise patients about an acupuncture treatment for chemotherapy induced nausea and vomiting (CINV) as part of the informed consent process. (S189-S191) In a review of the law of informed consent, they find no precedent for requiring such a disclosure, yet somehow come to the conclusion that evidence for acupuncture for CINV is “likely sufficient to make its disclosure material to patients’/parents’ decision.” (S191) This conclusion is based on the authors’ overconfident view of the evidence, a deficiency discussed by Orac and Drs. Novella and Crislip.
Like their evaluation of the evidence, their discussion of the law of informed consent is superficial at best and fails to take into account its complexity or its variations among jurisdictions.2 In fact, the only cases and treatises cited by the authors for their sweeping generalization are Canadian, which would have no applicability in the U.S. In my opinion, it is irresponsible to suggest to the physician-reader that he may be subject to a malpractice action for not discussing acupuncture as an alternative to drug treatments for CINV based on such a facile discussion of the medical evidence and legal precedent.
Conclusion
This Pediatrics supplement presents CAM for the most part as ineffective and sometimes dangerous. But instead of arguing for reasonable limitations on, or elimination of, CAM products and services, the main message is that physicians must accommodate CAM in their practices, even to the point of referring patients to CAM practitioners. This is the wrong solution to CAM.
This is the same sort of attitude CAM proponents tried to incorporate into the College of Physicians and Surgeons of Ontario’s (CPSO) draft policy on “non-allopathic” medicine, the subject of Dr. Novella’s post yesterday and an earlier post by Dr. Gorski. Fortunately, as noted in those posts, physicians pushed back against the recommendations. This resulted in changes to the more blatantly CAM-friendly proposals.
Dr. Novella recommended that “physicians, individually and as a profession, should actively advocate for and promote the science-based standard in medicine — in academia, regulation, and practice.” In publishing this supplement, Pediatrics has certainly failed physicians and the profession in this regard.
Notes
     1.  See, Robert L. Rabin, The Association of American Law Schools 2011 Annual Meeting: Section on Torts and Compensation Schemes Symposium: The Vaccine No-Fault Act: An Overview, 8 Ind. Health L. R. 267 (2011), for an explanation of the current vaccine compensation system and a discussion of its origin. Return to text
     2.  See, Jaime Staples King and Benjamin W. Moulton, Rethinking Informed Consent: The Case for Shared Medical Decision-Making, 32 Am. J. L. and Med. 429 (2006), for a review of the law of informed consent in various jurisdictions. Return to text

Alternative Medicine and the Vulnerable Child
Clay Jones on April 26, 2013
Link
A concept that has been well-recognized in pediatric medicine, at least since it was first described in 1964, is that of vulnerable child syndrome (VCS). Classically VCS occurs when a currently healthy child is felt to be at increased risk for behavioral, developmental, or medical problems by a primary caregiver, usually a parent, and typically follows a serious illness. It can lead to some pretty serious behavioral complications in the parent, and subsequently the child, and severely impact entire families.
In the past, I have mistakenly thought of this entity more as “sick child syndrome” but that is problematic. It implies that it only occurs in the aftermath of true illness or injury. As I will explain in detail, there is much more to the development of VCS and it is the concern of VCS in children without true medical problems that led me to amend my understanding and make the connection with alternative medicine.
Is VCS Really a Problem?
Every parent (well, most parents – I’ve seen some things), worries about the well-being of their children. The desire to protect our personal genetic repositories is hardwired. And as with many behaviors, there is a point where parental worry becomes pathologic and interferes with normal functioning. In the case of VCS, the relationship between the parent and child can be severely impacted and the consequences can be disastrous.
This irrational perception of vulnerability leads to abnormal parental behaviors, such as overprotection, difficulty setting limits and an excessive focus on future health complaints from that child. Not surprisingly, visits to primary care physicians, emergency departments and urgent care facilities well beyond what is typical for most children (several times each month in some cases), is commonly observed. Parents can also develop severe separation anxiety as well as difficulties with discipline, even to the point of allowing the child to physically abuse them.
Ultimately, these behaviors can result in the child suffering severe separation anxiety themselves, behavior and sleep problems, difficulty in school, and abnormal fixation on their own health. These children will often begin to develop psychogenic symptoms or take part in risky behaviors that further reinforce the concerns of the parent. They are often exposed to unnecessary medical testing, ionizing radiation from diagnostic imaging modalities such as CT scans, and prescription medications.
What Causes VCS?
VCS is a potential consequence of extreme parental anxiety in response to the perception of vulnerability in their child. They don’t have to actually be vulnerable, the caregiver just needs to think that they are. This anxiety tends to be initiated by the diagnosis of significant illness in a particular child, or by a high-risk pregnancy/delivery during which the life of the child or mother was felt to be at risk. But, and this is important, it can occur even when the illness in question is not serious, or when there isn’t any illness in the first place.
A large number of studies have demonstrated the occurrence of VCS in a variety of settings. This unfounded anxiety can even stem from something as seemingly innocuous as a false positive newborn screen result that is quickly determined to be spurious, or as shown in a 1967 study by Bergman and Stamm (The Morbidity of Cardiac Nondisease in Schoolchildren), even an innocent heart murmur. This common occurrence in young children led to 40% of parents restricting their child’s athletic activity even years later.
Children hospitalized early in life, even for relatively minor issues and who had full recoveries (in other words most of the children admitted to hospitals), were much more likely to have parents who assessed them as particularly vulnerable. One interesting study by Perrin demonstrated that past health issues, in this case the sequelae of premature birth, played a far larger role in determining the parental perception of vulnerability than did a current healthy status. This certainly jibes well with my anecdotal experience of having been forced to discuss my concerns of VCS with many a tearful parent as their playful toddler tears up the examining room.
Naturally, as with most disorders of a psychological nature, factors that can potentiate the untoward effects of VCS can include environmental and family stress, poor social support and low socioeconomic status. Multiple studies have shown that more educated parents are at higher risk. As to why that is, your guess is as good as mine but I don’t believe there is a causal relationship.
Another curious historical finding I’ve encountered in hyperanxious parents, and one which is commonly cited as a risk factor for VCS, is the death of a person very meaningful to the caregiver such as a family member or a sibling of the patient. In cases such as this, it is thought that the current patient has taken on a symbolic role for the parent and represents the deceased loved one. The VCS might be a manifestation of their unresolved grief. It makes sense.
What is the Role of Physicians in VCS?
I often discuss the role that medical professionals play in the development of VCS with colleagues and I am frequently disappointed with these interactions. I get the feeling that it is an issue that doesn’t receive the respect that it deserves. I think that for many providers, the fear of missing a potentially serious medical condition, even a very unlikely one, outweighs the risk of long-term psychological complications that can sometimes occur when we dust off the old diagnostic shotgun or go on investigatory expeditions with low pre-test probability of success.
There is also, I think, a general acceptance of performing tests to “rule-out” problems rather than to “rule-in” problems that are felt to be likely based on history and examination. This is common amongst medical practitioners as well as lay persons. Recently a friend asked me what harm lay in obtaining medical tests that may not actually be necessary but might serve as a means of comforting a family or physician worried about a particular disease process. The answer, of course, is that our tests often are imperfect and our ability to interpret them is frequently biased. This leads to a large number of false positive determinations and incidental findings. My wife, a pediatric oncologist and palliative care physician, calls this poking the skunk because these false positives and meaningless incidental findings can lead to more intervention, much of which has inherent risk associated with it, and they can lead to VCS in some instances.
A common example of this occurs when the prototypical febrile 15-month-old with symptoms consistent with a viral lower respiratory infection is brought into the emergency department or primary care doctor’s office during the winter months. The evidence is clear that these kids, with rare exception, do not have bacterial pneumonia and do not benefit from the routine ordering of chest films or complete blood counts but they are very frequently obtained anyway to rule out something which would require antibiotic therapy. These x-rays and labs are often equivocal or consistent with a viral lower respiratory process, but studies in these situations tend to serve as a Rorschach inkblot test with the interpreter seeing in them whatever he had already decided was causing the symptoms. In these cases, it is a bacterial process and antibiotics are prescribed. In some cases the child is admitted to the hospital for IV antibiotics because of their young age.
It is a very difficult task for a hospitalist to explain why an intervention that was just begun is being discontinued, especially one which makes such intuitive sense to a family. The physician ordering the antibiotics typically does not explain the ambiguities of such a diagnosis. They do not typically explain the extremely low incidence of bacterial pneumonia in such situations, or even discuss the difference between viral and bacterial pneumonia. They tend to walk in and confidently diagnose a bacterial pneumonia, and the use of antibiotics for pneumonia is seemingly hardwired in the psyche of the general public.
So when I stop the ceftriaxone, and begin talking about viruses and the reassuring chest x-ray obtained the night before, I sometimes meet up with parental anxiety and resistance to supportive, non-pharmaceutical interventions. On many occasions, I’ve seen these families during future admissions where a history of previous bacterial pneumonia is still given despite my prior attempts at education.
Sadly, I also have experienced on many occasions the subsequent concerning changes in how these children are cared for. Secondary to concern for another episode of bacterial pneumonia, these parents have sought out emergency care in the middle of the night for what is clearly another viral infection that could have been treated at home, or could have been easily handled by their primary care physician the following morning. I have cared for children whose parents believe they have had several episodes of bacterial pneumonia (which if true at a young age would be a red flag for a variety of serious predisposing conditions) that, based on review of old documents and films, were actually viral.
How Can Physicians Prevent VCS?
The key to preventing VCS is awareness of the concept and of the situations which might lead to its development, and the practice of science-based medicine. Avoiding unnecessary medical interventions is vital. We should also attempt to avoid exaggerated retrospective focus on past illness/injury and unintentionally alarming comments. But more important is recognizing the early stages of VCS, which can be aided by the use of available validated screening tools, so that proper psychological intervention can be initiated.
Alternative Medicine and VCS?
So what is the connection between alternative medicine and VCS? It is actually pretty obvious and I’m feeling rather sheepish about not having thought of this before. The science-based practice of pediatric medicine and the confusing jumble of unproven modalities lumped under the term “alternative medicine” differ in many ways. One of the most prominent is the plain fact that when a child is brought to a practitioner of (insert random alt med entity), or that child’s parents visit the website of a proponent of such an entity, they are rarely if ever told that nothing is wrong.
There is always something that can be fixed in the world of irregular medicine, often with multiple visits or supplements which just so happen to be sold right there in the office or by the author of the website. Chiropractors tend to find subluxations. Practitioners of traditional Chinese medicine discover stagnant chi. Naturopaths uncover ill effects of a toxic world. Numerous quacks order blood tests designed to confirm their suspicions of harmful heavy metal levels. Countless websites tout hypothyroidism and adrenal fatigue as near ubiquitous etiologies for any symptom you can dream up. Or maybe it is all because of abnormal body acidity. Or yeast. Or liver flukes. All of these have been proposed as the cause for almost all illness, and everybody is sick.
In contrast, as a pediatric hospitalist, someone who by definition only takes care of children sick enough to be admitted to a hospital, I still spend a large percentage of my day reassuring parents and patients that things are going to be okay, that their child’s condition is self-limiting or treatable, and that they will return to full health. On many occasions I prescribe no treatment at all, and participate in what has been called “masterly inactivity”, the calculated observation of a child in order to avoid unnecessary testing or pharmaceutical intervention. In the day-to-day workings of a primary care doctor, the overwhelming majority of visits are for well child check-ups or self-limited complaints with most receiving only advice and reassurance. We are able to do this because most of us strive to base management decisions on the best evidence available, as free as is humanly possible from biased interpretations and certainly free from the impact of an irrational devotion to any unscientific and unproven belief systems. There are exceptions of course, but these are not common.
I am forced to recognize that despite my best efforts to reassure some families, there will be times when a pathologic anxiety will develop. To give just one example, it seems painfully obvious that if the family of a healthy child brings their child to a chiropractor, and were told that one or more subluxations exist which need immediate treatment and long-term maintenance treatment to prevent their recurrence, that the risk of VCS would be very real. Just google the terms “SIDS” and “subluxation”, and you will find chiropractic websites and articles discussing that connection (or read my last post). Now imagine the fear that some families must go through believing that their child is at risk of dying in their sleep if they don’t see a chiropractor, as is recommended by many of them, in the newborn period. This is just one of many innumerable examples of alt med practitioners sowing the seeds of fear and anxiety by validating fictional problems. There are worse, much worse examples.
Unfortunately there is a lack of recognition of this problem by a large percentage of legitimate healthcare practitioners. An example of this was the 2010 publication of an article on the ethics of complementary and alternative medicine in Pediatrics in Review. Pediatrics in Review is a journal published by the American Academy of Pediatrics (AAP) and is geared towards continuing education for pediatricians. It contains review articles, quizzes and cases designed for maximized learning, and it is heavily used by pediatric residents. I’ve been reading it monthly since 2003 and have noticed the steady creep of alternative medicine nonsense into its pages, usually with review articles on the use of alt med for specific medical diagnoses. These articles tend to be poorly written and seem to rely on misinformed or biased sources such as the National Center for Complementary and Alternative Medicine (NCCAM), a propaganda machine for alt med that has also wasted over a billion taxpayer dollars on studying alternative practices with zero plausibility and heaps of prior negative studies. Sadly much of their budget goes towards supporting biased unscientific alt med education in medical schools, hence my use of the word propaganda.
Although this particular article was perhaps a little better than many treatments of alternative medicine by the AAP, it still left a lot to be desired. At no point in the discussion did the risk of VCS come up. I believe that although there are greater potential risks of exposing children to these unproven modalities, the development of VCS should certainly be included.
Another key component of science-based medicine is self-correction. There are heaps of studies on VCS and expert recommendations on how to limit it. There is a glaring lack of attempts to recognize and root out dangerous or ineffective practices in the alt med community. And when studies are done that show something doesn’t work or is potentially dangerous, they are generally ignored or denigrated by believers.
I don’t have high hopes that chiropractors, for instance, will shape up because of concern for the development of VCS. The worried well are the bread and butter of alternative practitioners. We shouldn’t give up of course. And increasing awareness of the harms of unnecessary testing within the ranks of conventional healthcare professionals is also necessary. The Choosing Wisely initiative is a good example of how to do it. The American Academy of Pediatrics recently submitted their list of 5 tests and treatments to question, and more are on the way. Will we see contributions from the world of alternative medicine?

Quackery for Kids
A brief rant and a few random observations on quackery for kids.
Clay Jones on June 2, 2017
Link

A brief and somewhat incoherent post today, written during breaks from preparing for my upcoming NECSS talk and patient care duties.
There are countless examples of the failures of so-called “complementary and integrative health” documented in the pages of Science-Based Medicine. Essentially, whenever judged by the same standards as commonly applied to conventional medicine, many popular pseudomedical entities such as acupuncture, homeopathy, and chiropractic are revealed to offer little more than theatrical placebo. At best, patients may experience a transient and minor improvement in subjective complaints.
Rarely do potential benefits outweigh the risk of harm to patients. And when a physician is involved, the deception required to materialize these meager potential benefits results in a sacrifice of patient autonomy that is ethically questionable. But it gets worse.
Sadly, these concerns have failed to prevent a growing public acceptance of blatant quackery. It has failed even to prevent acceptance by major academic institutions, or at least the acceptance by their administrators who are choosing profits over ethical patient care. Yet there are always credentialed believers at the ready to helm department after integrative medical department while rank and file healthcare providers simply shrug.
And taxpayer dollars in the millions are spent to help fortify this house of cards every year through the efforts of organizations like the National Center for Complementary and Integrative Health. There are days, many in fact as of late, where I find myself imagining a life where I had never been exposed to the realities of newborn chiropractic or homeopathic options for pertussis and drowning:
Drowning is a life-threatening emergency. Call an ambulance immediately if someone is drowning so they may be assessed by an emergency professional. After you call an ambulance, you may administer the remedy below.
Or you could just perform CPR. Reiki CPR, which can be performed secretly while compressing the chest or at a safe distance from the dying stranger, is apparently also an option.
Won’t somebody please think of the children???
My daughter, who just wrapped up a portrayal of Carl Sagan for a Living History project at her school, told me about a classroom discussion occurring one recent afternoon. Another student told the class about a session of acupuncture that they had undergone for some irrelevant reason. Several other students, as well as the teacher, then took turns relating their own positive experiences with acupuncture. My child, who is prone to outbursts of a skeptical nature, wisely held her tongue.
Granted there may be some degree of selection bias at play, considering that I do live in a town with more alternative medicine clinics than Starbucks and Dunkin’ Donuts combined. But I was surprised to hear that so many children in the class, all around 12 years old, had been to an acupuncturist. We know that children are exposed to a variety of pseudomedical entities, particularly when they are suffering from chronic illness or cancer, but most of this comes in the form of dietary interventions and herbal supplements. Only a small percentage tend to end up being treated by a practitioner of irregular medicine.
This isn’t because of a lack of effort.
Give me the child and I will give you the loyal, long term customer
There are many examples of alternative medical practitioners turning their focus on children. After all, if you convince a parent that their child’s spine requires regular chiropractic maintenance or that their chakras require balancing, you may have found a customer for life. At least some of them recognize that children are not just little adults:
Kids develop chakras at different stages of life. Not all of these will be intact until later, but it is good to get the conversation going.
The same can be said about the stages of puberty, and the paranasal sinuses. I recommend that parents sit down with their kids to discuss the paranasal sinuses at a young age, and to maintain an open and non-judgmental channel of communication throughout adolescence. You don’t want to find out about their neti pot use because of a brain-eating amoeba infection.
I did a bit of online research into kids and acupuncture. According to Robin Green L.Ac at KidsLoveAcupuncture.com, acupuncture offers “a safe, natural and effective approach to pediatric care.” In keeping with numerous other practice website marketing shtick, Green claims that acupuncture allows the body to harness its own healing and resilience, and that their treatment plans, unlike those from Western medicine, are customized holistically to each individual child:
Sometimes generic western treatments may not be able to adequately address the challenges faced by a child and parents may be told they’ll just “grow out of it.” No parent wants to accept such a fatalistic view when their child is suffering!
And they accuse us of bias against them. My wife, a pediatric palliative care physician, cares for suffering patients. I do sometimes as well. We both do everything we can to prevent and relieve suffering. If a child’s suffering can be alleviated by acupuncture, or is something that a child may outgrow, we may have to agree to disagree on what the word actually means. Honestly, I’m not even sure what she could mean by that last sentence.
Similar to the way chiropractors market their brand of pseudoscience to potentially nervous parents, pediatric acupuncture can be fundamentally changed to suit the population without concern of a loss of effectiveness. If Timmy is a little nervous about needles being shoved into his skin, or if he has trouble sitting still for a long session, he conveniently has little to fear:
For young children a rapid needling technique is used, where the needle is inserted and immediately taken out. Babies and children do not have to sit still for more than a few seconds at a time.
And:
A child is never forced to have acupuncture treatment and there are several other non-needle treatment techniques that your acupuncturist may use. They are easy, painless and have a similar therapeutic effect to acupuncture.
I doubt that ancient Chinese acupuncturists devoted much time to studying the effectiveness of various acupuncture techniques in infants and toddlers. But I am confident that the therapeutic effects of kid-friendly pediatric acupuncture are similar to acupuncture performed on adults, and even turtles.
All pediatric acupuncturists really want to do is address deficiencies, be they in the flow of mystical energy or the care of conventional pediatric providers:
Most acupuncturists offer well visits where they can address health issues before they become a major issue. Well visits allows the practitioner to address some of the deficiencies of conventional pediatric care such as nutritional counseling, attention to environmental toxins, emotional health and more. After the birth of a baby, guidance is provided for parents on all aspects of the baby’s care such as decisions regarding sleeping arrangements, support for breastfeeding mothers, treatment of common problems like colic and reflux.
At the Center for Advanced Acupuncture Pediatrics, the online practice building/training resource division of the Robin Green L.Ac pediatric acupuncture empire, you can learn about pediatric health in order to “grow a thriving practice.” During her $575 Pediatric Essentials course, reading a kid’s body language, herbs for babies, chronic low immunity, leaky guts, and more through the use of case studies and without having to actually be around children. According to one satisfied recent course graduate, “This course content is not provided in textbooks.”
If you are looking for an illustrated book to teach young children about homeopathy, look no further than Jackie Jormp-Jomp’s Rhymes for Remedies. Homeopathy is an amazing healing art that can simultaneously be both too individualized to be effectively studied by Western scientific methods and simple enough to be taught using nursery rhymes. Or you can find a remedy with “just 3 taps” using Boiron’s free smartphone app.
Hail to the king, baby
The undisputed king of marketing aimed at ensuring future customers is chiropractic. It just isn’t a state fair or neighborhood festival without one offering free spinal screens for the kids. And they put out an endless stream of stickers, coloring books, and juvenile fiction in the name of practice-building. Plus it’s so easy a toddler can do it. Okay, even I have to admit that one was pretty adorable. There may be hope for me yet.

Here be Dragons: Caring for Children in a Dangerous Sea of sCAM
John Snyder on September 11, 2015
Link

As a pediatrician working in a relatively sCAM-inclined region, it is not uncommon to find myself taking care of patients who are also being followed by so-called alternative medicine practitioners. This often creates a major obstacle to providing appropriate care and establishing an atmosphere of mutual trust in the provider-patient/parent relationship. It usually makes me feel like I’m battling invisible serpents in a sea of sCAM.
While these double-dipping parents utilize a variety of sCAM providers, including naturopaths, homeopaths, chiropractors, and a smattering of “holistic healers”, most are taking their children to one of a few “wellness” centers near my practice where they are seen by actual medical doctors practicing so-called “integrative medicine”. Many of these children have vague, chronic, usually non-specific complaints that are difficult to explain and thus to treat. Some have behavioral and mental health problems, or neurodevelopmental conditions such as autism for which parents are seeking explanations and treatments.
What I find to be a common theme with these patients is that they and their parents are summarily taken advantage of by their alternative care providers when they are given a fictitious diagnosis and treated with a variety of useless potions, elixirs, and false hopes. Often, parents bring their children to these providers because they are frustrated by their child’s chronic complaints of fatigue, pain, or other somatic issues that have eluded a satisfactory diagnosis or treatment. Invariably, the diagnosis that has remained so elusive to me is quickly found and treated by these much more “holistic” and open-minded providers. In fact, I have never seen a consultation note from one of these providers indicating any uncertainty as to diagnosis or treatment regimen. Typically a large battery of expensive, inappropriate, and sometimes outright fraudulent lab tests is ordered, often from equally questionable laboratories. Again, there are invariably interesting findings prompting tailored and bizarre treatments. In typical red-flag sCAM fashion, some of these providers have their own supplement store, available online only to their patients, prominently displayed on their website. These providers are perceived as being more holistically informed about health and wellness then “conventional” doctors like myself, as if there are two distinct ways of treating illness and maintaining health…as if there is truly such a thing as alternative medicine.
It can be very difficult to manage patients who are being simultaneously “treated” by such providers. Sometimes the treatments complicate or confuse the picture, but it always indicates a failure of trust in the “conventional” method of practice, which is science and evidence based, and in science itself.
Below are a few examples of patients cared for by my practice and simultaneously followed by alternative medicine practitioners. They provide a good picture of just how problematic these co-practitioners can be. No names or identifying information are revealed.
Case 1: an 8-year-old girl with autistic spectrum disorder, food and pollen allergies, and occasional constipation
AB is an 8-year-old girl with autistic spectrum disorder, food and pollen allergies, and occasional constipation. At a recent health maintenance visit we discovered that she had been taken to an alternative medicine provider twice. As is typical of these sCAM visits, no visit documentation was sent to us, the patient’s primary care providers. This line of communication between health care providers is critical to providing integrated and safe care to shared patients. It is ironic that these self-described holistic practitioners fail to understand this hugely important, holistic aspect of patient care. Once we requested and received copies of these visit notes, it became clear why they may not want us to see them. After a brief review of the patient’s history, including her history of pollen and food allergies and some constipation, the History of Present Illness section of the note states:
Additionally, AB presents with unspecified immune disorder and a history of malabsorption syndrome.
This is unusual for two reasons. First, the history recounted in the note (presumably obtained from the parent, though the historian is not identified), made no mention of any gastrointestinal or immunological issues. It is true that the patient did have a history of some food and environmental allergies, which happen to involve the immune and gastrointestinal systems. However, the patient did not have malabsorption syndrome (an inability to absorb certain nutrients producing abdominal complaints, diarrhea, and sometimes failure to be adequately nourished), nor did she have an immune disorder, unless you consider allergy an immune disorder, which no one does. The note concludes with the diagnoses:
     1.  Allergic rhinitis
     2.  Unspecified immune disorder
     3.  Malabsorption syndrome
Again, though she did have some allergies, the patient did not have these other two conditions. For these non-existent diagnoses, the following battery of lab tests was ordered:
    • IgA, IgE, IgM, IgG, IgG subclasses
These are tests of the different classes of immunoglobulins. Sometimes we order these when we are assessing immune function if an immunodeficiency is suspected (it isn’t in this patient). IgE is measured if there is a real question of whether an allergy is present. This had already been measured in this patient, and we already knew she had allergies.
    • Assays for copper, magnesium, and zinc
Rare deficiencies can exist, and dangerous elevations can occur in other rare disorders. This patient had none of these, nor was there any reason to suspect that she did.
    • Anti-streptolysin O
A test for an antibody against streptococcal bacteria. Usually ordered to follow rising levels of the antibody as an indication of active infection. There was no indication for this test in this patient.
    • Anti-DNAseB
Similar to anti-streptolysin O, it is sometimes ordered when there is a concern about certain complications of strep infections, such as rheumatic fever or glomerulonephritis. There were no such concerns with this patient.
    • 25-OH vitamin D
Ordered when vitamin D deficiency is suspected, either because of poor diet, lack of exposure to sunlight, or malabsorption. None of this applied to this patient.
    • Urine organic acids
A test for inborn errors of metabolism in which organic acids can build up in the body and are then found in elevated quantities in the urine. Though these conditions can present with developmental delays, there are other features as well that usually lead to the ordering of this and similar tests. This patient had none of the hallmarks of an inborn error of metabolism. Of note, this test was performed by The Great Plains Laboratory, Inc., which is used widely by sCAM providers to support bogus diagnoses (see below). It comes complete with unsupported interpretations of test results, and suggestions for the corresponding dietary supplements.
    • Fasting plasma amino acids
Used to look for certain endocrine, liver, muscle, neurological, and nutritional disorders. Though this and the urine organic acid test above were probably ordered because of the patient’s ASD diagnosis, these tests are not recommended routinely for everyone with this diagnosis, but much more selectively for children who are suspected for other reasons of having an aminoacidopathy.
    • Comprehensive Parasitology Profile
This is a proprietary test of Genova Diagnostics Laboratory, another darling of the sCAM crowd. Their website describes this test as:
a gastrointestinal stool test which evaluates for presence of parasites. Additionally the stool test evaluates levels of beneficial flora, imbalanced flora, pathogenic bacteria, and yeast. This stool test can help reveal hidden causes behind acute or chronic conditions that develop from parasitic infection or dysbiosis.
This is a bogus test designed specifically for sCAM providers so they can diagnose non-existent conditions that can then be treated with magic pixie dust cures. Though stool is often analyzed for parasites and their eggs when a parasitic intestinal infection is being considered, this was not a concern with this child. Also, testing for beneficial flora and yeast in the stool is not informative and has no real clinical value.
Any thoughtful, evidence-based health care provider reviewing this patient’s medical record would quickly recognize the lack of any medical justification for the tests ordered above, and no rationale for ordering any of these tests was provided in the sCAM provider’s note, though I’m sure to the parents this seemed like a thorough, state-of-the-art evaluation of their child. Most amazingly, other than the diagnosis and lab testing, the visit note contains no discussion of the provider’s assessment or plan, and no discussion of his thoughts on this child’s problems. Despite this, the provider used a time-based billing code for 45 minutes. This is used for visits of “45 minutes spent face-to-face with the patient, over 50% of time spent in face-to-face discussion about the above assessment and plan.” This code denotes a very high level of service, and thus can be billed at a high rate.
The sCAM provider saw the patient again several months later. In the interim, and based on the results of the unwarranted lab testing, she was diagnosed with:
    • “Numerous low or borderline amino acid levels” for which she was placed on a “customized amino acid blend” sold to her through the provider’s own supplement store.
    • “Fungal dybiosis”, based on the finding of “2+” Rhodotorula and Candida species in her stool and an elevated arabinose level in her urine. Of note, even the bogus lab noted that this level of yeast could be found normally in the stool. Also, an elevated level of arabinose in the urine has nothing to do with yeast in the stool, which is an insignificant finding any way. She was prescribed the oral anti-fungal medicine nystatin, and sold a proprietary probiotic blend, again from their own store.
Case 2: A 6-year-old boy with eosinophilic esophagitis
CD is a 6 year old boy with eosinophilic esophagitis, an allergic inflammation of the esophagus. Followed extensively by a multi-disciplinary team that includes gastroenterologists and allergists, he was also followed by several local naturopathic providers. As with the above patient, this child was reported by his sCAM providers to have an “unspecified immune disorder”, “intestinal malabsorption”, and “intestinal dysbiosis” (conditions he didn’t have), in addition to his eosinophilic esophagitis. Again, similar to the above patient, they ordered a barrage of bogus tests from multiple, made-for-sCAM labs. These tests included:
    • Intracellular micronutrient testing from Spectracell. You’ll only see this test and this lab used by sCAM practitioners, and for good reason. Its claims are unsupported by science yet the lab is used extensively by sCAM providers who then use its results to sell useless supplements.
    • 24 hour urine porphyrin testing: a test usually ordered when a patient is suspected of having a condition known as porphyria. This child was not suspected by anyone, including his sCAM doctors, of having this condition.
The visit notes from these providers were sketchy and offered absolutely no rationale for their lab testing or treatment recommendations. They prescribed multiple dubious products including:
    • Nystatin for “intestinal dybiosis”
    • A myriad of probiotics
    • OncoPlex Xymogen which, according to the company’s website, “can only be purchased from a registered XYMOGEN practitioner.”
    • Slippery elm
    • Transdermal magnesium
    • Flax oil
    • Cod liver oil
    • Calendula tincture
    • Fruit and vegetable powder
    • Multiple amino acids, vitamins, and minerals
Case 3: a 17-year-old male with a long history of intermittent fatigue and non-specific aches and pains
EF is a 17-year-old male with a long history of intermittent fatigue and non-specific aches and pains. Despite multiple laboratory evaluations in the past, all of which were negative, he was taken to a local integrative medical practice where he underwent extensive, unnecessary lab testing. Despite these findings being negative as well, including tests for multiple tick-borne diseases, he was immediately diagnosed with chronic fatigue syndrome due to Lyme disease and Epstein-Barr virus (EBV) infection, even though these tests were negative. He was treated with the following cocktail:
    • 3 months of doxycycline for his non-existent chronic Lyme disease, an excessive course of treatment, even for real Lyme disease
    • Valcyclovir for his non-existent EBV infection; this is not even a treatment for this infection
    • Tinidazole (an anti-parasitic drug) and low-dose naltrexone (used to block the effect of opioids); this is apparently part of their anti-science chronic fatigue syndrome protocol
    • Biofilm defense to “kill his biofilm”
The predictable pablum of the sCAM provider
Unfortunately I could continue this litany of sCAMed patients, but the story quickly becomes repetitive and predictable. The playbook reads like this:
     1.  The patient is labeled with fictitious and typically multiple diagnoses. Some of these may be real conditions, though the patient does not usually have any of them. Others may be pulled from the sCAMer’s grab-bag of fake, alternative diseases.
     2.  A multitude of lab tests are ordered. With a stretch of the imagination some of these tests may make sense based on the patient’s complaints, though they are often repeats of tests already performed by the patient’s real health care provider. Usually the tests ordered are completely unwarranted, and are performed with what we call a “shot-gun” approach. That is, the provider blindly orders tests in the hope that something will come up abnormal. This is a dangerous approach that is sure to turn up out-of-range values with no clinical significance, leading the provider to order more tests and possibly make erroneous diagnostic conclusions. The manner in which these providers order lab tests demonstrates a complete lack of clinical insight at best. At worst, it is fraud.
     3.  The laboratories used are typically geared toward, and often used exclusively by, sCAM providers. Typically these labs sell their own proprietary laboratory-developed tests (LDTs). Though these tests may provide valid results for a given specimen of blood, urine, saliva, or hair, the results are not necessarily, or even usually, clinically valid. As exemplified in the cases above, the finding of yeast elements in a stool sample or a slightly elevated arabinose level in a random urine sample has absolutely no clinical significance. Nevertheless, the sCAM providers who order these tests are quick to misinterpret the clinically meaningless results to generate false diagnoses and offer up useless and potentially dangerous treatment recommendations. Some of these labs make recommendations for dietary supplements based on the test results, and even sell their own products through their website or through the provider who ordered them. Typing the names of these labs into Google will bring up a barrage of woo-laden web sites, and sites for naturopaths, chiropractors, and other integrative medicine providers. Fortunately there are science-based takedowns as well (here and here). Try it:
        ◦ Genova Diagnostics and Metametrix Clinical Laboratory. After suing each other over who has the rights to run which bogus tests, these two giants of sCAM have now merged into one pseudo-science behemoth.
        ◦ Great Plains Laboratory
        ◦ SpectraCell Laboratories
        ◦ Neuroscience
     4.  Unnecessary or potentially dangerous treatment recommendations are made (see above). Invariably, some form of pseudoscience-based treatment regimen is foisted upon the credulous sCAM patient or their parent. This often comes in the form of a dietary supplement – either an herbal, homeopathic, vitamin, mineral, or biologic (amino acid, neurotransmitter) product. Sometimes the product is a proprietary concoction, obtainable only through that office. Either way, many sCAM providers have an on-site or web-based store through which their patients can purchase the recommended treatments.
Though regular readers of SBM will have come across most if not all of these features of sCAM practice, my purpose behind this post was to give you a providers’-eye view of just what we’re up against as we battle serpents in the sea of sCAM.

Medical Lore in Modern Pediatric Practice
Examples of modern medical lore that are passed down from doctor to doctor are commonplace in pediatric medicine and share similar features with the most egregious examples of medical pseudoscience
Clay Jones on March 10, 2017
Link

The concept of modern medical lore specific to pediatric care has been on my mind a lot lately. In fact, I’m pretty sure it will be the focus of my talk at the upcoming Northeast Conference on Science and Skepticism this summer. The addition of “modern” is meant to differentiate what I’m addressing from folk medicine, but the distinction isn’t clear.
Folk medicine, as defined in the William A. Wilson folklore archives at BYU, doesn’t sound all that much different from some of the claims I encounter regularly practicing conventional modern medicine:
Folk medicine could be considered any sort of medical treatment that is part of a cultural tradition that emphasizes anecdotal evidence and tradition rather than any kind of scientific authority.
I encounter modern medical interventions that fulfill this criterion on a daily basis. And I’m not talking about standard SBM fare like acupuncture and the usual irregular medical suspects. There are numerous examples of widely accepted pediatric medical beliefs that are utterly lacking in plausibility and non-anecdotal evidence and that are passed down from one generation of medical professionals to the next, adrift on the currents of their cultural inertia.
Teething results in teeth
I’ve discussed a few examples of this in previous posts. Teething is one of them and it’s a particular source of frustration. The end result of this week-long process is a tooth, not the myriad symptoms, such as fever, diarrhea, and significant pain, commonly attributed to it. Parents and pediatricians alike are unable to successfully predict when a child is teething until the tooth is visible erupting from a child’s gums.
The false belief that teething results in anything other than teeth and at most some mild discomfort, although even this is questionable, can be harmful. And it is often enabled by pediatric medical professionals. At least our interventions tend to be safe. We may no longer recommend dangerous “treatments” such as lancing of the gums in an effort to ease the tooth’s transition, but children are still exposed to treatments where risk outweighs benefit by orders of magnitude.
Burping advice is full of hot air
Another example of pediatric medical lore, and one which I have not discussed in a previous post, is burping. Burping is the almost ubiquitous and bizarre practice of taking a recently fed baby, or interrupting an actively feeding baby, and slapping them on the back until they burp. It’s so stupid even a chiropractor can do it.
Babies, their parents are frequently told by pediatricians, swallow concerning amounts of air during feeding. This swallowed air supposedly becomes trapped against its will in the stomach, resulting in discomfort, and increases the likelihood that a baby will have problems with reflux. Parents are advised to burp after every feed even if the baby shows no signs of discomfort, and sometimes 2 or even 3 times during a feed if a child is prone to spitting up or colic, whatever that may be.
The problem with this advice, and the belief it is based on, is that it is entirely made up. First off, the concept of swallowing large amounts of air during feeding is suspect. The esophagus, unlike the trachea, is not propped open by cartilage. It is compressed except during swallowing, when the cartilaginous epiglottis falls into place over the trachea and the esophagus is the path of least resistance. Air in the oral cavity during swallowing is more likely to escape through the nasal passages than to enter the esophagus.
A baby does not take air into their esophagus any more readily than readers of this post do when swallowing. Sure babies may swallow a small amount air while feeding but there is absolutely no plausible reason to blame fussiness or spitting up on this other than the desire to blame something, anything for what is essentially a random process in the vast majority of infants. Also babies don’t need help burping.
There is nothing about an infant’s physiology that prevents them from burping on their own. In fact, their physiology probably makes it easier for them to burp than older children. Infants, because of a general immaturity of the nervous system and gut, are prone to what have come to be labelled as “transient lower esophageal sphincter relaxation events” where the muscular valve between the esophagus and the stomach relaxes for no good reason. This tends to happen after feeds and it is the primary reason why babies spit up as much as they do.
So babies will burp regardless of whether or not we whack them on the back after feeds. The common anecdotal observation that burping helps babies to burp is understandable however…because human brain. Babies are typically burped after every feed, but if a parent were to keep a strict burp log and, for example, only burp their baby after every other feed, they would likely see that burping tends to occur regardless.
But is there a downside to burping? There actually appears to be one. In addition to wasting time and potentially agitating a calm or sleeping infant, burping may actually increase the likelihood that a baby will reflux after a feed. There is grand total of one study addressing the practice of infant burping in the medical literature, and it shows that burped babies are significantly more likely to spit up and no less likely to have episodes of fussiness.
For a different perspective, here is a 2007 study published in Medical Hypotheses that explores the potential role of infant burping as a means of reducing the risk of SIDS. This is absurd. Just for the record, the AAP may recommend burping all babies after every feed, proving that even they aren’t impervious to acting sans evidence, it does not include gas as a modifiable SIDS risk factor.
Conclusion: More science!
Medical lore is commonplace in modern pediatric medical practice. I focused on teething and burping in this post as just two of many possible examples of false beliefs passed down from generation to generation. The factors that promote the continued belief in modern medical lore, such as cultural inertia and confirmation bias, are essentially no different than the factors that play a role in the acceptance of so-called alternative medical practices such as acupuncture and chiropractic.
The harm caused by belief in entities like teething and burping, and perhaps most examples of modern pediatric medical lore, is thankfully minimal. But they serve as excellent examples of how vulnerable we are when it comes to belief in nonsense, even when there aren’t financial incentives or the bias that comes from an unscientific worldview. Is it truly any wonder that even the most prestigious academic institutions are now promoting abject pseudoscience?

Medical Neglect of Children
Medical neglect caused horrific suffering for these children, ending in death or permanent impairment. Their parents failed them, but so did society.
Harriet Hall on May 2, 2017
Link


I recently read something so horrific I can’t stop thinking about it. It continues to haunt me and will probably do so for a long time to come. When 911 responders answered a call, they were shocked to find an emaciated corpse:
Dressed only in a diaper and t-shirt, the 15-year-old boy weighed only 37 pounds. His waist was about three inches across. He had 44 ulcerating wounds on his body. Some were necrotic. One was so deep his jawbone was visible. A salivary gland was exposed in a neck wound…Most of his teeth had rotted down to the root. He had no neck muscles – the tissues had liquefied and the area was filled with pus. One worker said he looked “mummified.
Alex Radita had died of complications of untreated diabetes. More about his case later.
A few years ago, I wrote about faith healing and the conflict between religious freedom and child protection. Religious shield laws protect parents from prosecution if their actions were based on religious beliefs. Thanks to the hard work of Rita Swan and other activists, there are now sixteen states with no religious shield laws and religious parents can be prosecuted in those states. But elsewhere, notably in Idaho, children are dying because of medical neglect, and their parents are not being held responsible. The law allows Followers of Christ and other sects to literally get away with murder: letting their children die without medical treatment when they could have been successfully treated or cured. The pediatric death rate for these sects in Idaho is ten times the rate for the state of Idaho as a whole. The website CHILD (Children’s Healthcare Is a Legal Duty) is a great source of information on everything from faith-based medical neglect to quackery, sexual abuse, corporal punishment, and legislative actions. The quotation above and much of the information below is taken from the CHILD newsletter, from the latest issue, volume 3, 2016.
The Dyer Trial
At age 3, Stephanie Dyer started having seizures. A doctor ran tests, diagnosed epilepsy and prescribed the anti-seizure drug Lamictal. He explained the need for follow-up and dosage adjustment, but Stephanie was never seen by a doctor again. Various doctors authorized refills without seeing the child. The child’s grandmother, a retired nurse, notified the authorities that Stephanie was not attending school and had health issues. When they visited the home, they found a seven-year-old in a diaper in a room with cat litter and feces on the floor. They observed that she was underweight, drooling, unresponsive, staring, and had abnormal movements. In the hospital, they found that she had brain damage and was in a near-vegetative state, unable to walk, talk, eat, swallow, sit, or hold her head up. She had contractures in her legs and feet that required surgery. Three years after being placed in a foster home and getting intensive rehabilitation and treatment by multiple specialists, she was walking and attending special education classes. She was on 3 anti-seizure medications and had been seizure-free for a year and a half. She has behavioral problems and can communicate only through an electronic device; she will continue to require specialized care for the rest of her life.
Although they continued to give her seizure medication, Stephanie continued to have seizures. The Dyers did not believe she had epilepsy: they believed she was possessed. They had many superstitious and paranormal beliefs and were convinced their home was haunted by ghosts and spirits. They consulted paranormal investigators and psychics and tried to have the home “cleansed.” When evaluated by psychologists, the father was diagnosed with schizotypal personality disorder with paranoid and narcissistic features, the mother with histrionic personality with features of mistrust, disordered thinking, rationalization, intellectualization, and argumentative paranoia. But they were considered responsible, capable of distinguishing right from wrong, and competent for trial.
At trial, the defense arguments were interesting, to say the least. They claimed the parents were guided by their spiritual beliefs and should be exempt from prosecution under the religious exemption law that had been repealed in Colorado in 2001. They tried to blame the medical system for not explaining epilepsy well enough to the parents. They even faulted DHS for placing the child with a foster family that didn’t believe in ghosts!
The prosecution showed that the parents did understand that Stephanie had a medical problem requiring drug treatment, and they surely understood that she needed further medical care, especially when her condition deteriorated so drastically. The judge agreed: they were sentenced to 15 years in prison.
The Alex Radita case
Alex developed type I diabetes when he was two. His mother insisted he did not have diabetes and she and God would prove the doctors wrong. His parents apparently called in fake blood sugar readings, and when Alex was hospitalized at age five, his diabetes was out of control and he was near death. He was placed in foster care where he was properly treated and did well for a year. The social worker strongly recommended he not be returned to the parents; there were concerns about earlier neglect of two other children. The family had moved twice, preventing investigations from being completed, and the social worker was worried that they would move again. The judge ignored her advice and returned Alex to his parents, and he did well for the next three years. Then the mother refused to increase his insulin dosage and no doctor ever saw him again. As predicted, the family had moved again, from British Columbia to Alberta, and the BC social worker was instructed to close the file for lack of information.
Records in Alberta showed that he got thousands of dollars’ worth of diabetic drugs and equipment, but none in the last 6 months of his life. He did not attend school in Alberta. He was briefly enrolled in an online course but didn’t do the work and was dropped from the program with no follow-up.
When Alex died, the parents called members of their church to claim he had been resurrected from the dead. They belonged to the Romanian Apostolic Church, which has no objection to any medical care. They did give Alex insulin for several years before stopping treatment. According to the CHILD newsletter, “Their history suggests that they were determined to prove the doctors wrong even while giving insulin and used religion to justify their stubbornness.”
The crown prosecutor showed that the parents had been given plenty of information and had seen him deteriorate when insulin was withheld, yet they deliberately deprived him of insulin repeatedly and for long periods. The only reason he lived as long as he did was that he was starved; starvation was the only treatment that could prolong a diabetic’s life before we had insulin. The prosecutor argued that Alex’s death was planned and deliberate. The parents were convicted of first-degree murder and sentenced to life imprisonment with no possibility of parole for 25 years. They have seven surviving children who are collateral victims, deprived of their parents after the trauma of seeing them tried for murder.
Ryan Lovett
Ryan was born at home with no medical attention and his birth was not registered. He did not have an Alberta health card. He died at age seven in March 2013 in Calgary of meningitis, pneumonia, and a strep infection. His mother had been treating him with dandelion tea and oil of oregano for what she thought was “a cold or the flu.” He got progressively worse, with pain, slurred speech and a weight loss of 10 pounds over the last two weeks of his life. When he collapsed, his mother finally called for help. Too late: he was DOA. He had been enrolled in school, but his attendance had been very erratic. In January 2017 his mother was found guilty of failure to provide necessities and negligence causing death. She will be sentenced in June. In a police interview, she said she was a failure, but only because she had waited for paramedics instead of taking Ryan to the hospital herself, and because she should not have enrolled him in school because he might have picked up germs there and the stress from school might have compounded his illness.
Parents were convicted, but others share the blame
There are laws in most jurisdictions that require anyone who suspects a child is in danger to report the case to the authorities. In all the above cases, opportunities to intervene were missed. Ryan Lovett’s erratic school attendance could have been investigated. Alex Radita didn’t attend school and was dismissed from an online course with no follow-up. When Alex moved from BC to Alberta, his file was closed; there was no communication between provinces. When he stopped getting his diabetic drugs and equipment, the change in pattern could have been flagged; someone could have asked why.
Doctors also share the blame: they repeatedly refilled Alex’s and Stephanie’s prescriptions without seeing them. That’s unethical. At most, they should have offered a small supply of medication to tide them over until they could get in for an appointment.
Conclusion: We can do better
Society has a duty to protect children. Parents do not have the right to endanger their children because of their belief systems. There are still many jurisdictions that exempt parents from prosecution if they act according to religious or other belief systems. In my opinion, all remaining religious shield laws should be repealed.
These children died or were left permanently impaired because their parents failed them. But society failed these children too. There were opportunities to report or intervene that might have saved these children. CHILD is right: Children’s Healthcare Is a Legal Duty, and a moral duty. Surely we can do better.

Baby’s DNA in Mom’s Blood: Noninvasive Prenatal Testing
Harriet Hall on September 17, 2013
Link
Until recently, the moment of birth was a surprise. We anxiously awaited the obstetrician’s announcement: “It’s a boy!” or “It’s a girl!” Then we checked to see if any crucial parts were missing and we counted the fingers and toes. We had to wait for a baby to be born before we could know its sex and whether it was normal. Today, thanks to prenatal testing, we can know the sex of a fetus, diagnose a number of genetic abnormalities and malformations, and we can even operate on the fetus in utero to correct certain problems before birth. I had amniocentesis for my two pregnancies because of the higher risk of Down syndrome at my age (37 and 39). It was reassuring to know the baby didn’t have Down syndrome, and it was fun for my husband to point to my burgeoning belly and introduce it to people as “our daughter Kristin.”
Amniocentesis is invasive, carries risks, and can’t be done until the 15th to 20th week of pregnancy. Now there is a safe, noninvasive, accurate blood test that can be done as early as the 9th week. It analyzes cell-free fetal DNA (cfDNA) circulating in the mother’s blood. It sounds ideal, but there are some caveats. It’s not yet appropriate to recommend it to all pregnant women. An editorial in The New England Journal of Medicine expressed concern that pressures are promoting diffusion of cfDNA testing beyond the boundaries of available evidence.
What tests are available?
     1.  Standard screening tests on maternal blood for serum markers associated with chromosomal abnormalities (like the trisomy of Down syndrome) and neural tube defects (like spina bifida). Indicates elevated risk but doesn’t make a diagnosis. Further invasive testing required.
     2.  Ultrasound.
         (a)  Nuchal translucency, measured at end of first trimester
         (b)  Nuchal fold, measured at end of second trimester
         (c)  Can also visualize gross anatomical abnormalities
     3.  Combining serum marker tests with ultrasound nuchal measurements can decrease the number of false positives to 4-5% with a true positive rate of up to 90%. Not diagnostic: indicates a need for further invasive testing.
     4.  Chorionic villus sampling (CVS) samples placental tissue.
         (a)  Can be done at 8-10 weeks gestation
         (b)  2 approaches: through the vagina or the abdomen
         (c)  Risks: miscarriage (0.5-1%), infection, amniotic fluid leakage, limb reduction defects
         (d)  False positives can occur with mosaicism, where the placental cells are abnormal but the fetus is normal, and false negatives can occur if the sample is contaminated with maternal cells
         (e)  If the fetus is Rh positive and the mother is Rh negative, the procedure can introduce fetal cells into the maternal circulation and cause Rh sensitization
     5.  Amniocentesis.
         (a)  Needle inserted into amniotic fluid
         (b)  Done later than CVS, between 15th and 20th week of pregnancy
         (c)  Risks similar to those of CVS, but miscarriage rate is lower (estimates vary from 1 in 200 to 1 in 500)
         (d)  Can also predict fetal lung maturity
     6.  Percutaneous umbilical cord blood sampling
         (a)  Needle inserted through abdomen into baby’s umbilical cord under ultrasound guidance
         (b)  Can detect chromosomal abnormalities, infections, blood disorders and some metabolic disorders
         (c)  Can detect fetal anemia and treat with blood transfusion
         (d)  Done after 17 weeks pregnancy
         (e)  Risks: similar risks to amniocentesis but with a higher rate of miscarriage (1-2%)
     7.  cfDNA tests
         (a)  Noninvasive: require only drawing blood from the mother
         (b)  Can be done as early as 9 weeks
         (c)  High sensitivity and specificity
What can prenatal testing diagnose?
All the invasive tests and the new cfDNA tests collect fetal DNA and analyze it. They all require a 1-2 week wait for results. They can detect chromosomal abnormalities include Down syndrome, other trisomies, sex chromosome abnormalities like Turner syndrome, and fragile X syndrome. Specific tests can be done for cystic fibrosis, Tay-Sachs, sickle cell disease, muscular dystrophy, and other inheritable conditions when indicated by family history.
What if results are abnormal?
If a condition like Down syndrome is detected, about 90% of parents choose to terminate the pregnancy. For some conditions like spina bifida, fetal surgery may be an option. Parents who continue the pregnancy can use the information to plan for the care of a child with special needs, anticipate lifestyle changes, and identify support groups and resources.
Some people reject any testing because of religious or moral objections to pregnancy termination, because they are comfortable with the idea of raising the child no matter what handicaps it has, or because they reject any testing that poses any risk to the fetus.
Currently available cfDNA tests in the US are offered by 4 companies (Verinata, Sequenom, Ariosa, and Natera) at a cost of $795 to $2762. They all screen for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Some additionally offer sex determination and screening for sex-chromosome abnormalities like XO, XXX, XXY and XYY. They do not test for anything else. They are being aggressively marketed though channels like Facebook, and consumers may not understand the trade-offs and the limitations.
Caveats
Patients considering cfDNA testing should be aware that:
    • They do not provide all the information available through other tests
    • They are generally not covered by insurance
    • They are said to be accurate, but the reported sensitivities and specificities of these tests are based on studies with a high proportion of abnormals (with a prevalence as high as 1 in 8 for Down syndrome). They will be less accurate when applied to the whole population of pregnant women.
    • If the test is positive, what’s the likelihood that the individual really has the condition? In other words, what is the test’s positive predictive value (PPV)? We don’t know, because the companies have not reported that information. Sensitivity and specificity depend on the prevalence of the condition in the population being tested; we want to know the PPV for an individual in the specific population we are testing. In a low risk population a positive result will have a lower PPV than in a high risk population.
ACOG recommendations
The American Congress of Obstetricians and Gynecologists and other professional organizations recommend cfDNA testing only for high-risk pregnancies, and specify that abnormal results should be confirmed by invasive testing before any action is taken.
Conclusion
Who would have imagined that fetal DNA was circulating in the mother’s blood? Or that it could be separated from her blood to allow analysis of the fetus’s genetic makeup? This is an exciting scientific development. These new cfDNA blood tests have great promise, especially if they can be expanded to include broader screening of DNA for more abnormalities. Meanwhile, the currently available tests are only able to detect a few specific abnormalities and they shouldn’t be used as a screening test for all pregnancies. They are useful in high-risk pregnancies but abnormal results must still be confirmed by invasive testing.

The Science of Mom: A Science-Based Book about Baby Care
Harriet Hall on September 1, 2015
Link


When a baby is born, parents are often awed and alarmed to find themselves responsible for this tiny new person, and they desperately want to do their very best to keep their infant safe and healthy. New mothers worry about everything from SIDS to vaccines, from feeding practices to sleep hygiene, and they are bombarded with conflicting advice about caring for their babies. Myths and misinformation abound. Finally someone has written a truly science-based guide to the first year of life: The Science of Mom. The author, Alice Callahan, is a research scientist with a PhD in nutritional biology. When her first child was born, she had a lot of questions, and thanks to her background she knew how to look for reliable answers in the scientific literature. She started writing the Science of Mom blog and eventually turned her findings into a book.
Understanding science
Her first chapter covers the important concepts for understanding how to think about scientific studies:
    • Good science is a process that takes lots of experiments, time, and people.
    • Good science is peer-reviewed.
    • One study on its own isn’t worth much, but scientific consensus is trustworthy.
    • Some studies are more valuable than others (here she covers the various types of study from animal studies through observational studies in humans to RCTs and meta-analyses).
    • Numbers matter (sample sizes).
    • Don’t believe everything you read on the Internet (here she gives some practical tips for evaluating whether a website is reliable).
    • Correlation is not causation (she uses my favorite example of the correlation between autism diagnoses and the sales of organic food).
    • We can’t eliminate risks (but science can quantify the risks and benefits and families can use the information to decide what risks they are personally willing to take).
    • Find smart allies (experts and providers you can trust).
    • Forget about perfection and pay attention to your baby.
In subsequent chapters she delves into what science has to say about various topics. She finds that there is seldom a simple yes-or-no answer to these questions, and she presents the evidence on both sides fairly, adding a common-sense perspective.
When to cut the umbilical cord
There are clear benefits of delaying cord clamping, but there are also risks. We don’t know how long a delay is optimal. And there are practical problems like the logistics of resuscitating a baby in distress and of banking cord blood.
Vitamin K shots and eye goop
She explains why newborns are given vitamin K injections, illustrating the danger of vitamin K deficiency bleeding (VKDB) with a horror story about a baby who nearly died from a brain bleed after the shot was inadvertently omitted. The evidence shows that oral supplements are not as effective, and that the injections are safe.
Antibiotic eye ointment is routinely used to prevent blindness and other complications of gonorrhea and chlamydia, but the incidence of gonorrhea in the population has declined. If a woman is at very low risk of sexually transmitted diseases, eye prophylaxis might reasonably be omitted; but when European countries tried doing it selectively instead of universally, the number of gonococcal infections in newborns rose. And the risks of treatment are minimal.
Breast is best
For some families, breastfeeding is clearly the best choice, but for others it isn’t. The benefits of breastfeeding have been hyped beyond the actual evidence. It is definitely beneficial; but the advantages are not huge, and formula feeding is a perfectly good option for mothers who can’t breastfeed or prefer not to. There are even some benefits to formula: it is fortified with iron, so bottle-fed babies are less likely to become anemic than breast-fed babies.
Bed sharing
There are benefits to keeping your baby close, but sleeping in the same bed is dangerous. She covers the published evidence, cultural differences, SIDS, factors that might have influenced study findings, and how to minimize the risks if you choose to co-sleep.
Sleep patterns
One of the biggest problems for parents of newborns is chronic sleep deprivation. She covers the research on normal infant sleep patterns, arousability, and how infants learn self-soothing behaviors to fall asleep without help. Sleep training works, but not for all infants. It doesn’t harm babies, and it can help stressed parents get the sleep they need to be good parents.
Vaccines
This chapter starts with an affecting personal story. One of the author’s uncles died at age 6 of encephalitis caused by measles. What had appeared to be a typically benign, uncomplicated case of measles suddenly turned deadly. The benefits of vaccines are undeniable. She shows the statistics for lives saved and she debunks many of the common anti-vaccine myths. She gives a lucid explanation of herd immunity. She recognizes that vaccines are not without risk, but the evidence shows that the risk is very small and the risks of not vaccinating are much greater. She explains how vaccines are rigorously tested and monitored for safety. She tells how the first rotavirus vaccine caused intussusception in a few recipients and how the system responded to create a safer vaccine. The new vaccine has prevented thousands of hospitalizations for rotavirus infection, and has even decreased the incidence of the disease in the unvaccinated through herd immunity.
When to start solid foods
When I started practicing medicine we used to recommend starting rice cereal at 1 month so the solid food in the tummy would help the baby sleep through the night; it didn’t work. The evidence for when to start solid foods is conflicting, and there are confounding factors like varying hygiene practices and resources in different cultures. Starting between 4 and 6 months reduces the risk of anemia in breastfed babies and may reduce the risk of allergies, celiac disease, and type I diabetes. Starting at 6 months may lower the risk of diarrhea and the baby is more developmentally ready, making feeding easier. Waiting longer than 6 months is not advisable.
She says, “Take the focus off the calendar and put it where it belongs, with the little one doing the eating.” Babies develop at different rates and have different preferences. A baby is ready for solid food when he can be positioned upright for feeding, has lost the tongue thrust reflex that pushes the food right back out in younger babies, shows an interest in solid food, and can communicate when he doesn’t want something by closing his mouth or turning his head away.
Infant nutrition
Breastmilk is the perfect food for newborns, but it becomes inadequate in later infancy. It fails to provide the iron that babies need to prevent anemia, and it is lacking in a number of nutrients like vitamins A, C, D, and E and micronutrients like zinc and manganese. Our ancestors probably overcame this by feeding older infants meat and other foods, and the evidence shows that meat, egg yolks, and fish are good for babies. Vegetarian diets, especially vegan and macrobiotic diets, have been shown to result in nutrient deficiencies, stunted growth, muscle and fat wasting, and slower psychomotor development.
The risk of anemia can be counteracted by feeding infant cereals fortified with iron. Whole grains may be more nutritious, but refined grain cereals are a better source of iron. She recommends feeding babies a varied diet, avoiding sugar, and not adding salt. She found no evidence that organic food benefited children’s health. She emphasizes that the most important part of feeding isn’t the food: parents should relax and enjoy feeding and interacting with their babies.
Babies are amazing
She includes a chapter that amounts to a love letter to babies, urging parents to observe how their newborns explore, communicate, and learn. Newborns have special reflexes and are capable of more than most people realize. And they are unique individuals; parents need to learn to interpret their cues and respond appropriately.
Appendixes
In eight appendixes, she offers reassuring evidence-based answers to these questions:
    • Are the ingredients in the vitamin K shot safe?
    • Why is the HepB vaccine given at birth?
    • Do we give too many vaccines too soon?
    • Do vaccines cause autism?
    • Do vaccines increase the risk of SIDS?
    • Should we worry about the aluminum in vaccines?
    • How do we know that babies need so much iron?
    • Should we be concerned about arsenic in rice cereal?
Conclusion
This is science-based medicine writing at its best. Callahan doesn’t cherry-pick. She knows how to evaluate the entire body of research and put it into perspective along with practical parenting considerations. She enhances her message with a personal touch, including anecdotes about her own experiences as a new mother and about the experiences of her friends and family. If I had three thumbs, I would give this book a 3-thumbs-up recommendation. If every new parent could read this book, it would go a long way towards immunizing them against the misinformation they will inevitably encounter, misinformation that so often clouds their judgment and worries them unnecessarily.

Should the Incidental Discovery of Nonparentage be Disclosed?
Clay Jones on August 1, 2014
Link


The July issue of Pediatrics, the official journal of the American Academy of Pediatrics, contains an extremely thought provoking article discussing the risks and benefits of disclosing an incidental finding of nonparentage during pediatric genetic testing. Nonparentage occurs when one, or very rarely both, of the social parents did not serve as source code for a child’s genetic programming, so to speak. Naturally, we aren’t talking about known adoptions but rather when the nonbiological parent is unaware of the fact that they did not contribute an egg or sperm.
Authors Marissa Palmor and Autumn Fiester, both bioethicists at the University of Pennsylvania’s Perelman School of Medicine, take the position of universal nondisclosure when nonparentage is discovered. They acknowledge the pro-disclosure arguments and, in my opinion, successfully rebut them. They go on to make a compelling recommendation for the incorporation of a universal nondisclosure clause into consent forms which states clearly that parental status will not be discussed.
They start the article off with a case that nicely demonstrates how a healthcare professional might face the difficult decision of whether or not to disclose a finding of nonparentage. Rather than the exceedingly more common paternal nonparentage, the case involves a couple that required the use of in vitro fertilization (IVF) and the discovery that “Mrs. Johnson” is not the biological mother. This is not at all an unheard of complication of the IVF process, although it is rare, as all it takes is a clerical error to retrieve the wrong egg or sperm for fertilization, or even the wrong embryo for implantation.
Again, the possibility that an IVF clinic would make a mistake that would result in maternal or paternal nonparentage is very low. But the overall incidence of nonpaternity in general is probably higher than most dads would like to admit. This 2005 review of nonpaternity studies found rates ranging from 0.8% to 30% depending on the study population and risk factors, with a mean of 3.7% of children being fathered by someone other than the man who identifies himself as the biological father.
Specific paternity testing for legal reasons will likely always reveal the majority of cases of nonpaternity. But as our medical diagnostic capabilities continue to improve and more genetic testing takes place, the incidental discovery of nonparentage will assuredly increase. The ethical considerations of such a finding, and the repercussions of either disclosing or not, are considerable. So it shouldn’t be surprising that there are proponents of either course, with both sides able to cite a long list of arguments. The authors of the paper even admit that while they believe that the nondisclosure side has the stronger argument, they don’t claim to have solved the issue and state that this is an area of much controversy. There is not a consensus approach yet. Palmor and Fiester, after a careful weighing of the risks and benefits, present what is in their opinion a practical approach for the interim.
Arguments in favor of disclosure
So how do proponents of disclosure justify such a revelation? Before I go further, I feel that it’s important to point out that there is a dearth of evidence available for either side of the argument to turn to for support. Everything is a potential risk or benefit. The social variables are far too numerous, and the human reactions to such news too complex, for there ever to be a predictive algorithm, which of course plays a role in the reasoning behind the author’s recommendation of nondisclosure.
Here we go.
Argument 1 – Parents have a right to know.Argument 2 – The child has a right to know.Argument 3 – Not disclosing is paternalistic.Argument 4 – Physicians are obligated to tell the truthArgument 5 – There are potential medical benefits for the childArgument 6 – It’s better to disclose now because finding out later might be worse
The rebuttal and arguments in favor of nondisclosure
Argument 1 rebuttal – This approach often assumes that deception was involved, or at least negligence, leading to a gut feeling that a wrong must be righted in some way. A father is unknowingly devoting time and resources to someone else’s child for example, or the family is in the case of an error during the IVF process. I can certainly empathize with the desire to see that justice is served.
But, the authors’ offer up in response, “it is not possible to exercise this right in a way that guarantees the social parents an autonomous, informed decision to receive or waive the information.” Patient autonomy, or legal authority in the case of a minor, is a core principle of ethical medical practice which requires that decisions be based on appropriate education without undue pressure from the healthcare professional. We make recommendations and obtain informed consent, but we generally try to avoid making a decision for a patient.
Imagine the following conversation starter:
Geneticist- “I have information which I can either disclose or not. It was an incidental finding, unrelated to your child’s health, that might benefit certain members of your family but it also might lead to social upheaval in the form of divorce, relocation, loss of resources for childcare, negative psychological affects, etc. Will you consent for disclosure of this information.”
It is hard to imagine that a family would decline such an invitation. In the case of an incidental discovery of nonparentage, by either disclosing without consent or attempting to obtain consent, the parent(s) will almost certainly have had their right to autonomy sacrificed. Remember, the family did not come in actively seeking to investigate parentage. This isn’t like disclosing the result of a biopsy, where the patient has agreed to the procedure and the report of findings, and has had the opportunity to consider the repercussions.
Argument 2 rebuttal – Does the child have a right to know that his father isn’t who he thinks it is. The authors use the example of genetic testing for a disease with no known treatment, the prime example being that of Huntington’s disease. This is a genetic condition which typically presents later in life and results in death roughly 20 years after symptoms begin, usually from pneumonia, heart disease or suicide. Testing the child of a patient with Huntington’s isn’t ethical because a young child cannot give informed consent and, according to Palmor and Fiester, this parallels disclosing nonparentage because both result in only “negative information.”
Argument 3 rebuttal – Is not disclosing nonparentage paternalistic? Palmor and Fiester argue that it isn’t because the information withheld by the physician wasn’t sought out. A good example would be the intentional withholding of biopsy results showing metastatic cancer because a physician thought that the patient wouldn’t be able to handle it emotionally. If the patient consented to have the biopsy performed, and understood what the findings might or might not be, then it would be paternalistic to not disclose the findings. Again in the case of an incidental finding of nonparentage, no informed consent has been obtained regarding the information and the preferences of the family isn’t known.
The authors make the valid comparison to a third party disclosing infidelity of a spouse. Some might appreciate knowing that their husband or wife has been unfaithful while others may be resentful of the intrusion into their personal affairs. A physician with the burden of whether or not to disclose incidental nonparentage, unless some kind of a sociopath, will struggle with the decision and has no idea what impact their disclosure will have.
Physicians must, with every possible intervention, consider both the risks and the benefits. We often must strive to balance the seemingly contradictory duties of beneficence and non-maleficence. A treatment may cure a patient of a disease, but it may have serious side effects. Proper informed consent allows the opportunity for a patient or caregiver to decide for themselves, based on appropriate information from the physician, the personal importance of the risks and benefits. Going forward with disclosure of nonparentage, to me, is more deserving of the label of paternalism.
Argument 4 rebuttal – Are physicians obligated to tell the truth? Does dishonesty damage the relationship forged between a medical professional and a patient? The answer is of course a resounding yes. Palmor and Fiester argue, however, that nondisclosure does not constitute dishonesty in the way that intentionally giving inaccurate information does.
Is not telling a patient about to start a treatment course that there is a remote chance of developing an itchy rash an example of dishonesty? Or if a physician chose to not reveal an unrelated, transient and clinically meaningless mild lab abnormality while discussing a new diagnosis of inflammatory bowel disease? To say that the incidental finding of nonparentage warrants disclosure, while other information does not, requires knowledge of the involved parties that could only be obtained with appropriate informed consent. And if the family has already made it clear that they are interested in parentage testing, they can easily be directed to widely available resources for obtaining it elsewhere.
Argument 5 rebuttal – Can a child benefit medically from the disclosure of nonparentage? This seems obvious on a common sense level, considering how much emphasis is commonly put on family history when assessing health and the risk for future medical problems. Palmor and Fiester counter this argument with the claim that a child is very unlikely to benefit medically with the exception of very rare genetic conditions. The reason for this is that disclosure doesn’t reveal the genetic risks of the biological father or mother, and they may be the same as the nonbiological social parent for all they know.
Argument 6 rebuttal – To me, this argument seems the easiest to refute. It is based on the assumption that the child will eventually find out anyway, so you might as well tell them. But, as the authors state, that is pure speculation. Most of the potentially disastrous outcomes related to disclosure would only be possible when the child is young. The effect of parental divorce, for instance, has considerably more potential for harming the psychosocial development of a toddler than it does an adult.
Why universal nondisclosure?
Absent a compelling argument that not revealing nonparentage to a family risks significant harm, and in light of the very real potential for harm from disclosure, Palmor and Fiester believe that there should be a proactive move to put policies regarding universal nondisclosure into place. They argue that “To disclose or not to disclose?” is simply a question that health care professionals have no legitimate right to decide. They base this declaration on the realization that physicians, ethics committees and hospital administrators, among many other healthcare entities, have no real emotional or material stake in the information.
My personal experiences with nonparentage
As a newborn hospitalist, I spend a lot of time with happy parents and their newly arrived bundle(s) of joy. Unless informed otherwise, such as when the infant has been conceived with the assistance of IVF technology involving donor egg or sperm, there is a general assumption that the baby is the product of the genetic contributions of both parents. Obviously, this isn’t always the case.
In my line of work, the issue of potential nonparentage can come up every now and then. I never bring it up intentionally, but I’ve been asked by some fathers if paternity testing is available. I typically invite them to have that kind of testing performed elsewhere and then I worry about my patient’s future. It’s not a sign that things are going well at home.
Sometimes the issue is forced upon me in a much more uncomfortable way. While we don’t routinely need to determine the blood type of a newborn, it is sometimes necessary when there is a potential incompatibility with the mother. When a mother’s blood type is O, and the baby’s is either A or B, there is a potential for an immune response to have occurred prenatally which could lead to anemia and severe jaundice after the child has been born. Knowing the baby’s blood type helps us determine risk and manage accordingly.
At some point in every pediatrician’s career, particularly if they see newborns all day long as I often do, a father will put two and two together when the baby’s blood type reveals that it isn’t his child. If a mother has O (2 O alleles) blood, and a father has A (AO or AA) blood, for instance, a baby with B (BO or BB) blood would be suspicious for paternal nonparentage. That B had to come from somewhere.
It’s happened to me twice. My response, and it’s true, is that many people base what they think that their blood type is on what they remember from years ago. People are often mistaken. I recommended that they not pursue testing and stated that such testing was not available here but that there were resources available in the community. I then slowly backed out of the room, faked a seizure to get out of work and found the nearest pub.
Conclusion
I agree with the authors’ assessment of the arguments in favor of disclosure. I’m not a bioethicist, but my skeptical sixth sense didn’t go off. I don’t believe that there are any straw men being set up just to be burned down. I think that pro-disclosure arguments do have some merit, I just think that the arguments against disclosure win the day.

Is today’s generation of children “the sickest generation”?
Presidential candidate and New Age self-help guru Marianne Williamson has been repeating a claim that over half of our children have chronic illness and implying that the expansion of the vaccine schedule since the late 1980s is responsible. But is it true? Are over half of our children sick? Is this “the sickest generation”?
David Gorski on August 5, 2019
Link

One of the oddest things to have come out of the first two rounds of Democratic Presidential debates was the inexplicable prominence of one candidate, Marianne Williamson. Indeed, she was the most Googled candidate after the second debate last week. A New Age self-help guru who got her start over 30 years ago peddling her own interpretation of A Course in Miracles, an unholy fusion of New Age woo and Christian beliefs, she rose to prominence, thanks to several books and becoming Oprah Winfrey’s “spiritual advisor” and has a bevy of celebrity friends and admirers ranging from Elizabeth Taylor to the Clintons to Alyssa Milano, the last of whom is fundraising for her. It also came out over the last couple of months that she harbors antivaccine views and has some very Scientology-like views towards mental illness. True, she’s tried to backpedal as much as she can, imitating antivaxer Robert F. Kennedy, Jr., who has risibly called himself “fiercely pro-vaccine” by proclaiming herself “pro-science and pro-vaccine.” There’s always, however, a “but,” as in “but big pharma and the opioid crisis”:
I’m pro-vaccine & pro-science! Also pro-responsibility on part of Big Pharma & independent govt oversight. We’re currently indicting Big Pharma execs for opioid crisis. In every other area we should just assume they’re a paragon of pure intention and concern for the common good?
— Marianne Williamson (@marwilliamson) July 24, 2019
Or it’s “but childhood chronic illness”:
Jonas Salk was a great scientist. The polio vaccine did and does save lives. The current controversy about vaccines is not about their inherent value. It’s about the rise in chronic illnesses (from 12% to 54%) among American children since the “Vaccine Protection Law” in 1986.
— Marianne Williamson (@marwilliamson) July 24, 2019
Marianne Williamson has a number of horribly denialist views about medicine, particularly about vaccines and psychiatry and antidepressants (about which she sounds rather Scientology-like). She routinely takes a criticism of medicine that has a grain of truth (e.g., regulatory capture at the FDA and other regulatory agencies) and then runs right off the cliff with it (and has been at it for a long time), even having gone so far as to confuse correlation with causation regarding celebrities on antidepressants who commit suicide:
How many public personalities on antidepressants have to hang themselves before the FDA does something, Big Pharma cops to what it knows, and the average person stops falling for this? The tragedies keep compounding. The awakening should begin.
— Marianne Williamson (@marwilliamson) June 5, 2018
My primary purpose in this post is not to deconstruct all of Marianne Williamson’s pseudoscientific beliefs about vaccines and medicines. That’s been done more extensively here, here, here, here, and here. Rather, my purpose is to hone in on one very specific one. It’s one she’s Tweeted about and has repeated in nearly every recent media appearance that I’ve seen her on, including interviews with Anderson Cooper of CNN and Ari Melber of MSNBC. It’s also one that I’ve been meaning to address for a long time because it’s a frequent talking point used by antivaxers. Here’s a quote from her interview with Melber, in which Melber asked her, “Do you think vaccinations are contributing to things being worse now? Is that what you’re suggesting?” Looking a bit flustered, Williamson responded:
No, no, what I’m saying is that in 1986 there was this vaccine protection law. There was, and there have been $4 billion in vaccine compensation payments that have been made. There was much less chronic illness. There was something like 12% chronic illness in our children previous to that law, and there’s 54% now. I don’t see why in a free society. I mean, what is going on here? When you look at the fact tha big pharmaceutical companies lobbied Congress to the tune of $284 million last year alone, as opposed to oil and gas, which has lobbied Congress to the tune of $125 million last year, when you look at all the money that is spent by pharmaceutical companies even on our news channels, when you look at the fact that there are two pharmaceutical lobbies for every member of Congress, and even when you look at the tens and even hundreds of millions of dollars that have been paid into the coffers of even Presidential campaigns, why are we so okay with complete shutdown of any conversation about this topic?
The above response is, of course, a pastiche of antivaccine talking points, including calling the Vaccine Court, which was mandated by the National Childhood Vaccine Injury Act of 1986, the “vaccine protection court”; harping on the $4 billion in payouts over the last three-plus decades (which, when taken in context of the billions of doses of vaccines given to hundreds of millions of children during that time is not really that large a sum of money); and, the topic of this post, her claim that 54% of American children now have a chronic disease. She even uses a typical form of antivax sleight of hand to imply without saying directly that the increase in prevalence of chronic disease is due to the expansion of the vaccine schedule in the wake of the NCVIA, while recounting big pharma’s lobbying influence. It’s JAQing off at its finest.
The claim that over half of our children are chronically ill is a variation of what I like to call “the sickest generation” trope, often used by antivaxers and quacks to claim that their favorite bogeyman, be it vaccines, GMOs, wifi, or whatever, is making our children sick. Does the claim stand up to scrutiny?
The sickest generation?
Before I discuss whether, in fact, 54% of our children have one or more chronic illnesses, it is useful to take note of where that claim came from. The first time I heard Williamson make it a month or two ago, I immediately recognized it as an antivaccine talking point. Even though I don’t recall Williamson ever using the term, it is a variation of “the sickest generation” trope, a trope frequently invoked by antivaxer Robert F. Kennedy, Jr., such as when he referred to this generation of children as the “sickest generation in history.” Indeed, although the term didn’t originate with RFK Jr., as far as I can tell he is the first to have fused it with the very specific claim that 54% of children have some chronic illness or other. Basically, the first instance of the claim that I could find (and, I concede, I might have missed earlier instances, but I doubt it) was on RFK Jr.’s Childhood Health Defense website in a post “Too Many Sick Children” posted last December, complete with a video:
It opens with a simple statement, “The health of our children has declined dramatically over the past few decades.” After a list of prevalences of health problems among children, the video concludes, “VISION: A world free of childhood chronic health conditions caused by harmful environmental exposures” and:
Get involved. With your help and support, Children’s Health Defense will defend the health of our children in American and around the world, tackle the known exposures that are harming our children, hold those responsible accountable for their actions, and establish safeguards to prevent theses injuries from ever happening again.
Translation of “exposures”: Vaccines.
In any event, in the link above you can sign up for an e-book entitled The Sickest Generation: The Facts Behind the Children’s Health Crisis and Why it Needs to End. I took one for the team and entered a throwaway email address to sign up to get a link to the ebook. Fortunately it’s only 29 pages. It does, however, pack a lot of antivaccine tropes into its thin pages, including the bogus claim of an “autism epidemic” that ignores the effects of diagnostic substitution, broadening of the diagnostic criteria, and more intensive screening. 
Indeed, there’s so much deceptive weaving of statistics in the ebook that it might take multiple posts to unpack it, which is why for now I’ll stick with discussing the primary claim parroted by Williamson that 54% of our children are chronically ill. I will, however, show you just where this report is coming from by showing you a screenshot of a graph in the ebook. It’s about the most obviously deceptive attempt to confuse correlation with causation I’ve seen in antivaccine propaganda.
Back to the claim that 54% of our children have chronic illness. The primary study cited to back that figure up is a 2011 study based on the 2007 National Survey of Children’s health. The aims of the study were:
    • to evaluate national and state prevalence of health problems and special health care needs in US children
    • to estimate health care quality related to adequacy and consistency of insurance coverage, access to specialist, mental health and preventive medical and dental care, developmental screening, and whether children meet criteria for having a medical home, including care coordination and family centeredness
    • to assess differences in health and health care quality for children by insurance type, special health care needs status, race/ethnicity, and/or state of residence.
Basically, the investigators used the 2007 NSCH to derive national and state level estimates of prevalence of health problems.
The 2007 NSCH included 91,642 children aged 0–17 years. The key graph is here:
There are several things to note, The study found that, overall, 19.2% of children met the criteria for Children with Special Health Care Needs, defined as children who “have or are at increased risk for chronic physical, developmental, behavioral or emotional conditions and who also require health and related services of a type or amount beyond that required by children generally.” That is, of course, a rather broad definition and would be expected to produce larger estimate. As was pointed out at Vaccines Work, the estimate that 54% of children have chronic illness of some sort includes children who are obese (which has nothing to do with vaccines, although occasionally antivaxers will claim obesity is related to vaccination) and have risk of developmental delay, which is likely correlated with the number of premature babies surviving birth and the number of drug-addicted babies surviving birth, not vaccines. (We already have numerous studies that do not support a link between developmental delays and vaccines.) It was also noted that the children in this study were born before specific vaccines were routinely recommended during pregnancy; so that can’t be a factor either. In addition, we have numerous studies showing no link between vaccines and allergies and asthma, the latter of which far more likely to be associated with pollution and lack of exposure to the microbiome. In fairness, RFK Jr.’s report does mention pollution as a potential contributor to childhood chronic illness. (He was an evironmentalist before he became an antivaxer. How could he not mention pollution?) However, vaccines are by far the “potential cause” of chronic childhood illness given the most verbiage in this ebook.
Basically, the claim that 54% of children in the US are chronically ill takes the most inclusive definition of chronic illness. The comparison to a figure of only 12.8% of American children having a chronic illness before the NCVIA is also a deceptive sleight-of-hand. For one thing, the study upon which that estimate was based was an entirely different study published in JAMA in 2010 using a different data source and different methodology. The authors of this study used the National Longitudinal Survey of Youth–Child Cohort (1988-2006) of 3 nationally representative cohorts of children, an ongoing survey that collects annual data from a national probability sample of youth aged 14-21 years in 1979 regarding their health, education, and employment. The study focused on three cohorts of children aged 2-8 in the years examined: 1988 (Cohort 1); 1994 (Cohort 2); and 2000 (Cohort 3). The authors also asked about a different set of chronic conditions. The finding was that the end-study prevalence of any chronic health condition was 12.8% for cohort 1 in 1994, 25.1% for cohort 2 in 2000, and 26.6% for cohort 3 in 2006.
The authors noted:
Many factors may have contributed, including environmental changes, which may affect rates of chronic respiratory conditions46 and obesity,47 better survival rates of conditions such as prematurity,5 and the development of “late effects” of some treatments, such as chemotherapy.34 Medicaid expansions and the State Children’s Health Insurance Plan (S-CHIP) increased access to health care during the time this study was conducted,48,49 and children in later cohorts would have had greater opportunities for diagnosis and ongoing treatment of their chronic conditions. This may be especially true for less severe conditions that rarely flare to the point of needing emergent care. The push for increased surveillance for behavior/learning problems in children may have identified cases that would have previously gone undiagnosed. For some behavior/learning problems, patients qualify for therapies only with a diagnosis; thus, diagnosis may be influenced by pursuit of treatment.
Yes, you don’t diagnose what you don’t look for, especially milder conditions, and access to care will produce more diagnoses of chronic conditions. S-CHIP, as you might recall, was passed into law in 1997 and provided insurance to uninsured children in families with incomes that are modest but too high to qualify for Medicaid. Indeed, I can’t help but point out that the 1994 cohort was roughly around the time that the vaccine schedule started to expand and right when the diagnostic criteria for autism were broadened in the DSM-IV, also published in 1994. If you look at the percentage changes between the 1994 and 2000 cohorts, you’ll see that it’s not nearly as impressive. Indeed, even the change from the 1988 and 1994 cohorts isn’t as impressive as comparing the 12.8% prevalence of chronic illness in the 1988 cohort to the estimate of 54% in the 2011 study. It’s almost as though RFK Jr. and Children’s Health Defense were going out of their way to produce the largest increase in prevalence they could find that almost perfectly correlated with the introduction of the Vaccine Court the year after the NCVIA was passed, differences in methodology and databases be damned. After all, antivaxers wouldn’t play fast and loose with studies, would they?
The authors also noted:
A surprising finding is that many children with a reported chronic condition at ages 2 through 8 years did not have the condition 6 years later. Additionally, most chronic conditions at the end of each study period represented new conditions that developed in the previous 6 years. This dynamism challenges the notion that chronic conditions persist without change. Although having a chronic condition in childhood is a risk factor for having the same chronic condition later, many chronic conditions appear to remit for a significant period before relapsing or resolve completely. After cancer treatment, a child may no longer fit criteria for having a chronic condition, although late effects can result in other conditions.34 Many young children with developmental delay receive therapy during critical years before catching up.35,36 A child’s natural development helps resolve conditions such as chronic constipation. For conditions where symptoms wax and wane, mild cases may be more common and likelier to remit, while severe cases may persist.17
This brings up another point. Unlike the case in adults, the prevalences of individual chronic illnesses in children are dynamic, as discussed above. A significant portion of children with developmental delay “catch up” and lose the diagnosis. This makes a blanket statement about the prevalence of “chronic illness” of the type that RFK Jr. is making incredibly simplistic. Just to illustrate, I further note that in 2007 a whole issue of JAMA was devoted to children’s health, in which one systematic review reported that the definition of chronic illness was very critical in estimating prevalence, listing estimates of the prevalence of chronic illness in children ranging from 0.22% to 44%, depending on specific operationalization of the definition. Another review from that issue estimated that the 1994-1995 National Health Interview Survey on Disability indicated that chronic conditions of any type affect 15% to 18% of US children and adolescents but also noted that “these estimates substantially undercount some prevalent conditions, especially obesity and mental health conditions.” This was over 20 years ago.
So what is the actual state of our children’s health?
There is no doubt that the prevalence of chronic illness among children is higher now than it was 30 years ago. At the very least, changes in diagnostic criteria and more intensive screening for some conditions would have changed the apparent prevalence of common conditions even in the absence of changes in the “true” prevalence. Moreover, if you count obesity as a chronic illness you’ll definitely find a large increase, given the more than tripling in the prevalence childhood obesity over the last 40 years.
Dr. Vincent Ianelli, a pediatrician who runs Vaxopedia, tried to put things in perspective:
If you have only been listening to the alarmists who talk about the unhealthiest generation all of the time, you likely wouldn’t know that:
    • while 2.6% of kids were thought to be in fair or poor health in 1991, that is down to just 1.8% today (2015)
    • fewer kids today (4.5%) report having had an asthma attack in the previous year than they did in 1997 (5.4%), and that fewer kids have asthma today (8.5%) than in 2003 (8.7%)
    • since 1997, fewer children, whether or not they have insurance, are visiting the emergency room
    • fewer children are requiring overnight hospital stays, down from 5.5% to just 2.1% today (2015)
    • rates of hay fever or respiratory allergy are down since 1997, from 17.5% of kids to 15.6% of kids today (2015)
    • rates of epilepsy have been stable in children for at least 40 years
    • fewer kids have multiple ear infections since 1997, when 7.1% of kids had 3 or more ear infections, to just 5% of kids today (2015)
    • fewer kids are being prescribed antibiotics
    • childhood cancer rates have been rising, but only slightly, and mortality rates have been declining
    • suicide rates are rising, but only from historic lows – they used to be about the same or higher in the early 1990s
He does concede that the prevalence of some conditions is on the rise, including ADHD, type 1 diabetes, food allergies, eczema, obesity, and most autoimmune diseases. Why might that be? Perrin et al. commented on this in that 2007 issue of JAMA on childhood chronic illness:
A few conditions have decreased because of prevention (eg, lead encephalopathy), a few represent relatively new conditions (eg, human immunodeficiency virus type 1 infection), and some have increased after dramatic improvements in survival for individually low-prevalence childhood conditions that previously had high fatality rates (eg, leukemia, cystic fibrosis, congenital heart diseases).6 Most growth, however, reflects dramatic increases in incidence of a few high-prevalence conditions.
These high prevalence conditions include mainly obesity and associated type II diabetes, asthma, attention-deficit/hyperactivity disorder (ADHD), and autism. Perrin et al. also note that for ADHD and autism, diagnoses have definitely increased, although it’s not clear that actual prevalence has. (For instance, there was no entry for ADHD in the American Psychiatric Association manual until 1968). Even so, according to the 2015 National Health Interview Survey, among those under 18, more than 85% are in excellent or very good health, which is roughly in line with what we would expect if around 15% (or even a little more) of children had chronic health problems.
So are our children the “sickest generation”? My conclusion is that it’s highly unlikely that they are. At the very minimum, ironically enough, vaccines have prevented many sources of illness, including chronic illness. For example, polio is no longer paralyzing thousands of children every year. While it is true that there has been a rise in the prevalence of certain high prevalence chronic conditions, many of them are well-managed and it’s not clear for every illness or chronic condition how much of the observed increase in prevalence is due to increased diagnosis of previously undiagnosed conditions versus an actual increase in prevalence. More importantly, estimates of chronic illness in childhood are highly dependent on the operational definition of chronic illness. Worse, the claim that 54% of our children have some sort of chronic illness is based primarily on a single cherry-picked study that is compared with another cherry-picked study for the pre-NCVIA estimate of chronic illness used by antivaxers to make it look as though the overall prevalence of childhood chronic illness has increased more than four-fold in the last 30 years. Even more deceptive is the linking of that dubious estimated increase in childhood chronic illness to a timeline that allows antivaxers to spread a narrative that it’s vaccines causing it. Thus, even if we concede that today’s children represent “the sickest generation,” we already know that vaccines aren’t the cause, the efforts of RFK Jr. and his fellow antivaxers to promote the narrative that vaccines are the cause notwithstanding.
Finally, I’ll conclude by saying that we don’t need another President who spouts dubious statistics from conspiracy mongering websites.

The Business of Baby and the Monkey Business of Margulis
Harriet Hall on July 16, 2013
Link
A correspondent asked for my opinion of a new book by journalist Jennifer Margulis that is apparently getting a lot of attention in some circles: The Business of Baby: What Doctors Don’t Tell You, What Corporations Try to Sell You, and How to Put Your Pregnancy, Childbirth, and Baby Before Their Bottom Line. I got a copy from the library and read it. It was a painful experience. One of the customer reviews on the Amazon website accurately sums up my own reaction:
There is a great need for an incisive look at all sides of modern maternity care in the United States, because — let’s face it — we all know it’s not perfect. This, however, is not that book.
The author is a strong advocate of home birth, water birth, midwives, “embracing the pain to make you stronger,” “parents know better than doctors,” natural = good, and very early potty training. She thinks bathing a newborn is harmful. She questions the need for well baby checkups: she thinks they are mainly a gimmick to sell vaccines. She questions the (science-based) practice of giving newborns vitamin K and prophylactic eye drops. She is against the use of chemicals in general. She reports that Johnson’s Baby Wash contains “a host of unpronounceable chemicals, some of which are known toxins…and carcinogens.” She doesn’t seem to have grasped the basic principle of toxicology that the poison is in the dose. She is against formula, which she says is killing babies, and against disposable diapers because they contain chemicals and petroleum and because they can cause your child to become infertile. Her only evidence for “infertility” is one study showing that disposable diapers raise scrotal temperatures. Indeed, plastic underpants are probably warm.
She chooses anecdotes and words intended to bias the reader. For instance, a description of a C-section says electrocautery produced an “odor of burning meat” so awful that it caused two nurses to “step away and turn their heads in disgust,” and when the obstetrician exteriorizes the uterus to facilitate repairing the incision, she characterizes it as leaving the patient’s guts inside out on the operating table.
Prenatal ultrasounds
Margulis says we do way too many ultrasounds. She’s right about that. A New England Journal of Medicine study found that routine prenatal ultrasound screening in low-risk women does not improve perinatal outcomes. There are legitimate reasons for doing ultrasounds in high-risk pregnancies or when a specific problem is suspected, but not as a routine for every pregnant woman.
In an article I wrote a couple of years ago, I reviewed the arguments for and against ultrasounds. There is no actual evidence of harm, but since adverse effects might not be immediately obvious and since there is no way to entirely rule out any possibility of harm, the precautionary principle argues for restraint. Non-medical use is particularly objectionable, especially for long-exposure keepsake videos done just “for fun” and for sex-prediction ultrasounds done with the intention of aborting female fetuses.
She recommends that ultrasounds be done as infrequently as possible and as quickly as possible. So do most doctors. The American Academy of Radiology and the American Congress of Obstetricians and Gynecologists jointly published guidelines in 2007:
Fetal ultrasound should be performed only when there is a valid medical reason, and the lowest possible ultrasonic exposure settings should be used to gain the necessary diagnostic information.
Margulis strongly implies that ultrasounds cause autism, but she doesn’t have any actual supporting evidence. She herself reminds us that correlation is not causation. Yet the “evidence” she gives us against ultrasounds is a mishmash of correlations, hypotheticals, emotion-laced anecdotes, and speculations:
    • She gives a lot of credence to speculations based on rat studies and the untested hypotheses of a handful of researchers.
    • She says “High-risk women who receive multiple ultrasounds are at higher risk of having autistic children.” High-risk women are already at higher risk of having autistic children, whether they have ultrasounds or not. High-risk women will naturally get more ultrasounds for legitimate reasons because they are at high risk.
    • She claims that countries where ultrasounds are commonly done have higher rates of autism. Countries where ultrasounds are more available are countries where diagnosis of autism is also more available, so the reported rates might be higher even if the actual rates were the same.
    • “People who do not use ultrasound, like the Amish, are at lower risk for autism.” This is doubly wrong. Amish women don’t reject ultrasounds and the idea that the Amish don’t get autism has been shown to be a myth.
    • Someone who observed a long-exposure sonogram procedure thought the baby looked like it was in pain because it “flipped transverse and buried its face in the placenta and covered its ears with its hands.” But newborns are not capable of covering their ears with their hands in response to anything. They have poor control of their arms and don’t know what ears are or where they are located.
    • A patient was “bullied” by a doctor when she said she didn’t want ultrasounds. Admittedly his bedside manner was insensitive, but it sounds like he was only trying to persuade her to get a test that he thought was medically necessary and that was in her and her baby’s best interests.
    • She points out that x-rays were done on pregnant women before the link between cancer and x-ray exposure was recognized. True, but irrelevant.
    • She suggests that doctors’ decisions to order ultrasounds are often profit-motivated, but offers no supporting evidence. Do doctors who are on a fixed salary order fewer ultrasounds? Do doctors who bought their own machines order more tests to re-coup the purchase cost? Maybe, but I couldn’t find any studies.
    • She omits any mention of the evidence against the ultrasound/autism hypothesis. She cherry-picked only the studies that supported her opinion. I easily found this study showing there was no correlation between ultrasounds and autism. And this one. And this one.
Circumcision
There are many valid arguments against infant circumcision, but Margulis’ chapter on circumcision is a biased diatribe, full of distortions, exaggerations, and inflammatory verbiage. She describes some of the published studies about medical risks and benefits, but she refuses to accept them, preferring to rely on anecdotal evidence. She tells horror stories of botched circumcisions. She thinks there is a high incidence of unreported complications and deaths. She says hospitals encourage circumcisions because they make a profit from selling the foreskins.
She thinks babies suffer terribly during and after the procedure. When a doctor reported that his newborn son went right to sleep after the procedure, she refused to believe the baby could be comfortable: she argued that falling into a deep sleep is a coping mechanism babies use to deal with extreme pain. And then on the same page she tells us that newborns react to pain by screaming. You can’t have it both ways. As a family physician caring for newborns, I have personally observed hundreds of newborns in pain; every one of them cried, and not a single one went into a deep sleep. I have heard hundreds of babies cry vigorously, but it wouldn’t have occurred to me to describe their vocalizations as “screaming.”
Vaccines
The chapter on vaccines is by far the worst. She admits that vaccines save lives, but then she recites all the tired old anti-vaccine myths that have been repeatedly debunked. She defies the scientific consensus by insisting that “we know vaccines cause autism in some children.” She misinterprets the meaning of the Hannah Poling case and misrepresents the story of the removal of thimerosal from US vaccines. She believes Barbara Loe Fisher of the anti-vaccine NVIC and she misquotes what vaccine expert Paul Offit says about infants’ ability to handle multiple antigens. She claims that the US vaccine schedule is a result of profit motives and collusion between Big Pharma and the government. She says the chickenpox vaccine is more dangerous than the disease (clearly false, since the death rate from chickenpox dropped 97% after the introduction of the vaccine and no deaths have been reported from the vaccine). She claims that even the doctors who most vocally support the CDC’s current vaccine schedule are choosing an alternative route for their own children, delaying the schedule or refusing individual or all vaccines. She doesn’t offer a single reference to support that claim, and I don’t believe it for a minute.
It goes on and on, and gets worse. She digs herself deeper and deeper into the anti-vaccine party line, with no attempt at balance or acknowledgement that there are facts and arguments on the other side. It’s really pathetic.
A Condemnation of doctors
She mentions a lot of things doctors have done in the past that were later found to be harmful, such as x-rays, Twilight Sleep, and routine episiotomy. She describes episiotomy — an incision to enlarge the vaginal opening during labor — as “sexual assault”! And she says it has unnecessarily harmed millions of women, in “many” cases making lovemaking unbearably painful or even impossible. That can’t be true. I might be persuaded to believe “rare cases” but not “many” cases. Just think about how many women have gotten pregnant again through lovemaking after having an episiotomy. The number of children per woman peaked in the US during the years when episiotomy was routine.
Margulis sees past errors as a reason not to trust doctors. I see them as illustrating the value of the scientific process as it constantly asks better questions, accepts new evidence, and changes practices accordingly.
Things that need fixing
Common practices tend to lag behind published evidence. We should make sure obstetric practice is following the best available evidence:
    • Delayed cord clamping.
    • No routine episiotomy.
    • Allowing ambulation during labor.
    • Choice of positions during labor and delivery.
    • Having a birth attendant remain with the patient throughout labor and delivery.
    • Reducing the rate of C-sections.
    • No exorbitant overcharging on bills (hospitals have been known to charge the patient $41.85 for 8 Tylenol pills that only cost them 8 cents each; that’s abusive.)
    • Less use of continuous fetal monitoring.
    • Accommodating personal preferences during the birth process whenever possible.
    • Allowing women to eat during labor.
    • Not only strongly encouraging breast-feeding, but actively providing practical support to help women breast-feed successfully.
    • Allowing newborns to stay with Mom instead of in the nursery.
    • Not handing out free samples of formula (because it tends to undermine breast feeding).
    • Not doing routine ultrasounds on low-risk patients.
    • Recruiting nurse practitioners to do well-baby exams and provide practical advice to parents, thus freeing up pediatricians to spend more time on the more specialized tasks they were trained to do.
It really boils down to two things: following the evidence, and improving personal interactions with patients.
Legitimate problems, poor solutions
That which is broken in the medical system is fixable, but opting out of it doesn’t fix anything. She tells about a mother who worried about exposing her baby to sick children in the pediatrician’s waiting room and thought it didn’t make sense to follow the advice of a doctor who only saw her child for 10 minutes. Her solution? She switched from a pediatrician to a chiropractor trained in nutrition and homeopathy! If that isn’t the epitome of idiocy, I don’t know what is.
Conclusion
This is a dreadful book. It is inaccurate, biased, and inflammatory. It could do a lot of harm.
It is a polemical screed that promotes unscientific beliefs while masquerading as science journalism. As Amy Tuteur, the Skeptical OB wrote in her review, this book has nothing to do with science, and nothing to do with journalism.
Too bad. The baby business in the US is far from perfect. A responsible journalist could have produced a science-based analysis of its deficiencies, with useful suggestions for improvement. Instead, Margulis chose to produce a deplorable travesty.

The Bendectin Controversy Redux?
Harriet Hall on July 9, 2013
Link
When I read that a new study had shown that antihistamines were harmful for patients with morning sickness, I cringed and thought “Here we go again.”
Hyperemesis gravidarum (HG) is a serious complication of pregnancy. Simple morning sickness is more common and less serious. When I started out in medicine, we routinely treated morning sickness with Bendectin. It was a safe and effective remedy, a combination of the antihistamine doxylamine and a B vitamin, pyridoxine. Unfortunately the manufacturer, Merrill Dow Pharmaceuticals, was bombarded with numerous lawsuits claiming that Bendectin caused birth defects. There was a clear scientific consensus that the evidence did not show that Bendectin caused birth defects and there was plentiful evidence of its safety. The lawyers prevailed over the science, and in 1983, Dow voluntarily took Bendectin off the market to avoid further litigation expenses. After the drug’s withdrawal, the rate of birth defects did not decrease, but the rate of hospitalization for hyperemesis gravidarum doubled.
This was frustrating to those of us treating morning sickness, because it denied us a remedy that we knew was safe and left us with only less safe options for a potentially life-threatening condition. Some of us found a way to do an end run. We advised patients to buy doxlyamine (sold over-the-counter as the sleep aid Unisom), and to take it with pyridoxine, effectively reconstituting what we could no longer get as a single pill.
The Daubert Standard
One good thing came of the litigation against Dow. The controversy led to a landmark U.S. Supreme Court decision, Daubert v. Merrill Dow Pharmaceuticals in 1993, which set a new standard for rules for admission of expert testimony, including scientific evidence. Under Daubert, the trial judge assumes a gatekeeper responsibility. The judge decides whether an expert’s testimony is based on a reliable foundation of scientific knowledge and can exclude evidence not based on good science. Daubert is now embodied in Rule 702 of the Federal Rules of Evidence:
A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if:
(a) The expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue;
(b) The testimony is based on sufficient facts or data;
(c) The testimony is the product of reliable principles and methods; and
(d) The expert has reliably applied the principles and methods to the facts of the case
The Daubert standard is now the law in federal court and over half the states. While the original intent of Daubert and the rules of evidence the Supreme Court interpreted in that case was to liberalize the introduction of expert testimony, the general consensus is that Rule 702 has kept a good deal of junk science out of the courtroom. This is demonstrated by the history of the Daubert case itself.
The Dauberts had two children with serious congenital defects that they blamed on Bendectin. In the trial court, an expert for the defense testified that extensive published scientific studies had found no evidence that Bendectin was a risk factor for congenital anomalies, and there was widespread acceptance that it was not. The plaintiffs responded with the testimony of eight experts who disagreed, based on animal studies, chemical structure analyses, and the unpublished “reanalysis” of data from human statistical studies. Their star witness, Dr. William McBride, was the lead author of a study allegedly showing that Bendectin caused birth defects. When the paper was published, his co-authors protested about discrepancies, and he was eventually found guilty of falsifying data and of scientific fraud, and was struck off the register (no longer allowed to practice medicine).
The appellate court ruled (as summarized here) that:
The Plaintiffs’ experts did not conduct their research independent of the litigation and the theories have not been published in scientific journals or reviewed by peers, though there has been ample time to do so because the theories and litigation has been around for a decade…The Plaintiffs cannot show causation directly and attempt to show it through circumstantial evidence provided by their experts. The testimony cannot establish that the defects were not caused by an independent cause, since limb reduction defects occur in the babies of mothers who did not take the drug. The Plaintiffs’ experts cannot say that the drug more than doubled their risk of the defect, only that there was a statistical relationship between the drug and the birth defect.
New evidence against antihistamines?
A new study published in the European Journal of Obstetrics and Gynecology and Reproductive Biology, is titled “Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum.” The lead author is Marlena Fejzo, a respected researcher in the field. It is a case control study with 254 patients with hyperemesis serious enough to require intravenous fluids and/or total parenteral nutrition/nasogastric feeding tube, and 308 control patients. Subjects submitted their medical records and completed an online survey. A large number of demographic characteristics, pre-existing conditions, pregnancy symptoms and treatments, and maternal and fetal outcomes were included.
Objective: The stated purpose of the study was to determine the frequency of adverse perinatal outcomes in women with hyperemesis gravidarum and to identify prognostic factors.
Results: Several demographic characteristics were found to be associated with HG: gestational hypertension, immune problems, anxiety, bipolar disorder, and depression. Carrying a female fetus increased the risk of HG. None of the factors that were significantly different in women with HG were associated with adverse outcomes except for gestational hypertension. Onset of nausea and vomiting at 3-4 weeks gestation was associated with poorer outcome; onset of symptoms at 1-2 weeks and >4 weeks was not.
Adverse fetal outcomes (AFOs): Women with HG were more likely to report lower birth weight and prematurity. The overall rate of adverse fetal outcomes was 16.93% compared to 4.55% in controls. There was no significant difference in the rate of birth defects, perinatal mortality, or weight below the 10th percentile.
Medications/treatments: They explored the effect of treatments by comparing 43 HG subjects with an adverse fetal outcome (AFO) to 211 subjects with no AFO. They looked at 36 different medications and treatments. Acupuncture was associated with significantly fewer AFOs (but it was also reported to be ineffective in relieving symptoms). A statistically significant correlation was found between AFOs and Solumedrol, Phenergan, and some (but not all) antihistamines. For most of the 36 treatments there was no statistically significant correlation with AFO. I was puzzled to see dimenhydinate listed as one of the antihistamines associated with AFO but also listed among the anti-motion sickness medications that were not associated with AFO. Bendectin was in the list of antihistamines correlated with AFO, and they noted a “trend towards adverse outcome” with Bendectin itself, but noted that there were not enough subjects to reach statistical significance. In other words, this study did not show that Bendectin caused adverse fetal outcomes.
What about effectiveness? The only treatments self-reported as effective by more than 50% of patients were cannabis, intravenous fluids, methylprednisolone, and ondansetron (Zofran), and there was no significant association between self-reported medication effectiveness and outcome for any medication including the medications associated with poor outcome.
Problems with the study
Here are a few of the things that bothered me about this study:
    • The title may indicate bias. They could have called it “Frequency of adverse perinatal outcomes and prognostic factors in women with hyperemesis gravidarum” which would have been more in line with the stated objectives of the study, but they chose to emphasize antihistamines in the title. Maybe I’m just quibbling, and I admit this is a hot-button issue for me because of what happened with Bendectin.
    • The discussion at the end expressed more concern about the use of antihistamines than I felt was warranted. Again, that could be bias on my part.
    • They examined 36 different treatments. When you look at that many factors, you are almost guaranteed to find some spurious correlations. They did not do any statistical corrections for multiple endpoints.
    • The numbers were far too small to reach reliable conclusions for most treatments. They only looked at 43 subjects with HG and AFOs, and the numbers of subjects using each treatment were small.
    • Some of the numbers in the table struck me as odd. For example, for Motilium, there was a total of only 2 patients who got the treatment, presumably one in the AFO group and one in the no-AFO group. They nevertheless calculated a p value of 0.3105%. They calculated p values for several other treatments that were only used by 4-6 subjects total. Is it legitimate to calculate p values based on such small numbers? I don’t know, but it certainly isn’t very meaningful. And calculating out to 4 decimal places for a sample of 2 is beyond silly.
    • There are other studies that support the safety of antihistamines. One study even found that they protected against fetal malformations.
    • Data were based on patient recall, which is potentially unreliable.
    • Early symptoms were associated with more AFOs. I wondered whether patients with early symptoms were more likely to try antihistamines.
What Should We Make of this Study?
The mom/baby websites are already warning against antihistamines for morning sickness. A typical one says:
Poor outcomes were associated with early start of symptoms and treatment with methylprednisolone, promethazine and other antihistamines; Benadryl, Gravol, Unisom, Vistaril/Atarax and Diclectin/Bendectin, independent of effectiveness.
That’s inaccurate. The association they found was for a group of many antihistamines lumped together, and when they examined Bendectin separately, they did not find a significant association.
Should we change our practices based on this study? I think not. Better studies will be required before we can conclude that antihistamines are harmful.
In June, 2013, Bendectin (doxylamine/pyridoxine) returned to the US market under the new brand name Diclegis. We already had good evidence that Bendectin was safe, and this new study failed to find a significant association between Bendectin and adverse fetal outcomes. I see no reason to avoid the new formulation.
Note: Thanks to Jann Bellamy, JD for her assistance with the Daubert section.
Corrections: The Daubert case involved one Daubert child and a child from another family. McBride was not a witness in the original case, but his now-discredited study was relied on by other witnesses.

The ACOG Releases Watered Down New Guidelines on Immersion During Labor and Delivery
In its new report, the ACOG remains clear on the lack of solid evidence in support of claimed benefits of water immersion during the first stage of labor. Inexplicably, though, it has inappropriately softened its stance on restricting underwater delivery to proper clinical trials.
Clay Jones on December 16, 2016
Link

In March of 2014, I wrote a post discussing a joint clinical report on water immersion during labor and delivery published by the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG). To the surprise of nobody who is familiar with the current state of health journalism and the minds of true believers, the internet overflowed with poorly-written news articles and the fallacious logic of waterbirth proponents in response to the new guidelines. You can plunge into my previous post for a deeper dive than will be presented in this update, but for those of you who don’t wish to do more than splash around in the shallow end, the AAP-ACOG report concluded that immersion in water prior to delivery is likely not of much benefit to mother or baby and that delivery in water is potentially extremely dangerous and should be considered an experimental procedure restricted to ethically-run clinical trials.
On October 24th of this year, the ACOG Committee on Obstetric Practice released an updated AAP-endorsed statement titled “Immersion in Water During Labor and Delivery.” The new guidelines, described as “more accepting and less judgemental of the practice of water immersion” by the Chair of the AAP Committee on the Fetus and Newborn, actually aren’t that much different than the 2014 version. The ACOG remains clear on the lack of solid evidence in support of claimed benefits of water immersion during the first stage of labor. And they are still opposed to delivering a baby underwater, but they have inappropriately softened their stance and walked back the part about restricting underwater delivery to proper clinical trials.
Why has ACOG released new recommendations so soon?
While not unheard of, it is a little odd for there to be a release of new guidelines on a topic like this so soon. Although likely increasing in popularity, particularly water immersion during only the first stage of labor, nobody is keeping track in the United States. And the literature on the subject often fails to differentiate between immersion during early labor and underwater delivery. According to the guideline authors, in England, where there is better tracking, as many as 58% of women spend at least some part of the labor process in water in some birthing centers while rates are considerably lower in hospitals.
There also doesn’t appear to have been any game changing new research that would justify an update, with the focus still primarily being on a 2011 Cochrane review that I discussed in detail in my prior post. Sadly, it seems that they are simply reacting to negative responses to the 2014 clinical report from proponents of immersion during labor and waterbirth. Their goal may have been to be kinder and more understanding of different approaches, but this watered down new statement unfortunately may encourage more women to take part in a dangerous practice.
The updated ACOG recommendations
I will provide a brief summary of the new recommendations as well as my concerns with each:
Recommendation: Immersion in water up until complete cervical dilation may reduce labor duration and the need for spinal and epidural anesthesia and may be offered to healthy women with uncomplicated term pregnancies.
They conclude this despite the many flaws in the available literature and the high risk of bias, all of which is discussed in great detail in the ACOG document. There are many variables that go into immersion during the first stage of labor, variables which are rarely discussed in the mostly retrospective, and always unblinded, studies on the subject. And there are numerous potential outcomes that have been looked at. The weak findings on reduced labor duration and the reduced need for spinal and epidural anesthesia may simply be noise in the data or the result of factors other than the immersion in water.
Because nobody is keeping track of immersion during the first stage of labor, even in hospitals and birthing centers, I worry that there are women taking part in this practice who have risk factors or who haven’t reached 37 weeks of gestation. And women who labor in water are almost certainly more likely to deliver in water than women who don’t. Delivering a child underwater is dangerous and the evidence in favor of it is even more shallow.
Recommendation: There is currently not enough data to compare maternal and perinatal risks and benefits of actually delivering a baby underwater so ACOG doesn’t recommend it.
There is a difference between saying that there isn’t enough data to compare risks and benefits and that there is no plausible benefit and proven risk of catastrophic adverse outcomes. This topic is an excellent example of where evidence-based medicine fails and science-based medicine succeeds. This statement misses the point.
There is a reason why the amniotic membrane ruptures at the onset of labor. This is one of the important first steps in a baby’s structural and biochemical preparation to emerge from their fluid environment and to begin breathing air. There is nothing “natural” about being born into a tub full of water, blood, fecal matter, urine, and pathogenic bacteria.
Recommendation: Because of this lack of data, a woman interested in delivering her baby underwater can neither be supported nor discouraged but she should be informed of possible rare but serious neonatal complications.
Because of this lack of plausible benefit and clear risk of neonatal infection, injury, and death, a healthcare provider who practices ethically and based on scientific principles must discourage the delivery of a baby underwater. The patient must be supported in understanding the risks and the lack of benefit so that they might make an informed decision. There, I fixed it.
Recommendation: The ACOG would support prospective clinical trials designed to investigate maternal and perinatal risks and benefits associated with labor and delivery in water.
Labor yes. Delivery I’m not so sure. But if done, it should only be as part of an ethically-designed prospective trial. Frankly I don’t think that this is possible.
Recommendation: Facilities offering labor and delivery in water should have rigorous protocols regarding appropriate candidates, maintenance and cleaning of tubs and pools, infection control, monitoring of maternal and fetal health, and the removal of mothers from the water if maternal or fetal complications occur.
The fact that they don’t already is terrifying.
The bad, the worse, and the drowning babies
So what can go wrong with water immersion during labor and/or delivery? As I did in my 2014 post, I’ll provide a handy list:
     1.  Increased risk of infection, especially after rupture of the amniotic membranes that act as a barrier between baby and the outside world
     2.  Delay in providing resuscitation or other necessary medical care while transferring an ill or injured baby from the water
     3.  Problems with temperature regulation in the baby
     4.  Damage to the umbilical cord, or pulling of the cord out of the placenta, leading to severe bleeding complications
     5.  Respiratory distress, hyponatremia, seizures, and asphyxia from fresh water drowning
All of the above can result in the death of a child. All of the above can result in long term disability. And all of the above will result in a child requiring admission to a neonatal intensive care unit and separation from their family, which can negatively impact breastfeeding success and interfere with the bonding process. Although these are uncommon outcomes, they must be considered in the context of extremely low plausibility of benefit and no reasonable evidence to say otherwise.
Conclusion: Immersion during labor still has few benefits, significant risks
This new set of AAP-endorsed ACOG guidelines appears to be attempting to fix something that was not broken. Their 2014 position paper covered the subject of water immersion during labor in a thorough and rational manner, pointing out the weak evidence of benefit but acknowledging that it is fairly low risk in most circumstances. And it appropriately concluded that the risks of delivering underwater are such that it should not be taking place unless as part of a proper and ethical clinical study.
Although data is scarce, there are likely tens of thousands of women laboring in water in the United States every year. If even 1% of babies are delivered into water, that is roughly 40,000 per year. Many of these would be born in water regardless of what the ACOG or AAP has to say about it because of the unfortunate worldview of some mothers, and there are far too many irresponsible healthcare professionals and nonprofessional lay practitioners who are quick to condone or promote it. My fear is that the softened language in this new statement may provide a bit more encouragement for those who haven’t yet made up their mind.
Here is a response to the new ACOG statement by the American College of Nurse-Midwives.

An Update on Water Immersion During Labor and Delivery
Clay Jones on March 28, 2014
Link
Science Based Medicine last covered the increasingly common practice of laboring while immersed in water, in many cases followed by delivering the baby while still submerged, a little over four years ago. In that post, Dr. Amy Tuteur focused primarily on the contamination of the water with a variety of potentially pathogenic bacteria and the associated risk of infection. She also touched on the some of the other risks of giving birth underwater and made some excellent arguments against many of the claims made by proponents. I recommend reading that post and the ensuing comments.
This week, a new joint clinical report from the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG) on immersion in water during labor and delivery was published in both the April Pediatrics and on the ACOG website. The media has responded with the typical flurry of falsely dichotomous coverage, pitting maternal-fetal medicine experts against midwives and other waterbirth proponents and leaving it up to the reader to decide which side is right. This March 23rd, an NPR article by Nancy Shute is a particularly frustrating example of weak medical reporting. In the article she essentially portrays giving birth underwater as an established and safe practice and medical experts as overly focused on a few flimsy anecdotes and case reports:
“Case reports are the lowest form of evidence,” Shaw-Battista counters. She is completing a study of 1,200 women who labored or birthed in water, and says they did as well or better than women who did not. “Given the bulk of the data, I don’t think we should use case reports to reject options that women are currently enjoying.”
Like many proponents, Shaw-Battista, who is the director of the Nurse-Midwifery Education Program at UCSF, touts unpublished data and subjective claims. About the only thing she says in the article that I can’t argue with is that if a family is going to deliver underwater it should be “conducted with a trained professional, be planned, and follow established guidelines.” I may not support the practice, but there absolutely should be somebody present who knows to get the baby out of the water right away without causing an avulsion of the umbilical cord, to not put the baby back in what amounts to sewer water for any reason, and who can perform neonatal resuscitation if necessary. That’s more likely to happen when a waterbirth takes place at a hospital or birthing center, which many do, but is decidedly less likely to be the case during a home birth, many of which are attended by laypersons with little to no experience in dealing with complications of any kind.
In the article, Shute also significantly misrepresents a 2009 (updated a bit in 2011) Cochrane review of immersion in water in labor and birth, and not just by calling it a 2012 review, which is when it was made available online:
A 2012 Cochrane review found no harm to the baby in 12 randomized controlled trials of water labor or birth involving 3,243 women, and less use of epidural anesthesia.
Yes, the Cochrane review looked at 12 studies, but 9 of them only involved immersion during the first stage of labor, which ends upon complete cervical dilation. The AAP and ACOG aren’t too worried about the first stage of labor other than the possibility that sitting in a tub of water might possibly interfere with providing appropriate emergency medical care in the event of a complication. They also ask nicely that facilities providing water immersion during the first stage of labor to please keep the tubs clean, however.
They admit that there may be some benefit in that there appears to be a little, and I mean a little, less use of spinal/epidural analgesia and that progression to the second stage of labor (delivery of baby but not the placenta) might move a little faster. It is questionable how clinically significant these benefits are however. And there is absolutely no evidence whatsoever that water immersion improves outcomes related to the baby. Only three of the studies used in the Cochrane review looked at the actual delivery, and they were unable to draw any conclusions regarding safety and efficacy.
A fine example of complementary and alternative reality in regards to labor and delivery can be found at Waterbirth International, which is run by >Barbara Harper, a nurse who preaches the benefits of waterbirthing all over the world and who is a proud proponent of rebirthing-breathwork. Rebirthing-breathwork is the concept that suppressed negative emotions can be healed by reliving one’s birth…and breathing a lot. Also there is something in there about cells having feelings. Harper gets the last word in the NPR article:
“I think this is backlash from the gaining popularity of water birth,” says Barbara Harper, founder of Waterbirth International, an advocacy organization…One thing that happens in a water birth, you as the attending physician pretty much have to stand there with your hands in your pockets and let it happen without your participation. That is pretty scary to a physician-oriented institution.”
How’s that for a straw man? Medical experts are apparently only skeptical of waterbirth because we don’t get to participate, which I have little doubt is code for “we don’t like it cause we don’t get paid.” I wonder if she works for free.
I believe that most rational people, even those with no medical experience, intuitively understand that delivering a baby into a body of water, even a sterile one, would be inherently risky. Human newborns, as with all other primates (take that Discovery Institute) breathe almost immediately upon arrival into this world. This helps to initiate a chain of events that assists the neonate in transitioning from fetal to adult circulatory patterns, and there are millions of years of evolutionary momentum behind this process. But besides being a completely unnatural act, something that usually sends proponents of pseudoscience running, there are numerous potential risks involved with giving birth underwater.
Before I discuss the risks, however, allow me to pass along the proposed benefits so that you might make an informed risk-versus-benefit determination for yourself. The following information comes from a Waterbirth International FAQ on the subject and is fairly representative of what other organizations claim and of the degree of misinformation patients are subjected to. Here is another example of information supportive of waterbirthing available online that goes much further, even implying that premature infants and other babies at high risk of complications, such as large babies at risk of becoming stuck at the shoulders during delivery, are good candidates. There is also a reference to the “aquatic ape” hypothesis hidden in there.
The most common proposed benefit of water labor and birth is less pain, and therefore a better chance of achieving a “natural” childbirth without drugs for maternal comfort. This desire for a drug-free childbirth is based on the naturalistic fallacy, misleading claims of risk by proponents, a large helping of misogyny, and dubious ethics on the part of medical professionals who would otherwise never allow a patient to suffer. Other more objective claims are that it speeds up labor, decreases the need for C-sections, and reduces the number of trauma-requiring interventions. Proponents also claim that decreased maternal stress hormones are better for the baby, and that the newborn transition will be gentler which just has to be a good thing. The rest are entirely subjective, such as increased relaxation, improved sense of well-being and control, or involve how satisfied the mother was with the process.
So what kind of evidence base supports these claims of benefit? According to the recent statement from the AAP and ACOG, and I’m paraphrasing a bit, it ain’t good. The following quote works too:
Most published articles that recommend underwater births are retrospective reviews of a single center experience, observational studies using historical controls, or personal opinions and testimonials, often in publications that are not peer reviewed.
The authors also point out that there is a complete absence of any basic science, in either animals or humans, to support the proposed physiologic benefits of giving birth to a human underwater. Plenty for fish though.
Another huge problem with the evidence for water labor and birthing, whether published in peer reviewed journals or anecdotes on websites and documentaries, is the lack of consistent definitions. What defines water labor and waterbirth varies from situation to situation and between institutions. Timing, temperature, maternal health problems and location can vary significantly. And I’ve already given you an example of a so-called science reporter conflating safety data from just labor with safety of underwater birth, which is at the very least extremely misleading, and potentially dangerous. There is also a complete lack of blinding and virtually no controlling for the other aspects of the birthing environment when comparing standard to underwater deliveries.
What does the available evidence support after taking into account the poor quality of available data? Not a whole lot. As I stated earlier, there appears to be a modest, though perhaps not clinically significant, decrease in the use of pain-reducing procedures. There also appears to be a decrease of about half an hour in the time it takes for labor to progress to full dilation, but again this is hampered by a lack of controlling for potential confounders. There is no good data to support a difference in delivery-associated trauma, the need for vacuum or forceps assistance, or the need for a C-section. There is no evidence to support claims of benefit to the newborn. But it does seems that mothers are more satisfied with delivery underwater, which may only be a result of theatrical placebo employed by waterbirth attendants.
Now that I hope I’ve made it clear just how flimsy the case for giving birth underwater is, it is time to discuss the potential risks. Similar to the data held up by proponents as supportive of their claims of benefit, the risk of underwater birth is largely based on individual case reports and series, although the basic science foundation is solid. This means I can’t tell you how common it is for these complications to arise, but of course the burden of proof does fall on the proponents to show benefit. That being said, the risks that have been reported can be quite serious, even deadly. I’ll just list them:
     1.  Increased risk of infection, especially after rupture of the membranes acting as a barrier between baby and the outside world
     2.  Problems with temperature regulation in the baby
     3.  Damage to the umbilical cord, or pulling of the cord out of the placenta, leading to severe bleeding complications
     4.  Respiratory distress, hyponatremia, seizures and asphyxia from fresh water drowning
These risks, although rare, are potentially catastrophic. There are numerous case reports/series of deaths and significant morbidity. One study that was not included in the Cochrane review because it involved a comparison of standard delivery and waterbirth of infants with dystocia (abnormal or difficult childbirth/labor) showed that 12% of the babies born underwater required NICU admission while none of the babies born dry, relatively speaking, did. The only variable in a delivery that can lead to fresh water drowning, for instance, is the choice to have a waterbirth. That alone, in my opinion, is enough to establish that at this time the risk outweighs the benefit. The incidence of these adverse outcomes is likely much higher when an infant with risk factors is born underwater. Essentially the same issues that come up with home births in general are exacerbated by adding water.
Why don’t babies breathe when they are born underwater? According to Barbara Harper, there are many reasons, including that God doesn’t want them to, but four that stand out:
1. Prostaglandin E2 levels from the placenta which cause a slowing down or stopping of the fetal breathing movements. When the baby is born and the Prostaglandin level is still high, the baby’s muscles for breathing simply don’t work, thus engaging the first inhibitory response.
Healthy babies born without difficulty typically breathe within ten seconds of birth, but many breathe right away. The likely reason that there isn’t a higher incidence of aspiration of water after delivery is that the standard approach is for the attendant to remove the baby from the water right away, though with care to not damage the umbilical cord. A sick baby may have already begun gasping breaths while still in the womb, and they often pass stool prior to delivery which can be aspirated and cause a great deal of morbidity and mortality. If a sick baby were to be born into water, they are almost certainly at increased risk of drowning.
2. All babies are born experiencing mild hypoxia or lack of oxygen. Hypoxia causes apnea and swallowing, not breathing or gasping.
This demonstrates a complete misunderstanding of newborn physiology around the time of birth. Yes, oxygen saturation levels in newborn babies are not 100%. They slowly rise over the first several minutes of life to normal levels. So this is true in that sense. In regards to apnea, I can only assume that she means primary apnea. This occurs when an infant is unable to achieve adequate oxygenation through breathing once the placental supply of oxygen is diminished. It is never normal for a newborn to be apneic, but it is somewhat common.
Primary apnea, when it occurs, often responds to simple stimulation to breathe as occurs during drying and providing a clear airway, while secondary apnea, which occurs after a prolonged lack of oxygen delivery to the brain, requires more aggressive resuscitation. Again, babies typically breathe within a few seconds of birth. So the attendant at a water delivery must quickly retrieve them from the water. I’m sure they make it seem like a gentle and loving thing, but as soon as the kid hits the water, the clock is ticking and such a nonchalant reference to apneic newborns is frightening.
3. Fetal lungs are already filled with fluid. That fluid is there to protect the lungs, and keep the spaces open that will eventually exchange carbon dioxide and oxygen. It is very difficult, if not improbable, for fluids from the birth tub to pass into those spaces that are already filled with fluid. One physiologist states that “the viscosity of the fluid naturally occurring in the lungs is so thick that it would be nearly impossible for any other fluids to enter.
This is true, prenatally. But the onset of labor signals a surge of chemicals called catecholamines that signal the lungs to quickly reabsorb fluid. This is why babies that are born without labor, such as via a scheduled C-section, often have a transient period of fast breathing related to some retained fluid in the lungs. The lungs are not “filled with fluid” at the time of delivery however, and will readily accept a bolus of fresh water as has been reported many times. In fact, premature infants, and sometimes even those delivered at term, often have medicines purposefully squirted into the lungs via an endotrachial tube right after birth. They get in there just fine.
4. The last important inhibitory factor is the Dive Reflex and revolves around the larynx. The larynx is covered all over with chemoreceptors or taste buds. The larynx has five times as many as [sic] taste buds as the whole surface of the tongue. So, when a solution hits the back of the throat, passing the larynx, the taste buds interprets [sic] what substance it is and the glottis automatically closes and the solution is then swallowed, not inhaled.
The dive reflex occurs in aquatic mammals primarily but there is a weaker version in humans. It involves a reduction in heart rate and a shunting of blood from the peripheral vasculature to the vital organs, primarily the heart and brain, allowing for an extended duration of breath holding. This reduction in heart rate can actually sometimes be put to medical use in young patients presenting with one type of arrhythmia called supraventricular tachycardia. We hold a bag of ice water over the entirety of their face. Strange but true.
The dive reflex only occurs when the face is submerged in very cold water. Breath holding associated with submersion in cold water is an involuntary process where breathing is centrally inhibited. What waterbirth proponents are confusing the dive reflex with here is drowning. During drowning, when water hits the airway there is spasm of the surrounding musculature and closure of the epiglottis. This prevents aspiration and forces swallowing of the water, which is why there is risk of hyponatremia in fresh water drowning. Eventually the spasm will relax and water will be taken into the lungs.
These are the people delivering our babies. When waterbirths take place in cold water, which they never do because that would interfere with the pleasurable experience of the mother, they can talk about the diving reflex. Or if they are delivering a seal. You know what really interferes with the pleasurable experience of the mother? A dead baby.
One final time, the reason why more babies don’t tend to aspirate water after a waterbirth is timing and luck. They are retrieved prior to the first breath, which may be a little delayed because of reduced stimulation to a baby born underwater. It is as simple as that. Some babies will always breathe too soon. Sick babies are more likely to breathe too soon. If a baby develops primary apnea, and stimulation to breathe is delayed because they are underwater, their heart rate will plummet and prolonged lack of oxygen to the brain will lead to them requiring substantial resuscitation.
Final thoughts
The conclusion of the AAP/ACOG statement that has waterbirth proponents so bent out of shape is extremely well-reasoned. They admit that water immersion during the first stage of labor might have some very limited benefit as discussed above. But they stress that there isn’t evidence to support improved perinatal outcomes, and that if a mother chooses to relax in a pool filled with water it shouldn’t get in the way of other aspects of appropriate care. Of course lay midwives attending a home waterbirth might have a different opinion regarding what those are.
In regards to actually delivering in the water, the authors conclude that the safety and efficacy is not established. They state, based on the many case reports of severe complications and lack of quality evidence to support maternal or fetal benefit, that any underwater deliveries should be considered an experimental procedure and take place in the context of a clinical trial with informed consent. And there is the rub. I have grave concerns that appropriate informed consent is currently not being obtained, that the benefits are overhyped and the risks downplayed beyond what is supported by the evidence. A lack of proper informed consent violates one of the four foundational principles of medical ethics, which is a respect for the patient’s personal autonomy.
There are few things as intimate and emotionally powerful as the process of giving birth. The variables inherent in this process range from the fairly minor, such as what music a mother would like to listen to during labor, to the extremely important choices of where and how the baby is to be born and who is to be in attendance at the delivery. Many of these choices have relatively little if any impact on the health of the newborn baby or on the risk of maternal complications, but rather help to mold and shape the overall experience of childbirth to the mother’s liking. Regardless of the importance of each choice, it should come as no surprise that they are as subject to personal biases, logical fallacies, and social and cultural influences as any other decision.
Expectant mothers, and often their families, put a great deal of focus on the subjective experience of childbirth, and this is understandable as the memories being forged will last a lifetime. There is unfortunately, for many families, an idealized perfect labor and delivery experience that often appears to be based more on television and movie portrayals or the anecdotes of friends than on explanations by science-based healthcare professionals. But sometimes this ideal experience is molded and shaped by biased healthcare professionals employing motivated reasoning, or by nonprofessional lay practitioners who hold themselves up as birthing experts.
They all likely mean well and want what is best for the mother and baby, but that is not an excuse. Childbirth is a time of great vulnerability. All parents want their children to enter the world happy and healthy, and to stay that way as they grow. Unfortunately, when this all-too-human desire to have a positive birth experience and a healthy baby is hijacked by excessive worry based on false or misleading information, people can make uninformed and potentially deadly decisions. My provisional conclusion is that choosing to deliver a baby underwater is such a decision. If proponents are at some point able to present good evidence to show that the benefit of waterbirth outweighs the risk, I will gladly change my opinion.
-Here is a nice discussion published in Pediatrics in 2004, titled “Water Births: A Naked Emperor.” Here is the midwife response and subsequent destruction of that response by Dr. Schroeter.
-Dr. Jen Gunter, an evidence-based OB/GYN and pain medicine physician, also recently discussed the AAP/ACOG statement on her website. She agrees that introducing water to the birthing mix shouldn’t get a free ride.
-Finally, here is a satirical look at the extremes people go to in an effort to have a memorable birthing experience.

Water Birth (Again)
Harriet Hall on April 1, 2014
Link
Note: I had just finished writing this article when I discovered Dr. Jones had beat me to the punch with his March 28th article on the same subject. He did an excellent job, and of course reached the same conclusions I did (it’s not that great minds think alike, but that we base our conclusions on the same body of evidence). Rather than let my efforts go to waste, I decided to go ahead and publish my shorter, more idiosyncratic article. If it’s worth saying, it’s worth saying twice; and different approaches may appeal to different readers.

“Humani nihil a me alienum puto.”
Nothing human should be alien to me, and I can understand why people do most of the strange things they do, but water birth is something I have really had difficulty with. Why would anyone want a baby to be born underwater? Why would they want to buy a special pool, set it up in the living room, fill it with water, keep the water at the right temperature, and then have to deal with emptying the pool and cleaning up afterwards? I read about it and tried to understand, and now I have some insight into their reasons; but I think they are poor reasons, and the whole concept remains pretty alien to my mind.
The claims
I found a fuzzy feel-good rationale on the Waterbirth International website. Mothers feel it is the gentlest of gentle births. Warm, luxurious water cradles you and gives you complete freedom to move during the greatest achievement of your life. “The women who have experienced the support and comfort of water for their labors and held their newborns in their arms speak more than any scientific article or paper on the subject.” In other words, “We don’t need no stinkin’ science!”
They went on to make some specific claims of benefits:
    • Water facilitates mobility and allows the mother to assume a comfortable position
    • Speeds up labor
    • Reduces blood pressure
    • Gives mother more feelings of control
    • Provides significant pain relief
    • Promotes relaxation
    • Conserves energy
    • Reduces the need for drugs and interventions
    • Gives mother a private protected space
    • Reduces perineal trauma and eliminates episiotomies
    • Reduces C-section rates
    • Is highly rated by mothers and by “experienced providers”
    • Encourages an easier birth for mother and a gentler welcome for baby
    • Placing a pool of water in a birth room changes the atmosphere immediately. Voices get softer, everyone becomes less stressed
    • The easier movement with buoyancy helps open the pelvis
    • The body is less likely to secrete stress-related hormones and more likely to produce pain-relieving endorphins
The research
They said these benefits are supported by research. They didn’t provide any citations, so I consulted PubMed. Here’s what I found:
    • There have been only two randomized controlled trials of water birth vs. land birth. They found minimal benefit to the mother and no benefit to the baby.
    • A Cochrane review found a reduction in epidurals but no reduction in C-sections, assisted vaginal deliveries, or perineal trauma.
    • Another Cochrane review found a decrease in reported maternal pain with no effect on labor duration, operative delivery rate or neonatal outcomes.
    • Still another Cochrane review found no difference in the use of pain relief, duration of labor, meconium staining or perineal trauma.
    • A 2004 systematic review found 16 citations of adverse effects including drowning, neonatal hyponatremia, neonatal waterborne infectious disease, cord rupture with neonatal hemorrhage, hypoxemic encephalopathy and death.
In short, there was only one systematic review suggesting a decrease in epidurals and it was contradicted by another systematic review. There was no research to support any of the other claims. Even the reported decrease in epidurals is suspect because of confounders. These women had strong expectations of pain relief and were part of a culture that frowns on epidurals.
The history
I couldn’t help wondering who ever thought up the idea in the first place. I found this:
We tend to think of labouring in water as relatively new. However, a writer on water births, Janet Balaskas, says that’s not so. She describes legends [emphasis added] of South Pacific Islanders giving birth in shallow seawater and of Egyptian pharaohs born in water. In some parts of the world today, such as Guyana, in South America, women go to a special place at the local river to give birth. [Maybe they want ready access to water to wash away the blood and amniotic fluid. River water and sea water are cold, not warm. And why would anyone want to imitate legends or the practices of a few women from a pre-scientific culture?]
Giving birth in water (rather than labouring in it) is a relatively recent development in the Western world. The first water birth that we know about in Europe was in 1803 in France. A mother whose labour had been extremely long and difficult was finally helped to give birth in a tub of warm water. [Uncontrolled anecdotal evidence. How do we know she wouldn’t have given birth just as soon without the warm water?]
Expert opinion
A joint Committee Opinion from the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics says water birth is not recommended and should not occur outside the setting of a clinical trial due to the potential risks. You can read their whole report here.
Their conclusions:
Immersion in water during the first stage of labor may be appealing to some and may be associated with decreased pain or use of anesthesia and decreased duration of labor; however, there is no evidence that immersion in water during the first stage of labor otherwise improves perinatal outcomes. Immersion therapy during the first stage of labor should not prevent or inhibit other elements of care, including appropriate maternal and fetal monitoring.
In contrast, the safety and efficacy of immersion in water during the second stage of labor have not been established, and immersion in water during the second stage of labor has not been associated with maternal or fetal benefit. Given these facts and case reports of rare but serious adverse effects in the newborn, the practice of immersion in the second stage of labor (underwater delivery) should be considered an experimental procedure that only should be performed within the context of an appropriately designed clinical trial with informed consent.
Although not the focus of specific trials, facilities that plan to offer immersion in the first stage of labor need to establish rigorous protocols for candidate selection, maintenance and cleaning of tubs and immersion pools, infection control procedures, monitoring of mothers and fetuses at appropriate intervals while immersed, and protocols for moving women from tubs if urgent maternal or fetal concerns develop.
The Skeptical OB, Amy Tuteur, has stronger opinions. She considers water birth tantamount to delivering in a toilet. The water in the birthing tub will unavoidably become contaminated with skin and fecal bacteria. In fact, it is even worse than the water in a toilet because the warm environment promotes bacterial growth. The number of reported complications continues to rise; even deaths have occurred. The idea that the “diving reflex” will prevent babies from inhaling the water has been refuted. In compromised infants, the diving reflex is over-ridden and we know they can inhale thick meconium (essentially prenatal feces) in utero. Would you want to risk your baby inhaling toilet water?
Conclusion
Laboring in water offers minimal benefits if any, and delivering in water offers only risks without benefits. Patients who understand the science may still want to try it for their own personal fuzzy reasons, and I support patient autonomy as long as patients can give truly informed consent; but I suspect that most women who choose water birth are not adequately informed about the scientific evidence (or rather the lack thereof). And I wonder about the ethics. Mothers may have the right to reject science and believe that “The women…speak more than any scientific article or paper…,” but do they have the right to risk the health of their helpless infants?

Vaginal Birth After C-Section: How Safe Is It?
Harriet Hall on January 12, 2016
Link


Doctors used to insist “once a C-section, always a C-section.” Today it is standard practice to allow vaginal births after C-section (VBAC) for appropriately selected patients. The American Congress of Obstetricians and Gynecologists (ACOG) has issued a Practice Bulletin to guide obstetricians in determining which patients are appropriate candidates for VBAC.
We frequently hear criticisms of practice guidelines like these. The doctors who write the guidelines are accused of conflict of interest, turf protection, and biased evaluation of the evidence. For those who believe doctors put profits before patients, this should be an eye-opener. It would presumably be in the best financial interests of obstetricians to do as many C-sections as possible, since they can charge more for them than for vaginal births. It would have been easy for the ACOG to put a spin on the data to make repeat C-sections look like a better choice. The fact that they offer VBACs despite their conflict of interest makes me think that their evaluation of the evidence was probably fair and unbiased.
So just how safe is VBAC? What are the pros and cons? What does the evidence say?
Background: Why is VBAC an issue?
The earlier prohibition of vaginal deliveries after C-sections was due to the risk of uterine rupture and other complications. In the 1970s, doctors began to reconsider. The percentage of women with a VBAC rose from 5% in 1985 to 28% in 1996; but then the number of reports of uterine rupture began to increase, and by 2006 the VBAC rate had dropped to 8.5%. Between 2003 and 2006, 26% of obstetricians stopped offering it. An NIH panel examined the evidence in 2010. They concluded that VBAC was a reasonable option and called on the ACOG and other organizations to facilitate access to it.
Trial of labor doesn’t always succeed
There are three possible outcomes for a trial of labor: a successful vaginal birth, an emergency C-section, or an elective C-section. Only 74% of women who attempt VBAC succeed; the other 26% ends up needing a C-section, often on an emergency basis. Emergency surgeries are inherently more risky than planned ones. A number of factors have been identified that affect the chance of a successful vaginal delivery, including race, maternal age, fetal size, fetal position, gestational age, mother’s weight, number of previous C-sections, a previous vaginal birth, the reason the C-section was done, cervical effacement and dilation at the time of admission, rupture of membranes, induction of labor, and the presence of meconium. Screening tools have been developed to help predict outcomes. The models make good predictions at the population level, but they haven’t been verified as useful for individual women.
Benefits and harms to mothers with VBAC
The NIH panel graded the available evidence. They found:
    • High-grade evidence for a lower death rate for women attempting VBAC: 4 per 100,000 compared to 13 per 100,000 with elective repeat C-section
    • Moderate-grade evidence for increased risk of uterine rupture. 778 per 100,000 compared to 22 per 100,000 for elective repeat C-section:
        ◦ No maternal deaths from uterine rupture
        ◦ 6% of ruptures are fatal for the infant
        ◦ 14-33% of ruptures require hysterectomy
        ◦ A number of factors are known to increase the risk of rupture, including induction of labor and the number of previous C-sections
        ◦ A prior vaginal birth reduces the risk of rupture to 600 per 100,000
    • Moderate-grade evidence for a lower risk of placental abnormalities like placenta previa in future pregnancies
    • Low-grade evidence for a shorter hospital stay and a lower rate of deep venous thrombosis with VBAC
Harms and benefits of VBAC for infants
The NIH found:
    • Moderate-grade evidence that perinatal mortality is increased: 130 per 100,000 compared to 50 per 100,000 for elective repeat C-section
    • Low-grade evidence for higher fetal mortality in utero (50-100 per 100,000 versus 0-40 per 100,000)
    • Low-grade evidence for a higher rate of hypoxic ischemic encephalopathy
    • Insufficient evidence for a difference in respiratory problems, sepsis, birth trauma, breastfeeding practices or mother-infant bonding
Nonmedical factors that influence utilization of VBAC
    • Professional guidelines require that VBAC be offered only where emergency C-sections are “immediately available.” 30% of hospitals stopped offering VBAC because they couldn’t guarantee immediate surgical and anesthesia services. Oregon midwives are upset because the Oregon Health Plan excluded VBACs from coverage for non-hospital births. Midwives are still attempting VBACs in home births, and some have called VBAC a “success” even when the baby died. At least the mother had a “natural” experience and avoided surgery!
    • Professional liability concerns. There have been lawsuits: a patient whose doctor informed her about the risk of uterine rupture sued because she claimed she was not specifically told there was a possibility that the baby could die
    • Informed decision-making is problematic due to insufficient data and the impact of how the risk is presented to the patient
    • High volume settings tend to have better outcomes
    • Patient and provider preferences: considerations like the belief that vaginal delivery is deeply empowering, the expectation of an easier recovery, a desire for sterilization at the time of delivery, the desire to avoid labor pain, the expense, a previous bad experience, etc.
Conclusions of the NIH
The NIH panel concluded that a trial of labor is a reasonable option for many pregnant women with one prior C-section with a low transverse uterine incision. The reduced risk for the mother and the increased risk for the infant pose a profound ethical dilemma that is made worse by the paucity of high-quality evidence and the difficulty of providing precise quantification of the risks and benefits for informed consent.
ACOG guidelines
The American Congress of Obstetricians and Gynecologists Practice Bulletin (as of 2015) essentially agrees with the findings of the NIH group. It reviews the evidence for risk and benefit and provides practical guidelines for managing and counseling patients who will give birth after a previous C-section.
They point out that there are no randomized controlled trials, and that the available evidence is from observational studies. They remind us that the appropriate comparison is not between VBAC and surgery, but between trial of labor after C-section (TOLAC) and elective repeat C-section, since many of the attempts end in a C-section anyway and most of the morbidity from TOLAC occurs when a repeat C-section becomes necessary.
VBAC is associated with fewer complications, and a failed TOLAC is associated with more complications, than elective repeat cesarean delivery. Consequently, risk for maternal morbidity is integrally related to a woman’s probability of achieving VBAC.
They point out that some studies have lumped together catastrophic uterine ruptures and asymptomatic scar dehiscences. They estimate the risk of rupture as 0.5-0.9% after TOLAC. After a woman has had a uterine rupture, the risk of a repeat rupture is 6%; they recommend early delivery by C-section for those patients.
Women who achieve VBAC avoid major surgery with its inherent risks and its consequences for the success of future pregnancies (like abnormal placentation). They have lower rates of hemorrhage, infection, and a shorter recovery period.
They stress that the probability of a successful VBAC depends on a combination of factors. They list those factors and they mention a model that may be helpful in quantifying predictions. They cover a lot of special situations like twin gestations and intrauterine demise. As with so much else in medicine, it’s complicated. Counseling should involve consideration of all the relevant individual factors that might increase or decrease risk beyond the average, and the ultimate decision should be made by the woman.
They point out that there should be “immediately available” emergency resources, which may preclude offering VBAC in smaller facilities.
They offer detailed recommendations and specify which recommendations are based on which levels of evidence: A (good and consistent scientific evidence), B (based on limited or inconsistent scientific evidence) or C (primarily based on consensus and expert opinion). They propose a performance measure: the percentage of women who are candidates for TOLAC for whom discussion of the risks and benefits of TOLAC compared with a repeat C-section are documented in the medical record.
Conclusion: Easier for moms, harder on babies
How safe is VBAC? The evidence is not as extensive or as high-quality as we would wish, so there are no definitive answers. But based on the evidence we do have, VBAC appears to be a trade-off, with a small decrease in risk for mothers and a small increased risk for babies. Those risks vary according to a lot of different factors, and patients should be counseled by obstetricians who can use their clinical judgment to estimate how the individual’s risk factors might affect the interpretation of the overall statistics. The Skeptical OB has described how this individualized approach works. There are non-medical factors to consider, and ultimately the woman has to decide what risks she is willing to accept for herself and her child.

Lotus Birth: No Benefit, Plenty of Risk
The practice of refusing to cut the umbilical cord after delivery of a newborn has no benefit and risks serious infection. A recent case series illustrates the risks of so-called Lotus birth.
Clay Jones on December 28, 2018
Link

I was surprised to find that we haven’t covered Lotus birth on SBM, at least not that I could find. We do cover a lot of nonsense here, some of it very dangerous and with very little if any potential benefit. That’s a pile onto which I would throw the practice of Lotus birth, known as umbilical cord nonseverance in medical parlance.
What and why is Lotus birth?
Lotus birth occurs when, despite a complete lack of plausible benefit and the warnings of pediatric and obstetrical experts, the decision to leave the placenta attached to a newborn infant by an intact umbilical cord is made. This decision is made because of the influence of medical misinformation and the desire for a special birth experience. Information available online often plays up the benefits while downplaying the risks.
Genevieve “Mama Natural” Howland describes the relationship between a fetus and their umbilical cord in almost magical terms, even referring to it as a “teddy bear” to be nuzzled up to. She claims to be providing objective information so that curious mother’s can make an informed choice, yet refers to Lotus birth as a “quiet and respectful transfer of attachment, without the trauma of being cut from the mother.”
There are no nerve endings in the cord. Cutting it is painless and absolutely not traumatic. It is magical thinking that leads to such a false statement.
Howland’s article further confuses her readers by claiming that Lotus birth has been practiced for hundreds of years:
And records of not cutting the umbilical cord appear on the American continent as early as the pioneer days. In Western nations, lotus birth seems to be a new birth trend steeped in early tradition.
The link she provides, however, is about delaying the clamping of the umbilical cord but not Lotus birth, which involves allowing the cord to naturally separate. This can take anywhere from a few days to a couple of weeks. During this time, the placenta, now lacking a blood supply to deliver oxygen and remove metabolic waste, begins to rot. In reality, Lotus birth is a lot like placentophagy in that it has only entered the scene in the past few decades. It is essentially just New Age nonsense.
According to Howland, there is a sacred relationship between baby, cord, and placenta. But, she adds, there may be other benefits such as the transfer of extra blood to the baby. This is potentially true, although the placenta would need be carefully positioned so as to not allow gravity to drain blood from the baby. In conventional obstetrical care, as long as the baby does not require urgent resuscitation, we typically delay the clamping of the cord for a minute or two for just this purpose. The benefit in most babies is a reduction in the risk of iron deficiency, which can result in poor brain development.
The remainder of the proposed benefits mentioned by Howland are nonsense, particularly that it is better for maternal healing or the baby’s emotional well-being. Especially ridiculous are claims that it reduces risk of infection in the baby. You’ll soon see why that is wrong and quite dangerous.
Why is Lotus birth dangerous?
As I mentioned above, Lotus birth involves leaving a baby attached to the placenta via a tube containing blood vessels that allow blood to travel back and forth. This connection also allows the passage of pathogenic bacteria as said placenta begins to rot. It really is just that simple.
To illustrate the risk, a recent case series published in Clinical Pediatrics provided details on three Lotus births. In the second of three cases, the association of Lotus birth with severe jaundice was tenuous in my opinion. This is a common medical problem in newborns, particularly when breastfeeding is not going well. This case does illustrate how irrational medical decisions tend to cluster. In this case, the mother also refused the solidly evidence-based recommendation for intrapartum antibiotic prophylaxis in the setting of a positive screen for group B strep. But that’s a topic for another day.
The baby in the first case was born at home and underwater after limited prenatal care (more clustering), and brought in for medical attention because of labored breathing. The baby was found to be dangerously hypoglycemic and to have an abnormally elevated percentage of red blood cells, both of which can result in injury to the brain. The baby ultimately was found to have a bloodstream infection and bacterial grown on one of the heart valves, an extremely dangerous diagnosis, and required inpatient care for several weeks.
In the third case, a baby who was still attached to the placenta developed an infection of the umbilical stump and surrounding abdominal wall in the first two days of life. Known as omphalitis, this infection is dangerous because it can easily spread to the umbilical vessels and cause a systemic infection. Because of this, the mortality rate can be as high as 15%. Luckily the baby had a good outcome.
Conclusion: Cut the cord!
There is no reasonable expectation of benefit from delaying clamping and cutting of the umbilical cord after delivery for more than a couple of minutes. There is, however, plenty of plausible risk, particularly that of serious bacterial infection. Lotus birth is a dangerous practice and anyone promoting it is putting the lives of newborn babies at risk. Cut the cord.

Hiccups: From Acupuncture to Quantum Touch
Clay Jones on September 26, 2014
Link


nOne of the most common questions I get in the newborn nursery, especially from first time parents, involves hiccups. Babies hiccup in the womb and most, if not all of them, will have periodic bouts of hiccups in the neonatal period. But many new parents are surprised by their baby’s first spasmodic contractions of the diaphragm. When brought up, it is often to simply acknowledge that their baby had a run of a few hiccups, usually associated with a feed, with some parents expressing surprise and others nervousness. Regardless of their assumed motivation, I always provide reassurance that hiccups are a normal experience for babies, as they are across the entire spectrum of age.
The medical term for hiccups, which I admit I only learned while researching this topic, is “singultus.” We doctors like to use our own peculiar language as much as possible in order to maintain a sense of superiority when dealing with today’s internet savvy customers, I mean patients, and their families. The rumbling of your stomach, that’s actually borborygmus. You don’t have a unibrow above your nose, that’s a synophrys. It isn’t abdominal or pelvic discomfort associated with ovulation that keeps annoying you midway through your menstrual cycle, it’s mittelschmerz. But since this is a forum meant for general public consumption, I’ll use the rather pedestrian and philistine “hiccup” for the duration of the post.
What are hiccups and who gets them?
Simply put, a hiccup is the sudden occurrence of a spasm involving the diaphragm, usually the left half of it, and the intercostal (between the ribs) muscles, that occurs without warning. The muscular contraction causes a hard inspiration of air followed quickly by an involuntary closing of the vocal folds. This produces the “hic” that we all know and love. In the individual, the frequency of hiccups during any one bout are fairly consistent, ranging from a couple per minute to one per second, with a lot of variability episode to episode.
In the vast majority of cases, hiccups are classified as a bout. This means that they may last for less than a couple of days, but usually persist for only a few minutes. Longer episodes that last less than a month are defined as persistent, and are very rare. People with intractable hiccups, whose cases occasionally make the news (not always just for the hiccups!), have them for longer than one month. Intractable hiccups are exceedingly rare, but can result is significant problems for the sufferer depending primarily on how frequently they occur. Very frequent hiccups can interfere with eating and social functioning, for example.
There have been very few studies looking into hiccups, particularly the fairly rare intractable presentations, and no adequate controlled trials. The largest I could find involved 4 patients. We don’t know with certainty if there are any particular predilections, such as ethnicity or socioeconomic background, but a few small studies have found links between intractable hiccups and older age, gastric reflux associated inflammation of the esophagus and a variety of other chronic conditions. They also seem to occur a bit more frequently in men. The fact that the hiccup is such a largely misunderstood onomatopoeia, despite what you may read online or hear from your neighbor/chiropractor, naturally allows for them to be a frequent target of practitioners of all manner of so-called alternative medical practices as well as myriad culturally diverse home remedies.
What causes hiccups?
We don’t know for certain what hiccups are all about, which is not to say that we are flying completely blind. We may not know what provokes most individual bouts, but we have a general idea of precipitating factors and hiccups can even be reliably initiated in some people. We don’t know if hiccups serve some kind of beneficial purpose in mammalian development, or are a holdover from amphibian gill ventilation, not that there even has to be a reason for them at all. Not everything has to have a purpose or survival advantage. It is certainly very interesting that the hiccup only occurs in mammals, and in fact is found universally in them. But we do at least have the neural pathway mapped out…sort of.
Hiccups, we are fairly certain, occur via a reflex arc of neural activity. A signal comes into the brainstem, perhaps also targeting the nucleus of the phrenic nerve in the cervical spine and the hypothalamus, a vital forebrain structure found in all vertebrates, via the phrenic and vagus nerves, and maybe the sympathetic chain. The medulla oblongata and reticular formation of the brainstem, and again maybe the hypothalamus and phrenic nucleus, interact in some way, perhaps a miracle occurs, and a signal is sent back out via the phrenic nerve and other connections to the throat, diaphragm and chest wall. Hiccup.
We think that most bouts of hiccups are related to gastric and esophageal distention from a variety of causes, such as eating a bit too much or from drinking carbonated beverages. Hiccups can be induced with intentional dilation of the esophagus in many people, for instance, and many folks at least think that they get them every time they engage in a particular activity such as drinking or eating at the all you can eat buffet. Of course this could easily be attributable to confirmation bias. There are also associations with alcohol and changes in gastric temperature, as well as emotional stress. For the most part these are all just assumptions based on limited data and some animal studies.
The causes of persistent and intractable hiccups are a bit better understood, although not without a fair amount of assumptions as well. Vascular, infectious and structural diseases of the CNS have all been linked to severe episodes of hiccups, likely because of interference with the above mentioned neural pathways. Direct irritation of the vagus and phrenic nerve, such as from an inflammatory process or tumor, is believe to be a common culprit, as are gastrointestinal disorders that lead to distention and irritation of the stomach and esophagus. There are many more proposed causes, like reactions to a variety of drugs and even inflammation of the heart, but again most of them can only be considered to be associated with persistent or intractable hiccups. Evidence for a true causal relationship is lacking for pretty much everything, and in most cases no hidden cause is discovered.
Psychogenic factors probably play a large role in many cases of intractable hiccups, although this should always be considered a diagnosis of exclusion. This shouldn’t come as much of a surprise though. If stress and anxiety can result in psychogenic non-epileptic seizures, a foe I’ve battled many times as a pediatric hospitalist, they can certainly cause hiccups that aren’t related to any activation of the reflex arc. As with psychogenic seizures, psychogenic hiccups may emerge as an inappropriate coping strategy or as a means of achieving primary or secondary gain. And some patients, I have no doubt, are just plain faking them although I bet that malingering is considerably less common.
Is there a science-based approach to hiccups?
Just because we don’t fully understand everything about hiccups yet doesn’t mean that it’s the Wild West when it comes to evaluation and management. Well, it’s a bit like the Wild West. But if anything, simply recognizing that we don’t have all the answers separates us from the practitioners of irregular medicine. In most cases, which are usually brief and uneventful, people do not seek out medical care but many do attempt a variety of home remedies which I’ll get to in a bit. Persistent hiccups, and the rare intractable case, do deserve a thoughtful medical evaluation because of the possible link to underlying medical conditions, and there are treatments that might help.
A thorough history taking and physical exam is vital to the evaluation of persistent and intractable hiccups, and it is often all that is needed. Questions naturally should target the many possible underlying causes. One simple question that can potentially help immensely is whether or not the hiccups occur during sleep. It would be unlikely for purely psychogenic hiccups to occur while a patient is asleep.
If the history and physical are unhelpful, there are baseline labs that are recommended. These include tests of electrolyte levels, liver and kidney function and blood counts. Depending on any clues discovered, imaging may be warranted to look for disease in the head or chest. Direct visualization via endoscopy or bronchoscopy may even be needed to rule out disease in the GI and respiratory tracts respectively.
Time is by far the most successful and low-risk treatment for hiccups because, with some very notable exceptions, they are self-limited. Everything else, whether a home remedy or a conventional medical intervention, is largely based on anecdotes and other weak forms of evidence like case reports and the occasional case series. There are no legitimate RCTs and a 2013 Cochrane review, for what it’s worth, concluded that “There is insufficient evidence to guide the treatment of persistent or intractable hiccups with either pharmacological or non-pharmacological interventions.”
In general, if evaluation reveals a possible cause of the patient’s persistent or intractable hiccups, such as a tumor in the chest irritating the recurrent laryngeal nerve, treatment targeting the possible cause would seem prudent. But that is rarely the case. Because as physicians we must weight both the risks AND the benefits of a treatment plan, most would agree that a cautious initial approach to hiccups is best because even intractable cases tend to be more of an extreme annoyance than a dangerous medical problem. That being said, more severe and bothersome presentations might justify a more aggressive plan.
Physical maneuvers are usually tried first. These involve attempts to, at least theoretically, interrupt the reflex arc. Breath holding, drinking cold water, applying pressure to the diaphragm and bearing down against a closed airway to increase activity of the vagal nerve are common recommendations. Stranger physical maneuvers have been looked at, most infamously the use of digital rectal massage (1,2). The authors of these two papers shared a 2006 Ig Nobel Prize in Medicine for their effort.
The use of medications to treat persistent and intractable hiccups is usually tried only after physical maneuvers fail and a careful assessment of the risks and benefits. Pharmaceutical interventions do not have supporting evidence any more robust than physical maneuvers. The most commonly used drug historically, and the only one actually approved by the FDA for this purpose, is chlorpromazine. This is a dopamine blocking medication more commonly prescribed for its anti-psychotic properties to treat patients with schizophrenia, but it has a wide variety of uses ranging from migraines to “brain-eating” amoeba infections. Because the dose for hiccups is considerably lower than that used for other conditions, it has a low risk of any significant side effects.
Many other drugs have been tried for hiccups, including marijuana, and some have replaced chlorpromazine as the recommended first line therapy depending on which resource you use for help deciding. Even surgical implantation of devices that stimulate either the phrenic or the vagus nerve has been attempted. It’s hard to find a negative report about any hiccup treatment because if the drug that is being investigated doesn’t help, nobody is going to want to write it up.
Hiccup home remedies
The internet is overflowing with advice on how to stop hiccups. A quick internet search reveals a seemingly-endless number of articles listing foolproof remedies and quick cures, with many overlapping with the physical maneuvers recommended as first line treatment by physicians. There are of course the classics, like eating sugar or peanut butter and breathing into a bag. Not at the same time of course. These websites often try to give scientific justifications, frequently mentioning the stimulation of the vagus nerve or the raising of CO2 levels in the blood for example.
Some home remedies are just plain silly, like drinking a glass of water after you dropped a lit match into it, or drinking water while upside down. I found several references to gulping water with your fingers jammed into your ears, and was even told this by a physician assistant in our emergency department recently. Everything supposedly works every time, or at least people remember when the hiccups stop soon after a treatment and forget the times they don’t. Of course the evidence base for any of these recommendations is as pitiful as for any other method, and they are certainly harmless if not done while driving or trying to defuse a bomb.
This 13-year-old girl just re-branded sour lollipops as a hiccup cure and will probably make millions of dollars.
Here is a list of 250 hiccup cures, including to “think of all the bald men you can” and “threateningly point a gun at the subject.” There has been at least one fatality related to the latter.
Alternative medical treatment of hiccups
Like the interventions of conventional physicians for persistent and intractable hiccups, there is no good evidence to support the use of any alternative medical modality, even the popular ones. As you might imagine, the chiropractic presence on the internet lists hiccups as something they can handle with great success, because nerves. There are countless websites providing testimonials and anecdotal experiences with chiropractic. Here is a case report provided by the American Chiropractic Association where a patient with hiccups for ten days improved while also seeing a chiropractor. They also recommend icing the phrenic nerve and giving the tongue a good yank.
This holistic chiropractor/ear acupuncturist/homeopath tells us how to stop hiccups in ten seconds. PubMed yields nothing.
There are many trials looking at the use of acupuncture for persistent and intractable hiccups, none of which are randomized controlled trials. They involve the usual wide variety of acupuncture styles, such as Korean hand acupuncture, acupressure, auricular acupuncture and regular acupuncture at a variety of locations. Most are in Chinese and unavailable for review, and they are all positive of course. But don’t be fooled. I have little doubt that were a proper study with appropriate controls and blinding ever to be done, acupuncture would once again be revealed to perform no better than placebo.
Hypnotherapy is also a popular alternative treatment for hiccups, although I can’t figure out why. Again there are no controlled trials. I can’t find anything on it other than two case reports that are over 50 years old (1,2). Yet recommendations for trying hypnosis can be found everywhere, even on typically solid sources like UpToDate. This therapist can cure hiccups and provide a virtual gastric band at the same time to help with weight loss. She can even teach you how to use her techniques to increase your business and profits. I doubt it’s cheap and I doubt it’s covered by insurance.
There are many other alternative therapies aimed at stopping or at least improving cases of prolonged hiccups. You can pay this lady to perform Quantum Touch to cure your hiccups, or just annoy her while she’s in the library for a free treatment. Homeopathy has much to offer hiccup sufferers. They recommend Hyoscyamus Niger, for instance, if your hiccups only occur while urinating at night.
Conclusion
Although usually a brief, mild and sometimes humorous annoyance, hiccups can in rare cases be severe and protracted to the point of causing very serious sequelae. Unfortunately, they remain somewhat of a mystery and science-based therapies are lacking because of the difficulty performing large controlled trials on such a rare condition. And because even intractable cases do often resolve spontaneously, a very long list of medical therapies, home remedies and treatments provided by various alternative medical practitioners likely only have the appearance of efficacy.
Despite the fact that nobody has much to offer patients with persistent or intractable hiccups, the key difference between science-based providers and researchers, and the world of alternative medicine, is the humility to admit it. And though the irregular remedies discussed above are generally safe, patients who do not seek appropriate medical care may have delayed diagnosis and treatment of one of the possible associated serious conditions. Legitimate medical researchers will continue to work on finding more effective therapies for hiccups, while champions of these other approaches will continue to offer their theatrical placebos while refusing to evolve as new evidence emerges.

Do Canadian Babies Really Cry the Most?
Despite an exaggerated and largely inaccurate interpretation by the media, a recently published study in the Journal of Pediatrics does little to update our understanding of infant crying and colic.
Clay Jones on April 7, 2017
Link

I’ve written about infant crying, particularly the nebulous entity known as colic, a few times on SBM. It’s a subject of special interest to me, not just because I am a pediatrician but because I find the psychology behind our varied interpretations of a baby’s cry and the range of our responses to it fascinating. Infant crying, typically when interpreted as “fussiness”, is also a gateway for many families into the world of irregular medicine, which is my thing that I say.
Earlier this week, as Syrian children were being murdered with chemical weapons and (insert Trump reference), many journalists were furiously describing the results of a new study on infant crying and the prevalence of colic in different countries:
     1.  “Canadian Babies Cry the Most, Study Says“
     2.  “Canada tops list of countries with most crybabies“
     3.  “Babies cry more in UK, Canada and Italy, less in Germany, study finds“
     4.  “Babies in Britain, Canada and Italy cry more than elsewhere – study“
     5.  “Want the baby to stop crying? Be Danish. Don’t breastfeed“
And a press release from the University of Warwick, where the study originated, made some bold claims:
Babies cry more in Britain, Canada, Italy and Netherlands than in other countries – proved for first time by new research by the University of Warwick.
Psychologists have created world’s first universal charts for normal amount of crying in babies during first three months
In Denmark, Germany and Japan, parents deal with the least amount of crying and fussing
Trust me, I could go on. Not unexpectedly, none of the reports of the study’s findings got it right. Some were worse than others of course, but they all seemed to ultimately miss the point of the study. They were distracted by the bright shiny object, the sexy but inaccurate claim that babies in a particular country or three cry more than babies in other countries around the world. But that isn’t really what the study found.
But don’t take my word for it. Here is a link to the entire study. No relying on an abstract, a press release, or a couple of the study author’s quotes in hyperbolic news articles this time!
The study specifics
In the study, which is “a systematic review and meta-analysis of fuss/cry durations reported in diary studies from around the world,” the researchers set out to document with improved accuracy the changes in crying that takes place over the first 12 weeks of life. Based on smaller and inconsistent prior studies, according to the authors, we tend to expect crying to gradually increase over the first few weeks of life, peak at 5-6 weeks, and then begin to decrease. By looking at data from multiple countries, they wanted to see if a “universal crying curve” exists.
In addition to average fuss/cry time in different countries, they wanted to see if how a baby is fed plays a role and also to quantify the prevalence of colic in different countries at different ages during the first 3 months of life. Although not stated explicitly as a goal of the study, they also appear to have set out to come up with a percentile chart that might be used clinically to help determine if a baby is crying too much and needs evaluation. This idea would never work, and the fact that they came up with the concept really is not surprising considering that none of the study authors actually take care of infant patients. The lead author is a psychologist at the University of Warwick.
Inclusion criteria required that each study in the analysis must be observation only, include at least one 24-hour cry/fuss diary, involve only an unselected population of infants between 1 and 13 weeks, and report or have average cry/fuss durations and distribution indices available. In order to analyse data on colic prevalence, only studies with at least three 24-hours cry/fuss diaries were used. This is because they strictly adhered to the modified Wessel criteria for colic, which require an infant to cry for more than three hours a day for three days in a one-week period. This is already enough to make their colic data fairly questionable.
They also used a metric to determine the quality of each included study which is too cumbersome to get into, but it’s in the paper and pretty standard. And as previously stated, their major outcome measure was average total cry/fuss duration over 24 hours at different ages in the first 3 months. Specifically, they looked at 1-2 weeks, 3-4 weeks, 5-6 weeks, 8-9 weeks, and 10-12 weeks.
Their systematic literature search came up with 4,109 articles for possible inclusion, and after what sounds like a lot of work they determined that only 28 met their criteria. But because some of the articles included multiple population samples, they actually were able to analyze 33 distinct groups of infants. So right off the bat we aren’t talking about a huge number, but it isn’t insignificant. That isn’t my main concern with the interpretations however.
What did the study analysis reveal?
First, we’ll look at average crying overall. They found that average fuss/cry time over the first six weeks of life was 117-133 minutes, and that this was consistent at 1-2 weeks, 3-4 weeks, and 5-6 weeks. So the idea that crying gradually builds to a peak at 6 weeks appears to be inaccurate. This was followed by a decent decrease in crying at 8-9 weeks, and then again at 10-12 weeks when crying averages were about half what they were in the first 6 weeks of life. This jibes with the common understanding that colic tends to resolve by 3-4 months.
As we would expect based on the above data, the prevalence of colic followed a similar pattern. There was a solid significant difference between the percent of babies assigned the label of colic at 10-12 weeks (0.6%) and all of the other time periods. The peak of colic, again not surprising anyone, occurred at 5-6 weeks with a prevalence of 25.1%. This also jibes with the common understanding that colic tends to ramp up at roughly 3 weeks and that about a third of babies end up being assigned the “diagnosis.”
As trumpeted by the media, when the authors took country of origin into account they found a few interesting outliers in average crying time and the prevalence of colic, but only one that I think is meaningful. And it wasn’t Canada.
German babies, bless their hearts, were found to have statistically less crying averages at 1-2 weeks and at 3-4 weeks compared to the overall average, crying about a half hour less each day. Japanese infants cried a bit less each day at the 5-6 week mark. Infants in Denmark, where little ones are left in strollers outside restaurants while their parents dine, appear to cry less at every time period except 8-9 weeks, and cry about an hour less per day at 5-6 weeks. What the media latched onto was the finding that infants in Canada had crying times greater than the overall average at 3-4 weeks and that infants in The Netherlands cried more at 5-6 weeks.
When it comes to colic, the study found that UK babies had a significantly higher prevalence at 1-2 weeks. The media’s exaggerated claims aside, Canadian babies were only found to have more colic at 3-4 weeks while Italian infants were significantly above average at 8-9 weeks. Babies in Denmark and Germany were found to have significantly less colic at 3-4 weeks. All included countries had equivalent crying at 5-6 weeks.
Feeding type was also looked at as a possible variable in the amount of overall crying and the prevalence of colic, and there were some significant findings. Although not likely to be included as part of the breastfeeding support provided by many lactation consultants, and certainly not in any “baby-friendly” initiatives (but I won’t name any names), bottle-fed babies were found to have significantly less crying at 3-4 weeks onward and less colic at 5-6 weeks. The media largely ignored this aspect of the study, however.
What’s wrong with the study?
There are a lot of limitations to this research. A lot. First off, the studies involved subjective parental assessments of infant crying. As I’ve written about before, how a parent quantifies how much time their baby cries can be significantly impacted by stress and fatigue as well as by personal and cultural expectation. This study was working with a very limited number of crying diaries and doing a lot of extrapolating.
Their strict use of modified Wessel criteria to diagnose colic may be convenient, but it almost certainly leads to an inaccurate estimation of how many infants acquire the label in the real world. In practice, pediatricians and family doctors don’t really have parents keep crying diaries and then strictly follow any criteria. They just ask generally how much a baby cries, perhaps after mentioning the rule of 3’s.
Parents who have sought medical attention out of concern that their baby cries for an excessive amount of time are more likely to be tired and anxious, and to overestimate the amount of time that their child spends wailing. The perception of crying intensity and duration is also affected by expectations of what is normal, something that is extremely variable as well. Most pediatricians don’t really worry about labels like colic, although they may mention it during discussions with caregivers, and focus more on ruling out pathology and reassurance. To the author’s credit, although they mention the possibility that their findings reveal a genetic or biological difference between babies from different countries, they state that any real differences are more likely to be cultural. They do not, unfortunately, mention that all of these findings may simply be random noise in the data.
The most glaring limitation, considering how this study was reported by the media and the University of Warwick’s press release, is that it in no way represents an assessment of crying patterns in babies around the world. It included samples from very few countries, so few in fact that I will just list them: the UK (10 samples), Canada (6 samples), the United States (5 samples), Italy (2 samples), The Netherlands (1 sample), Germany (4 samples), Australia (1 sample), Denmark (3 samples), and Japan (1 sample).
That’s it. Japan was the only Asian representative. Australia had one sample which wasn’t even included in the colic data. The Netherlands had one as well. No data came from developing countries. Nothing from Africa, Central or South America, Eastern Europe, India, etc., etc. To makes claims that this data represents crying around the world is more than simple exaggeration. It’s dishonest. To be clear however, the authors point this out adequately in the paper. It is the media and University press release that are at fault. Even within the represented countries it is a stretch to make any confident claims.
What does it all mean?
So at the end of the day, what does this study really add to our understanding of infant crying and colic? Not much, and definitely not what the many news articles seem to think it does.
Based on this study, it appears that crying doesn’t gradually increase over the first few weeks of life. Babies on average just tend to cry a lot until a point, likely some key period of neurological development, when they begin to gradually cry less and less. This isn’t really earth shattering new information, but it’s at least something.
All the stuff about different rates of crying and colic in various countries is probably noise. The exception, maybe, is Denmark. Based on this study, as limited as it is in worldliness and documentation, babies in Denmark appear to either cry less, or are perceived to cry less by caregivers, than in the other included countries. If real, this is very likely related to a general cultural approach to parenting and unique expectations regarding infant crying. But to an unbiased observer taking objective daily measurements of crying over the first 12 weeks of life, the children in all of these countries probably cry about the same average amount.
But perception is reality when it comes to crying. It doesn’t matter if a particular baby actually cries a lot or if caregivers just think that they do. They still need to be evaluated for pathology and, if the baby is healthy, the parents need education and reassurance. So the study authors were absolutely correct when they wrote that “further analysis of caretaking patterns may prove to provide clues for effective preventative strategies.”
In regards to the role of different feeding types in crying and colic, this new data supports some earlier studies showing increased crying and more challenging temperaments in breastfed babies during the first six weeks of life. This effect is likely real but minimal in most babies. I certainly wouldn’t use this new paper as a reason to recommend against breastfeeding, but it is definitely one of many reasons to be supportive of mothers who do choose to feed their babies formula.
Are there any clinical implications from this study?
No, not really. Based on the data from the study, the authors put together a percentile chart for minutes spent crying each day at different ages during the first 3 months. It’s like the charts pediatricians use to plot weight, length, and head circumference in young infants to follow over time and help them pick up on any concerning trends in growth. The study authors offer this up as a potential clinical tool to help reassure caregivers.
While I appreciate their good intentions, thinking for one minute that a chart like this might be clinically useful reveals their lack of clinical experience. You can’t use a chart like this for such a subjective experience. It would be like making a percentile chart for cough…or nausea. What we know about infant crying epidemiology, even with the addition of this study, is still limited. Does gestational age matter, to give just one example. Should there be different charts for breast versus formula fed babies? Should I worry more if a baby from Denmark is at the 90th percentile than if it’s a Canadian child?
If a parent is worried about their child’s crying, an assessment is mandatory. This requires a thorough history and physical exam. Sure there are many examples of serious pathology that result in excessive crying, although typically it’s of the sudden onset variety rather than the chronic crying we think of with colic, but plenty of bad things don’t. I could never simply reassure a parent based on the fact that they their child’s crying isn’t above the 90th percentile. And if the assessment is reassuring, crying above some arbitrary cutoff wouldn’t change my management.
Conclusion: Don’t cry over bagged milk?
It is important to always remain skeptical when reading news reports and press releases about recently published studies. The media often will pick out one small but sexy aspect of a study and run with it, perhaps because of journalistic/intellectual laziness, a lack of critical thinking skills, or a poor understanding of how to interpret scientific research. Or perhaps because a desire for more clicks has biased their judgement. Many probably just assumed that a university press release was trustworthy.
In this case, a lot of likely well-meaning journalists, for whatever reason, followed a false lead and reported an exaggerated version of a minor finding of this study. Babies don’t cry more in Canada than in the rest of the world. At most we can say that babies in Denmark may cry less than in some other countries, but even that is likely the wrong conclusion. Parents in Denmark likely just don’t worry about crying as much as in some other countries.
The good news, and this was absolutely confirmed by the study in question, is that after 6 weeks of life the amount of average daily crying begins to decrease. And by 3 months of age very few babies will be perceived as crying excessively by caregivers. There is a light at the end of the tunnel. Our job as medical providers who work with worried parents is to provide reassurance when appropriate, and education that may help either reduce the total amount of crying, or at least improve the perception and tolerance of it.

Separating Fact from Fiction in Maternal-Fetal Medicine: Anti-D Immunoglobulin for the Prevention of Hemolytic Disease of the Fetus and Newborn
The Healthy Home Economist, a pseudoexpert in health and wellness with no actual education or training in medicine, is telling mothers to avoid a safe and effective approach to preventing a deadly pregnancy complication that used to result in the death of thousands of babies every year.
Clay Jones on April 20, 2018
Link


I have encountered a great deal of harmful nonsense over the years. Vaccine and vitamin K refusal, vaginal seeding, placentophagy, and waterbirth are all topics I’ve covered in the past on SBM, and all are recommended by so-called experts in natural or holistic health. So when I was alerted to recommendations by a popular pseudoexpert to avoid yet another safe and effective means of preventing the suffering of children, I wasn’t surprised. Angry, yes. Frustrated, definitely. But not surprised at all. Sigh.
A follower on Twitter recently shared a link to an article written by Sarah Pope, a Weston-Price Foundation board member with training in economics and financial management who refers to herself as “the healthy home economist.” Pope, who has in the past recommended that parents avoid all vaccines, preferring homeoprophylaxis and immune boosting diets, refuse the newborn vitamin K shot, and lie to their pediatricians about giving babies raw milk, has come out against a safe medical therapy that has saved countless lives: anti-D immunoglobulin for the prevention of hemolytic disease of the fetus and newborn, caused by a mismatch in mother-fetal blood type. As expected, her article is dense with factual errors and anti-medicine propaganda.
Before I tackle Pope’s article, which is 97% fearmongering and links to whale.to, I’ll provide a brief primer on anti-D immunoglobulin and the disease it prevents. This is a complex topic that I plan on doing a reasonable, if not deep, dive into. As with most aspects of science-based medical care, there is nuance and we don’t have all the answers. But I’ll do my best.
How is blood type determined and what are the clinical implications?

Human blood type is identified using the presence or absence of major blood group antigens on our red blood cell membranes, specifically A, B, and Rhesus, which is commonly referred to as simply Rh. The most clinically important Rhesus antigen, and the one designated by the + or – in your blood type, is D. There are actually a total of 48 antigens in the Rhesus system, but most of them, as well as the over 300 different minor blood group antigens, are much less frequently expressed and often not particularly immunogenic. There are exceptions that are beyond the scope of this post.
When a patient is A+, for example, her red blood cells express A antigen and D antigen. An O- patient, on the other hand, does not express any A, B, or D antigen and thus her immune system would not recognize them as having been produced by her own body. Our immune system, shaped by at least a few thousand years of evolution, has a tendency to make note of such foreign antigens when first encountered by producing immunoglobulins. Perhaps more commonly known as antibodies, these specialized proteins are tailored to recognize specific invading antigens quickly and to initiate a more robust response with each subsequent exposure. It’s a process that helps to keep us healthy and free from disease, but these antibodies are problematic in certain situations, such as when the foreign protein might be useful or isn’t actually foreign.
One example of the former is when a patient requires a blood transfusion. Haphazardly giving improperly matched blood can result in a fatal transfusion reaction, which is why O- blood, the so-called “universal donor”, is so useful in emergencies. In reality, it is possible for even O- blood to result in a reaction when non-D Rhesus or minor blood group antigens are present and the recipient has been previously sensitized. So when blood is needed less urgently, additional screening for the presence of unexpected antibodies is performed, and typically a crossmatch between the patient’s blood and potential donor blood is performed in order to completely avoid the risk of a transfusion reaction.
As I mentioned above, there is the potential for an immune response (sensitization) to several blood group antigens other than A, B, or D. These may or may not result in clinically important reactions, or in disease in a fetus or newborn. Plus they are significantly less commonly expressed. In this post, I’m going to focus on the Rh(D) antigen and maternal production of anti-D antibody because it is what Pope discusses in her article. It is also the only scenario where we have an effective strategy for preventing disease in the baby.
What is hemolytic disease of the fetus and newborn?
All pregnant women undergo blood typing and screening for the presence of antibodies against major and minor blood group antigens at the first visit, again at 28 weeks, and finally at delivery. The first two are geared towards assessing risk to the baby and the check at delivery is in case the mother has a complication and requires a blood transfusion. When a mother is Rh-negative, meaning that the D blood group antigen is not expressed on the outer membrane of her red blood cells, she has the potential of bearing a child affected by hemolytic disease of the fetus and newborn (HDFN).
HDFN can only occur once an Rh-negative mother has become sensitized to D antigen. This typically happens during a previous pregnancy when fetal Rh-positive blood has crossed the placenta and entered into the maternal circulation. This is referred to as fetomaternal hemorrhage and it likely happens in most if not all pregnancies to some degree. Unfortunately it doesn’t take much mixing of blood to sensitize a mother, and the risk increases with each exposure during a pregnancy and with larger amounts of fetal blood. Sensitization to D antigen used to happen to thousands of women every year. Now, not so much.
Exposure through fetomaternal hemorrhage occurs most commonly during delivery, but it can take place earlier in pregnancy in the event of miscarriage, abdominal trauma, or invasive intrauterine procedures, to name just a few. Or, because the universe doesn’t care about us, for no clear reason whatsoever. Historically this happened in roughly 15% of Rh-negative mothers after two deliveries of Rh-positive babies. Sensitization can rarely occur through other means of exposure, such as an improperly matched blood transfusion of Rh-positive blood or a contaminated needle.
When sensitization occurs, anti-D antibodies that are produced are of the IgM class. They can’t cross the placenta, so the current occupant of mother’s uterus is safe. Over time, the immune system begins to produce IgG class anti-D that can cross the placenta. So it is the next baby, provided that they are also Rh-positive, that can develop HDFN when some of their blood enters the maternal bloodstream and elicits a more intense immune response. With each additional pregnancy, and each additional exposure to D antigen, the immune response can be increasingly robust and result in more severe disease.
IgG antibodies are supposed to cross the placenta for very good reason. In yet another evolutionary scheme to keep enough of us alive just long enough to reproduce, these antibodies can help protect newborn humans from a variety of infectious organisms during a vulnerable transition period. But when maternal anti-D IgG antibody crosses the placenta, it attaches to Rh-positive fetal blood and marks it for destruction by the child’s own spleen. This can result in severe anemia requiring intrauterine blood transfusions, hydrops fetalis, and jaundice requiring exchange transfusion to prevent permanent injury to the brain.
What is anti-D immunoglobulin?
As I explained above, anti-D immunoglobulin (aka antibody) is produced when an Rh-negative human is exposed to Rh-positive blood. Also as stated above, if the human in question is a sensitized pregnant woman, the transition from IgM to IgG anti-D antibodies over time will result in their ability to cross the placenta and harm the fetus/newborn. Wouldn’t it be great if we could somehow prevent or at least significantly reduce the likelihood of this chain of events ever taking place?
Well, we can. Since the 1960s, we have been successfully preventing maternal sensitization to D antigen during pregnancy by giving strategic doses of the very thing we don’t want mom to produce on her own: anti-D antibodies. How this works isn’t quite clear, but the leading hypothesis is that the exogenous antibodies lead to rapid clearance of any fetal red blood cells in the maternal circulation. If timed right, the mother theoretically doesn’t have time to become sensitized.
As I mentioned earlier, antibody screening of pregnant women is recommended at the first visit. If an Rh-negative mother is already producing her own anti-D, focus then shifts to the recognition and management of HDFN in the fetus and newborn. Anti-D treatment of the mother will do nothing to prevent disease in that case.
In non-sensitized pregnant Rh-negative women, the combined strategy of giving a dose of anti-D immunoglobulin at 28 weeks of gestation and after any high risk antenatal events, and then giving a dose after delivery if the child is Rh-positive, has dramatically reduced the incidence of sensitization. Without sensitization, there can be no HDFN. Unsurprisingly, the condition has gone from common to rare in the United States and other developed regions, but sadly is still a common cause of morbidity and mortality in the rest of the world.
Anti-D for use in pregnant women used to be collected from sensitized women. It quickly became so rare for a woman in the US to be sensitized that we have to purposefully sensitize male donors. It is increasingly difficult to keep up with demand, however, so scientists are working on means of producing anti-D synthetically, which would do away with supply issues and the small but real risk from using a blood product. Studies are already underway so stay tuned.
The (Un)healthy Home Economist swings and misses…a lot
The article by Sarah Pope is bad. It’s real bad. She tells pregnant Rh-negative women to avoid anti-D dosing during pregnancy. She even tells them it’s okay to skip it after delivery of an Rh-positive baby, which is when it is most effective. But don’t take my word for it, read the article for yourself. I will provide a few of the most blatantly ignorant claims along with some commentary.
Pope starts off with a rather misleading, likely intentionally so, comparison:
The Rhogam shot is an injected vaccination given to all pregnant women with Rh negative blood. Rhogam works very much like an immunization. It puts a small amount of Rh antibody into the mother’s blood to effectively fool it into thinking the foreign Rh protein has been eliminated.
Rhogam is the trade name for the most commonly used anti-D immunoglobulin in the United States, but there are several other products available that are used here and in other countries. There are some differences in their manufacture, but no anti-D product is in any way a vaccine. That’s just ridiculous.
A vaccine stimulates the production of antibodies in the recipient in order to protect against an infectious disease should exposure occur. Anti-D dosing involves the transient employment of exogenous antibodies against a red blood cell membrane antigen to prevent maternal development of those antibodies herself. Pope is rabidly anti-vaccine, so I can’t help but consider that this comparison is an ad hominem done in an attempt to establish guilt by association.
She continues…
This small risk arises if there is any mixing of blood between the mother and the fetus. Under normal circumstances, this never occurs, but in the event of a car accident or trauma to the mother’s belly, some mixing of blood is possible. Mixing may also occur if there is a miscarriage, amniocentesis, chorionic villus sampling (CVS), or birth interventions during the labor/birth process.
Or for no clear reason. And it isn’t a small risk. Many thousands of women became sensitized every year and thousands of babies suffered and died prior to the development of anti-D dosing to prevent it. I wonder how many dead babies it would take to meet Pope’s threshold for concern.
More nonsense:
The Rhogam shot does work, but only if the immunoglobulin is administered within 72 hours of the trauma that caused the blood mixing in the first place. What also makes no sense is that doctors recommend that all Rh negative women get RhoGam during pregnancy even if the father is also Rh negative! There is absolutely no need for Rh negative women with Rh negative partners to ever get RhoGam as the baby will always also be Rh negative and the risk from Rh antibodies is zero!
Wrong again. While true that anti-D dosing is most effective if given within 72 hours of a high risk event, such as trauma or delivery, it still reduces the risk for weeks after dosing during an otherwise uneventful pregnancy. Postnatal dosing is definitely the more important intervention, reducing risk of sensitization from 13-16% to 1-2%, but the addition of antenatal dosing at 28 weeks lowers it to .1-.3%. Also, it is incredibly naive of Pope to assume that the partner is always the father of the baby. Paternal nonparentage happens more than many might want to admit.
Pope then contradicts herself:
The Rh antibodies from the RhoGam shot hang around in the mother’s bloodstream for up to 12 weeks following the shot. As a result, if blood mixing occurs during that period of time (as in a car wreck or other trauma), it is possible for some of the Rhogam antibodies to find their way into the fetus’ bloodstream and attack them causing the very Rh Disease in the fetus that the shot is supposed to prevent!
So which is it? Is the 28 week antenatal shot ineffective because it has to be given within 72 hours or do the antibodies stick around for weeks and potentially harm the baby? In reality, they stick around for weeks, potentially removing fetal red blood cells from maternal circulation, and never harm the baby. The amount that might cross the placenta is just too small. Rarely testing of a newborn’s blood will reveal evidence of anti-D antibody but there is no evidence that this has ever resulted in clinically meaningful anemia or jaundice.
More fearmongering:
There is also the possibility of side effects from the RhoGam shot. Swelling, inflammation, hives and even anaphylactic shock are not out of the question. More concerning is that the Rh antibodies have the potential to negatively affect the immune response of either the mother or baby to other foreign substances that enter the bloodstream.
No evidence exists to support the claim that anti-D administration negatively affects the immune response of baby or mother. And risk of severe adverse events is incredibly low. One study found 11 reports of possible adverse events out of 2.9 million doses.
Anti-D is pooled antibody collected from many different donors, typically sensitized Rh-negative men who have been “encouraged” to produce antibody by repeated injection of small amounts of D antigen. So it could potentially contain IgA antibodies and other immunogenic plasma proteins. This matters because a fair amount of healthy people don’t produce their own IgA, which means that antibodies against IgA can develop and put them at risk of severe allergic reaction if exposed via blood transfusion or injection of intravenous blood products.
So the potential of an allergic reaction, even a serious one, is plausible. Even after processing, some anti-D products may still contain trace amounts of IgA and must be given via intramuscular injection to avoid this risk. RhoGAM is one, which is why pregnant women in the United States typically get a shot. Others, which are more expensive, are processed in such a way as to remove even the trace amounts and can be given via IV. Bottom line, a severe allergic reaction is extremely unlikely to occur.
Pope also mentions the risk of acquiring a viral infection from administration of anti-D. As I just mentioned, it is a blood product so this isn’t an unreasonable concern. Donated plasma is tested for the potential presence of hepatitis C, hepatitis B, HIV, and parvovirus B19, but no test is perfect. Additional steps are taken, however, such as ethanol fractionation followed by viral-clearance ultrafiltration, that greatly reduce the risk even further. The risk is real, but so low that the potential benefit far outweighs it.
Pope heads right back into the weeds:
Studies performed by Health Advocacy in the Public Interest (HAPI) in 2004 found that despite vaccine manufacturers’ claims that thimerosal was no longer being used…All vaccine vials tested by HAPI that were labeled “mercury free” did, in fact, contain this neurotoxin. All the vials also contained aluminum which enhances the toxicity of the mercury causing rapid death of brain neurons.
In 2001, the FDA mandated that thimerosal be removed from anti-D products. There was no evidence that this mercury preservative caused any harm, but there was significant public concern based largely on anti-vaccine propaganda that I’ve no doubt you are quite familiar with. The “studies” mentioned in the above Pope quote are really one study, which was funded by an anti-vaccine advocacy group run by Dawn Winkler. For $500, she sent 4 samples of anti-D to Doctor’s Data, a lab known for telling quacks and cranks exactly what they want to hear.
Pope goes on to play the shill card, of course, claiming that anti-D dosing during pregnancy lines the pockets of Big Pharma. She also claims that anti-D is never given during pregnancy in Europe, only after delivery. This is blatantly false, as antenatal anti-D is absolutely given in Europe, although it is given less often.
Some European countries rely on cfDNA blood typing and give anti-D during pregnancy only when the fetus is found to be Rh-positive. It’s a pretty accurate test if performed after 11 weeks, but not perfect and ACOG doesn’t recommend using it for this purpose. My hunch is that they will eventually as the cost comes down. This approach would reduce the need for antenatal anti-D dosing by about 30% but there would likely be a few cases of sensitization every year that would have been prevented with universal dosing.
Pope concludes her article by rehashing her previous false claims and scare tactics. She restates that mothers absolutely do not need anti-D dosing at all if the father is Rh-negative, which is dangerously naïve. She again claims that it endangers the life and health of the child. She says doctors are “WRONG.”
Pope once more writes that antenatal dosing is arbitrary and useless unless an at-risk mother is in a car accident. She implies that the risk of anti-D dosing after delivery might be greater than the benefit even when the baby is known to be Rh-positive, especially if the birth was “natural.” She finishes by giving nutritional recommendations to help “tone the uterus” and prevent mixing of blood, and somehow even manages to blame fluoride.
All of this is wrong.
Conclusion: Following advice from The (Un)healthy Home Economist puts your baby at risk
Hemolytic disease of the fetus and newborn is a potentially deadly, but nearly completely preventable, complication of an otherwise normal and healthy pregnancy. It is a great example of how evolution doesn’t have to be perfect, just good enough, because nature doesn’t care about a few thousand dead babies as long as the species survives. The development of a safe and effective means of preventing HDFN is one of the most incredible examples of the benefit of applying science to the practice of medicine.

The American Academy of Pediatrics Weighs in on “Alternative Perinatal Practices”: Part 1
In a soon-to-be published clinical report, the AAP tackles potentially risky “alternative practices” involving labor and delivery of human newborns.
Clay Jones on February 4, 2022
Link

The American Academy of Pediatrics (AAP) doesn’t always get it right when it comes to so-called alternative medicine. In fact, as I wrote back in 2017, they have a bit of an integrative medicine problem. So I was intrigued when I learned of a soon-to-be-published clinical report that is focused on the risks of infectious diseases in newborns exposed to various alternative perinatal practices.
In the report, authors representing the Committee on Infectious Disease and the Committee on Fetus and Newborn tackle seven alternative perinatal practices, a few of which you have undoubtedly heard of. Long time readers might even remember my previous posts discussing four of these seven practices, which I will link to shortly. The authors start with justifications for their effort:
An increasing number of alternative peripartum and neonatal practices have emerged in delivery settings. Pediatric providers may be asked about these practices during prenatal counseling, or they may encounter situations in which these practices have already occurred. Being familiar with the risks and benefits associated with these alternative practices allows the pediatric practitioner to provide balanced education and counseling to families and perform appropriate evaluation and treatment when indicated.
Let’s see how they did.
Water immersion for labor and delivery
Proponents of water immersion claim that it improves maternal comfort during the first stage of labor, while also reducing the need for surgical interventions, and eases the transition from womb to world for the baby during the second stage. Much like the claims of boosting the immune system made by supplement slingers, I have yet to see a meaningful definition of easing a newborn’s transition. It’s a sure sign that the person spouting them doesn’t have a firm grasp of newborn physiology.
My opinion on the subject hasn’t changed since writing about it back in 2014. The evidence for laboring in water is weak, but I could still be convinced that benefit outweighs the risk by better studies. It is virtually non-existent when it comes to delivering in water, however. And there are significant potential risks such as infection, hypothermia, injury, and drowning. Though rare, all of these outcomes have occurred and would be expected to increase if more deliveries take place in water.
In the AAP’s new clinical report, the authors reveal that more recent data provides a bit more support for the role of laboring in water as a means of improving comfort but does not support claims of preventing C-sections. Though the 2018 meta-analysis they discuss did not find benefit for actually delivering a baby in water, it also didn’t find an increased risk of adverse outcomes. The two studies included were small, however, and not well designed to look for the type of infections that might be seen in neonates born in water.
The authors conclude that risk outweighs benefit:
Families should be cautioned against water birth during and past the second stage of labor, in the absence of any current evidence to support maternal or neonatal benefit, and with reports of serious and fatal infectious outcomes in infants.
And please, for the love of Greb don’t have your baby in a stream or in the ocean with dolphin midwives.
Vaginal seeding
Few topics are as popular among both legitimate medical researchers and complete charlatans as the microbiome and various interventions aimed at nudging it in such a way as to improve health. In my opinion, the hype far outweighs the evidence. This is particularly true when it comes to vaginal seeding, which I wrote about in 2017, and my opinion hasn’t changed.
Proponents of vaginal seeding claim that infants born via C-section miss out on the important exposure to maternal vaginal bacteria, which they believe promotes the establishment of a healthy microbiome. Have a less than ideal microbiome might result in an increased risk of lifelong adverse health outcomes such as allergies, asthma, and obesity, all of which have been epidemiologically linked to C-section delivery. One way to mitigate this potential risk, they assume, is to swab a newborn’s mouth, nose, and/or skin with a swab covered in fluid from their mother’s vagina.
This is an incredibly complex issue and it is challenging to tease out the many variables at play when we look at how early environment alters health over the lifespan. We simply do not have evidence to support claims that different outcomes over time when comparing babies born vaginally to those born via a C-section are related to exposure to vaginal flora. Our understanding of the microbiome is limited by only being able to know what we can grow (or detect with PCR tech), and evidence to date has found that any differences associated with the mode of delivery disappear after a few months.
No evidence supports claims that this transient difference is meaningful. The factors that resulted in the need for a C-section delivery, rather than any brief alterations in the types of bacteria on a baby’s skin or in their gut, could play a much larger role. Correlation, after all, doesn’t necessarily equal causation. And as the authors of the report point out, caution is warranted when it comes to vaginal seeding:
Vaginal seeding may facilitate transmission of pathogens normally acquired by vertical transmission.
There are very important pathogens in the neonatal population, such as group B streptococcus, herpes simplex virus, HIV, hepatitis B, and syphilis that can be spread from mother to baby via infected vaginal secretions. Thoughtless vaginal seeding essentially exists as an unethical experiment that potentially exposes a newborn to increased risk of very serious diseases. The AAP report recommends limiting the practice to research settings, ensuring that appropriate screening of mothers has been performed, and counseling parents on the potential risks.
Umbilical nonseverance
During a typical birth, the umbilical cord is cut 30-60 seconds after delivery of the baby unless distress necessitates a more urgent evaluation for the need for resuscitation. Also known as “lotus birth”, umbilical nonseverance involves delivery of the placenta without cutting the cord until several days have passed. I wrote about lotus birth in a 2018 post and again in a 2020 post when news broke that it was implicated in the tragic death of an Australian newborn.
My opinion has not changed one bit since then:
There is no reasonable expectation of benefit from delaying clamping and cutting of the umbilical cord after delivery for more than a couple minutes. There is, however, plenty of plausible risk, particularly that of serious bacterial infection. Lotus birth is a dangerous practice and anyone promoting it is putting the lives of newborn babies at risk. Cut the cord.
What are the proposed benefits of lotus birth according to believers? Naturally, it involves a list of subjective nonsense and pseudoscience but the primary claim is of improved newborn emotional well being and maternal postpartum healing. But as the authors state in the new AAP clinical report, umbilical nonseverance has no clear evidence-based benefit. And while we can appreciate parental spiritual beliefs involving the placenta, we cannot ignore that it becomes dead tissue capable of rotting and causing life threatening infection in an attached baby.
In part 2 of this discussion, I’ll discuss what some mothers do with the placenta other than leaving it attached to their baby. Also covered in the AAP report are the risks of refusing the newborn hepatitis B vaccine and recommended antibiotic ointment for newborn eyes. I’ll wrap things up with a nuanced dive into the potential risk and benefits of delaying a newborn’s first bath.
        ◦ See you next time.

The American Academy of Pediatrics Weighs in on “Alternative Perinatal Practices”: Part 2
In a recently published clinical report, the AAP tackles potentially risky “alternative practices” involving labor and delivery of human newborns.
Clay Jones on February 18, 2022
Link

In my last post, I began discussing a clinical report on the risks of infectious diseases newborns face when exposed to certain “alternative perinatal practices” that has now been published in Pediatrics, the flagship publication of the American Academy of Pediatrics. In the report, authors representing the Committee on Infectious Disease and the Committee on Fetus and Newborn tackle seven of these practices. In my previous post, I went through the first three: water immersion for labor and delivery, vaginal seeding, and umbilical nonseverance. Today I will discuss the rest of them.
Placentophagy
Placentophagy, specifically maternal placentophagy, occurs when a mother ingests the placenta, or at least some portion of it, in order to derive a health benefit. This is a practice with no legitimate historical precedent that was invented in the 1970s but didn’t really become mainstream until celebrities like Kim Kardashian promoted the practice a few years ago. Another factor in its rise in popularity was the transition to dehydration and encapsulation of the placenta.
The authors of the AAP clinical report correctly point out that placentophagy is observed in nonhuman mammals, likely for nutrition or to reduce the risk of being eaten themselves during a vulnerable period. But this is conjecture. They leave out that marine mammals and camels do not consume their placentas and that dogs and rabbits do consume their own feces.
They mention claimed potential benefits of reducing postpartum depression, bleeding, and pain, improved breast milk production, less iron deficiency, and increased energy. But, as they also state in the report, there have been absolutely no studies that support these claims other than self-reported surveys. I’ll point out that there is also very little if any plausibility to these claims. For more detail, check out my 2017 post on placentophagy.
Risks to the newborn of a mother who is practicing placentophagy come from the potential for bacterial contamination with pathogenic bacteria from the gastrointestinal or genitourinary tracts. This could include group B streptococcus, the most common cause of invasive bacterial disease in newborns, but also HIV, hepatitis B virus, and hepatitis C virus. The authors point out correctly that preparation of placentas for consumption is an entirely unregulated industry and that there are no proven standards.
The authors discuss a case which they claim offers direct evidence of harm to a newborn from maternal placentophagy but I’m not so sure. I actually discussed this case, which involved recurrent group B streptococcal sepsis in a newborn, in my previous post on the subject linked to above. It is certainly possible that consuming a contaminated placenta increased maternal colonization and the chance of spread to the baby, but false negatives during maternal screening and recurrent disease in newborns occur without it.
Regardless of whether or not this one case report represents proven direct harm, the plausibility of potential for harm is high. Plausibility for potential benefit from placentophagy is extremely low and thus far unproven. Therefore the practice should be avoided.
Nonmedical deferral of the hepatitis B vaccine birth dose
Though uncommon, infants who become infected with the hepatitis B virus have a very high chance (around 90%) of developing chronic disease that will alter the course and possibly the duration of their lives in several unfortunate ways. What is fortunate, however, is that this can be prevented by screening of pregnant women, which is an imperfect human endeavor, and universal dosing of the hepatitis B vaccine for newborns. This vaccine is extremely safe and effective and there is no legitimate reason for a parent to refuse or defer it.
Sadly, this vaccine is often refused or deferred until later and hundreds of babies in the United States acquire the infection every year. There are roughly 4 million infants born every year and low risk is not zero risk. Some facilities have adopted recommendations by the AAP and CDC to have standing orders for the vaccine and “opt out” policies in order to increase uptake, but many children are increasingly born at non-hospital “birthing centers” or at home where these safety net policies are less likely to be implemented.
I wrote in greater detail about newborn hepatitis B vaccination back in 2015.
Deferral of ocular prophylaxis
Babies can develop infection of the eyes no differently than older children. Conjunctivitis, more commonly known as “pink eye”, is fairly common in kids, but eye infections in newborns are more worrisome because of the possibility of exposure to bacteria more typically associated with sexually transmitted infections. Neisseria gonorrhea in particular can cause a severe form of conjunctivitis in newborns that can lead to scarring of the cornea and blindness. It’s uncommon overall but a child born to a mother with gonorrhea has roughly a coin flip’s chance of eye infection if nothing is done to prevent it.
It is standard of care for mothers to be screened for gonorrhea, among other sexually transmitted infections like chlamydia, syphilis, and HIV, but as with screening for hepatitis B this process is not perfect. In an effort to prevent newborn eye infection with gonorrhea, universal application of erythromycin ointment (previously the more irritating silver nitrate) has been required by law in the United States for decades. An increasing number of parents have been refusing this intervention, however.
The reason these parents refuse is often not based on legitimate concerns, but they aren’t completely off-base in questioning the practice. There is controversy regarding the universal nature of the current recommendation, and not ever country does this. Some organizations, such as the Canadian Pediatric Society, cite increasing resistance to erythromycin, effective treatments in the case of diagnosed eye infection, and reassuring data from other regions with a more targeted approach as reasons to avoid routine ocular prophylaxis.
The AAP has actually called into question the need for legal mandates, which are typically ignored by all involved parties, and recommends focusing on prenatal screening and treatment of infected mothers. The United States Preventive Services Task Force disagrees, and in 2019 reaffirmed their recommendation for universal prophylaxis of newborns. This was based on a conclusion that the intervention has reasonable benefit and is safe, which is true. There really is no downside to individual infants, though many parents who refuse have been told by people with no expertise in newborn medicine that it can suppress the immune system, cause allergic reactions, or interfere with bonding. None of this is accurate.
This is a tough one. When parents refuse this intervention, and mother has been screened and is low risk for an STI, I don’t get too worked up over it. I explain the reasoning behind the recommendation, provide reassurance in regards to any safety concerns, and counsel on signs to watch out for, but I don’t try multiple times to change their minds like I might in other circumstances. I certainly don’t involve the authorities. But people practicing in a different area with a different patient population might feel differently. Or they might just feel differently, and that’s okay. They aren’t wrong.
Delayed bathing
Newborns have traditionally been bathed soon after delivery, or at least within the first several hours. Over the past few years, however, there has been a significant change in this trend with many parents requesting a delay, with some wanting to wait more than 24 hours or even declining the newborn bath altogether. A growing number of hospitals have also changed their practice, establishing delayed bathing as a policy in an effort to help mothers initiate breastfeeding despite the lack of quality evidence that bathing somehow interferes with that goal.
Another claim made by proponents of delayed bathing involves the skin microbiome. This is similar to beliefs held by the vaginal seeding camp and is based more on speculation and hype than actual evidence. To be fair, there are potential risks from early bathing. We are cautious when it comes to premature infants and babies that are small for their gestational age because of the low risk of hypothermia. We also wouldn’t rush to bathe a baby that is unstable.
Obviously we take parental preferences into account when it comes to bathing. There are circumstances where cleaning the baby with soap and water is more important, however, such as when a baby has been potentially exposed to HIV or herpes simplex virus during a vaginal delivery. According to the report authors, there is also a lack of research into the risks of delaying the first bath. So, for example, it is unknown if delayed bathing increases the risk of infection with group B streptococcus, syphilis, or hepatitis B and C virus.
Refusing the newborn dose of intramuscular vitamin K
Refusal of the newborn dose of intramuscular vitamin K was not included in the report because there is no associated increased risk of an infectious disease. But it is certainly an alternative perinatal practice that puts newborns and young infants at risk of death and severe neurologic injury from catastrophic bleeding into the brain or intestines and it is something that we deal with much more frequently than lotus birthing. I wrote about this vital intervention back in 2013 and just wanted to include it here because it is extremely important to the health of babies.
Conclusion: Alternatives to standard newborn care practices are unproven and may expose a baby to significant risk of harm
With the potential exception of refusing newborn eye prophylaxis, so-called alternative perinatal practices are not based on good science or backed by reasonable evidence of safety and benefit. In many cases, the opposite is in fact true and they expose babies to the risk of potentially severe infectious diseases. Like vitamin K refusal, there are many more examples that could be discussed which do not involve increased risk of infection, and even some, such as the Baby Friendly Hospital Initiative, that are not considered to be alternative at many hospitals. This is what happens when belief and bias trump science in the newborn medicine.

The American Academy of Pediatrics has an Integrative Medicine Problem
The American Academy of Pediatrics is usually a trustworthy source of high quality information for patients, caregivers, and pediatric medical providers. But when it comes to so-called integrative medicine, they have a massive biased blind spot. In this post, I discuss a recently updated clinical report from their Section on Integrative Medicine.
Clay Jones on October 20, 2017
Link


The American Academy of Pediatrics (AAP) has an integrative medicine problem. It’s a wonderful organization, don’t get me wrong, and they do a lot of good work advocating for children and their families, and providing evidence-based guidelines for clinical care. In fact, they claim to be “committed to the optimal physical, mental, and social health and well-being for all infants, children, adolescents, and young adults”, and I have never really questioned this goal. But they have a huge biased blind spot when it comes to quackery.
The AAP Section on Integrative Medicine
The AAP, while often speaking as a unified voice, is also subdivided into 52 sections. These sections consist of different groups of members dedicated to one particular aspect of pediatric medicine or another, each with their own internal leadership hierarchy, and they are integral in helping to develop policy and in educating fellow AAP members as well as the public. One of them is the Section on Integrative Medicine (SOIM).
Since at least as far back as the late 1990s, the AAP has shown some interest in alternative therapies, in no small part because of the influence of Kathi Kemper, who refers to herself as “the holistic pediatrician” pretty much every chance she gets. She did essentially write the book on the subject after all. She was the founding chairman of the SOIM in addition to establishing the non-AAP affiliated Council on Bioenergetic Healing, which does not appear to have ever existed except on her CV (at least there is no trace of it online). The AAP evolved along with other proponents/PR departments over the years, officially referring to alternative medicine as “integrative medicine” with the establishment of the SOIM in 2005.
The SOIM then set out to establish an integrative medicine presence in pediatrics, complete with all the standard propaganda we have come to know and love. It encourages members to speak at conferences and gives grants for various endeavors that support the cause. It supports research into integrative medicine. It promotes educational resources for medical schools and residency programs and designs CME activities.
The SOIM strategic plan
In 2013, the AAP SOIM released their strategic plan, which unfortunately is only available to members. As I’ll explain in detail, it’s pretty much just integrative medicine boilerplate that occasionally mentions children. Their mission statement starts out okay, however. I mean, who wouldn’t support “optimal health and well-being for all children and families”? But it quickly goes the expected route, all the while making the assumption that their true mission is reasonable and even necessary:
The mission of the Section on Integrative Medicine (SOIM) is to promote optimal health and well‐being for all children and families through the promotion of high quality research, education and clinical care from the integrative perspective. To accomplish its mission, the section will promote a broad view of health and wellness involving patients, caregivers and providers; educate pediatricians and other pediatric providers on how to integrate evidence‐based, safe and effective integrative therapies into high quality pediatric practice; promote research on principles of integrative medicine; and respectfully collaborate with diverse health professionals dedicated to enhancing the health of infants, children, and adolescents.
High quality research you ask? This will come up again later in the post when I describe what such research looks like according to the SOIM. I’ll just tell you that it rhymes with shmanecdote for now. And what exactly is the integrative perspective? Let’s just say it involves two types of pie.
The rest of the SOIM strategic plan discusses their belief that the philosophy of integrative medicine is somehow different than what I do, for example, because it focuses on providing “high quality and patient-centered care that prioritizes patient and family wellness and planning”. Deep breath Dr. Jones, you’re a professional. They add that only through the addition of complementary therapies can every patient “flourish in the presence or absence of disease or disability”, and that physicians should be capable of competently discussing integrative medicine principles with patients and families. I agree with that last one, but the SOIM might not appreciate my approach.
The SOIM, according to its section on values, wants all medicine to be integrative because they believe it is required for the practice of “good medicine”. They call for all therapies to be judged on a level playing field “regardless of their origin”. They then list “nutrition, movement and exercise, mind-body connection, sleep, growth and spirituality, positive relationships and the physical environment” as being in their armamentarium for “enhancing wellness”. Physical environment? Do they mean earthing?
Their “Goals and Objectives” section spells out a desire to indoctrinate educate pediatric residents with the implementation of standardized core competencies and the inclusion of integrative medicine questions on board examinations. They want to produce more educational opportunities for residents and AAP members, write policy statements for members to follow, link themselves to the NCCAM (now NCCIH), and “promote integrative medicine as a philosophy for caring for children”.
The SOIM Clinical Report
I’ve known about this issue for a long time. As part of SOIM educational outreach, for nearly ten years the AAP has provided “Complementary, Holistic, and Integrative Medicine” CME opportunities in the form of review articles in Pediatrics in Review. These invariably consist of cherry picked studies with weak methodology, biased assumptions, appeals to popularity, and calls for more research to prove what they already know is true, even after pointing out how weak the available data actually is.
But what inspired me to write about this topic today was the September publication in Pediatrics of an updated Pediatric Integrative Medicine Clinical Report from the SOIM, which is meant to guide AAP members in their approach to patient care. It’s pure propaganda with little actual substance and all the typical canards we’ve come to expect. You know something isn’t going to involve much critical thinking when it opens with “The National Center for Complementary and Integrative Health defines…”
The AAP, according to a press release announcing the publication, feels differently:
The report aims to raise awareness about this emerging field, improve pediatric preventive health and expand treatment options for children and adolescents living with a wide range of medical conditions.
They then employ a classic bait and switch and some serious question begging:
Children and adolescents face serious health challenges and stressors in today’s society. Integrative medicine seeks to promote a comprehensive approach to healthy nutrition, physical activity, stress management and coping skills, sleep and judicious use of complementary therapies that can help children and their families reduce risk of preventable chronic illness across the lifespan.
As we’ve discussed countless times on the pages of SBM, there is nothing alternative about recommendations on nutrition, exercise, stress management, or sleep. There is no “complementary therapy” that reduces the risk of preventable illness. This is historical revisionism that proponents need pediatricians and the public to buy into because any unique aspects of integrative medicine offer little if any benefit. Pediatricians (and family medicine providers) have been promoting these things for a long time without the help of recommendations from the SOIM.
But that’s just the press release. Unlike the SOIM strategic plan, their clinical report is available for everyone to read so I’ll simply discuss a few highlights that stood out to me. Not all of it is bad, but it adds very little to the discussion in my opinion, serving primarily as an attempt to justify an increasing presence of integrative pediatrics in medical schools, residency programs, and pediatric CME opportunities. Most of it comes across as a regurgitation of NCCIH talking points.
     1.  They define integrative medicine as a combination of complementary and conventional therapies that are “evidence-informed” and patient-centered. This is code for lacking quality evidence and recommended or condoned because it seems to make the patient or their family happy. They say that complementary approaches may also serve as the primary treatment, but that we shouldn’t confuse this with alternative therapies, which are not evidence-based and not discussed in the report. Despite this, they do discuss herbal remedies, acupuncture, chiropractic, and biofield therapies, among many others, often implying benefit or the promise of future benefit once better studies are performed.
     2.  They devote several paragraphs to the popularity of integrative medicine in pediatric populations, particularly children with chronic diseases, and claim that this justifies a need for more pediatric integrative medicine training programs. This is almost immediately followed up with the actual data showing that pediatric use has been stagnant based on NHIS data. They mention that the bulk of CAM use in pediatrics consists of things like supplements, exercise in the form of yoga, and chiropractic manipulation. Only the latter has any business being considered CAM. They also strongly imply that the use of CAM by children, again particularly by kids with chronic illness, is so common because of how helpful it is.
     3.  They really want education/training in integrative medicine to be in all medical schools and pediatric residency programs, and they remind us that there is an actual board certification in integrative medicine through the American Board of Physician Specialties. They do not comment on the fact that the American Board of Pediatrics gives no such certification. 16 of 143 pediatric programs as of 2012 do offer integrative medicine training, however, so it’s likely going to come at some point.
     4.  They claim that CAM research is as good as research into conventional medicine. Better even in the case of systematic reviews. According to the authors, publication bias is actually reversed with CAM, meaning that negative studies are more likely to be published in the better journals than positive studies. But, they add, because CAM can be ancient and challenging to study, “experiential evidence” and N-of-1 trials are “particularly useful”. So which is it?
     5.  They are attempting to integrate a wide variety of CAM therapies into conventional medicine, and to make fundamental changes to the philosophy of patient care, yet they admit that the evidence stinks. The authors reveal that “to be comprehensive, high-quality data about both safety and effectiveness are needed…to inform policy and practice.”
     6.  They mention the role of placebo effects almost in passing, essentially to plant the seed that it’s real, and it’s spectacular. You know, just in case you have any reservations about biofield therapies.
     7.  They discuss DSHEA in detail but in such a way as to imply it’s doing a pretty good job.
     8.  They discuss the ethics involved when a patient/family chooses CAM, and I actually agree in principle although I bet the authors and I would likely disagree in many specific cases. Providers should always assess the potential risks and benefits of any intervention. If there is significant risk without benefit, it would be appropriate to discourage the treatment. If it is determined to be effective and safe, we should obviously recommend it. Safe but ineffective, it would be reasonable to condone the approach. But if there is risk and only potential benefit, either monitoring the patient closely or discouraging the intervention could be the way to go. Easy, right?
     9.  They actually provide almost no helpful information regarding specific interventions, mentioning only a handful by name, most of which aren’t CAM. Fish oil for ADHD isn’t CAM, nor is it very effective. Melatonin for sleep has similar issues. Probiotics are also fairly weak sauce. Herbal remedies are just dirty drugs, not CAM. Dietary interventions also are unfairly lumped into this report.
     10.  They actually comment on the anti-vaccine tendencies of chiropractors who treat infants and children, and mention the lack of evidence supporting chiropractic for non-musculoskeletal complaints – but they stop short of saying outright that parents shouldn’t bring their baby to a chiropractor.
     11.  They frequently mention how evidence of benefit for various therapies, such as acupuncture, is accruing or promising. Again, why are they calling for a fundamental shift in pediatric care prior to figuring out if these interventions actually work for anything?
     12.  My final observation is again one that I agree with. Pediatricians in general don’t know much about CAM or integrative medicine. And what they do know is very likely wrong because it is based on information they get from resources such the SOIM. We don’t know about them and often we don’t ask about them. And patients and their families are often reluctant to share what unconventional therapies they are using with us. This can result in harm to patients.
Conclusion: Take the integrative out of the medicine
Yes, the AAP has an integrative medicine problem and, unfortunately, it only appears to be getting worse. For the time being, at least, it is sectioned off and we aren’t seeing recommendations for quackery being incorporated into general policy. There is nothing at all about this in the AAP five-year strategic plan, for instance. I still consider the majority of AAP resources to contain high quality information, but this report, and the existence of the SOIM, grants undeserved legitimacy to integrative medicine as a concept and to the individual CAM therapies that it is attempting to incorporate into pediatric medical practice.
(Here is a AAP endorsed lecture that Kathi Kemper gives. It provides a paper thin overview of the history of integrative pediatrics and includes a great deal of propaganda. In particular, she focuses on how popular these interventions are, then smoothly transitions into how to increase the presence of integrative medicine in pediatric training and medical care. We are apparently left to assume that there is solid evidence in support of this.
My favorite is the section on “Threats to Integrative Pediatric Care”, which includes “Misinformation on internet and media; negative press about CAM”. Here is another one, where she implies that critics of integrative medicine are equivalent to the KKK waving around a Confederate flag. Seriously. It’s in there.)

American Academy of Pediatrics Calls for End to Pediatric Codeine Use…Again
Clay Jones on September 23, 2016
Link


The safe and effective management of subjective symptoms in the pediatric population, in particular pain, has always been difficult. Young patients, even premature infants at the limit of viability, experience pain, a fact that sadly was not widely accepted until the late last century. But even with full recognition of pain as a potential concern in all pediatric patients, undertreatment of pain remains a system wide issue.
Pediatric pain management is especially challenging for a variety of reasons. Overall there are fewer pediatric friendly pharmaceutical options to choose from and limited data on available pain medications for children, leaving pediatric providers fitting square pegs in the round hole of adult medicine. Further complicating the situation is the fact that kids can have significantly different absorption and metabolism of drugs compared to adults. Finally, young children are more likely to be undertreated because of the reluctance to prescribe, or to consent to the use of, opioid medications by providers and caregivers respectively.
As if things weren’t difficult enough, the AAP Section on Anesthesiology and Pain Medicine has published a clinical report in the September Pediatrics that aims to remind providers that it is “time to say no” to one of the our most popular pain medications: codeine. Sadly, the authors are not raising new concerns. Instead, they are once again pointing out serious problems with this drug, problems we have known about for over a decade that have resulted in deaths and inadequately treated pain.
What is codeine?
Codeine, a natural component of opium first discovered in 1832, has been a commonly prescribed medication for over 50 years and is the most popular outpatient opioid in use worldwide. It is typically prescribed for its analgesic property, usually for the outpatient treatment of moderate pain such as after a surgical procedure, or as a cough suppressant (OTC in 28 states!) despite the lack of good evidence to support this indication. In children, codeine has historically been a very popular pain medication because of the belief that it was a weaker opioid and unlikely to cause dangerous side effects.
Technically, codeine doesn’t actually have any analgesic properties. In order for pain relief to occur, codeine must be metabolized to morphine in the liver. This is where the problems with this drug begin. Researchers have discovered that the ability of the liver to convert codeine into morphine can vary significantly from person to person depending on which two of over 70 alleles have been inherited from their parents, with some people inheriting more than two because of gene duplication.
Most people metabolize codeine normally and might benefit from its weak analgesic effect when dosed appropriately, although numerous studies have shown it to be no more effective than ibuprofen and to have a much worse side effec profile with nausea being common. But depending on the enzyme activity and the number of inherited alleles, some individuals can fail to metabolize codeine at all, resulting in side effects without analgesia. On the other end of the spectrum, some individuals have more than 2 highly active alleles and are so-called ultrametabolizers. They are capable of converting codeine into a larger amount of morphine than expected and are at much greater risk of respiratory suppression.
The numbers of these ultrametabolizers are significant and varies based on ethnicity. Roughly a third of African/Ethiopian patients are at increased risk of overdose, and a quarter of patients from Saudi Arabia and other Middle Eastern countries. 3.5% to 6.5% of African-American and white patients are similarly at risk. Asian patients are more likely to have intermediate metabolism.
What’s the harm?
The main concern when it comes to the potential overdose of morphine after taking a codeine-based medication is respiratory depression. This can happen in anyone taking codeine but would generally require an overdose in people who have normal codeine metabolism. In ultrametabolizers, appropriate dosing can result in more severe side effects, such as nausea, itching, and constipation, and ultimately even death.
Numerous cases of pediatric deaths associated with codeine use have been reported for over a decade. A 2015 FDA review, discussed in the AAP’s clinical report, uncovered 64 cases of severe respiratory depression and 24 deaths in children from 1965 to 2015. These cases tended to involve children in the post-operative period, often after tonsillectomy, taking recommended doses of the medication. Some of these events occurred when children were prescribed codeine for cough rather than for pain.
A lesser harm, but still a harm, is the fact that many children being prescribed codeine will not benefit from any analgesic effect.
As I mentioned previously, these concerns are not new by a long shot. In fact, in 2011 the WHO took codeine off its essential medications for children list because of them. The AAP also raised concerns that year. The FDA followed suit, issuing a safety alert in 2012 and adding a black box warning in 2013, specifically for the use of codeine in children who have had their tonsils out. The European Medicines Agency and Health Canada added restrictions in children in 2013 and 2015.
Sadly, prescription patterns and use of OTC cough preparations with codeine don’t appear to have changed that much. The authors discuss how codeine continues to be widely available and to be one of the more commonly prescribed pain medications in children. There truly is no excuse for this. There is some room for hope though as we don’t have more recent data on codeine use. Maybe things have improved. Anecdotally, I haven’t seen codeine used in a long time but there can be large differences in prescribing patterns from region to region.
Conclusion
Codeine is a terrible drug. It should be wiped from our collective awareness. Even without any risk of severe adverse events, it is at best no more effective an analgesic than ibuprofen or acetaminophen. And it is not an effective treatment for cough in children. When taking into account the risk of respiratory depression and death, the risk to benefit ratio is extremely unfavorable.
Unfortunately, children have limited options when it comes to pain. As the authors of the report suggest, research should focus on maximizing the safety and efficacy of pain medications in children. In the meantime, we should continue to carefully make use of more consistently metabolized opioids for moderate to severe pain and safer non-opioid medications. Although not mentioned in the report, hospitals and clinics should make an effort to improve use of science-based non-pharmaceutical treatments for subjective complaints.

Adverse Events Linked to Pediatric “Alternative Medicine” in the Netherlands
A study out of the Netherlands documented pediatric adverse events associated with complementary and alternative medicine over three years. Thankfully there weren’t a lot of kids harmed, but when there is no potential benefit from an intervention, even one is way too many.
Clay Jones on April 16, 2021
Link

In the March European Journal of Pediatrics, researchers from the Netherlands published a review of adverse events associated with so-called complementary and alternative medicine (CAM) culled from three years of data from the Dutch Pediatric Surveillance System.
In the study, authors Bjorn Vos, Jan Peter Rake, and Arine Vlieger rely on the standard WHO definition of CAM:
a broad set of healthcare practices that are not part of that country’s own tradition or conventional medicine and are not fully integrated into the dominant healthcare system
I don’t particularly care for this definition, which isn’t surprising given the track record of the WHO when it comes to this sort of medical pseudoscience. The WHO distinguishes CAM from traditional medicine as well as “conventional medicine”, which we here at SBM would obviously prefer to call science-based medicine. Traditional medicine, such as Ayuverda and traditional Chinese medicine, is no different than CAM where it counts, which is the degree to which it has been studied and shown to work and to which a proper assessment of risk and benefit has been applied and respected.
According to the authors, pediatric CAM use is common in the Netherlands. They point out that 5% of kids under the age of 12 years, and 2% between 12 and 18 years, were seen by a practitioner of some flavor of CAM in 2017. This is roughly equivalent to the United States, with the bulk of visits here involving chiropractors. The best data from the United States is from 2012 though, so things may have changed. But if I had to guess, more kids were likely being exposed to chiropractic care in 2019 than in 2012. The pandemic almost certainly resulted in a drop in those visits, however.
The authors were unable to provide much data on home use of alternative medicine, but at least 12% of kids going to pediatricians were found to be taking a supplement or herbal remedy. It’s easy to imagine that overall use of alternative medicine in general is higher than that, particularly for children with chronic illnesses and cancer. That is definitely true in the United States. Fear and perceptions of vulnerability can be powerful motivators to explore so-called “other ways of knowing” when it comes to healthcare.
As I mentioned earlier, this study was based on data from the Dutch Pediatric Surveillance System or DPSS. This a surveillance system in place to keep tabs on a variety of “diseases, disorders, or incidents” by surveying more than a thousand pediatricians every month. The authors used DPSS data from January 2015 through December 2017 for this study, specifically looking for adverse events involving CAM use in children under the age of 19 years.
The authors specifically looked for CAM practices like chiropractic and massage therapy, as well as natural health products. These could include herbs, supplements, and vitamins and minerals not being prescribed to treat clinically relevant deficiencies. Pediatricians responding to the DPSS surveys were asked to assess the likelihood that an adverse event was caused by the CAM modality, and in cases where it was unclear they were contacted by the study authors. Adverse events were categorized as either indirectly, directly, or potentially caused by CAM, and further described as mild, moderate, severe, life-threatening, or fatal.
A total of 31 cases of adverse events related to CAM use were found during the 3 years of collected data and involved children from 10 weeks to 16 years of age. Two thirds of the cases (22) were described as indirectly harming a child by a delay or discontinuation of appropriate medical care (16), an extremely restrictive diet (4), or an incorrect diagnosis by a CAM provider (2). Of the nine cases of direct harm, three involved infants.
Of the 31 cases of adverse events, eight were documented as causing mild harm, twelve were associated with moderate harm, eight were severe, and three were life-threatening. Five of the children were admitted to a hospital, with one requiring intensive care for a month. More than half (18) of the cases were felt to have a certain causal relationship with CAM use, two were described as probable, nine as possible, and in two cases the likelihood of causation was determined to be “unassessable”.
While a variety of CAM modalities were documented in the DPSS data, the most common to be associated with adverse events were dietary supplements/vitamins, orthomolecular therapy, homeopathy, and naturopathy. Cases of direct harm were linked to supplements/vitamins, manual therapies, and herbal remedies. In eight of the cases, the CAM modality was provided by a physician.
Here are a few of the documented cases of severe and life-threatening harm:
     1.  A 15-year-old diagnosed with sensitivity to electromagnetic radiation and being treated with bioresonance therapy was imprisoned in his home and socially isolated.
     2.  An 8-year-old with autoimmune hypothyroidism had his prescribed mediation replaced with an herbal remedy.
     3.  A 14-year-old with appendicitis developed septic shock with multiple organ failure after a delay in adequate treatment and despite homeopathy.
     4.  A 14-year-old had a flare of his ulcerative colitis requiring colectomy after having his prescribed medication stopped by a naturopathic provider.
     5.  A 5-year-old developed secondary adrenal insufficiency after his eczema was treated with herbs and a Chinese herbal ointment that contained large amounts of a corticosteroid.
What does it all mean?
This was the first study of its kind in the Netherlands, but it is consistent with similar data collected in numerous other countries. As expected, quackery is potentially very dangerous. The total number of adverse events may have been small, but when looked at through the prism of a rational assessment of risk versus benefits it is clear that unscientific approaches to health should be avoided. In particular, it appears that the biggest risk comes from discontinuing treatments prescribed by legitimate medical professionals and delaying appropriate evaluation.
In their discussion of the study results, the authors point out, and I fully agree, that this data is almost certainly limited by massive underreporting. Most adverse events are going to be mild and not make it to the attention of a child’s pediatrician. And caregivers often don’t report CAM use so a link to an adverse event might not be recognized.
They also discuss what is at the heart of why seeking care from a believer in alternative medicine is potentially harmful, although they put it a lot more nicely than I would have. Essentially, people who promote and practice quackery don’t have a clue what they are doing and are often incapable of recognizing real pediatric illness or the risks associated with changing or stopping a child’s treatment regimen. They don’t know what they don’t know and that makes them extremely dangerous.

Breastfeeding Improvement Initiatives May Increase Risk of Newborn Falls
Newborn falls during the postpartum period are a serious potential adverse event and are almost always a result of maternal fatigue. There is reason to be concerned that well-meaning but overzealous promotion of breastfeeding may increase the risk.
Clay Jones on January 11, 2019
Link


In 2016, I wrote a post on the risk of sudden unexpected postnatal collapse (SUPC) in newborns being associated with kangaroo mother care recommended for the promotion of breastfeeding and a variety of other health measures. My take-home point was that there is a need to rationally weigh the meager benefits in term, healthy (and typically unmonitored) newborns in the context of the risk of death and disability from cardiorespiratory insufficiency. In that post, I also made a brief reference to the risk of newborn falls. Today, inspired by a paper in this month’s Pediatrics, I’ll discuss this problem in a bit greater detail.
Unfortunately, falls during the newborn hospitalization period are more common than most people realize. Thankfully not so common that I can’t joke about it to help ease the anxiety of an occasional mother whose baby I’m separating her from for the first time (“Don’t worry, I haven’t dropped one yet.”). But I’ll probably stop doing even that after reading this report.
Newborn falls, which can result in fractures and injury to the brain, are believed to occur somewhere between 200 and 1,600 times each year according to the available data. But because there are roughly 4 million babies born each year, and the fact that there is no national reporting system in place, they likely occur much more frequently than that. And they are likely on the rise. Based on what we know about reported cases, they almost always happen when the mother falls asleep while holding her baby. Not surprisingly, they also tend to occur at night.
There are many potential factors that might increase the risk of a newborn fall, the most important being maternal fatigue. With rare exception, mothers in the postpartum period tend to experience fatigue, but there are additional variables that might play a role in just how tired a new mom is. For example, how rested was she prior to delivery? What time of day (or night) did she deliver? What complications occurred around delivery that may increase sleepiness, such as blood loss, prolonged or difficult labor, or a need for sedating pain medications? Are there maternal complications that require more frequent checks, and thus interruptions of sleep? And are there psychosocial factors that may interfere with mother’s ability to rest after delivery, such as anxiety, an abusive partner, or frequent visits from well-meaning family members?
One potential factor that I have worried about for many years is the emphasis on “rooming-in”. Mothers are increasingly encouraged to keep the baby in the hospital room as much as possible, rather than the hospital nursery. Many hospitals have gone so far as to restrict access to the nursery, or in some cases to do away with them entirely, and I worry that they aren’t taking maternal fatigue and increased risk of SUPC and newborn falls into account. In more and more facilities, these steps are being taken in an effort to be in compliance with the draconian criteria set forth by the Baby-Friendly Hospital Initiative (BFHI) to improve breastfeeding success, which is a laudable goal but a misguided approach.
The “Ten Steps to Successful Breastfeeding” put forth by the BFHI, one of which focuses on 24-hour rooming-in, have never been appropriately studied yet they are even promoted by the Surgeon General. BFHI accreditation is optional, and costs thousands of dollars to complete and maintain each year. In my perhaps cynical opinion, however, the impetus for many hospitals to do this is more about marketing than actual patient care. Check out Harriet Hall’s 2016 post for a bit more background on BFHI and some more detail regarding my concerns with their increasing popularity.
In the new report, the authors reviewed adverse event reports that involved newborn falls from January of 2011 through February of 2018:
In this series, we review a cluster of neonatal falls temporally associated with policy and practice changes to promote breastfeeding. This represents a reported increase in neonatal falls that began within 1 year of commencing a longitudinal project to improve breastfeeding rates through achievement of the Baby Friendly USA 10 Steps to Successful Breastfeeding
So within a year of initiating changes to meet BFHI criteria, the biggest being encouraging rooming-in for all mothers, there were 3 falls, one of which resulting in a skull fracture and post-traumatic seizures. All 3 occurred between midnight and 6 AM and could reasonably be blamed on excessive maternal fatigue. In response, the hospital educated parents and staff on fall prevention, relaxed on the rooming-in thing, and instituted new protocols geared at reducing maternal fatigue. No falls occurred during the remainder of the study period.
So what does it all mean? The authors of the paper were careful in their wording and did not make any firm claims regarding a causal relationship between BFHI-induced practice changes and newborn fall risk. This is understandable with such a small number of events, and to be honest it is difficult to get anything published that might even remotely come across as anti-breastfeeding. The falls occurring after the switch over absolutely could have just been a coincidence, but it would be unreasonable to disagree with their concern and their call for improved surveillance, particularly as more hospitals attempt to achieve BFHI accreditation.
In my opinion, however, the data is clear that strict adherence to BFHI recommendations that involve more, and especially forced, rooming-in, and skin-to-skin without appropriate education and monitoring increases the risk of SUPC. And this is a direct result of mother’s falling asleep while their baby is pressed against their chest. So it is a very reasonable conclusion to draw that these babies would also be at increased risk of falling off of mother’s hospital bed and onto the hard floor. And of course, this risk doesn’t go away at discharge so families should always be educated on ways to reduce the risk of infant fall injuries.

A Nuanced View on Breast vs Formula
While there is strong evidence that breast is best, a new study suggests that the benefits have been overstated, and may be mostly due to non-specific factors such as better education and overall health care.
Steven Novella on September 26, 2018
Link

This is a very practical question that every new mother faces – how much effort should they make to breastfeed their children, should they breastfeed exclusively, and for how long? The consensus of official recommendations is that mothers should exclusively breastfeed for the first six months, and then breastfeed along with other food for up to two years.
These recommendations are based on a large literature that shows that breastfeeding correlates with fewer infections, higher IQ, and overall better health. These claims are plausible. Breast milk contains passive antibodies from the mother, which is something you cannot get in formula. Breast milk has also evolved over millions of years to provide optimal nutrition. The best we can hope to do with formula is match it, but it’s easy to miss micronutrients.
Many women, however, have difficulty breastfeeding for various possible reasons. They may be on medication that will pass through the breast milk. They may struggle with borderline nutrition themselves, and need to take advantage of the availability of formula. Or they may simply have difficulty producing sufficient milk and breastfeeding. So the real question is – how strong is the recommendation that “breast is best?” Also, is there any downside to putting excessive pressure on mothers who may be having difficulty?
The answer to these important questions depends partly on how strong the evidence is for the superiority of breastfeeding, and the magnitude of any apparent benefit. Relevant to this has been a looming question in the literature – is the measured beneficial effect of breastfeeding due to the breastfeeding itself, or to confounding factors?
The reason this is a burning question is that the vast majority of the breastfeeding literature is observational, not experimental. This means that mothers are typically questioned about their intention to breastfeed, and their breastfeeding activity, but they are not themselves randomized to either breastfeed or formula. Therefore – breastfeeding mothers are a self-selective group, which introduces a host of potential confounding factors. Therefore, while there is a solid correlation between breastfeeding and positive outcomes, it is much more difficult to draw any causal conclusions.
A 2007 systematic review made this issue clear:
A history of breastfeeding is associated with a reduced risk of many diseases in infants and mothers from developed countries. Because almost all the data in this review were gathered from observational studies, one should not infer causality based on these findings. Also, there is a wide range of quality of the body of evidence across different health outcomes.
A new study throws a little gas on this burning controversy. The study authors took a clever approach to this question – they asked pregnant mothers enrolled in the study if they intended to breastfeed, and then followed their actual breastfeeding behavior, and various health outcomes for their children. The data is based on 1,000 participants in the Infant Feeding Practices Study II:
The researchers found that mothers who while pregnant said they intended to exclusively breastfeed, but then used formula once the baby was born, had children with health outcomes similar to exclusively breastfed infants. Only about half of mothers who intend to breastfeed are able to do so, and often their ability to breastfeed is beyond their control and not known until their baby is actually born.
This was a good way to get a peek at possible confounding factors. The intention to exclusively breastfeed, even if the mothers did not breastfeed, was very similar in outcomes to mothers who actually breastfed. This supports the hypothesis that the improved outcomes from breastfeeding are at least partly explained by the characteristics of the self-selective population who breastfeed. To further support this:
What we found is that intending mothers had more information about nutrition and diet; they more frequently consulted their physicians; and had better access to information related to infant health than those moms who did not intend to breastfeed.
So breastfeeding mothers simply were better informed and took better care of themselves and their children. This is exactly the confounding factors that were suspected. Similarly, the data on breastfeeding and IQ is hugely confounded by the fact that breastfeeding mothers have a higher baseline IQ, and when you control for this factor the benefits of breastmilk are greatly reduced.
None of this means that there is no benefit from breastfeeding. Especially within the first six months, there is enough data and plausibility to suggest that breastfed babies have fewer infections and improved outcomes. However, a simplistic interpretation of the evidence may overstate the benefits. It should also be mentioned that the long term benefits, beyond two years, are not well established. By five years of age any differences disappear.
What all of this suggests is that, while the basic recommendation that breast is best is valid and a reasonable default, we should not overstate the benefits to the public. Further, new mothers should not be overly pressured or shamed into breastfeeding. Formula feeding is a perfectly acceptable option for those mothers who have difficulty breastfeeding, cannot breastfeed, or choose not to for various reasons. Most of the apparent benefits of breastfeeding can be had through better educating new parents, supporting them, and making sure they have access to health care.
The more general lesson from this new study, relevant to science-based medicine broadly, is the power of confounding factors. Simply being better educated and taking better care of oneself or one’s children can have a powerful effect on outcomes, and if such factors are not carefully considered they can make any intervention seem to be effective. This is essentially part of what we consider “placebo” or non-specific effects. When assessing any study, review, or question in the literature, such factors should be carefully considered.

Questioning the Evidence for Breastfeeding
Is breast best? Yes, but it’s really not much better than formula in the United States. The better you account for confounding factors, the more benefits of breastfeeding disappear.
Harriet Hall on April 19, 2016
Link
Six years ago I wrote about the evidence for breastfeeding. I questioned an article that claimed 900 babies’ lives could be saved every year in the US if 90% of mothers breastfed for at least 6 months. I didn’t think that was true, but I did think the evidence supported the claim that breastfeeding was clearly better for babies. Now I’m not so sure we can trust that evidence.
A new study reevaluated the evidence from previous studies and found that the studies hadn’t adequately ruled out significant confounders. There are social, cultural and economic factors that contribute to the choice to breastfeed, factors that may have skewed the results of those studies to favor breastfeeding. The new study tried to correct for these issues.
Results from standard multiple regression models suggest that children aged 4 to 14 who were breast- as opposed to bottle-fed did significantly better on 10 of the 11 outcomes studied. Once we restrict analyses to siblings and incorporate within-family fixed effects, estimates of the association between breastfeeding and all but one indicator of child health and wellbeing dramatically decrease and fail to maintain statistical significance. Our results suggest that much of the beneficial long-term effects typically attributed to breastfeeding, per se, may primarily be due to selection pressures into infant feeding practices along key demographic characteristics such as race and socioeconomic status.
Breastfeeding rates are socially patterned in the US
    • Race: 75% of White infants and 59% of Black infants were ever breastfed; and the rates of continued breastfeeding at 6 months were 47% vs. 30%.
    • Family income: 74% breastfeeding for incomes above 185% of the federal poverty level; 57% for incomes below that
    • Education: mothers who completed some high school, were high school graduates, or attended some college were 64%, 60%, and 39% less likely to breastfeed than mothers who graduated from college.
Sibling comparisons
They used data from the National Longitudinal Study of Youth to find discordant sibling pairs where one sibling was breastfed and the other was not. They looked at three measures of physical health (BMI, obesity, and asthma), three behavioral indicators (hyperactivity, parental attachment, and behavioral compliance), and five outcomes designed to predict academic achievement. They looked at a large number of maternal variables including age, race, marital status, educational attainment, income, employment, insurance, smoking, alcohol, and prenatal care. They used sophisticated statistical analyses to compare the impact of and account for these factors.
They found that the benefits of breastfeeding were not statistically significant and that for some outcomes, breastfed children may actually be worse off than children who were not breastfed. They say:
This study provides evidence that the link between breastfeeding and childhood health and wellbeing may not be as robust as originally thought; however, the conclusions drawn should be considered in the context of its limitations.
And they list and discuss several limitations of their study.
Other considerations
This study looked at long-term outcomes for children. It did not look at short-term outcomes or at the effects on maternal health. But it would seem logical that those outcomes would be similarly affected by socioeconomic confounders. This is enough to make us question previous breastfeeding studies that did not control for those confounders or use discordant sibling comparisons, and it points the way to better research in the future.
Breastfeeding entails sacrifices. It impacts jobs, working hours, and family income. Some women are physically unable to breastfeed, and others find it impossible or impractical for other reasons. If there were a strong benefit to the health of children, society should do everything possible to facilitate and encourage breastfeeding. But if the benefit is minimal or questionable, it is wrong to overstate the evidence and make women who don’t breastfeed feel guilty for endangering their child’s health. Bottle-feeding results in healthy babies too.
A recent episode of “Call the Midwife” (Season 5, Episode 2) on PBS highlighted this issue. A midwife nun had led a new mother to believe that she absolutely had to breastfeed for her baby to be healthy. Breastfeeding was unsuccessful and the baby nearly died of dehydration. Fiction, but it provided insight into the beliefs and feelings involved.
Conclusion: Breast is best marginally better
This study is not enough to negate the conclusion that “breast is best,” but it reinforces the conclusion I reached in my earlier article, that breast may be best, but it’s only marginally better than bottle feeding. As the authors of the study comment:
The line between providing information about the benefits of breastfeeding and stigmatizing mothers facing structured, valid, and often difficult trade-offs in the care and financial support of their children or in fulfilling their own human potential must be drawn sensitively.

Breast Milk Testing: Scaremongering, Not Science
Harriet Hall on November 3, 2015
Link
New mothers, especially first-time mothers, tend to worry about whether they are doing what is best for their babies. A new service, Happy Vitals, will only add to those worries. We know that breast is best, but these folks make women question whether their breast milk is good enough. They say:
Happy Vitals provides families with the tools they need to monitor and improve the long-term health of their children. With our simple and easy-to-use tests, mothers can learn for the first time about the nutrient make-up of their breast milk, improve their diet and nutrition, and safeguard against exposure to heavy metals and other toxins that are harmful to a child’s growth and development.
After a crowdfunding/pre-sale campaign, they plan to start shipping kits this month. They offer various packages. For $149.95, they will analyze a sample of breast milk for four key nutrients: glucose, lactose, protein, and fat. For $559.95, they will also test for:
    • Four “indicators of immunity”: cortisol, IgA antibodies, IgG antibodies, IgM antibodies.
    • Eleven micronutrients: calcium, folate, iron, vitamin D, vitamin A, ferritin, magnesium, phosphorous, sodium, potassium, and vitamin B12.
    • Four heavy metal toxins: arsenic, lead, mercury, and cadmium (based on samples of infant’s hair and nails.)
This qualifies as “too much information.” What do the results mean, and how will knowing them make a difference for the infant’s health? They promise to provide raw test results, a graph showing the trends over time, and a detailed explanation of what each biomarker means for child development and how to manage it to stay healthy. They acknowledge that breast milk varies in content over time, and they recommend testing four times during the infant’s first year of life. There is no good science to support such testing. There is no evidence that knowing the levels of those biomarkers and trying to change them by manipulating maternal diet and lifestyle would have any significant effect on an infant’s health.
They are also planning a Happy Children’s Health Study, where those who have purchased their kits will be asked to share their health information. Such a study would be inherently flawed because the participants would not be a representative sample. Only those who are overly concerned about their health and who can afford the testing would be included. They are already accepting tax-deductible donations to the Happy Children Foundation. In my opinion, your money would be better invested elsewhere to support more meaningful scientific research.
Other breast milk testing offers
DHA: Omega 3s and 6s: An article in The Guardian describes My Milk Count, a service that analyses breast milk for levels of DHA, in less than favorable terms. They say, “The idea that human breast milk may not be good enough for human babies is clearly absurd.” They cite an article by Analytical Armadillo that questions the rationale for testing and points out that optimal levels of DHA have not been established; estimates are based on studies from Japan, a country that has the second highest level of DHA in the world. Also, breast milk composition varies markedly, even during a single feeding, and the optimal timing of collection has not been established. Unicef UK, which designed the Baby Friendly Initiative along with the World Health Organization in part to support breast feeding, said, “Unicef UK is not aware of any reason why women should get their breast milk tested for nutrients.” If a woman wants to increase the omega 3/omega 6 ratio in her diet, she can do that simply by eating more fish. There is no need to spend £99 to test her breast milk.
Alcohol: Mothers who are concerned that they might be drinking too much can buy test strips to detect alcohol in breast milk from Amazon.com. Another article in The Guardian questions the validity of the test and worries that relying on it could harm babies and encourage excessive drinking in lactating women.
Worried about environmental toxins?
Environmental toxins can be detected in breast milk, but the poison is in the dose, and we are talking about very low levels that have never been demonstrated to cause harm. Florence Williams wrote the book Breasts: A Natural and Unnatural History to address toxins in breast milk. She had her own breast milk tested for flame retardants (PDBEs). She says breasts “soak up pollution like a pair of soft sponges.” An article on the Best for Babes website counters her scaremongering with some facts:
    • Levels of some chemicals in breast milk have been going down.
    • There are toxins in formula too
    • Breast milk may actually protect babies from toxins
    • Research has found no adverse consequences of key chemicals found in breast milk
    • Not everything in the environment or diet gets into breast milk
    • Short of you being poisoned, breastfeeding is recommended
An article in Scientific American says:
Although breast milk tends to attract heavy metals and other contaminants due to its high-fat and protein content, some recent research has shown its toxic load to be smaller than that in the air most city dwellers breathe inside their homes.
The infamous Dr. Mercola is concerned about glyphosate levels in breast milk and quotes a “world GMO expert” who says glyphosate may be even more toxic than DDT. He even suggests sending Monsanto a thank-you note for your gluten allergy. But to his credit, he does say breastfeeding is still the healthiest option.
Epidemiologist and physician Miriam Labbok says:
To date, no environmental contaminant, except in situations of acute poisoning, has been found to cause more harm to infants than does lack of breast-feeding. I have seen no data that would argue against breastfeeding, even in the presence of today’s levels of environmental toxicants.
Evidence-based reasons for testing
Human milk donation: Peer-to peer donation of breast milk can be hazardous. A recent study found that 3.3% of volunteer, unpaid milk donors tested positive for communicable diseases like syphilis, hepatitis B, hepatitis C, HTLV and HIV. There are human milk banks that screen donors and have established standards for collection, handling, processing and testing to ensure safety.
Premature infants: There is some evidence that testing milk for protein content can guide supplementation to improve the growth rate of preemies.
A disturbing trend
There are many ill-conceived offers for direct-to-consumer lab tests. They capitalize on human fears and scientific illiteracy. Doctors already order too many tests, and patients can’t be expected to have better judgment. False positive results are common when a condition has low prevalence in the population being tested. Patients don’t know how to evaluate their test results or put them into perspective. They don’t know whether they can do anything about worrisome results that will actually make a difference in their health outcomes. Tests like breast milk tests are not likely to accomplish anything good, and they can be expected to do a lot of harm in the form of wasted money and unnecessary anxiety.
What’s next? Here is a warning about blood: it contains more than 4000 chemicals including:
…formaldehyde, acetone, ethanol, ketone bodies, dihydrogen monoxide, tryptophan, urea, dehydroepiandrosterone, hexosephosphate P, and at least 20 kinds of acids. Nearly every chemical constituent will, in certain concentrations, kill children and adults.
If I were an unscrupulous businessperson, I would be tempted to market tests for some of those substances in blood. I would advertise that if you had any of a long laundry list of symptoms from fatigue to dry skin it could be due to a dangerous substance in your blood. I would send out a kit with a lancet and filter paper with instructions for collecting a finger-prick specimen to mail in. I would report the findings along with information about the potential hazards of each component and suggestions about how the levels might be influenced by diet, supplements, etc. I would recommend diet supplements and detoxification products to reduce risk, and I would sell them at inflated prices. I would promote repeat testing at frequent intervals to monitor progress. I could make millions. But I wouldn’t be able to sleep at night.

Using Intranasal Breast Milk to Treat Premature Infants with Intraventricular Hemorrhages
A recent study investigated intranasal breast milk as a treatment for brain bleeds in premature infants. It’s a neat idea, but I don’t find it all that plausible and the study conclusion is overly optimistic.
Clay Jones on March 8, 2019
Link

As a newborn hospitalist, I am frequently called upon to discuss the benefits of breastfeeding and breast milk with families. There is good evidence to support encouraging breastfeeding in a reasonable manner that emphasizes maternal choice, and providing assistance that increases the likelihood of success. There is equally compelling evidence that aggressive “support” can be harmful to newborns, and can result in sometimes significant maternal psychosocial distress. There are many ways to approach feeding of the newborn that will result in a healthy child and a happy mother. Breast is not always best.
I’m not going to get into the specific details regarding the benefits of breastfeeding compared to formula in this post. It’s a complex topic and unfortunately the literature is full of biased studies seemingly designed to show that breastfeeding is superior by not taking into account important socioeconomic factors. Historically there has been much “white hat bias” in breastfeeding research, with proponents having already decided that it is the morally right thing for mothers to do. This bias influences the way that many proponents interpret the available data, design research protocols, and implement campaigns meant to increase rates.
In my opinion, much of the benefit of breastfeeding comes from the environment surrounding a child who is breastfed rather than the actual chemicals in the milk. There are almost certainly some components specific to human breast milk that are beneficial to babies and are not found in modern formula, but differences in outcomes are mostly appreciated only in large populations rather than individual newborns. Many, many babies need to be breastfed to prevent one case of gastrointestinal infection or asthma, for example. This means that most breastfed babies will not have any appreciable advantage over most formula fed babies if their environment is taken into account.
There is one population of newborns that I do think of as unique when it comes to benefits from breastfeeding and breast milk. Premature infants, particularly those born close to the current limits of viability, appear to reap far greater rewards than the typical near-term or term infant. One of the best examples of this is the significant reduction in the occurrence of necrotizing enterocolitis (NEC) in babies who receive donor or maternal expressed breast milk compared to those who are fed formula. NEC is a terrible condition that can result in severe illness, perforation and subsequent loss of bowel, and death.
Another clear benefit of breast milk in premature infants is improved neurocognitive outcomes. It isn’t as obvious as the reduced risk of NEC, and it isn’t the only important factor, but it’s real. The authors of a recently published study in the European Journal of Pediatrics are attempting to add another potentially huge benefit to this list.
Intranasal breast milk for premature infants with severe intraventricular hemorrhage – an observation
Along with NEC, the diagnosis of intraventricular hemorrhages (IVH) is a common and frustrating occurrence in neonatal intensive care units. The earlier and smaller that a baby is born, the more likely they are to suffer bleeding into the hollow cavities inside the brain, which are called the ventricles. These bleeds typically occur in the first few days after birth and, depending on the severity, can result in severe damage to the brain and lifelong neurological sequelae such as cerebral palsy.
The authors of the new study investigated the application of breast milk into the nasal passages of premature infants who have suffered a severe IVH as a possible treatment. My initial reaction was not exactly positive because miraculous uses for breast milk are not new and they are virtually always implausible and based on personal anecdotes. Still, this was published in a respectable journal and a safe and effective (not to mention cheap) therapy that improves neurocognitive outcomes in these babies would be a really big deal. There is currently no treatment for IVH, only the treatment of other conditions that might worsen overall outcomes or the surgical placement of drains to reduce excess pressure inside the brain.
Is it plausible?
Yes…kind of. According to the paper, the reason that this study even took place was because one of the neonatologists decided to just give it a try in a premature infant who had suffered a severe IVH. They dropped a little of mother’s milk into each nostril three times a day for several weeks and the child had an “intriguing good course”, which served as impetus for treating 15 additional babies over the next two years.
But why would the neonatologist decide to give this treatment a try? As described by the authors of the study, there is murine data showing that certain molecules can bypass the blood-brain-barrier after intranasal administration. Furthermore, breast milk is known to contain chemicals associated with growth, development, and survival of neurons. There are also stem cells in breast milk with multipotent and perhaps even pluripotent capabilities.
So they thought that perhaps these brain friendly chemicals in breast milk might access the brain via the nasal passage and improve recovery. The plausibility of this is definitely not homeopathy level, not even close, but it’s a stretch in my opinion. And while there is evidence of better general neurocognitive outcomes in premature infants receiving breast milk, there is no evidence that these babies have faster resolution of IVH or better outcomes specific to that diagnosis such as less severe brain injury or need for surgery.
And virtually all young infants, particularly those with immature feeding mechanisms, have intranasal penetration of feeds. Even when fed with a tube that bypasses the oral cavity, reflux of feeds into the nasal passages is almost equally universal. So it is hard to imagine that intentional intranasal application of breast milk is somehow different and would have unique benefits in the setting of severe IVH.
Were the results interpreted fairly?
As mentioned above, the study involved the initial baby with her “intriguing good course” and then 15 subsequent anecdotes over the following 2 years (2012-2014) where the mother’s breast milk was administered by drops into the nose for several weeks after diagnosis of severe IVH. They then looked back over the previous 4 years (2010-2014) to find 15 babies with severe IVH who were also breastfed but who did not undergo intranasal application. So this was a very small, retrospective case-control study, meaning that confounding variables might play a role in any outcome differences.
All of the babies received the standard of care for their institution, so they all had serial brain ultrasounds which were read by pediatric radiologists blinded to whether or not a baby had been receiving the intranasal breast milk. The tracked initial IVH grading and worst severity at any point, degree of ventricular dilatation, white matter damage (degree of cystic defect) at discharge and worst severity at any point, death within 2 weeks of birth, survival to discharge, and need for surgical intervention.
Despite choosing not to adjust for the multiple comparisons, citing the study’s “exploratory character” as the reason, no outcomes differences were found to be statistically significant. But despite the small number of subjects, and the lack significance, they concluded that they had discovered a “trend for less severe cystic defects” and called for “further controlled investigation”. This, in my opinion, is not an appropriate interpretation of these results. A more honest conclusion might have been that this data did not show benefit from intranasal breast milk, but we still think it’s a pretty neat idea and want to see how this pans out. I also think it’s important to point out that even if this trend ends up being real, these structural changes wouldn’t necessarily equate to improved long-term neurocognitive outcomes.
Is there any risk?
Use of freshly pumped milk from the child’s mother for intranasal application would not be risk free, but it’s far from dangerous. I mean, we do feed this milk to the babies. The volume is very low such that aspiration into the lungs would not really be a problem. There are infections agents that are sometimes found in breast milk, but again this would be unlikely to be much of a concern unless someone were to use a less safe supply of breast milk. One potential risk would be the creep that occurs when unproven ideas reach a wider audience. I can imagine people extrapolating to older babies and different conditions. Ultimately, I don’t really see this as a risky intervention. I just don’t think it is going to work.
Conclusion: Let’s withhold judgement on intranasal breast milk
This study doesn’t really tell us whether or not intranasal breast milk will be beneficial to premature infants with intraventricular hemorrhages. But I don’t think it’s particularly plausible. That being said, it isn’t really risky and it is cheap as far as interventions in this population go. I’m not opposed to further studies, but I won’t exactly be holding my breath.

Yes, You Can Swaddle Your Baby…But a Sleep Sack is Probably the Safest Option
Taking care of a baby can be scary, and there is a lot of conflicting advice out there. This is especially true when it comes to recommendations on the safety of swaddling. While not completely risk free, swaddling can be done safely and the benefits likely outweigh the risk. But you can always just use a sleep sack.
Clay Jones on February 5, 2021
Link

As a newborn hospitalist, a large part of my job involves educating parents on a variety of newborn care topics. One of the most important discussions that I make a point to have even with experienced caregivers involves safe sleep. Every year in the United States around 3,500 infants die unexpectedly during sleep and there are a number of modifiable risk factors that can play a role in these tragic outcomes.
I take this aspect of my job very seriously, and not just because it might save lives. Educating parents on ways to make their child safer during sleep reduces anxiety and helps them to get some much-needed rest themselves. Caregiver anxiety reduction and improved sleep has many positive health benefits for all involved parties and should never be underestimated as an intervention.
As much as I am pleased when caregivers are empowered and their fears calmed by legitimate medical information, I am equally frustrated when I encounter misinformation that does the opposite. Longtime SBM readers will know that I often focus my ire on chiropractors who swerve far out of their lane by giving pediatric medical advice. For example, I recently spent some time watching a number of videos produced by chiropractors who promote the absurd idea that infants are being harmed by improper diaper changing technique. I watch videos like this and have to wonder if these people actually know any babies.
Some of the discussions I have with parents are complicated by a lack of clear guidelines based on solid evidence. I do my best with the available data and I make sure to communicate this uncertainty to caregivers while giving them the tools to make an informed decision. Unfortunately, the internet is full of information that doesn’t always help clear up these complex issues.
A few weeks ago I encountered an example of this in the form of an article on safe infant sleep published by Today’s Parent, which bills itself as “Canada’s #1 source for parenting content that informs, inspires and builds a sense of community.” While I wouldn’t put it in the same league as infant chiropractic, it has a few problems. Here goes.
In the article, author Vanessa Milne does what many authors of such pieces do and opens with a question: Is swaddling dangerous? Betteridge’s law of headlines, which states that “any headline that ends in a question mark can be answered by the word no”, may have been proven wrong, but it still often comes across as clickbait. Nobody is perfect, however. Unfortunately, many people won’t read past the first paragraph and will come away thinking that swaddling should absolutely be avoided. Even when reading the entire article it is still a bit confusing.
Another common approach to medical articles written for the lay public is opening with an anecdote. In Milne’s article, the anecdote involved a confused parent:
When Melissa Romain had her first baby at a Toronto hospital in 2016, the nurses demonstrated how to swaddle him and encouraged her to continue doing it at home. But by the time she had her second baby four years later, things had changed. The nurses swaddled her baby the whole time they were on the maternity ward; then, as she was being discharged, they told her she shouldn’t swaddle at home because it was too dangerous. They said this was because the baby was under closer supervision in the hospital, but Romain says there was plenty of time that she and her baby were alone together in her room. “I was confused and a little frustrated,” says Romain. “Nobody explained why swaddling is no longer a best practice. They just said that this is how it is now.”
I get why this was done, of course. Stories are powerful and they are meant to be a hook to help reel the reader into the rest of the article. And this is a good hook. A lot of people will read it and worry that they are putting their baby at risk. Or they may worry about the baby of a loved one. They may be concerned that hospitals are giving confusing or even risky advice to caregivers. But it is unlikely that this one woman’s experience can be generalized to all or even most hospital nursery care. And as I’ll explain, swaddling can be done safely.
In the article, Milne claims that the Registered Nurses Association of Ontario advises against swaddling. But they don’t. In their most recent guidelines on safe sleep, the RNAO states that ‘There is currently no evidence on the “safe way” to swaddle an infant, and hence caution regarding swaddling should be expressed…’, which is accurate if not a bit melodramatic.
The RNAO points out that a swaddle can potentially become a loose blanket that could be a risk factor during sleep, and that excessive bundling can overheat a baby, which is also a risk factor for death during sleep. But they don’t advise against swaddling. I point these concerns out to parents as well, but there is actually data to support a nuanced position that takes risks AND benefits into account, rather than a blanket proscription. I’ll get to that data shortly.
Milne also claims that Perinatal Services BC advises against swaddling. This is true, but needs some context. When looking into their specific recommendations, the first document I came across was a 2015 Newborn Care Guideline where swaddling is mentioned only twice. The first time is when it’s recommended for newborn pain control and the second is under the heading of heat control in infants where skin-to-skin care is recommended instead. But this document only addressed care in the newborn nursery.
I eventually was able to find the PSBC “Safe Sleep Environment Guideline” that Milne was referring to, which was released in 2011. It is aggressively anti-swaddling, claiming that it can cause overheating, decreased arousal and subsequent death from SIDS, chest infections, restricted breathing, and inability to use the arms to move away from harm. It also claims that there are very few benefits from swaddling and it is essentially unnecessary. It’s hyperbolic and I don’t agree with their approach.
PSBC also puts out a brochure for families aimed at educating them on safer sleep. It also includes a section on swaddling that repeats the previously described risks. Of note, it implies that skin-to-skin care is more desirable than swaddling. In my post on this practice, conveniently linked to above, I discuss the serious risks of skin-to-skin care that are often ignored.
In Milne’s Today’s Parent article, a nurse is quoted claiming that swaddling can result in a loose blanket that may cover a sleeping baby’s face. If this were to happen, I agree it would be concerning. We strongly recommend avoiding loose blankets, stuffed animals, or anything that might find itself blocking a baby’s supply of fresh air. But does that mean putting a baby down to sleep in a swaddle results in a higher chance of unexpected death during sleep? Are the warnings of PSBC are legitimate?
This question was actually addressed in a 2016 meta-analysis published in Pediatrics, but to be completely honest it’s still not entirely clear. The answer is probably no, however, as long as you avoid a couple things. It is difficult to study something as complex as infant death during sleep, and data is necessarily retrospective. So it will likely always be challenging to draw firm conclusions. The 2016 Pediatrics analysis of several studies looking at swaddling and its relationship to SIDS showed that swaddling does not appear to significantly increase the risk of death during sleep except for when a swaddled baby is placed face down (please never do this) or when an baby old enough to roll over is swaddled.
The Today’s Parent article repeats the concern that swaddling a baby may lead to overheating, but this is easily avoided by using the one to two thin layers rule and educating caregivers on appropriate room temperature. Claims that swaddling may restrict breathing and increase the risk of chest infections are just not true. It is true, however, that restrictive swaddling that forces a baby’s hips into extension can increases risk of hip dysplasia, so don’t do that.
The article correctly points out that swaddling can improve baby sleep (which I’ll add can improve caregiver sleep and thus numerous other outcomes), and that the American Academy of Pediatrics and Canadian Pediatric Society say that swaddling is low risk if done correctly. Milne also provides some helpful information on proper swaddling and safe sleep positioning. The article ends with the very important reminder to check with a baby’s healthcare provider there are questions.
One statement towards the end was just…odd. A Toronto pediatrician is quoted claiming that there are “some infants who shouldn’t be swaddled under any circumstances, such as babies who are very jaundiced or underweight”. I am wholly unfamiliar with this recommendation and can’t think of any reason why this would be true.
So the bottom line, in my opinion, is that swaddling is fine. There is a very small increased risk of SIDS but that data was based on a tiny number of SIDS cases in swaddled babies and the biggest risk comes when a baby is placed face down. The benefit of improved sleep, both for the baby and the parents, outweighs the risk when swaddling follows the recommendations given by the AAP.
The studies performed so far haven’t looked at how the babies who died during sleep were swaddled. Common sense says don’t make it too loose, don’t use thick or multiple blankets, and don’t swaddle once a baby is rolling over on their own. And again, always place a baby on their back to sleep.
Sleep sacks can substitute for a swaddle. These typically involve zippers, Velcro, or the dreaded snaps, and thus can’t become a loose blanket. Use the kind that have wings so that baby’s arms can be restricted to get the same benefit as from swaddling. And of course, the same safety rules apply.

New AAP Policy on Circumcision
Harriet Hall on September 4, 2012
Link
Back in 2008, I tried to look objectively at the scientific evidence for and against circumcision. I got a lot of flak from commenters who focused on the ethical issues rather than the scientific evidence. I concluded that the evidence showed small benefits and small risks, and I didn’t advocate either for or against the procedure. At the time, the American Academy of Pediatrics’ position was:
Existing scientific evidence demonstrates potential medical benefits of newborn male circumcision; however, these data are not sufficient to recommend routine neonatal circumcision. In circumstances in which there are potential benefits and risks, yet the procedure is not essential to the child’s current well-being, parents should determine what is in the best interest of the child.
On August 27, 2012, the American Academy of Pediatrics issued a revised Circumcision Policy Statement saying that the benefits outweigh the risks.

The revised policy is based on the findings of a multidisciplinary task force that did a systematic evaluation of the peer-reviewed literature from 1995 through 2010. The new statement has been endorsed by the American College of Obstetricians and Gynecologists. It says: 
…preventive health beneﬁts of elective circumcision of male newborns outweigh the risks of the procedure. Although health beneﬁts are not great enough to recommend routine circumcision for all male newborns, the beneﬁts of circumcision are sufﬁcient to justify access to this procedure for families choosing it … Parents ultimately should decide whether circumcision is in the best interests of their male child.
They cite evidence that circumcision reduces the risk of urinary infections in infancy and reduces the risk of HIV and other sexually transmitted infections in later life. They point out that complications are infrequent and far less likely in the newborn period than if circumcision is performed later in life. Evidence for other benefits and detailed information about risks are included in the Technical Report by the panel along with a discussion of the arguments and with further recommendations. 
They report the scientific data. The decision to circumcise or not to circumcise is based on those data along with non-scientific considerations like religion, ethics, and cultural practices. It seems that most people are unable to discuss the risk/benefit data without getting all riled up about those other issues.
This confusion between scientific data and other issues is illustrated by a detailed 20 point critique of the AAP report that was published by an anti-circumcision group, the Circumcision Resource Center. 
It’s worth looking at the 20 points in detail. I’ve commented on some of them in parentheses and left it to my readers to spot the logical fallacies in the rest:
     1.  The underlying flawed assumption is that the way to evaluate circumcision is to perform medical studies. They say all that is needed is feelings and common sense.
     2.  Committee members were biased because many of them were circumcised or had performed circumcisions.
     3.  Other countries recommend against circumcision.
     4.  Many of the cited studies have been challenged. (The challenges they cite are unconvincing or based on issues outside of the studies themselves.)
     5.  The report doesn’t mention the word “condom.”
     6.  The report says circumcision prevents penile cancer. (They try to refute this by citing cancer incidence in two countries with different rates of circumcision.)
     7.  The decrease in UTIs is small and they can be treated with antibiotics.
     8.  Preventive benefits are not actual health benefits.
     9.  Is doesn’t mention the effects of circumcision pain. (The report advised adequate anesthesia).
     10.  It doesn’t mention ethical objections or all circumcision risks. (False. It has a whole section about ethical issues, and it covers all reported risks.)
     11.  It doesn’t mention physician coercion and unauthorized circumcisions.
     12.  It makes an issue of penile hygiene.
     13.  It doesn’t mention the functions of the foreskin. (Actually it does, and it provides evidence that foreskin removal doesn’t affect sexual pleasure or cause any significant loss of function.)
     14.  It doesn’t examine the connection between circumcision and erectile dysfunction. (There’s no credible evidence of any connection.)
     15.  It doesn’t mention psychological harm. (Because there’s no evidence in the literature.)
     16.  It lacks balance, devoting more space to benefits than to harms. (Because there is more evidence of benefits than harms.)
     17.  It calls for more research into potential benefits but doesn’t specifically call for more research into the harms.
     18.  It ignores difficulties with informed consent.
     19.  It shifts responsibility from physicians to parents.
     20.  It ignores serious ethical questions. (same point as #10)
This critique is far less credible than the AAP statement. It gets some of its facts wrong, moves the goalposts, says studies are not the way to look at the problem but then cites studies… the whole thing amounts to anti-circumcision apologetics rather than a reasoned scientific critique.
    • It refers to removing 12 square inches (77 square centimeters) of tissue. That’s an overestimate. According to this study the average area of the adult foreskin is more like 37 to 43 sq. cm.
    • It says some infants don’t cry during circumcision “because they go into shock.” That’s ridiculous. They are clearly not in circulatory shock, and the idea that they are in some state of emotional shock is nothing more than a fanciful speculation. I would argue that it’s more likely to be because they aren’t experiencing pain. My own anecdotal observation: I’ve seen babies cry from being restrained but then calm down before anything else was done and not cry during the actual procedure, even when it was done without anesthesia. The cutting itself would not be expected to hurt, because the tissue that is cut has already been crushed and numbed by the application of hemostats and clamps.
    • They say anesthetics are injected into the penis and don’t eliminate pain. That’s misleading. For the most effective anesthesia, the dorsal penile nerve block, two injections are given adjacent to the base of the penis, and they prevent pain from the circumcision, although the injections themselves are painful.
    • They cite some poor quality cherry-picked studies.
    • They engage in wild speculation:
the effect of circumcision on male distrust, anxiety, and anger toward women is unrecognized and unexamined. Do the psychological and sexual consequences of circumcision affect America’s uniquely high divorce rate? We do not know.
Conclusion: Science cannot decide nonscientific issues
The AAP policy is based on a fair evaluation of the scientific evidence for and against circumcision. Ethical, religious, legal, and cultural issues are outside the sphere of science, and the AAP rightfully leaves those issues for parents and society to decide.

Does acetaminophen during pregnancy raise the risk of behaviour problems?
Scott Gavura on August 18, 2016
Link

In my career as a pharmacist I’ve answered a lot of questions about medication use in pregnancy. Pharmacists are among the most accessible health professionals, and we’re usually found near a wall of medicines and supplements. Many don’t trust Dr. Google, and for good reason: There are conflicting answers online. When it comes to medication use in pregnancy and effects on the fetus, we have no perfect data. Since no-one is randomizing women to drug treatment or placebo, we must rely on weaker, less definitive evidence. An appropriate response from a health professional will describe known risks and expected benefit, summarizing what we know, and how confident we are in that answer. One of the most popular drugs used in pregnancy is acetaminophen (sometimes called paracetamol or APAP), and commonly known by the brand name Tylenol. An emerging concern with acetaminophen is whether use during pregnancy raises the risk of attention deficit hyperactivity disorder (ADHD) and related behavioural problems. While I covered this question once, back in 2014, there’s a new paper that’s putting this issue back in the news. From Evie Stergiakouli and colleagues is the paper, “Association of Acetaminophen Use During Pregnancy With Behavioral Problems in Childhood: Evidence Against Confounding“, published this week in JAMA Pediatrics.
Google “Tylenol and pregnancy” and you get 15 million results. What are the facts?
It should come as no surprise that acetaminophen has generated several posts over the years at SBM. It’s one of the most commonly-used medicines worldwide, starting in infancy for fever, right through towards end-of-life pain control in the elderly. As an ingredient, acetaminophen is packaged into hundreds of prescription and non-prescription drugs. Acetaminophen has a good safety profile when used appropriately. However it is among the most harmful of drugs in overdose, and the ease at which overdose can occur makes acetaminophen the cause of hundreds of cases of liver failure per year. The consequences of acetaminophen poisoning are a major public health issue. Given the frequency of use, and the unique risk profile, there are continued questions about whether widespread usage is doing more harm than good. (If the product were to be invented today, I personally doubt it would even be approved for sale an an over-the-counter drug.) But acetaminophen has a long history of (usually) safe use, so regulators (and manufacturers) continue to experiment with ways to make the drug available to consumers for self-selection, while trying to reduce the risk of unintentional harm.
Pain in pregnancy is common. Beyond the non-pregnancy causes of pain everyone can experience, like headaches and colds, the pregnant body is undergoing a rapid transformation that may not be painless. Weight gain of 25 or more pounds leads to posture changes and painful joints. Low back pain is common, and it can be worse at night, leading to insomnia. While non-drug measures should always be attempted before considering drug treatment, severe or prolonged pregnancy pain may lead to questions about the safety of analgesics like acetaminophen.
Acetaminophen is the current go-to drug for pain control in pregnancy. There is good evidence to show that it does not increase the risk of major birth defects above the baseline risk (2-3%) that is inherent to any pregnancy. Acetaminophen is generally considered to be safe throughout pregnancy, and as long as the dosing is appropriate, side effects are rare. With a safe history of use, and a low risk of serious side effects, acetaminophen is widely used for pain control in pregnancy.
Using medication in pregnancy requires a close consideration of risks, benefits and alternatives. Doing nothing is always an alternative for pain, but the consequences of untreated pain need to be examined as well. Stacked up against other pain relievers, acetaminophen has some attractive features. Anti-inflammatory drugs like ibuprofen must be avoided in the later stages of pregnancy, due to the concerns about cardiovascular toxicity. Compared to the anti-inflammatory drugs, acetaminophen is unlikely to cause gastrointestinal ulcers, blood disorders, or kidney problems. Nor does acetaminophen appear to increase the risk of cardiovascular events such as heart attacks and strokes. Moreover, compared with anti-inflammatory drugs, acetaminophen has few interactions with other drugs, so it can safely be used for pain relief in pregnant women on other medications, or with other medical conditions where other pain relievers might have unwanted effects.
Beyond acetaminophen and the anti-inflammatories are the narcotics. The addictive properties of narcotics are well known, and they affect the fetus too. Compared to a drug like codeine or morphine, acetaminophen provides a non-addictive alternative that may be more appropriate for short-term or even long-term pain issues when drug treatment is considered. (The FDA’s 2015 statement on pain relievers in pregnancy provides a concise summary.)
What is the new data?
The new paper is an analysis of 7,796 mothers from Bristol, England. A prospective cohort study (the Avon Longitudinal Study of Parents and Children) allowed researchers to assess associations between acetaminophen and subsequent behaviours. Acetaminophen use (in the previous three months) was collected based on self-reports at 18 and 32 weeks of pregnancy. The same question was asked based on maternal and partner self-report after the child was born. When the children were 7 years old, an analysis based on these surveys was conducted that looked for the presence of behaviour issues.
Acetaminophen use was common. At 18 weeks gestation, 53% of mothers in the study reported using acetaminophen in the previous three months. At 32 weeks, 42% reported using acetaminophen in the previous 3 months. 90% used acetaminophen after birth.
Overall, 5% of children were determined to have behavioural issues. After adjustment, the researchers found a modest association between acetaminophen at 32 weeks and behavioural problems at age 7, based on a conduct disorder scale (RR 1.42, 95% CI 1.25 – 1.62) and a hyperactivity scale (RR 1.31, 95% CI 1.16 – 1.49). There was a significant (but smaller) association at 18 months. Post-partum use was not associated with any behavioural issues. These are relative risks. The absolute risk of behavioural issues was small, so the finding suggests a small increase in an already small number.
Some strengths, but also limitations
This was a prospective study that raises some interesting questions. As the researchers didn’t observe any correlation between post-partum acetaminophen use and behavioural issues, they hypothesize that the difference may not be explained by hidden confounders, like other behavioural or social issues. But while the study controlled for many confounders, there’s still the potential for some other factor to be influencing the findings. Some of the risks appeared to decrease, not increase, with acetaminophen use.
One of the biggest limitations to this study is that there was no collection of data on actual acetaminophen use. Not only was this data self-reported, no dosage or duration of use data was collected.
Despite the limitations, we shouldn’t dismiss data like this out of hand. While the actual effect (if it actually is real) is small, we need more data to give us greater confidence in this finding. From a public health perspective, understanding if acetaminophen is having a negative effect is an important question to answer.
Is acetaminophen still considered safe in pregnancy?
Acetaminophen is widely used in pregnancy, and has traditionally been considered a safe drug. Consequently, it’s no surprise that this new finding has generated a lot of attention. This new study suggests that acetaminophen may be having subtle effects on behaviour. We need to consider this study in the context of other evidence. Ideally, this finding needs to be confirmed by other researchers using other datasets – hopefully with better data collection on actual use. But we can be reassured that even if this effect is real, it is very slight. Unwarranted panic isn’t justified, but it does remind us that evidence is constant emerging and we need to continuously reassess our practice (and advice) against the best evidence. No drug, not even acetaminophen, should be taken in pregnancy unless it’s felt necessary. However, pregnant women shouldn’t suffer in pain needlessly. Acetaminophen continues to be the preferred pain reliever in pregnancy.

Hitting Children in School: Bad?
The title of this post is silly. Hitting kids in school is always bad, and there is very good reason to expect the same negative outcomes from school-based corporal punishment as are seen when kids are hit at home. The AAP recently recently released a policy statement calling for a national ban.
Clay Jones on October 13, 2023
Link

A quick public service announcement from Science-Based Medicine, or at least from me: hitting children is fundamentally wrong. It’s also not effective when done in an attempt to improve their behavior. Back in 2014, I wrote about the use of corporal punishment to discipline children, mostly focusing on its use by caregivers in the home. Sadly, not much has changed since I wrote this opening paragraph:
One of the most commonly practiced strategies used by parents to alter the long term behavior of their children is corporal punishment, commonly referred to as spanking. But use of the term spanking is problematic in that how caregivers interpret it varies widely, and there is frequent overlap with what pediatricians consider to be abuse. Despite a great deal of evidence showing that spanking is ineffective, is a risk factor for greater forms of physical abuse, and can negatively impact the behavioral and cognitive development of children in a variety of ways, it remains a controversial issue in the United States. The American Academy of Pediatrics and numerous other professional organizations have come down firmly against the use of physical punishment by parents, but unlike 34 other developed nations there are no federal laws banning spanking.
There are still no federal laws banning spanking, either in the home or in schools, which is what today’s post will focus on. Pediatricians, though not all of us unfortunately, are generally united in their stance that this is a problem. The American Academy of Pediatrics is naturally opposed to the practice of physical violence against children in all forms and recently issued a policy statement to specifically address when it is used as a form of discipline in schools.
Children in many states are still at risk of being hit as a form of punishment while at school, and this isn’t just in private schools. In my 2014 post, I wrote how laws regarding corporal punishment vary from state to state:
19 states currently allow the striking of a child in any school setting. Of the 31 states and the District of Columbia that ban the practice in public schools, only New Jersey and Iowa also include private schools. Many schools give the misbehaving child a choice between suspension and being beaten with a paddle. It is also common for schools to require a parent to opt out of their child receiving corporal punishment rather than having to sign a consent form before such physical correction is applied. Corporal punishment in schools is more prevalent in the South and in lower socioeconomic school districts, leading to poor black children being by far the most likely to face it.
I’ve realized that I used to write much longer paragraphs than I do now. Otherwise not much has changed in the past 9 years. As of 2023, hitting kids at school is still perfectly legal in private schools in every state except for New Jersey, Iowa, and (yay!) now Maryland. School beatings have also been banned in public schools in Colorado and Idaho since then, bringing the number of states where hitting a child at school instead of educating them down to 17. Kentucky, Louisiana, Mississippi, have also banned physical punishment of students with disabilities since 2014, as have Oklahoma and Tennessee unless parents sign a consent to allow it.
Why is beating children in schools allowed? Great question. In 1977, the Supreme Court had an opportunity to protect children but failed. A 5-4 decision in Ingraham v Wright provided constitutional cover for school-based physical punishment, saying that 8th amendment protections against cruel and unusual punishment don’t apply to students. They left it up to the states, many of which are seemingly incapable of thinking about the (born) children in any meaningful capacity.
The majority of children being hit at school in the United States live in the South, with the majority (nearly 3 out of every 4) living in Alabama, Arkansas, Georgia, Mississippi, and Texas. Mississippi and Texas are the worst offenders, with a third of all kids being attacked by teachers or other school administrators living in those two states. It gets worse.
When a school allows faculty to hit students, which students tend to get hit? Another great question, and one which requires a thoughtful and nuance re..black kids. It’s black kids. Children with disabilities have it the worst, however, with national data showing that 16.5% of kids who are hit at school being served under the Individuals with Disabilities Education Act. The tragic reality is that the more marginalized a child is, for example a black child with autism, the more likely they are to be physically attacked at school by someone charged with their education and safety.
The AAP is calling for corporal punishment in all school settings to be banned in every state, and one would think that all organizations comprised of pediatricians would be on board with this. But one would be wrong. The American College of Pediatricians, an anti-vaccine, homophobic, and transphobic hate group made up of old white Christian male pediatricians that sometimes fools journalists into thinking that they deserve to have their opinion heard, came out in support of hitting kids in a 2018 statement:
Despite the recent avalanche of biased research against all physical punishment, evidence indicates ordinary spanking to be a valid and needed disciplinary option when 2- to 6-year-olds refuse to cooperate with milder measures.
To support this claim, they cite a couple studies from 20 years ago and one from 2016, the latter of which found a link between spanking and increased risk for detrimental child outcomes:
Thirteen of the 17 child outcomes examined were found to be significantly associated with parents’ use of spanking. Among the outcomes in childhood, spanking was associated with more aggression, more antisocial behavior, more externalizing problems, more internalizing problems, more mental health problems, and more negative relationships with parents. Spanking was also significantly associated with lower moral internalization, lower cognitive ability, and lower self-esteem. The largest effect size was for physical abuse; the more children are spanked, the greater the risk that they will be physically abused by their parents.
The authors conclude that the numerous meta-analyses they evaluated showed, in addition to the potential harms mentioned above, that there is was no evidence of improved child behavior related to spanking. And this was seen in the highest quality studies, not just in small and methodologically weak studies. In their new policy statement, the AAP discusses multiple studies since my last post that further support calls to ban corporal punishment because of a lack of effectiveness as well as short and long term adverse effects. These include “increased incidence of behavioral and mental health problems, impaired cognitive development, poor educational outcomes, impaired social-emotional development, problems with the ongoing relationship between parents and children, a higher risk for physical abuse, increased aggression and perpetration of violence, antisocial behavior, and decreased moral internalization of appropriate behavior.”
Although there is less available data when it comes to school-based corporal punishment, there is no reason to expect it to be any different. A 2019 survey of 18 to 23 year old adults who went to school in the United States found that, among the 16% who had been hit by school personnel, there was an association with lower grades. There is better data from other countries, but this is definitely an area where more research would be helpful, not because there is much doubt regarding the negative consequences but because it might help convince people in states where hitting kids at school is allowed to change their policies.
The ACPeds statement calls studies on hitting kids into question, latching on to one sentence from the 2016 meta-analysis and ignoring the entirety of the rest of the analysis:
“As most of the included studies were correlational or retrospective (72%), causal links between spanking and child outcomes cannot be established by these meta-analyses.”
This is, of course, quite true. And the authors of the 2016 study, in addition to those of the new AAP policy statement, address the argument that you can just ignore all the available data because it doesn’t involve…(checks notes)…prospectively assigning half of a study population to being beaten by their caregivers or teachers. Obviously observational data is all that is available, but the consistency and the strength of the signals being picked up are such that a causal relationship is the most rational conclusion.
In 2019, I posted a delightful (according to my mom) and satirical take on the absurdity of corporal punishment for behavior management involving imaginary AAP guidelines on appropriate dosing.

Update: More Evidence Supports Delaying School Start Times for Sleep Deprived Teens
Sleep deprivation is a serious health and academic concern for teenagers. A new study adds more support for calls to push back school start times as an effective strategy.
Clay Jones on December 14, 2018
Link

In October of 2014, on this very blog, I wrote about the new AAP policy statement calling for delayed school start times for adolescents. I agreed with their labeling of insufficient sleep as “one of the most common, important, and potentially remediable health risks in children”, and I still do. Since that post, the evidence in support of pushing start times back to at least 8:30 AM has continued to mount.
A new study involving children in the Seattle School District was published on Wednesday in Science Advances, and it has been making the rounds in various medias. It gives us even more data to support efforts to improve teen sleep by allowing extra time in the morning. Not only did it show that the extra time resulted in more overall sleep, because there has been some concern that kids will just stay up later, but it also had academic benefits. I’ll discuss the study shortly, but first a brief recap of concerns regarding teen sleep deprivation.
What are the common adolescent sleep challenges?
Teenagers these days are often fighting an uphill battle when it comes to getting adequate sleep, which is considered by most sleep experts to be in the 8.5 to 9.5 hours per night range. Some teens do well with less than the recommended amount of sleep, but for far too many it adversely affects school performance and can even lead to long-term mental and physical health problems. It also increases the risk of traffic accidents and fatalities.
Technology is one of the most obvious reasons why older children are getting less sleep. Most of them have electronic media in their rooms, if not attached to their bodies in the form of a smart phone, at all times. The evidence is clear that the internet and social media are a major factor in delayed sleep initiation. Popular energy drinks, with their large amounts of caffeine and other stimulants, can also play a role.
From a biological perspective, among the many changes that a child undergoes with the onset of puberty is an alteration of the internal circadian rhythm and sleep drive. Most adolescents gradually shift towards favoring staying up later and subsequently sleeping later. Even without the influence of social media and caffeine, teens often have difficulty falling asleep before 11 PM and waking before 8 AM. With chronic insufficient sleep, a teen may not feel truly alert until after 10 AM. Again, there is variability between individuals but this affects the vast majority of even healthy teenagers.
It is the combination of multiple factors, such as those discussed above, but also including the need to wake up earlier on weekdays for school, that leads to a buildup of daytime fatigue. Many teenagers will try to catch up on the weekends or holidays. While this is a manifestation of their underlying biological sleep preference, it is also driven by sleep pressure accumulated during the week. It doesn’t actually solve the problem, and may make it harder for teens to adjust sleep cycles over the long haul.
How common is insufficient sleep in adolescents?
According to the technical report that accompanied the 2014 AAP policy statement, the concern that teenagers are not getting enough sleep is based on solid epidemiological data, and is likely even underestimated because self and parent reporting tends to overestimate actual hours slept. With that in mind, the 2006 National Sleep Foundation Sleep in America Poll revealed that 3 out of 4 kids average less than 8 hours of sleep each night by their senior year. The 2014 NSF poll found that only 10% of children aged 15-17 get the recommended amount of sleep, and almost 60% get less than 7 hours.
These surveys and others reveal the fact that most teens feel tired at school, with many reporting episodes of falling asleep in class. Furthermore, most teens feel the need to compensate with stimulants and extra weekend sleep. Unfortunately, also per a number of surveys, parents are largely unaware of these issues and believe that their teenage children are getting the recommended amount of sleep.
How does insufficient sleep harm adolescents?
The list of potential harms from insufficient sleep in the adolescent population is long and varied, and includes both immediate and long term effects. The 2014 AAP report highlights three categories of negative effects: Physical health and safety, mental health and behavior, and school performance. I’ll highlight some of the major potential consequences in each.
Obesity and long term cardiovascular events like heart attacks and stroke have been linked to insufficient sleep starting in the teenage years. More acute is the major issue of “drowsy driving” and the risk of motor vehicle accidents, with 50,000 fatigue-related accidents occurring each year involving a driver under the age of 25. Increased consumption of caffeine, and potential associated toxicity, is clearly linked to poor sleep, but use of prescription stimulants that have been diverted from their intended indications is also a concern.
Teenagers with chronic inadequate sleep are more likely to have anxiety conditions and depression. They are also at risk for difficulties with impulse control and self-regulation, increasing risk-taking behaviors. Poor sleep can also interfere with the ability to process stress, which can exacerbate the likelihood of illness and maladaptive coping strategies. And not surprisingly, adequate sleep plays an important role in cognitive function, memory, and attention. Poor sleep thus can interfere with academic success, increase missed days of school, and lead to higher rates of dropping out.
More experts weight in
In April of 2017, the American Academy of Sleep Medicine published their policy statement on the subject of adolescent sleep and delayed school start times. It echoes the concerns of the AAP:
During adolescence, internal circadian rhythms and biological sleep drive change to result in later sleep and wake times. As a result of these changes, early middle school and high school start times curtail sleep, hamper a student’s preparedness to learn, negatively impact physical and mental health, and impair driving safety. Furthermore, a growing body of evidence shows that delaying school start times positively impacts student achievement, health, and safety.
They also point a lack of public awareness of sleep deprivation in teens and how school start times are partly to blame. Like the AAP, they also call for pushing start times back to at least 8:30 AM for older children.
Now back to the new study
In 2016, after significant community effort to address transportation logistics and scheduling of after school activities, start times in the Seattle School District middle and high schools were pushed back to 8:45 AM. Researchers at the University of Washington saw this as a golden opportunity. They could assess the amount of sleep students got both before and after the switch, as well as academic performance.
Students in the study got, on average, a bit more than 30 minutes of extra sleep each school night. This may seem trivial to some, although I bet most readers recognize how significant an extra half hour of sleep can be, particularly when it is consistent over a lengthy period of time. Improvements were seen in daytime sleepiness, grades, and tardiness, with the biggest effect in students in low socioeconomic groups. Although not studied, it is reasonable to consider that decreased sleep inertia would result in safer driving.
There were a couple interesting aspects of this study that I believe are worth pointing out. The first is that it didn’t rely only on each student’s recall of sleep amounts. Rather the study involved the use of wrist activity trackers to log sleep-wake cycles. Also, they employed a simple but clever method of determining if delaying school start time brought students more into alignment with their natural circadian timing and reduced social jet lag. As predicted, students had less discrepancy between sleep patterns on school and non-school nights.
Conclusion: What are we waiting for?
What the study cannot do is prove beyond all doubt that the increased sleep is what resulted in the improved outcomes. The students were not blinded. They knew that they were involved in the research and thus there could have been an observer effect. But data collected over the years certainly seems to be triangulating on the conclusion that if you allow kids to sleep more, they will do better in school and live healthier and safer lives.
Transitioning to later school start times can be challenging. It takes buy-in from schools, parents, and the community. But it can be done. As I said in 2014, it certainly appears to be worth a difficult transition period. We shouldn’t ignore other modifiable behaviors that interfere with adolescent sleep, however.

Fever Phobia
Should you be afraid of your child having a fever? It depends, but probably not.
Clay Jones on December 21, 2012
Link
Fever is a mighty engine which Nature brings into the world for conquest of her enemies.”
— Thomas Sydenham
The occasional abnormal elevation in body temperature associated with infection is as much a part of the human condition as abstract thought or the desire to lose weight without exercise or cutting calories. Commonly known as fever, this powerful yet misunderstood physiologic response has been documented in a variety of animal species including fish, reptiles and of course humans. We have all had fever at least once in our lives, and probably several times. And many of us have undoubtedly spent a few anxious nights cradling febrile little ones, afraid more of the repercussions of the fever itself than the potential sequelae of the underlying cause.
Along those lines, fever is one of the most common reasons for parents to seek medical care for their children, with roughly a third of pediatric acute care visits related to it, as well as a frequent impetus for late night nursing calls to sleepy hospitalists. Actually only about half of after-hours calls are about fever but who’s counting. Unfortunately most medical professionals, including many pediatricians, have a poor understanding of the pathophysiology of fever, and their panicked approach to its management in many children involves unnecessary laboratory tests, imaging studies, and doses of broad spectrum antibiotics. It also adds to parental anxiety and helps to establish a vicious cycle as patients of over worried caregivers tend to undergo more aggressive evaluation and treatment.
What isn’t fever?
Any discussion of what fever is must first be tempered by information on what fever isn’t. Fever is not hyperthermia. Hyperthermia is not a physiologic response to infection but instead is overheating despite our thermostat (I’ll get into this in a bit) being set at normal. Hyperthermia occurs when we retain excess heat from an external source, such as when a young child is forgotten in the car on a hot Louisiana Summer day, or when there is overproduction of heat caused by a reaction to certain medications. A diagnosis of hyperthermia carries with it significant risk of direct morbidity and mortality while fever rarely leads to direct harm. Perhaps some of the fear experienced by the mere thought of febrile children stems from the muddling of these two concepts. This post is about fever, not hyperthermia.
The physiology of temperature
The temperature of our bodies is amazingly steady despite significant variations in environmental temperature and physical exertion. This is achieved by an amazing interplay of our autonomic nervous and endocrine systems as well as some evolved instinctive behaviors. The thermoregulatory center of our bodies is the hypothalamus. It can be thought of as our “thermostat” and it maintains a temperature set point by balancing heat production with heat loss. We primarily produce heat by metabolic activity in the liver and muscle while heat is lost through the skin and lungs.
What is fever?
Fever occurs when our set point is raised above the current body temperature and is a homeostatic process. When the body is exposed to infectious organisms such as viruses and bacteria, a number of so-called pyrogens (another name for fever is pyrexia) are produced as part of the inflammatory response. These pyrogens can then act on the thermostat to raise the temperature set point by release of prostaglandin, primarily prostaglandin E2.
Now here comes the really fascinating stuff. Once the set point is raised, heat generating actions are taken by the body to raise core temperature to that new point and we enter the “chill” phase of fever. We increase cellular metabolism in a number of areas but the most dramatic response occurs in skeletal muscle. We conserve heat by constricting the blood vessels in our skin, decreasing the supply of warm blood to our extremities. In other words, we feel cold and we shiver. The evolved behavioral response should be obvious at this point. We grab the blankets and crank up the heat. All this happens before we actually have a measurable increase in our body temperature.
How high our body temperature goes with fever is limited by a number of factors, largely genetic or specific to the inciting infectious organism. But there is a negative feedback mechanism that involves production of cryogens which serves to keep things in check. When the illness resolves, or when antipyretic medications that target production of prostaglandins are given, the temperature set point returns to normal. This leads to the “flush” phase of fever. The blood vessels in our skin open up, bringing more warm blood to the surface to increase dissipation of heat via sweating, our cellular metabolism decreases, and we kick off the blankets. No more fever.
What is fever phobia?
When I take care of patients with fever I see a wide variety of parental reactions, ranging from reasonable concern to extreme worry, even terror occasionally. My personal experience is that the typical response is much closer to the latter. I always make a point to ask parents what they are worried about and I get a range of responses, from continued discomfort to brain damage to death. Again, anecdotal experience has led me to believe that folks are far more worried about fictional serious complications of fever than mere fussiness or malaise. At the core of these concerns is the misconception that the elevation in temperature represents a potentially dangerous disease in and of itself rather than a relatively benign symptom resulting from an infectious process. This is fever phobia and it has the potential for serious, even deadly, repercussions.
The number of blatant misconceptions regarding childhood fever is truly staggering. Since the 1980’s, when Barton Schmitt published the seminal paper on the subject of fever phobia in the American Journal of Diseases of Children, there have been several additional studies confirming and cataloging the causative factors and potentially dangerous resulting behaviors. These studies have shown that fever phobia exists in both parents and pediatric medical professionals.
Schmitt found that 94% of parents thought that fever could cause harmful side effects. It can’t, except very rarely in extremely critically ill children secondary to the increased metabolic demand. 63% of parents were very worried about serious direct harm from fever with 18% believing that brain damage could occur with temperatures less than 102 degrees. 16% believed that temperatures could rise to 110 to 120 degrees if untreated. Fever does not cause brain damage, hearing loss, blindness, etc. And it cannot rise above the rare 107 degrees (remember those cryogens?). Even then it does not directly harm the body. I imagine that one would feel pretty miserable however.
But that was in 1980. Things have changed, right? Not really. A 2001 paper revisiting fever phobia published in Pediatrics revealed that 91% of caregivers thought fever could cause harmful side effects including seizure (32%), brain damage (21%) and death (14%). Coma and blindness also made the list. With the exception of febrile seizures, a common and benign entity seen only in young children, fever just doesn’t do these things.
More than half of caregivers were very worried about significant harm with many worried even about temperatures less than 100 degrees. That isn’t considered a fever by pediatricians. More than half of caregivers checked temperature every hour (or more frequently!) during illness. My memory fails me, but I imagine two dozen rectal temperatures in a day is uncomfortable, and they certainly can cause injury. Taking the temperature of an older child may not require a rectal thermometer, but it is excessive, and children need sleep. But 85% of caregivers would wake sleeping children to give antipyretics (please don’t do that). A quarter of caregivers gave antipyretics for temperatures not considered a fever. Many children with temperatures of even 101 or 102 degrees aren’t symptomatic.
Here is where it gets dangerous. More than half of caregivers dosed antipyretic medications too frequently. Many studies done since 2001 have confirmed that parents frequently dose antipyretics incorrectly, putting their children at risk for serious liver and kidney injury. Unwarranted fear of fever leads to unnecessary medications, and if a dose that is too high is given too frequently, well, you get the picture. Nearly three quarters of caregivers admitted to the use of sponging to reduce fever, a practice which is ineffective even when done in a safe way. Two thirds of these caregivers however sponged incorrectly, using cool or cold water, or even rubbing alcohol. The former can causes discomfort and impede the ability to dissipate heat by constricting skin blood vessels, and the latter can cause toxicity and death.
Whose fault is fever phobia?
Parental fever phobia, which exists across socioeconomic classes, is strongly reinforced by the actions of pediatric medical professionals who are widely considered to be primary resources on the subject. Fever is often the first symptom we ask about and the first vital sign we check. We emphasize that our lab and imaging investigations are necessary because of the elevated temperature. We tend to treat any and all fever with antipyretics like acetaminophen and ibuprofen. Fever also plays a large role in discharge instructions from emergency departments and inpatient facilities, which commonly contain warnings to call or return if fever develops or persists.
Yet we often give incomplete, inconsistent and even incorrect information. That is when we actually give any information at all. In the early 1990’s, May and Bauchner looked into the role pediatricians play in fostering the development of fever phobia. They performed a survey of pediatricians in Massachusetts which found that 10% almost never discussed the definition of fever, 25% almost never discussed the effects of fever and 15% almost never discussed the cause of fever.
The survey revealed incongruence between the education of families and the practice of pediatricians. Pediatricians for the most part agreed that parents should not wake a sleeping child to check temperature or give antipyretics, but the majority advocated treating low and likely asymptomatic temperatures. These mixed messages remain in existence today. But it gets worse. In the same survey, May and Bauchner found 65% of pediatricians believed that fever could be dangerous with 21% listing brain damage as a potential complication. Just over a quarter of them listed death as a possible result of the fever itself, not the disease actually causing the fever.
In 2000, Mayoral et all published survey results in Pediatrics revealing that nearly a decade later pediatricians still commonly held false beliefs about fever and its management. 50% of the respondents recommended alternating antipyretics for instance. This generally mean giving acetaminophen and ibuprofen three hours apart, typically scheduling them until the child has recovered from the illness in order to prevent fever rather than just using them as fever occurs. Nearly a third of the pediatricians in the survey cited a nonexistent policy of the American Academy of Pediatrics as support of the practice. The AAP actually strongly recommends against such an approach to fever as it has not been shown to be more effective and it increases the likelihood of dosing errors.
Pediatricians tend to only discuss fever when children are sick, and when they do discuss it at well-child visits it usually involves warnings of when to seek medical care without education on the many commonly held false beliefs. Our emphasis of fever without accurately explaining what fever is leaves parents anxious and forces them to rely on alternative sources of information, such as the internet, which I’m told pretty much allows anybody to publish just about anything.
According to The Baby Adjustors,
If you child has a fever and acts abnormally, call your family chiropractor. Your child may be suffering from a spinal subluxation. This condition interferes with normal body function and can cause many childhood symptoms, including a fever.
Or your child may have meningitis that can progress to death in a matter of hours but that is just my Western medical bias. They don’t even explain what “acts abnormally” means. If your kid has a fever and is a Saints fan, he may have a subluxation. But this isn’t about how painfully bad and dangerous irregular medical advice can be, it is about how painfully bad and even sometimes dangerous real medical advice can be and how it can lead to parents and other caregivers treating benign childhood fever as a medical emergency.
Some have described fever as our friend. There is merit to the idea that fever has a beneficial purpose but it remains somewhat controversial. Elevating our core body temperature in response to infection is a primitive and almost universal response, seen even in cold-blooded species. Lizards have been observed staying in the sun longer and fish seeking out warmer water when ill for example. This implies at least that there is some degree of survival advantage in being able to develop a fever.
Some bacteria and viruses do grow poorly when exposed to higher temperatures. Iron is required for growth by many pathogenic bacteria, and it appears that fever decreases availability of it in the blood. Test tube studies have shown that elevated temperatures may increase the activity of various components of the immune system. There are a few non-primate experiments, particularly in rats and rabbits, that have shown improved outcomes with fever and even some human studies showing prolonged symptoms when fever is treated aggressively.
But everything seems to increase the activity of various components of the immune system in test tubes, and those studies were small and difficult to extrapolate to all humans or to all specific fever causing infections. Plus there is also data showing that the immune system may actually become impaired during high fevers above 104-105 degrees. And there is also evidence in animals and human patients that raises concerns of poorer outcomes from some illnesses, particularly in critically ill patients, with very high fever. It is a mixed picture essentially and the jury is still out. Regardless, any benefit of fever is likely so minimal that it would not preclude treatment of a miserable toddler with a temperature of 102.
Does this all mean that fever shouldn’t be taken seriously? Of course it doesn’t. In certain patient populations, fever requires immediate intervention. Very young or unimmunized children are at high risk for severe infections of the blood and brain. Febrile neonates and immune compromised patients, such as in Sickle Cell disease for just one of many examples, require laboratory investigation and even empiric antibiotic coverage even if they are completely well appearing. Prolonged and unexplained fever that lasts longer than a week, also justifies a work up. Fever is simply a clue, sometimes the only clue, that there is an infection going on. Thankfully in the vast majority of children, and I mean the vast majority, the infection is self-limited and viral.
Most pediatricians, emergency room doctors, nurse practitioners, and other medical professionals that care for children are well meaning folks who practice good medicine most of the time. But we are human and we are vulnerable to all of the weaknesses inherent in being human. Why are we so afraid of fever? Perhaps because of the biases, logical fallacies, and intellectual stumbling blocks that plague us all to varying degrees, particularly during such complicated endeavors as the practice of medicine. Or is it that we are simply parroting behaviors learned during impressionable years as medical learners.
Old habits are infamously hard to break in medicine. There will always be a subjective component to what I do, an art to the practice of medicine. But the science of medicine, preferably bolstered by the acquisition of good critical thinking skills, is necessary to recover from or avoid problems like fever phobia.

Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Umbilical Cord Blood Banking
Clay Jones on October 11, 2013
Link
For those who can’t get enough of Clay Jones, he is now available in multimedia through the magic of podcasts! Dr. Jones was interviewed for The Prism blog last Monday, discussing the general topic of alternative medicine and pediatrics, followed by a dive into fluoride and cavities in kids. It is available for your listening pleasure at their website or on iTunes. Next step, a semi-hostile takeover of Mark Crislip’s multimedia empire – Ed
A family has many choices to make as the arrival of a new baby approaches. What will they name their child? Will they breast or bottle feed? Should they use cloth of disposable diapers? What about circumcision? Will they vaccinate or not? Some of these choices are relatively minor while some may significantly impact the health of their child for years to come. A fairly recent addition to the long list of choices that parents are burdened with, thanks to a push from reputable organizations like the American Academy of Pediatrics, as well as private companies looking to turn a profit, is what to do with the blood in their newborn infant’s umbilical cord.
Currently the most commonly-chosen option remains to simply leave it in there. In that case, it will be discarded along with the mother’s placenta or even occasionally eaten although that is a topic for another post perhaps. Another option is to have blood from the umbilical cord donated to a public cord blood bank. These have been popping up all over the place and public banking is currently recommended by the AAP whenever possible. The final option, which is by far the most controversial (and expensive), is paying to have the umbilical cord blood banked privately for personal use by the donating child or a family member. As I will explain, while not entirely without potential benefit, the private banking of cord blood is probably not a good idea and the thousands of dollars that it costs might be better spent elsewhere. Unfortunately, because of the fear of making a wrong choice, many parents are vulnerable to being persuaded by the calculated misinformation produced by these companies.
Why umbilical cord blood?
There is a very good reason why the question of banking umbilical cord blood is such an important one. The use of cord blood, or more accurately the multipotent (possibly pluripotent) hematopoietic stem cells which are present within cord blood, is a modern medical advance that has greatly improved outcomes in a subset of very ill patients. These are patients with a variety of life threatening conditions including cancers and other diseases of the blood, genetic disorders and inborn errors of metabolism.
At times, either because of a side effect of treatment or the purposeful intent of it, a patient’s own bone marrow is wiped out and must be replaced with stem cells in order to regain function – the function in question being the patient’s immune system and ability to produce red blood cells and platelets. This is known as a hematopoietic stem cell transplant (HSCT) or perhaps still more commonly, a bone marrow transplant. These stem cells can come from either the patient themselves, if harvested prior to the initiation of therapy, or from a donor. Whether their own (autologous) stem cells, or from a relative or unrelated donor (allogenic), historically stem cells were harvested from bone marrow or peripheral blood. The use of cord blood stem cells has, in more recent years, added a third option that is better in some instances and less helpful in others.
HSCT is very risky, with mortality rates as high as 10%, and many more patients must live with chronic side effects after the procedure. Life threatening infections and debilitating breakdown of a patient’s mucous membranes are probably the two most well-known examples of possible morbidity, but severe liver disease, complications from bleeding and graft-versus-host disease (GVHD) are also common. GVHD occurs when the patient’s new immune system targets a variety of tissues in the body. It can be quite severe and it can become chronic. There is even the increased risk of other cancers down the road. With this in mind, HSCT is only attempted after a thorough assessment of the risks and benefits and it is never something that is taken lightly by those who provide care for these patients.
During our training, every pediatric resident quickly learns a healthy respect for HSCT on their first Heme/Onc rotation. The patients are challenging to say the least, and we’ve all seen kids saved from their cancer only to suffer greatly from the side effects of the cure. Any advancement that might lead to an improvement in outcomes is celebrated, and the use of cord blood stem cells is one of those advances.
What are the benefits of HSCT with cord blood?
We know that the likelihood that transplanted stem cells will take hold and begin producing progenitors, a process called engraftment, and the ultimate survival rates of patients undergoing HSCT, are better when donor and patient are genetically matched. This is easier said than done unfortunately, particularly in the case of patients that aren’t of northern European descent. Avoiding the issue altogether by simply using the patient’s own stem cells is preferred when possible, but there are many instances where it isn’t a good idea, such as when the disease being treated involves that patient’s bone marrow.
Full siblings are a great option when available, but each has only a 25% chance of being a full match. Next on the list of preference would be an unrelated but fully-matched donor. There is a national registry of altruistic potential donors but the process takes time and often there isn’t an available match. Many patients have died while going through this system. Use of a mismatched donor is done, but it is considerably more risky with much higher rates of morbidity, in particular GVHD, and mortality. This is where cord blood has come into play.
The potential benefits of using cord blood are impressive, and these days there are almost always available units for children who need it. First off, it is available relatively quickly because testing for safety and genetics has already been done. There is no need for the preparatory regimens required for harvesting peripheral blood from a donor, which does have risk, or even the painful procedure of obtaining stem cells from a donor’s bone marrow. In fact, there is no risk to baby or mother with procurement of cord blood at the time of birth.
Cord blood transplant is also considerably less likely to transmit any blood-borne infection. There is also the well-established benefit of less risk of GVHD compared to equally mismatched bone marrow or peripheral blood stem cells from a donor. The donor pool of cord blood is also much more easily expanded, and in fact there already is greater coverage of ethnic minorities in public cord blood banks than on bone marrow donor registries. It does not require any commitment from potential donors and there is no donor attrition. Most importantly, survival is better and morbidity less when compared to HSCT using equally mismatched bone marrow or peripheral blood stem cells in some conditions.
Is cord blood too good to be true?
The benefits of the appropriate use of cord blood as a source of stem cells for HSCT are rock solid, but there are downsides. Unfortunately, the risk of engraftment failure is higher with cord blood stem cells, and it can take longer for the new immune system to function. This allows more time for serious infection to occur. Cord blood is also limited by how much is available. There is a finite amount from any one donor, and often one aliquot, typically around 50ml of cord blood, is not enough for HSCT in larger children and adults. This issue has recently begun to be dealt with by using units from multiple donors, and the data is good so far. There are also certain indications for HSCT where use of cord blood stem cells may be less desirable because the patient’s new immune system might be less likely to attack any residual cancer (graft-versus-tumor-effect) and increase the chance of relapse.
Private vs. public banking
There are two ways for cord blood to be stored for potential future use. Parents can donate their child’s cord blood to a public bank or privately store it for use by that child or a family member. There is some overlap because public banks will often do directed cord blood banking for expecting families who have another child with a condition potentially treatable with HSCT. Private banks will also often provide this particular service free of charge, a practice which in my opinion is more for marketing purposes than out of the kindness of their hearts. I’ll explain why soon.
Public banking involves the collection and storage of cord blood units which are then entered into public databases and made available for anyone. Though in the past they were few in number, making availability a limiting factor, now they are fairly widespread. Also cord blood can now be shipped to central locations, opening up most of the country to public banking. They are typically non-profit. Private banks are for-profit businesses that collect and store cord blood units for possible future use by the donating child or a family member. Costs average about $3,000 to $3,500.
Since cord blood stem cells have such a potential for improving outcomes, it is easy to see why parents would be interested in private banking. They may believe that they are taking out biological insurance for their child. They might feel that the peace of mind afforded by private banking is worth the high price. Unfortunately, they are often misled by shady marketing techniques and blatant misinformation.
What is wrong with private banking?
So why does the AAP discourage private banking for future use? Why does the American College of Obstetricians and Gynecologists warn its members to provide “balanced and accurate” information on the subject to avoid misleading emotionally vulnerable parents? Essentially because the likelihood of a patient ever using a privately banked unit of their own cord blood is extremely remote, it is very expensive and there is a lot of bad information out there. There is a greater likelihood, although still quite small, that a unit of privately banked cord blood will be used for a family member, typically a sibling. These make up the majority of private bank success stories, but this is a service also frequently provided by public banks for free. Overall, the chance of a physician calling up a private bank for a child is somewhere around 1 out of 2,700.
There are limitations of using personal cord blood. There is only evidence to support its potential use for specific genetic, hematologic and oncologic conditions. There is insufficient evidence to support claims that privately stored cord blood will one day be used to cure diabetes, heart disease, or autism for just a few examples of what is often included in the marketing hype. The AAP and other organizations, such as the National Cord Blood Program, specifically speak out against speculation on future uses and against banking for “biological insurance.”
Private cord blood bank marketing
It’s hard to know where to begin when discussing the marketing schemes of private cord blood banks. There are just so many examples of fear mongering, use of deceptive testimonials, exaggerating the likelihood of ever needing to retrieve the donated unit, and much more. There are several large private banks, but I will focus on Cord Blood Registry (Cbr) because it is the biggest.
I first became aware of the shady practices of Cbr while my wife was pregnant with our second child. I was sitting in her obstetrician’s waiting room and picked up what appeared to be a generic parenting magazine. It was full of the standard boilerplate on how to prepare for a new arrival, but I found it odd that there were four separate references to private cord blood banking in the content, and a full page ad for Cbr. One such reference came in the form of a “top ten things for every expecting family to check off their list”. On the list was private cord blood banking. There was also an article promoting private banking by Dr. Robert Sears, a fellow pediatrician who I had not yet lost all respect for back in 2008. Sears is a medical consultant for Cbr by the way.
After discovering the outside back page to be a full-page ad for Cbr, I scoured the magazine and finally discovered in the fine print that Cbr had also published the magazine. The entire thing was nothing but an advertisement. I didn’t know that much about private banking at the time, but that experience inspired me to investigate further. Here are a few examples of their deceptive marketing techniques:
1. Testimonials, celebrity endorsements and arguments from authorityThe Cbr website and print media contain many testimonials about successful use of cord blood stem cells, complete with videos of grateful families relating their tragic story and subsequent happy ending thanks to Cbr. They use quotes from physicians and researchers, even from a celebrity physician:
My patients and their families mean the world to me and I want to make sure they have the best treatment possible. Saving cord blood is something every expectant family should know about and consider because the potential therapeutic uses continue to expand. Research in the use of cord blood is very important and cannot continue if parents do not consider banking.
– Dr. Jennifer Arnold, neonatologist, member of the American Academy of Pediatrics and star of TLC’s The Little Couple.
Notice she didn’t say anything about private banking being a benefit, or that personal use of cord blood is likely to be recommended. It is true that parents need to consider banking, but in a public program. This is their angle with these quotes though. Almost all of these quotes apply just as well if not better to HSCT with allogenic cord blood obtained from a public bank, which costs a family nothing and is almost always an available option. Here is another example:
I strongly recommend that all expectant parents ask their doctor about the lifesaving potential of cord blood… Today, cord blood is being used to treat such life-threatening diseases as leukemia and other cancers, as well as certain blood and immune disorders that formerly necessitated a bone marrow transplant.
– Dr. Marianne Neifert, Pediatrician, Baby Talk Magazine, October 1997
Again, this actually supports public banking even more so than private and certainly doesn’t support autologous transplant with cord blood stem cells, which would not be used for cancers of the blood or immune disorders. One more:
Recipients of cord-blood transplants from HLA-identical siblings have a lower incidence rate of acute and chronic GVHD than recipients of bone marrow transplants from HLA-identical siblings.
– Drs. Vanderson Rocha, John E. Wagner, Jr., Eliane Gluckman, et. al. New England Journal of Medicine, June 22, 2000
Yes, this is true. And this is a service that is regularly provided by public cord blood banks, for free. Private banks also don’t tend to charge for storing the cord blood of siblings of a child with a potentially transplant treatable condition, but they do so because they really really need to be able to use them for marketing. If not for the use of sibling cord blood, they would almost never use any of their stored units.
2. Speculation in order to prey on parental fear of making a bad decisionThe folks at Cbr love to speculate about the future benefits of stem cells. Don’t we all. But it is inappropriate to use this speculation to take advantage of a vulnerable population. They also frequently discuss the future potential of stem cells in general, leaving the parent to assume that the benefit would only apply to cord blood derived stem cells. If we are talking about benefits decades down the line, who is to say that we won’t be able to simply use peripheral stem cells or make those harvested from skin pluripotent. Here are two examples:
Just like we didn’t envision the powers of PCs thirty years ago, we may not be seeing all the uses of cord blood yet.
– Dr. LeeAnn Jensen, Immunologist, National Institutes of Health
A really exciting area that’s just now in the basic science lab, is the area where stem cells…can be used for going over to muscle cells like your heart muscle if you had a heart attack…or brain cells if you had Parkinson’s Disease…Hopefully, in 20 or 30 or 40 years…these might be potential applications for stem cells including umbilical cord blood stem cells.
– Dr. Stanton Goldman, Pediatric Hematologist Oncologist and stem cell transplant physician, Medical City, Dallas, Texas
3. Using unpublished ongoing clinical trials and experimental treatments as marketingThis video from the Cbr website involves an infant who had injury to her brain following removal of a brain tumor. In addition to intensive therapy, she received an infusion of her own cord blood stem cells. She improved and her mother is now pleading for more parents to take out biological insurance like you would have dental insurance. There is even a disclaimer that the results were not published and may be simply due to her other interventions. There are many more like this.
Also on the website are links to a number of clinical trials that are ongoing and involve the infusion of autologous cord blood stem cells. In this example, the trial is looking at the possible benefit of cord blood stem cells on language in children with autism. There is no guarantee that any of these trials will pan out. In fact, they almost certainly won’t. It is shameful to use this as a marketing ploy to scare parents into buying a service like this.
4. Exaggerating the need and ignoring the limitationsCbr and the other private banks claim that cord blood stem cells will still be viable even decades later, and this is likely true. What they conveniently leave out is the fact that once a child is over about 50 kg, the amount of stem cells in their privately banked unit would likely be insufficient. In adults, this is dealt with by batching multiple units of donor cord blood. If they are banking on future advances in technology, then why not just figure that cord blood stem cells will be obsolete in 50 years anyway? I don’t see the difference.
The evidence to date shows that the chance of an individual one day benefiting from HSCT using cord blood stem cells is about 1 out of 2,700. But Cbr and the other private banks state the following: “1 in 217 – for an individual (by age 70), using his or her own stem cells or someone else’s”. Even if true, the majority would not require privately banked cord blood. But this claim, which comes from a 2008 publication in Biology of Blood and Marrow Transplantation is highly speculative. The authors admit that many assumptions were made to come up with their final results. It is almost certainly overestimating the likelihood.
5. Bait and switchCbr and its ilk frequently point out the many conditions that doctors have attempted to treat with HSCT. Naturally they include references to how cord blood stem cells may lead to improved outcomes for some of these conditions compared to bone marrow or peripheral blood derived stem cells. What they frequently omit is the fact that most of these conditions would never be treated with a child’s own hematopioetic stem cells because that is where the disease process originated from in the first place. HSCT transplant would only be performed using donor stem cells. A good example is none other than acute lymphocytic leukemia, the most common cancer in childhood.
What do pediatricians have to say about cord blood banking?
The stance of the AAP is reasonable and based on good evidence, but it doesn’t do much good if the pediatricians practicing on the front lines aren’t aware of it. So what is the state of understanding of cord blood banking among pediatricians? Periodically the AAP surveys its members to answer such questions. One such survey, in this case examining counseling practices and attitudes regarding cord blood banking, was initiated by the AAP Section on Hematology/Oncology and ran from October 2007 to March 2008.
Just over 1,100 pediatricians responded, and this was whittled down to the 700 that actually provide health supervision. The results were discouraging. Most of the respondents weren’t familiar with the AAP statement, with more than half being completely unaware of its existence or only vaguely familiar. Only 4% claimed to have a good working knowledge of the AAP’s stance on cord blood banking.
Most pediatricians weren’t aware of the options for cord blood banking in their area of practice. Not surprisingly, cord blood banking does not appear to be something that is commonly discussed with expectant mothers, and it is almost always brought up by the parents rather than the physician. Equally unsurprising is that almost a third of pediatricians reported that they were aware of parents in their practice being solicited by private cord blood banking companies.
Pediatricians likely do not discuss cord blood banking with families for a variety of reasons. Almost all practicing pediatricians do see expectant mothers (84% of survey respondents), so it isn’t because of a lack of opportunity. Many simply aren’t comfortable bringing it up. Six out of ten respondents reported that they lack confidence in their ability to discuss the science behind cord blood banking. Only 18% reported that they think they have a good understanding and are comfortable talking about it.
Conclusion
Stem cells derived from cord blood collected at the time of birth are a wonderful addition to science-based treatment of a variety of life threatening conditions, including some of the most common causes of cancer in children. The benefits of their use are substantial, but they are far from perfect. Just what to do with a child’s cord blood is controversial, but it shouldn’t be. Public cord blood banking is increasingly available and is recommended by the majority of experts because it helps make sure that a match is always available for every child who would benefit from cord blood-derived stem cells.
The chance that privately-banked cord blood will ever be used by the donating child is extremely small. And both public and private systems allow for free storage of cord blood when there is a family member with a condition that might require stem cell transplant. If you have the money, it isn’t wrong to use a private bank, just don’t believe the marketing hype put out by private cord blood banks. Pediatricians should serve as a source of unbiased information but unfortunately it seems that most have not kept up to date with this issue.

Separating Fact from Fiction in the Not-So-Normal Newborn Nursery: Undescended Testes in Babies
There is a safe and effective science-based approach to the undescended testicle in newborns. This hasn’t stopped some from proposing alternatives that are neither.
Clay Jones on April 21, 2017
Link

A missing testicle is a fairly common finding when examining newborn infants, particularly when they are born prematurely. We commonly refer to this finding as cryptorchidism, although by strict definition that term specifically applies to testes that haven’t fully completed their epic journey into the scrotum by 4 months of age. Cryptorchidism, which is also diagnosed initially when one or both testes is absent, is the most common congenital abnormal finding related to the male genitourinary tract.
Most cases of cryptorchidism involve undescended but healthy testes. As mentioned above, sometimes one or both of the testicles are missing, or shriveled and useless, because of vascular compromise that occurred at some point prior to delivery. Testicles that have descended, but are prone to retracting out of the scrotum, are called retractile testes and while the phenomenon usually resolves over time they are at increased risk of evolving into a true undescended state. Rarely testes descend but do not end up in a normal anatomical position, settling in surrounding tissue such as the superficial inguinal pouch or suprapubic region.
But the vast majority of the time, when I am unable to palpate a testicle during a newborn or early infant exam, it is because it simply hasn’t yet descended, even when asked politely.
Epidemiology, risk factors, and causes of cryptorchidism
As many as five of every 100 term newborn male infants will have an undescended testicle, and it occurs in 30% of premature infants. One out of ten cases will affect both testes. Most of these children will experience spontaneous descent in early infancy, but by a year of age roughly 1% will have yet to resolve.
There are some notable potential risk factors for cryptorchidism. Generally, we tend to see it more commonly in premature and/or low birth weight babies. There have also been proposed genetic and environmental factors at play, including exposure to endocrine disruptors in pesticides and maternal medications/conditions that interfere with normal fetal hormone levels. At almost 10%, the condition appears to be significantly more common in Denmark, the land of babies that maybe perhaps don’t cry as much as some other babies, compared to the rest of the world.
As to why some testes are unusually shy, nobody really knows. We know a lot about how normal descent occurs but it isn’t clear which step or steps go wrong when it doesn’t. Each testicle starts out in the abdomen and migrates downward, reaching the inguinal canal early in the 3rd trimester. Normal descent is regulated by androgen hormone levels and a complicated interplay of neurotransmitters and numerous other chemical factors as well as mechanical changes in abdominal pressure and the opening up of a pathway into the scrotum. Essentially, developmental changes are probably key which is why abnormal descent is more common in premature infants.
Why do we care about undescended testes?
First off, the presence of a hidden testis or testes can be a clue that something more sinister is going on, in particular when there is a finding of bilateral non-palpable testes. Although usually it is the only abnormality on exam, there are associations with various other disorders and genetic syndromes, including disorders of sexual development. So a thorough evaluation of the entire infant is always in order, although that is true regardless of how many of their boys are home.
In the case of true undescended testes, as opposed to absent or retractile testes, there are many possible future complications. This can include an increased risk of developing a hernia through the inguinal canal, loss of the testicle because of vascular compromise (testicular torsion), and trauma from compression of the testicle against the pubic bone. Fertility can also be impaired, and there is even an increased risk of testicular cancer.
Pediatricians and family doctors caring for newborns will generally require the expertise of specialists, such as an endocrinologist or even a multidisciplinary team whenever there is concern for a disorder of sexual development or the possibility of a life-threatening condition. In most cases, however, only one testicle is involved and the rest of the evaluation is normal. These children can be referred to a pediatric urologist or surgeon at 4-6 months of age.
Why a surgeon?
While most cases of cryptorchidism will not require the services of a specialist or pediatric surgeon, after 6 months of age it is very unlikely to resolve without intervention. Treatment before a year of age will prevent some of the associated complications (hernia, trauma, vascular injury) and may reduce the risk of others (subfertility). Unfortunately, while the increased risk of malignancy of the testicle can be reduced with appropriate management prior to puberty, it cannot be removed entirely and there is even a small increased risk in the testicle that descended normally.
The only proven management of a true undescended testicle is surgery. During the procedure, known as orchiopexy, viability of the testicle is determined and, if warranted, it is fixed in the normal anatomical position in the scrotum. The best timing for correction is as early as possible after 4-6 months of age and ideally before the child’s first birthday. Spontaneous descent can occur, but it is rare after six months and early correction can improve testicular growth and function.
Historically, hormonal therapy has been recommended in an effort to induce descent into the scrotum. There is some evidence of a small increased chance of descent, but this was primarily seen when the testes were already close to the scrotum and may be a result of inappropriately labeling retractile testes as undescended. And with hormonal therapy, we don’t have long term data on complications such as fertility and malignancy. It is not recommended by the American Urological Association, however it is still sometimes attempted, particularly outside of the United States.
Are there alternative approaches to the science-based management of cryptorchidism?
I am usually inspired to write these posts after I encounter a particular diagnosis while rounding on my patients. Invariably as I sit at the computer to refresh my knowledge of a diagnosis or to access the most current treatment recommendations, I become curious how the world of so-called alternative medicine might addresses these specific medical problems. My searches rarely come up empty. The topic of undescended testes was no exception.
I thought that I would have a little fun with this post, however. I will briefly present four alternative medical management options for congenital cryptorchidism, but one of them will be completely fictional. And by fictional I mean made up by me rather than someone else. The others will be based on actual information available online for worried caregivers to stumble on and potentially take as a serious option to pursue. See if you can tell the difference!
     1.  Abnormal descent of one or both testicles can occur due to misalignment of the pelvic complex. Applied kinesiology is helpful in making this diagnosis in a young child. Having the parent hold the child allows for a melding of the energy fields and the ability to uncover abnormalities in a child through standard muscle testing of the caregiver. One such case was presented in 2003 at a meeting of the International College of Applied Kinesiology-USA. An infant was found to have a bilateral sacroiliac sprain/strain, causing subluxations in cervical and thoracic spinal segments in a pattern commonly associated with this type of pelvic lesion. Gentle correction was performed after entrainment of the caregiver and child’s breathing patterns was allowed to develop because the straighter spinal curve during inspiration allows for easier adjustment of the subluxation. After repeat adjustment one week later, there was resolution of the right undescended testicle which remained in the scrotum 4 years later.
     2.  Homeopathy can be a great help for children of all ages with undescended testicles, stimulating the body to remedy the condition and helping to avoid surgery. Concerned parents can give Thyroidinum 30c. Sometimes just one dose is all it takes. If this doesn’t work, the following algorithm may prove useful: If the left testicle is undescended, but not the right, Clematis 6c should be given twice daily. If neither has descended and the boy is puny for his age, give Aurum 30c twice daily. If there is no improvement after 2 months, consult your family homeopath for a full constitutional review and start daily neck exercises to stimulate the thyroid gland.
     3.  Failure of the testicle to descend occurs because of an interruption in the natural developmental process, so the Eight Extraordinary Channels can be used for treatment. The Ren and Du channels are the most relevant because they originate from the groin and govern sexual development. The Liver and Gall Bladder Channels can also be used to move qi to the groin. Instead of needles, microcurrent stimulation and qigong applied by touching the chosen points can assist in moving qi to the desired areas.
     4.  There is a cosmic connection between mother and child that exists on both physical and quantum planes. Each plane has conduits to the other and each acts upon both their own influences as well as reciprocal entities. While our ability to communicate with an infant with undescended testicles is limited by physical reality, it is not bound by any such constraints at the quantum level of consciousness. Forging a physical connection, such as occurs when a mother places her naked infant against her bare chest or abdomen, allows for communication through surrogate guided imagery techniques that tap into the cosmic consciousness. The mother can be assisted in forming a mental construct to represent her child’s testicle and visualizing its descent through the inguinal canal and into its scrotal home. This process can be repeated in the case of bilateral undescended testicles but a different mental construct should be conjured so as to not confuse the original testicle.
Conclusion: A tough nut to crack?
Congenital undescended testes are common in newborns. We may not have a complete understanding of why they occur, but there is a science-based approach to their management that is safe and prevents or reduces the known complications. There are no legitimate alternative options to true undescended testes, although there may be some anecdotal reports of success because of a misunderstanding of the natural course of the condition. Or, more likely, because of an initial misdiagnosis.
See if you guessed which of the four alternative approaches was made up on the spot by me by clicking on the following links:
1. Chiropractic care for the undescended testicle
2. Homeopathic care for the undescended testicle. It’s a simple cure! Of note homeopathic Aurum metallicum, which is metallic gold diluted out of existence, is also good for depression, qualmishness, and violent erections.
3. Acupuncture for the undescended testicle.
4. Surrogate visualization for the undescended testicle.

Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Pacifiers and Nipple Confusion
Clay Jones on September 27, 2013
Link

My first “real world” employment after completing residency was as a full-time newborn hospitalist in Houston. After spending three years in Space City, often rounding on as many as 30 newborn infants in the Level 1 and Level 2 units each day at the county hospital, I feel as if I’ve probably about seen it all when it comes to the nursery. I then left the babies behind while working as a pediatric hospitalist in Baton Rouge for four years, but now I’m back in the newborn business up here in Boston. While there have certainly been a few changes since 2009, many things remain exactly the same.
I help take care of a very vulnerable population in my current position: parents. Parents, in particular the young and first time variety, often approach parenting with a blank slate. Sure there is frequently a grandparent or four there for assistance, but the healthcare professionals working in the nursery are looked to for vital knowledge about how to care for the new arrival. Even some of the more experienced parents will still have questions, and most respect and follow the advice given during those first few days while at the hospital. These questions most commonly focus on topics such as feeding, vaccinations and vitamin supplementation, but I am regularly asked about a variety of routine parenting skills such as swaddling, and even baby “gear” like Angel monitors.
Parents love their children and want what is best for them, and they frequently express fear and anxiety over some of these topics. Love and fear are two powerful factors in the acceptance of pseudoscience and bad advice, which is why parents are set up to be fooled. Over the next few posts, I plan to cover some examples of newborn issues known to cause excessive parental anxiety and that sometimes lead to poor decisions, in large part because of bad information received from people who should know better.
First up is a concept that is well-known in the nursery, and strikes fear in the hearts of lactation consultants all over the world. I’m talking about nipple confusion. This is a concept that may seem silly to those unfamiliar with the world of parenting, but it is something that newborn doctors deal with daily and there is a great deal of controversy. Not “vaccines and autism” controversy unfortunately, but if after reading this post you find yourself feeling let down because I didn’t start with something sexier, take solace in the fact that winter is coming.
What is nipple confusion?
If you don’t know what nipple confusion is, don’t feel bad. Most people probably don’t. And many who think they understand the concept have fallen for what I believe is hype based on scant evidence. Beliefs regarding nipple confusion transfer from generation to generation propelled by misinformation and cultural momentum. And based on questionable recommendations from organizations like the WHO and the AAP, many healthcare professionals encourage these beliefs, which tend to be very firmly held. On many occasions I have witnessed intense arguments over the existence of nipple confusion and the degree of respect it deserves.
According to proponents, nipple confusion occurs when a breastfeeding newborn is given a bottle or pacifier. They believe that because the mechanics of sucking on bottle nipples and pacifiers are so different, it confuses the infant and causes them to pick up bad feeding habits. When they attempt to put these newly acquired skills to use on their mother’s breast it results in frustration, maternal pain, and premature cessation of breastfeeding.
La Leche League International, a group which (to put it nicely) strongly supports breastfeeding, has the following to say about nipple confusion:
Pacifier use in the early weeks may affect milk supply and lead to slow weight gain. It is important that nursing sessions are not delayed and that all sucking is done at the breast in order to establish a good milk supply.
Using a pacifier may also result in latch-on and sucking problems for the baby. This is because the shape of the pacifier is different from your soft breast and the baby may get confused as to how to suck. This may result in sore nipples for mom. In addition to sore nipples, introducing a “dummy” may lead to mastitis because baby is not sucking as much at the breast. Also, you may find your fertility returns more quickly if you use a pacifier as your hormonal balance is affected by less sucking at the breast.
There may also be an increased risk of ear infections for a baby if regularly sucking on a pacifier. Thrush can also be a problem, as it thrives on moist surfaces at room temperature. Not only can it cause thrush infection, but unless pacifiers are boiled each day for five minutes and replaced each week during an outbreak of thrush, the pacifier can cause reinfection, too.
Regular pacifier use has also been shown to affect the growth of teeth and the shape of the mouth, increasing the need for braces later on. Also, it can increase the levels of bacteria in the mouth that cause dental caries. Regular pacifier use is also associated with early weaning.
There is almost too much misinformation in that quote to deal with in one post, but I will do my best. Moving on.
The Sears family, a group of pediatricians who (to put it nicely) are easily confused by scientific evidence and prone to things like alternative vaccine schedules, bad advice about SIDS prevention and poorly produced daytime talk shows, agrees with the LLLI:
There are some basic mechanical differences between how a baby gets milk from a bottle and how a baby gets milk out of the breast. Giving bottles or pacifiers to young, breastfeeding babies often leads to nipple confusion. Baby tries to use the bottle-feeding technique on the breast and has difficulty latching-on and sucking. Baby gets very frustrated, and so does mother. Nipple confusion can even lead to baby refusing the breast.
Though not a new concern, the real fuss over nipple confusion started when the World Health Organization’s Division of Child Health and Development and UNICEF issued a joint statement on breastfeeding in 1989. The statement included the now famous (infamous perhaps depending on whether or not you work for Ross or Mead-Johnson) Ten Steps to Successful Breastfeeding. The following year WHO/UNICEF policymakers released the Innocenti Declaration, which called upon the governments of the world to adopt the Ten Steps in all hospitals providing maternity services. We now live in a society where the hospital’s pacifiers are sometimes locked in cabinets that require a special code, fingerprint analysis and retinal scan to open. Okay, maybe not the retinal scan.
What are the Ten Steps to Successful Breastfeeding?
The Steps are pretty straightforward and reasonable with the exception of number 9, which is the source of the nipple confusion controversy.
Every facility providing maternity services and care for newborn infants should:
1. Have a written breastfeeding policy that is routinely communicated to all health care staff.2. Train all health care staff in skills necessary to implement this policy.3. Inform all pregnant women about the benefits and management of breastfeeding.4. Help mothers initiate breastfeeding within a half-hour of birth.5. Show mothers how to breastfeed, and how to maintain lactation even if they should be separated from their infants.6. Give newborn infants no food or drink other than breast milk, unless medically indicated.7. Practice rooming-in — allow mothers and infants to remain together — 24 hours a day.8. Encourage breastfeeding on demand.9. Give no artificial teats or pacifiers (also called dummies or soothers) to breastfeeding infants.10. Foster the establishment of breastfeeding support groups and refer mothers to them on discharge from the hospital or clinic.
The American Academy of Pediatrics, in its 1997 policy statement on breastfeeding, did not mention the Ten Steps but made recommendations equivalent to number 6 and 9. In their reaffirmation of the policy in 2005, again there was no specific mention of the Steps. There was, thankfully, a somewhat more nuanced discussion of the use of pacifiers:
Pacifier use is best avoided during the initiation of breastfeeding and used only after breastfeeding is well established. In some infants early pacifier use may interfere with establishment of good breastfeeding practices, whereas in others it may indicate the presence of a breastfeeding problem that requires intervention. This recommendation does not contraindicate pacifier use for non-nutritive sucking and oral training of premature infants and other special care infants.
This change allowed some interpretation. A pediatric resident at the time, I felt that I could counsel families that pacifier use was okay if breastfeeding was going very well, even in the nursery. There was also a lot more data available at the time that questioned the concept of nipple confusion as an entity that should even be on our radar. Also that year, emerging evidence on the benefit of pacifier use for reduction of the risk of SIDS led to the AAP recommendation that they be used in all infants less than one year of age during sleep initiation.
The AAP officially endorsed the WHO/UNICEF statement and their Ten Steps in 2009, and reaffirmed their endorsement in 2011. Of note, the AAP does not fully accept the ninth step, as is made clear in the most current policy statement on breastfeeding:
The AAP does not support a categorical ban on pacifiers because of their role in SIDS risk reduction and their analgesic benefit during painful procedures when breastfeeding cannot provide the analgesia. Paciﬁer use in the hospital in the neonatal period should be limited to specific medical indications such as pain reduction and calming in a drug-exposed infant, for example. Mothers of healthy term breastfed infants should be instructed to delay pacifier use until breastfeeding is well-established, usually about 3 to 4 weeks after birth.
All of this has led to the current predicament when caring for newborn infants being exclusively breastfed. How do pediatricians and family doctors appropriately discuss the use of pacifiers with their parents? What does “well-established” even mean exactly? Can we support breastfeeding while also reducing the risk of SIDS? More to the point of this post, is the ninth step or even the more nuanced AAP stance even reasonable?
But before I delve into whether or not pacifiers actually impact breastfeeding success, first a quick discussion about why this discussion even matters. Breastfeeding is, hands down, one of the most beneficial actions a mother can take in raising a healthy child. If proponents of Step 9 are correct, and pacifier use can impair the ability of a young infant to establish breastfeeding, then this issue should be taken very seriously.
Why breastfeeding matters?
Infants fed human milk, and the mothers that feed them benefit from a wide variety of well-established health outcomes, even in developed countries. In many areas, there is benefit even with partial breastfeeding. Here are a few of the improved outcomes seen in breastfed infants and their mothers:
1. Significant reductions in the risk of lower respiratory infections and hospitalizations for lower respiratory infections during the first year of life.
2. Significant reduction in the incidence of gastrointestinal tract infections while being breastfed and up to 2 months after breastfeeding is stopped.
3. Significant reduction in the risk of necrotizing enterocolitis (trust me, it’s as bad as it sounds) in premature infants. One surgery or death prevented for every 8 premies being fed exclusively with human milk. This is a big reason why human milk banks are being established in many areas.
4. Significant reduction in the risk of SIDS (#1 cause of death from 1 to 12 months of life in the US) and infant mortality around the world.
5. Reduced risk of asthma, eczema, celiac disease (the real kind) and inflammatory bowel disease.
6. Breastfed infants are less likely to become obese children and adults.
7. Reduction in the risk of type 1 diabetes, childhood leukemia and lymphoma.
8. Improved neurodevelopmental outcomes in premature infants (best supported) and likely even term infants (probably not significant enough to matter in most healthy kids) even when accounting for social variables.
9. Mothers who breastfeed have less postpartum bleeding, less risk of postpartum depression, are less likely to abuse their children even after accounting for social variables and have lower risk of breast and ovarian cancer.
10. Lactational amenorrhea helps to prevent subsequent pregnancy while still breastfeeding.
And I didn’t even get into the economic benefits. One possible benefit that is probably more fiction than reality, however, is improved postpartum weight loss. If there even is a difference, it probably doesn’t manifest until breastfeeding has lasted longer than 9 months and the effect is probably minimal.
While the benefits of breastfeeding are huge, please to not misinterpret my support of the practice. I love and encourage breastfeeding but I do not endorse tactics to coerce uninterested mothers into doing it. There are few medical contraindications to breastfeeding, but many personal ones, and I support those mothers just as much. Despite the long list above, formula fed infants do very well. The one possible exception for me is when it comes to extremely premature infants. I consider breast milk as vital to their health as I would an antibiotic in a patient with meningitis. Mothers should be strongly encouraged to provide breast milk to the best of their ability, and they should be made aware of the potentially lifesaving benefits in this population of newborns. And I strongly support the development of more human milk banks so that human milk is available for premature infants whose mothers are unable or unwilling to provide it.
Now back to pacifiers!
Is nipple confusion real?
From a plausibility standpoint, I don’t think that nipple confusion makes a whole lot of sense. Though I am often the first to point out that newborn babies are helpless (thanks evolution), and would not survive long without significant intervention from caregivers, I must admit that they are actually quite good at what they can do. They can’t see much of anything, control their movements, or communicate their specific needs very well but healthy babies know how to suck. It is, in fact, a reflex action that they do not control. Sucking is a natural means of soothing a crying baby.
Put anything in an infant’s mouth and it will suck on it. I use this to my advantage during every newborn exam, placing my gloved pinky finger in the oral cavity, not just to assess this normal reflex or to check for a cleft palate but also to quiet them down so that I might check their little hummingbird hearts for murmurs. Newborns suck on their hands, their feet, blanket edges, and essentially whatever they can get into their mouths. It is actually quite common to find self-inflicted suction blisters on various body parts that were acquired prenatally. Somehow this does not alter the mechanics of their suck and lead to early cessation of breastfeeding, but even intermittent use of a pacifier is felt to do so.
In addition to the argument that pacifier use alters feeding mechanics, the claim is often made that choosing the pacifier instead of putting the baby to the breast will cause a delay in milk let down and increase the likelihood of breastfeeding cessation. There is some truth to this. It is a definite issue when it comes to bottle feeding, again not because of altered mechanics but because formula feeding leads to satiety.
The more that a baby feeds from the breast, the faster the milk will come in, and a baby full of formula will feed less from the breast. A pacifier will not appreciably space out breastfeeding because hungry babies will rarely be soothed by one. If anything, lack of a pacifier would seem to be more likely to encourage turning to formula in the nursery because many babies spend much of their 2nd day of life crying. The 2nd day is often the hardest because it is the time between the sleepy 1st day of life and mom’s milk coming in. A pacifier can help between feeding attempts, but formula works much better. But to be clear, a pacifier should not be used as a substitute for feeding a hungry baby.
In my opinion, any strict ban of pacifiers is unreasonable and even cruel considering how effective pacifiers are, particularly when combined with sucrose, in alleviating pain during procedures such as heel sticks, venipuncture and circumcision. Furthermore, I do not accept that use of pacifiers interferes with breastfeeding at all. It probably hurts breastfeeding efforts. So what does the evidence reveal?
When WHO/UNICEF handed down their Ten Steps in 1989, the evidence for Step 9 was very poor. The available studies were small and did not account for a variety of variables that might affect breastfeeding other than pacifier use. And according to their own 1998 paper discussing the evidence in support of The Ten Steps, while the evidence suggested that pacifiers may be to blame for breastfeeding difficulties, “their use may be a marker of the desire to stop breastfeeding early rather than a cause of discontinuation.” So are mothers neglecting breastfeeding in favor of the pacifier, or grabbing the pacifier because breastfeeding is going poorly for some other reason?
The WHO paper also outlines a number of other reasons why pacifiers are evil, which were also in that earlier statement from the LLLI on nipple confusion. These included concerns of tooth decay, dental malocclusion (misalignment of teeth), ear infections, thrush, toxic chemicals and choking. Most of these concerns are overblown by nipple confusion proponents.
Tooth decay is primarily an issue of propping a formula-filled bottle in the crib, but pacifiers can contribute somewhat to the development of caries. This can easily be avoided by not dipping a pacifier in honey or other sugary liquid. Also parents should avoid “spit cleaning” pacifiers, which can allow for the transfer of cavity causing bacteria and lead to caries. According to the American Academy of Pediatric Dentistry, concerns of malocclusion should not scare parents away from using the pacifier as a SIDS risk reduction strategy, stating that “Dental effects are generally reversible and unlikely to cause any long-term problems if the habit is discontinued by the age of 5.”
Children who use a pacifier are more likely to develop ear infections, but not by much and not typically during the first six months of life when the risk of SIDS is highest. There appears to be about a 1-2 fold increased risk in older infants and children. Pacifier-using infants are also more likely to be colonized with the species of yeast that causes thrush, although many children who don’t use them are as well, and colonization does not equal infection. Many exclusively breast fed infants develop thrush. It is not uncommon for the nipples and areolae of breastfeeding mothers to become infected as well and, like pacifiers, serve as a source of reinfection. Pacifiers can be cleaned and mom’s nipples can be treated. This should not deter pacifier use.
But what about the impact on breastfeeding? There have been a number of larger and better controlled studies that have come out in recent years, and they have not supported the concerns of nipple confusion advocates. A Cochrane review of pacifier use in breastfeeding term infants looked at the three best available studies through 2012 and found no detrimental effect up to four months of age. There isn’t enough good data to make a conclusion about longer term problems, but I would be very surprised if there were any. This more recent 2013 paper in Pediatrics looked at over 2,000 newborns both before and after pacifiers were literally put under lock and key in a hospital nursery. It raises serious concerns that restricting pacifier availability in the newborn period may even increase the likelihood that breastfeeding mothers will reach for formula. It appears that, as the old saying goes, correlation does not equal causation in this case and pacifiers may even be protective.
Conclusion: Do no fear pacifiers
Newborns may lack orientation to person, place, time and situation but they do not become confused simply because of having a pacifier placed in their mouth. Pacifiers are an effective means of soothing a crying infant and treating their pain during brief procedures, and they protect against SIDS. The evidence to date does not support concerns that pacifier use will interfere with breastfeeding and they may even help exhausted mothers say no to formula. Additional health concerns blamed on pacifiers are overblown and should not serve as a reason to miss out on the benefits of their use.
There is a lot of bad information out there that unfortunately will not be going away anytime soon, so I expect to continue to have to reassure parents that the pacifier is perfectly appropriate. Breastfeeding is a wonderful endeavor with myriad benefits to both mother and child, and it should be encouraged, but not with the use of propaganda and misinformation. Hopefully the American Academy of Pediatrics will take this new evidence into account when the time to reaffirm their breastfeeding policy comes around again in a few years.

Separating Fact From Fiction in the Not-So-Normal Newborn Nursery: Vitamin K Shots…..
Clay Jones on December 6, 2013
Link
In August, news emerged from Vanderbilt University that four cases of a rare bleeding condition seen in young infants had been diagnosed since February. Three of these infants suffered intracranial hemorrhages, requiring surgical intervention to evacuate the blood and save their lives, although there will almost certainly be neurological and developmental repercussions down the road. The fourth child presented with gastrointestinal bleeding and also survived. The parents of all four babies had refused an extremely safe and effective intervention on the day that they were born, one recommended by pediatricians since the early 1960’s, that would have prevented these outcomes.
When a baby is born, there are a number of rituals that parents and medical professionals take part in. Some are largely ceremonial, more rites of passage than anything medically necessary, such as the first bath or the assignment of APGAR scores. As a physician, I play my part in some of these rituals, the baby’s first exam being the most important. Unlike many medical examinations that pediatricians perform, the newborn exam involves a good deal of showmanship. It’s the only exam where I make a point of talking through each aspect with the parents, showing them all the normal but sometimes surprising (at least to new parents) things that babies do and common physical exam findings that many folks don’t know about and might lead to unnecessary concern. Really hammering home how healthy a new baby is can go a long way towards relieving parental anxiety. And anticipating and addressing common newborn issues during the exam helps save me a lot of time on the back end as well.
Nursing plays the largest role in the rituals of caring for a newborn baby. They give the first bath, change the first dirty diapers and typically assist with the first latch if a mom is breastfeeding. They perform common procedures, such as heel sticks for newborn screening and jaundice assessments if necessary. They really do a lot, providing a great deal of vital education for parents while doing it, and their role in the care of the newborn far outshines my contribution for the majority of healthy babies.
Another ritual that nursing plays a major role in, and one that has significant medical benefits associated with it, are vitamin K injections. But before I discuss why it is so important for newborns, especially those that are going to be primarily breastfed, to receive these injections, a little primer on vitamin K is in order.
What is vitamin K?
Vitamins in general are organic substances that are necessary for normal metabolic processes that cannot be made by the human body. We have to take vitamins in by eating foods that contain them. The beginning of our understanding of vitamin K goes back to 1929 when Danish researcher Henrik Dam discovered that a substance existed which could help correct bleeding induced by restricting cholesterol from the diet of chickens. This substance, named Koagulationsvitamin in the German journal that first reported the findings, has since been known as vitamin K. The fat soluble vitamin K was first isolated from alfalfa sprouts only a year later.
There are two main forms of vitamin K. We take in vitamin K1 when we eat leafy green vegetables like kale and spinach, but it is also found in broccoli. Because it plays a major role in photosynthesis, it isn’t found in root vegetables in large amounts. Vitamin K2 can also be obtained from the diet, usually in the form of aged cheeses, fermented vegetables and organ meats. Much of the vitamin K2 in our bodies is actually synthesized by bacteria in our intestines and then absorbed. In general, vitamin K1 is the most active form.
In order to absorb vitamin K, we need a functioning pancreas and biliary system. The vitamin K that we take in is bound to proteins that require pancreatic enzymes in the small intestine to be broken down. Bile salts then render the liberated vitamin K able to be absorbed into intestinal cells for processing and transport to the liver. So biliary and pancreatic disease can increase the risk of deficiency, which is actually quite rare in adults. Babies, now that’s a different story as I’ll soon explain.
What does vitamin K do?
The primary role of vitamin K in the human body is blood clotting. It is also involved in bone growth and density, but at this time there isn’t great evidence that supplementation is particularly helpful in preventing osteoporosis or fractures. In some countries, however, various formulations of vitamin K have been recommended for just that purpose. There is ongoing research into vitamin K’s role in the development of Alzheimer’s disease, heart disease and even some cancers, but these are hypothetical and may not pan out.
Vitamin K is a cofactor necessary for a number of key enzymes involved in clotting to work properly. In particular, clotting factors VII, IX, X and prothrombin produced in the liver require vitamin K-fueled activation. Without enough vitamin K, ultimately these proteins will not be attracted to circulating platelets and blood clotting will be impaired, which can lead to life-threatening bleeding complications. The medication warfarin takes advantage of this by blocking the conversion of inactive precursors into active vitamin K. This is why patients on warfarin are warned to avoid excessive dietary vitamin K intake as that may reverse the anti-clotting effects.
Why do babies need vitamin K shots?
Newborn infants are considered to be universally deficient in vitamin K. This happens for a variety of reasons. There is poor transfer of vitamin K across the placenta and the immature liver has both decreased storage capability and is inefficient at using available vitamin K. Naturally, this is even more pronounced in premature infants. Adding to this, breast milk does not contain sufficient amounts of vitamin K and the initially-sterile gut of the newborn does not significantly contribute to vitamin K levels in the body for several weeks.
There isn’t anything a mother can do about these etiologic factors. But some things can add to the risk even further. There are a number of medications, in particular warfarin and some anti-seizure drugs, that when taken by a mother during pregnancy increase the risk of vitamin K deficiency and bleeding complications in the new baby. Certain antibiotics used to treat tuberculosis can have a negative impact as well.
Without supplementation, newborns are at risk for a potentially devastating condition known as vitamin K-deficient bleeding (VKDB), formerly known as hemorrhagic disease of the newborn. VKDB is a better designation because life-threatening bleeds can occur as late as 3 months of age, particularly in breastfed babies who did not receive an intramuscular dose of vitamin K on the first day of life. Most bleeding occurs during the first week, however.
The really scary thing about VKDB is that it occurs in perfectly healthy babies and it happens spontaneously, not because they were dropped on their head for instance. Bleeding can present in many ways, ranging from mild to fatal. Skin bruising, bleeding into mucosal tissues (mouth, nose, throat, intestine, uterus, urethra), bleeding at the umbilical stump or circumcision site, and bleeding into the brain can all happen.
One of the most common presentations of easy bleeding in newborns is something called a cephalohematoma. These are bleeds under the periosteum, a dense connective tissue membrane that covers bone, and typically involve the parietal bones of the skull because of pressure to the scalp during even uneventful deliveries. Because the blood is trapped under the periosteum, these present as immobile but squishy (think silly putty) scalp masses, sometimes shockingly large, that can take weeks to resolve. Large cephalohematomas are a major risk factor for severe jaundice.
Without supplementation, as many as 1.7% of babies would be expected to have some kind of bleeding complication during the first week. This is known as “early VKDB” or classic hemorrhagic disease of the newborn, and it can be easily prevented by an intramuscular vitamin K injection on day one of life. It can also be prevented with oral supplementation. The evidence to support the efficacy and safety of these interventions is rock solid, but there are problems with oral supplementation when it comes to bleeding after the first week.
When there is a bleeding complication from vitamin K deficiency that occurs between 2 and 12 weeks of life, this is called “late VKDB.” This happens almost exclusively in babies fed primarily breast milk who did not receive adequate vitamin K prophylaxis, or who have some other major risk factor such as liver disease or cystic fibrosis. Late VKDB, as it did in the children treated at Vanderbilt Children’s Hospital, where I completed my pediatric training and a fantastic facility by the way, tends to present as unexpected bleeding into the brain.
The risk of late VKDB is felt to be around 4.4 to 7.2 per 100,000 children not receiving vitamin K prophylaxis. Oral vitamin K given on day one of life does not substantially reduce the risk, while intramuscular dosing renders it virtually nonexistent barring some other significant risk factor. Some countries promote longer-term oral vitamin K prophylaxis, and there are a variety of approaches. One common method is to dose vitamin K orally with the first feed and again at one, four and eight weeks of age. In the Netherlands, small daily doses have been recommended. While not every approach to oral prophylaxis has been extensively studied, such as the small daily dose regimen, many have been and it appears that there remains a risk of about 1-2 cases of late VKDB per 100,000 births.
Why would oral prophylaxis not work? There are just too many variables. Adherence to the recommended regimen may be poor for a variety of reasons. A child may be ill and vomiting, or on antibiotics which interfere with gut production by killing off intestinal flora. A family may simply forget. The amount of vitamin K in the breast milk may be affected by external factors as well. So while oral vitamin K may be cheaper and does not cause any procedural discomfort, and it may be better than none at all, the evidence supports intramuscular prophylaxis, especially when you consider the potential outcomes of late VKDB. Some countries that switched to oral regimens have seen spikes in the incidence of late VKDB, and Australia switched back to intramuscular. Of note, premature infants must receive intramuscular dosing because of poor absorption of oral formulations. Also, liquid oral vitamin K is not available in the United States.
Why would a family refuse vitamin K?
I imagine that regular readers of SBM are not surprised by the fact that vitamin K prophylaxis refusal is something that pediatricians and family practice doctors deal with, although not as frequently as vaccine refusal. Why do parents do it? Why would a parent reject an intervention that is so effective at preventing such a devastating consequence as bleeding into the brain of their baby and a potential lifetime of seizures, developmental delay and cognitive impairment? And one that is virtually risk free to boot!
Many families who refuse simply have a world view where medical intervention is perceived as unnatural. Many of these children are born at home or in birthing centers attended by midwives and doulas. They tend to have extensive and demanding birth plans when they deliver in the hospital and frequently also refuse antibiotic prophylaxis against neonatal conjunctivitis, another newborn ritual with less controversy attached to it. Eye and vitamin K prophylaxis are collectively referred to in nurseries as the “eyes and thighs”. These families also typically refuse the newborn hepatitis B immunization, perhaps a topic for another post, and go on to refuse or spread out childhood immunizations in the future.
Though not as widespread as anti-vaccine propaganda, and certainly lacking that particular entity’s infrastructure and celebrity support, there is an online presence of bogus anti-vitamin K information to be found. Naturally the chiropractic community is all over the place about this topic as they are with everything else. This particular practice warns that synthetic intramuscular vitamin K might cause cancer, kill your baby, or make them sterile, and questions the need for prophylaxis at all.
In March of 2010, our friend Dr. Mercola interviewed biochemist Cees Vermeer, who appears to be an expert on vitamin K who is involved in research to find new commercial applications, and published an article on the subject of newborn vitamin K prophylaxis that questions the mainstream approach. I also found several message boards and mommy groups citing this information as a reason to question the intramuscular injections. I’ll start off with what the article gets right. He appears to appreciate the need for vitamin K in newborns, and discusses some of the risks of deficiency. He is absolutely right when he says that newborns can feel pain, and that pain in the neonatal period can sometimes have long lasting effects. He is right when he says that oral vitamin K prophylaxis can be effective. Maybe I’ve been too hard on this guy.
I was shocked to find that Mercola even agrees with mainstream science that intramuscular vitamin K prophylaxis does not cause cancer. Because of some small, poorly done studies in the early 1990’s there was a brief period of concern that vitamin K prophylaxis increased the likelihood of pediatric leukemia. The question was thoroughly addressed by better studies and is not considered a problem. However it does occasionally come up as a reason to refuse, or as something that parents are worried about and want to discuss. For more information on this non-controversy, here is the AAP policy statement.
So now let’s tackle what Mercola gets wrong. I’m not sure how much of this represents his versus Vermeer’s understanding of VKDB, but they don’t appear to have a good understanding of it. He makes some pretty glaring mistakes (I’m being generous) in the article that are easily addressed. First off, he doesn’t seem to understand the differences between early and late VKDB. He mentions the risk of up to 1.7%, but not that this specifically is for the early form. He then declares that this is rare. I do not consider almost 2 out of every 100 births to be rare. The incidence of late VKDB is considerably lower and could reasonably be thought of as rare, but when it happens it usually results in a messed up brain. If nearly 2 out of 100 kids had brain bleeds, that would be horrific!
He states that there was no evidence to support the standard of care in regards to vitamin K prophylaxis when it was first implemented. Vitamin K became a routine standard of practice in 1961. I was able to easily find numerous papers going back a decade before that investigating the use of vitamin K prophylaxis in newborns. He likens what we do to a “shotgun approach” that was convenient. You know what is inconvenient? Brain bleeds.
He blames increased rates of circumcision on the push to give intramuscular vitamin K injections. This is absurd. It has been known for decades that oral prophylaxis is just as effective as intramuscular for early VKDB. Most circumcisions take place on day 2 or 3 of life. Intramuscular injections are recommended only because they work better than oral regimens for preventing bleeding complications in the 2nd to 12th week of life.
So why is Mercola so worked up about vitamin K? He just cares too much, I suppose, and can’t bear to think that newborn babies might be suffering from the pain of an intramuscular injection. Anyone who read my last post on pediatric pain should know how much I hate poorly managed pain, but even I think his concerns are over the top. Mercola likens the discomfort from an IM injection of vitamin K to psycho-emotional damage and trauma that causes an “emotional wound that the helpless and innocent baby needs to overcome to achieve health and wellness.”
Poorly managed pain in the neonate does have potential downstream repercussions. I really do need to go into more detail in a post on the subject. But to compare a one-time IM injection to a 25-week-premature infant riding a vent without appropriate pain control for 5 weeks, or twenty heel sticks over the first few days of life to follow blood sugars in the growth-restricted infant of a diabetic mother, is more than a little ridiculous. Untreated bouts of acute pain in neonates, such as a circumcision without any local anesthesia or sugar water, may increase their pain/stress response to future painful events in infancy such as routine childhood immunizations, but they do not “remember it” or have psychological problems further down the road. Infants who suffer chronic pain, usually premature babies that require mechanical ventilation and/or surgery, have actually been shown to have a blunted pain response. We don’t have good data on longer term issues regarding chronic pain in babies.
Mercola raises concerns about the safety of the dose of intramuscular vitamin K, stating that it is 20,000 times the needed dose. His source is “givingbirthnaturally.com.” Even if true (the needed dose for what?), he acts as if it is being injected straight into a vein. It is an intramuscular injection. The vitamin K is slowly metered out similar to penicillin shots that we give in place of lengthy courses of oral antibiotics for strep throat or the prevention of rheumatic heart disease flares. He worries about toxic preservatives injuring the baby’s immune system but gives no evidence to support this because there is none.
He mentions that an injection is an infection risk because the baby has an immature immune system and hospital bugs are so dangerous. This is theoretically true but the risk would be considerably lower than the risk of bleeding in a child not appropriately prophylaxed against VKDB, and he cites no data to support his concern. Intramuscular injections do have real risks, but they are very minor. A bruise or treatable local infection, for instance, must be weighed against the risk of a brain bleed.
Mercola recommends oral vitamin K as an equally effective alternative to the intramuscular dose. He says it is absorbed efficiently enough and there is no risk of overdosing or a bad reaction. He claims that oral dosing is even equivalent in exclusively breastfed babies, which is potentially very dangerous advice, but then says that future research is needed to find better “pinpoint guidelines.” Well, we have current research that says most oral regimens are less effective and we lack evidence to show that daily dosing is as effective as intramuscular injections for preventing late VKDB. If future evidence shows daily dosing to work as well as injections, then it may be a reasonable approach in some infants. But to completely ignore the fact that giving a medicine orally to a baby for long periods of time is prone to adherence issues shows his lack of any true understanding of this topic or of babies.
He quotes Vermeer as saying that if breastfeeding women just eat enough foods rich in vitamin K, their babies don’t need the intramuscular injection or the oral supplementation. Levels of vitamin K in breast milk are low, much lower than in infant formula, and it is not clear at all if dietary modification is good enough. And if a mother goes on a course of antibiotics, for instance, or is ill and unable to eat a diet high in green leafy vegetables for a period of time, her vitamin K levels may decrease and put the baby at risk for a bleed. Vermeer is a biochemist, not a physician and I would ignore his advice on the matter. I would ignore what Mercola has to say about this and everything else.
Conclusion
Newborn babies are amazing things. I don’t pretend to know everything there is to know about them, and I certainly don’t understand the evolutionary underpinnings of vitamin K deficiency in newborns. I guess it is uncommon enough that there was no pressure to evolve better transport of vitamin K across the placenta or to increase levels of vitamin K in breast milk. But the why is not so important in this instance. Babies, through no fault of their own, are born at increased risk of life threatening bleeding complications from vitamin K deficiency. Vitamin K prophylaxis via the intramuscular route is safe and effective at preventing these life threatening complications, and based on the evidence available it is better than oral regimens. This may change in the future.
When a parent refuses the vitamin K, I can’t force it upon them. I try to get to the bottom of their concerns and address them as best as possible. In the vast majority of instances, parents agree to the injection. When they don’t, we don’t notify child protective services or call the police. We document, document and then document some more so that it is clear in the medical record that the parents were given the appropriate information to make an informed decision and that even knowing the risk they still refused. There is no oral vitamin K solution available in the United States, but I guess you can get anything on the internet these days. Oral dosing is better than nothing. I leave that discussion up to their primary care physician.

Separating Fact from Fiction in the Not-So-Normal Newborn Nursery: Newborn Jaundice
Clay Jones on May 9, 2014
Link


By far the most common medical problem in newborn infants is jaundice, typically appreciated as a yellowish discoloration of the skin caused by increased blood levels of a pigment called bilirubin. In my role as a newborn hospitalist, I manage jaundice every day. If I am not treating jaundice, in every single baby I see I am at least determining the risk of the child developing jaundice severe enough to require treatment. I then use that assessment to help guide my recommendations on when the infant should follow up with their primary care pediatrician after discharge home.
Fortunately for the millions of infants who develop jaundice every year, in the vast majority it is a self-limited process and often considered to be just a normal part of the first few days of life. But in a significant minority of them, careful management is required in order to prevent complications. Some infants need treatment to prevent neurological symptoms from developing, and to reverse them when they do occur. And in a very small percentage of babies who develop severe jaundice, permanent brain damage and even death can occur.
Because newborn jaundice tends to resolve without any intervention, and complications are now uncommon, it isn’t surprising that a variety of myths and superstitions have arisen that involve preventing or curing the condition. And naturally there are practitioners of unproven alternative medical modalities that can be found claiming to be able to manage it as well. As expected, if you’ve spent any time reading Science-Based Medicine or researching the nonsensical claims of chiropractors, homeopaths and their ilk, their understanding is limited and their recommendations potentially dangerous.
But first a crash course on newborn jaundice.
What is jaundice?
Jaundice occurs when there is an elevation in the amount of bilirubin in the blood. In older kids and adults, anything above 1 mg/dl is considered abnormal. But virtually all babies have levels higher than this within a day or two of birth, and often considerably higher. I routinely see bilirubin levels in newborns of 15-20 mg/dl and occasionally much higher.
The higher the level of bilirubin in the blood, generally the more jaundiced a baby looks and the lower down on the body it progresses. But using a visual assessment is problematic because it doesn’t reliably predict levels in the blood in all babies. We have all been fooled by little pumpkins with low levels as well as babies with high levels despite little apparent jaundice. It can be particularly challenging in infants with more natural pigment in their skin to begin with.
Of course long before the development of techniques to measure serum bilirubin levels, people noticed that newborn infants often developed a transient yellow discoloration of the skin with no apparent associated symptoms. Historically this bore the name Icterus neonatorum, which is based on ikteros, the Greek work for what we now know as jaundice. The word jaundice is derived from the French word for yellow, jaune .
Also known to physicians of the past was a more severe form of newborn jaundice given the name Icterus gravis. They noted severe anemia, neurological effects and typically death in addition to the yellowish skin. It would be many years before the cause of this condition, as well as the many risk factors associated with jaundice in general, would be understood by medical scientists and incorporated into our care of newborns.
Why newborns?
Bilirubin in the human body, at least about 90% of it, is a by-product of the breakdown of hemoglobin from our blood. Once produced, bilirubin is bound by the protein albumin in the blood and transported to the liver where it is prepared for excretion by undergoing conjugation with glucuronic acid by the enzyme UGT1A1. This more water-soluble conjugated bilirubin is excreted into the intestines via bile from our gallbladder and leaves our bodies as metabolic waste in our feces.
In the newborn human, there is a problem at every step in this process, which is why even perfectly healthy babies are at risk of developing jaundice. Newborns make more bilirubin normally than at any other time during the lifespan because they have, on average, more hemoglobin than at any other time. Babies can even be born with too much hemoglobin, leading to a condition called polycythemia where the increased viscosity of their blood can reduce oxygen delivery to vital organs. Fetal red blood cells also have a shorter life span than adult. So more blood, and more breakdown of that blood, leads to more bilirubin in the blood.
The ability of the newborn to conjugate bilirubin in the liver is impaired because of a deficiency of the necessary enzyme. This occurs in all babies but can actually be worse in some populations, particularly in families designated as Eastern Asian. It takes over three months for the liver to reach adult capacity to conjugate bilirubin. So babies produce more bilirbubin, and more of it stays in the blood in the unconjugated form that can cause problems. It’s important to note that patients of all ages can develop a buildup of conjugated bilirubin in the blood as well which is typically related to a variety of liver diseases. That, however, is a horse of a different color. Well, technically it’s still yellow.
Finally, there are even problems with the bilirubin that does make it into the gut in the conjugated form. Older kids and adults further break conjugated bilirubin down with the help of bacterial enzymes, but it takes time for the newborn gut to become colonized. As conjugated bilirubin sits in their intestines, a human-produced enzyme deconjugates it, thus allowing it to be reabsorbed back into the body in a process called enterohepatic circulation.
We call the end result of these normal barriers to removing bilirubin from the body “physiologic jaundice” to differentiate it from the many disease states and environmental factors that can also lead to severe elevations in bilirubin. Again, this occurs in every single baby to varying degrees. It can, even without any pathological assistance, lead to jaundice bad enough to cause symptoms or require treatment, although alone it would be extremely unlikely to lead to permanent injury or death. Physiologic jaundice tends to peak at around the fourth day of life, although that peak can be higher and further out in premature and Eastern Asian infants.
What is pathologic jaundice?
There are a variety of diseases and environmental insults which can exacerbate physiologic jaundice in newborns or lead to severely elevated levels of bilirubin all by themselves. Rather than give an exhaustive review, I’ll focus on the two most important. Increased production of bilirubin from excessive destruction of red blood cells is the most common cause of pathologic jaundice. This typically occurs when the blood type of the mother and baby are mismatched, usually with the mother having O+ blood while the baby is A+ or B+, leading to the production of maternal antibodies. These antibodies can cross the placenta and signal baby red blood cells for destruction in the spleen.
ABO incompatibility can be severe, but often isn’t. But there is an extremely severe and often deadly form of this kind of mismatch which I’ve never seen thanks to advances in modern medicine. Rh incompatibility, when a mother with negative blood gives birth to a baby with positive blood, used to kill a lot of babies prior to the development of Rho(D) immune globulin (RhoGAM) because the maternal immune response is so intense. The first use of Rho(D) immune globulin in a mother, which facilitates destruction of fetal red blood cells before an immune response can occur, was in 1968. Research and treatment of Rh disease in the three decades leading up to that year is credited as the impetus for the development of neonatology as a unique specialty within pediatrics.
The second most common cause of pathologic jaundice is known as “breastfeeding jaundice”. Unfortunately, it is a well-established fact that breastfeeding is a major risk factor for the development of a severe elevation of bilirubin, which is why pediatricians tend to want earlier follow up visits after discharge from the nursery with breastfed babies. The process by which breastfeeding can negatively impact bilirubin levels is by increasing the enterohepatic circulation I mentioned earlier. If things are going well with breastfeeding, the risk is actually not much higher than in babies receiving formula. But when breastfeeding is going poorly during the pivotal first few days of life, the inadequate intake of calories and fluid leads to more unconjugated bilirubin being reabsorbed from the gut back into the blood.
The possibility of breastfeeding-failure jaundice is something we take very seriously in the newborn nursery. It isn’t the only reason why there is such a push for improving breastfeeding support of course, but it is a big part of it. We provide extensive education on lactation, document successful latching, track weight loss and the number of wet and dirty diapers, and troubleshoot a variety of potential roadblocks such as nipple pain and maternal fatigue. We are especially careful with breastfeeding premature infants, who are at increased risk of breastfeeding failure and physiologic jaundice already tends to be more pronounced.
A related but benign cause of jaundice in young infants, typically occurring during the 2nd week of life, is “breast milk jaundice.” It occurs after breastfeeding has been well established in exclusively-breastfed babies when physiologic jaundice persists after the usual rapid decline of bilirubin around the fifth day of life, and it can last for several weeks without intervention. Although the exact cause is unknown, it is believed that there is a component within breast milk that promotes intestinal absorption of bilirubin. A brief interruption in breastfeeding, usually just one to two days, leads to rapid resolution, although many pediatricians do not recommend this as there is no harm from the elevated bilirubin at that point.
How does jaundice affect newborns?
In most newborns with jaundice and even moderately elevated levels of bilirubin in the blood, there are likely no adverse acute or long term effects. The standard approach to screening and treatment of the condition, which admittedly can seem overly aggressive at times, is primarily geared towards preventing a very rare outcome known as kernicterus. This involves permanent damage to specific regions of the brain and can result in death in some cases. We believe that it should never happen, that it should be preventable virtually 100% of the time. In fact, The Joint Commission, who certifies health care institutions and programs, designates it as a sentinel, or “never” event.
As with many medical conditions, there is a spectrum of severity when it comes to symptomatic jaundice. At a certain point in any baby, the bilirubin in the blood can reach such a level that it is able to cross the blood-brain barrier and begin binding to neural tissue, which leads to cell death. The more brain tissue involved and the longer a child goes untreated, the more severe the symptoms. Although we can never perfectly predict at what level this will begin to occur in for any individual child, we tend to see subtle symptoms when levels hit around 20 mg/dl, with the more overt injury evident at 25-30 mg/dl. Anything that can impact the permeability of the blood-brain barrier, such as prematurity or infection, can lower the level that causes brain injury.
Bilirubin-induced neurologic dysfunction (BIND) can be broken down into acute encephalopathy, which is reversible with appropriate treatment, and kernicterus, which isn’t. At first, babies with increasing bilirubin levels become sleepy and begin to feed poorly. They may seem floppy or have a different sounding, high-pitched cry. As things progress, a baby can develop fever and extreme lethargy, or they may become extremely irritable and jittery. They may have no suck at all or develop an aggressive suck. Their cry may become more high pitched and urgent sounding and they may be very difficult to console. Stiffness can set in, the first sign of which is often arching of the neck and body when touched.
Without emergency treatment at this point, the damage will become irreversible. They will begin to have periods without respiratory effort and will stop feeding altogether. Fever and seizures are common as they become more persistently stiff and arched at the neck and back and progress into a comatose state. They will ultimately die from either respiratory failure or prolonged seizure activity.
Kernicterus is diagnosed when signs of brain injury become evident during the first year of life. Because bilirubin deposition in the brain tends to occur predominantly in the areas that regulate movement (basal ganglia) and hearing, cerebral palsy and hearing loss are common, as are difficulties with eye movement. The development of the teeth can also be affected. Cognition tends to be unaffected but there is some controversy regarding the possibility that even moderate levels of bilirubin elevation are a risk factor for neurologic problems later in life. At this time, the evidence is mixed but trending against any association with autism, learning disabilities, ADHD or any other psychological disorders.
How is newborn jaundice evaluated?
The key to managing newborn jaundice is awareness of risk factors, such as prematurity, genetics and whether or not the baby is being breastfed. Most hospitals incorporate universal pre-discharge bilirubin screening into our decision-making process and always attempt to establish appropriate follow up post-discharge. Our goal is the prevention of severe elevations of bilirubin in order to prevent the development of symptoms and ultimately of kernicterus.
Since the early 1990s, a systematic approach to newborn jaundice has been recommended. Every baby goes through the process of screening, risk assessment, breastfeeding evaluation (if breastfeeding), and use of an established treatment algorithm based on the bilirubin level and the infant’s hours of age. This has led to a decrease in the number of babies that develop severe elevations of bilirubin. The rarity of kernicterus has made it difficult to assess whether our interventions have successfully decreased its incidence, but it is reasonable to use severe bilirubin elevation as a surrogate outcome for kernicterus. The US Preventive Services Task Force disagrees with the AAP on this, and does not recommend universal screening, which I believe is a good example of the difference between evidence-based and science-based medicine.
I can certainly understand the hesitancy in initiating universal screening of pre-discharge bilirubin levels. Historically this has required a heel stick to obtain a few drops of blood from the baby. Heel sticks hurt without proper procedural pain measures such as use of a pacifier and sucrose, and probably aren’t that comfortable even with them. Labs aren’t free either. A fairly recent development in the management of newborn jaundice has significantly ameliorated these concerns, however.
Rather than the testing of a baby’s blood for elevated bilirubin, an increasing number of hospital nurseries are now using transcutaneous bilirubinometers (TcB). These handheld devices use multiwavelength spectral reflectance from the skin to estimate the level of bilirubin in the blood. A number of large studies have demonstrated their accuracy in various ethnic groups, but they aren’t perfect. They are unreliable once a baby has started phototherapy, possibly even if they’ve just been exposed to direct sunlight, and they have decreased accuracy at high bilirubin levels.
The typical approach to use of TcB is to confirm the bilirubin level with a blood test if the result is greater than the 75th percentile on the standard bilirubin nomogram. My personal rule of thumb is to add 3 to the result, and if that changes my management I confirm the level with a heel stick. Use of these devices significantly decreases the number of heel sticks performed, and they save money in the hospital, but they have not been recommended for use in the outpatient setting yet.
There are a variety of additional tests often incorporated into the evaluation of risk for severe jaundice, such as the infant blood type and presence of maternal antibodies when there is a mismatch. This is often performed whenever a mother has the O blood type. And naturally there are diagnostic tests when other pathology is suspected, such as red blood cell membrane defects, enzyme abnormalities, or genetic/metabolic conditions. We sometimes get even fancier. Some facilities are able to measure the amount of carbon monoxide, another break down product of hemoglobin, exhaled through the nose as a very sensitive test for abnormal destruction of red blood cells.
How is newborn jaundice treated?
Historically the treatment of jaundice was time and perhaps prayer. Infants who developed “icterus gravis” either died or had severe lifelong disability. As medical science advanced and we determined that elevated bilirubin was the underlying cause of symptomatic jaundice, a means of removing it from the blood was developed. The exchange transfusion, where blood is removed from the baby in small aliquots, dumped and then replaced with suitable donor blood, became the treatment of choice. Unfortunately the procedure was, and is, risky although its safety has improved greatly.
Fortunately, as is often the case in science, hard work, keen observation and a measure of luck led to the discovery and development of means to prevent many severe cases and safer treatment alternatives that have become the gold standard. As I’ve already mentioned, the implementation of screening of maternal blood type and use of Rho(D) immune globulin has rendered Rh disease almost nonexistent in developed nations. Again, in ten years of practice I’ve never seen a case of it.
The second advance was the realization, as infant formula was introduced and became a common alternative to breastfeeding, that breastfeeding difficulty increased the risk and severity of jaundice. Greater focus on improving breastfeeding, and at times strategic use of infant formula and mechanical breast pumping, has prevented many cases of severe jaundice. The final significant advance was phototherapy. This combination of interventions has drastically reduced the need for exchange transfusion. I’ve participated in only one. As the intern on the team it was my duty to sit in sterile gown and gloves at the bedside for 6 hours while performing the transfusion manually.
What is phototherapy?
While the practice of exchange transfusion did revolutionize the treatment of severe jaundice, and certainly improved the outcomes of thousands of newborns, it was risky. And we now know that it was done too often in babies that likely would never have developed kernicterus. This was a time before established risk factors and handy iPhone app algorithms to determine the need for treatment.
But in 1956 a nurse in England, working in the nursery at Rochford General Hospital, noticed that babies placed in sunlight for extended periods of time were less jaundiced. Biochemists in the lab were also perplexed by oddly-low serum bilirubin levels in blood samples left sitting in the sunlight. The rest is history. In 1968, a landmark randomized controlled trial published in Pediatrics by Jerold Lucey showed that phototherapy was a safe and effective treatment for newborn jaundice.
The history of phototherapy after that publication, and the struggle between two factions of practitioners over the direction of jaundice treatment is fascinating. Led by “princes of light and dark” at dueling hospitals in New York City during the decade after the paper came out, the battle over phototherapy was heated but ultimately the evidence won out and the exchange transfusion has nearly gone the way of the Dodo. And I “light kids up” weekly.
How does phototherapy work?
Phototherapy isn’t just regular light, and despite what you can find written on numerous alt med websites it isn’t ultraviolet light either. Phototherapy is blue-green light, although more recent evidence has supported a shift over to predominantly blue light, specifically between 460 and 490 nanometers. When this light hits bilirubin molecules in the infant’s skin, bilirubin is affected in three ways.
The most important effect is the irreversible conversion of bilirubin into a more soluble form via structural isomerization. The new form, lumirubin, passes into the gut and urine for excretion without the need for conjugation. Furthermore, phototherapy alters some of the bilirubin into a less neurotoxic form via a reversible photoisomerization. This doesn’t result in an appreciable drop in the level but reduces the risk of brain injury. Finally, photo-oxidation of bilirubin converts some to a form that is excreted only in the urine. This likely only accounts for a small percentage of the drop in total levels however. All in all, and please pardon the pun, phototherapy is brilliant. It is a safe, effective and all-natural treatment but it does line the pockets of “Big Light.”
“Alternative” approaches to newborn jaundice
So now you know the science-based approach to newborn jaundice. It is an approach which does “medicalize” some children that would not go on to develop symptomatic jaundice or kernicterus, but it is extremely safe and effective. Now let’s explore what some of our friends in the world of complementary and alternative medicine have to say about this common condition. Just a quick perusal, as an exhaustive discussion would both take up too much of your time and ruin my day, the first day that actually feels like spring up here.
Practitioners of craniosacral therapy get partial credit, describing jaundice as “yellowness of the skin due to the fact that the baby’s young and small liver is unable to process and [sic] excess of blood and so has to use the skin as it’s [sic] organ for release instead of the intestines or urine.” They make the common mistake of describing phototherapy for jaundice as “ultra-violet”, which if true would cause horrendous skin injury during the many hours a baby requiring therapy will typically spend under the lights. Phototherapy does not burn or increase freckling or mole development. And modern versions don’t even produce much heat as they are LED lights, thus the infant is not at risk of dehydration. Despite a lack of any evidence, they claim that CST can improve clearance of bilirubin, which could lead to false reassurance and a delay in seeking out appropriate medical care.
Believers in traditional Chinese medicine have a unique approach to newborn jaundice:
The causative factors of icterus neonatorum are dampness-heat and cold-dampness which are affected from the mother, or during delivery, or after birth. The hypofunctioning organs, particularly the spleen, fail to eliminate dampness-heat, leading to its retention in the liver and gallbladder and its distribution to the skin. Moreover, on the basis of the deficiency of healthy qi which results from congenital insufficiency or longstanding disease, the maladies of dampness-heat and cold-dampness may lead to the deficiency of spleen-yang and then the retention of the evils, and jaundice results.
Unfortunately, phototherapy has yet to be proven effective for “retained evil.”
One practitioner of homeopathy claims to be able to prevent and treat jaundice using a variety of nonexistent remedies. Please do not try to decipher which remedy is appropriate for your baby yourself, however. Only a fully trained homeopath can tell the difference between sluggish bowels and constipation.
This particular practitioner recommends letting your baby “bask” in the sunlight to treat jaundice, but I can’t just pick on homeopaths about this. The question of using natural sunlight for mild jaundice comes up frequently when caring for newborns. I don’t have data on this, but my best guess would be that a recommendation to put a kid in the sun is as common as recommendations to alternate acetaminophen and ibuprofen for fever, with most pediatricians doing it. And similar to alternating fever medicines, it isn’t recommended by experts because of risk and efficacy concerns.
We know that sunlight lowers bilirubin levels, that isn’t the issue. The problem is that in order to achieve that end, a child would need to be placed naked in direct sunlight for hours. This would place a baby at risk for hypothermia and/or sunburn. It also may only make the skin appear less jaundiced while not necessarily lowering the level of bilirubin in the blood appreciably, giving a false sense of security and potentially delaying care. This happens with conventional phototherapy as well. Once a kiddo is lit up, we have to rely on blood tests instead of a transcutaneous level.
The advice I hear most frequently given to parents, to put a baby in sunlight through a window for 10-15 minutes 3-4 times a day, would be very unlikely to lower bilirubin levels any faster than doing nothing. But because jaundice so often resolves on its own, it is easy to see why so many people think sunlight or any alternative approach “works.”
Naturopath Dr. Christopher and his son David, who “generated new ideas on the management of high blood pressure, diabetes and auto-immune diseases, and was one of the first to discourage the use of Prozac in favor of natural methods”, provide us an example of a natural approach to infant jaundice. It demonstrates a fundamental lack of any understanding of the concept. Here are a few of their pearls of wisdom:
     1.  Jaundice is caused by drugs given to the mother during the birth process.
     2.  Physiologic jaundice only affects blond babies, Native American babies, drug babies, premature babies, and babies not allowed to breastfeed.
     3.  Catnip, comfrey and dandelion tea are excellent treatments for newborn jaundice.
     4.  Wheat grass juice is also helpful.
     5.  Phototherapy causes irritability and sluggishness, diarrhea, lactase deficiency, intestinal irritation, dehydration, feeding problems, riboflavin deficiency, disturbance of bilirubin-albumin relationship, poor visual orientation with possible diminished responsiveness to parents, DNA-modified effects and it might even make their lungs bleed.
     6.  Severe jaundice can cause brain damage, and the best approach is to follow your maternal intuition.
Here is the scariest chiropractic “case report” I’ve ever read. It involves the chiropractic treatment of an unresponsive and jaundiced 36-hour-old infant with a heart rate in the 70’s (chest compressions are recommended when the heart rate is < 60 beats per minute in a newborn). The baby responded to the adjustments with an increase in heart rate, immediate resolution of his jaundice and a hearty breastfeed. And he was removed from the list of likely “candidates for SIDS.” But that isn’t the best part:
Interestingly, his testicles had also descended within that hour. That may have been a coincidence, but it seems noteworthy given all the other healthy indicators we witnessed as a result of the adjustments.
These examples are scary, and a little funny, but I realize that they don’t represent all practitioners of alternative medicine. Like few other fields of practice, alternative medicine is comprised of so many disparate and mutually-exclusive approaches to health that their ability to hang out under the same tent is a testament to just how much they don’t like conventional medicine. Trust me, if somehow they won and regular medicine faded away into history, it would be a bloodbath as they turned on each other in an effort to become the dominant modality.
Conclusion
Jaundice is the most common medical problem in the newborn, and though typically benign it can result in severe complications with permanent injury to the brain and even death a possibility if mismanaged. The pathophysiology of jaundice in babies is unique, fascinating, and simple enough that almost anyone can get a handle on it. Even more interesting is the history of how we came to understand the cause of jaundice and the progression from being unable to offer any treatment to only having the risky exchange transfusion as an option, and finally to the safe and effective use of phototherapy.
As our understanding of the many risk factors which play a role in the development of severe jaundice has advanced, the management of newborn jaundice has become more nuanced but also systematic and streamlined in such a way that it is essentially a process on autopilot these days. All babies are assessed for risk and, at least with the vast majority of births, universal screening of bilirubin levels is obtained prior to discharge home from the nursery. Even the decision when to treat can be made with the use of handy algorithms that take seconds to master.
Unfortunately, once we step outside the borders of science-based medical practice there are any number of practitioners of so-called alternative medical modalities that have essentially no understanding of how and why jaundice develops, which babies are most at risk and what are the most safe and effective approaches to treatment. Babies subjected to their machinations are at risk of poor outcome because of a delay in appropriate medical care.

Separating Fact from Fiction in Pediatric Medicine: Facial Nerve Palsy
Clay Jones on July 29, 2016
Link

There are numerous medical conditions that are seemingly designed to allow proponents of “irregular medicine” to proclaim their treatments to be effective. These conditions tend to be chronic and subjective in nature, or to have waxing and waning courses such that a parent or patient might easily be fooled into assigning a causal relationship between a bogus intervention and a clinical improvement. Brief, self-limited maladies are also quite convenient for people with nothing to offer but false information and false hope. After a recent encounter with a patient, I’ve added a new one to the list: idiopathic facial nerve palsy.
What is idiopathic facial nerve palsy?
Although not the first to do so, facial nerve dysfunction resulting in the sudden and unexplained weakness of all muscles on one side of the face was most famously described by Scottish neurophysiologist Sir Charles Bell in 1830. Hence it is commonly, if not always accurately, referred to as “Bell’s palsy.” Since then our understanding of the condition has progressed considerably, thanks to scientific investigation and improved diagnostic testing. In particular, we have learned that many cases are the result of infection, with ear infections, various human herpes viruses, and the spirochete responsible for Lyme disease being the most common culprits in children.
There are many other potential causes of facial nerve palsy in addition to infections, however. These include birth injury, congenital syndromes, cancer, metabolic and autoimmune diseases, and toxic exposures to name just a few. Bell’s palsy, which represents about half of all cases of facial nerve palsy in children, is the diagnosis given when symptoms appear to be idiopathic, meaning that they occur spontaneously and without an obvious cause. In reality, however, many of these cases are actually caused by viral infections or Lyme if the patient lives in an area where it is endemic.
Overall about 20-30 people out of every 100,000 are diagnosed with Bell’s palsy each year, with a predominance in the adult population. It is fairly uncommon in very young children and there is no particular increased risk based on race, gender, or location. It is not a reportable condition, so exact estimates are hard to determine, but roughly 40,000 people are believed to be diagnosed each year and you have about a 1 in 65 chance over your lifetime.
The key in sorting out these apparently idiopathic acute cases from those that may represent a more concerning underlying condition, like cancer or an aneurysm, is appropriate evaluation by a trained medical professional and judicious use of imaging and laboratory testing. It is not uncommon for pediatric neurologists to become involved, particularly in cases that are severe or persistent. Overall in children, the most common causes of facial nerve palsy are ear infections, Lyme disease (most common in endemic areas), idiopathic (Bell’s palsy), varicella (chicken pox), and herpes zoster (shingles).
What are the signs and symptoms of idiopathic facial nerve palsy?
In most cases of idiopathic facial nerve palsy, weakness of the facial muscles comes on suddenly. Patients or parents will notice decreased movement of the forehead, manifesting as difficulty raising the eyebrow as well as weakness in, if not complete inability to close the affected eyelid. One obvious sign is the disappearance of the nasolabial fold that runs between the cheek and the upper lip. The corner of the patient’s mouth typically droops at rest, and sufferers will have trouble smiling.
Because of the facial nerve’s complex anatomy and function, some patients will experience associated symptoms not related to muscular function. This can include a decreased ability to make tears on the involved side, loss of taste on the anterior two-thirds of the tongue, and increased sensitivity to sound. There is a very crude joke that I learned in medical school regarding one of these, but I won’t repeat it here. Those curious enough can practice their google-fu skills to find it.
An important aspect of the neurological examination of patients presenting with facial nerve palsy is careful attention to the muscles of the forehead. As previously mentioned, with idiopathic facial nerve palsy these muscles should be involved. But what if they aren’t?
We have two facial nerves exiting the brainstem, one for each half of the face, which travel through the skull to the various muscles of the face. The origins of most of each facial nerve’s motor functions lie in the cerebral cortex of the contralateral (opposite side) brain hemisphere. If injury occurs in these “upper motor” neurons, such as from a stroke, a patient will have facial paralysis on the opposite half of the face.
But, because the division of the facial motor nucleus responsible for the forehead actually receives some input from the ipsilateral (same side) hemisphere as well, those muscles are generally spared in the case of a stroke or other problem in the brain itself. Problems with the facial nerve distal to where these motor fibers combine, such as the classic idiopathic facial palsy, will result in total facial involvement. This is known as a peripheral palsy. If the forehead isn’t involved, we worry about something more sinister.
Along these same lines, activation of the facial nerve occurs both intentionally and automatically, such as during a spontaneous display of what you humans call laughter. The peripheral facial nerve and the muscles innervated by its branches don’t know the difference between the two. If the problem occurs after the nerve emerges from the brainstem, nothing works.
But different areas of the brain are involved with these two aspects of facial movement. An injury in one will still allow the other to function. So if you can’t smile on command but watching Dane Cook elicits spontaneous laughter, you need neuroimaging and a better sense of humor.
How is idiopathic facial nerve palsy diagnosed and treated?
Idiopathic facial nerve palsy is a diagnosis of exclusion, requiring a thoughtful history and a thorough physical exam. We need to be even more careful in children because idiopathic palsy is less likely to occur compared to the adult population. All the muscles of the face must be involved to some degree and the onset must be fairly sudden. Weakness/paralysis should not continue to worsen after three weeks and recovery should begin no later than six months after the first sign of weakness.
Again, other causes must be ruled out to the best of our ability. This often includes laboratory testing for Lyme disease in children who may have come into contact with ticks capable of spreading the disease. Although many if not most patients don’t require additional studies, some may undergo electrodiagnostic studies, MRI or CT scanning, or lumbar puncture to obtain cerebrospinal fluid, depending on the specifics of their presentation.
As with most conditions, treatment of facial nerve palsy in children is determined by the specific cause and the severity of the presentation. If there is a specific underlying etiology discovered, such as Lyme disease or a bacterial infection of the middle ear or surrounding bone, it should be treated. Congenital or severe acquired cases that result in permanent loss of movement may benefit from nerve grafting and/or muscle transplantation.
If no cause is discovered, and the diagnosis is idiopathic facial nerve palsy, the gold standard of therapy in adults is an oral steroid as early as possible in the course, and some experts recommend the addition of an antiviral medication that targets herpes simplex virus. The evidence of benefit from this is extremely meager, however. Physical therapy can also be helpful in some cases, serving to preserve function and avoid contracture of the involved muscles.
There is little evidence available to guide treatment in children with idiopathic facial nerve palsy. Based on adult data and expert consensus, steroids are commonly initiated when other causes, particularly leukemia, have been ruled out. In Lyme endemic regions, many children are empirically treated while studies are pending but no consensus has yet been reached on this approach. Antivirals, as with adults, aren’t well supported and are generally reserved for empiric treatment of the most severe cases or when the cause can be clearly attributed to shingles.
In addition to the cosmetic difficulties, one of the more distressing aspects of this condition is drying out of the affected eye and the possible development of corneal abrasions because of an inability to blink or close the eye. Artificial tears are generally prescribed and overnight use of a longer lasting lubricating ointment as well as patching are standard. Sometimes surgical intervention or the placement of a weight into the upper eyelid is necessary to avoid discomfort and injury.
What is the prognosis of idiopathic facial nerve palsy?
The overall prognosis for facial nerve palsy is challenging because such a variety of potential causes exist. Some, such as congenital cases associated with genetic syndromes, are very unlikely to resolve. In these cases, the facial nerve may not have even formed. Traumatic cases, such as after a forceps delivery, almost always demonstrate recovery because the nerve is simply swollen. With idiopathic facial nerve palsy, the prognosis is generally excellent, particularly if it never progresses to complete paralysis and recovery begins within three weeks of onset.
Close to 90% of patients with idiopathic facial nerve palsy will begin to experience recovery within three weeks even without treatment, with many seeing return of function within ten days. The earlier that recovery begins, the more likely it is to be complete. Nearly all patients who have early recovery will have no residual weakness. And most patients with late recovery will at least have moderate improvement. Cases that don’t demonstrate at least partial recovery by a few months were likely misdiagnosed.
Some “alternative” approaches to idiopathic facial nerve palsy
So now that you know the science-based medical understanding of idiopathic facial nerve palsy, it should be easy to see why so many practitioners of quackery CAM integrative medicine quackery claim treatment success, and why their patients might believe that an ineffective remedy worked. If diagnosed correctly, it is a largely self-limited condition and recovery begins fairly soon after onset in most cases. Of course the key is the “if diagnosed correctly” part. There are serious conditions that can present with facial palsy that may require specific treatment to prevent worsening. Imagine a child with leukemic infiltrate of the facial nerve or a brain tumor undergoing months of acupuncture before seeing a real doctor.
A quick online search reveals all the usual suspects. I’m not going to provide an exhaustive debunking of every implausible therapy, however. Maybe another time. Consider this more of a shallow yet fun dive into nonsense that might serve as inspiration for your own investigations, a frustrated laugh, or a cathartic primal scream.
Chiropractic
There is no shortage of chiropractic websites claiming success in treating this condition and making the expected claims about “removing nerve interference” we’ve all come to know and love. But the anatomical assumptions are a bit of a stretch. Each facial nerve leaves the brainstem and exits via a hole in the skull near the ear. It isn’t a spinal nerve and it would be very unlikely that a chiropractic subluxation of the upper vertebrae, if they even existed, would somehow interfere with it.
But they do love their case reports. There are two commonly used as justification for chiropractic care, both of which require a poor understanding of the natural course of the diagnosis to be taken seriously. In the first, a patient reported 70-80% improvement after a chiropractic adjustment and application of low level laser therapy at only 14 days after onset of weakness. Many patients see improvement this quickly even without treatment, plus he had been seen by his primary care doctor first and put on oral steroids. Must have been the chiropractic though. The second report, which sadly doesn’t involve any lasers, documents a patient that recovered steadily with chiropractic manipulation of multiple spinal segments and her skull…over a six month period.
TCM and acupuncture
Not to be outdone, proponents of Traditional Chinese Medicine and acupuncture claim to able to improve symptoms and reduce time to recovery without even accessing the spine. In addition to numerous herbs, vitamins, and a full body massage, they include the following helpful information on the etiology of idiopathic facial nerve palsy:
In traditional Chinese medicine (TCM), the diagnosis for Bell’s Palsy is termed “External Wind-Cold attacking the channels of the face”. According to TCM principles, one of the main implications of this condition is an underlying qi (a person’s inherent energy) deficiency. In China, acupuncture has been used for thousands of years to assist in Bell’s Palsy recovery, and the initial treatment goal according to TCM would be to expel Wind and resolve Damp, as well as to invigorate qi and promote blood circulation to the face. Consistent acupuncture treatments (usually recommended once or twice per week), can help soothe a patient, expedite the paralysis from dissipating, and enhance nerve function.
Of course, readers of Science-Based Medicine know that claims of ancient acupuncture are largely fictional. Modern acupuncture bears little resemblance to what was being done a hundred years ago let alone thousands. It was more akin to astrology-based bloodletting with large spikes than the placement of stainless steel filiform needles gently into the skin while relaxing music plays.
Here is a video of an “acupuncture” treatment involving running an electrical current into the muscles of a patient’s face. Electrical stimulation as a form of physical therapy is a treatment approach that has been tested and shown to not speed or induce recovery. Acupuncturists are simply taking advantage of the post hoc ergo propter hoc fallacy when they claim electroacupuncture, or any other flavor of acupuncture, helps. Here is non-electric acupuncture being used to treat facial palsy. Here is another example, which you know is fake because they are wearing sterile gloves.
This video is actually a very interesting look into the thought process of an average person when faced with something like facial nerve palsy. You’ll notice her demonstrating many of the biases and logical fallacies we discuss on Science-Based Medicine. In the final video documenting the one month course of her weakness, she credits acupuncture as the most helpful intervention, not the steroids, time, or any of the many different interventions she tried, but she admits that she didn’t get needled until the tenth day.
Apparently acupuncture “works” better if you wiggle the needle. In a study that did not include sham acupuncture or a regular care group, patients whose needles were wiggled demonstrated statistically significant improvement in subjective outcomes compared to patients whose needles did not go wee wee wee all the way home. The only objective end point assessed revealed a tiny improvement that is likely clinically meaningless and probably represents noise in the data. My conclusion is that the patients having their needles wiggled knew they were getting “special” acupuncture.
For something a bit more academic, check out these guidelines for a prime example of the failure of EBM when it comes to alternative medicine. Notice all the “Grade A” recommendations. Garbage in, garbage out.
Homeopathy and more!
The University of Michigan Health System, one of many examples of academic medical centers choosing marketing over patient care, provides patients with this handy discussion of the use of homeopathy for Bell’s palsy.
Have you ever wondered which crystal is good for someone with facial nerve palsy? Well wonder no more! It’s obviously Lavender Jade, but be sure it has been freshly cleansed before each application.
If crystals aren’t your thing, practitioners of Face Reflexology claim to be able to reattach severed facial nerves years after the injury.
While perusing the internet looking into alternative remedies for idiopathic facial nerve palsy, I discovered Mudra therapy. This is an alternative practice that involves holding the fingers and hands in specific positions in order to “restore a state of balance in the body and raise the level of the performer’s resistance.” The fingers and thumb represent the “panchamahabhootas” that make up the entire universe: sky, air, fire, water, and earth. According to believers, holding specific finger positions in place can cure a variety of illnesses. Even facial palsy.
Here is a video of a hypnosis session on a patient with facial palsy. It does not appear to have helped despite the claim of amazing results.
Conclusion: Facial nerve palsy doesn’t need quackery
Idiopathic facial nerve palsy may not tend to be a life-threatening or even a serious medical condition in most cases, but it can be extremely distressing to patients and potentially very uncomfortable if appropriate care is not provided. Although there are no medical therapies that have been shown to significantly hasten recovery, it is important for the correct diagnosis to be made, particularly in children who are more likely than adults to have a more concerning etiology of their facial weakness. Rather than one of the many implausible and unproven alternatives, your best bet is science-based care from an appropriately trained medical professional.

Separating Fact from Fiction in Pediatric Medicine: Infant Teething
Clay Jones on November 8, 2013
Link

Teething is one of the most common sources of parental concern in the world of pediatric medicine. All children go through it, typically starting at about 6 months of age, and the current list of signs and symptoms attributed to the eruption of teeth in infants is long and varied, with most if not all of them inaccurate if not highly suspect. And although teething as a concept may seem rather commonplace, it is an entity with an interesting history and a frequent impetus for exposing young children to ineffective and even risky treatments.
What is teething?
Simply put, teething occurs when a tooth nears completion of its journey into the oral cavity, a journey which begins early in fetal development. The tooth erupts though the gum, often preceded by a small lump. Occasionally there can be a larger eruption cyst, and the area may appear somewhat bluish and swollen from bleeding into the tissue, but this is uncommon. The most widely accepted duration of a bout of teething is a roughly 8 day period, with tooth emergence generally felt to occur on day 5. The whole process usually takes about two years, with an average of one tooth emerging each month until the full complement of 20 baby teeth are present. 
Teething past
In my opinion, the history of teething is a great example of the extreme degree of absurdity that conclusions based on a prescientific approach to illness often resulted in, right up there with humors and homeopathy. Early philosophers like Hippocrates attributed a wide variety of minor symptoms, such as itching gums and loose stools, to teething, and many of these still make the current list. But because of our once-poor understanding of human physiology, infants were felt to be extremely vulnerable to any derangements in their nervous system and more serious outcomes were attributed to the eruption of teeth, including death. Yes, death.
As crazy as this sounds, it actually isn’t that hard to understand why it was believed for at least a couple thousand years that teething could result in serious illness and even death. Remember how frequently a tooth emerges? Once a month, on average, for a couple of years, in early childhood. People attributed severe illness and death to teething for the same reason that some people continue to blame autism on vaccines: Pure coincidence and a lack (or the in the case of vaccines and autism the denial of) a systematic and logical approach to documenting and evaluating natural phenomena.
Until the advancements of scientific medicine, such as vaccines for instance, children frequently died or suffered through a variety of common ailments during the same time period as teething. And of course the true cause of these afflictions was unknown. So it became widely accepted that teething was a source of fever, diarrhea, vomiting, seizures, tetanus and meningitis, to name just a few, and even death. It was not uncommon for teething to be listed as the cause of death in children prior to the late 19th century. Unfortunately, many of these children probably died as a result of the misguided attempts at treating the perceived symptoms of teething.
Teething present
Though we have come a long way in our understanding of human physiology since the 19th century, there remains widespread misunderstanding of what symptoms can reasonably be attributed to teething. Parents and other caregivers are quick to list fever, difficulty sleeping, fussiness, drooling, changes in feeding amount and frequency, nasal congestion, and diarrhea, in addition to the most frequently cited symptom of pain, but the evidence has not been very supportive of these beliefs. To put it bluntly, it does not appear that the eruption of a tooth can be successfully predicted by any collection of symptoms. I have spoken to many parents who believe that their child has been teething for weeks without a tooth revealing itself. It just doesn’t work that way.
Experts do not believe that any systemic symptoms can be caused by the teething process. This includes poor appetite, congestion, difficulty sleeping, diarrhea, vomiting, cough, rash, or fever. At most, there may be some discomfort that goes along with the teething process. As with colic, a significant factor is the variability or fit of the parent-child dyad. The same child may be perceived as being more or less symptomatic, or not symptomatic at all, depending on which caregiver is observing them. Many new parents are exposed to misinformation regarding what to expect from teething and it is likely that at least in some instances it is a self-fulfilling prophecy of sorts.
The eruption of permanent teeth, which begins around age 6 years, is not typically associated with discomfort. This may be because of differences in sensitivity to pain between infants and older children, but it also might be evidence that the process just doesn’t really hurt that much. It is a myth that the new tooth cuts its way through the bone and gum. In reality a pathway emerges because of the remodeling of the tissue. Many children felt to be teething, and in need of treatment, may in reality be feeling no discomfort whatsoever. An indirect danger in continuing to attribute systemic symptoms to teething, and perhaps even pain, is the possible delay in seeking out appropriate investigation into their true cause.
Popular (but ineffective and potentially dangerous) teething treatments
More troublesome than any indirect harm of the misattribution of systemic symptoms to teething is the potential direct harm of actively trying to manage them. Historically the risk of serious harm from teething treatments was much greater. Many therapies used in the past were extremely toxic, such as lead- and mercury-based compounds. Consistent with beliefs in homorism, vomiting and diarrhea were frequently induced in order to purge the body of excess humors. The use of opiate based preparations could cause respiratory suppression and honey was a source of infant botulism.
The belief that tension on the gums played a prominent role in teething symptomatology was widespread. As a result, surgically cutting the gums in order to open up a path for the emerging tooth was a common procedure until the late 19th and early 20th century in developed countries. In some less developed regions around the world, the gums of infants were still frequently sliced open and the teeth removed. Sadly, well-meaning but dangerous efforts such as this still exist in some areas, and children continue to die of infection or live with significant malformations of the lower jaw and remaining teeth.
Many historical remedies for teething were based on a belief in magic. This hasn’t changed appreciably considering that one of the most common treatments used today is homeopathy. The pages of SBM are filled with articles discussing the mind-boggling inanity of homeopathy, so I won’t go into great detail in this post. In a nutshell, homeopathic remedies consist of concoctions diluted to the point that there is no possible means of therapeutic efficacy, if not non-existence. The proposed hypothetical underpinnings of these remedies are irrelevant as the reality is that there is no remedy in the remedy.
Hyland’s homeopathic teething tablets is one of the most popular examples of this. Continued belief in homeopathic remedies despite our improved knowledge of the pathophysiology of human illness, and how to treat it, is based on the naturalistic fallacy and an overemphasis on personal anecdotes rather than actual quality scientific evidence. Check out their website and provided video testimonials, and count up the logical fallacies. Their disclaimers, and reassurances that the amount of belladonna in the product is completely safe, are quite telling. The reason for all the fuss on their website is because of FDA concerns about the inconsistency in the amount of belladonna in the tablets and reports of toxicity in children. Hyland’s appears to disagree with these concerns. I’d go with the guy with all those medals though. Camilia from Boiron is another popular homeopathic product marketed for teething.
Another popular but ineffective remedy for teething symptoms is amber, typically incorporated into a necklace or bracelet. The claims regarding just how wearing amber might treat teething symptoms range from complete woo, such as it being charged with reiki energy, to somewhat more reasonable claims of analgesic chemicals being absorbed by the skin. These claims are implausible and thoroughly unproven, and amber jewelry represents a worrisome choking risk in young children.
Since it is believed by many that the source of any potential pain related to teething is localized to the area around where the tooth erupts, naturally a variety of topical preparations have been developed. These products typically contain the anesthetic agent benzocaine. Even assuming that teething does cause discomfort amenable to being numbed by a local anesthetic, there is a lack of evidence to support that these products are effective. But even if they were helpful in teething infants, the risks far outweigh any possible benefit. Children, particularly those under the age of 2 years, are at risk for a potentially deadly condition called methemoglobinemia when benzocaine is ingested or absorbed through oral mucosa. Methemoglobinemia interferes with the bloods ability to transport oxygen and can occur within minutes or hours after exposure, even after the very first use.
The FDA has issued warnings about this risk, and most pediatricians discourage the use of products containing anesthetics as well as those containing aspirin-like chemicals. There are also homeopathic gels, and teething oils that commonly contain clove oil. These only appear to work via parental placebo. The manufacturers of Orajel, probably the most widely known line of products used for teething and pain from oral ulcers or hardware, has jumped on the bandwagon and now offer their own homeopathic gel.
Use of oral analgesics like acetaminophen and ibuprofen (in babies over 6 months of age) is also common. There are no studies proving their effectiveness. Instead their use, as with all other interventions, is based on personal anecdotes and likely only appear to help because of any number of placebo effects. While these medications are relatively safe, and certainly safer than historical remedies or some of the other current popular treatments, they do have risk. Acetaminophen is associated with severe liver injury when overdose occurs and ibuprofen can cause bleeding in the stomach and kidney injury with regular dosing. These adverse effects aren’t common but they do occur.
How should teething be managed?
The safest approach to teething is to return whatever “remedy” you just purchased, thus avoiding anything that may potentially be harmful. Most experts will concede that although there are no systemic symptoms caused by teething, there may be some local discomfort. But it may be very mild, or there may be no pain at all. So any risk is likely too much when it comes to treatment.
If you believe that your child is experiencing discomfort, there are teething rings which can be chilled in the refrigerator which he or she can chew on. The thought process is that cold and pressure may help relieve discomfort. Avoid anything that may serve as a choking hazard in young infants, such as teething biscuits or cold bagels. And if you do choose to give acetaminophen or ibuprofen, check your dosing very carefully and avoid other products, such as cough and cold medicines, that may also contain acetaminophen.
Conclusion: TLC for teething tots
Everyone has an opinion about teething and how to treat it, and most of that advice is wrong or at least not based on any evidence. Though historically teething was seen as a life threatening malady, it does not cause systemic symptoms and may not even actually cause significant discomfort. If your child has fever, diarrhea, significant changes in behavior, or excessive irritability, talk to their doctor before blaming these symptoms on teething. If your child appears to have some minor discomfort, supportive care (i.e. TLC) is the safest and likely most effective remedy.

Separating Fact from Fiction in Pediatric Medicine: Burping Doesn’t Prevent SIDS, and Other Gas Related Nonsense
Though a seemingly worldwide practice, there is little plausibility and no evidence to support burping infants before, during, or after feeds. And it doesn’t have anything to do with SIDS.
Clay Jones on June 11, 2021
Link

We often write posts about very serious topics here on SBM. Some readers may not believe that this is going to be one of them, and they might be correct depending on their threshold for seriousness. What I’m going to discuss today certainly isn’t causing widespread suffering in the world, and it isn’t at all related to vaccine hesitancy or the SARS-CoV-2 pandemic, but that doesn’t mean that it isn’t important to many caregivers of young infants. And if it’s important to them, it’s important to me.
As a pediatric hospitalist that primarily takes care of newborns, the subject of burping comes up frequently. Most parents, from the new and nervous to the seasoned veterans of baby wrangling, take part in this particular example of medical folklore every time that they feed their baby. They calmly hold the child and tap or rub their back until they hear a noise that they label a burp, and then, satisfied with their active role in the proper order of the universe, they gently put the baby down for a nice nap. Maybe they even get some sleep themselves. It doesn’t always go down like this, however.
Most parents don’t ask me about burping their baby. They just do it and everything goes well. We have been told by society, medical professionals, friends, family, and pretty much anyone else you can think of that this is a normal and necessary thing to do. Maybe more parents question the practice than I’m aware of and just don’t say anything, perhaps wishing to avoid the shocked responses and potential shame they might feel should their reckless parenting choices be revealed.
I do tend to hear from the parents who want to burp their baby but are concerned that they are doing it wrong. Are they patting the baby’s back to hard? Could they injure their precious bundle of joy during a session of overzealous burping? I also hear from parents who are anxious whenever their baby doesn’t burp after a feed. Will they spit up and choke during sleep? Will their baby have reflux? Will they have excess gas in their tummy and be in pain? I’ve known many caregivers to spend inordinate amounts of time during and after feeds trying to get even the tiniest little burp out.
I get these questions a lot and sometimes do wonder about the origins of their worry. It’s all those sources I mentioned above of course, but I mean the origin of baby burping itself. Unfortunately, I have been unable to ever find a reliable resource discussing the history of this practice. This paper on the history of infant feeding is quite interesting but does not even mention burping or even tummy gas. I also cannot find any helpful discussion of the prevalence of baby burping across cultures, but my assumption has always been that it is a widespread phenomenon. I meet caregivers from all over the world practicing in the Boston area, and burping is fairly ubiquitous.
So why am I writing about this topic today? Because of the wiggle butt of course. What? You haven’t heard of the wiggle butt? Don’t feel bad. I don’t watch the TikToks either, but someone on Twitter was nice enough to bring the video, which has now been viewed many millions of times, to my attention. The technique, which is chiropractor approved, is nothing special. And sure, it “works”. I’ve never argued that jostling a kid around a bit doesn’t increase the possibility of them burping after a feed, only that caregivers don’t need to do it and that there is no proven benefit. More on that shortly.
So I watched the wiggle butt video and then started watching other videos on burping, like the one I linked to above from the chiropractor who sounds like he was in the cast of The Crown. And it’s about as medically accurate as that show is historically accurate. But I’m fairly confident that it’s the video that inspired the wiggle butt mom. I then started reading what medical doctors and fancy academic research centers have to say about burping and found that in many cases it isn’t any better than the information promoted on chiropractic websites. Then I really got into the weeds.
But first, what’s the deal with burping? Why do we do it? Is there any evidence to support the practice?
WTB? (What the Burp?)
Parents are almost always advised to burp their babies by pediatricians and other pediatric healthcare providers. The AAP even recommends it to reduce episodes of reflux or “spitting up“:
Extra gas in your baby’s stomach has a way of stirring up trouble. As gas bubbles escape, they have an annoying tendency to bring the rest of the stomach’s contents up with them. To minimize the chances of this happening, burp not only after, but also during meals.
Where do these tummy bubbles come from? As opposed to rectal gas that exits as flatulence, which is primarily composed of byproducts of intestinal bacterial fermentation, any gas in the stomach of a baby consists of air swallowed during feeding unless they are being fed a carbonated beverage. This swallowed air supposedly becomes trapped in the stomach, resulting in discomfort, and it increases the likelihood that a baby will spit up or develop reflux disease.
Parents are frequently advised to burp after every feed. If a parent seeks guidance because of suspected GI issues, they may get advice such as these recommendations from Johns Hopkins All Children’s Hospital:
Try burping your baby every ounce during bottle-feeding or every 5 minutes during breastfeeding if your baby:
    • tends to be gassy
    • spits a lot
    • has gastroesophageal reflux disease (GERD)
    • seems fussy during feeding
If your baby doesn’t burp after a few minutes, change the baby’s position and try burping for another few minutes before feeding again. Always burp your baby when feeding time is over.
The problem with this advice, other than that it results in feeds taking an hour or more and a mother who never gets any sleep, is that the belief it is based on has never been anything more than conjecture. Again, it does not appear that anyone knows where, when, or why this focus on tummy gas problems started. If I had to hazard a guess, baby burping behaviors preceded our attempts/ability to come up with a physiologic justification.
I imagine that over the past few centuries, the practice has evolved from child raising “common sense” into medical folklore that has been carried forward through the years by its own cultural inertia. It also doesn’t hurt that it is an active process that likely gives parents a feeling of some degree of control in the swirling chaos of colic. Rather than screaming into the void, they have the wiggle butt to provide a bit of solace and stability.
The concept of swallowing large amounts of air during feeding is suspect, however. The esophagus, unlike the trachea, is not propped open by cartilage. It is compressed except during swallowing, when the cartilaginous epiglottis falls into place over the trachea and the esophagus is the path of least resistance. Air in the oral cavity during swallowing is more likely to escape through the nasal passages than to enter the esophagus.
A baby shouldn’t take air into their esophagus any more readily than readers of this post do when swallowing non-carbonated beverages. We all may swallow a small amount air while feeding but there is absolutely no plausible reason to blame fussiness or spitting up on this other than the desire to blame something, anything for what is largely a random process in the vast majority of infants. When an older child or adult consumes a carbonated beverage and experience a distended stomach and the need to burp, pain is rarely a complaint. And just like them, babies don’t need really help burping either.
There is nothing about an infant’s physiology that prevents them from burping on their own, even if it wouldn’t be intentional. In fact, their physiology probably makes it easier for them to burp than older children. Infants, because of a general immaturity of the nervous system and gut, are prone to what have come to be labelled as “transient lower esophageal sphincter relaxation events” where the muscular valve between the esophagus and the stomach relaxes for no good reason. This tends to happen after feeds and it is the primary reason why babies spit up as much as they do.
So babies will burp when there is gas in the stomach regardless of whether or not we pat them on the back after feeds. They almost certainly burp all the time and caregivers don’t realize it because it isn’t loud or they aren’t in the room. The common anecdotal observation that burping helps babies to get the gas out is understandable though, because it almost certainly does sometimes. But again, babies burp just fine on their own and there may also be a bit of confirmation bias at play. If a parent were to keep a strict burp log, they might find that the process is a bit more random than they thought.
But is there a downside to burping? There actually just might be one. In addition to lost caregiver sleep and potentially agitating a calm or sleeping infant, burping may actually increase the likelihood that a baby will spit up after a feed. There is grand total of one study addressing the practice of infant burping in the medical literature, and it shows that burped babies are significantly more likely to spit up and no less likely to have episodes of fussiness. It was a small study with some limitations, but it is all we have and it certainly doesn’t support the practice of burping.
Now the weeds I mentioned getting into earlier. This 2018 CNN Health article on 10 mistakes that parents make with newborns lists burping issues twice, up there with safe sleep concerns and car seat safety. One of their “mistakes” is not “pre-burping” a baby:
Most of us think about burping after the baby eats. But experts say that you should also take the time to pre-burp your baby.
I have never heard of pre-burping a baby before they feed. I don’t know any experts that recommend this. A Google search only yields similar articles on the top 10, 15, or even 20 parent mistakes. In my opinion, pre-burping is even less of a thing than burping during or after feeds. Post-burping? No.
I found this brief article claiming that failure to burp a Ugandan baby prior to putting him down to sleep caused his death. According to the autopsy, the child “suffocated because of the reflux of food that had gone to his lungs”. If true, this is terrifying and it is a very common fear parents bring up in the hospital. Imagine being a parent and being told that your baby died because you didn’t gently pat them on the back before putting them down to sleep.
But unless this child had some kind of anatomical or neurological abnormality not mentioned in the article, the likelihood of a healthy infant choking to death in their sleep is essentially zero. It just doesn’t happen and the information provided in the rest of the article does not inspire confidence in its accuracy. I can think of several more plausible potential reasons for this child’s death than failure to burp.
Finally, here is a 2007 study published in Medical Hypotheses (yes, that Medical Hypotheses) that explores the potential role of infant burping as a means of reducing the risk of SIDS. This is just pure nonsense. Just for the record, the AAP may recommend burping all babies after every feed, proving that even they aren’t impervious to acting sans evidence, but it does not include gas as a modifiable SIDS risk factor because that would be even more embarrassing than having a section on integrative medicine.
Please check out this short documentary on the invention of a revolutionary machine designed to burp babies while leaving caregiver hands free to make a sandwich or defend themselves.

Separating Fact from Fiction in Pediatric Medicine: Infant Gastroesophageal Reflux
Clay Jones on May 23, 2014
Link

By now, regular SBM readers should be aware of the Choosing Wisely initiative. Just in case, Choosing Wisely is a campaign developed by the ABIM Foundation to bring together experts from a variety of medical specialties in order to identify common practices that should be questioned by patients and providers, if not outright discontinued. Their ultimate goal was not to establish treatment guidelines or dictate care, but to foster discussion. As I’ve written about in a prior post on the overuse of antibiotics in pediatrics, it doesn’t appear to have caught on. I routinely ask colleagues, residents and students if they are aware of it, and am frequently disappointed by their response.
The American Academy of Pediatrics issued a list of five questionable practices back in February of 2013 and I loved it. All five are important:
     1.  Stop treating viruses with antibiotics
     2.  Stop prescribing and recommending cough and cold medicines for young children
     3.  Stop routine use of CT scans for minor head injuries
     4.  Stop routine use of neuroimaging for simple febrile seizures
     5.  Stop routine use of CT scans for abdominal pain
While reviewing current evidence-based guidelines on managing gastroesophageal reflux in children for this post, I was surprised to find that in March of this year the AAP had released an additional five questionable practices for Choosing Wisely:
     6.  Stop high-dose steroids for the prevention or treatment of bronchopulmonary dysplasia in preterm infants
     7.  Stop blindly ordering food allergy screening panels without taking medical history into account
     8.  Stop prescribing acid blockers and motility agents for physiologic reflux
     9.  Stop surveillance cultures for screening and treatment of asymptomatic bacteriuria
     10.  Stop routine use of infant home apnea monitors to prevent SIDS
Naturally, I took number 8 as a sign that I was on the right track.
The problem of gastroesophageal reflux comes up frequently in pediatric medicine, especially during the first few months of a child’s life. Early in our residency training we learn about the existence of the so-called “happy spitter”, the baby who spits up for no apparent reason and without apparent symptoms. We learn to educate worried parents about this phenomenon, jokingly pointing out how this is usually a laundry problem rather than a medical problem. We are taught the signs and symptoms of gastroesophageal reflux disease (GERD) in children of varying ages, the behavioral modifications that might ameliorate the condition and the potential pharmacological and surgical interventions sometimes necessary in severe cases. While reflux is extremely common in babies, GERD is not.
But, as is often the case, something goes wrong after residency. Too many of us begin to alter our approach because of the influence of practicing in the real world and of common hardwired errors in how we interpret reality. Overuse of prescription medications, unnecessary formula hopping and potentially unsafe recommendations on sleep positioning are unfortunately widespread. Our pharmaceutical interventions carry significant risk with little evidence of benefit for most patients, and the combination of stress and a general lack of understanding of the pathophysiology of reflux leads to many parents seeking alternative treatments. Practitioners of irregular medicine are of course more than happy to claim expertise and success in treating what is largely a self-limited condition.
What is gastroesophageal reflux?
Gastroesophageal reflux, henceforth referred to simply as reflux, occurs when stomach contents pass into the esophagus. It is incredibly common in early infancy but occurs throughout the lifespan and is considered a normal aspect of our physiology. It is arguable that 100% of young infants have multiple episodes of reflux daily, with many being clinically silent because the stomach contents only ascend partially up the esophagus and are quickly cleared. Even when the bolus ascends to the oral cavity, infants often simply swallow it back down and caregivers are none the wiser.
But virtually 100% of children will have at least one episode of actual regurgitation (“spitting up”) at some point in early infancy, with most having several. Half of infants under 3 months of age will have a daily episode of regurgitation, and by 4 months of age, which tends to be the peak of incidence and severity, this will occur in two thirds. Incidence drops off steadily after 4 months, with only 5% of infants having daily regurgitation at one year of life. It is very uncommon for children over 18 months of age to still regurgitate, and even less so for them to start spitting up after that age.
Although in most children reflux is an uncomplicated and physiologic (normal) process, there are a variety of disease states and anatomical abnormalities that promote reflux or cause symptoms which might be confused for it. It is always very important for a child’s pediatrician or family doctor to evaluate them for any red flags such as bile-stained or bloody vomit, or vomiting that is consistently forceful in nature. Many neurologic conditions and systemic illnesses can result in either pathologic vomiting or increase the likelihood of severe symptomatic reflux in children of all ages.
Why is reflux so common in babies?
A convergence of physiology and anatomy occurs at the distal end of the esophagus which acts to limit retrograde movement of stomach contents. When not swallowing, the muscular tissue of the esophagus at the entry point into the stomach tends to remain contracted. This entry point occurs just beneath the diaphragm in most individuals, the pressure from which adds to the increased resting tone of the esophageal muscle. The angle of entry of the esophagus into the stomach is rather acute as well, leading to it being squeezed shut by a distended stomach.
In healthy people of all ages, but particularly infants, the normal high resting tone of the lower esophageal sphincter relaxes for no apparent reason during the time between feeds. This can occur upwards of 30 times each day in a young infant, likely because of general immaturity of many such processes. Older children and adults have the benefit of gravity when these events occur. When upright, all that tends to escape is gas in the form of a burp. But an infant is supine for significant periods of time and the entry point of the esophagus into the stomach is frequently covered with liquid breast milk or formula.
Young infants consume their entire caloric intake in the form of liquid, often taking in as much as 180 milliliters per kilogram each day. For a 75 kg adult that would equal just under 14 liters of fluid. And young infants feed much more frequently than older children and adults, so their stomachs are very full much of the day. Try drinking a couple of liters of milk every 3-4 hours. This extreme gastric distention increases the likelihood of transient relaxation events. Add to all this the fact that the angle of esophageal entry into the stomach is more obtuse than in older kids and adults, which is why distention of the stomach doesn’t squeeze it shut as effectively.
What is physiologic reflux, and more importantly, what isn’t it?
Physiologic reflux, even when the episodes of regurgitation are frequent, doesn’t result in weight loss or significant difficulty with feeds. The episodes of spitting up are typically not associated with crying or unusual movements, and there usually are not any red flags for a more concerning disease process. Reassurance really is the best approach as this almost always resolves on its own within a few months.
But parents will sometimes report that their otherwise “happy spitter” with physiologic reflux has difficulty sleeping or persistent nasal congestion. More common are complaints of general fussiness or irritability which have already been attributed to reflux in the minds of the caregivers. These symptoms, however, are very unlikely to be related to reflux, a revelation that I find most parents and often other medical professionals have great difficulty accepting.
As you can probably imagine with such subjective concerns, there are many different potential causes of apparent discomfort in an infant ranging from the benign to the life-threatening. And as with infant colic, psychosocial factors must always be taken into account since they can alter parental perception of reality and exacerbate, if not cause entirely, the subjective symptoms being attributed to reflux in a baby. With colic, how long and how severe the episodes of crying truly are is often warped by parental stress and sleep deprivation. How many times each day that a baby regurgitates, and the degree of fussiness during or between those episodes, is no different. Few parents are going to keep a detailed reflux diary.
There really is little in the way of solid evidence linking reflux to pain in the overwhelming majority of babies. Parents and physicians have historically made assumptions based on adult data and “experience”, but a review of the literature reveals a different story. Most studies have not supported the connection, even those that evaluate infants using monitoring of esophageal pH. And the best placebo-controlled studies have found that medications which decrease the production of gastric acid have no better impact than placebo on parental perception of infant irritability.
There are conservative and low risk behavioral and dietary interventions that can be recommended when reassurance fails or when parental quality of life is significantly affected. Unfortunately, these are often only discussed in the mildest cases of reflux. And prescription medications are far too quickly recommended despite a lack of evidence of efficacy, hence their inclusion on the AAP Choosing Wisely list.
The vast majority of episodes of reflux are very brief, and even if there is a significant acid component it is quickly cleared by the esophagus. And a layer of mucous is typically present which protects the esophageal lining from any injury. These normal protective mechanisms can be overwhelmed, particularly in children with neurological and anatomical risk factors, but significant symptoms related to reflux can occur, although uncommonly, even in otherwise-healthy babies leading to a diagnosis of GERD.
What is gastroesophageal reflux disease?
True GERD can present in a variety of ways depending on the age of the child, but is notoriously difficult to diagnose with any real certainty in a baby. An infant, for instance, doesn’t have the capacity to describe their heartburn. In babies, symptoms traditionally attributed to GERD are difficulty feeding or even feeding refusals, frequent episodes of arching of the back and crying that occur when a child regurgitates, and poor weight gain. In reality, GERD is an uncommon cause of these problems in infants, and many children are diagnosed with GERD simply based on parental descriptions of what the child does and the assumption that their behaviors are a result of pain from acid induced injury to the esophagus.
When babies fail to thrive, typically evident in poor or absent weight gain, GERD should be a diagnosis of exclusion because the most common causes are psychosocial in nature and there are a variety of other medical conditions that need to be ruled out with a thorough history taking, physical exam and targeted diagnostic testing. Respiratory symptoms that are often attributed to GERD include apparent life-threatening events (blue baby, trouble breathing, terrified caregiver), cough, recurrent pneumonia and wheezing. While certainly possible, persistence of these issues requires investigation for other causes, recurrent viral respiratory infections being considerably more common than true GERD in a young infant.
There are a few diagnostic modalities used to evaluate children with suspected GERD or some other condition presenting in a similar fashion. These techniques are infrequently used in infants, however, because of either poor sensitivity and specificity or their invasive nature. We can, using probes placed in the esophagus, quantify the pH and impedance. This can tell us when reflux happens and if it is acidic, but in infants this information doesn’t mean much because apparent symptoms often don’t correlate well with measured reflux events because they usually aren’t caused by the reflux. But this type of investigation can be helpful when a child has the sudden onset of severe symptoms to see if they really do occur at the same time as reflux, although there is still the possibility of a coincidence.
Imaging, specifically what is known as an upper gastrointestinal series, should never be used for routine reflux because it involves a large amount of ionizing radiation and will only reveal what we already know: infants reflux. We don’t need to see it in real time with contrast-laden formula to prove it. This technique is reserved for when there are red flags for an underlying anatomical abnormality. Unfortunately, I still see the occasional perfectly healthy baby who has been diagnosed with reflux using fluoroscopy. Ultrasound imaging of the stomach is also sometimes useful when infants have red flags.
The gold standard in diagnosing GERD, because it allows direct visualization and the ability to take tissue biopsies, is endoscopy. Inserting a scope down the esophagus is usually reserved for when a patient doesn’t respond to less invasive interventions, such as lifestyle modification, medications and dietary changes, and even then it is more about ruling out non-GERD causes of symptoms. It isn’t perfect though. Findings on biopsy do not correlate well with presence or resolution of symptoms in babies.
What is the science-based approach to treating infant reflux/GERD?
To stress again, reassurance is often all that is needed when a baby spits up, and even when there is some concern that they might have mild to moderate GERD. So-called lifestyle modifications are all that is needed in more troublesome cases, even if all that they really do is buy a little time while the reflux resolves on its own. The risks associated with these modifications are very low. If a baby is exposed to cigarette smoke, stop it. Give smaller feeds. Feeds may need to be given a little more frequently or formula can be concentrated to give more calories per ounce, allowing a smaller volume feed. Many babies with reflux are simply overfed, particularly if they are on formula, but this can occur with breastfeeding as well. If breast milk oversupply is a possible issue, lactation experts do have methods of dealing with this.
In general, hopping from formula to formula is not recommended. The differences between competing standard formula brands are clinically meaningless with extremely rare exceptions. But in babies with mild-moderate GERD, many experts recommend an empiric trial of removing cow’s milk from the diet because milk protein allergy is a common GERD mimic. A specialized formula can be used which contains broken down “hypoallergenic” proteins or the mother can attempt to remove dairy from the diet although that can be difficult to achieve and maintain.
Thickening feeds with rice cereal or oatmeal can help, primarily by reducing the number of regurgitation episodes. It likely won’t treat true GERD, however, but it may help change parental perception of symptoms. It isn’t worth it for breastfeeding mothers, as they would need to pump, thicken and feed via a bottle. Thickening significantly increases the caloric density of the formula or breast milk, so weight gain can become an issue. There are also formulas on the market which are “pre-thickened”. They should be of similar effectiveness theoretically but they haven’t been studied enough to say for certain.
Gravity plays a role in causing reflux, and parents can take advantage of it also. Although not well studied, keeping a baby completely upright for 10-20 minutes after each feed is often recommended to reduce reflux episodes. There is no real downside other than the extra time involved. I’ve seen many parents, and a number of medical professionals, who have extrapolated from the likelihood that upright positioning helps to placing a child in, or recommending, partial supine positioning. Sitting in an infant seat actually increases the likelihood of reflux, and achieving a partial incline by placing the child on an elevated mattress might increase the chance of rolling onto a prone position before they are developmentally ready. Prone positioning does decrease reflux but it isn’t worth the increased risk of SIDS.
What about those drugs for reflux/GERD?
As a pediatric hospitalist, I’m hardly shy about throwing evil synthetic pharmaceutical agents at kids. But in the case of reflux and most cases of mild-moderate GERD in infants, they aren’t going to help and will only expose the child to the potential side effects. There are times when they are appropriate, however, such as when endoscopy findings reveal significant inflammation or when there are anatomical/medical conditions that increase the likelihood of GERD. When symptoms are severe and don’t respond to conservative measures, a trial is also reasonable. But they shouldn’t be continued for more than a couple of weeks without clear improvement. Even surgery is sometimes indicated in the most severe cases of GERD, although that is most likely to be required when a child has a neurologic problem that places them at risk of aspirating feeds into the lungs.
As I stated earlier, most babies can’t reliably be diagnosed with GERD because the symptoms are based on parental report for the most part. Parental report can only really be suggestive of GERD. We know that these symptoms almost always respond to lifestyle changes/placebo and regurgitation episodes decrease quickly after 4 months in most infants. There are many studies demonstrating that the conservative approach is best and that medications which decrease or stop acid production often aren’t better than placebo, particularly for the perception of general fussiness.
But these medications are some of the most commonly prescribed in infants, with use of newer (meaning more expensive and more potent) proton pump inhibitors increasing dramatically over the past ten years. This wouldn’t be an issue if they were only prescribed for babies that were more likely to have actual esophageal injury because PPIs are more effective at stopping acid production and allowing the esophagus to heal. They were a game changer in the adult population, where GERD and heartburn are much more easily diagnosed. Many infants are placed on older histamine type 2 receptor blockers, which decrease acid production but don’t stop it. They also have the downside of tachyphylaxis, where a drug loses effectiveness over time, in this case allowing acid production to rebound. They are considerably cheaper though.
What are the risks? Antacids are generally avoided in babies because of the lack of efficacy and risk of toxicity. H2 blockers are pretty safe but lose effectiveness after a few weeks. PPIs are where the real risk is, increasing the likelihood of pneumonia and intestinal infections such as the dreaded Clostridium difficile. Stomach acid plays a role in killing potentially pathogenic bacteria after all. When I was a resident, the drug metoclopramide was all the rage and it used to drive me nuts. It is a prokinetic agent that can enhance emptying of the stomach. Delayed emptying is only rarely a problem in healthy kids and the risks of this medication are considerable, including impressive dystonic muscular contractions and increased risk of seizures.
What about an alternative approach to infant reflux/GERD?
It is a good thing that infant reflux is a generally self-limited and benign condition, although it is often frustrating when excessive parental concern becomes the predominant issue. But most, if not all, pediatricians would much rather work hard to reassure the parent of a well child than have a suffering child. Unfortunately, a combination of many factors frequently lead parents to seek out alternative approaches to infant reflux.
Some parents who bring their baby to a chiropractor because of concerns about reflux, for instance, were going to bring their kid in anyway because it fits into their world view. They will buy unproven herbal concoctions, allow deluded theatrical placebo artists to poke their baby with acupuncture needles, and try just about anything they perceive as a natural remedy. It is unlikely that we are going to have much of an impact on that sad reality.
Certainly some parents are just frustrated by a seeming lack of options with conventional medicine. They may be uncomfortable with giving medications to such a young child. They may just be tired, stressed and online, a combination that probably is to blame for the majority of bad medical decisions. But the children of most parents who seek out natural cures for apparent reflux are also cared for by pediatricians and family doctors. These caregivers are simply seeking out additional help and have been fooled by the pretty wrapping paper on the empty box that is alternative medicine. Maybe we can reach these parents before they take the plunge, wasting money or worse, putting their child’s health at risk.
It isn’t that many proponents of irregular medicine don’t provide some useful information for parents. I’ve spent hours investigating the approach of chiropractors, homeopaths, naturopaths, acupuncturists, etc to reflux and found that we frequently agree. Like me, they tend to stress the benign nature of most cases of reflux and the fact that the attributed symptoms tend to resolve on their own. They talk about the conservative recommendations, and even if the details aren’t always exactly right I didn’t see much of anything that was dangerous. If only they stopped there.
As is always the case, there is little time devoted to educating parents on the nuance of a condition like reflux in a baby. This is likely because nuance is not something that alternative medical practitioners understand themselves. They are more about the big picture. Natural is better. Subluxations are to blame for everything. So forth and so on. They get that reflux is almost always benign but not that the symptoms may not even really exist or may not be caused by reflux. They denigrate drugs because they don’t work but fail to realize that their placebo-based interventions are no different, and they absolutely do not have the training to rule out more concerning conditions that might initially cause symptoms similar to GERD.
A good example I found was a discussion of infant reflux by The Holistic Mama. It contains some good advice, but also a great deal of common bogus concepts like detoxing, essential oils and overzealous elimination diets for breastfeeding mothers. One alternative approach to reflux which was completely new to me was the use of hazelwood reflux jewelry. These are similar to the amber teething necklaces that John Snyder wrote about recently in that they seem to work, defy all plausibility and may serve as a choking hazard.
Chiropractic appears to be the most commonly recommended alternative treatment for infant reflux. The proposed mechanism of action is removing nerve interference cause by subluxations acquired during birth. Despite how easily I found a large number of chiropractic practice websites touting success, Pubmed contained only one published paper on the use of chiropractic for infant reflux, which naturally was a case report. Frequently linked to on said chiropractic websites, this report is another perfect example of why anecdotes usually aren’t helpful for much other than generating a hypothesis. The child in question began chiropractic at exactly the same time that reflux tends to peak and then quickly improve. Also the complaints were subjective and could have easily been affected by a variety of placebo effects.
Conclusion: Reflux in infants is common and usually benign
Gastroesophageal reflux is a common complaint, and affects essentially all young infants. The symptoms related to reflux, the most common being general fussiness, are largely subjective and the connection is not well supported in the literature. It is very likely that in many cases of apparent reflux, parental perception of their child’s symptoms is altered by stress and fatigue.
Despite the knowledge that reflux in babies is a normal aspect of physiology, and almost always benign and self-limited, it has unfortunately become medicalized. This has led to a frequent parental demand for relief from healthcare professionals and the overuse of reflux medications. These medications are unlikely to impact the course of infant reflux beyond the effect of placebo on parental perception of the symptoms, and are not risk free. Rarely is direct and clear evidence of esophageal injury found in an infant, but in some cases a tentative diagnosis of GERD is warranted and a trial of acid-reducing medications indicated. In nearly all cases of reflux in infants, and even with suspected GERD, conservative measures are indicated and should be attempted prior to starting medications.
Because reflux is benign and tends to resolve spontaneously, proponents of unproven alternative medical modalities claim to have both success in curing it and, depending on the type of practice, special knowledge about what causes it. What they do not have is any evidence to support treatment recommendations that aren’t already a component of the conventional approach to management. But even when they give semi-reasonable advice it is often jumbled together with misinformation.

More Evidence that Ignoring Safe Sleep Advice Puts Babies at Risk of Unexpected Death
A new study of thousands of cases confirms that sharing a sleep surface with a caregiver significantly increases the risk of unexpected death in infancy.
Clay JonesonMarch 1, 2024
Link

Despite the efforts of pediatric healthcare professionals to educate families on the risks of unsafe sleep practices, and to encourage adherence to safe sleep guidelines, sleep-related sudden unexpected infant deaths (SUID) remain stuck at around 3,400 cases each year. SUID, as I explained in more detail in a 2021 post, includes SIDS, accidental suffocation and strangulation in bed (ASSB), and unknown causes. In that post, which discussed data from 2011 through 2017, I pointed out the frustrating fact that most SUID cases occurred in the setting of modifiable environmental risk factors:
After analyzing the data, the authors determined key implications for pediatric healthcare professionals. Because more than 70% of SUID cases involved unsafe sleep environments, it is crucial that we figure out why caregivers aren’t following our recommendations. It is imperative that we develop more effective ways to educate these caregivers and help them adhere to the guidelines
https://sciencebasedmedicine.org/cdc-data-reveals-frustrating-infant-death-statistics/
A study looking at CDC data from 2015 through 2020, which I also covered last year, found additional concerns. in 2020, there was a 15% increase in SIDS cases despite improvements in overall infant mortality in general. The increase in cases of SIDS, as I explain in that post, appeared to be real and to involve a specific group of infants:
What really stood out in the 2020 numbers was that every group had SUID rates that were either lower or stable except for Black infants. This group saw an increase of 11%, from 189.9 to 214 cases per 100,000 live births. So if the increase in SIDS cases is real, and I think it is, it isn’t a stretch to imagine that most of those additional deaths involved Black infants.
https://sciencebasedmedicine.org/was-the-sars-cov-2-pandemic-to-blame-for-an-increase-in-unexpected-infant-deaths-in-2020/
The factors behind the increase in SUID cases in black infants almost certainly involved pandemic-related socioeconomic stressors that negatively impacted the day to day lives of their caregivers. Essentially, financial as well as physical and mental health challenges in the hardest hit communities likely resulted in decreased adherence to safe sleep recommendations. Hopefully subsequent years will have seen a return to “normal”, which again is still bad for babies of color, but that data isn’t available yet.
What I want to write about today is a new study in Pediatrics which provides further confirmation that we need to work much harder to convince families to follow safe sleep recommendations, and to help establish an environment where following those recommendations is easier. In the study, researchers set out to gather data involving the “characteristics and circumstances” of SUID cases in order to determine differences and similarities between cases where infants were sharing or not sharing a sleep surface with a caregiver. Surface sharing significantly increases the risk of all forms of SUID, and specifically SIDS by nearly 300%, which is why pediatricians so strongly recommend against it. Despite the fact that half of all SUID cases occur on a shared sleep surface, it remains a common practice with roughly a third of infants sharing a caregiver’s sleep surface for significant periods of time.
Using data from the CDC SUID Case Registry, which contains child death review program information (death certificates, autopsy reports, medical records), the researchers looked at surface sharing status, found location of the dead infant and person(s) sharing the surface, infant demographic data, birth characteristics, sleep environment, and potential suffocation mechanisms. In total, 7,595 SUID cases occurring from 2011 to 2020 and from 23 different U.S. jurisdictions were evaluated. Gathering this kind of data, according to the study authors, could drive future research and help us to better educate families.
60% of the SUID cases involved sleep surface sharing, which was a bit higher than expected. Also keep in mind that this particular datapoint is self-reported and very likely an underestimation of the true association. Most (73%) of the co-sleeping infants were 0 to 3 months compared to 57% of nonsharing infants. Most cases of SUID occur in younger infants, so this tracks. The largest group of infants sharing a sleep surface were non-Hispanic Black at 42%. Non-Hispanic White infants made up the largest nonsharing group at 46%. Sharing a sleep surface was more common with publicly insured infants.
46% of infants who died while sharing a sleep surface were found in a riskier face down or side position compared to 61% of nonsharing SUID cases. Nonsharing significantly lowers the risk of SUID, but it is not the only potential problem. This is an example of how data like this might help us to better educate families. Some caregivers might have a false sense of security and bend the rules a bit when placing a baby to sleep in a bassinet rather than co-sleeping. A baby is safest when all the recommendations are followed.
Another finding of concern is the clumping of risk factors in surface sharing scenarios. A third of bed sharing infants died in soft/loose bedding, sleeping on an adult bed, and face down or in the side position. 21% of nonsharing infants had all three risk factors, which is also shockingly high. 76% of these cases overall involved more than one SUID risk factor. Finally, infants sharing a sleep surface were more likely to have been exposed to maternal cigarette smoking during pregnancy, which is actually more of a risk factor than postnatal exposure.
The findings in this study were consistent with previous analyses when it comes to the clear dangers of sharing a sleep surface. We need to find a way to effectively communicate this risk to caregivers, but communication is only part of the issue. Many caregivers who decide to co-sleep likely know that it is riskier but have no other options. One example mentioned in the paper is that some families may not have a crib. There are often resources that hospitals can access to help in these situations.
These bed sharing families are more likely to have younger infants, to be black, and to rely on public health insurance. The first several weeks of parenting a new baby can be a time of great physical and emotional, and perhaps also economic stress, with the potential for sleep deprivation among many other issues. Focusing on easing the burden of caring for a young infant with a biopsychosocial approach might result in less sleep surface sharing.
Counseling of infant caregivers on the safe sleep is a challenge. It needs to be comprehensive. Heavy focus on only one aspect, even if it as important as providing a separate sleeping surface for an infant, might not always be the right approach. Though we don’t like to think about it, some families are going to bed share no matter what we say and there are ways to make it as safe as possible. Establishing an open and non-judgmental dialogue with caregivers can allow for honest disclosure and an ability to help reduce risk without endorsing practices that aren’t in line with AAP guidelines.

Nightmares, Night Terrors and Potential Implications for Pediatric Mental Health…..
Clay Jones on March 14, 2014
Link
Earlier this month, the typical media outlets were abuzz (“Childhood nightmares may point to looming health issues“) with the results of a newly published study linking early childhood nightmares and night terrors with future psychotic experiences. Expressing little in the way of skepticism, most reports simply regurgitated the University of Warwick press release. The research, published in the quite legitimate journal Sleep, is interesting but I’m not sure it tell us anything that we don’t already know. And it certainly doesn’t support any causal relationship between sleep disorders of any variety and “delusions, hallucinations, and thought interference”. But before we delve into the specifics of the paper, I believe a quick review of sleep, and sleep problems, in children is in order.
What is sleep?
To the outside observer, sleep appears as an altered level of consciousness where response to our environment and voluntary movements are noticeably decreased. But, with a certain degree of variability, the line between sleep and wakefulness is pretty thin. This distinguishes it from the increasing stimulation required to reverse other states of altered consciousness such as lethargy, obtundation, stupor and ultimately coma, which is not acutely reversible. I don’t plan on getting too technical, but there is obviously much more to sleep than that. Physiologically our metabolic demands drop a bit, and we enter a generalized anabolic or “growth” state during which a number of beneficial processes take place, predominantly, we think, involving the brain.
Sleep is a vital aspect of human life that has appears to have both physiological and psychological purpose, and is essentially universal in the animal kingdom. All you need to do is observe a cat for more than five minutes to see that we aren’t the only animal species that both needs and seemingly enjoys sleep. In fact, if you could talk to a nematode, it would likely go on for hours about how much it enjoys sleeping in on Sundays. Humans spend roughly a third of their lives asleep, but the percentage of each day devoted to sleep is significantly higher during infancy and early childhood.
We don’t know why the need to sleep became part of the blueprint for life so early on in our evolutionary history, and researchers certainly haven’t worked out all of the nuances of why humans and other animal species continue to be so dependent on it throughout the lifespan. It is likely that its purpose has broadened over time as species branched out into new environments. There are a number of leading hypotheses, however. And barring some amazing technological or medical advance, we appear to be stuck with sleep.
Why do we sleep?
Again, there are many proposed purposes for sleep. Much of the evidence relies on the observation of what happens to our bodies when we don’t get any. Poor sleep affects a number of physiologic processes, and there are probably consequences that we aren’t even aware of yet. Ultimately, a complete lack of sleep, although rare, is fatal.
Many of the hypotheses for the purpose of sleep involve its potential restorative powers, with proponents invoking evidence of increased clearance of waste products from the brain during sleep, as well as improved wound healing and immune system function. How do you truly boost your immune system? Sleep is probably a better means than any supplement or bogus healing modality and considerably cheaper. Sleep also may play a role in clearing out the cobwebs so to speak, by weeding out weak neuronal connections, allowing memory and learning to function optimally and supporting cognition. There are numerous studies detailing the effects of poor sleep on these processes.
Another school of thought involves the role of sleep in development. This stems from observations that babies sleep more than older kids and adults, and in particular active or REM sleep occurs for longer periods of the day in the very young in the vast majority of animal species. We also know that interference with REM sleep in the young can lead to a variety of negative development outcomes later in life. Perhaps this explains the origins of both muscle inhibition and dreams, as activating the brain without the risk of injury may be a pivotal aspect of proper development. Maybe REM sleep persists into adulthood as part of general brain maintenance. Who knows? But this doesn’t hold water in all species. Marine mammals don’t develop REM sleep until adulthood.
The weakest of the potential purposes for sleep appear to involve energy conservation and life preservation. Metabolic processes only slow down by about 5-10% during sleep, and animals that hibernate, a time of more significant drop in energy usage, still need to sleep afterwards. And decreasing consciousness with predators around seems like a risky means of taking a rest if that was all it was about. Avoiding predators by sleeping during their peak activity doesn’t explain why apex predators sleep or why sleep is still required the day after a sleepless night.
Clearly there is also a behavioral component to our desire to sleep. We get sleepy when we need sleep, although this doesn’t always translate to actually being able to fall asleep. At times our bodies face an almost overwhelming demand. It makes sense that this drive to sleep occurs because of some vital physiological importance, but sometimes we feel the urge to sleep for purely psychological reasons, even when we have consistently been obtaining a reasonable amount. There can be great pleasure in taking a nap on a day off. Sleepiness seems to occur with certain environmental cues as well, often accompanying boredom and sadness.
When asked about the reasons we sleep, William Dement, a sleep expert who was part of the early research on REM sleep, famously said “As far as I know the only reason we need to sleep that is really, really solid is because we get sleepy.”
Sleep problems in kids
Sleep is incredibly important to growth and development in children. Unfortunately sleep problems are very common, occurring across the age spectrum. They range from mild and occasional inconveniences accepted by most parents as normal aspects of childhood development to full blown disorders with a significant negative impact on the quality of life for patients and their loved ones. In general, anywhere from a quarter to half of children have difficulty with sleep at some point.
The structure and patterns of sleep are in flux throughout childhood. How many hours each day that we sleep, the specific percentages of REM and non-REM sleep, the duration of sleep cycles and how sleep is distributed over a day all change over time. So do the behaviors associated with sleep. Sleep problems manifest in a variety of ways during childhood as well.
An infant deprived of the recommended average of 15 hours of daily sleep over the first year of life (newborns often need 16-20 hours) may be irritable, feed poorly, and have delays in the acquisition of developmental milestones. And adding parental lack of sleep to the mix can be disastrous as it decreases their ability to handle stress appropriately. Lack of sleep in older children can result in learning difficulties and continued developmental challenges. Behavior, memory and attention problems can affect school performance. Even issues with weight gain and obesity have been linked to lack of sleep. And unfortunately, difficulties with sleep in childhood have often been found to be predictive of a wide range of future problems such as depression and anxiety, drug use, obesity and sleep disorders.
As in the adult population, there are a variety of sleep disorders found in children. The typical screening tool used by pediatricians is the BEARS, which consists of trigger questions for different age groups that can help reveal problems in one or more of five sleep related categories: Bedtime problems, Excessive daytime sleepiness, Awakenings during the night, Regularity and duration of sleep and Snoring. Probably the most common sleep disorder in kids is behavioral insomnia. Though it is extremely common for young children to wake up during the night, it can be a big problem if they have not learned how to fall back asleep without parental assistance and it occurs repeatedly each night. Behavioral insomnia also occurs, typically in older kids, because of a lack or inconsistency of limit-setting. These children simply refuse to go to bed. Again, it is common for there to be some resistance to calling it a night during childhood but at a certain point it becomes excessive.
Children can also suffer from disorders of the circadian rhythm, typically presenting in adolescence or young adulthood. The most common circadian rhythm problem is delayed sleep phase syndrome, where there is an inability to fall asleep and wake up during conventionally desired time periods. Sleep-related breathing disorders, in particular obstructive sleep apnea, is an increasingly common problem in children. This occurs when there is intermittent blocking of the upper airway, either partial or complete, that impedes airflow during sleep. It can lead to drops in the amount of oxygen in the blood and is associated with heart disease and hypertension in addition to behavior and learning difficulties.
The final category of sleep disorders commonly seen in children, and the one which the study on nightmares and future psychosis looked at, are the parasomnias. These are, at least to me, the most fascinating of the sleep disorders and certainly the group that gets the most coverage in the media. Parasomnias are discrete behavioral episodes that happen at any point during the sleep process, causing an interruption but generally not impacting the overall quality of sleep like insomnia or circadian rhythm disorders do. They do often lead to a great deal of parental distress however.
The parasomnias, which include nightmares, night terrors, sleepwalking, sleep talking, confusional arousals, bedwetting, teeth grinding, excessive or unusual movements and sleep paralysis are very common. There isn’t a lot of long term data, but one large cross-sectional study revealed that nearly 90% of children had at least one between the ages of 2.5 to 6 years of age. My 5-year-old daughter for example both talks in her sleep and often has confusional arousals during the night. It’s adorable. There appears to be a huge decrease in incidence once children reach school age but some parasomnias do persist or occur later in childhood and even in adulthood. Some only occur in adults. Studies on kids have primarily consisted of parental recall however, and mild events may not be recognized by parents. So we have to take the numbers in older kids with a grain of salt.
Night terrors
I could write an entire post just on these parasomnias, but for this post I’ll focus on nightmares and night terrors as they were focused on in the study. Night terrors occur during stage 3 and 4 non-REM sleep and are classified as a disorder of partial arousal along with confusional arousals and sleepwalking. They tend to happen as children are transitioning into lighter sleep or even into wakefulness.
There appears to be a genetic predisposition to having this type of parasomnia. One twin study that looked 323 pairs was very supportive, showing 6 times the incidence in identical versus fraternal twins, and another study revealed more than twice the likelihood of night terrors in the child of a sleepwalking parent. There are common triggers for these arousals as well, including obstructive sleep apnea, restless leg syndrome and reflux. Removing the trigger can stop the parasomnia. Anxiety, poor sleep and fever have also been shown to be triggers. The partial arousal parasomnias all typically occur during early childhood and gradually go away with time as the amount of slow wave sleep decreases, with very few teens and adults having them. EEG findings reveal unstable deep sleep.
Night terrors can be very impressive and scary for parents. The child appears to be sleeping soundly when suddenly they begin screaming. They are red faced and sweat profusely, reflecting the increase in autonomic nervous system activity. Their hearts are racing. They may even jump out of bed as if fleeing from some invisible monster and they are inconsolable or very confused and disoriented if awakened. Eventually, after 10-20 minutes of seeming terror, they fall back asleep and will have no recollection of the event in the morning. It’s no wonder that historically these events may have been attributed to demon possession or evidence of other paranormal activities.
We think that night terrors occur in anywhere from 1% to 6.5% of young children, and in about 2.5% after adolescence. Again, there appears to be a substantial genetic predisposition. They are usually infrequent and benign, perhaps occurring only once or twice a month, so parental reassurance is usually all that is needed. When causing a problem, the first step is making sure that the child is getting adequate sleep. Toddlers need naps during the day for instance but many aren’t given time to do so. Addressing other potential triggers is also an important step in managing significant night terrors. Finally, there are cases of severe refractory events, sometimes putting the child at risk of injury, that require a low dose sedative for a few months. Although there are only anecdotal reports, scheduled awakening prior to the typical time of the event, followed by reassurance and allowing the child to fall back asleep may help.
Nightmares
Nightmares are disturbing dreams, differentiated from night terrors by occurring during REM sleep, that lead to sudden wakefulness and emotional distress. They can involve a variety of intense emotions, such as sadness, anger, or disgust, not just the stereotypical fear and anxiety. Nightmares tend to occur during the early morning, as opposed to late evening with night terrors, and patients usually have good recall of the events of the dream although there ability to describe them varies with age. Also, unlike after night terrors, children with nightmares tend to achieve full wakefulness and have difficulty falling back asleep because of residual distress. There is an absence of symptoms such as flushing and sweating on awakening, but kids may have some mild increased heart rate, and excessive body movements during the nightmare are uncommon because of REM sleep inhibition.
Nightmares occur in a large percentage of children, and often can interfere with sleep and lead to parental awakening. Stress in general, and traumatic events can induce nightmares, so it shouldn’t be surprising that nightmares are more common in kids with PTSD. Similar to night terrors in this regard, poor sleep and anxiety can increase the incidence of nightmares. Unlike night terrors, there are some medications that can also increase the risk. Nightmares tend to peak between 5 and 10 years of age and then significantly decrease in incidence.
Reassurance is also in order with nightmares, and improved sleep hygiene. Simple techniques such as night lights and avoiding any potentially overstimulating television before bed can help, as can relaxation strategies. But with very frequent and severe events, there is potential association with anxiety disorders so a referral to mental health or a developmental-behavioral pediatrician may be necessary.
Nightmares, night terrors and psychotic experiences
The study making the rounds this month is a prospective birth cohort study using data from the Avon Longitudinal Study of Parents and Children (ALSPAC). A longitudinal cohort study, as opposed to a cross-sectional study, follows a group of subjects without a condition and who share common characteristic over time, sometimes even decades, to investigate various exposures or risk factors and their possible link to the development of a condition. The common experience of the cohort used for this study was being born in 1991 or 1992, and in or around Bristol, England. 6,796 children (3,462 girls, 50.9%) who completed a psychotic experiences interview made up the subject pool.
Although prospective cohort studies can be very helpful in telling if a certain risk factor, such as heavy smoking, plays a causal role in the development of lung cancer for example, they aren’t as effective as the randomized controlled trial. But they are a solid epidemiological tool even if there is some increased risk of missing a confounding variable. Of course RCTs aren’t always appropriate. Imagine assigning a study group to smoke a certain amount of cigarettes each day, or having a random assignment to the “no vaccines” arm of a trial. Only IRBs made up of family members and meeting in your basement would approve a study like that.
An advantage of a prospective cohort study is determining potential risk factors for a condition by following subjects over long periods of time. And when information is collected frequently over time, there is less need to rely on potentially biased recall of information. As with any prospective design, subjects can drop out, die, or disappear. And longitudinal cohorts running for decades take time and money, but are often worth it because of the improved reliability over studies that look back retrospectively or involve samples of subjects taken at one moment in time.
The authors compared subsets within the cohort, in this case children whose mothers reported frequent nightmares between age 2.5 and 9 years, to children who did not have frequent nightmare episodes during that period, and then 12-year-old children who self-reported nightmares, night terrors, or sleepwalking during the previous 6 months to those who did not. All of the children were asked about psychotic experiences at age 12 years. The goal of the authors was to examine any link between these parasomnias and psychotic experiences.
According to the authors, potentially confounding variables such as sex, family adversity, emotional or behavioral problems, IQ and potential neurological problems were accounted for, but I think some glaring potential confounders were missed. After analyzing the data, they concluded that “Nightmares and night terrors, but not other sleeping problems, in childhood were associated with psychotic experiences at age 12 years. These findings tentatively suggest that arousal and rapid eye movement forms of sleep disorder might be early indicators of susceptibility to psychotic experiences.” I appreciate their use of the word “tentatively”.
Also, the study does not tell us what having psychotic experiences at age 12 means in regards to future risk of mental health problems. The same authors, using the same cohort data set, actually addressed this in a 2013 study published in the American Journal of Psychiatry. In that paper they found a very poor positive predictive value of non-clinical psychotic experiences at age 12 years. Only 1.7% of 12-year-old subjects reporting psychotic experiences went on to meet criteria for a psychotic disorder at age 18 years. Sadly, only half of the 1.7% had received any mental health services.
Mothers were interviews roughly every 16 months between age 2 and 9 years, which seems like plenty of time for there to be some error in recall to creep in but it could be worse. Children whose mothers reported only one period of nightmares were 16% more likely to have psychotic experiences at age 12 years. Kids with 3 or more periods of nightmares were 56% more likely. Of the 12-year-old children asked about recent parasomnias, those with nightmares were 3.5 times more likely to have psychotic experiences while those reporting night terrors had twice the risk. The specific psychotic experiences they asked about were hallucinations, interrupted thoughts, and delusions and only 4.7% reported having one.
As I said in the intro, this study is interesting but I’m not sure if it adds much to what we already know. And naturally much of the news coverage is over-hyped and at times comes across as implying that somehow nightmares and night terrors might play a causal role in psychotic experiences in older kids, which is completely unfounded. There is also the implication that psychotic experiences at age 12 are a good predictor of psychiatric illness. The authors are absolutely not making that claim. But if this gets parents and healthcare professionals to pay a little more attention to sleep hygiene and pediatric mental health, I’m okay with that.
I feel like if a mother approached a pediatrician about her child having persistent severe nightmares or night terrors, especially if they had aged out of the typical peak years, most of us would consider the possibility that something more was going on, and not just mental illness. We would get a feel for the home and school situation and ask about risk factors for abuse, neglect, exposure to violence and poor sleep hygiene. We would also review potential worrisome indications for mental health issues. And I’d like to think that we would make the appropriate referral if necessary. But I don’t think that we should approach nightmares in the overwhelming majority of young children as a sign of mental illness.
Of course the major issue with pediatric mental health in this country is the abysmal lack of pediatric mental health in this country. There is often nowhere for poor kids to go for care, and often long waits for even those with money. Many get to the point of suicidal ideation or self-harm having never been evaluated. Suicide is an all too common cause of death in teens. Many don’t enter the system until they are forced to sleep in an emergency department for 3 days while waiting for a bed in an inpatient psychiatric facility.
Not surprisingly, the apparent relationship between parasomnias and psychotic experiences was stronger in the 12-year-old subjects who were currently having parasomnias. We already know that there is an association between stress and anxiety with parasomnias, and mental illness, or maybe just worrying about mental illness, certainly could be a strain. Many adolescent patients with schizophrenia for instance will self-medicate with marijuana. Marijuana can cause psychotic experiences. Some kids with schizophrenia are missed because their symptoms are blamed on the pot. As stated above, parasomnias almost always resolve by the time children are this age, so it stands to reason that there might be more to the situation at that point.
I realize that the authors attempted to account for potential psychosocial confounders, but this was based on self-report. I imagine that there might have been some under-reporting of some potential confounders, like marijuana use perhaps, or perhaps even under-reporting of psychotic symptoms. These children weren’t evaluated by a psychiatrist or other mental health professional. They just answered a list of questions.
We also know that there is a genetic predisposition at play with parasomnias, particularly night terrors. This also appears to be the case with many psychiatric conditions. This supports a possible link between the two issues. We also know that poor sleep is a factor in parasomnias. Sleep deprivation also plays a role in a variety of neuropsychiatric complaints. This wasn’t accounted for in the study questions. Neither was the possible use of illicit drugs, which could play a role in both conditions.
Psychotic experiences are actually fairly common in the 9-12 years age group according to the largest systematic review/meta-analysis to date. A median of 17% of kids in that age range compared to 7.5% of kids aged 13 to 18 years. They occur in about 5% of adults. Most kids who have these experiences in early adolescence won’t have them a few years later. Unfortunately, according to the authors of this review we should think more broadly because early psychotic symptoms may be a risk factor for much more than future psychosis. It should probably be considered a warning sign for future depression and other psychopathology. Still, most kids who have some thought interruptions or a hallucination or two at age 10 won’t go on to have any psychiatric condition. It probably represents some remnant of what would have been considered normal behavior a few years earlier.
I hope that parents won’t be losing sleep over their child having a nightmare or a night terror, or even bunch of them. The main author, Professor Dieter Wolke, stated in the press release, and I agree, that “We certainly don’t want to worry parents with this news; three in every four children experience nightmares at this young age. However, nightmares over a prolonged period or bouts of night terrors that persist into adolescence can be an early indicator of something more significant in later life.”
Conclusion
Sleep is an extremely important and often overlooked component of health in all age groups. But it is particularly important in kids because of the long-term implications of early sleep deprivation on development and a variety of other conditions. Pediatric healthcare professionals should be asking parents about their children’s sleep and be prepared to offer solutions for common sleep problems.
There may be a link between some sleep problems in kids, in this case nightmares and night terrors, and self-report of psychotic experiences in young adolescents. But it remains unclear what this means in regards to future diagnosis of true psychiatric illness. I don’t think that the study in question really should change what we do, and it should not lead to increased parental anxiety. Parents have enough to worry about.
There are a number of risk factors, such as family history and early environment, that serve as red flags for potential psychiatric illness in kids. Some of them also likely play a role in difficulties with sleep and the occurrence of parasomnias. And in some kids mental illness itself likely does cause sleep problems. It isn’t beyond possibility that some children with mental illness will present with a complaint of severe or persistent nightmares or night terrors. We should always consider the possibility of mental illness and ask the appropriate follow-up questions.

Peanut Allergy Prevention Advice Does a 180
New guidelines suggest that preventing peanut allergies may be as simple as giving peanut-containing food, beginning in infancy. How did old guidelines, which recommended avoidance, get it so wrong?
Scott Gavura on January 12, 2017
Link


Severe food allergies, in particular peanut allergies, have become a significant public health issue. Peanut butter sandwiches, once a staple of school lunches, are disappearing as schools and daycares are declared “nut-free zones”. Children today are forbidden from sharing food at school. All of this is in reaction to the growing numbers of children with severe, life-threatening allergies to peanuts. The American prevalence has grown from an estimated 0.4% of children and 0.7% of adults in 1999, to approximately 2% among children in 2010. While anaphylactic (life-threatening) allergies can occur to other food products, peanut allergy is the leading cause of food-related anaphylactic death, and its growing prevalence has driven considerable research into its causes. New parents are anxious to prevent peanut allergies in their children if possible, so there have been persistent questions about whether peanut allergies were preventable, either by modifying the diet of the mother or the infant. There’s been a lack of good science to answer this question – until now.
Searching for the cause of life-threatening allergies
Allergies are a product of our immune systems, with multiple biochemical pathways triggered in response to a specific antigen. “Allergy” can cause reactions that range from mild to potentially fatal. Most food-related allergic reactions are not life-threatening. Anaphylaxis is the term that describes a rapid and severe immune response, which can occur in response to a drug (the most common cause of anaphylaxis), an insect, or food. Eight foods cause over 90% of anaphylactic reactions: milk, eggs, peanuts, tree nuts, fish, shellfish, soy, and wheat. Reactions may involve multiple body systems (gastrointestinal, skin, respiratory) including breathing difficulties and swelling of the throat. Fatal reactions are thankfully rare, particularly if they’re treated promptly with epinephrine (sold for consumer use as the Epi-Pen.) Death occurs due to upper airway obstruction, vascular fluid shifts, and depressed heart function. The risk of anaphylaxis, and how quickly it can appear in any individual with a history of allergy, is difficult to predict, and can be influenced by age, the type of allergen, the extent of exposure, and underlying illnesses, like asthma.
Some anaphylactic food allergies (e.g., milk and egg), can resolve over time. Tree nut and peanut allergies, however, are more likely to be life-long conditions. The price of life is eternal vigilance. Every food, every bit, forever. Desensitization trials look promising but we’re not there yet. The only proven way to prevent reactions in those with a history of anaphylactic allergies is strict and complete avoidance of the allergen.
The evolution of the guidelines
In the absence of knowing what’s causing anaphylactic allergies, guidance from health professionals has been mainly empirical, seemingly based more on professional experience than data. The oldest specific guidance seems to date back to 2000. Here’s the American Academy of Pediatrics guidance on hypoallergenic infant formulas. It notes:
Elimination of cow’s milk, eggs, fish, peanuts and tree nuts, and other foods from the maternal diet may lead to resolution of allergic symptoms in the nursing infant.
There is no reference given for this statement. The guideline includes the following recommendation:
Conclusive studies are not yet available to permit definitive recommendations. However, the following recommendations seem reasonable at this time:
a)  Breastfeeding mothers should continue breastfeeding for the first year of life or longer. During this time, for infants at risk, hypoallergenic formulas can be used to supplement breastfeeding. Mothers should eliminate peanuts and tree nuts (eg, almonds, walnuts, etc) and consider eliminating eggs, cow’s milk, fish, and perhaps other foods from their diets while nursing. Solid foods should not be introduced into the diet of high-risk infants until 6 months of age, with dairy products delayed until 1 year, eggs until 2 years, and peanuts, nuts, and fish until 3 years of age.
b)  No maternal dietary restrictions during pregnancy are necessary with the possible exception of excluding peanuts;
Again, no citations are given as recommendations were entirely empirical – that is, based on expert opinion. It’s possible these recommendations were followed by thousands, if not hundreds of thousands women through the 2000s. And all this time, the prevalence of nut allergies continue to climb.
In 2008, because of evolving evidence, the”American Academy of Pediatrics recommendations on the Effects of Early Nutritional Interventions on the Development of Atopic Disease“, were updated. There was now much more data, much of it equivocal, and the guideline’s authors were far more circumspect with respect to what the appropriate approach was. The biggest change was the elimination of recommendation for pregnant women to restrict their diet. And there was no longer a recommendation to avoid potential allergens after about 4-6 months:
     1.  Although solid foods should not be introduced before 4 to 6 months of age, there is no current convincing evidence that delaying their introduction beyond this period has a significant protective effect on the development of atopic disease regardless of whether infants are fed cow milk protein formula or human milk. This includes delaying the introduction of foods that are considered to be highly allergic, such as fish, eggs, and foods containing peanut protein.
     2.  For infants after 4 to 6 months of age, there are insufficient data to support a protective effect of any dietary intervention for the development of atopic disease.
     3.  Additional studies are needed to document the long term effect of dietary interventions in infancy to prevent atopic disease, especially in children older than 4 years and in adults.
There was a lack of evidence to show that avoiding potential allergens was advisable, but there was an open question about whether either exposure or avoidance could reduce the appearance of allergies. Happily, there was an excellent clinical trial published in 2015 that provides definitive proof that avoidance was worsening the problem.
The study that overturned the consensus
The Learning Early About Peanut (LEAP) study, published in 2015 in The New England Journal of Medicine, was the definitive trial that proved that old approaches to preventing allergies were wrong. The investigators’ question was formed out of an observation: The risk of peanut allergy among Jewish children in the United Kingdom was 10x as high than Israeli children with similar ancestry. It was noted that while peanuts were generally withheld in the first year of life in the United Kingdom, they tended to be introduced at around 7 months in Israel. The investigators’ hypothesis was that early introduction of peanut protein into the diet might reduce the risk of peanut allergy.
This was a randomized, open-label study of 640 children in the United Kingdom. To be eligible to participate, children had to be 4 months to 11 months of age, and had severe eczema, egg allergy or both. The average age at screening was 8 months. All children received skin tests for peanut allergy and were then randomly assigned to dietary peanut consumption or avoidance. Children randomized to peanut consumption received 6 grams of peanut protein per week until 60 months of age. The peanut product used was an Israeli product called Bamba. (Wikipedia tells me this product makes up 25% of the Israeli snack market).
The primary outcome was the prevalence of peanut allergy at 60 months of age. Of the 530 infants who initially had negative skin tests and were analyzed at 60 months, peanut consumption had a dramatic effect: The rate of peanut allergy was 13.7% in the “avoidance” group and 1.9% in the “peanut consumption” group. This is an 86% relative reduction in the prevalence of peanut allergy.
Peanut consumption was beneficial even in children who had positive results on their initial skin test. At 60 months, the prevalence was 35.3% vs. 10.6% in the peanut consumption group, which is an impressive 70% relative risk reduction.
What this study showed was that peanut consumption at an early age could reduce the prevalence of peanut allergy in children, whether they were sensitized (secondary prevention) or not (primary prevention.)
The new guidance
A few weeks ago, the National Institute of Allergy and Infectious Disease (NIAID) issued addendum guidelines for the prevention of peanut allergy. The NIAID worked with 25 professional organizations, federal agencies and patient advocacy organizations to develop this new guidance. These guidelines incorporate the findings of the LEAP study and summarize the best evidence in making recommendations. There are actually three specific guidelines for infants at different risk levels. I am not going to review them in detail, as they’re all online, including specific guidance for parents, which I have excerpted below:
Guideline 1 recommends that if your infant has severe eczema, egg allergy, or both (conditions that increase the risk of peanut allergy), he or she should have peanut-containing foods introduced into the diet as early as 4 to 6 months of age [but only in conjunction with an evaluation by an Allergist]. This will reduce the risk of developing peanut allergy.
Guideline 2 suggests that if your infant has mild to moderate eczema, he or she may have peanut-containing foods introduced into the diet around 6 months of age to reduce the risk of developing peanut allergy. However, this should be done with your family’s dietary preferences in mind. If peanut-containing foods are not a regular part of your family’s diet (and your infant does not have severe eczema, egg allergy, or both), do not feel compelled to introduce peanut at such an early stage.
Guideline 3 suggests that if your infant has no eczema or any food allergy, you can freely introduce peanut-containing foods into his or her diet. This can be done at home in an age-appropriate manner together with other solid foods, keeping in mind your family’s dietary routines and preferences as described in Guideline 2.
The new guidance is summarized in Table 1 of the guideline:

Oops
In a period of 15 years, there’s effectively been a 180° change in dietary advice, from peanut avoidance to early introduction of peanuts. It’s something akin to a “medical reversal”, a term coined by Vinay Prasad and Adam Cifu:
Medical reversal occurs when a new clinical trial — superior to predecessors by virtue of better controls, design, size, or endpoints — contradicts current clinical practice.
Prasad and colleagues have identified 146 medical practices that were ultimately contradicted. While this research studied new medical practices, not dietary guidelines, it highlighted that better controlled studies often contradict preliminary conclusions and medical practices, when treatment decisions are made based on low quality evidence. It’s a phenomenon that’s also been described, with respect to clinical trials, by John Ioannidis:
Contradiction and initially stronger effects are not unusual in highly cited research of clinical interventions and their outcomes. The extent to which high citations may provoke contradictions and vice versa needs more study. Controversies are most common with highly cited nonrandomized studies, but even the most highly cited randomized trials may be challenged and refuted over time, especially small ones.
Ioannidis, Prasad and Cifu highlight the reproducibility problems in the medical literature. While it is a reality that there will always be a baseline rate of reversal in medicine, owing only to statistical probability, there are a number of factors that make reversals far more common than necessary. The primary cause of medical reversal is obviously the quality of the evidence that informs any new health intervention. As evidentiary standards are lowered, the likelihood that any conclusion is wrong will grow, and the risk of subsequent reversal climb. While Prasad and Cifu outline other factors that can lead to eventual reversal, we don’t need to go much further than the evidence base itself when we examine peanut allergy guidance. The 2000 guidelines were based on expert opinion, not high quality evidence. While they may have sounded cautious and appeared reasonable, they were ultimately wrong. And it’s hard to deny that we have a greater prevalence of peanut allergies today as a result.
But the peanut avoidance guidance was also distinct from other types of medical reversals. This was not the adoption of a new test, treatment or technology, but a decision about dietary timing. There was a lack of good evidence, but guidance was offered nevertheless. Would we have been better off without any advice from the AAP? There’s a case to be made for withholding any guidance unless it’s based on the best evidence. There was no data to support any specific dietary advice. Ultimately the AAP felt it needed to offer advice. It was wrong.
Learning from this reversal
A high-quality clinical trial has led to updated guidance on how to minimize the risk of developing peanut allergies. This new evidence contradicts old guidelines, which were based entirely on expert opinion. There is now good data to show that the introduction of peanuts at an early age to select children will decrease the risk of developing an anaphylactic allergy. Given the impact of this guidance, it is essential that these findings be widely disseminated. Unfortunately we cannot turn back the clock and reverse the allergies that have emerged, some a likely consequence of well-intentioned, but wrong, advice. We can only study these decisions as we develop our advice today, with the intention of trying to be “less wrong” in the future.

Cleveland Clinic Drops the Ball in an Attempt to Educate Parents on Safe Sleep
Just when I thought I was out, they pull me back in. More Cleveland Clinic more problems, this time it’s some questionable advice on safe sleep for infants.
Clay Jones on June 10, 2022
Tweet

The discussions that I have with caregivers are sometimes limited by a lack of clear and evidence-based guidelines. Using the available data and my clinical judgement I attempt to communicate this uncertainty and, hopefully, provide enough information to make an informed decision. Sadly, I can’t always rely on the internet for help. Even worse is when online misinformation comes from what should be a reliable source, such as a major academic medical facility.
The most egregious offender is Cleveland Clinic, and we have sacrificed many electrons pointing out problems with their social media and patient/parent education efforts over the years. Most of the time this has involved various promotions of implausible and even disproven interventions such as acupuncture and…(sigh)…functional medicine. On this go round, however, the focus of my attention is a recent article posted online and promoted on Twitter that discusses a subject that I’ve tackled before, the choices parents make regarding how they put their babies down to sleep.
A little over a year ago I wrote on the issue of sleep sack safety versus traditional infant swaddling during sleep. In that post, I took the author of a Today’s Parent article to task for promoting inaccurate information. Call me naïve, but I usually hold world class academic medical centers to a higher standard than parenting magazines. So I was shocked, shocked I say, to see an article put out by their pediatric institute that really dropped the ball.
Published on June 3rd, the Cleveland Clinic article poses the question, “Are Sleep Sacks Safe for Babies?” The title alone is potentially problematic. Many people who just see the title as they scroll through their feeds could, after a bit of time has passed, recall only that they saw something about sleep sacks being unsafe, which is the opposite of what the article claims. It would have been better to use a title that clearly stated the conclusion, which is that sleep sacks are safe options for infant sleep.
My problem with this short article isn’t that I think sleep sacks aren’t safe. The issue is that it pushes the questionable narrative that swaddling is dangerous. It isn’t. There is some nuance, which I’ll get into, but it is wrong to make a blanket statement that swaddling is somehow going to kill babies. See what I did there? The article also makes some odd claims that might leave parents confused.
Feel free to read the short article I’m breaking down here, but I will be quoting liberally.
But a sleep sack isn’t a mere fashion statement. View it more as a layer of protection. A 2019 analysis found that infant sleep sacks “are as safe, if not safer, than other bedding” when it comes to preventing sudden infant death syndrome (SIDS).
Why are sleep sacks so effective? Pediatrician Heidi Szugye, DO, IBCLC, offers an explanation.
I think a lot of people reading that will come away with the wrong idea about sleep sacks because it is misleading. Sleep sacks do not lower the risk of SIDS independently. They aren’t magic. The 2019 paper that they reference doesn’t add anything new to what we already know based on a more focused 2016 meta-analysis published in Pediatrics. As I wrote last year, the question is really about the safety of swaddling and if a sleep sack is a safer option, rather than whether or not sleep sacks independently reduce the risk of SIDS:
The 2016 Pediatrics analysis of several studies looking at swaddling and its relationship to SIDS showed that swaddling does not appear to significantly increase the risk of death during sleep except for when a swaddled baby is placed face down (please never do this) or when a baby old enough to roll over is swaddled.
As you can see, swaddling can be considered an independent risk factor for unexpected death during sleep, albeit a fairly minor one. But it is really only dangerous if you combine swaddling with other modifiable risk factors, specifically when a very young baby is also placed face down to sleep or, to a lesser extent, when a baby is old enough to wiggle themselves into a prone position on their own. This skill typically develops at around 4 to 6 months of age, which is actually past the peak of SIDS incidence at 2-3 months. Though the exact mechanism for why this raises the risk of death isn’t known, it is reasonable enough to assume that a prone baby whose arms are wrapped snugly against their chest might have difficulty moving their face away from a mattress or other plush surface that shouldn’t be near a sleeping baby, like a large stuffed animal or a crib bumper.
Two infants that are put down to sleep following all safe sleep guidelines, with one being placed in a sleep sack and the other in a swaddle blanket, are both extremely unlikely to die unexpectedly in their sleep. The exact same can be said when comparing babies in sleep sacks to babies put down for sleep in just an outfit. The baby in the sack is not safer than the baby in an adorable onesie.
A sleep sack is basically a way to safely keep your child warm while they sleep. It truly is designed as a wearable blanket, with your baby’s torso, legs, feet and teen-tiny toes housed within the sack.
The garment should be sleeveless, allowing those little arms and hands to move freely without any restrictions.
Most babies don’t have any difficulty maintaining a normal body temperature once they have successfully transitioned after delivery and have begun to feed. Unless they are significantly premature, growth restricted, or left soaking wet after a bath on the back porch during a blizzard, there is very low risk of harmful hypothermia. They would be just fine in one thin layer of clothing. The purpose of a sleep sack, when they have wings, or a swaddle blanket is not to keep a baby warm but to help them sleep by reducing general stimulation and limiting reflexive arm movements.
Sleep sacks with wings work essentially like a swaddle blanket. The difference is that when a baby busts out of them, the wings fall to the side and can’t be accidentally pulled up over the face. Seep sacks that lack wings, like the ones recommended in the article, do not help an infant sleep. They don’t really do anything.
Sleep deprivation is a very underappreciated complication of the postpartum period and beyond, and it can contribute to numerous bad outcomes. Impact injuries can occur if a baby is dropped when a caregiver falls asleep holding them. There is increased risk of car accidents, as well as non-accidental trauma when an exhausted and stressed caregiver is faced with a baby that is difficult to calm. Poor sleep also plays a role in postpartum depression and psychosis, and it even increases the risk of SIDS or suffocation because exhaustion interferes with following recommended safe sleep guidelines. The Cleveland Clinic article completely disregards the potentially life-saving benefit of improved maternal rest.
The article goes on to list 3 benefits of sleeveless sleep sacks. According to the author, sleep sacks provide warmth without the risk of placing a blanket around a baby that could become a suffocation risk. Again, there is some plausibility to this and pediatricians don’t recommend loose blankets during sleep. But as I stated earlier, when it comes to a blanket snugly swaddled around a baby, it’s not so clear that the risk of unexpected death during sleep is much different unless said baby is also placed face down or old enough get that way on their own.
The second benefit mentioned is essentially an extension of the first. The author points out that sleeveless sleep sacks allow free movement of a baby’s arms and the ability to use them to move into a safer sleep position should they roll on to their tummy. This is true. Pediatricians also don’t recommend restricting the arms of babies who can turn over. These babies are just as safe in a sleeveless sack at that point as they are out of one, however. Parents should be on the lookout so that they can determine when to stop swaddling, whether they use a blanket or a sleep sack with wings.
The final benefit involves a reduced risk of a condition known as developmental dysplasia of the hips, or DDH. DDH is an instability of the hip joint that allows for dislocations and can result in significant long-term disability, even a need for hip replacement in early adulthood. It is most common in female infants and infants who were breech late into pregnancy, but genetics and tight swaddling of the lower extremities that forces the legs into a straight extended position are risk factors as well. Sleeveless sleep sacks do allow room for babies to move their legs, and that does lower the risk of DDH, but a baby can easily be swaddled in a hip friendly fashion.
In the final section of the article, the author attempts to specifically address the issue of swaddling, which they admit is very common, versus putting a baby to sleep in a sleeveless sack.
The snug feeling is supposed to mimic the feeling of being in the womb. Done correctly and with adult monitoring while in use, swaddling can be an effective technique to calm infants and promote sleep, according to the AAP.
Don’t anthropomorphize babies…they hate that! Claims of mimicking the womb are a convenient framework but they are just an assumption and honestly, they don’t make much sense. It’s true that as a baby nears delivery deep into the 3rd trimester, they do have somewhat restricted movement of their arms and legs. But a term fetus close to delivery still moves around quite a bit. Plus, they are subject to being jostled around as their mother moves about during her day. It’s hardly comparable to the nearly motionless state of a sleeping and swaddled infant lying on a still, firm mattress.
I’m not sure what they mean by “adult monitoring”. Are they saying that an adult must be awake and directly observing a swaddled baby at all times? If so, that’s terrible advice. Caregivers need sleep and they should be reassured that they can sleep when their baby sleeps. Monitoring using technology is an equally unsound recommendation. These devices have never been shown to prevent unexpected death during sleep and are a significant source of caregiver anxiety that can result in false alarms and unnecessary trips to the emergency department in the middle of the night.
The remainder of the article repeats earlier admonitions to avoid putting a swaddled baby face down or using a swaddle once a baby can roll over on their own. And once again, I agree. Don’t do that.
In the grand scheme of things, this article isn’t nearly as bad as the nonsense put out by Mark Hyman and other promoters of pseudomedicine gainfully employed by Cleveland Clinic. Still, I expect better education than this. In particular, it’s unfortunate that there wasn’t any discussion of the importance of caregiver sleep. It is critical to take both risks and benefits into account, and in my opinion sleeveless sleep sacks are fine but any benefit is likely outweighed by the harm from sleep deprivation. Leaving this out of any discussion with caregivers means that they aren’t truly making an informed decision.

Baby Translating Technology: Revolutionary Parenting Tool or Confirmation Bias Bonanza
Clay Jones on January 15, 2016
Link

Caring for a young infant, although a potentially rewarding means of producing a labor force for chores and minor home repairs, can be a trying ordeal for both new and experienced parents. The peaks and valleys of parental experience can leave a caregiver both exhilarated and agonizingly frustrated during a single hour of childcare, let alone the first few months. It is not an uncommon experience for a parent to rapidly alternate between extreme states of emotional arousal, one minute gazing down at their sleeping baby with seemingly limitless feelings of joy and love, and the next panicking at the perception that it has been too long since their baby’s last breath.
Babies, especially stupid ones, require near constant attention during the first several weeks of life, and that’s if it is going well. There is no user manual for the care of the newborn human that could possibly describe every situation and how to effectively respond to it in each individual child. A trial and error approach is always necessary to some degree, and it tends to result in a lot of sleepless nights, with many parents finding themselves more exhausted than they ever dreamed possible. So it shouldn’t be surprising that parents are a particularly vulnerable population when it comes to the marketing claims of bogus technology aimed at making their lives even the slightest bit easier.
Introducing the Infant Cries Translator
With that in mind, consider yet another example of technology that violates the “too good to be true” dictum: the Infant Cries Translator. Developed by a team of Taiwanese researchers from the National Taiwan University Hospital Yunlin and credulously reported on by the media over the past two weeks, this “new” development in childcare comes in the form of a smartphone application and carries the claim of being able to translate what the cries of a young infant actually mean. It’s nonsense. Complete and utter nonsense.
Why the scare quotes around new? Well, because despite the implications of the researchers and press, this exact technology already exists and previous versions have even had their own rounds of uncritical reporting in both 2009 and 2013. The only differences are the developer and the price. Though equally worthless, the more recent smartphone applications are at least considerably cheaper than the older baby translating devices that had to be plugged in near a wailing infant.
So what does this latest iteration of baby translator claim to be able to do? According to the developers it can tell the difference between four different cries within just 15 seconds of recording. The potential results include hunger, having a wet diaper, sleepiness, and pain. Conveniently for the developers, as I’ll explain shortly, the application is most accurate when used on infants that are less than 2 weeks of age. They in fact claim a whopping 92% accuracy in this age group. As a child ages, their cries are increasingly more difficult to translate, resulting in an accuracy of 85% in a 1-2 month old and 77% in a 4 month old. They say to not even waste your time once a child is more than 6 months old.
An exhaustive review of the extensive literature on baby cry interpretation
What are these accuracy claims based on? The researchers, Chang Chuan-yu and pediatrician Dr. Chen Si-da, first collected and analyzed 200,000 cries from 100 newborns for their “subtle differences in acoustics.” Then a miracle occurs, after which they collected feedback from users in order to come up with those numbers. That’s it.
There is no study, or even an explanation that I can find, of how they turned the 200,000 cries into an algorithm for the application. And despite the complete lack of actual data looking into accuracy, not that it would even be possible, or comparing infants of varying ages or locations, the app requires input of your baby’s date of birth and nationality. It’s hard to imagine that their 100 “subjects” were representative of too many regions of the world. Of course it doesn’t really matter because it’s all nonsense.
One of the earlier versions of cry interpretation technology, the Cry Translator from Biloop Technologies, claims to be able to tell a worried parent within 3 seconds if their baby is hungry, sleepy, annoyed, stressed, or bored. Guess which one I am. But at least this company provides a link to a clinical trial.
The study, designed and run by one of the product’s developers, was published in Spanish. But thanks to the wonders of Google, I was able to translate this clinical trial into English and to appreciate the full glory of its methodology. Dr. Portugal Ramirez, a “leading pediatrician and specialist” collected data from 104 infants over a roughly 2 year period. Data collection involved using the translator to determine why the baby was crying, which was then confirmed by a physician.
If the intervention suggested by the device led to calming of the infant’s crying, it was counted as a positive result, which occurred 96% of the time. Dr. Portugal Ramirez, based on the astounding success of his device and a profound misunderstanding of infant neurodevelopment, goes on to imply that regular use of the technology will increase a baby’s IQ. So what’s the problem with this study?
The validation technique employed in this study is comical. First off, the physician operating the device is unblinded and so just happens to have been involved in its development. He used it to translate each episode of crying and followed the recommended interventions. If the baby responded to the intervention by calming, it is counted as an accurate “diagnosis.”
The five possible reasons for crying and their respective interventions are as follows:
Hungry– Give the bottle– Check thirst
Nerves– Go to a quiet place– Gentle rocking in arms
Sleep– Reposition– Talking soft– Rocking in the fetal position– Check room temperature
Discomfort– Check diaper– Check gas– Burp the infant– Check for constipation
Bored– Check temperature– Stimulate the baby– Gentle rocking– Talking softly to baby
Notice anything? Each category involves a physical interaction with the crying child. Simply picking a crying infant up is often effective at calming them. So is feeding them, regardless of whether or not it is time for them to eat because sucking is a natural calming reflex in the young infants and an effective distraction even as they age. So if a child’s cries were interpreted as being related to boredom, which is a rather silly concept (don’t anthropomorphize babies, they hate that), the interventions from any of the possible category would still likely work.
And just what constitutes the successful calming of a subject isn’t defined at all in the study. Was it complete cessation of all crying or perhaps just a noticeable decrease in intensity? This is a rather large researcher degree of freedom. It’s almost as if this study was designed to be positive in order to support the marketing of the device.
The younger a baby is, the more likely such simple physical interventions will be effective. Gentle rocking will simply not be as helpful when dealing with a 6-month-old brute as it is in a newborn. This is why the misguided (or malicious) researchers behind the latest cry interpretation app found such amazing results in infants that were less than 2-weeks-old.
Why do babies cry?
The elephant in the room when it comes to these devices and applications is the question of how did the developers come up with their algorithms in the first place. That is if we assume that they aren’t just Magic 8-Ball equivalents that spit out random responses. Unfortunately, there really is no reliable means of determining why a young infant is crying in the vast majority of circumstances, hence the trial and error approach I mentioned previously.
Obviously babies will cry if hungry or uncomfortable, but they also cry for no discernible reason. We assume that they have to mean something but many episodes are likely just the result of a developing brain being stimulated. The fact of the matter is that we don’t really know why babies cry most of the time and it doesn’t matter how much experience or training an observer has, how big of a database researchers work with, or how many “subtle acoustic variations” they discover.
It’s true that parents will sometimes claim that they can differentiate different types of crying in their own child. They will describe a hunger cry, a scared cry, or a cry that they interpret as one caused by some kind of discomfort such as gas or constipation. But these anecdotes are largely based on confirmation bias. We forget the misses and remember the hits because it helps us feel better when we have something to blame or focus on during times of uncertainty. Unfortunately this universal human approach to uncertainty that has led to many false beliefs and subsequent risky interventions.
There are of course extreme examples where the nature of a baby’s cry is unusual and perhaps more indicative of a specific cause, such as a craniofacial abnormality, genetic syndrome, or significant pain. But for the most part the nature of a child’s cry isn’t a very helpful clue for either parents or physicians. This technology only worsens the confusion.
Conclusion: Worry + pseudosolution = profit!
Baby translating technologies are implausible and unproven. The only thing these applications and devices do if used as recommended is translate a parent’s worry into profits for disreputable businessmen and gullible developers. Any pediatricians involved in the development or marketing of these products should be ashamed of themselves.
Thankfully, I don’t think much harm would come from their use. It isn’t as if they are diagnosing crying children with demonic possession or some fictional medical diagnosis like baby adrenal insufficiency. And I could see this being a funny gag gift meant purely for entertainment purposes.
I can’t help but imagine how much easier my job would be if this kind of technology actually worked, if baby cries actually were attempts to communicate specific complaints or desires. It truly would be a boon to parents and medical professionals caring for young infants. This is the impetus for parents of disabled older children to seek out other demonstrably ineffective but considerably more harmful technologies like facilitated communication.

Amber Waves of Woo
John Snyder on April 11, 2014
Link
As a pediatrician I have an opportunity to observe a wide variety of unusual and sometimes alarming parental efforts meant to help children through illness or keep them well. I have recently noticed one particular intervention that seems to be becoming more prevalent, at least in my practice. I’ve begun to see more and more infants sporting Baltic amber teething necklaces. These consist of multiple small beads of amber on a string that is worn around a baby’s neck, and are supposed to relieve the discomfort of teething. Before I had any idea what these necklaces were for or how they were supposed to work, my first reaction was to inform these parents of the dangers of necklaces or anything placed around an infant’s or young child’s neck. Strangulation is a known cause of accidental injury and death in children, and pediatricians are trained to discuss this as part of the routine anticipatory guidance we give to parents. In addition, we strongly advise against giving infants or young children any small items that could be accidentally aspirated, such as the beads found in a necklace of this sort. But I was equally surprised to learn that these necklaces are not intended for babies to chew or gum. Instead, they are supposed to ease a baby’s teething discomfort simply by lying against the skin.
I will not discuss teething here, or the many myths that surround it; that was well covered in a previous post. I will reiterate that there is little-to-no evidence that the majority of concerns parents have about teething are actually due to teething, including fever and diarrhea. The irritability associated with teething also tends to wax and wane for only several days before and after the emergence of a tooth. But let’s assume for the moment that these necklaces actually work to ease the discomfort of teething, and whatever other problems parents tend to associate with the long period of time during which infants and young children develop their teeth. Assuming these necklaces work as recounted in the glowing testimonials on countless websites and parent blogs, how do they produce their dramatic results?
Implausible mechanisms of action
The alleged mechanism of action of wearing Baltic amber against your skin varies considerably based on whom you speak to, and which snake oil salesman you are buying from. They range from the hilarious to the just barely plausible. On the absurd end of the spectrum we have:
    • Activates the solar plexus and root chakra
    • Bactericidal and electrostatic properties
    • A powerful antioxidant that helps fight toxic free radicals
    • Slight sedative effect
    • Amber is electromagnetic and produces large amounts of organic, natural energy
    • Ionization helps protect the human body from various magnetic fields (amber absorbs some waves, including radioactive ones)
But the most commonly cited mechanism of action (and the most plausible, with that term being used very liberally here) is that the amber beads, when warmed by body heat, release tiny amounts of succinic acid which passes trans-dermally into the blood stream where it acts as an analgesic. I refer to this mechanism as plausible for the following reasons only:
    • Baltic (Class Ia) amber does indeed contain succinic acid
    • Some molecules, including some drugs used in science-based medicine, are absorbed through the skin to produce physiologic effects
    • Succinic acid (also known as 1,4-butanedioic acid) is found naturally in the body as an intermediate in the all-important Krebs cycle; altering the levels in the body could therefore have potential physiologic effects
The plausibility for this mechanism ends there, however, and then quickly begins to break down. First, though Baltic amber does contain succinic acid, there is no evidence that it has analgesic effects at any dose, let alone the miniscule amounts that might conceivably enter the body through this route (more on that in a moment). As mentioned above, succinic acid is an important intermediate in a very important biochemical pathway. It resembles many other similar molecules found in our body and is considered safe. Toxicity studies have shown that even large doses produce no adverse effects. The FDA even allows it to be used as a food additive and to be sold as a dietary supplement. Ironically, it is classified as a skin irritant.
The next step in the plausibility break down is the notion that succinic acid in the amber beads gets released at body temperature, and is then absorbed through the skin. There is no evidence that succinic acid is released from amber on contact, or that warming it to body temperature would facilitate this. If it was released, there is similarly no evidence for transdermal absorption. Many factors contribute to the ability of a molecule to enter the body through the skin. In addition to the physical and chemical properties of the molecule, clearly the dose is an important factor. Generally speaking, the larger the concentration the easier it is for a molecule to get through the skin. The amount of surface contact is important as well, and this would have to be considered pretty small in the case of a string of beads worn around the neck. As for the amount of succinic acid likely to be found in one of these necklaces, let’s assume the following:
    • Baltic amber contains 50-400 ppm of succinic acid
    • 1 mg/kg = 1 ppm
    • Necklace weighs 1 oz = 0.028 kg
    • Necklace contains 1.4-11.2 mg succinic acid
Even if you were to assume that succinic acid is released from the necklace onto the skin, the amount released would have to be an extraordinarily miniscule fraction of the total 1.4-11.2 mg contained in the entire necklace. For a therapeutic effect at this sort of dose one would need to invoke homeopathy, but that is an entirely different subject altogether. Interestingly, corrosive formic and acetic acids were found to off-gas as volatile degradation products from Baltic amber. Acetic acid is vinegar, and formic acid is found in fire ant venom and can cause blindness.
Multiple extraordinary claims
Putting aside the mechanism of action, do these necklaces actually work? Perusing many of the websites that either sell or discuss them, I came across a multitude of purported benefits to wearing a Baltic amber necklace:
    • Provides natural pain relief for babies, toddlers, and children
    • Helps to ease teething pains in children as well as colic and gas and other ailments
    • Reduces inflammation of the throat, ear and stomach
    • Fights irritation, infections, and respiratory disease
    • Dramatically improves the body’s immunity
    • Breaks the cycle of chronic inflammation
    • A completely non-invasive remedy for side effects associated with teething (lack of appetite, upset tummies, ear ache, fevers and colds)
    • Antispasmodic and anti-fever
    • Improvement of arthritis
    • Improves blood circulation
    • Eases muscle pains
    • Transmutes negative into positive energy
    • Promotes positive thinking and attitude
    • Revitalizes mind, body and soul
    • Helps to relieve depression
    • Supports physical healing and detoxification
    • Alleviates disorders of the adrenals, liver and spleen
A major red flag for fraud if ever there was one, the making of multiple, extraordinary claims should raise our skeptical radar, and of course demands extraordinary evidence.
The evidence
A search of PubMed and MEDLINE reveals not a single study of any kind or quality exploring the efficacy or safety of amber teething necklaces for infant teething. In fact, I could find only two studies that were related in any way to the therapeutic use of amber. These were published by a single research team from India, and examined the effects of an amber-containing “polyherbal” compound on chemically induced gastric ulcers in rats. The authors exposed rats to either aspirin or ethanol, and in both cases found that rats pre-treated with the compound demonstrated lower ulcer scores than controls.The authors exposed rats to either ethanol or aspirin, and in both cases found that rats pre-treated with the compound demonstrated lower ulcer scores than controls.
As for succinic acid, the most commonly-cited mechanism of action for amber necklaces, I did find a study whose abstract, at least, claims to have demonstrated promising anti-inflammatory activity in 44 succinic acid derivatives. The article was published in 1987 in the Russian language journal Farmakologiia i toksikologiia, which I was unable to obtain for review. There does not appear to be any other evidence for the therapeutic effect of succinic acid.
So why do people believe such an implausible treatment will work for teething? First, we need to understand that teething has an odd place in the folklore and mythology of parenting. Parents clearly never want to see their children suffer, and teething can be uncomfortable, albeit for very brief intervals. One contributing factor to the overblown concern about teething is the historical fact that in previous centuries, infants and young children once routinely died during the age range when the primary teeth typically come in, and teething was often erroneously implicated as the culprit. Treatments used for teething in those times were often dangerous or even lethal themselves. Thanks to modern science, parents are no longer in constant fear that their children will succumb to disease. Still, some common illnesses and even normal developmental stages and behaviors are to this day erroneously attributed to teething. Combine this historical baggage with our tendency to fall into the logical fallacy trap, and you have the perfect set-up for this myth to take hold.
The logical fallacies rear their ugly heads
Appeal to ancient wisdom –Websites touting the healing and restorative properties of Baltic amber teething necklaces abound with references to the centuries of use of medicinal amber, and to its ancient record of success. The scientific revolution is a very recent accomplishment, and most of our recorded past took place in an age when our understanding of the world was laughably inaccurate. To use the age of those beliefs as a way to validate them is akin to claiming that the Earth is flat because we thought it was so for most of human history.
Appeal to nature – Parents who swear by amber teething necklaces usually mention that it’s natural and therefore safe. Or that it’s natural, so it’s preferable to using drugs such as acetaminophen or topical anesthetic gels. First of all, the use of drugs to treat teething is not recommended. Teething pain tends to be transient and intermittent, and chasing it with serum levels of medication doesn’t make much sense. And topical anesthetics are potentially quite dangerous in infants, as they can lead to a serious condition called methemoglobinemia. They can also be easily overdosed. I recently took care of an infant who had been given around the clock Baby Orajel and nearly stopped breathing. In any case, assuming something is safe simply because it is natural defies logic when the most deadly toxins known to man are entirely natural. It is also extremely contradictory to make the assertion that drugs and man-made chemicals are somehow bad, but a naturally occurring chemical must be assumed to be perfectly safe. Let’s again assume that succinic acid gets released from the Baltic amber necklace, and that it does actually cross into the baby’s blood stream in a concentration sufficient to effect a real physiologic change in her body. Why, I wonder, are the parents who put these things on their children okay with that? It’s astounding that the same parents who shy away from man-made “chemicals”, buy organic produce, steer clear of GMOs, and are afraid of vaccine ingredients have no problem with the leeching of natural chemicals into their child’s bloodstream.
A survey exploring the perceptions and beliefs of parents in southwestern France about the use of teething necklaces illustrated the significant concern these parents had about teething symptoms, and the difficulty many have accurately assessing true risks and benefits. Even when informed of the real potential danger to their children by wearing the necklaces, many parents preferred to take that risk for the potential perceived benefits. This is no different than the parent who is fearful of giving a vaccine, and prefers taking the risk of their child getting a preventable infectious disease, or a parent who will risk giving their child an unregulated dietary supplement for perceived, unfounded benefits. This profound inability to accurately assess risks and benefits and correctly set priorities to maximize outcomes is what keeps the door open for pseudoscience, and allows belief to obscure our understanding of the world.

Melatonin poisonings in children are increasing
Melatonin use is increasing, and accelerated during the pandemic. Overdoses are also increasing in children, and in rare cases are linked to serious harms.
Scott Gavura on July 7, 2022
Link

Insomnia can be a persistent issue for both children and adults. While there are a few over-the-counter and multiple prescription drugs used for insomnia, many people are understandably apprehensive about using them. Tell someone there’s “natural supplement” for sleep, and there’s usually a lot of interest. That’s what I’ve seen with melatonin, a hormone that is sold without a prescription in many countries. It is widely perceived as safe and effective and many health professionals recommend it for treating sleeping problems in both adults and children. In the United States, sales of melatonin have increase from $285 million in 2016 to $821 million in 2020. With this growing popularity the number of pediatric poisonings reported to poison control centres has also increased. In 2020, melatonin also became the most frequently-reported pediatric poisoning reported. A new report from the Centers for Disease Control and Prevention documents how these poisonings are causing an increase in serious adverse effects.
In the early 1900s it was observed that the pineal gland secreted a substance with physiologic effects, and the hormone itself was named in 1958. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. And it’s definitely a natural substance: melatonin is found in vertebrates, invertebrates, animals, bacteria, fungi, algae and plants. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age. It has been explored in clinical trials mainly for the prevention and treatment of sleep disorders like insomnia and jet lag. The evidence suggests melatonin is modestly effective. It seems to be most effective for sleep-onset insomnia, and may give a slight increase in total sleep time. In children melatonin may be recommended for long-term use in autism spectrum disorder and attention deficit hyperactivity disorder.
Melatonin is generally very well tolerated. The most common side effects reported include daytime sleepiness, dizziness and headaches. Melatonin’s long-term effectiveness and safety are not clear. Given melatonin is a hormone, and receptors for this hormone are distributed throughout the body (including the sex organs), the safety, particularly during puberty, has not been established. So the advice is to use with caution and when necessary. Moreover, given the problems with quality of dietary supplements in many countries, there are legitimate concerns about product consistency and safety.
Poison control center reports
This new paper, published by the CDC in Morbidity and Mortality Weekly Report, is a study of all pediatric and young adult (<19 years old) melatonin ingestions reported to poison control centers in the United States between 2012 and 2021. During that period, 260,435 ingestions were reported, representing 2.25% of all reports. Ingestions were primarily in those <5 years old (84%), were unintentional 94% of the time, and occurred in the home 99% of the time. Reassuringly, most ingestions were without any symptoms (84.4%). When side effects were reported, the most common effects were central nervous system, gastrointestinal, and cardiovascular.
Of the 260,435 ingestions, 27,795 were treated at a health care facility. 71.6% were discharged, 14.7% were hospitalized, and 1% (287 cases) required intensive care unit support. Five children required mechanical ventilation, and two children died. Both of those children were under the age of two.
Interestingly, the largest increase in ingestions occurred between 2019 and 2020. (The authors speculate that this could conceivably have been driven in part by stay-at-home orders, school closures, and pandemic-related sleep disturbances.) By 2021, melatonin was accountable for almost 5% of all poisonings reported to poison control centers, compared with 0.6% in 2012. It’s a linear trend:
FIGURE 1. Rate* of pediatric† melatonin ingestions reported to poison control centers, by year§ — United States, 2012–2021
* Ingestions per 100,000 population, based on U.S. Census Bureau Annual Estimate.
† Aged ≤19 years.
§ Linear trend, p<0.001.
The authors noted the following limitations with their analysis: (1) data is collected based on self-reports that may underestimate actual exposures (2) poison control centers are not able to verify the accuracy of all case reports, and (3) poison control data does not allow one to confirm if deaths are due to the toxic effects of melatonin or because of other factors.
In the discussion, the authors discuss the quality control issues that have been identified with supplements, including melatonin, where products may not match the labelled claim. Given melatonin is treated as a dietary supplement in the United States, it continues to be marketed without manufacturing being held to “drug-like” standards for quality, consistency, and even packaging.
Treat melatonin like a drug
Melatonin is considered innocuous, safe, and effective, and its use has exploded over the last decade. There is widespread use and marketing of melatonin for children and it is even available in “gummy” form for that population. Likely due to growing popularity and use, accidental ingestions are increasing in frequency. While these products may not be packaged in child-resistant containers or considered to be potentially harmful, health professionals and consumers alike should be aware of the risks of melatonin toxicity and take steps to avoid accidental poisonings.

Kangaroo Mother Care, Skin-To-Skin Contact, and the Risk of Sudden Unexpected Postnatal Collapse
Clay Jones on February 12, 2016
Link
In January, a study published in Pediatrics, the American Academy of Pediatrics’ flagship peer-reviewed journal, presented evidence in support of Kangaroo Mother Care (KMC) and its primary intervention: prolonged skin-to-skin contact (SSC) between a mother and her newborn child. I was originally asked to discuss this report at the time by the editors of The Scientific Parent, which is a great resource by the way, but I wanted to expand on my initial thoughts after letting them simmer for a bit over the past few weeks. Please check out the great work done by Leslie and Julia over at TSP after you finish this post.
Another media fail
As is often the case, the mainstream media picked up the story, as presented in a press release from Harvard’s School of Public Health, and blindly ran with it. Without exception the reports tout the benefits found in a specific subset of newborns, exaggerate and extrapolate those benefits inappropriately to all newborns, and make no mention whatsoever of potential risk (see these reports by Livescience, Reuters, and The New York Times). The Daily Mail decided to educate readers on “How ‘kangaroo’ care could SAVE your baby” and even the AAP’s own healthychildren.org posted a glowing report on the study’s findings.
None of this is at all surprising given the study authors’ conclusions (and the media’s track record in handling complex medical topics):
KMC is protective against a wide variety of adverse neonatal outcomes and has not shown evidence of harm. This safe, low-cost intervention has the potential to prevent many complications associated with preterm birth and may also provide benefits to full-term newborns. The consistency of these findings across study settings and infant populations provides support for widespread implementation of KMC as standard of care for newborns. Additional research is needed to determine the ideal duration and components of KMC. Successful strategies for KMC implementation in various contexts should be disseminated among clinicians and policymakers.
As I will explain in today’s post, while there are absolutely some benefits in specific newborn populations, in most infants they do not appear to be clinically meaningful and there are undeniable risks associated with SSC. This risk includes severe injury to an infant’s brain and, as has been demonstrated around the world in numerous reports, even the possibility of death. That this risk has been ignored while endorsing an intervention for groups of newborns unlikely to reap objective benefit is upsetting to say the least. That this risk has not been addressed appropriately by medical professionals, organizations claiming to support the health of newborn infants, and government agencies tasked with protecting us from unnecessary harm is even more concerning.
What is Kangaroo Mother Care?
Kangaroo care, or more commonly just called skin-to-skin, is nothing new in the United States, although its implementation is quite variable from institution to institution. As a pediatric resident training at Vanderbilt Children’s Hospital over a decade ago, I remember encouraging monitored skin-to-skin contact in medically stable premature infants in the neonatal intensive care unit. We referred to it as kangaroo care as I recall. We also supported the practice in the NICU at Texas Children’s Hospital, also in medically stable kids being watched carefully. The current trend is to promote SSC in all newborns, even healthy term infants who will be staying in the room with their parent(s) and largely unmonitored. True KMC as practiced globally can be a bit different, yet it still varies depending on the available resources and the unique culture within and surrounding each individual facility.
As defined by the WHO, KMC involves “early, continuous, and prolonged skin-to-skin contact between the newborn and mother, exclusive breastfeeding, early discharge from the health facility, and close follow-up at home.” Infants are generally expected to be medically stable, so in the case of extremely premature or ill newborns this may mean that time lying against a caregiver’s bare chest is delayed for days to weeks. Some proponents consider this a problem because they feel that the stress caused by separation from the mother plays a significant role in why the baby is unstable in the first place, and they place great emphasis on SSC being initiated immediately after birth and uninterrupted. If “technology” must be added, they argue, it should be “with the baby in her SAFE place, on mother’s chest.”
The two mechanisms believed to be the driving force behind any potential benefits of KMC are SSC and breastfeeding, which proponents believe is more likely to be successfully initiated and maintained as the exclusive source of nutrition when KMC is prioritized. My goal with this post is to focus on the SSC component, which is the aspect of kangaroo care that contrary to the conclusions of the study in question, and pretty much all information available for parents online, does pose a significant risk to newborns as commonly practiced.
What did the new study actually show?
The study in question is a systematic review and meta-analysis of available published and unpublished data from 2000 to 2014 that involved some amount of SSC, even if the full WHO KMC criteria were not met. They excluded small studies of less than ten babies as well as studies that looked at subjective outcomes or that didn’t include a control group. Any quantitative endpoint was accepted, and when all was said and done 124 studies from countries around the world were found to be acceptable.
Among the outcomes included in the analysis were mortality, breastfeeding initiation and exclusivity, infection, heart rate, respiration, oxygenation, temperature, blood glucose and cortisol levels, length of initial hospitalization and readmission rate, growth, and pain response. The individual studies in the meta-analysis also contained numerous additional outcome measures that the authors were unable to finagle into a summary measure because of their one-off nature or the excessive heterogeneity in trial methodology. So what did they find?
The study’s big finding, and the one which the media jumped on, was that when a baby lives long enough after birth to undergo some amount of SSC there was a statistically significant decrease in mortality out to 3, 6, and 12 months compared to babies that did not. But this effect was only found to be truly significant in the subgroup of low birth weight (LBW) babies that were born weighing less than two kilograms. It did not appear to matter in which country the child was born or what the available resources were. It also did not seem to matter when SSC was initiated or how much the child received, which is curious.
In addition to the benefit of increased survival in that specific population, the study revealed a relationship between SSC and a moderate, across-the-board increase in exclusive breastfeeding up to 4 months of age, but did not show an effect of SSC on how quickly breastfeeding was initiated, which is one of the major benefits touted by proponents. SSC also appeared to lower the overall risk of newborn sepsis, but not any other type of infection, to improve regulation of blood sugar in LBW newborns only, and to lower the chance of hospital readmission slightly. Findings of differences between groups receiving SSC in vital signs, growth, and every other outcome were negligible and unlikely to be clinically relevant in most babies, such as a reduction in respiratory rate by three fewer breaths per minute. They were unable to demonstrate a dose response curve for any outcome, which also raises some interesting questions.
And now that risk nobody is talking about
I agree that a low-tech intervention like SSC is potentially beneficial in many babies, particularly in regards to premature and low birth weight infants, and it is certainly inexpensive. While the effects may not be substantial in healthy babies born at term and at an appropriate weight for their gestational age, reducing metabolic distress and stabilizing blood glucose levels in more medically fragile newborns is probably a good thing. And it appears that the most meaningful potential benefit, reduced mortality in low birth weight newborns, is realized even in resource rich regions like the United States.
Based on prior research, particularly in premature infants and in breastfeeding outcomes, there has already been a significant trend for this kind of intervention to be promoted by pediatric-focused organizations like the AAP, by private organizations like “Baby-Friendly USA “, as well as the CDC (which emphatically recommends that all hospitals be “Baby-Friendly”), and the WHO. Their intention for the most part is to have policies in place that support early and successful breastfeeding. These organizations also stress the importance of so-called “rooming in,” and increasing numbers of hospital in the U.S. are doing away with the option for a child to leave the mother’s room for any reason, even maternal pain or exhaustion.
When a mother spends time holding her newborn baby against her skin soon after delivery, there is good reason to believe that this may help improve breastfeeding success when exclusivity is the desired result. And it is a great way to help cement the connection between a mother (dad too) and her child. But it must be pointed out that both of these outcomes can and generally do occur even if no SSC takes place at all. I really have to stress that you are still a good mother even if you aren’t attached to your baby 24 hours a day, as recommended by some KMC proponents.
So KMC and SSC are promoted as a panacea for many newborn issues despite the lack of solid evidence for most objective outcomes in the average baby. When something is too good to be true, of course, it usually is. This is especially true in medicine where there have historically been a grand total of zero truly risk-free interventions. The media reports and the study conclusions that they are based on are flawed in at least one very important way, and this is likely putting babies at risk of injury to their brain and even death. There is in fact very good reason to suspect that SSC as commonly recommended, and in the current “baby-friendly” climate experienced in many hospitals, is a risk factor for something known as sudden unexpected postnatal collapse (SUPC).
What is sudden unexpected postnatal collapse?
SUPC occurs when a low-risk newborn without signs or symptoms of illness or injury has a sudden and unexpected episode of cardiorespiratory insufficiency within the first week of life, often occurring in the mother’s hospital room within the first few postnatal hours. The terminology used in reports around the world varies, with early SIDS, severe apparent life threatening event (ALTE), and sudden unexpected early neonatal death (SUEND) being common. But what doesn’t vary is that the outcome is frequently tragic. Roughly half of the children in these events die and many of the remaining newborns become disabled because of a period of low oxygen supply to the brain.
How common is SUPC? Thankfully, the overall incidence in low-risk (healthy term and near-term) babies is very low, but exact incidence figures are challenging because of different definitions and inclusion criteria used is the literature. This extensive 2013 review of the literature, which found highly variable rates ranging from 3/100,000 to more than 100/100,000, concluded that many studies have likely underestimated the true risk. To put this in perspective, the CDC and AAP have recommended the universal intramuscular injection of vitamin K into newborns within the first hour of life since the 1960s in order to prevent serious bleeding events that occur with a frequency of less than 10/100,000.
Although impossible to peg down exact numbers, the authors estimate that even with the lowest reported figures there could be 500 SUPC cases and around 150 newborn deaths out of 5 million births each year in the European Union alone. In reality, it is likely to be much worse than that. In comparison, there are roughly 4 million babies born in the United States annually which means that if investigated, SUPC would likely represent one of the most common causes of death in healthy term newborns.
Their literature review found 400 cases of SUPC documented within the first week of life. These were cases where they had enough information to rule out complications (premature birth, illness, injury, etc.) that increased the likelihood of collapse. They discuss 3 published cases that exemplify the range of SUPC presentations in detail, all of which occurred during SSC with a baby in the prone position (face down), something that pediatricians have universally recommended against since 1994.
During their review of the 400 well-documented SUPC cases, the authors found that three out of every four were associated with prone positioning of the infant, typically during SSC and initial attempts at breastfeeding. Their findings fall in line with other reports that have listed “prone positioning, first breastfeeding attempts, cobedding, mother in episiotomy position, a primiparous mother, and parents left alone with baby during first hours after birth” as risk factors. I hope this makes it clear how absurd and potentially dangerous the claim that SSC “has not shown evidence of harm” is.
SSC is a set up for the biggest risk factor for SUPC and potential death of an otherwise healthy newborn baby: prone positioning during sleep. And it isn’t just infant sleep I am worried about. Prolonged SSC in the early days of a baby’s life is very likely to result in infant prone positioning, often with their face pressed against the mother’s chest and breast, while the exhausted mother is also asleep. This is known as bed sharing, and it is a well-documented risk factor all on its own.
The scenario that increasingly is becoming the norm in many countries, and which is most likely to result in SUPC, not to mention an increased risk of a baby falling out of the bed and suffering a head injury, is a tired mom lying in bed in a quiet, dimly lit room that promotes “rest”, a lack of nursing presence in the room or monitoring of the baby for long stretches of time, and SSC. In many cases this scenario is encouraged without discussion of the potential risk. It should now be clear how CDC and WHO endorsed programs like “Baby-Friendly” might increase the likelihood of an overtired mother falling asleep during SSC.
What causes SUPC?
Why are newborn infants at increased risk of SUPC during SSC? If you think about it, it makes perfect sense. First and foremost, and especially during the first few hours of life when most of these incidences occur, this is a time of transitioning. The first 24 hours of life is typically a very sleepy period where newborns have diminished responsiveness to the outside world. They often barely arouse even with feeding attempts.
As in SIDS, there is likely some vulnerability in the brain during this pivotal period of development. When a baby is stressed by an environmental insult, such as being deeply asleep and lying prone against the body of an exhausted mother, this might result in failure to arouse, cessation of breathing, decreased oxygenation, and ultimately SUPC. And some babies are simply suffocated by their sleeping mother. Even more terrifying is the fact that this can occur while dad and other family members are admiring the beautiful, but dead, new arrival and the peacefully sleeping mother, the unfortunate outcome discovered only when a nurse comes by to grab a set of vitals.
Conclusion
Don’t get me wrong. I don’t mean to throw the baby out with the bathwater. Although perhaps exaggerated, there are some potential benefits to SSC. It isn’t anything earth shattering in healthy term infants of appropriate size, but I’m not going to tell a mother that her subjective experience while holding her newborn child against her bare skin is wrong or a waste of time. And even in appropriate weight term infants SSC may help establish breastfeeding or reduce the likelihood of sepsis. My desire is for hospitals and healthcare providers that take care of mothers and babies to be honest about the risks and provide a safe environment for the intervention, and I’m hardly alone in this observation.
In order to reduce the risk of SUPC during SSC, hospital staff and pediatricians must first recognize which newborns may be at particular risk and provide appropriate monitoring. A term and well-grown newborn whose mother was on a medication that may result in a sedated baby would be just one of many examples. If a nurse isn’t available to monitor the child continuously (family members don’t count), then perhaps unobtrusive monitoring of the child with continuous pulse oximetry, as is standard in Japan for SSC in all newborns, would be appropriate. In fact, I wouldn’t have a problem with following their lead on this.
Education for the family is just as important. They should be given appropriate information regarding SSC that includes the risk of SUPC in order to decrease the likelihood of a collapse taking place after leaving the hospital. Supine positioning and maintenance of an open airway should be encouraged, as should all SIDS risk reduction strategies for that matter, and the mother should be advised to place the baby in the bassinet or hand them off to another caregiver if she is feeling sleepy.

From the Vault: Infant Teething Myths and Misconceptions
Enjoy this classic post from the vault as we close out 2023. A few myths and misconceptions about infant teething.
Clay Jones on December 22, 2023
Link

As a pediatrician, I have prescribed steroids for countless children, most commonly a short course for an asthma flare or life-threatening allergic reaction. For the first time in my life, however, I am currently taking prednisone for hearing loss and tinnitus in my right ear and it has given me a newfound respect for what these kids experience in regards to potential side effects. I will say that they are still much more tolerable than the severe vertigo that put me in the emergency room a few days ago. 0 out of 10, would not recommend.
I’m doing my best getting this post out, so please appreciate my effort even if it is just pulling out a “classic” from the vault that I wrote ten years ago. The issue, namely teething and teething related nonsense, remains something that I encounter frequently as a pediatrician. But it was a random check of the Wikipedia page for the topic that inspired me. It is an unfortunate mix of good information with many errors, assumptions, and confusing claims.
Teething may cause a slightly elevated temperature, but not rising into the fever range of greater than 38.0 °C (100 °F). [3] Higher temperatures during teething are due to some form of infection, such as a herpes virus, initial infection of which is extremely widespread among children of teething age.[4]
Not off to a great start misunderstanding one 2016 meta-analysis and then referencing a 30-year-old reference. The reality is that there is a normal range of healthy body temperatures throughout infancy, and any findings of “slightly elevated temperature” during teething are normal fluctuations rather than a true increase. Fever is not a result of the teething process, but it can be caused by an infection, most of which are viral. Some of these viral infections fall into the family of herpes viruses, such as roseola (HHV6), and none should reasonably be confused for teething.
The section on medications is particularly unfortunate. Bottom line, don’t use the article to establish a treatment approach to teething. Here is a talk I gave on medical folklore, with teething as a prime example, at NECSS in 2017 that is much more informative and fun, if I do say so myself.
Opening the vault…..
Teething is one of the most common sources of parental concern in the world of pediatric medicine. All children go through it, typically starting at about 6 months of age, and the current list of signs and symptoms attributed to the eruption of teeth in infants is long and varied, with most if not all of them inaccurate if not highly suspect. And although teething as a concept may seem rather commonplace, it is an entity with an interesting history and a frequent impetus for exposing young children to ineffective and even risky treatments.
What is teething?
Simply put, teething occurs when a tooth nears completion of its journey into the oral cavity, a journey which begins early in fetal development. The tooth erupts though the gum, often preceded by a small lump. Occasionally there can be a larger eruption cyst, and the area may appear somewhat bluish and swollen from bleeding into the tissue, but this is uncommon. The most widely accepted duration of a bout of teething is a roughly 8 day period, with tooth emergence generally felt to occur on day 5. The whole process usually takes about two years, with an average of one tooth emerging each month until the full complement of 20 baby teeth are present.
Teething past
In my opinion, the history of teething is a great example of the extreme degree of absurdity that conclusions based on a prescientific approach to illness often resulted in, right up there with humors and homeopathy. Early philosophers like Hippocrates attributed a wide variety of minor symptoms, such as itching gums and loose stools, to teething, and many of these still make the current list. But because of our once-poor understanding of human physiology, infants were felt to be extremely vulnerable to any derangement in their nervous system and more serious outcomes were attributed to the eruption of teeth, including death. Yes, death.
As crazy as this sounds, it actually isn’t that hard to understand why it was believed for at least a couple thousand years that teething could result in serious illness and even death. Remember how frequently a tooth emerges? Once a month, on average, for a couple of years, in early childhood. People attributed severe illness and death to teething for the same reason that some people continue to blame autism on vaccines: Pure coincidence and a lack (or the in the case of vaccines and autism the denial of) a systematic and logical approach to documenting and evaluating natural phenomena.
Until the advancements of scientific medicine, such as vaccines for instance, children frequently died or suffered through a variety of common ailments during the same time period as teething. And of course the true cause of these afflictions was unknown. So it became widely accepted that teething was a source of fever, diarrhea, vomiting, seizures, tetanus and meningitis, to name just a few, and even death. It was not uncommon for teething to be listed as the cause of death in children prior to the late 19th century. Unfortunately, many of these children probably died as a result of the misguided attempts at treating the perceived symptoms of teething.
Teething present
Though we have come a long way in our understanding of human physiology since the 19th century, there remains widespread misunderstanding of what symptoms can reasonably be attributed to teething. Parents and other caregivers are quick to list fever, difficulty sleeping, fussiness, drooling, changes in feeding amount and frequency, nasal congestion, and diarrhea, in addition to the most frequently cited symptom of pain, but the evidence has not been very supportive of these beliefs. To put it bluntly, it does not appear that the eruption of a tooth can be successfully predicted by any collection of symptoms. I have spoken to many parents who believe that their child has been teething for weeks without a tooth revealing itself. It just doesn’t work that way.
Experts do not believe that any systemic symptoms can be caused by the teething process. This includes poor appetite, congestion, difficulty sleeping, diarrhea, vomiting, cough, rash, or fever. At most, there may be some discomfort that goes along with the teething process. As with colic, a significant factor is the variability or fit of the parent-child dyad. The same child may be perceived as being more or less symptomatic, or not symptomatic at all, depending on which caregiver is observing them. Many new parents are exposed to misinformation regarding what to expect from teething and it is likely that at least in some instances it is a self-fulfilling prophecy of sorts.
The eruption of permanent teeth, which begins around age 6 years, is not typically associated with discomfort. This may be because of differences in sensitivity to pain between infants and older children, but it also might be evidence that the process just doesn’t really hurt that much. It is a myth that the new tooth cuts its way through the bone and gum. In reality a pathway emerges because of the remodeling of the tissue. Many children felt to be teething, and in need of treatment, may in reality be feeling no discomfort whatsoever. An indirect danger in continuing to attribute systemic symptoms to teething, and perhaps even pain, is the possible delay in seeking out appropriate investigation into their true cause.
Popular (but ineffective and potentially dangerous) teething treatments
More troublesome than any indirect harm of the misattribution of systemic symptoms to teething is the potential direct harm of actively trying to manage them. Historically the risk of serious harm from teething treatments was much greater. Many therapies used in the past were extremely toxic, such as lead- and mercury-based compounds. Consistent with beliefs in humorism, vomiting and diarrhea were frequently induced in order to purge the body of excess humors. The use of opiate based preparations could cause respiratory suppression and honey was a source of infant botulism.
The belief that tension on the gums played a prominent role in teething symptomatology was widespread. As a result, surgically cutting the gums in order to open up a path for the emerging tooth was a common procedure until the late 19th and early 20th century in developed countries. In some less developed regions around the world, the gums of infants were still frequently sliced open and the teeth removed. Sadly, well-meaning but dangerous efforts such as this still exist in some areas, and children continue to die of infection or live with significant malformations of the lower jaw and remaining teeth.
Many historical remedies for teething were based on a belief in magic. This hasn’t changed appreciably considering that one of the most common treatments used today is homeopathy. The pages of SBM are filled with articles discussing the mind-boggling inanity of homeopathy, so I won’t go into great detail in this post. In a nutshell, homeopathic remedies consist of concoctions diluted to the point that there is no possible means of therapeutic efficacy, if not non-existence. The proposed hypothetical underpinnings of these remedies are irrelevant as the reality is that there is no remedy in the remedy.
Hyland’s homeopathic teething tablets is one of the most popular examples of this. Continued belief in homeopathic remedies despite our improved knowledge of the pathophysiology of human illness, and how to treat it, is based on the naturalistic fallacy and an overemphasis on personal anecdotes rather than actual quality scientific evidence. Check out their website and provided video testimonials, and count up the logical fallacies. Their disclaimers, and reassurances that the amount of belladonna in the product is completely safe, are quite telling. The reason for all the fuss on their website is because of FDA concerns about the inconsistency in the amount of belladonna in the tablets and reports of toxicity in children. Hyland’s appears to disagree with these concerns. I’d go with the guy with all those medals though. Camilia from Boiron is another popular homeopathic product marketed for teething.
Another popular but ineffective remedy for teething symptoms is amber, typically incorporated into a necklace or bracelet. The claims regarding just how wearing amber might treat teething symptoms range from complete woo, such as it being charged with reiki energy, to somewhat more reasonable claims of analgesic chemicals being absorbed by the skin. These claims are implausible and thoroughly unproven, and amber jewelry represents a worrisome choking risk in young children.
Since it is believed by many that the source of any potential pain related to teething is localized to the area around where the tooth erupts, naturally a variety of topical preparations have been developed. These products typically contain the anesthetic agent benzocaine. Even assuming that teething does cause discomfort amenable to being numbed by a local anesthetic, there is a lack of evidence to support that these products are effective. But even if they were helpful in teething infants, the risks far outweigh any possible benefit. Children, particularly those under the age of 2 years, are at risk for a potentially deadly condition called methemoglobinemia when benzocaine is ingested or absorbed through oral mucosa. Methemoglobinemia interferes with the bloods ability to transport oxygen and can occur within minutes or hours after exposure, even after the very first use.
The FDA has issued warnings about this risk, and most pediatricians discourage the use of products containing anesthetics as well as those containing aspirin-like chemicals. There are also homeopathic gels, and teething oils that commonly contain clove oil. These only appear to work via parental placebo. The manufacturers of Orajel, probably the most widely known line of products used for teething and pain from oral ulcers or hardware, has jumped on the bandwagon and now offer their own homeopathic gel.
Use of oral analgesics like acetaminophen and ibuprofen (in babies over 6 months of age) is also common. There are no studies proving their effectiveness. Instead their use, as with all other interventions, is based on personal anecdotes and likely only appear to help because of any number of placebo effects. While these medications are relatively safe, and certainly safer than historical remedies or some of the other current popular treatments, they do have risk. Acetaminophen is associated with severe liver injury when overdose occurs and ibuprofen can cause bleeding in the stomach and kidney injury with regular dosing. These adverse effects aren’t common but they do occur.
How should teething be managed?
The safest approach to teething is to return whatever “remedy” you just purchased, thus avoiding anything that may potentially be harmful. Most experts will concede that although there are no systemic symptoms caused by teething, there may be some local discomfort. But it may be very mild, or there may be no pain at all. So any risk is likely too much when it comes to treatment.
If you believe that your child is experiencing discomfort, there are teething rings which can be chilled in the refrigerator which he or she can chew on. The thought process is that cold and pressure may help relieve discomfort. Avoid anything that may serve as a choking hazard in young infants, such as teething biscuits or cold bagels. And if you do choose to give acetaminophen or ibuprofen, check your dosing very carefully and avoid other products, such as cough and cold medicines, that may also contain acetaminophen.
Conclusion: TLC for teething tots
Everyone has an opinion about teething and how to treat it, and most of that advice is wrong or at least not based on any evidence. Though historically teething was seen as a life threatening malady, it does not cause systemic symptoms and may not even actually cause significant discomfort. If your child has fever, diarrhea, significant changes in behavior, or excessive irritability, talk to their doctor before blaming these symptoms on teething. If your child appears to have some minor discomfort, supportive care (i.e. TLC) is the safest and likely most effective remedy.

Vitamin K Refusal – The New Anti-Vax
Steven NovellaonAugust 20, 2014
Link

A small but increasing number of parents are refusing vitamin K injections for their newborns, an intervention recommended since 1961. This is yet another example of the difference between a science-based and philosophy-based approach to medicine. Science has given us the tool of knowledge, and in medicine that knowledge can have very practical applications.
The term “vitamin” was coined in 1912 by the Polish biochemist Kazimierz Funk. A vitamin is an organic nutrient that an organism requires in small amounts but cannot synthesize in adequate amounts and therefore must obtain from the diet. Knowledge of specific vitamins, their food source, and their biochemical activity in the body, has allowed medical scientists to cure many serious nutritional diseases, such as scurvy, rickets, and blindness.
The Vitamin K family are derivatives of 2-methyl-1,4-naphthoquinone, a fat-soluble molecule. It is a cofactor necessary for the formation of factors that function in blood clotting and in bone formation. The primary effect of vitamin K deficiency is therefore bleeding. Infants are at risk for vitamin K deficiency because this molecule does not cross the placenta well. Infants are therefore born relatively deficient in vitamin K. Further, breast milk contains little vitamin K (regardless of the mother’s diet) so infants are at risk for vitamin K deficiency until they start eating solid food at around 6 months (see Clay Jones’ post on the topic here).
The standard of care for many decades has been to give all newborns a vitamin K intramuscular injection. This contains enough of the vitamin to cover them for 6 months until they start getting enough vitamin K in their diet.
Without supplementation, there is an incidence of vitamin K deficiency bleeding (VKDB) in the first week of life of 0.25-1.7%. There is also a late VKDB that is more severe but has a lower incidence of 4.4-7.2 per 100,000 live births. Bleeding most commonly occurs in the brain, and when severe it can be devastating and even fatal.
A single injection of vitamin K at birth significantly reduces the risk of VKDB. In fact, it virtually eliminates the risk. Recent studies looking at infants who have VKDB show that most or all of them did not receive vitamin K prophylaxis. This is a simple, safe, and effective preventive measure, essentially just giving a vitamin to newborns, that prevents a common and potentially devastating outcome. Why would anyone refuse such a clear homerun intervention?
As you might suspect – ideology can trump science and reason. A study published this week in Pediatrics by Sahni et. al. found that 0.3% of those in the study refused neonatal vitamin K. Those who did refuse were 14.6 times more likely to also have refused all recommended vaccines up to age 15 months. They were also 4.9 times more likely to have a planned home birth, and 3.6 times more likely to have delivered at a birth center. A New Zealand survey also published this year found that 100% of medical staff, but only 55% of midwives, agreed that all newborns should receive vitamin K.
One way to interpret this data is that there is a pattern of distrust of the medical establishment or distrust of science in general, and reliance upon so-called “alternative” approaches to birth and childcare. In other words, this is a result of ideology trumping science. As a result, there is an increasing incidence of early and late bleeding in infants.
The numbers of refusals are still low, but are rising fast, clustering in certain centers and hospitals. A recent Tennessee abstract found that in one hospital the refusal rate was as high as 3.7%. They also found that:
Of 102 vitamin K refusers surveyed, 47 (46%) responded; 31/47 (66%) identified bleeding as a risk of refusing prophylaxis. The leading reasons for refusal were desire for a natural birthing process (43%) and believing prophylaxis was unnecessary (43%). Hepatitis B vaccine and erythromycin eye ointment were also refused by 65% of respondents.
In other words, an irrational adherence to the naturalistic fallacy was largely to blame. This was possible combined with misinformation, but I have to wonder if the bleeding risk excuse was simply a post-hoc justification and not the true reason for refusal. Further, we see that those who refuse vitamin K also refuse other recommended interventions, including erythromycin eye ointment used to prevent blindness.
Conclusion
In my opinion, what we are seeing here are the downstream effects of the “alternative medicine” philosophy and world-view. Promoters of CAM often instill a general distrust in science and the institution of medicine. They promote dubious treatments with the notion that “natural” (even though poorly defined) is somehow inherently superior, and therefore interventions that seem technological are to be feared.
They have been unfortunately successful in marketing their philosophy. As a result there are parents who refuse for their newborn children safe and effective interventions supported by solid scientific evidence.

Update on Vitamin K Refusal
Vitamin K shots at birth are a safe and effective method for preventing bleeding, but that doesn’t stop some parents from refusing.
Steven Novella on February 26, 2020
Link

It has been six years since I’ve posted anything on Vitamin K refusal – in 2014 I described it as the new anti-vax (though Clay provided a repost last November). Unfortunately it continues to be a problem for newborns, despite efforts at public education.
Why vitamin K?
Newborns lack sufficient vitamin K, largely because the vitamin does not easily cross the placenta. It also exists in low quantities in breast milk, and so babies may be deficient until around six months of age when they start to include other food in their diet. Vitamin K is necessary to form clotting factors, and so the primary risk of being deficient it an increased risk of bleeding, including spontaneous bleeding (i.e. not provoked by trauma or any external event), known as vitamin K deficient bleeding (VKDB). Bleeding can occur early, within the first week of life, or late, after the first week but within the first six months. According to a recent review:
Without prophylaxis, estimates of the incidence per 100 000 births of VKDB range from 250 to 1700 for early VKDB and from 10.5 to 80 for late VKDB.
The absolute risk is therefore low but still significant. The most common locations for VKDB in newborns is either the brain or the bowels. Bleeding in the brain can impair neurological development and even cause death. Intestinal bleeding can also be life-threatening. But worry not – one shot of intramuscular vitamin K at birth significantly reduces that risk (relative risk in that study was 0.19, with a number needed to treat of 74). The shot immediately increases vitamin K levels, with most of the vitamin being stored in the liver where it is slowly released over the next six months.
Medical interventions are all about risk vs benefit, so what are the potential risks of one IM shot of vitamin K at birth? The risks are actually minimal, and specific risks are rarely cited as reasons for refusal. There was one preliminary study showing a potential correlation between vitamin K shots and childhood cancer, but this correlation was later completely refuted by larger and more rigorous studies. I have only seen mention of it in resources, like this one, citing the evidence to refute a correlation. So unlike the myth that vaccines cause autism, this debunked correlation does not seem to be driving vitamin K refusal.
Right now the recommendation of the American Academy of Pediatrics and other medical organizations is for every newborn to receive one IM dose of vitamin K at birth. This ensures universal coverage for the first six months of life, it reduces the risk of VKDB and all the morbidity and mortality that results, and it is extremely safe. However, some still find reasons to refuse this safe and effective medical intervention.
Why people refuse vitamin K
In my original 2014 article I discussed a review of Nashville area hospitals conducted in 2013 which found that:
At hospitals, 3.0% of infants did not receive injectable vitamin K due to parental refusal in 2013, a frequency higher than in 2011 and 2012. This percentage was much higher at birthing centers, where 31% of infants did not receive injectable vitamin K. The most common responses for refusal were a belief that the injection was unnecessary (53%) and a desire for a natural birthing process (36%). Refusal of other preventive services was common, with 66% of families refusing vitamin K, newborn eye care with erythromycin, and the neonatal dose of hepatitis B vaccine.
Three percent is low, but that still represents a lot of potentially avoidable VKDB. The more concerning figure is the 31% in birthing centers who refuse. This may be due to self-selection of the type of parents who choose birthing centers, but there is concern that it also reflects the philosophy of the midwives and other practitioners at these centers. In a good 2019 article on the topic, pediatrician Rachel Pearson relates stories of patients told by their midwives not to get the vitamin K shot. We need good data on this practice, but the 31% figure is alarming in any case.
A 2020 review found essentially the same results:
The frequency of refusal of intramuscular vitamin K by parents ranged from 0% to 3.2% in US hospitals, up to 14.5% in home births, and up to 31.0% in birthing centers. Reported reasons for refusal were concern of harm from the injection, a desire to be natural, and a belief in alternative methods of prophylaxis. Parents who refused intramuscular vitamin K were more likely to refuse immunizations.
So essentially nothing has changed. The main reason for objection to vitamin K is not based in evidence or any solid logic, but is rather philosophical – the desire to be “natural”. This is a downstream effect of the appeal to nature fallacy that is ubiquitous in the marketing of alternative medicine. It also strikes me as interestingly selective. When CAM providers give high dose intravenous vitamins for their treatments, the vitamins are considered “natural” remedies, and the high doses justified. When doctors give an evidence-based dose of a needed vitamin with clear benefits, that is not “natural”.
The notion that the shot is “unnecessary” is a claim that is subject to facts. It is based in a misconception, that a healthy newborn without trauma does not need the vitamin K. On one “mommy” blog, the author explains their reasons for refusing vitamin K:
Yes, I believe there may be instances where a newborn may need it if there are bleeding issues, but my daughter was completely healthy and normal with no visible signs of trauma after coming out of the birth canal unassisted.
This is a myth. Otherwise-completely-healthy newborns without signs of trauma can still have VKDB. Also, by the time you notice the signs of a bleed, it’s too late, the (potentially catastrophic) damage is done. Yet again, there is selective use of logic here – CAM proponents market themselves (falsely) as being more focused on prevention. Well here is an evidence-based preventive measure, criticized for being preventive rather than reactive.
I point out these inconsistencies because what is at work here is not evidence and reason, but marketing and world-view. The important factor here is a lack of trust in the medical and scientific establishments, a lack of trust resulting from the CAM culture that is constantly beating the drum of paranoia and conspiracy theories. This is the result.
The alternative methods usually refers to oral vitamin K. So far there is no evidence-based oral regimen shown to work. There is evidence that single dose oral vitamin K is less effective than the IM shot. It is still an open question if multiple oral doses can be as effective as IM, but even if this does work the problem is compliance. You have to keep up with the regimen of oral doses. A single IM dose at birth, however, is all you need. So the real-world effectiveness of the single shot will always be better.
The evidence is crystal clear in this case – single dose IM vitamin K at birth is a very safe and effective method for preventive VKDB in newborns and infants. Objection to this effective intervention is based on misconceptions rooted in the alternative medicine marketing and philosophy, and spread mostly by non-physicians. We have to stay ahead of this phenomenon, and perhaps a dose of science-based information may be preventive.

From the Vault: Newborn Vitamin K Shots Save Baby Lives
I’ve gone into the vault in order to save new content until after technical difficulties have been ironed out. Here is one of my earliest and most memorable (to me) posts on the newborn vitamin K shot and risks of refusing it.
Clay Jones on November 15, 2019
Link

Due to the ongoing technical difficulties, I decided to go deep into the vault and re-post one of my earliest contributions to Science-Based Medicine with a little added commentary. This article on newborn intramuscular vitamin K shots and the dangers of parental refusal was originally posted in December of 2013 and I don’t even think that I was a regular contributor at the time. I was just a nobody submitting posts on a trial basis and hadn’t yet been handed the keys to the kingdom. I’m still a nobody, but for better or worse I don’t have to have my posts screened by David anymore.
This post was particularly memorable because it resulted in a few minutes of “fame”. I got to go on a podcast with Chris Mooney and Indre Viskontas called Inquiring Minds and was quoted in a dozen or so articles. I was interviewed live on a Canadian radio show and even had the immense pleasure of turning down an appearance on the Sunday Fox & Friends with Tucker Carlson to debate this topic. They wouldn’t tell me who would be taking the pro-dead baby position. I’ve spend the past seven years trying desperately to recapture that feeling but have had to settle for co-hosting a podcast with Grant Ritchey. Sigh.
It may come as a shock, but my article and many media appearances did not stem the tide of vitamin K refusal. As a newborn hospitalist, I still have to have this discussion with parents a few times a year. My most recent encounter with a hesitant family was just a few weeks ago and, after about an hour of discussion and a night to sleep on it, we were able to protect a baby from a potentially devastating injury with a virtually risk free intervention.
Separating fact from fiction in the not-so-normal newborn nursery: Vitamin K shots…
In August, news emerged from Vanderbilt University that four cases of a rare bleeding condition seen in young infants had been diagnosed since February. Three of these infants suffered intracranial hemorrhages, requiring surgical intervention to evacuate the blood and save their lives, although there will almost certainly be neurological and developmental repercussions down the road. The fourth child presented with gastrointestinal bleeding and also survived. The parents of all four babies had refused an extremely safe and effective intervention on the day that they were born, one recommended by pediatricians since the early 1960’s, that would have prevented these outcomes.
The news out of Vanderbilt came out in August of 2013. In May of 2014, more cases were reported and physicians there called for a national reporting system to track these cases out of fear that this is a growing concern as more families refuse. It hasn’t happened as of November, 2019.
When a baby is born, there are a number of rituals that parents and medical professionals take part in. Some are largely ceremonial, more rites of passage than anything medically necessary, such as the first bath or the assignment of APGAR scores. As a physician, I play my part in some of these rituals, the baby’s first exam being the most important. Unlike many medical examinations that pediatricians perform, the newborn exam involves a good deal of showmanship. It’s the only exam where I make a point of talking through each aspect with the parents, showing them all the normal but sometimes surprising (at least to new parents) things that babies do and common physical exam findings that many folks don’t know about and might lead to unnecessary concern. Really hammering home how healthy a new baby is can go a long way towards relieving parental anxiety. And anticipating and addressing common newborn issues during the exam helps save me a lot of time on the back end as well.
Nursing plays the largest role in the rituals of caring for a newborn baby. They give the first bath, change the first dirty diapers, and typically assist with the first latch if a mom is breastfeeding. They perform common procedures, such as heel sticks for newborn screening and jaundice assessments if necessary. They really do a lot, providing a great deal of vital education for parents while doing it, and their role in the care of the newborn far outshines my contribution for the majority of healthy babies.
Another ritual that nursing plays a major role in, and one that has significant medical benefits associated with it, are vitamin K injections. But before I discuss why it is so important for newborns, especially those that are going to be primarily breastfed, to receive these injections, a little primer on vitamin K is in order.
What is vitamin K?
Vitamins in general are organic substances that are necessary for normal metabolic processes that cannot be made by the human body. We have to take vitamins in by eating foods that contain them. The beginning of our understanding of vitamin K goes back to 1929 when Danish researcher Henrik Dam discovered that a substance existed which could help correct bleeding induced by restricting cholesterol from the diet of chickens. This substance, named Koagulationsvitamin in the German journal that first reported the findings, has since been known as vitamin K. The fat soluble vitamin K was first isolated from alfalfa sprouts only a year later.
There are two main forms of vitamin K. We take in vitamin K1 when we eat leafy green vegetables like kale and spinach, but it is also found in broccoli. Because it plays a major role in photosynthesis, it isn’t found in root vegetables in large amounts. Vitamin K2 can also be obtained from the diet, usually in the form of aged cheeses, fermented vegetables and organ meats. Much of the vitamin K2 in our bodies is actually synthesized by bacteria in our intestines and then absorbed. In general, vitamin K1 is the most active form.
In order to absorb vitamin K, we need a functioning pancreas and biliary system. The vitamin K that we take in is bound to proteins that require pancreatic enzymes in the small intestine to be broken down. Bile salts then render the liberated vitamin K able to be absorbed into intestinal cells for processing and transport to the liver. So biliary and pancreatic disease can increase the risk of deficiency, which is actually quite rare in adults. Babies, now that’s a different story, as I’ll soon explain.
What does vitamin K do?
The primary role of vitamin K in the human body is blood clotting. It is also involved in bone growth and density, but at this time there isn’t great evidence that supplementation is particularly helpful in preventing osteoporosis or fractures. In some countries, however, various formulations of vitamin K have been recommended for just that purpose. There is ongoing research into vitamin K’s role in the development of Alzheimer’s disease, heart disease and even some cancers, but these are hypothetical and may not pan out.
Vitamin K is a cofactor necessary for a number of key enzymes involved in clotting to work properly. In particular, clotting factors VII, IX, X and prothrombin produced in the liver require vitamin K-fueled activation. Without enough vitamin K, ultimately these proteins will not be attracted to circulating platelets and blood clotting will be impaired, which can lead to life-threatening bleeding complications. The medication warfarin takes advantage of this by blocking the conversion of inactive precursors into active vitamin K. This is why patients on warfarin are warned to avoid excessive dietary vitamin K intake as that may reverse the anti-clotting effects.
Why do babies need vitamin K shots?
Newborn infants are considered to be universally deficient in vitamin K. This happens for a variety of reasons. There is poor transfer of vitamin K across the placenta and the immature liver has both decreased storage capability and is inefficient at using available vitamin K. Naturally, this is even more pronounced in premature infants. Adding to this, breast milk does not contain sufficient amounts of vitamin K and the initially-sterile gut of the newborn does not significantly contribute to vitamin K levels in the body for several weeks.
There isn’t anything a mother can do about these etiologic factors. But some things can add to the risk even further. There are a number of medications, in particular warfarin and some anti-seizure drugs, that when taken by a mother during pregnancy increase the risk of vitamin K deficiency and bleeding complications in the new baby. Certain antibiotics used to treat tuberculosis can have a negative impact as well.
Without supplementation, newborns are at risk for a potentially devastating condition known as vitamin K-deficient bleeding (VKDB), formerly known as hemorrhagic disease of the newborn. VKDB is a better designation because life-threatening bleeds can occur as late as 3 months of age, particularly in breastfed babies who did not receive an intramuscular dose of vitamin K on the first day of life. Most bleeding occurs during the first week, however.
The really scary thing about VKDB is that it occurs in perfectly healthy babies and it happens spontaneously, not because they were dropped on their head for instance. Bleeding can present in many ways, ranging from mild to fatal. Skin bruising, bleeding into mucosal tissues (mouth, nose, throat, intestine, uterus, urethra), bleeding at the umbilical stump or circumcision site, and bleeding into the brain can all happen.
One of the most common presentations of easy bleeding in newborns is something called a cephalohematoma. These are bleeds under the periosteum, a dense connective tissue membrane that covers bone, and typically involve the parietal bones of the skull because of pressure to the scalp during even uneventful deliveries. Because the blood is trapped under the periosteum, these present as immobile but squishy (think silly putty) scalp masses, sometimes shockingly large, that can take weeks to resolve. Large cephalohematomas are a major risk factor for severe jaundice.
Without supplementation, as many as 1.7% of babies would be expected to have some kind of bleeding complication during the first week. This is known as “early VKDB” or classic hemorrhagic disease of the newborn, and it can be easily prevented by an intramuscular vitamin K injection on day one of life. It can also be prevented with oral supplementation. The evidence to support the efficacy and safety of these interventions is rock solid, but there are problems with oral supplementation when it comes to bleeding after the first week.
When there is a bleeding complication from vitamin K deficiency that occurs between 2 and 12 weeks of life, this is called “late VKDB”. This happens almost exclusively in babies fed primarily breast milk who did not receive adequate vitamin K prophylaxis, or who have some other major risk factor such as liver disease or cystic fibrosis. Late VKDB, as it did in the children treated at Vanderbilt Children’s Hospital, where I completed my pediatric training and a fantastic facility by the way, tends to present as unexpected bleeding into the brain.
The risk of late VKDB is felt to be around 4.4 to 7.2 per 100,000 children not receiving vitamin K prophylaxis. Oral vitamin K given on day one of life does not substantially reduce the risk, while intramuscular dosing renders it virtually nonexistent barring some other significant risk factor. Some countries promote longer-term oral vitamin K prophylaxis, and there are a variety of approaches. One common method is to dose vitamin K orally with the first feed and again at one, four and eight weeks of age. In the Netherlands, small daily doses have been recommended. While not every approach to oral prophylaxis has been extensively studied, such as the small daily dose regimen, many have been and it appears that there remains a risk of about 1-2 cases of late VKDB per 100,000 births.
Why would oral prophylaxis not work? There are just too many variables. Adherence to the recommended regimen may be poor for a variety of reasons. A child may be ill and vomiting, or on antibiotics which interfere with gut production by killing off intestinal flora. A family may simply forget. The amount of vitamin K in the breast milk may be affected by external factors as well. So while oral vitamin K may be cheaper and does not cause any procedural discomfort, and it may be better than none at all, the evidence supports intramuscular prophylaxis, especially when you consider the potential outcomes of late VKDB. Some countries that switched to oral regimens have seen spikes in the incidence of late VKDB, and Australia switched back to intramuscular. Of note, premature infants must receive intramuscular dosing because of poor absorption of oral formulations. Also, liquid oral vitamin K is not available in the United States.
Why would a family refuse vitamin K?
I imagine that regular readers of SBM are not surprised by the fact that vitamin K prophylaxis refusal is something that pediatricians and family practice doctors deal with, although not as frequently as vaccine refusal. Why do parents do it? Why would a parent reject an intervention that is so effective at preventing such a devastating consequence as bleeding into the brain of their baby and a potential lifetime of seizures, developmental delay and cognitive impairment? And one that is virtually risk free to boot!
Many families who refuse simply have a world view where medical intervention is perceived as unnatural. Many of these children are born at home or in birthing centers attended by midwives and doulas. They tend to have extensive and demanding birth plans when they deliver in the hospital and frequently also refuse antibiotic prophylaxis against neonatal conjunctivitis, another newborn ritual with less controversy attached to it. Eye and vitamin K prophylaxis are collectively referred to in nurseries as the “eyes and thighs”. These families also typically refuse the newborn hepatitis B immunization, perhaps a topic for another post, and go on to refuse or spread out childhood immunizations in the future.
Though not as widespread as anti-vaccine propaganda, and certainly lacking that particular entity’s infrastructure and celebrity support, there is an online presence of bogus anti-vitamin K information to be found. Naturally the chiropractic community is all over the place about this topic as they are with everything else. This particular practice warns that synthetic intramuscular vitamin K might cause cancer, kill your baby, or make them sterile, and questions the need for prophylaxis at all.
In March of 2010, our friend Dr. Mercola interviewed biochemist Cees Vermeer, who appears to be an expert on vitamin K who is involved in research to find new commercial applications, and published an article on the subject of newborn vitamin K prophylaxis that questions the mainstream approach. I also found several message boards and mommy groups citing this information as a reason to question the intramuscular injections. I’ll start off with what the article gets right. He appears to appreciate the need for vitamin K in newborns, and discusses some of the risks of deficiency. He is absolutely right when he says that newborns can feel pain, and that pain in the neonatal period can sometimes have long lasting effects. He is right when he says that oral vitamin K prophylaxis can be effective. Maybe I’ve been too hard on this guy.
I was shocked to find that Mercola even agrees with mainstream science that intramuscular vitamin K prophylaxis does not cause cancer. Because of some small, poorly done studies in the early 1990’s there was a brief period of concern that vitamin K prophylaxis increased the likelihood of pediatric leukemia. The question was thoroughly addressed by better studies and is not considered a problem. However it does occasionally come up as a reason to refuse, or as something that parents are worried about and want to discuss. For more information on this non-controversy, here is the AAP policy statement.
So now let’s tackle what Mercola gets wrong. I’m not sure how much of this represents his versus Vermeer’s understanding of VKDB, but they don’t appear to have a good understanding of it. He makes some pretty glaring mistakes (I’m being generous) in the article that are easily addressed. First off, he doesn’t seem to understand the differences between early and late VKDB. He mentions the risk of up to 1.7%, but not that this specifically is for the early form. He then declares that this is rare. I do not consider almost 2 out of every 100 births to be rare. The incidence of late VKDB is considerably lower and could reasonably be thought of as rare, but when it happens it usually results in a messed up brain. If nearly 2 out of 100 kids had brain bleeds, that would be horrific!
He states that there was no evidence to support the standard of care in regards to vitamin K prophylaxis when it was first implemented. Vitamin K became a routine standard of practice in 1961. I was able to easily find numerous papers going back a decade before that investigating the use of vitamin K prophylaxis in newborns. He likens what we do to a “shotgun approach” that was convenient. You know what is inconvenient? Brain bleeds.
He blames increased rates of circumcision on the push to give intramuscular vitamin K injections. This is absurd. It has been known for decades that oral prophylaxis is just as effective as intramuscular for early VKDB. Most circumcisions take place on day 2 or 3 of life. Intramuscular injections are recommended only because they work better than oral regimens for preventing bleeding complications in the 2nd to 12th week of life.
So why is Mercola so worked up about vitamin K? He just cares too much, I suppose, and can’t bear to think that newborn babies might be suffering from the pain of an intramuscular injection. Anyone who read my last post on pediatric pain should know how much I hate poorly managed pain, but even I think his concerns are over the top. Mercola likens the discomfort from an IM injection of vitamin K to psycho-emotional damage and trauma that causes an “emotional wound that the helpless and innocent baby needs to overcome to achieve health and wellness”.
Poorly managed pain in the neonate does have potential downstream repercussions. I really do need to go into more detail in a post on the subject. But to compare a one-time IM injection to a 25-week-premature infant riding a vent without appropriate pain control for 5 weeks, or twenty heel sticks over the first few days of life to follow blood sugars in the growth-restricted infant of a diabetic mother, is more than a little ridiculous. Untreated bouts of acute pain in neonates, such as a circumcision without any local anesthesia or sugar water, may increase their pain/stress response to future painful events in infancy such as routine childhood immunizations, but they do not “remember it” or have psychological problems further down the road. Infants who suffer chronic pain, usually premature babies that require mechanical ventilation and/or surgery, have actually been shown to have a blunted pain response. We don’t have good data on longer term issues regarding chronic pain in babies.
Mercola raises concerns about the safety of the dose of intramuscular vitamin K, stating that it is 20,000 times the needed dose. His source is “givingbirthnaturally.com”. Even if true (the needed dose for what?), he acts as if it is being injected straight into a vein. It is an intramuscular injection. The vitamin K is slowly metered out similar to penicillin shots that we give in place of lengthy courses of oral antibiotics for strep throat or the prevention of rheumatic heart disease flares. He worries about toxic preservatives injuring the baby’s immune system but gives no evidence to support this because there is none.
He mentions that an injection is an infection risk because the baby has an immature immune system and hospital bugs are so dangerous. This is theoretically true but the risk would be considerably lower than the risk of bleeding in a child not appropriately prophylaxed against VKDB, and he cites no data to support his concern. Intramuscular injections do have real risks, but they are very minor. A bruise or treatable local infection, for instance, must be weighed against the risk of a brain bleed.
Mercola recommends oral vitamin K as an equally effective alternative to the intramuscular dose. He says it is absorbed efficiently enough and there is no risk of overdosing or a bad reaction. He claims that oral dosing is even equivalent in exclusively breastfed babies, which is potentially very dangerous advice, but then says that future research is needed to find better “pinpoint guidelines”. Well, we have current research that says most oral regimens are less effective and we lack evidence to show that daily dosing is as effective as intramuscular injections for preventing late VKDB. If future evidence shows daily dosing to work as well as injections, then it may be a reasonable approach in some infants. But to completely ignore the fact that giving a medicine orally to a baby for long periods of time is prone to adherence issues shows his lack of any true understanding of this topic or of babies.
He quotes Vermeer as saying that if breastfeeding women just eat enough foods rich in vitamin K, their babies don’t need the intramuscular injection or the oral supplementation. Levels of vitamin K in breast milk are low, much lower than in infant formula, and it is not clear at all if dietary modification is good enough. And if a mother goes on a course of antibiotics, for instance, or is ill and unable to eat a diet high in green leafy vegetables for a period of time, her vitamin K levels may decrease and put the baby at risk for a bleed. Vermeer is a biochemist, not a physician and I would ignore his advice on the matter. I would ignore what Mercola has to say about this and everything else.
Conclusion: Brain bleeds in babies are a bad thing
Newborn babies are amazing things. I don’t pretend to know everything there is to know about them, and I certainly don’t understand the evolutionary underpinnings of vitamin K deficiency in newborns. I guess it is uncommon enough that there was no pressure to evolve better transport of vitamin K across the placenta or to increase levels of vitamin K in breast milk. But the why is not so important in this instance. Babies, through no fault of their own, are born at increased risk of life threatening bleeding complications from vitamin K deficiency. Vitamin K prophylaxis via the intramuscular route is safe and effective at preventing these life threatening complications, and based on the evidence available it is better than oral regimens. This may change in the future.
When a parent refuses the vitamin K, I can’t force it upon them. I try to get to the bottom of their concerns and address them as best as possible. In the vast majority of instances, parents agree to the injection. When they don’t, we don’t notify child protective services or call the police. We document, document and then document some more so that it is clear in the medical record that the parents were given the appropriate information to make an informed decision and that even knowing the risk they still refused. There is no oral vitamin K solution available in the United States, but I guess you can get anything on the internet these days. Oral dosing is better than nothing. I leave that discussion up to their primary care physician.

The CDC and WHO Have Reported an Unusual Cluster of Severe Pediatric Hepatitis Cases
An unusual cluster of severe liver disease in children is being reported around the world. The cause isn’t entirely clear, but it may be an uncommon presentation of a common viral infection that isn’t COVID-19.
Clay Jones on April 29, 2022
Link

In May of 2020, I discussed a rare and mysterious inflammatory condition that at the time had only been diagnosed in a few hundred children around the world. This Multisystem Inflammatory Syndrome in Children (MIS-C), which involves severe systemic inflammation and potential injury to numerous organs, in particular the heart, was ultimately linked to prior infection with the SARS-CoV-2 virus. As of March 28th of 2022, MIS-C has been diagnosed in almost 8,000 children in the United States alone, and there have been 66 known deaths.
The cases of COVID-19 that eventually result in MIS-C tend to be mild or even asymptomatic, a fact often ignored by people downplaying the potential harms of infection in young children. It also occurs in a mostly random pattern, meaning that any child who is infected with SARS-CoV-2 is at risk. Death is clearly not the only outcome of concern in kids, who are also not immune to the potential for lingering and potentially life-altering symptoms related to long-haul COVID.
Here we go again. Maybe. Well, probably not. Still…sheesh!
Last week, the CDC issued a health advisory via the CDC Health Alert Network to notify clinicians and public health authorities of a worrisome cluster of children diagnosed with severe inflammation of the liver, some of which ultimately required a liver transplant. They also warned of a possible link to a viral infection, though it doesn’t appear to be SARS-CoV-2 this time around. In this case, the most likely culprit is an adenovirus, specifically adenovirus serotype 41.
Back in 2018, I actually wrote about adenovirus infections after several children in a New Jersey nursing home died from severe respiratory disease during an outbreak of adenovirus serotype 7. I discussed the existence of a safe and effective vaccine that has historically only been available for military use but reasonably could, and probably should, be used in a focused manner in high-risk populations. Please check out that post for a more thorough primer on this fascinating family of viruses.
In a nutshell, however, adenoviruses are a well-known cause of febrile illnesses in children, but they can cause disease throughout the human lifespan. Typically when we think of adenoviruses, upper respiratory infections come to mind as they are primarily a cause of the common cold. But there are seven species of adenovirus that infect humans, with more than 60 serotypes between them, and exhibit a variety of clinical presentations. In addition to upper and lower respiratory infections (colds and pneumonia), adenoviruses can infect the GI tract (vomiting and diarrhea), the genitourinary tract (hemorrhagic cystitis), the eyes (pink eye), brain (meningitis and encephalitis), and heart (myocarditis). They can also cause disseminated disease, meaning that the virus gets pretty much everywhere.
Some of the specific clinical presentations seen with various adenovirus infections can provide clues as to the specific serotype involved. Serotypes 3 and 7 are associated with the combination of sore throat and pink eye while 11 and 21 are more likely to infect the bladder. 40 and 41 mostly cause diarrhea. Respiratory symptoms can be caused by many different serotypes, though severe disease is often the result of infection with 3, 4, 7, 14, and 21. Most adenoviral disease is mild and resolves with simple supportive care, but any serotype can cause severe, atypical, or even fatal disease in someone who can’t mount an effective immune response.
An unusual cluster of hepatitis cases
The first reported spike in cases of pediatric liver inflammation, known generally as hepatitis, came out of Alabama. In November of last year, a single hospital reported five children with severe liver injury, three of which would ultimately develop liver failure. All five of these children were found to have an adenoviral infection and all were negative for COVID-19.
A targeted search led to the discovery of four additional cases, bringing the total to nine children, all young (1-6 years) and previously healthy, from October 2021 through February 2022. These children had no identified common exposures or epidemiological link. Genetic sequencing revealed that seven of the nine cases were associated with adenovirus serotype 41, which is not a known cause of hepatitis except in patients who have a severely compromised immune system. Healthy children infected with adenovirus 41 normally develop respiratory symptoms, vomiting, and diarrhea.
Hepatitis isn’t an uncommon condition, even in children. And it is typically caused by a viral infection. Hepatitis caused by the hepatitis A virus, which is easily spread via the fecal-oral route, used to be common in the United States but has decreased by 95% thanks to a childhood vaccine that was added to the schedule in the mid-90s. The hepatitis B, C, D, and E viruses are also well-known causes of liver inflammation, though not particularly common in children, at least not here.
Cytomegalovirus, herpes simplex virus, varicella-zoster virus (chickenpox), various enteroviruses, rubella, parvovirus, and some adenoviruses are all potential causes of hepatitis as well. As a pediatric hospitalist closing in on twenty years of practice, I’ve seen several cases of hepatitis which have almost always been mild and associated with Epstein-Barr virus, which is more infamously known for causing infectious mononucleosis or “mono”. I’ve managed one teenage patient with chronic hepatitis B infection and also diagnosed one child with an autoimmune hepatitis. And I have taken care of a handful of patients with liver damage caused by an intentional acetaminophen overdose.
Severe hepatitis in kids, especially young children, is pretty darn uncommon. A cluster of nine such cases in one hospital over just a few months stands out as quite unusual, hence the CDC alert. And this was not the only cluster.
The United States is not the only country experiencing a spike in cases of severe pediatric hepatitis. The World Health Organization released a similar alert last as the number of regions involved quickly grew. In their April 23rd Disease Outbreak News publication, the WHO revealed that at least 169 cases had been reported from 11 countries in the European Region and one the Region of the Americas (that’s us). The United Kingdom and Ireland, were the first reports originated, had by far the most cases at 114.
Of the 169 total cases at that point, all involved children under the age of 17 years. 17 of these patients ended up requiring a liver transplant and at least one had died. Adenovirus was detected in at least 74 cases, 18 of which were further specified as serotype 41. 20 were positive for SARS-CoV-2 and 19 had co-infection with SARS-CoV-2 and adenovirus. The WHO says that common viral causes of hepatitis were ruled out in each case and that no particular risk factors, such as international travel, were identified.
Since the CDC and WHO alerts were issued last week, there have been additional cases reported in other states. Although not confirmed by the CDC, it appears that the first death related to this condition in the United States has now occurred in Wisconsin. Cases have also been reported in North Carolina. From a global perspective, Canada and Japan have also joined the list of countries reporting possible cases. There is good reason to worry that this is just the beginning, but cases are still thankfully rare.
What is going on and could it be related to COVID-19?
With everything that has happened over the past two years, it is understandable to try to make a connection between the SARS-CoV-2 pandemic, which again has already been causally linked to other unusual outcomes, and a surprising cluster of severe liver disease in kids. But so far, the leading hypothesis really is adenovirus serotype 41. The United Kingdom, where the bulk of these cases have been diagnosed, has seen a significant increase in community adenovirus infections and detection in wastewater compared to 2020 and 2021. It’s unlikely that this is a coincidence.
But adenovirus serotype 41, or really any adenovirus serotype, shouldn’t be causing severe hepatitis like this in children that are healthy. So what gives? Over the past two years, with the exception of COVID-19 children have largely been spared from viral infections in many regions because of increased caution, masks, school closures, etc. Thus there is a much larger than typical number of non-immune children at risk of adenovirus infections as things relax. With larger numbers of infected kids, the possibility of seeing even very rare potential complications increases.
It is possible that there has been a genetic mutation in adenovirus serotype 41 which has increased its virulence, or that co-infection with adenovirus serotype 41 and another virus, such as SARS-CoV-2, is causing atypical disease. One thing that is clear is that this is not a side effect of any COVID-19 vaccine because most of the cases have been seen in children too young to have received one. Ultimately, we need more data from detailed investigation into these and additional cases that pop up as surveillance increases, and we need to keep an open mind to a possible cause that nobody has even thought of yet.

More Data Supports Delayed Antibiotic Prescribing for Kids with respiratory infections
Overuse of antibiotics is a big problem. New data supports delaying that prescription for kids with respiratory infections.
Clay Jones on April 2, 2021
Link

One of the hardest things to do in medicine is nothing. In pediatric medicine, where our younger patients typically come down with 6-8 viral illnesses a year on average*, this is especially true. For myriad reasons, which I’ll get into, we have a lot of trouble recommending masterful inactivity when caring for children with symptoms consistent with an upper respiratory infection. Despite the efforts of the American Academy of Pediatrics, the Choosing Wisely campaign, and my 2013 post on the subject, overuse of antibiotics is still rampant.
As I wrote in 2013, and still believe today, medicine is hard:
So what is the deal with us pediatricians? Why can’t we keep our Hannah Montana brand non-latex examination mitts off of the prescriptions pad every time little Timmy has a runny nose or a cough? Why don’t we listen to the well-meaning experts from the AAP and our own inner voices? To put it bluntly, it’s because medicine is hard. It’s messy, it’s complicated, and it is practiced by humans beleaguered by the same propensity for bias and intellectual laziness as everyone else.
Y’all don’t need me to tell you why overusing antibiotics is problematic. And every single healthcare professional who does it knows why as well. The issue isn’t that we aren’t aware of the individual and societal harm we are causing. So why do we do it? In my 2013 post on antibiotic overuse, I mention the following reasons:
     1.  Caregiver pressure – Some parents are not comfortable with seeing how things go. They may have unrealistic expectations and a poor understanding of the natural course of viral illnesses in children. They may be scared that their child is going to suffer or even die if antibiotics aren’t prescribed. This is a legitimate reason but it is a poor excuse in my opinion.
     2.  Defensive medicine – Some providers may prescribe antibiotics that they don’t believe are truly necessary out of fear of being sued for malpractice. My personal belief is that excuse tends to be more of a post-hoc rationalization than a true impetus to overprescribe.
     3.  Economic pressure – Some providers may worry that if they are seen as being unhelpful it will impact their ability to maintain a stable pool of patients and to make enough money to pay the bills and maintain the lifestyle that they desire. This is a concern that thankfully I’ve never had to face as a salaried hospitalist, but I know that this can be a real problem in some areas.
     4.  Intellectual laziness – Some providers just don’t care and do whatever moves things along the most efficiently. They may want to avoid tough conversations because they are annoying. They may have developed a number of powerful rationalizations designed to reduce cognitive dissonance and truly believe that each and every antibiotic prescription is the right thing to do.
     5.  Discomfort with uncertainty – But what if it is a bacterial infection? What if the patient doesn’t get better? What if they get worse? What if that cold turns into pneumonia? What if…..ahhhhhhhh! Some of us just don’t do well with the uncertainty of medicine. It may not be every patient, but they may have a lower than average threshold for prescribing antibiotics out of genuine concern for their patient’s well-being.
     6.  Medicine is hard – I’ve come full circle. There will always be an overuse of antibiotics unless some kind of groundbreaking diagnostic tool comes on line. It is sometimes legitimately challenging to differentiate bacterial from viral infections and, especially in certain high-risk populations, we must err on the side of caution. Ultimately, most of us just want children to get better and we try our best to practice good medicine.
In the March edition of Pediatrics, the flagship journal from the AAP, there was a randomized clinical trial out of Spain that looked at the use of delayed antibiotic prescriptions for pediatric respiratory infections. Specifically, they took a few hundred kids with likely viral respiratory infections (ear infection, sore throat, sinusitis, bronchitis) and randomized them into three groups: immediate antibiotic prescription (IAP), delayed antibiotic prescription (DAP), or no antibiotic prescription (NAP). They found that there were no differences when it came to how long it took for the illness to resolve.
I mentioned the concept of delayed, or Safety Net Antibiotic Prescribing (SNAP), in my 2013 post as well. I’ve never understood why it hasn’t become more commonplace. It involves prescribing an antibiotic in cases where it isn’t entirely clear that treatment is necessary, but parents are counseled to only fill the prescription if the child doesn’t improve or shows signs of worsening. The prescription is written such that it cannot be filled after a certain point, usually a few days after the visit. Previous studies have shown that these prescriptions are never filled in the majority of cases.
In the Spanish study, very few children in the DAP and NAP groups ended up getting an antibiotic. And again, the outcomes were similar to the group of kids who were prescribed an antibiotic with the intention to fill it immediately. In that group, 96% were at least started on the treatment. As a secondary outcome, and one that shouldn’t surprise anyone, the study found that children who were started on an antibiotic had more gastrointestinal side effects. So this large study supports an approach that involves caregiver education on symptomatic care (fluids, fever medications, TLC) and methods to delay antibiotic prescribing, which can be done using a SNAP protocol or advising that the child be brought back should they not improve or worsen.
There is an accompanying commentary co-written by Bonnie Offit, a pediatrician in Philadelphia who I believe is Paul Offit’s wife. Neat. She writes that children in the United States average more than 1 antibiotic prescription each year, the vast majority of which are written for acute respiratory tract infections that are largely viral in origin.
According to the CDC, up to a half of all antibiotic prescriptions are not necessary. It’s higher in kids. Again, this is bad. Offit points out the elephant in the room in her commentary. We already know that we should reduce antibiotic prescribing. There is already ample evidence to support watchful waiting for most pediatric respiratory infections, especially ear infections, which are by far the most common illness for which children are prescribed an antibiotic. I can’t argue with this.

*Not in 2020, however. If the reason for the shockingly low incidence of common viral respiratory illnesses in kids last year wasn’t a deadly worldwide pandemic, pediatricians would be dancing in the streets. Sure, it’s a good thing that for the first time in my nearly 20 years of pediatric medicine I did not take care of a single severely ill child with bronchiolitis, but it’s not worth the cost. Plus there is a high likelihood that these ailments will make a huge comeback once life returns to all its germ-spreading normalcy because there will not be a reservoir of older infants and toddlers with full or partial immunity from the previous Winter’s seasonal spike.

Delabeling Penicillin Allergies: A Public Service Announcement from Science-Based Medicine
Is your child allergic to penicillin? Are you sure about that? Penicillin allergy is much less common than widely believed and there is a big push to delabel pediatric and adult patients who actually can tolerate these antibiotics.
Clay Jones on July 7, 2023
Link

It’s 10PM, do you know where your children are? How about if that penicillin allergy on your child’s chart is the real deal or a hoax perpetrated by Big Pharma and the entirety of the medical-industrial complex working together across the globe in a concerted and sinister effort to make you think that sweet little Timmy will suffer a painful end if he even looks at a drop of amoxicillin? I think that maybe I’ve been on Twitter too long.
As the title suggests, today’s post is a bit of a public service announcement aimed at addressing the confusion surrounding penicillin allergies in both children and adult humans. I’ll also cover why it is important to take appropriate steps to have an unfair allergy expunged from your medical record like a presidential impeachment. Let’s get started.
Though allergy to penicillin, which implicates a number of important antibiotics used to treat a wide variety of infections, is by far the most commonly reported medication allergy, the number of patients who are truly at risk of a life-threatening reaction is small. Of the 10-15% of humanity who believes they can’t safely take a penicillin, more than 95% have been mistakenly labelled as such. These people, along with the entire human population when the risk of antibiotic resistance is taken into account, can benefit from having the scales wiped from both their eyes and medical record.
As I will repeatedly emphasize, it is important to go about the so-called delabeling of a patient’s penicillin allergy in a thoughtful manner. Though not remotely as common as it may have seemed, true hypersensitivity to this class of medications is still a leading cause of anaphylaxis, the most severe form of an acute allergic reaction that can result in obstruction of the airway and/or shock. This pathological response to penicillin kills somewhere between 500 and 1000 people each year in the United States. So please don’t rush out and start gulping down Augmentin like Diet Coke while sharing top secret military documents with friends and acquaintances at your private luxury resort.
But before we get into how to delabel a patient with a likely bogus penicillin allergy, a quick primer on the subject is in order.
Allergy to penicillin can develop at any age, though it is most commonly first reported in childhood. Children, because they are disgusting, are frequently diagnosed with all manner of upper and lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections that are appropriately treated with antibiotics in the penicillin family. Even more are inappropriately prescribed these antibiotics for viral infections and prescriber discomfort with uncertainty. So the opportunities to be labelled as allergic to these drugs, rightly or wrongly, are frequent.
There are several different types of adverse reactions to medications that can occur. In this case, we are worried about a specific kind of abnormal response to a medication by the immune system known as a type I, IgE-mediated reaction. This can result in the immediate and potentially catastrophic release of a number of different chemicals, such as histamine, that can cause dilation of blood vessels, leaking of fluid into surrounding tissues, poor perfusion of vital organs, and spasm of the airway smooth muscle.
Previously sensitized patients having such a reaction, usually within an hour of re-exposure to the offending antigen, can develop any combination of a host of potential complaints. This can range from itching, flushing, and hives, to swelling of the face, difficulty breathing, or even complete airway obstruction. Gastrointestinal distress is also common, though rarely isolated, and can involve nausea, vomiting, diarrhea, or pain. Finally, and sometimes fatally, severe reactions can cause a dangerous drop in blood pressure that compromises the body’s ability to supply oxygen to vital organs, which is known as shock.
So you can see why it is so important to recognize who is truly allergic to these medications. This is scary stuff. Patients can go from absolutely fine to unresponsive and unable to breath in an extremely short time. Mere minutes in fact. Recognition and proper management with epinephrine (EpiPen or equivalent device) can save lives. Wasting time on unproven treatments, or even on legitimate allergy remedies like Benadryl that aren’t meant to be used in anaphylaxis, can be a deadly mistake.
But why are so many kids and adults inaccurately labelled as allergic to penicillins? It’s actually pretty understandable and largely involves a combination of the known limitations in our ability to interpret sensory information and then to recall it, potentially years later. And there is also just the simple fact that even well-meaning and competent medical professionals sometimes believe things that are wrong.
The low hanging fruit here is that a penicillin allergy is often added to a patient’s medical record for clearly nonallergic indications. For example, if a parent or sibling is allergic. This is not recommended practice, however. Sometimes after a patient suffers a known side effect from an antibiotic, such as an upset stomach or diarrhea, and this is falsely labeled as an allergy.
Probably the most common reason is the development of a nonspecific bumpy red rash at some point during a treatment course. Rather than hives, which are a specific rash known to be associated with true allergic reactions, nonspecific red bumps are extremely common during viral infections and have nothing to do with the penicillin being used to treat a child’s “ear infection”. We often have to rely on a parents description, which is obviously subjective. And, sadly, medical providers also sometimes mistakenly believe that any rash means the patient is allergic.
Once a patient is labelled as penicillin allergic, that label tends to stick with them. Even if they are seen by a provider who doesn’t have access to the patient’s medical record, the patient or their caregiver will still likely mention the allergy. Historically we have assumed these labels to be accurate, or perhaps just as frequently we have been skeptical of them but not felt empowered to do anything about it at the time. And when trying to obtain a detailed description of the supposed allergy, often so much time has passed that reliable recall of the specific signs or symptoms that resulted in the allergy label are hard to come by.
So, again, an allergy label is hard to get rid of unless clear action is taken. They aren’t like classified materials that can simply be declassified with a thought by a president packing boxes on moving day. This clear action, usually consisting of skin testing or an oral challenge, has typically been performed by an allergist in a specialty clinic. And though sometimes this is indicated, particularly when there is a reliable history of a reaction that is consistent with true allergy, oral challenges are increasingly being done in a variety of inpatient and outpatient settings.
If you or your child is felt to be a low risk for true allergy, an oral challenge in their pediatrician’s office is a very safe and reliable means of removing the label and expanding treatment options to include penicillins. There are several historical findings that are consistent with low risk for true allergy:
     1.  The patient has had a penicillin again without any concerning reaction
     2.  There is no clear recollection of symptoms
     3.  A delayed onset nonspecific bumpy red rash
     4.  The reaction in question occurred greater than 10 years ago
     5.  The only reason for the label was family history
     6.  The only symptoms were isolated gastrointestinal side effects
     7.  The only reason for the label was a yeast infection
     8.  The only reason for the label is a history of reaction to other antibiotics
An oral challenge typically involves giving a patient 10% of the treatment dose followed by close observation for 30 minutes. Though an allergist does not always need to be involved, the ability to rapidly treat a potential severe reaction should always be ensured prior to the challenge. If this goes well, the rest of the full dose can then be given and the patient observed for another hour or two for good measure. If there are no signs or symptoms of an acute allergic reaction, the patient is extremely unlikely to have an allergy and the label can be removed from their chart. Patients and/or caregivers should also be counseled to avoid self-reporting an allergy in the future to avoid confusion and relabeling.
Why does this matter? Unfortunately there are significant clinical, public health, and economic costs that occur when there are limitations in what antibiotic can be prescribed to treat an infection. Very often an antibiotic in the penicillin family is the best choice in that it is more effective, more narrow, associated with fewer side effects, and much cheaper. The use of antibiotics that are overly broad, meaning that they work on a wider variety of bacterial pathogens than necessary, increases the risk of resistance and the loss of that agent as a useful treatment of other types of infections. Inappropriate treatment of ear infections in toddlers could one day result in it being much harder to treat bacterial meningitis in the future, for example.
If you believe that you or your kiddo is allergic to penicillin, maybe that’s true. But maybe it’s all a lie and you’ve been missing out on all the fun while helping to line the pockets of the people who make Zithromax. Please consider checking with your doctor about the possibility of an oral challenge and delabeling that allergy. Though it can be done in a pinch when a patient is ill and needs an antibiotic, it’s always better to do these things in a more controlled fashion.

Clinical Practice Guidelines: Cholesterol Tests for Children?
Harriet Hall on October 9, 2012
Link
The American Academy of Family Physicians journal American Family Physician (AFP) has a feature called Journal Club that I’ve mentioned before. Three physicians examine a published article, critique it, discuss whether to believe it or not, and put it into perspective. In the September 15 issue the journal club analyzed an article that critiqued the process for developing clinical practice guidelines. It discussed how two reputable organizations, the United States Preventive Services Task Force (USPSTF) and the American Academy of Pediatrics (AAP) looked at the same evidence on lipid screening in children and came to completely different conclusions and recommendations.
The AAP recommends testing children ages 2-10 for hyperlipidemia if they have risk factors for cardiovascular disease or a positive family history. The USPSTF determined that there was insufficient evidence to recommend routine screening. How can a doctor decide which recommendation to follow?
What Are Clinical Practice Guidelines?
They are “cookbooks” developed for the convenience of doctors in practice. A group of experts asks a practical question (for instance, should we screen the general population for prostate cancer with a PSA test?) and does the dirty work, plowing through mountains of evidence so when a doctor in practice asks that question, a handy science-based answer will be available to him. There is a National Guideline Clearing House that has compiled 2476 of these guidelines, with as many as 20 guidelines on a single topic. They don’t provide any oversight of quality or of how the guidelines were developed. In general, guidelines from specialty groups tend to be methodologically less sound and to recommend a more aggressive strategy than guidelines from primary care organizations. I recently wrote about prostate cancer screening, where most groups now recommend against routine PSA testing but urologists strongly disagree. Another problem is that published guidelines are not always current; they must be updated as new evidence comes in.
Comparison of the USPSTF and AAP Guideline Development Process
Why did the USPSTF and the AAP disagree? This table offers some clues:
Standard	USPSTF	AAP
Clear description of methods used to identify and analyze scientific data	Yes	No
Method of updated literature review that is referenced and outlined	Yes	No
Standard process for appraisal and grading the quality or sufficiency of the evidence	Yes	No
Conflicts of interest rigorously vetted	Yes	No
External peer and public review	Yes	No
The Journal Club participants felt the USPSTF process was “best in class,” and they chose to follow the more rigorous, more conservative, USPSTF recommendation over the AAP recommendation for childhood lipid screening.
Problems with the Process
All too often, there is no good clear-cut evidence to answer the question, so guidelines fall back on consensus recommendations from a group of experts. A review of American Heart Association/American College of Cardiology guidelines found that only 11% were based on multiple randomized trials or meta-analyses, and nearly half were based only on experts expressing their opinions. Also, 56% of guidelines had an author who disclosed a conflict of interest. Worse yet, 87% of guidelines had ties to the pharmaceutical industry.
In one documented case, a prominent nonprofit organization received $11 million dollars from a pharmaceutical company and then placed 6 members with ties to that company on a 9-person committee charged with determining the role of the company’s drug in a guideline.
Another problem is lack of transparency. Published guidelines seem to imply unanimity, but individual committee members may have disagreed. It would be helpful to know whether the vote was 9-0 or 5-4. And why.
Improving the Process
The Institute of Medicine (IOM) has proposed these 8 standards:
     1.  Complete transparency
     2.  Conflict-of-interest disclosure
     3.  Multidisciplinary member composition
     4.  Systematic literature review meeting IOM standards
     5.  Clear and consistent rating and description of evidence
     6.  Recommendations articulated in detail and in a standard form
     7.  External review by the full spectrum of stakeholders
     8.  Appropriate updating of guidelines
There is no requirement to follow these standards, and no way to enforce them. The American Cancer Society has said it will follow them. The WHO has also proposed its own rigorous 19-step process.
Conclusion
The Journal Club analysis concludes with a summary of key points, including:
    • There are no controlled trials demonstrating that lipid screening in children improves long-term health outcomes.
    • The level of evidence of clinical practice guidelines should be reviewed before widespread implementation.
I would add: Clinical practice guidelines are very useful and the USPSTF guidelines are the most trustworthy.

More Evidence Supports Infant RSV Shot Safety and Effectiveness
As RSV season rapidly approaches, some “real world” data out of France provides even more support for the RSV antibody shot for babies.
Clay Jones on September 13, 2024
Link

The beginning of respiratory virus season, a large part of which involves infections with respiratory syncitial virus (RSV), is right around the corner. The CDC is predicting that it will be about as bad for kids as it was last year, and perhaps even better. Last year wasn’t great, but it was definitely better than the train wreck that was 2022-2023. Those were rough times for pediatricians, particularly in hospitals in many regions around the country.
I wrote about my experience in the Boston area at the time here and here. Last year was still hard but much more manageable without the severe shortage of intensive care and hospital beds that had us managing critically ill babies in hallways at a community hospital with no PICU. As I discussed last summer here, pediatric healthcare providers and families with young children were excited about the prospect for better days ahead because of the roll out of a new medication that could prevent severe RSV in infants and high risk toddlers.
Nirsevimab (brand name Beyfortus) is an injection that contains antibodies against the F protein on the surface of the virus, rather than a vaccine that would encourage the body to make the antibody itself. That would work, and it does with the RSV vaccine recommended for pregnant people during RSV season and all people over 75 years, or 60 years if they have risk factors for severe disease or live in a nursing home. The F protein helps the RSV virus enter human cells, particularly in the lungs, which is why the shot was so promising as a prevention of severe disease.
Nirsevimab almost certainly reduced the severity of last year’s RSV season. Millions of doses were given out but there were huge issues with getting shots into arms. These ranged from expected logistical problems with a new drug that required staff training, space for refrigeration, and ironing out insurance coverage, but there was also the unexpected lack of supply when the manufacturers dropped the ball. Then, of course, there were difficulties with caregiver hesitancy and refusal, which varied from region to region in the usual ways. Florida, I’m talking about you.
Data from before the roll out looked really good, with an excellent safety profile and great efficacy at preventing RSV disease that required medical care. Preliminary data from after the roll out looked even better:
So what did they find? Ultimately 699 infants met criteria, 407 of which were positive for RSV and 292 of which weren’t. 1% of RSV positive patients had received Beyfortus compared to 18% of the RSV negative patients. Using multivariable logistic regression models (some kind of math, I think?), they found the shot to be 90% effective at preventing hospitalization, which is 12.5 percent better than what was seen in prelicensure data. There are some limitations/caveats, however.
These aren’t big numbers. A very small percentage of these hospitalized infants actually received Beyfortus. And most of the infants who did had risk factors for more severe disease. In fact, just under half of high risk babies in the study got the shot compared to only 6% of those at low risk. The results may not be fully generalizable to all infants. But if Beyfortus works really well in kids who are more likely to require admission to a hospital, it is going to work even better for lower risk kids, and there does not appear to be any concerning downsides. So the risk to benefit ratio is still rock solid in support of giving it to all babies.
That was back in December. Since then, there has been additional data that supports continued excitement about the prospects of dramatically improved RSV seasons, assuming of course that these babies get the shot. In July, the New England Journal of Medicine published a large post-licensure study that investigated the shots effectiveness at preventing hospitalization from RSV:
We conducted a prospective, multicenter, matched case–control study to analyze the effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis in infants younger than 12 months of age. Case patients were infants younger than 12 months of age who were hospitalized for RSV-associated bronchiolitis between October 15 and December 10, 2023. Control patients were infants with clinical visits to the same hospitals for conditions unrelated to RSV infection. Case patients were matched to control patients in a 2:1 ratio on the basis of age, date of hospital visit, and study center. We calculated the effectiveness of nirsevimab therapy against hospitalization for RSV-associated bronchiolitis (primary outcome) by means of a multivariate conditional logistic-regression model with adjustment for confounders. Several sensitivity analyses were performed.
The study found a reduction in the risk of hospitalization of 83%. There was also a 70% reduction in the risk of RSV disease severe enough to require admission to a critical care unit and 67% protection against the need for “ventilatory support”. These results, along with all the previous positive findings, strongly support recommendations for providing this medication to all infants.
Final final thoughts?
On a personal note, this will be my final regular contribution to Science-Based Medicine. I submitted my first post just under 12 years ago, after having been an avid reader since the debut in 2008, and a couple months after meeting David, Kimball, Steve, and Harriet at CSICon 2012 in Nashville. It was Kimball who invited me to send something in. We actually ended up working in the same hospital a year later after I moved from Baton Rouge to Boston.
12 years and over 250 posts later, I couldn’t be happier having been a part of this team. I got to meet and work with some amazing people. It gave me some recognition with journalists and even got me a brief and unsatisfying appearance on Inside Edition. I had the opportunity to speak at NECSS 3 times, and sit on several SBM panels. One of many memorable highlights for me was the time I led a panel discussion with David, Steve, and Paul Offit in 2019 right after having had a lovely green room chat with with Carl Zimmer and his wife about vaccine hesitancy.
I truly appreciate all of the experiences I’ve had related to SBM. I appreciate all the helpful, and sometimes not so helpful, feedback in the comment section. I definitely appreciate that David never told me enough already with the science-based satire posts. I obviously will never be able to quit my day job to work for The Onion.
I will probably contribute here from time to time in the future. Maybe this will just be a break for me to work on a book, perhaps a thorough take down of baby chiropractic or a collection of old Knudsen’s News posts. Here is the new Knudsen’s News site, by the way. Who knows what the future holds?
One last shameless plug. My wife, Emma Jones, is a hospice and palliative care doctor who recently published her first book. It’s about her experience with burnout as a healthcare professional and how she learned to manage it. Please consider sharing it with anyone who your feel might benefit.

The 2022-2023 Respiratory Virus Season Hits Early and Hard: Part 1
RSV, and a few of it’s buddies, are back with a vengeance this year and hitting young children earlier and harder than during typical respiratory virus seasons.
Clay Jones on November 11, 2022
Link

This will be the shorter of a two-part series on the 2022-2023 respiratory virus season so far, which has been brutal for the nation’s infants and toddlers. I will mostly be focusing on RSV, the infamous (at least among pediatricians and family docs) initialism for respiratory syncitial virus, because it has been causing most of the problems. In this post, I’ll discuss the current situation in hospitals around the country and give some personal perspective. Next time, I’ll go into more detail on RSV and the potential for a new vaccine that is showing promise in reducing the risk of severe disease in the most vulnerable population.
The 2022-2023 season got off to an unusually early start for pediatric providers in the United States, with reports in July of unusual RSV activity serving as an omen of a particularly bad Fall and Winter ahead. I saw this in my patient population as well, and our Summer in the Boston area was definitely a bit busier on the inpatient service than expected. As Fall approached, admissions for lower respiratory infections continued to increase, and we saw an odd, but not entirely unexpected, surge in rhinovirus and other respiratory enteroviruses causing wheezing and asthma flares that required inpatient management.
I wrote about a specific enterovirus that is linked to cases of a polio-like illness in young children in mid-September. At that point, we were very busy and had easily surpassed the total number of similar admissions in all of 2020 and 2021 combined. Still, it was manageable. But in the month leading up to the midterm elections, which understandably have now taken center stage, news of hospitals being overrun with pediatric patients infected with viral lower respiratory infections, particularly RSV, began making the media rounds.
In early October, NBC reported on five states (California, Illinois, Massachusetts, North Carolina, Rhode Island) having significant capacity problems. On October 21st, Axios reported that the surge had blown past the peak of 2021 and featured the situation in Connecticut and Colorado. An October 24th article from NPR focused on Texas, Washington, D.C., Maryland, and Washington, all of which were dealing with having more children that required inpatient or ICU care than available pediatric beds. It was clear, and remains so, that this is not an isolated problem.
I have been a pediatrician since 2003, and generally aware of medical stuff since starting medical school in 1999, and I have never personally experienced a month like the one we are having. Prior to the pandemic-related lull over the past two seasons, RSV had always kept us busy. It is the most common reason for infants to be admitted to a hospital every year, after all. But I have never seen admissions come in at this pace, which has far surpassed any previous busy Winter.
So what happens when a child is in the emergency department and needs to be admitted to an inpatient unit, but there aren’t any beds available in that facility? Well, they can be transported from the ED to a pediatric inpatient bed at a different facility. Easy, right? Not so fast.
What if there aren’t any pediatric inpatient beds available at any nearby facility? No big deal, you can just transport them to a facility that is not so nearby, and in some cases these children are being moved hundreds of miles away from where they entered the system. And if there are no beds to be found, the child has to board in the emergency department, sometimes for days, waiting for a bed to open up. None of this is ideal. It increases expense and, much more importantly, the chance that a mistake is going to be made somewhere along the line.
It gets worse. Not only are the numbers of children requiring admission historically high, these patients are trending sicker than usual. Traditionally, most children with RSV infections have a mild and self-limited illness that is essentially a case of the common cold. Children under the age of 2 years are more likely to develop lower respiratory involvement, but most don’t. And when they do, most don’t end up needing to be in the hospital. When they are admitted because of RSV, they usually just need supportive care for 2-3 days with IV fluids, oxygen, and perhaps a brief period of feeds through a nasogastric tube.
Some kids, particularly young or premature infants and children with underlying heart or lung disease, need help with high-flow nasal cannula or even CPAP, and some will even require mechanical ventilation. The vast majority of admitted patients, however, can be cared for in an inpatient unit. This year has been very different. Kids are coming in sicker. And in addition to the babies we are used to managing, older toddlers are requiring admission in unusually high numbers as well.
When a child needs a higher level of care than can be provided on an inpatient unit, they are transferred to a pediatric intensive care unit. I have never seen so many need to be sent out before. So what happens when there are no PICU beds available…anywhere? We do our best. For the first time in my career, I have seen children sitting on an inpatient unit receiving critical level care because there is literally nowhere else for them to go. Not only is this less than ideal for the patient, it causes extreme physical, emotional, cognitive, and moral fatigue for the people providing the care.
I practice in the Boston area, a region that boasts Boston Children’s Hospital, Massachusetts General for Children, University of Massachusetts Children’s Medical Center, and a handful of community hospitals with inpatient pediatric capacity to varying degrees. So, while we aren’t Houston, there are a lot of inpatient and PICU beds around here. But for the past several weeks, and particularly in the past month, we start most days with none available for new admissions or transfers anywhere.
I work at a decently sized community hospital with a 12-bed pediatric unit. We have been at 100% capacity for weeks and managing 20+ patients some days, about 75-80% having RSV. Our ED is struggling to keep up. Myself and my partners have been working numerous extra hours, even staying overnight, to help each other out. We will make it, but it has been rough. In the Boston area today (11/10/22), there were 7 of 142 staffed PICU beds available to start the day. That’s better than some days, but still not great because they can fill up fast.
Next time, I’ll go into a bit more detail on RSV. I will also discuss the potential reasons for why this season is as bad as it is, and it has nothing at all to do with “immune debt”. Finally, there is hope around the corner (in a year or two) as a promising vaccine is close to being ready for prime time.

The 2022-2023 Respiratory Virus Season Hits Early and Hard: Part 2
What is RSV and why is it so bad this season? I discuss this and a promising new vaccine candidate.
Clay Jones on November 25, 2022
Tweet

Two weeks ago, I wrote about how children’s hospitals were being overwhelmed by an early and severe onset of the winter respiratory virus season, with respiratory syncytial virus (RSV) infections being particularly problematic. Since then, the problem has continued with many regions of the country still seeing record numbers of hospitalizations and extreme difficulty finding inpatient and intensive care beds for children in need of them. States are declaring emergencies and the AAP has asked the Biden administration to do so federally, though in keeping with the historical response to pediatric healthcare issues they have declined to do so.
On a personal note, the Boston area has seen some improvement over the past week or so and we all are very hopeful that this is not a fluke. We are still busy, but there is breathing room in regards to getting kids from the ED to the inpatient unit, and we have put on a hold on our surge staffing plan…for now. PICU beds are holding at around 90% full in the region as well. Unfortunately, cases of influenza are now rapidly on the rise so it’s unclear how long this much-needed breather will last.
You may be wondering why RSV is so bad this season. You may have even heard the phrase “immunity debt” tossed around. Many people are blaming our response to the SARS-CoV-2 pandemic, claiming that preventing children from getting the usual viral infections for a couple years has resulted in a lazy and less effective immune system. While there is some truth to the association between pandemic control measures and a worse than typical RSV season, the kids’ immune systems are alright and so-called “immunity debt” is nonsense.
But before I explain why this RSV season is hitting children so hard, a brief primer on the disease that practically defines pediatric inpatient medical training and practice.
What is RSV?
RSV is a single-stranded, negative-sense RNA virus that targets the respiratory tract in humans and causes seasonal outbreaks all over the world. In the United States, RSV season typically runs from October to May with a peak around January or February. Clearly, as the past three years have shown us, this seasonal pattern can be impacted by behavioral factors such as school closures, masks, and distancing. We saw spring and summer spikes of RSV in 2021, for example, when people cut back on these measures.
Virtually every child catches RSV by the age of 2 years. This age group, particularly the very young infants, tends to have the most severe disease because it is usually a child’s first RSV infection and they have smaller airways. Long-lasting protection from additional infection doesn’t occur after these initial cases, and we are potentially reinfected year after year. RSV is a common cause of colds in older children and adults, and again becomes a serious health concern in the elderly, or never stops being one in people of any age with certain immune deficiencies or underlying respiratory, cardiac, or neurologic disease.
In these younger children, RSV is the most common cause of lower respiratory tract infections and the most likely reason for them to be hospitalized. Hospitalization with RSV has been much more common than I bet most people realize, even before this season’s historic rates. Globally, roughly 4 out of every 1,000 children under 5 years become ill enough to need a hospital bed. If you focus on the highest risk groups, it gets much worse with 20 per 1,000 children less than 6 months and 60 per 1,000 premature infants being hospitalized every year.
Hospitalization is less likely in the United States, where the general nutritional status of children is more stable than in developing regions of Africa and Asia, for example, but it is still common. Here roughly 3 per 1,000 kids under 5 years are hospitalized. In our highest risk populations of infants less than 6 months, roughly 15 per 1,000 need an inpatient or PICU bed.
Death from RSV is uncommon in the United States, but this isn’t the case everywhere. RSV is to blame for about 2% of deaths in the first month of life worldwide, and 7% from months 2 through 12, making it second only to malaria in that age range. Most of these deaths occur in term infants, largely because premature infants tend to die from prematurity-related complications in resource-limited regions.
In the United States, deaths from RSV still occur, typically in premature infants or young children with immune deficiencies or underlying heart disease. As I mentioned earlier, RSV also causes problems across the lifespan in certain high-risk groups, but I’m a pediatrician and am keeping this focused on kids. Sorry.
What do RSV infections do?
Before RSV starts wreaking havoc in the upper and lower airways of babies and grandparents all over the world, it has to gain access to them first. Usually the virus is spread by secretions or surfaces full of or covered in the virus, meaning direct contact is the most likely way someone catches RSV. The virus can remain viable for several hours on surfaces, including our unwashed hands. Large droplets of nasty RSV-containing mucous likely also help spread RSV, which is why in the hospital I wear a gown, gloves, and a mask in patient rooms.
Infants who become ill with RSV usually acquire it from an older sibling, who may or may not even be symptomatic. The virus can be shed in mucous secretions for days to weeks, though it tends to peak in the first week of illness, which is why measures such as hand washing and distancing during RSV season play such an important role in reducing spread. Add in masks and you can see how we had a season like 2020-2021 with virtually no RSV activity in the United States.
So before making these little ones sick, RSV has to gain access to their ocular or nasopharyngeal mucous membranes. Once there, it has to get past the immune system. Sadly, it is very good at doing just that.
I mentioned above that essentially every child catches RSV in the first couple years of existence, and also that we continue to catch it over and over again throughout our lives. This means that infection doesn’t result in protection against reinfection. But previous infection, and the subsequent development of antibodies against RSV, does reduce the severity of future infections even years later. Infants born to mothers with high levels of RSV antibodies are also less likely to have a severe infection. Keep that nugget handy for later on in the post because it’s important.
Once RSV gains access to our bodies, evades the immune system, and begins replicating in the nasal passages and throat, it can begin moving towards the lungs. And again, this is much more likely to happen in young and small children with their first RSV infection. The virus, having infected the lining of the airway, moves from cell to cell or is carried by the movement of secretions from the upper to the lower tract. Within 1 to 3 days of symptom onset, the smallest airways deep in the lungs, known as bronchioles, are involved. These bronchioles end in the tiny air sacs, the alveoli, where oxygen and carbon dioxide are exchanged.
RSV causes necrosis of the cells lining the respiratory tract as well as an inflammatory response that results in airways full of nasty, thick gunk (non-medical term). These airways, from the nose down to the bronchioles, can become obstructed and this can make it very difficult for children to breath. It can also make it difficult for the lungs to perform gas exchange, which is kind of their point.
The name for the clinical presentation of RSV infections in these young children is bronchiolitis, meaning inflammation of the bronchioles, and there is really nothing else like it in pediatric medicine. It is such a classic pattern, in fact, that it can be diagnosed without any blood tests or imaging, just an old fashioned history and exam. RSV happens to be the most common cause of bronchiolitis by far, though several other viruses can do it as well. There is no way to clinically differentiate bronchiolitis caused by RSV from bronchiolitis caused by one of these other viruses, however, which is why testing can sometimes be helpful.
Children with bronchiolitis have copious amounts of nasal secretions that alone would make it hard for a small and potentially obligate nasal breathing infant to breathe and feed. They also tend to have significant cough that can be quite uncomfortable, and in general these kids are pretty miserable even when their work of breathing isn’t too bad. Children who require hospitalization sometimes just need help with maintaining hydration because of poor feeding, and/or supplemental oxygen to make up for impaired gas exchange in the alveoli. Many have true difficulty breathing though.
In order to move air in and out with thick secretions plugging their airways, young children with bronchiolitis breathe harder and faster. This often involves the use of accessory respiratory muscles of the chest and the development of retractions, where the skin can be seen sucking in above the collar bones, between the ribs, or under the sternum and ribs. In severe cases, children will have nasal flaring or even grunting at the end of expiration.
Grunting is an attempt by the child to provide a bit of positive end expiratory pressure for themselves at the end of each breath, which is known as PEEP when dialing it into the settings of a ventilator. In babies with bronchiolitis, however, it is an automatic process that helps to keep the alveoli at the end of the bronchioles from completely collapsing and is a last ditch effort to make the next inhalation a bit easier. Grunting in an infant is an ominous sign of impending respiratory failure.
If you lay a stethoscope on the chest of one of these babies, you might hear a range of abnormal sounds such as coarse breathing, crackles, or wheezing. Regardless of what you hear, you will almost certainly see a child who is breathing hard, fast, and uncomfortably. Some babies, mostly when premature and still only a few weeks old or less, may even have significant periods of time where they just stop breathing altogether without stimulation.
How do we treat RSV infections?
Unfortunately, there is no specific therapy that improves the outcomes of RSV. There is no antiviral, steroid, or breathing treatment that has ever been proven to make these kids get better faster. What we do in the hospital for the most part is provide supportive care, with fluids, tube feeds, oxygen, and nasal suctioning. A lot of these babies require higher levels of respiratory support that provides positive pressure into the airway via the use of a high-flow nasal cannula, CPAP, or even mechanical ventilation through an endotracheal tube. Thankfully, in the vast majority of cases RSV infections are self-limited and there is a full recovery.
Can we prevent RSV infections?
At this time, there aren’t any great options for preventing RSV infections. Infection control measures like handwashing, distancing, and masks are clearly helpful. There is also a monoclonal antibody (palivizumab) that is given to certain very high-risk populations of premature infants that is extremely expensive and must be dosed every month during RSV seasons. It lowers the risk of hospitalizations but has not been shown to reduce mortality.
Several RSV vaccine candidates are in the works, but one that was reported on just this month looks particularly promising. Pfizer has completed a phase 3 study involving more than 7,000 subjects that studied the effectiveness of a vaccine given to pregnant women at reducing the risk of severe RSV in infants. The results are impressive:
In a phase 3 study, the Pfizer vaccine was about 82% effective against severe illness from respiratory syncytial virus, or RSV, in the first 90 days of life in babies born to vaccinated women, according to the company. The vaccine was also about 70% effective against severe infections through the first six months of life.
The vaccine appears to be less effective at preventing any infection, however. Still, a reduction of any case of RSV in this high-risk population by 57% in the first 90 days and 51% in the first 6 months would be of huge benefit. The FDA will get a chance to review the data this year, and there is a good chance this vaccine will be available in time to make a difference during the 2023-2024 RSV season.
Why is this RSV season so awful?
Why is this season so awful? As I mentioned earlier, it isn’t because of lazy immune systems caused by overzealous COVID precautions. That’s just nonsense. But it is because of appropriate COVID precautions that saved thousands of lives during the pandemic so far.
When it comes to RSV, the first infection is usually the most severe and more likely to shed virus for a longer period of time. In a typical year prior to the pandemic, lots of babies got RSV for the first time and a certain percentage of them required hospitalization. But many babies who might have gotten infected by an older sibling didn’t because that big brother or sister had their first round of RSV during the previous season and either didn’t catch it again or had less severe disease.
Because of COVID precautions, many infants who would have gotten RSV in 2020 and 2021 did not. So the pool of children with no immunity whatsoever against the virus in late 2022 was dramatically larger than any previous year because it included young infants and those now 2-3 year old toddlers. Now that most people and schools have relaxed those COVID precautions, record numbers of children have become infected with RSV for the first time, and that certain percentage requiring hospitalization, though it hasn’t changed, is now out of a much larger number and has overwhelmed the system.
If I’m correct, this means that the next RSV season should be considerably milder than the current one. I wouldn’t be surprised if it is milder than the pre-pandemic average in severity. In fact, and I’m just spitballing here, it might take a few seasons to re-equilibrate, assuming that there isn’t a return to widespread masking and distancing.
Perhaps I’m being naïve, but it seems like a reasonable thing to do would be for schools and the general public to maybe consider the health of children and perhaps put some precautions in place during peak respiratory virus season that mitigates the severity to a meaningful degree. Does it have to be all or nothing when it comes to masks, for example? I still wear a mask when I’m in stores or on the subway because I don’t want to potentially catch and spread RSV to a high-risk child.
Conclusion: Wash those hands, keep some distance when possible, and mask up
That’s it really. RSV is bad. It’s a lot worse than usual this year because more kids are susceptible to catching it for the first time. It might be better next year but we should do things that help make it better now. You can catch and spread RSV, so wash your hands after potential exposures, be careful about getting close to young children (or the elderly or immune compromised) when you have any viral symptoms, and consider wearing a mask in high risk situations until things settle down.

RSV Season is Here, So Where is Our Beyfortus?
RSV season is here. So far it’s better than last year, which was the absolute worst, but it should have been much better. The roll out of a safe and effective drug that dramatically reduces risk of severe disease was botched, and we still don’t know why it happened.
Clay Jones on December 8, 2023
Link

The winter respiratory season is in full swing, which means that homes, offices, and hospitals are full of children sick with respiratory syncitial virus, or RSV as it is commonly known. So far, this season is nowhere near as busy as it was a year ago, an ordeal I discussed in detail last November. I followed up that post with a primer on RSV, so please check it out if you want to catch up with the rest of the class.
In a nutshell, RSV is a respiratory virus that causes a yearly cold in most people but has the ability to invade the lungs and wreck havoc in infants, the elderly, and anyone between those extremes of age with a compromised immune system or risk factors for more severe disease. Last year, a record breaking wave of children requiring hospitalization crashed down upon us in the fall and lasted into the new year. Thankfully, at least so far, it isn’t as bad right now but it’s still bad. There is the definite possibility that a similarly severe peak is just around the corner, though that is unlikely even with recent CDC data showing a big spike in cases. My fingers are crossed…hard.
Just how bad an RSV season can be tends to vary from region to region. Though last year was pretty rough in most areas, there were some hospitals that didn’t have an atypically severe season, or whose peak numbers didn’t plateau for quite so long. Then there were places like Boston, where we spent several weeks far above capacity with kids lining the ER halls waiting on hospital beds and limited available space in pediatric intensive care units throughout New England. This forced small to medium sized community hospitals like mine to push past typical limits and to manage patients that would have been better off in a tertiary care center.
There were many days last season where my colleagues and I didn’t feel like we were able to provide safe and appropriate care for all of our patients, and we haven’t fully put it behind us. As this season approached, there was a sense of dread, as if we all shared one collective raw nerve. Thankfully the season so far has been manageable, for the most part. We didn’t see huge numbers of children in respiratory distress in October or November and instead there has been a more typical steady increase over the past few weeks.
It could have been much better, however. It could reasonably be argued that many children hospitalized right now, or who will require inpatient or PICU admission over the next few months, missed out on a safe and highly effective means of preventing significant RSV disease because of what increasingly appears to be incompetence. In fact, a lot of pediatricians, family doctors, and parents are not very happy right now.
In August, I wrote about nirsevimab (brand name Beyfortus), which had just been approved for use in children at risk for severe RSV disease:
On August 3rd, the Advisory Committee on Immunization Practices and the CDC voted unanimously in favor of recommending the use of a recently approved injection proven to reduce the risk of severe RSV disease in young children. And just this week, the American Academy of Pediatrics has come out with their recommendations for which young children should be the focus of the drug’s roll out.
The injection contains a monoclonal antibody and works through passive immunity. These are protective antibodies usually only produced by the immune system when a child is infected with RSV, and one dose safely reduces the risk of medically attended (urgent care, clinic, physician office, ER visit, hospitalization) RSV by 75%. The plan was to get every child under 8 months and higher risk kids through 19 months immunized before the virus made its way up to the United States. We were hopeful that it would make a significant difference this season, but some roadblocks were expected:
There are several issues that will impede the roll out for this season:
     1.  Pediatric practices will be busy dealing with the transition to a commercialized COVID-19 vaccine. Adding a new recommended medication that still lacks billing codes for its administration will result in these practices taking an intolerable financial hit, so they might wait until 2024-2025.
     2.  Nirsevimab administration will likely require many pediatric practices to train staff or hire new staff in order to follow state guidelines. They might have to pay for and make room for additional storage capacity. They will have to pay, up front, for the doses. And all of this has to be done knowing that there might be significant hesitancy from caregivers and that it may take up to a year for insurance payments to reach their bank accounts. Many practices could opt out.
     3.  Many children rely on the Vaccines for Children program to receive recommended immunizations. Nirsevimab, though not a vaccine, will be included in the program. This is a really good thing but VFC-funded products take longer to reach children than those that are payed for privately. RSV will get to many of these kids before they have access to the shot.
So here we are, nearly 4 months after that August post on nirsevimab. How is it going so far? Thanks for asking, but unfortunately not great. There were, not unexpectedly, significant problems with the roll out of the medication. Just not the problems that anyone predicted.
Things got off to a rocky start when, in early October and after significant strides had been made in reducing the risk of the potential financial concerns mentioned in the above quote, Sanofi announced that the demand for the drug was significantly higher than they expected. We were told to have very low expectations of receiving anywhere close to the number of doses being ordered. This didn’t sit well with the thousands of pediatricians and family doctors who knew that families would be clamoring for the chance to protect their little ones.
A supply problem wasn’t one of the potential issues predicted to possibly keep qualifying patients from getting their shot. There were supposed to be plenty of doses available for whoever needed one, so this October surprise from Sanofi was disheartening to say the least. Some shipments have gone out, however, and Massachusetts did better than many states, though we are talking about doses numbered in the thousands at best. We have only given somewhere between 100 and 150 doses at my hospital, which delivers around 300 babies every month.
Premature and very high risk infants have been prioritized, of course, but this still leaves the vast majority of qualifying children unprotected. That’s millions of infants. So many that it was almost comical, not that we would turn down even one dose, when there was an announcement in mid-November of a release of 77,000 additional doses for distribution across the country. This issue has even reached the hallowed (at some point in the past probably) halls of Congress, and a group of Senate Democrats is demanding answers.
There is a way for babies to achieve a similar degree of protection without receiving a dose of nirsevimab. An RSV vaccine, called Abrysvo, was also recently approved for use in pregnant women between the 32nd and 36th week of pregnancy as well as adults over age 60. In addition to reducing a mother’s risk of severe disease, protective antibodies have time to cross the placenta to the baby.
Adding insult to injury, however, many expectant mothers have been unable to get the vaccine. I have had many over the past month ask about nirsevimab availability as soon as I walk in the room. Demand is high, and pediatricians knew it would be. So why didn’t Sanofi? My assumption is incompetence. Somebody dropped the ball.
As of right now, it looks like there will be no additional shipments of nirsevimab going out until next RSV season. Available doses are understandably going to premature infants and older infants at very high risk of severe disease. And I’m am left forced to disappoint a lot of worried families. Nirsevimab has to potential to completely change the game when it comes to RSV in young pediatric patients. Next year really could be unlike any I’ve ever experienced. Again, my fingers are crossed.

A Common Virus Wreaks Uncommon Havoc in a New Jersey Nursing Home for Medically Fragile Children
Ten children have died in the past few weeks as a result of a common viral infection that typically causes mild symptoms. But there is much more to the many adenoviruses than meets the eye.
Clay Jones on November 2, 2018
Link

On October 23rd, the New Jersey Department of Health confirmed an outbreak of adenovirus at the Wanaque Center for Nursing and Rehabilitation. At that time, 18 children had become ill and 6 had died. Since that report and the resulting media coverage, an additional 9 children have been diagnosed with the infection, and there have been 4 more fatalities.
Adenovirus, or more accurately the family of adenoviruses, isn’t one of those sexy infectious agents that gets a lot of press, like that flesh-eating bacteria or those brain-eating amoebas. But it’s a very safe bet that anyone reading this post, unless they are an extremely precocious toddler, has fought off more than one adenovirus serotype during their lifetime. In fact, adenovirus infections, which are common in every country and in every season, are the culprit in up to 10% of all febrile illnesses in young children and virtually 100% of adults have antibodies in their blood signaling a prior infection.
But adenovirus infections aren’t commonly fatal. They aren’t even commonly severe. They typically just cause what would be described as the common cold, though perhaps are more likely to be accompanied by a sore throat and a pink eye. That being said, they certainly have the potential to cause severe and fatal disease, particularly in children with compromised immune systems. And they are also associated with a number of less common, and much more interesting, presentations.
A brief, yet satisfying primer on human adenovirus infections!
As previously mentioned, there isn’t just one adenovirus out there ruining people’s week with a bad cold and, or ending the lives of an unlucky few. There are actually 7 species of adenovirus that infect humans, designated as A through G, which consist of more than 60 serotypes between them. A few of these, which I’ll discuss shortly, are more likely to cause problems than others.
Adenoviruses are very immunogenic. When we are infected by a particular serotype, there is typically a vigorous response from both the innate and adaptive immune system. At the same time, these viruses are known to make use of a number of immune-modulating mechanisms to evade recognition and survive long enough to replicate. These mechanisms, which are way beyond the scope of this post, may also play a role in the persistent shedding of adenoviruses for weeks after a patient has recovered from the acute illness.
Persistence of virus in the body can last much longer in those with compromised immune systems. There are also reports of acute adenovirus illness occurring in the recipients of an infected solid organ transplant. And there are concerns, thus far unproven, of the possibility of herpes-like reactivation of prior adenovirus infection as a result of the extreme immune suppression required for bone marrow transplantation. The hypothesis is that there may be latent virus hanging out in tonsillar tissue or intestinal lymphocytes potentially for years.
After most adenovirus infections, antibodies are produced which are specific to, and reduce the likelihood of future infection with, that serotype. Cell-mediated immunity, particularly involving the production of memory CD+ T cells, plays the most important role, however, in acquiring protection against multiple serotypes. This is why immune deficiencies, especially those involving cell-mediated immunity, are present in the majority of fatal cases.
As in the outbreak making the rounds over the past couple of weeks, adenovirus infections frequently pop up when people, usually young children, are clustered closely together. Daycare centers, summer camps, army barracks, and even hospitals have been associated with large numbers of cases and difficulty containing spread from person to person, which can occur via multiple routes. Breathing in floating particles, eating contaminated foods, and touching contaminated surfaces are all possible routes of transmission. It’s a hardy virus that requires bleach, formaldehyde, or killing it with fire to remove it from hard surfaces.
Serotypes 3, 2, 1, 4, 7, and 14 have been the most commonly reported over the past 15 years or so, but you have to take this information with a large grain of salt. We really don’t have a good grasp of which serotypes cause the most illness because the overwhelming majority of patients aren’t tested since they have mild disease. And specific typing isn’t always performed in patients with severe, or even fatal infections. And while testing has improved over recent years with more widespread availability of PCR technology, it is far from perfect.
The variety of clinical presentations associated with adenovirus infections is astounding, and depends on the specific serotype as well as the age and immune function of the patient. Though the most common picture is that of a typical viral upper respiratory infection, it is more likely to also involve sore throat that mimics infection with group A streptococcus (“strep throat”) and conjunctivitis (“pink eye”). Lower respiratory involvement, particularly in young children, is also common in infection with several serotypes, but serotype 7 is the most significant.
Another presentations of infection with various adenoviruses is pharyngoconjunctival fever, which is a known mimic of a dangerous childhood vasculitis called Kawasaki Disease. In fact, this condition is so worrisome and notoriously squirrelly in its early course, that our gain is turned up so high (11?) we know that we are mixing it up with an adenovirus infection sometimes. But a missed diagnosis of Kawasaki is just too dangerous to risk.
Adenovirus is also associated with diarrhea. In fact, it’s to blame in up to 10% of acute diarrhea episodes in young children. The liver, heart, skeletal muscle, urinary tract, and brain are also known targets of this group of viruses. But the most dangerous presentation is disseminated infection. It’s rare, and it is seen even in patients with normal immune systems, but 60-80% of patients die when the virus spreads throughout the body.
With some specific clinical presentations, we have a decent idea which serotypes are going to be involved. For example, serotypes 3 and 7 cause most of the pharyngoconjunctival fevers and 11 and 21 cause most cases of hemorrhagic cystitis (essentially an inflamed and bleeding bladder). Got diarrhea? That’s 40 and 41 for the most part. But the more common respiratory infections can be caused by many different serotypes, though severe respiratory disease is often associated with serotypes 3, 4, 7, 14, and 21. Of course, any serotype can kill someone who can’t mount an immune response.
Clear as mud, right?
The New Jersey pediatric nursing home outbreak
Outbreaks of adenovirus are common. As I mentioned above, these can happen in daycare centers, summer camps, and even neonatal intensive care units. It’s easy to spread and difficult to disinfect surfaces where it can live for weeks. Outbreaks of eye infections have been associated with insufficient chlorine levels in public swimming pools as well. So news of several cases at a childcare setting wasn’t a surprise because this sort of thing happens hundreds of time each year.
What is different about this outbreak is the number of deaths. Ten dead children in a matter of a few weeks is horrific. It should come as no surprise though that this facility cares for children who are medically fragile. I could not find information on any specific diagnoses, but several outlets have described the children involved as having compromised immune systems. The specific serotype involved in this outbreak is 7, which is known to cause more severe respiratory symptoms.
Also not surprising are the questions being raised about the care provided at this facility. Piecing together multiple reports, it appears that this likely isn’t a case of negligence, at least not egregiously so. Like many such facilities, they have had minor deficiencies in the past that were addressed. The state inspectors showed up unannounced on October 21st, two days prior to the outbreak being announced publicly, and found that hand hygiene wasn’t ideal but that the facility was doing a decent job in response to the outbreak.
I don’t think we should rush to judgement here. Preventing spread of adenovirus is very difficult. In addition to the challenges in disinfecting hard surfaces, patients can shed the virus for weeks. And patients with poor immune function can shed it for months. But handwashing, though an incredibly important means of reducing spread of most infections from patient to patient, isn’t particularly helpful with adenovirus because soap and water, even those alcohol scrubs, don’t reliably get rid of it. The report found that the things that matter, such as gloves and other protective barriers, were appropriately being used.
Why don’t we have an adenovirus vaccine?
We actually do have a safe an effective vaccine against adenovirus, just not every serotype and you can’t have it. At least you can’t have it unless you are in the United States military. Sorry.
Outbreaks of acute respiratory disease in military training camps were a recognized problem for many years before it was discovered that adenovirus infections were to blame. In 1971, recruits began taking an oral live vaccine against serotypes 4 and 7 and cases plummeted. In 1996, the manufacture just up and quit manufacturing the vaccine, resulting in the resurgence of respiratory infections and several fatalities.
In 2011, a new version of the oral vaccine was brought back into service, leading to a significant decrease, about 100-fold if you’re keeping score, of adenovirus infections in trainees. Go figure. The new vaccine still just covers serotypes 4 and 7, which is obviously good. Unfortunately in 2005 serotype 14 emerged as a significant threat in this population. Since the vaccine does provide some cross-protection against 14, it appears that the gap in vaccine coverage is what allowed serotype 14 to get a foothold.
Conclusion: Wait, there’s a vaccine?
Adenovirus infections are extremely common and typically benign. But sometimes they aren’t, as evidenced by the several dead children at this New Jersey nursing home. In this particular case, and in many others it would seem, a safe and effective vaccine against the very serotype that killed these kids sure would have been nice.
It certainly seems that use of the available vaccine, which costs $150 per person, would be cost effective, particularly if only high-risk populations are involved. There is of course the issue of using a live vaccine in patients with certain immune deficiencies. Well, vaccinate the workers and caregivers surrounding these children and provide a cocoon of protection. We should at least consider expanding its use in my opinion.

The Overuse of Antibiotics for Viral Infections in Children
Clay Jones on August 2, 2013
Link
“For every complex problem there is an answer that is clear, simple, and wrong.”
-H. L. Mencken

As I sit in an apartment full of unpacked boxes and grumpy children, only a few days removed from driving 1,600 miles to a 3rd floor walk-up and a better life just outside of Boston, I find the task of writing a post somewhat daunting. But I must admit that this new town is not without the potential for inspiring future musings. In fact, I find myself surrounded by irregular medicine of all shapes, sizes and dilutions.
Next door is a chiropractor who cures Tourette’s syndrome and, according to the pamphlet available outside the clinic entrance, only uses the in-house x-ray machine on select patients who truly need it. A few buildings down from me is an acupuncturist that treats athletic injuries with ear acupuncture and Kinesio-tape while liberally sprinkling references to his practice of “sports medicine” and “orthopedics” throughout the clinic’s promotional material. But at least I was reassured that acupuncture is completely harmless because it is a natural medicine. Finally, a block further down the road, completing my welcome committee of woo is a clinic that uses homeopathy to treat just about every real and fictional condition under the sun. I checked out their website and it’s a good thing that the walls are well insulated or my neighbors would have surely been forced to ignore the sound of my forehead pounding a wooden desk like a flagellant monk hoping for divine intervention.
So for the sake of time and sanity I am aiming at some pretty low-hanging fruit with this post. How low you ask? The inappropriate prescription of antibiotics for apparent viral infections is listed first on the American academy of Pediatrics contribution to the Choosing Wisely campaign. I’ve mentioned Choosing Wisely briefly in a prior post but it was explained in a little more detail in a discussion by SBM’s own science-based drugslinger Scott Gavura a little over a year ago. I of course mean that term in the cool, Roland of Gilead from The Dark Tower novels sense that I hope he appreciates.
Sadly it seems as if the campaign has been largely ignored since awareness of it appeared to peak in February when 17 groups, the AAP being one of them, contributed lists of clinical no-noes. And there has even been some backlash as well that frankly I find rather silly. Hopefully, there are plans in place to ramp up public and physician awareness in the near future.
One criticism that certainly isn’t valid is that the issues raised by the AAP aren’t pertinent to real world practice. The AAP went through lengthy process to determine their “Five Things Physicians and Patients Should Question”:
The American Academy of Pediatrics employed a three-stage process to develop its list. Using the Academy’s varied online, print and social media communication vehicles, the first stage invited leadership of the Academy’s 88 national clinical and health policy-driven committees, councils and sections to submit potential topics via an online survey. The Second stage involved expert review and evaluation of the management groups that oversee the functions of the committees, councils and sections. Based on a set of criteria (evidence to document unproven clinical benefit, potential to cause harm, over-prescribed and utilized, and within the purview of pediatrics) a list of more than 100 topics was narrowed down to five. Finally, the list was reviewed and approved by the Academy’s Board of Directors and Executive Committee.
So I am confident that they represent concerns that are important, require addressing urgently, and adequately represent the opinions of the vast majority of pediatricians. But are we just talking the talk?
Despite some decent evidence that overall prescriptions for antibiotics in pediatric populations have decreased over the past two decades, the trend appears to have plateaued and fairly widespread overuse is still occurring. This overuse primarily comes in the form of recommending antibiotics for what are in reality self-limited viral infections of the upper and lower respiratory tract and ear infections, which remain the number one diagnosis resulting in a prescription for antibiotics despite the majority of cases resolving without intervention other than TLC or chiropractic care. Misuse, if not overprescription, also comes in the form of writing for newer and broader agents when older and narrower antibiotics are equally, and often more effective, but that is a topic perhaps for another post.
Inappropriate use of antibiotics results in significant unnecessary medical costs, increasing rates of infections with resistant organisms and frequent adverse events ranging from fairly benign loose stools to life-threatening/altering skin conditions (Stevens-Johnson syndrome) and deadly allergic reactions. Antibiotics may have saved countless lives, and hopefully will continue to do so far into the future, but despite what many seem to believe they are not risk free.
So what is the deal with us pediatricians? Why can’t we keep our Hannah Montana brand non-latex examination mitts off of the prescriptions pad every time little Timmy has a runny nose or a cough? Why don’t we listen to the well-meaning experts from the AAP and our own inner voices? To put it bluntly, it’s because medicine is hard. It’s messy, it’s complicated, and it is practiced by humans beleaguered by the same propensity for bias and intellectual laziness as everyone else.
Pediatrics, in my biased opinion, is particularly difficult. Our patients can’t or won’t (teenagers) even talk to us most of the time so we must rely on second-hand accounts of symptoms. Our patients, I admit, don’t tend to get sick as seriously or as frequently as the average adult patient, but there is something fundamentally albeit subjectively different about a gravely ill or dead 9-year-old compared to a gravely ill or dead 90-year-old. Maybe that balances things out. Trust me it’s no picnic for any physician caring for the sick and/or dying, and of course it isn’t really a contest. But you never hear people say that it was just Timmy’s time and that he lived a good life, or that he did it to himself with lifestyle choices.
There is also something very different about dealing with a parent. Again, kids tend to be pretty healthy, and the most common ailments are usually self-limiting. Obviously there are many exceptions but children usually just get sick but not sick-sick, as the kids like to say. At least I think that they say that. I’m pretty sure some kids say that but I’ll need to re-watch season 3 of Good Luck Charlie to be certain. Very few of my patients watch Game of Thrones or even The Sopranos. This is the life I chose.
One of my favorite broken-record-quotes that rarely will fail to elicit groans of familiarity from the nurses during teaching rounds is that kids will usually get better despite what we do, not because of it. But parents often don’t see it that way. Many parents seem to interpret every sign or symptom as a distant but rapidly approaching death knell. Thus it can be considerably more difficult to explain why it is better to do nothing rather than something and to dispel the assumption that we are gambling with their child’s life. “Don’t just do something, stand there”, that’s another good one. “Masterly inactivity” is too. Somewhere a pediatric nurse I’ve worked with just rolled his eyes.
Then there are times when it seems as if our patients’ parents are evenly split between folks who present a list of demands and folks who refuse to end their cell phone conversations while you try to take a history or give treatment recommendations, but I admit that there is likely some selective recall bias at play here. Many parents are just scared and uncomfortable with a “wait and see” approach. But while I recognize the pressure that parents place on pediatricians and the reality that prescription writing patterns can be influenced by that pressure, I personally refuse to accept that it is a valid excuse for overprescription of antibiotics. One of many possible reasons perhaps, but not an excuse. Ultimately it is our signature on the pad, not the parent’s.
I hear a lot of talk about defensive medicine from my colleagues and the media but I don’t buy it as a major motivator either, at least not for the overprescription of antibiotics. More of a post hoc rationalization perhaps, but maybe that is a narrow perspective based on my own pediatric experience. There are far too many other more reasonable culprits in my opinion.
I doubt that any pediatricians set out to overprescribe antibiotics. Yet I personally am unaware of any pediatrician, including myself, that has never at some point in their career knowingly prescribed an antibiotic for what they were fairly confident was a viral process. I don’t believe that any of us is above reproach in this regard. I do know many pediatricians, however, that will pick their battles, recognizing when to just write for what the parent wants and when to stand their ground, with the latter being significantly more common.
As a hospitalist I tend to discontinue antibiotics as frequently as I start them and I’ve made many parents uncomfortable doing it. I’ve made my partners uncomfortable at times. But there have absolutely been occasions where, based on the specifics of the case and my interactions with the family, I have agreed to continue what I felt were unnecessary antibiotics.
Some pediatricians, unfortunately, drift towards the other end of the spectrum. There are bad pediatricians just as there are bad plumbers. The first pediatrician I shadowed during medical school had prefilled prescriptions for Augmentin (a broad spectrum antibiotic commonly prescribed for upper respiratory infections) that he gave out at almost every sick visit. I remember cringing at the intellectual contortions he worked himself into when coming up with reasons to hand that barely legible chicken scratch-covered piece of paper over to the caregiver with a smile. “Just in case” was his favorite excuse though. And in pediatrics, at least with new prescriptions, adherence appears to actually be pretty decent. Close to 90% of those antibiotics were probably taken, or at least started.
I think that extreme cases like this are an exception. We certainly don’t learn to treat viruses with intramuscular ceftriaxone in residency, often for fear of being taken to task by an attending or questioned into submission by a fellow resident or ambitious medical student. We learn good evidence-based practice and conserving antibiotics is a major part of our educations. So what goes wrong?
For some, I believe it is a path of least resistance that is taken after some time practicing in the real world. It is easier to do something rather than nothing. It is easier to write a prescription than to give reassurance and detailed instructions on expectant management. It is easier to treat than to learn how to accept, deal with and communicate uncertainty, skills which are not necessarily honed during medical training.
How long it takes an individual practitioner to fall into the unfortunate pattern of handing out antibiotic prescriptions for nasal drainage that looks “a little yellow” depends on many factors. Without more senior members in a practice that are supportive of antibiotic stewardship and science-based practice, for instance, it can be very difficult for recently graduated residents practicing without a safety net. Involvement with a local academic hospital, or with teaching students/residents, and constant effort to maintain one’s fund of knowledge and familiarity with current practice guidelines are all protective as well. But that takes a considerable amount of time and energy, things which many pediatricians have dwindling supplies of as they struggle to juggle work and family.
So while there are exceptions, I firmly believe that the most compelling and by far the most common reason why pediatricians write antibiotic prescriptions for viral infections is that they think that they are treating a bacterial infection. It is as simple as that. Naturally, the explanation for why we might think this is quite complex.
Sometimes it is impossible to tell the difference between viral and bacterial infections based on symptoms alone. Viral and bacterial pneumonia, for example, can present in a pretty similar manner in the average 15-month-old child: high fever, cough and infiltrates on a chest x-ray. Group A streptococcal infection of the throat (“strep throat”) is virtually indistinguishable from viral pharyngitis. 14 days of persistent runny nose and intermittent fever can be caused by acute bacterial sinusitis or back-to-back colds. These are just a few quick examples.
If the patient actually has strep throat or pneumococcal pneumonia rather than a viral mimic, the patient will generally get better more quickly, avoid potentially deadly complications and show up for the next well check if they are prescribed a course of an antibiotic. If it was a virus all along, the patient will also get better and no one will be the wiser for it. Either way, the parent will be happy with the care their child received.
The negative aspects of overprescription are unlikely to make a significant impact on the practice of an individual pediatrician. Parents have become conditioned over the decades to expect their child to have a little diarrhea or upset stomach while taking an antibiotic so it doesn’t really register as a reason to avoid antibiotics unless truly necessary. And despite the potential for serious complications when looking at large populations, the risks to any one child of a serious allergic reaction, an idiosyncratic process like Stevens-Johnson, or infection with Clostridium difficile remain pretty low. Resistance issues also don’t tend to affect the individual pediatrician in the office enough to serve as punishment for sloppy practice. They affect me in the hospital however.
So it is easy to see how a pediatrician can, over time, develop a nasty habit of handing out antibiotics carelessly. In order to avoid falling into the habit of prescription creep, a pediatrician can sometimes rely on the rational use of testing in certain clinical scenarios, such as the rapid detection of Group A streptococcal antigens. But more often than not determining the source of an infection comes down to historical variables and exam findings.
Pediatricians need to trust their clinical skills and be comfortable following evidence-based practice guidelines. They need high level critical thinking skills. They also need to be expert communicators and educators, with the ability to convince a distraught parent that antibiotics are not always the answer and that often watchful waiting is safe and appropriate. Not every pediatrician is capable of this but it doesn’t mean they can’t improve their skills and increase their prescriptive accuracy. There are many resources available to do just that.
There will always be some degree of overprescription of antibiotics. It isn’t realistic to expect us to get it just right, although people are working on it. There are many scenarios in pediatrics where a “shoot first, ask questions later” approach is justified. There is certainly room for much improvement and educating the public to question the use of antibiotics is probably the key to achieving this. If we can get parents to simply question why their child is being prescribed an antibiotic and if it is truly necessary it will make a big impact. Hopefully efforts like Choosing Wisely will gain more momentum.
So there you have it. A solution to a complex problem that is fuzzy, complicated, full of excuses and thus almost certainly correct…sort of.
Speaking of changing parental behavior, here is some good information from the AAP and Choosing Wisely on when kids need antibiotics for sore throat, cough, or runny nose and when they don’t.

Hospitals Slow to Adopt Pediatric Pneumonia Guidelines
Clay Jones on December 4, 2015
Link
While it is both easy and fun to point out the inadequacies of unscientific modalities such as chiropractic and homeopathy, our goal at Science-Based Medicine is the application of a single standard to all medical practice, even if it stings a bit. We are far from perfect. While I firmly believe that most conventional healthcare professionals are good people who strive to provide the best care possible for their patients, I accept that there is room for improvement and pediatric medicine is certainly no exception.
In fact, one of the characteristics that best distinguishes conventional from so-called alternative medicine is the simple fact that we systematically attempt to recognize and correct our errors on an individual and system wide level. That we evolve in the light of new and better evidence, albeit sluggishly as a rule rather than an exception, allows me to sleep at night. There is no quality control in alternative medicine. There are only shifting trends in the marketing of nonsense to the curious, desperate, and gullible.
Necessary steps: Making antibiotics harder to use
One of the most recognized areas where improvement is needed in regular medicine is in the use of antibiotics. For too long we have been cavalier when it comes to prescribing antibiotics in situations where supportive care and appropriate observation would suffice, and too liberal with our use of broad-spectrum agents. In fact, up to half of all antibiotic prescriptions are unnecessary according to the CDC. Based on my own clinical experience, admittedly anecdotal as it is, this seems about right. As a hospitalist, once a child arrives on the inpatient unit I probably discontinue more antibiotic courses than I start.
Over the past few years there has been a significant increase in the awareness of this problem, however. Many hospitals have even dedicated resources and personnel to antibiotic stewardship programs in order to study patterns of antibiotic use in their facility, design protocols to reduce antibiotic misuse, and to even enforce their implementation. It is a sad reality that inappropriate practice is sometimes best addressed by restricting a physician’s ability to order certain tests or medications, or to at least set up enough hoops to jump through to make them think twice about it.
The best way to improve care, however, is through education and guidance, often in the form of practice guidelines published by reputable organizations such as the American Academy of Pediatrics. In 2011, the Pediatric Infectious Disease Society and Infectious Disease Society of America published guidelines on the management of pneumonia in children. As with most new guidelines, pediatricians have been slow to change their practice, but new data presented at IDWeek 2015 revealed a more nuanced pattern.
A common baby killer: Pneumonia
Pneumonia, which kills more young children around the world than any other condition, is also one of the most common infections diagnosed in the pediatric population in the United States. It can be caused by a variety of viral, bacterial, and even fungal pathogens, and despite the overwhelming success of the childhood vaccination program, pneumonia remains a leading cause for admission to the hospital. Well over 100,000 children are hospitalized because of pneumonia each year, and many more cases are treated in an outpatient setting. It is also the leading indication for antibiotic use among hospitalized children.
The 2011 pediatric pneumonia guidelines, which gave evidence-based recommendations on numerous aspects of medical management of children with lower respiratory infections, put considerable emphasis on antibiotic choices. Based on the latest antibiotic resistance data, for example, the drug amoxicillin was preferred as the first line agent when treating children in the office, urgent care or emergency department, while the intravenous drug ampicillin was recommended for children requiring hospital admission. These medications are much more narrow in coverage yet as effective if not more so than other popular choices, in particular oral 3rd generation cephalosporins like cefdinir (Omnicef) and the parenteral (i.e. IV or intramusclar) antibiotic ceftriaxone (Rocephin). And when it comes to antibiotic use, the more narrow the coverage the better since this reduces the opportunity for resistance and the development of complications.
Inappropriate care: Antibiotics are overprescribed
In the study presented at IDWeek 2015, researchers compiled data from pediatric pneumonia admissions to hospitals across the United States in 2013, particularly looking at antibiotic prescribing patterns. The study consisted of a retrospective cross-sectional analysis of admissions to over 323 hospitals, 49 of which were identified as children’s hospitals, which was defined as a facility where more than 75% of the admissions, not counting newborns, were children. In this study, 15,495 cases of pediatric pneumonia requiring admission were identified, with a bit over 9,000 of the admissions being to children’s facilities.
So what did they find? In general, children’s hospitals were more likely to adhere more closely to the guidelines than community, non-children’s facilities. But the overall numbers were terrible, with not even half (46%) of the patients admitted to hospitals specializing in pediatric care receiving appropriate antibiotics for their pneumonia. Only 15% of pediatric admissions to non-children’s hospitals got guideline therapy. And this was after weeding out high risk patients and patients with a complicated pneumonia that would be more likely to justify use of a more broad-spectrum antibiotic.
Conclusion: Conventional medicine rises to the occasion…slowly
Ignoring evidence and refusing to update clinical practice is one of the hallmarks of quackery. Conventional medicine must always work to avoid sinking to such depths. Unfortunately, because the practice of medicine is ultimately a human endeavor, there will always be challenges. And although new data such as this is upsetting, I stand by my trust in the overall process.
Medicine is hard and the human mind is complicated. As I wrote over two years ago,the reasons why we are slow to adopt new guidelines in medicine, even years after their publication, or why we continue to throw antibiotics at viral infections, while somewhat understandable are still extremely frustrating; I am no more able to fully wrap my head around it today than I was back then.
Organizations like the AAP and Pediatric Infectious Disease Society will continue to do their part, as will hospitals and committed, science-based pediatricians. I will continue to do my best to practice according to the evidence and to model this approach for the medical students and resident physicians under my guidance. Parents and patients can help us do a better job by becoming better informed and taking a more active role when possible. I don’t believe that the response to this newly-presented information should be to avoid non-children’s hospitals if your child has pneumonia, however. But it should serve as a reminder that it is always okay to ask questions, and even to question the recommendations of a treating physician or other healthcare professional.

Nirsevimab is Great News for Infants, Caregivers, and Exhausted Pediatricians
RSV is a terrible infection that puts thousands of kids in the hospital every year and can be deadly. We will soon have a safe and effective way to prevent many of these severe cases, but it won’t be easy to get shots into arms this season.
Clay Jones on August 18, 2023
Link

The respiratory virus season of 2022-2023 was bad. Real bad. I discussed this last November in a bleary-eyed post:
I have been a pediatrician since 2003, and generally aware of medical stuff since starting medical school in 1999, and I have never personally experienced a month like the one we are having. Prior to the pandemic-related lull over the past two seasons, RSV had always kept us busy. It is the most common reason for infants to be admitted to a hospital every year, after all. But I have never seen admissions come in at this pace, which has far surpassed any previous busy winter.
Though it wasn’t the only virus causing problems, the main culprit behind the surge of admissions last season was respiratory syncitial virus, commonly referred to as simply RSV. It’s incredibly prevalent and pediatric hospitalists like me take care of thousands of cases over a typical career. I go into some detail on the viral pathogen in this post:
In these younger children, RSV is the most common cause of lower respiratory tract infections and the most likely reason for them to be hospitalized. Hospitalization with RSV has been much more common than I bet most people realize, even before this season’s historic rates. Globally, roughly 4 out of every 1,000 children under 5 years become ill enough to need a hospital bed. If you focus on the highest risk groups, it gets much worse with 20 per 1,000 children less than 6 months and 60 per 1,000 premature infants being hospitalized every year.
Hospitalization is less likely in the United States, where the general nutritional status of children is more stable than in developing regions of Africa and Asia, for example, but it is still common. Here roughly 3 per 1,000 kids under 5 years are hospitalized. In our highest risk populations of infants less than 6 months, roughly 15 per 1,000 need an inpatient or PICU bed.
As the end of summer looms ominously in the far too near future, we are all gearing up for another rough fall and winter surge of respiratory admissions. Pediatricians and family docs are hopeful that it won’t be quite as bad this go around, however, given that a lot of kids will have some residual immunity left over from a year ago. Immunity to RSV doesn’t last long, but reinfection within a year or so might be less severe disease. There will still be plenty of vulnerable young infants enjoying their first (insert meaningful wintertime cultural event) and, even in a good year, RSV season can be pretty awful.
Good news, everyone!
On August 3rd, the Advisory Committee on Immunization Practices and the CDC voted unanimously in favor of recommending the use of a recently approved injection proven to reduce the risk of severe RSV disease in young children. And just this week, the American Academy of Pediatrics has come out with their recommendations for which young children should be the focus of the drug’s roll out. Nirsevimab (brand name Beyfortus), like palivizumab (Synagis) before it, is a monoclonal antibody* that provides passive immunity rather than a vaccine that induces the body to produce its own antibodies. But there are some important differences, primarily that palivizumab requires monthly injections, and, even more importantly, it just doesn’t work as well as we would like:
As detailed in the accompanying technical report, the benefit resulting from this drug is limited. Palivizumab prophylaxis has limited effect on RSV hospitalizations on a population basis, no measurable effect on mortality, and a minimal effect on subsequent wheezing.
While far from useless, and extremely safe, the AAP has recommended palivizumab only for infants born significantly premature and those born a bit further along with specific risk factors for severe disease. Nirsevimab, which is also remarkably safe, has on the other hand has been found to reduce the risk of medically attended (urgent care clinic, physician office, ER visit, hospitalization) RSV by 75% in clinical trials. Thus their recommendations for its use are much more broad:
The AAP recommends a single dose of nirsevimab for:
    • All infants younger than 8 months born during or entering their first RSV season.
    • Infants and children aged 8 through 19 months who are at increased risk of severe RSV disease and entering their second RSV season.
In an ideal scenario, nirsevimab will become available for all children who qualify for it this season and completely replace palivizumab (sorry Sobi) for those infants who would have received that drug. Unfortunately, that is unlikely to be the case as the logistics of it all are going to be complicated and expensive. There are several issues that will impede the roll out for this season:
     1.  Pediatric practices will be busy dealing with the transition to a commercialized COVID-19 vaccine. Adding a new recommended medication that still lacks billing codes for its administration will result in these practices taking an intolerable financial hit, so they might wait until 2024-2025.
     2.  Nirsevimab administration will likely require many pediatric practices to train staff or hire new staff in order to follow state guidelines. They might have to pay for and make room for additional storage capacity. They will have to pay**, up front, for the doses. And all of this has to be done knowing that there might be significant hesitancy from caregivers and that it may take up to a year for insurance payments to reach their bank accounts. Many practices could opt out.
     3.  Many children rely on the Vaccines for Children program to receive recommended immunizations. Nirsevimab, though not a vaccine, will be included in the program. This is a really good thing but VFC-funded products take longer to reach children than those that are payed for privately. RSV will get to many of these kids before they have access to the shot.
There is reason for parents and pediatric healthcare providers to be excited when it comes to nirsevimab. I certainly am. I can’t imagine having another RSV season like the last one, though I fully realize that it might be just as bad in a few months. But I’m hopeful that all the bumps in the road will be smoothed out for 2024-2025. Then we will just have to focus on how to reassure caregivers, reduce the expected hesitancy to this new drug, and counteract the tidal wave of misinformation that is certainly heading our way.
*Nirsevimab specifically binds to the RSV fusion (F) protein, which is the site where the virus binds to cilliated cells that make up the bulk of our human respiratory epithelium.
**The cost of one dose for each child will likely be less than a tenth of palivizumab’s total seasonal cost, but will still likely cost a few hundred bucks. It will almost certainly be cost effective system wide but many families will not be able to afford it without assistance.

Home birth tragedies lead to changes in Oregon
Jann BellamyonDecember 10, 2015
Link

Oregon Health Plan (OHP), the state’s Medicaid insurer, will no longer cover planned home and birth center births for women whose pregnancies aren’t classified as low risk, based on newly-established criteria. The Health Evidence Review Commission (HERC), a group of experts designated by the state, came up with criteria that will exclude women with a substantial list of conditions, such as high blood pressure, diabetes, previous cesarean section, multiple gestation (more than one fetus), and various complications in previous pregnancies. Feelings ran high on both sides of the issue, which was described as the most contentious ever to come before the HERC.
The HERC’s decision was based on an exhaustive 100-page evidence review; a review, according to them, hampered by the low quality of the evidence on the safety of planned out-of-hospital births. Actually, there is a paucity of evidence altogether. Studies and statistics from other countries, like the Netherlands, were of limited utility because those countries have more stringent midwifery education and training requirements and non-hospital births are better integrated into the health care system.
Most planned out-of-hospital births in Oregon are attended by what are known as direct-entry midwives (DEM), as opposed to nurse midwives, and a few naturopathic doctors. (We’ll look at the many variations of midwifery in a minute.) Since OHP pays for 23% of Oregon births, the economic impact on direct-entry midwives could be substantial. This effect will be amplified when other insurers, who are expected to follow OHP’s new criteria, change their own coverage rules.
(In this post, we are talking about only planned out-of-hospital births at home or in birth centers. Sometimes, confusingly, the term “home birth” seems to reference both. Also confusing is the fact that some birth centers are connected to hospitals.)
Underlying all of this is an animosity between direct-entry midwives and physicians, many of whom regard them as woefully untrained for the task to the point of being dangerous. The official position of the American Congress of Obstetricians and Gynecologists is that hospitals and birthing centers are the safest place for birth, the latter only if the birth attendants are certified by the American Midwifery Certification Board. (These are overwhelmingly nurse midwives.) The ACOG says it respects the right of a woman to choose home birth, as long as she is properly informed of the risk. The American Academy of Pediatrics endorses this view, with the further admonition that newborns must receive proper pediatric care.
On the direct-entry midwifery side, there is a distinct anti-medicine, anti-vaccination, pro-CAM vibe. (See, for example, the list of recommended websites for pregnancy and parenting of the Oregon Midwifery Council, which includes Mothering Magazine and Holistic Moms Network, whose advisory board includes a rogues gallery featuring Barbara Loe Fisher, a chiropractor, Sherri Tenpenny, and Dana Ullman.) A big emphasis is put on the lack of need for medical interventions, the high rate of C-sections, and the fact that birth is a natural process and women and babies have an “inner wisdom necessary for birth.”
Oregon only recently imposed minimal training requirements for direct- entry midwives, required them to obtain a state license to practice, and permitted OHP reimbursement for their services, motivated in part by some high profile tragedies that occurred during home births. Traditional midwives may still practice without a license but are not covered by OHP. The Oregon Legislature also passed a law requiring birth certificates to record the planned place of birth and attendant type. This allowed for better collection of statistics on the risk of death by attendant type and location.
This collection of data resulted in a startling discovery, one relied upon by the HERC in making its decision to tighten coverage requirements. For 2012:
The term [ 37 weeks’ gestation] perinatal mortality rate for planned out of-hospital births (4.0/1,000 pregnancies) was nearly twice that of in-hospital births (2.1/1,000).
However, when pregnancies that did not meet low-risk criteria were excluded, the perinatal mortality rate dropped to 1.0/1,000. (And, no, that doesn’t mean that non-hospital births are safer than those in the hospital, because the hospital rate includes all births, no matter what the mother’s risk level.)
While non-hospital births accounted for only 4.8% of all births in Oregon for 2012, they included 6.5% of all term fetal deaths and 13.3% of all early neonatal deaths (during the first 6 days of life). A fatality case review discovered that planned birth attendants for these cases were 1 certified nurse midwife, 4 licensed direct-entry midwives, 1 unlicensed midwife, 1 of undetermined licensure, and 1 naturopathic doctor.
Confused about midwifery?
I was too. So, let’s take a detour here to look at the many iterations of midwife in the U.S. By my count, there are seven types: certified nurse midwife, certified midwife, direct-entry midwife, certified professional midwife (of which there are two types), traditional midwife, and naturopathic doctor. (Yes, the latter can be midwives, as you’ll see.) The requirements for obtaining various types of certification are created by the practitioners themselves and do not necessarily correspond with the licensing requirements or scopes of practice for midwives specified by state regulation, although states often defer to these certifying organizations to set the education and training requirements for midwives. (The American Midwifery Certification Board, has a nice chart explaining the differences among several types of midwives.)
To become a certified nurse midwife (CNM), one must have a nursing degree (or be an RN without a BSN who completes additional requirements) and graduate from an accredited university-affiliated nurse midwifery program. This is generally a 3 year program of clinical and classroom education and results in a master’s degree in nursing.
There is a similar program for those who have a bachelor’s degree in another field to become a Certified Midwife (CM), a fairly new type of midwife, which also results in a master’s degree. CNMs are licensed in all states but CMs in only a few. In addition to birth attendance, CNMs and CMs can provide other reproductive care, like annual exams, and have limited prescription privileges, depending on their scope of practice under state law. They practice mostly in hospitals, although some practice in birth centers and will attend home births.
One can become a direct-entry midwife through self-study, apprenticeship or a midwifery school, although one that is not affiliated with nursing education. An organization called the Midwives Alliance of North America sets professional standards for midwifery, but there doesn’t seem to be any test, peer review, or other mechanism to determine whether a midwife is practicing according to the standards. Direct-entry midwives can become licensed or registered in states that allow them to practice, usually by imposing certain educational and in-the-field experience requirements.
A direct entry-midwife can also become what is known as Certified Professional Midwife (CPM), although, in my view, the use of the term “professional” is misleading here. Their education and training can be minimal.
There are two ways to become a CPM under a process set by the North American Registry of Midwives (NARM). Of the two, most CPMs now practicing have gone through what is essentially an apprenticeship, called the “Portfolio Evaluation Process” or “PEP,” which doesn’t even require a high school education. The student works under a midwife preceptor, who must have practiced for at least three years and attended at least 50 non-hospital births. The program is largely on-the-job training, although there is a list of reading materials a candidate is supposed to complete.
The supervising midwife must verify that her student has attended:
    • 10 births as an observer;
    • 20 births, 20 prenatal exams, 20 newborn exams, 10 postpartum visits as an assistant under supervision; and
    • 20 births, 75 prenatal exams, 20 newborn exams, 40 postpartum exams as a primary midwife under supervision.
The student is then eligible to sit for the NARM exam, and, if she passes, must attend 5 more births to become a CPM. That’s it.
Or, a CPM candidate can attend a direct-entry midwife educational program at a school accredited by the Midwifery Education Accreditation Council. (Students who graduate from unaccredited schools must go through the PEP program described above.) There are 10 MEAC-accredited schools, with variations in the degree awarded. Some schools award certificates, another an associate’s degree, still others award bachelors, masters and doctoral degrees. However, like naturopathic and chiropractic schools, none of these schools are affiliated with a mainstream American university. In fact, one of the schools is part of Bastyr, the naturopathic school.
Graduation qualifies one to sit for the CPM exam. (If you are interested in seeing what the exam is like, you can find out here, starting at page 37.) The NARM dictates clinical requirements for CPM candidates who graduate from midwifery school as well, although presumably this takes place during the candidate’s schooling.
Traditional midwives have no particular education or training. According to the Midwives Alliance of North America, they:
believe that they are ultimately accountable to the communities they serve; or that midwifery is a social contract between the midwife and client/patient, and should not be legislated at all; or that women have a right to choose qualified care providers regardless of their legal status.
Finally, there are naturopathic doctor midwives. In some states where they are licensed, NDs can practice what is called natural childbirth attendance with additional education and training. Confusingly, their professional organization is called the American Association of Naturopathic Midwives, while their credentialing organization is called the American College of Naturopathic Obstetrics (ACNO). (Note that the ACNO doesn’t even have its own website; it has a page on the Naturopathic Midwives website.) So, naturopathic midwives practice naturopathic obstetrics, also known as naturopathic childbirth attendance. Go figure. It is indeed interesting that NDs claim their education and training qualifies them to practice as primary care physicians, but with additional education and training, they are qualified to practice as midwives.
The ACNO exam, which is accepted in some states as the credentialing exam for naturopathic childbirth attendance, is a 3-hour test given once a year. To sit for the exam, one needs an ND degree, 100 academic hours of midwifery education at an ND school, and to have attended 15 births. (No, that is not a typo; it’s 15.) The ACNO notes that naturopathic birth attendance certificate programs, available at ND schools, generally require more clinical education, consisting of anywhere from 40 to 100 births. (For a look at naturopathic midwifery/obstetrics/childbirth attendance practice, consult our good friend Orac.)
To be complete, let’s compare the education and training of a midwife to that of an obstetrician. To become board certified, OB/GYNs must graduate from medical school and complete a 4-year residency, plus pass their board exams. The minimum standards for residency include:
    • Spontaneous vaginal delivery: 200
    • Cesarean delivery: 145
    • Operative vaginal delivery: 15
However, according to the Review Committee for Obstetrics and Gynecology of the Accreditation Council for Graduate Medical Education:
Achievement of the minimum numbers of listed procedures does not signify achievement of an individual resident’s competence in a particular listed procedure . . . [They] represent only a fraction of the total operative experience expected of a resident within the designated program length . . . [U]pon a resident’s completion of the program, the program director must verify that he or she has demonstrated sufficient professional ability to practice competently and without direct supervision.
Oregon’s experience
Despite the wide variation in education and training (or none at all), any of these practitioners, except a CM, can supervise the conduct of labor and delivery and provide prenatal, intrapartum (during labor and delivery) and postpartum care in Oregon for any woman, no matter what her condition. OHP’s decision to tighten the restrictions on out-of-hospital births limits insurance coverage only; it has nothing to do with the legal scope of practice.
This has led to some disturbing results. In addition to the statistics I’ve already mentioned, testimony before the Oregon Legislature indicated that, for 2012, the intrapartum and neonatal mortality rate for births where the planned attendant was a direct-entry midwife was 6-8 times higher than the rate for planned in-hospital births. The combined intrapartum and neonatal death rate for home births attended by direct-entry midwives was 5.8 per 1,000. By comparison, the in-hospital rate was 0.6 per 1,000.
However, there were actually no intrapartum deaths at Oregon hospitals for 2012, while there were 4 for non-hospital births, 3 of which were attended by licensed direct-entry midwives. Intrapartum death almost never occurs in a hospital because most fetuses in prolonged distress are delivered by Caesarean section.
Parents whose babies were injured in home births attended by direct-entry midwives have lobbied for changes in the law to limit the direct-entry midwives scope of practice. One of these parents is Kristine Andrews. Direct-entry midwives at a home birth center failed to transfer her to a hospital even though her blood pressure was 140/95, among other errors. After her son, Andrew, was born with cerebral palsy due to lack of oxygen, she met with the midwives, who, in response to her inquiries about what went wrong, asked clueless questions such as whether she subconsciously didn’t want to have a baby. (This news report details another family’s terrible experience with home birth. You can find another here.)
Needless to say, Oregon direct-entry midwives are not happy with OHP’s decision. Especially controversial among midwives are exclusions based on a woman’s having had a previous cesarean section and multiple gestation. With the OHP’s (and possibly other insurers’) newly imposed coverage limits, limitations on direct-entry scope of practice will likely happen as a matter of financial consequences, as women who would otherwise choose direct-entry midwives may well elect to have hospital births so that their expenses are covered.
The new criteria are already having an economic impact. According to news reports and announcements made on birth center websites, several birth centers will close.
Yet, no one can say the HERC review wasn’t thorough. The midwives had a full and fair opportunity to present their case, but their position was rejected. According to Dr. Catherine Livingston, associate medical director for the HERC, their evidence just wasn’t persuasive. Unfortunately, midwives aren’t always up front about the evidence. Research on the safety of home births on the website of the Oregon Midwifery Council is cherry-picked.
As to the midwives’ objection that lack of coverage would take choices away from women who aren’t high risk, Dr. Livingston, acknowledging that some low-risk women would be unnecessarily excluded, replied with a comment well worth keeping in mind when the inevitable “health freedom” argument comes up:
We’re making a policy for a population level, so this needs to be the best it can for the vast majority of the population.
Indeed. We aren’t all special snowflakes whose every wish for accommodation by the health care system must be granted. Especially when costs are being shared, either through taxpayer dollars or private insurance risk sharing, which covers just about all of the health care spending in the U.S.

Vaginal Seeding. Ew. That’s nuts. Hmmm, interesting.
Mark Crislip on May 13, 2016
Link


Sometimes a headline will cause me to run through a series of reactions in rapid sequence. For example “Mothers facing C-sections look to vaginal ‘seeding’ to boost their babies’ health”:
Early studies show that swabbing a mother’s vagina and transferring it to her baby’s mouth, eyes and skin may stimulate microbiome development similarly to babies born naturally – and protect it from health issues later in life
I mean ick.
But take a step back. Not really. I tend to think of people like “Pig Pen” in Charlie Brown, shedding skin and bacteria into the environment. If we were to really think about each other’s microbiome, we might not have intimate contact with our significant other. Or any other animal. I always point out, when someone lets their dog lick them, that they (the dog) had probably just licked its rear, AKA dog-ass seeding. And no, a dog’s mouth is not cleaner than a human’s, unless your dog brushes and flosses with greater frequency than you.
Mmmm…flora
What is birth but exposing the mouth, skin, and eyes of the baby to moms vaginal flora? So the ick factor is not really reasonable upon reflection, although anything that involves the eyes still gives me the willies.
The whole question of the microbiome and its relationship to health and disease is fascinating, but its application is closer to trying to construct a mnemonic memory circuit using stone-knives and bear-skins.
For the newborn, acquiring a microbiome is a complex and dynamic process with bacteria coming from exposure at birth, then from breastfeeding, then food, and finally becoming stable at about age 3. A C-section does result in a different microbiome in the baby, and is associated (with the usual association/causation caveat) with a variety of diseases later in life. But the microbiome differences between normal and C-section birth is gone in a year.
I have to admit I have always been enamored of the hygiene hypothesis and I find such speculation interesting, but not ready for prime time. Certainly I would never write a microbiome diet book.
And that is presuming that Mom’s microbiome, with all the issues related to what constitutes a ‘correct’ microbiome, is in fact the correct one for the child.
What is a normal microbiome and on what part of the body? Does diet and hygiene lead to an altered microbiome? Interesting studies suggest that people with no contact with the modern world have more complex microbiomes:
We characterize the fecal, oral, and skin bacterial microbiome and resistome of members of an isolated Yanomami Amerindian village with no documented previous contact with Western people. These Yanomami harbor a microbiome with the highest diversity of bacteria and genetic functions ever reported in a human group.
And depressingly:
Despite their isolation, presumably for >11,000 years since their ancestors arrived in South America, and no known exposure to antibiotics, they harbor bacteria that carry functional antibiotic resistance (AR) genes.
But Yanomami evolution has been on a separate track than the West, so one would expect a different microbiome. So a different microbiome may not be a better microbiome. I wonder as we are evolving towards those massive craniums so popular in science fiction shows if we will become dependent on C-sections. We must if our children will be born with the same proportionately larger skulls. Or will there be other mutations that will make conception and birth of massive headed babies possible? Now there is a mental picture I don’t need.
In my experience, speculation is fun
It is interesting to speculate on how diet in the past and present has altered our microbiome. My favorite example is dental cavities. Cavities started showing up in humans about 15,000 years ago, although evidently Neanderthals were not good at flossing either. The theory is that a farming life lead to increase in carbohydrate intake which lead to more oral Streptococcus mutans, the leading bacteria in causing human cavities.
The issue of the microbiome and weight gain and loss is also interesting. Low levels of antibiotics in animal feed promotes growth, probably in part by altering the animal gut flora to a fat-promoting microbiome. How much the human microbiome is involved with the regulation of weight is uncertain, but most of the information suggests at least a part. I especially like the case of the patient with C. difficile who had a stool transplant from an obese donor and proceeded to gain 40 lbs. So a bit more plausible than taking on the characteristics of the person who donated your heart. But I would never get a hand transplant from a murderer. That is asking for trouble.
The data on antibiotics use and obesity in children is variable, but some antibiotic regimens are more likely to result in weight gain, probably by altering the microbiome, but then human genetics may determine the microbiome rather than the other way around. So maybe the host determines whether or not there is an obesity-promoting microbiome.
How could this go horribly, horribly wrong?
The assumption of these experiments is that altering a microbiome is only beneficial, but microbiomes do have the potential for harm.
One grumpy doc notes that the child could be at risk for acquiring sexually transmitted or other disease from vaginal transfer, but then would that not be the case for regular births as well? That is why we do prenatal screening, so I would not fret overly much about that.
There are a number of infections spread by the fecal-oral route and there are bacteria, such as B. fragilis and others, that might promote bowel and other GI cancers. People seem to assume there is a microbiome, perhaps from Eden, that has not known sin and search for it. I suspect that the idea that no good deed goes unpunished will apply here as well, that a microbiome that has benefits in one area will have downsides in another.
And some take it to extremes: DYI microbiome transplant. With an uncertain diagnosis of his GI problems (irritable bowel or inflammatory bowel disease?) one person tried, in the most half-assed way imaginable, to eradicate his own microbiome and substitute another. It is right up there with DIY surgery.
So vaginal transfer is an interesting and perhaps plausible idea, but far from being ready for prime time. But I would choose a microbiome from a thin person with no infections or family history of cancer for my transfer. And if you give your child your microbiome, you are banned for life from saying vaccines are too many too soon.
But our understanding of the complexity of the interactions of the microbiome and the human genome is in its infancy, and the wise person leaves well enough alone.

Vaginal Seeding: To Swab or Not to Swab Your Newborn Baby
More mothers are requesting vaginal seeding, but does the evidence support this potentially risky intervention?
Clay Jones on February 10, 2017
Link

Back in May of last year, Mark Crislip penned a surprisingly optimistic post which touched on the concept of vaginal seeding. This is the journey embarked upon by mothers who have delivered a newborn infant via Caesarean section and who would like to “scientifically grace the baby with their seed.” The process involves taking saline-soaked gauze that was placed in the mother’s vagina an hour prior to the surgery and rubbing it in her newborn baby’s mouth and on the skin.
This post will provide a bit more detail on vaginal seeding and the potential risks and benefits. I will also discuss how more recent data is calling the practice further into question.
Why vaginally seed your baby?
The process of vaginally seeding newborns was largely the brainchild of Dr. Maria Dominguez-Bello, an Associate Professor at the NYU School of Medicine who specializes in research on vertebrate microbiota. She has published numerous studies specifically looking at the human microbiome, including that of the newborn. The impetus for vaginal seeding was found in her 2010 paper, “Delivery Mode Shapes the Acquisition and Structure of the Initial Microbiota Across Multiple Body Habitats in Newborns.”
In this paper, the microbiota of four vaginally-delivered infants were compared to six born via C-section. They also compared the infant findings to that of their mothers. The authors concluded that “vaginally delivered infants acquired bacterial communities resembling their own mother’s vaginal microbiota, dominated by Lactobacillus, Prevotella, or Sneathia spp., and C-section infants harbored bacterial communities similar to those found on the skin surface, dominated by Staphyococcus, Cornybacterium, and Propionibacterium spp.”
This finding was quickly assimilated into our existing knowledge of long term health differences between vaginally delivered infants and those born via C-section. Research has found small but significant increases in rates of obesity, asthma, and autoimmune conditions associated with C-section birth, though there remains the issue of correlation versus causation. There is also interesting research linking alterations in the human microbiome with various pathologies, and there is legitimate plausibility to the concept of microbiome manipulation as a means of improving human health.
So it isn’t unreasonable to propose that altering the microbiome of the human newborn may have health benefits. Dr. Dominguez-Bello has even published a more recent pilot study looking at the effects of vaginal seeding on the microbiota of babies born by C-section. But in medicine there is no free lunch. All interventions to my knowledge carry some risk and vaginal seeding is not an exception to this rule.
Why you should consider putting down the swab
So what is the potential harm of vaginal seeding? Babies are born vaginally all the time, after all. Don’t we screen mothers for potential pathogens that might harm a newborn?
Well, yes we do. In the United States, we screen mothers for Group B streptococcus (GBS), hepatitis B, Chlamydia, and HIV. Some women are screened for herpes simplex virus (HSV) and gonorrhea. Not all countries follow the same screening guidelines as the United States, however. All of these organisms can be spread to a newborn infant via vaginal secretions, and all can cause significant morbidity and mortality.
GBS is the most common cause of serious bacterial infection in newborns, including pneumonia, bloodstream infections, and meningitis. Hepatitis B infection in a newborn results in liver failure in a majority of cases and frequently is fatal. Chlamydia is one of the most common causes of blindness in children around the world. HSV causes life-threatening systemic infections and meningitis. Gonorrhea isn’t a picnic either, and HIV needs no further explanation of its pathology.
So we do screen for some pathogenic organisms, but no screening process is perfect. Take GBS, for example. Mothers are typically tested at 35-37 weeks gestation and, if positive and delivering via a vaginal delivery or C-section after labor has started and her membranes have ruptured, she is given antibiotics prior to delivery in order to reduce the risk to the baby. But some mothers deliver too quickly for antibiotics to be administered. And some, labeled as GBS unknown, deliver prior to testing, don’t get full prenatal care, or even refuse GBS testing for a variety of ill-conceived reasons.
So, you might ask, why not consider vaginal seeding when the mother is known to be GBS negative but proscribe it when she is positive or unknown? It’s actually a good question and similar to one that I get from medical students frequently: “Why worry about GBS infection at all when a mother is GBS negative and a newborn is showing early signs of an infection?”
The reason that being GBS negative shouldn’t change clinical management in these situations is that many women who are negative when tested may be positive by the time that they deliver. And GBS isn’t the only bacteria in vaginal fluid that puts an infant at risk. With the decline in GBS infections related to antibiotic prophylaxis, we have seen an increase in the rates of serious neonatal infections with E. coli.
All of the potential pathogens listed above can be found in the vaginal fluid of asymptomatic women and missed because of imperfections in the screening process or a lack of screening altogether. They can all potentially be spread to a newborn via seeding maneuvers. Admittedly the risk would likely be low in most situations, but if vaginal seeding becomes more widespread, and if women are encouraged by certain providers to participate in high-risk seeding, we will see babies harmed by the practice.
Do the benefits of vaginal seeding outweigh the risks?
In medicine, there is a constant requirement to weigh both the risks and benefits of an intervention. There are many treatments, such as a bone marrow transplant, that carry extreme risk, even of death, but offer a cure in the face of a uniformly fatal condition. Some treatments fall decidedly on the opposite end of the risk-benefit spectrum, providing little or no benefit whatsoever and significant risk. Vaginal seeding must be evaluated no differently than any other intervention.
As it stands, there is currently only the speculation of benefit from vaginal seeding. First off, there is no evidence to date that possible differences in the microbiota of newborns is a causal factor in the small increased risk of some conditions seen in babies born by C-section. And the studies being used to support these microbiota differences are only a portion of what is a fairly inconclusive literature. There is recent evidence calling into question that the mode of delivery plays an important role at all, with some researchers claiming that the maternal condition leading to a C-section is more important.
The initial paper from 2010 which showed differences in microbiota between vaginally and C-section delivered newborns looked at 10 babies. A January 2017 paper in Nature Medicine looked at 81 and found that any potential differences essentially wash out within a few weeks. This doesn’t mean that the minor differences found prior to 6 weeks aren’t involved in long term health, but proof is still lacking.
Even if there were a proven difference between these populations, we don’t have good evidence that vaginal seeding is a replacement for a vaginal delivery. The pilot study mentioned earlier only looked at 18 infants. Of the 11 born via C-section, only 4 underwent seeding. They did find some overlap between these 4 babies and the 7 vaginally delivered newborns at 30 days of life, and a larger study by the same author is currently enrolling. But it all may just be noise in the background.
Conclusion: To swab or not to swab
I get it. The microbiome is a hot topic right now. As with epigenetics, people are jumping on the bandwagon left and right and enthusiasm is outpacing the evidence. It may pan out, and there is certainly a plausible connection between the microbiome and our health, but it is far too premature to be promoting novel interventions in newborns. Currently the very real possibility of harm should be a rate-limiting factor in the implementation of vaginal seeding, at least until we have more data.
Here is the ACOG comment on vaginal seeding. The AAP has yet to comment. And here is a comment from a “holistic psychiatrist’s” website discussing vaginal seeding:
Some animals purposefully bring their newborns into contact with the mother’s feces. Animals do not go to the university and do not give birth in a hospital…They simply use their innate wisdom! We all but forgot about Nature (not the magazine!).
Have a great weekend.

Cases of Newborn Syphilis are Increasing at an Alarming Rate
Cases of syphilis are being diagnosed in infants in record numbers in the United States.
Clay Jones on October 1, 2021
Link

Syphilis is a sexually transmitted infection caused by the corkscrew-shaped spirochete bacterium Treponema pallidum that you are possibly familiar with. Millions of cases occur across the globe each year, predominantly in lower resource regions, but we are far from immune here in the United States. The CDC first began collecting data on syphilis in 1941 and cases began to decline dramatically after the introduction of penicillin and dedicated public health campaigns in the late 1940s. This decline persisted until the 1980s when cases spiked, largely in heterosexual men and women, during the crack cocaine epidemic. Once again, a dedicated public health effort bolstered by the general public’s growing focus on HIV prevention was successful, and cases plummeted.
There was a steady decline in cases of primary and secondary syphilis, which is when a person can most easily spread the disease to others, starting in 1990. We experienced what would be a nadir in syphilis incidence in the United States in 2000, with just under 6,000 total cases or 2.1 for every 100,000 Americans. This was the lowest rate since tracking of cases began.
Syphilis was fairly concentrated in the South and a few urban centers at that point. In fact, half of all new cases were diagnosed in only 21 counties and the city of Baltimore, which had a bit of a problem back then. 2,520 counties, which is about 80% of the total, reported zero primary or secondary cases of syphilis in 2000. The CDC got excited, and George W. Counts, MD, director of CDC’s syphilis elimination program, released a call to action:
“We have a brief window of opportunity to eliminate syphilis,” said Counts. “We must work together to rid our communities of this scourge. We cannot let this chance slip from our grasp.”
Alas, it wasn’t meant to be.
Cases of syphilis crept up slightly in 2001 and a trend of steady yearly increases in new infections has continued ever since. In 2019, the most recent year with complete and official data, almost 39,000 cases of primary and secondary syphilis were reported to the CDC. Since case counts began to increase in 2001, the majority of cases have been diagnosed in men, in particular men who have sex with men. Over the past few years, however, cases in men who have sex with men have leveled off at around 55-60% of total male cases, and significant increases are occurring in heterosexual men and women. Rates of syphilis have also increased across the United States and are no longer relegated to the South and a few large cities in other regions.
Not surprisingly, as cases of syphilis have increased in women there has been an increase in the incidence of babies infected during pregnancy. After a few years of stability, 2013 saw an increase in congenital syphilis with 9.2 cases for every 100,000 live births. Every year since 2012 has been worse than the year before. In 2019, there were 1,870 cases reported or 48.5 per 100,000 live births, which was about 40% more than in 2018, and an increase of about 400% from 2012. Not only are cases increasing in number, but they are more distributed across the country, with 43 states and the District of Columbia reporting at least once case of congenital syphilis in 2019.
A brief primer on congenital syphilis
Congenital syphilis typically occurs when a fetus becomes infected with the T. pallidum bacteria after it is transmitted across the placenta. Though uncommon, a newborn can also become infected during delivery when exposed to bacteria shed from infectious skin lesions. Transmission can occur at any point during pregnancy, though risk is increased if the mother is infectious earlier in pregnancy. Congenital infection is most likely to happen when mom has primary or secondary syphilis, with a 60-90% overall chance. The risk to the baby is low, around 2%, if at least 4 years have passed since mother became infected.
More than a million cases of congenital syphilis are estimated to occur around the world each year. Though the number of cases diagnosed in the United States make up a small percentage, it is still a major public health concern, particularly as rates have been steadily increasing. The reason most congenital syphilis happens in the United States is ultimately the same as why it might happen anywhere else. Whenever there is system with disparity in care, with large numbers of people having poor access to appropriate prenatal care or receiving inadequate management even when syphilis is diagnosed, it’s going to be a problem.
And it is a problem.
When a fetus is infected, the bacteria that cause syphilis have access to numerous organs via the bloodstream. This can cause an intense inflammatory reaction and severe damage, most commonly involving the bones, liver, pancreas, intestines, kidneys, and spleen, but other organs are also at risk. 40% of these pregnancies will end with a spontaneous abortion if mother has primary or secondary syphilis.
Most live born babies with syphilis will not have obvious problems, particularly if the baby was infected late in pregnancy or if the mother received partial but inadequate treatment. If an asymptomatic case is missed, and therefore goes untreated (penicillin), most of these babies will develop obvious disease by a few weeks of age. This can involve liver disease, characteristic rashes, swollen glands, bone defects, and syphilitic rhinitis, more commonly referred to as “snuffles“. It’s not as cute as it sounds.
Although less common, early congenital syphilis can present with a wide array of other abnormal findings, of which I’ll just name a few. Pseudoparalysis of Parrot is the name for when a baby with syphilis is unable to move an extremity because of severe pain caused by injury to a bone. Babies can also develop pneumonia, inflammation of the heart muscle or deeps structures of the eye, or severe and diffuse swelling (hydrops fetalis). Involvement of the central nervous system is common in affected babies, though severe symptoms are rare in infants treated in a timely fashion.
As with syphilis in adults, babies born with the infection can develop long term complications that present years after the initial presentation. Late congenital syphilis is usually seen after a child is at least 2 years of age, and can occur despite appropriate early diagnosis and treatment, though that does decrease the risk and severity. Late disease can involve characteristic changes in the bones of the face, inflammation of the cornea, hearing loss, malformed teeth, scarring around the mouth, abnormal development of some bones and joints, and intellectual disability.
To summarize, congenital syphilis can present as a mild or even asymptomatic infection that is picked up by lab or imaging findings in a newborn born to an infected mother. Those children, if properly treated, usually do well. If early infection is missed, symptoms can arise later in childhood that can be debilitating. Unfortunately, some babies are born already severely ill, or quickly go that route. And many cases of congenital syphilis result in death despite modern medical care.
Of the 1,306 cases reported in 2018, for example, there were 79 stillbirths and 16 infant deaths. In 2019, the number of syphilitic stillbirths increased to 94, and the number of congenital syphilis related infant deaths jumped to 34. Hot off the presses, recently released preliminary data from 2020 reveals that there were likely around 2,100 cases. 139 of these cases resulted in stillbirth or infant death.
Conclusion: This trend needs to end
Congenital syphilis is a preventable disease. These are all completely preventable deaths. There is an inexpensive test used to screen pregnant women and the treatment is penicillin. This is one of last conditions that not only can we use the original antibiotic to treat, we should use it. It is the standard of care to screen pregnant women, but the reality is that many pregnant women are not screened. And even when syphilis is diagnosed during pregnancy, appropriate treatment is not always administered.
Why would this be? As is often the case, it comes down to disparities in healthcare availability and quality. Black, Hispanic, and Native American women are significantly more likely to have late or absent prenatal care, and their babies are 5 times more likely to be diagnosed with congenital syphilis compared to white infants. Part of the problem is the fact that very little money goes towards this problem.
To put things in perspective, HIV in newborns is diagnosed less than 50 times a year compared to the roughly 2,000 cases of baby syphilis. But CDC funding for HIV has steadily increased to almost a billion dollars this year while funding for the prevention of other sexually transmitted infections has been decreasing, with a drop of 40% since 2003, despite these historic increases in incidence. I’m not trying to downplay the overall impact of HIV at all, but the difference in current fiscal emphasis is a bit frustrating.
        ◦ Health and Human Services has developed a 5 year plan to tackle the rise in syphilis cases, as well as other sexually transmitted infections, and pregnant women are one of the prioritized populations. It will need to plug holes in maternal screening and treatment. One change over the past year in obstetrical medicine was a new recommendation to screen women for syphilis twice during pregnancy rather than only once in the 2nd trimester, but again they need to have access to care to benefit. It will need to stabilize supplies of penicillin formulated for intramuscular injections. And it will need to find ways to reach people who are not seeking prenatal care.

More Newborns are Being Diagnosed With Syphilis as Adult Cases Continue a Dramatic Rise
With more pregnancy women being diagnosed with syphilis, there has been a steady rise in potentially deadly congenital infections.
Clay Jones on May 24, 2024
Link

Babies have it tough enough these days, what with having to compete with TikTok and Instagram for attention from their caregivers and the near certainty of catastrophic global chaos in their lifetimes resulting from climate change, H5N1 bird flu, or artificial intelligence gone rogue. The last thing that they need is syphilis. But here we are…again.
In October of 2021, I wrote about how cases of syphilis had been steadily increasing since a nadir in 2000 and a significant shift in the affected populations:
Cases of syphilis crept up slightly in 2001 and a trend of steady yearly increases in new infections has continued ever since. In 2019, the most recent year with complete and official data, almost 39,000 cases of primary and secondary syphilis were reported to the CDC. Since case counts began to increase in 2001, the majority of cases have been diagnosed in men, in particular men who have sex with men. Over the past few years, however, cases in men who have sex with men have leveled off at around 55-60% of total male cases, and significant increases are occurring in heterosexual men and women. Rates of syphilis have also increased across the United States and are no longer relegated to the South and a few large cities in other regions.
Not surprisingly, as cases of syphilis have increased in women there has been an increase in the incidence of babies infected during pregnancy. After a few years of stability, 2013 saw an increase in congenital syphilis with 9.2 cases for every 100,000 live births. Every year since 2012 has been worse than the year before. In 2019, there were 1,870 cases reported or 48.5 per 100,000 live births, which was about 40% more than in 2018, and an increase of about 400% from 2012. Not only are cases increasing in number, but they are more distributed across the country, with 43 states and the District of Columbia reporting at least once case of congenital syphilis in 2019.
https://sciencebasedmedicine.org/cases-of-newborn-syphilis-are-increasing-at-an-alarming-rate/
This trend continued the following year, which I wrote about in April of 2022:
Primary and secondary syphilis, which are the stages when the infection is easily spread from person to person through intimate contact, increased by about 7% in 2020 with 41,655 reported cases. Congenital syphilis, which puts children at risk for debilitating sequelae and even death, increased by 15% with 2,148 cases and 149 deaths, continuing the alarming trend I discussed in that October post.
https://sciencebasedmedicine.org/new-cdc-data-confirms-continued-rise-in-sexually-transmitted-diseases/
Cases of syphilis, in adults and newborns, have continued to increase. In 2021, the number of primary and secondary cases reported to the CDC increased by 30% to 53,767. Rates were higher in all age groups, in both men and women, and in all regions of the United States. Syphilis in all women increased by 55% (200% since 2017), and 52% when focusing on women between the ages of 15 and 44 years. To make this concerning trend even more clear, the number of states reporting more than 100 cases of syphilis in women of reproductive age increased from 3 in 2012 to 29 in 2021.
More younger women with syphilis, and continued disparities in healthcare access, unsurprisingly continued to result in more cases of congenital infection. There were 2,855 cases reported in 2021, an increase of 30% compared to the previous year, and 219% compared to 2017. 220 of these cases resulted in either stillbirth or infant death. 46 states as well as the District of Columbia reported at least one case of congenital syphilis.
But wait, there’s more.
In 2022, reported cases of primary and secondary syphilis increased another 9% to 59,016. Rates in women of reproductive age increased in 35 states and 17% overall. Syphilis diagnosed in newborns increased 30%, with 3,755 cases reported to the CDC, which was the most since 1991, and which included 282 stillbirths and infant deaths.
We are still months away from the publication of 2023 syphilis data, but it is hard to imagine that it will be good or even improved. In November, when 2022 data was being finalized, the CDC and the American Academy of Pediatrics appropriately raised the alarm and began calling for action, both pointing out that the vast majority of cases of congenital syphilis were preventable:
    • Almost 9 in 10 cases of newborn syphilis in 2022 might have been prevented with timely testing and treatment during pregnancy.
    • More than half were among people who tested positive for syphilis during pregnancy but did not receive adequate or timely treatment.
    • Nearly 40 percent were among mothers who were not in prenatal care.
https://www.cdc.gov/media/releases/2023/s1107-newborn-syphilis.html
One way to address the rising rates of syphilis in pregnant women and the increased risk of congenital syphilis would be to reverse centuries of systemic racism and to do away with all disparities in healthcare experienced by women across all racial, ethic, and socioeconomic groups. Universal healthcare and better prevention and treatment of substance use disorder would also be nice. While we are coming together as a country to begin working on that, another approach would be to increase testing.
For decades, screening of pregnant women for syphilis has been a standard part of the first prenatal visit. Repeat testing later in pregnancy, typically at around the 28th week of gestation and again at the time of delivery, has been recommended for patients at increased risk of exposure to syphilis. Though it has depended on the state, as laws vary, and the particular provider, many women have been tested at 28 weeks regardless of risk factors. The screening test at the time of delivery, except for those high risk patients, is not generally a common practice.
In response to the rising rates of syphilis in younger women who are not always checking those historical high risk boxes, the American College of Obstetrics and Gynecology issued new recommendations last month:
According to the new ACOG Practice Advisory, obstetrician–gynecologists and other obstetric care professionals should screen all pregnant individuals serologically for syphilis at the first prenatal care visit, followed by universal rescreening during the third trimester and again at birth. This is a change from previous guidance, which recommended risk-based testing in the third trimester only for individuals living in communities with high rates of syphilis and for those who have been at risk of syphilis acquisition during pregnancy.
https://www.acog.org/news/news-releases/2024/04/acog-recommends-obstetrician-gynecologists-increase-syphilis-screening-for-pregnant-individuals
40% of congenital syphilis cases are diagnosed in infants born to mothers who, for a variety of reasons, did not receive prenatal care. So the above recommendation is not going to prevent all cases since in requires early and consistent visits to an obstetrician, family doctor, or certified midwife. The CDC is calling for syphilis screening and treatment during pregnancy whenever the opportunity arises for women who have not yet, and may not ever, establish prenatal care. This includes settings such as emergency departments, jail intake, syringe service programs, and mother and child health programs.
        ◦ More screening is clearly necessary to help reduce the disease burden in women who may become or who already are pregnant. But just as important is treatment and further testing once syphilis is diagnosed. Immediate treatment at the time of diagnosis, usually with an intramuscular dose of penicillin, is key. Unfortunately, there have been significant issues with shortages of this medication that are expected to continue for months. Oh yeah, we should fix that too.

Pediatric Hepatitis, A Medical Rorschach Test
Because they are from an old, established cause, pediatric deaths from COVID have receded into the background, overshadowed by pediatric hepatitis.
Jonathan HowardonMay 6, 2022
Link

The mysterious outbreak of severe pediatric hepatitis has affected nearly 300 children in 20 countries. At least 16 children have needed liver transplants. In the US alone, the CDC announced that it is investigating 109 cases in 25 states and territories, and 5 children have died. No one knows what is causing it, though that hasn’t stopped many people from speculating.
Anti-vaxxers are blaming vaccines, of course. They reflexively blame vaccines for everything and will do so for the next pediatric ailment that arises. The fact that most affected children are unvaccinated isn’t a barrier for them. Lockdown opponents are blaming lockdowns, of course. They reflexively blame lockdowns for everything will do so for the next pediatric ailment that arises. The fact that some affected children are from places like Alabama, where the lockdowns ended long ago, or Sweden, which never locked own at all, isn’t a barrier for them. They are also not bothered by the fact that children as old as 16 have been affected, though they spent their childhood in a pre-COVID world.
Naturally, many people were quick to blame COVID, though there’s a plausible case to be made for this. Certainly, the cause seems to be something contagious. Why else would it be happening in so many different parts in the world? Moreover, COVID is still a relatively new virus, it’s been full of surprises already, and it’s everywhere. Perhaps new variants are affecting children differently. The initial MIS-C cases surprised a lot of people too, though there have now been over 7,800 cases of this devastating disorder in the USA alone.
Additionally, there’s precedent. A case series reported on 4 children who developed “significant hepatitis as the primary manifestation of COVID-19 infection”, while another paper reported on a 1-month-old infant with this condition. A report from India described 37 cases pediatric hepatitis due to COVID, though they were not severe. They also described 10 children with MIS-C hepatitis, who were very sick. Three of these children died. Another report on 44 children with MIS-C found that “Hepatitis is common in children with MIS-C and is associated with a more severe presentation”. Another study from Israel, found that 11 out of 12 children with pediatric hepatitis contracted COVID last year.
As such, it’s entirely possible that pediatric hepatitis is a rare manifestation of COVID, which is just now being widely recognized and reported. Given that hundreds of millions of children contracted the virus around the world, even rare events add up. Perhaps doctors are only now collectively noticing and reporting these cases – a medical version of the Baader-Meinhof phenomenon or frequency illusion. Basically, if people start looking for something specific, they might find more examples of it than they expected. If I had to place a bet, I’d say COVID is to blame for all of the above reasons, though I wouldn’t want to wager a lot of money.
Reasonable people, such as Dr. Clay Jones, have argued that COVID is unlikely to be responsible. If COVID was to blame, why are so many cases are popping up now, two years into the pandemic? Moreover, in a sample of children from the UK, where most cases have occurred, only 16% of the cases tested positive for COVID. In a CDC investigation of 9 children in Alabama, all cases tested negative for acute COVID infection, none had a known history of prior infection, and the liver biopsies of 6 children showed no viral inclusions or particles. However, these children were not tested for antibodies against SARS-CoV-2, and the liver biopsies were not stained specifically for the SARS-CoV-2. The CDC and health authorities from the UK suggested that an adenovirus may be responsible, though as Dr. Farid Jalali, a liver specialist, pointed out this is a common virus and likely an incidental finding as it is not known to have caused hepatitis before.
Hopefully people with the relevant expertise will figure it out, though it will be a challenge. At present, there is no standard definition of the disorder. France, for example, apparently excludes children who test positive for SARS-CoV-2. Additionally, children also make lower levels of antibodies to SARS-CoV-2, complicating the ability to rule-out COVID with this test. Those who pronounce its cause with great certainly today reveal more about themselves than pediatric hepatitis. It’s become a medical Rorschach test.
Whatever the cause may be, the reaction to this new condition illustrates the point I made previously: we’ve grown numb to the suffering and death of children from known causes. This week alone, nineteen children were added to the grim COVID death tally maintained by the American Academy of Pediatrics. There were no news articles about this. There was no outrage on social media. Why would there be? It was just an average week.
Overall, over 1,500 children have died of COVID in the US and tens of thousands more have been hospitalized, many needing ICU-level care and mechanical ventilation. Even though these grave outcomes are largely preventable with a vaccine for children older than 5-years, because they are from an old, established cause, they’re not interesting to most people. They’ve receded into the background and are overshadowed by pediatric hepatitis.
This condition is shiny and new – for now.

Separating Fact from Fiction in the Newborn Nursery: Hepatitis B Vaccine for Newborns
Clay Jones on July 17, 2015
Link


For those of you new to Science-Based Medicine, I am a pediatric hospitalist and spend the majority of my time caring for newborns. It’s an extremely rewarding experience on most days. The babies are usually healthy, the parents are usually happy and appreciative, and I get to give a lot of good news. I also get to dispel a lot of myths and misconceptions regarding the care of infants, which as you can probably imagine, I take great pleasure in.
Parents ask a lot of questions, which I appreciate and encourage, but they also make a lot of claims about the care of children based on their prior experience, advice from well-meaning friends and family, or their evaluation of the online “literature.” Some of these claims I will challenge, nicely of course, when they are demonstrably wrong or increase the risk for a bad outcome. (“We read that babies should sleep inverted like a bat in order to increase blood flow to the brain.”) Some of these claims I acknowledge as an acceptable approach, even if I don’t agree with them myself, if there is low risk or a lack of available quality evidence to guide me. (“We burped our last baby every five minutes during feeds to prevent colic.”) Sometimes I even learn a thing or two from parents.
The safe, universally-recommended hepatitis B vaccine
A topic that frequently leads to both questions and claims from concerned parents during rounds in the newborn nursery is the vaccination against the hepatitis B virus (HBV), something that has been recommended universally for infants by the Advisory Council on Immunization Practices (ACIP) since 1991. Their strategy was, and still is, to wipe this awful disease out in the United States. Over the years, the recommendation for timing of the first dose has changed from “at birth before hospital discharge or at age 1-2 months” to simply “newborns before hospital discharge” in 2002, with qualifiers of medical stability and weight greater than 2,000 grams added in 2005. Babies that weight less than 2 kg at birth still will get the vaccine at discharge home or at 1 month of age if still in the hospital. This last change was recommended because of concerns over efficacy rather than safety. It’s an extremely safe vaccine.
In addition to questions about the vaccine, the most common being about any associated risks and the necessity for a newborn dose, I also get a fair amount of refusals despite attempts to educate and reassure. Most of the time these aren’t anti-vaccine parents, they just don’t understand why it can’t wait until they take the baby in to see their primary care pediatrician. They may assert that their child doesn’t need it at such a young age, that it’s not necessary considering the infant’s low risk of exposure. Many are medically savvy enough to question the need for the vaccine given negative testing in the mother. Thankfully, most of these families do go on to allow their babies to receive all the recommended vaccines on the ACIP schedule.
Only once in my career of roughly 12 years have I had a mother with active HBV refuse the immunization for their newborn. That is an entirely different issue which I will get into shortly. Questions about the need for giving the baby of a mother who has tested negative for hepatitis B infection a vaccination to protect them from a disease commonly thought of as an adult affliction, and related to “adult” behaviors, are understandable. But before I explain why we have this recommendation in place, a primer on the disease we are trying to avoid is in order.
What is hepatitis B?
Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV). According to the CDC, there were 3,050 cases of acute infection reported in the United States in 2013, which comes out to roughly 1 case per 100,000 people. In children under the age of 15 years, the incidence is now only .02 per 100,000. The numbers of reported acute infections in kids has plummeted since the vaccine was first recommended for all infants in 1991, and is down from nearly 14 per 100,000 in the 1980s. Overall there has been an almost 90% reduction in the diagnosis of new cases.
It’s important to point out that these numbers likely significantly underestimate the actual number of new infections with HBV. Because the acute infection frequently doesn’t cause any symptoms, many cases go unreported. After taking this into account, the CDC estimates that there were actually close to 20,000 new cases in 2013. Most acute HBV cases will fully resolve without any need for intervention, however a certain percentage will go on to develop chronic infection, with younger patients being at higher risk. It is estimated that between 700,000 and 1.4 million people currently have chronic hepatitis B in the United States.
From a global perspective, HBV causes significantly more illness and death than in the United States. The World Health Organization, which also recommends universal immunization of newborns against HBV, puts worldwide cases of chronic disease at around 240 million people. And three quarters of a million people die each year from acute (130,000) or chronic (650,000) infection.
Acute hepatitis B infection
The presentation of acute infection with HBV is extremely variable, ranging from a complete absence of symptoms to severe and sudden onset of liver failure that is life-threatening and requires aggressive treatment. This is a rare complication that occurs in less than 1% of cases, however. In general, when signs and symptoms of illness do occur, they tend to be similar in presentation in all age groups with loss of appetite, nausea, an inflamed and tender liver, and jaundice being typical. Fatigue can be severe in some patients, and persist long after the other complaints have resolved, which usually takes one to three months. Some patients will also develop more significant systemic symptoms consisting of muscle and joint pain, hive-like rashes, and tender swollen lymph nodes.
Most patients over the age of five years who are acutely infected with HBV will clear the virus and go on to benefit from lifelong immunity. But almost 90% of infants and 25%-50% of children between the ages of one and five years will not be so lucky. In contrast, 95% of older children and adults will fight off the virus during the initial exposure. The ability to fight off the virus clearly improves with age. The younger the patient, the more likely they will develop chronic infection and be at risk for devastating future complications.
Chronic hepatitis B infection
Patients with chronic HBV infection are often asymptomatic for decades. Children typically develop as expected and without any disability, but can present with kidney disease long before any liver problems. But it is the slow and steady injury to the liver, although sometimes it can be sudden and severe, that can occur which causes the greatest risk for eventual morbidity and mortality.
How chronic HBV infection naturally plays out in kids is complicated, and like acute infection it presents in different ways. The complicating factor is something called immune tolerance, a unique result when infection occurs in younger patients, particularly newborns who acquire the infection from their mother around the time of birth. Immune tolerance is the state where, although there is evidence of viral replication in the patient, there is little to no laboratory evidence of liver inflammation. This phase can last for months to decades and can go undetected. Even when identified, treatment is generally not recommended because of poor efficacy and concern for inducing antiviral resistance.
Seroconversion and clearance of infection
At any point during the immune tolerant phase, it is possible for the patient to develop antibodies against a key component of the virus (“seroconversion”) and rarely, to even clear the infection. This is very unlikely to occur when a child is infected in early infancy, with a conversion rate of about 5% per year. Kids who acquire the infection a bit later and from a source other than their mother have better chances, even as high as 70%-80% over the first 20 years. Again, development of these antibodies doesn’t mean that a patient will clear the virus and be cured, only that they have a chance. And unfortunately, conversion and even clearance of the virus doesn’t necessarily prevent all long term complications.
Immune active infection
The next potential component of chronic HBV infection is the so-called immune active phase. For reasons we don’t fully understand, at any time a patient can develop increased replication of the virus and increased inflammation of the liver. This is where significant and prolonged liver injury can occur but it is also the time when the patient has the best chance to develop antibodies against critical components of the virus.
The longer that a patient is in the immune active phase, the higher the risk of cirrhosis of the liver and ultimately the development of hepatocellular carcinoma (HCC). That’s right, the hepatitis B vaccine was the first vaccine to successfully prevent cancer, not the vaccine against human papillomavirus. This stage is typically treated with antiviral medications in order to limit injury to the liver and help increase the likelihood of seroconversion, although the success rates aren’t great in children.
Inactive carriers, aka Hepatitis Mary
After seroconversion occurs, these patients are considered inactive carriers. They have no liver inflammation and low or undetectable viral replication. They have developed important antibodies against the virus, and have a chance to clear the infection, but they are still at risk. As many as 20% will revert back to the immune active phase at least once, and 20-30% will enter a reactivation phase where their viral load will increase and liver inflammation can return despite the improved immune response. The reactivation phase can result in rapid deterioration of liver function and is also frequently treated with antiviral medications, but these patients will rarely go on to ever clear the virus so will always be at risk for long term complications.
What are the long term complications of chronic hepatitis B virus infection?
Cirrhosis of the liver and hepatocellular carcinoma (HCC) are the primary long term complications of chronic infection with HBV acquired during childhood. These don’t tend to occur until much later in life but injury in the form of fibrosis, essentially scarring of the liver, is common within just a few years of infection. Unchecked fibrosis is what can lead to cirrhosis, and ultimately loss of liver function, years to decades down the road.
Liver cancer in the form of hepatocellular carcinoma, unlike fibrosis and cirrhosis, remains a potential bad outcome even in patients who have converted to less inflammatory phases of HBV infection, and even in patients who do eventually clear the virus. Adults who were infected as infants can have a rate of HCC diagnosis as high as 5% per year. In general, the more time that a patient spends with active inflammation of the liver, and the longer it takes for antibody conversion (if it happens at all), the higher the risk of HCC.
According to the CDC, one out of every four children who develop chronic infection with HBV will die as a result. Of the patients who are exposed outside of childhood and are unlucky enough to develop a chronic infection, 15% will ultimately die earlier than they should have because of it. There are a few thousand people every year that die from this vaccine-preventable illness, despite improvements in drug therapies and even liver transplantation.
How is the hepatitis B virus spread?
Historically in the United States, and currently in countries where HBV infections are endemic, the virus has most commonly been spread from an infected mother to their baby during the birth process. Babies are frequently exposed to a significant amount of blood and body fluids at delivery, so this should make sense. As it stands in the United States now, because of the success of the vaccine the virus is no longer endemic and infections are much less common. So the most common route of spread here is through sex with an infected partner or by being stuck with a contaminated needle.
But the virus can be transmitted from one person to the other through a variety of routes that don’t involve shooting up, healthcare workplace accidents, or risky sexual activity. Viral particles can be found in other infected body fluids, such as saliva contaminated by bleeding gums or biting the inside of the cheek. Children can spread it to each other during close contact in a household or if one toddler bites another. Transmission can also occur when sharing a toothbrush or borrowing a razor. These are all unlikely, but the risk is real and cases happen every year in young children and low-risk adults.
The people who spread the virus to others are often asymptomatic and don’t even know that they are infected. Furthermore, HBV can survive on surfaces for more than seven days and still retain the ability to cause infection. Think about that as your infant crawls around the floor of the gym at their daycare center putting everything within reach straight into their mouth.
Why newborns?
So now we’ve come full circle. As I stated at the beginning of the post, many parents are hesitant to consent to a vaccine that they believe isn’t really necessary in such a young child. They may question the risk of exposure to HBV because all they know about it comes from sources like Dr. Bob Sears:
Let’s take a look at the two different schedules. One of the main differences that the CDC schedule dictates is they suggest the hepatitis B vaccine be given the day a baby’s born, one month later, and then six months later. Now, if you look at hepatitis B, it’s a sexually transmitted disease. The only way a baby can catch it is through blood or body-fluid exposure, and that’s extremely unlikely to happen for any baby or young child in the United States.
So what I did on my schedule is, I took a more logical look at hepatitis B, and I realized that babies have no risk of catching this disease, so let’s not do the hep B vaccine while a baby’s young and small and more vulnerable. Let’s do a hepatitis B vaccine when a child’s more of a preschool age, where he or she is going to be entering school and be running around with a lot of other kids, and there could be some blood or body-fluid exposures in those kinds of situations. To me, that’s just a more logical time frame to do the hepatitis B vaccine. And some parents would even take it a step further and decide to delay their children’s hep B vaccine until their children are teenagers and the real risks of hepatitis B, such as sexual activity or [intravenous] drug abuse, come into play.
His rationale amounts to waiting until they are completely past the stage where children have the highest risk of developing chronic infection and ultimately dying of liver disease or cancer. And babies are exposed to blood and body fluid, as are toddlers who haven’t started preschool, when they have siblings or are in daycare. We do test mothers for HBV activity during pregnancy but no test is perfect and information transfer from the OB or lab to the newborn service can be lost or accidentally altered.
There are 25,000 infants born to mothers that carry the virus every year in the United States that we know of. If something goes wrong and a mother is falsely labeled as negative or unknown status, that baby can have up to a 90% chance of acute infection depending on what phase she is in (immune active with high viral load has the highest risk). If infected, most will develop chronic infection and of those chronically infected 25% will die because of it.
Sears is spreading dangerous misinformation but he’s not the worst of the fearmongering anti-vaccine crowd. Our friends Mercola and the NVIC unsurprisingly take it much further. Perhaps I’ll cover their nonsense in a future post.
In addition to serving as a safety net and protecting those most vulnerable to the devastating potential outcomes of this infection, we also recommend the newborn dose because it increases the likelihood that the child will go on to get the full series of 3-4 shots and be fully protected. And protected kids can’t spread the infection to the unprotected. And despite claims from the usual suspects of antivaccine rhetoric, the safety and efficacy of this vaccine is firmly established.
Conclusion: Vaccination can be scary, but it is necessary; it is necesscary
We expect a lot from parents in the newborn nursery. They are asked to allow their little bundle of joy to go through a long list of interventions that take the baby away from their sight and can cause discomfort: antibiotic eye ointment, vitamin K injections, heel sticks for metabolic screening, hearing testing, jaundice levels, screening for heart defects, and finally, the hepatitis B vaccine. And that’s in a perfectly healthy baby. Considering this, and the lack of good public understanding of hepatitis B and the need for immunizing the very young, I’m not surprised that many refuse.
But these concerns, as understandable as they are, are unfounded. The vaccine is extremely safe, and the benefit far outweighs any small degree of risk. Protection from hepatitis B infection, which thanks to the success of the vaccine is now uncommon in the U.S., is still very important considering the potentially life-threatening complications. Complications which are significantly more likely to occur in patients infected when they are infants.

CDC Data Reveals Frustrating Infant Death Statistics
Since the significant decrease in the rates of sudden unexpected infant deaths in the 90s, we have hit a bit of a wall and there is much we don’t know about this complicated problem. A new study analyzing CDC data is a step in the right direction.
Clay Jones on May 14, 2021
Tweet

In the United States, the sudden and unexpected death of an infant, particularly during sleep, is the leading cause of mortality between the neonatal period (1st month of life) and a child’s first birthday. Despite this fact, and some significant advances that have been made over the past 30 years, the biological and pyschosocial factors involved in these deaths are still not fully worked out. A study in the May issue of Pediatrics doesn’t provide solutions to this problem, but it support what we do know about risk factors and it might help to shine a light on some of the gaps in our approach to prevention.
The study, which I’ll break down shortly, also reveals just how far we have to go in effectively educating infant caregivers on modifiable risk factors for unexpected infant death. We have come a long way when it comes to making sleep safer for babies, but this is a complex problem without easy answers. Even determining how to classify infant deaths has been challenging.
What is Sudden Unexpected Infant Death and when is it SIDS?
How we define outcomes in medicine plays an important role in how we study these outcomes and the variables that may or may not play a role in causing them. Historically, we haven’t done a great job when it comes to the unexpected death of infants and this has made large scale surveillance difficult. How can we learn which populations of infants are most at risk of unexpected death, or develop strategies for reducing their risk through research and targeted caregiver education if we don’t have a solid grasp of when these deaths occur and in what environments?
There have been several attempts to track these unexpected infant deaths over the years. These efforts have been hampered by varying definitions and the difficulty inherent in classifying events that tend to be unobserved by caregivers. In 2009, the CDC created a specific registry for sudden unexpected infant death (SUID) cases with the goal of supplementing death certificate data in order to add depth to our ability to map out the factors that might play a causal role. The key to this registry is the use of standardized definitions and criteria, as well as a focus on documenting detailed information from death scene investigations and autopsies, in order to break SUID into appropriate subgroups consistently. This could theoretically help us to tweak and focus existing risk reduction strategies, tailor our approach to education, and even tease out potential new avenues of research.
As defined by the CDC, SUID is a general category that includes all cases of both unexplained and explained unexpected deaths in infancy. The subgroup of explained cases contains those deaths attributed to accidental suffocation and strangulation in bed. This often involves a parent rolling on to a child, or a child becoming wedged between a caregiver and a couch cushion, but bedding or objects in the sleep space can also play a role. Sudden infant death syndrome (SIDS) falls into the subgroup of unexplained cases but requires a thorough case analysis that includes an autopsy, death scene investigation, and evaluation of the clinical history. Without this degree of investigation, unexplained SUID cases are labelled as unknown cause.
The Back to Sleep Campaign and recent epidemiological trends
SIDS has long been recognized as the most common cause of death in infants after the first month of life. Prior to the early 1990s, when pediatricians in the United States and several other countries first began recommending supine sleep, the risk of SIDS was 1.2 out of every 1,000 live births. It was, and still is, much higher in Black and American Indian/Alaskan native children and slightly more common in boys for unclear reasons.
Cases of SIDS plummeted by more than 50% when parents began putting their babies to sleep on their backs. The campaign was a stunning success and has saved thousands of lives. Unfortunately, the steady decline in overall cases of SUID began to level off after a few years.
SIDS cases dropped dramatically deep into the 90s and have continued to fall ever since, though at a much less impressive rate:See also the CDC SIDS dashboard.
Overall SUID rates naturally fell as well, for a while, likely because of refinement in our risk reduction strategies for safe sleep. Since the late 90s, however, they stalled because the decrease in SIDS cases has been matched by an increase in SUID cases attributed to suffocation or labelled as unknown.
Why are cases of SIDS continuing to fall, though less dramatically than they did immediately after the Back to Sleep campaign began, while other SUID subgroups are increasing in incidence? Some of it is obviously a diagnostic substitution. More complete investigations into SUID cases are certain to increase the likelihood of discovering a potential cause. More focus on consistent proper labeling might also result in less instances where a death was simply labelled as SIDS without a proper investigation out of ignorance or incompetence, thus bumping the number of cases in the unknown cause category.
Another potential explanation, sadly, is that caregivers might not be following safe sleep recommendations throughout infancy. SIDS tends to occur earlier in infancy, so perhaps some caregivers are becoming less focused on the modifiable risk factors after the highest risk in the first 2-3 months of life. This is where the psychosocial complexity of SUID comes in to play as there are seemingly infinite potential reasons for poor adherence to our recommendations: cultural practices, caregiver fatigue, a false sense of security, social or financial upheavals, inadequate counseling, etc.
I’m confident that there are potential explanations that I’m not smart enough to think of. And again, our ability to understand and manage this complicated problem is limited when our data is incomplete. This is where studies such as the one in Pediatrics that I mentioned above come into play.
CDC SUID data from 2011-2017
The study looked at the more than 12,000 SUID cases captured by the CDC registry from 2011 to 2017 with a more detailed and systematic approach than previous studies. For example, they used classification categories that did not overlap in order to avoid confusion and allow easier analysis. They found that 18% of deaths were fully explained by suffocation with another 13% possibly caused by suffocation. In 41% of cases, though suffocation couldn’t be determined, there were factors that clearly went against safe sleep recommendations. In total, 72% of SUID cases were associated with unsafe sleep and 74% of the cases where suffocation was proven or possible involved soft bedding.
One of the more interesting findings was that certain SUID cases trended a bit older than what would be expected based on earlier data. For example, cases that were unexplained but likely caused by suffocation had a mean age of 4 months. Historically SUID cases peak between 2-4 months, the bulk of which being SIDS. The study authors hope that having more detailed data such as this might help tease out different underlying causes and guide future research.
After analyzing the data, the authors determined key implications for pediatric healthcare professionals. Because more than 70% of SUID cases involved unsafe sleep environments, it is crucial that we figure out why caregivers aren’t following our recommendations. It is imperative that we develop more effective ways to educate these caregivers and help them adhere to the guidelines. One potential way to improve adherence and save infant lives would be to determine high risk groups and target educational outreach. The authors also call for improved documentation in the medical record, particularly involving autopsy and death scene investigations.

U.S. Infant Mortality Increases for First Time in 20 Years
Recently published CDC data has revealed an increase in the number of infant deaths in 2022, the first in two decades. The United States continues to struggle with serious healthcare disparities and to lag behind other countries when it comes to keeping young children alive.
Clay Jones on November 10, 2023
Link

Despite spending more on healthcare, the United States has the highest infant and maternal mortality rate of any similarly wealthy country. This is widely accepted to the result of generational disparities in healthcare access, quality, and affordability, with lower socioeconomic and minority populations being disproportionately affected, and it appears to be worsening. Our infant mortality rate, defined as the number of infant deaths for every 1,000 live births, had been slowly improving over the past couple of decades, decreasing 22% between 2002 and 2021, though this trend now appears to have reversed.
According to recently published data from the CDC, 2022 saw a significant increase in the infant mortality rate of 3%, going from 5.44 (19,928) in 2021 to 5.60 (20,538 deaths) last year. While this might be a fluke, it represents the first year-to-year increase since 2002. And even if considered a random fluctuation that will regress to the mean, our mean is tragically and consistently terrible.
For some perspective, the infant mortality rate in Germany was 2.344 in 2022, which was down more than 8% from the previous year. Germany is not the outlier. France decreased by 2.5%. Portugal’s rate dropped by almost 5%. Japan’s dropped nearly 2.5% as well, and their infant mortality rate was already extremely low. Now it sits 1.6. Iceland has a rate of 1.4 and also saw a decrease. Country after country, many with less resources than the United States, had fewer dead babies in 2022. We are the outlier.
There are differences in how live births are reported in the United States compared to some other countries that make our numbers look a little worse. Babies that were born prematurely at the edge of viability, and who subsequently died, might be reported as miscarriages or stillbirths in another country while we might count it as a live birth. When accounted for, however, this only narrows the gap by a small amount. When comparing apples to apples, our shockingly high infant mortality rate still stands out.
There are patterns in the deaths that tell a story we have sadly been hearing for a very long time in this country. They were not evenly distributed. First off, the mortality rate of infants of American Indian and Alaska Native (AIAN) women increased from 7.46 to 9.06 per 1,000 live births. Contrast that with infants of Asian, non-Hispanic women, who died at a clip of 3.5 per 1,000 live births in 2022. That group has the lowest of any in the United States, followed by infants of White, non-Hispanic women with a mortality rate of 4.52.
Children most likely to die before their 1st birthday in this country, however, are Black, non-Hispanic infants. Although not a statistically significant difference compared to 2021, infant mortality rates in this group increased from 10.55 to 10.86 in 2022. Though the math is pretty obvious, I feel it’s important to point out here that Black babies are more than twice as likely to die than their White counterparts in this country, which is consistent with the stark difference in mortality between Black and White women during pregnancy.
The most common causes of infant death in 2022 were consistent with previous years. Topping the list was congenital malformations, followed by complications from prematurity and low birthweight, SIDS, unintentional injuries, and maternal complications of pregnancy. With regards to prematurity/low birthweight and pregnancy complications, both of which being more likely when a mother has limited or absent prenatal care, it shouldn’t come as much of a surprise that the health of a mother and her baby are linked. The rate of infant deaths caused by maternal complications increased by 9% last year.
Again, even if the increase in infant mortality seen last year ends up being being a fluke and the general trend of decreasing rates resumes in 2023, there still would’t be much of a reason to celebrate. We have a very long way to go to even approach the rates seen in similarly rich countries. Unfortunately, the roots of our abysmal numbers, and the huge disparity in deaths when comparing different populations, run deep in this country.
You would think that keeping children alive to see their first birthday would be a goal capable of uniting people despite their political differences.
But here we are…again.

A Rational Approach to Managing Acute Pain in Children
Clay Jones on November 22, 2013
Link
Pain is one of the most common reasons for a parent or caregiver to seek medical attention for their child. Children experience pain for a wide variety of reasons, many that are similar to if not exactly the same as causes of adult pain, but historically pediatric patients have been grossly undertreated. I am 37-years-old and, sadly, if I had undergone a surgical procedure as an infant there would have been a significant chance that I would have received no analgesia at all. Things are better now, but there remains a large gap between what is recommended and how pediatric pain management is practiced in the real world.
The appropriate management of a child’s pain is a vital aspect of compassionate and high quality care, and it is simply the right thing to do. Failing to treat pain effectively is ethically no different than purposefully causing pain in a child, and it can have serious repercussions. Poorly controlled pain can interfere with a child’s recovery because of the negative impact of catecholamine surges and other stress-related chemicals, and impair the ability to take part in physical or occupational therapy. It can also make future encounters with health care professionals more challenging because of anxiety and mistrust.
Untreated pain can interfere with deep breathing, potentially leading to prolonged need for supplemental oxygen and increased risk of pneumonia. It can prevent restful sleep, which has myriad health consequences beyond just cognitive impairment. Pain can interfere with the family unit by significantly increasing parental or caregiver anxiety, which can lead to neglect, abuse, and increased utilization of healthcare resources. Poorly-managed acute pain can increase the likelihood of a patient, even a child, developing chronic pain. There is even good evidence in neonates (my next post I think), that poorly managed acute pain can lead to increased sensitivity and an increased pain response to future occurrences of procedural pain, such as routine immunizations.
Multiple reports throughout the 1970’s and 1980’s revealed that pediatric patients received substantially less pain treatment compared to adults for equivalent conditions, such as broken bones and hernia repair. Despite steady improvement in pain management in kids over the past few decades, we still have a long way to go. Though appropriate anesthesia is now standard of care in children of all ages, many physicians are uncomfortable with evaluating and treating acute pain (chronic pain is another topic) in children. And many parents are resistant to the use of safe and effective pain medications.
Even with physicians that might profess their comfort with recognizing and treating pediatric pain, my admittedly personal experience is that many still allow kids to be in pain at times for a variety of reasons. However, it isn’t that these physicians and caregivers are heartless or enjoy watching their patients, or their children if it is a parent putting up a roadblock, suffer. Even knowing a child is in pain can sometimes be challenging. And there are many misconceptions regarding pain in children that interfere with appropriate treatment. The bulk of these misconceptions involve the use of opioids. All of these misconceptions and false beliefs should be amenable to education and increased awareness of science-based guidelines.
Pediatric pain is a challenging entity. So much so that many institutions have pediatric pain teams. My wife is an expert on pediatric pain and spends her days, and often nights, as a palliative care pediatrician helping to manage pain and other symptoms in children who are approaching the end of life. Her insights and expertise on this topic have been invaluable in my own encounters with pain as a pediatric hospitalist. Her experience, like mine, is that even at major academic institutions pain management is regularly not approached systematically, nor based on the best available evidence.
So what is pain exactly, and how is it assessed in kids?
A brief primer on pain
At its core, pain is an unpleasant sensation or emotional experience that can occur when there is tissue injury, when we expect tissue injury to occur, or when we think there has already been tissue injury. It is entirely subjective and personalized. Each individual learns over time, through their own personal experiences, what sensations and emotions to label as pain and how to express the severity of that pain verbally once they have achieved that stage of cognitive development. There are many ways that this process can get tripped up, leading to chronic pain even after any tissue injury has healed, but that deserves its own discussion so I will stick to acute pain. Of course children with chronic pain can have acute pain as well. It’s complicated.
We generally break pain down into two categories, nociceptive and neuropathic, and nociceptive is further broken down into somatic and visceral pain. The label nociceptive pain is given to pain initiated by otherwise-healthy pain receptors present in injured or inflamed tissue. Somatic describes pain associated with skin, soft tissue, muscle and bone while pain from our internal organs is visceral. The difference clinically is that with visceral pain it is hard for patients to describe a specific location of their dull- or cramping-type pain, while somatic pain is sharp, throbbing and they can point right to it. Neuropathic pain involves damaged sensory nerves rather than specific pain receptors and is typically more of a burning, tingling, or shooting pain.
Pediatric pain assessment basics
The key to appropriately managing pain in a child involves deciphering the clues obtained from a thorough history taking and physical exam, in order to assess the type of pain, where it is coming from and the severity. We use self-reporting methods when we can, but obviously it often isn’t as simple as just asking the patient to rate their pain on a 1 to 10 scale. There are behavioral observational scales validated on pediatric patients, such as young infants and toddlers, who are unable to self-report but we must frequently rely on details provided by caregivers. These caregivers, no different than the rest of us, can fall prey to stress and cognitive biases that alter their memory and perception. Also, there is always concern that observational assessment may underestimate pain compared to self-report.
We must also frequently deal with adolescent patients whose ability to reliably rate their own pain using a numerical scale is suspect because of psychiatric conditions, maladaptive responses to stress, and even malingering, though this isn’t common. In general, it is considered best practice to take the patient’s word for their pain severity, at least until you have a good relationship with them and ample evidence that their pain reporting is unreliable. Not treating pain is unacceptable and I would rather treat a thousand kids for pain unnecessarily, but safely, than allow one child to suffer needlessly.
As in the adult world, we are called upon to assess neurologically impaired patients that might be in pain or may simply be agitated for some other reason. These children, who are unable to communicate because of neurological impairment, are particularly challenging. The best practice is to make use of observational clues and to trust the caregiver, who is usually quite familiar with the patient’s typical patterns of behaviors and vocalizations when facing regular day-to-day stresses. They are best able to point out when these patterns have changed or are inconsistent with other possible etiologies for the concerning changes. The parent of a severely cognitively impaired 15-year-old boy may be able to tell us, for instance, that a particular period of moaning, grunting, change in muscle tone or posture, or other behavior is not what is typical for him when he is merely hungry or has a cold. That being said, this population of pediatric patients still are often victims of untreated pain.
Pediatric pain management pearls
Compared to when I was an infant in the late 1970’s, the options for treating pain in children have only improved a little. There are few new pharmaceutical agents and there has been an expansion of adult approaches to pain into the pediatric sphere. These improvements, whether talking about the use of an old drug in a new way like methadone for pain in kids or transdermal fentanyl patches, are typically only used by experts like my wife. It is not even entirely clear that these newer approaches are better.
The bulk of the improvement in pediatric pain management, and again there is plenty of room for improvement, is that we somewhat more reliably treat kids who are in pain that would have suffered through it in the past. A physician doesn’t need to be an expert, and to be comfortable using every drug in the book, to be able to provide good care for most children with pain. The key for managing pediatric pain effectively is to become familiar with the use of just a few drugs, to not be afraid to use them when appropriate, to make use of non-pharmaceutical methods of pain control and to be consistent and systematic in our approach. Our goal should always be to control and prevent acute pain.
Decades ago, the World Health Organization (WHO) developed guidelines for treating pain and an analgesic ladder of pain management that has now been adjusted for use in pediatric patients. It entails a stepwise approach to pain based on the severity and response to any intervention. I’ll give you the quick and dirty version of the WHO guidelines:
     1.  Assess for pain, and severity of pain, regularly in injured or sick kids.
     2.  Use non-pharmaceutical methods like massage, play therapy, distraction techniques and cognitive psychotherapy in addition to drugs, especially with painful procedures like blood draws and abscess drainage if not sedated. (Please don’t get me started on acupuncture.)
     3.  With anything more than minor pain, schedule pain medication around the clock instead of waiting until they are hurting.
     4.  Use oral pain medications whenever possible and avoid uncomfortable intramuscular or rectal administration.
     5.  Anticipate and treat side effects.
     6.  Use non-analgesic medications when appropriate to treat neuropathic pain, anxiety, or swelling that might be adding to the perception of pain.
The 2-step pediatric analgesic ladder essentially amounts to using big drugs for big pain and little drugs for little pain, as my wife likes to say. We generally use non-opioid medications like acetaminophen and ibuprofen on step one (little pain) and opioids on step two (big pain) or when little pain doesn’t respond to the step one approach. Non-analgesic medications can be given on any step depending on the circumstances, and non-pharmaceutical measures should always be put into use.
I like the QUEST approach as a framework for a physician learning about pain management to build on:
Question the childUse a pain scaleEvaluate behaviorSecure parent involvementTake cause of pain into accountTake action and evaluate results
Comfortable children or: How you should learn to stop worrying (too much) and love morphine
No pharmaceutical intervention is risk free. But, as has been pointed out time and time again on SBM, the poison is typically in the dose. Dosed appropriately based on a child’s weight, and used appropriately based on science-based guidelines, opioid medications are extremely safe and effective in the treatment of pain in children of any age. They are just one piece of the puzzle, but unfortunately they are most often the missing piece.
First off, with rare exception, non-opioid medications like acetaminophen and ibuprofen should always be used for mild pain and in conjunction with opioids for more severe pain. They are safe when dosed right and very effective. For some causes of pain, ibuprofen is preferred over acetaminophen because of its anti-inflammatory properties. And because I’m a pediatrician, I’m compelled to mention that aspirin should never be given to a child less than 19 years of age unless directed to do so by a physician because of the association with Reye syndrome, a sometimes deadly encephalopathy that can injure multiple organs systems.
Now the good stuff. There are many options for using opioid medications and they can be given by the IV, oral, transmucosal (fentanyl lollypops), and transdermal (fentanyl patch) route. Generally IV morphine is the first-line opioid for severe pain, but hydromorphone (dilaudid) is also commonly used in kids, as is fentanyl, although it is used mostly when sedation is desired along with pain control during an invasive procedure. Children with moderate acute pain are typically given oral agents such as oxycodone or tramadol, at least they should be, but are often given combination products containing acetaminophen and codeine or hydrocodone (lortab). I’ll explain why this is not a good idea.
Historically combination drugs like acetaminophen and codeine, or acetaminophen and hydrocodone, have been given to people of all ages for moderate pain, often after surgical procedures for use at home while recovering. In the pediatric population, which is all I can really speak for, we have been trying to move away from their use, and especially the use of codeine, for years. Unfortunately it is still commonplace to see these drugs prescribed by non-pediatric surgeons and dentists, and I do still see them used by some pediatricians.
What’s the problem with these medications? Why should codeine in particular be wiped from the minds of anyone with the ability to prescribe it? Because the potential risks far outweigh the potential benefit. Here’s why.
In August of 2012 the FDA, which had been made aware of 3 pediatric deaths in children receiving standard doses of codeine for analgesia after having their tonsils and/or adenoids surgically removed, and one case of severe respiratory suppression, issued a warning. A few months later they issued a stronger “boxed warning” for inclusion on product labeling. Many pediatricians stopped using it and pediatric hospitals began removing it from their formularies in droves.
It shouldn’t have taken these deaths to get to this point though, because we have better options available. But codeine had developed a reputation as a good choice when a weak opioid was needed. People thought it was safer than just giving lower doses of what are commonly thought of as stronger drugs like oxycodone and morphine. It isn’t.
The way codeine provides analgesia is by its conversion to morphine in our bodies. The problem is that in some people, around 1-2%, this conversion is more robust than would be expected. In these hyper-metabolizers, the body doesn’t have to time to return to baseline before the next dose is given. So over multiple doses, this can lead to a stacking of adverse effects, primarily respiratory suppression and sedation, without an improvement in analgesia.
Another problem with codeine is that a larger percentage of the population doesn’t metabolize it much at all. They won’t stop breathing, assuming an appropriate dose is given, but they aren’t protected from the side effects. And they will get no analgesia except from the added acetaminophen if there is any. There are also a number of medications that interfere with the conversion to morphine, thus limiting its ability to provide pain relief. Remember this the next time a physician tries to prescribe codeine for you or your child for pain or cough, which it doesn’t work for either!
Why don’t we like combination pain medications that don’t include codeine? They aren’t a good option either in most situations, but it’s because of the acetaminophen, not the weak opioid. With combination products, we lose the ability to safely change dosing on the fly, such as taking two pills when the pain is worse instead of the prescribed single pill. In some circumstance, the acetaminophen can accumulate and lead to potentially-fatal toxicity. We also lose the ability to give acetaminophen if there is an associated fever. Finally, many people take OTC products that contain acetaminophen without even realizing it. Again, we have better options, so why take the risk in kids.
Speaking of risks
Naturally it isn’t all sunshine and daisies with opioids. There are risks and side effects. But when dosing is done with care and based on the child’s weight, the risk of serious adverse events is very low and far outweighed by the benefits. And when side effects are anticipated, they can almost always be managed safely and effectively when they arise. These include sedation, respiratory depression, constipation, nausea, urinary retention, itching, and rarely, repetitive involuntary twitching of some muscle groups. Tolerance to these effects tends to occur within a couple of days so most patients can get by with symptomatic treatment (medication for nausea or itching) but not with constipation. This is why it is a good idea for anyone on an opioid to also be on a stool softener.
Sometimes the side effects, like itching or nausea, or simply not tolerable to the patient. We will typically try a different opioid when this occurs, and in many cases that does the trick. Another drug to add to the list of opioids best forgotten is meperidine (demerol). Reasonable increases in the dose of most opioids in response to poorly controlled pain do not tend to lead to an increased risk of adverse effects if a patient is tolerating the drug. Meperidine is an exception because of unique products of its metabolization, which can lead to severe toxicity with dose increases. It’s a bad drug.
Pediatric pain misconceptions and some counterarguments
So what are the many barriers to effective management of pain, which includes the appropriate use of opioid medications? There are a lot of them unfortunately, and the patient, their caregivers, and the treating nurses and physicians can all fall prey to them. Patients may be reluctant to report their pain for fear of being labelled a drug seeker, concern over poorly-managed side effects, or because of social issues at home. What happens when mom needs to sell them to pay the light bill, or is taking them herself because she is addicted? The patient or caregiver may be afraid of the development of an addiction, or physical dependency on the medication.
Medical professionals may be afraid of harming their patient, or worried about the development of addiction or misuse. They may be concerned about prescribing controlled substances. Many physicians are uncomfortable with children nearing the end of life, and the possibility of contributing to their death by prescribing an opioid. The most common barrier is simply inadequate training in pain management and the lack of skills needed to assess pain in children however.
These barriers are, for the most part, understandable but unfounded. The key to removing them is education and developing a good approach to pain management. As stated above, severe side effects are uncommon when doses are appropriate and the others are generally able to be dealt with or subside after a few days. There is no difference between lower dosing of a stronger opioid and a weaker opioid when it comes to side effects. Dependence on opioids is rare as well. So is drug-seeking. Pediatric patients seeking a higher dose are considerably more likely to be doing so because of undertreatment or the development of tolerance than to be drug seeking. And the use of opioids in a patient that is receiving end-of-life care does not contribute to their death when used appropriately.
There are a number of misconceptions regarding pain in children that are not so understandable, but still should respond to education. Children do not always scream or cry when they are in pain. Sometimes they just shut down. This is where a thorough history and physical should come in very handy. If a 15-month-old who just had a hernia repair is clingy, or curled up with their eyes closed refusing to interact with anyone, they are likely in pain even if there are no tears. This is especially true after a lengthy period of undertreated pain. Think of it as learned helplessness.
Children who would be expected to have significant pain because of an injury, illness, or surgical procedure should be treated for pain. A common issue I have with nursing is when scheduled pain medications are not given because the child is asleep. A child who just had a broken femur screwed back together is sleeping because the pain management has thus far been effective. Waiting until they are awoken by pain is cruel. The point of scheduling pain medications rather than giving them as needed is to prevent pain, which is every bit as important as treating pain once it occurs. As my brilliant wife likes to say, PRN = Patient Receives Nothing.
Pain is never good for kids. There is never a benefit to pain, no lesson to be learned from it. Treating pain will not impair a physician’s ability to do a physical exam, it will only improve it. A common misconception that I’ve personally encountered a number of times, although not typically when a pediatric surgeon is involved, is that a child’s pain should not be treated if there is suspicion of a surgical process, typically appendicitis, until the surgeons arrive to assess them. This is cruel and simply untrue.
Conclusion
This discussion is far from comprehensive. Pain management in kids is complex and this just scratches the surface. There are even plenty of misconceptions about pediatric pain management that I left out so this wouldn’t drag on too much. But I believe that this is a good overview, perhaps more of a deep scratch or gouge into the surface of the thing that I hope will lead to better pain management should a reader find themselves in need of it for their own child or for the child of a friend or family member. If you don’t think that a child is being treated appropriately, speak up.
It can’t be said enough that the best way to approach pediatric pain is consistently and systematically. Pain is one of the few instances where kids and adults should be thought of as equivalent. We all feel pain, even premature infants, and we all deserve to be treated for it. There are adult patients with neurological impairment that are non-communicative just as there are in pediatrics. Both populations have psychiatric issues that increase the complexity of treatment. Both adult and pediatric practitioners must rely on caregiver report at times. The drugs used to manage acute pain are the same, though the doses sure are different, and we all can be helped with non-pharmaceutical interventions. Although an adult is perhaps less likely to respond to a bubble machine and a Dora the Explorer video in quite the same way as a young child.

Audio Therapy for Postoperative Pediatric Pain: Randomized Controlled Nonsense
Clay Jones on March 25, 2016
Link


In January of 2015, a study on “the effect of audio therapy to treat postoperative pain in children” performed at Lurie Children’s Hospital and published in Pediatric Surgery International made the media rounds. It was the typical story where numerous news outlets further exaggerated already exaggerated claims made in a university press release, in this case Northwestern University in Chicago. Some of the reporting was quite silly.
    • “New study explores healing power of Taylor Swift“
    • “Rude Boy singer can get you back to rude health in no time according to new studies“
    • “Listening to music and audio books is a viable alternative to medication for post-surgery pain in children“
The study authors, the chair of pediatric anesthesiology at the hospital and his daughter, a biomedical engineering student at Northwestern who is now a fourth year medical student at Johns Hopkins, make some reasonable points in the introduction. Fear of opioid-related side effects, in particular respiratory suppression, does often result in poorly managed postoperative pain in kids. And there isn’t great data on the safety and efficacy of non-opioid medications for this purpose.
What is non-pharmacological pain management?
They are also correct when they say that non-pharmacological approaches are an important aspect of treating pediatric pain. What are non-pharmacological therapies? Simply put, they are methods of managing pain that don’t involve a drug; rather they are an attempt to change how a patient thinks about or focuses on their pain.
Much of non-pharmacological pain management actually involves distraction and the reduction of the stress associated with pain or potentially painful procedures. This is where, at least in the emergency department and hospital setting, that Child Life services can be invaluable. The simple act of explaining to a patient what is about to happen in a developmentally appropriate way, for example, can work wonders in relieving anxiety that might exacerbate the perception of pain.
Anything that reduces the patient’s expectation of or distracts from their pain can help them to perceive it as less intense. Pain, as they say, is largely in the brain after all. This is why non-pharmacological methods such as biofeedback, massage, meditation, and cognitive behavioral therapy can lower subjective ratings of pain and even improve functionality. They aren’t magic, and they can’t take the place of appropriate medications for moderate to severe acute pain caused by tissue injury, but for other types of pain, particularly chronic pain, they can make a difference and in some cases reduce the amount of medications needed to achieve adequate control.
In the pediatric population, non-pharmacological approaches to pain do not need to be fancy, they just need to be a positive experience. Bubbles, toys that produce interesting (at least to a toddler) lights and sounds, and play are frequently employed to great effect. Music too. The authors of this study didn’t just pull that out of thin air. Music therapy is a well-established component of what we do. Some facilities have dedicated staff for it, while many just have Child Life and a guitar.
Which non-pharmacological method works best depends on the type of pain and the type of kid. Not every child responds to the same intervention. Some patients don’t respond at all. Pediatric nurses and Child Life specialists are usually adept at working these things out and for that I am extremely grateful.
As readers of Science-Based Medicine know all too well, the nonspecific benefit from placebo effects, which would include some of what I’ve just discussed, are commonly used as a foot in the door for abject nonsense. Acupuncture is the most well-recognized and accepted by people who should know better. But many hospitals and pediatric offices have also turned to forms quackery like homeopathy and reiki, among many others, in order to maximize non-pharmacological benefits at the expense of ethical patient care.
The authors of the study are again correct in pointing out that much of the data on non-pharmacological therapies has looked at its use for procedural pain. For example, blowing bubbles and singing a song with a toddler who is having blood drawn. The pain is generally mild to moderate and typically of short duration. Think getting an intramuscular shot of antibiotics for strep throat, or a few stitches. There hasn’t been much investigation into the use of these techniques after major surgeries, however. I know that they are often used in such circumstances, they just haven’t been studied all that much.
About the study
The “prospective, randomized and controlled study,” which ran from July to December of 2010, was approved by the hospital Institutional Review Board and funded by a Northwestern undergraduate research grant. Their focus was on the potential for music and audiobooks to reduce pain in children during the first two days after a major surgical procedure. The control that they chose was silence. Not simply the absence of the music or audio book, but silence using noise-cancelling headphones. The results will not surprise you, I promise.
They recruited children from between the ages of 6 and 18 years who were undergoing orthopedic, neurosurgical, urological, plastic, or general surgeries, excluding any hearing or cognitively impaired patients. Children with a history of long-term opioid use or chronic pain were also left out. Subjects were randomized into one of three groups: music, audio book, or silence. Kids in the music and audiobook groups were allowed to choose from a list of songs or books prior to their procedure.
Using the Faces Pain Scale-Revised (FPS-R), which consists of 6 facial patterns representing pain severity in increments of two from zero to ten, pain was evaluated prior to the subject listening to their chosen song or book, or enduring the silent treatment, and again after thirty minutes of the intervention. This was done twice during the first 48 postoperative hours by the chair of pediatric anesthesiology in that hospital. They looked at the difference between pain scores before and after the intervention as the primary outcome. Patients in all three groups received standard pain management, including patient controlled opioid analgesia, IV bolus opioid dosing, epidural, and non-opioid medications, as clinically indicated.
What did they discover and what does it all mean?
After a lengthy discussion of their statistical gymnastics (p-hacking?), what did their audio intervention amount to? I’ll allow the study authors the honors:
The most important finding of the current investigation was the reduction in post-surgical pain in children exposed to music or audiobooks compared to control after major surgery. The reduction in pain burden was one point (0–10 scale) over 1 h of total treatment that the audio therapy groups received compared to control. Our results suggest that audio therapy should be available to minimize post-surgical pain in children undergoing major surgeries.
A 1 point decrease in the subjective reporting of pain on a scale of 0-10 is clinically fairly meaningless. Can a child, or anyone for that matter, truly differentiate between a 10 and a 9 or a 2 from a 1. Of course not. That isn’t how measurement tools like the FPS-R are used in the real world. They are just one piece of the puzzle when we evaluate pain, and often not one that does much to move help solve it. A better approach would have been to look at more objective outcomes such as a decrease in opioid dosing required to achieve pain control, or time to achieve appropriate activity goals. And to make a causal claim based on such a small number of subjects (a total of 56 patients completed the study) just seems absurd.
Were you surprised by any of this? It hardly seems worthy of media coverage that an unblinded psychologically positive intervention reduced pain better than essentially torturing a child with sensory deprivation. No wonder the press had to render the study conclusions virtually unrecognizable (“alternative to medication for post-surgery pain”) and focus on the meaningless fact that among the available songs were tracks by Rihanna and Taylor Swift. Why didn’t any of the news reports claim that listening to James and the Giant Peach is the key to improved recovery after major surgery?
Although in the study conclusions as well as media reports, the “patient-preferred” aspect of this study was discussed as if it mattered, I’m not sure how they were able to make that conclusion. Both treatment groups were able to have some choice in what they listened to, but that was compared to silence rather than to a selection that the patient did not prefer. For all we know, rather than the music and audiobook helping to reduce pain perception, kids forced to sit in silence for half an hour just were more sensitive to pain. Maybe the utter silence increased anxiety and reduced the effectiveness of the pharmacological management of their pain.
The study authors call for audio therapy to be included in postoperative pain management guidelines. They claim it is effective, harmless, and cheap:
In contrast to opioid analgesics, the lack of side effects of audio therapy seems to pave a promising pathway for the implementation of this intervention for children undergoing major surgeries…Improvement in analgesic control after surgery has been associated with improvements in important economic outcomes in the adult population such as reduction of hospital length of stay or unanticipated hospital readmission after surgery.
But it is ridiculous to make such a comparison. Of course listening to music has fewer side effects than morphine and dilaudid. It also has a fraction of the analgesic potential in moderate to severe acute pain caused by tissue injury, such as during an invasive surgery or the reason for having surgery in the first place. And the improved analgesic control that they refer to has been shown to improve outcomes through implementing a systematic approach to pain management largely focused on appropriate use of opioid and non-opioid medications and physical therapy. Kanye and Harry Potter are unlikely to get kids home faster or keep them from bouncing back after a major surgery.
Conclusion: Music is not a substitute for medication
This study comes across like a vanity project set up by someone in a position of influence for his child. We already know that non-pharmacological interventions can help reduce the perception of pain in kids, and even have an entire profession that is trained to provide it in the hospital setting. And we’ve been providing it for postoperative pain well before this study. We don’t care whether a child is in pain from a brief procedure or a major surgical intervention. A child in pain is a child in pain.
The study is also severely limited in its ability to make causal claims. It is small, there was zero blinding, and the chair of pediatric anesthesiology did the data collection. This could have altered interactions between nursing and the subject. Parents, who play a huge role in how a child experiences pain, may also have been effected by the lack of blinding. That being said, the result of the study is entirely plausible. It is the conclusions of the authors and the media response that are off base.
Music and books are a wonderful distraction for some kids who are stressed or in pain. It is easy to offer as a non-pharmacological intervention in the clinic, emergency department, or hospital, and it is cheap. But don’t expect it to take the place of appropriately dosed opioids in kids who are recovering from major surgery. That would be cruel.

The Buzzy: Revolutionary Acute Pain Management or Simple Distraction…
Clay Jones on July 4, 2014
Link
I’ve written about the management of acute pain in children in the past, and unfortunately my feelings haven’t changed in the interim. Acute pain, particularly pain related to procedures such as venipuncture for blood sampling and intravenous access, and intramuscular administration of medications such as antibiotics and vaccines, is commonly undertreated, downplayed and even ignored altogether by medical professionals and even caregivers. So when I was made aware of a device being used in pediatric clinics and emergency departments (and even available for home use) with apparent success in preventing or reducing procedural pain in children, I was intrigued and more than a bit hopeful.
The device in question, known as the Buzzy, is touted by the manufacturer as an all-natural and seemingly miraculous device. I’ve put a few words/phrases in bold to highlight what I want to discuss later:
Invented by a pediatrician and pain researcher, Buzzy is a reusable breakthrough personal pain device that provides natural pain relief. Gate control is the basis for Buzzy, physiologically overwhelming the body’s pain nerves with benign cold (ice wings) and vibration (Buzzy’s body). Like a dentist jiggling a jaw or putting a burned finger under cool water, cold and vibration dull or eliminate sharp pain from shots, itching, or burning from medications. Independently verified research shows Buzzy works!
I was asked by my department to look into the effectiveness of the Buzzy, and to help decide if purchasing these devices and putting them into use in our clinics and emergency department was worthwhile. According to the product website, the Buzzy is already in wide use. And there are numerous testimonials provided by satisfied customers, even from some using the device for reasons unrelated to blood draws or shots such as itching or dental cleaning. It’s even won awards for its design.
Buzzy for Aches, Arthritis, and InjuriesBuzzy for Allergies and ItchingBuzzy for Botox, Dermatology and Cosmetic ProceduresBuzzy for InjectionsBuzzy for Lab Draws/PhlebotomyBuzzy for Vaccines
Funded by a 1.1M NIH SBIR grant, multiple studies show Buzzy® significantly decreases phlebotomy pain in adults and in children. Not only did Buzzy® significantly decrease pain by child and parent report, IV success increased three times on the first try! Healthcare professionals use Buzzy® for diabetes, dentistry, travel immunizations, fertility shots, finger testing, splinter removal, flu injections and more! Over 1200 hospitals and more than 36,000 users have adopted Buzzy®. Buzzy® was a 2011 Medical Design Excellence Awards recipient and Top 10 Innovative Technology Company in 2012.
Well, if it didn’t come across as a little too good to be true I probably wouldn’t be writing this post, would I? And while looking into this product, I found more than just well-intentioned excitement that outpaces the available evidence. My journey also led to the discovery of some nice examples of how information can be manipulated to sell a product.
What is the Buzzy and how is it used?
As seen in the accompanying picture, the Buzzy is designed to look like a bumblebee, which is admittedly cute. Its body vibrates vigorously when activated and its detachable wings are soft plastic pouches containing a freezable gel. The Buzzy functions primarily in two ways in order to maximize its ability to take advantage of the gate control theory of pain, according to the manufacturer. The cold gel numbs the area of needle insertion for 30-60 seconds; however, they recommend moving the device 3-5 cm proximal to the expected sharp pain to allow the vibration to “confuse the nerves and interrupt pain pathways to the brain.”
Claiming the same proposed mechanism of action, the product website gives information on a variety of indications where the Buzzy could be helpful in addition to just blood draws and intramuscular shots. They state that distracting pain fibers as they travel to the brain from the site of insult can help with itching, such as with eczema or when performing allergy testing, intraoral injections and cleaning at the dentist’s office, removing splinters from a finger, daily diabetes care, wound cleaning and insect bites and stings. A lack of reasonable supporting evidence doesn’t appear to be required before touting a benefit, as the following example from the page on use of the Buzzy for allergy testing shows.
Buzzy won’t stop sneezing, but he can be very helpful for kids itching from allergies or adults who don’t like shots. Since pain and itching pass on the same nerves, Buzzy can relieve eczema itching as well.
Rubbing and cold have long been effective to reduce itching. For eczema itching, put the ice wings under Buzzy’s elastic strap and rub Buzzy where the itching is. Buzzy can provide a few minutes of relief while you wait for creams or medications to kick in.
Followed by
N of 1 (Volunteer Miles, potentially biased son of Dr. Amy):Itching was relieved after 7 seconds when Buzzy was used with ice pack. Itching was relieved after 12 seconds when used with vibration alone. Buzzy was more effective when pressed in place at the top of the spine, but was not as effective when simply lying on the back as in the picture. After removing Buzzy, the itching returned after 17 seconds following the buzzy-plus-ice wing trials, and after 13 seconds following the vibration only trials.
That’s the evidence base for use of this device for itching. Aside from the fact that the above anecdote is worthless, did you pick up on the glaring potential confounding variable? Buzzy helps relieve eczema by rubbing the itching area of skin. I wonder if there would be a difference between using the Buzzy and say your own hand in this regard.
The manufacturers make many additional claims of potential benefit for the device, all of which are attributed to “unsolicited testimonials.” These include reducing pain with breastfeeding and dermatological procedures, in addition to pain from arthritis and musculoskeletal injuries, if you need a few more examples. I can’t help but start to think of the Buzzy as the “one true cure” for acute pain, which isn’t the complement it may sound like.
What is the gate control theory of pain?
The Buzzy is claimed to work primarily not by simple numbing of the skin with cold and distraction from pain, but by taking advantage of modulatory mechanisms. This gate control theory, first proposed in the 1960s, is widely accepted by neuroscientists and pain experts even if there is still some debate over the exact mechanism behind it. With gate control, a typically non-painful stimulus “closes the gates to painful input”, which reduces CNS awareness and dulls the sensation of pain.
The fine details aren’t entirely understood, but the accepted general thinking is that pain fibers in the peripheral nervous system exist in a state of inhibition until injury occurs. With tissue injury, a pain signal travels towards the spinal cord and ultimately to the brain, in the process inhibiting the inhibition from interneurons. When mechanoreceptors in the skin are stimulated, such as when you rub a sore elbow, the inhibitory interneurons are activated which decreases our sensation of pain.
Gate theory also helps to explain the development of chronic pain even after tissue injury has resolved. Modulation of pain fibers and altering our normal state of pain inhibition, perhaps in part with the prolonged use of opioid medications, can lead to the sensation of pain seemingly without a cause. Phantom limb pain as well as transcutaneous electrical nerve stimulation (TENS) are examples of the dueling nature of gate control theory.
Does the Buzzy work?
Before I get into the evidence base for this device, I wanted to dig a little deeper into its marketing.
Being invented by a pediatrician, even one who is a pain researcher, is an appeal to authority in the same vein as Airborne being invented by a teacher. Sure it is true that most pediatricians are very interested in reducing pain in their patient population, but typical pediatric training in no way establishes us as experts on the mechanisms of pain or on its treatment. In this case the inventor, Dr. Amy Baxter, is an accomplished physician who completed a residency in pediatrics and fellowships in child abuse and emergency medicine. She is involved in research, some of which is on the recognition and treatment of acute pain in an emergency department setting. As a pediatric emergency medicine practitioner she certainly sees more than her fair share of children in pain, but this, and her clinical research, don’t serve as evidence in support of the Buzzy’s efficacy.
According to a More magazine article on Dr. Baxter and her now million-dollar device, the idea for the Buzzy came when she noticed that her hands felt numb after driving a car with misaligned wheels and a vibrating steering column. Upon arriving home, and with the assistance of a bag of frozen peas, a black and yellow personal massage device and her son, she tested her hypothesis that the skin under and distal to an application of cold and vibration would be less sensitive to pain. Sure enough, her child’s skin was numb to a hard pinch and her creative husband even helped by decorating the massager like a bumblebee. It’s a cute story, it really is. An article written just a few months earlier included the same genesis story, although some of the details were different. That doesn’t mean the story was made up, but it is a good example of how our memories are often changed over time and with numerous recollections.
Dr. Baxter lists being a Scholar (delegate?) at the Washington, D.C. TEDMED conference in 2013 on her resume, which means that her registration application was accepted and she could pay the upwards of $5,000 to attend the for-profit organization’s yearly conference. TED is a non-profit organization by the way. They do offer a limited number of need-based partial scholarships, which is perhaps why she wrote scholar instead of simply delegate, but she was not invited to speak. Regardless, I imagine that this was a very meaningful networking experience and it looks great on a resume (too cynical?).
I did however come across a talk she gave at a TEDx event in Georgia in 2013. As readers likely already know, TEDx is not burdened with the same level of quality control as its parent organization TED. This, in my opinion, is a good example of that sad fact as her talk is essentially a commercial for her product. While I agree wholeheartedly with the call to take pediatric pain seriously, she makes a number of unproven assumptions while discussing the potential negative impact of poorly treated pediatric pain.
She educates the crowd on the significant increase in the number of childhood immunizations over the past few decades, which is true, but she blames this for a rise in “severe needle phobia”, which is controversial. It is unclear if more children are truly needle phobic, as she describes her own child as being, or whether the children being labeled as such are simply expressing normal avoidance behavior. Her message comes across as if prior to the Buzzy there were no means of effectively reducing procedural pain and anxiety related to shots, although again I admit that these proven techniques are too-often underutilized.
She goes on to equate the rise in needle phobia to decreasing vaccination rates. There is no evidence that I could find that pediatric needle phobia plays a significant role in vaccine hesitancy or refusal, and her logic is convoluted. She claims that fear of harm from vaccines, such as the development of autism, might just be a rationalization used by parents who really just don’t want their child to experience the pain of multiple shots. As if that’s not enough, she questions whether these needle-phobic children will grow up to become adults who avoid routine medical care and treatment, describing needle phobia as a “public health tsunami that is going to crush us.”
She absolutely comes across as a genuinely caring person and a supporter of vaccines, although she did slip in a comment supportive of spreading vaccines out. She didn’t go into any detail but there is no good evidence to support changing the recommended vaccine schedule and this would leave more children at risk of vaccine-preventable illnesses, even if only for a short time. I do agree with her that it would be great if we were able to administer more vaccines per shot (there are some combination vaccines available already). I do not get the impression that this was a calculated attempt to promote her product, but she sure didn’t mention any other method to reduce or prevent pain in kids.
Many of the posts at SBM have pointed out the fallacy of appealing to nature. This is the argument that a treatment is good simply because it is natural. Consequent to this is the implication, if not outright claim, that when something is unnatural or synthetic it is inherently bad.
Proponents of many unscientific modalities are quick to label drugs as dangerous products of heartless pharmaceutical companies while natural herbs, for one example, are beneficial creations with no associated risk. Chiropractic is natural. So are homeopathy and acupuncture for that matter. The Naturopaths even put it in their name. And companies too numerous to list have employed shady marketing strategies to take advantage of the appeal to nature. Probably the vast majority of these products have little to offer in the way of true efficacy.
Unfortunately reality doesn’t work like this. Nature has certainly given us a variety of medically useful chemical compounds, of which we’ve harvested much of the low hanging fruit. But it has also given us potent toxins, carcinogens and a seemingly endless supply of chemicals that are unsafe for consumption or therapeutic use. The Buzzy is touted as providing “natural pain relief.” So do “poppy tears” and biting on a leather strap. I’ll accept that using the device is safe, although the question has been raised of its potential impact on some test results (Dr. Baxter’s response, which I agree with), but does it work? And not only does it work, does it work better than already established methods?
To truly know if the Buzzy works, it would need to be studied in a controlled and blinded fashion. It would need to be studied in sufficiently large numbers of children as well. And we would need to take the prior plausibility of the claimed benefits into account.
Thankfully, the product website provides a comprehensive list of the available research on the Buzzy. Before we look at it, I’ll go ahead and say that I think that there is reasonable plausibility that the Buzzy would have a positive impact on the perception of mild to moderate episodes of acute pain. Whether by simple distraction or via gate control, I think it could help. And if proven effective, the question of whether it works better than cheaper, widely available methods would remain.
First off, their research page is confusing. It lists 8 items, numbered 1-5, 5, 5 and 5. Upon closer inspection, only five of the items are published papers in peer-reviewed journals. The additional three items consist of repeating one of the first five papers twice and one presentation at a trauma symposium of a small unblinded, uncontrolled and nonrandomized compilation of 100 emergency department patients. It showed that the Buzzy decreased pain compared to no pain control intervention.
Study #1 – Looked at use of the Buzzy AND local anesthetic for monthly penicillin injections in patients with rheumatic fever. It was unblinded and only half of the subjects responded to the survey. Patients who used both interventions reported less pain and fear than those who just got the anesthetic with their injection. Maybe the Buzzy helped or maybe it was simple distraction by a novel intervention or a host of other placebo effects.
Study #2 – This study involved 120 6-12 year old children. It was unblinded but randomized, with some using the Buzzy and others normal phlebotomy. Those using the Buzzy were rated as having less pain and anxiety by the staff and parents. Again, simple distraction could account for this difference. It can think of an easy way to test this. Just don’t turn the buzzy on in half the kids and don’t freeze the wings.
Study #3 – This study, done by the same researchers in #2, involved 120 6-12 year old children. It was unblinded but randomized, with some using distraction cards and others normal phlebotomy. Kids using distraction cards had less pain and anxiety than those not being distracted. I’m not sure why this was included as evidence that the Buzzy works as it supports use of distraction. The cards do not vibrate.
The lead author for the following two studies was Dr. Amy Baxter, the inventor of the Buzzy. That fact alone should not disqualify them but you should know that.
Study #4 – 81 children aged 4-18 years were randomized to either the Buzzy plus routine care (half got topical anesthetic and 9 got vapocoolant spray) or routine care alone, which involved placement of a topical anesthetic in about 50% and use of vapocoolant spray in all but 2, for IV placements and blood draws. It looked at self and parent assessment of pain (unblinded) and assessment of behavior on video by unblinded reviewers and showed that use of the Buzzy helped. But it wasn’t blinded and there was no placebo control. I honestly am surprised this paper was accepted considering it appears designed to be positive and serves as an advertisement for the product.
Study #5 – Older study and in adults. Unblinded. No placebo control. Only 30 subjects. Results not clinically significant.
The website lists ongoing trials involving the use of the Buzzy for influenza vaccination, dental pain and eyelid injections.
That’s it. There is no evidence provided for any of the numerous additional claimed on the website.
Conclusion
Appropriate management of pain in the pediatric population is important for a number of reasons, not the least of which being that it’s just cruel to let a child feel pain or suffer when it can be avoided or ameliorated. While I don’t agree with the more alarmist and hyperbolic concerns raised by the inventor of the Buzzy regarding poor prevention and treatment of pain in children, it is true that untreated pain does potentially lead to problems down the road. Untreated pain, whether it is in a neonate or an adult, can alter the way our bodies experience pain in the future. And it could lead to an impaired relationship between an individual child and the medical system, just not with such far-reaching implications as claimed by Dr. Baxter.
The Buzzy probably does have some utility. I’m not surprised at all that so many people, according to the manufacturers, are pleased with the results. Cold can desensitize the skin somewhat. And vibration might help via gate control of pain sensation. But the evidence provided doesn’t support a claim that this device works via that specific mechanism or any better than simple distraction techniques. If the Buzzy works via a mechanism other than distraction, it should have some benefit in populations where placebo effects, although still present, might have less influence on outcomes. Neonates for instance. While this study only looks at vibration alone for reducing neonatal heel stick pain, and suffers from similar limitations, it was interesting.
Many pediatric facilities employ a variety of distraction techniques that can be very effective. Some have at their disposal child life specialists who are experts in helping children get through painful procedures, in addition to many other very useful skills. The problem isn’t that what they do doesn’t make a difference. The problem is that many painful procedures involving children take place in facilities without child life specialists available. And in many of the more adult-oriented facilities, painful procedures are performed with no effort given to pain prevention and treatment. The notion that kids should just suck it up is unfortunately still alive and well.
The Buzzy might serve as an effective means of distraction, particularly in younger children (they recommend age 4 years and up), and it only costs about $40 per device, which is pretty cheap. And it is incredibly safe as far as medical interventions go. So if a parent wants to buy one for home use, I certainly wouldn’t have a problem with that. And I could see the benefit of a non-pediatric facility using these devices. They do appear to be better than nothing and having some around might help encourage staff to take mild to moderate procedural pain more seriously. But for pediatric facilities that already have available distraction resources, especially if there is a child life specialist available, and who already have a focus on proper pain management in kids, it is probably a waste of money.

Music for Reducing Pain in Newborns
Newborns are exposed to painful procedures for good reason every day. Treating pain is important in this population, and music might play a role. At least it definitely won’t hurt.
Clay Jones on February 16, 2024
Tweet

Music may have charms to soothe a savage breast*, to distract us from our everyday trials and tribulations and perhaps even numb our emotional distress, but can it reduce physical pain or our perception of it? Is that even a distinction that matters? I think that there is a great deal of plausibility, and some evidence behind claims that music might play a role in mild to moderate pain relief, mostly in adults. But is this apparent benefit a specific effect unique to how music alters human neurophysiology or simply a distraction?
Does the type of music matter? Would music that a patient enjoys work better as an analgesic than music that they find unpleasant or even offensive, perhaps because of physical properties of the sound, such as loudness, dissonance, discord, lyrical content, or even the listener’s feelings** about the source? I can imagine both a connection with music as well as a repulsion by it being factors that play a role in altering pain perception in the face of an acute exposure, with the latter achieving some kind of counterirritant effect.
But even this is complicated. It is difficult, if not impossible, to separate human response to pain from biopsychosocial “wellness”. Listening to music that irritates you could easily exacerbate pain, particularly chronic pain. It might make acute procedural pain worse too. Pain, as they say, is in the brain and numerous factors alter our perception of it in positive and negative ways. Adult patients have cognitive capabilities unavailable to young children that can be both a blessing and a hindrance, and young children have their own host of issues that can complicate the experience and management of pain. Few things are simple when it comes to this issue.
Does the auditory stimulus even need to be music? I think that the human brain is incredibly sensitive to patterns in our sensory input, and music can be a powerful tool in medicine, but could any noise that potentially distracts from a painful experience be helpful? A loud noise that forces a patient to pay attention to it at the same time that a needle is entering their arm just might work. And, to finally come around to the topic of today’s post, what about the potential for reducing pain in newborn patients, whose brains haven’t developed to the point where personal emotional attachments to music could possibly play a role?
We won’t find answers to all of these questions today. We may not find answers to any of these questions today. But we will at least explore the possibility of using music for pain relief in term newborns undergoing a minor procedure likely to cause brief pain, and distress that might last a bit longer, because that is what the authors of the study we’ll dig into looked at.
As a newborn hospitalist who has played a key role in subjecting thousands of young infants to painful procedures over the past 20+ years, I take pain in this population very seriously. Most people who are involved in the care of newborns do. Sadly, this wasn’t always the case.
Though infant pain was widely recognized historically, and attempts (for better or much, much worse) to treat it were commonplace, a belief that infants did not feel pain took hold in the 19th and early 20th centuries. This horrific false track in the care of infants resulted in even open heart surgeries being performed without any pain control into the 1980s. The development of a skepticism, or more accurately a cynical ignorance, of infant pain has numerous origins:
These experiments used pinprick and electric shock, and the results were generally interpreted as evidence of infants’ underdeveloped pain perception, attributed to their lack of brain maturation. Even clear responses to noxious stimuli were often dismissed as reflex responding. Later these experimental findings were used by anesthesiologists to support the lessened use of anesthesia for infants. Based on the reviewed literature, this paper suggests that 4 interrelated causes contributed to the denial of infant pain: the Darwinian view of the child as a lower being, extreme experimental caution, the mechanistic behaviorist perspective, and an increasing emphasis on brain and nervous system development.
https://www.jpain.org/article/S1526-5900%2813%2900025-4/fulltext
It is now beyond any reasonable doubt that newborns experience pain. The newborn’s developing nervous system may even result in an increased sensitivity to pain on average than older children and adults. Pain perception is extremely subjective, however, and any individual response is highly complex and influenced by countless physical and psychological factors. Newborns don’t worry about the future, but they have distress without context, an evolutionary hardwired discomfort when hurt or removed from reassuring care that results in behaviors aimed at reestablishing that care. But it isn’t a competition. Let’s just try to manage pain appropriately in everybody.
It has become increasingly clear that untreated acute and chronic pain during the newborn period can result in immediate adverse physiological changes. There is also growing concern regarding future repercussions. In some cases, for example, pain during the newborn period might increase sensitivity to pain during later childhood and even into the adult years.
It is important to treat pain in all children, but again we will focus more on the newborn population in this post. Even healthy term infants undergo procedures that can cause acute pain. Every child born in the United States, and most other countries as well, has a few drops of blood sent for analysis designed to catch a variety of diseases as early as possible in order to improve outcomes. The newborn screening program began in Massachusetts in the early 1960s with testing for phenylketonuria, or PKU. Each state decides which diseases to screen for, though there is significant overlap, and Massachusetts now uses those drops of blood to screen for more than 30.
We obtain blood for the newborn screen with a heel stick. This involves a poke through the skin on the side of the heel using a lancet, and then milking the heel with repetitive pressure along the foot in order to collect enough blood to saturate four marked circles on the newborn screen card that will be sent to the state lab for analysis. Though I have definitely seen infants sleep through a heel stick, without some kind of pain control intervention they will typically have a startle reaction with an immediate cry that is sustained until they are consoled.
As with an older child or adult who is stuck with a needle and able to communicate their experience, newborns absolutely feel sudden but brief pain during a heel stick. They then experience distress as a result, though it is from reflexive neural functioning rather than an emotional response such as fear or anxiety, which doesn’t mean it should be discounted. This video demonstrates proper technique for the procedure as well as how failure to consider infant pain can result in obvious discomfort.
When it comes to pain control for brief procedures like a heel stick, the focus has largely been on non-pharmaceutical interventions. This can involve the use of a pacifier, a snug swaddle, or being held tight by a caregiver. A baby can even nurse or take a bottle during the procedure. One very effective approach to procedure pain in newborns involves the use of sucrose, typically given as a few drops on the pacifier or directly into the infant’s mouth. We don’t know with certainty how sucrose reduces the pain response in infants, but most experts will say “Something, something, something, endogenous opioids.”
But what about music? Could music be used to reduce pain in newborns undergoing a heel stick or similar procedure associated with a needle poke such as venipuncture or an intramuscular injection? Could it be a helpful adjunct to sucrose? In a study published last year in Pediatric Research, the official publication of the American Pediatric Society, the European Society for Pediatric Research, and the Society for Pediatric Research, researchers set out to “assess the effectiveness of recorded music in a meticulously controlled setting as an adjuvant to the standard of care oral sucrose to relieve acute pain in term newborns undergoing heel pricks in a community hospital newborn nursery.”
In the study, 100 healthy term newborns undergoing a heel stick were randomized to a music exposure or control group. Both also received .5 cc of 24% sucrose 2 minutes prior to the procedure but the treatment group was exposed to recorded music from 20 minutes before the procedure until 5 minutes after completion. The music used in the treatment group was an instrumental lullaby, “Deep Sleep”, from an album named Bedtime Mozart: Classical Lullabies for Babies***.
As you can probably imagine, determining the amount of pain experienced by a newborn is not easy. It certainly isn’t objective, although we have certain tools that attempt to achieve that fantasy. Obviously we can’t ask a baby to give a numerical pain assessment or to point at the face on a chart with the pained expression that best matches their feelings. An outside observer must observe baby behavior and convert what they see to a score.
In this study, trained assessors used the neonatal infant pain scale (NIPS) to evaluate facial expression, crying, breathing patterns, limb movements, and arousal. In general, NIPS scores have good interrater reliability and internal consistency, but it is still a subjective assessment that could easily be influenced by bias, such as in a study where the person assessing an infants pain knew if they were in the treatment group. It also does not include an physiological input, such as heart rate, blood pressure, or specific respiratory rate parameters, because it was designed for ease of widespread use.
This is the breakdown of NIPS scoring:
Facial expression	0	Relaxed
	1	Grimace
Cry	0	No cry
	1	Whimper (mild moaning or intermittent)
	2	Vigorous crying or silent cry (based on facial movements if intubated)
Breathing pattern	0	Relaxed
	1	Change in breathing (irregular, increased, gagging, breath holding)
Arms	0	Relaxed
	1	Flexed/extended (tense straight arms, rigid and/or rapid extension)
Legs	0	Relaxed
	1	Flexed/extended (tense straight legs, rigid and/or rapid extension)
State of arousal	0	Sleeping/awake (quiet, peaceful, settled)
	1	Fussy (alert, restless, and thrashing)
NIPS score interpretation	0–1: no pain; 2: mild pain; 3–4: moderate pain; 5–7: severe pain
As you can see, there are several opportunities in scoring a baby that could swing to a 0 or 1 because of unconscious bias, or even unfamiliarity with normal baby behaviors. I am very personally very familiar with the use of such scoring systems, particularly for assessing the degree of potential withdrawal after prenatal exposure to opioid medications, and I have lost count of how often a score changes meaningfully depending on who is doing the unblinded assessment. I’m not arguing that use of such tools are worthless, you just need to understand their limitations.
In this particular study, blinding was attempted. I’m not confident that it was always successful, but I have no definitive evidence to the contrary. Each baby, regardless of whether or not they were exposed to music, had smartphone speakers placed near their head. The pain assessor would enter the room wearing active noise-cancelling headphones that were also playing a random song. The nurse caring for the baby, and who would be charged with performing the heel stick, was not blinded in any fashion.
Noise cancelling headphones are not magic. They generally reduce incoming decibels, most effectively from lower frequency sounds, by up to 30 decibels. They are less effective with midrange and high frequency sounds. Classical music is generally going to be in the midrange of frequencies. The study actually did track the decibel level of the music that babies in the treatment group were exposed to, with a goal of keeping it below 45 decibels but allowing max transient volume of up to 60 decibels, which is at the level of normal conversation. So the noise cancelling headphones alone would likely not completely block out the music and preserve blinding.
Playing music through the noise-cancelling headphones would definitely decrease the likelihood of hearing the lullaby played for half (roughly) the babies in the study, but I’m still not confident that blinding wasn’t compromised in some cases. The nurse caring for the babies being unblinded is a weakness. They easily could have provided unintentional clues to the pain assessor. They also might have interacted differently with babies depending on what group they were in. Finally, wearing headphones that cancel noise and that are playing loud music themselves might interfere with the ability to properly score a baby on the NIPS, though that would apply to all babies equally.
Babies in the study were not allowed to have a pacifier during the heel sticks, which is unfortunate. The authors state that this was in order to reduce other sensory inputs and assess the pure effect of music, but I’m skeptical of the rationale. Infants were also not allowed to be cuddled by caregivers during the study period. So essentially these babies were denied proven pain reduction interventions in order to see if an unproven intervention works, and I’m left quite curious as to the wording of the parental consent form.
NIPS scores were documented 5 minutes before each heel stick, at the time of the heel stick, and at 1 minute intervals for 5 minutes after completion. Their primary outcome measure was the NIPS score 5 minutes after the heel stick, and they considered a reduction of 3 points to be clinically meaningful, which I think is quite reasonable.
When the dust settled, mean and median NIPS scores were found to be lower in the treatment group at all time intervals except for 3 minutes after the heel stick. That’s odd and the authors had no explanation. I would chalk it up to random noise. It is also odd that babies who were in the treatment group had lower NIPS scores at baseline 5 minutes prior to the heel stick, with control group babies being found to have mild pain (average score between 2 and 3). The authors chalk it up to the early exposure to the lullaby, but that is an answer to the wrong question.
Why were babies who were not listening to music in pain? Even if it’s only “mild pain”, why would these healthy term infants who per the guidelines of the study had not had any previous painful procedures performed on them not also have a score of 0-1? The answer is, of course, because these pain scoring systems are imperfect. And, perhaps, the pain assessor had an inkling as to which babies were in the treatment group and which weren’t. It certainly call into question any results moving forward.
The difference between median NIPS scores, as opposed to mean scores, was determined to be statistically significant at the time of the heel stick and at each minute (except for the 3rd) through 5 minutes after the painful procedure. They claim that there was a clinically meaningful difference at each check (again, except for minute 3 for some reason), but I’m not so sure. It definitely at least appears that way at minute 0 and 1, but I think for most babies at minutes 3-5 that likely wasn’t the case.
There are others potential problems with the study methodology, and the authors discuss them to their credit. They did not account for when each baby had most recently been fed or snuggled by a caregiver. Being fed just prior to being taken for a quick but painful procedure, for example, could absolutely alter a babies reactivity. They also admit that measuring objective physiologic responses to the heel stick, such as heart rate, would have been helpful in better assessing infant pain. Finally, they acknowledge that recording babies during the study period and having multiple pain assessors watch muted videos to determine pain scores would have reduced the potential for bias.
Conclusion: Don’t Throw the Mozart Out With the Questionable Methodology
I don’t think that this study proves that exposing newborns to music reduces their pain or distress. It might. It might also improve the mood of caregivers, which is a good outcome as well. And there is no obvious downside to music for babies at any point, provided it isn’t too loud and that it isn’t used (ever again) in place of interventions that are proven safe and effective.
This study absolutely shouldn’t be used to support claims of a specific effect from a specific composer or even genre of music. I would recommend choosing something that the people caring for the baby enjoy. Well, I would actually recommend “Folk Song” by The Sundays. But that’s just me, and only if you want to have a cool baby that has great taste in music.
*Yes, I used that correctly. In the original 1697 tragedy The Mourning Bride by playwright William Congreve, a grieving Almeria opens the play with the oft misquoted line: “”Music hath charms to soothe the savage breast. To soften rocks, or bend the knotted oak.”
**Would a Taylor Swift song relieve or worsen the pain felt by someone having a boil lanced who believes that she is part of a deep state operation attempting to keep Trump from winning a second term in the White House?
***Because the album has the name Mozart attached to it, and there is a history of nonsense associated with that name and infant development, the news reports of the study heavily focused on it. The authors of the study even issued a correction with an updated version clarifying that the music on the album was not necessarily composed by Mozart and that they make no claims of specif benefits from a particular composer. They don’t even claim that only music is potentially beneficial, proposing that using a recording of a parent’s voice might be equally effective.

Efforts to Encourage Breastfeeding Like the Baby-Friendly Hospital Initiative (BFHI) May Have Unintended Consequences
Harriet Hall on August 30, 2016
Link


“Breast is best,” but current efforts to increase the rate of breastfeeding may be misguided. A recent article in JAMA Pediatrics by pediatricians Joel Bass, Tina Gartley, and Ronald Kleinman is titled “Unintended Consequences of Current Breastfeeding Initiatives.” They criticize the Baby-Friendly Hospital Initiative (BFHI), saying “there is now emerging evidence that full compliance…may inadvertently be promoting potentially hazardous practices and/or having counterproductive outcomes.”
The BFHI
The Baby-Friendly Hospital Initiative was launched by WHO and UNICEF in 1991 and has been adopted in 152 countries. In the US it has been promoted as the standard of care by government agencies like the CDC and the Joint Commission, and has been implemented by a growing number of hospitals. The criteria for a hospital’s Baby Friendly accreditation include:
     1.  Have a written breastfeeding policy that is routinely communicated to all health care staff.
     2.  Train all health care staff in skills necessary to implement this policy.
     3.  Inform all pregnant women about the benefits and management of breastfeeding.
     4.  Help mothers initiate breastfeeding within one half-hour of birth.
     5.  Show mothers how to breastfeed and maintain lactation, even if they should be separated from their infants.
     6.  Give newborn infants no food or drink other than breastmilk, not even sips of water, unless medically indicated.
     7.  Practice rooming in – that is, allow mothers and infants to remain together 24 hours a day.
     8.  Encourage breastfeeding on demand.
     9.  Give no artificial teats or pacifiers (also called dummies or soothers) to breastfeeding infants
     10.  Foster the establishment of breastfeeding support groups and refer mothers to them on discharge from the hospital or clinic.
In addition, the program restricts hospitals from using free formula donated by formula companies and recommends that when formula is medically needed, it should be given in a small cup or spoon, rather than a bottle and should only be used to supplement breastfeeding.
That all sounds good. What could possibly go wrong?
Apparently a lot of things could go wrong. Bass et al. expressed a number of concerns.
Sudden unexpected postnatal collapse
In order to initiate breastfeeding in the first half hour of life, the guidelines state that “all mothers should have continuous skin-to-skin contact with their baby immediately after birth until completion of the first feeding and that skin-to-skin contact should also be encouraged throughout the hospital stay.” Last February our own Clay Jones wrote about the unfortunate association between prolonged maternal skin-to-skin contact (SSC) as commonly practiced in newborn nurseries in the United States and the potentially devastating outcome of sudden unexpected postnatal collapse (SUPC). These babies suddenly stop breathing; half of them die and many of the rest become disabled.
SUPC is admittedly rare, but its true incidence may have been underestimated; it might even be one of the most common causes of death in healthy newborns. In most places, SUPC is not tracked as a unique entity. Bass et al. reviewed data on all categories of sudden unexplained deaths among newborns in Massachusetts. Sudden infant death syndrome (SIDS) is thought to be uncommon in the first month of life, so they didn’t expect to find many cases, but they found that 14% of SIDS cases occurred during the first 28 days of life. 22.2% of the cases categorized as newborn SIDS and 35.1% of the newborn deaths categorized as “sudden unexplained deaths” occurred in the first 5 days of life. This is consistent with higher estimates of SUPC risk from Europe and suggests that there are cases of SUPC that are not being counted, and that the American Academy of Pediatrics report may have underestimated the risk.
A study in Sweden found that the majority of cases of SUPC were associated with prone positioning during skin-to-skin contact and initial unsupervised attempts at breastfeeding. Hospitals should not leave these patients unattended, but in practice they often do. The mother is often left alone to “rest” and may fall asleep from post-partum exhaustion. Infants should either be monitored or kept under direct observation by medical personnel.
Rooming in and breastfeeding exclusivity
When rigidly enforced, rooming-in policies may result in an exhausted or sedated mother attempting to feed her infant in bed overnight when she is not able to do so safely. Risks include prone positioning, suffocation from co-sleeping on a soft surface, and the possibility of the newborn falling out of bed. There is evidence that formula supplementation for medical indications has no adverse effects on the duration of breastfeeding.
Pacifier use
There is strong evidence that pacifiers reduce the risk of sudden infant death syndrome (SIDS). The authors feel that “the recommendation to proscribe the use of pacifiers is difficult to defend based on risk.”
The authors’ recommendations
Bass et al. conclude by pointing out the 2011 Surgeon General call to action to make all hospitals in the United States meet Baby-Friendly Hospital Initiative requirements. They think that call to action needs to be rethought, and they propose a better way to focus our resources in order to support both breastfeeding and newborn safety. Instead of focusing on the monitoring of Baby-Friendly practices and breastfeeding exclusivity, we should emphasize breastfeeding initiation rates and lactation support during and after the newborn hospitalization. We should also focus on compliance with safe sleep recommendations and work on ways to educate families so that breastfeeding and SIDS risk reduction go hand in hand.
A rebuttal
Joan Younger Meek and Lawrence Noble have published a rebuttal in JAMA Pediatrics titled “Implementation of the Ten Steps to Successful Breastfeeding Saves Lives.” It essentially reads like an ad for BFHI. They stress the health benefits of breastfeeding and report that the BFHI increases exclusive breastfeeding by 49%. They stress the benefits of skin-to-skin contact and argue that the risk of SUPC can be reduced by measures implemented by hospital staff. They downplay the risk of SUPC as “rare;” but surely even rare cases are tragic, especially if they are preventable. While acknowledging that pacifiers reduce the risk of sudden death, they show evidence that pacifiers are associated with shortened duration of breastfeeding.
In reality, the original article and the rebuttal are not so far apart. They both support most of the measures of the BFHI and both recommend taking precautions to improve safety. I wonder if both sides might be willing to meet in the middle and adopt policies that would reduce the risks without interfering with breastfeeding success, policies like better monitoring during skin-to-skin contact, less emphasis on continuous skin-to-skin, allowing fatigued mothers to send the baby to the nursery part-time if they feel they need to do so to get adequate rest, and allowing judicious use of pacifiers.
Has breastfeeding been oversold?
Breastfeeding is better than bottle-feeding but it’s not that much better. We have addressed this subject repeatedly on Science-Based Medicine. When I reviewed the evidence for breastfeeding six years ago I concluded, “Breastfeeding is clearly better for babies…but I think the facts leave us room to support those women who make an informed choice not to breastfeed.” Studies showing health benefits for infants have recently been criticized for failing to rule out confounders like socioeconomic status. And when obstetrician Amy Tuteur examined five long-term outcomes, she found that the existing scientific evidence shows that breastfeeding has either no benefit or a small benefit for those outcomes.
While breastfeeding is “better” in general, there are different degrees of “better” in different populations, for instance in areas where the water used to mix formula may be contaminated. There may be individual cases where formula is better and where judicious supplementation with formula is better than exclusive breastfeeding. Much of the benefit of breastfeeding in the US appears to come from the environment that surrounds the child rather than from the content of breast milk.
Conclusion: We should think again about the BFHI
The BFHI seemed like a good idea at the time, but evidence-based concerns have been raised and draconian implementation of BFHI policies may be harmful. Hospitals have achieved a greater than 90% breastfeeding initiation rate while allowing pacifiers and allowing mothers to put their babies in the nursery part-time. Most doctors agree that bottle-feeding is also a healthy option and that women who are unable to breastfeed for medical reasons or who decide not to breastfeed for personal or practical reasons should be supported and not made to feel guilty. A growing number of women are speaking out about how badly treated they felt at BFHI-certified facilities.

A Nice Chat with The Infant Feeding Alliance on Breastfeeding Promotion Pitfalls
Last week I had the pleasure of sitting down with Ruth Harpur from the Infant Feeding Alliance for a nice chat about problems with aggressive breastfeeding promotion.
Clay Jones on September 29, 2023
Link

As a newborn hospitalist, I often find myself talking about feeding. In fact, this is the issue that takes up by far the greatest amount of my time when speaking with new parents, and the discussion surrounding the seemingly simple concept of feeding a baby is, in unfortunate reality, rendered extremely complex by a number of societal forces. There is a veritable minefield of misinformation and propaganda to navigate each and every time I meet a mother and ask how they are planning to feed their baby.
Mothers are generally bombarded with societal pressure to breastfeed their babies, often at the expense of their physical and mental well-being and in a way that infantilizes them. The only reason a mother would choose to feed their baby formula rather than breast milk, it is assumed, is ignorance and a lack of enough support. This is not to say that there is no benefit from education and lactation support for some women, but a heavy handed approach is less than ideal.
Most mothers who choose to breastfeed make it through the process okay, and this has resulted in a large degree of societal survivorship bias. A lot of mothers don’t do well, however. Many struggle through periods of poor sleep, physical and emotional discomfort, and economic challenges. Being sleep deprived for long periods of time has numerous known health consequences, from car accidents and dropping babies during feeding attempts to post partum depression and even suicide.
I often refer to the 3 Fs of maternal guilt: Friends, Family, and Facebook. The amount of pressure that many mothers face is undeserved, not based on good science, and thoroughly unhelpful. I lost count long ago of how many mothers I’ve met over the years who were experiencing extreme feelings of guilt over their decision to not breastfeed or even to thoughtfully supplement a baby with formula and it breaks my heart.
Not all babies make it through the early days of breastfeeding without problems, some of which are even life threatening. Severe dehydration accompanied by an elevation in serum sodium levels can be dangerous. Readmission to a hospital for treatment of severe jaundice to prevent permanent brain damage is often associated with breastfeeding difficulty as well. And, as I mentioned earlier, some babies are dropped or suffer sudden unexpected postnatal collapse, which can result in neurological injury or death, during prolonged skin-to-skin promoted aggressively by many in the lactivist communities.
Breastfeeding can be, and often is, a wonderful experience. There are some potential benefits demonstrated at the population level, although in my opinion the data mostly reveals that the environment surrounding a breastfed baby is more meaningful than the breastfeeding itself. And when I’m speaking with an individual mother, I can’t in good faith say that her child will be one of the small percentage of infants who will benefit in any specific way if breastfed exclusively. Discussions with individual mothers should be supportive, nuanced, and honest.
Last week I sat down for an interview with Ruth Ann Harpur from the Infant Feeding Alliance, a group of parents and advocates in the United Kingdom that are focused on countering bad information found online or even spread by healthcare professionals, and on broadening the conversation to include voices that are critical of the current mainstream approach to feeding young infants. They have the ultimate goal of ensuring that compassion, autonomy, and safety are emphasized when counseling individuals and when developing policies that effect large numbers of families:
WE WANT COMPASSION
    • Ensure antenatal education reflects the full range of families’ experiences and encourages parents to approach infant feeding with self-kindness.
    • Make the mental and physical health of all family members a key consideration when providing infant feeding support and information.
    • Show respect for all families by having positive representations of all safe feeding methods on public display and offer inclusive and comprehensive support for all families.
WE WANT AUTONOMY
    • Empower us to make our own informed decisions by giving a balanced perspective on the health effects of different feeding options. This should use the full range of high-quality scientific evidence and acknowledge uncertainties in the field. We want to see accurate statistics and clear representations about the benefits and risks of each feeding method.
    • Give us information about what options are available to help address feeding problems, along with the strength of the evidence behind them. We can then decide whether to accept help, continue with the current feeding method or change course.
    • Recognise the ways in which infant feeding decisions interplay with other aspects of family life, such as sharing parenting responsibilities, work, sleep and looking after older children. Our right to make decisions according to our own needs and values must be respected. 
WE WANT SAFETY
    • Make it the priority to prevent newborn babies suffering unnecessarily from low blood sugar, jaundice, dehydration, excessive weight loss, faltering growth and other feeding complications.
    • Ensure that information about sterilising equipment and milk preparation and storage is easily available to parents and included in antenatal education.
    • Recognise the risks of maternal sleep deprivation for a woman’s mental health, as well as for the safety of her children. Adequate maternal sleep should be a key consideration in all infant feeding support.
During the interview, we discuss a variety of issues surrounding breastfeeding promotion. In particular, we talk a lot about so-called Baby Friendly Hospital Initiative, which in reality aren’t always very friendly to babies or their families. We also talk about ways to communicate with mothers who are trying to make a personal decision about how to feed their child. Please check it out and let us know what you think.

CDC Warns Against Honey Pacifier Use After 4 Texas Infants Develop Botulism
Experts are warning caregivers and healthcare professionals about pacifiers filled with raw honey after four infants in Texas were diagnosed with botulism. They are probably right. And you should probably listen.
Clay Jones on November 30, 2018
Link


Earlier this month, the Texas Department of State Health Services issued a health alert after four infants were diagnosed with botulism since August. The cases were believed to be linked to the use of infant pacifiers containing raw honey. Botulism, which I’ll discuss in more detail shortly, is a potentially life-threatening condition and a bad way to go. Thankfully there were no deaths among the Texas cases thought to be related to the tainted pacifiers, which are widely available in Mexico and for purchase online.
Honey pacifiers are not a new phenomenon. Their use is fairly common in Mexico, as is simply giving infants raw honey. During my three years as a newborn hospitalist in Houston, where I primarily worked at a county hospital almost exclusively caring for babies born to mothers from Mexico, I frequently confiscated pacifiers filled with honey, and sometimes corn syrup. They often were sticky because of seepage or because they were additionally dipped in honey. This 2013 study of families seen at a county clinic in Houston is consistent with my experience, finding that about 10% of families offered honey pacifiers to their infants.
Offering honey, or honey pacifiers, to infants is a traditional intervention felt by many Mexican parents to be preferred by infants. Belief in medical benefits also appears to be common, such as reduced crying and less constipation. The Houston survey also revealed that roughly 80% of responding caregivers were not aware of the risk of botulism associated with raw honey exposure in babies.
The Texas cases and subsequent alert were heavily featured by news media, which actually did a decent job for a change. They didn’t, as far as I could find, feature any proponents of infant honey consumption for “balance”. These people do exist and they are as awful as you would expect. The FDA has also weighed in, as has the American Academy of Pediatrics.
Concerns regarding infant exposure to raw honey are not new. In fact, pediatric healthcare professionals have been warning caregivers ever since the first cases of infant botulism were reported in 1976. Unfortunately, widespread educational campaigns have not been very successful in reducing the incidence of this condition. This is because the actual risk from honey is probably low compared to exposure from other environmental sources, such as from ingestion of soil or dust containing the causative bacterial spores. Still, it isn’t a risk worth taking.
What is infant botulism anyway?
Botulism is a toxin-mediated neuroparalytic syndrome caused by infection with the bacterium Clostridium botulinum. And though the condition has been known for almost 200 years, being first identified in southern Germany during a cluster of “sausage poisoning” cases in the 1820s, the causative organism wasn’t isolated until many years later. That discovery occurred during a cluster of cases in Belgium that were linked to some bad ham.
The name “botulinum” was based on the Latin word for sausage, which shouldn’t come as a surprise given the historical association with digging on swine. But the bacteria’s hardy spore form is fairly ubiquitous in soil and marine sediment worldwide. Because of this they are often found on the surface of fruits, vegetables, and various foods of the sea. They are also found in raw honey, although I’m pretty sure you’ve put that together by now. Spores are also frequently dispersed into the air by digging and construction work.
When exposed to the right environment, such as the infant gut or a deep wound, the combination of low oxygen, low acidity, and an ideal temperature range allows these spores to germinate. The resulting bacteria can then begin to multiply and, as the numbers increase, produce the deadly toxin. And I do mean deadly. Botulinum toxin, the same stuff that Jenny McCarthy believes is safer than vaccines, is the most potent poison known, with a lethal dose in experimental mice of 0.003 micrograms per kilogram. That works out to roughly a gram of toxin being capable of killing over a million non-experimental humans.
How does botulinum toxin affect the body?
Botulinum toxin prevents the neurotransmitter acetylcholine from being released by axons which terminate at the junction between the nerve and the muscle it innervates, resulting in paralysis. The more neurons that are involved, the more severe the weakness. This process can also inhibit release of other important neurotransmitters like dopamine, serotonin, and GABA, and the clinical presentation of botulism can vary considerably.
The classic form initially starts with abnormal function of one or more cranial nerves, often resulting in blurred or double vision, difficulty speaking or swallowing, or facial weakness. This is soon followed by a symmetric weakness that descends from the head and neck down to the lower extremities, often causing difficulty urinating and constipation. Though the severity of the muscle weakness is variable, many patients become too weak to generate enough force to breathe and require mechanical ventilation to survive. The toxin does not alter a patient’s mental status, so they are awake and fully aware of their dire situation.
The bacteria that causes botulism can enter the body in different ways, and this can alter a patient’s symptoms somewhat. For example, consuming contaminated home-canned foods tend to result in more substantial gastrointestinal symptoms such as vomiting and abdominal pain prior to the onset of the classic features described above. Infant botulism has some of its own unique signs and symptoms.
What is infant botulism?
Infant botulism is by far the most common form of botulism diagnosed in the United States every year, with about 3 out of every 4 cases being diagnosed in babies under the age of 12 months. This comes out to roughly 150 cases per year. Infant botulism has been diagnosed on every continent, but the distribution is very uneven. This is likely because of a lack of resources and of mandated reporting.
Although the risk exists throughout the first year of life, most cases occur during the first few months. Young infants are at increased risk because the so-called “good bacteria” and other organisms that make up the intestinal microbiome have yet to fully coat the lining of the gut. This gives certain pathogenic bacteria a better chance of establishing a foothold. An infant’s smaller size also likely plays a role.
Because of differences in prevalence of toxin producing strains of Clostridium species, most cases occur in Western states, particularly California, but Utah and Pennsylvania (higher prevalence of a different strain associated with botulism) also see more than their fair share. Finally, most cases in the United States result from the ingestion of spores found in soil and dust rather than honey.
As with classic botulism, the infant form also typically involves cranial neuropathy followed by a descending weakness/paralysis. Unlike in adult cases, caregivers are most likely to bring their baby in with concerns of constipation and poor feeding prior to the development of floppy muscles. Infants are also more likely than adults to progress quickly to respiratory failure and about 50% of cases ultimately involve a need for mechanical ventilation. Some infants have only a brief period of poor feeding before suffering severe and rapid deterioration.
Infant botulism, as with other forms, used to have a very high mortality rate but is generally a self-limited condition. The nerves will eventually regenerate working connections to the muscle if enough time is allowed by not dying. With supportive modern medical interventions, infant botulism survival did improve significantly, but prior to the development of a safe and effective therapy it often meant months of hospitalization and several weeks on a ventilator. With appropriate dosing of botulinum antitoxin, however, the average total time in the hospital is down to less than 3 weeks.
Conclusion: Put down the honey pacifier
Infant botulism is a rare condition, and most cases are not caused by the ingestion of honey. But honey is not risk free and there is no benefit to potentially leaky honey pacifiers compared to the safer versions. So a rational assessment of risk versus benefit yields a clear answer: put down the honey pacifier.
Again, infant botulism is a rare condition. So excessive parental worry is definitely not my desired outcome. I don’t want parents of constipated infants demanding testing for the presence of botulinum toxin or Clostridium spores in their child’s stool. But pediatric healthcare providers do need be aware of the classic signs and symptoms so that testing and treatment can be initiated in a timely fashion. Studies have shown that more than half of infants ultimately found to have botulism were initially misdiagnosed and their treatment delayed.

Pertussis Cases are Rising Sharply in 2024
As the pandemic “winds down”, cases of whooping cough are on the rise in dramatic fashion.
Clay Jones on June 7, 2024
Link

In late May, an outbreak of pertussis (whooping cough) was declared by the Lexington-Fayette Health Department in Kentucky. This small cluster of 21 cases, as of two days ago, is not an outlier. Outbreaks are occurring across the country. According to CDC data as of May 25th, there have been 4,876 cases of pertussis reported in the United States and U.S. territories, which is roughly three times more than the same period last year.
Rather than some new phenomenon, this increase likely represents a return to an unfortunate normal after a lull in cases during the early years of the pandemic. Though not as common as in the days prior to the roll out of an effective whole-cell vaccine in the 1940s, when pertussis was reported around 200,000 times per year in the United States, this horrid respiratory infection has always been more persistent than other vaccine-preventable infections like measles, polio, and rubella. But we did appear to have it on the ropes at one point.
After a nadir of just over 1,000 cases in 1976, cases began to increase as more parents refused the vaccine because of concerns of permanent neurologic injury that were ultimately proven to be false. Another reason for higher numbers was the switch from a more effective whole-cell vaccine to an acellular vaccine for infants in 1991 out of an abundance of caution and in the hopes of increasing vaccine uptake. Despite numerous studies confirming that the safety concerns over the whole-cell vaccine were largely exaggerated, there are no plans to resurrect it and additional booster doses every ten years will continue to be necessary to maintain decent immunity.
The need for a booster throughout adulthood means that a large percentage of people have minimal if any immunity to pertussis. For a variety of reasons, such as limited access to care in certain populations, not seeking regular care even when it is available, and, of course, refusal of the shot when offered, there has been a large reservoir of unprotected adults. These individuals are capable of spreading the virus to the infants and high risk adults who are more likely to suffer serious outcomes or even die.
Now back to the numbers.
As I mentioned earlier, the pace of pertussis cases so far this year is tracking with a typical pre-pandemic year, and not a bad one at that:
2000	7,867
2001	7,580
2002	9,771
2003	11,647
2004	25,827
2005	25,616
2006	15,632
2007	10,454
2008	13,278
2009	16,858
2010	27,550
2011	18,719
2012	48,277
2013	28,639
2014	32,971
2015	20,762
2016	17,972
2017	18,975
2018	15,609
2019	18,617
2020	6,124
202120222023	2,1162,3885,611(provisional)
https://www.cdc.gov/pertussis/php/surveillance/pertussis-cases-by-year.htmlhttps://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2023_PROVISIONAL.pdf
There is good reason to be concerned, however. Cases of pertussis during the peak of the pandemic almost certainly had to do with more distancing and the use of other protective measures. It certainly wasn’t because of more people being vaccinated. And as more people act as if everything has returned to normal, cases will return to pre-pandemic numbers and will likely be worse because of the general increase in anti-vaccine sentiment that has emerged because of largely partisan propaganda and irrational pushback against the COVID-19 vaccines.
Pertussis cases are also on the rise around the world now that the pandemic-related effects are waning:
In England, provisionally there were 4,793 laboratory confirmed cases of pertussis reported to the UK Health Security Agency (UKHSA) between January and April 2024 with 555 cases in January 2024, 920 in February, 1,430 in March and 1,888 cases in April (Figure 1). This compares with 858 (provisional) laboratory confirmed cases of pertussis reported in 2023. There have been 8 reported deaths in infants who developed pertussis between January and April 2024.
https://www.gov.uk/government/publications/pertussis-epidemiology-in-england-2024/confirmed-cases-of-pertussis-in-england-by-month
And:
China recorded over 32,000 cases of pertussis in just the first two months of 2024 — a 20-fold increase from a year ago. The Philippines, the Czech Republic, the Netherlands and many other places have also reported a surge in cases.
https://www.bloomberg.com/news/newsletters/2024-04-15/whooping-cough-makes-a-return-even-in-the-vaccinated
Are you up to date with your pertussis vaccine? If not, get on that…please. You are significantly reducing the risk of a really bad illness if you are generally healthy, and hospitalization or even death if you aren’t. And you might save the life of someone else, like a precious little baby. There is also the added benefit of being protected from tetanus when you get your pertussis booster because it’s a combo shot. And who wants that?

A Perhaps Not-So-Unexpected Spike in Pediatric Brain Abscesses
The surge in viral infections last year appears to be to blame for a significant increase in cases of brain abscesses in children. They remain rare, and panic is not warranted, but they are a life-threatening complication of common bacterial infections that should be taken seriously.
Clay Jones on June 9, 2023
Link

Last November I wrote about the severe respiratory virus season that had pediatric hospitals, and community hospitals with pediatric units like mine, overwhelmed across the country. At my hospital, with it’s 12-bed pediatric unit and no PICU, for example, we had all hands on deck providing PICU level care for many patients over several weeks because there were no higher level beds available in Boston or the surrounding area. It was scary at times, and we were beyond exhausted by the time things began to settle down in early 2023.
Unsurprising to anyone familiar with the complexities of human pathophysiology, we are now learning that this unprecedented surge in pediatric viral respiratory infections had some unexpected complications. As reported by the CDC earlier this month, there was a significant increase in the incidence of brain abscesses in children over the past several months, with a peak in December that was 200% higher than the typical pre-pandemic average. This followed a trend of increasing cases that essentially began when society decided to relax the precautions in place to reduce the risk of COVID-19, which also prevented millions of infections with the usual viral suspects.
Cases of intracranial (brain) abscesses are not typically reported to the CDC, so we don’t have good data going back decades like we do for measles and gonorrhea. I took part in the care of a child with brain abscess a few months ago, the first in my now 20 years of practice, and had no idea that the CDC would ever know about it. But in May of last year, because of an unusual cluster of cases in a California hospital, the CDC began an investigation that collected data from every state.
One of these was Nevada, where the only pediatric neurosurgeon in the state had also sounded an alarm. She reported seeing a more than 3-fold increase in brain abscesses in children, from a average yearly incidence of 4 or 5 cases to 18 in 2022. These cases seemed to coincide with increases in viral respiratory infections. Soon other doctors in other states chimed in:
After a presentation on the Nevada cases the Epidemic Intelligence Service Conference on Thursday, doctors from other parts of the country said they are seeing similar increases in brain abscesses in kids.
“We’re just impressed by the number of these that we’re seeing right now,” said Dr. Sunil Sood, a pediatric infectious disease specialist at Northwell Health, a health system in New York. He estimates they are seeing at least twice as many as usual, though they haven’t done a formal count. He urged the CDC to continue investigating and work to get the word out.
The CDC is now doing just that after reviewing data from multiple state and federal sources going back as far as January of 2016. They found that while there was certainly some month-to-month variation, the number of cases per month didn’t tend to stray too far from the historic average. Until last year, that is.
From January of 2016 through December of 2019, the largest number of brain abscess cases diagnosed in one month was 61, with an average of around 30. This actually went down from March of 2020 through May of 2021, likely because COVID-19 precautions were keeping kids from getting sick with typical respiratory viruses. I’ll never forget how odd that winter was, with hardly any admissions for RSV. It was unlike anything I had ever experienced.
Cases began to increase in June of 2021, and they continued to run at the upper limit of the historical range through September of 2022. That’s when things really took off. From November of 2022 through March of 2023, the last month with available data, between 62 and 102 cases were diagnosed each month. January, February, and March saw a downward trend that was still above pre-pandemic levels. And with the steady decline in pediatric respiratory infections that has occurred in April, May, and June so far, experts expect that there will be a coinciding decrease in brain abscess.
What do viral respiratory infections have to do with brain abscesses in kids, which are typically a bacterial infection? It makes a lot of sense once you realize that viral infections are a well known risk factor for the development of secondary bacterial infections, particularly in the upper respiratory region. That includes the ears, and more importantly in the case of brain abscess risk, the paranasal sinuses.
A brain abscess occurs when bacteria, or in some cases a fungus or parasite, invades the brain either by direct spread from a local source or via the bloodstream from a more remote source. Direct spread is by far the most common route in children, usually in the setting of an infection of the middle ear, mastoid, sinuses, or the teeth and gums. Sinus infections are the leading initiating even, and all of these, except for dental infections, are more likely to occur when a child has a viral upper respiratory infection.
Many different bacteria are known to cause brain abscesses, but several different Streptococci species are most common in children. These are common causes of sinusitis and ear infections as well as dental infections. Staph aureus is also an important potential pause, though it is more likely as a result of penetrating head trauma.
The diagnosis of a brain abscess in children is often delayed because the signs and symptoms can be vague and nonspecific. The classic triad of headache, fever, and focal neurological deficits is only seen in around 20% of patients. Headache is by far the most common presenting complaint, but fever is only seen in about half of patients. By the time focal neurological deficits or seizures occur, the infection may have been going on for weeks. Changes in mental status, and coma even more so, are extremely worrisome and predict a poor outcome.
In addition to appropriate antibiotics, the treatment of brain abscesses almost always requires surgical drainage, though this isn’t always possible depending on the location of the infection. Antibiotics are often necessary for several weeks. Though outcomes have definitely improved over the years, there is still a fatality rate of more than 10%. And only about 70% of patients can expect a full recovery without residual neurological deficits.
Conclusion: The Worst is Probably (Hopefully) Over
Pediatric brain abscesses are rare. And despite the significant increases seen during recent surges in viral respiratory infections, they remain rare. The vast majority of children with viral infections do not go on to develop a brain abscess. But it is still important for pediatric healthcare professionals to recognize their possibility and to consider neuroimaging when appropriate.
Parents definitely shouldn’t panic. Again, a child’s risk of a brain abscess is remote even if they have a rip roaring sinusitis. And appropriate treatment of these infections will reduce the risk. Overdiagnosis, unfortunately, is also a huge problem that can be inspired by fear of rare bad outcomes. It is very often safe to treat viral infections and even many suspected ear and sinus infections conservatively without antibiotics. But certainly you should talk to your child’s doctor if they have unusual persistent headaches, particularly if accompanied by fever or worrisome changes in behavior.

A Desperate Choice
A therapy for brain tumors in young children involves deliberately infecting them with a virus. Scary, and is it worth it?
Harriet Hall on July 26, 2022
Link

In a recent article in the New England Journal of Medicine I read about a novel possibility for treating cancer that I had not been aware of. The study’s title was “Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma”.It started by saying that pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less than 1 year. DNX-2401 is an oncolytic adenovirus that selectively replicates in tumor cells. 12 patients with newly diagnosed DIPG were given a single infusion of the virus through a catheter placed in the cerebellar peduncle, followed by radiotherapy.
Results
Treatment resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events including headache, nausea, vomiting, and fatigue. Hemiparesis and tetraparesis developed in 1 patient each.
The study was done in Spain at the Clínica Universidad de Navarra.
Follow-up
Over a median follow-up of 17.8 months (range, 5.9 to 33.5), a reduction in tumor size, as assessed on magnetic resonance imaging, was reported in 9 patients, a partial response in 3 patients, and stable disease in 8 patients. The median survival was 17.8 months. Two patients were alive at the time of preparation of the report, 1 of whom was free of tumor progression at 38 months.
First impression: Wow!
My first reaction was delight and amazement. I had never imagined that a virus could infect and kill a tumor. That’s welcome knowledge that could potentially have many useful clinical applications. Cutting edge science.
Second impression: What about informed consent?
As I thought more about this, my enthusiasm ebbed. The news from this study is not really so favorable. I reflected that parents of these children would have to give informed consent, and I wondered how many of them would give that consent if they fully understood all the facts.
    • This is an experimental treatment that has only been tried in 12 patients age 3 to 18.
    • The patient has to undergo surgery and brain biopsy. Surgery carries its own risks. The idea of brain biopsy itself is scary; the idea of inserting a cannula deeper into the biopsy tract is even scarier.
    • Deliberately injecting a virus into the brain to cause infection would strike many people as rather barbaric.
    • A 25% reduction in tumor size was seen in 75% of patients. The clinical significance of this was uncertain.
    • At 18 months after treatment, only 50% of the patients were still alive. At 33.5 months after treatment, only 3 of the 12 patients were still alive. Two patients were still alive at the time of preparation of the article, 1 of whom was free of tumor progression at 38 months.
    • Patients were hospitalized for 0.6 to 6.8 days for the procedure and recovery.
    • After treatment, 11 of the 12 patients continued to receive radiation therapy. The parents of 1 patient declined radiotherapy and any further treatment.
    • When there was evidence of tumor progression, other treatments were given at the discretion of the oncologist, including chemotherapy, reirradiation, antiangiogenic therapy, or investigational agents.
    • 75% of the patients had side effects from the treatment.
        ◦ 9 patients each had headache, neurologic deterioration, or vomiting
        ◦ 8 patients had fatigue
        ◦ 6 patients developed a fever
    • Three serious adverse events were reported:
        ◦ One patient had transitory grade 3 hemiparesis which lessened in severity to mild hemiparesis after 12 weeks.
        ◦ One patient had grade 3 neurologic deterioration of increased bilateral oculomotor paresis and tetraparesis, which started after hospital discharge and worsened during radiotherapy.
        ◦ A third patient was hospitalized for abdominal pain; no cause was found
To summarize, this experimental treatment reduced tumor size for some patients but was associated with adverse events. It required hospitalization, surgery, and iatrogenic infection with a virus. Patients continued to receive radiotherapy and other treatments. Due to the small study size, the effect of the treatment on survival could not be calculated.
What to do?
I tried to imagine I was the parent of a child with newly diagnosed DIPG with a median survival of less than a year, especially if they were too young to understand. I would desperately want my child to live, but I hope I would be able to prioritize the best interests of my child over my own feelings. Would I want to subject them to the pain, suffering, and potential side effects of this treatment regimen for such a small chance of benefit? I think I would not. Desperate situations lead to desperate decisions; sometimes those decisions may not be the most rational.

CDC Issues Warning: Be on the Lookout for a Surge in Pediatric Paralysis Cases This Fall
The CDC is warning parents and pediatric medical professionals to be on the lookout for a potentially devastating viral disease this fall. It isn’t the novel coronavirus, but the impact of the pandemic might make things worse…or better.
Clay Jones on August 21, 2020
Link

Earlier this month, the CDC issued a warning for parents, caregivers, and pediatric professionals to be on the lookout for children developing weakness and paralysis. As I’ll explain shortly, we are due for a surge in cases of a relatively new polio-like illness over the next few months. Adding to these concerns, we don’t know how the novel coronavirus pandemic will impact the incidence or the timeliness of diagnosis of these cases.
Acute flaccid myelitis, a new version of a classic disease
In 2012, although there were perhaps a few cases as early as 2009, the first clusters of what would come to be known as acute flaccid myelitis (AFM) emerged in the United States and Europe. These cases primarily involved early school-aged children developing sudden weakness, and in many cases the loss of the use of one or more of their extremities following a mild viral infection. Many of these children even lost the ability to breathe on their own. If this sounds familiar, it’s because that is the exact description of the clinical presentation of infection with the poliovirus.
As with poliomyelitis, more commonly known simply as polio, patients suffering from AFM present with dysfunction or death of anterior horn cells within the gray matter of the spinal cord which can be seen on MRI of the spine. These lower motor neurons innervate skeletal muscle, which become weak or flaccid as the disease progresses, often resulting in paralysis of the involved limbs. Historically, this clinical presentation has been labeled acute flaccid paralysis (AFP), which prior to the development of a safe and effective vaccine was almost universally caused by the poliovirus. AFM is the term now used to specifically designate these modern cases and to differentiate them from polio and from other rare infectious and non-infectious causes.
Most patients eventually diagnosed with AFM have a prodromal viral upper respiratory infection, vomiting, and/or diarrhea in the week or so prior to the onset of weakness. Once a child begins to have difficulty moving one or more of their extremities, progression of neurologic symptoms tends to occur relatively quickly. Hours to days, not weeks or months. Many have additional neurological concerns, such as incontinence or the loss of cranial nerve function. Virtually all patients require hospitalization and a third end up needing to be placed on a ventilator as the weakness progresses to involve respiratory muscles or the muscles of the mouth and throat. Not all patients survive.
A pattern emerges and the culprit is discovered
Cases of AFM continued to be reported after 2012, and a pattern of late summer and early fall predominance was established. A Colorado outbreak in 2014 led to the development of a national surveillance program run by the CDC and significant spikes were again seen in 2016 and 2018. The numbers have remained relatively low, but there has been a consistent increase in yearly totals with each biennial bump. There were 120, 153, and 236 proven cases in 2014, 2016, and 2018 respectively, with many more suspected but unproven cases. In the intervening years, case totals have dropped dramatically, with each having less than 50 proven cases.
Since those early reports, we have learned that the cause of almost all cases of AFM is enterovirus D68 (EV-D68), although there are other infectious agents to blame for some. One thing that has been conclusively proven is that none of these cases have been caused by the poliovirus, which does also happen to be an enterovirus. Enteroviruses are incredibly common and varied. In addition to the poliovirus (an enterovirus C species), another well-known example comes from the enterovirus A species, although it is better known as a coxsackievirus and the cause of hand, foot, and mouth disease.
There are non-polio enteroviruses known to cause a similar presentation as AFM. There are even non-enterovirus viral pathogens, such as the flavivirus that causes West Nile fever and at least one adenovirus, that can cause paralysis in children. There are also autoimmune conditions that are very rare. Only the poliovirus, EV-D68, and EV-A71 have been associated with endemic and epidemic cases of paralysis, however. EV-D68 was first isolated in California in 1962 and was a rare cause of illness until the last decade. Unlike the poliovirus, it behaves more like a respiratory virus with fewer of the gastrointestinal symptoms that are commonly experienced with polio.
It hasn’t been easy to prove a causal link between AFM and EV-D68. As with the poliovirus, it is difficult to culture or even find DNA fragments in spinal fluid, even using modern PCR technology. With polio, stool samples provided the most reliable source for diagnosis, but this isn’t true with EV-D68 infections. Researchers have had to rely on more creative and indirect means, such as the measurement of anti-enteroviral antibody synthesis in spinal fluid. EV-D68 has also frequently been found in respiratory samples from AFM patients, which again is indirect evidence but there has been no other candidate pathogen identified in these samples with any consistency. The biennial spikes also coincide with surges in EV-D68 circulation.
The search for an effective treatment continues
Sadly, there is no proven effective treatment for AFM. Supportive care, such as providing respiratory assistance when needed, and interventions aimed at limiting damage to the spinal cord are key aspects of acute management. Rehabilitation, starting as early as possible, is very important for improving long-term outcomes. Numerous immune-modulating pharmaceutical interventions have been tried, such as steroids and immune globulin, as well as various antiviral medications, but nothing has been shown to be helpful thus far. There really is no clear guidance for physicians caring for these patients.
Unfortunately, most children with AFM still have residual neurologic limitations despite aggressive rehabilitation when followed up a year or so after diagnosis. Not that there isn’t room for hope. The data is limited and this condition is still fairly new. It does appear that slow progress occurs, so we don’t really know how these patients will be doing in the more distant future.
Conclusion: Acute flaccid myelitis in the setting of the coronavirus pandemic
The bottom line is that we don’t know how the ongoing pandemic will change the course of this year’s predicted spike in AFM cases. It is possible, perhaps even likely, that we will see many fewer cases than expected if continued social distancing and the use of masks reduce the risk of spreading EV-D68. We have certainly seen fewer cases of just about every other communicable pediatric infectious disease over the past few months. Easily 75% of my non-newborn admissions since March have been mental health related, but that’s a topic for another day perhaps.
We might also see a delay in the timely diagnosis of AFM when it does occur. This might happen because of hesitance out of concerns for exposure to the novel coronavirus and fear of developing COVID-19. I’m not really worried that any children with blatant paralysis won’t be brought in for evaluation, although I suppose that it is possible. The problem is that a caregiver might not seek care when a child has the milder weakness typically seen earlier in the course. This might make a difference in that child’s prognosis. We just don’t have enough data yet to really know what, if anything, might improve outcomes, and we don’t know if earlier treatment prior to the development of frank paralysis makes a difference either.
So, spread the word and be on the lookout for young kids with weak arms or legs. There have been 16 cases so far in 2020, which is on track with previous years prior to the biennial fall surges. As summer draws to a close, we are going to know how this is going to go pretty soon.

CDC Issues Warning as the Virus Associated with a Rare Polio-Like Illness in Children Returns
After a pandemic related lull, pediatric respiratory infections are roaring back. Unfortunately, this means that there will likely be a spike in cases of a polio-like illness caused by enterovirus D68.
Clay Jones on September 16, 2022
Link

In August of 2020, I wrote about a CDC warning involving the potential for a spike in cases of a rare polio-like illness called acute flaccid myelitis (AFM), which has been linked to infection with enterovirus D68 (EV-D68). The enterovirus genus that EV-D68 calls home, in addition to extremely common non-polio enteroviruses like the rhinoviruses and coxsackieviruses, also contains the polioviruses and echoviruses. The 12 enterovirus species, and their over 200 known serotypes, are to blame for a wide spectrum of disease including the common cold, hand, foot, and mouth disease, pneumonia, hepatitis, gastroenteritis, pericarditis, aseptic meningitis, AFM, and classic polio. This genus of viruses, particularly the rhinoviruses (common cold), causes more human infections than any other.
The timing of the late Summer 2020 warning, and a CDC Health Alert Network advisory issued last week, isn’t a coincidence. AFM related to EV-D68, which can cause mild to severe weakness and even permanent paralysis in young children, first emerged in 2012 and, as I explained in my earlier post, has demonstrated a fairly reproducible pattern:
Cases of AFM continued to be reported after 2012, and a pattern of late summer and early fall predominance was established. A Colorado outbreak in 2014 led to the development of a national surveillance program run by the CDC and significant spikes were again seen in 2016 and 2018. The numbers have remained relatively low, but there has been a consistent increase in yearly totals with each biennial bump. There were 120, 153, and 236 proven cases in 2014, 2016, and 2018 respectively, with many more suspected but unproven cases. In the intervening years, case totals have dropped dramatically, with each having less than 50 proven cases.
In 2020, however, the pattern broke down. During that season, there were only 33 confirmed cases of AFM. The CDC was right to issue the warning, but there was already good reason to expect a low number of cases, as I explained back then:
It is possible, perhaps even likely, that we will see many fewer cases than expected if continued social distancing and the use of masks reduce the risk of spreading EV-D68.
If you guessed it had something to do with the pandemic, you were right. That respiratory virus season, at least in the amazing world of pediatric medicine, will go down as one of the most unusual that I have ever experienced. During a typical Fall and Winter, offices, urgent care facilities, emergency departments, and inpatient pediatric units are full of children with viral respiratory infections, particularly kids under the age of 2 years.
The most common culprit is usually respiratory syncitial virus (RSV, which is not mistaken for COVID-19), though there are many other viral pathogens known to cause respiratory illnesses in children. RSV alone is to blame for more than 2 million yearly outpatient visits and anywhere from 60,000 to 100,000 hospitalizations in children under the age of 5 years in the United States. And each year RSV kills a few hundred children, with premature infants and children with chronic lung or heart disease being at the highest risk of severe disease.
Non-RSV respiratory infections aren’t exactly uncommon, however. Viruses like human metapneumovirus, influenza, and parainfluenza virus types 1, 2, and 3 each put roughly 20,000 infants and toddlers in the hospital every year in the United States. Even the rhinoviruses, which are mostly associated with mild upper respiratory symptoms like a stuffy nose, can cause disease severe enough to require an admission. By the end of a three-year pediatric residency, pediatricians may have already diagnosed a thousand children with viral respiratory infections and managed more than a hundred in an inpatient setting, particularly those infected with RSV.
Though there has always been some fluctuation in how bad a particular RSV season is, as well as variation from region to region, they have always been consistently busy. Nobody has ever seen anything like what we saw in late 2020 and early 2021. At my hospital we had almost no RSV admissions and for good measure we had almost no influenza admissions. We had almost no admissions for any classic and typically common pediatric infections of any kind at all for that matter.
What was I doing in 2020? Along with many pediatric residents and hospitalists in cities hit hard by COVID-19, I could often be found helping our adult medicine colleagues, who were overwhelmed at times, by managing some younger adult inpatients with relatively mild COVID-19 infections or conditions not completely unfamiliar to a pediatrician. I truly hope to never be put in that position again.
So with so few children getting viral infections in general, thanks to the measures in place to reduce the risk of COVID-19 specifically, there were few opportunities for EV-D68 to cause AFM. And though there were some significant spikes in RSV in 2021, particularly in the South, and in the Summer oddly enough, it was another unusually mild season. During the Fall and Winter of 2021-2022, there were only 28 confirmed cases of AFM, which was consistent with typical odd numbered years since 2012.
There have only been 13 cases confirmed so far in 2022, but it’s early. And there is very good reason to expect that we will see a spike in cases this Fall that put us back on historical track, if you can call a period of only 10 years historical. The reason, essentially, is that the respiratory virus season of 2022-2023 is already hitting us hard as more and more people have returned to pre-pandemic behavior. In just the past two weeks, we have already admitted more children with viral respiratory infections than in 2020, and we will easily eclipse 2021 soon at this pace. And we are not an outlier.
Unsurprisingly, cases of EV-D68 are being reported from surveillance centers across the country per the CDC alert:
Healthcare providers and hospitals in several regions of the United States notified the Centers for Disease Control and Prevention (CDC) during August 2022 about increases in pediatric hospitalizations in patients with severe respiratory illness who also tested positive for rhinovirus (RV) and/or enterovirus (EV)…Upon further typing, some specimens have been positive for enterovirus D68 (EV-D68).
Though less than a hundred cases of EV-D68 were reported to the CDC as of August 4th, that is more than the last three years combined and is almost certainly an undercount. There are only seven regional centers that make up the surveillance network but there are reports of significant spikes in pediatric respiratory infections across the country, so it is reasonable to assume that some of these have been caused by EV-D68. We will have a much better idea how bad this AFM season is going to get by the end of September, as it takes 1-4 weeks for weakness/paralysis to develop after the initial infection.
Stay tuned. In the meantime, I’ll just point out that the same methods helpful in reducing the risk of infection with SARS-CoV-2 apply to the enterovirus genus as well as RSV and all the other potential causes of viral respiratory disease. That means good hand hygiene at all times, and masks and social distancing when prudent and possible are key to protecting children. There is no vaccine, unfortunately.

The Shocking Link Between a Popular Toy Company and Preventable Infant Deaths
The 2019 recall of a dangerous infant sleep product helped uncover how corporate greed and poor federal regulations contributed to preventable deaths and helped lead to improvements that will save lives.
Clay Jones on June 24, 2022
Link

Fisher-Price and the era of inclined sleepers
In 2019, the American toy company Fisher-Price voluntarily recalled nearly 5 million Rock ‘n Play Sleepers, an extremely popular product that essentially ushered in an era of inclined infant sleep when they first hit the market in 2008. The recall came only after the Rock ‘n Play was implicated in the death of at least 32 infants over the preceding 10 years. But this was just the tip of a giant floating mass of corporate greed and inept governmental regulations.
As long as I have been a pediatrician, which is just shy of 20 years, I have recommended that babies sleep flat on their backs rather than in inclined sleepers like the Rock ‘n Play. This has, in fact, been a part of the official American Academy of Pediatrics policy on safe sleep going back to the mid ’90s. This policy also strongly recommends avoiding plush bedding and any restraints used to force a baby into a certain position. The Rock ‘n Play and copycat products that emerged soon after it hit store shelves ignored all of these recommendations, yet they quickly became very popular with parents and made millions in profits for manufacturers.
Inclined sleep didn’t begin with the Rock ‘n Play, rather it was simply the first product specifically designed and marketed for that purpose. Prior to 2008, some babies were propped up in other ways, such as by placing a pillow under their mattress or letting them sleep in a “bouncer” or car seat despite warnings from the manufacturers. There was a time when some pediatricians and pediatric gastroenterologists even recommended inclined sleep, usually at an angle of 30 degrees or less, for fussy infants with reflux disease or nasal congestion. Sadly, some still do, despite the fact that no evidence supports this practice and inclined positioning can actually worsen reflux. But because these products were marketed as a way to improve infant sleep and quickly benefited from parental placebo-infused word of mouth, the Rock ‘n Play and its ilk saturated the market.
As I mentioned above, since 1994 the official recommendation from the AAP has been a flat sleeping surface. Although not always entirely clear, the most common mechanism for injury and death in these cases is suffocation. A baby that is propped up can more easily roll onto their side or stomach with their face potentially pressed against soft bedding or other plush material (stuffed animal, blanket, pillow, etc.) in their sleep environment. Children can also become trapped in an unsafe position by restraints meant to keep them from falling out of the chair. And very young infants, or infants with medical conditions that cause muscle weakness, might have difficulty maintaining an adequate airway because of poor neck strength, which can result in lengthy periods of decreased oxygen levels and even death.
I remember being angry when I heard of the deaths and somewhat relieved by the recall. I was frustrated at the reality that these products were allowed to be sold to parents and I worried that Fisher-Price and other companies had been prioritizing profit over safety. I had no idea just how bad their behavior was, and how lacking safety regulations were, until a new warning from the U.S. Consumer Product Safety Commission (CPSC), again involving infant deaths in a Fisher-Price product, inspired a deeper look into this issue.
The Rock ‘n Play recall of 2019
When Fisher-Price issued a voluntary recall of the Rock ‘n Play, it wasn’t because they had just discovered that babies were dying in their product. It took a damning report from Consumer Reports to reveal the serious safety concerns to the public. According to a 2021 Committee on Oversight and Reform investigation, both Fisher-Price and the CPSC were aware of the danger, but neither were interested in a recall until Consumer Reports forced their hand by disclosing information on infant injuries and deaths that the CPSC had accidentally sent to them. More on all this a bit later.
The AAP, which had been warning against these products for years, issued a statement demanding a recall after the Consumer Reports bombshell, and stressed the need for improved regulation of infant products that don’t follow safe sleep recommendations. At the time, the chair of the AAP’s Council on Injury, Violence, and Poison Prevention Executive Committee raised a serious and prescient concern:
While this recall is specific to the Rock ‘n Play, there are other inclined and padded sleeping products on the market that can put infants’ safety at risk.
These concerns weren’t new, however. Consumer Reports CEO Marta Tellado shined a light on the problem of weak regulation at the federal level and, it seems with hindsight, perhaps threw some shade at Fisher-Price, which was less than forthcoming about the many reports of injuries and deaths that they had received over the years:
The Fisher-Price recall of the Rock ‘n Play is long overdue. It took dogged investigation and the voices of doctors, victims’ families, and advocates across the country to make this recall a reality. Congress needs to take a hard look at the CPSC and make sure it is a watchdog that consumers can rely on.
As I mentioned above and will discuss in more detail soon, Congress would eventually take that hard look, though the wheels turned slow which allowed many more kids to die. Fisher-Price offered a full refund to consumers who had purchased a Rock ‘n Play less than 6 months prior to the recall, and a voucher to some of those who had owned one for a bit longer. Safety experts at the time were less than impressed, however, and called for full refunds for all owners so that parents would be more likely to return the sleepers. That didn’t happen and millions of used inclined sleepers remained in homes, daycare centers, and available for purchase on secondary markets online.
One of the biggest concerns that this episode raised was obviously the lack of adequate safety regulations. Many, and perhaps even most parents do not realize that a product sold for use by infants is not necessarily safe just because it can be legally purchased in a store or online. Sadly, despite the 2019 recall of the Rock ‘n Play and widespread media coverage, infants continued to die in inclined sleepers and other similar products because the core problem wasn’t solved.
Corporate greed and weak regulations
In December of 2019, Consumer Reports published an investigative piece that looked behind the scenes of the development of the Rock n’ Play and its continued availability despite knowledge of the risk posed to babies. As articles about dangerous products often do, it started with an emotional anecdote about an injured child and a lawsuit:
Courtney and David Goodrich of Atlanta had brought the case after their 7-week-old son Asher had nearly died in the sleeper in July 2014. He was napping when Jan Hinson, Asher’s grandmother, noticed his head oddly flopped forward and to the side. When Hinson got closer, she saw that Asher wasn’t breathing and that his face was blue.
Thankfully Asher did not die, but his family wasn’t satisfied with Fisher-Price’s response to their concerns over the safety of the Rock ‘n Play. In a nutshell, the company disagreed and had no plans to look any further into the issue. The lawsuit that resulted from this event revealed that Fisher-Price already knew that the product was unsafe and was implicated in at least 14 deaths at that point. A 7-week-old infant in Tennessee even died in a Rock ‘n Play on the same day in early 2018 that the product’s inventor was being deposed.
In April of 2019, the recall involving Fisher-Price discussed above happened. Soon after, two additional companies (Kids II and Dorel) recalled incline sleepers that had been implicated in additional deaths. In total, these products were to blame for at least 70 infant deaths and more than 1,000 events similar to what happened to Asher in the above anecdote, many of which resulted in serious injuries. In reality, there were certainly many more than this that weren’t captured by the investigation.
By the end of 2019, most major retailers were pulling all inclined sleepers from sale regardless of whether or not they had been recalled. More good news came that December when lawmakers in Washington finally began to move on legislation that would ban the sale of these products entirely. The process, which also included a lengthy congressional investigation, ultimately took more than two years from when the Rock ‘n Play was recalled to when the Safe Sleep for Babies Act of 2021 was signed into law by President Biden in May of this year:
This bill makes it unlawful to manufacture, sell, or distribute crib bumpers or inclined sleepers for infants. Specifically, inclined sleepers for infants are those designed for an infant up to one year old and have an inclined sleep surface of greater than 10 degrees. Crib bumpers generally are padded materials inserted around the inside of a crib and intended to prevent the crib occupant from becoming trapped in any part of the crib’s openings; they do not include unpadded, mesh crib liners.
The Safe Sleep for Babies Act may have finally gone into effect last month, but it allows 180 days for manufacturers to comply. So parents may still see these dangerous products for sale on store shelves or online until late November. This obviously has taken way too long and, again, the people who put these products into the marketplace should have known better from the beginning.
The December 2019 Consumer Report exposé uncovered numerous problems with the way Fisher-Price went about designing and marketing the Rock ‘n Play. Though hard to believe, at no point in the process was safety really even considered:
But members of that safety team didn’t research the medical premise of the Rock ‘n Play Sleeper, either. “That was not part of my charge at that time,” said Michael Steinwachs, the project’s product integrity engineer on the hazard analysis team, who was deposed in the Goodrich lawsuit a day after Chapman. That was the responsibility of Kitty Pilarz, he said, who was then a director of product safety for Fisher-Price’s parent company, Mattel.
Pilarz, however, did nothing of the sort despite her job title. She never spoke to a single pediatrician or consulted any infant sleep expert. And it turns out that they chose an angle of 30 degrees for the amount of incline provided by the product almost randomly, assuming that anything less than 45 degrees, which is typical for car seats, would be fine. No independent safety testing was performed and the one physician involved had no pediatric expertise and was eventually forbidden from seeing patients by the Texas medical board after he practiced medicine high or drunk with an expired license.
When the Rock ‘n Play first hit store shelves, it was marketed as a bassinet, a designation regulated by the non-governmental ASTM International that required some minimal safety standards to be met. The angle of incline was not one of these standards, but 6 months after first going on sale in 2008 the CPSC proposed a limit of 10 degrees. This would have caused serious problems for Fisher-Price if enacted, so they requested that the Rock ‘n Play be given a brand new distinction as an “inclined infant sleep product” and allowed to have an incline up to 30 degrees and to provide restraints to hold a baby in place. It worked:
The CPSC agreed, paving the way for Fisher-Price to propose a new product category to ASTM called infant inclined sleep products. The chairman of the ASTM subcommittee charged with creating the standard was none other than Michael Steinwachs, the Fisher-Price product engineer who helped develop the Rock ‘n Play Sleeper.
This “safety standard” was based on no safety testing and potentially fooled many parents into believing that these inclined sleepers were safe. Fisher-Price met with resistance in other countries, in particular Australia, England, and Canada, who either banned sales of the Rock ‘n Play or forced Fisher-Price to stop promoting them as safe for sleep or unsupervised use. Despite this, and an increasing number of deaths, these products remained available and parents remained unaware.
Fisher-Price knew, however. And so did the CPSC. The CPSC, though, was limited by law from disclosing injuries and deaths without permission from the involved manufacturer. It also does not have the power to recall products without taking the company to court, unless they can convince them to voluntarily comply. In that case, the manufacturer has the right to control the language used in any press releases.
There is actually even more to this story, such as how Fisher-Price blamed parents for the death of their babies and how the CPSC tried to prevent Consumer Reports from going public with the data on infant deaths caused by Rock ‘n Play use. The article also goes into detail on the absurdly long and arduous journey that eventually led to the CPSC warning parents to avoid all inclined sleepers and the beginning of the lengthy process required to ban them outright. I encourage you to read the entire article. Here is the link again.
Two years later…
After the recall of 2019 and the subsequent fall out that resulted in increased awareness of the dangers of inclined sleepers by the public and the federal government, infants continued to die. Sometimes these deaths involved continued use of recalled products. Many deaths involved inclined products not promoted for sleep but used for that purpose anyway. There have been additional recalls of these products, such as the Fisher-Price 4-in-1 Rock ‘n Glide Soother in 2021. It was linked to 4 deaths of sleeping infants. The answer obviously wasn’t to just to slap a warning label on a package because the problem is the incline.
As I referenced earlier, in June of 2021 a report summarizing the findings of a 2-year-long investigation by the House Committee on Oversight and Reform on infant inclined sleep products was published. Along with copious detail supporting them, the report included the following findings in the executive summary:
     1.  Fisher-Price failed to ensure the Rock ‘n Play was safe, ignored warnings that it was dangerous, and marketed it for overnight use despite risks
     2.  CPSC does not have adequate regulatory or enforcement powers to protect the public
In the report’s conclusion, a very important point was made:
Manufacturers are private companies driven by profit, and they have an obvious financial incentive to keep their products on the market. They should not be empowered to determine whether these product are safe for the public.
Infants remain at risk but there may be a light at the end of the tunnel
What inspired me to look into the history of inclined sleepers, and the Fisher-Price recall of 2019, was a June 14th CPSC warning about two more Fisher-Price product being linked to at least 13 infant deaths. This time the products are the Infant-to-Toddler and Newborn-to-Toddler Rockers and the deaths were attributed to their use for sleep, which if you’ve learned anything from this post it should be that this is a dangerous practice when an incline is involved. And now you know why this was just a warning rather than a recall.
It’s the same nonsense all over again. Fisher-Price isn’t going to voluntarily agree to a recall and the CPSC isn’t going to invest time and money into forcing one. As of yesterday, however, new CPSC regulations are now in effect requiring all infant products marketed for use during sleep to follow a universal federal guideline that includes an incline of 10 degrees or less, but that won’t magically make all the unsafe older versions disappear and that won’t make products like rockers, swings, and bouncers any safer when a baby falls asleep in one.
One potential legislation that might make a big difference is Richard Blumenthal’s Sunshine in Product Safety Act. If passed, it would give the CPSC more freedom to disclose safety concerns to the public. Fingers crossed.

Infant and Toddler Swimming Programs: Are They Safe and Effective?
Clay Jones on July 5, 2013
Link
It’s now officially summertime, but people have been hitting the pools and beaches for weeks in many parts of the nation. In fact it has been well into the 90’s for over two month here in Baton Rouge, which is what I blame for the early exit of LSU from the College World Series. Our boys just weren’t used to that cold and dry northern weather.
Not surprisingly, the media has already been busy reporting on some of the many tragic drowning incidents that have occurred thus far, and Facebook profiles have been full of commentary from worried parents. And, as usual, there are businesses offering infant and toddler swimming lessons costing hundreds and even thousands of dollars per course, some of which come with claims of decreasing the risk of drowning in the young participants.
At what age can a child begin swimming lessons? According to Jan Emler of Emler Swim School, teaching a child to swim can start “As soon as the umbilical cord falls off.” Emler, like more reputable proponents of infant and toddler swimming programs, doesn’t actually put newborns into swimming pools for lessons (I’ll leave water birthing enthusiasts out of this discussion). For the most part these programs only cover bath time activities to help younger babies grow comfortable being in the water. Truly teaching infants and toddlers behaviors aimed at reducing the likelihood of drowning in the event of falling into a body of water doesn’t usually start until 6 months of age. There are exceptions.
But when should these lessons start, are they safe and do they work? Or do they actually put children at risk of injury and the parent at risk of having a false sense of security? Until their updated 2010 policy statement on the prevention of drowning, the American Academy of Pediatrics came down firmly against initiating swimming lessons in children less than 4 years of age for a number of very good reasons. Why did they soften their stance and does their change of opinion support the claims that are being made by infant and toddler swimming programs? First some background information.
An Overview of Drowning
What is drowning?
The most widely accepted definition of drowning, determined during a 2002 international Utstein-style consensus conference in Amsterdam, is “the process of experiencing respiratory impairment from submersion/immersion in liquid.” This definition, as well as recommendations by the World Congress on Drowning and the WHO to avoid confusing terminology such as “near-drowning”, “wet”, “dry”, “silent”, or “secondary drowning”, has helped to make discussion and collection of data more consistent and reliable. They recommend categorizing drowning outcomes as death, no injury, or with injury (moderately disabled, severely disabled, vegetative state/coma and brain death). Determination of disability is primarily based on cognitive impairment but does take into account involvement of other organ systems. In 2010, the American Heart Association endorsed this approach as well.
How does drowning affect the body?
If you happen to have a phobia about drowning, you may want to skip this section as it will make clear why the process is so terrifying. All drowning incidents involve a liquid, usually water, invading at least the opening into the airway and leading to an inability to breathe air. Injuries are usually preceded by the onset of panic and loss of normal rhythmic breathing patterns. We hold our breaths as long as possible but eventually develop air hunger and are overcome by involuntary reflex attempts at breathing.
As the liquid enters the opening to the airway in the mouth and throat, the musculature reacts quickly to keep water out of the lungs by an intense spasm despite respiratory effort increasing dramatically. Often large amounts of liquid are swallowed. Oxygen levels in the blood continue to drop and carbon dioxide levels rise, leading to increasing acidity of the blood. (And we all know that people with acidic blood are at high risk for cancer, poor immune function and the dreaded Low T.) Eventually the muscle spasm will relax and water will be actively taken into the lungs in varying amounts.
During this process, no gas exchange is taking place in the lungs. This means that decreasing amounts of oxygen will be delivered to vital organs like the brain and heart. Water in the lungs adds insult to injury by causing increased blood pressure in the pulmonary blood vessels and abnormal shunting of blood. The worsening acidosis and hypoxia (lack of oxygen) can cause fatal heart arrhythmias, renal failure, and clotting abnormalities, but cerebral hypoxia is the primary means of disability and death.
How does drowning impact children?
By far the most common causes of death in young children are unintentional injuries. And of these fatal injuries, drowning is the most common culprit in children aged 1 to 4 years. It is the second-most common cause of injury related death overall through 18 years of life, killing about a thousand kids each year in the United States.
But it isn’t just fatal outcomes that make drowning injuries such a scourge in pediatrics. For every fatality there are many more nonfatal drowning injuries that are seen in emergency departments each year, of which many require hospitalization and about 5-10% lead to long-term disabilities caused by damage to the central nervous system. Caring for severely disabled children is often a significant emotional strain on parents, the result of which can be devastating for the family unit. Least of the many well-recognized negative aspects of pediatric drowning in my opinion, but important nonetheless, is the monetary cost. The lifetime expense of caring for pediatric drowning victims runs up a bill of roughly 3 billion dollars each year.
Which kids drown?
Drowning related injury and death occurs across the pediatric spectrum but it is an entity that does discriminate to a certain degree. Young children, for instance, are considerably more likely to die compared to kids over the age of 4 years. Another way in which drowning discriminates is based on ethnicity. Although white children of all ages drown more often than any other ethnicity in the United States when looking at total numbers, black and Hispanic children have a much higher rate of drowning (1.95 versus 1.29 deaths per 100,000). In fact, the group at highest risk for drowning are black teenagers (over 4 deaths per 100,000) with white toddlers a not-too-close runner up.
There are a variety of proposed explanations regarding why minorities, in particular black children, are at such increased risk of drowning. Many black families place less emphasis on swimming as a desirable life skill, often because of a paradoxical parental fear of their child drowning. Other cultural and socioeconomic factors such as lack of access to or awareness of affordable lessons are also at play. Parents of black children are also more likely to be unable to swim themselves.
A tragic 2010 drowning incident that occurred in Shreveport, LA illustrates these concerns perfectly. 6 black teenagers drowned in the Red River when they accidentally went from waist deep water into a deeper area with a stronger current. Their parents watched helplessly. Nobody present at the scene could swim.
Where and when do children drown?
Geographically, children that live in states that experience longer and more intense summers are at higher risk. The reason for this is obvious, or at least should be. More obvious at least than the reason why ice cream consumption correlates with drowning but isn’t causally related, even if consumed less than an hour before heading back into the water. Longer and more frequent access to water is the key, and kids eat more ice cream in the summer. If you really are worried about your child drowning, move to New England. That is not the reason I’m moving there, however. I just really like lobsters and drinking out of bubblers instead of water fountains.
Younger children are much more likely to drown in bath tubs and swimming pools but have been known to drown in almost any larger containers of water including toilets, buckets, fish tanks and fountains. Even deep puddles can be dangerous. Younger children, particularly toddlers that have gained mobility through cruising/walking, have large heads and little bodies. They also have poor balance, coordination and strength. This is why you will never see a 15-month-old on an Olympic gymnastics team. They are also curious. This is a recipe for disaster if poor supervision is added to the volatile mix, and it very often is.
Older kids, mostly boys once into the 5 years of age and older group, increasingly tend to drown in open water as they age. Teenage victims are most likely to both drown in a lake, river, or ocean and to be drunk while doing so. When looking at the impact of ethnicity on drowning location, white children overall tend to drown more in backyard pools while black children are more likely to drown in public or hotel pools.
Why do children drown?
The single most important factor in pediatric drowning is the level of supervision. There are other potentially important issues like swimming ability (we’ll get to that shortly), intoxication, use of personal flotation devices (not water wings!) and medical conditions like seizure disorders, but even a seizing teenager who can’t swim and just polished off a liter of MD 20/20 would be very unlikely to drown if a sober adult is there watching closely. Although he would probably just tell you how embarrassing you are. I can’t wait for my kids to be teenagers. But despite most people being aware of the importance of proper supervision, there are frequently lapses that occur. Many drowning injuries, both fatal and nonfatal, occur when a parent or caregiver leaves the scene for only a brief period and sometimes even when they are within a few feet of the child but aren’t paying close attention. We recommend never being more than an arms length away when watching young children.
Swimming Ability and the Role of Swimming Lessons in Pediatric Drowning
Before delving into the nuances of this topic, let me be completely clear about one thing: there is absolutely no such thing as “drown-proof” young child, or any age child for that matter, regardless of their ability to swim or initiate any learned safety maneuvers. The Titanic could sink and, if they have access to a large enough body of liquid, any child can drown. The only thing that comes close to perfect prevention is direct and unwavering observation by a competent adult.
So does swimming instruction decrease the risk of drowning? This question isn’t exactly on par with whether or not parachute use prevents “death and major trauma related to gravitational challenge.” Common sense would seem to tell us that of course there must be a decrease in the risk of drowning as the ability to swim increases, and for what it is worth I believe it myself. But common sense, as we all know, often steers us in the wrong direction. Intuition on the other hand…
In older swimmers, the relationship is the most plausible but remains unproven because of a dearth of good evidence. Better swimmers likely spend more time in and around water and may take risks a less proficient swimmer wouldn’t, so it isn’t entirely implausible that there may actually be an increased risk of an incident. Also, as I attempted to make clear earlier, swimming proficiency certainly doesn’t remove the risk of drowning entirely. In one study, 16% of victims of drowning fatalities were reported to be average or strong swimmers. Remember, a majority of adolescents who drown are in open water and many are intoxicated.
In children ages 1 to 4 years the benefit of swimming ability and instruction, regardless of whether or not it specifically includes emergency maneuvers like rolling onto the back and floating/kicking for the pool edge, is less clear. Pediatricians have had a number of very plausible concerns and until recently there was a complete lack of any good data to work with. Also, there was data to support the fear that parents of young children enrolled in swimming programs might develop a false sense of security and increase the likelihood of poor supervision. Or that those children who have taken part in such a program may be less fearful of water and more likely to attempt to swim while not being observed.
As I stated earlier, for years the AAP came down firmly against swimming instruction under age 4 years, citing a lack of neurological maturity, but relaxed their position in 2010 based on a few new studies that showed a possible benefit. These studies were small and I believe should be considered preliminary. They probably should be interpreted as showing that there doesn’t appear to be any increased risk rather than conclusively showing that there is great benefit. And they don’t address which type of instruction might work best or whether the apparent small decrease in drowning risk is because of improved supervision, as many programs teach general water safety, rather than any new skill the child might have learned.
The current AAP statement includes language to the effect that the evidence, as weak as it is, does not support prohibition nor does it support a blanket recommendation in favor of swimming lessons in this age group. It depends on the child’s readiness and that must be determined by the caregiver and physician. The AAP still strongly discourages programs dedicated to infants less than 1 year of age because there is no evidence whatsoever of decreased risk of drowning.
The American Red Cross Advisory Council on First Aid, Aquatics, Safety and Preparedness agrees with the AAP but pushes the age up to 2 years. They specifically disagree with claims that instruction in back floating prevents drowning in very young children. This issue has required addressing by pediatricians and water safety experts because there are a large number of programs specifically targeting infants down to 6 months. Check out the first video on this site and see if it nauseates you as much as it did me.
Again, there is no evidence that this actually saves lives. What dramatic anecdotes like this rely on is a normal reflex seen in aquatic mammals (and penguins), including humans to a lesser degree, known as the diving reflex. When the face of an infant is exposed to cold water, the heart slows down and blood is shifted away from the peripheral muscles to conserve oxygen for the brain and heart, and they typically hold their breath. The reflex is much stronger in the young, and allows for prolonged submersion under water, something useful for whales but less so for human infants.
This can’t be taught, despite what some programs claim. Physicians, however, can sometimes take advantage of this reflex to treat a condition called supraventricular tachycardia but it does have risk. A bag of ice water to the face might correct a heart rate of 250 secondary to SVT but in children with long QT syndrome, a cardiac rhythm problem that predisposes to sudden death, the diving reflex can trigger a fatal arrhythmia. Thankfully this is a very rare occurrence.
Another aspect of exposing young infants to submersion is spasm of the respiratory muscles when the oral cavity and upper airway is hit with cold water. This non-painful reflex does typically prevent aspiration of water into the lungs for brief periods but it does not prevent the swallowing of large amounts of water, which is common. For this reason, diluting the level of sodium in the blood is a potentially deadly outcome in infants submerged in water several times in a short period of time. Some programs are aware of this risk and claim to limit the number of submersions per session in infants.
The cold water required for the diving reflex to kick in also predisposes young infants to hypothermia. Additionally, exposure to pools is a risk for gut and respiratory infections as well as respiratory illness caused by the chemicals used to treat the water. These risks are not extreme, but taking into account the complete lack of any evidence of benefit, I believe that the AAP and other safety organizations are right to frown upon these programs and focus on educating adults on proper supervision and water/boating safety.
What can you do to prevent pediatric drowning?
There are steps to take even if you don’t personally have children. Most importantly, never leave a child under your care alone while they are in or around enough water to drown in, even for a few seconds. If you happen upon one while looking for sea glass, be a good citizen. Avoid distractions and don’t rely on other children to alert you in case of trouble.
Putting an appropriate fence around your home pool is a proven means of decreasing the risk of pediatric drowning. It must provide a complete barrier separating the pool from the house and yard. It should have a self-latching gate and be difficult to climb or squeeze through but not obstruct the view of the pool. Pool covers on the other hand have not been proven to be an adequate substitution for proper fencing and some are dangerous because a child can become entangled. The same goes for pool alarms.
Avoid, if possible, allowing younger children to swim in areas where a lifeguard is not present if you can’t be a good observer and learn CPR. Learn to swim and, yes, make sure your kids know how to swim. If you want to start them after age 1, that is an individual decision but discuss it with their doctor. Definitely start lessons once they are 4 years of age. All young children, and all children on a boat, should wear a lifejacket-type personal flotation device. Make sure that pool drains have appropriate covers to avoid a child becoming entrapped or entangled under the water. Talk to your older kids about pool safety, especially avoiding alcohol while swimming or boating, and don’t drink and supervise yourself. Oh, and always wear sunscreen.
For a more complete breakdown of water safety, check out this handout from the AAP.

Summer is Here, and Infant Swimming Programs are Still Unproven
Summer is in full swing and many babies are hitting the beaches and pools for some fun in the sun. Unfortunately, those swimming lessons for infants that you might have seen advertised online are still unproven and potentially dangerous.
Clay Jones on July 9, 2021
Link


In one of my earliest posts for SBM, I wrote about a leading cause of death and severe neurologic injury in the pediatric population: drowning. In particular, I discussed the promotion of infant (< 12 months of age) swimming programs despite a complete lack of evidence in support of their effectiveness in preventing drowning. I also discussed the latest AAP policy statement on drowning prevention.
That was eight years ago. In the interim, people have continued to drown at terrifying rates. In the United States, there are 11 fatal drownings every day and twice as many nonfatal drownings, meaning that thousands of people die or suffer long-term disability every year. When it comes to kids, drowning kills more toddlers (1-4 years) than anything except for birth defects and is the third most common cause at 9% of unintentional deaths in children aged 5 to 19 years behind car accidents (60%) and drug poisoning (13%). Drowning is just as big of a problem worldwide. And though there have been improvements in these statistics, particularly when compared to the 1980s, these have stalled in recent years.
I recently happened upon some of the same advertising for infant swimming lessons that I discussed back in 2013. Current ads and program websites are making the same claims of drowning prevention that I saw back then and had described as implausible, unproven, and potentially dangerous. Here is an example from Infant Swimming Resource, “the global leader” in “survival swimming lessons for infants”:
ISR’s core conviction is that the child is the most important part of a drowning prevention strategy and our over 300,000 ISR graduates and 800 documented survival stories are proof that children can save themselves. Children are curious, capable, and have an uncanny ability to overcome obstacles like pool fences; at ISR we take that ability and teach them skills to potentially save themselves if they find themselves in the water alone.
Putting the onus of drowning prevention on an infant is more than a bit ridiculous. To be fair, ISR does discuss other means of drowning prevention such as parental supervision and proper fencing around pools, but they frequently call them unreliable. And even if they didn’t downplay the role of those interventions, paying lip service to them doesn’t make it okay to make claims about their swimming lessons that aren’t backed by evidence.
Of course, they say that the proof is in the many documented survival stories that they have received. I went back through several years of their blog and found none that involved a child less than a year of age. Some don’t even involve use of any specific ISR techniques and just come down to luck or the assumption that a child might have used an ISR technique if they had actually fallen into a pool. Poor supervision, however, is a consistent theme in the anecdotes that I was able to find. I am not aware of any published research showing a benefit.
But have I missed something? Was research published during the past 8 years that found these programs can save lives? Has the AAP changed their tune on infant swimming lessons for drowning prevention? A quick search did bring to my attention that there was a major policy statement update in 2019 that I hadn’t seen yet. With an open mind, I dove/dived back into the topic.
But first….
The pathophysiology of drowning
Drowning is defined as “The process of experiencing respiratory impairment from submersion/immersion in liquid”. Terms such as “near-drowning”, “wet”, “dry”, “silent”, or “secondary drowning” are inaccurate and confusing, and should be avoided. Drowning outcomes include death, no injury, or with injury (moderately disabled, severely disabled, vegetative state/coma, and brain death). Disability is primarily based on the degree of cognitive impairment.
The drowning process during complete submersion is complex and terrifying. As liquid occludes the opening into the airway and prevents breathing, panic ensues and breath is voluntarily held. Air hunger inevitably wins out and you are overcome by involuntary reflex attempts at breathing, allowing liquid to enter the mouth and throat. A powerful spasm of the muscles surrounding the upper airway occurs which prevents the liquid from entering the lungs despite the desperate involuntary attempts to breathe. Large amounts of liquid are often swallowed at this point.
As this is going on, blood oxygen levels are dropping while carbon dioxide levels simultaneously rise, leading to metabolic and respiratory acidosis. Eventually the muscles of the upper airway relax and allow the liquid into the lungs, rendering them incapable of gas exchange. Starved of oxygen, vital organs such as the brain and heart will be damaged. Pulmonary hypertension, worsening acidosis and lack of oxygen result in fatal heart arrhythmias, kidney failure, and abnormal clotting, but lack of oxygen to the brain is the primary cause of disability and death.
Pediatric drowning 101
As I mentioned above, drowning kills a lot of kids every year and children under the age of 4 years are especially at risk. And while white children of all ages drown in larger total numbers than other ethnic groups in the United States, a higher percentage of black and brown children suffer fatal drowning injuries. Black teenagers specifically are the group most at risk, followed by white toddlers.
Largely due to social and cultural factors, children from ethnic minority groups are more likely to drown because they are less likely to know how to swim. Their parents are also less likely to have acquired this skill and tend to place less emphasis on swimming than white parents in general. This almost certainly has roots in historical (and current) systemic societal racism, but it is a complex problem with multiple factors at play.
When it comes to where kids drown, the answer is also complex. Geographically speaking, there are more drownings in regions with higher temperatures over longer periods of time. More time in or around pools or natural bodies of water means more drownings. But curious toddlers also drown in bath tubs, fountains, buckets of water, and even deep puddles because of a combination of increased mobility, bodies with disproportionately heavy heads, and poor coordination and strength.
Older children are more likely to drown in natural bodies of water such as lakes, rivers, and oceans. Alcohol intoxication, or really any illicit or prescribed drug that impairs judgement and/or coordination, is also more likely to play a role. Home swimming pools are more likely to be involved when white kids drown while black children are more likely to die in public or hotel pools. The most important factor involved in almost all pediatric drownings, however, is an absence of supervision. But even the most attentive caregivers are only human, and mistakes are often made that allow unsupervised young children access to bodies of water. So it’s understandable that many caregivers might seek out a way to reduce their child’s risk.
What about those swimming lessons?
General water safety education that might go along with swimming lessons is almost certainly beneficial, especially when it involves caregivers of young children and older swimmers that are more likely to be on their own. But what about the specific techniques learned by the children themselves? What about skills like treading water, turning to float on the back (a common focus in infant lessons), and instruction on the basic strokes? Does this prevent drowning?
Although there is some plausible nuance, swimming lessons do decrease the overall risk of drowning in older children and there is evidence to back this up, although this isn’t something that can ethically be studied using a prospective trial where some children are not allowed to learn how to swim. But it is possible, on an individual basis, that increased confidence in one’s own swimming ability might lead to more risky behaviors. This might also simply result in more chances for an accident to happen in a body of water. Neither is a reason to avoid swim lessons for older children, however.
But what about toddlers? One of the main points of my 2013 post was that the AAP had done a bit of an about face on lessons for children aged 1 to 4 years in their 2010 policy statement. They went from strongly recommending against them to stating that they haven’t been proven to prevent drowning but at least probably don’t make it more likely to happen. There was some evidence for decreased risk in that age group at that time but it wasn’t clear if that was because of any specific skill learned by the child or because of water safety education for the parents. Maybe they just result in improved caregiver supervision.
The American Red Cross Advisory Council put out a policy statement in 2009, which has not been updated since, stating that swimming instruction in younger children hadn’t been shown to increase the risk of drowning but didn’t decrease it either. They didn’t proscribe introduction to water/water safety classes for any age, but felt that there was no proven drowning risk reduction benefit linked directly to skills taught to children less than essentially 2 years of age. Their take home point was that any classes for younger kids should focus on teaching a comprehensive approach to water safety that involves caregivers and their behaviors as well as means of preventing unsupervised access to water.
In their 2010 statement, the AAP did not yield when it came to pushback against claims of drowning safety benefits when it came to infants. The Red Cross Advisory Council agreed. They both specifically went after the common tactic of teaching back floating to infants who are first forced under the water, pointing out the absence of evidence in support of it as a specific risk reduction strategy. In my 2013 post, I discuss how the videos demonstrating babies doing this are unrealistic marketing videos and how this technique is unreliable and potentially dangerous.
The AAP updates its policy on drowning prevention
In 2019, the AAP released an updated policy statement on the prevention of drowning. Although I’m focusing on infant swimming lessons in this post, there are some important issues discussed in the new update. One aspect of drowning that was fleshed out a bit more was the role of certain underlying medical conditions, such as epilepsy, autism, and cardiac arrhythmias, all of which increase the risk of drowning. The AAP also went into more detail regarding the potential impact of some culture and traditions, as well as a lack of resources ($$$) on the ability for a child to learn how to swim, and they offer some potential ways to work around them.
The statement places importance on children developing water competency as well as swimming skills, but they appropriately place these in the context of layers of general drowning prevention strategies that are equally important. They discuss a matrix for preventing drowning that involves personal, physical environment, and social environment factors as well as equipment. For example, this could include caregiver supervision, swimming where lifeguards are present, laws to increase access to affordable swim lessons that are culturally competent, and 4-sided fencing respectively.
When it comes to infant swimming lessons being promoted as a means of reducing the risk of drowning, the AAP hasn’t budged:
In contrast, infants younger than 1 year are developmentally unable to learn the complex movements, such as breathing, necessary to swim. They may manifest reflexive swimming movement under the water but cannot effectively raise their heads to breathe. There is no evidence to suggest that infant swimming programs for those younger than 1 year are beneficial.
So yes, this is dangerous nonsense.
Here is an example of how to do it right.
And here is a nice summary of the AAP policy statement.
Don’t be fooled by infant swim lesson marketing hype
You can find many videos online showing older infants being pushed underwater who then float to the surface and turn on their backs for a few moments before being picked up by a caregiver or instructor. I’m not saying that infants can’t sometimes or even often do these behaviors in a controlled environment. But these are cherry picked videos. You won’t see marketing videos of infants sputtering with water in their mouths or noses, or being quickly grabbed when the instructor sees that they aren’t going to get their faces clear of the water in order to breathe. You also won’t see videos of babies with hypothermia or electrolyte aberrations caused by swallowing large amounts of pool water during these lessons, although admittedly this is a rare occurrence.
More importantly, these lessons do not translate to the events that lead up to drownings. It is dangerous to believe that any toddler, and certainly any mobile infant, will reliably perform these skills when falling into a pool and not immediately lifted up by a caregiver or lifeguard. And what if the water is cold? What if they aspirate when their face hits the water as they fall into it? What if they hit their head on the side of the pool? What if it’s a toilet or bucket of water and they can’t push themselves up and out of it? What if it’s a pond and they become stuck in mud or tangled in water plants? What if a child’s caregivers develop a false sense of security and relax their supervision, even for a few minutes?
That’s all it takes. Minutes. Maybe less.
Classes where infants and a caregiver spend time in the water are fine. They should include general water safety education. They should promote constant supervision and encourage water competence and safety skills appropriate to your child’s developmental stage. They should not claim or even imply that they somehow teach your child to save themselves from drowning.

Drowning Deaths Continue Post-Pandemic Rise
More people, mostly kids, are drowning these days, in no small part because of the pandemic.
Clay Jones on July 19, 2024
Link

Summer is here, again, and reports of deaths from drowning are a common occurrence. They always have been. But recently released CDC data from 2022 confirm that the significant increase in the number of these fatalities seen during the first year of the pandemic, and again in 2021, were not a fluke. The increase in drowning deaths over the past three years, and perhaps even four or five based on some preliminary 2024 data, represents a reversal of a decades long decline.
Drowning deaths were common before 2020, with about 4,000 each year for the past two decades. Since 2019, however, that number has increased by about 500 deaths per year with pediatric and adult populations all seeing higher numbers. Though guns are the leading cause of death in childhood, drowning kills more children aged 1 to 4 years than anything else, and there has been a 28% increase in that age group since 2019.
And like firearm deaths, there are significant disparities when it comes to drowning, with certain minority groups, particularly black and indigenous people, being at higher risk. Black people specifically have also experienced a 28% increase in drowning deaths since 2019. Poverty and cultural differences are likely to blame for much of the disparity seen in these numbers considering that swimming lessons and even access to pools don’t tend to come cheap, and there may be less emphasis on swimming as a skill in some communities. This leaves many at risk when they do find themselves in water, even adults, 40 million of which do not know how to swim according to recent CDC data:
    • More than 1 in 3 Black adults (37%) reported not knowing how to swim compared to 15% of all adults.
    • About 2 in 3 Black adults (63%) reported never taking a swimming lesson.
    • About 3 in 4 Hispanic adults (72%) reported never taking a swimming lesson.
https://www.cdc.gov/vitalsigns/drowning/index.html#:~:text=Over%204%2C500%20people%20drowned%20each,in%202022%20compared%20to%202019.
Drowning kills a lot of kids every year and, as I mentioned earlier, children under the age of 4 years are particularly at risk. And while white children of all ages drown in larger total numbers than other ethnic groups in the United States, a higher percentage of black and brown children suffer fatal drowning injuries. Black teenagers specifically are the group most at risk, followed by white toddlers.
Again, social and cultural factors play a key role in the increased risk of drowning seen with children from ethnic minority groups. Like their parents, they are simply less likely to know how to swim compared to white kids. This almost certainly has roots in historical (and current) systemic racism, but it is a complex problem with multiple factors at play, all of which were likely exacerbated by the societal upheaval caused by the pandemic.
When it comes to where kids drown, the answer is also complex. Geographically speaking, there are more drownings in regions with higher temperatures over longer periods of time. More time in or around pools or natural bodies of water means more drownings. And the higher than typical temperatures being seen in many regions as a result of climate change almost certainly play a role in higher numbers of drownings. But curious toddlers also drown in bath tubs, fountains, buckets of water, and even deep puddles because of a combination of increased mobility, bodies with disproportionately heavy heads, and poor coordination and strength.
Older children are more likely to drown in natural bodies of water such as lakes, rivers, and oceans. Alcohol intoxication, or really any illicit or prescribed drug that impairs judgement and/or coordination, is also more likely to play a role. Home swimming pools are more likely to be involved when white kids drown while black children are more likely to die in public or hotel pools. The most important factor involved in almost all pediatric drownings, however, is an absence of supervision. But even the most attentive caregivers are only human, and mistakes are often made that allow unsupervised young children access to bodies of water.
The title of my post may seem a bit provocative. Are we really blaming the significant increase in the number of deaths caused by drowning since 2019 on a virus? Is this another COVID-19 conspiracy? Nope.
As I’ve hopefully made clear, drowning is a complex and multifactorial issue. Although it is perhaps only conjecture at this point, I believe that it is fairly safe to say that the pandemic played a role in increasing the risk for a lot of people, especially children, for a number of reasons. For example, the availability of swimming lessons decreased when public facilities were closed, meaning many children may have missed an opportunity to participate. Also the early months of the pandemic found more children at home instead of schools or at supervised activities during the warmer months when a pool or other body of water was nearby.
Many caregivers of young children who are most at risk of drowning have had to deal with a lot over the past few years. Economic turmoil, like any significant stressor, can have myriad negative downstream repercussions that might result in less capable or consistent supervision. Millions of children lost primary caregivers to COVID-19, perhaps leaving them in the care of other relatives or family friends not as prepared to provide diligent supervision. And daycare options were, and still are, limited. These and many other concerns remain a significant challenge for many families.
Although it looks like the drowning numbers from 2023 will be worse than more recent prepandemic years, hopefully we will see some improvement when that data is finalized. 2022 wasn’t quite as bad as 2021 or 2020, after all. Maybe things are settling down as the economy improves and more younger children are getting back into swimming lessons. Even if we do get back to how things were, that still leaves us with thousands of preventable deaths every year and we need to do better.
Here is some important drowning prevention information from the CDC. They discuss some key factors to focus on, such as the importance of supervision of young children and of knowing and taking into account the potential problems associated with natural bodies of water. Adults, even those who know how to swim and aren’t in a high risk group, need to take this seriously as well and avoid making unsafe choices. A James Beard award winning chef died in a river just last week because she didn’t follow basic safety recommendations.
Here is another great resource for pediatric drowning prevention.
Have fun, but be safe out there.

More Marijuana More Problems for Young Children
Young children explore their environment with their mouths. As more marijuana edibles make their way into homes, more potentially dangerous unintentional ingestions are going to happen.
Clay Jones on July 27, 2018
Link

On Wednesday, Steve wrote about the lack of high quality evidence in support of medicinal marijuana for most of the myriad conditions for which people claim benefit. In his post, he touched briefly on the issue of safety when he included the following quote from a 2018 systematic review on the use of cannabinoids for multiple sclerosis:
However, cannabis use has been associated with an increased risk of psychosis and schizophrenia in at-risk individuals, there is growing evidence that cannabis can increase the risk for cardiovascular diseases, including myocardial infarction (MI), hypertension, heart failure, and stroke, and a recently recognized adverse effect of cannabis is cannabinoid hyperemesis syndrome.
Coincidentally I was also planning on writing a post about the subject, although from the angle of safety concerns in young children, specifically the risk of harm from accidental ingestion. Before I get to that, I would like to point out that some of the issues listed in the above quote do effect pediatric patients. I have personally taken care of one teenager who have developed psychosis believed to be attributed to heavy marijuana use, and several older children who had developed debilitating chronic nausea.
Canadian cannabis chocolate sends a toddler to the hospital
What got my attention this week was an article written by this Yvette d’Entremont (not that Yvette d’Entremont) in The Star Halifax about a local 4-year-old child that had been hospitalized after eating 15 pieces of a chocolate bar containing cannabis. One piece would have been the typical daily dose for an adult, and 15 is a lot more than that, even using the metric system. The article doesn’t go into the details of her clinical presentation, but I assume it was severe if it warranted admission. Thankfully she recovered and was discharged home in good health.
On October 17th, marijuana possession will become legal in Canada, although the selling of edibles will remain illegal. It’s easy to imagine that marijuana in all its various forms will soon become more widely prevalent, just like it has in the states that have legalized medicinal, and especially recreational, marijuana. Increasing prevalence of edibles, particularly those that come in candy, cookie, brownie, or chocolate varieties, means that more children will live in homes and ride in cars as in the Halifax case, where marijuana is present. And this means that more children will suffer toxic effects from unintentional ingestion.
I assume you have evidence to justify your concerns, Dr. Jones
Yes, yes I do.
Probably the best place to look into this potential outcome is in Colorado, the first state to legalize recreational marijuana. A 2016 JAMA Pediatrics paper did just that. In fact, this was the first paper to specifically look at the effect of recreational marijuana in the pediatric population.
This retrospective cohort study involved inpatient and outpatient visits to Children’s Hospital Colorado, Aurora and its associated urgent care centers as well as Colorado regional poison control cases from January 1, 2009 to December 31, 2015. The study focused on children under the age of 9 years and found that hospital visits related to marijuana exposure were twice as frequent 2 years after legalization compared to 2 years prior, and that edibles were to blame for half of them.
In addition to this, poison control cases were 5 times more frequent in 2015 compared to 2009, an increase of 34% each year. The rest of the country only saw a 19% increase. Edibles also accounted for half of these calls, and poor child supervision or inappropriate product storage were common factors. The authors concluded that legalization of recreational marijuana played a role in the significant increase in pediatric ingestions.
Vous avez surement plus de preuves que ca!
Oui, oui je fais.
Cannabis is illegal in France, but it is an extremely popular recreational drug, particularly among teenagers and young adults. The most popular form of marijuana used in France is hashish, a resin that is either smoked or eaten. There has been a trend of increasing use and increasing THC concentrations in marijuana over several years, which raised concerns of pediatric exposure risk.
In September of last year, French researchers published a report in Pediatrics that looked at admissions for pediatric unintentional cannabis intoxication over an eleven year period ending in 2014. This retrospective, national, multicenter, observational pediatric cohort study involved all children under the age of 6 years admitted to a pediatric emergency department for symptoms proven via toxicological testing to be caused by cannabis ingestion. They found some alarming trends.
During the study period, annual admissions increased by a factor of 13, and as would be expected hashish resin was to blame in about 3 out of every 4 cases. In addition to the significant increase in proven toxicity from cannabis in children, they found that the age at admission was also trending younger and that the clinical presentations were more severe, in particular the incidence of coma was substantially higher. Cannabis-related admissions outpaced all other ingestions in this age group.
The study authors rudely point out that these factors are also an issue in the United States, and are more concerning where marijuana has been decriminalized. Furthermore, they add, attractive packaging and names that mimic actual food products, such as “Pot Tarts” and “Munchy Way”, that are increasingly popular in the United States, likely increase the risk of unintentional ingestion. In countries where THC concentrations have remained low, or where use primarily consists of smoking in coffee shops, pediatric unintentional ingestions are almost unheard of.
One more study for good measure
In November of 2017, The Journal of Pediatrics published a systematic review of published reports of unintentional cannabis ingestions in children, specifically children under the age of 13 years. Unsurprisingly, they found a bunch of them. Here are a few take home tidbits from this paper:
     1.  Children with cannabis toxicity more commonly present with lethargy, difficulty walking, poor muscle tone, fast heart rates, and low respiratory rates.
     2.  Young children explore their environment with their mouths, so ingestions most likely result from discovery of cannabis-infused food items left unsecured by an adult.
     3.  Older children like to eat things that look and/or taste good, and many edibles come in the form of cookies, candies, and cakes in attractive and familiar packaging.
     4.  Commercial edibles can contain extremely high doses of THC and are meant for consumption over time, but kids like to eat the whole damn thing.
     5.  Hashish is often mistaken for chocolate by young children.
     6.  Unintentional pediatric ingestions have increased in states where marijuana has been legalized, particularly recreational use, and this is expected to continue.
     7.  In these states, the perception of toxicity risk is lower compared to states where marijuana is not legal.
     8.  Acute and chronic marijuana use by adults can impair cognitive and executive function, attention, and memory, which might increase the risk of improper storage.
     9.  There are no federal regulations on the packaging of cannabis products, as there are with all other toxic household products, OTC medications, and prescription medications.
     10.  This is going to get worse before it gets better.
Conclusion: Pediatric ingestions are inevitable but we can reduce the risk
It’s hard to argue with the claim that as more marijuana is around children, and particularly more edibles that look and taste like candy, there will be more unintentional ingestions of it. Eating stuff that they shouldn’t is just a thing that young children do. Unfortunately, there is reason to worry that partaking caregivers, older siblings, and visitors to the home are not going to be as diligent about keeping pot and pot products out of reach of children as they might bleach or rat poison.
Marijuana obviously isn’t going anywhere, and I personally don’t think that the issue of pediatric ingestion should be used as an unwieldy cudgel in someone’s fight against legalization. As is often the case, education and regulation is the key. This means recognition of this potential problem by healthcare professionals and frank discussions with families. Public health campaigns need to be implemented. In addition, our elected leaders need to step up and enact laws that will help to protect children.
Ingestions are going to happen, but you can reduce the risk. In fact, you can start right now by putting that stuff out of the reach of children. Finally, if you are seeking medical attention for a child that may have ingested marijuana, even if you weren’t exactly obeying your particular state’s laws regarding marijuana possession and use, please be honest with the medical professional caring for them.

More Marijuana More Problems for Young Children Part 2: Additional Problems for the Aforementioned Children
A recent study found that young children are increasingly being harmed by accidental ingestion of cannabis in the form of edibles.
Clay Jones on May 12, 2023
Link

In the summer of 2018, when the SARS-CoV-2 pandemic was on the distant horizon and full facial nudity was rampant in our nation’s hospitals, I wrote about the problem of increasing numbers of young children becoming ill after accidental ingestion of cannabis as laws, social norms, and perception of risk continued to relax. I particularly focused on a 2017 systematic review of unintentional cannabis ingestions in children which had several interesting findings:
     1.  Children with cannabis toxicity more commonly present with lethargy, difficulty walking, poor muscle tone, fast heart rates, and low respiratory rates.
     2.  Young children explore their environment with their mouths, so ingestions most likely result from discovery of cannabis-infused food items left unsecured by an adult.
     3.  Older children like to eat things that look and/or taste good, and many edibles come in the form of cookies, candies, and cakes in attractive and familiar packaging.
     4.  Commercial edibles can contain extremely high doses of THC and are meant for consumption over time, but kids like to eat the whole damn thing.
     5.  Hashish is often mistaken for chocolate by young children.
     6.  Unintentional pediatric ingestions have increased in states where marijuana has been legalized, particularly recreational use, and this is expected to continue.
     7.  In these states, the perception of toxicity risk is lower compared to states where marijuana is not legal.
     8.  Acute and chronic marijuana use by adults can impair cognitive and executive function, attention, and memory, which might increase the risk of improper storage.
     9.  There are no federal regulations on the packaging of cannabis products, as there are with all other toxic household products, OTC medications, and prescription medications.
     10.  This is going to get worse before it gets better.
In May of 2023, a full decade later in COVID years, there are still no federal regulations on the packaging of cannabis products. Many states, however, have enacted specific laws regarding labeling and child-resistant packaging. For example, my home state of Massachusetts has some of the strictest rules and regulations. Obviously states like Texas, where neither medical or recreational marijuana has been legalized, have no such safety regulations. And no laws on the books are capable of preventing caregivers of young children from haphazardly leaving their stash of edibles where kids can get their grubby mitts on them.
The last interesting tidbit from the 2017 systematic review on that list was sadly, and unsurprisingly, extremely accurate. In fact, according to a paper published in February in Pediatrics, there was a roughly 1,400% increase in the number of young children that were unintentionally exposed to edible cannabis products from 2017 through 2021 based on the most recent available national poison control center data. That wasn’t a typo.
The authors of the paper found that in 2021 there were 3,054 reports of children in the United States under the age of 6 years that had ingested edible cannabis. In 2017, that number was 207. Virtually all of these ingestions occurred at someone’s home, with 90% of them taking place at the home of the child. Also of note, these events increased from .2 per every 1,000 national poison data system (NPDS) cases to 3.6 per 1,000 at the end of the 5 year study period.
During the period of 2017 to 2021, just over seven thousand edible cannabis exposures were reported in infants and toddlers. And despite the fact that cannabis has a largely undeserved health halo and is often thought of as low risk, it is far from harmless. This is particularly true in children, from newborns to adolescents, who have developing brains that can be negatively affected in ways that weren’t appreciated when exposure was less frequent and the potency of THC delivery systems was much lower.
The study found that 22.7% (1,600) of the reported cases resulted in a hospital admission, with 8.1% of them, or around 600 of these young children requiring PICU level care. 2.2% (155) involved a major adverse effect, which is defined in the NPDS as “life-threatening or causing residual disability or disfigurement.” Almost 22% (1,539) of the cases were moderate. The NPDS defines moderate effects as “more pronounced, more prolonged or more of a systemic nature than minor symptoms.” Moderate effects typically require medical treatment but are not life-threatening and allow a return to a pre-exposure level of health.
Not surprisingly, the organ most commonly affected by cannabis ingestion was the the brain. Central nervous system depression was documented in 70% of the almost 5,000 where clinical effects were documented. Of these, just under 2% had “more severe CNS effects, including major CNS depression or coma.” Other concerning effects documented were ataxia (poor muscle control and difficulty with balance and walking) and agitation, both in over 7% of cases, as well as confusion (6.1%), seizures (1.6%), and respiratory depression (3.1%). 35 children, or about .7%, required placement on a mechanical ventilator.
A few more interesting tidbits from the study:
     1.  While the number of NPDS cases involving edible cannabis exposures were increasing, the overall case volume in this age range decreased substantially from 956,871 to 846,296.
     2.  The severity of acute cannabis toxicity increased significantly, with more hospitalizations, more requiring PICU care, and a decrease in young children being “treated and streeted” by the emergency department.
     3.  Less than 2% of exposures occurred in infants, which makes sense because they have limited mobility and ability to open things. Toddlers aged 2 and 3 years beat the 4 and 5-year-olds 52% to 31%, likely because they are mobile, can open things surprisingly well, and more resistant to behavior manipulation.
     4.  It looks like the pandemic threw gas on the fire as there was a 300% increase in reported cases in 2020-2021 compared to 2017-2019. This was likely a result of more edibles and more kids around the home during quarantines and school/childcare closures.
     5.  There was also a 50% increase in both moderate and severe cases during the two pandemic years included in the study.
Conclusion: Education and regulation are still vital in protecting curious kids from edible ingestions
Sadly, my conclusion is essentially unchanged from what I wrote back in the summer of ’18:
Marijuana obviously isn’t going anywhere, and I personally don’t think that the issue of pediatric ingestion should be used as an unwieldy cudgel in someone’s fight against legalization. As is often the case, education and regulation is the key. This means recognition of this potential problem by healthcare professionals and frank discussions with families. Public health campaigns need to be implemented. In addition, our elected leaders need to step up and enact laws that will help to protect children.
Here in the future…I mean the present, we still need to educate the public on the risks of unintentional (and, well, also intentional) ingestion of cannabis products on many levels, which doesn’t mean that adult people can’t still have fun. But, you know, try harder to keep it out of the reach of children.
The authors of the study make the following recommendations:
Because most of these exposures occur in the child’s home (90.7%), educating caregivers and other adults in the home on how to safely store their cannabis products could significantly reduce exposures in young children. Ideally, these products should be stored in a location unknown to the children and kept in a locked container. Using locations outside the kitchen, away from other food items, may help reduce the risk of a child viewing these products as normal food items. Adults should be cautioned against using cannabis edibles in front of children because they may be likely to imitate the adult and attempt to ingest these products. Primary care providers can help prevent exposures by incorporating screening questions about cannabis use in the home and counseling caregivers on these practices.
And there are still no federal laws regulating how these products can be packaged and labeled, or how much THC they can contain. It’s absurd that only children in states where cannabis containing products are legalized in some fashion benefit from local laws that might require safer packaging and warning labels. But even those kids might be exposed to products imported from other, more Texas-like states, such as Texas, for example.
What will the data from 2022 look like once it’s available? It’s hard to imaging that it will be better. But now that the pandemic is over, perhaps I should be more optimistic and throw my bad attitude in the trash along with these face masks, bottles of hand sanitizer, and streaming service subscriptions. I’m going to go hug a stranger. See you in two weeks!

Young Children are Ingesting Dangerous Batteries at an Alarming Rate
Small children have been ingesting batteries at increasing numbers over the past decade, and many are suffering severe injuries. New rules and regulations may finally be helping, however.
Clay Jones on September 2, 2022
Link

A relatively short post this week as I am still recovering from a COVID-19 infection brought home from Cape Cod a couple weeks ago by my amazing wife, whom I love very much despite this unfortunate attempt on my life. Please go out today and get your vaccine or booster if you haven’t already and qualify. I certainly will be lining up for my next dose just as soon as I’m allowed.
In early 2019, I wrote about new research at the time that revealed a startling increase in pediatric foreign body ingestions and pointed out a few interesting facts and findings from the study:
     1.  20% of kids under age 3 years have swallowed a foreign object.
     2.  3 out of every 4 foreign-body ingestions occur in kids 5 years of age and younger.
     3.  With almost 68,000 Poison Center calls, foreign-body ingestions in kids under 6 years was the 4th most common complaint in 2016.
     4.  Neodymium magnet toys, tiny and extremely dangerous if ingested, are now back on the market despite efforts by the U.S. Consumer Product Safety Commission and Senator Gillibrand, as well as warnings from the medical community.
     5.  Between 1995 and 2015, 759,074 children under 6 years were seen in American emergency departments for suspected or confirmed foreign body ingestions, about 100 every day. There was a 4.4% annual increase.
     6.  The number of ingestions in 2015 were 93% higher than in 1995, with an increase from 9 to 18 out of every 10,000 kids in this age group.
     7.  Roughly 2 out of every 3 ingestions over this time period involved a coin, mostly pennies, but quarters were much more likely to result in hospitalization.
     8.  10% of children seen for a foreign-body ingestion were hospitalized.
     9.  Virtually 100% of ingestions, when the location was known, occurred at home.
     10.  Battery ingestions increased from .1% of the total number in 1995 to 8% in 2015, with 86% being the dangerous button variety, and were the 2nd most common cause of hospitalization after coins.
That last point involving button battery ingestion, and new research showing that the problem is getting worse, is the focus of my post today, Kids, it would seem, didn’t learn anything from my previous post. They continue to explore their environment in developmentally appropriate yet potentially harmful ways.
This week, a paper published in Pediatrics on battery-related emergency department visits in the United States has been making the rounds. The American Academy of Pediatrics, when they aren’t shaking in their boots because of attacks from non-expert internet users like Vinay Prasad, are attempting to raise awareness of the dangers of battery ingestions and calling for better safety regulations.
From January of 2010 through December of 2019, there were over 70 thousand ED visits as a result of cylindrical and button batteries in pediatric patients, which works out to roughly 1 in every 10,000 children each year. A significant majority, at 85% of visits, involved button batteries, and 9 out of every 10 ED visits were related to ingestions. The remainder involved children shoving small batteries into their nose, ears, or mouth, which can also cause serious tissue injury.
During this time period, there was a significant increase in how many children were seen in emergency departments, particularly those 5 years of age and younger. From 2010 to 2017, visit rates in that age range increased from 1.7 to 3.8 per 10,000. From 2017 to 2019, this increase did appear to level off, so I guess there may be some reason to be hopeful. But caregivers, as well as battery manufacturers, shouldn’t be complacent.
Why are button batteries so dangerous?
When ingested, or shoved into any body orifice for that matter, a button battery comes into contact with moisture. If lodged in place, the electrical current produced by the battery changes this water into highly alkaline hydroxide ions though hydrolysis, and this leads to a liquefactive necrosis that can progress even after removal of the offending battery. Although the most common injuries involve the esophagus, these batteries can cause destruction of the nasal septum and ear drum as well as important structures in the surrounding facial tissue.
Mild symptoms can begin within minutes of ingestion and there can be severe injury within just a couple of hours. In the new study, 12% of the over 70 thousand children brought to an emergency department for concerns related to batteries required hospitalization, which is a significant increase from previous data collected between 1990 and 2009. Other studies have also found an increase in both morbidity and mortality associated mostly with ingestions. There are more children ending up with major complications such as perforation of the esophagus, erosion into the trachea, scaring that causes blockage of the esophagus, vocal cord paralysis, and injury to nearby blood vessels that can cause catastrophic bleeding.
In 2019, I discussed how multiple factors were likely playing a part in the increase in battery ingestions seen at the time. In addition to better data collection, there are simply many more household electronic devices around these days, a lot of which require small batteries that are easily swallowed by young children. Other changes over the past 30 years, in particular the switch to larger lithium cells, have increased the risk of impaction and injury to surrounding tissue after ingestion.
So these batteries are in pretty much every home these days. In addition to this, they are often far too easy to remove from some packages and devices, sometimes even children’s toys. There have been several public education campaigns over the past few years, and some stricter regulations of the design of battery compartments so that they must a bit more childproof. Manufacturers have even played around with adding non-toxic bitter chemicals to small batteries, though this has never been proven to reduce ingestions.
Perhaps these changes are behind the plateau in ED visits from 2017-2019. Hopefully this isn’t a fluke, but more still needs to be done. On that front, I do have some good news. Just this month, “Reese’s Law” was passed by Congress and signed into law by President Biden. The Consumer Product Safety Commission must now develop child-resistant standards for battery packaging and device battery compartments and there must by information on ingestion risk and child safety instructions on labels.
Conclusion: Keep small batteries out of the reach of those little hands
This conclusion pretty much speaks for itself. Young children are curious and extremely successful at getting into things that could prove harmful. We need to make it as difficult for them as possible. Still, it is unlikely that the risk of battery ingestions will ever go away entirely. If a battery ingestion is suspected, help should be sought immediately. There is also good evidence that honey, as long as a child at least 12 months old and able to swallow safely, can reduce the risk of severe injury to the esophagus.

New Study Reveals Increase in Babies Injured by Nursery Products
After years of steady decline, a new study reveals a concerning increase in overall baby product-related injuries since 2003 and a sharp rise in concussions.
Clay Jones on May 5, 2017
Link


You are probably familiar with the occasional manufacturer recall warnings announced when a toy or other gadget, the majority of which can be categorized as “nursery products,” is found to be potentially dangerous. Unfortunately, most of these warnings go unheard or unheeded and as many as 80% of these recalled products remain in the home, where most early childhood product-related injuries occur. This, along with unique anatomic and developmental factors, is only one of the reasons why these injuries occur so frequently.
A historic victory for pediatric injury prevention advocates
While a variety of nursery products are known to play a role in early childhood injuries, the most infamous historically are baby walkers, and to a lesser extent the related jumpers and exercisers. These were once extremely popular products designed to support an older infant in a standing position and allow increased mobility, even the ability to push themselves across rooms (or over the edge of stairs), on wheeled platforms. The benefit of these products, it was claimed (and still often is), is improved motor and cognitive development, a belief that is not supported by evidence or endorsed by the American Academy of Pediatrics.
The AAP, which has repeatedly called for a total ban of this type of mobile product, once took part in a campaign aimed at educating parents and lawmakers, and increasing the awareness of potential harm. The reason pediatric healthcare professionals care so much is that these products allow infants to hurt themselves in a variety of terrible ways, the most serious of which being fatal head and spinal cord injuries occurring when children would tip over or fall down stairs during use. The campaign was very successful, resulting in an almost 90% decrease in injuries involving these products. Parents can still buy walkers, which we don’t recommend, but they are now much safer thanks to federal regulations mandating certain safety features.
The targeted intervention involving walkers and similar products worked and young children are safer because of it. But a study recently published in Pediatrics has revealed that nursery-product related injuries are still extremely common, and uncovered a concerning increase over the past several years.
Carriers, cribs, and strollers, oh my!
In the study, the first to evaluate a nationally-representative sample of children injured by nursery products, researchers retrospectively analyzed data obtained from 1991 to 2011 by the US Consumer Product Safety Commission’s National Electronic Injury Surveillance System. This tool is used to keep track of consumer product-related, sports, and recreational activity-related injuries seen in American emergency departments. They specifically looked at children under the age of 3 years.
The researchers found that nearly 1.4 million children under the age of 3 years required emergency department evaluation for nursery product-related injuries between 1991 and 2011, which works out to about 66,000 every year. The majority, around 60% or so, occurred before the first birthday, with the single most impacted age range being 6 to 11 months. This group was involved in 35% of the total injuries, which may make sense considering that this is when babies are becoming mobile, more interactive with their environment, and harder to carry around. A little over half of injuries involved male children and almost 90% took place at home.
Concerning trends in the data
From 1991 to 2003, largely thanks to the efforts to reduce injuries from baby walkers, the number and rate of nursery product-related injuries each year plummeted by 33% and 34% respectively. Then they began to increase, and by 2011 had jumped back up by 24%. While no one type of nursery product can be blamed for the increase, replacing walkers as the primary causes of injuries were baby carriers, cribs/mattresses, and strollers/carriages.
The most interesting trend, in my opinion, regarded a diagnosis rather than a specific product. Increasing by over 100% since 2005, the diagnosis of concussion and closed head injury played a large role in the increasing number of reported injuries. This makes sense for two reasons.
Falls, either directly involving a child or when a parent takes a tumble while holding/carrying a child, was the most common documented inciting event. Infants and young toddlers have large heads in proportion to their bodies, a high center of gravity, and are unable to effectively use their arms to help shield their enormous noggins*. Also, concussion awareness has skyrocketed over the past several years. So I can’t be sure if more kids were actually concussed during this time period than in years prior.
Baby carriers, such as the detachable car seats commonly used by parents to transfer babies from the car to the house caused the most injuries overall, again only because walker injuries decreased so precipitously by 2003. Baby carriers are unwieldy and can be dropped or increase the chance of a parent falling while lugging one around. And many injuries occur when they are placed in precarious positions on elevated or slippery surfaces. They are also sometimes involved in cases of SIDS/SUID when used as a sleeping surface, something we strongly recommend against.
A close second was the category of cribs/mattresses, which were involved in nearly 19% of injuries. These products were also the most likely by far to be involved in fatal injuries, largely because of SIDS/SUID and suffocation caused by entrapment. I can’t stress enough how important it is to only allow young infants to sleep on a single, firm, and snug fitting mattress, and on a flat surface without pillows, blankets, or other soft materials. And please, no bumper pads.
Number three on the list of offenders, involving around 16% of injuries, was the category of strollers/carriages, mostly because of falls and tip overs. I will never forget the feeling of terror I experienced when the stroller carrying my first child got away from me once when walking down a sloped driveway. I watched in horror as it gained speed, moving further and further out of reach. Luckily it crashed into some bushes across the street and remained upright, but it could have resulted in a severe injury.
A few nursery product injury prevention recommendations
So what can we learn from this study? The authors provide a few suggestions for preventing nursery product-related injuries based on this new epidemiological data. Fall prevention strategies are key. Products should be installed correctly, making use of safety devices such as straps and harnesses, and young children should be appropriately supervised while using products which might result in a fall.
Caregivers should attempt to reduce the risk of tripping by keeping paths clear of clutter, something much more easily said than done. Avoiding carrying objects in addition to a child carrier if possible, particularly on stairs so that handrails can be used, may help reduce severe injuries from caregiver falls. Additional safety features, such as non-stick surfaces on the bottom of carriers and “dead man locks” on strollers, might also reduce risk of falls from elevated surfaces and runaway strollers respectively.
The authors point out that the data they worked with almost certainly underestimated the number of injuries that occurred during this time period. The NEISS only tracked injuries seen in emergency departments and many injuries would have been evaluated in primary care offices or urgent care facilities. It may have also missed fatal injuries that occurred at home or in the hospital after inpatient admission from an emergency department. On a happier note, safety regulations associated with the Consumer Product Safety Improvement Act of 2008 were still being rolled out during the tail end of the study period, so it is possible that injury risks have decreased since 2011.
*Older kids have better control of their flailing limbs as they go down and are thus increasingly prone to arm injuries after falls.

Think Twice Before Giving Young Children Reflux Medications
A recent study demonstrates an association between reflux medications in infancy and increased risk of fractures in early childhood, yet another reason to be cautious when using pharmaceutical interventions to manage a mostly benign and self-limited condition.
Clay Jones on July 26, 2019
Link

A little more than 5 years ago I wrote about gastroesophageal reflux in infants, focusing on bogus treatment claims made by some chiropractors. But pediatric medical professionals are far from perfect in our management of this common and almost always benign condition, as I explained in 2014:
Too many of us begin to alter our approach because of the influence of practicing in the real world and of common hardwired errors in how we interpret reality. Overuse of prescription medications, unnecessary formula hopping and potentially unsafe recommendations on sleep positioning are unfortunately widespread. Our pharmaceutical interventions carry significant risk with little evidence of benefit for most patients…
Sadly not much has changed since then, despite the inclusion of a recommendation to avoid acid blocking medications when treating physiologic infant reflux in the Choosing Wisely campaign.
What do I mean by “physiologic reflux”? I use that term to differentiate the common occurrence of the passage of stomach contents into the esophagus, and often into the oral cavity and onto the infant’s clothing, blanket, or caregiver’s face, from reflux disease associated with pathology such as severe pain and/or poor weight gain. Virtually all young infants have episodes of reflux upwards of 30 times every day, with more than half spitting daily up at the typical peak around 4 months of life. By one year, almost none do.
Reflux is commonly blamed by parents and pediatricians for general fussiness, something which is not supported by evidence. The assumption is that acid from the stomach causes damage to the esophagus and subsequent pain, resulting in excessive crying but this is actually rare. Reflux to the point of feeding difficulty and poor weight gain is also very uncommon.
I go into far greater detail in my previous post on the subject, which I encourage you to read. The bottom line, though, is that medications aimed at treating subjective symptoms attributed to reflux are generally no better than placebo. In this post, I want to focus on the inappropriate use of these acid blocking drugs and a recent study further demonstrating that the risk outweighs benefit in most cases.
In 2014, I listed pneumonia and gut infections, such as the infamous Clostridium difficile, as the primary risks associated with popular proton pump inhibiting (PPI) medications. Since then, there have been increasing concerns regarding the risk of bone fractures. A study published in Pediatrics this month adds more fuel to that fire.
In this retrospective cohort study, researchers collected data from the Military Healthcare System on children born between October 1, 2001 and September 30, 2013, focusing on those who received care for at least their first 2 years of life and as long as 14 years. After excluding children with conditions that might predispose to fractures, such as bone disease, prematurity, or abuse, they were left with nearly 852,000 low-risk children. Of these, roughly 97,000 had been started on acid suppressing medications in the first year of life. The remaining 754,345 children served as a control for comparison.
The researchers looked at whether children receiving acid suppression were prescribed a histamine blocker such as Zantac, a PPI, or both, and for how long. They followed the subjects out through five years looking for any diagnoses of bone fractures. After analysis and adjustment for time and the occurrence of previous fractures, they found a clear signal in the data.
Compared to controls, children prescribed a PPI in the first year of life were roughly 20% more likely to suffer a fracture before age 5 years. Those on both a PPI and a histamine blocker had an increased risk of more than 30% if initiated in the first 6 months of life. Children only prescribed a histamine blocker were not found to be at increased risk of fracture. Risk of fracture was generally higher the earlier that children were placed on a PPI or PPI and histamine blocker, and the longer that they were on them.
The mechanism for the increased risk of fracture with PPIs isn’t known, but it appears to be a direct inhibitory effect on the function of osteoclasts. These are cells that play a role in the repair and maintenance of bone. There is even less known about why histamine blocking acid suppressing drugs might increase fracture risk when combined with PPIs but not when used alone.
It’s important to point out that while this study adds to our understanding of potential risks in young children taking acid suppressing medications, we can’t say that they are a cause of fractures. Non-accidental trauma is unfortunately a common cause of injury in infants and young children. Regardless of what medications a child may be on, we should not be distracted from consideration of the possibility of physical abuse in the setting of fractures.
Conclusion: Judicious use of acid suppression in infants is warranted
Though overprescribed, there are circumstances where medications that suppress gastric acid are appropriate in infants. The take home shouldn’t be to never use them, but to be cautious. In most cases of reflux, and sometimes even reflux disease, non-pharmaceutical interventions (not chiropractic) do the trick. If these fail, or if a child has severe reflux disease, PPIs in particular should be used for as short an amount of time as possible.

A Medical Myth: The Centers for Disease Control and Prevention has quietly changed their standards for early childhood development
We should strive to retain our ability to be shocked and upset at doctors who pollute the COVID landscape with misinformation.
Jonathan Howard on February 25, 2022
Link

I’ve always wondered where medical myths come from, such as absurd the notion that we only use 10% of our brains. Sadly, this pandemic, we’ve all had the opportunity to witness firsthand how such farcical falsehoods are created.
For example, an article tilted “CDC Quietly Lowers Early Childhood Speech Standards” recently appeared in The Post Millennial, a conservative Canadian publication with a history of spreading misinformation about COVID-19. According to the article,
The Centers for Disease Control and Prevention has quietly changed their standards for early childhood development, as the effects of pandemic policies on children’s development, from speech to reading to other basics, becomes increasingly more apparent.
The big news was soon shared on Twitter by credulous doctors (here and here) who have long opposed masks – and all other measures to protect children from the virus – based on fantasized harms. “This would seem to be problematic,” one said. “CDC just quietly lowered early childhood speech standards for children. I wonder why the CDC thinks children are not meeting developmental milestones?” asked another before discouraging masks in children.
A smoking gun?
So, have these doctors found their smoking gun?
Not at all.
Doctors such as Dr. Dan Freedman, who care more about being accurate than pandering to their Twitter followers, actually read the CDC report and learned that the guidelines were changed based on “broad literature search” that “was conducted in March 2019”. The CDC changed its guidelines based on data collected before any of us had heard of COVID-19. As Dr. Shawna McCafferty explained, the previous guidelines were 20 years old and in need of revision. Moreover, as Dr. Freedman also noted, there was nothing “quiet” about what the CDC did.
Did this have any effect on the doctors who blamed masks for the revisions in the CDC guidelines? Of course not. This is 2022, where contrarian doctors boast of their “nuanced” ideas and claim to be “silenced” when their misinformation is exposed.
Even after it had been explained to him that the CDC guidelines were changed based on pre-pandemic data, Dr. Marty Makary agreed with a Fox News host who blames masks for harming kids and then said,
People are hungry for honesty right now, and what we are starting to see is data on just how catastrophic the entire two years of restrictions are on children, who bore the highest burden of restrictions even though they are the absolute lowest risk.
A medical myth is born
And thus we see in real time how a medical myth is born.
Lazy or dishonest journalists with an ideological bias create myths which then get spread by lazy or dishonest doctors. Alternatively, lazy or dishonest doctors with an ideological bias create myths which then get spread by lazy or dishonest journalists. Incredibly, this is all done under the guise that only the doctor propagating the myth is telling the truth.
I’ve discussed this noxious feedback loop before. In an article written June 10th 2021 titled “Think Twice Before Giving the COVID Vax to Healthy Kids”, Dr. Makary wrote:
In reviewing the medical literature and news reports, and in talking to pediatricians across the country, I am not aware of a single healthy child in the U.S. who has died of COVID-19 to date.
Though it took only seconds to discover that healthy children had died of COVID-19, Dr. Makary’s myth was further propagated by doctors with a large social media presence, as well as by anti-vaxx propagandist Tucker Carlson, who repeated Dr. Makary’s claim verbatim on his program. This myth persists to this day, falsely reassuring people that healthy children have no risk from the virus.
This latest sad episode, where “pandemic policies” are accused of time-traveling to 2019, is really nothing special. It’s actually become quite routine – another drop in the ocean of COVID misinformation spread by doctors who will never treat a sick child. As such, it’s easy to shrug when highly-credentialed doctors at prestigious universities again create and spread easily refutable myths to their large audiences, debasing our COVID discourse.
However, we should resist this dulling of our senses. We should strive to retain our ability to be shocked and upset at doctors who pollute the COVID landscape with misinformation, always minimizing the harms of the virus and always exaggerating the supposed harms of the measures used to protect children, all while pretending that no one but them is telling the truth.

Separating Fact from Fiction in Pediatric Medicine: Nocturnal Enuresis
Nocturnal enuresis, more commonly known as bedwetting, is a normal problem that resolves on its own for most children. Chiropractors claim they can treat it. They can’t, but they will take the credit for kids doing it themselves.
Clay Jones on August 15, 2014
Link


In pediatrics, very few things are completely black and white. This is an aspect of conventional medicine in general that tends to separate the approach of science-based practitioners from that of proponents of the many forms of irregular medicine commonly discussed on SBM. They appear to experience no shame in claiming absolute certainty while doling out all manner of implausible remedies for ailments ranging from the well-established to the fictional.
While we do face questions from patients and their caregivers regarding largely invented diagnoses in pediatrics, with chronic Lyme disease and non-celiac gluten sensitivity being just two of many increasingly encountered concerns, my experience has been that alternative medical providers tend to focus their efforts on the same real problems that pediatricians and family practitioners deal with on a daily basis. And I don’t believe that it is mere coincidence that these conditions are largely self-limited in nature, a fact often not shared. Parental and patient buy-in is often more easily obtained with certainty rather than nuance.
Chiropractors, for example, seem to pride themselves on their ability to cure ear infections. Of course in greater than 80% of children with acute ear infections, symptoms will resolve without any intervention whatsoever. This is why the AAP has been trying for years to decrease the rates of antibiotic prescriptions for ear infections, unfortunately with little in the way of success thus far. And when the infections don’t resolve on their own, there is no good evidence that anything a chiropractor has to offer can help. The same can be said for their claims regarding colic and gastroesophageal reflux, which I’ve written about before.
Another condition frequently mentioned by chiropractors as being particularly in their wheelhouse is nighttime bedwetting, the medical term for this being nocturnal enuresis. Rarely have I seen a chiropractic website with a section on the benefits for children that does not mention their success in curing bedwetting. Fred Clary, DC, even claims on his website to be able to cure bedwetting in the newborn baby. And to think I’ve just been ignoring the problem as a newborn hospitalist. Is it because the thought of a newborn infant gaining continence is absurd, or am I just a shill for Big Pampers? 
With nocturnal enuresis, as with all of pediatric healthcare, there is a science-based approach that takes a variety of factors into account. In fact, bedwetting is an excellent example of the success that comes with considering the biology, psychology and social environment of a patient. You could even call it a holistic approach if that weren’t such a loaded description. I prefer biopsychosocial.
In keeping with my usual pattern, before I delve into the idiocy of the chiropractic conceptualization of bedwetting and its approach to treatment, please allow me to present a science-based understanding:
What is nocturnal enuresis?
Incontinence is essentially universal in infants and toddlers, particularly while asleep for long periods of time. Nobody, with perhaps the exception of Fred Clary, expects a 2-year-old, let alone an infant, to consistently make it through a substantial period of sleep without voiding urine. Most readers, especially those with kids or who have worked with younger children, realize that there is a normal range of a few years during which kids will usually acquire the ability to stay dry through the night. What many readers may not realize is how common it is for kids to take longer than expected. In general, we consider children over the age of 5 years who continue to have intermittent episodes of nighttime incontinence as having the diagnosis of nocturnal enuresis (NE).
As many as 10-15 out of every 100 6-year-old children are unable to hold urine in the bladder for long periods of sleep. As these children age, the numbers tend to decrease with roughly an additional 15 per 100 achieving nighttime continence all on their own each year. When all is said and done, 1%-2% of adults continue to have occasional bedwetting. These older kids, and the few adults, who are unable to ever completely maintain overnight continence for a period of at least 6 months without assistance, and who otherwise are healthy, have primary monosymptomatic nocturnal enuresis (PMNE).
When kids have nocturnal enuresis in the setting of additional conditions, such as urinary tract infections, urine incontinence while awake, anatomical abnormalities, or neurologic bladder dysfunction, they are diagnosed with nonmonosymptomatic nocturnal enuresis (NMNE). Children who are able to go 6 months without wetting the bed, and without any of the treatment approaches I’ll be discussing, who then have a recurrence have secondary nocturnal enuresis. Accuracy of the diagnosis is important when deciding on a treatment plan and for prognostic implications.
When is nocturnal enuresis a problem?
When nighttime incontinence becomes a problem really depends on the individual child and his unique social environment, in particular the expectations of the caregivers. If the parents aren’t worried about their healthy 6-year-old wetting the bed occasionally, and the kid is oblivious, then starting any kind of treatment plan would likely not be worth the trouble. And it may even backfire. Simple reassurance and expectant management usually will suffice.
Some families may only be interested in an approach that will allow for continence on a short-term basis, such as for a summer camp or a slumber party, while still allowing nature to take its course for the most part. Unfortunately, not all parents have such a laid back response to NE. It is common for children to develop feelings of guilt, and to be repeatedly punished for something they have no control over. The potential for physical abuse is a very real concern, especially when parents begin to blame or resent the child.
In general, NE is a problem and requires a comprehensive treatment approach when the family unit asks for help, not just the caregivers. For the child, the desire to achieve continence typically becomes urgent once wetting the bed begins to limit his or her ability to interact socially. And it is important to strike while the iron is hot, so to speak, in order to then prevent untoward psychological repercussions. It is actually critical to the success of any management approach, however, that the child is bothered by the NE enough to demonstrate their readiness to assume responsibility for their own treatment.
Why does primary monosymptomatic nocturnal enuresis happen?
The development of mature bladder function, and the ability to maintain continence while asleep, relies upon the coordination of the autonomic (involuntary) and somatic (voluntary) nervous systems within the spinal cord and brain. Ultimately, we are able to store urine in a relaxed bladder until we consciously decide to urinate. During urination, the muscles in the bladder wall squeeze and the pressure at the bladder outlet decreases to allow urine to exit the bladder via the urethra.
Initially we have no conscious control over this process. As the infant bladder fills, it will eventually begin to contract in order to empty. As we age, awareness of having a full bladder begins to develop followed by the ability to purposefully hold off contraction of the bladder wall muscles. As more time passes, the ability to time bladder contraction with relaxation of the bladder outlet comes online. Thus continence while awake comes first, followed ultimately by the ability to make it through a long sleep period at around age 5 years, give or take a year, for the majority of children.
There are many factors that can contribute to the development of PMNE, which again occurs in otherwise healthy kids and makes up the vast majority of nocturnal enuresis cases. At the core, however, is the absent or inconsistent arousal from sleep in response to the need to urinate, and children are often described by caregivers as especially deep sleepers. Delayed maturation of bladder function likely plays some role, which might explain why it tends to resolve over time even without intervention. But PMNE likely will still occur in many children despite normal bladder function if the limits of their ability to hold urine overnight are pushed to the breaking point and they simply don’t wake up in time.
A smaller than average capacity to hold urine while asleep as well as excessive urine production can exacerbate this problem. This can occur when a child drinks a large amount of fluid right before bed, or if there is a relative insensitivity or underproduction of antidiuretic hormone (ADH, also known as vasopressin), a chemical in the body which helps to regulate water retention in the kidneys. It is thought that ADH secretion is normally increased overnight following a circadian pattern and that this pattern is developmental, perhaps explaining why some children simply grow out of PMNE.
There is a large genetic component to PMNE as well. When one identical twin has delayed continence, there is a 68% chance that the other twin will as well, while the concordance with non-identical twins is still significant at 36%. Three of every four children born to parents with a history of PMNE will also have delayed continence, while the risk is 50% when just one parent was affected.
Naturally, when a child presents with concerns of bedwetting at an older than typical age, it can’t be assumed to be a primary and largely self-limiting condition such as PMNE. It is extremely important to consider and rule out, with a thorough history and physical exam usually being all that is necessary, more worrisome potential causes. A number of serious medical conditions can present with bedwetting, such as seizures and diabetes, as well as anatomical abnormalities involving the spinal cord.
Even simple constipation, although not as serious as a tethered spinal cord or spina bifida, can cause bedwetting in an older child. There are many more examples of pathological causes of NE, some of which are not intuitively linked to bedwetting such as pinworms, obstructive sleep apnea and psychologic comorbidities. I’ll spare you the full differential breakdown. I hope that it is abundantly clear how inappropriate it is for inadequately-trained alternative medicine practitioners to consider themselves experts on this topic.
Science-based treatment of primary monosymptomatic nocturnal enuresis
As I mentioned earlier, our understanding PMNE is biopsychosocial in nature. The approach to treatment also takes into account the psychosocial aspects of the condition as well as the biology. In fact, lifestyle changes, sometimes aided by some nifty technology, are first line treatments. With few exceptions, such as a pressing need to achieve continence quickly in order to preserve declining psychosocial functioning, pharmaceutical interventions take a backseat to lifestyle modifications.
In general, the goals of PMNE intervention don’t include achieving immediate and permanent continence as quickly as possible. In order to reduce the risk of frustration, the focus is on incremental improvement. And treatment shouldn’t even be initiated until the child as well as the caregivers demonstrates readiness. The child must be responsible for his treatment and understand that the process can be lengthy. The parents must be supportive and aware of the need to avoid blaming the child or incorporating punishment into the treatment regimen.
Lifestyle modifications can, and probably always should, include the limiting of fluid intake in the hour before bedtime, keeping in mind that hydration status takes precedence over bedwetting. Establishing a pattern is rarely easy with children, but a consistent bedtime routine, including an appropriate amount of total nightly sleep, can help reduce bedwetting by preventing excessive fatigue. Keeping a calendar for documenting dry versus wet nights, along with other details such as the number of nightly episodes and new symptoms can also be very helpful.
Appropriate means of motivating a child to actively take part in achieving continence overnight can involve the use of reward systems, such as sticker or star charts. When a child makes it through a night without wetting the bed, or meets some other agreed upon goal, he or she can place a sticker or star on the chart. Once requirements have been met, such as a certain number of consecutive dry nights, the child is rewarded. Passive interventions such as this are often tried for several weeks or longer if more urgent continence is not needed.
The use of bedwetting alarms or pharmaceutical intervention, particularly in older children with increasing social concerns or negative psychological sequelae, can be extremely effective. And medication is the only way to achieve immediate continence when desired, although NE may return as soon as the drug is discontinued. Alarms work via a moisture detector typically positioned in the child’s underwear, and can be audible or vibratory. Initially, the alarm simply wakes the child up once he has already begun to wet the bed. Over time, the child is conditioned to wake up prior to actually voiding, or to suppress urination without waking. They work well but are limited to older kids with a strong will to achieve continence, and who will wake up to the alarm. They are not ideal in situations where continence is needed quickly or only for intermittent short periods.
The drug most commonly used to prevent bedwetting is desmopressin, a synthetic version of the antidiuretic hormone naturally secreted by the brain. This is the hormone that is believed to deficient, or less active because of receptor insensitivity, in some children with PMNE. It works by binding to specific receptors in the collecting ducts in our kidneys, increasing the reabsorption of water into the blood and decreasing urine output. This effect is rapid in onset, and the drug is often successful on the first night of use.
It is not risk free, although complications are pretty rare. The most significant potential adverse effect can occur in the setting of a child drinking a large amount of fluid prior to taking the medication. The combination of increased intake and decreased urine output can lead to dilution of the blood and a potentially dangerous drop in the serum sodium level. This dilutional hyponatremia can, in rare instances, cause changes in mental status, seizures, coma and even death. This outcome was more common with intranasal administration of the drug, which is no longer recommended in children with bedwetting.
Medical interventions, whether simple education and reassurance, lifestyle modifications, or pharmaceutical agents, are highly successful. But they aren’t perfect by any means. PMNE is a condition which takes time to resolve. And, as stated previously, it will eventually resolve completely on its own in time in roughly 98% of children.
For a more detailed discussion of the evaluation and treatment of PMNE, here are the 2010 recommendations of the International Children’s Continence Society, which is the worst name for a superhero team ever, just beating out the International League Against Epilepsy. I do admire their work however.
What is the chiropractic approach to noctural enuresis?
Now that you know the science-based medical understanding of why nocturnal enuresis occurs and our approach to treatment, let’s take a look through the looking glass at how this condition is conceptualized by the chiropractic community. As expected, their take runs the gamut from the utterly devoid of rational thought to the only slightly nutty, with many chiropractic websites getting a number of things right. Many, for example, explain how NE is not the child’s fault and that punishment can be counterproductive.
One common theme I discovered on my journey was the blaming of bedwetting on an immature “phrenic reflex” and subsequent development of elevated levels of carbon dioxide in the blood, with one chiropractor going so far as to claim that “The typical bed wetting child sleeps in a high state of carbon dioxide intoxication.” Their explanation goes like this: infants are incontinent because an elevated carbon dioxide level fails to stimulate the phrenic reflex, which causes diaphragmatic contraction and increased respiratory activity which in turn lowers carbon dioxide levels. Carbon dioxide acts as a relaxant for smooth muscles (muscles we don’t control consciously, like the bladder wall), so high levels cause relaxation of the smooth muscle in the bladder outlet and undesired nocturnal urination. (1)(2)(3)(4)(thousands more)
And what is to blame for this supposed delayed maturity of the “phrenic reflex?” After a brief mention of the possibility of a genetic contribution, which is of course true but not in the way they are claiming, the bulk of their discussions focus on, you guessed it, the subluxation. This fictional cause of all ailments is behind the poor functioning of the phrenic nerves. Something, something, something nerve interference of the 3rd, 4th and 5th cervical spinal nerves which innervate the diaphragms by way of the phrenic nerves, one for each of the left and right hemidiaphragm. Many chiropractic websites also claim that subluxations involving lower thoracic, lumbar and sacral spinal nerves directly lead to incontinence.
It may sound compelling, but it’s all complete baloney. First off, their version of the “phrenic reflex” is a fiction. In newborns, there is a little-known reflex called the intercostal-phrenic reflex which actually inhibits breathing when the rib cage is distorted. It has absolutely nothing to do with levels of carbon dioxide in the blood and it doesn’t increase respiration.
Speaking of carbon dioxide, rising levels do tend to increase the respiratory drive, but by stimulating chemoreceptors in the aorta, carotid arteries, and brainstem, rather than by a “phrenic reflex.” The increase in breathing keeps the levels in check in healthy individuals. If a young infant were to fail to respond to this signal to increase the respiratory drive, as sometimes happens for reasons poorly understood, they die. This is actually one of the proposed mechanisms of Sudden Infant Death Syndrome (SIDS).
Hypercapnia, the abnormal persistent elevation of carbon dioxide in the blood, can cause acidosis and a number of symptoms including but not limited to difficulty breathing, headache, altered mental status, cardiac arrhythmias, seizures, coma and death. It does not cause isolated bedwetting. In fact, if elevated levels of carbon dioxide in the blood caused relaxation of bladder smooth muscle it would cause urinary retention rather than incontinence. Urination requires contraction of the bladder wall, not just relaxation of the bladder outlet. Medications that relax smooth muscle in the bladder are actually often used to treat incontinence related to overactive bladder syndrome.
Finally, if both phrenic nerves, which again contain contributions from the 3rd, 4th and 5th cervical spinal nerves, were not functioning properly a child would have paralyzed diaphragms (C, 3, 4, 5, keeps the diaphragm alive!) and severe respiratory problems if not an inability to breath at all. This actually happens sometimes during vaginal deliveries when significant lateral force on the head and neck is required to deliver a large baby that has become stuck at the shoulders. This can stretch the cervical spinal nerves to the point of injury or even complete transection, causing diaphragmatic paralysis as well as other unfortunate injuries.
Despite hours of reading chiropractic claims regarding bedwetting, I failed to find any legitimate discussion of the potentially serious causes of nocturnal enuresis. Parents could likely search hundreds of chiropractic websites without coming across any mention of red flags for conditions that would need evaluation and treatment by a real physician or surgeon. These are the people that want to work as primary care providers to children.
In addition to chiropractic, a wide variety of alternative medical treatments have been used to treat nocturnal enuresis in children. The folks at Cochrane reviewed the available evidence in 2011, and didn’t have anything positive to say in their conclusion:
There was weak evidence to support the use of hypnosis, psychotherapy, acupuncture, chiropractic and medicinal herbs but it was provided in each case by single small trials, some of dubious methodological rigour. Robust randomised trials are required with efficacy, cost-effectiveness and adverse effects clearly reported.
That’s about as negative as Cochrane gets, but I disagree with any calls for more research. This pattern of weak evidence is typical of modalities that work via the many placebo effects when investigated as a treatment for a largely self-resolving condition. Let’s think of an activity off the top of our heads. How about knitting? Knitting by a caregiver in the same room as a sleeping child. Wait. Knitting in a different country while simply thinking of the little bedwetter. I am confident that intercessory knitting would be found to have weakly positive benefits for children with PMNE if studied by proponents. Some kind of an alternative sewing circle perhaps.
Here is a nice breakdown of two of the frequently cited, but painfully weak, studies cited by chiropractors to support their claims of success treating nocturnal enuresis.
Conclusion: Chiropractors can’t cure bedwetting
Bedwetting is a common pediatric complaint with a multifactorial etiology. It is usually benign and almost always improves over time, with 98% of children with primary monosymptomatic nocturnal enuresis eventually becoming fully continent. Interventions exist which can involve simple reassurance and education, bedwetting alarms, or pharmaceutical agents. They all have solid evidence of success and relatively few risks.
Any time a child continues to wet the bed past the typical age of roughly 6 years, and whenever a continent child has a recurrence of nocturnal enuresis, it is vital to rule out a number of potentially-serious problems. When practitioners of chiropractic, or any field inadequately trained in pediatric healthcare, believe that they are capable of assuming the role of primary care provider for children, there is a very real risk of a delayed diagnosis of one of these conditions. One need look no further than the information available for caregivers online to see that chiropractic education is vastly inferior to that of practitioners of science-based medicine.

Inappropriate Antibiotic Use is Rampant in U.S. Pediatric Hospitals
A recent study looked at antibiotic use in thousands of hospitalized children and the results weren’t great. Too many kids are receiving suboptimal antibiotic prescriptions. One potential solution is an increased focus on, and improved resources for, antibiotic stewardship programs.
Clay Jones on February 14, 2020
Link
As I wrote in a 2013 post on the subject of antibiotic overuse in the setting of treating viral infections in kids, the practice of medicine is more than a bit challenging at times:
So what is the deal with us pediatricians? Why can’t we keep our Hannah Montana brand non-latex examination mitts off of the prescriptions pad every time little Timmy has a runny nose or a cough? Why don’t we listen to the well-meaning experts from the AAP and our own inner voices? To put it bluntly, it’s because medicine is hard. It’s messy, it’s complicated, and it is practiced by humans beleaguered by the same propensity for bias and intellectual laziness as everyone else.
Nothing has changed in the past 7 years that makes the decision of whether or not to prescribe antibiotics any easier. Sure, there are a few new tests these days. And reams of data have been published on the harms that come from inappropriate use of these lifesaving medications. Something, something, something, microbiome. Unfortunately, the factors that are at the heart of this issue remain unchanged. Doctors are still human, at least until we are replaced by artificial intelligence or aliens.
Most studies on the uses and abuses of antibiotics in children come from the outpatient world. In hospitals, particularly those fancy academic pediatric facilities, things have to be better…right? Sadly, this doesn’t appear to be the case. What follows is a discussion of a study recently published in Clinical Infectious Diseases, the flagship journal for the Infectious Diseases Society of America, that demonstrates just how pervasive suboptimal antibiotic therapy is.
Appropriateness of antibiotic prescribing in U.S. children’s hospitals
In the study’s introduction, the authors point out that antibiotics are the most commonly prescribed class of medications in outpatient pediatric medicine and are ordered for more than half of hospitalized children. Most of these are for respiratory infections, which are very often viral. This doesn’t surprise me because there really seems to be a cavalier attitude regarding their use. I see this in members of the lay community, where there tends to be little awareness of the risks inherent in the use of antibiotics despite attempts at large scale educational outreach, but also far too often in those who really should know better.
Inappropriate use of antibiotics is a big problem. Antibiotics, even when used appropriately can harm patients, but prescribing them carelessly results in significant unnecessary medical costs, increases rates of infections with resistant organisms, and inches us ever closer to a return to a time when doctors were powerless against bacterial infections. Adverse effects from antibiotics, which naturally become more common with increasing numbers of prescriptions, can involve fairly benign nausea and diarrhea, but also life-threatening C. difficile infections and potentially deadly allergic reactions and immune system dysfunction. Antibiotics may have saved countless lives, and hopefully will continue to do so far into the future, but they are far from risk free.
Adult data has revealed that 30-50% of antibiotics ordered in U.S. hospitals are done so inappropriately. Pediatric data has been very limited, typically involving small numbers of children from only one study location. Using data from 32 U.S. children’s hospitals, and over a period of 18 months, the study authors attempted to answer several questions regarding antibiotic use, particularly what percentage is suboptimal, what errors are being made, and where improvement efforts might be best focused.
Another interesting aspect of this study was the involvement of what are known as antibiotic stewardship programs (ASP). With an ASP in place at a hospital, there are infectious disease experts charged with monitoring the use of specific antibiotics in certain situations. They will frequently put limits in place or require justification for continued use of these particular drugs, and they provide recommendations for medication changes and education to help reduce antibiotic related misadventures. Not all hospitals have them, and they can’t monitor and provide global assistance for every single clinical encounter where antibiotic choices are made.
In the study, each of the participating children’s hospitals completed several single-day antimicrobial use surveys, essentially one every 3 months, between July of 2016 and December of 2017. On the designated days, charts from every current patient aged 0-17 admitted prior to 8 AM were reviewed, and those with an active antibiotic order were analyzed by members of the ASP at that facility. In addition to standard demographic data, they collected the dose, route, and indication for each antibiotic being administered to the patient. They also made note of whether or not the hospital ASP would have otherwise been involved.
They determined the appropriateness of each antibiotic, which was based on the clinical judgement of the reviewing ASP member using an option from a list of predetermined reasons, and whether modification should be recommended. The designated reasons that an antibiotic might be deemed inappropriate included the need to change an antibiotic based on available lab data, unnecessary duplicate antibiotic therapies, use of an IV antibiotic when an oral agent was adequate, inappropriate surgical prophylaxis, and “other”. The selection of “other” was based on each facilities specific ASP practices.
There were 18 specific antibiotic modifications that could be recommended by the ASP reviewers at each hospital. These included options such as stopping an antibiotic, changing to a more narrow antibiotic based on either lab data or clinical judgement, and “other”. Each antibiotic was allowed only one reason for being inappropriate, if applicable, and one modification recommendation, so reviewers were instructed to pick the one that they felt was most clinically meaningful.
The results were…not so good
The primary outcome for the study was the percentage of suboptimal antibiotics, as defined by its being inappropriate, requiring modification, or both. They also looked at a few interesting secondary outcomes, which I’ll get into shortly. Because the “other” option for inappropriateness was used so often, the authors created new categories after the fact based on the provided explanations from the ASP members at each study site.
When all the surveys were collected, the study authors had antibiotic data and ASP assessments on just over thirteen thousand pediatric patients with 17,844 total antibiotic orders. Patients receiving antibiotics represented 35% of the total number of inpatients with nearly 70% getting antibiotics through a vein rather than by mouth. A lot of the data is interesting to me, such as how many patients were on more than one antibiotic and what antibiotic was most commonly prescribed (SMX/TMP, Bactrim), but I’ll spare you those details and get to the good stuff.
The most common indication for antibiotics wasn’t surprising at all: bacterial lower respiratory tract infection (LRTI) or pneumonia. The next most common indication, which reveals the difference between pediatric hospitals and community hospitals like mine that admit kids, was prophylaxis for medical problems. This means that they admit a lot of medically complex kids that are high risk for serious bacterial infections, such as patients with immune system problems or cancer.
Now the juicy stuff. The authors found that 21% of antibiotics were suboptimal, with about twice as many designated as inappropriate compared to those just needing some modification. Overall, 26% of patients received at least one suboptimal antibiotic. It’s important to point out that there were huge differences between some hospitals, with one reporting that almost half of patients on an antibiotic needed a prescription modified and one coming in at less than 10%.
Among the suboptimal antibiotic orders deemed inappropriate, the most common reason was that it was the wrong antibiotic based on available lab data. That means someone, actually multiple someones, dropped the ball on each of these 635 patients, putting them at risk of worsening of their infection. Among those orders that just needed tweaking, the ASP team recommended stopping the antibiotic almost half the time. That’s not as bad as having a sick patient on the wrong treatment, but it still risks harm and adds to resistance concerns.
Data on one particular antibiotic class, namely the oral 3rd generation cephalosporins, caught my attention even if they were not one of the top ten most prescribed hospital antibiotics. Though very commonly, and wrongly, prescribed in the outpatient setting, they didn’t crack the top ten in this study because most hospitalized kids are on IV antibiotics. But when used, they were the most likely (50%) to be suboptimal. Though they certainly have a place in medicine, they are second only to azithromycin as my least favorite antibiotic. I even wrote an entire post about them a few years ago.
There were a few additional interesting findings in this study. Of the antibiotics ordered specifically to treat pneumonia, 22% were suboptimal. This certainly fits with my experience, where pneumonia is frequently overdiagnosed in the emergency department because of overzealous imaging and discomfort with uncertainty, and the choice of initial antibiotic is almost always too broad.
The antibiotic indication most likely to be associated with suboptimal use was surgical prophylaxis. This occurred in 40% of instances where it was ordered, most commonly when the antibiotic was continued for longer than 24 hours. Current recommendations recommend one dose. Finally, almost half of the suboptimal antibiotic orders would not have been reviewed by an ASP program outside of this study. Just imagine how things might look at hospitals where there is no ASP at all.
Conclusion: We need to expand antibiotic stewardship in our hospitals
So what’s the bottom line from this study? A lot of kids admitted to pediatric hospitals are on antibiotics. And although it appears that we do better than the doctors that manage adults, we need to do better. Of the thousands of kids in this study receiving inpatient antibiotics, 1 of every 4 did so suboptimally. Half of the suboptimal antibiotics should have been stopped and another 20% needed to be changed to an antibiotic that was more narrow, both of which are risk factors for the development of resistant bacteria.
There was huge variation between hospitals in this study. Some appeared to have a much better grasp of proper antibiotic use than others. It’s important to figure out why there are such disparities and what can be done about it. Every participating hospital in this study has an antibiotic stewardship program, although the quality and effectiveness of each is unknown. That may be a factor in the differences in rates of suboptimal antibiotic use. But nearly half of the suboptimal orders wouldn’t have even been reviewed by an ASP, and many non-pediatric hospitals don’t an ASP.
As I mentioned earlier, it isn’t feasible for every hospital to have an ASP that monitors 100% of antibiotic orders. But this is an area that deserves focus and resources wherever possible because we are running out of antibiotics and we are running out of time. Expanding ASP services is just one way to reduce antibiotic misuse, but it is an important one.

Separating Fact from Fiction in Pediatric Medicine: Ear Infections
Clay Jones on November 20, 2015
Link


As discussed numerous times on the pages of Science-Based Medicine, children are increasingly a target of chiropractors, with some even pushing for recognition as primary care practitioners. Despite a thoroughly inadequate training, and a lack of experience with ill pediatric patients, they believe that they have what it takes to recognize and manage common pediatric conditions or refer to an actual pediatric medical professional when they deem it appropriate. While a significant percentage of pediatric illness is self-limited, and thus might appear to respond to chiropractic manipulation, I have seen many deteriorate quickly and with little warning. The idea of an ill child suffering at the hands of a charlatan is terrifying.
Many chiropractors are of course more than happy to see pediatric patients without acting as their PCP. They love to claim that children are at risk of developing misalignment of the bones of the skull and spine, chiropractic subluxations, and numerous other conditions unique to alternative medical reality, particularly during the first few years of life. They tell caregivers that these insults can be subtle, or even silent for years, and that regular maintenance care is required to prevent severe problems, even going so far as to blame SIDS and “shaken baby syndrome” on these fictional entities.
Many chiropractors are also quick to claim that they can prevent or cure some of the most common conditions seen by pediatricians and family healthcare providers, such as viral infections of the upper respiratory tract, asthma, bedwetting, and ear infections to name just a few. By simply improving the function of the nervous system, chiropractors believe that they can “boost” the immune system’s ability to fight infections, improve control over bladder function, and even reduce airway inflammation and bronchoconstriction. If you think that sounds like nonsense, you’re right!
I’d like to focus on ear infections in the pediatric population in this post, and to contrast a science-based understanding and approach to treatment, warts and all, with that of the chiropractic profession. As you’ll see, the chiropractic understanding is overly simplistic, its management makes no sense, and the research base is a house of cards toppled by the slightest breeze of skeptical evaluation.
Ear infections in kids
Infection of the middle ear, commonly referred to as “acute otitis media” or simply as an ear infection by physicians (and some chiropractors), is the most common reason for a parent to seek urgent medical care for their child. In fact, by the age of three years, roughly 90% of children will have had at least one ear infection. Many children suffer through multiple acute episodes with some even developing chronic infections that are managed with long courses of antibiotics and surgical drainage of the middle ear via the tympanic membrane or “ear drum.”
Ear infections are considerably more common in younger children, with the highest incidence in the first two years of life. It isn’t entirely clear why there is such a drop off in incidence after the early school age years. As with most pediatric conditions, it is likely highly multifactorial and the true answer is probably a combination of changes in the anatomy and physiology of the middle ear and its ability to drain, as well as an improved response of the immune system to pathogenic bacteria. Other factors that influence the incidence of ear infections in children are family history, day care attendance, breastfeeding, exposure to cigarette smoke, pacifier use, and numerous other minor items.
Not surprisingly, ear infections are also the most common reason why children receive a prescription for a course of antibiotics. This is problematic for a number of reasons. Historically, doctors have been too quick to diagnose ear infections, which has resulted in large numbers of unnecessary prescriptions for antibiotics. This has almost certainly played a role in the development of resistance to common antibiotics and has caused more harm than benefit considering expense and adverse events like allergic reactions and colitis caused by overgrowth of Clostridium difficile in the gut.
How are ear infections diagnosed and treated?
Physicians diagnose acute otitis media (AOM) based on direct visualization of the tympanic membrane using an otoscope, with some versions even providing a magnified view to aid recognition. In general, we look for the presence of purulent fluid in the middle ear that is causing an outward bulge of the drum. Just as important however, is the clinical assessment of the signs and symptoms of the child’s illness and an understanding of the caregivers’ perception of them.
Ear infections have been misdiagnosed and overtreated for a variety of reasons. Looking at the ear drum of a squirming child with an ear full of wax is extremely difficult. And even with a cooperative child it isn’t always easy to get a great look. Pediatricians are also human and we sometimes see what we want or expect to see, especially when the pressures of time, nervous parents, and a genuine desire to help children get better are added to the mix.
Until 2004, when the AAP released a new set of guidelines for the diagnosis and treatment of AOM, the criteria were fairly subjective and there weren’t strong recommendations for a wait-and-see approach. In 2013, the AAP further refined diagnostic criteria, making them considerably more simple and objective. Unfortunately, evidence from 2010 suggested that pediatricians largely ignored the 2004 update on treating acute otitis media. We continued to give out antibiotics like candy on Halloween and increase our use of newer and broader agents that don’t improve outcomes. I look forward to seeing if the 2013 update leads to better care but I’m not exactly holding my breath.
Don’t get me wrong, I’m not saying that antibiotics don’t play an important role in the treatment of ear infections in kids. When used appropriately, they work amazingly well. They reduce pain associated with ear infections, which can be severe, speed recovery tremendously, and reduce the risk of potentially severe complications such as spread of infection to surrounding tissue of the head and neck, even meningitis.
There is a bit of a myth out there that the vast majority of ear infections will resolve without antibiotics because they are viral in nature. As with most complex medical concepts, this is partially true and partially completely wrong. It’s nuanced. Based on the studies using the latest and most sensitive techniques, only about 5% of ear infections are caused by viruses alone. Most are caused by a combination of viral and bacterial pathogens, which makes sense because most ear infections occur in the setting of a viral upper respiratory infection.
Based on old criteria and the studies using them, it is true that 80-90% of ear infection will resolve on their own however. But this number falls to about 50% when more stringent criteria are in place. In the real world outside of a study, many kids diagnosed with ear infections simply have a cold and perhaps just some fluid behind their ear drums rather than a true infection of the middle ear.
Because of this, it is challenging to determine whether or not a treatment actually works or just appears to work when the outcome being looked at is simply that the patient gets better. When strict objective otoscopic criteria are used to determine resolution of the infection, the number needed to treat drops from the double digits down to 3-4. This doesn’t mean that observation isn’t often a reasonable approach, as delineated in the AAP guidelines, when the patient is older than 6 months and the infection is mild. This group makes up a large percentage of ear infections. But for younger children and kids of any age with significant symptoms, assuming that the newer diagnostic criteria are used, antibiotics are absolutely appropriate.
Vaccines, is there anything they can’t do?
The overall incidence of ear infections does at least appear to be on the decline, perhaps because of attempts by the American Academy of Pediatrics to tighten up the diagnostic criteria but more likely because of the success of the 13-valent penumococcal vaccine (PCV13). Introduced in 2010 as an improvement over PCV7, PCV13 is given during early childhood to prevent infection with the 13 strains of pneumococcus most likely to cause severe illness in kids. Pneumococcus, notorious as a cause of meningitis and severe pneumonia, also happens to be the most common bacterial pathogen associated with ear infections.
For a nice science-based discussion of the diagnosis and management of ear infections in the pediatric population, here is the 2013 updated AAP clinical practice guideline.
What role does chiropractic play in managing ear infections in kids?
Despite numerous claims to the contrary, chiropractic manipulation plays absolutely no role in the management of ear infections in kids. The American Association of Chiropractic disagrees, claiming that adjustments to the back of the skull and the first cervical vertebra can improve drainage of the middle ear. If true, this would be helpful, but it is utter nonsense as no chiropractic manipulation can move the bones of the skull around without causing pain or injury, and there is no proven link between the position of the first cervical vertebra and the drainage of the middle ear.
While many chiropractors believe that their manipulations “boost the immune system,” the bulk of their claims regarding ear infections focus on drainage of the middle ear via the Eustachian tube, and for very good reason. The Eustachian tube connects the middle ear with the back of the throat and allows drainage of normal secretions and potential pathogens, but it is a two way street. When inflammation and swelling, usually caused by a viral upper respiratory infection, interfere with the function of the tube, viruses and bacteria which get into the middle ear have no way of getting out. Infection and accumulation of pus lead to symptoms and eventually diagnosis.
Young children are more at risk for infection of the middle ear partly because of their unique anatomy, specifically that the Eustachian tube is horizontal and thus does not drain efficiently. As we grow, the tube takes on a path closer to vertical. Manipulation of the spine or skull cannot change the orientation of the Eustachian tube. Other factors, such as exposure to cigarette smoke and nasal allergies, can also play a role in poor drainage.
Information from the International Chiropractic Pediatric Association, which offers certification and diplomate programs in pediatric chiropractic, is even worse. They claim that the pneumococcal vaccine is dangerous and ineffective, and that antibiotics and surgery are never necessary. The article also contains several links to articles written by Joseph Mercola, a “friend” of SBM.
Is there any evidence in favor of chiropractic?
Is there evidence that can be held up by chiropractors to support their claims? Of course there is, and lots of it. But it is evidence of the lowest order, primarily anecdotes, case series, and trials that fail to take into account the difficulty in making the diagnosis and the natural course of the infection. A perfect example is the study most commonly cited on chiropractic websites. It is a retrospective nonrandomized study of 46 children treated with adjustments and “the doctor’s own modified applied kinesiology.” 90% of the children got better without antibiotics, which is exactly what would be expected considering the difficulty in diagnosis and the fact that children with severe symptoms more consistent with a true ear infection would be less likely to go to a chiropractor as opposed to a medical doctor. The report even states that children with only isolated ear discomfort were more likely to get better sooner than those with more significant symptoms. As expected, the better-designed the trial, the smaller the effect.
Why are children with isolated ear discomfort even included in a study looking at the treatment of ear infections? More importantly, how are chiropractors even diagnosing ear infections in the first place? Pediatricians with years of training and experience looking in the ears of thousands of children of various ages and sizes find it difficult. How can a chiropractor, whose educational experience typically involves interaction with very few if any ill people, let alone children, hope to become even remotely proficient? It isn’t any wonder why so many of them believe that their intervention works because any intervention, even no intervention, would appear to be effective when the symptoms resolve on their own. These patients are getting better despite the chiropractic, not because of it.
Conclusion: Chiropractors cannot treat ear infections
Ear infections in kids are extremely common and are the leading reason for antibiotic prescriptions in young children. Science-based research has revealed that although they will often resolve without specific treatment, simple observation isn’t always the best approach and there must always be a plan in place if symptoms fail to improve or they worsen. Severe complications, although uncommon, do occur in observed and treated patients although to a lesser degree.
As in their approach to most other medical conditions, chiropractors who treat pediatric patients generally have a simplistic if not an outright inaccurate understanding of the pathophysiology of ear infections. And although it may be somewhat understandable given the difficulty in determining if a treatment actually works for ear infections diagnosed in the real world, it is still inexcusable that they even try. At best the patient gets better on their own, but a delay in appropriate care will unnecessarily prolong a child’s pain and suffering, and increase the likelihood of a complication. Parents who bring their child to a chiropractor will also likely be exposed to other forms of pseudomedical nonsense, bogus nutritional advice, and vaccine misinformation.
And then there’s this.

A Popular Class of Antibiotics May Increase Risk of Birth Defects
A new study in the British Medical Journal has revealed a possible association between taking a popular antibiotic during early pregnancy and major congenital malformations.
Clay Jones on February 28, 2020
Link

This will be my second post in a row to point out problems with the practice of conventional medicine, specifically when it comes to potential harm from widespread suboptimal use of antibiotics. So I hope that any naysayers out there will henceforth refrain from using straw man arguments involving claims of our ignoring certain topics and only focusing on so-called alternative medicine. We know that conventional medicine isn’t perfect. Far from it, in fact. Still, I would rather trust my life, and the lives of my family, with science-based medicine than with modern day fairy tales based on the arbitrary prescientific claims we so often discuss here on SBM.
Making the news last week was a study in The BMJ revealing a possible link between the use of a certain popular class of antibiotics during pregnancy and major birth defects, particularly cardiovascular anomalies. Before I get into the details, I think it’s important to first point out two things. One is that this is a retrospective cohort study. It’s a pretty large retrospective cohort study, but it still can’t answer the question of causality with certainty. But it certainly can raise our level of concern and even potentially help to guide clinical decision making.
The other thing is that this didn’t come out of left field. Though the data has been somewhat mixed, concern regarding the use of macrolide antibiotics during pregnancy is far from new. To give just one example, based on concerns of association with cardiac defects, Sweden issued a warning in 2005. The approach has varied in other countries. In the United States, for example, neither the American College of Obstetricians and Gynecologists or the American Academy of Pediatrics warn against their use in pregnancy.
In the study, researchers reviewed anonymized public medical records on over a million British children born between 1990 and 2016, finding just over 100,000 whose mothers were prescribed either a macrolide or a penicillin at any time during their pregnancy. They excluded children with chromosomal abnormalities or whose mothers took drugs known to cause birth defects. Including the penicillin cohort was an effort to minimize potential confounding by the effect of infections during pregnancy, because the two antibiotic classes are often used to treat the same types of infections and penicillins have a long track record of safety during pregnancy. The researchers also attempted to account for a number of other potential confounding variables, such as maternal age, alcohol/drug use, and diabetes.
There were two negative control cohort populations used in the study as well. These included roughly 82,000 children born to mothers who were prescribed a penicillin or macrolide prior to conception and a group of 53,000 or so siblings of children who were exposed to these antibiotics prenatally. The primary outcomes they were on the lookout for were the diagnosis of any major malformation or one of four neurodevelopmental disorders: cerebral palsy, epilepsy, ADHD, and autism.
The authors found that roughly a third of mothers received at least one course of antibiotics during pregnancy, with penicillins and macrolides accounting for 69% and 10% respectively. Among children exposed to macrolides in the first trimester, there were 27.7 major malformations per 1,000 live births. Children exposed during the 2nd or 3rd trimester were found to have a rate of 19.5 major malformations per 1,000 live births. Prenatal penicillin exposure at any point during pregnancy was associated with roughly 17.5 major malformations per 1,000 live births.
If real, this reveals a significant increase in these malformations when mothers take a macrolide in the first trimester. The association was particularly robust when looking specifically at cardiovascular malformations. The study found that for every 1,000 women who receive a macrolide instead of a penicillin, there would be 4 additional children born with a heart defect. Genital malformations were also found to be associated with macrolides compared to the penicillin cohort, with about 1.7 extra cases per 1,000 live births. There was no association with increased risk of any of the neurodevelopmental disorders.
It’s important to sort out whether or not these medications are safe for a developing fetus. Previous studies have shown that about a quarter of pregnant women receive an antibiotic at some point during pregnancy. This study found it to be a bit higher at about 30%. And macrolide antibiotics are frequently what pregnant women get. They are frequently what everyone gets. Odds are, in fact, that most of the people reading this post have been prescribed a macrolide at some point in their lives.
In 2017, nearly 45 million prescriptions for a macrolide were written in the outpatient setting in the United States, making it the second most common behind the penicillins. The vast majority of macrolide prescriptions, around 43 million or so, come in the form of the more recently developed (approved in 1988) azithromycin (Zithromax, Z-Pak). As any student or resident who has rounded with me for any significant amount of time can attest to, it is by far my least favorite antibiotic.
Don’t get me wrong, azithromycin is a great antibiotic that is very effective in a number of clinical scenarios, but it is terrible for the same reasons that it is great. It’s cheap, conveniently dosed once per day and for a shorter course than penicillins for common indications, and more broad in its coverage than them as well. And because I’m a pediatrician, I have to also point out that it tastes decent in its liquid formulation. Add to this the catchy trade name, and you’ve got a recipe for improved patient adherence to your treatment recommendation.
Unfortunately, you also have a perfect set up for overprescribing. Of the roughly 43 million prescriptions for it, which is actually down from closer to 60 million per year a decade ago, most are suboptimal. Doctors have become cavalier with use of this antibiotic more so than any other, frequently prescribing it for what are clearly self-limited viral respiratory infections but are labelled as ear infections, sinusitis, bronchitis, “strep throat”, or pneumonia. Azithromycin is also the antibiotic most often asked for by name by patients and parents. The marketing was very, very effective.
Part of what makes me so grumpy about this antibiotic, in addition to the fact that it is so often prescribed when an illness is clearly caused by a virus, is that prescribing it reveals a fundamental knowledge gap in many medical professionals. The most common bacterial pathogen known to cause ear infections, sinusitis, and pneumonia is pneumococcus. That’s one of the bugs that we have developed highly successful vaccines against, preventing many life threatening cases of pneumonia, bloodstream infections, and meningitis across the lifespan. But it’s still a common cause of human infections, and it is highly resistant to azithromycin. I’m talking a coin flip’s chance or worse of it working.
So in summary, this study is raising serious concern that a very commonly prescribed antibiotic, which provides little to no benefit for a large percentage of the patients it is prescribed for, might increase the risk of serious birth defects in children whose mother’s take it early in pregnancy. That being said, there are proper indications for using a macrolide. Severe penicillin allergy, for example, is a common reason. Also chlamydia infections, tuberculosis, and atypical pneumonia in some instances. And poorly treated maternal infections can cause harm to her fetus as well. So I don’t want to completely throw the baby out with the bathwater here.
The bottom line is that there is legitimate reason to be cautious about macrolide use during pregnancy. Of course, it would be great if we stopped treating viruses with antibiotics, but that is a steep hill to climb at this point. There is, however, lower hanging fruit. More than 90% of people who think that they are allergic to penicillins probably aren’t. For a variety of reasons, not just avoiding macrolide antibiotics during pregnancy, there really should be a more concerted effort put into delisting penicillin allergies. It isn’t hard to do.

Seizure Medications Safer Than Previously Thought for Breastfed Babies
A new study, recently published in JAMA Neurology, further supports the safety of breastfeeding while taking medications for epilepsy. But there are a couple caveats to be aware of.
Clay Jones on January 10, 2020
Link
As a newborn hospitalist, I am frequently called upon to counsel mothers on the risks and benefits of breastfeeding versus formula feeding their baby. Often this comes up in the context of concerns for potential harm to the newborn from medications that their mother is taking. Unfortunately, I don’t always have good data upon which to base a recommendation and the decision of whether or not to breastfeed can be quite challenging.
Pregnancy and epilepsy
Epilepsy is a common and potentially life-threatening condition diagnosed in over a million women of childbearing age in the United States, and it used to be designated as an absolute contraindication to pregnancy. Historically, pregnancy was known to increase seizure occurrence and to risk serious injury to mother and baby. Today, thanks to the development of safe and effective antiepileptic drugs (AEDs) and advances in obstetrical care, more than 24,000 babies are born each year to women with epilepsy.
There are, however, unique challenges facing women with epilepsy during pregnancy, particularly concerns of potential harm to the developing fetus from AEDs. Although uncommon, AED exposure can result in major congenital malformations, poor intrauterine growth, and long term developmental deficits. This has mostly been associated with the AED valproate, which is safe and effective in many patients and not just for epilepsy, but is now generally avoided in women who may become pregnant. In most cases, the benefit of AED use during pregnancy outweighs the risk and is safe when managed by a specialist with expertise in choosing the safest medication(s) and in appropriate monitoring of levels in the bloodstream.
Breastfeeding and epilepsy
Once a baby is born, the assessment of risk versus benefit when it comes to exposure to maternal medications necessarily changes. Because of concerning animal data showing neuronal injury from certain AEDs, and the known potential risk for neurodevelopmental problems in children born to mothers taking them, there has been disagreement over recommendations on breastfeeding. There just hasn’t been much in the way of data to base a decision on, and what we have involves very small numbers of babies. For many years, though, the standard recommendation has been slowly shifting towards comfort, particularly as newer AEDs have been rolled out, and a new study recently published in JAMA Neurology further supports their safety.
Previous studies have looked at levels of various AEDs in the breast milk. In this new study, researchers collected blood from 164 breastfed infants of mothers being treated for epilepsy between 5 and 20 weeks after birth. They found that in about half of the subjects, levels of AEDs in the blood were less that the lower limit of quantification. For most of the medications the mothers were taking, including the most commonly prescribed newer medications such as Keppra (levetiracetam), the majority of blood levels were found to be below the lower limit. Only one medications, lamotrigine, consistently had reliably detectable levels in the infant subjects.
So what does this mean? This study, which was the largest of its kind to date, shows that levels of AEDs in infants who are breastfed by mothers taking them are well below what they would have been exposed to for months in the womb. So taking into account the benefits of breastfeeding, the risk of exposure to AEDs through breast milk is low enough to have confidence in supporting a mother’s decision to do it.
Two quick caveats
There are two potential concerns that caregivers and medical professionals should be aware of when it comes to the babies born to mothers taking AEDs. Some of these medications interfere with the absorption of folate, thus increasing the risk of birth defects. In particular, inadequate maternal folate levels are associated with neural tube defects such as spina bifida and anencephaly. This is why since 1998 folate has been added to grain products in the United States, which has resulted in 35% fewer neural tube defects. Women taking AEDs should ensure that they are getting adequate folate intake, which may require taking a supplement in addition to a healthy diet.
The other potential health issue in breastfed infants born to mothers taking AEDs is vitamin D deficiency. Vitamin D deficiency is common, but even more so in women taking medications for epilepsy. Breast milk is also known to be low in the prohormone (it isn’t actually a vitamin since we make it ourselves with the help of sunlight), even when mothers are taking a supplement. Because of this, pediatricians and family docs have been recommending that young infants be given 400 IU, usually in the form of Vitamin D drops, every day until they are getting at least a liter of formula or adequate intake through solid food. I’ve seen rickets in a baby and it isn’t pretty.

Corporal Punishment in the Home: Parenting Tool or Parenting Fail…
Clay Jones on January 3, 2014
Link
One of the most commonly practiced strategies used by parents to alter long term behavior of their children is corporal punishment, commonly referred to as spanking. But use of the term spanking is problematic in that how caregivers interpret it varies widely, and there is frequent overlap with what pediatricians consider to be abuse. Despite a great deal of evidence showing that spanking is ineffective, is a risk factor for greater forms of physical abuse and can negatively impact the behavioral and cognitive development of children in a variety of ways, it remains a controversial issue in the United States. The American Academy of Pediatrics and numerous other professional organizations have come down firmly against the use of physical punishment by parents, but unlike 34 other developed nations there are no federal laws banning spanking.
Laws regarding corporal punishment vary from state to state. 19 states currently allow the striking of a child in any school setting. Of the 31 states and the District of Columbia that ban the practice in public schools, only New Jersey and Iowa also include private schools. Many schools give the misbehaving child a choice between suspension and being beaten with a paddle. It is also common for schools to require a parent to opt out of their child receiving corporal punishment rather than having to sign a consent form before such physical correction is applied. Corporal punishment in schools is more prevalent in the South and in lower socioeconomic school districts, leading to poor black children being by far the most likely to face it.
Currently no state has a law that explicitly bans corporal punishment in the home. In fact, most state laws have specific language in their statutes on abuse, assault, battery, or domestic violence that make exceptions for spanking by a caregiver. In 2012, new child abuse legislation in Delaware made the news because it might possibly be interpreted as making spanking illegal. The law was put into place to serve as a means of improving the ability to protect children from physical abuse, but the language was vague. The lawmakers claim that it is not meant to interfere with parents who choose to use “reasonable force”, whatever that means, and do not cause injury.
There are many examples of folks being arrested for “spanking”, but these invariably involve the use of an instrument like a spoon or metal rod, or the use of excessive force that leaves long lasting marks or bruising. The use of the word “spanking” in these reports confuses the issue. I certainly wouldn’t call it that and it doesn’t fit the definition of spanking used by the AAP. I was unable to find a single case of a parent or caregiver being arrested for spanking as defined by “reasonable people”. Again, whatever that means.
I have always felt strongly that spanking children is a parenting technique that reflects more on the poor coping skills of the caregiver than on the behavior of the child. Spanking is a practice that appears to be carried from generation to generation primarily by anecdotal reports of success, cultural momentum and weak science. Odd, at least to me, is the fact that many parents who spank seem to proudly wear their own history of being spanked as some kind of a badge of honor. “Look at me. I was spanked and I turned out just fine!” The psychology of this makes sense to me though. I doubt many parents look at a newborn child and plan to make use of corporal punishment to mold them into an upstanding citizen. More likely they do so out of anger and frustration, and only then find the need to justify the act.
But in any one individual case, it very well may be true that an adult who was submitted to recurrent episodes of corporal punishment as a child has turned out just fine. Of course they would have almost certainly turned out just fine if they had never been spanked. They might have turned out better though. The evidence just doesn’t support the practice, and many children almost certainly do not turn out just fine. Some end up being more severely abused, many have long term difficulties and most grow up to use corporal punishment as a technique themselves.
Examples of spanking apologetics are everywhere online. What inspired me to finally cover this topic, something I’ve been toying with for months, was when an acquaintance on Facebook recently “liked” a meme which blames spanking for the “psychological condition known as ‘respect for others.'” But that is just the tip of the iceberg. Here is a terrible article giving 8 Reasons to Spank Your Kids. Here is one that explains Why Spanking is Necessary that is based on the Biblical principle that young children must be absolved of their guilt through physical punishment as an act of love. If you aren’t scared already, this is the very same concept put forth in the infamous To Train Up a Child book which has led to several deaths. Religiously-motivated pro-spanking websites are extremely common.
In 2010 a study, that supposedly showing that children who were spanked grew up happier and more successful, made the rounds (1, 2, 3). There are countless links to these press releases and news reports on parenting boards and blogs attempting to endorse or justify spanking. All leave out important facts, such as how the study was a small and unpublished outlier. But if you google “benefits of spanking”, this is pretty much the only “science” you’ll find.
what is corporal punishment and when is it physical abuse?
Simply put, corporal punishment is the use of physical pain in response to behavior that has been deemed inappropriate. As with many behaviors, there is a spectrum of severity. Anything from a light slap on the back of the hand to holding your child’s foot in scalding water is technically corporal punishment. One end of this spectrum is clearly accepted as physical abuse by rational people while much of the rest of it is not, which is a big part of what makes this such a touchy subject.
Many parents who use one form of corporal punishment would take offense at the notion of being put in the same category as other parents who use a different form of corporal punishment. Not everyone agrees on where the line between acceptable physical punishment and abuse, or even between what are appropriate and inappropriate non-abusive techniques, should be placed. The AAP defines spanking as “striking a child with an open hand on the buttocks or extremities with the intention of modifying behavior without causing physical injury.” They differentiate spanking from other forms of physical punishment that incorporate the use of an object, target other areas of the body, leave bruises or red marks that persist more than a few minutes, or involve pulling the hair or jerking the child by an extremity.
The AAP lumps physical punishment doled out while angry, or with the intent to cause pain, with these and states that they are all unacceptable and should never be used. But how does one spank without the intent to cause pain? And available research doesn’t support that corporal punishment is able to be planned or initiated when the caregiver is calm, which is integral to the recommendations of most pro-spanking resources. In one survey, 85% of respondents “felt moderate to high anger, remorse, and agitation while punishing their children” with 44% reporting that more than half of the time they had “lost it.” This makes sense to me because it fits with how most episodes of more severe physical abuse occur when a parent or caregiver snaps. I imagine that few people in jail for hurting a child thought it was something that they were capable of before the event.
We are still left with the question of what is child abuse, or at least how do we differentiate it from spanking or other forms of less severe corporal punishment. When an angry parent uses a belt to slap a child on the buttock, are they committing child abuse or just using an inappropriate form of spanking? Unfortunately, many still find this completely acceptable. What if the belt leaves a bruise that lasts for a few days? What if a plastic pipe is used? What if they do this repeatedly over the child’s first few years of life? What if it is a 4-month-old? When should child protective services be notified? These can be tough questions. I know how I feel but am not always comfortable in my role as arbiter. I am considerably more comfortable when it comes to the discussion of effectiveness and risk of spanking.
The AAP, in their policy statement on the evaluation of suspected physical abuse, recognizes this problem:
The recognition and reporting of physical abuse is hindered by the lack of uniform or clear definitions. Many state statutes use words such as “risk of harm,” “substantial harm,” “substantial risk,” or “reasonable discipline” without further clarification of these terms. Many states still permit the use of corporal punishment with an instrument in schools; on the other hand, the American Academy of Pediatrics has proposed that “striking a child with an object” is a type of physical punishment that “should never be used” and has recommended that corporal punishment be abolished in schools. The variability and disparities in definitions may hinder consistent reporting practices.
I believe that this puts it lightly. And they don’t say that “should never be used” equates to child abuse or that use of an object should be illegal. I have little doubt that there are many children out there who are disciplined in ways that should probably be categorized as abuse but are not. I believe that many pediatricians and other pediatric healthcare professionals employ compartmentalization when it comes to acceptable corporal punishment versus physical abuse, and rationalize the probable abuse as a parental right. Many of us are likely hindered by a general discomfort telling parents how to raise their children. But more on what pediatricians think about corporal punishment later.
Who uses corporal punishment and who is on the receiving end?
Spanking is extremely common. I found a number of sources (1, 2, 3, 4, 5, 6) with slightly different statistics but all make it clear how prevalent corporal punishment in the home is. Data from the 1970’s revealed that more than 90% of families in the United States used corporal punishment in the home at least once. More recent data supports the continued high prevalence, with roughly 80% of young children and more than half of kids through age 13-14 years being disciplined by a caregiver with physical punishment several times each year.
There are many socioeconomic and cultural factors which increase the likelihood that corporal punishment will be used by caregivers, and that it will be used more frequently. Spanking is more common with boys and tends to be harsher. Use increases as family income decreases, and black children are much more likely to be spanked than white kids. Parents who were spanked are also more likely to spank their own children, as are caregivers who are more stressed in general.
Although corporal punishment is most widespread in low socioeconomic households, a 1996 survey revealed just how common, and how severe, it can be in middle class families. 25% of participants acknowledged weekly use and 35% admitted to occasionally using an object. An object was used half of the time in 17%. 12% of the occurrences of corporal punishment were felt to have caused considerable pain with 5% leaving lasting marks on the child’s body.
Spanking is most commonly used to discipline preschool and school-aged children, but sadly about 15% of children under the age of 1 year are spanked. This number is considerably higher in poor families, with about a third of infants being hit. Women who experienced physical or sexual abuse, or were exposed to violence in the home, are much more likely to practice infant spanking and to have a positive view of corporal punishment in general. Children this young, and often even older kids, do not understand the connection between the physical punishment and the undesired behaviors, and even the vast majority of spanking proponents do not recommend it in babies.
What about the evidence? What is so bad about spanking?
I’d love to make this section very short to save time as I sit in our neighborhood library during my first blizzard and a rapidly approaching subzero wind chill. The default after all should be that nobody should intentionally inflict pain on a child without evidence to support the benefit outweighing the risk, such as with an immunization or surgical procedure. And the burden of proof should naturally be on the proponents to provide this evidence. So far, there is no scientific evidence to support that corporal punishment is an effective behavior modification technique and only a meager gruel of studies which at best show that it may not be quite as harmful as most experts think. Done.
The problems with this approach, however, is that it is far too late. As described above, the use of spanking for behavior modification is commonplace, even among otherwise well-meaning and reasonable folks. And there is good, although imperfect, data showing that there are considerable risks. Even proponents of spanking, who question what the available literature appears to show, strongly recommend limits on its use. Limits, such as not using an object or leaving a persistent mark, or not hitting children under one or over six years of age, that are often not followed.
First and foremost, spanking doesn’t tend to work very well, and certainly is a less effective form of punishment than time-out strategies or other negative punishments like removal of privileges. A positive punishment like spanking may in the acute setting stop an unwanted behavior but it loses effect over time. Thus in order to achieve the same result, it often must be increased in intensity, which is part of why it can lead to clear abuse. So there is room to argue that in a very few specific instances, such as a child about to put their finger in an electrical outlet, an immediate slap on the hand might stop the behavior. Of course so would simply removing them from the area and putting a cover on the outlet, and explaining the danger once they are old enough to understand.
There are a variety of potential harms that studies have linked to the recurrent use of corporal punishment on children. In addition to the potential to lead to physical abuse, repeated spanking may cause agitation and lead to aggressive behaviors through observational learning of poor coping skills. Spanking risks negatively impacting the parent-child dyad, making other forms of discipline less effective when the child is too old/large for the use of physical punishment. Children who are spanked may come to accept it as a parental right, which increases the likelihood that they will spank their own children and even that they will abuse their spouse. Use of corporal punishment has also been linked to negative cognitive outcomes, in particular decreased receptive and expressive vocabulary. (1, 2, 3)
The ability to study the harm of spanking is hindered by a lack of prospective studies. It would be unethical to have a randomized trial where some children are intentionally subjected to corporal punishment. So the available data is retrospective and often based on maternal report. There have been few longitudinal studies and, as you can probably imagine, there are a number of potentially confounding socioeconomic and caregiver variables.
While discussing this recently on Twitter (@skepticpedi), I was asked how we know that bad and more aggressive kids aren’t just spanked more. That certainly sounds plausible. The two studies I provided links to above are the most recent and best to date, and provide solid evidence to support concerns that spanking actually plays a causal role in future aggressive behavior and interference with cognitive development. Using data from the Fragile Families and Child Well-Being Study, which was a longitudinal birth cohort study of over 4,000 kids from 20 major US cities through age 9 years, both were able to take into account a large number of potential confounders involving “family characteristics and risk with the potential to affect parenting stress and family functioning.”
What do pediatricians think about corporal punishment in the home?
The AAP periodically surveys its Fellows on a variety of topics. In 1998, one such survey looked into the attitudes and counseling on corporal punishment in the home. The results were based on responses from 603 post-residency Fellows who provide direct patient care. Here is what it revealed:
53.4% of responding pediatricians were generally opposed to the use of corporal punishment by parents, but not to an occasional spanking for certain reasons. I guess that is the finger in an outlet clause. 31.4% were completely opposed to the use of corporal punishment under any circumstances. Only 14.4% supported limited, which I take as non-abusive, use while just 1.5% were unsure of what they think about it. Sadly, only about half ever discussed the pros/cons of corporal punishment with parents. Of note, about 75% of pediatricians in the survey reported that they had been spanked as a child and a full third admitted to spanking their own kids, although less than 1% said it was their most commonly employed disciplinary strategy.
It’s entirely possible that this data is not reflective of current trends. Hopefully even fewer pediatricians are supportive today compared to 15 years ago. And hopefully more are taking time to discuss it.
Conclusion
The limited use of mild corporal punishment, in very isolated and specific circumstances, may have some benefit but prevention/protection is almost always a better option. Its use as a strategy to improve overall behavior is fraught with risk. Although imperfect, there is good evidence that recurrent use can lead to physical abuse, interfere with learning and increase aggression. And it may worsen behavior in the long run.
There is an absence of any data showing it to be more effective than other techniques, such as negative punishment strategies like time outs. Unfortunately, the internet is full of pro-spanking propaganda that relies on anecdotes, old fashioned thinking and one study that didn’t survive peer review. The best initial resource for questions regarding discipline should always be a child’s physician. We aren’t perfect, but most pediatricians accept that corporal punishment is a poor method of discipline and should be able to provide education and help accessing local resources.

Psychic Mediums and Grieving Children
Self-proclaimed psychic mediums find a new way to exploit vulnerable children.
Steven Novella on February 3, 2021
Link

Grieving is a normal and healthy part of life, coping with the inevitable loss we all must face. But a significant minority of people suffer from complicated grief following a major life event, which can involve prolonged and disabling grief. Grieving can also be especially difficult for children who are still grappling with basic concepts of death and loss.
Grief counseling is not always required, and may even be counterproductive. This is a complicated area of ongoing research, and at present a cautionary approach seems to be warranted – only engaging in grief counseling for those with complicated grief who seek it out themselves. Again this can be tricky in children, where their guardians must make this determination on their behalf. The bottom line is that there is potential for harm, and a cautious evidence-based approach is best. Certainly addressing grief in children should not be left to those without proper training or system of professional conduct or ethics.
This is why it is disturbing when self-proclaimed psychic mediums insert themselves into the grieving process, especially when children are involved. Alleged medium Thomas John, for example, is planning a Zoom group “spirit circle” for children who have lost loved ones. Grieving children are a doubly vulnerable population, and such an event can only be described as exploitative. There is also tremendous potential for harm.
On his website promoting the event we find the usual “quack Miranda warning”:
We ask that guardians please use your own judgment whether or not your child is mentally able to attend group as conversations about death, grief, spirits and afterlife will be throughly [sic] discussed in session.
All Sales are Final
John clearly recognizes the delicacy of the situation, or else he would not feel the need to indemnify himself from any harm his services might cause. Basically – it’s all on the parents. And in case there were any doubt what his services are all about, he also makes it clear that “All Sales are Final”.
Unfortunately there has not been a lot of direct research looking specifically at the effect of those who are grieving consulting an alleged psychic medium. A qualitative review, however, points to both potential benefits and harms. The potential benefits are the obvious ones frequently pointed to by defenders of mediums – the person can feel a connection to the lost one, resolve issues, and get some sense of closure. These benefits are speculative, but worse, they are likely to be negated by the risks involved. Psychologist Baugher lists many potential negative outcomes:
    • Confusion as to whether real contact was actually made
    • The person contacted is often not the desired loved-one
    • The medium lacks the skill to put on a convincing performance
    • Negative messages are conveyed (presumably to motivate further reading and exploitation)
    • Guilt or shame from the stigma that may be attached to consulting a psychic
    • Dependence on the high produced by the apparent connection to a lost loved-one
    • Disruption in the normal course of grieving
    • Post-high letdown after the session
In John’s video promoting the event, he signals many of these potential issues, saying that he cannot promise to connect to the desired spirit, for example. Many of these potential negative outcomes are likely to be more severe in children, who will be more susceptible to confusion and may have a harder time dealing with disappointment on top of their grieving.
The National Alliance for Grieving Children recommends as a core to the approach to the grieving child is to be honest.
Although it may be challenging to share the truth about how someone died, honest answers build trust, help provide understanding and allow children to feel comfortable approaching us with questions because they know they can trust us to tell them the truth. Children know more than we think they do and by not telling the truth, we risk leaving children to process complicated information on their own, rather than with the loving adults in their lives.
They also point out that childhood grieving is often an important growing experience. The flip side of this is that deceiving children can destroy trust, reduce understanding, and may generate new problems as listed above, such as dependence.
Context is also important – we must remember that there is no evidence that any self-proclaimed medium is legitimate. Like all alleged psychics they largely rely on cold-reading techniques. This puts the burden on the person being read to make all the connections, and they are blamed if they cannot do this. That is one near-universal feature of faith-healers and psychics – they are never to blame. If the faith healing fails, that is because you lacked faith. If the message through the medium makes no sense, it is because you are failing to see the significance.
From any reasonable perspective, offering grieving children the deception of a medium performance is exploitation of a vulnerable population with the potential for psychological harm. I would urge any parent to consider the information here very carefully, and if complicated grieving is suspected, seek professional guidance. The more complicated question is – can anything be done to stop such exploitation? Efforts to shield children from harmful practices such as faith healing or unproven alternative treatments has run up against claims of parental rights and religious freedom. Parents have successfully employed this defense even when allowing their child to die a painful and preventable death because of their personal philosophy. I would argue that the state has a superior interest in protecting children from obvious exploitation and harm, but politically the state is often reluctant to exercise that duty and instead often prefer to defer to parental rights.
Still we won’t shy away from pointing out that such exploitation is wrong.

Pseudoscience in Child and Adolescent Psychotherapy
This new book addresses the neglected field of research on child and adolescent psychotherapy and does an excellent job of distinguishing treatments that have been proven to work from treatments that are based on pseudoscience.
Harriet Hall on April 30, 2019
Link

Pseudoscience in Child and Adolescent Psychotherapy: a Skeptical Field Guide, is a new book with multiple authors, edited by Stephen Hupp. They point out that “It is difficult to prove that something works, especially in the field of psychotherapy, and particularly in attempting to help children”. There is little research on children, and research in adults may not apply to children. This very useful book addresses this neglected field. It does a wonderful job of separating psychotherapeutic treatments that have been scientifically proven to work and therapies that are based on pseudoscience.
The format of the book
19 chapters by skeptical experts address everything from tics to toileting, from depression to anxiety, from sleep to substance abuse. The first chapter is an introduction to critical thinking about psychotherapy, covering pseudoscience and skepticism, plausibility, and good science. Each chapter covers myths, questionable ideas, treatments that are implausible, ineffective, or harmful. Then it explains which therapies are supported by good scientific research, followed by a succinct “Conclusion”. As a bonus, each chapter features a sidebar by a prominent interdisciplinary science communicator on peripheral subjects like dolphin-assisted therapy, gay conversion therapy, fear of GMOS, alien abduction, and breatharians. Four of the sidebars were contributed by authors who have also written for Science-Based Medicine, and others are by skeptics who have spoken at national conferences, like Britt Hermes and Sheldon Helms.
As an example, here are some of the implausible, untested treatments they list for anxiety: homeopathy, crystals, thought field therapies, moxibustion, Tappy Bear (a really silly idea that was new to me), acupuncture, and neurofeedback video games like MindLight.
Some of the intriguing or surprising facts in the book
The book is full of fascinating information and is extensively referenced. Joe Nickell reveals that breatharians have been caught making nighttime forays for junk food. Indre Viskontas debunks the idea that children should be taught based on their preferred learning style; in fact, research has shown that conditions that make learning seem more difficult are actually more effective for long-term retention. Medications for ADHD may be more effective if behavior therapy is implemented first. Brain Gym has been widely adopted by schools but is not supported by evidence. Tics are a brain disorder, not a spinal disorder that could be corrected with chiropractic adjustments; nevertheless, some chiropractors try.
Treatment of psychosis has evolved from “maintenance” to “recovery”, with coordinated specialty care programs that have been proven effective in randomized controlled trials.
The evidence for cognitive behavioral therapy is good, but not perfect; scientific conclusions are provisional and subject to revision as new data comes in.
Phobias describe behavior but don’t explain it. Sally runs away when she sees a dog, because she has a phobia. But that’s circular reasoning. Why does she behave that way?
Pitfalls in research: if you add a placebo to cognitive behavioral therapy (CBT) the results will seem to improve, but that doesn’t mean the placebo is an effective treatment. Tolerating pseudoscientific treatments degrades the profession; failing to act is condoning fraud. One of the reasons pseudoscientific practices proliferate is that evidence-based practices are underutilized.
Obsessive compulsive disorder (OCD) involves rituals, and rituals can have psychological benefits even if they are not based on reality. In Heart Centered Hypnotherapy, therapists use past life regression to “wash off the child” that was dirtied, which supposedly cures OCD. When a pseudoscientific treatment fails to work, proponents often come up with ad hoc hypotheses. Callahan explained failures of his thought field therapy by positing “individual energy toxins”, which could be any substance consumed or inhaled, including common foods. He made patients severely restrict their diets for no good reason.
Some attachment therapists claim that emotional attachment of infant to mother occurs prenatally as a result of telepathic communication that begins at the time of conception. There is positive research on Eye Movement Desensitization and Reprocessing (EMDR) but only because the research methods were flawed and because factors like patient engagement are common to all successful psychotherapies.
Eating behavior responds to reinforcement, but studies have shown that rewards for eating are counterproductive. Crib bumpers were designed to prevent infants from getting heads or limbs stuck between the slats. They are no longer needed because safety regulations have changed the size of crib slats. But they are still being sold and have been implicated in several infant deaths.
Lying is not always a sign of psychological problems. Social skills in adolescents improve when they become more effective liars. Lying in moderation could be considered a sign of psychological health.
Research has shown that venting anger, Scared Straight programs, the DARE program, and Boot Camps are harmful.
The last chapter says,
The mind is a terrible thing – there are so many ways that our minds can be deceived… reading through these chapters, it’s really exhausting to think about how much time, money, and effort are spent using therapy practices that are questionable, ineffective, or even harmful.
When the book calls an idea “questionable” that leaves the door open for some of these practices to develop an evidence base.
One pessimistic writer deplores Counter-Enlightenment trends in the US that lead people to reject or deny scientific findings.
If indeed a general anti-rationalist posture is responsible for pseudoscientific thinking about children’s mental health, it is difficult to see how the public can be convinced of the need for evidence-based treatments.
Conclusion: an invaluable guide
There is an incredible amount of silliness out there, but it’s reassuring to see how many writers they found who understood science and could cogently critique pseudoscience in this book. There is reason to hope that good science will prevail and that this book will be instrumental in making progress. This book would be instructive for psychotherapists and it is an invaluable resource for parents who are trying to find an effective psychotherapy for their children and adolescents. They need all the help they can get.

A British Teenager is Blind, But Not Because of Junk Food or “Fussy Eating”
A recent case report about a British teenager blinded by severe nutritional deficiencies resulted in widespread media coverage, much of which missed the point. He wasn’t blinded by junk food and he wasn’t just a fussy eater.
Clay Jones on September 6, 2019
Link


A tragic story out of England involving a teenager rendered permanently blind because of a severe nutritional deficiency is making the rounds this week. People, even children, go blind all the time unfortunately, so it may seem odd that there would be such coordinated coverage of this particular case by all the major news outlets. But there are some unique aspects to the child’s history that had these journalists salivating.
According to the authors of the Annals of Internal Medicine case report, the 17-year-old boy had an extremely limited diet:
He had a daily portion of fries from the local fish and chip shop and snacked on Pringles (Kellogg), white bread, processed ham slices, and sausage.
Many of the news reports have referred to the 17-year-old as “picky” or “fussy” about what foods he would eat, with one article even claiming that he was “blinded by junk food”. To be fair, that was essentially the title of the case report that these articles are based on. And everyone knows that “junk food” is bad for you, right? Most of the articles even feature pictures of French fries or potato chips to help focus the readers attention on the dastardly and muttly culprits.
As a pediatrician, I work with many families who become overly concerned about their child’s health because of something that they have hear or read in the news. While unintentional I’m sure, some articles discussing this case may result in undue anxiety. One example of this is the opening paragraph of the coverage in Ars Technica, which involves a joke in poor taste about using the fear of blindness to deal with “picky eaters”:
In the past, parents may have tried to coax their picky eaters to dinner with misguided reminders of starving children—or perhaps letting them imitate farm animals. But, the parents of today now have a scarier prompt.
Parents, like all humans, aren’t always rational. Yes, this is a joke. A very bad joke. But it is at the beginning of an article discussing the terrible outcome of what is largely being described as picky or fussy eating. Normal picky eating behaviors in childhood have no place even being mentioned in this context. Maybe it’s a bit of a stretch, but I worry that this may be confusing to some readers. And while the article goes on to provide good information, it isn’t until the final paragraph.
As is often the case, a lot of the media coverage lacked nuance, and an opportunity to educate the public about a severe and recently recognized eating disorder was largely wasted. What the patient suffered from was far more than simply being a fussy eater. He likely experienced extreme anxiety, potentially even the fear of death, at the mere thought of eating most foods.
Blinded by junk food?
The child in question first presented with symptoms of fatigue related to nutritional deficiency at the age of 14. He was found to have anemia caused by a vitamin B12 deficiency, which was ultimately blamed on “fussy eating” after a limited work-up for causes of poor intestinal absorption was performed. He was prescribed B12 injections and given advice on proper diet. This was a missed opportunity to recognize and properly manage his eating disorder.
By age 15, he had developed hearing difficulty and unspecified “visual problems”, and was evaluated by both an ENT surgeon and an ophthalmologist but no underlying cause was found. Another missed opportunity, particularly given the history of known issues with his diet and the fact that he had not been adherent to the B12 injections for undisclosed reasons. After 2 years of progressive vision loss, he was seen by a neuro-ophthalmologist and diagnosed with permanent optic neuropathy.
Optic neuropathy, which is the term for essentially any injury to the optic nerve, has a long list of potential etiologies but is very rare in the pediatric population. A thorough work-up involving laboratory and genetic testing, neuroimaging, and intestinal biopsies was completed, and the cause was narrowed down to multiple severe nutritional deficiencies. In particular, vitamin B12 deficiency was again found and believed to be the primary cause of the patient’s visual loss. It was at this point that his extremely restricted food intake came to light.
Avoidant Restrictive Food Intake Disorder
This unfortunate child was not blinded by junk food. He suffered from a recently recognized eating disorder known as Avoidant Restrictive Food Intake Disorder, or ARFID. The concept of a pathologically restrictive diet isn’t new, of course. It’s more fair to say that the ARFID is a new label for the older “Selective Eating Disorder”, complete with a better description of the presentation, that was incorporated into the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders in 2013.
Patients with ARFID are not just picky eaters. They avoid or restrict themselves from certain foods because of severe anxiety related to eating them, or because of extreme emotional discomfort related to certain food textures. Many of these patients become physically unable to eat many foods because of gagging and vomiting that occurs when attempting to do so. Some experience an intense fear of choking to death when even thinking about eating certain foods.
This degree of avoidance and restriction of foods, by definition, results in physiological harm in addition to the adverse effects on psychosocial functioning. Failure to maintain appropriate weight isn’t as common as it is with the more well known anorexia nervosa, but it can occur. As in the case discussed above, nutritional deficiencies are also a major concern. Also by definition, ARFID does not involve a disturbance in how the patient experiences their body. They don’t have concerns about being overweight.
Here is a description of a typical case of ARFID. I have admitted several extremely ill patients with this condition to the hospital and each one has been hard to witness and challenging to treat. It takes involvement from medical doctors, particularly experts in adolescent medicine and psychiatry, as well as dietitians and social workers. It is not unusual for patients to require anxiety medications with each meal in the early stages of treatment, just to help correct nutritional deficiencies and stabilize organ function, before long-term cognitive behavioral therapy can be initiated.
Missed opportunities
The authors, the lead being an ophthalmologist, appeared to be more into the discussion of optic neuropathy than the patient’s ARFID, but at least they do mention it in passing at the very end. Like much of the news coverage, however, they focused on the fact that his diet consisted of mostly “junk food”, a nebulous label that often serves to demonize food and the people consuming it rather than to educate them on healthy dietary choices. This was evident in the press release:
The researchers concluded that the patient’s ‘junk food’ diet and limited intake of nutritional vitamins and minerals resulted in the onset of nutritional optic neuropathy. They suggest the condition could become more prevalent in future, given the widespread consumption of ‘junk food’ at the expense of more nutritious options, and the rising popularity of veganism if the vegan diet is not supplemented appropriately to prevent vitamin B12 deficiency.
That seemed like an unnecessary cheap shot at veganism given the context of this case.
The news article I just linked to has a giant picture of French fries, but while French fries are a convenient scapegoat that makes this whole thing cognitively easier to digest, demonizing specific foods is not what we should be focusing on. The focus should be on mental health as it relates to eating, and how systemic factors can lead to a child like this going so long without appropriate help. We should be talking about how this was a preventable tragedy, not about junk food and veganism.
Popular media have highlighted the risks for poor cardiovascular health, obesity, and cancer associated with junk food, but poor nutrition can also permanently damage the nervous system, particularly vision.
This wasn’t simply a case of “poor nutrition”. The child was avoiding a wide variety of foods necessary for complete nutrition because he was suffering from untreated severe anxiety. This could have happened even if the foods he could eat weren’t classic junk foods.
I highly doubt that there are many people out there who would not recognize his diet as extremely high risk. So this case report raises many more questions than it answers. How did this kid slip the cracks so egregiously? Why was he not admitted to a hospital for inpatient management when he presented with blatant ARFID and associated hearing and vision loss two years prior to the involvement of the case report authors?
Ironically, approaching a case like this as a consequence of the “junk food” rather than the ARFID induced avoidance of foods necessary for vital organ function might actually play a role in causing an eating disorder in some people. What people define as a bad food is often subjective and often not based on science. Gluten, for example, is now frequently seen as something to avoid even if celiac disease isn’t a concern.
When we demonize particular foods rather than encourage healthy diets it fosters an environment where excessive fear of unhealthy foods can result in disordered eating. I’ve seen many patients who have, over time, added more and more “unhealthy” foods to their list of things to avoid until they are left with a very limited diet. This has come to be known as orthorexia, and is widely accepted even if it hasn’t yet been officially recognized as an eating disorder.
Conclusion: A missed opportunity to discuss disordered eating
This was a preventable case of blindness in a pediatric patient. Somehow this child didn’t get the medical care he should have. His dietary restrictions, caused by a severe eating disorder and not “fussy eating”, should have been recognized and managed prior to his loss of vision. Rather than demonizing the foods he ate, however, we should be focusing on preventing children like this from slipping through the cracks.
One important step in that process is awareness of ARFID as an entity. The overwhelming majority of picky eaters do not have ARFID and will never develop it. But if the behaviors seem extreme or persistent, talk to your child’s pediatrician or family doctor about it. The National Eating Disorder Association is a great resource as well.

New Research Reveals a Startling Increase in Pediatric Foreign-Body Ingestions
New research has revealed a significant increase in pediatric foreign-body ingestions over the past 20 years, including life-threatening batteries and magnets.
Clay Jones on April 19, 2019
Link

Kids…is there anything they won’t eat? I’ll briefly explore this question in what may be the shortest post in the history of Science-Based Medicine, or at least from me, as I am currently on assignment in France.
Parents and pediatric medical professionals have long known that infants and toddlers explore their environment with their mouths, shoving anything small enough into their pacifier holes without any semblance of a rational assessment of the risks and benefits. Because of this, a frequent reason for caregivers to seek medical attention is for the suspected ingestion of a foreign body. Though often benign, the coin or small toy passing though the GI tract without injury, there have been innumerable sedations for endoscopy, thousands of surgical interventions, and several deaths in this population when powerful magnets or button batteries were involved.
The epidemiology of these ingestions has largely been based on small-scale studies. We know that they are common, and almost certainly underestimated considering how many occur without caregiver awareness, but a paper published in this month’s Pediatrics gives us the best data to date. It reveals an almost doubling of the incidence of suspected or confirmed foreign-body ingestions resulting in visits to an emergency room in the United States over the past 20 years.
Some interesting facts and findings from the study:
     1.  20% of kids under age 3 years have swallowed a foreign object.
     2.  3 out of every 4 foreign-body ingestions occur in kids 5 years of age and younger.
     3.  With almost 68,000 Poison Center calls, foreign-body ingestions in kids under 6 years was the 4th most common complaint in 2016.
     4.  Neodymium magnet toys, tiny and extremely dangerous if ingested, are now back on the market despite efforts by the U.S. Consumer Product Safety Commission and Senator Gillibrand, as well as warnings from the medical community.
     5.  Between 1995 and 2015, 759,074 children under 6 years were seen in American emergency departments for suspected or confirmed foreign body ingestions, about 100 every day. There was a 4.4% annual increase.
     6.  The number of ingestions in 2015 were 93% higher than in 1995, with an increase from 9 to 18 out of every 10,000 kids in this age group.
     7.  Roughly 2 out of every 3 ingestions over this time period involved a coin, mostly pennies, but quarters were much more likely to result in hospitalization.
     8.  10% of children seen for a foreign-body ingestion were hospitalized.
     9.  Virtually 100% of ingestions, when the location was known, occurred at home.
     10.  Battery ingestions increased from .1% of the total number in 1995 to 8% in 2015, with 86% being the dangerous button variety, and were the 2nd most common cause of hospitalization after coins.
Why such a large increase in ingestions, particularly those involving button batteries? It could be better data collection. Another factor is that there are just more things around to potentially ingest. The reason isn’t clear, but it is almost certainly a combination of factors. In the case of button batteries, which have been around for over 30 years, I think that it’s pretty obvious that the massive increase in the number of household electronic devices that use them plays a large role.
The authors add the following insight regarding button batteries (BB):
The past 3 decades have seen increased morbidity and mortality resulting from BB use, likely related to increased battery diameter and a move to lithium cells, which have longer shelf lives and carry more voltage than previous cells. These batteries can enact more mucosal destruction and are more likely to become impacted.
Young children are never going to stop being curious about small, colorful, or shiny objects, and they aren’t going to stop putting them into their mouths as a means of investigation. I’m sure there is some purpose for this type of exploration. Something, something, something, microbiome perhaps.
While we can thankfully say that 90% of accidental ingestions in this population don’t end up requiring hospitalization and don’t result in any significant morbidity or mortality, that still leaves thousands of injured babies and toddlers every year. We need to up our game when it comes to getting the safety message out there, especially when it comes to the more dangerous items. To start, caregivers should make sure that button batteries are completely out of reach of children and should not have any dangerous magnets in the home.

Rabies Claims the Life of a 6-Year-Old Florida Child: The Tragic Case of Ryker Roque
Rabies is an incredibly deadly infection, but one that is virtually 100% preventable. Unfortunately a Florida child recently paid the ultimate price when his parents failed to seek out appropriate medical care for a bat bite, and despite an experimental but flawed treatment protocol.
Clay Jones on January 26, 2018
Link

On January 10th, the first reports of a Florida child, infected with rabies and undergoing an experimental treatment protocol, began making the rounds. 6-year-old Ryker Roque, according to the news coverage, had come into contact with an injured bat that his father had placed in a bucket outside the family’s home. At some point over the next few days, Ryker had unsupervised access to the bat and, despite his father’s warnings, let curiosity get the better of him. This proved fatal on January 14th when Ryker was declared brain dead, the last ditch therapy having failed to save him.
But first…
Before I delve into this tragic cautionary tale, I wanted to give a brief primer on rabies. Most of you likely knows the basics of rabies, such as the potential for aggression, the hydrophobia, and the high mortality, but the finer details are really interesting. I learned a lot reading up for this post. For instance, I did not realize that rabies is caused by several different viruses in the Rhabdoviridae Family, genus Lyssavirus. I had thought there was just the one rabies virus. And all mammals can potentially become infected but some, like the opossum, are extremely resistant.
Each virus in this genus can cause a disease that we know clinically as rabies, but which particular one can actually make a difference in the clinical course. Using genetic sequencing of the particular virus, we can tell if a patient is infected with bat rabies as opposed to dog or raccoon rabies. Bat rabies virus tends to have a less aggressive course, though still nearly always fatal, than dog rabies virus. The virus specific to canines was officially eliminated from the United States in 2007, but dogs can still become infected with bat rabies or raccoon rabies, for example, and imported dogs can be infected. So still vaccinate your pooch.
The viruses that cause rabies love neural tissue. Once they have entered the body, almost always via the bite of an infected animal, they infect peripheral nerves and travel along them towards the spinal cord at a clip of 50 to 100 mm each day. Once there, their migration speed picks up and they quickly reach the brain, resulting in widespread inflammation. Symptoms start around this time, signaling the point of no return for nearly 100% of patients. The virus then travels back out of the brain and throughout the body, but the salivary glands in particular are supportive of viral replication.
From a global perspective, dogs are the leading source of human rabies infections, accounting for more than 90% of cases. And rabies is seen throughout the world with few exceptions, such as Antarctica, New Zealand, Japan, Sweden, and Spain. Of note, Hawaii is the only state spared. Roughly 60,000 people die every year from rabies, even though there is an extremely effective vaccine. As would be expected, however, most deaths occur in resource-poor regions with limited access to vaccines and medical care, and endemic infection among domesticated animals.
The United States, like most of the developed world, rarely sees rabies deaths anymore. There were less than 100 cases between 1980 and 2015, with a third of these being acquired abroad. When cases do occur in the United States, it’s almost always after exposure to a bat, although raccoons, skunks, and foxes are also considered high risk. Wild small mammals, such as gerbils, squirrels, and rabbits, rarely transmit rabies to us because they are typically killed and eaten by the animal that infects them.
Speaking of bats…
According to his father, Ryker was scratched on a finger by the bat. When reading the early reports, this was the first claim that struck me as odd. It’s incredibly unlikely to get rabies from a scratch. You really need saliva from the bite of an infected mammal with extremely rare non-bite exception. There have, for example, been cases where rabies has been transmitted from person to person via the transplantation of infected tissue, most infamously involving corneal transplants. There have also been reports of infection being acquired by lab personal working with a rabies virus, and even one case linked to aerosolized virus from millions of cave bats, although it is impossible to fully rule out a bite with that kind of exposure.
Poor Ryker was almost certainly bitten. But considering how small bat teeth are, and the fact that he was only 6-years-old, it’s easy to see how he might have been confused. Bat bites often go unrecognized, and in many cases they do not even leave a mark. This, and the difficulty in immunizing one-fifth of the mammal population, is why bats are the most common source for human rabies infections in the United States.
A decision with deadly consequences…
What happened next will undoubtedly haunt Ryker’s parents for the rest of their lives. Reports of the parents’ thought process, and their understanding of the implications of Ryker’s injury, are a bit confusing. It isn’t clear that they knew how dangerous bats can be, but they were at the very least worried enough to consult the internet, just not enough to call Ryker’s pediatrician or family doctor.
The earliest news articles, which quoted Ryker’s father, give the impression that his parents knew that the bat posed some risk to their son. Ryker was warned to stay clear after all, and when the injury was discovered his father “frantically googled it real quick“. Of course, I don’t know what search terms were used, or what website(s) were accessed, but Mr. Roque claims to have found a recommendation to wash the area with soap and water for five minutes, which they did.
As readers of SBM are likely to know all too well, the internet is full of all manner of bad medical advice. But when it comes to rabies, you aren’t going to find much nonsense, although it is there if you dig deep, because we aren’t talking about a condition that has subjective symptoms and a high rate of spontaneous recovery. There is some nuance to the discussion, but rabies remains, even with advanced critical care, an essentially 100% fatal disease.
So it is hard to imagine, unless there was some next level bad luck, that Mr. Roque stumbled onto a source that wouldn’t recommend immediate medical attention. And even using search terms that would otherwise be likely to bring up untrustworthy sources, it is challenging to find much that says anything other than to seek proper care, which involves prophylaxis with rabies immune globulin and vaccine injections. This, and only this, has been proven to prevent the deadly disease, and it is considered to be virtually 100% effective.
So if their search in any way involved the words “bat” and “scratch”, they almost certainly knew at that point that the potential for rabies was very real, and that appropriate medical intervention to prevent rabies was critically important. Based on an interview of the father, early news coverage implied, or outright claimed, that the parents were aware. But they didn’t seek medical attention and Ryker’s fate was sealed.
Ryker’s parents apparently knew the risk but chose to forego medical evaluation for their son because, and this is the part that really made for some angry online comments, he was emotionally upset by the possibility of needing shots. That was the only reason given. It is possible that other factors, such as distrust of the medical system or fear of the vaccine outweighed their concern for possible rabies infection, but I don’t think that’s the case this time. And it would probably have been reported if they chose an alternative therapy of some kind over science-based medicine.
But I digress…
Not that some people don’t seek out alternative care for the non-specific symptoms experienced at the onset of rabies infections, which often includes fever, headache, muscle pain, nausea, and malaise. Sounds a lot like a common viral illness known as influenza, doesn’t it? The chiropractor in this case report failed to recognize early rabies in an adult patient over numerous visits during a six day period. The patient, who had awoken with a bat on his left arm 9 months previously, had presented to the chiropractor with rapidly worsening numbness and weakness of the same extremity.
As is the norm, the patient died. He would have died anyway, so the chiropractor didn’t increase the patients risk of death. But they did waste precious time that could have been spent settling affairs and establishing palliative care, and they likely gave false hope of recovery. More importantly, there are treatable conditions that are much more common than rabies which can present in a similar fashion. For some, time is of the essence.
The story changes…maybe…
Most of the news coverage came out as Ryker was about to undergo an experimental therapy, which I’ll address shortly, and then was simply updated when he died. They all repeated the same initial quotes from the father. In an interesting twist, the events as described in an Orlando Sentinel article, which was the only source to speak directly to the family after Ryker’s death, didn’t quite match up with the earlier account.
In the Sentinel piece, Ryker’s mother relates how she didn’t want the bat kept in the house, but said that they didn’t know of any connection between bats and rabies at the time. When Ryker notified them of his injury, which they initially believed to be a scratch, she Googled it and followed a recommendation to cleanse the area with hot water. There is no mention of the fear of needles, or of any awareness that urgent medical attention was warranted. It reads like they just did what they thought was appropriate and were completely caught off guard when the symptoms began. It’s implied that if they had only known at the time that it was a bite, rather than just a scratch, things might have been different.
Now of course it is possible that the reporter simply chose to leave out certain details, to not kick this poor family while they are down. I get that. It isn’t going to bring back their child and they have suffered enough. And they are trying to raise awareness to help prevent future tragedies. But I also know how the human mind tends to work when facing a situation sure to create the kind of cognitive dissonance that would keep most people from having a good night’s sleep for a long time. These types of life changing events often result in broken marriages and significant mental health repercussions.
These are loving parents, at least I have no evidence to think otherwise, and probably reasonably intelligent people. But they did something that most folks, even when taking into account the risk of making a fundamental attribution error, would ascribe to mind-boggling bad judgement that might raise questions about their ability to make appropriate medical decisions in general. I certainly would understand it if their personal narrative shifted a bit to provide some degree of psychological stress reduction.
Ryker’s diagnosis and likely discussion of management
The timing of Ryker’s bat exposure and the development of symptoms is somewhat hard to tease out. Reports differed, ranging from “a week or so” to “a few weeks later”, but Ryker eventually began to show concerning signs of illness. A week would be extremely unlikely, even with a high risk exposure, but I can’t say it’s impossible.
The incubation period, the time between exposure and the onset of symptoms, tends to be much longer than a week. It often takes months, rarely even years, although in cases of apparent extreme incubation periods it can be difficult to rule out additional exposures that happened closer to the onset of symptoms. The incubation period varies depending on factors such as location and severity of the wound, genetics, host specific immune response, adequacy of prophylaxis, and which virus is involved. Ryker, with a small bat bite about as far from the brain as you can get in a young child, would be more likely to have had a longer incubation period, but it is difficult to predict these things with any certainty.
Regardless, what we know is that at some point Ryker complained of numbness in the same hand as the bite, a huge red flag for rabies, and headache. One report mentions that he began to have unusual jerking movements of the arm, which has been reported with bat rabies virus infection, confusion, and difficulty walking. At this point, apparently concerned about the possibility of a head injury, his parents sought medical care at Arnold Palmer Hospital for Children.
Ryker’s exposure to a bat was naturally very worrisome to the treating physicians and he was admitted to the hospital for an extensive work-up, which included testing for rabies. This typically, although I’m not privy to his specific medical information, involves looking for evidence of the virus and/or an immune response to the virus in the patient’s blood, spinal fluid, saliva, and skin. After consultation with experts, a family meeting was held to discuss their concerns, and the parents were informed of the low likelihood of survival should rabies be the cause of his symptoms. After a few days, laboratory results confirmed the diagnosis.
The treatment of rabies remains primarily palliative in most cases, which is largely dictated by the fact that most rabies cases occur in regions without access to advanced critical care. Aggressive management, which Ryker did receive, is more likely to occur in developed regions, particularly in younger and healthier patients. But even with the full, kitchen sink approach there have only been 15 well-documented cases of survival, and a smattering of anecdotal reports, once symptoms have started. All were young and healthy, and all but one had at least one dose of rabies vaccine prior to developing symptoms. We actually have no idea if any aspect of aggressive treatment beyond supportive cardiac and respiratory care in an ICU improves survival, and there are factors other than specific therapies that likely play a larger role.
The palliative approach, at least when modern critical care is available, is typically undertaken in cases where survival is less likely, such as older patients with more medical problems, when disease is already severe, when dog rabies virus is involved, or when there is no lab evidence of an immune response against the virus. Almost all survivors have had significant neurologic problems after recovery, something that should also be discussed with patients, if possible, and family prior to deciding a course of action.
The goal of palliative care is to reduce suffering. This involves the use of medications to sedate patients and to treat pain because agitation and discomfort can be severe. Patients can become confused, delirious, even aggressive. So a quiet and calm environment is also key. When this course is chosen, complications that can result in death, such as cardiac arrhythmia or respiratory failure are not treated. Palliative care can also take place at home, depending on the desires of the patient and family.
In contrast, aggressive management requires admission to an intensive care unit where cardiac and respiratory support is available, as well as various experts in critical care and infectious disease. Complications are managed with intent to cure and patients are provided intravenous nutrition if needed. It is probably safe to say that ICU care is the main reason we have seen a handful of survivors over the past few decades.
Various other therapies have been tried over the years in addition to supportive ICU management. This has been based on the notion that some serious infections, as well as many cancers, require a combination of therapies with different goals to improve rates of survival. In this effort, drugs that modulate the immune system, antiviral medications, and therapies aimed at protecting the brain from injury and improving access of medications to the central nervous system have been tried in various combinations. None have been proven to work, and each has potential for severe side effects.
The Milwaukee protocol
I’ve mentioned an experimental treatment that Ryker underwent a few times already in this post. Virtually all of the news reports described it as having worked in the past, and implied that it was a patient’s only hope. The treatment, known as the Milwaukee Protocol [PDF, initiates automatic download] (sometimes the Wisconsin Protocol) was developed by Dr. Rodney Willoughby, a pediatric infectious disease doctor at Children’s Hospital of Wisconsin, to treat a now famous 15-year-old girl diagnosed with rabies in 2004. She was the 6th well-documented case of survival since the first in 1970, and the first ever to survive rabies without having at least received one dose of vaccine prior to developing symptoms.
The protocol involves placing the patient into a medically induced “therapeutic coma” using ketamine and a benzodiazepine for a week with the intent of protecting the brain from theorized “excitotoxic” effects of the virus on neural tissue. Patients also receive a cocktail of an antiviral medication, vitamin C, and a drug used to theoretically prevent vasospasm of cerebral blood vessels. In 2004, the first time this combination of therapies was used, the patient lived, shocking the world and forever changing rabies management.
Unfortunately, it is very likely all smoke and mirrors. From a basic science standpoint, solid evidence supporting the efficacy of any component of the Milwaukee protocol is lacking. And therapeutic coma is extremely risky. Since that seemingly miraculous case in 2004, the protocol has been put into use many more times and has failed rather spectacularly.
When studied by experts other than Willoughby, the results have been dismal. According to Willoughby, there have been 18 survivors so far, but he can’t reveal details about their cases. Two prior “success stories” where documentation was available were found to have actually died. Sometimes credit is given because a patient lives a little longer than expected. But even if a few patients have survived on the protocol, the success rate is still incredibly low, and their recovery likely should be credited more to modern supportive critical care and luck (genetics, the particular virus, robust immune response) than any specific therapy.
Despite the lack of non-anecdotal evidence for the Milwaukee protocol, and more plausible explanations for the few survivors, it has become commonplace in the treatment of rabies in the United States. There is concern that this is distracting from appropriate palliative care efforts and research into novel approaches. I can’t say if the jury is completely out, but it doesn’t look good.
Conclusion: Prevention, prevention, prevention
The take-home point from the tragic case of Ryker Roque is, I hope, obvious. Don’t mess around with bats and supervise young children when a bat is anywhere close by. Call a professional to have it removed. And if you do come into contact with a bat, or if you find a bat in the room of a sleeping child or someone unable to know if they had been bitten (drunk, cognitively impaired), essentially if there is even the slightest chance that a bat might have bitten someone, seek appropriate medical care and get the post-exposure prophylaxis when recommended.
If you are bitten by an unknown animal, especially if it is an unprovoked attack, don’t mess around. There are protocols for this. You can often avoid the need for shots if the animal can be observed or if it is low risk beast. But if recommended, do it.
People used to be terrified of the rabies vaccine. This is because it used to hurt…a lot. It was a large volume of medicine that they injected into your abdominal muscles and you needed like 500 doses. Okay, I’m exaggerating, but it was a lot. After decades of advancement in vaccine science, you can prevent a horrible death with 4 fairly painless 1 ml immunizations and a dose of rabies immune globulin. Again, do it if recommended.

Have Researchers Developed a Potential Microbial Miracle for Phenylketonuria Patients?
Researchers specializing in synthetic biology are developing a new therapy for PKU, a potentially devastating metabolic disorder, and they have some promising preliminary human data. But it’s just too early to get excited.
Clay Jones on September 7, 2018
Link

As a pediatric hospitalist that primarily cares for newborns, there is a short but important list of topics that I discuss with parents. This can include the intramuscular dose of vitamin K given to all newborns (unless refused by the parent) to prevent life-threatening bleeding, the hepatitis B immunization given to prevent serious liver disease and even cancer, and recommendations for the prevention of unexpected death during sleep. During my initial exam, while counting digits and pointing out how adorable the new arrival is, I always discuss evidence-based screening procedures that every baby undergoes.
Standard screening for newborns includes a hearing test, screening for critical congenital heart defects with pulse oximetry, and obtaining a transcutaneous bilirubin level. Since the early 1960s, screening of newborns has also involved testing for a steadily increasing number of diseases which aren’t apparent in the early newborn period, including enzyme defects, immune deficiencies, blood disorders, and many, many more. These conditions can result in a wide spectrum of organ injury and impairment, including severe intellectual impairment and even sudden death.
Largely made possible by the efforts of Robert Guthrie, the initial newborn screening programs in the 1960s only included one test. His development of an assay for the amount of the amino acid phenylalanine in drops of whole blood collected on special filter paper, also of his design, allowed for the universal screening for a disease knows as phenylketonuria, or “PKU”. Decades later there are now more than thirty tests included in newborn screening programs, with some variation between states, but it is still commonly referred to as “the PKU” by medical professionals working in nurseries.
What is PKU?
Phenylketonuria (PKU) is a genetic condition caused by a deficiency of phenylalanine hydroxylase enzyme (PAH), which is critical in the conversion of the essential amino acid phenylalanine to tyrosine. Loss of this enzyme results in the build up of excessive amounts of phenylalanine in the blood and urine, which for not entirely clear reasons is harmful to the developing brain. In general, there appears to be interference with brain growth and development, the insulation of axons with myelin, and the synthesis of several neurotransmitters.
PKU effects roughly 1 out of every 15,000 births in the United States, but its incidence varies between populations and countries. Turkey has the highest incidence rate at 1 in roughly 2,500 births. In Japan and Finland, PKU is quite rare with rates of less than 1 in 100,000. PKU is also very rare in African-American populations.
PAH deficiency, and resulting PKU, isn’t an all or nothing situation. In most cases, there is an autosomal recessive inheritance of a defective gene on chromosome 12q24 from two carrier parents, but there are many possible mutations with varying degrees of PAH deficiency and mild to severe clinical presentations. Total PAH deficiency causes classic PKU, the hallmark of which is severe intellectual impairment. Children often will also develop seizures, poor motor function, and an unusual odor often described as a musty or “mousy”. And because tyrosine is further metabolized into melanin, patients with PKU are often very lightly pigmented.
Classic PKU is rarely seen clinically because of the success of newborn screening programs. In the rare untreated patient, clinically-apparent impairment begins in early infancy as phenylalanine levels build and injury to the brain adds up. The progression of intellectual disability becomes most noticeable during early childhood when myelination should be in full swing. In most patients, mental decline stabilizes in adulthood.
How is PKU treated?
Once diagnosed, hopefully in the first week of life, the primary treatment of classic PKU is lifelong dietary restriction of phenylalanine using specialized formulas and medical foods. Babies can be breastfed, although mother’s milk can only safely make up about a quarter of the child’s intake. Children still need to rely on specialized formula. It becomes increasingly difficult to maintain a safe diet as children age because of the poor palatability of available protein substitutes. The services of an experienced dietitian can be extremely helpful in ensuring that patients are receiving optimal nutrition for growth and development.
In recent years, a few drugs have been developed that have shown some clinical usefulness in children with milder forms of PKU. The primary example is tetrahydrobiopterin (BH4), which is a PAH cofactor that maximizes activity of the reduced amount of available enzyme and can lower phenylalanine levels in some patients. There isn’t much long term data, and it is not known if BH4 dosing can replace dietary restriction yet. But it is promising and appears to be very safe.
Maternal PKU can harm a developing fetus
Monitoring and management of elevated phenylalanine levels into adulthood is important for a number of reasons. Even though the potential for IQ loss decreases dramatically after the brain is fully developed, high levels of the amino acid in the blood are associated with mood disorders as well as deficits in attention and processing. But normal phenylalanine levels are especially important in the setting of pregnancy because the developing fetus can be harmed. Harm can occur even when a mother with PKU has normal levels because of the fact that phenylalanine concentrates in the fetal circulation. The clinical presentation of these infants is similar to fetal alcohol syndrome, with poor growth, microcephaly, and subsequent intellectual impairment.
Could a microbial cure for PKU be just around the corner?
Earlier this week, Carl Zimmer reported on a potential new treatment for PKU involving the manipulation of a specific bacterium by synthetic biologists at a company called Synlogic, whose aim is to develop novel “living medicines” to treat a variety of human diseases. It’s a great article that explains the basics of this burgeoning field well, but I’m not convinced that this will be a game changer.
Scientists at Synlogic took a harmless gut bacteria and inserted genes that would turn on once it was in a low-oxygen environment such as the human intestinal tract. Once activated, these genes encode the development of a membrane pump that pulls in phenylalanine and then the production of an enzyme that breaks it down. The resulting waste is excreted and absorbed by the gut, ultimately finding its way into our urine.
Buoyed by studies in mice and primates, Synlogic performed a trial in humans, the results of which have just been announced but have not been published. They had healthy subjects ingest the study bacteria in varying amounts and then consume a high protein meal. They found that the microbial mixture was well-tolerated and that with larger doses there were more breakdown products of phenylalanine found in the subjects’ urine. The next step for the researchers will be to assess blood levels of the amino acid in actual PKU patients.
Conclusion: It’s okay to be optimistic, but don’t get too excited just yet
This is a neat proof of concept kind of result, but let’s not let the hype get too far ahead of the research and the reality. The preliminary studies were in mice and primates, the positive results of which often don’t pan out in human trials. And we don’t know if the increased amount of phenylalanine bits in the urine equate to clinically meaningful reductions in levels in the blood. We also don’t know how much of this stuff people will have to ingest to achieve benefit.
I can more easily see this approach as being potentially helpful in adults with milder forms of PKU whose brains are pretty locked in. At least, I’d need to see some pretty robust data before telling a parent that they don’t have to restrict protein intake in their newborn with classic PKU. I don’t think this is going to replace what we already recommend as primary management, but it may at least end up being cheaper than other pharmaceutical options.
I’ve never been shy about my skepticism of microbiome manipulation as a medical intervention. Other than a few exceptions, primarily fecal transplants for C. difficile colitis and specific probiotics for the treatment and prevention of pouchitis, there isn’t much to it just yet. I sincerely hope that this one is the real deal. I also hope to see these studies published somewhere.

Topical Barley Flour for the Management of Newborn Jaundice: A Real Study Done by Actual Pediatricians
Ever heard of coating a newborn in barley flour as a treatment for jaundice? Me neither…but here we are. And there’s a study! This is not satire.
Clay Jones on January 8, 2021
Link

Mama Natural, the nickname of college graduate Genevieve Howland, runs an extremely successful “natural parenting” brand with a large online presence reaching millions of people every month. Her website, a wretched hive of quackery and advertising, contains articles on a wide variety of pediatric medical topics and frequently makes specific recommendations based on anecdotes and flimsy evidence. She often uses emotionally charged language designed to denigrate medical interventions, such as the safe, and lifesaving, newborn dose of intramuscular vitamin K.
Howland writes with an unearned air of expertise and her website should be scuttled, but she’s not what I’m going to focus on today. But the website, specifically an article she penned on “natural ways to treat jaundice in newborn babies” did serve as a conduit through which I discovered a very interesting, and thoroughly bogus, treatment for the common and potentially dangerous condition. It also pointed the way to a real paper written by actual pediatricians that is an excellent example of how not to design, implement, and interpret a study.
So you don’t need to read Howland’s article unless you really are just asking to be annoyed. It does get a few things right, but overall it’s awful and even manages to go out of its way to imply that the newborn vitamin K dose might be harmful. Save the time and a bit of your sanity by just checking out the part that caught my attention:
As odd as it may sound, researchers found that barley seed flour sifted over a baby’s skin along with light exposure improved jaundice in newborn babies. The barley flour helps decrease indirect bilirubin levels and functions as an antioxidant. This traditional Iranian remedy probably won’t be effective on its own, but it can boost the effects of light therapy.
Odd is an understatement. It’s a baby, not a fritter. Howland actually recommends that parents take barley flour and sift it over a baby as an adjunct to using “light therapy”. That’s a bold claim and thankfully Howland does provide a link to the “research” backing it up.
She doesn’t specify what she means by light therapy but based on the linked study I’m fairly confident that she means conventional phototherapy rather than merely placing a baby in sunlight, which she does also recommend despite it being extremely problematic. I discuss the use of sunlight in the management of newborn jaundice in a 2014 post:
We know that sunlight lowers bilirubin levels, but that isn’t the issue. The problem is that in order to achieve that end, a child would need to be placed naked in direct sunlight for hours. This would place a baby at risk for hypothermia and/or sunburn. It also may only make the skin appear less jaundiced while not necessarily lowering the level of bilirubin in the blood appreciably, giving a false sense of security and potentially delaying care.
Most newborn jaundice doesn’t require any treatment and goes away as feeding improves and the ability of a baby to process (liver) and remove (pee and poop, mostly poop) the chemical that causes it (indirect or unconjugated bilirubin) ramps up. But when needed, phototherapy is extremely safe and effective in the treatment of severe jaundice and can prevent permanent brain damage. Although intriguing, my initial assessment of the use of topical barley flour along with phototherapy was that it sounded extremely implausible, although perhaps not homeopathy level impossible.
Is topical barley flour a plausible treatment option for newborn jaundice?
The first question I wanted to answer, before even looking at the study, was why barley flour? Why any topical treatment for that matter? I’m not aware of any topical therapy for lowering the amount of any toxin in the blood.
According to the Mama Natural article, barley flour is a traditional Iranian treatment. I was able to confirm that it appears to have originated in western Iran’s Lorestan Province, where it is used to treat a variety of ailments, but I was unable to find any information on when and why it became a part of the traditional medicine in that region. A Google search pretty much just resulted with more Mama Natural style articles and the one study she linked to.
I know that prescientific therapies often amount to arbitrary associations based on flawed anecdotal observations, but I couldn’t completely dismiss barley flour out of hand. After all, the concept of phototherapy was initially discovered in the 1950s when some British nurses happened to notice that babies placed in front of a window tended to be less jaundiced than those who weren’t. So I allowed my mind to remain just a bit ajar.
It seems more than a little far-fetched, but there could be some scenario, perhaps involving the children of bakers, where an astute observer noticed an improvement in jaundice. And yes, I’m being extremely charitable here. But there is more to plausibility than that anyway. A lot more.
How would a layer of barley flour theoretically improve the effectiveness of phototherapy, as claimed in the Mama Natural article and concluded in the study that I promise I will eventually get to? It wouldn’t increase the amount of exposed body surface area. It wouldn’t increase the spectral irradiance, which is largely based on the distance of the light from the patient. If anything, if there were a layer of something on the child’s skin it might block some of the light.
Maybe some component of the flour is being absorbed and then it interacts with bilirubin molecules in the bloodstream. Or perhaps it might stabilize red blood cell membranes and extend their life span. Baby RBCs have a shorter lifespan than adult versions, you see, and higher bilirubin levels are a result of the subsequent increased heme metabolism. The theoretical mystery chemical could increase albumin mediated transport of unconjugated bilirubin to the liver, or improve the conjugating capacity of the liver, either of which would help lower levels. But then why would barley flour only be recommended as an adjunct to phototherapy and not as a standalone preventative or treatment measure? I’m pretty sure that I know the reason, but I’ll save it for my conclusion.
Regardless of the potential mechanism of action, based on the natural course of newborn jaundice and challenges with how we measure bilirubin levels, any study looking into this would have to be well designed. You will likely not be surprised to learn, however, that this study was not well designed. It’s a bit of a mess in fact.
Here we go.
A double-blind, randomized, and controlled waste of time
The study, “Phytotherapy with Hordeum Vulgare: A Randomized Controlled Trial on Infants with Jaundice”, was published in March of 2017 in the Journal of Clinical Diagnostic Research. It is a double-blind, randomized, and controlled trial involving 70 infants admitted to a hospital for treatment of jaundice at Hajar Hospital of Shahrekord in Southwest Iran from July to December of 2014. These babies were all full term, “over three-days-old”, breastfed, and healthy, meaning that they did not have any significant pathological risk factors for severe jaundice.
There are already potential issues. When it comes to bilirubin clearance in the newborn, you can’t just lump all term babies together. Newborns that have just completed a 38th week of gestation and those that have completed 41 weeks are all full term, but they don’t necessarily have an equal ability to remove unconjugated bilirubin from the systemic circulation. So if this wasn’t accounted for in the analysis of the study’s results, it calls any interpretation into question. A similar issue applies to a baby’s age. A five-day-old term infant, even without treatment, is likely already at a point where serum bilirubin levels are stable or even dropping. They would likely still be rising on day 3.
Although it doesn’t apply to this particular study, the age of a baby is also important in determining when to treat them. When interpreting a bilirubin level and assessing the need for initiating phototherapy, we look the hour of age not the day. A three-day-old baby can be anywhere from just over 48 hours old to 72 hours old depending on the time of birth, and it can make a huge difference in the ability of a baby’s blood-brain barrier to keep neurotoxic bilirubin from causing damage. For a healthy term baby at 48 hours of life, the cutoff for starting lights is 2.4 mg/dl lower than it would be for the same baby at 72 hours.
34 of the newborn subjects were allocated to a control group that would receive phototherapy. 36 subjects received phototherapy plus topical barley seed flour three times a day. This involved applying 150 grams of sieved flour to the body excluding the head, face, and area around the umbilical cord. That’s because of infection risk. Barley flour wouldn’t be sterile and omphalitis, infection of the umbilical stump, is a rare but very serious problem in newborns. We also recommend keeping the stump dry, and the flour was rinsed off after each application.
The primary outcome being measured in this study was indirect bilirubin at hospital discharge. After statistical analysis, they found that the treatment group had a lower mean indirect level at discharge, with a p value of 0.009, thus deeming it statistically significant. The authors concluded that topical barley flour was an effective means of lowering indirect bilirubin levels when used along with phototherapy and implied that it might help prevent severe complications of newborn jaundice.
They go on to postulate that the flour works through the absorption of antioxidants that then enhance liver function. But, and stop me if you’ve heard this before, it is generally a good idea to make sure if something happened before worrying about how it happened. In this case, the evidence provided doesn’t at all support the claim that topical barley flour does anything at all.
A few limitations of the present study
The study authors list only two limitations to their study. They were unable to extract the effective compounds of barley flour and they did not investigate the mechanism of action. I’m not sure that they understand what a study limitation is. I’m here to help.
     1.  They didn’t take into account when phototherapy was started. If babies in the treatment group were older, even by less than a day, they might clear bilirubin faster than babies in the control group.
     2.  They didn’t take into account how feeding was going. They state that the babies were all breastfed, but not how breastfeeding was going, if formula supplementation was given, and what the average weight loss compared to birth weight was. Even small amounts of formula can significantly improve bilirubin clearance from the gut.
     3.  They didn’t take into account duration of time under phototherapy. Because time under the lights is largely parent driven in the hospital, it isn’t uncommon for babies to be kept out of the lights for periods of time longer than we recommend. It’s easy for a 20-30 minute feed to turn into an hour long snuggle session.
     4.  They didn’t take into account the error bars of serum indirect bilirubin values, which are notoriously inaccurate. You can run the same sample ten times and get ten different results, with higher levels showing larger variation. The variation for bilirubin levels in the range documented in this study would be larger than the difference they found between the treatment and control groups. This issue alone renders the study virtually meaningless.
     5.  They claim double-blinding but don’t describe how it was done. Who applied and rinsed off the flour? It is easy to imagine that caregivers or physicians might find remaining small clumps of flour in a babies nooks and/or crannies. This could result in changes in care, such as keeping a baby under the lights longer, or medical decision making, such as when to stop phototherapy and discharge a baby.
     6.  Speaking of discharging the babies, another tidbit that practically invalidates this whole study is that the treatment group didn’t get home any sooner. So clinically there was no real difference whatsoever.
Conclusion: Flour is for baking, not babies
Ultimately this study is an answer to a question that nobody was asking. We already have safe and effective treatments for newborn jaundice, which often consists merely of breastfeeding support, strategic use of formula supplementation, and sometimes phototherapy. But the study was done and I gave it a fair assessment. It’s worthless, and it doesn’t leave me confident that the pediatricians who ran it know much about study design, jaundice, or babies.

“Hands On Learning Solutions”: Untested Solutions for Problems That May Not Even Exist
Harriet Hall on July 21, 2015
Link


Hands On Learning Solutions, a business in Gig Harbor, Washington, evaluates and treats children for learning disabilities and claims to identify the underlying causes and help eliminate the symptoms. Much of what they do is questionable, and at least one of their methods is clearly bogus. Their program is reminiscent of the Brain Balance program that I wrote about in 2010. I’ll describe one child’s encounter with Hands On Learning Solutions and let you decide for yourself whether it sounds like a legitimate, helpful service.
Billy (not his real name) is an 11-year-old boy who is in the fifth grade at a Catholic school. He didn’t learn to talk until age 3, but he got speech therapy and is currently doing well in school, with a GPA of 86%. On his last report card, the section on “Successful Learner” rated him above average on working cooperatively with others, and satisfactory in all other categories, such as organizational skills, using time well, listening attentively, following directions, and completing work on time. His mother took him to Hands On Learning Solutions on the recommendation of a friend. On the intake questionnaire she expressed concerns about his written/oral expression, organization, study skills, attention focus, and motivation/behavior. She did not check the boxes for concerns about reading, spelling, comprehension, letter reversals, graphomotor skills, math, memory, poor grades, or slow work.
Previous evaluations
At age 5 Billy’s primary physician had him evaluated in the neurodevelopmental clinic at a children’s hospital because of concerns about speech and social delays and possible autism spectrum disorder. The clinic felt that he had shown some autistic features in the past but that these had improved over time, and he did not meet the criteria for autism spectrum disorder. They recommended he enter special education kindergarten and get speech therapy.
At age 9 he was evaluated by a specialist in developmental behavioral pediatrics because of continuing concerns about atypical social skills, repetitive behaviors, and possible autism spectrum disorder. His mother reported that he performed repetitive behaviors like circular wrist and rhythmic finger movements when excited or bored. His teacher reported that he had a hard time working with other students and tried to hide his work so others wouldn’t copy. He was in public school where he was getting speech therapy. He was also receiving counseling for social skills, self-esteem, and pragmatic skills. The specialist felt his developmental attainment was at or above his age. He thought Billy met some of the diagnostic criteria for Asperger’s disorder including atypical pragmatic communication skills, delayed and/or atypical socialization and play skills, variably decreased eye contact with others, variably decreased and/or atypical joint attention and social referencing, intense interests and/or behavioral preferences, sensory and/or emotional regulation problems, and repetitive movements when overly excited or unfocused. But he did not feel that Billy met the diagnostic criteria fully, and he was not willing to make that diagnosis. His only recommendation was continued monitoring by his primary physician and continuing individual and/or family counseling as long as clinically indicated.
The Hands On Learning Solutions evaluation
The report runs to 19 single-spaced pages plus several attachments with photos and examples of Billy’s writing. It describes the results of a battery of tests including the Gibson Cognitive Test Battery, the Test of Auditory Processing Skills (TAPS-3), the Test of Visual Perceptual Skill 3rd Edition (TVPS-3), the Ekwall/Shanker Reading Inventory, Neurology of Learning Screening, a Neuro-Reflex Assessment, and the Learning and Behavior Rating Scale. They reported scores as low as 6.7 years behind his “developmental” age (I think they meant chronological age). And the scores on different tests were all over the map: for instance, visual memory corresponded to age 5 and sequential memory to age 18! They report a huge mass of confusing data; I don’t know how to interpret it all, and I’m sure most parents wouldn’t know either.
They made detailed observations of his behavior during the testing, such as swinging his feet, rubbing his eyes, yawning. The testing session lasted 4 ½ hours, and I would expect an 11-year-old to show signs of fatigue and boredom. They commented that he tends to look to his right side before answering a question. (The idea that the direction of gaze means anything is a myth from neurolinguistic programming (NLP), a largely discredited pseudoscience.)
They diagnosed abnormalities or “challenges” in these eight areas:
    • Food issues: sugar
    • Un-integrated reflexes (12 items listed, including Moro, palmomental, rooting, sucking, and head righting reflex)
    • Auditory processing
    • Oculomotor skills
    • Visual processing
    • Visualization
    • Attention
    • Study skills
Their recommendations
    • One of three neuro-reflex integration programs with a professional trained in that program.
    • Movement programs to improve organization movement issues; he should start at the lower level of the Learning Skills Pyramid in the neurology of learning area.
    • An auditory stimulation program to improve auditory memory, social skills, organization, and attention. (They recommend Samonas Sound Therapy.)
    • Evaluation by a specialized developmental optometrist for possible eye tracking, saccade, and teaming issues.
    • Attention and organization training, preferably through the Processing and Cognitive Enhancement program.
    • The Visualizing and Verbalizing Program to address his weak concept imagery and support his oral expression, auditory comprehension, reading comprehension and written expression skills.
    • The On Cloud Nine math program to develop the underlying sensory-cognitive functions needed for math processing.
    • A study skills program.
The cost
They gave the mother a statement of fees:
    • Foundational Learning Skills: 1 ½ hours 3 days a week in clinic for 13 weeks for $5,510 with additional sound stimulation at home requiring rental or purchase of ILS unit at $195 a month.
    • Memory, Comprehension, and Expression: Visualizing and Verbalizing program and On Cloud Nine programs for 150 hours at $95 an hour.
    • Study Skills: Study Smart for 36 hours at $95 per hour
That all adds up to around $14,000. They require a non-refundable $475 deposit.
Examples of their reasoning
They are concerned about sugar simply because Billy told the examiner that he has dandruff and that he believes his body is exceptionally sensitive to sugar. “If Billy is eating food that is negatively affecting his body his reflexes can become un-integrated and contribute to low muscle tone.”
They attached a number of photographs of Billy during the long testing session. He slumps, holds his head close to the desk or supports his head with his hands. They interpret this to mean he has an unintegrated STNR (Symmetrical Tonic Neck Reflex) that will not support muscle tone in the upper back. I interpret it to mean he is bored and tired.
Retained neonatal reflexes
The term “Retained Neonatal Reflexes (RNR)” was coined by Keith Keen, an Australian chiropractor who registered it as a trademark in 2009. He uses bogus techniques like applied kinesiology and craniosacral manipulation. He provides a list of questions that would indicate “retention of retained neonatal reflexes [sic]” such as “Did your child have recurrent ear infections?” “Does he suffer from motion sickness?” “Does he wet the bed?”
He describes tests parents can do at home. In the Galant reflex, when the newborn is supported face down by a hand under its stomach and one side of the spine is stroked, the trunk curves towards the side of the stimulus. In Keen’s instructions for home testing he has the child supporting himself on hands and knees and he gets the direction of the curvature exactly wrong, saying the trunk should curve away from the stimulus!
The Hands On Learning Solutions people seem to have fallen for this chiropractic nonsense hook, line, and sinker. They diagnosed Billy with the following “un-integrated” reflexes: fear paralysis reflex, Moro, Palmar, Palmomental, Grasp, STNR, ATNR, rooting, sucking, tonic labyrinthine reflex, head righting reflex, and hands-pulling. They convinced themselves that Billy was “extremely sensitive to touch on cheeks, feels hunger sensation,” indicating a retained rooting reflex (the reflex that helps the newborn infant find the nipple to nurse). They convinced themselves he had a retained left grasp reflex because “examiner can remove finger from grasp in left hand easily [wouldn’t it be just the opposite?]” They thought he had a retained palmar reflex because his pencil grip was maladaptive. They were clearly imagining subtle abnormalities where none existed and interpreting them as retained neonatal reflexes that were causing learning problems and needed to be “re-integrated.” I shared the report of retained neonatal reflexes with my colleagues. Pediatrician Clay Jones found it “jaw-dropping.” Neurologist Steven Novella further confirmed my opinion that it was utter nonsense by pointing out that if these reflexes persist beyond the appropriate developmental stage, they are signs of serious brain disease or damage, not of learning disabilities.
My opinion
From the documents I reviewed, it appears to me that Billy is a likeable, essentially normal although somewhat “quirky” kid who has overcome a speech delay and some early Asperger-like problems and is coping well in school. That is also the opinion of his primary physician, who has known him and his family for many years. Because of his early problems, his mother is naturally concerned and wants to do the best for him. In my opinion, Hands On Learning Solutions is taking advantage of a vulnerable mother’s anxiety. I can’t help but wonder if Hands On Learning Solutions evaluations have ever found that a child was perfectly normal and needed no interventions.
They are doing bogus tests along with legitimate ones, and they are accepting false positive results as real and over-interpreting every little observation of his behavior as a sign of a neurologic disorder. They are recommending very expensive interventions that have not been adequately tested. Most often the “scientific evidence” behind those interventions consists of poorly designed studies that measure performance before and after the intervention rather than comparing it to a control group. Uncontrolled studies are particularly problematic for learning disabilities, because children naturally learn and improve over time, and they respond to any kind of attention and tutoring.
When a child is labeled as having problems like these, it affects his self-image; and the idea that he has a learning disability may become a self-fulfilling prophecy. Perhaps the saddest thing was one of Billy’s writing samples, where he expressed a belief that he was “losing his memory” because of an injury at age 6 where his head hit the sidewalk. One wonders where he got that idea, since his mother didn’t express any concerns about his memory and his school performance doesn’t suggest any difficulties with memory. This belief doesn’t augur well for his future: if you believe your memory is deficient, you tend not to try as hard to remember things.
I couldn’t help comparing what happened to Billy to what happened to a family member of mine. He was highly intelligent but was getting barely passing grades in high school; he showed little interest or motivation and neglected his homework. His parents took him to a child psychiatrist who evaluated him and reassured them that there was nothing wrong with him. And there wasn’t. He grew up to be a well-adjusted adult with a successful career and no mental health problems. I shudder to think what might have happened if he had gone to Hands On Learning Solutions… Just as I weep to think how much better it might have been for Billy if, instead of being labeled as defective, he had been praised for overcoming his early difficulties and encouraged to continue doing his best.
On a final humorous note, at the top of the report they list Billy’s date of birth as 07/22/2015. Apparently he hadn’t even been born yet when they did their evaluation!

The Windi: Revolutionary Relief for Colic or a Pain in the Butt
Clay Jones on June 19, 2015
Link


We tend to cover some very serious topics here on Science-Based Medicine. In fact, most of our posts are downright depressing. This will hopefully not be one of them.
In just the past few weeks we have written about the public health menace of anti-vaccine pseudoscience, autistic children being subjected to dangerous bleach enemas, and chiropractic-induced stroke in children. Unsurprisingly, there is typically no shortage of rage and heartache on the pages of this blog. But not today. Today will be a reprieve from the misery.
I’ll be discussing two products that were recently brought to my attention by colleagues. The last product I skeptically evaluated was the Buzzy, a device designed to reduce procedural pain in kids that is little more than a clever distraction technique. That product, however, was considerably more complex in concept and design than the ones I’ve chosen for this post. But the NoseFrida and the Windi are marketed to parents using equally dubious claims of efficacy, and use of one of them has an unfavorable risk-benefit analysis in my opinion. At least they’re funny…kind of.
The NoseFrida and the Windi come from the Miami-based FridaBaby LLC. The company website provides a succinct mission statement:
FridaBaby specializes in baby products you actually need! Our products are for the important stuff, you know, like breathing. Instead of using harsh chemicals to relieve your baby of discomfort, we opt for more natural solutions. Our focus on pragmatic and “gross” products (their words, not ours, nothing grosses us out!) that really work has garnered us a cult like following of ENTs, pediatric GIs nurses, doulas, midwives, lactation consultants, bloggers, and parents.
Okay, they help promote a needless anxiety over chemicals in baby products, and yes, that statement contains a straw man implication that all other options require the use of “harsh chemicals”, but they seem like decent enough folks. Who doesn’t like breathing? I do it daily and recommend it to all my patients.
They are also likely exaggerating a bit when referring to their “cult-like following.” They sell products, some people buy them, and a certain percentage of those purchased are subsequently used. There aren’t FridaBaby fan conventions. People don’t dress up as their favorite product for midnight screenings of FridaBaby commercials. Users don’t identify themselves as part of the FridaBaby community and get into arguments with fans of competing product lines over irrelevant minutiae.
FridaBaby’s biggest claim to fame so far is their NoseFrida. It’s a nasal aspirator that requires the parent to personally suck snot out of their baby’s nose using their mouth and a plastic tube. I understand the appeal, if not the ability to stifle a vomit reflex. Parents of children admitted to the hospital often ask if they can have a hospital-grade nasal suction device at home that is similar to what we use for babies with severe nasal congestion and subsequent difficulty feeding. Babies primarily breathe through their nose for the first few months of life and sometimes do prefer to breathe rather than eat. Hospital-grade devices don’t improve outcomes in these babies but they give us something to do instead of just “masterful inactivity.”
There are a variety of battery-powered electric nasal aspirators on the market but the NoseFrida is equally effective, cheaper, and appeals to a certain demographic because it’s Swedish and doesn’t produce a toxic electromagnetic field. It also works as well as any other non-electric home nasal suction device, like the classic bulb syringe, which is to say that it gives the parents something to do that might elicit a bit of placebo. The filter keeps snot from reaching the parent’s mouth, it’s perfectly safe, and it’s easy to clean.
None of these devices really have a clinically-meaningful impact on the ability of a baby to breathe through their nose, but many parents swear by them. All require the use of nasal saline, which is what actually helps. The mixture of saline and snot can either drain into the throat or be sucked out in quantities that inspire positive placebo-driven parental testimonials. Either way, at most there may be a brief and minor increase in air flow through the nose. Of course all the saline and suction in the world won’t reduce swollen nasal passages caused by viral-mediated inflammation, and aggressive suctioning might actually make things worse. But if using a NoseFrida or renting a professional grade industrial NoseVac from Home Depot keeps a parent from giving their baby an ineffective and unsafe OTC cold medications, then I’m on board.
The Windi is definitely a horse of a different color as described on the website (I’ve emboldened the more concerning statements):
Overview
A natural solution for colic, constipation, and other gas-related problems, The Windi works instantly and does not require ingestion of any drops or medication. The Windi is a single-use catheter that helps babies get rid of excess gas. Designed to be safe and effective, The Windi cannot harm your baby if used as instructed. Most pediatric professionals are familiar with the method of using a rectal thermometer to relieve gas, colic, and constipation. The Windi is designed specifically for this purpose. The soft, pliable, hollow tube features a rounded tip that is long enough to reach past the muscle that prevents the release of the gas, and also has a stopper to prevent an insertion too far.
Instructions
     1.  Gently massage the child’s stomach with your hand in a downward motion towards the rectum. Massage one side of the belly at a time. Repeat three times on each side.
     2.  Lift the child’s legs towards the head and carefully insert the catheter into the rectum (as if you were using a thermometer). Always use baby oil on the tip of the catheter to ease insertion. You will hear a “whistling” sound when the gas comes out and notice immediate relief in the child. Remove The Windi and dispose of it.
     3.  It should only take a few seconds after inserting The Windi to achieve the desired effect. If it does not work immediately, repeat the procedure with massage and try again. Sometimes you need to repeat several times and in this case, the same catheter can be reused.
Warning
    • Never leave The Windi in the rectum of the child!
    • Always discard The Windi after you have finished the treatment to prevent infection. Reuse of the same Windi may pose a risk of infection.
    • Never use The Windi treatment more than three times per 24 hour period.
    • Always use baby oil on the tip of The Windi.
    • The Windi is not a toy – keep all parts out of reach of children
There is a lot to unpack here, like how I’m not entirely sure what’s so natural about shoving a molded plastic device into a child’s rectum. The provided product information is full of half-truths and blatant misrepresentations of reality. It’s also a bit confusing at times, such as when it states that symptom relief may require sessions of several repeat insertions but that exceeding three daily “treatments” is strongly discouraged. Is it three total insertions or three sessions during which a child can undergo the procedure several times?
I’ve discussed colic on SBM in the past, going into great detail in a prior post. But here is a brief synopsis. Colic is the name we have given to the behavior of babies, typically between the ages of three weeks and four months, that seem to cry more than other babies based on a fairly arbitrary cutoff. It’s a diagnosis of exclusion, meaning actual illness or injury needs to be ruled out first, and the best science we have on the subject points towards colic being primarily a psychosocial construct in most children.
As with most behaviors, there is a bell curve to crying and some babies tend to fuss more than others. But what is likely the most important factor in a child receiving a diagnosis of colic is the caregiver’s perception of that crying. Parental perception can be significantly impacted by many factors, such as stress and lack of sleep, that increase their sensitivity to crying. These factors can also negatively impact interactions between the parent and child, increase crying, and alter the perception of it in a vicious cycle.
Some babies have medical conditions that mimic colic, but they almost always have other findings or historical clues that differentiate them. Milk protein allergy is the one that has the best evidence in support of empiric treatment, typically with a specialized formula, in babies that fail to respond to soothing techniques and attempts to manage parental perception problems. But colic is not caused by reflux or constipation, and it is not caused by gas.
Babies produce gas as their feeds are digested just like older children and adults. All babies are gassy. All babies have periods of fussiness. They are rarely related, and when they are it is more plausibly because of gaseous distention of the stomach which is usually relieved by burping. But even that example is based more on lore than evidence.
Adults will sometimes describe a bloated feeling caused by gas, but pain related to gas is an infrequent medical complaint. The overwhelming majority of humans old enough to express their feelings experience varying amounts of gas every day without any problem, yet we assume that virtually all babies experience frequent episodes of discomfort or pain to the point of excessive crying because of it. Gas in the rectum in particular doesn’t hurt and removing gas from the rectum with a device only seems to work via manipulation of parental perception of their baby’s demeanor.
In addition to simple cultural inertia, there is a condition in young infants, really a description of normal development, that probably plays a role in widespread belief in the power of baby gas and the need to intervene with products like the Windi. Infant dyschezia is the name for when babies strain, grunt, and cry for at least ten minutes several times a day prior to passing gas or stool. It is affects most babies at some point in the first several weeks of life and is the result of an inability to coordinate relaxation of the pelvic floor musculature and intra-abdominal pressure (valsalva).
Infant dyschezia is nearly always misinterpreted as pain related to gas or constipation. It is neither. Crying and straining is merely the baby’s reflexive attempt to valsalva harder against closed anal sphincters. It is not caused by pain or discomfort. When these episodes result in stool, it is normal soft baby poop.
Unfortunately it is common for parents to experience anxiety related to infant dyschezia and to seek out medical care for gas and/or constipation. Many parents have been told, by well-meaning friends and family, and even the occasional medical professional, that using a rectal thermometer (or the Windi) to open up the anus is necessary to relieve their baby’s suffering. And this will sometimes result in a rush of gas or poop. The concerning baby behavior will then stop, which reinforces the parental desire for more intervention.
The problem with this is that infant dyschezia is part of normal development. They will eventually reach the milestone of being able to coordinate defecation and passing gas easily. Frequent rectal stimulation will actually delay this process and even potentially result in a baby that is dependent on rectal insertion in order to stool normally. So despite what is cleverly implied on the Windi website, most pediatric professionals specifically recommend against this method.
As far as use of the Windi for constipation goes, this is also inappropriate. First off, young infants who have yet to begin solid foods are rarely constipated. In the uncommon case of a young infant with acute constipation, or with the much more common occurrence of acute constipation in older kids, the safest and most effective treatment is from above with something to soften the stool. In children with chronic constipation who have developed an impaction, it is sometimes necessary to treat from below in order to remove old hard stool while lifestyle modification and use of oral stool softeners are optimized. A product like the Windi will not suffice as these children need a glycerin suppository or enema.
Conclusion: Not dangerous, also not useful
New parents are bombarded with recommendations for products to help make caring for their baby more tolerable, and they range from the silly to the dangerous. The NoseFrida and the Windi are certainly not dangerous, but they are likely a waste of money. Luckily they are fairly inexpensive.
In the grand scheme of things, it is unlikely that these two products will cause the downfall of our modern civilization. And I’m certainly not comparing promotion or use of these products to the bogus remedies and risky pseudoscience typically found in the posts on SBM. I doubt we will see any NoseFrida or Windi-related deaths.
But the Windi will likely be used by parents to treat a harmless and normal aspect of development and is not risk free. Frequent use may actually delay development of the ability to pass stool and gas easily in young infants. Removal of gas from the rectum will not treat colic because gas in the rectum is not the cause of colic or fussing in infants in general.

Science-Based Satire: 8th Edition of the Neonatal Resuscitation Program to Address Tongue-Tie
Is the NRP really updating its guidelines to include assessment and management of tongue-tie during newborn resuscitation? Should babies maintain skin-to-skin contact with their mother while receiving chest compressions? No. None of this is even remotely true.
Clay Jones on January 25, 2019
Link

Itasca, IL – In response to requests from the American Academy of Pediatrics (AAP) Section on Breastfeeding and Baby-Friendly USA (BFUSA), the next edition of the Neonatal Resuscitation Program (NRP) will include recommendations on the diagnosis and management of “tongue-tie”, also known as ankyloglossia, at the time of delivery.

“Resuscitation of the newborn is nuanced and multifaceted,” BFUSA Board of Directors Chair Theresa Landau explained. “We aren’t asking for there to be a delay in providing effective ventilation, at least not yet, but the evidence is overwhelmingly clear that breastfeeding provides optimal nutrition and should be encouraged at every step of the process.”
As part of the upcoming 8th edition of the program, which is jointly sponsored by the AAP and the American Heart Association, a new lesson module will cover the basics of assessing for the presence of ankyloglossia during the initial steps of resuscitation. If a baby does not respond to stimulation and suctioning of the mouth and nose, positive pressure ventilation using a bag and mask or aided by the placement of an endotracheal tube is still recommended. Once the baby is breathing without assistance and has a heart rate greater than 100 beats per minute, corrective measures should be considered. The most common corrective measure, a procedure known as a frenotomy, typically involves using sterile scissors to snip the tight attachment between the tongue and the floor of the mouth. This has been shown in some studies to be associated with improvements in breastfeeding in a percentage of the participants.
(M)ask adjustment(R)eposition airway(S)uction mouth and nose(O)pen mouth(P)ressure increase(A)lternative airway(F)renotomy
(“MR.SOPAF” mnemonic for corrective measures during resuscitation from the NRP 8th edition)
Several additional changes to the NRP guidelines will further support breastfeeding. These will include maintaining direct skin-to-skin contact between the newborn and mother while placing an endotracheal tube or umbilical vein catheter and offering counseling on the benefits of breastfeeding over infant formula during the first minute after delivery of all infants born at less than 32-weeks gestation. Some experts, like Billy Gilravey, MD, a surgeon who specializes in laser-frenotomy in breastfeeding newborns, think that the new guidelines don’t go far enough. “Pediatricians are fools if they think that we should be waiting until birth to manage ankyloglossia!”
It is not uncommon for new editions of the NRP to include major changes. Based on mounting evidence against the practice, the prior update recommended against routine tracheal suctioning of non-vigorous newborns when the amniotic fluid is found to contain meconium, which is the medical term for an infant’s first stool. According to AAP President Colleen Kraft, MD, FAAP, pediatricians will likely be quick to adopt the latest guidelines as well. “Pediatricians care for children who are developing, who are rapidly achieving new milestones as they age. You might say that we are experts in change.”

Science-Based Satire: American Academy of Pediatrics Releases New Guidelines on Corporal Punishment
In December of last year, the American Academy of Pediatrics updated their policy statement on effective discipline. Did it include an algorithm to help caregivers safely dose corporal punishment? No, that’s actually pretty absurd. Offensive even, if you think about it. Don’t though. Look…a squirrel!
Clay Jones on March 22, 2019
Link

Elk Grove Village, IL – The American Academy of Pediatrics (AAP), the primary professional organization responsible for establishing pediatric healthcare standards, has released updated recommendations on the dosing of infantile spanking and corporal punishment in children.
“This represents a huge step forward for pediatricians and parents,” Mort Fishman MD, Head of Disciplinary Pediatrics at Children’s Hospital of Philadelphia, explained. “Until now, parents have had to call the pediatrician, make an appointment, and travel to the office sometimes hours to days after the undesired behavior has occurred. Or they bring the child to an emergency department, urgent care center, or retail-based clinic that may not have pediatric-trained staff. Sometimes the parents just wing it.”
It is this “winging it” by many parents that has concerned pediatric medical professionals for decades. Since the discovery of corporal punishment in the 1930’s, when a Harvard researcher inadvertently dropped a heavy glass beaker on the head of a stubborn lab assistant, a number of children have overdosed. Some have suffered permanent injury or even died. Researchers have long blamed the lack of pediatric guidelines and the inappropriate extrapolation of adult dosing, shouting out the oft-repeated axiom that kids are not simply smaller adults.
Recent studies have revealed an alarming upward trend in the inappropriate use of home corporal punishment based on recommendations found online and popularized by social media influencers. The usual suspects are frequently mentioned by pediatricians, researchers, and public officials. “Anybody can publish anything on the internet,” Fishman, who co-authored the AAP paper, adds. “There are literally thousands of websites offering up unproven techniques, inconsistent dosing, and pseudoscientific mechanisms of action.”
Parent groups have also become a loud voice in the discussion of pediatric corporal punishment over the past several years, calling for more research and for guidelines for home use. Members of such organizations as Mother’s Against Time Out, and the more influential National Spanking Society, have raised awareness and millions of dollars with 5K running races, bake sales, and van-based mobile spank clinics. Many pediatricians are giving credit to these groups for speaking out on behalf of those who cannot speak for themselves, and for pushing the AAP to act.
Dr. Fishman and the AAP hope that the new guidelines will not only help healthcare professionals appropriately dose corporal punishment in children, but also serve as an evidence-based source of education for parents and other caregivers such as teachers, daycare workers, babysitters, and strangers at Target. As stated in the paper’s conclusion, “Empowered and educated caregivers can now confidently dole out safe and effective corporal punishment in a timely fashion without the need to clog up an already overburdened medical system.”
Are the new infantile spanking and corporal punishment guidelines user friendly enough for caregivers without medical training to put into use? They couldn’t be simpler according to Matt Stevens, a mechanical engineer and parent of 3 young children, one of which is kind of a jerk. “When one of my kids talks back or forgets to do a chore, usually Matty Jr., we go to the handy flow chart taped to the wall by the fridge. After a few quick calculations, I know just how hard to smack him.”
The responses to the new guidelines are not all positive, however. Despite the experience of highly educated parents such as Matt Stevens, a vocal minority of pediatricians are raising concerns over the ability for most caregivers without medical experience to decipher the recommendations. Dr. Percival Bordeaux, academic pediatric hospitalist and discipline researcher near the Mayo Clinic, is one of the more prominent voices of opposition. “Is Timmy just being a bit lazy or is he exhibiting stage 3 lollygagging? Is he a smart aleck or a wisenheimer? I have trained in pediatrics for almost thirty years and sometimes I still can’t tell the difference!”
And…scene!
If you’ve made it this far, thanks for indulging me my attempts at science-based satire. In reality, the American Academy of Pediatrics did publish a new policy statement on the topic of effective discipline in December of last year. Their recommended approach, and warning of the harms of corporal punishment, is more firm than it was when I last wrote about this issue back in early 2014. In that post, I came to the following conclusion:
The limited use of mild corporal punishment, in very isolated and specific circumstances, may have some benefit but prevention/protection is almost always a better option. Its use as a strategy to improve overall behavior is fraught with risk. Although imperfect, there is good evidence that recurrent use can lead to physical abuse, interfere with learning and increase aggression. And it may worsen behavior in the long run.
There is an absence of any data showing it to be more effective than other techniques, such as negative punishment strategies like time outs. Unfortunately, the internet is full of pro-spanking propaganda that relies on anecdotes, old fashioned thinking and one study that didn’t survive peer review. The best initial resource for questions regarding discipline should always be a child’s physician. We aren’t perfect, but most pediatricians accept that corporal punishment is a poor method of discipline and should be able to provide education and help accessing local resources.
In the new statement, based on a large amount of data that has emerged since the 1998 issuance of their last official statement on effective discipline, the AAP has removed language that in any way supports hitting kids. They also discuss the risks of non-physical forms of discipline that are also risky and ineffective. Here is a nice summary of the many potential physical and psychological downsides of unhealthy discipline strategies, but the new statement essentially boils down to the following:
The AAP recommends that adults caring for children use healthy forms of discipline, such as positive reinforcement of appropriate behaviors, setting limits, redirecting, and setting future expectations. The AAP recommends that parents do not use spanking, hitting, slapping, threatening, insulting, humiliating, or shaming.
Thankfully, the current crop of new parents are less and less likely to use corporal punishment than older generations. It is still far too common. Another issue, which I discussed in more detail in my 2014 post, is the sad fact that despite calls for a ban from the AAP and other organizations, there are still several states that allow school officials to hit kids:
As of October 2, 2018, corporal punishment is still legal in private schools in every U.S. state except New Jersey and Iowa, legal in public schools in 19 U.S. states, permitted in 18, and practiced in 15 U.S. states.
More than 100 countries around the world ban hitting kids in school. The United States is, in fact, the only Western country to have not banned this practice.

Science-Based Satire: Pacifier Vaporizer Manufacturer Denies Marketing to Infants
Have e-cigarette companies really been marketing to infants? Could this actually be a real product? It’s an undeniable fact that children have been targeted in an effort to produce customers for life, but thankfully this is satire. The littlest ones are safe…for now.
Clay Jones on November 29, 2019
Link

San Francisco, CA – When confronted with concerns over inappropriate marketing tactics during a congressional hearing this week, representatives from Happy Baby Labs, Inc., the manufacturer of the popular Paci-Vape line of vaping products, vigorously denied targeting infants.
“At no point in the history of this company have we ever attempted to entice infants into using one of our sugar infused, pacifier vaping products,” Happy Baby Labs, Inc. founder Jewel Snively explained. “It isn’t our fault that they are naturally curious and ignore the prominent warning labels stating that our pacifiers are not for babies.”
The Paci-Vape e-cigarette brand is extremely popular among infant vapers, with a market share of nearly 90%. Only Druul and blu binky have managed to carve out a small corner of the market. Druul in particular managed to capitalize off of its prominent role in the popular Netflix Original series, The Boss Baby: Money Never Sleeps.
Congresswoman Alexandria Ocasio-Cortez challenged Snively, raising concerns that Paci-Vape’s choice of spokesperson gives the impression that babies are being marketed to despite their claims to the contrary. “It’s a baby. Your spokesperson is an actual baby, in a diaper, and the baby is vaping. Are you telling me that this does not indicate a desire for infants to use your product?” Ocasio-Cortez also grilled Snively on the possible side effects in such young children.
Also present at the hearing was Happy Baby Labs, Inc. medical consultant and board certified vapologist Mort Fishman, MD, who claimed that the health effects in human infants are probably minimal. “It’s such a small amount of nicotine, and only a handful of other ingredients. Tiny really when compared to what is found in products we market to older children. But in answer to your extremely important question, oh my God, how did that bear get in here!” Fishman and Snively were nowhere to be found when Ocasio-Cortez and the other members of the committee looked back at the witness table.
Pay attention to the truth behind the curtain
E-cigarette makers undeniably marketed their products to children, helping to make vaping trendy, and their use is now rampant. Roughly 1 out of every 4 older teens are vaping at least occasionally, and numbers are also increasing in middle schools. As a hospitalist, I have personally seen a remarkable increase in the number of children admitted to the hospital who vape. It is not uncommon for them to be nicotine addicted and to require medical assistance with withdrawal symptoms while hospitalized.
Most of these vaping children and young adults that I take care of in the hospital are admitted for unrelated conditions. That being said, I have also seen a rise in the number of patients who admit to using vaping products for the inhalation of marijuana. These illicit and counterfeit vape cartridges, the most prominent being “Dank Vapes“, are the likely culprit for an increasing number of cases of severe acute lung disease in 2019. I’ve had the unfortunate displeasure of caring for one of these cases, which nearly resulted in the patient’s death.
In addition to concerns over these acute cases of severe pulmonary injury, we have absolutely no idea what the long-term effects on the lungs may be. Vaping, in all of its forms, is a massive uncontrolled experiment involving the human population. There may be some benefit to those adults attempting to reduce their use of cigarettes, but the unexpected consequences are piling up.
A recent BMJ study helped to illustrate the sad fact that manufacturer damage control efforts are too little too late because the youth themselves are now providing their own unintentional marketing. To my knowledge, however, no company has promoted infant vaping, which would be incredibly irresponsible. It’s a good thing that this post is satire…for now.
I hope everyone had a happy Thanksgiving, if you are into that sort of thing. See you in two weeks. Oh, here is another one along the same lines. Enjoy!

Science-Based Satire: More Parents Relying on Fetal Body Language Analysis
Are worried parents-to-be seeking out the services of fetal body language analysis experts? Is body language a scientifically proven window into our secret thoughts and desires? Is this just satire? Obviously it is, because I’ve got a closed-lip grin on my face and I haven’t blinked this entire time.
Clay Jones on October 2, 2020
Link

Newark, NJ – A recent Parenting Magazine survey has revealed that more parents-to-be are taking advantage of fetal body language analysis using advanced prenatal ultrasound technology in order to help plan for their new arrival.
“There is so much uncertainty out there for new parents,” Kim Jacobs, a fetal body language expert and owner of the Getting to Know You 4D Ultrasound Studio in Newark, explained. “What is the baby’s favorite color? Do they want to be fed breast milk or formula? What pronouns should the medical team use? Parents are desperate for any information that might help them prepare.”
The use of cutting edge 4D ultrasound systems has revolutionized fetal body language analysis in recent years. In the past, experts like Jacobs were forced to rely on 2D flipbooks that were crudely fashioned from printed ultrasound pictures in order to perform an analysis. “Looking back on those days, I have to laugh at how generalized we had to be. I could see that a baby is interested in art, but not what particular style or period. Parents had to make a lot of assumptions.”
Thanks to these advances in ultrasound technology, experts can now acquire and display 3D data sets in real time, just like a movie in the DC Extended Universe. This allows for analysis that is significantly more accurate, but also a lot more expensive. Jacobs says that most parents find that her service is worth the cost. “We can make a list of songs to play in the birthing suite that incorporates input from the developing fetus. How can you put a price tag on something like that? Also, we can set up a monthly payment plan.”
Though the science of fetal body language analysis is still in its infancy, testimonials from pleased parents are piling up. Recent Getting to Know You clients Wild and Carli Howell are helping to spread the word around Newark. “We loved learning about our baby’s personality and her preferences before the birth. It helped us prepare. It gave us hope.”
Be skeptical of body language analysis claims
Human language is, obviously, an incredibly complex endeavor and I would never claim that nonverbal communication isn’t an important component of it. The scientific study of nonverbal behavior related to movement of the human body, known as kinesics, is fascinating and important. But the way that we move or position one or more of the many parts of our bodies isn’t language in and of itself, and it cannot provide the kind of detailed information that so-called body language experts claim to derive from it.
I’m confident that you have seen these “experts” on TV or read articles, like this nonsense from Business Insider, involving the supposed analysis of body language to gain access to the secret inner workings of the human mind. They analyze the behavior of subjects, often celebrities or politicians, and describe hidden emotions and motivations. Naturally it is implied that their analysis is based on solid scientific research demonstrating standardized and reproducible algorithms. It’s all a sham, however.
In reality, the claims made in articles such as the one I’ve linked to above are not supported by research. They are full of assumptions and opinion that disregard what is actually known about human communication, which is that so-called body language has few universals and that there are large variations in the meaning of facial expressions and other movement based behaviors both within and between cultures. These variations in meaning can be reduced down to the level of the individual, and even then it often depends greatly on the context in which the behavior is expressed.
Essentially, the only way that an analysis of an individual’s body language has a chance of being accurate is if the analyst knows the subject very well. Even then it’s still subjective and there is a high risk of error. The bottom line is that the so-called body language analysis experts are largely making it up as they go along, regurgitating unproven clichés, or simply performing an amateurish cold reading.

Science-Based Satire: Area Child Killed by Unwieldy Backpack
Was a child recently murdered by a heavy backpack? Do unwieldy backpacks cause scoliosis and long term general health problems? Should we care what chiropractors have to say about pediatric spinal health? No. This isn’t remotely true and honestly I’m a little surprised that you would even ask me that. It’s satire.
Clay Jones on August 7, 2020
Link

Lexington, KY- Chiropractic Pediatricians are warning parents of the dangers of heavy backpacks after a 5-year-old Kentucky kindergarten student died from total spinal collapse (Accordion syndrome) on Friday.

“We are seeing massive numbers of children with early-onset back, neck and shoulder pain,” American Pediatric Chiropractic College (APCC) President Scott Shaw explains. “Backpack stress also impairs the function of spinal nerves, which can lead to organ malfunction. Death is still a rare outcome, but I expect to see more as backpack engineers continue to focus on load bearing capacity rather than safety.”
Historically, backpacks were initially about the size of a loaf of bread or a small poodle, and were only able to carry a small textbook, a few notebooks, and perhaps a calculator before tearing. Using synthetic fabrics and space age metamaterials, modern backpacks can easily handle several full size books, a laptop computer, a full pencil case, and a mellophone. Combined with the popular trend of single shoulder carriage (SSC), kids with heavy backpacks are often just one Trapper Keeper away from catastrophe. In fact, a study conducted near Harvard found that the typical American child carries the equivalent of an adult bull elephant to school every day, and that nearly all of them will eventually admit to experiencing back pain at some point in their lives.
As the crisis continues to worsen, some states are proactively passing laws to compel schools to act. According to Shaw, legislators in nearby Tennessee recently voted to install scales at all school entrances. If a backpack weighs more than 10% of the child’s body weight, an alarm will sound and a designated staff member will assist the child in carefully removing heavier items. “Nobody wants to wait until after we’ve had to dig mass graves for toddlers to do something about a problem.”
The APCC has released a list of questions so that parents and teachers can identify children affected by heavy backpacks and seek appropriate chiropractic care:
     1.  Is your child/student complaining of headaches, neck or back pain, or intermittent fullness of the bladder or bowels.
     2.  Does your child/student have difficulty paying attention at home or in school, sometimes becoming distracted by more interesting objects or activities?
     3.  Has your child/student ever had, or have you ever wondered if they might have, any medical problems involving any part of their body?
     4.  Does your child/student’s entire body lean to one side, seemingly defying the laws of physics like in those old V8 Juice commercials?
     5.  Has your child/student’s spine begun to collapse and expand over and over again like an accordion?
If you answered yes to one or more of these questions, it may not be too late. With advances in modern chiropractic care of the pediatric patient, the days of hospital backpack injury wards are far behind us. Most children seen by chiropractic pediatricians can expect a long and productive life1.

1Online Publishing Module #27,811 – Chiropractic Pediatric Outcomes and Marketing Strategies for a Dynamic Practice
Unpacking the nonsense
Although this fall will see fewer children attending school in person, I guarantee that you will still see many articles and news stories about backpack safety concerns involving local chiropractors. They will inevitably involve warnings of injuries on the rise among young children and concerns of long-term health problems. Like the bogus “text neck” fears that started up within the past few years, backpack safety warnings are marketing in the guise of public health and local news teams always fall for it.
I’m not saying that heavy or lopsided backpack use doesn’t sometimes result in complaints of neck, shoulder, or back discomfort. Of course they do, and rarely the pain can be significant although it is often an assumption that the backpack is the root of the problem. The American Academy of Pediatrics provides helpful information on the subject, as does the American Academy of Orthopedic Surgeons.
But despite what many chiropractors claim, backpacks do not cause nerve injury, circulation problems, scoliosis, severe and debilitating pain, or long term health problems. Or spinal collapse. The common minor aches and pains resolve quickly with adjustment of the backpack use and perhaps some ibuprofen.
Here is one more out of many, many available discussions of backpacks online by chiropractors. It is particularly revealing when he discusses a research paper and confuses true orthopedic abnormality of kyphosis with chiropractic subluxation and general poor posture. He goes on to conflate the outcomes used in the study, which were measures of disability, with overall health in general. Chiropractic adjustments do not safely or effectively treat kyphosis and I’m pretty sure he knows that and also that backpacks have nothing to do with it. But maybe I’m being too generous and he truly just didn’t understand the paper.

Science-Based Satire: More Parents Turn to Kinesiology Diapers for Fussy Infants
Are parents really turning to diapers made using kinesiology tape to help their fussy babies? Of course not. That would be incredibly silly, and profitable. This is satire.
Clay Jones on April 26, 2024
Link

American Fork, UT – KT Tape®, the leader in sports related drug-free pain and injury relief through the use of their advanced recovery products, is revolutionizing the baby care industry by combining their recognized kinesiology tape with standard disposable diapers.
A baby, shown here wearing a conventional disposable diaper without kinesiology tape to help support pelvic and abdominal muscle and soft tissue, who is unable maintain an appropriate upright posture
“The disposable diaper is an amazing product that parents and other caregivers of young children depend on,” KT Tape® CEO Jessica Klodnicki explained. “But there hasn’t been a design upgrade since the introduction of a super-absorbent polymer to the crotch in 1984.”
The new diapers from KT Tape® will utilize the same “lift and lock” technology that makes their popular line of kinesiology tapes so effective. According to Klodnicki, there is the potential for significant medical benefit in addition to the established convenience of modern disposable diapers. “Our KT Diapers® will gently, but powerfully, lift the skin and subcutaneous tissue in the pelvis and lower abdomen, improving blood flow and lymphatic drainage and helping to reduce fussiness from gas, constipation, and colic.”
Helping to enable athletes and fitness enthusiasts to perform at their best has always been a fundamental guiding principle of the KT Tape® philosophy. With the introduction of KT Diapers®, this goal of improved comfort and functionality hasn’t changed. They will be distributed to caregivers, medical professionals, and daycare centers through major retailers, specialty baby stores, and medical supply distributors worldwide.
“These diapers are built for performance,” KT Tape® Product Design Director Lucinda Crepe explained. “Yes, they are going to help these babies feel better, function better, and probably start walking earlier than kids using conventional diapers, but they are also going to soak up a lot of urine and feces so that a baby can reliably do their business without fear of leaks or blowouts.”
KT Diapers® are designed to be applied to an infant’s skin by caregivers without specific training. But in order to achieve maximum benefit, Crepe revealed that some training would be necessary. “Seeking out a fully certified kinesiology taping practitioner for every diaper change isn’t practical. We do recommend that caregivers undergo KT Diaper® specific training on our website in order to avoid injuries, however. And for a small annual fee, anyone who changes diapers regularly can obtain a full certification that will give them the confidence to train others and even charge for the service.”
Tossing out the diaper full of nonsense
We’ve discussed so-called kinesiology tape a few times on SBM over the years, most recently in a serious 2023 post by Scott Gavura on implausible claims involving improved cell oxygenation and sports performance. Way back in the Before Times of 2018, I also discussed a very real study that investigated the influence of kinesiology tape color on athletic performance. Feel free to read it, though I doubt you will be surprised to learn that tape color doesn’t matter or that the authors still called for more research regardless of that fact.
Kinesiology tape is just stretchy tape that gently lifts the skin. In the few years that have passed since my 2018 post, no evidence has come to light that counters my assessment at the time:
Though these products are popular, the explanations given by proponents are highly implausible and the evidence to date is resoundingly negative. The specific patterns, which proponents believe provide a unique benefit, are irrelevant. KT appears to be just a more expensive equivalent to the old-fashioned athletic tape traditionally used to help stabilize a joint or to provide compression bandaging to reduce swelling after an acute injury.
When it comes to pain relief or athletic performance, there may be a non-specific benefit that comes from expectation or, as has been skillfully argued* by our own (sadly no longer) Paul Ingraham, the application of a novel sensory input. So kinesiology taping might serve as either a simple distraction from discomfort or a less impressive version of Dumbo’s magic feather, but there is no evidence to support benefit from unique “biomechanical tuning”. This would explain why perceived benefits tend to be transient as novel sensations quickly attenuate when continuously applied to the skin.
* https://www.painscience.com/articles/kinesio-taping.php
My earlier post should have been satire but was about an actual study designed and implemented by real scientists. My post today, however, clearly is satire but is based on very real claims made by proponents/believers in kinesiology tape. And to be honest, I’m kind of surprised that somebody hasn’t tried to sell a kinesiology diaper yet.
This would be a logical next step that is no sillier than promoting tape to help cells suck up more oxygen and improve muscle function. And parents of young infants are a population often desperate for anything that might help with a fussy baby and thus primed to part ways with loads of cash. What do you say? Any potential angel investors out there? Let’s do this!

Science-Based Satire: Integrative Baby Monitor Combines the Best of Conventional and Alternative Features
Are there really baby monitors on the market that can alert a parent to stagnant chi as well as dangerously low oxygen levels? No, that’s ridiculous! Will a company sell one at some point in the future? Probably. But for now, it’s satire.
Clay Jones on August 24, 2018
Link
Measles has been in the news this week as cases in Europe are skyrocketing. If you are keeping count, 41,000 cases and 37 deaths have been reported thus far in 2018. In the United States, there have been far fewer cases to date this year, 107 to be exact. Frankly, when it comes to measles cases however, even one is too many.
I had planned to discuss this worrisome trend in more detail, but Orac beat me to it. Orac, a friend of SBM, is a 6-Disc CD changer from a 2003 Buick LeSabre that gained sentience and a hatred of pseudoscience after being struck by lighting while parked outside The Chopra Center. Rather than cover the same territory, I figured that a little satire was long overdue. But first, the set up.
Home baby monitors are a bad idea
I was inspired to post this by a recent Reuters article on the questionable accuracy of two popular baby monitors: the Owlet and the Baby Vida. I’m more familiar the former, and am frequently asked about monitor use by parents in the newborn nursery. Parents are often worried about the potential for the unexpected death of their child during sleep, something that is thankfully quite unlikely to occur. That being said, it remains one of the most common causes of death in the developed world and, again, like measles and the eggs in Smithers’ brain, even one is too many.
There is no evidence that even these cutting edge monitors, which measure oxygen levels and heart rate, actually prevent death during sleep. And they aren’t approved by the FDA for such claims. But, as with supplements and herbal remedies, worried parents are encouraged to make the connection and assume that is just what these monitors do. They are led to believe that they will get an alert on their phone and be able to save their dying child, but that just isn’t how it works.
Some children, particularly former premature infants still at risk of stopping breathing because of immaturity of the brain, are sent home on monitors. But the American Academy of Pediatrics has long maintained that home monitor use in healthy children is not beneficial and often increases anxiety because of false alarms. The study discussed in the Reuters piece supports our stance, raising concern of not only false alarms, but also of missing actionable abnormalities in blood oxygen levels, potentially giving parents a false sense of security, especially if inappropriately relied on during a respiratory illness.
The folks from Owlet disagree. They cite studies showing that their product is as accurate as hospital-based assessments, but the quality of their data is poor and probably doesn’t generalize to the population whose parents they are targeting. I think that I’ll go into more detail on this in a future post, but for now, enjoy some Science-Based Satire.
Integrative baby monitor combines the best of conventional and alternative features
Portland, OR – Parents of young infants have a lot to be worried about. Hoping to ease the burden of these nervous parents, Globodyne Industries has developed the OptiHover™ Integrative Baby Monitor, the first baby monitor to combine the best of conventional and alternative features.

“Raising a human infant can be pretty scary,” Globodyne Science Officer and medical school graduate Mort Fishman MD explained. “When parents bring a baby home from the hospital, birthing center, or dolphin-assisted delivery paddock, they face many nights of fear and anxiety over the future returns on their precious social capital investment. They also don’t want their baby to die.”
In addition to traditional features, such as audio and video feeds, the OptiHover™ will also be able to detect movement and transmit oxygen saturation and pulse rate data to a caregiver’s smartphone or tablet device. While parents and other caregivers do appreciate these cutting-edge scientific features, they are increasingly looking to other ways of knowing that their little bundles of joy are safe and experiencing wellness. That’s where the OptiHover™ truly shines.
According to Fishman, Globodyne researchers didn’t limit the functionality of the device to the boundaries of methodological or even metaphysical naturalism. “Today’s parents want more than just biophysical statistics. They realize that their baby isn’t just some number on a spreadsheet. The OptiHover™ also includes a variety of holistic monitoring capabilities, such as meridian patency and aura integrity. The OptiHover Deluxe™, which will be coated in an antimicrobial and antidemonic holy water infused polymer resin, will even ward off evil spirits and changelings.”
